<SEC-DOCUMENT>0001564590-22-007633.txt : 20220228
<SEC-HEADER>0001564590-22-007633.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228162310
ACCESSION NUMBER:		0001564590-22-007633
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Atara Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001604464
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				460920988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36548
		FILM NUMBER:		22690005

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD
		STREET 2:		SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-278-8930

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD
		STREET 2:		SUITE 900
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>atra-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-28T19:05:26.5025772+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:atra="http://www.atarabio.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
atra-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001604464_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001604464_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001604464_20210101_20211231">0001604464</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001604464_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000403" name="dei:EntityIncorporationDateOfIncorporation" contextRef="C_0001604464_20210101_20211231">2012-08-01</ix:nonNumeric>
			<ix:nonNumeric id="F_000621" name="atra:LeaseAgreementRenewalTermOptionOne" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000625" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000835" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">P2Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000606" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_20210101_20211231">2025-05-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000616" name="atra:LeaseOptionToExtendAdditionalTerm" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000624" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231">2026-02-28</ix:nonNumeric>
			<ix:nonNumeric id="F_000628" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231">2024-04-30</ix:nonNumeric>
			<ix:nonNumeric id="F_000615" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331">0</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000640" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001604464_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000642" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001604464_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000654" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001604464_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000656" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001604464_20211231">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" contextRef="C_0001604464_20190101_20191231" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000826" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20200101_20201231">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000827" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000828" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000829" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231">P4Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000843" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001604464_20210101_20211231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000844" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001604464_20200101_20201231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000845" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001604464_20190101_20191231">P5Y10M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001604464_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001604464_20201231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="atra-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001604464_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_20220218">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-18</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_atraSegment">
				<xbrli:measure>atra:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:CurrentLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:LongTermLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-10-01</xbrli:startDate>
					<xbrli:endDate>2021-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:LongTermLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-02-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-14</xbrli:startDate>
					<xbrli:endDate>2018-02-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20180215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-02-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:AuroraColoradoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-31</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-18</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-18</xbrli:startDate>
					<xbrli:endDate>2019-07-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-18</xbrli:startDate>
					<xbrli:endDate>2019-07-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-18</xbrli:startDate>
					<xbrli:endDate>2019-07-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190201_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-01</xbrli:startDate>
					<xbrli:endDate>2019-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211101_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-01</xbrli:startDate>
					<xbrli:endDate>2021-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-02-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-02-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_atraFromDateOfGrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">atra:FromDateOfGrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_atraTenPercentShareHolderMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">atra:TenPercentShareHolderMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:InducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:InducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandEighteenInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">atra:OtherStatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">atra:OtherStatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001604464</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-26</xbrli:startDate>
					<xbrli:endDate>2022-01-26</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001604464_20210101_20211231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentAnnualReport" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001604464_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001604464_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentTransitionReport" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;<span style="text-decoration:underline;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;to <span style="text-decoration:underline;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;<ix:nonNumeric id="F_000018" name="dei:EntityFileNumber" contextRef="C_0001604464_20210101_20211231">001-36548</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:21pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001604464_20210101_20211231">ATARA BIOTHERAPEUTICS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001604464_20210101_20211231">46-0920988</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation or organization)</p></td>
<td valign="bottom" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine1" contextRef="C_0001604464_20210101_20211231">611 Gateway Blvd.</ix:nonNumeric>, <ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine2" contextRef="C_0001604464_20210101_20211231">Suite 900</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001604464_20210101_20211231">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001604464_20210101_20211231">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001604464_20210101_20211231">94080</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <span style="font-weight:bold;">(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001604464_20210101_20211231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001604464_20210101_20211231">278-8930</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:Security12bTitle" contextRef="C_0001604464_20210101_20211231">Common Stock, par value $0.0001 per share</ix:nonNumeric>,</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001604464_20210101_20211231">ATRA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:SecurityExchangeName" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None<span style="font-weight:bold;"> </span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001604464_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">NO</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;<span style="text-transform:uppercase;">YES</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span>&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001604464_20210101_20211231">No</ix:nonNumeric></span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0001604464_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">NO</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000030" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001604464_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;<span style="text-transform:uppercase;">NO</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:16.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:58.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top" style="width:16.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:59.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:16.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:58.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntitySmallBusiness" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:16.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:58.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:16.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:58.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000033" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;<span style="text-transform:uppercase;">YES</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;<span style="text-transform:uppercase;">NO</span>&#160;<span style="font-size:9pt;font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of common stock held by non-affiliates of the Registrant, based on the closing sales price for such stock on June&#160;30, 2021 as reported by The Nasdaq Stock Market, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000014" name="dei:EntityPublicFloat" contextRef="C_0001604464_20210630" decimals="0" format="ixt:numdotdecimal">1,149,785,847</ix:nonFraction>. This calculation excludes 10,812,902 shares held by executive officers, directors and stockholders that the Registrant has concluded are affiliates of the Registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the Registrant. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of outstanding shares of the Registrant&#8217;s Common Stock as of February 18, 2022 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000013" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001604464_20220218" decimals="INF" format="ixt:numdotdecimal">93,097,679</ix:nonFraction>.</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000344" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">Portions of the Registrant&#8217;s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonNumeric><span style="font-size:5pt;"> </span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="TOC">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART I</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_1B"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_2"><span style="text-decoration:underline;">Properties</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_3"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART&#160;II</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">[Reserved]</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">73</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_7"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_7A"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9"><span style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9A"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_9B"><span style="text-decoration:underline;">Other Information</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9C.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART&#160;III</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_10"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_11"><span style="text-decoration:underline;">Executive Compensation</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_12"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_13"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_14"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART&#160;IV</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16"><span style="text-decoration:underline;">Form 10-K Summary</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements, which represent our intent, belief or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases you can identify these statements by forward-looking words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;expect&#8221; or the negative or plural of these words or similar expressions. The forward-looking statements include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the timing of initiating clinical studies, opening client sites, enrolling clinical studies and reporting results of clinical studies for our programs, including in light of the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the likelihood and timing of regulatory submissions or related approvals for our product candidates, including the initiation, completion and expectations about the timing of approvals for our biologics license application (BLA) and marketing authorization application (MAA) for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for patients with Epstein-Barr virus with post-transplant lymphoproliferative disease (EBV+ PTLD)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential indications for our product candidates, if approved for commercial use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential market opportunities for commercializing our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our Research, Development and License Agreement with Bayer, including potential milestone and royalty payments under such agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our Commercialization Agreement with Pierre Fabre Medicament, including potential milestone and royalty payments under such agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the potential market size and the size of the patient populations for our product candidates, if approved for commercial use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">estimates of our expenses, capital requirements and need for additional financing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectation regarding the length of time that our existing capital resources will be sufficient to enable us to fund our planned operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to commercialize our product candidates, if approved for commercial use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the initiation, timing, progress and results of future preclinical studies and clinical studies and our research and development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to enter into and maintain contracts with clinical research organizations, manufacturing organizations and other vendors for clinical and pre-clinical studies, supplies and other services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of protection we are able to obtain and maintain for the intellectual property rights covering our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our financial performance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments and projections relating to our competitors and our industry&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to manufacture our product candidates for our clinical studies, or if approved, for commercial sale&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of COVID-19 to our business and operations, as well as the businesses and operations of third parties on which we rely&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to sell or manufacture approved products at commercially reasonable values&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the satisfaction of the conditions precedent to the consummation of the asset sale related to the Atara T-Cell Operations and Manufacturing facility, including the receipt of regulatory approvals&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">timing and costs related to qualification of our manufacturing plant for commercial production. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These statements are only current predictions and are subject to known and unknown risks, uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success&#59; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock&#59; the sufficiency of our cash resources and need for additional capital,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this report in greater detail under the heading &#8220;1A. Risk Factors&#8221; and elsewhere in this report. You should not rely upon forward-looking statements as predictions of future events. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In this Annual Report on Form 10-K, unless the context requires otherwise, &#8220;Atara,&#8221; &#8220;Atara Biotherapeutics,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; means Atara Biotherapeutics, Inc. and, where appropriate, its subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary Risk Factors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. These risks are more fully described below. These risks include, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we currently have no approved products and thus have no revenues from commercialization of any products and may never generate revenues from the sale of products or achieve profitability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we are generally early in our development efforts, have only a small number of product candidates in clinical development, and we will need to successfully complete preclinical and clinical testing of our product candidates before we can seek regulatory approval and potentially generate commercial sales&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we will require substantial additional financing to achieve our goals, which may not be available to us on acceptable terms, or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of preclinical studies or earlier clinical studies are not necessarily predictive of future results, and our existing product candidates in clinical studies, and any other product candidates we advance into clinical studies may not have favorable results in later clinical studies or receive regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical drug development, both in the U.S. and international jurisdictions, involves a lengthy and expensive process with an uncertain outcome and even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our T-cell immunotherapy product candidates and our next-generation CAR T programs represent new therapeutic approaches that could result in heightened regulatory scrutiny and delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not be able to obtain or maintain orphan drug exclusivity for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the COVID-19 pandemic continues to impact our business and operations and could materially and adversely affect our business and operations in the future, as well as the businesses and operations of third parties on which we rely&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our success depends upon our ability to obtain and maintain sufficient intellectual property protection for our product candidates, and we may not be able to protect our intellectual property rights throughout the world&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not be able to obtain and maintain the relationships with third parties that are necessary to develop, commercialize and manufacture some or all of our product candidates.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> I</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item&#160;1. Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Atara Biotherapeutics is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, we are the most advanced allogeneic T-cell immunotherapy company and intend to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-driven diseases or other serious diseases through incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Atara is applying this one platform, that does not require TCR or HLA gene editing, to create a robust pipeline of product candidates, all in the preclinical or investigational stage. Our strategic priorities are:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="Background-color:#FFFFFF;">: Atara&#8217;s most advanced T-cell immunotherapy, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (tabelecleucel), is </span><span style="color:#000000;">partnered with Pierre Fabre </span><span style="Background-color:#FFFFFF;">Medicament (Pierre Fabre) for commercialization in Europe and select emerging markets and is currently in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or </span><span style="color:#000000;">rituximab</span><span style="Background-color:#FFFFFF;"> plus chemotherapy, as well as other EBV-driven diseases&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA188</span><span style="Background-color:#FFFFFF;">: T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of </span><span style="color:#000000;">primary</span><span style="Background-color:#FFFFFF;"> and secondary progressive multiple </span><span style="color:#000000;">sclerosis</span><span style="Background-color:#FFFFFF;">&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;">CAR T Programs</span>:</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA2271</span><span style="Background-color:#FFFFFF;">: Autologous</span> CAR T immunotherapy, currently in clinical development, targeting solid tumors expressing the tumor antigen mesothelin, which is partnered with Bayer AG (Bayer)&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA3271</span><span style="Background-color:#FFFFFF;">: </span>Allogeneic CAR T therapy, currently in preclinical development, targeting mesothelin, which is partnered with Bayer&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA3219</span><span style="Background-color:#FFFFFF;">: Allogeneic CAR T targeting CD19, currently in preclinical development, and being developed as a potential best-in-class product, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our T-cell immunotherapy platform includes the capability to progress both allogeneic and autologous programs and is potentially applicable to a broad array of targets and diseases. Our off-the-shelf, allogeneic T-cell platform allows for rapid delivery of a T-cell immunotherapy product manufactured in advance of patient need and stored in inventory, with each manufactured lot of cells providing therapy for numerous potential patients. This differs from autologous treatments, in which each patient&#8217;s own cells must be extracted, genetically modified outside the body and then delivered back to the patient, requiring a complex logistics network. We currently have on hand sufficient tab-cel</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="Background-color:#FFFFFF;"> drug product inventory to supply commercial demand, if approved and subject to the specifications set forth in such approval, for at least 12 months. For our allogeneic programs, we select the appropriate set of cells for use based on a patient&#8217;s unique immune profile. In addition, our manufacturing facility has the flexibility to manufacture multiple T-cell and CAR T immunotherapies while integrating research and process science functions to enable increased collaboration for rapid product development. We are currently in the process of completing our facility&#8217;s commercial production qualification activities for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> while building inventory according to our commercial product supply strategy. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Commercialization Agreement with Pierre Fabre (Pierre Fabre Commercialization Agreement), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute <span style="color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia following regulatory approval. We will retain full rights to <span style="color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> </span>in other major markets, including North America, Asia Pacific and Latin America. Under the terms of the Pierre Fabre Commercialization Agreement, we are currently negotiating a Manufacturing and Supply Agreement as well as a number of ancillary agreements to further advance our collaboration with Pierre Fabre. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2020, we entered into a Research, Development and License Agreement with Bayer (the Bayer License Agreement) pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271. In March 2021, as contemplated by the Bayer License Agreement, we entered into (i) a Manufacturing and Supply Agreement (Bayer Manufacturing Agreement)&#59; (ii) a Pharmacovigilance Agreement&#59; (iii) a Quality Agreement&#59; and (iv) a Technology Transfer Agreement, in each case, with Bayer, to further advance our collaboration with Bayer. See section &#8216;Terms of Certain License and Collaboration Agreements&#8217; below for additional details. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have </span><span style="Background-color:#FFFFFF;">also </span><span style="Background-color:#FFFFFF;">entered into research collaborations with leading academic institutions such as Memorial Sloan Kettering Cancer </span><span style="Background-color:#FFFFFF;">Center (MSK), the Council of the Queensland Institute of Medical Research (QIMR Berghofer) and H. Lee Moffitt Cancer Center and Research Institute (Moffitt)</span><span style="Background-color:#FFFFFF;"> pursuant </span><span style="Background-color:#FFFFFF;">to </span><span style="Background-color:#FFFFFF;">which we </span><span style="Background-color:#FFFFFF;">acquire</span><span style="Background-color:#FFFFFF;">d</span><span style="Background-color:#FFFFFF;"> rights to novel and proprietary technologies and programs</span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pipeline</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our pipeline is </span>summarized<span style="Background-color:#FFFFFF;"> below: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="gbn5n5jlnzog000001.jpg" title="" alt="" style="width:659px;height:322px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.83%;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These investigational agents are not approved by any regulatory agencies. Efficacy and safety have not been established.</p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.83%;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBV+ PTLD: EBV-Associated Post-Transplant Lymphoproliferative Disease&#59; RR: rituximab relapsed/refractory&#59; HCT: allogeneic hematopoietic cell transplant&#59; SOT: solid organ transplant. </p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.83%;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into an agreement with Pierre Fabre to commercialize Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV+ cancers in Europe, Middle East, Africa, and other select emerging markets. </p>
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.83%;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other programs: ATA2431 (B-cell malignancies), and EBV vaccine </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Phase 2 multi-cohort study, with possible indications including EBV+ PTLD with CNS involvement, EBV+ PID/AID LPD, EBV+ LMS and other potential EBV-associated diseases.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Phase 1b/2 study in combination with anti-PD-1 therapy, KEYTRUDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pembrolizumab), in patients with platinum-resistant or recurrent EBV-associated NPC.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Targeted antigen recognition technology&#59; Phase 2 Randomized Controlled Trial.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Our CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.83%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Worldwide license agreement and research, development and manufacturing collaboration with Bayer to develop our allogeneic off-the-shelf mesothelin CAR T program (ATA3271) and autologous program (ATA2271).</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">EBV+ PTLD</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its discovery as the first human oncovirus, EBV has been implicated in the development of a wide range of diseases, including lymphomas and other cancers. EBV is widespread in human populations and persists as a lifelong, asymptomatic infection. In healthy individuals, a small percentage of T cells are devoted to keeping EBV in check. In contrast, immunocompromised patients, such as those undergoing hematopoietic cell transplants (HCT) or solid organ transplants (SOT) have a reduced ability to control EBV. Left without appropriate immune surveillance, EBV-transformed cells can, in some patients, proliferate and cause an aggressive, life-threatening cancer called <span style="Background-color:#FFFFFF;">EBV+ PTLD</span>. Nearly all cases of PTLD that occur following HCT are EBV positive while approximately 60% of PTLD cases that occur following SOT are EBV positive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historical studies suggest a high unmet medical need for improved therapies in patients with EBV+ PTLD <span style="color:#000000;">who have failed rituximab or </span>rituximab plus chemotherapy<span style="color:#000000;">, with approximately 40% to 60% </span>of patients either not responding to or progressing following this first line of therapy. Expected median overall survival in patients with EBV+ PTLD following HCT who have failed rituximab-based first line therapy is approximately 1.7 months, and for patients with EBV+ PTLD following SOT who have failed rituximab-based first line therapy, the median overall survival is approximately 3.3 months. The use of chemotherapy in patients with EBV+ PTLD <span style="color:#000000;">who have failed rituximab</span> is frequently associated with significant rates of treatment-related mortality due to the frailty of the patients and severe toxicities associated with chemotherapy. Based on our market research, we estimate there were several hundred EBV+ PTLD patients who failed rituximab or rituximab plus chemotherapy in the U.S. in 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="Background-color:#FFFFFF;"> for EBV+ PTLD</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In June 2015, we licensed certain patent rights, know-how and a library of T cells and cell lines specific to EBV from </span><span style="color:#000000;">MSK</span><span style="Background-color:#FFFFFF;"> under an exclusive license agreement. In accordance with the license agreement, we agreed to use commercially reasonable efforts to commercialize the licensed products and to make milestone payments with respect to the licensed programs and to make royalty payments to MSK to the extent product candidates arising from the collaboration are commercialized. Our most advanced product candidate, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, is part of this MSK collaboration and targets EBV.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is an allogeneic EBV-specific T-cell immunotherapy that is currently in Phase 3 development for the treatment of patients with EBV+ PTLD who have failed rituximab or rituximab plus chemotherapy. Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is also under development for other EBV+ diseases with significant unmet medical need through a Phase 2 multi-cohort study that was initiated in the third quarter of 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of patients with EBV+ PTLD&#160;after HCT who have failed rituximab, PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the same indication, and orphan designation in the U.S. and European Union (EU) for the treatment of patients with&#160;EBV+ PTLD&#160;following HCT or SOT.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In clinical studies conducted at MSK that have enrolled patients with&#160;<span style="Background-color:#FFFFFF;">EBV+ PTLD</span>&#160;following HCT and SOT, efficacy following treatment with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> monotherapy compared favorably with historical data in these patient populations. Patients with&#160;<span style="Background-color:#FFFFFF;">EBV+ PTLD</span>&#160;after HCT who have failed rituximab and were treated with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> had&#160;two-year&#160;overall survival of approximately 83% in two separate clinical studies. In the setting of&#160;<span style="Background-color:#FFFFFF;">EBV+ PTLD</span>&#160;after SOT in patients who have failed rituximab, similar results were observed, with&#160;two-year&#160;overall survival of approximately 86% in tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>-treated patients. A response rate of greater than or equal to 50% was observed in HCT and SOT patients in these studies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we initiated two Phase 3 studies for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> intended to support approval in two separate indications, the treatment of EBV+ PTLD&#160;following HCT (which was referred to as the MATCH study) and SOT in patients who have failed rituximab (which was referred to as the ALLELE study). In 2019, after discussion and alignment with regulators, we combined MATCH and ALLELE into a single study (which we now refer to as the ALLELE study) that now consists of an HCT cohort for EBV+ PTLD patients who have failed rituximab, and a single SOT cohort for EBV+ PTLD patients who have failed prior treatment with rituximab with or without chemotherapy. Additionally, we expanded the ALLELE study geographically to include clinical sites in Europe and Canada<span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, we completed an interim analysis for the ALLELE study. Data from the interim analysis showed a 50 percent objective response rate (ORR) to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> with independent oncologic and radiographic assessment (IORA) in patients with relapsed-refractory EBV+ PTLD following HCT or SOT, that had reached at least six months follow-up after the ORR assessment. This ORR is consistent with previously published investigator assessed data. The tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> safety profile is also consistent with previously published data, with no new safety signals.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Pierre Fabre Commercialization Agreement, pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia following regulatory approval. We will retain full rights to tab-cel</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in other major markets, including North America, Asia Pacific and Latin America. See section &#8216;Terms of Certain License and Collaboration Agreements&#8217; below for additional details.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we submitted, and the EMA fully validated, an EU marketing authorization application (MAA) for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in patients with EBV+ PTLD. Under the accelerated assessment granted by the EMA, review of the MAA is progressing as planned following the EMA day 80 critical assessment report and we anticipate a decision with respect to potential approval of the MAA in the fourth quarter of 2022. We are working with Pierre Fabre to prepare for the potential approval and commercialization of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2021, we presented new analysis from the ALLELE study at an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Top-line data with additional patients and extended follow up confirm a strong ORR in line with prior results, demonstrate durability of response, and supported the MAA submission. There were no new safety signals, consistent with previously published data. We also presented additional data on tab-cel<span style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> through several abstracts, including a second oral presentation on long term overall survival from Phase 2 and multi-center EAP studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We have performed extensive studies demonstrating analytical comparability between the tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> manufacturing process versions used for the pivotal ALLELE study and that intended for commercialization.&#160;&#160;Comprehensive comparability analyses included all 74 available product lots manufactured by us and covered 21 key attributes for potency, purity and alloreactivity. We believe analytic comparability between tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> process versions has been demonstrated based on well-established statistical methodology and application of International Council for Harmonization (ICH) guidelines and is further supported by significant and consistent clinical experience. These comparability data analyses were submitted to the EMA through our MAA filing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a potential BLA submission for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the United States, we have been in discussions with the FDA on the content of chemistry, manufacturing and controls (CMC) module 3, including the assessment of comparability between the product used in the pivotal ALLELE study and that intended for commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late February 2022, we held a Type B CMC meeting with the FDA to discuss and potentially align on comparability between commercial and pivotal clinical trial process versions.&#160;&#160;Preliminary meeting responses and discussion did not result in alignment on comparability and the FDA has initially recommended we conduct a clinical study with commercial product as FDA does not agree that comparability has been demonstrated between product used in the pivotal ALLELE study and the intended commercial product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have responded with additional questions to clarify the FDA&#8217;s view and proposed several alternative approaches to progress to a BLA submission. We expect additional interactions with the FDA, including receipt of final Type B CMC meeting minutes.&#160;&#160;Based on the preliminary feedback received from the FDA, we no longer expect to file a BLA in the second quarter of 2022. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to adapt our investment in pre-commercial activities and are continuing our commercial readiness activities based on the progress and timing of potential approval and commercialization of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the U.S. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="Background-color:#FFFFFF;"> Multi-Cohort Study</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to pursue development of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in additional patient populations, with a primary focus on immunodeficiency-associated lymphoproliferative diseases (IA-LPDs), given the commonality of their EBV-driven mechanism of disease in immunocompromised patients, high unmet medical need and positive clinical data to date with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="color:#000000;">. </span>In patients where previous treatments have failed, the objective response rates, including complete response, were 33.3% (three out of nine patients) in AID-LPD and 37.5% (three out of eight patients) in PID-LPD groups. Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> was generally well-tolerated with a favorable safety profile consistent with previously published clinical studies. These clinical data demonstrated that tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> was well-tolerated and showed encouraging clinical activity in this patient population, with objective response rates ranging from 50% (two out of four patients) to 80% (four out of five patients). <span style="color:#000000;">The overall survival (OS) rate at one year in patients with EBV viremia treated in the EAP-201 study was 100 percent for a median follow-up of 14.6 months (min 12.2, max 17.8).</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, we initiated a Phase 2 multi-cohort study and are actively opening sites and enrolling in six patient populations, including four within IA-LPDs and two in other EBV-driven diseases, in both the U.S. and EU. Data from this study is expected in 2023. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel</span><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="Background-color:#FFFFFF;"> for </span><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">NPC</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that is primarily associated with EBV. Standard treatment for NPC typically includes radiation therapy, platinum-based chemotherapy or a combination of both. Surgical intervention is only rarely employed and is usually only utilized in select early-stage cases. There are no approved therapeutic agents available to treat relapsed/refractory NPC, although there are multiple agents in development for this patient population. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="color:#000000;">Phase 1b study, which was initiated in 2018, achieved its safety endpoints and stable disease in some patients. </span>Due to the evolving treatment landscape of EBV-driven nasopharyngeal carcinoma (NPC), we are not actively conducting any development activities while we reassess our approach and the development and regulatory pathways for patients with platinum resistant or recurrent EBV-drive NPC. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ATA188</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Sclerosis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing ATA188, an allogeneic T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS) that disrupts the myelination and normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss. The evolution of MS results in an increasing loss of both physical and cognitive (e.g., memory) function. This has a substantial negative impact on the approximately 2.3 million patients worldwide diagnosed and living with MS, with approximately one million of those patients having a progressive form of MS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are two categories of MS: progressive MS (PMS) and relapsing-remitting MS (RRMS). RRMS is a form of MS that<span style="color:#000000;"> is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery</span> and quiescence during which the disease does not progress. PMS is a severe form of MS that is characterized by persistent progression and worsening of MS symptoms and physical disability over time for which there are few therapeutic options. There are two types of PMS: primary progressive MS (PPMS) and secondary progressive MS (SPMS). PPMS occurs when the patient has a disease course characterized by steady and progressive worsening after disease onset. SPMS initially begins as RRMS, but once patients have continuous progression of their disease, they have developed SPMS. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific and clinical findings support a potential biologic connection between EBV and MS. EBV is present in nearly all patients with MS. The MS disease course has been shown to correlate with measures of EBV activity, and with exhaustion of endogenous EBV-specific T cell populations. In addition, in separate studies, clear differences in location and frequency of EBV-infected B cells and plasma cells were evident between the brains of subjects without MS and the brains of MS patients, where EBV-infected B cells and plasma cells were in close proximity to areas of active demyelination. Further data suggest that EBV-positive B cells and plasma cells in the CNS have the potential to catalyze an autoimmune response, resulting in the typical MS pathophysiology. In patients with MS, their T cells may be unable to control EBV-positive B cells and plasma cells so that B cells and plasma cells could then accumulate in the brain, function as antigen-presenting cells and generate antibodies that attack and destroy myelin, the protective layer that insulates nerves in the brain and spinal cord. This loss of myelin ultimately leads to MS symptoms. The role of B cells in MS is supported by the approval by the FDA of ocrelizumab for PPMS, which broadly targets B cells (and not plasma cells) outside of the CNS through their expression of a cell surface marker known as CD20.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our analysis of industry data and assumed increases in treatment rates and market share for a best-in-class treatment, we estimate that the potential annual U.S. market opportunity in PMS could be at least $3.5 billion by 2025. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ATA188 for MS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We licensed rights to certain know-how and technology from QIMR Berghofer that uses targeted </span>antigen recognition to create off-the-shelf T-cell immunotherapy product candidates applicable to a variety of diseases, including autoimmune conditions such as MS. Our license agreement with QIMR Berghofer requires that we make various milestone and royalty payments to QIMR Berghofer based on the sales of products arising from this collaboration, if any. We are also working with QIMR Berghofer on the development of EBV-targeted and other virally targeted T cells. Through this technology, we are expanding the role of T-cell-based immunotherapy beyond oncology and viral infections to autoimmune diseases.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our&#160;T-cell&#160;immunotherapy product candidate utilizing this technology, ATA188</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is an off-the-shelf EBV-specific T</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cell preparation that utilizes a</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n MS-specific</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> targeted antigen recognition technology that enables the T cells we administer to selectively identify cells expressing the EBV antigens that we believe are important for the potential treatment of MS. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATA188 is </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designed to selectively target only those cells which are EBV-positive while sparing those that are not. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent studies published in </span><span style="font-style:italic;">Science</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-style:italic;">Nature</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provide new epidemiological </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suggesting</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that EBV</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is the leading cause</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of MS</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and mechanistic data suggesting EBV infection can initiate and propagate the autoimmune attack on the brain in MS. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that eliminating only EBV-positive B cells and plasma cells has the potential to benefit some patients with </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MS</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and SPMS.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2017, we initiated an open label, single arm, multi-center, multi-national Phase 1 study with allogeneic ATA188 for patients with PMS. The primary objective of this Phase 1 study is to assess the safety of ATA188 in patients followed for at least one year after the first dose. Key secondary endpoints in the study include measures of clinical improvement, using recognized scales for MS symptoms, function and disability including Expanded Disability Status Scale (EDSS), Fatigue Severity Score, MS Impact Scale-29 (physical), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test, 12-Item MS Walking Scale (MSWS-12) and Visual Acuity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment for the fourth and final dose escalation cohort in the Phase 1a portion of the study was completed in the third quarter of 2019 and we presented updated efficacy and safety results from this study at the MSVirtual2020: 8<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Joint ACTRIMS-ECTRIMS Meeting in September 2020. The data demonstrated that ATA188 was well-tolerated across all four dose cohorts, with no dose-limiting toxicities and no fatal adverse events. Additionally, patients who demonstrated sustained disability improvement (SDI) at any timepoint maintained improvement at all future timepoints, and higher proportion of patients showed SDI with increasing dose (42% in cohorts 3 and 4 (higher doses) versus 17% in cohorts 1 and 2 (lower doses)). SDI is defined as clinically significant improvement in EDSS or T25FW observed at two consecutive time points. ATA188 treatment showed no clinically meaningful effect on cytokine levels and no dose-related safety trends were identified. Rhinorrhea (runny nose) was the only treatment-related event that occurred in more than one subject. No dose-limiting toxicities and no fatal adverse events have been reported. The safety profile has remained consistent with previously reported data. We also presented preclinical translation data at ACTRIMS-ECTRIMS that further support the proposed mechanism of action of ATA188 targeting EBV-infected B cells. These combined analyses of T cells comprising ATA188 are consistent with its proposed mechanism of targeting EBV-infected B cells by recognizing MS-relevant EBV antigens on these cells via defined TCRs. While these data will need to be confirmed in a double-blind, placebo-controlled, randomized study, they indicate the potential for the first treatment option in PMS to halt or reverse the progression of disease. We believe these results align with the body of evidence supporting the important role of EBV-infected B cells in the chronic autoimmune pathology of MS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently progressing an open-label extension (OLE) of the Phase 1 study of ATA188 for patients with primary and secondary PMS. We presented long-term two-year clinical data from the OLE and translation data from the Phase 1 study in October 2021 at the 37<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Based on the clinical data, <span style="color:#000000;">most patients either demonstrated sustained disability improvement or stable disease</span>. The presentation also featured new imaging biomarker data considered to reflect the state of myelination in the central nervous system, known as magnetization transfer ratio (MTR). MTR may provide important insights into the mechanism of EDSS improvement in our clinical assessment of ATA188.&#160;&#160; We also presented encore data at <span style="color:#000000;">the 29th Annual Meeting of the European Charcot Foundation in November 2021, including an overview of the methodology planned to determine the potential pharmacodynamic effect of ATA188, by quantifying a decrease of EBV infected cells following treatment with ATA188. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we enrolled the first patient in our Phase 2, randomized, double-blind, placebo-controlled <span style="color:#000000;">dose-expansion trial (EMBOLD) </span>to evaluate the efficacy and safety of ATA188 in patients with PMS<span style="color:#000000;"> and we continue to enroll patients in this study</span>. Based on the data from the Phase 1a portion of the study, we selected the cohort 4 dose for enrollment in the Phase 2 EMBOLD study. In addition to measuring change in disability measures compared to baseline, especially SDI over time, the study also includes multiple measures of patients&#8217; function as well as various biomarkers.<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, we discussed updates to the design of the EMBOLD study with the FDA and gained alignment on several points, as well as potential registrational studies: (i) a disability improvement endpoint is appropriate, with the FDA articulating a preference for EDSS improvement&#59; (ii) the criteria used to enroll the study population of SPMS and PPMS are appropriate&#59; and (iii) the Phase 2 trial should run for at least 12 months, and a properly conducted interim analysis is appropriate. We also submitted a protocol amendment to the FDA, increasing the number of patients to 80, changing the primary end point of the study to EDSS disability improvement and maintaining the biological and functional endpoints. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submitted a request for fast track designation for ATA188 for treatment of PPMS and SPMS, and <span style="color:#231F20;">in December 2021 the FDA granted fast track designation to ATA188 for treatment of PPMS and SPMS. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to advance enrollment in the EMBOLD study and expect to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> planned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formal </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interim analysis of the EMBOLD study in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">second quarter</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to assess efficacy</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> safety</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and biomarker data to inform adjustments to sample size, if needed, and to confirm our development strategy moving forward</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Following completion of the interim analysis, w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e plan to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discuss potential development pathways for ATA188 with the FDA and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">communicate our decision on next steps for the program, including rationale, while maintaining the integrity of the study. We expect to complete</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> target</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enrollment</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in this study</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shortly after completion of the interim analysis</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CAR T Programs </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current CAR T pipeline is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><img src="gbn5n5jlnzog000002.jpg" title="" alt="" style="width:662px;height:259px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DNR: Dominant Negative Receptor</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Worldwide license agreement and research, development and manufacturing collaboration with Bayer to develop Atara&#8217;s allogeneic off-the-shelf mesothelin CAR T program (ATA3271) and autologous program (ATA2271)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ATA2271/ATA3271</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our next-generation CAR T immunotherapy programs include autologous ATA2271 and allogeneic ATA3271 targeting mesothelin, which is a tumor antigen expressed on a number of solid tumors including mesothelioma, ovarian cancer, pancreatic cancer, non-small cell lung cancer and other tumors over-expressing mesothelin</span><span style="Background-color:#FFFFFF;color:#000000;">. </span><span style="Background-color:#FFFFFF;">Both programs were licensed to Bayer</span><span style="Background-color:#FFFFFF;color:#000000;"> in December 2020,</span><span style="Background-color:#FFFFFF;"> pursuant to an exclusive, field-limited license (the Bayer License Agreement).</span><span style="Background-color:#FFFFFF;color:#000000;"> See section &#8216;Terms of Certain License and Collaboration Agreements&#8217; below for additional details.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we entered into several agreements to expand our collaboration with MSK to the development of CAR T immunotherapies, with a license in May 2018 related to multiple collaboration targets and a license in December 2018 related to our next-generation CAR T program targeting mesothelin. Under these<span style="Background-color:#FFFFFF;color:#000000;"> CAR T agreements, we agreed to use commercially reasonable efforts to develop, obtain regulatory approval and, if approved, commercialize certain collaboration targets and to make certain milestone and royalty payments. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ATA2271 is designed to improve efficacy persistence, and durability of response versus CD28/CD3z-based CARs by using a novel 1XX CAR co-stimulatory signaling domain and cell intrinsic checkpoint inhibition technology with a PD-1 dominant negative receptor (DNR). Data from investigational new drug application (IND) enabling studies for ATA2271 were presented at the American Association for Cancer Research (AACR) Virtual Meeting II in June 2020. These data support the first application of the combination of 1XX co-stimulatory domain and cell intrinsic checkpoint inhibition technology with a PD-1 DNR that are associated with less cell exhaustion, improvements in functional persistence, serial cell killing and in vivo efficacy, which was maintained through multiple tumor re-challenges when compared with first-generation CD28/CD3z-based mesothelin CAR. The FDA accepted the IND application submitted by our collaborators at MSK in August 2020, and in September 2020, MSK initiated an open-label, single-arm Phase 1 clinical study of ATA2271 for patients with advanced mesothelioma. The first preclinical, clinical and translational data from the lowest dose cohorts of this study, demonstrating early safety and persistence of ATA2271, was presented during a mini oral </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">session at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in December 2021. MSK has enrolled </span><span style="Background-color:#FFFFFF;">and dosed the third cohort of</span><span style="Background-color:#FFFFFF;"> this study</span><span style="Background-color:#FFFFFF;">. </span><span style="color:#000000;">In February 2022, MSK notified the FDA of a fatal serious adverse event associated with a patient treated in the third, higher dose cohort in this study. MSK has voluntarily paused enrollment of new patients in this study on a temporary basis while additional information regarding this case is gathered and reviewed. The FDA notified MSK of its agreement with MSK&#8217;s decision. Subject to the outcome of this review and resumption of enrollment of new patients in this study</span><span style="color:#000000;">,</span><span style="Background-color:#FFFFFF;"> we expect </span><span style="Background-color:#FFFFFF;">to provide a data update from this </span><span style="Background-color:#FFFFFF;">Phase 1 study in </span><span style="Background-color:#FFFFFF;">2022.</span><span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are also developing and continue to advance the IND-enabling studies for ATA3271, an off-the-shelf, allogeneic CAR T therapy targeting mesothelin using a PD-1 DNR and 1XX CAR co-stimulatory signaling domain through our EBV T-cell platform, and we expect our partner Bayer to file the IND in the fourth quarter of 2022. We do not believe the temporary pause in the ATA2271 study enrollment impacts the IND-enabling work to advance ATA3271, a separate, off-the-shelf, allogeneic CAR T therapy. Preclinical data for ATA3271 demonstrates, we observed anti-tumor activity that we believe indicated functional persistence and significant survival benefit, and we found no evidence of allocytotoxicity in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers. These data were presented at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting in November 2020. In November 2021, we presented additional preclinical data for ATA3271 at the SITC 36th Annual Meeting. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ATA3219</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are also developing ATA3219, an off-the-shelf, allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies as a potential best-in-class therapy without the need for TCR gene editing, using our next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform. While other approaches use gene editing to address alloreactivity and potential graft-vs-host disease (GVHD), our EBV T-cell platform does not require TCR gene editing and leverages partial matching for the EBV T-cell and the patient HLA genotype, which has not shown any signs of product-associated GVHD in patients. Data from preclinical studies for ATA3219 suggest enhanced functional persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells both in vitro and in vivo with a manufacturing process that focuses on T cell stemness. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on academic data from a clinical study, an EBV T-cell platform has the potential to generate off-the-shelf, allogeneic CAR T immunotherapies with high response rates, durable responses and low risk of toxicity that can be rapidly delivered to patients. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We continue to make progress on IND-enabling studies and plan to submit an IND for ATA3219 for patients with B-cell malignancies in the fourth quarter of 2022</span><span style="Background-color:#FFFFFF;color:#000000;">. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Programs and Platform Expansion Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the prioritized programs described above, we have a number of preclinical programs. We are collaborating with Moffitt to develop ATA2431, a multi-targeted CAR T immunotherapy targeting B-cell malignancies. We are also collaborating with QIMR Berghofer to develop a potential next generation EBV vaccine which is differentiated from earlier EBV vaccine efforts that solely focused on B cell responses to EBV. We have also discontinued some preclinical programs and returned them to our collaborators. For example, we returned ATA2431, an acute myeloid leukemia (AML) program, to Moffitt in August 2021 and returned the ATA368 program for patients with human papillomavirus (HPV) associated cancers to QIMR Berghofer in December 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our platform will have utility beyond the current set of targets to which it has been directed. <span style="Background-color:#FFFFFF;color:#000000;">We continue to evaluate additional product candidates, including those derived from collaborations with our partners</span>. We also continue to evaluate opportunities to license or acquire additional product candidates or technologies to enhance our existing platform. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions for our current product candidates. Some of these competitors or potential competitors have significantly greater established presences in the market, financial resources and technical expertise than we do. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our T-cell product candidates be approved for use, we will face substantial competition. In addition to the current standard of care for patients, commercial and academic clinical </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are being pursued by a number of parties in the field of immunotherapy. Early results from these </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have fueled continued interest in T-cell immunotherapy. In addition, if approved, our T-cell programs would compete with currently marketed drugs and therapies used for treatment of the indications we are addressing, and potentially with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> candidates currently in development for the same indications.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EBV+ PTLD<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no FDA- or EMA-approved products for the treatment of EBV+ PTLD. However, some marketed products and therapies are used off-label in the treatment of EBV+ PTLD, such as rituximab and combination chemotherapy regimens. In addition, a number of companies and academic institutions are developing product candidates for EBV+ PTLD and other EBV-driven diseases including: Viracta Therapeutics, Inc., which is conducting a pivotal, Phase 2 clinical study for nanatinostat (formerly named tractinostat, or VRx-3996) in combination with antiviral drug valganciclovir in relapsed/refractory EBV+ lymphomas&#59; AlloVir (formerly known as ViraCyte), which has completed a Phase 2 clinical study for posoleucel (formerly named Viralym-M, (ALVR105)), an allogeneic, multi-virus T-cell product that targets six viruses in allogeneic HSCT recipients with &#8805;1 treatment-refractory infection, including EBV, and is conducting a pivotal study for Virus-Associated Hemorrhagic-Cystitis, as well as a Phase 2 proof of concept trial for the prevention of BKV, CMV, AdV, EBV, HHV06 and JCV in post-allogeneic HSCT patients&#59; and Tessa Therapeutics Pte Ltd., is conducting a Phase 12 clinical study of its autologous CD30 CART in CD30+ NHL and funding a Phase 1, investigator-sponsored study at Baylor College of Medicine, for its allogeneic CD30-CAR EBVST product candidate. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Multiple Sclerosis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition in the MS market is high with at least 20 therapies, including four generics or bioequivalents, approved in the U.S. and EU for the treatment of various forms of MS, including clinically isolated syndrome, relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). There are many competitors in the MS market, including major multi-national fully-integrated pharmaceutical companies and established biotechnology companies. Most recently, Ponvory (S1P modulator), marketed by Johnson &#38; Johnson, and Kesimpta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (anti-CD20 monoclonal antibody), marketed by Novartis, were approved in the U.S. and/or EU for the treatment of relapsing forms of MS. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous development candidates in Phase 3 studies for both relapsing and/or progressive forms of MS and additional novel agents could be approved in either or both indications in the future including TG Therapeutics&#8217; anti-CD20 monoclonal antibody ublituximab (estimated PDUFA 09/2022), Merck KGaA&#8217;s Bruton&#8217;s tyrosine kinase (BTK) inhibitor, evobrutinib, Roche&#8217;s BTK inhibitor, fenebrutinib, Sanofi&#8217;s BTK inhibitor, tolebrutinib and AB Science&#8217;s tyrosine kinase inhibitor, masitinib. Medicinova is planning to initiate a Phase 3 study of its PDE inhibitor, ibudilast (MN166) in non-active SPMS. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CAR T Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently five autologous CAR T therapies approved in the U.S. and/or EU: Novartis&#8217; Kymriah<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (tisagenlecleucel), Gilead/Kite&#8217;s Yescarta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (axicabtagene ciloleucel) and TecartusTM (brexucabtagene autoleucel) and Bristol-Myers Squibb&#8217;s Breyanzi<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel) with bluebird bio. There are many CAR-mediated cell therapies in development, and, although the majority are autologous, they include allogeneic and off-the-shelf cell therapies. There are multiple allogeneic CAR platforms being developed with differences in approaches to minimize instances of donor cells recognizing the patient&#8217;s body as foreign or rejection of the donor cells by the patient&#8217;s body. These approaches include the use of gene-editing to remove or inhibit the TCR and the use of cell types without a TCR. The majority of clinical stage allogeneic CAR programs utilize alpha beta T cells as the cell type and gene editing of the T-cell receptor and HLA as the preferred technology approach, however, other strategies are also in development. It is possible that some of these other approaches will have more favorable characteristics than the approach we utilize, which may result in them being favored by potential partners or customers over our products. Depending on the diseases that we target in the future, we may face competition from both autologous and allogeneic CAR therapies and other modalities (e.g., small molecules, antibodies) in the indication of interest. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Terms of Certain License and Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Out-licensing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bayer License and Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we entered into the Bayer License Agreement, pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271 (the Licensed Products), in each case, targeting mesothelin. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Bayer License Agreement, we will be responsible at our cost for all mutually agreed preclinical and clinical activities for ATA2271 through the first in human Phase 1 clinical study</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in collaboration with MSK</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, following which Bayer will be responsible for the further development of ATA2271 at its cost. Bayer will be responsible for the development of ATA3271, except for certain mutually agreed preclinical, translational, manufacturing and supply chain activities to be performed by us relating to ATA3271, in each case at Bayer&#8217;s cost. Bayer will also be solely responsible for commercializing the Licensed Products at its cost.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we received an upfront cash payment of $45.0 million from Bayer for the exclusive license grant, and an additional $15.0 million upfront reimbursement payment for certain research and process development activities to be performed by us. We are also entitled to receive (i) up to $5.0 million for additional, specified translational activities under the Bayer License Agreement and (ii) an aggregate of up to $610.0 million in milestone payments upon achieving certain development, regulatory and commercial milestones relating to the Licensed Products. In addition, we are eligible to receive from Bayer tiered royalties at percentages up to low double digits on worldwide net product sales of the Licensed Products on a country-by-country and product-by-product basis until the later of 12 years after the first commercial sale in such country or the expiration of specified patent rights in such country, subject to certain reductions and aggregate minimum floors. We also granted Bayer a time limited, non-exclusive right to negotiate a license to additional Atara CAR-T product candidates if we decide to pursue an out-license of such CAR-T product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, as contemplated under the Bayer License Agreement, we entered into (i) a Manufacturing and Supply Agreement (Bayer Manufacturing Agreement)&#59; (ii) a Pharmacovigilance Agreement&#59; (iii) a Quality Agreement&#59; and (iv) a Technology Transfer Agreement (Bayer Tech Transfer Agreement), to further advance our collaboration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bayer Tech Transfer Agreement defines the transfer to Bayer of the ATA3271 manufacturing process being developed as part of the CMC services in the Bayer License Agreement. Upon entering into this agreement, we invoiced Bayer 20 percent of the total fee of $15.3 million under the Bayer Tech Transfer Agreement, or $3.1 million, which we received in the second quarter of 2021 and invoiced 40 percent of the total fee, or $6.1 million, in January 2022. The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bayer Manufacturing Agreement defines the terms for the manufacture of Phase 1 and 2 allogeneic mesothelin-directed CAR T-cell therapies for Bayer to use in clinical trials at a price based on our costs plus a reasonable margin, which is consistent with our standalone selling price. Under the Bayer Manufacturing Agreement, we will also provide storage and distribution services to Bayer at a price that is consistent with our standalone selling price for these services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the Bayer Manufacturing Agreement, Bayer submitted, and we approved, a binding purchase order for manufacturing services and storage services. Any fees for the manufacturing services will be invoiced as follows: (i) 50 percent upon written acceptance by us of the binding purchase order, and (ii) the remainder upon delivery of the certification of analysis of such lots to Bayer. Storage and distribution services are billed monthly as those services are provided to Bayer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we invoiced Bayer 50 percent of the total estimated supply price of $13.1 million for manufacturing services under the initial purchase order for the supply of six lots, or $6.6 million, which we received in the second quarter of 2021. The remainder of the supply price will be billed upon the release of the lots ordered by Bayer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pierre Fabre Commercialization Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Pierre Fabre Commercialization Agreement, pursuant to which, we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia (the Territory) following regulatory approval. Atara will retain full rights to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in other major markets, including North America, Asia Pacific and Latin America. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible at our cost for the conclusion of the ongoing Phase 3 ALLELE clinical study and the Phase 2 multi-cohort clinical study. We will also be responsible at our cost for certain other activities directed to obtaining regulatory approval for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV-positive lymphoproliferative disease pursuant to the terms of the Pierre Fabre Commercialization Agreement in Europe. Pierre Fabre will be responsible at its cost for obtaining and maintaining all other regulatory approvals and for commercialization and distribution of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the Territory. We will own any intellectual property rights developed solely by us under the Pierre Fabre Commercialization Agreement. We are responsible for manufacturing and supplying Pierre Fabre with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for commercialization in the Territory at Pierre Fabre&#8217;s cost. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2021, Pierre Fabre has paid us an upfront cash payment of $45.0 million for the exclusive license grant. We are also entitled to receive an aggregate of up to $318.0 million in milestone payments upon achieving certain regulatory and commercial milestones. In addition, we are eligible to receive significant double-digit tiered royalties as a percentage of net sales of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> until the later of 12 years after the first commercial sale in such country, the expiration of specified patent rights, or the expiration of all regulatory exclusivity for such product on a country-by-country basis. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">In-licensing</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">MSK License and Collaboration Agreements<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, we entered into a license agreement with MSK, under which MSK granted us a worldwide, exclusive license to certain patent rights, know-how and a library of T cells and cell lines, to research, develop, manufacture and commercialize three clinical stage T-cell therapies. We are obligated to make payments to MSK based on achievement of specified regulatory and sales-related milestones, as well as mid single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. In addition, under certain circumstances, we must make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also obligated to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. The license agreement expires on a licensed product-by-product and country-by-country basis, on the latest of: (i) expiration of the last licensed patent rights related to a licensed product, (ii) expiration of any market exclusivity period granted by law with respect to a licensed product, and (iii) a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May and December 2018, we licensed additional technology from MSK. We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we amended and restated our license agreement with MSK to: (i) terminate our license to certain rights related to WT1 and cytomegalovirus (&#8220;CMV&#8221;)&#59; and (ii) license additional know-how rights not otherwise covered by our existing agreements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">QIMR Berghofer License and Collaboration Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive and worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology. We exercised this option in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to terminate our license to certain rights related to cytomegalovirus (CMV). In addition, we further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2020 to terminate our license to certain rights related to BK polyomavirus and JC polyomavirus. In December 2021, we further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer to terminate our license to certain rights related to HPV associated cancers. We refer to our August 2020 third amended and restated license agreement with QIMR Berghofer as the QIMR License Agreement and our August 2020 third amended and restated research and development collaboration agreement with QIMR Berghofer as our QIMR Collaboration Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The QIMR License Agreement provides for various milestone and low to mid single-digit royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of the QIMR Collaboration Agreement, we are required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. The QIMR Collaboration Agreement also provides for various milestone payments to QIMR Berghofer based on the achievement of certain developmental and regulatory milestones. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. We seek to protect our proprietary position by, among other methods, filing U.S. and non-U.S. patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. Some of patents, trademarks, trade secrets, know-how and other intellectual property rights we rely on are owned by us and others are in-licensed from our partners. When we refer to &#8220;our&#8221; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license. Additionally, we expect to benefit from a variety of statutory frameworks in the U.S., Europe and other countries that relate to the regulation of biosimilar molecules and orphan drug status. These statutory frameworks provide certain periods of regulatory exclusivity for qualifying molecules. See &#8220;Government Regulation.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patents</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek composition-of-matter and/or associated method patents, including method-of-treatment patents, for each of our product candidates in key therapeutic areas. The U.S. patent system permits the filing of provisional and non-provisional patent applications. A provisional patent application is not examined for patentability by the U.S. Patent and Trademark Office (USPTO), and automatically expires 12 months after its filing date. As a result, a provisional patent application cannot mature into an issued patent. Provisional patent applications are often used, among other things, to establish an early effective filing date for a later-filed non-provisional patent application. A non-provisional patent application is examined by the USPTO and can mature into a patent once the USPTO determines that the claimed invention meets the standards of patentability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual patents extend for varying periods of time depending on the date of filing of the patent application, the priority date claimed, and the legal term of patents as determined by the applicable law in the countries in which those patents are obtained. Generally, patents issued from applications filed in the U.S. are effective for 20 years from the earliest non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period&#59; however, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. Additionally, patent term adjustments can extend term to account for certain delays by the USPTO during prosecution before that office. The duration of non-U.S. patents varies in accordance with provisions of applicable local law, but typically, the life of a non-U.S. patent is 20 years from the earliest international filing date, not inclusive of any patent term extension that may be available. The actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of extensions of patent term, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National and international patent laws concerning protein-based biologics such as our products remain highly unsettled. No consistent policy regarding the patent-eligibility or the breadth of claims allowed in patents in this field has emerged to date among the U.S., Europe or other countries. Changes in either the patent laws or in interpretations of patent laws in the U.S. or other countries can diminish our ability to protect our inventions and enforce our intellectual property rights. Accordingly, we cannot predict the breadth or enforceability of claims that may be granted in our patents or in third-party patents. The biotechnology and pharmaceutical industries are characterized by extensive intellectual property litigation. Our ability to maintain and solidify our proprietary position for our product candidates and technology will depend on our success in obtaining effective claims for our patents and enforcing those claims once a patent is granted. We do not know whether any of our patent applications will result in the issuance of any patents. Our issued patents may be challenged, invalidated or circumvented, and the rights granted under any issued patents may not provide us with sufficient protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop and commercialize similar drugs or duplicate our technology, business model or strategy without infringing our patents. Because of the extensive time required for clinical development and regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our global patent estate consists of both solely-owned and in-licensed patents and patent applications, is directed to compositions of matter and/or associated methods, including methods of treatment, and consists of 33 patent families having a total of more than 290 issued patents or patent applications. Our patents and patent applications (if issued) are expected to expire between 2023 and 2042, not inclusive of any patent term extension that may be available in any associated jurisdiction. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Trade Secrets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed by an employee. These agreements may be breached, and we may not have adequate remedies for any such breach or any unauthorized disclosure of our proprietary information. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Trademarks</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely upon trademarks to develop and maintain our competitive position, and we continue to pursue and obtain trademark rights relating to our business. We have a vigorous global program of trademark registration and enforcement to maintain and strengthen the value of our trademarks and prevent the unauthorized use of those trademarks. Our global trademark portfolio consists of sixteen different trademark families comprised of more than 178 registrations and pending applications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approval</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our T-cell immunotherapies, if approved, will be products regulated as biological products, or biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with current good manufacturing practice (cGMP) for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our product candidates are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, tracking and tracing, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the U.S. and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Product Development Process </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act (FDCA), the Public Health Service Act (PHSA), and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or other enforcement letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the U.S. generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices (GLPs), and applicable requirements for the humane use of laboratory animals or other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval by an independent Institutional Review Board (IRB), or ethics committee at each clinical site before the trial is commenced&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices (GCPs), and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency of the drug from analytical (CMC) studies and from results of nonclinical testing and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">satisfactory completion of an FDA Advisory Committee review, if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices (GTPs) for the use of human cellular and tissue products&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">potential FDA </span><span style="color:#000000;">inspection</span><span style="color:#000000;"> of the nonclinical study and clinical trial sites that generated the data in support of the BLA</span><span style="color:#000000;">&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval, i.e., licensure of the product candidate that is the subject of the BLA. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including applicable GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical trial protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to unacceptable and significant risks to clinical trial subjects or non-compliance with FDA requirements. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent document that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Phase 1</span><span style="color:#000000;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Phase 2</span><span style="color:#000000;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Phase 3</span><span style="color:#000000;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and to investigators for serious and unexpected adverse events, findings from other studies that suggest a significant risk in humans exposed to the drug, laboratory animal testing or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over the rate listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the FDCA, PHSA and FDA&#8217;s implementing regulations emphasize the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product, FDA approval of a BLA for an innovator biological product must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, as amended (PDUFA), each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees for licensed innovator biological products on an annual basis. PDUFA also imposes an annual program fee for innovator biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for innovator biological products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also determines whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit and obtain approval for a proposed REMS. The FDA will not approve a BLA without a REMS, if required. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and cellular and tissue-based products (HCT/Ps), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act (PREA), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those pediatric study plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant deferrals for submission of data or full or partial waivers on its own initiative or at the request of the applicant. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. Pediatric exclusivity is a type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied&#59; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drug Designation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug or biologic for this type of disease or condition will be recovered from sales in the U.S. for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expedited </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development and </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Review </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Programs</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product, submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. The FDA intends to take action on applications under priority within 6 months of the application filing date, compared with 10 months from the filing date for regular applications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies to demonstrate clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regenerative Medicine Advanced Therapy (RMAT) designation was established by FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions&#59; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition&#59; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records&#59; through the collection of larger confirmatory datasets&#59; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of Fast Track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. In addition, the FDA may revoke any of these designations if the product no longer meets applicable criteria. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-Approval Requirements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physician deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product&#8217;s approved labeling.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription drug products, including most biological products that require a prescription, are subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Marketing Exclusivity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act (BPCIA), amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish that its molecule is highly similar to an approved innovator biologic, notwithstanding minor differences in clinically inactive components, and shows no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, which can generally be shown through analytical studies, animal studies, and a clinical study or studies. Separately, a product that is biosimilar to the reference product is considered interchangeable if the product demonstrates that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the interchangeable biosimilar and the reference biological product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. A product shown to be biosimilar or interchangeable with an FDA-approved reference biologic which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles and have slowed implementation of the BPCIA by the FDA. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA, however, bars the submission of BLAs for biosimilars to an approved application until four years after the licensure date for the reference biologic. In addition, the FDA may not approve biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. During this 12-year period of reference product exclusivity, another company may obtain FDA licensure and market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests, and the innovator company completes pediatric clinical investigations of the product. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and, if approved, marketing of biosimilars is subject to user fees under the Biosimilar User Fee Amendments of 2017 (BsUFA), which currently apply through September 2022 and may be renewed or amended thereafter. Sponsors must submit an initial biosimilar biological product development (BPD) fee on the earlier of the submission of an IND or within 5 calendar days of FDA granting a first BPD meeting, and annually thereafter until the sponsor submits a BLA that is accepted for filing, or the sponsor discontinues participation in the BPD program. Sponsors who discontinue participation in the BPD program but want to reengage FDA on product development must also pay a reactivation fee and will be subject to annual BPD fees. Once a sponsor submits a BLA for a biosimilar, they are subject to application fees. And, once a biosimilar BLA is approved, the sponsor is subject to annual program fees. FDA amends the specific fee amounts under BsUFA are amended on an annual basis. BsUFA currently applies through September 2022, and may be renewed or amended thereafter. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, there has been discussion of whether Congress should reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation of the BPCIA is subject to significant uncertainty. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In both domestic and foreign markets, sales and reimbursement of any approved products will depend, in part, on the extent to which the costs of such products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. Third-party payors determine which medications they will cover and establish reimbursement levels. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the U.S. Third-party payors in the U.S. often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our drug products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party payors are increasingly challenging the prices charged for medical products and services and imposing controls to manage costs. The containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. <span style="color:#000000;">In the U.S. there have been several recent Congressional inquiries and </span>proposed<span style="color:#000000;"> and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. For example, included in the </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">Consolidated Appropriations Act of 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the Departments of Health and Human Services, Labor and the Treasury. Additionally, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drugs, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, the Department of Health and Human Services issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation.</span><span style="color:#000000;"> </span><span style="color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within the U.S., if we obtain appropriate approval in the future to market any of our product candidates, we may seek approval and coverage for those products under Medicaid, Medicare and the Public Health Service (PHS), pharmaceutical pricing program and also seek to sell the products to federal agencies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, manufacturers are required to pay a rebate for each unit of a covered outpatient drug reimbursed by the state Medicaid programs. The amount of the rebate for each product is set by law and may be subject to an additional discount if certain pricing increases more than inflation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare is a federal program administered by the federal government that covers individuals age 65 and over as well as those with certain disabilities. Medicare Part D provides coverage to enrolled Medicare patients for self-administered, outpatient drugs (i.e., drugs typically dispensed by a pharmacy and that do not need to be administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, subject to CMS rules and requirements, which the drug plan may modify from time-to-time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare Part B covers most injectable drugs given in an in-patient setting, and some drugs administered by a licensed medical provider in hospital outpatient departments and doctors&#8217; offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the responsibility of making coverage decisions in accordance with CMS rules and requirements. Subject to certain payment adjustments and limits, Medicare generally pays for Part B covered drugs based on a percentage of manufacturer-reported average sales price. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for a drug product to be covered and paid for by certain federal agencies and for coverage under Medicaid, Medicare Part B and the PHS pharmaceutical pricing program, commonly referred to as the 340B Drug Pricing Program. FSS pricing is negotiated periodically with the Department of Veterans Affairs. FSS pricing is intended to not exceed the price that a manufacturer charges its most-favored non-federal customer for its product. In addition, prices for drugs purchased by the Veterans Administration, Department of Defense (including drugs purchased by military personnel and dependents through the TRICARE retail pharmacy program), Coast Guard, and PHS are subject to a cap on pricing (known as the &#8220;federal ceiling price&#8221;) and may be subject to an additional discount if pricing increases more than inflation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To maintain coverage of drugs under the Medicaid Drug Rebate Program, manufacturers are required to extend discounts to certain purchasers under the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive health services grants from the PHS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the Affordable Care Act), which included changes to the coverage and payment for drug products under government health care programs. Since its enactment, there have been judicial and Congressional challenges to numerous elements of the Affordable Care Act, as well as efforts by both the executive and legislative branches of the federal government to repeal or replace certain aspects of the Affordable Care Act. For example, former President Trump signed Executive Orders designed to eliminate the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. In addition, the U.S. Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the Affordable Care Act, such as removing penalties, starting January 1, 2019, for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance, delaying the implementation </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of certain mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. In December 2019, the U.S. Court of Appeals for the 5th Circuit upheld a District Court ruling that the individual mandate was unconstitutional and remanded the case back to the Texas District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. The U.S. Supreme Court granted certiorari on March 2, 2020 and heard oral arguments on November 10, 2020. On June 17, 2021, the U.S. Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments. On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the healthcare reform measures of the Biden administration and any future litigation will impact the Affordable Care Act and our business. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Health Care Laws</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products. As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal healthcare Anti-Kickback Statute, which, for example, governs our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws that impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government&#59; the FDCA and PHSA, which prohibit the misbranding and adulteration of biological products that are regulated as drugs, and which regulate the marketing of biological products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information as well as their covered subcontractors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Physician Payments Sunshine Act, implemented as the Open Payments Program, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations. Beginning in 2022, applicable manufacturers are also required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">state and foreign laws and regulations that are analogous to the federal laws and regulations described in the preceding subsections of this risk factor, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government&#59; including those that require drug manufacturers to report information regarding pricing and marketing information related to payments and other transfers of value to physicians and other healthcare providers as well as those that require the registration of pharmaceutical sales representatives. Some state laws require the protection of the privacy and security of health information in a manner that may differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, California enacted the California Consumer Privacy Act (CCPA), effective January 1, 2020, and the California Privacy Rights Act of 2020 (CPRA) was recently approved by California voters&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">similar healthcare and privacy laws and regulations in the European Economic Area (EEA), the UK and other jurisdictions, such as, the General Data Protection Regulation (EU) 2016/679 (GDPR), which imposes obligations and restrictions on the collection and use of personal information relating to individuals located in the EEA (including health information). </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement, and the curtailment or restructuring of our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we are subject to a variety of foreign regulations governing clinical studies and commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we may commence clinical studies or market products in those countries or areas. The approval process and requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain countries outside of the U.S. have a process that requires the submission of a CTA, which is much like an IND in the U.S., prior to the commencement of human clinical studies. In the EU, for example, in accordance with the requirements of the EU Clinical Trials Directive, as implemented in national law by Member States, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical studies. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical study development may proceed in that country. In all cases, the clinical studies must be conducted in accordance with GCP and other applicable regulatory requirements. In 2014, a new Clinical Trials Regulation 536/2014, replacing the current directive, was adopted. The new Regulation will become directly applicable in all EU Member States (without national implementation) once the EU Portal and Database are fully functional. It is expected that the Regulation will apply in late 2021. The new Regulation seeks to simplify and streamline the approval of clinical trials in the European Union. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State, who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under EU regulatory systems, a company may submit marketing authorization applications under centralized or decentralized, or mutual-recognition procedures. We expect to utilize the centralized procedure, which is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing application is submitted to the EMA, where it will be evaluated by the Committee for Medicinal Products for Human Use. If this committee delivers a favorable opinion, this typically results in the grant by the European Commission of a single marketing authorization that is valid for all EU member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. C<span style="letter-spacing:0.05pt;">onditiona</span>l<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">marketin</span>g<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">authorization</span> in the European Union is permitted<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">base</span>d<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">incomplet</span>e<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">clinica</span>l<span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:0.05pt;">dat</span>a<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">fo</span>r<span style="letter-spacing:0.3pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span><span style="letter-spacing:0.05pt;">limite</span>d<span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:0.05pt;">numbe</span>r<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">medicina</span>l<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">product</span>s<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">fo</span>r<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">human use</span>,<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">includin</span>g<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">product</span>s<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">designate</span>d<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">a</span>s<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">orpha</span>n<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">medicina</span>l<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">product</span>s<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">unde</span>r<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">EU</span><span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">law</span>,<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span>f<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">(1</span>)<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">risk-benefi</span>t<span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:0.05pt;">balanc</span>e<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">produc</span>t<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">i</span>s<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">positive</span>,<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">(2</span>)<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>t<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">is </span>likely<span style="letter-spacing:0.4pt;"> </span>that<span style="letter-spacing:0.3pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>applicant<span style="letter-spacing:0.65pt;"> </span>will<span style="letter-spacing:0.3pt;"> </span>be<span style="letter-spacing:0.2pt;"> </span>in<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.1pt;"> </span>position<span style="letter-spacing:0.55pt;"> </span>to<span style="letter-spacing:0.15pt;"> </span>provide<span style="letter-spacing:0.55pt;"> </span>the<span style="letter-spacing:0.25pt;"> </span>required<span style="letter-spacing:0.6pt;"> </span>comprehensive<span style="letter-spacing:1pt;"> </span>clinical<span style="letter-spacing:0.5pt;"> </span>study<span style="letter-spacing:0.3pt;"> </span>data,<span style="letter-spacing:0.35pt;"> </span>(3)<span style="letter-spacing:0.25pt;"> </span>unmet<span style="letter-spacing:0.45pt;"> </span>medical<span style="letter-spacing:0.55pt;"> </span>needs<span style="letter-spacing:0.4pt;"> </span>will<span style="letter-spacing:0.3pt;"> </span>be<span style="letter-spacing:0.2pt;"> </span>fulfilled<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.3pt;"> </span>(4) <span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">benefi</span>t<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">publi</span>c<span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:0.05pt;">healt</span>h<span style="letter-spacing:0.55pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">immediat</span>e<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">availabilit</span>y<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">marke</span>t<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">medicina</span>l<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">produc</span>t<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">outweigh</span>s<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">ris</span>k<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">inheren</span>t<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">fac</span>t<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">that</span> <span style="letter-spacing:0.05pt;">additiona</span>l<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">dat</span>a<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">ar</span>e<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">stil</span>l<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">required</span>.<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">Specifi</span>c<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">obligations</span>,<span style="letter-spacing:0.95pt;"> </span><span style="letter-spacing:0.05pt;">includin</span>g<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">wit</span>h<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">respec</span>t<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">completio</span>n<span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">ongoin</span>g<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">ne</span>w<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">studies</span>,<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">an</span>d<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">wit</span>h<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">respec</span>t<span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">the collectio</span>n<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">pharmacovigilanc</span>e<span style="letter-spacing:1.3pt;"> </span><span style="letter-spacing:0.05pt;">data</span>,<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">ma</span>y<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">specifie</span>d<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">conditiona</span>l<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">marketin</span>g<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">authorization</span>.<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">Conditiona</span>l<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">marketin</span>g<span style="letter-spacing:0.75pt;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="letter-spacing:0.05pt;">authorization</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">ar</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">vali</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">for </span><span style="letter-spacing:0.05pt;">on</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">yea</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">an</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">ma</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">renewe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">annually</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.05pt;">th</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">risk-benefi</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.9pt;"> </span><span style="letter-spacing:0.05pt;">balanc</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">remain</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.65pt;"> </span><span style="letter-spacing:0.05pt;">positive</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">an</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">afte</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">assessmen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">th</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">nee</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">fo</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:0.05pt;">additiona</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.3pt;"> </span><span style="letter-spacing:0.05pt;">modified </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditions.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the U.S., we may apply for designation of a product as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits, including up to 11 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the European Union that <span style="Background-color:#FFFFFF;">demonstrate potential for a major therapeutic advantage in areas of unmet medical need.</span> Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.58%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, companies developing a new medicinal product must agree to a PIP with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The marketing authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., there are additional challenges in ensuring adequate coverage and payment for our products. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory approval for a product and may require us to conduct a clinical study that compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of this type of clinical study could be expensive and result in delays in our commercialization efforts. Third-party payors are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly-approved health care products. Budgetary pressures in many European Union countries are also causing governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates. If budget pressures continue, governments may implement additional cost-containment measures. Cost-control initiatives could decrease the price we might establish for products that we may develop or sell, which would result in lower product revenues or royalties payable to us. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the United Kingdom </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the United Kingdom and the EU, the United Kingdom was subject to a transition period until December 31, 2020 (the Transition Period) during which EU rules continued to apply. A UK-EU Trade and Cooperation Deal (the Deal) that outlines the future trading relationship between the United Kingdom and the European Union was agreed in December 2020 and has been approved by each EU member state and the United Kingdom. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, Brexit has had, and will continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom and the EU. Great Britain (made up of England, Scotland and Wales) is no longer covered by the EEA&#8217;s procedures for the grant of marketing authorizations (Northern Ireland will be covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). A separate marketing authorization will be required to market drugs in Great Britain. It is currently unclear whether the Medical Healthcare products Regulatory Agency (MHRA) in the United Kingdom is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, would delay or prevent us from commercializing our product candidates in the United Kingdom or the EU and restrict our ability to generate revenue and achieve and sustain profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the Deal provides for the tariff-free trade of medicinal products between the United Kingdom and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period. Further, should the United Kingdom diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future. We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) to operate our business, which could significantly and materially harm or delay our ability to generate </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan designation in Great Britain following Brexit is granted on an essentially identical basis to in the EU, but is based on the prevalence of the condition in Great Britain. It is therefore possible that conditions that are currently designated as orphan conditions in Great Britain will no longer be and that conditions that are not currently designated as orphan conditions in the EU will be designated as such in Great Britain.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations. These and other laws govern our use, handling and disposal of various biological and chemical substances used in, and waste generated by, our operations. Our research and development involves the controlled use of hazardous materials, chemicals and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing facility in Thousand Oaks, California has the flexibility to manufacture multiple T-cell and CAR T immunotherapies while integrating research and process science functions to enable increased collaboration for rapid product development. Our research and development and process and analytical development labs are currently supporting preclinical and mid/late phase development activities. Our facility is designed to global regulatory standards, and the required facility commissioning and qualification activities to support clinical manufacturing are complete. We are in the process of completing our facility&#8217;s commercial production qualification activities for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> while building inventory according to our commercial product supply strategy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to scale our EBV T-cell manufacturing platform to improve product yields from a single donor leukapheresis collection and have generated data confirming the use of stirred-tank bioreactors to improve yield and cell growth productivity. We believe our scalable technology can potentially be a key enabler to deliver biologic-like cost of goods manufactured and could be leveraged across our portfolio, including our CAR T programs. There have been transient interruptions in the supply of raw materials and consumables used in the development and manufacturing of our preclinical and clinical cell therapies related to the COVID-19 pandemic, including leukapheresis collections, which supply raw materials used for our product candidates. If we are unable to obtain such raw materials or other necessary raw materials in a timely manner, our business operations and manufacturing capabilities could be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our manufacturing facility in Thousand Oaks, California, we also work with <span style="color:#000000;">Cognate BioServices, Inc. (Cognate) pursuant to a </span>Commercial Manufacturing Services Agreement (the Manufacturing Agreement) <span style="color:#000000;">that we entered into in December 2019</span>. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement, as amended, runs until May 31, 2022. We may terminate the Manufacturing Agreement for convenience on six months&#8217; written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. In March 2021, Charles River Laboratories Inc. (CRL) acquired Cognate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current manufacturing strategy is to evaluate each product candidate and determine which site in our manufacturing network provides the phase-appropriate technical, quality and regulatory compliance requirements. In addition, the long-range supply requirements of our product candidates are evaluated periodically to ensure we are planning manufacturing capacity and capabilities accordingly across our network. Our manufacturing network is comprised of our own facility and the manufacturing capabilities of our partners, including MSK and an affiliate of QIMR Berghofer, and contract manufacturing organizations (CMOs), including Cognate. This strategic approach provides us with the <span style="color:#000000;">flexibility to support our clinical and commercial production needs, address time or capacity constraints as well as provide supply redundancy, where appropriate. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our T-cell product candidates require blood-derived starting materials which are received from healthy, consenting third-party donors through FDA- and EMA-compliant collection centers. Our manufacturing operations are conducted under Code of Federal Regulations Good Manufacturing Practices (GMPs), as well as Good Tissue Practices (GTPs). GTPs are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through agreements with our partners, we have acquired the right to use certain manufacturing process know-how related to producing clinical research-related drug supply. These include materials to support the manufacturing of clinical study material, including key starting materials and intermediates as well as existing inventory of clinical study materials. We also have the ability to obtain supply from third parties to ensure we have the necessary starting materials donated from healthy consenting third-party donors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Management</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 578 employees. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel. Our human capital strategy is designed to enable successful execution of our business objectives, while fostering a collaborative and innovative culture, that embraces diversity and inclusion. We monitor our success with insights across human capital metrics such as employee engagement, vacancy rates, time to hire, promotion rates, performance ratings, succession depth, retention, EEO compliance, pay equity, and diversity representation. The principal purposes of our compensation policies and equity incentive plans are to attract, retain and motivate employees and directors by paying for performance through the granting of stock-based compensation awards and cash-based performance bonus awards. None of our employees are represented by a labor union or are a party to a collective bargaining agreement and we consider our relations with our employees to be good.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Business Update</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to closely monitor the impact of the ongoing and evolving COVID-19 pandemic on our business and operations and have taken steps designed to ensure the health and safety of our employees, staff, clinical site staff and patients and to maintain business continuity. Based on guidance issued by federal, state and local authorities, we have temporarily transitioned most of our workforce to a remote, work-from-home model, while maintaining essential in-person manufacturing and laboratory functions in order to advance key research, development and manufacturing priorities. We implemented safety protocols and procedures to support our onsite workforce.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to implementing measures designed to protect the health and safety of our workforce, our clinical study and operational teams are working closely with clinical sites to support the safety of site staff and patients as well as preserve data integrity and access to treatment as appropriate. Where needed, remote study visits, tele-medicine, home health care, and other methods have been leveraged to ensure continuity of care for patients while preserving key endpoint data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the COVID-19 pandemic has not materially impacted our or our partners&#8217; clinical, research and development, regulatory and manufacturing operations or timelines. However, at the onset of the COVID 19 pandemic, we experienced some transient delays in clinical study operations, and may again experience delays associated with the pandemic in the future. we experienced, and depending on the evolving impacts of the ongoing COVID-19 pandemic, we may again experience, some transient delays in clinical study operations, as a result COVID-19. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, financial condition and operations, see the section titled &#8220;1A. Risk Factors&#8221; under Part I, Item 1A in this Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in 2012. Our principal corporate offices are located at 611 Gateway Blvd., Suite 900, South San Francisco, California 94080 and our telephone number at that address is (650) 278-8930. Our website address is www.atarabio.com.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements and other materials with the Securities and Exchange Commission (SEC). We make these reports available free of charge through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. The information contained on, or that can be accessed through, our website is not a part of or incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the SEC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC also maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information contained in this Annual Report on Form 10-K, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes, before investing in our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The risks described below may not be the only ones relating to our company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including those described below, materialize, our business, competitive position, reputation, financial condition, results of operations, cash flows and future prospects could be seriously harmed. In these circumstances, the market price of our securities could decline, and investors may lose all or a part of their investment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Results and Capital Needs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that product candidates will fail to prove effective, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from product sales, and have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception. For the year ended December 31, 2021, we reported a net loss of $340.1 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to generate product revenues in the near future, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses to increase as we continue to research, develop and seek regulatory approvals for our product candidates and any additional product candidates we may acquire, in-license or develop, and potentially begin to commercialize product candidates that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical studies or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We anticipate that our expenses will increase in the future as we continue to invest in research and development of our existing product candidates, investigate and potentially acquire new product candidates and expand our manufacturing and commercialization activities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our company was formed in August 2012. Our operations to date have been limited to organizing and staffing our company, acquiring product and technology rights and conducting product development activities for our product candidates. We have not yet demonstrated our ability to successfully complete any Phase 2 or Phase 3 clinical studies, obtain regulatory approval, consistently manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization for any of our product candidates. In addition, the adoptive immunotherapy technology underlying our T-cell product candidates, including our next-generation CAR T programs, is new and largely unproven. Any predictions about our future success, performance or viability, particularly in view of the rapidly evolving immunotherapy field, may not be as accurate as they could be if we had a longer operating history or approved products on the market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. If we commercialize tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the US, subject to submission and approval of a BLA filing for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by the FDA, we would need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, any of our quarterly or annual periods&#8217; results are not indicative of future operating performance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approved products and thus have no product</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> revenues. We may never generate revenues </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from the sale of products </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or achieve profitability.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenues from product sales. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when we will generate revenues from product sales or become profitable, if at all. Our ability to generate revenues from product sales and achieve profitability will depend on our ability to successfully commercialize products, including any of our current product candidates, and other product candidates that we may develop, in-license or acquire in the future. Our ability to generate revenues from the sale of products and achieve profitability also depends on a number of additional factors, including our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successfully complete development activities, including the necessary clinical studies with positive results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">complete and submit regulatory submissions to the FDA, EMA or other agencies and obtain regulatory approval for indications for which there is a commercial market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain coverage and adequate reimbursement from third parties, including government and private payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">set commercially viable prices for our products, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop manufacturing and distribution processes for our novel T-cell immunotherapy product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop commercial quantities of our products at acceptable cost levels&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish and maintain adequate supply of our products, including cell lines with sufficient breadth to treat patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish and maintain manufacturing relationships with reliable third parties or qualify our manufacturing facility such that we can maintain the supply of our products by ensuring adequate, manufacturing of bulk drug substances and drug products in a manner that is compliant with global legal requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieve market acceptance of our products, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">attract, hire and retain qualified personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">protect our rights in our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets in which we choose to commercialize on our own&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">find suitable distribution partners to help us market, sell and distribute our approved products in other markets.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues for any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice, treatment guidelines or a reduction in the incidence of the addressable disease, we may not generate significant revenues from sales of our products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved product candidate. As a result, even if we generate revenues, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to expend substantial resources for the foreseeable future to continue the clinical development and manufacturing of our T-cell immunotherapy product candidates, and the advancement and expansion of our preclinical research pipeline. We also expect to continue to expend resources for the development and manufacturing of product candidates and the technology we have licensed or have an exclusive right to license from our partners.&#160;These expenditures will include costs associated with research and development, potentially acquiring or licensing new product candidates or technologies, conducting preclinical and clinical studies and potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any. Under the terms of our license agreements with each of our in-license partners, we are obligated to make payments upon the achievement of certain development, regulatory and commercial milestones.&#160;We will also need to make significant expenditures to develop a commercial organization capable of sales, marketing and distribution for any products, if any, that we intend to sell ourselves in the markets in which we choose to commercialize on our own. In addition, other unanticipated costs may arise. Because the design and outcome of our ongoing, planned and anticipated clinical studies is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements depend on many factors, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates, if clinical studies are successful, including any costs from post-market requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of commercialization activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and distribution costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing or contracting for the manufacture of our product candidates for clinical studies in preparation for regulatory approval and in preparation for commercialization&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs to develop, acquire or in-license future product candidates or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing, receipt and amount of sales of, or royalties on, our future products, if any&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the emergence of competing technologies or other adverse market developments.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021, together with the anticipated $100.0 million from FUJIFILM Diosynth Biotechnologies California Inc. (FDB), payable upon closing of the strategic transaction with FDB, will be sufficient to fund our planned operations into the fourth quarter of 2023. See Note 12 &#8211; Subsequent Events for further information. As of December 31, 2021, we had total cash, cash equivalents and short-term investments of $371.1 million. However, our operating plan may change as a result of many factors currently unknown to us, and we may need additional funds sooner than planned. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any committed external source of funds other than reimbursements, milestone and royalty payments that we may receive under the Bayer Agreements and milestone and royalty payments that we may receive under Pierre Fabre Commercialization Agreement. While we expect to continue to opportunistically seek access to additional funds through additional public or private equity offerings or debt financings, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing, additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other activities that may be necessary to commercialize our product candidates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on terms that are unfavorable to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek required additional capital through a variety of means, including through private and public equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, or if existing holders of warrants exercise their rights to purchase common stock, the ownership interest of existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of stockholders. To the extent equity valuations, including the trading price of our common stock, are depressed as a result of economic disruptions or other uncertainties, for example due to the COVID-19 pandemic or other factors, the potential magnitude of this dilution will increase. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, including incurring additional debt, making capital expenditures, entering into licensing arrangements, or declaring dividends. If we raise additional funds from third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses or other rights on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for our product candidates, grant to others the rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or take other actions that are adverse to our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development of Our Product Candidates</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are generally early in our development efforts and have only a small number of product candidates in clinical development. All of our other product candidates are still in preclinical development. If we or our collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are generally early in our development efforts, and only a small number of our product candidates are in clinical development. The majority of our product candidates are currently in preclinical development. We have invested substantial resources in identifying and developing potential product candidates, conducting preclinical and clinical studies, manufacturing activities and preparing for the potential commercial launch of our product candidates. Our ability to generate revenues from the sale of products, if approved, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on many factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of preclinical and clinical studies with positive results, demonstrating the safety, purity, and potency of our product candidates to the satisfaction of the FDA or other regulatory agencies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receipt of regulatory approvals from applicable authorities, including required authorizations for clinical trials and marketing authorizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing or making arrangements with third-party manufacturers or qualifying our own manufacturing facility for clinical and commercial manufacturing purposes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing manufacturing and distribution processes for our novel T-cell product candidates and next-generation CAR T programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing or contracting with third parties for the manufacture of our product candidates at an acceptable cost&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">effectively competing with other therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintaining a continued acceptable benefit/risk profile of the products following approval&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could materially harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic, in particular with respect to any new variants or resurgences of the pandemic. The COVID-19 pandemic continues to impact our business and operations and could materially and adversely affect our business and operations in the future, as well as the businesses and operations of third parties on which we rely.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely affected by health epidemics and pandemics, including the ongoing COVID-19 pandemic, which has presented a substantial public health and economic challenge around the world and has affected, and continues to affect, our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. As a result of the ongoing COVID-19 pandemic, the work-from-home model we implemented in March 2020 for most of our employees remains in place. We continue to maintain essential in-person manufacturing and laboratory functions in order to advance key research, development and manufacturing priorities. In connection with these measures, we may be subject to claims based upon, arising out of, or related to COVID-19 and our actions and responses thereto, including any determinations that we may make to continue to operate or to re-open our offices and facilities where permitted by applicable law. The effects of current and potential future state executive orders, local shelter-in-place orders, government-imposed quarantines, our work-from-home policies and potential return-to-office strategy and other similar actions may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further quarantines, shelter-in-place or similar restrictions and other actions taken by foreign, federal, state and local governments, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur or could be reinstated, related to the ongoing COVID-19 pandemic or other infectious diseases, could impact our manufacturing capabilities and third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, standard transportation channels have been impacted and we and other manufacturing, testing, product disposition, contract manufacturing organizations (CMOs) and external testing laboratories are subject to enhanced risk assessment and mitigation measures. In addition, there have been and may continue to be interruptions in the supply of leukapheresis collections, which supply raw materials used in our products.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trials may also be affected by health epidemics and have been affected by the ongoing and evolving COVID-19 pandemic. Clinical site initiation and patient enrollment have experienced delays as a result of the COVID-19 pandemic, including due to the prioritization of hospital resources toward COVID-19 and away from clinical trials or as a result of changing practice patterns that impact the diseases our trials address. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services or if patients contract COVID-19 or are forced to quarantine. For example, while most clinical trial sites for our studies, including our Phase 3 clinical trial of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in patients with EBV+ PTLD, remain open to enrollment for patients, some sites have limited the screening and enrollment of new patients due to governmental orders related to COVID-19, or fear of infection of COVID-19, have limited, and may continue to limit, patients&#8217; abilities to access clinical sites. COVID-19-related travel restrictions may also interrupt key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses. At the outset of the COVID-19 pandemic, we observed a temporary slow-down in stem cell and solid organ transplant volumes, which may have decreased the eligible patient population for the tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Phase 3 study. In April 2020, we initiated a temporary pause in the screening and enrollment of patients in our EMBOLD study of ATA188 in patients with PMS. Although we were able to resume the screening and enrollment of patients in our EMBOLD study and enrolled the first patient in the study in June 2020, the ongoing COVID-19 pandemic may require us to institute another pause in the screening and enrollment of patients in our EMBOLD study. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect the ongoing and evolving COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our clinical development and regulatory efforts and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. In addition, to the extent the evolving effects of the ongoing and evolving COVID-19 pandemic adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success is dependent on the regulatory approval of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. Currently, our prioritized clinical-stage product candidates include tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and ATA188. Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to successfully commercialize our product candidates in a timely manner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize product candidates in the U.S. without first obtaining regulatory approval for the product from the FDA&#59; similarly, we cannot commercialize product candidates outside of the U.S. without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical and clinical studies that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical and clinical studies and depends upon numerous factors, including the substantial discretion of the regulatory authorities. The novel nature of our product candidates may create further challenges in obtaining regulatory approval. For example, the FDA and comparable foreign regulatory authorities have limited experience with regulating the development and commercialization of T-cell immunotherapies, particularly allogeneic T-cell product candidates, and CAR T therapies, including assessing the comparability of different versions of such product candidates. In addition, approval policies, regulations, regulatory positions or the type and amount of clinical and other data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and throughout regulatory interactions, and may vary among jurisdictions, particularly for novel therapies. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons, including:</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement with the design or conduct of our clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate positive benefit/risk profile of the product candidate for its proposed indication&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;">failure of clinical sites to conduct the study in accordance with applicable regulatory&#160;requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of clinical studies to meet the level of statistical significance required for approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement with our interpretation of data from preclinical studies or clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the insufficiency of data collected from clinical studies of our product candidates to support the submission and filing of a BLA or other submission or to obtain regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to reach agreement with the FDA or comparable foreign regulatory authorities on the methodologies for, and assessment of, comparability of different versions of product candidates used in non-pivotal studies, pivotal studies and for intended commercial use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes or inconsistencies in the requested or required methodologies, statistical analyses, specification criteria or regulatory submission requirements for a product candidate, including changes to, or inconsistencies with, applicable industry practice or precedent&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the: (i) approval policies or regulations that render our preclinical and clinical data insufficient for approval&#59; or (ii) positions, guidance or feedback communicated by the FDA or comparable foreign regulatory authorities. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or a comparable foreign regulatory authority may require more information, including additional CMC information, preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. &#160;&#160;For example, at a Type B meeting in February 2022, <span style="color:#000000;">we were not able to align with the FDA on comparability between product used for in the pivotal ALLELE study and the intended commercial product. The FDA&#8217;s preliminary feedback recommended we conduct a new clinical trial with the commercial product to address the lack of alignment on comparability.&#160;&#160;While </span>we intend to continue explore alternative pathways with the FDA to enable filing of a BLA for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> based on data from the pivotal ALLELE study, if we are unable to establish comparability to the FDA&#8217;s satisfaction or otherwise reach agreement with the FDA on a pathway to BLA submission, we will be required to perform additional clinical trials prior to submitting the BLA for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, which would result in considerable delay to a BLA submission<span style="color:#000000;">. The requirement to conduct an additional clinical trial could lead us not to pursue a BLA submission.&#160;&#160;Conducting a clinical trial may prove too difficult or too expensive, and the process of designing a clinical trial, enrolling enough patients, and completing treatment and data collection under the protocol could take a significant amount of time, effort, and resources.&#160;&#160;Even if we complete the clinical trial, the study may not meet its prespecified endpoints, and even if it does, the FDA may still disagree with our determination that the clinical trial is sufficient to support submission and approval of a BLA for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. </span>In addition, if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical studies, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. In addition, the clinical study requirements of the FDA, EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates, such as our novel T-cell product candidates and next-generation CAR T programs, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Novartis&#8217; Kymriah<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Gilead&#8217;s Yescarta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, may not be indicative of what these regulators may require for approval of our therapies.&#160;&#160;We have multiple clinical trials of our product candidates currently ongoing. If an adverse safety issue, clinical hold or other adverse finding occurs in one or more of our clinical trials, such event could adversely affect our other clinical trials of the same or related product candidates.&#160;&#160;Moreover, our product candidates may not perform successfully in clinical studies or may be associated with adverse events that distinguish them from those that have previously been approved, such as existing autologous CAR T therapies. For instance, allogeneic product candidates may result in adverse events not experienced with autologous products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development and commercialization activities could be harmed or delayed by governmental or regulatory delays due to limitations on the availability of governmental and regulatory agency personnel to review regulatory filings or engage with us, caused by global health concerns, including the ongoing and evolving COVID-19 pandemic, changes to governmental regulatory requirements, policies, guidelines or priorities, reallocation, or availability of government resources, or for other reasons, which may significantly delay the FDA&#8217;s, or other regulatory agency, ability to review and process any submissions we have filed or may file or cause other regulatory delays. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, or impact reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.&#160;&#160;For example, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">most inspections of foreign manufacturing facilities and products inspections of domestic manufacturing facilities through April 2020. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. On July 10, 2020, the FDA announced that it is working toward the goal of restarting on-site inspections it deems to be &#8220;mission critical.&#8221; </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FDA updated its guidance, first published in August 2020, clarifying how it intends to conduct inspections during the COVID-19 pandemic, including how it plans to determine which inspections are &#8220;mission critical.&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Additionally, on April 14, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> It is unclear how FDA&#8217;s and other health agencies&#8217; policies and guidance will impact any inspections of our facilities, including our clinical trial sites.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our T-cell immunotherapy product candidates and our next-generation CAR T programs represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success is dependent on the successful development of T-cell immunotherapies and our next-generation CAR T programs in general and our development product candidates in particular. Because these programs, particularly our pipeline of allogeneic T-cell product candidates that are bioengineered from donors, represent a new approach to immunotherapy for the treatment of cancer and other diseases, developing and commercializing our product candidates subject us to a number of challenges, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining regulatory approval from the FDA and other regulatory authorities, which have limited experience with regulating the development and commercialization of T-cell immunotherapies, particularly allogeneic T-cell product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing and deploying consistent and reliable processes for procuring blood from consenting third-party donors, isolating T cells from the blood of such donors, activating the isolated T cells against a specific antigen, characterizing and storing the resulting activated T cells for future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate partially HLA-matched cell line from among the available T-cell lines, and finally infusing these activated T cells into patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">utilizing these product candidates in combination with other therapies (e.g., immunomodulatory approaches such as checkpoint inhibitors), which may increase the risk of adverse side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">educating medical personnel regarding the potential side effect profile of each of our product candidates, particularly those that may be unique to our allogeneic T-cell product candidates and to our next-generation CAR T programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to manufacture product in a reliable and consistent manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing processes for the safe administration of these products, including long-term follow-up and registries, for all patients who receive these product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing or making arrangements with third-party manufacturers to manufacture, or manufacturing on our own, product candidates to our specifications and in a timely manner to support our clinical studies and, if approved, commercialization&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sourcing clinical and, if approved by applicable regulatory authorities, commercial supplies for the materials used to manufacture and process these product candidates that are free from viruses and other pathogens that may increase the risk of adverse side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing a manufacturing process and distribution network that can provide a stable supply with a cost of goods that allows for an attractive return on investment&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">establishing sales and marketing capabilities ahead of and after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing therapies for types of diseases beyond those initially addressed by our current product candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that the manufacturing processes used in connection with our T-cell immunotherapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure, potent, comparable to those T cells produced by our partners historically, scalable or profitable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical studies, or, if one of our product candidates is approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment mechanics or of patients to provide consent to receive a novel treatment despite its regulatory approval. The FDA or other applicable regulatory authorities may require specific post-market studies or additional information that communicates the benefits or risks of our products. New data may reveal new risks of our product candidates at any time prior to or after regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physicians, hospitals and third-party payors often are slow to utilize new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training on this novel therapy, may decide the therapy is too complex to adopt without appropriate training or not cost-efficient, and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results of preclinical studies or earlier clinical studies are not necessarily predictive of future results. Our existing product candidates in clinical studies, and any other product candidate we advance into clinical studies, may not have favorable results in later clinical studies or receive regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Success in preclinical studies and early clinical studies does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical studies or clinical studies. Despite the results reported in earlier preclinical studies or clinical studies for our product candidates, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, we do not know whether the clinical studies we may conduct, or clinical studies in progress, will demonstrate adequate efficacy and safety to result in regulatory approval to market tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, ATA188, any product candidates resulting from our next-generation CAR T programs or any of our other product candidates in any particular jurisdiction. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> has been predominantly evaluated in single-center studies under investigator-sponsored investigational new drug (INDs) held by MSK and in our EAP, utilizing different response criteria and endpoints from those we may utilize in later clinical studies. The findings may not be reproducible in late phase studies we conduct. For instance, the current protocol for our ALLELE study is designed to rule out a 20% ORR as the null hypothesis. This means that if the lower bound of the 95% confidence interval on ORR among patients receiving at least one dose of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> exceeds 20% at the end of the study, then the study would be expected to meet the primary endpoint for the treatment of PTLD. For example, assuming enrollment of 33 patients in a cohort of ALLELE, an observed ORR above approximately 37% would be expected to meet the primary endpoint for that cohort. In addition, our amended ALLELE study protocol includes an interim analysis as well as a final study analysis. Depending on discussions with regulators, we may, for example, file a marketing application on the basis of interim data from a subset of the required patients or file a marketing application on the basis of the final data. We have previously received feedback from the FDA that an interim analysis may not be sufficient to support approval of a BLA. A marketing application based on interim data would impact the required ORR, may impact the approved indication, and may also result in post-marketing requirements that must be fulfilled. Similarly, if conditional marketing authorization is granted from the European Commission, we may be subject to ongoing obligations, including the need to provide additional clinical data at a later stage to confirm a positive benefit/risk balance. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For regulatory approvals of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, we plan on using independent radiologist and/or oncologist assessment of responses which may not correlate with the investigator-reported assessments. In addition, the Phase 2 clinical studies with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> enrolled a heterogeneous group of patients with a variety of EBV-driven malignancies, including EBV+ PTLD after HCT and EBV+ PTLD after SOT. These Phase 2 studies were not prospectively designed to evaluate the efficacy of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the treatment of a single disease state for which we may later seek approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, final study results may not be consistent with interim study results. Efficacy data from prospectively designed studies may differ significantly from those obtained from retrospective subgroup analyses. In addition, clinical data obtained from a clinical study with an allogeneic product candidate may not yield the same or better results as compared to an autologous product candidate. If </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">later-stage clinical studies do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical studies.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim &#8220;top line&#8221; and preliminary data from clinical studies that we or our partners may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we or our partners may announce or share with regulatory authorities interim &#8220;top line&#8221; or preliminary data from clinical studies. Interim data from completed clinical studies are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously announced. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could impact the regulatory approval of, and significantly harm the prospects of any product candidate that is impacted by the applicable data.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical and clinical studies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in our ongoing or future clinical studies and we do not know whether clinical studies will begin or enroll subjects on time, will need to be redesigned or will be completed on schedule, if at all. There can be no assurance that the FDA or comparable foreign regulatory authorities will not put clinical studies of any of our product candidates on clinical hold in the future. Clinical studies may be delayed, suspended or prematurely terminated for a variety of reasons, such as:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in enrollment due to travel, shelter-in-place or quarantine policies, or other factors, related to the ongoing COVID-19 pandemic or other epidemics or pandemics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a study design that we are able to execute&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in obtaining authorization to commence a study or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and study sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in obtaining institutional review board (IRB) approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical study at each site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical study sites from our clinical studies or the ineligibility of a site to participate in our clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in recruiting and enrolling eligible subjects to participate in a study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in subjects completing a study or returning for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical sites and investigators deviating from study protocol, failing to conduct the study in accordance with regulatory requirements, or dropping out of a study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an FDA or other regulatory authority clinical site inspection reveals serious violations of regulations applicable to clinical investigations, which may result in requests for additional data analyses and/or rejection of data deemed unreliable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to identify and maintain a sufficient number of study sites, including because potential study sites may already be engaged in competing clinical study programs enrolling the same population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of our third-party clinical study managers to satisfy their contractual duties, meet expected deadlines or return trustworthy data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or failure in adding new study sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interim results or data that are ambiguous or negative or are inconsistent with earlier results or data&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">feedback from the FDA, the IRB, data safety monitoring boards or comparable foreign authorities, or results from earlier stage or concurrent preclinical and clinical studies, that might require modification to the protocol for a study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decision by the FDA, the IRB, comparable foreign authorities, or us, or a recommendation by a data safety monitoring board or comparable foreign authority, to suspend or terminate clinical studies at any time for non-compliance with regulatory requirements, safety issues, including a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risk, or for any other reason&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unacceptable benefit/risk profile, unforeseen safety issues or adverse side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate a benefit from using a product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in manufacturing or obtaining from third parties sufficient quantities and breadth of appropriate partially HLA matched cell lines from among the available T-cell lines to start or to use in clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">lack of adequate funding to continue a study, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional studies or increased expenses associated with the services of our CROs and other third parties&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in governmental regulations or administrative actions or lack of adequate funding to continue a clinical study.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment, a significant factor in the timing of clinical studies, is affected by many factors including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and nature of the patient population&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possibility that the rare diseases that many of our product candidates address are under-diagnosed&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changing medical practice patterns or guidelines related to the diseases or conditions we are investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the severity of the disease under investigation, our ability to open clinical study sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the proximity of subjects to clinical sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patient referral practices of physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the design and eligibility criteria of the clinical study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to obtain and maintain patient consents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risk that enrolled subjects will drop out or die before completion&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">competition for patients from other clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our or our partner&#8217;s ability to manufacture the requisite materials for a study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risk that we do not have appropriately matched HLA cell lines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the diseases or conditions we are investigating&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disruptions caused by man-made or natural disasters or public health pandemics or epidemics, including, for example, the ongoing COVID-19 pandemic.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an example, we activated additional clinical sites for the ALLELE study of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> over the course of 2018 and increased HLA coverage during this period. As a result, enrollment in our studies was limited in the early part of 2018 and increased through the course of the year as we increased clinical sites and HLA coverage. However, in May 2019, we announced that enrollment in our Phase 3 studies of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for patients with EBV+ PTLD was proceeding slower than anticipated. Many of our product candidates are designed to treat rare diseases, and as a result, the pool of potential patients with respect to a given disease is small. We may not be able to initiate or continue to support clinical studies of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, ATA188 or any other product candidates if we are unable to locate and enroll a sufficient number of eligible participants in these studies as required by the FDA or other regulatory authorities. We have experienced some transient delays in clinical trial site initiation and patient enrollment in certain of our clinical trials, including our Phase 3 clinical trial of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, as a result of the evolving impact of the ongoing COVID-19 pandemic, and if the COVID-19 pandemic continues and persists for an extended period of time, we could experience significant disruptions to our clinical development timelines. Even if we are able to enroll a sufficient number of patients in our clinical studies, if the pace of enrollment is slower than we expect, the development costs for our product candidates may increase and the completion of our studies may be delayed or our studies could become too expensive to complete. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on CROs, other vendors and clinical study sites to ensure the proper and timely conduct of our clinical studies, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. Reliance on CROs entails risks to which we would not be subject if we conducted our clinical studies ourselves, including reliance on the CRO for clinical site initiation and monitoring, the possibility that the CRO does not maintain the financial resources to meet its obligations under our agreements, the possibility of breach of these agreements by the CRO because of factors beyond our control, including a failure to properly perform their obligations under these agreements, and the possibility of termination or nonrenewal of the agreements by the CROs, based on their own business priorities, at a time that is costly or damaging to us. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan, study protocols for the trial, statistical analysis plan and other study-specific documents (for example, monitoring and blinding plans). Moreover, the FDA requires us to comply with standards, commonly referred to as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good Clinical Practice</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (GCP), International Council for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Harmonization of Technical Requirements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceuticals</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for Human Use, or ICH, guidelines, and regulations regarding the informed consent process, safety reporting requirements, data collection guidelines, and other regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA, also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP and other applicable regulations. In addition, our clinical trials must be conducted with product produced under applicable current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) regulations. Our failure to comply with these regulations may require us to conduct new clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays or quality issues in the conduct, completion or termination of any clinical study of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical studies will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any delays in completing our clinical studies for our product candidates may also decrease the period of commercial exclusivity. In addition, many of the factors that could cause a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by our product candidates, their delivery methods or dosage levels could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we or our partners may experience in our clinical studies, we or our partners may not receive approval to market any product candidates, which could prevent us from ever generating product or royalty revenues or achieving profitability. Results of our studies could reveal an unacceptably high severity and incidence of side effects, or risks that outweigh the benefits of our product candidates. In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the study or result in potential product liability claims.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be forced to suspend marketing of that product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities, IRBs, or other clinical trial oversight bodies may place a hold on any ongoing clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw or change their approvals of that product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to conduct post-marketing studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to change the way the product is administered&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we could be sued and held liable for harm caused to subjects or patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our products may be seized, or we may be required to recall our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our products may become less competitive in the marketplace&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation may suffer.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA often approves new cancer therapies initially only for use in patients with relapsed or refractory metastatic disease. We expect to initially seek approval of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and our other oncology product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we may seek approval for earlier lines of treatment and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the diseases we are targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy, and who have the potential to benefit from treatment with our product candidates, are based on our current beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or our own market research, and may prove to be incorrect, including if the COVID-19 pandemic and associated responses impact our ability to engage with key stakeholders within the transplant center in person. Further, new studies, product approvals or market research may change the estimated incidence or prevalence of these diseases, and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect our lead product candidate, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, to initially target a patient population that suffers from aggressive EBV+PTLD who have failed rituximab or rituximab plus chemotherapy. At the outset of the COVID-19 pandemic, we initially observed a temporary slow-down in stem cell and solid organ transplant volumes. These reductions were transient, but if a reduction in such volumes resumes, it could result in lower PTLD incidence and thus reduce the demand for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain or maintain orphan drug exclusivity for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the U.S., EU and the United Kingdom (U.K.), may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the U.S. Both the FDA and the EMA have granted us orphan designation for <span style="Background-color:#FFFFFF;color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> for <span style="Background-color:#FFFFFF;color:#000000;">EBV+ PTLD</span> after HCT or SOT.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same biologic for the same indication for that time period. The applicable period is seven years in the U.S. and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In the U.S., the FDA may still approve a later marketing application blocked by an ongoing period of orphan drug exclusivity in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the biological product was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve or license other drugs or biological products that have a different active ingredient for use in treating the same indication or disease. Further, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not be maintained or effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a new drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BTD by the FDA and PRIME designation by the EMA may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have obtained BTD and PRIME designation for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for rituximab-refractory EBV+ PTLD in the U.S. and the EU, respectively, these designations may not lead to faster development or regulatory review and do not increase our likelihood of success. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the study can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for other expedited review programs, such as priority review. Based on our BTD, we may pursue a rolling submission strategy for our BLA for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV+ PTLD in the U.S. While rolling review process may provide the opportunity for ongoing communications with and feedback from the FDA, it may not result in a faster timeline to marketing approval or result in approval at all. The FDA may raise issues and pose questions to us that may delay the initiation and completion of our BLA submission, acceptance of the complete BLA for filing, and approval of the BLA. We may not be able to provide a satisfactory or a timely response to FDA questions or we may not be able to timely gather the required data to prepare our BLA submissions as we plan. If we are unable to address all questions or concerns the FDA may raise or if we do not have timely access to the data required for the preparation of the BLA, we may not be able to timely initiate and complete our BLA and ultimately receive FDA approval. In addition, even if we submit our BLA under the rolling review process, the FDA may decide not to review portions of our BLA under the rolling review process until the submission is deemed to be complete. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRIME designation supports the development and accelerated review by the EMA of new therapies to treat patients with unmet medical need.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a breakthrough therapy is within the discretion of the FDA, and access to PRIME is at the discretion of the EMA. Receipt of a BTD or PRIME designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA or EMA review procedures, and does not assure ultimate approval by either the FDA or EMA. In addition, the FDA or EMA, respectively, may later decide that the product no longer meets the conditions for qualification and rescind the BTD or PRIME designation or decide that the time period for FDA or EMA, respectively, review or approval will not be shortened. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A Fast Track designation by the FDA, even if granted for other current or future product candidates, may not lead to a faster development or regulatory review, licensure process and does not increase the likelihood that our product candidates will receive marketing licensure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Fast Track designation for one or more of our future product candidates. In December 2021, ATA188 received Fast Track designation. If a drug or biological product is intended for the treatment of a serious or life-threatening disease or condition and it demonstrates the potential to address unmet medical needs for such a disease or condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast Track designation for our product candidates, but there is no assurance that the FDA will grant this designation to any of our proposed product candidates. Marketing applications submitted by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not assure any such qualification or ultimate marketing licensure by the FDA. The FDA has broad discretion whether or not to grant Fast Track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or licensure compared to conventional FDA procedures or pathways and receiving a Fast Track designation does not provide assurance of ultimate FDA licensure. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., to market and sell our products in the EU, the U.K., many Asian countries and other jurisdictions, we, or our current or future commercialization partners, must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements, both from a clinical and manufacturing perspective. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval and may include additional risks. Clinical studies accepted in one country may not be accepted by regulatory authorities in other countries. In addition, many countries outside the U.S. require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities or payor authorities outside the U.S. on a timely basis, if at all. Approval by and regulatory agency or payor does not ensure approval by any other regulatory or payor authorities in other countries or jurisdictions. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by regulatory or payor authorities in the US, EU, the U.K., Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we, or our partners obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance by us and/or our CMOs and CROs for any post-approval clinical studies that we conduct. They also include any post-approval requirements or commitments imposed by FDA as a condition of approval, or any risk evaluation or mitigation strategies (REMS), if applicable. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may require labeling changes or establishment of a risk evaluation and mitigation strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of drug products and their facilities are subject to initial and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices (cGMP), current Good Clinical Practices (GCP), current good tissue practices (cGTP) and other regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue warning letters or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek an injunction or impose civil or criminal penalties or monetary fines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend, withdraw or modify regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend or modify any ongoing clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refuse to approve pending applications or supplements to applications filed by us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend or impose restrictions on operations, including costly new manufacturing requirements&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may also generate negative publicity or inhibit our ability to successfully commercialize our products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising and promotion of any product candidate that obtains approval in the U.S. will be heavily scrutinized by the FDA, the Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (HHS), state attorneys general, members of the U.S. Congress and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by comparable foreign entities and stakeholders. For example, a company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or comparable foreign bodies. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to regulations, recommendations or other guidelines advocating alternative therapies for the indications we treat could result in decreased use of our products. For example, although treatment with EBV-specific T cells is recognized as a recommended treatment for persistent or progressive <span style="Background-color:#FFFFFF;color:#000000;">EBV+ PTLD</span> as set forth in the National Comprehensive Cancer Network Guidelines, future guidelines from governmental agencies, professional societies, practice management groups, private health/science foundations and other organizations could lead to decreased ability of developing our product candidates, or decreased use of our products once approved by applicable regulatory authorities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not successfully identify, acquire, develop or commercialize new potential product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to expand our product pipeline through internal development, in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them. Any product candidates we identify, acquire, in-license, or develop may not be safe or effective for their targeted diseases, and may not receive marketing authorization in a timely manner, or at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with the in-license of our existing product candidates, we acquired manufacturing process know-how and, in some cases, inventory of process intermediates and clinical materials from our partners. Transferring manufacturing processes, testing and associated know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time.&#160;In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility.&#160;Each stage is retroactively and concurrently verified to be compliant with appropriate regulations. As a result, there is a risk that all relevant know-how was not adequately transferred to us from our partners or that previous execution was not compliant with applicable regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we need to conduct significant development and scale-up work to transfer these processes and manufacture each of our product candidates for various studies, clinical studies and commercial launch readiness. To the extent we elect to transfer manufacturing within our network or to third-party CMOs, we are required to demonstrate that the product manufactured in the new or &#8220;receiving&#8221; facility is comparable to the product manufactured in the original or &#8220;sending&#8221; facility. The inability to demonstrate to each of the applicable regulatory authorities that comparable drug product was manufactured could delay the development of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The processes by which our product candidates are manufactured were initially developed by our partners for clinical purposes. We intend to evolve the existing processes with our partners to support advanced clinical studies and commercialization requirements. Developing commercially viable manufacturing processes is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical studies or commercialization, including cost overruns, potential problems with process </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scale-up, process reproducibility, comparability issues, stability issues, consistency and timely availability of reagents or raw materials. The manufacturing facilities in which our product candidates will be made could be adversely affected by the ongoing COVID-19 pandemic, earthquakes and other natural or man-made disasters, equipment failures, labor shortages, power failures, and numerous other factors.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In addition, there have been, and there may continue to be, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transient </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interruptions in the supply of </span><span style="color:#000000;">raw materials and consumables used in the development and manufacturing of our preclinical and clinical cell therapies </span><span style="color:#000000;">related to the COVID-19 pandemic</span><span style="color:#000000;">, including</span><span style="color:#000000;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">leukapheresis collections, which supply raw materials used in our product candidates. If we are unable to obtain such raw materials or other necessary raw materials in a timely manner, our business operations and manufacturing capabilities could be adversely affected</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of manufacturing cellular therapies is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes, and other supply disruptions. Product defects can also occur unexpectedly. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, these manufacturing facilities may need to be closed for an extended period of time to allow us to investigate and remedy the contamination. Because our T-cell immunotherapy product candidates are manufactured from cells collected from the blood of third-party donors, the process of manufacturing is susceptible to the availability of the third-party donor material. The process of developing products that can be commercialized may be particularly challenging, even if they otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated or unusable product. This type of contaminations could result in delays in the manufacture of products which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects. Furthermore, our allogeneic products ultimately consist of many individual cell intermediate or cell product lots, each with a different HLA profile. As a result, the selection and distribution of the appropriate cell product lot for therapeutic use in a patient requires close coordination between clinical operations, supply chain and quality assurance personnel. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of our drug product which could delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Delays in receiving regulatory approvals for product candidates produced in our manufacturing facility or at our CMOs&#8217; facilities could delay our development plans and thereby limit our ability to generate revenues. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research and development and process and analytical development labs within our manufacturing facility in Thousand Oaks, California are currently supporting preclinical and mid/late development activities. The facility commissioning and qualification activities required to support production at our facility were completed in 2018. Product-specific qualification to support clinical development is complete and commercial production qualification activities are ongoing. If the appropriate regulatory approvals for manufacturing product candidates in our facility or at our CMOs&#8217; facilities are delayed, we may not be able to manufacture sufficient quantities of our product candidates, which would limit our development activities and our opportunities for growth. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the similar manufacturing risks described in &#8220;Risks Related to Our Dependence on Third Parties,&#8221; our manufacturing facility, and our CMOs&#8217; facilities, will be subject to ongoing, periodic inspection by the FDA, EMA or other comparable regulatory agencies to ensure compliance with cGMP and GTP. Our, or our partner&#8217;s, failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use, may result in the termination of or a hold on a clinical study, or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieving adequate inventory of clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs&#59;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">shortages of qualified personnel, raw materials or key contractors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieving and maintaining ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical studies, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could harm our business.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing advanced manufacturing techniques and process controls is required to fully utilize our facility. Without further investment, advances in manufacturing techniques may render our facility and equipment inadequate or obsolete. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of the product candidates in our portfolio, if approved by applicable regulatory authorities, may require significant commercial supply to meet market demand. In these cases, we may need to increase, or &#8220;scale up,&#8221; the production process by a significant factor over the initial level of production. If we are unable to do so, are delayed, or if the cost of this scale up is not economically feasible for us or we cannot find a third-party supplier, we may not be able to produce our product candidates in a sufficient quantities to meet future demand. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our sole clinical or commercial manufacturing facility or our CMO is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any manufacturing facility in our manufacturing network or our CMOs&#8217; facilities or the equipment in any such facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could delay our clinical studies or reduce our commercial product sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Maintaining clinical and commercial timelines is dependent on our end-to-end supply chain network to support manufacturing&#59; if we experience problems with our third party suppliers or CMOs we may delay development and/or commercialization of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely in part on our CMOs or our partners for the current production of our product candidates and the acquisition of materials incorporated in or used in the manufacturing or testing of our product candidates. Our CMOs or partners are not our employees, and except for remedies available to us under our agreements with our CMOs or partners, we cannot directly control whether or not they devote sufficient time and resources, including experienced staff, to the manufacturing of supply for our ongoing clinical, nonclinical and preclinical programs. Our CMOs for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> will need to be prepared to undergo pre-approval inspection in connection with our MAA filing and our anticipated BLA submission, and we cannot be certain that we will be able to adequately support them through such inspection nor that they will successfully pass any such inspection. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To meet our projected supply needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, ATA188, any product candidates resulting from our next-generation CAR T programs or any other product candidates, we will need to transition the manufacturing of these materials to a CMO or our own facility. Regardless of where production occurs, we will need to develop relationships with suppliers of critical starting materials or reagents, increase the scale of production and demonstrate comparability of the material produced at these facilities to the material that was previously produced. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. We would expect additional comparability work will also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by us or our CMO.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to successfully transfer and produce comparable product candidates, our ability to further develop and manufacture our product candidates may be negatively impacted. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our manufacturing facility in Thousand Oaks, California provides us with flexibility within our manufacturing network, we still may need to identify additional CMOs for continued production of supply for some of our product candidates. Given the nature of our manufacturing processes, the number of CMOs who possess the requisite skill and capability to manufacture our T-cell immunotherapy product candidates, and the critical intermediates or reagents used to manufacture such products, are limited. We have not yet identified alternate suppliers in the event the current CMOs that we utilize are unable to scale production, or if we otherwise experience any problems with them. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing cellular therapies is complicated and tightly regulated by the FDA and comparable regulatory authorities around the world, and although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers, transfer manufacturing procedures to these alternative suppliers, and demonstrate comparability of material produced by such new suppliers. New manufacturers of any product candidate or intermediate would be required to qualify under applicable regulatory requirements. These manufacturers may not be able to manufacture our product candidates at costs, or in sufficient quantities, or in a timely manner necessary to complete development of our product candidates or make commercially successful products. If we are unable to arrange for alternative third-party manufacturing sources, or to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them. In addition, should the FDA or comparable regulatory authorities not agree with our product candidate specifications and comparability methodologies or assessments for these materials, regulatory authorities may require that we conduct additional studies, including bridging comparability testing, and further clinical development or commercial launch of our product candidates could be substantially delayed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility that the third-party manufacturer does not maintain the financial resources to meet its obligations under the manufacturing agreement, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, including a failure to manufacture our product candidates or any products we may eventually commercialize in accordance with our specifications, misappropriation of our proprietary information, including our trade secrets and know-how, the possibility that the third-party does not devote sufficient time or resources to our product candidates or any products we may eventually commercialize based on its own business priorities, the possibility that the third-party is acquired by another party and changes its business priorities, and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP, cGTP and similar regulatory jurisdictional standards. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory agencies may also implement new standards at any time or change their interpretations and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards and although we monitor our manufacturers, we depend on them to provide honest and accurate information. Any failure by our third-party manufacturers to comply with cGMP or cGTP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical studies, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction or imposing civil and criminal penalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on third party suppliers and testing laboratories for key materials used to produce or test our product candidates. Any significant disruption in our supplier relationships could harm our business. Any significant delay in the supply of a product candidate for an ongoing clinical study could considerably delay initiation or completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If raw materials or components cannot be purchased or fail to meet approved specifications, the commercial launch of our product candidates could be delayed, or there could be a shortage in supply, which could impair our ability to generate revenues from the sale of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bayer is generally responsible for the conduct and funding of the development and commercialization of ATA2271 and ATA3271. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Bayer License Agreement, Bayer holds an exclusive, field-limited license to ATA2271 and ATA3271. As a result, other than the development of ATA2271 through Phase 1, Bayer is generally responsible for the development and obtaining and maintaining regulatory approval and commercialization of ATA2271 and ATA3271. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have joint governance and certain decision making rights, we do not control the development activities being conducted or that may be conducted in the future by Bayer, including, but not limited to, the timing of initiation, termination or completion of clinical trials, the analysis of data arising out of those clinical trials or the timing of release of data concerning those clinical trials, which may impact our ability to report on Bayer&#8217;s results. Bayer may conduct these activities more slowly or in a different manner than we would if we controlled the development of ATA2271 after Phase 1 and ATA3271. Bayer is responsible for submitting future applications to the FDA and other regulatory authorities for approval of ATA2271 and ATA3271 and will be the owner of marketing approvals issued by the FDA and other regulatory authorities for ATA2271 and ATA3271, if approved. If the FDA or other regulatory authorities approve ATA2271 and/or ATA3271, Bayer will also be responsible for the marketing and sale of the resulting product. However, we cannot control whether Bayer will devote sufficient attention and resources to the development of ATA2271 and/or ATA3271 or will proceed in an expeditious manner. Even if the FDA or other regulatory agencies approve ATA2271 and/or ATA3271, Bayer may elect not to proceed with the commercialization of the resulting product in one or more countries, unless otherwise specified in the Bayer License Agreement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into the Bayer Manufacturing Agreement for the supply of allogeneic mesothelin-directed CAR T-cell therapies for clinical trials. Delays to the activities contemplated by the Bayer Manufacturing Agreement may result in a delay in the ATA2271 and/or ATA3271 programs and would delay and could prevent us from obtaining revenues for this product candidate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise between us and Bayer, which may delay or cause the termination of any clinical trials of ATA2271 and/or ATA3271, result in significant litigation or cause Bayer to act in a manner that is not in our best interest. The costs associated with the continuing development of ATA2271 and/or ATA3271 may cause Bayer to reconsider the terms of its investment and seek to amend or terminate our agreement or to suspend the development of ATA2271 and/or ATA3271. If development of ATA2271 and/or ATA3271 does not progress for these or any other reasons, we would not receive milestone payments or royalties on product sales from Bayer with respect to ATA2271 and/or ATA3271. If the results of one or more clinical trials with ATA2271 and/or ATA3271 do not meet Bayer&#8217;s expectations at any time, Bayer may elect to terminate further development of ATA2271 and/or ATA3271 or certain of the potential clinical trials for ATA2271 and/or ATA3271, even if the actual number of patients treated at that time is relatively small. In addition, Bayer generally has discretion to elect whether to pursue or abandon the development of ATA2271 and/or ATA3271 and may terminate our strategic alliance in whole or on a product-by-product basis for any reason upon 120 days prior notice. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Bayer abandons ATA2271 and/or ATA3271, it would result in a delay in or could prevent us from commercializing ATA2271 and/or ATA3271 and would delay and could prevent us from obtaining revenues for this product candidate. If Bayer abandons development of ATA2271 and/or ATA3271 prior to regulatory approval or if it elects not to proceed with commercialization of the resulting product following regulatory approval, we would have to seek a new partner for development or commercialization, curtail or abandon that development or commercialization, or undertake and fund the development of ATA2271 and/or ATA3271 or commercialization of the resulting product ourselves. If we seek a new partner but are unable to do so on acceptable terms, or at all, or do not have sufficient funds to conduct the development or commercialization of ATA2271 and/or ATA3271 ourselves, we would have to curtail or abandon that development or commercialization, which could harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on Pierre Fabre for the potential commercialization of tab-cel in the European Union and several countries outside the United States. The failure of Pierre Fabre to meet its contractual, regulatory or other obligations could adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into the Pierre Fabre Commercialization Agreement for tab-cel in Europe and select emerging markets in the Territory for EBV-positive cancers. As a result, we are entirely dependent on Pierre Fabre for marketing and commercialization of tab-cel, if approved, in the Territory. The timing and amount of any milestone and royalty payments we may receive under these agreements, as well as the commercial success of tab-cel in the Territory, will depend on, among other things, the efforts, allocation of resources and successful commercialization of tab-cel by Pierre Fabre. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in the process of negotiating various ancillary agreements as contemplated by the Pierre Fabre Commercialization Agreement, including an agreement for the manufacture and supply of tab-cel to Pierre Fabre for commercialization in the Territory. Delays to the negotiation and execution of the ancillary agreements, or the activities contemplated by the ancillary agreements may result in a delay to the commercialization of tab-cel in the Territory and would delay and could prevent us from obtaining revenues for tab-cel in the Territory. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Pierre Fabre Commercialization Agreement, if we receive the EU marketing authorization for tab-cel in patients with EBV+ PTLD, we are required to transfer the marketing authorization to Pierre Fabre. Pierre Fabre will be responsible for obtaining all other regulatory approvals in the Territory and maintaining all regulatory approvals in the Territory. We will depend on Pierre Fabre to comply with numerous and varying regulatory requirements governing, if and when applicable, the manufacture, quality control, further development, labeling, packaging, storage, distribution, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-marketing information. We do not control the individual efforts of Pierre Fabre and have limited ability to terminate the Pierre Fabre Commercialization Agreement if Pierre Fabre does not perform as expected. The failure of Pierre Fabre to devote sufficient time and effort to comply with regulatory requirements and maintain the EU marketing authorization and other regulatory approvals in the Territory and/or to meet their obligations to us, could have an adverse impact on our financial results and operations. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also depend on Pierre Fabre to comply with all applicable laws relative to the commercialization of tab-cel in the Territory. We do not control the individual efforts of Pierre Fabre and have limited ability to terminate the Pierre Fabre Commercialization Agreement if Pierre Fabre does not perform as expected. The failure of Pierre Fabre to devote sufficient time and effort to the commercialization of tab-cel&#59; to meet their obligations to us, including for future royalty and milestone payments&#59; to adequately deploy business continuity plans in the event of a crisis&#59; and/or to satisfactorily resolve significant disagreements with us or address other factors could have an adverse impact on our financial results and operations. In addition, if Pierre Fabre violates, or are alleged to have violated, any laws or regulations during the performance of their obligations for us, it is possible that we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any termination, breach or expiration of the Pierre Fabre Commercialization Agreement could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive fees, milestones and royalties. In such an event, we may be required to devote additional efforts and to incur additional costs associated with the transfer of regulatory approvals and commercialization of tab-cel in the Territory. Alternatively, we may attempt to identify and transact with a new commercialization partner, but there can be no assurance that we would be able to identify a suitable partner or transact on terms that are favorable to us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not realize the benefits of strategic alliances that we may form in the future or of potential future product acquisitions or licenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may desire to form additional strategic alliances, create joint ventures or collaborations, enter into licensing arrangements with third parties or acquire products or business, in each case that we believe will complement or augment our existing business. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are 48 the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive benefit/risk profile. Any delays in entering into new strategic alliances agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements &#8211; both that we own or possess or that are owned or possessed by our partners that are in-licensed to us &#8211; to protect the intellectual property related to our technology and product candidates. When we refer to &#8220;our&#8221; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. For example, the product candidates and platform technology we have licensed from our partners are protected primarily by patent or patent applications of our partners that we have licensed and as confidential know-how and trade secrets. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office (USPTO) and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of such claim. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the U.S. or in other countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also desire to seek a license from a third party who owns intellectual property that may be useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain a license from such a third party on commercially reasonable terms, or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our partners have filed a number of patent applications covering our product candidates or methods of using or making those product candidates. We cannot offer any assurances about which, if any, patents will be issued with respect to these pending patent applications, the breadth of any such patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate. We or our partners may also become involved in proceedings regarding our patents, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and <span style="font-style:italic;">inter partes</span> and post-grant review proceedings before the USPTO the European Patent Office and other non-U.S. patent offices. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if granted, patents have a limited lifespan. In the U.S., the natural expiration of a patent generally occurs 20 years after it is filed. Although various extensions may be available if certain conditions are met, the life of a patent and the protection it affords is limited. If we encounter delays in our clinical studies or in obtaining regulatory approvals, the period of time during which we could exclusively market any of our product candidates under patent protection, if approved, could be reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be vulnerable to competition from biosimilar products, as we may be unable to prevent competitors from entering the market with a product that is similar or identical to our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result, the government has certain rights to these patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to practice the invention for or on behalf of the U.S. These rights may permit the government to disclose confidential information on which we rely to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in any inventions that result from government-funded research may be subject to certain requirements to manufacture products embodying these inventions in the U.S.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, on us and our partners not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, and <span style="font-style:italic;">inter partes</span> and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties&#8217; patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert infringement claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our partners are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. If any issued third-party patents were held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expired. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party&#8217;s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending against intellectual property claims could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. In the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business. We may also elect to enter into license agreements in order to settle patent infringement claims prior to litigation, and any of these license agreements may require us to pay royalties and other fees that could be significant. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the U.S. may be less extensive than those in the U.S. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the U.S. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the U.S., or from selling or importing infringing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the U.S. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our licensors initiate, and even if we or our licensors are successful the damages or other remedies awarded, if any, may not be commercially meaningful.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold rights under license agreements with our partners, including MSK, QIMR Berghofer and Moffitt that are important to our business. Our discovery and development platform is built, in part, around patent rights in-licensed from our partners. Under our existing license agreements, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable to pay damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners would materially adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our drug discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. Furthermore, a disagreement under any of these license agreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners&#8217; intellectual property rights, to protect our or our partners&#8217; trade secrets or to determine the validity or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference or derivation proceedings provoked by third parties, brought by us or our partners, or brought by the USPTO or any non-U.S. patent authority may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, <span style="font-style:italic;">inter partes</span> review, post-grant review or other pre-issuance or post-grant proceedings in the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property of others. An unfavorable outcome in any of these proceedings could require us or our partners to cease using the related technology and commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any intellectual property proceedings can be expensive and time-consuming. Our or our partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners&#8217; efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as in the U.S. Even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. The T-cell immunotherapy product candidates and platform technology we have licensed from our partners are protected primarily as confidential know-how and trade secrets. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants, and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the U.S. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and financial condition.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efficacy and safety of the product candidates as demonstrated in clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications and patient populations for which the product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance by physicians and patients of the drug as a safe and effective treatment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the administrative and logistical burden of treating patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to identify in a timely manner the appropriate patients who will benefit from specific therapy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the consideration of novel cellular therapies by physicians, hospitals and third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential and perceived advantages of product candidates over alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the safety of product candidates seen in a broader patient group, including its use outside the approved indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any restrictions on use together with other medications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product labeling or product insert requirements of the FDA or other regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction of our products as well as competitive products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the development of manufacturing and distribution processes for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of treatment in relation to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of coverage and adequate reimbursement from, and our ability to negotiate pricing with, third-party payors and government authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">relative convenience and ease of administration&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of our sales and marketing efforts and those of our collaborators.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. In some countries such as the U.S., greater cost-shifting from the payor to the patient is also a trend, and higher patient copayments or other administrative burdens could lead to reduced demand from patients or healthcare professionals. This could particularly be the case in a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenging economic climate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval, and ultimately our ability to successfully commercialize any product candidate for which we obtain regulatory approval. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the U.S. Third-party payors in the U.S. often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our drug products. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. In particular, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical industry.&#160;The Affordable Care Act and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and established a new Medicare Part D coverage gap discount program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the U.S. since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments, will remain in effect into 2031 unless additional Congressional action is taken. COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Sequestration will start again on April 1, 2022. From April 1 to June 30, 2022, payment for Medicare fee-for-service claims will be adjusted downwards by 1%&#59; beginning July 1, 2022, the payment will be adjusted downwards by 2%. In January 2013, the American Taxpayer Relief Act of 2012 (the ATRA) was enacted which, among other things, further reduced Medicare payments to several providers, including hospitals and outpatient clinics, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been judicial and Congressional challenges to numerous elements of the Affordable Care Act, as well as efforts by both the executive and legislative branches of the federal government to repeal or replace certain aspects of the Affordable Care Act. In addition, the U.S. Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While the U.S. Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the Affordable Care Act, such as removing penalties, starting January 1, 2019, for not complying with the Affordable Care Act&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual mandate to carry health insurance, eliminating the implementation of certain mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021, the U.S. Supreme Court dismissed a legal challenge to the law brought by several states arguing that, without the individual mandate, the entire Affordable Care Act was unconstitutional. The Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments. While the legal challenge to the Affordable Care Act was pending, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. In the future, there may be additional challenges and/or amendments to the Affordable Care Act. It is unclear how the United States Supreme Court ruling, other such litigation, and the healthcare form measures of the Biden administration will impact the Affordable Care Act and our business. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of governments, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare, including by imposing price controls, may adversely affect the demand for our product candidates for which we obtain regulatory approval and our ability to set a price that we believe is fair for our products. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the U.S. or foreign regulations, guidance or interpretations will be changed, or what the impact of these changes on the regulatory approvals of our product candidates, if any, may be. In the U.S., the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices for certain products in certain markets. In the U.S., there have been several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the Consolidated Appropriations Act of 2021 included several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of Health and Human Services, Labor, and the Treasury. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have also been administrative developments in the U.S. related to drug pricing. For example, included in the Consolidated Appropriations Act of 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the Departments of Health and Human Services, Labor and the Treasury. Additionally, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drugs, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, the Department of Health and Human Services issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Furthermore, the increased emphasis on managed healthcare in the U.S. and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales. These pressures can arise from rules and practices of managed care groups, other insurers, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there is significant uncertainty regarding the reimbursement status of newly approved healthcare products. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, the payors may not cover our products after approved as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly member states of the EU and the U.K., the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our collaborators, may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions for our current product candidates. Our commercial opportunities will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. Additionally, our commercial opportunities will be reduced or eliminated if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of our current or future target diseases. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no FDA- or EMA-approved products for the treatment of EBV+ PTLD. However, some marketed products and therapies are used off-label in the treatment of EBV+ PTLD, such as rituximab and combination chemotherapy regimens. In addition, a number of companies and academic institutions are developing product candidates for EBV+ PTLD and other EBV-driven diseases including: Viracta Therapeutics, Inc., which is conducting a pivotal, Phase 2 clinical study for nanatinostat (formerly named tractinostat, or VRx-3996) in combination with antiviral drug valganciclovir in relapsed/refractory EBV+ lymphomas&#59; AlloVir (formerly known as ViraCyte), which has completed a Phase 2 clinical study for Viralym-M (ALVR105), an allogeneic, multi-virus T-cell product that targets six viruses in allogeneic HSCT recipients with &#8805;1 treatment-refractory infection, including EBV, and is conducting a pivotal study for Virus-Associated Hemorrhagic-Cystitis, as well as a Phase 2 proof of concept trial for the prevention of BKV, CMV, AdV, EBV, HHV06 and JCV in post-allogeneic HSCT patients&#59; and Tessa Therapeutics Pte Ltd., is conducting a Phase 1 clinical study of its autologous CD30 CAR T in CD30+ NHL and funding a Phase 1, investigator-sponsored study at Baylor College of Medicine, for its allogeneic CD30-CAR EBVST product candidate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition in the MS market is high with at least 20 therapies, including four generics or bioequivalents, approved in the U.S. and EU for the treatment of various forms of MS, including clinically isolated syndrome, relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). There are many competitors in the MS market, including major multi-national fully-integrated pharmaceutical companies and established biotechnology companies. Most recently, Ponvory (S1P modulator), marketed by Johnson &#38; Johnson, and Kesimpta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (anti-CD20 monoclonal antibody), marketed by Novartis, were approved in the U.S. and/or EU for the treatment of relapsing forms of MS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous development candidates in Phase 3 studies for both relapsing and/or progressive forms of MS and additional novel agents could be approved in either or both indications in the future including TG Therapeutics&#8217; anti-CD20 monoclonal antibody ublituximab (estimated PDUFA 09/2022), Merck KGaA&#8217;s Bruton&#8217;s tyrosine kinase (BTK) inhibitor, evobrutinib, Roche&#8217;s BTK inhibitor, fenebrutinib, Sanofi&#8217;s BTK inhibitor, tolebrutinib and AB Science&#8217;s tyrosine kinase inhibitor, masitinib. Medicinova is planning to initiate a Phase 3 study of its PDE inhibitor, ibudilast (MN166) in non-active SPMS. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently five autologous CAR T therapies approved in the U.S. and/or EU: Novartis&#8217; Kymriah</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (tisagenlecleucel), Gilead/Kite&#8217;s Yescarta</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (axicabtagene ciloleucel) and TecartusTM (brexucabtagene autoleucel) and Bristol-Myers Squibb&#8217;s Breyanzi</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel) with bluebird bio. There are many CAR-mediated cell therapies in development, and, although the majority are autologous, they include allogeneic and off-the-shelf cell therapies. There are multiple allogeneic CAR platforms being developed with differences in approaches to minimize instances of donor cells recognizing the patient&#8217;s body as foreign or rejection of the donor cells by the patient&#8217;s body. These approaches include the use of gene-editing to remove or inhibit the TCR and the use of cell types without a TCR. The majority of clinical stage allogeneic CAR programs utilize alpha beta T cells as the cell type and gene editing of the T-cell receptor and HLA as the preferred technology approach, however, other strategies are also in development. It is possible that some of these other approaches will have more favorable characteristics than the approach we utilize, which would result in them being favored by potential partners or customers over our products. Depending on the diseases that we target in the future, we may face competition from both autologous and allogeneic CAR therapies and other modalities (e.g., small molecules, antibodies) in the indication of interest. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the approved or commonly used drugs and therapies for our current or future target diseases, including <span style="Background-color:#FFFFFF;color:#000000;">EBV+ PTLD</span> and MS, are well established and are widely accepted by physicians, patients and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products or specific branded products. We expect that, if any of our product candidates are approved, they will be priced at a significant premium over competitive generic products. Absent differentiated and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies, which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will become as our products continue in clinical development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors or potential competitors have significantly greater established presence in the market, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage companies may also prove to be significant competitors, including through collaborative arrangements with large and established companies or if they are acquired by larger companies. These third parties compete with us in recruiting and retaining qualified scientific, commercial and management personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these factors, these competitors may obtain regulatory approval of their products before we are able to obtain patent protection or other intellectual property rights, which will limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and cheaper than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover the expenses of development and commercialization. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We expect the product candidates </span>we<span style="Background-color:#FFFFFF;"> develop will be regulated as biological products (biologics) and therefore they may be subject to competition sooner than anticipated.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for our biological products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of the product candidates we develop that is approved in the U.S. as a biological product under a BLA should qualify for the&#160;12-year&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the approval of a biologic product biosimilar to one of our products could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> from the sale of our products</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are at an early stage of establishing an organization that will be responsible for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities, or entering into agreements with third parties to market and sell our products, would adversely impact the commercialization of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without a sufficiently scaled, appropriately timed and trained internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to grow the size of our organization, and we may experience difficulties in managing this growth.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 578 employees. We have made the decision to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we may need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">managing our preclinical and clinical studies effectively&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identifying, recruiting, maintaining, motivating and integrating additional employees, including the additional personnel needed to support continued development and potential commercialization of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">improving our managerial, development, operational, information technology, and finance systems&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expanding our facilities.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical and clinical studies effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has fluctuated in the past and can be expected to be volatile in the future. From January 1, 2019 through December 31, 2021, the reported sale price of our common stock has fluctuated between $4.52 and $41.97 per share. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. In particular, the ongoing COVID-19 pandemic has further heightened the volatility of the stock market for biopharmaceutical companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock may be influenced by many factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competitive products or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory actions with respect to our product candidates or products or our competitors&#8217; product candidates or products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated changes in our growth rate relative to our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">results of clinical studies of our product candidates or those of our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory or legal developments in the U.S. and other countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the recruitment or departure of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of expenses related to any of our product candidates or clinical development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of our efforts to in-license or acquire additional product candidates or products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inconsistent or unusual trading volume levels of our shares or derivatives thereof&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcement or expectation of additional financing efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our common stock by us, our insiders or our other stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of healthcare payment systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, industry and market conditions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the other risks described in this &#8220;Risk Factors&#8221; section.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have experienced significant volatility that has often been unrelated to the operating performance of particular companies, including in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and healthcare spending and delivery, including the possible repeal and/or replacement of all or portions of the Affordable Care Act or changes in tariffs and other restrictions on free trade stemming from U.S. and foreign government policies, or for other reasons, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These market fluctuations may adversely affect the trading price of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such litigation brought against us could result in substantial costs and divert management&#8217;s attention and resources, which could result in delays of our clinical studies or commercialization efforts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal stockholders own a significant portion of our outstanding common stock. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock. The interests of our significant stockholders may not always coincide with the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the market price for our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, certain holders of shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted and will adopt additional rules and regulations, such as mandatory &#8220;say on pay&#8221; voting requirements, that now apply to us. Stockholder activism, the current political environment and the potential for future regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules and regulations applicable to public companies have substantially increased our legal and financial compliance costs and make some activities more time-consuming and costly. To the extent these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential gain for our stockholders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock in one or more transactions at prices and in a manner we determine from time to time. These future issuances of common stock or common stock-related securities, together with the exercise of outstanding options or warrants, and any additional shares issued in connection with acquisitions or in-licenses, if any, may result in material dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock. To the extent equity valuations, including the trading price of our common stock, are depressed as a result of economic disruptions and uncertainty concerning the COVID-19 pandemic or other factors, the potential magnitude of this dilution will increase. Pursuant to our equity incentive plans, our compensation committee is authorized to grant equity-based incentive awards to our employees, non-employee directors and consultants. Future grants of RSUs, options and other equity awards and issuances of common stock under our equity incentive plans will result in dilution and may have an adverse effect on the market price of our common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some terms of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation (Certificate of Incorporation) and amended and restated bylaws (Bylaws), as well as Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include terms that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">permit our board of directors to issue up to 20,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish that our board of directors is divided into three classes, with each class serving three-year staggered terms, which makes it more difficult to replace a majority of our directors in a short period of time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that special meetings of our stockholders may be called only by our board of directors, the chairperson of our board of directors or our chief executive officer.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the factors listed above may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any term of our Certificate of Incorporation or Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us and our business. In the event securities or industry analysts who cover us downgrade our stock or publish unfavorable research about us or our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent upon our executive officers and other key employees and the loss of the services of any of our executive officers or other key employees, including scientific, technical or management personnel, could impede the achievement of our corporate objectives. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on our ability to recruit, retain, manage and motivate our employees. Although we enter into employment agreements or offer letters with our employees, these documents provide for &#8220;at-will&#8221; employment, which means that any of our employees could leave our employment at any time, with or without notice. Competition for skilled personnel in our industry and geographic regions is intense and may limit our ability to hire and retain qualified personnel on acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity awards that vest over time. The value to employees of equity awards may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, privacy and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products. As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs, distribution agreements, discounting, commission compensation, certain patient support offerings, and other business arrangements generally. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned here, among other foreign laws. Restrictions under applicable federal and state healthcare laws and regulations that may affect certain business arrangements and our ability to operate include, but are not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal healthcare Anti-Kickback Statute, a criminal law that governs, for example, our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDCA and PHSA, which prohibit the misbranding and adulteration of biological products that are regulated as drugs, and which regulate the marketing of biological products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provisions enacted under the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) impose criminal and civil liability for knowingly and willfully executing or attempting to execute, a scheme or artifice to defraud any healthcare benefit program and also impose criminal liability for, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by HITECH also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Physician Payments Sunshine Act, implemented as the Open Payments Program, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations. Beginning in 2022, applicable manufacturers are also required to report information regarding payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">state and foreign laws and regulations that are analogous to, and may be broader in scope than, the federal laws and regulations described in this risk factor, such as state anti-kickback and false claims laws, may apply to sales or marketing or other arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government&#59; some state laws require drug manufacturers to report information regarding pricing and marketing information related to payments and other transfers of value to physicians and other healthcare providers as well as those that require the registration of pharmaceutical sales representatives&#59; and some other state laws require the protection of the privacy and security of health information, which may differ from each other in significant ways and often are not preempted by HIPAA.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, <span style="color:#000000;">disgorgement, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement, </span>and the curtailment or restructuring of our operations, reputational harm, contractual damages, and diminished profits and future earnings, any of which could adversely affect our ability to operate our business and our results of operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical studies and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical studies, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for any product candidates or products that we may develop&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical holds or termination of clinical study sites or entire study programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injury to our reputation and significant negative media attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical study participants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant costs to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to study subjects or patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of revenue&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of management and scientific resources from our business operations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize any products that we may develop.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we and our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our or our third-party manufacturers&#8217; use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials with a policy limit that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The actual or perceived failure by us, our customers, or vendors to comply with increasingly stringent laws, regulations and contractual obligations relating to privacy, data protection, and data security could harm our reputation, and subject us to significant fines and liability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are or may become subject to numerous domestic and foreign laws and regulations regarding privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations and may be inconsistent among countries, or conflict with other rules. We are also subject to the terms of our contractual obligations to customers and third parties related to privacy, data protection, and data security. The actual or perceived failure by us, our customers, our vendors, or other relevant third parties to address or comply with these laws, regulations, and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, cause regulators to reject, limit or disrupt our clinical trial activities, result in reputational harm, lead to a loss of customers, reduce the use of our products, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the EU adopted the General Data Protection Regulation (EU) 2016/679 (EU GDPR), in May 2018 which has direct effect in all EU member states and has extraterritorial effect where organizations outside of the EU <span style="font-style:italic;">inter alia </span>process personal information of individuals in the EU in relation to the offering of goods or services to those individuals (&#8220;targeting test&#8221;) or monitoring of their behavior (&#8220;monitoring test&#8221;). As such, the EU GDPR applies to us to the extent we are processing personal information in the context of an establishment in an EU Member State or we meet the requirements of either the targeting test or the monitoring test. The EU GDPR impose onerous and comprehensive privacy, data protection, and data security obligations onto controllers and processors, including, as applicable: (i) contractual privacy, data protection, and data security commitments, including the requirement to implement appropriate technical and organizational measures to safeguard personal information&#59; (ii) establishing means for individuals to exercise their data protection rights&#59; (iii) limitations on retention of personal information&#59; (iv) additional requirements pertaining to sensitive information (such as health data)&#59; (v) data breach notification requirements to supervisory authorities without undue delay (and no later than 72 hours where feasible) and/or concerned individuals&#59; (vi) high standards for obtaining valid consent from data subjects&#59; (vii) obligations to consider data protection as any new products or services are developed&#59; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and (viii) the provisions of more detailed privacy notices for clinical trial subjects and investigators. The EU GDPR also provides that EU member states may introduce further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use and share </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> data, cause our compliance costs to increase, require us to change our practices, adversely impact our business, and harm our financial condition. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU GDPR also restricts the transfer of personal information from the European Economic Area (EEA) to the United States and other countries that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless the parties to the transfer have implemented an appropriate data transfer mechanism in accordance with the EU GDPR. Data protection laws in the U.K. (as discussed below) and Switzerland impose similar restrictions. One of the primary mechanisms allowing U.S. companies to import personal information from the EU has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks. However, the EU-U.S. Privacy Shield framework was invalidated as a mechanism to legitimize international transfers in July 2020 in a decision by the Court of Justice of the EU (CJEU) and subsequent guidance required additional compliance efforts to analyze international data flows and take steps to ensure adequate protections for personal information transferred to the U.S. and other certain jurisdictions, including in certain cases by implementing supplementary measures that provide privacy protections in addition to those provided under the Standard Contractual Clauses (or SCCs). Similarly, the Swiss-U.S. Privacy Shield Framework was declared as inadequate by the Swiss Federal Data Protection and Information Commissioner in light of the CJEU&#8217;s July 2020 decision. Moreover, new versions of the European Commission&#8217;s SCCs (new EU SCCs), now the primary mechanism for the lawful transfer of personal information from the EU have been released requiring additional compliance and implementation efforts. If we are unable to implement a valid solution for personal information transfers to the United States and other countries, we will face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from the EU, and we may be required to increase our data processing capabilities in Europe at significant expense. Inability to import personal information from the EU to the United States or other countries may decrease demand for our products and services as our customers that are subject to the EU GDPR may seek alternatives that do not involve personal information transfers out of the EU. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assisting our customers, partners, and vendors in complying with the EU GDPR, or complying with the EU GDPR ourselves, may cause us to incur substantial operational costs or require us to change our business practices. There may also be a risk that the measures will not be implemented correctly or that individuals within the business will not be fully compliant with the required procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU GDPR imposes significant fines for serious non-compliance of up to the greater of &#8364;20 million or four percent of consolidated global turnover and restrictions or prohibitions on data processing, which could impair our ability to do business in the EU, reduce demand for our services and adversely impact our business and results of operations. The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, following the United Kingdom&#8217;s exit from the EU, known as Brexit, the EU GDPR&#8217;s obligations continue to apply to the United Kingdom in substantially unvaried form under the so called &#8220;UK GDPR&#8221; by virtue of section 3 of the European Union (Withdrawal) Act 2018. The UK GDPR exists alongside the UK Data Protection Act 2018 which implements certain derogations in the UK GDPR into UK law. Under the UK GDPR, companies established in the United Kingdom and companies not established in the United Kingdom but who process personal information in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. It should also be noted that the new EU SCCs do not automatically apply in the UK since Brexit, and the UK Government has not yet formally acknowledged the new EU SCCs, i.e., as a valid data transfer mechanism under the UK GDPR. Indeed, on 11 August 2021, the UK Information Commissioner&#8217;s Office (ICO) launched a public consultation on its draft international data transfer agreement and guidance. This included the publication of a draft UK addendum that can be used with the new EU SCCs &#8211; however, this is yet to be finalized and as such, for the time being transfers from the UK to a third country should continue to be made in reliance on the &#8220;old&#8221; SCC. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other countries outside of Europe continue to enact or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil recently enacted the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais or LGPD) (Law No. 13,709/2018), which broadly regulates the processing of personal information and imposes compliance obligations and penalties comparable to those of the EU GDPR. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation of privacy, data protection and data security has also become more stringent in the United States. For example, the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. The CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act of 2020 (CPRA) becomes fully operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, further restrict the use of cross-contextual advertising, establish restrictions on the retention of personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, provide for increased penalties for CPRA violations concerning California residents under the age of 16, and establish a new California Privacy Protection Agency to implement and enforce the new law. Other states have already passed similar comprehensive privacy laws that will also go into effect in 2023, and several more are considering their own versions of privacy legislation, demonstrating a strong trend towards more stringent state privacy, data protection and data security legislation in the U.S., which could increase our potential liability and adversely affect our business. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and foreign privacy, data protection, and data security laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign privacy, data protection, and data security laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with privacy, data protection, and data security laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our security measures are compromised, or our information technology systems or those of our vendors, and other relevant third parties fail or suffer security breaches, loss or leakage of data, and other disruptions, this could result in a material disruption of our services, compromise sensitive information related to our business, harm our reputation, trigger our breach notification obligations, prevent us from accessing critical information, and expose us to liability or other adverse effects to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we may collect, process, and store proprietary, confidential, and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties. It is critical that we do so in a secure manner to maintain the confidentiality, integrity, and availability of such information. We face several risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party service providers who handle elements of our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, our partners, our CROs, our CMOs, and other business vendors on which we rely depend on information technology and telecommunication systems for significant elements of our operations, including, for example, systems handling human resources, financial reporting and controls, regulatory compliance and other infrastructure operations. Notwithstanding the implementation of security measures, given the size and complexity of our information technology systems and those of our third-party vendors and other contractors and consultants, and the increasing amounts of proprietary, confidential and sensitive information that they maintain, such information technology systems are potentially vulnerable to breakdown, service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our personnel, third-party vendors, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information), which may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risk of a security breach or disruption, particularly through accidental actions or omissions by trusted insiders, cyber-attacks or cyber intrusions, including by computer hackers, viruses, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Additionally, the increased usage of computers operated on home networks due to the shelter-in-place or similar restrictions related to the COVID-19 pandemic may make our systems more susceptible to security breaches. For example, in March 2021, MSK provided notice that MSK was one of many customers impacted by a data breach at Accellion, Inc., which provides a document-sharing system. MSK subsequently notified us that certain documents related to one of our discontinued programs were subject to the breach, which compromise we deemed immaterial. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, we and our third party service providers frequently defend against and respond to cyber attacks, and our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to personnel error, malfeasance, or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost, or stolen. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions to our operations, including preventing us from conducting tests or research and development activities and preventing us from managing the administrative aspects of our business. For example, the loss of clinical study data from completed, ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed and our business could be otherwise adversely affected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to anticipate all types of security threats, and we may not be able to implement preventative measures effective against all such security threats. We also may not be effective in responding to, containing or mitigating the risks of an attack. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, hostile foreign governments or agencies, or cybersecurity researchers. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our third-party vendors and other contractors and consultants, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our products and services could be delayed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs related to significant security breaches or disruptions could be material and could exceed the limits of the cybersecurity insurance we maintain, if any, against such risks. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of our services and technologies could be delayed. Furthermore, significant disruptions of our internal information technology systems or those of our third-party vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to personnel error, malfeasance, or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost, or stolen. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such access, breach, or other loss of information could result in legal claims or proceedings, liability under domestic or foreign privacy, data protection and data security laws such as HIPAA and HITECH, and penalties. Notice of certain security breaches must be made to affected individuals, the Secretary of HHS, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such notice could harm our reputation and our ability to compete. Although we have implemented security measures, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, conduct research and development activities, collect, process and prepare company financial information, and manage the administrative aspects of our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include significant civil monetary penalties and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state afford greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. Similarly, the CCPA allows consumers a private right of action when certain personal information is subject to unauthorized access and exfiltration, theft or disclosure due to a business&#8217; failure to implement and maintain reasonable security procedures. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, for the treatment of genetic data, along with increased customer demands for enhanced data security infrastructure, could greatly increase our cost of providing our products, decrease demand for our products, reduce our revenues and/or subject us to additional liabilities.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax laws or regulations that are applied adversely to us or our customers may have an adverse effect on our business, cash flows, financial condition or results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to income and non-income based taxes in the U.S. and various jurisdictions outside the U.S. Our business and financial condition could be adversely affected by changes in federal, state, local or international tax laws, changes in taxing jurisdictions&#8217; administrative interpretations, decisions, policies and positions, changes in accounting principles, applicability of withholding taxes, and changes to our business operations. For example, US legislations such as the Tax Act, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), and the American Rescue Act, made significant changes to the corporate tax rate, the potential realization of net deferred tax assets relating to our operations, taxation of foreign earnings, and deductibility of expenses, and could have a material impact on our financial position or results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use net operating loss carryforwards and certain tax assets to offset future taxable income or taxes may be subject to certain limitations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to use our federal and state net operating losses (NOLs) and certain other tax attributes to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs or other tax attributes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had significant U.S. federal and state NOLs due to prior period losses. Under the Tax Cuts and Jobs Act (the Tax Act), federal NOLs generated in tax years beginning on or after January 1, 2018 may be carried forward indefinitely, but the utilization of such federal NOLs is limited to 80% of current year taxable income. The CARES Act temporarily suspends this 80% taxable income limitation, allowing an NOL carryforward to fully offset taxable income in tax years beginning before January 1, 2021. It is uncertain if, and to what extent, various states will conform to the Tax Act or the CARES Act. The Tax Act nor the CARES Act had a material impact to our financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Section 382 of the Internal Revenue Code of 1986, as amended (the Code), our ability to utilize these NOLs and other tax attributes, such as federal tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change&#8221;. Generally, a Section 382 ownership change occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a three-year testing period. Similar rules may apply under state tax laws. We performed a Section 382 analysis of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 of the Code will result in limitations on our ability to use certain pre-change NOLs and credits. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our financial statements could be limited and, in the case of NOLs generated before January 1, 2018 before may expire unused. Any such material limitation or expiration of our NOLs may harm our future operating results by effectively increasing our future tax obligations. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes. Regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, may cause our existing tax attributes to expire, decrease in value or otherwise be unavailable to offset future income tax liabilities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. Two of our corporate locations are located in California, an area prone to earthquakes and fires. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of product candidates could be disrupted, if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption, including, for example, the ongoing COVID-19 pandemic. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_1B">Item&#160;1B. Unresolved Staff Comments</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_2">Item&#160;2. Properties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in South San Francisco, California and consists of approximately 13,670 square feet of office space under a lease agreement that expires in May 2025. We also lease approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California under a lease for which the initial 15-year term commenced in February 2018. Additionally, in November 2018, we entered into a lease agreement for approximately 51,160 square feet of office space in Thousand Oaks, California that expires in February 2026. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a new lease agreement for approximately 33,659 square feet of office, lab and warehouse space in Thousand Oaks, California. The initial 10.5-year term of this lease commenced in August 2021. We have the option to extend this lease for two additional five-year periods after the initial term. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_3">Item&#160;3. Legal Proceedings</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_4">Item&#160;4. Mine Safety Disclosures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART&#160;II</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_5">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#8220;ATRA&#8221; since October 16, 2014. Prior to that time, there was no public market for our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2022, there were 6 stockholders of record of our common stock. We are unable to estimate the total number of stockholders represented by these record holders, as many of our shares are held by brokers and other institutions on behalf of our stockholders. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph compares the cumulative total return on an indexed basis of a $100 investment, made at the beginning of the five-year period ended December 31, 2021, in the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section&#160;18 of the Exchange Act or incorporated by reference into any filing of Atara Biotherapeutics, Inc. under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing.<span style="color:#000000;"> The past performance of our common stock is not an indication of future performance.</span></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COMPARISON OF FIVE-YEAR CUMULATIVE TOTAL RETURN</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbn5n5jlnzog000003.jpg" title="" alt="" style="width:650px;height:355px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Composite</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Biotechnology</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127.46</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128.24</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121.06</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244.65</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123.26</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109.77</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115.99</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166.68</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136.56</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138.24</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239.42</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171.64</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110.99</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290.63</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170.55</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">Item 6. [Reserved]<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Required. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_7">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Atara Biotherapeutics is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, we are the most advanced allogeneic T-cell immunotherapy company and intend to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-driven diseases or other serious diseases through incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Atara is applying this one platform, that does not require TCR or HLA gene editing, to create a robust pipeline. Our strategic priorities are: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="Background-color:#FFFFFF;">: Atara&#8217;s most advanced T-cell immunotherapy program, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (tabelecleucel), is partnered with Pierre Fabre Medicament (Pierre Fabre) for commercialization in Europe and select emerging markets and is currently in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA188</span><span style="Background-color:#FFFFFF;">: T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of primary and secondary progressive multiple sclerosis&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;">CAR T Programs</span>:</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:14.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA2271</span><span style="Background-color:#FFFFFF;">: Autologous</span> CAR T immunotherapy, currently in clinical development, targeting solid tumors expressing the tumor antigen mesothelin, which is partnered with Bayer&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:14.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA3271</span><span style="Background-color:#FFFFFF;">: </span>Allogeneic CAR T therapy, currently in preclinical development, targeting mesothelin, which is partnered with Bayer&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:14.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">ATA3219</span><span style="Background-color:#FFFFFF;">: Allogeneic CAR T targeting CD19, currently in preclinical development, and being developed as a potential best-in-class product, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our T-cell immunotherapy platform includes the capability to progress both allogeneic and autologous programs and is potentially applicable to a broad array of targets and diseases. Our off-the-shelf, allogeneic T-cell platform allows for rapid delivery of a T-cell immunotherapy product manufactured in advance of patient need and stored in inventory, with each manufactured lot of cells providing therapy for numerous potential patients. This differs from autologous treatments, in which each patient&#8217;s own cells must be extracted, genetically modified outside the body and then delivered back to the patient, requiring a complex logistics network. We currently have on hand sufficient tab-cel drug product inventory to supply commercial demand, if approved and subject to the specifications set forth in such approval, for at least 12 months. For our allogeneic programs, we select the appropriate set of cells for use based on a patient&#8217;s unique immune profile. In addition, our manufacturing facility has the flexibility to manufacture multiple T-cell and CAR T immunotherapies while integrating research and process science functions to enable increased collaboration for rapid product development. We are currently in the process of completing our facility&#8217;s commercial production qualification activities for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> while building inventory according to our commercial product supply strategy. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Commercialization Agreement with Pierre Fabre (Pierre Fabre Commercialization Agreement), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute <span style="color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia following regulatory approval. We will retain full rights to <span style="color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> </span>in other major markets, including North America, Asia Pacific and Latin America. Under the terms of the Pierre Fabre Commercialization Agreement, we are currently negotiating a Manufacturing and Supply Agreement as well as a number of ancillary agreements to further advance our collaboration with Pierre Fabre. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have also entered into research collaborations with leading academic institutions such as Memorial Sloan Kettering Cancer Center (MSK), the Council of the Queensland Institute of Medical Research (QIMR Berghofer) and H. Lee Moffitt Cancer Center and Research Institute (Moffitt) pursuant to which we acquired rights to novel and proprietary technologies and programs.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing facility in Thousand Oaks, California has the flexibility to manufacture multiple T-cell and CAR T immunotherapies while integrating research and process science</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> functions</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enable increased collaboration for rapid product development. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the process of completing our facility&#8217;s commercial production qualification activities for tab-cel</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> while building inventory according to our commercial product supply strategy.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our manufacturing facility, we also work with <span style="color:#000000;">Cognate pursuant to the </span>Manufacturing Agreement <span style="color:#000000;">that we entered into in December 2019</span>. Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. <span style="color:#000000;">The initial term of the Manufacturing Agreement, as amended, runs until May 31, 2022. We may terminate the Manufacturing Agreement for convenience on six months&#8217; written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. In March 2021, Charles River Laboratories Inc. (CRL) acquired Cognate.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a limited operating history. Since our inception in 2012, we have devoted substantially all of our resources to identify, acquire and develop our product candidates, including conducting preclinical and clinical studies, acquiring or manufacturing materials for clinical studies, constructing our manufacturing facility and providing general and administrative support for these operations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net losses were $340.1 million, $306.6 million and $291.0 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, we had an accumulated deficit of $1.5&#160;billion. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, our cash, cash equivalents and short-term investments totaled $371.1&#160;million, which we intend to use to fund our operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never generated revenues from the sale of products and have incurred losses since inception. We do not expect to receive any revenue from product sales unless and until we obtain <span style="color:#000000;">regulatory approval for and commercialize one of our current or future product candidates. Our revenues to date have been derived solely under agreements with Bayer and Pierre Fabre and are primarily related to upfront license fees, fees for research, process development and translational activities and technology transfer fees. We expect that any revenue we generate from our Bayer Agreements, the Pierre Fabre Commercialization Agreement and any future collaboration and research and license partners will fluctuate from year to year as a result of the timing and number of milestones and other payments.</span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our total operating expenses since inception has been our investment in research and development activities, including the preclinical and clinical development of our product candidates. Research and development expenses consist primarily of compensation and benefits for research and development employees, including stock-based compensation&#59; expenses incurred under agreements with contract research organizations and investigative sites that conduct preclinical and clinical studies&#59; the costs of acquiring and manufacturing clinical study materials and other supplies&#59; payments under licensing and research and development agreements&#59; other outside services and consulting costs&#59; and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue investment in the development of our product candidates. Our current planned research and development activities include the following:<span style="color:#000000;"> </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continuing to initiate sites and enroll patients in our Phase 3 clinical study of </span><span style="Background-color:#FFFFFF;color:#000000;">tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;"> for the treatment of patients with </span><span style="Background-color:#FFFFFF;color:#000000;">EBV+ PTLD</span><span style="color:#000000;"> after HCT and SOT who have failed rituximab&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">process development, testing and manufacturing of drug supply to support clinical studies and IND-enabling studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continuing development of ATA188 in progressive MS&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continuing to develop product candidates based on our next-generation CAR T programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continuing to develop our product candidates in additional indications, including tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV+ cancers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continuing to develop other preclinical product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">leveraging our relationships and experience to in-license or acquire additional product candidates or technologies. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we believe it is important to invest in the development of new product candidates to continue to build the value of our product candidate pipeline and our business. We plan to continue to advance our most promising early product candidates into preclinical development with the objective to advance these early-stage programs to human clinical studies over the next several years<span style="color:#000000;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs, and timing of clinical studies and development of our product candidates will depend on a variety of factors, including<span style="color:#000000;">:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the availability of qualified drug supply for use in our ongoing Phase 3 or other clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope, rate of progress, and expenses of our ongoing clinical studies, potential additional clinical studies and other research and development activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the potential review or reanalysis of our clinical study results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">future clinical study results&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">uncertainties in clinical study enrollment rates or discontinuation rates of patients, including any potential impact of the COVID-19 pandemic&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changing medical practice patterns related to the indications we are investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant and changing government regulation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">disruptions caused by man-made or natural disasters or public health pandemics or epidemics, including, for example, the COVID-19 pandemic&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing and receipt of any regulatory approvals, as well as potential post-market requirements. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of conducting the necessary clinical research to obtain approval from the FDA and other regulators is costly and time consuming and the successful development of our product candidates is highly uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in the section of this report titled &#8220;1A. Risk Factors.&#8221; As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of compensation and benefits for legal, human resources, finance, commercial and other general and administrative employees, including stock-based compensation&#59; professional services costs, including legal, patent, human resources, audit and accounting services&#59; other outside services and consulting costs, including those related to pre-commercial activities&#59; and information technology and facilities costs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest and Other Income, net<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expense), net consists primarily of interest earned on our cash, cash equivalents and short-term investments and translation gains and losses on transactions denominated in foreign currencies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our provision for (benefit from) income taxes consists primarily of income taxes in U.S. states and foreign jurisdictions. Our effective tax rate was 0% for the years ended December 31, 2021, 2020, and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our management&#8217;s </span>discussion and analysis of our financial condition and results of operations is based on our <span style="Background-color:#FFFFFF;">consolidated </span>financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. <span style="Background-color:#FFFFFF;">On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our significant judgments and estimates </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">are detailed below, and our significant accounting policies are more fully described in Note 2 of the accompanying consolidated financial statements</span><span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from out-license agreements is recognized when our customer obtains control of the promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue generated from our out-license agreements is not subject to repayment and typically includes upfront fees, development, regulatory and commercial milestone payments and royalties on the licensee&#8217;s future product sales.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our out-license agreements may include the transfer of intellectual property rights in the form of licenses, promises to provide research and development services and promises to participate on certain development committees with the collaboration party. We assess whether the promises in these agreements are considered distinct performance obligations that should be accounted for separately. Judgment is required to determine whether these promises are distinct. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price in each agreement is allocated to the identified performance obligations based on the standalone selling price (SSP) of each distinct performance obligation. Due to the early stage of our licensed technology, the license of such technology is typically combined with the additional promises in these agreements as one combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with nonrefundable upfront license fees where the license fees and other promises cannot be accounted for as separate performance obligations is deferred and recognized as revenue over the expected period of performance using an appropriate recognition method based on the nature of the performance obligations. We utilize judgment to assess the pattern of delivery of the performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete our performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. A time-based input method requires management to evaluate and estimate the pattern at which the performance obligation will be satisfied over the performance period. The cumulative effect of revisions to estimated costs to complete our performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in the assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each agreement that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is allocated to each performance obligation in the agreement based on relative SSP. We typically determine SSPs using an adjusted market assessment approach model. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of each such milestone and any related constraint, and if necessary, adjust our estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our financial statements, we are required to estimate and accrue expenses, the largest of which is related to research and development expenses, including those related to clinical studies and drug manufacturing. This process involves reviewing contracts and purchase orders, identifying and evaluating the services that have been performed on our behalf, and estimating the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, there were no material changes from our estimates of accrued research and development expenses. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates of accrued research and development expenses. However, if actual results are not consistent with our estimates, we may be exposed to changes in accrued research and development expenses that could be material or the accrued research and development expenses reported in our financial statements may not be representative of the actual economic cost of accrued research and development.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have stock-based compensation programs, which include restricted stock units (RSUs)&#59; stock options and an employee stock purchase plan. See Note 2 &#8211; &#8220;Summary of Significant Accounting Policies&#8221; and Note 10 &#8211; &#8220;Stockholders' Equity&#8221; in the Notes to Consolidated Financial Statements, included in Item 8. Financial Statements and Supplementary Data of this report for a complete discussion of our stock-based compensation programs. We account for stock-based compensation expense, including the expense for grants of RSUs and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumptions for the Black-Scholes valuation model used for employee stock awards include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Expected term &#8211; We derived the expected term for employee stock awards using the &#8220;simplified&#8221; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. Expected term for non-employee awards is based on the remaining contractual term of an option on each measurement date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Expected volatility &#8211; Prior to 2021, expected volatility was estimated using comparable public companies&#8217; volatility for similar terms. Beginning in 2021, volatility is estimated using an average of Atara&#8217;s historical volatility and comparable public companies&#8217; volatility for similar terms.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Expected dividend rate &#8211; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends&#59; therefore, we have assumed an expected dividend yield of 0%.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Risk-free interest rate &#8211; The risk-free interest rate is based on the yields of U.S. Treasury securities with expected terms similar to that of the associated award. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">The fair value of our common stock is measured at the market price on the measurement date. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to determine stock-based compensation expense. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to changes in stock-based compensation expense that could be material or the stock-based compensation expense reported in our financial statements may not be representative of the actual economic cost of the stock-based compensation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting for Income Taxes<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 11 &#8211; &#8220;Income Taxes&#8221; in the Notes to Consolidated Financial Statements, included in Item 8. Financial Statements and Supplementary Data of this report for a complete discussion of the components of Atara's income tax expense, as well as the temporary differences that exist as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated effective income tax rate is influenced by tax planning opportunities available to us in the various jurisdictions in which we conduct business. Significant judgment is required in evaluating our tax positions, including those that may be uncertain. Atara is also required to exercise judgment with respect to the realization of our net deferred tax assets. Management evaluates all positive and negative evidence and exercises judgment regarding past and future events to determine if it is more likely than not that all or some portion of the deferred tax assets may not be realized. If appropriate, a valuation allowance is recorded against deferred tax assets to offset future tax benefits that may not be realized.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that there is a reasonable likelihood that there will be a material change in our liability for uncertain income tax positions or our effective income tax rate. However, if actual results are not consistent with our estimates or assumptions, we may be exposed to losses that could be material. Atara recorded a valuation allowance of approximately $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376.1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million as of December 31, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> related primarily to net operating losses, capitalized expenses and stock-based compensation.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2021, 2020 and 2019</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p>
<p style="margin-bottom:10pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues for the periods indicated were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 compared to 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 compared to 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,340</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,340</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues were $20.3 million in 2021 as compared to zero in 2020 and 2019. The amount recorded in 2021 relates primarily to revenue recognized under the Bayer Agreements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consisted of the following costs, by program, in the periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 compared to 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 compared to 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,086</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,196</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,110</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATA188, CAR T and other program expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,424</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,124</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,869</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,300</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,745</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee and overhead expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,491</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,330</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,049</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,161</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,281</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">282,001</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244,650</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216,097</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,351</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,553</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> <span style="color:#000000;">expenses were $50.1 million in 2021 as compared to $61.2 million in 2020 and $49.2 million in 2019. The decrease in 2021 was primarily due to higher production activities in 2020 related to the build-up of our tab-cel</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="color:#000000;"> and process performance qualification activities at our manufacturing facility. The increase in 2020 was due to increased clinical trial costs and process performance qualification activities at our manufacturing facility, as well as increased activity to support our tab-cel</span><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><span style="color:#000000;"> BLA filing</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATA188, CAR T and other program expenses were $36.4 million in 2021 as compared to $25.1 million in 2020 and $34.9 million in 2019. The increase in 2021 was primarily related to research, development, and clinical trial costs to further advance ATA188 and our CAR T programs. The decrease in 2020 was primarily due to lower clinical study, manufacturing and other outside services costs for programs that are no longer in active development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee and overhead expenses were $195.5 million in 2021 as compared to $158.3 million in 2020 and $132.0 million in 2019. The increases were primarily due to higher compensation-related costs from increased headcount and higher facility-related costs in support of our continuing expansion of research and development activities. Payroll and related costs increased by $19.3 million in 2021 as compared to 2020 and by $21.2 million in 2020 as compared to 2019. Facility-related costs increased by $11.7 million in 2021 as compared to 2020 and by $5.1 million in 2020 as compared to 2019. Outside service costs increased by $6.2 million in 2021 as compared to 2020 and remained consistent in 2020 as compared to 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses for 2021 and 2020 were not significantly impacted by the COVID-19 pandemic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and administrative expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the periods indicated were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;ended&#160;December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 compared to 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 compared to 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,801</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,402</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,399</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,182</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $78.8 million in 2021 as compared to $64.4 million in 2020 and $79.6 million in 2019. The increase in 2021 was primarily due to higher compensation-related costs from increased headcount and activities to support our anticipated tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> launch. The decrease in 2020 was primarily due to decreases in outside services costs and non-cash stock-based compensation expenses. Total general and administrative expenses for 2021 and 2020 were not significantly impacted as a result of the COVID-19 pandemic. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2012, we have funded our operations primarily through the issuance of common and preferred stock, issuance of pre-funded warrants to purchase common stock and from upfront fees from the Bayer License Agreement and the Pierre Fabre Commercialization Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we completed an underwritten public offering of 5,102,041 shares of common stock at a public offering price of $24.50 per share and pre-funded warrants to purchase 2,040,816 shares of common stock at a public offering price of $24.4999 per warrant. We received net proceeds of approximately $164.3 million after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, we completed an underwritten public offering of 14,958,039 shares, inclusive of the exercise of the full option granted to the underwriters, of common stock at a public offering price of $11.32 per share and pre-funded warrants to purchase 2,866,961 shares of common stock at a public offering price of $11.3199 per warrant. We received net proceeds of approximately $189.3 million after deducting underwriting discounts and commissions and offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we completed an underwritten public offering of 6,871,727 shares of common stock at a public offering price of $15.28 per share and pre-funded warrants to purchase 2,945,026 shares of common stock at a public offering price of $15.2799 per warrant. We received aggregate net proceeds of approximately $140.7 million after deducting underwriting discounts and commissions and offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past three years, we have entered into three separate sales agreements with Cowen and Company, LLC (Cowen): in February 2019 (the 2019 ATM Facility), in February 2020 (the 2020 ATM Facility) and in November 2021 (the 2021 ATM Facility). Each ATM facility provides or provided for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million, through Cowen, as our sales agent. The issuance and sale of these shares by us pursuant to the ATM facilities are deemed &#8220;at the market&#8221; offerings defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and were registered under the Securities Act. Commissions of up to 3.0% are due on the gross sales proceeds of the common stock sold under each ATM facility. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, we sold an aggregate of 6,240,601 shares of common stock under the ATM facilities, at an average price of $16.23 per share for net proceeds of $98.9 million, after deducting commissions and other offering expenses payable by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we have fully utilized the 2019 ATM Facility and the 2020 ATM Facility, and we had $78.3 million of common stock remaining and available to be sold under the 2021 ATM Facility.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2022 through February 15, 2022, we sold an additional 1,319,878 shares of common stock under the 2021 ATM Facility, at an average price of $15.88 per share, for gross proceeds of $21.0 million and net proceeds of $20.5 million, after deducting commissions and other offering expenses payable by us. As of February 15, 2022, we had $57.4 million of common stock remaining and available to be sold under the 2021 ATM Facility, subject to certain conditions as specified in the agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and negative cash flows from operations in each year since inception. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to receive any revenues from the sale of products unless and until we obtain regulatory approval for and commercialize any of our product candidates. As such, we anticipate that we will continue to incur losses in the foreseeable future. We expect that our operating expenses will continue to increase. As a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We may borrow funds on terms that may include restrictive covenants, including covenants that restrict the operation of our business, liens on assets, high effective interest rates and repayment provisions that reduce cash resources and limit future access to capital markets. In addition, we expect to continue to opportunistically seek access to additional funds through additional public or private equity offerings or debt financings including by utilizing the 2021 ATM Facility, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses or other rights on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash, cash equivalents and short-term investments are held in bank and custodial accounts and consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and short-term investments balances as of the dates indicated were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,084</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,404</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,984</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,255</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and short-term investments</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371,068</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,659</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease our corporate headquarters in South San Francisco, California under a non-cancellable lease agreement for approximately 13,670 square feet of office space. In October 2020, we entered into an amendment of this lease to extend the lease term by one year and in December 2021, we entered into a further amendment to extend the lease for an additional three years. The amended lease expires in May 2025. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a lease agreement for approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California. The initial 15-year term of this lease commenced in February 2018, and the contractual obligations during the initial term are $16.4 million in aggregate.&#160;We have the option to extend this lease for two additional periods of ten and nine years, respectively, after the initial term. In connection with this lease, we were required to issue a letter of credit in the amount of $1.2 million to the landlord, which is recorded as long-term restricted cash in our consolidated balance sheet. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into a lease agreement for approximately 51,160 square feet of office space in Thousand Oaks, California.&#160;The initial term of this lease expires in February 2026. The contractual obligations during the initial term are $8.5 million in aggregate. We have the option to extend the lease for an additional period of five years after the initial term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a new lease agreement for approximately 8,800 square feet of office and lab space in Aurora, Colorado. The initial term of this lease expires in April 2024. In February 2021, we further amended this lease to add an additional 2,861 square feet of lab space. The contractual obligations during the lease term are not material. We have the option to extend this lease for two additional five-year periods after the initial term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a new lease agreement for approximately 33,659 square feet of office, lab and warehouse space in Thousand Oaks, California. The initial 10.5-year term of this lease commenced in August 2021 and the contractual obligations during the initial term are $21.0 million in aggregate. We have the option to extend this lease for two additional five-year periods after the initial term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contractual obligations primarily consist of our obligations under non-cancellable operating and finance leases and contracts we enter into in the normal course of business with clinical research organizations for clinical studies, with contract manufacturing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">organizations for clinical supplies, and with other vendors for preclinical studies and supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, with the exception of one of our contract manufacturing agreements which we may terminate for convenience upon six months&#8217; written notice.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table details the primary sources and uses of cash for each of the periods set forth below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220,522</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235,626</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,258</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120,728</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,459</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,944</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,574</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,786</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,320</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,087</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,619</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $220.5 million in 2021 as compared to $180.8 million in 2020. The increase of $39.7 million was primarily due to an increase in net loss of $33.5 million and increased usage of net working capital, partially offset by $45.0 million received as a result of the Pierre Fabre Commercialization Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $180.8 million in 2020 as compared to $235.6 million in 2019. The decrease of $54.9 million was primarily due to $52.9 million received as a result of the Bayer License Agreement, a $14.9 million increase in other net operating liabilities and a $2.2 million increase in the amortization of investment premiums, partially offset by a $15.6 million increase in net loss. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities in 2021 consisted primarily of $334.0 received from maturities and sales of available-for-sale securities, partially offset by $301.1 million used to purchase available-for-sale securities and $10.6 million in purchases of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities in 2020 consisted primarily of $425.9 million used to purchase available-for-sale securities and $4.5 million in purchases of property and equipment, partially offset by $309.7 million received from maturities and sales of available-for-sale securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities in 2019 consisted primarily of $336.3 million received from maturities and sales of available-for-sale securities, partially offset by $270.2 million used to purchase available-for-sale securities and $5.7 million in purchases property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities in 2021 consisted primarily of $98.7 million of net proceeds from ATM facilities and $6.8 million of net proceeds from employee stock award transactions, partially offset by $1.2 million of taxes paid related to the net share settlement of RSUs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities in 2020 consisted primarily of $353.8 million of aggregate net proceeds received from the two underwritten public offerings of common stock and pre-funded warrants, $69.2 million of net proceeds from ATM facilities and $6.7 million of net proceeds from employee stock award transactions, partially offset by $1.5 million of taxes paid related to the net share settlement of RSUs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities in 2019 consisted primarily of $140.9 million of net proceeds received from an underwritten public offering of common stock and pre-funded warrants, $47.7 million of net proceeds from ATM facilities and $7.4 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of net proceeds from employee stock award transactions, partially offset by $6.7 million of taxes paid related to the net share settlement of RSUs. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Capital Requirements and Plan of Operations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the accumulated losses to increase as we continue the development of and seek regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all of the risks inherent in the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need to raise substantial additional funding in connection with our continuing and expected expansion of our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 together with the anticipated $100.0 million from FUJIFILM Diosynth Biotechnologies California Inc. (FDB), payable upon closing of the strategic transaction with FDB, will be sufficient to fund our planned operations into the fourth quarter of 2023. See Note 12 &#8211; Subsequent Events for further information. In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding. In addition, we expect to continue to opportunistically seek access to additional funds through additional public or private equity offerings or debt financings, through potential collaborations, partnering or other strategic arrangements, or a combination of the foregoing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to<span style="color:#000000;">: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing, costs and results of our ongoing and planned clinical and preclinical studies for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our success in establishing and scaling commercial manufacturing capabilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the number and characteristics of product candidates that we pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the outcome, timing and costs of seeking regulatory approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">subject to receipt of regulatory approval, costs associated with the commercialization of our product candidates and the amount of revenues received from commercial sales of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing of proceeds from the Bayer License Agreement and the Pierre Fabre Commercialization Agreement, as well as the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which we in-license or acquire other products and technologies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing of capital expenditures, including the qualification of our manufacturing facility.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until we are able to generate a sufficient amount of product revenue and generate positive net cash flows from operations, which we may never do, meeting our long-term capital requirements is in large part reliant on access to public and private equity and debt capital markets, augmented by cash generated from operations and interest income earned on the investment of our cash balances. We expect to continue to seek access to the equity and debt capital markets to support our development efforts and operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration or partnering arrangements, we may be required to relinquish some of our rights to our technologies or rights to market and sell our products in certain geographies, grant licenses or other rights on terms that are not favorable to us, or issue equity that may be substantially dilutive to our stockholders.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of economic conditions, general global economic uncertainty, political change and other factors, including the ongoing COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we will be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_7A">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest Rate and Market Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates. As of December 31, 2021, we had total cash, cash equivalents and short-term investments of $371.1 million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S.&#160;interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase,<span style="color:#000000;"> which could result in a realized loss if we are forced to sell an investment before its scheduled maturity</span>. <span style="color:#000000;">We&#160;currently do not hedge our interest rate risk exposure. </span>Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate change in interest rates of 10 basis points would not result in a significant change in the fair market value of our portfolio.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. To achieve this objective, we maintain our portfolio of cash equivalents and short-term and long-term investments in a variety of securities, including money market funds, U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. These securities are all classified as available-for-sale and consequently are recorded on the balance sheet at fair value, with unrealized gains or losses reported as a separate component of accumulated other comprehensive income (loss). Our holdings of the securities of any one issuer, except for obligations of the U.S. Treasury, U.S. Treasury-guaranteed securities or money market funds, do not exceed 5% of our portfolio. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item&#160;8. Financial Statements and Supplementary Data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:9.9pt;">
<td valign="bottom" style="width:93.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="text-decoration:underline;"> </span>(PCAOB ID <ix:nonNumeric id="F_000035" name="dei:AuditorFirmId" contextRef="C_0001604464_20210101_20211231">34</ix:nonNumeric>)</p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_COMBINED_STATEMENTS_OPERATI"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_COMBINED_STATEMENTS_CONVERT"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and the Board of Directors of Atara Biotherapeutics, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Atara Biotherapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue and Deferred Revenue &#8211; Accounting for Out- License Agreement &#8211; Refer to Note 2 and 7 to the Financial Statements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Critical Audit Matter Description</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into certain out-license agreements with Bayer and Pierre Fabre. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, the Company entered into a Technology Transfer Agreement and a Manufacturing and Supply Agreement with Bayer AG (&#8220;Bayer&#8221;), both of which were contemplated as part of the existing Bayer License Agreement. Under the terms of these agreements, the company will be responsible for technology transfer services, supply of materials required for technology transfer services, and for manufacturing, storage, and distribution of therapies to Bayer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, during 2021, the Company entered into a commercialization agreement with Pierre Fabre Medicament (&#8220;Pierre Fabre&#8221;). Under the terms of the agreement, the Company granted Pierre Fabre a license to commercialize and distribute therapies and will be responsible for manufacturing and supplying the therapies to Pierre Fabre, along with related cell selection services.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue on out-license agreements as they satisfy their performance obligations and when a customer obtains control of the promised goods or services. As of December 31, 2021, the Company recognized $20.3 million of revenue under the out-license agreements and deferred revenue amounted to $96.5 million, of which $40.8 million is included in current liabilities and $55.7 million is included in long-term liabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified accounting for the out-license agreements, the revenue recognized, and the estimated deferred revenue to be recognized as revenue over time as a critical audit matter. Given the judgments necessary to determine the accounting literature to apply to an out-license agreement, the method to estimate and measure the progress toward the completion of the performance obligation and the estimated contractual term over which the performance obligation would be completed, auditing such judgments and estimates required extensive audit effort due to the complexity of the out-license agreements and the high degree of auditor judgment applied when performing audit procedures and evaluating the results of those procedures.<span style="font-weight:bold;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How the Critical Audit Matter Was Addressed in the Audit</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit procedures related to determining the accounting literature to apply to the agreements and, where applicable, assessing management's estimates of costs used in the cost-based input method for measuring progress included the following, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We tested the operating effectiveness of controls over out-license related revenue, including those related to the identification of distinct performance obligations and the determination of the timing and amount of revenue recognized.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We reviewed and obtained an understanding of the Company&#8217;s revenue generating agreements and related transactions during and at the end of the year via review of internal and external presentations, news and publications, and discussions with management.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We evaluated management&#8217;s determination that the agreement is within the scope of ASC 606.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We tested management's identification of the performance obligation(s) by evaluating whether the promises were highly interdependent and interrelated</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We evaluated management's determination of the contractual term and the appropriateness of management's method to measure its progress over that term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We evaluated the assumptions used in the estimates of total costs and the estimated measure of progress for recognizing revenues over time revenue by:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Performing corroborating inquiries with the Company's project and business development managers, and comparing the assumptions used in the estimates to management's work plans and cost estimates, and costs reported to date</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Comparing costs incurred for activities completed to date to the costs forecasted for those activities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Testing the mathematical accuracy of management&#8217;s revenue and current and long-term deferred revenue balances based on the estimated revenue to be recognized over time.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses &#38; Prepaid Research and Development Expenses (Clinical Trial Accrued and Prepaid Expenses) - Refer to Note 2 to the financial statements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Critical Audit Matter Description</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes costs it incurs for preclinical studies, clinical studies, and manufacturing activities as research and development expenses based on an evaluation of its vendors&#8217; progress toward completion of specific tasks. Payment timing may differ significantly from the period in which the costs are recognized as expense. Costs that are paid in advance are deferred as a prepaid expense and amortized over the service period as the services are provided. Costs for services incurred that have not yet been be paid are recognized as accrued expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In estimating the vendors&#8217; progress toward completion of specific tasks, the Company uses data such as patient enrollment, clinical site activations or vendor information of actual costs incurred. This data is obtained through reports from or discussions with Company personnel and outside service providers as to the progress or state of completion of trials, or the completion of services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the number of ongoing preclinical study, clinical study, and manufacturing activities and the subjectivity involved in estimating clinical study accrued and prepaid expenses, auditing the clinical study accruals and prepaid expenses involved especially subjective judgment.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How the Critical Audit Matter Was Addressed in the Audit</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit procedures related to clinical study accrued and prepaid expenses included the following, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We tested the design and effectiveness of controls over the estimation of clinical study accrued and prepaid expenses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We obtained and read a sample of research, collaboration, and manufacturing agreements and contracts, as well as amendments thereto. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We evaluated publicly available information (such as press releases and investor presentations) and board of directors&#8217; materials regarding the status of clinical trial and manufacturing activities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We obtained the listing of all contracts related to research and development expenses to evaluate the completeness of accruals and prepaid expenses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">For a sample of agreements and contracts, we compared the amount of accrual or prepaid expenses at the end of the prior period to current year activity and evaluated the accuracy of the Company&#8217;s estimation methodology.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We obtained a written confirmation of the ending inventory balance held at the Company&#8217;s manufacturing vendor.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We made selections of specific amounts recognized as research and development expense as well as those recognized as accrued and prepaid expenses to evaluate management&#8217;s estimate of the vendor&#8217;s progress and performed the following procedures: </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Read the related statement of work, purchase order, or other supporting documentation (such as communications between the Company and vendors).</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Performed corroborating inquiries with Company clinical operations and manufacturing operations personnel.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Confirmed progress directly with the vendor and compared the reported amounts to the Company's estimate.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Evaluated management&#8217;s judgments compared to the evidence obtained.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="font-style:italic;"><ix:nonNumeric id="F_000034" name="dei:AuditorName" contextRef="C_0001604464_20210101_20211231">DELOITTE &#38; TOUCHE LLP</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000036" name="dei:AuditorLocation" contextRef="C_0001604464_20210101_20211231">San Francisco, California</ix:nonNumeric>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2013.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Atara Biotherapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">106,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">200,404</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:ShortTermInvestments" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">264,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:ShortTermInvestments" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">300,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short-term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001604464_20201231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AssetsCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">384,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AssetsCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">523,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long-term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" scale="3">827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Assets" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">468,127</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:Assets" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">588,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="atra:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="atra:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:DeferredIncomeCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:DeferredIncomeCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - long-term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:DeferredIncomeNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,708</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:DeferredIncomeNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - long-term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:Liabilities" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:Liabilities" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 9)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000079">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock&#8212;$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001604464_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001604464_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001604464_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">500,000</ix:nonFraction></ix:nonFraction> shares authorized as of December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021 and 2020, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">91,671</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001604464_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001604464_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">83,372</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2021 and 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:CommonStockValue" contextRef="C_0001604464_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommonStockValue" contextRef="C_0001604464_20201231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,744,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,586,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001604464_20211231" decimals="-3" sign="-" scale="3">368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001604464_20201231" decimals="-3" scale="3">296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001604464_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,464,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001604464_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,124,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">279,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">462,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">468,127</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">588,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Atara Biotherapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_COMBINED_STATEMENTS_OPERATI">Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">282,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">244,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">216,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OperatingExpenses" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">360,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:OperatingExpenses" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">309,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:OperatingExpenses" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">295,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,462</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">309,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">295,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) gain:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" scale="3">664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000134" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001604464_20210101_20211231" decimals="2" sign="-">3.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000135" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001604464_20200101_20201231" decimals="2" sign="-">4.15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000136" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001604464_20190101_20191231" decimals="2" sign="-">5.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding used to calculate</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;basic and diluted net loss per common share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000137" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Atara Biotherapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_COMBINED_STATEMENTS_CONVERT">Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="us-gaap:SharesOutstanding" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">866,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">526,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">339,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock through underwritten offerings, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231" decimals="-3" scale="3">284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="atra:IssuanceOfCommonStockNetOfOfferingCostsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="atra:IssuanceOfCommonStockNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="atra:IssuanceOfCommonStockNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">140,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="atra:IssuanceOfCommonStockNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">140,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock through ATM facilities, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions and offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU settlements, net of shares withheld</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000153" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to employee stock awards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:SharesOutstanding" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,108,516</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">817,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">290,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock and pre-funded warrants through</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; underwritten offering, net of offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" scale="3">583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000171" name="atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">353,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">353,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock through ATM facilities, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions and offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of pre-funded warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000178" name="atra:StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU settlements, net of shares withheld</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000179" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to employee stock awards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000182" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" scale="3">76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000191" name="us-gaap:SharesOutstanding" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,586,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,124,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">462,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock through ATM facilities, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions and offering costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000197" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU settlements, net of shares withheld</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000201" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to employee stock awards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000204" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetIncomeLoss" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" scale="3">664</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000213" name="us-gaap:SharesOutstanding" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,744,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,464,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquity" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">279,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Atara Biotherapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)<span style="font-size:12pt;font-weight:normal;">&#160;</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:ProfitLoss" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:ProfitLoss" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:ProfitLoss" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:ShareBasedCompensation" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:ShareBasedCompensation" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:ShareBasedCompensation" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash operating lease expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="atra:NonCashOperatingLeaseExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="atra:NonCashOperatingLeaseExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="atra:NonCashOperatingLeaseExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization (accretion) of investment premiums (discounts)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposals of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset retirement obligation accretion expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:AccretionExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:AccretionExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:AccretionExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="atra:IncreaseDecreaseInOperatingLeaseAssets" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="atra:IncreaseDecreaseInOperatingLeaseAssets" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="atra:IncreaseDecreaseInOperatingLeaseAssets" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" scale="3">815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="atra:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="atra:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="atra:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" scale="3">394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="atra:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="atra:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="atra:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" scale="3">731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">220,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">180,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">235,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">301,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">425,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">270,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities and sales of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">333,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">309,653</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">336,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">120,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of common stock and pre-funded warrants in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;underwritten offerings, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">353,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">140,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock through ATM facilities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from employee stock awards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes paid related to net share settlement of restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments on finance and capital lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other financing activities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">427,574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">94,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">201,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">201,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-cash investing and financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable and other</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued costs related to underwritten public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued costs related to ATM facility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock through ATM facilities not yet received</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow disclosure</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:InterestPaidNet" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:InterestPaidNet" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">62</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:InterestPaidNet" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.08%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Atara Biotherapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000345" name="atra:BusinessDescriptionTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc. (&#8220;Atara&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;the Company&#8221;) was incorporated in August 2012 in <ix:nonNumeric id="F_000402" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric>. <span style="Background-color:#FFFFFF;color:#000000;">Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (&#8220;CAR T&#8221;) programs. Our most advanced T-cell immunotherapy program, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (tabelecleucel), is currently in Phase 3 development, and in October 2021, we entered into a commercialization agreement (&#8220;Pierre Fabre Commercialization Agreement&#8221;) with Pierre Fabre Medicament (&#8220;Pierre Fabre&#8221;), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia, following regulatory approval. Atara will retain full rights to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in other major markets, including North America, Asia Pacific and Latin America. See Note 7 for further information. In December 2020, we entered into a research, development and license agreement (&#8220;Bayer License Agreement&#8221;) with Bayer AG (&#8220;Bayer&#8221;) pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271. In March 2021, as contemplated under the Bayer License Agreement and to further advance our collaboration, we entered into (i) a Manufacturing and Supply Agreement&#59; (ii) a Pharmacovigilance Agreement&#59; (iii) a Quality Agreement&#59; and (iv) a Technology Transfer Agreement (collectively, the Bayer License Agreement, the Manufacturing and Supply Agreement and the Technology Transfer Agreement are referred to as the &#8220;Bayer Agreements&#8221;). See Note 7 for further information. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;), rights related to our next-generation CAR T programs from MSK and from H. Lee Moffitt Cancer Center (&#8220;Moffitt&#8221;), and rights to know-how and technology from the Council of the Queensland Institute of Medical Research (&#8220;QIMR Berghofer&#8221;). See Note 6 for further information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000346" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000346_dcnt_b5992052-a4c5-49c7-971a-d77babf6bc35">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000357" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and follow the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p></ix:nonNumeric><ix:nonNumeric id="F_000358" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Atara and our wholly owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. </p></ix:nonNumeric><ix:nonNumeric id="F_000359" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment <span style="color:#000000;">and Geographic Information</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate and manage our business as <ix:nonFraction unitRef="U_atraSegment" id="F_000404" name="us-gaap:NumberOfReportableSegments" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_atraSegment" id="F_000405" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, which is the business of developing and commercializing therapeutics. Our Chief Executive Officer, who is our chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Substantially all of our assets are located in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">20.3</ix:nonFraction> million license and collaboration revenue recognized in 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231" decimals="-5" scale="6">19.8</ix:nonFraction> million related to our agreements with Bayer, a German company, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231" decimals="-5" scale="6">0.5</ix:nonFraction> million related to our agreements with Pierre Fabre, a French company. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_b5992052-a4c5-49c7-971a-d77babf6bc35" continuedAt="F_000346_dcnt_228b4e7c-53d9-4f5d-911d-1a379ec459b6"><ix:nonNumeric id="F_000360" name="atra:LiquidityRiskPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and have relied primarily on public and private equity financings and receipts from license and collaboration agreements to fund our operations. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. </p></ix:nonNumeric><ix:nonNumeric id="F_000361" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds&#59; U.S. Treasury, government agency and corporate debt obligations&#59; commercial paper&#59; certificates of deposit&#59; and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: our ability to obtain future financing&#59; regulatory approval and market acceptance of, and reimbursement for, our product candidates, if approved by applicable regulatory authorities&#59; our ability to collect amounts due from our collaboration partners, future customers or distribution partners&#59; performance of third-party clinical research organizations and manufacturers upon which we rely&#59; development of sales channels&#59; protection of our intellectual property&#59; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors&#59; and our ability to attract and retain employees necessary to support our growth. </p></ix:nonNumeric><ix:nonNumeric id="F_000362" name="us-gaap:UseOfEstimates" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000363" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions and monetary assets and liabilities that are denominated in a foreign currency are translated into U.S. dollars at the current exchange rate on the transaction date and as of&#160;each balance sheet date, respectively, with gains or losses on foreign exchange changes recognized in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. Foreign currency-denominated monetary assets and liabilities as of December 31, 2021 were not material.</p></ix:nonNumeric><ix:nonNumeric id="F_000364" name="atra:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000364_dcnt_1c96e279-c07c-4519-a7d1-fb806ab287c2">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents and Short-Term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are defined as short-term, highly liquid investments with original maturities of <ix:nonNumeric id="F_000409" name="atra:CashAndCashEquivalentsMaturityPeriod" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:durday">90</ix:nonNumeric>&#160;days or less at the date of purchase, and generally consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, and commercial paper. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than <ix:nonNumeric id="F_000410" name="atra:InvestmentMaturityPeriod" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:durday">90</ix:nonNumeric> days are classified as short-term investments on the balance sheet, and consist primarily of U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As <span style="color:#000000;">our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale and as current assets, even though the stated maturity may be more than one year from the current balance sheet date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheet.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both recorded to interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_228b4e7c-53d9-4f5d-911d-1a379ec459b6" continuedAt="F_000346_dcnt_a9134917-a752-482b-a9f8-c2796cfd6ec2"><ix:continuation id="F_000364_dcnt_1c96e279-c07c-4519-a7d1-fb806ab287c2">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the fair value of available-for-sale securities impact the consolidated statements of operations and comprehensive loss only when such securities are sold, if an allowance for credit losses is recognized or if an impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security&#8217;s cost basis. We regularly review our investment portfolio to determine if any security is impaired, which would require us to record an allowance for credit losses or impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, our intent to sell or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. Realized gains and losses, allowances for credit losses and impairments on available-for-sale securities, if any, are recorded to interest and other income, net in the statements of operations and comprehensive loss</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;">&#160;</span></p></ix:continuation><ix:nonNumeric id="F_000365" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain of our financial instruments including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Short-term investments are comprised of available-for-sale securities, which are carried at fair value. </p></ix:nonNumeric><ix:nonNumeric id="F_000366" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial assets are measured at fair value <span style="color:#000000;">on a recurring basis using the following hierarchy to prioritize valuation inputs,</span> in accordance with applicable GAAP: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities that we have the ability to access</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs that are unobservable data points that are not corroborated by market data</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. </p></ix:nonNumeric><ix:nonNumeric id="F_000367" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from <ix:nonNumeric id="F_000411" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_a86802d6-8853-481d-a316-0346a59c973a">three</ix:nonNumeric> to <ix:nonNumeric id="F_000412" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">five<ix:continuation id="C_a86802d6-8853-481d-a316-0346a59c973a"> years</ix:continuation></ix:nonNumeric>. Costs incurred to acquire, construct or install property and equipment during the construction stage of a capital project or costs incurred to purchase and develop internal use software during the application development stage are recorded as construction in progress. Leasehold improvements are amortized over the lesser of the life of the leasehold improvements or the lease term. Maintenance and repairs are charged to operations as incurred. </p></ix:nonNumeric><ix:nonNumeric id="F_000368" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate the carrying amount of our long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. To date, there have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001604464_20210101_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> such impairment losses. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_a9134917-a752-482b-a9f8-c2796cfd6ec2" continuedAt="F_000346_dcnt_e957f755-5d91-4742-a2fe-b726e6af6eb8"><ix:nonNumeric id="F_000369" name="us-gaap:AssetRetirementObligationsPolicy" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Retirement Obligations (&#8220;ARO&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO are legal obligations associated with the retirement of long-lived assets pertaining to leasehold improvements. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Subsequent to initial recognition, the Company records period-to-period changes in the ARO liability resulting from the passage of time and revisions to either the timing or the amount of the original estimate of undiscounted cash flows. The Company derecognizes ARO liabilities when the related obligations are settled.</p></ix:nonNumeric><ix:nonNumeric id="F_000370" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement is a lease at inception in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span>. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet&#59; we recognize short-term lease expense for these leases on a straight-line basis over the lease term. Finance leases are included in other assets, other current liabilities, and other long-term liabilities on our consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The lease term includes renewal options that we are reasonably certain of exercising as of the commencement date. None of the lease terms used to calculate the future minimum lease payments at commencement date include renewal options. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. Lease assets also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized over the shorter of the lease term or the asset&#8217;s estimated useful life.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facilities and equipment operating leases have lease and non-lease components and we have made a policy election to account for the lease and non-lease components as a single lease component. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000371" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000371_dcnt_e32fd8c7-0178-4fa5-a149-e9c30252ba6b">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception, we determine whether contracts are within the scope of Accounting Standards Codification Topic 606 (ASU No. 2014-09), <span style="font-style:italic;">Revenue from Contracts with Customers</span>, and all subsequent amendments (collectively, &#8220;ASC 606&#8221;) or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer&#59; (ii) identify the performance obligations in the contract&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when or as we satisfy a performance obligation. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for our out-license agreements in Note 7. Our out-license agreements do not contain a significant financing component. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_e957f755-5d91-4742-a2fe-b726e6af6eb8" continuedAt="F_000346_dcnt_6e671c59-71c1-418c-8289-7c5ba0d29876"><ix:continuation id="F_000371_dcnt_e32fd8c7-0178-4fa5-a149-e9c30252ba6b">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> typically determine standalone selling prices using an adjusted market assessment approach model.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced or (iii) our performance does not create an asset with an alternative use to the entity and we have an enforceable right to payment for performance completed to date. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring control of a promised good or service to a customer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, our deferred revenue is related to the Bayer Agreements and the Pierre Fabre Commercialization Agreement, which are both within the scope of ASC 606. As discussed in further detail in Note 7, the terms of these arrangements include potential payments to us for some or all of the following: nonrefundable, upfront fees&#59; development, regulatory, and commercial milestone payments&#59; research and development funding payments&#59; and royalties on the net sales of licensed products. These payments relate to promised goods or services for which revenue will be recognized upon our satisfaction of the underlying performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property<span style="font-style:normal;">: If the license of our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Upfront payments</span>: Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the we have satisfied our obligations under these arrangements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Milestone payments</span>: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a significant reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenues and the consolidated statements of operations and comprehensive loss in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Royalties</span>: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue resulting from our out-licensing agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_6e671c59-71c1-418c-8289-7c5ba0d29876" continuedAt="F_000346_dcnt_17e5c90f-a860-4597-8d94-2b419fd55cef"><ix:nonNumeric id="F_000372" name="atra:ContractBalancesPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive payments from our customers based on billing schedules established in each contract. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Our contract liabilities consist of deferred revenue.</p></ix:nonNumeric><ix:nonNumeric id="F_000373" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000373_cnt_1">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation expense, including the expense of restricted common stock awards (&#8220;RSAs&#8221;), grants of restricted stock units (&#8220;RSUs&#8221;), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the closing market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. Stock-based compensation expense for awards with time-based vesting criteria is recognized as expense on a straight-line basis over the requisite service period. Stock-based compensation expense for awards with performance and other vesting criteria is recognized as expense under an accelerated graded vesting model. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key assumptions used in the Black-Scholes valuation model used for employee stock awards include:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;"> &#8211; We derived the expected term using the &#8220;simplified&#8221; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;"> &#8211; Prior to 2021, expected volatility was estimated using comparable public companies&#8217; volatility for similar terms. </span><span style="color:#000000;font-style:normal;">Beginning in 2021, volatility is estimated using an average of Atara&#8217;s historical volatility and comparable public companies&#8217; volatility for similar terms. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend<span style="font-style:normal;"> &#8211; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends&#59; therefore, we assumed an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001604464_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction>%. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;"> &#8211; The risk-free interest rate is based on the yield on U.S. Treasury securities with the expected term of the associated award. </span></p></ix:nonNumeric><ix:continuation id="F_000373_cnt_1">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of our common stock is measured at the closing market price on the measurement date. <span style="color:#000000;">We account for forfeitures of stock-based awards as they occur.</span> </p></ix:continuation><ix:nonNumeric id="F_000375" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of costs incurred in performing research and development activities, including compensation and benefits for research and development employees, including stock-based compensation&#59; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies&#59; the costs of acquiring and manufacturing clinical study materials and other supplies&#59; payments under licensing and research and development agreements&#59; other outside services and consulting costs, and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred. </p></ix:nonNumeric><ix:nonNumeric id="F_000376" name="atra:ClinicalTrialAccrualsPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Study Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_17e5c90f-a860-4597-8d94-2b419fd55cef"><ix:nonNumeric id="F_000377" name="atra:DefinedContributionPlanPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Defined Contribution Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have one qualified <ix:nonNumeric id="F_000415" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" contextRef="C_0001604464_20210101_20211231">401(k)</ix:nonNumeric> plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000416" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0001604464_20210101_20211231" decimals="INF" scale="-2">50</ix:nonFraction>% of each dollar contributed up to the first <ix:nonFraction unitRef="U_xbrlipure" id="F_000417" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001604464_20210101_20211231" decimals="INF" scale="-2">6</ix:nonFraction>% of an individual&#8217;s eligible earnings, up to the annual IRS maximum. For the years ended December 31, 2021, 2020, and 2019 we recorded matching contributions of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="atra:DefinedContributionPlanContributionsByEmployer" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="atra:DefinedContributionPlanContributionsByEmployer" contextRef="C_0001604464_20200101_20201231" decimals="-5" scale="6">2.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="atra:DefinedContributionPlanContributionsByEmployer" contextRef="C_0001604464_20190101_20191231" decimals="-5" scale="6">1.6</ix:nonFraction> million, respectively. </p></ix:nonNumeric><ix:nonNumeric id="F_000378" name="atra:OtherCurrentLiabilitiesPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Current Liabilities</p><ix:nonNumeric id="F_000382" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued operating expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of finance lease liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0001604464_20201231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000379" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the asset and liability method to account for income taxes. We record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2021 and 2020. We intend to maintain valuation allowances until sufficient evidence exists to support their reversal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. </p></ix:nonNumeric><ix:nonNumeric id="F_000380" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. Our other comprehensive income (loss) is comprised solely of unrealized gains (losses) on available-for-sale securities and is presented net of taxes. We have not recorded any reclassifications from other comprehensive income (loss) to net loss during any period presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000381" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider the applicability and impact of any recent ASU issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Based on our assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on our condensed consolidated financial statements. </p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000347" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000347_dcnt_7e117e37-c054-41d7-a5a5-45ce80ace45f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Common Share </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000347_dcnt_7e117e37-c054-41d7-a5a5-45ce80ace45f">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential dilutive securities, which include unvested restricted stock units (&#8220;RSUs&#8221;), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (&#8220;ESPP&#8221;), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p><ix:nonNumeric id="F_000383" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,253,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000432" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,868,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000433" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,910,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">9,200,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">7,832,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">6,934,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP share purchase rights</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000437" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">27,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">26,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000439" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">20,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">14,480,922</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">10,727,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001604464_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">8,865,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000348" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000348_dcnt_67e76feb-03a0-4214-ba68-350bd698d58b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div><ix:nonNumeric id="F_000384" name="atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000384_dcnt_6bfa77a2-72cf-43ea-b6af-9149fdc8dfd0">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" scale="3">190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231" decimals="-3" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">369,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" scale="3">376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">369,472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000509">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000511">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="atra:CashEquivalentsAmortizedCost" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="atra:CashEquivalentsFairValue" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">265,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" scale="3">376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">264,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">230,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" scale="3">113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">230,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,537</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="atra:CashEquivalentsAmortizedCost" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">199,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="atra:CashEquivalentsFairValue" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">199,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">299,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" scale="3">311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">300,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000348_dcnt_67e76feb-03a0-4214-ba68-350bd698d58b"><ix:continuation id="F_000384_dcnt_6bfa77a2-72cf-43ea-b6af-9149fdc8dfd0">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000385" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing within one year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">278,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">278,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">434,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">435,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one to five years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">369,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">369,472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. <span style="color:#000000;">During the years ended </span>December 31, 2021<span style="color:#000000;">, 2020 and 2019, we did not recognize any impairment losses on our investments. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our consolidated balance sheet. As of December 31, 2021 and 2020, accrued interest receivable was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:InterestReceivable" contextRef="C_0001604464_20211231" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:InterestReceivable" contextRef="C_0001604464_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have <ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="atra:WriteOffOfAccruedInterestReceivable" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="atra:WriteOffOfAccruedInterestReceivable" contextRef="C_0001604464_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="atra:WriteOffOfAccruedInterestReceivable" contextRef="C_0001604464_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t written off any accrued interest receivables for the years ended December 31, 2021, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of December 31, 2021 and 2020, restricted cash totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:RestrictedCash" contextRef="C_0001604464_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:RestrictedCash" contextRef="C_0001604464_20201231" decimals="-5" scale="6">1.4</ix:nonFraction></ix:nonFraction> million. </p><ix:nonNumeric id="F_000386" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">106,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">200,404</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short-term</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:RestrictedCashCurrent" contextRef="C_0001604464_20201231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long-term</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">201,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000349" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000349_dcnt_b690e537-443f-40e5-9f6d-1c29caf46789">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment </p></td></tr></table></div><ix:nonNumeric id="F_000387" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">879</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,676</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000349_dcnt_b690e537-443f-40e5-9f6d-1c29caf46789">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">9.3</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20200101_20201231" decimals="-5" scale="6">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001604464_20190101_20191231" decimals="-5" scale="6">7.1</ix:nonFraction> million for the years ended December 31, 2021<span style="color:#000000;">, 2020 and 2019</span>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000350" name="atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000350_dcnt_076af87a-2dc0-484a-84bf-ec615cfee82f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In-license and Manufacturing Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MSK Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies. <span style="color:#000000;">We are required to make </span>payments<span style="font-size:12pt;">&#160;</span>to MSK based on achievement of specified regulatory and sales-related milestones, <span style="color:#000000;">as well as </span>mid-single-digit percentage tiered royalty payments based on<span style="font-size:12pt;"> </span><span style="color:#000000;">future sales of products resulting from the development of the licensed product candidates, if any. </span><span style="Background-color:#FFFFFF;color:#000000;">In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. </span><span style="color:#000000;">The license agreement expires on a product-by-product and country-by-country basis on the latest of: (i)&#160;expiration of the last licensed patent rights related to each licensed product, (ii)&#160;expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii)&#160;a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May and December 2018, we licensed additional technology from MSK.&#160;We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we amended and restated our license agreement with MSK to: (i) terminate our license to certain rights related to WT1 and cytomegalovirus (&#8220;CMV&#8221;)&#59; and (ii) license additional know-how rights not otherwise covered by our existing agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Agreements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology that we exercised in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to terminate our license to certain rights related to CMV and again in August 2020 to terminate our license to certain rights related to BK polyomavirus and JC polyomavirus. Our current license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other In-license and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next-generation CAR T programs from the National Institutes of Health in December 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of December 31, 2021 and 2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="atra:DueToLicensorsCurrentAndNoncurrent" contextRef="C_0001604464_20211231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="atra:DueToLicensorsCurrentAndNoncurrent" contextRef="C_0001604464_20201231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> outstanding obligations for milestones and royalties under our license and collaboration agreements.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000350_dcnt_076af87a-2dc0-484a-84bf-ec615cfee82f">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cognate Manufacturing Agreement<span style="font-weight:normal;"> </span>&#8211;<span style="font-weight:normal;"> In December 2019, we entered into a Commercial Manufacturing Services Agreement (the &#8220;Manufacturing Agreement&#8221;) with Cognate Bioservices, Inc. (&#8220;Cognate&#8221;). Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement, as amended, runs until May 31, 2022. We may terminate the Manufacturing Agreement for convenience on six months&#8217; written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. </span></p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000351" name="atra:OutLicenseAgreementsDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000351_dcnt_23656401-e609-4b0b-9a94-1c0bacdbef69">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Out-license Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bayer Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research, Development and License Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we entered into the Bayer License Agreement to develop mesothelin-directed CAR T-cell therapies for the treatment of solid tumors, pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271 (the &#8220;Licensed Products&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Bayer License Agreement, we will be responsible at our cost for all mutually agreed preclinical and clinical activities for ATA2271 through the first in human Phase 1 clinical study in collaboration with MSK, following which Bayer will be responsible for the further development of ATA2271 at its cost. Bayer will be responsible for the development of ATA3271, except for certain mutually agreed preclinical, translational, manufacturing and supply chain activities to be performed by us relating to ATA3271, in each case at Bayer&#8217;s cost. Bayer will also be solely responsible for commercializing the Licensed Products at its cost.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we received an upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="atra:UpfrontCashPaymentReceived" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" decimals="-5" scale="6">45.0</ix:nonFraction> million from Bayer for the exclusive license grant, net of applicable withholding taxes, which were fully recovered in August 2021, and an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="atra:AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million upfront reimbursement payment for certain research and process development activities to be performed by us. We are also entitled to receive (i) up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231" decimals="INF" scale="6">5.0</ix:nonFraction> million for additional, specified translational activities under the Bayer License Agreement, of which we have invoiced $<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million, and (ii) an aggregate of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231" decimals="INF" scale="6">610.0</ix:nonFraction> million in milestone payments upon achieving certain development, regulatory and commercial milestones relating to the Licensed Products. In addition, we are eligible to receive from Bayer tiered royalties at percentages up to low double digits on worldwide net product sales of the Licensed Products on a country-by-country and product-by-product basis until the later of <ix:nonNumeric id="F_000570" name="atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" format="ixt-sec:duryear">12</ix:nonNumeric> years after the first commercial sale in such country or the expiration of specified patent rights in such country, subject to certain reductions and aggregate minimum floors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bayer and we have formed a joint steering committee (&#8220;JSC&#8221;) that will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer License Agreement represent transactions with a customer. We concluded that the Bayer License Agreement contains the following promises: (i) a development and commercialization license&#59; (ii) performance of early-stage research and development (&#8220;R&#38;D&#8221;) services, including technology transfer services&#59; (iii) JSC participation&#59; and (iv) chemistry, manufacturing and control (&#8220;CMC&#8221;) services. In accordance with ASC 606, we determined that the license, early-stage R&#38;D and CMC services were not distinct from each other, as the license, early-stage R&#38;D and CMC services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&#38;D and CMC services. Accordingly, we determined that these promises should be combined into a single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price at inception consisted of a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="atra:DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" decimals="-5" scale="6">45.0</ix:nonFraction> million upfront payment for the license, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="atra:DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million for certain research and process development activities and the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="atra:DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231" decimals="INF" scale="6">5.0</ix:nonFraction> million for additional specified translational activities, and this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Technology Transfer Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a Technology Transfer Agreement with Bayer (the &#8220;Bayer Tech Transfer Agreement&#8221;), which was contemplated as part of the Bayer License Agreement, to transfer to Bayer the ATA3271 manufacturing process being developed as part of the CMC services in the Bayer License Agreement. Upon entering into the agreement, we invoiced Bayer <ix:nonFraction unitRef="U_xbrlipure" id="F_000574" name="atra:LicenseAgreementPercentage" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331" decimals="2" scale="-2">20</ix:nonFraction> percent<span style="font-size:12pt;">&#160;</span>of the total fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="atra:LicenseAgreementTotalFee" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331" decimals="-5" scale="6">15.3</ix:nonFraction> million under the Bayer Tech Transfer Agreement, or $<ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="atra:LicenseAgreementAmount" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331" decimals="-5" scale="6">3.1</ix:nonFraction> million, which we received in the second quarter of 2021 and invoiced <ix:nonFraction unitRef="U_xbrlipure" id="F_000575" name="atra:LicenseAgreementPercentage" contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131" decimals="2" scale="-2">40</ix:nonFraction> percent of the total fee, or $<ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="atra:LicenseAgreementAmount" contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131" decimals="-5" scale="6">6.1</ix:nonFraction> million, in January 2022. <ix:nonNumeric id="F_000579" name="atra:TechnologyTransferAgreementsFeeRemainder" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231">The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion</ix:nonNumeric>. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000351_dcnt_23656401-e609-4b0b-9a94-1c0bacdbef69" continuedAt="F_000351_dcnt_289adee3-edc1-41cd-9bfe-621cbeb0df1f">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer Tech Transfer Agreement represent transactions with a customer. We concluded that the Bayer Tech Transfer Agreement should be combined with the Bayer License Agreement and accounted for as a modification of that agreement and that the Bayer Tech Transfer Agreement contains the following promises: (i) technology transfer services and (ii) supply of materials required for the technology transfer services. In accordance with ASC 606, we determined that the technology transfer services and supply of materials required for the technology transfer services were not distinct from each other, as they are highly interdependent upon one another. In addition, we concluded that the technology transfer services and supply of materials required for the technology transfer services were highly interdependent with the license, early-stage R&#38;D and CMC services identified in the Bayer License Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bayer Tech Transfer Agreement, in order to evaluate the appropriate transaction price, we determined that the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="atra:TransactionFeePrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231" decimals="-5" scale="6">15.3</ix:nonFraction> million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Manufacturing and Supply Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a Manufacturing and Supply Agreement with Bayer (the &#8220;Bayer Manufacturing Agreement&#8221;), which was contemplated as part of the Bayer License Agreement, to manufacture Phase 1 and 2 allogeneic mesothelin-directed CAR T-cell therapies for Bayer to use in clinical trials at a price based on our costs plus a reasonable margin, which is consistent with our standalone selling price. Under the Bayer Manufacturing Agreement, we will also provide storage and distribution services to Bayer at a price that is consistent with our standalone selling price for these services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the Bayer Manufacturing Agreement, Bayer submitted, and we approved, a binding purchase order for manufacturing services and storage services. Any fees for the manufacturing services will be invoiced as follows: (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000581" name="atra:WrittenAcceptanceOfBindingPurchaseOrderPercentage" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20211231" decimals="2" scale="-2">50</ix:nonFraction> percent upon written acceptance by us of the binding purchase order, and (ii) the remainder upon delivery of the certification of analysis of such lots to Bayer. Storage and distribution services are billed monthly as those services are provided to Bayer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we invoiced Bayer <ix:nonFraction unitRef="U_xbrlipure" id="F_000582" name="atra:LicenseAgreementPercentage" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331" decimals="2" scale="-2">50</ix:nonFraction> percent of the total estimated supply price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:ManufacturingCosts" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331" decimals="-5" scale="6">13.1</ix:nonFraction> million for manufacturing services under the initial purchase order for the supply of six lots, or $<ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:ManufacturingCosts" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331" decimals="-5" scale="6">6.6</ix:nonFraction> million, which we received in the second quarter of 2021. The remainder of the supply price will be billed upon the release of the lots ordered by Bayer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the manufacturing and supply agreement represent transactions with a customer. We concluded that the Bayer Manufacturing Agreement contains the following promises: (i) manufacturing services&#59; (ii) storage services provided on a month-to-month basis&#59; and (iii) distribution services. In accordance with ASC 606, we determined that the manufacturing services for the initial purchase order of six lots, that are expected to be provided prior to completion of the technology transfer, are not distinct as they are highly interdependent on the manufacturing process being developed and transferred under the Bayer License Agreement and the Bayer Tech Transfer Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. We also determined that each of the other services were distinct and separate performance obligations. We determined that the initial binding order for the manufacture and supply of six lots should be combined with the Bayer License Agreement and accounted for as a modification of that agreement along with the Bayer Tech Transfer Agreement. We also concluded that a binding purchase order from Bayer, together with the Bayer Manufacturing Agreement, form the contract for manufacturing services and storage services and a shipping order from Bayer forms the contract for distribution services. We also determined that the storage services provided on a month-to-month basis and distribution services are distinct and separate performance obligations. All the performance obligations identified above are priced at their standalone selling price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bayer Manufacturing Agreement, in order to evaluate the appropriate transaction price, we determined that the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="atra:DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231" decimals="-5" scale="6">13.1</ix:nonFraction> million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. Revenue for the manufacturing services for the initial six lots will be recognized based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. Revenue for the storage services will be recognized over time as those services are provided. Revenue for the distribution services will be recognized at a point in time when the product is delivered to a clinical site designated by Bayer. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000351_dcnt_289adee3-edc1-41cd-9bfe-621cbeb0df1f" continuedAt="F_000351_dcnt_939dcd40-f14f-4a9a-9b0a-fbc30aecc5c1">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Bayer Revenue Recognition</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. For the year ended December 31, 2021, we recognized license and collaboration revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231" decimals="-5" scale="6">19.8</ix:nonFraction> million under the Bayer License Agreement, Bayer Tech Transfer Agreement and Bayer Manufacturing Agreement, collectively, the Bayer Agreements. We did <ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="atra:LicenseAndCollaborationRevenue" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any license and collaboration revenue in 2020 under Bayer License Agreement. Deferred revenue related to the Bayer Agreements aggregated to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20211231" decimals="-5" scale="6">51.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20201231" decimals="-5" scale="6">61.3</ix:nonFraction> million as of December 31, 2021 and 2020, respectively. Of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231" decimals="-5" scale="6">51.5</ix:nonFraction> million of deferred revenue as of December 31, 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231" decimals="-5" scale="6">40.8</ix:nonFraction> million is included in current liabilities and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231" decimals="-5" scale="6">10.7</ix:nonFraction> million is included in long-term liabilities. This revenue is expected to be recognized over approximately the next <ix:nonNumeric id="F_000594" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. <ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> development or sales-based milestone payments have been earned or received through December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre Commercialization Agreement<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Pierre Fabre Commercialization Agreement, pursuant to which, we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia (the &#8220;Territory&#8221;) following regulatory approval. Atara will retain full rights to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in other major markets, including North America, Asia Pacific and Latin America. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible at our cost for the conclusion of the ongoing Phase 3 ALLELE clinical study and the Phase 2 multi-cohort clinical study. We will also be responsible at our cost for certain other activities directed to obtaining regulatory approval for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV-positive lymphoproliferative disease pursuant to the terms of the Pierre Fabre Commercialization Agreement in Europe and the UK. Pierre Fabre will be responsible at its cost for obtaining and maintaining all other regulatory approvals and for commercialization and distribution of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the Territory. We will own any intellectual property rights developed solely by us under the Agreement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre paid us an upfront cash payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="atra:UpfrontCashPaymentReceived" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031" decimals="-5" scale="6">45.0</ix:nonFraction> million for the exclusive license grant in October 2021. We are also entitled to receive an aggregate of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211031" decimals="INF" scale="6">318.0</ix:nonFraction> million in milestone payments upon achieving certain regulatory and commercial milestones. In addition, we are eligible to receive double-digit tiered royalties as a percentage of net sales of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> until the later of <ix:nonNumeric id="F_000597" name="atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031" format="ixt-sec:duryear">12</ix:nonNumeric> years after the first commercial sale in such country, the expiration of specified patent rights, or the expiration of all regulatory exclusivity for such product on a country-by-country basis. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will negotiate a separate manufacturing and supply agreement with Pierre Fabre for us to manufacture tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for Pierre Fabre to use in the Territory based on a fixed price until January 1, 2024 and cost plus a margin post January 1, 2024. We are responsible for manufacturing and supplying Pierre Fabre with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for commercialization in the Territory at Pierre Fabre&#8217;s cost for a minimum of <ix:nonNumeric id="F_000598" name="atra:YearsOfManufacturingAndSupplyingCost" contextRef="C_0001604464_20210101_20211231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. Following this period, we have the option to transfer the related manufacturing technology to Pierre Fabre. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also responsible for cell selection services at our cost until January 1, 2024 unless the parties agree to transfer the related cell selection technology to Pierre Fabre prior to this date. From January 1, 2024 onwards, if we agree to continue to provide cell selection services, it shall be at the sole expense of Pierre Fabre. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre and we have formed a joint steering committee (&#8220;JSC&#8221;) that will provide oversight, decision making and implementation guidance regarding the commercialization activities covered under the agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Pierre Fabre Commercialization Agreement represent transactions with a customer. We concluded that the Pierre Fabre Commercialization Agreement includes transfer of intellectual property rights in the form of a license, the potential to manufacture and supply tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for a minimum of <ix:nonNumeric id="F_000599" name="atra:YearsOfPotentialToManufacturingAndSupply" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric> and until tech transfer, the potential to perform cell-selection services for a minimum of <ix:nonNumeric id="F_000600" name="atra:YearsOfPotentialToPerformCellSelectionServices" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231" format="ixt-sec:durwordsen">three years</ix:nonNumeric> and until tech transfer, and obligation to participate in the JSC. We concluded that the promises are not distinct because Pierre Fabre cannot benefit from the license without the other services and vis versa. Consequently, the license, manufacture and supply, cell selection and participation in the JSC is a single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pierre Fabre Commercialization Agreement, in order to evaluate the appropriate transaction price, we determined that the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="atra:DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031" decimals="-6" scale="6">45</ix:nonFraction> million upfront payment, constituted the entire consideration to be included in the transaction price at the outset of the arrangement. Revenue associated with the upfront fee for the single performance obligation will be deferred until the initial delivery of services related to the manufacture and supply and cell selection and then recognized over the contract performance period&#8203;. We did <ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="atra:UpfrontPaymentRecognized" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="atra:UpfrontCashPaymentReceived" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031" decimals="-5" scale="6">45.0</ix:nonFraction> million upfront payment as revenue in 2021. All of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211231" decimals="-5" scale="6">45.0</ix:nonFraction> million of deferred revenue as of December 31, 2021 is included in long-term liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. <ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> development or commercial milestone payments have been earned or received through December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000351_dcnt_939dcd40-f14f-4a9a-9b0a-fbc30aecc5c1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000352" name="atra:LeasesDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000352_dcnt_35218ea1-d203-438c-a699-74480ef332df">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease our corporate headquarters in South San Francisco, California under a non-cancellable lease agreement. In December 2021, we entered into a second amendment with the landlord to extend the lease term through <span style="-sec-ix-hidden:F_000606">May 2025</span>. The amended lease agreement does not include an option to extend the lease term. In connection with the amended lease, we are required to maintain a letter of credit in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million to the landlord, a decrease of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="atra:LetterOfCreditDecreaseFromPriorLeaseAgreement" contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million from the prior lease agreement, and which expires and is renewed every <ix:nonNumeric id="F_000608" name="atra:LetterOfCreditRenewalTerm" contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231" format="ixt-sec:durmonth">12</ix:nonNumeric> months, and is classified as restricted cash in our consolidated balance sheet. As of December 31, 2021, we were still working to update our letter of credit and continued to report an amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="atra:RestrictedCashRelatedToLetterOfCredit" contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million as restricted cash related to this letter of credit on our consolidated balance sheet. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="letter-spacing:-0.2pt;">n March 2021, we entered into a new lease agreement for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000611" name="atra:LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331" decimals="0" format="ixt:numdotdecimal">33,659</ix:nonFraction> square feet of office, lab and warehouse space in Thousand Oaks, California. </span>During the third quarter of 2021, the initial <ix:nonNumeric id="F_000612" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331" format="ixt-sec:duryear">10.5</ix:nonNumeric>-year lease term commenced, upon substantial completion of the landlord&#8217;s work as defined under the agreement. The contractual obligations during the initial lease term are $<ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:ContractualObligation" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331" decimals="-5" scale="6">21.0</ix:nonFraction> million in aggregate. Base rent is subject to annual increase of <ix:nonFraction unitRef="U_xbrlipure" id="F_000614" name="atra:LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331" decimals="2" scale="-2">3</ix:nonFraction>% with each annual anniversary of the rent commencement date.<span style="letter-spacing:-0.2pt;"> We have the option to extend this lease for two additional <span style="-sec-ix-hidden:F_000616">five-year</span> periods after the initial term.</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a lease agreement for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000617" name="atra:LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215" decimals="0" format="ixt:numdotdecimal">90,580</ix:nonFraction> square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California. The initial <ix:nonNumeric id="F_000619" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215" format="ixt-sec:duryear">15</ix:nonNumeric>-year term of the lease commenced on <ix:nonNumeric id="F_000618" name="atra:LeaseCommencementDate" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215" format="ixt:datemonthdayyearen">February 15, 2018</ix:nonNumeric>, upon the substantial completion of landlord&#8217;s work as defined under the agreement. The contractual obligations during the initial term are $<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:ContractualObligation" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215" decimals="-5" scale="6">16.4</ix:nonFraction> million in aggregate. We have the option to extend the lease for two additional periods of ten and <ix:nonNumeric id="F_000622" name="atra:LeaseAgreementRenewalTermOptionTwo" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215" format="ixt-sec:durwordsen">nine years</ix:nonNumeric>, respectively, after the initial term. In connection with the lease, we were required to issue a letter of credit in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20180215" decimals="-5" scale="6">1.2</ix:nonFraction> million to the landlord, which is recorded as long-term restricted cash in our consolidated balance sheet. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into a lease agreement for additional office space in Thousand Oaks, California that expires in <span style="-sec-ix-hidden:F_000624">February 2026</span> and for which <ix:nonNumeric id="F_000626" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231">we have the option to extend the lease for an additional period of <ix:nonNumeric id="F_000627" name="atra:LeaseOptionToExtendAdditionalTerm" contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after the initial term.</ix:nonNumeric> Additionally, in 2021, we entered into an amended lease agreement for our office and lab space in Aurora, Colorado, to add additional lab space. Incremental contractual obligations under the lease amendment are $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="atra:IncrementalContractualObligationsUnderLeaseAmendment" contextRef="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million, and the lease term continues to expire in <span style="-sec-ix-hidden:F_000628">April 2024</span>. </p><ix:nonNumeric id="F_000388" name="atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000388_dcnt_41891952-5816-4fce-bd37-6d09ac542947">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of lease liabilities under our operating and finance leases as of December 31, 2021 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001604464_20211231" decimals="-3" scale="3">181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001604464_20211231" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="C_0001604464_20211231" decimals="-3" scale="3">210</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001604464_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:FinanceLeaseLiability" contextRef="C_0001604464_20211231" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - long-term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0001604464_20211231" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:FinanceLeaseLiability" contextRef="C_0001604464_20211231" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_35218ea1-d203-438c-a699-74480ef332df" continuedAt="F_000352_dcnt_834d9fa8-5d1b-4b67-9a4b-73a8c7e7a515"><ix:continuation id="F_000388_dcnt_41891952-5816-4fce-bd37-6d09ac542947">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000389" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="us-gaap:OperatingLeaseCost" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:OperatingLeaseCost" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:OperatingLeaseCost" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:ShortTermLeaseCost" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:ShortTermLeaseCost" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:ShortTermLeaseCost" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="atra:OperatingLeaseCostIncludingShortTermLease" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="atra:OperatingLeaseCostIncludingShortTermLease" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="atra:OperatingLeaseCostIncludingShortTermLease" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="atra:FinanceLeaseCost" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="atra:FinanceLeaseCost" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="atra:FinanceLeaseCost" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000390" name="atra:SummaryOfOtherInformationRelatedToLeasesTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands,&#160;except lease&#160;term&#160;and discount rate)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Cash Flows Information</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; lease liabilities:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating leases</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:OperatingLeasePayments" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:OperatingLeasePayments" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:OperatingLeasePayments" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for finance leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">62</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows for finance leases</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets obtained in exchange for lease obligations:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease assets obtained in exchange for lease obligations:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash increase to operating lease assets due to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remeasurement of lease liabilities:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">639</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Lease Term</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000694" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20211231" format="ixt-sec:duryear">9.2</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000695" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20201231" format="ixt-sec:duryear">9.4</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000696" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20191231" format="ixt-sec:duryear">10.3</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000697" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20211231" format="ixt-sec:duryear">1.0</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000698" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20201231" format="ixt-sec:duryear">1.7</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000699" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001604464_20191231" format="ixt-sec:duryear">2.5</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Discount Rate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000700" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20211231" decimals="3" scale="-2">9.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000701" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20201231" decimals="3" scale="-2">10.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000702" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20191231" decimals="3" scale="-2">10.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000703" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20211231" decimals="3" scale="-2">9.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000704" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20201231" decimals="3" scale="-2">9.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000705" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001604464_20191231" decimals="3" scale="-2">10.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Retirement Obligation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ARO consists of a contractual requirement to remove the tenant improvements at our manufacturing facility in Thousand Oaks, California and restore the facility to a condition specified in the lease agreement. The Company records an estimate of the fair value of its ARO in long-term liabilities in the period incurred. The fair value of the ARO is also capitalized in property and equipment, net and depreciated over the lease term. The fair value of our ARO was estimated by discounting projected cash flows over the estimated life of the related assets using our credit adjusted risk-free rate. </p><ix:nonNumeric id="F_000391" name="us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000391_dcnt_bc7419ef-98ea-4229-b3b9-e7b5cc9ec3f1">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for our ARO liabilities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO Liability</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:AssetRetirementObligation" contextRef="C_0001604464_20201231" decimals="-3" scale="3">866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:AssetRetirementObligationAccretionExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:AssetRetirementObligation" contextRef="C_0001604464_20211231" decimals="-3" scale="3">953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_834d9fa8-5d1b-4b67-9a4b-73a8c7e7a515"><ix:continuation id="F_000391_dcnt_bc7419ef-98ea-4229-b3b9-e7b5cc9ec3f1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000353" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Research and Development Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into contracts in the normal course of business with clinical research organizations <span style="color:#000000;">for clinical trials, with contract manufacturing </span>organizations for <span style="color:#000000;">clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on </span>notice. As of December 31, 2021 and 2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="atra:AccruedTerminationCharges" contextRef="C_0001604464_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="atra:AccruedTerminationCharges" contextRef="C_0001604464_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> amounts accrued related to termination charges for minimum purchase volumes not being met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we consider the fair value of these indemnification agreements to be minimal. Accordingly, we did <ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="atra:LiabilitiesRelatedToIndemnificationAgreements" contextRef="C_0001604464_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="atra:LiabilitiesRelatedToIndemnificationAgreements" contextRef="C_0001604464_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record liabilities for these agreements as of December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000354" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000354_dcnt_95474825-e296-4b7e-8bf6-b25d85d93d04">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of <ix:nonFraction unitRef="U_xbrlishares" id="F_000713" name="us-gaap:CapitalUnitsAuthorized" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal">520,000,000</ix:nonFraction> shares, all with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000714" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001604464_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000716" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001604464_20211231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> per share, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000715" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction> shares are designated as common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000717" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal">20,000,000</ix:nonFraction> shares are designated as preferred stock. <span style="color:#000000;">There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000718" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001604464_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000719" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001604464_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding as of </span>December 31, 2021 and 2020<span style="color:#000000;">. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Offerings</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000720" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731" decimals="INF" format="ixt:numdotdecimal">6,871,727</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000721" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731" decimals="INF">15.28</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000722" name="atra:ClassOfWarrantOrRightNumberOfWarrantsIssued" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731" decimals="INF" format="ixt:numdotdecimal">2,945,026</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000723" name="atra:ClassOfWarrantOrRightPricePerShare" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731" decimals="INF">15.2799</ix:nonFraction> per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this offering were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731" decimals="-5" scale="6">150.0</ix:nonFraction> million, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731" decimals="-5" scale="6">140.7</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses payable by us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each pre-funded warrant entitles the holder to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000726" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> share of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000727" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718" decimals="INF">0.0001</ix:nonFraction> per share and expires <ix:nonNumeric id="F_000728" name="atra:ClassOfWarrantOrRightTerm" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718" format="ixt-sec:durwordsen">seven years</ix:nonNumeric> from the date of issuance. These warrants were recorded as a component of stockholders&#8217; equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder&#8217;s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed <ix:nonFraction unitRef="U_xbrlipure" id="F_000729" name="atra:MaximumOwnershipPercentage" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718" decimals="4" scale="-2">9.99</ix:nonFraction>% after giving effect to the exercise (&#8220;Maximum Ownership Percentage&#8221;). Upon at least <ix:nonNumeric id="F_000731" name="atra:PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718" format="ixt-sec:durday">61</ix:nonNumeric> days&#8217; prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed <ix:nonFraction unitRef="U_xbrlipure" id="F_000730" name="atra:MaximumOwnershipPercentage" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718" decimals="4" scale="-2">19.99</ix:nonFraction>%. As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000732" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,888,526</ix:nonFraction> of the pre-funded warrants from the July 2019 offering were outstanding.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000354_dcnt_95474825-e296-4b7e-8bf6-b25d85d93d04" continuedAt="F_000354_dcnt_eda501eb-ccd2-4610-8c5c-670cb1237505">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, we issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000733" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">12,633,039</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000734" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630" decimals="2">11.32</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000735" name="atra:ClassOfWarrantOrRightNumberOfWarrantsIssued" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630" decimals="INF" format="ixt:numdotdecimal">2,866,961</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000736" name="atra:ClassOfWarrantOrRightPricePerShare" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630" decimals="4">11.3199</ix:nonFraction> per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. We granted the underwriters an option to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000737" name="atra:StockIssuedDuringPeriodAdditionalSharesNewIssues" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630" decimals="INF" format="ixt:numdotdecimal">2,325,000</ix:nonFraction> additional shares of our common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000738" name="us-gaap:SharePrice" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630" decimals="2">11.32</ix:nonFraction>, less underwriting discounts and commissions. The full option was exercised by the underwriters in June 2020. The gross proceeds from this public offering were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630" decimals="-5" scale="6">201.8</ix:nonFraction> million, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630" decimals="-5" scale="6">189.3</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses payable by us. The terms of the pre-funded warrants issued and sold as part of this public offering were similar to those above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000741" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">5,102,041</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000742" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231" decimals="2">24.50</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000743" name="atra:ClassOfWarrantOrRightNumberOfWarrantsIssued" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,040,816</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000744" name="atra:ClassOfWarrantOrRightPricePerShare" contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231" decimals="4">24.4999</ix:nonFraction> per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this public offering were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231" decimals="-5" scale="6">175.0</ix:nonFraction> million, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231" decimals="-5" scale="6">164.3</ix:nonFraction> million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, all of the pre-funded warrants issued and sold as part of the 2020 underwritten public offerings were outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ATM Facilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into a sales agreement (the &#8220;2019 ATM Facility&#8221;) with Cowen, which provided for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="atra:AggregateOfferingPriceOfCommonStock" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200229" decimals="INF" scale="6">100.0</ix:nonFraction> million through Cowen, as our sales agent.<span style="color:#000000;"> </span>We paid a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000751" name="atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200201_20200229" decimals="INF" scale="-2">3.0</ix:nonFraction>% of gross sales proceeds of the common stock sold under the 2019 ATM Facility.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we entered into a sales agreement (the &#8220;2020 ATM Facility&#8221;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="atra:AggregateOfferingPriceOfCommonStock" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211130" decimals="INF" scale="6">100.0</ix:nonFraction> million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and did not replace the 2019 ATM Facility in any way. We paid a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000752" name="atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211101_20211130" decimals="INF" scale="-2">3.0</ix:nonFraction>% of gross sales proceeds of any common stock sold under the 2020 ATM Facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we entered into a sales agreement (the &#8220;2021 ATM Facility&#8221;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="atra:AggregateOfferingPriceOfCommonStock" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190228" decimals="INF" scale="6">100.0</ix:nonFraction> million through Cowen, as our sales agent. The 2021 ATM Facility is separate from and does not replace the 2020 ATM Facility in any way. We pay a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000750" name="atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190201_20190228" decimals="INF" scale="-2">3.0</ix:nonFraction>% of gross sales proceeds of any common stock sold under the 2021 ATM Facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended <span style="letter-spacing:-0.2pt;">December 31, 2020</span>, we sold an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000754" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,785,514</ix:nonFraction> shares of common stock under the ATM facilities, at an average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000757" name="atra:CommonStockAveragePrice" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="2">14.60</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">69.9</ix:nonFraction> million and net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">68.0</ix:nonFraction> million, after deducting commissions and other offering expenses payable by us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, we sold an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000753" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">6,240,601</ix:nonFraction> shares of common stock under the ATM facilities, at an average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000756" name="atra:CommonStockAveragePrice" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="2">16.23</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-5" scale="6">101.3</ix:nonFraction> million and net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231" decimals="-5" scale="6">98.9</ix:nonFraction> million, after deducting commissions and other offering expenses payable by us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#FF0000;"> </span><span style="color:#000000;">issuance and sale of these shares by us pursuant to the ATM facilities are deemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and are registered under the Securities Act. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, we had<span style="color:#000000;"> fully utilized the 2019 ATM Facility, and the 2020 ATM Facility and we had</span> $<ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="atra:CommonStockValueAvailableToBeSold" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211231" decimals="-5" scale="6">78.3</ix:nonFraction> million of common stock <span style="color:#000000;">remaining and available to be sold under the 2021 ATM Facility. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2022 through February 15, 2022, we sold an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000755" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215" decimals="INF" format="ixt:numdotdecimal">1,319,878</ix:nonFraction> shares of common stock under the 2021 ATM Facility, at an average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000758" name="atra:CommonStockAveragePrice" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215" decimals="2">15.88</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="atra:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215" decimals="-5" scale="6">21.0</ix:nonFraction> million and net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="atra:ProceedsFromIssuanceOfCommonStockNet" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215" decimals="-5" scale="6">20.5</ix:nonFraction> million, after deducting commissions and other offering expenses payable by us. As of February 15, 2022, we had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="atra:CommonStockValueAvailableToBeSold" contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220215" decimals="-5" scale="6">57.4</ix:nonFraction> million of common stock remaining and available to be sold under the 2021 ATM Facility, subject to certain conditions as specified in the agreement. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000354_dcnt_eda501eb-ccd2-4610-8c5c-670cb1237505" continuedAt="F_000354_dcnt_66360f2a-0da9-4dfe-ba81-71fac7f4460b">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, we adopted the 2014 Equity Incentive Plan (&#8220;2014 EIP&#8221;), which was amended and restated on October 15, 2014 upon the pricing of our initial public offering (&#8220;IPO&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 EIP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000767" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="-2">five</ix:nonFraction> percent of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the 2014 EIP, we may grant stock options, RSAs and RSUs to employees, directors, consultants and other service providers.&#160;RSUs generally vest over <ix:nonNumeric id="F_000768" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_atraFromDateOfGrantMember_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. In 2020, we granted performance-based awards to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based awards that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee&#8217;s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of RSUs, including those with performance conditions, is determined as the closing stock price on the date of grant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are granted with exercise prices at no less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000769" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231" decimals="INF" scale="-2">100</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that <ix:nonNumeric id="F_000770" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="C_0001604464_20210101_20211231">the exercise price of an option granted to a <ix:nonFraction unitRef="U_xbrlipure" id="F_000771" name="atra:ShareholderOwnershipPercent" contextRef="C_0001604464_20210101_20211231" decimals="INF" scale="-2">10</ix:nonFraction>% shareholder cannot be less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000772" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_atraTenPercentShareHolderMember_20210101_20211231" decimals="INF" scale="-2">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant. The estimated fair value is generally equal to the closing market price of the Company&#8217;s common stock on the measurement date. Options granted generally vest over <ix:nonNumeric id="F_000773" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001604464_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and expire in <ix:nonNumeric id="F_000774" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_b40709fb-758f-4f77-9b94-2e2c3a2a5b7e">seven</ix:nonNumeric> to <ix:nonNumeric id="F_000775" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231" format="ixt-sec:durwordsen">ten<ix:continuation id="C_b40709fb-758f-4f77-9b94-2e2c3a2a5b7e"> years</ix:continuation></ix:nonNumeric>.</ix:nonNumeric> As of December 31, 2021, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000776" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">16,086,987</ix:nonFraction> shares of common stock were reserved for issuance under the 2014 EIP, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">4,018,597</ix:nonFraction> shares were available for future grant and <ix:nonFraction unitRef="U_xbrlishares" id="F_000777" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">12,068,390</ix:nonFraction> shares were subject to outstanding options and RSUs, including performance-based awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we adopted the 2018 Inducement Plan (&#8220;Inducement Plan&#8221;), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees.&#160;In September 2020, we amended the Inducement Plan to reserve an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000779" name="atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance under the Inducement Plan, and in September 2021 we made a further amendment to reserve an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000780" name="atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance" contextRef="C_0001604464_20210930" decimals="INF" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance under the Inducement Plan. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, <ix:nonFraction unitRef="U_xbrlishares" id="F_000781" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">4,022,184</ix:nonFraction> shares of common stock were reserved for issuance under the Inducement Plan, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000782" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,278,379</ix:nonFraction> shares were available for future grant and <ix:nonFraction unitRef="U_xbrlishares" id="F_000783" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,743,805</ix:nonFraction> shares were subject to outstanding options and RSUs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of RSUs granted during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000784" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">16.42</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000785" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">12.19</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000786" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="2">27.04</ix:nonFraction>, respectively. The estimated fair value of RSUs that vested in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="-5" scale="6">27.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-5" scale="6">23.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="-5" scale="6">13.8</ix:nonFraction> million, respectively. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="-5" scale="6">75.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of <ix:nonNumeric id="F_000791" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" format="ixt-sec:duryear">2.8</ix:nonNumeric> years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S. GAAP. The aggregate intrinsic value of the RSUs outstanding as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span> was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="-5" scale="6">88.1</ix:nonFraction>&#160;million.</p><ix:nonNumeric id="F_000392" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">3,829,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000798" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">15.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000794" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,624,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">16.42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000795" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,307,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000800" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">14.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000796" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,553,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">17.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000797" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="INF" format="ixt:numdotdecimal">5,592,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="2">16.22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000354_dcnt_66360f2a-0da9-4dfe-ba81-71fac7f4460b" continuedAt="F_000354_dcnt_370cb465-8e91-4b3c-8c08-2c1becc3af67">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our RSU settlement procedures, for some of the RSUs granted to our employees, we withhold shares at settlement to cover the estimated payroll withholding tax obligations.&#160;During 2021, we settled <ix:nonFraction unitRef="U_xbrlishares" id="F_000803" name="atra:RestrictedStockSharesIssued" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,553,893</ix:nonFraction> shares underlying RSUs, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000805" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">154,341</ix:nonFraction> shares underlying RSUs were net settled by withholding <ix:nonFraction unitRef="U_xbrlishares" id="F_000807" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">61,385</ix:nonFraction> shares.&#160;The value of the shares underlying RSUs withheld was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="atra:SharesWithheldForTaxObligationsValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="-5" scale="6">1.2</ix:nonFraction> million, based on the closing price of our common stock on the settlement date. During 2020, we settled <ix:nonFraction unitRef="U_xbrlishares" id="F_000804" name="atra:RestrictedStockSharesIssued" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,218,945</ix:nonFraction> shares underlying RSUs, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000806" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">276,822</ix:nonFraction> shares underlying RSUs were net settled by withholding <ix:nonFraction unitRef="U_xbrlishares" id="F_000808" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">106,459</ix:nonFraction> shares.&#160;The value of the shares underlying RSUs withheld was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="atra:SharesWithheldForTaxObligationsValue" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-5" scale="6">1.5</ix:nonFraction> million, based on the closing price of our common stock on the settlement date.&#160;The value of RSUs withheld in each period was remitted to the appropriate taxing authorities and has been reflected as a financing activity in our consolidated statements of cash flows. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options </p><ix:nonNumeric id="F_000393" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for <ix:nonFraction unitRef="U_xbrlishares" id="F_000811" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="INF" format="ixt:numdotdecimal">275,000</ix:nonFraction> shares of our common stock which were issued in 2017 outside of these plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<span style="font-family:Calibri;">&#160;</span>Average Exercise&#160;Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000812" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">7,851,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000819" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231" decimals="2">22.89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,643,378</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000820" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="2">15.97</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000814" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">246,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000821" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="2">13.97</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000815" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,028,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000822" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231" decimals="2">25.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">9,219,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000823" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="2">20.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000827">6.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">9,219,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000824" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="2">20.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000828">6.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">5,073,289</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000825" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="2">24.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000829">4.8</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on <span style="letter-spacing:-0.2pt;">December 31, 2021</span> and the exercise price of outstanding, in-the-money options. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231" decimals="-5" scale="6">41.9</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 2.5 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options for <ix:nonFraction unitRef="U_xbrlishares" id="F_000836" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">246,867</ix:nonFraction>, <ix:nonFraction unitRef="U_xbrlishares" id="F_000837" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001604464_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">268,938</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000838" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001604464_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">347,716</ix:nonFraction> shares of our common stock were exercised during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019, with an intrinsic value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001604464_20200101_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001604464_20190101_20191231" decimals="-5" scale="6">3.8</ix:nonFraction> million, respectively. As we believe it is more likely than not that no stock option related tax benefits will be realized, we do <ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:DeferredTaxExpenseFromStockOptionsExercised" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t record any net tax benefits related to exercised options.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000394" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000394_cnt_1">The fair value of each option issued was estimated at the date of grant using the Black-Scholes valuation model. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model and resulting weighted-average grant date fair values of stock options granted during the periods indicated:</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000394_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assumptions:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000843">6.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000844">6.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001604464_20210101_20211231" decimals="3" scale="-2">75.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000847" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001604464_20200101_20201231" decimals="3" scale="-2">76.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000848" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001604464_20190101_20191231" decimals="3" scale="-2">76.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000849" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001604464_20210101_20211231" decimals="3" scale="-2">0.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000850" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001604464_20200101_20201231" decimals="3" scale="-2">0.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000851" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001604464_20190101_20191231" decimals="3" scale="-2">2.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000852" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001604464_20210101_20211231" decimals="INF" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000853" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001604464_20200101_20201231" decimals="INF" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000854" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001604464_20190101_20191231" decimals="INF" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average estimated grant date fair value per share</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_20210101_20211231" decimals="2">10.52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000856" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_20200101_20201231" decimals="2">7.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000857" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001604464_20190101_20191231" decimals="2">18.06</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000858" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001604464_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,643,378</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000859" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001604464_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,641,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000860" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001604464_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,535,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total estimated grant date fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" contextRef="C_0001604464_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,808,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" contextRef="C_0001604464_20200101_20201231" decimals="0" format="ixt:numdotdecimal">21,023,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" contextRef="C_0001604464_20190101_20191231" decimals="0" format="ixt:numdotdecimal">45,790,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of stock options that vested in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">26.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001604464_20200101_20201231" decimals="-5" scale="6">29.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001604464_20190101_20191231" decimals="-5" scale="6">31.6</ix:nonFraction> million, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000354_dcnt_370cb465-8e91-4b3c-8c08-2c1becc3af67">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, we adopted the 2014 Employee Stock Purchase Plan (&#8220;2014 ESPP&#8221;), which became effective on <ix:nonNumeric id="F_000867" name="atra:EmployeeStockPurchasePlanEffectiveDate" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" format="ixt:datemonthdayyearen">October 15, 2014</ix:nonNumeric> upon the pricing of our IPO. The 2014 ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Eligible employees can purchase shares of the Company&#8217;s common stock at <ix:nonFraction unitRef="U_xbrlipure" id="F_000868" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the common stock at <ix:nonNumeric id="F_000869" name="atra:EmployeeStockPurchasePlanDescription" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231">(i) the beginning of a 12-month offering period, or (ii) at the end of one of the two related 6-month purchase periods</ix:nonNumeric>. No participant in the 2014 ESPP may purchase shares of common stock valued at more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000871" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction> per calendar year. The first offering under the 2014 ESPP commenced on <ix:nonNumeric id="F_000870" name="atra:EmployeeStockPurchasePlanOfferingCommencedStartDate" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" format="ixt:datemonthdayyearen">June 1, 2016</ix:nonNumeric>, and subsequent offerings commence on each anniversary of this date. The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="-5" scale="6">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">1.3</ix:nonFraction> million of expense related to the 2014 ESPP in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021,</span> 2020 and 2019, respectively. A total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000875" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">319,190</ix:nonFraction>, <ix:nonFraction unitRef="U_xbrlishares" id="F_000876" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">282,514</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000877" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">139,466</ix:nonFraction> shares were purchased under the ESPP during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231" decimals="-5" scale="6">0.6</ix:nonFraction> million of unrecognized stock-based compensation expense related to the ESPP that is expected to be recognized by the end of second quarter of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 ESPP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to the lower of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000879" name="atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="-2">one</ix:nonFraction> percent of the number of shares of our common stock outstanding as of such date, (ii) <ix:nonFraction unitRef="U_xbrlishares" id="F_000880" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">230,769</ix:nonFraction> shares of our common stock, or (iii) a lesser number of shares as determined by our board of directors. As of December 31, 2021, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,817,511</ix:nonFraction> shares authorized under the 2014 ESPP.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reserved Shares</p><ix:nonNumeric id="F_000395" name="atra:CommonStockReservedForFutureIssuanceTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares of common stock were reserved for future issuance under our equity incentive plans as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares Reserved</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000882" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">16,086,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Inducement Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000883" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">4,022,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000884" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">862,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total reserved shares of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000885" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001604464_20211231" decimals="INF" format="ixt:numdotdecimal">20,971,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation Expense</p><ix:nonNumeric id="F_000396" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense related to all stock awards was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,527</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000889" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000892" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000893" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000355" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000355_dcnt_49aaf28b-3c76-4a72-abaf-5f1fb0e0c45f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div><ix:nonNumeric id="F_000397" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Losses before provision for income taxes were as follows in each period presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">291,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">340,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001604464_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000355_dcnt_49aaf28b-3c76-4a72-abaf-5f1fb0e0c45f" continuedAt="F_000355_dcnt_ed8ffc48-eedf-4fab-a740-9c57082e04e9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000398" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000398_cnt_1">The components of provision for (benefit from) income taxes were as follows in each period presented:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000398_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current provision for (benefit from) income taxes:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision for (benefit from) income</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001604464_20210101_20211231" decimals="-3" scale="3">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001604464_20190101_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000399" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes at statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000913" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001604464_20210101_20211231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000914" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001604464_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000915" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001604464_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of stock compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000916" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001604464_20210101_20211231" decimals="INF" sign="-" scale="-2">2.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000917" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001604464_20200101_20201231" decimals="INF" sign="-" scale="-2">2.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000918" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001604464_20190101_20191231" decimals="INF" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible executive compensation</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000919" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001604464_20210101_20211231" decimals="3" sign="-" scale="-2">0.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000920" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001604464_20200101_20201231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000921" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001604464_20190101_20191231" decimals="3" sign="-" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000922" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001604464_20210101_20211231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000923" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001604464_20200101_20201231" decimals="3" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000924" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001604464_20190101_20191231" decimals="3" sign="-" scale="-2">0.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000925" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001604464_20210101_20211231" decimals="INF" sign="-" scale="-2">18.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000926" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001604464_20200101_20201231" decimals="INF" sign="-" scale="-2">18.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000927" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001604464_20190101_20191231" decimals="INF" sign="-" scale="-2">20.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000928" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001604464_20210101_20211231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000929" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001604464_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000930" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001604464_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric id="F_000400" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000400_cnt_1">Significant components of our deferred tax assets and liabilities were as follows for each of the dates presented:</ix:nonNumeric> </p><ix:continuation id="F_000400_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">308,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">237,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000937" name="atra:DeferredTaxAssetsLicenseFees" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000938" name="atra:DeferredTaxAssetsLicenseFees" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000939" name="atra:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000940" name="atra:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000941" name="atra:DeferredTaxAssetsLegalFees" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000942" name="atra:DeferredTaxAssetsLegalFees" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,136</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000943" name="atra:DeferredTaxAssetsTaxCredits" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000944" name="atra:DeferredTaxAssetsTaxCredits" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">383,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">291,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">376,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="atra:DeferredTaxLiabilitiesOperatingLeaseAssets" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="atra:DeferredTaxLiabilitiesOperatingLeaseAssets" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001604464_20201231" decimals="-3" scale="3">868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000355_dcnt_ed8ffc48-eedf-4fab-a740-9c57082e04e9" continuedAt="F_000355_dcnt_53734ed2-c09e-4c00-8085-4f174569433c">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes, as well as for tax attribute carryforwards. We regularly evaluate the positive and negative evidence in determining the realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance and reported cumulative net losses since inception, we maintained a full valuation allowance on the net deferred tax assets as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span> and 2020. We intend to maintain a full valuation allowance on our&#160;deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001604464_20210101_20211231" decimals="-5" scale="6">88.7</ix:nonFraction> million for the year ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span> primarily due to federal and state NOLs and other U.S. deferred tax assets, which includes accelerated Bayer revenue recognition for tax purposes during 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law on March 27, 2020, providing companies with various tax relief provisions and other stimulus measures. Such measures include, but are not limited to, temporary changes regarding the prior and future utilization of net operating losses, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property, acceleration of AMT credit refunds, and changes to business interest limitations. The Consolidated Appropriations Act was also signed into law on December 27, 2020 to provide further relief measures and renew various expiring tax provisions. Additionally, the IRS issued final regulations and proposed regulations on calculating the limitation on business interest expense, the allowance for the first-year depreciation deduction under IRC Section 168(k), as amended by the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), for qualified property acquired and placed in service after September 27, 2017, and meals and entertainment deductions. Based on our evaluation, these regulations did not have a material impact on the income tax provision for the years ended December 31, 2021, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Tax Act, federal net operating losses generated in tax years beginning on or after January 1, 2018 and in future years may be carried forward indefinitely, but the utilization of such federal net operating losses is limited to 80% of current year taxable income. The CARES Act temporarily suspends this 80% taxable income limitation, allowing a net operating loss carryforward to fully offset taxable income in tax years beginning before January 1, 2021.<span style="color:#000000;"> It is uncertain if, and to what extent, various states will conform to the Tax Act or the CARES Act. </span>The Tax Act nor the CARES Act had a material impact to our financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, for federal income tax purposes, we had net operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="C_0001604464_20211231" decimals="-5" format="ixt:numdotdecimal" scale="6">1,064.4</ix:nonFraction> million, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">65.2</ix:nonFraction> million <ix:nonNumeric id="F_000966" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">begin to expire in 2032</ix:nonNumeric> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">999.2</ix:nonFraction> do not expire, research &#38; development tax credits of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">18.0</ix:nonFraction> million which begin to expire in <ix:nonNumeric id="F_000969" name="atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2032</ix:nonNumeric>, and orphan drug tax credits of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001604464_20211231" decimals="-5" scale="6">94.5</ix:nonFraction> million which begin to expire in <ix:nonNumeric id="F_000971" name="atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" contextRef="C_0001604464_20210101_20211231">2035</ix:nonNumeric>. For California income tax purposes, we had net operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="C_0001604464_20211231" decimals="-5" format="ixt:numdotdecimal" scale="6">1,045.5</ix:nonFraction> million which <ix:nonNumeric id="F_000973" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">begin to expire in 2032</ix:nonNumeric>, and research &#38; development tax credits of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">30.4</ix:nonFraction> million which do not expire, and Competes tax credit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0001604464_20211231" decimals="-5" scale="6">2.0</ix:nonFraction> million which begins to expire in <ix:nonNumeric id="F_000976" name="atra:DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" contextRef="C_0001604464_20210101_20211231">2024</ix:nonNumeric>. For other states income tax purposes, we had net operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20211231" decimals="-5" scale="6">226.6</ix:nonFraction> million which <ix:nonNumeric id="F_000978" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20210101_20211231">begins to expire in 2030</ix:nonNumeric>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, our ability to utilize net operating loss carryforwards or other tax attributes in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section&#160;382 &#8220;ownership change&#8221; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Similar rules may apply under state tax laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have performed a Section 382 analysis of transactions in our stock through December 31, 2021. <span style="color:#000000;">We have experienced ownership changes since inception and our utilization of net operating loss carryforwards will be subject to annual limitations. However, it is not expected that the annual limitations will result in the expiration of tax attribute carryforwards prior to utilization</span><span style="color:#000000;">. </span></p><ix:nonNumeric id="F_000401" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true" continuedAt="F_000401_dcnt_976e2c0a-e673-4203-b2f9-e1435571a189"></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000355_dcnt_53734ed2-c09e-4c00-8085-4f174569433c"><ix:continuation id="F_000401_dcnt_976e2c0a-e673-4203-b2f9-e1435571a189">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the years ended December 31, 2019, 2020 and 2021 are as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20200101_20201231" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">110,601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001604464_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any uncertain tax position be favorably settled in the future. For 2021, 2020, and 2019 total unrecognize benefits in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20211231" decimals="-5" scale="6">144.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20201231" decimals="-5" scale="6">110.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001604464_20191231" decimals="-5" scale="6">86.0</ix:nonFraction> million, respectively, <ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0001604464_20211231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> amount, if recognized, would affect the Company&#8217;s effective tax rate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to account for interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company has not accrued interest and penalties as of December 31, 2021 due to available tax losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our significant jurisdictions are the U.S. federal jurisdiction and the California state jurisdiction. All of our tax years remain open to examination by the U.S. federal and California tax authorities. We also file in other state, local and foreign jurisdictions in which we operate, and such tax years remain open to examination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2017 Tax Act imposed a mandatory transition tax on accumulated foreign earnings and generally eliminated U.S. taxes on foreign subsidiary distribution. As of December 31, 2021, the Company is not permanently reinvested with respect to its foreign earnings and has not recorded deferred income taxes and withholding taxes as these taxes are immaterial to the financial statements.<span style="font-size:9pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000356" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001604464_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 26, 2022, the Company announced it has entered into an asset purchase agreement with FUJIFILM Diosynth Biotechnologies California, Inc. and, for certain limited purposes, FUJIFILM Holdings America Corporation, to sell all of the Company&#8217;s right, title and interest in and to certain assets related to the Atara T-Cell Operations and Manufacturing facility located at 2430 Conejo Spectrum Street, Thousand Oaks, California for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="atra:AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126" decimals="-6" scale="6">100</ix:nonFraction> million in cash, plus or minus certain closing adjustments pursuant to the asset purchase agreement. The closing of the proposed transaction is expected to occur in the quarter ending June 30, 2022, subject to certain closing conditions, including clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_9">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_9A">Item&#160;9A. Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>. Based on that evaluation,<span style="font-weight:bold;"> </span>our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2021 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span> based on the criteria established in <span style="font-style:italic;">Internal Control - Integrated Framework</span> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>. The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm, as stated in its report which is included in this Item 9A of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inherent Limitations on Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures and our internal controls will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints&#59; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. As these inherent limitations are known features of the financial reporting process, it is possible to design into the process safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. While our Chief Executive Officer and Chief Financial Officer have concluded that, as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, the design of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, was effective, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the three months ended <span style="letter-spacing:-0.2pt;">December 31, which were </span>identified in connection with our evaluation required by Rules&#160;13a-15(d) and 15d-15(d) of the Exchange Act<span style="letter-spacing:-0.2pt;">, </span>that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that many of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation to minimize the impact to the design and operating effectiveness of our internal controls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K includes an attestation report from our independent registered public accounting firm. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and the Board of Directors of Atara Biotherapeutics, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the internal control over financial reporting of Atara Biotherapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet and related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows as of and for the year ended December 31, 2021, of the Company and our report dated February 28, 2022, expressed an unqualified opinion on those financial statements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying &#8220;Management&#8217;s Report on Internal Control over Financial Reporting&#8221;. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ DELOITTE &#38; TOUCHE LLP</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_9B"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ite</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">m&#160;9B. Other Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PA</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RT&#160;III</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information required by Part&#160;III is omitted from this Annual Report on Form&#160;10-K since we intend to file our definitive proxy statement for our 2022 annual meeting of stockholders (the Definitive Proxy Statement), pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended, not later than 120&#160;days after December 31, 2021, and certain information to be included in the Definitive Proxy Statement is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-9.07%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_10">Item&#160;10. Directors, Executive Officers and Corporate Governance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_11">Item&#160;11. Executive Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_12">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_13">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Item_14">Item&#160;14. Principal Accountant Fees and Services</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is hereby incorporated by reference to our Definitive Proxy Statement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">P</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ART&#160;IV</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item&#160;15. Exhibits and Financial Statement Schedules</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(1)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this portion of Item 15 is set forth under Item 8 above.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(2)</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All schedules have been omitted because they are not required or because the required information is given in the financial statements or notes thereto set forth under Item 8 above.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(3)</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;" id="EXHIBIT_INDEX">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:3.75pt;">
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="middle" style="width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514243829/d692340dex32.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Atara Biotherapeutics, Inc.</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/20/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514243829/d692340dex34.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of Atara Biotherapeutics, Inc.</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/20/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514265496/d692340dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/10/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312519199083/d781708dex41.htm"><span style="text-decoration:underline;">Form of 2019 Pre-Funded Warrant</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312520154264/d909916dex41.htm"><span style="text-decoration:underline;">Form of May 2020 Pre-Funded Warrant</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/28/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312520313909/d47039dex41.htm"><span style="text-decoration:underline;">Form of December 2020 Pre-Funded Warrant</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/09/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.5</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020007027/atra-ex44_327.htm"><span style="text-decoration:underline;">Description of Securities</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/27/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459016023141/atra-ex102_415.htm"><span style="text-decoration:underline;">Amended and Restated 2014 Equity Incentive Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/08/2016</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514243829/d692340dex102.htm"><span style="text-decoration:underline;">Forms of Option Agreement and Option Grant Notice under the 2014 Equity Incentive Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/20/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex101_105.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2014 Equity Incentive Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514265496/d692340dex108.htm"><span style="text-decoration:underline;">2014 Employee Stock Purchase Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/10/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312521286789/d230923ds8.htm"><span style="text-decoration:underline;">Second Amended and Restated 2018 Inducement Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/29/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex102_106.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the Inducement Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459018011469/atra-ex103_119.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement and Stock Option Grant Notice under the Inducement Plan</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/08/2018</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459017016028/atra-ex103_160.htm"><span style="text-decoration:underline;">Forms of Inducement Grant Notice and Inducement Grant Agreement</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/07/2017</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312514243829/d692340dex109.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement made by and between Atara Biotherapeutics, Inc. and each of its directors and executive officers</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/20/2014</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459018018263/atra-ex104_165.htm"><span style="text-decoration:underline;">Form of Employment Agreement by and between Atara Biotherapeutics, Inc. and its executive officers.</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/01/2018</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019030426/atra-ex102_118.htm"><span style="text-decoration:underline;">Form of Executive Employment Agreement</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/08/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312519158431/d748666dex101.htm"><span style="text-decoration:underline;">Executive Employment Agreement, dated May 23, 2019, by and between Pascal Touchon and Atara Biotherapeutics, Inc</span></a><span style="text-decoration:underline;">.</span></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/28/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000119312515239519/d945261dex1030.htm"><span style="text-decoration:underline;">Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated as of June&#160;12, 2015</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/29/2015</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019004275/atra-ex1014_521.htm"><span style="text-decoration:underline;">Amendment No. 1 to the Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated as of August 30, 2018</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/26/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459018018263/atra-ex101_191.htm"><span style="text-decoration:underline;">Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Council of the Queensland Institute of Medical Research, dated September 23, 2016, as amended</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/01/2018</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459018018263/atra-ex102_192.htm"><span style="text-decoration:underline;">Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Council of the Queensland Institute of Medical Research, dated September 23, 2016, as amended</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/01/2018</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:3.75pt;">
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="middle" style="width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex103_107.htm"><span style="text-decoration:underline;">Second Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August 28, 2019</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex104_104.htm"><span style="text-decoration:underline;">Second Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August 28, 2019</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020052503/atra-ex101_113.htm"><span style="text-decoration:underline;">Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August 26, 2020</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020052503/atra-ex102_111.htm"><span style="text-decoration:underline;">Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August 26, 2020</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459018018263/atra-ex103_6.htm"><span style="text-decoration:underline;">Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated August 10, 2015, as amended</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/01/2018</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex105_108.htm"><span style="text-decoration:underline;">Amended and Restated Amendment No. 2 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 4, 2018</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459019041368/atra-ex106_109.htm"><span style="text-decoration:underline;">Amendment No. 3 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated June 28, 2019</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/07/2019</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020007027/atra-ex1022_255.htm"><span style="text-decoration:underline;">Amendment No. 4 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 4, 2019</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/27/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020007027/atra-ex1023_254.htm"><span style="text-decoration:underline;">Amendment No. 5 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 27, 2019</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/27/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020007027/atra-ex1024_253.htm"><span style="text-decoration:underline;">Commercial Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated January 1, 2020</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/27/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459021054261/atra-ex101_82.htm"><span style="text-decoration:underline;">Amendment No. 1 to Commercial Manufacturing Services Agreement, between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated September 1, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/04/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459016014061/atra-ex1029_1043.htm"><span style="text-decoration:underline;">Office Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated as of December 9, 2015</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/04/2016</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459020052503/atra-ex104_206.htm"><span style="text-decoration:underline;">First Amendment to Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated October 21, 2020</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/2020</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001604464/000156459017008828/atra-ex101_265.htm"><span style="text-decoration:underline;">Standard Industrial Lease by and between Thousand Oaks Industrial Portfolio, LLC and Atara Biotherapeutics, Inc. dated February 6, 2017</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/04/2017</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459021023337/atra-ex101_42.htm"><span style="text-decoration:underline;">Research, Development and License Agreement, by and between Atara Biotherapeutics, Inc. and Bayer AG, dated December 4, 2020</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/04/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459021023337/atra-ex102_118.htm"><span style="text-decoration:underline;">Lease Agreement between LA Region No. 2, LLC and Atara Biotherapeutics, Inc. dated March 17, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/04/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459021023337/atra-ex103_119.htm"><span style="text-decoration:underline;">First Amended and Restated Exclusive License Agreement by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated March 22, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/04/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1604464/000156459021042636/atra-ex101_176.htm"><span style="text-decoration:underline;">Deed of Amendment Number 1 to Third Amended and Restated License Agreement dated April 21, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/09/2021</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:3.75pt;">
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="middle" style="width:29.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="middle" style="width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex1035_105.htm"><span style="text-decoration:underline;">Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament, dated October 2, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex1036_104.htm"><span style="text-decoration:underline;">Second Amendment to Lease, by and between Atara Biotherapeutics, Inc. and 611 Gateway Center LP, LLC, dated December 9, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex1037_103.htm"><span style="text-decoration:underline;">Fourth Amended and Restated Research and Development Collaboration Agreement between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38+</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex1038_102.htm"><span style="text-decoration:underline;">Fourth Amended and Restated Exclusive License Agreement between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39*</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex1039_101.htm"><span style="text-decoration:underline;">Form of Atara Biotherapeutics, Inc. Executive Employment Agreement</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex211_9.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex231_6.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Power of Attorney (included on signature page)</span></a></p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex231_6.htm"><span style="text-decoration:underline;">Certification of the Chief Executive Officer pursuant to Rules 13A-14A and 15D-14A of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex312_8.htm"><span style="text-decoration:underline;">Certification of the Chief Financial Officer pursuant to Rules 13A-14A and 15D-14A of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1(1)</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="atra-ex321_7.htm"><span style="text-decoration:underline;">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-Top:0pt;padding-Bottom:0pt;width:51.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:10.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:6.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-Top:0pt;padding-Bottom:0pt;width:8.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Confidential treatment has been granted for a portion of this exhibit.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted as being both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-variant: small-caps;"></span>Indicates management contract or compensatory plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">The certifications attached as Exhibit&#160;32.1 accompany this Annual Report on Form&#160;10-K pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16">Item&#160;16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNA</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TURES</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the 28<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of February, 2022. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pascal Touchon</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pascal Touchon</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pascal Touchon and Utpal Koppikar, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pascal Touchon</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pascal Touchon</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director <br />(<span style="font-style:italic;">principal executive officer</span>)</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Utpal Koppikar</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utpal Koppikar</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer <br />(<span style="font-style:italic;">principal financial and accounting officer</span>)</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ronald Renaud</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ronald Renaud</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, Chairman</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Roy Baynes</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roy Baynes, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Eric L. Dobmeier</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eric L. Dobmeier</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew K. Fust</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew K. Fust</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:10.74%;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carol G. Gallagher</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carol G. Gallagher, Pharm.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William K. Heiden</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William K. Heiden</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ameet Mallik</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ameet Mallik</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Maria Grazia Roncarolo</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maria Grazia Roncarolo, M.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
<tr>
<td valign="middle" style="width:40.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="width:40.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Beth Seidenberg</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:35.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:40.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beth Seidenberg, M.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:35.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:18.05pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>2
<FILENAME>atra-ex1035_105.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex1035_105.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk83984633"></a>Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.35</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk95475050"></a>[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Between</font>:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">And</font>:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre Medicament</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;border-bottom:Solid 1.5pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMERCIALIZATION <font style="color:#000000;">AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1.5pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated October 2, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">TABLE OF CONTENTS</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:12.82%;"></td>
<td style="width:83.33%;"></td>
<td style="width:3.85%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 1 Definitions</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 2 Licenses; Knowledge Transfer</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant to Partner</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sublicenses.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No Other Rights or Implied Licenses</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Restrictive Covenants.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Existing Agreement</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 3 Right Regarding Option Countries</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 4 Joint Steering Committee</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Composition</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responsibilities</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subcommittees Establishment</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Meetings</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Minutes</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alliance Managers</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Scope of Governance</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Decision Making.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 5 Transition Plan</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transition Plan.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 6 Development Matters</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responsibilities &#8211; Primary Indication and Clinical Studies.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responsibilities - Additional Indications and Clinical Studies.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reports</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Records</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ownership of Development Data and Partner Inventions</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right to Audit Development Activities</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Right of Reference</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 7 Regulatory Matters</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Obtaining Regulatory Approval.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Transfer of Marketing Authorization for Europe and UK - Primary Indication</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:12.82%;"></td>
<td style="width:83.33%;"></td>
<td style="width:3.85%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmacovigilance</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Global Safety Database.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Early Access Programs</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Audits</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 8 Commercialization and Promotion Matters</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responsibilities</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diligence</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Plan</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pricing</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Promotional Materials</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ownership and Use of Product Trademarks and Product Trade Dress.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reports</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Compliance</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Global Branding Strategy</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.10</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cell Selection</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.11</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notification</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.12</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Order Handling. Order to Cash</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.13</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitation on Developing and Commercializing the Product Outside the Field</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.14</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitation on Activities Inside the Field and Territory</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.15</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Partner Non-Compete</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;8.16</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitation on Pursuit of Generic Product</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 9 Manufacturing and Supply Matters</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Supply Agreement</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Diligence</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Quality Agreement</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Return of Product</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Atara Supply Obligation.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 10 Intellectual Property Matters</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ownership of Atara Intellectual Property</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prosecution</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Enforcement in the Territory</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Infringement of Third Party Patent Rights</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Marking</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 11 Payments</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Upfront Payment</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Development Milestones</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercial Milestones</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:12.82%;"></td>
<td style="width:83.33%;"></td>
<td style="width:3.85%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Royalties on Net Sales.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Third Party Licenses</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Generic Competitor</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Academic Hospital Manufacturer</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Milestone Reports and Payments.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Royalty Reports and Payments.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;11.10</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Audits</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;11.11</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Taxes.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;11.12</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional Studies.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 12 Representations and Warranties; Disclaimer</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No Representation of Success</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties of Atara</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Representations and Warranties of Partner</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Representations of Both Parties</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certain Rights and Obligations of Atara.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Certain Rights and Obligations of Partner.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;12.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No Other Warranties</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 13 Indemnification; Insurance; Disclaimer</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;13.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by Atara</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;13.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification by Partner</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;13.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notice of Claim</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;13.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;13.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 14 Confidentiality; Publications; Data Protection</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreement Confidentiality</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exceptions</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Disclosures Required by Applicable Law</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Injunctive Relief</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ownership of Confidential Information</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Return or Destruction of Confidential Information</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Data Protection</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;14.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Publications.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;14.10</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Publicity</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 15 Subcontracting</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;15.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Atara</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;15.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Partner</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;15.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Responsibility For Subcontractors</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:12.82%;"></td>
<td style="width:83.33%;"></td>
<td style="width:3.85%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 16 Term and Termination</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination for Material Breach, Transfer or Assignment, Insolvency</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Event.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination for Patent Challenge</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination for Convenience by Partner</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination by Mutual Agreement</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination for Safety Reasons</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alternative to Termination for Material Breach</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consequences of Termination.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;16.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Termination Not Sole Remedy</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Article 17 General Provisions</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.2</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.3</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.4</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Counterparts</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.5</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Third Party Beneficiaries</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.6</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.7</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.8</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Waiver</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;17.9</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.10</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution.</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.11</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Headings</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.12</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interpretation</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.13</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Further Assurances</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.14</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No Partnership or Joint Venture</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;17.15</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Survival</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMERCIALIZATION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Commercialization Agreement (this &#8220;<font style="font-weight:bold;text-decoration:underline;">Agreement</font>&#8221;) is made as of October 2, 2021 (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Effective Date</font>&#8221;), by and between Atara Biotherapeutics, Inc., incorporated under the laws of Delaware and having its registered office at 611 Gateway Blvd., Suite 900, South San Francisco, CA 94080 (&#8220;<font style="font-weight:bold;text-decoration:underline;">Atara</font>&#8221;), and Pierre Fabre Medicament, having its registered office at 45, place Abel Gance, 92100 Boulogne Billancourt, France (&#8220;<font style="font-weight:bold;text-decoration:underline;">Partner</font>&#8221;).&nbsp;&nbsp;Atara and Partner are referred to in this Agreement individually as a &#8220;<font style="font-weight:bold;text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight:bold;text-decoration:underline;">Parties</font>.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc519935463"></a><a name="_Toc519934697"></a>WHEREAS, Atara is engaged in the development and manufacture of T-cell immunotherapies; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Atara is conducting pivotal clinical studies with the Product (as defined below); </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Partner has expertise in commercializing biological and pharmaceutical products for the treatment of oncologic diseases in the Territory (as defined herein); and </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Atara desires to enter into a relationship with Partner wherein Partner will Commercialize the Product in the Field (each, as defined herein) in the Territory pursuant to the terms and conditions of this Agreement and certain Ancillary Agreements (as defined herein) and Partner agrees to do so. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, Atara and Partner hereby agree as follows:</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="qsTmp"></a><a name="_Toc221533290"></a><a name="_Toc256000112"></a><a name="_Toc83283183"></a><a name="_Toc256000000"></a><a name="_Toc84000517"></a>Article 1<br /><br /><a name="_Toc256000112"></a><a name="_Toc83283183"></a><a name="_Toc256000000"></a><a name="_Toc84000517"></a>Definitions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Accounting Standards</font><font style="font-weight:normal;">&#8221; shall mean, with respect to Atara, GAAP, and with respect to Partner, IFRS.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Additional Indication</font><font style="font-weight:normal;">&#8221; means an indication in the Field other than the Primary Indication, including, but not limited to, a Multi-Cohort Indication.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Adverse Event</font><font style="font-weight:normal;">,&#8221; &#8220;</font><font style="text-decoration:underline;">Serious Adverse Event</font><font style="font-weight:normal;">&#8221; and &#8220;</font><font style="text-decoration:underline;">Serious Adverse Drug Reaction</font><font style="font-weight:normal;">&#8221; shall have the meanings provided to such terms in the ICH guideline for industry on Clinical Safety Data Management (E2A, Definitions and Standards for Expedited Reporting).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.4<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Affiliate</font><font style="font-weight:normal;">&#8221; means, with respect to a Party, any Entity that controls, is controlled by, or is under common control with that Party.&nbsp;&nbsp;For the purpose of this definition, &#8220;control&#8221; means </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">direct or indirect ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the Entity controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Alliance Manager</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 4.6.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.6<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Ancillary Agreements</font><font style="font-weight:normal;">&#8221; means, collectively, the Manufacturing and Supply Agreement, the Pharmacovigilance Agreement, and the Quality Agreement.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.7<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Anti-Corruption Laws</font><font style="font-weight:normal;">&#8221; means the United States Foreign Corrupt Practices Act, the United Kingdom Bribery Act, and any other Laws of a similar nature for the prevention of fraud, corruption, racketeering, money laundering and terrorism, in each case as they may be amended from time to time.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.8<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Approved Sublicensee</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 2.2(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.9<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara 205 Study</font><font style="font-weight:normal;">&#8221; means the multicenter, multicohort, open-label, single-arm, Phase 2 Clinical Study having the ClinicalTrials.gov identifier NCT04554914, as designed as of the Effective Date.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara 302 Study</font><font style="font-weight:normal;">&#8221; means the multicenter, open-label, Phase 3 Clinical Study having the ClinicalTrials.gov identifier NCT03394365, as designed as of the Effective Date.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara 902 EAP Observational Study</font><font style="font-weight:normal;">&#8221; means the ongoing Observational Study describing the analysis of data collected as part of the Atara EU EAP/SPU Program, as designed as of the Effective Date</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara CMO</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 9.5(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.13<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara EU EAP/SPU Program</font><font style="font-weight:normal;">&#8221; means Atara&#8217;s ongoing Early Access Program that provides Product for named-patient use in the Territory as designed as of the Effective Date.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref83848415"></a><a name="_Hlk83244966"></a>1.14<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;"><a name="_Hlk83244966"></a>Atara Manufacturing Facility</font><font style="font-weight:normal;">&#8221; means one or more facilities of (a) [***], or (h) any other facility of an Atara Affiliate or Third Party subcontractor designated after the Effective Date by Atara, in each case (i) subject to prior notice to Partner sufficiently in advance if the use of any such Atara Manufacturing Facility will require a change to any Regulatory Filing, Regulatory Approval, or Marketing Authorization for the Product in the Territory, and (ii) subject to Partner&#8217;s prior written consent in the event that Atara&#8217;s use of such other facility in connection with the performance of its obligations under this Agreement would adversely impact in any material respect a Regulatory Filing, Regulatory Approval, or Marketing Authorization, in each case, in the Territory, which consent shall not be unreasonably withheld or delayed, or in accordance with Section 9.5. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.15<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara Indemnified Person</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 13.2.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.16<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara Intellectual Property</font><font style="font-weight:normal;">&#8221; means (a) Atara Patent Rights, and (b) Know-How, Product Trademarks, and applicable web domain name registrations (as they may be determined), that are (i) Controlled by Atara as of the Effective Date or during the Term, and (ii) necessary or reasonably useful to Develop, seek Regulatory Approvals, and Commercialize a Product in the Field in the Territory, perform qualified person release, and secondary Packaging and Labeling of the Product for use and Commercialization in the Territory; as well as Cell Selection and Manufacturing if and when these activities are transferred to Partner pursuant to this Agreement.&#160; [***].&#160; For the avoidance of doubt, Atara Intellectual Property shall include all Development Data.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara Officers</font><font style="font-weight:normal;">&#8221; means the officers listed in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit I</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara Patent Rights</font><font style="font-weight:normal;">&#8221; means (a) the Patent Rights listed on Exhibit D and/or (b) any Patent Rights Controlled by Atara as of the Effective Date or during the term of the Agreement that, but for the licenses granted under this Agreement, would be infringed by the Development of, seeking Regulatory Approval for, performing quality control testing, qualified person release of, secondary Packaging or Labeling of, or Commercializing of the Product in the Field in the Territory, as well as Cell Selection and Manufacturing if and when these activities are transferred to Partner pursuant to this Agreement; and (c) all additions, divisions, continuations, substitutions, re-issues, re-examinations, registrations, patent term extensions, supplemental protection certificates, and renewals of any of the foregoing Patent Rights covered in subsections (a) and (b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.19<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Atara&#8217;s knowledge</font><font style="font-weight:normal;">&#8221; means the knowledge of the Atara Officers after having conducted reasonable internal inquiries on matters that a reasonably prudent person in a comparable position to each of such Atara Officers would be aware of having made reasonable inquiries. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.20<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Business Day</font><font style="font-weight:normal;">&#8221; means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in the State of New York, United States or Paris, France. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.21<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Calendar Quarter</font><font style="font-weight:normal;">&#8221; means each three (3) month period commencing January 1, April 1, July 1 or October 1 of any year; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.22<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Calendar Year</font><font style="font-weight:normal;">&#8221; means the period beginning on the 1st of January and ending on the 31st of December of the same year; provided, however, that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year of the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or expiration of this Agreement.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.23<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Cell Selection</font><font style="font-weight:normal;">&#8221; means the process of [***], as such process may (i) be amended or modified by Atara from time to time, provided that any such amendment or modification may not be implemented with respect to Commercialization of the Product in the Territory without </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">reasonable prior notice to Partner if such change will require a change to any Regulatory Filing, Regulatory Approval, or Marketing Authorization for the Product in the Territory and without Partner&#8217;s prior written consent if it would be reasonably expected to materially and adversely impact a MA or MAA or the Commercialization of the Product by Partner, and (ii) be transitioned once to any of Partner, its Affiliates, or a&nbsp;&nbsp;single Approved Sublicensee pursuant to Section </font><font style="font-weight:normal;">8.10</font><font style="font-weight:normal;">, wherein transition to an Approved Sublicensee requires the prior written consent of Atara, which consent shall not be unreasonably withheld, conditioned or delayed. Upon such transfer, Cell Selection may not be further transferred by such Partner, Affiliate or Approved Sublicensee without the further prior written consent of Atara, which, in the event that Parties mutually agree that the single party to whom Atara transitioned responsibility for Cell Selection activities is no longer able to satisfactorily perform such activities, shall not be unreasonably withheld or delayed.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.24<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Cell Therapy Restricted Product</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 8.14. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.25<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Change of Control</font><font style="font-weight:normal;">&#8221; means (a) a merger or consolidation of a Party with a Third Party that results in the voting securities of a Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of a Party, or (c) the sale or other transfer to a Third Party of all or substantially all of a Party&#8217;s and its Affiliates&#8217; assets.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.26<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Claim</font><font style="font-weight:normal;">&#8221; means a Third Party demand, claim, action, proceeding, order, finding or verdict (whether criminal or civil, in contract, tort or otherwise) seeking or awarding losses, damages, legal costs, other expenses of any nature, or equitable remedies of any nature, including restitution and injunctive relief.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.27<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Clinical Study</font><font style="font-weight:normal;">&#8221; means any interventional human clinical study of the Product and specifically excludes any Observational Study.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.28<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">CMC</font><font style="font-weight:normal;">&#8221; means chemistry, manufacturing and controls.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.29<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Combination Product</font><font style="font-weight:normal;">&#8221; means a product comprising the Product plus one or more Other Component(s).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.30<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Commercialize</font><font style="font-weight:normal;">&#8221; and &#8220;</font><font style="text-decoration:underline;">Commercialization</font><font style="font-weight:normal;">&#8221; are used interchangeably to mean any and all activities directed to the use, sale, offer for sale and import of the Product, and inclusive of Pre-Launch, launch, promotion, marketing, pricing, reimbursement, sale, and distribution of the Product, including: (a) strategic marketing, sales force detailing, advertising, and market and Product support; (b) all customer support, Product distribution, invoicing and sales activities, (c) market access activities (pricing, Pricing Approval, and reimbursement) and (d) medical activities with respect to the Product in the Territory in support of the sales, promotion, marketing or use of the Product in the Territory.&nbsp;&nbsp;For the avoidance of doubt, &#8220;Commercialize&#8221; and &#8220;Commercialization&#8221; shall include any activities directed or relating to Early Access Programs, and Observational Studies (other than the Atara 902 EAP Observational Study and the Atara EU </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">EAP/SPU Program), and exclude any activities directed or relating to Development, Cell Selection or Manufacturing. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.31<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Commercially Reasonable Efforts</font><font style="font-weight:normal;">&#8221; means, with respect to particular obligations or tasks, such level of efforts and resources applied to carry out such obligations or tasks in a sustained manner consistent with the efforts and resources commonly used in the biopharmaceutical industry by a company of comparable size in connection with the development, manufacture or commercialization of products, as the case may be, to accomplish such obligations or tasks, at the same stage of development or commercialization, as applicable, for internally developed healthcare products in a similar area with similar market potential, at a similar stage of their product life taking into account, [***].</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.32<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Commercialization Plan</font><font style="font-weight:normal;">&#8221; means the written plan directed to Commercialization of the Product in the Field in the Territory prepared, reviewed, discussed, updated and amended from time to time in accordance with Section 8.3.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.33<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Commercial Sale</font><font style="font-weight:normal;">&#8221; means an invoiceable sale by Partner, its Affiliate, or Approved Sublicensee to a Third Party, excluding any sales under an Early Access Program. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.34<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Confidential Information</font><font style="font-weight:normal;">&#8221; means all proprietary Know-How, unpublished patent applications and other information and data of a financial, commercial, business, operational or technical nature that: (a) the Disclosing Party or any of its Affiliates has supplied or otherwise made available to the other Party or any of its Affiliates in connection with this Agreement, whether prior to or during the Term and whether made available orally, by observation, in writing or in electronic form; or (b) the Receiving Party has learned from the disclosing Party in the course of this Agreement, in each case including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.35<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Control</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">Controlled</font><font style="font-weight:normal;">&#8221; means with respect to any material, Know-How or other information or intellectual property right, the possession (whether by license, other than solely by virtue of licenses granted in this Agreement, or ownership) by a Party or its Affiliates of the ability to grant to the other Party access, a license, or a sub-license or other right thereunder without breaching or violating the terms of any applicable agreement or other arrangement with a Third Party. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.36<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Cost-Plus</font><font style="font-weight:normal;">&#8221; means the actual cost incurred by Atara for Manufacturing Product, plus [***], where actual costs include, without limitation, raw materials, intermediates, direct labor, and direct and indirect allocation of facilities and other overhead costs as further detailed in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;"> and the Manufacturing and Supply Agreement. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.37<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">CTA</font><font style="font-weight:normal;">&#8221; shall mean a clinical trial application (including any amendments thereto) as provided for in European Community Directive 2001/20/EC and/or European Union Regulation 536/2014 and the regulations promulgated thereunder, as applicable, filed with a Regulatory Authority in the European Union before the commencement of Clinical Studies for a Product, or any comparable filing with any Regulatory Authority in any other jurisdiction within or outside the Territory (including any Investigational New Drug Application filed with a Regulatory Authority in the United States pursuant to 21 C.F.R. &#167;312).</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.38</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Cover</font><font style="font-weight:normal;">&#8221; means with respect to any Patent Right and activity, that such Patent Right would be infringed by such activity in the absence of the licenses granted pursuant to this Agreement.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk82600460"></a>1.39<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Current Studies</font><font style="font-weight:normal;"><a name="_Hlk82600460"></a>&#8221; means the Atara 205 Study, the Atara 302 Study, the Atara 902 EAP Observational Study, and the Atara EU EAP/SPU Program. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.40<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Data Protection Laws</font><font style="font-weight:normal;">&#8221; means all applicable Laws, including the Health Insurance Portability and Accountability Act, the California Consumer Privacy Act of 2018, and the General Data Protection Regulation 2016/679, and any national other legislation relating to privacy and data protection, direct marketing or the interception or communication of electronic messages, in each case as amended, consolidated, re-enacted or replaced from time to time.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.41<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Data Subject</font><font style="font-weight:normal;">&#8221; means a natural person who is an identified or identifiable natural person.&nbsp;&nbsp;An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.42<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Develop</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">Development</font><font style="font-weight:normal;">&#8221; means any and all activities related to research, non-clinical, pre-clinical and Clinical Studies with respect to the Product, including, without limitation, supporting any Investigator Sponsored Clinical Trials, but excluding Manufacturing of the Product for the purpose of conducting the foregoing activities.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.43<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Development Data</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 6.6.&nbsp;&nbsp;Development Data includes, but is not limited to, Regulatory Data.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.44<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Dispute</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 17.10(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.45<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Distributor</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 2.2(b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.46<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">DMF</font><font style="font-weight:normal;">&#8221; means a drug master file and all equivalents in any country or jurisdiction for the Product, and any components of such Product, submitted by a Party, its Affiliates and/or a sublicensee, to Regulatory Authorities. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.47<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Dollar</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">$</font><font style="font-weight:normal;">&#8221; means the legal tender of the United States.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.48<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Early Access Approvals</font><font style="font-weight:normal;">&#8221; means the permissions, exemptions, approvals, authorizations and/or waivers required by Regulatory Authorities for medical treatments pursuant to an Early Access Program, where the use of such Product is not intended to obtain information about the safety or effectiveness of the Product. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.49<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Early Access Program</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">EAP</font><font style="font-weight:normal;">&#8221; means the activities directed to (a) supporting a physician&#8217;s request(s) for the Product for named-patient use, compassionate use, expanded access and hospital exemption in the Territory through an Early Access Approval (b) the securing of Early Access Approvals for Product, for the use of such treatments, and (c) the labeling, packaging, distribution and sale (as appropriate) of such treatments pursuant to such Early Access Approvals.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.50</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">EBV Restricted Product</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 8.14.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.51<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">EC</font><font style="font-weight:normal;">&#8221; means the European Commission, or any successor entity thereto performing similar functions.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.52<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">EMA</font><font style="font-weight:normal;">&#8221; means the European Medicines Agency, or any successor entity thereto performing similar functions. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.53<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Entity</font><font style="font-weight:normal;">&#8221; means a partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.54<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Epstein Barr Virus</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">EBV</font><font style="font-weight:normal;">&#8221; means human herpesvirus 4. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.55<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">EBV+PTLD</font><font style="font-weight:normal;">&#8221; means EBV-positive post-transplant lymphoproliferative disease. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.56<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Europe</font><font style="font-weight:normal;">&#8221; means (a) the twenty-seven (27) countries of the European Union as constituted on the Effective Date, and (b) Iceland, Liechtenstein, and Norway.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.57<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">European Territory</font><font style="font-weight:normal;">&#8221; means Europe and the United Kingdom (UK).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.58<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Executive Officers</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 4.8(b), hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.59<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Existing Agreement</font><font style="font-weight:normal;">&#8221; means Atara&#8217;s exclusive license agreement with MSK as Amended and Restated on March 22, 2021, as it may be further amended from time to time and subject to the terms and conditions of this Agreement.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.60<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Extended Royalty Term</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 11.4(b), hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.61<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Field</font><font style="font-weight:normal;">&#8221; means all human therapeutic uses for any EBV-positive disease, except multiple sclerosis and other autoimmune conditions. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.62<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">First Commercial Sale</font><font style="font-weight:normal;">&#8221; means, with respect to any country in the Territory the first Commercial Sale in the Field by or on behalf of Partner, its Affiliate or its Approved Sublicensee to a Third Party (including to a Distributor) in such country.&#160; Notwithstanding the foregoing, any </font><font style="font-style:italic;font-weight:normal;">bona fide</font><font style="font-weight:normal;"> invoiced sales of Product for a commercial margin in a country in the Territory by Partner, its Affiliate or its Approved Sublicensee following receipt of Regulatory Approval, but prior to obtaining Pricing Approval (e.g., sales of Product at a commercial margin under the Temporary Authorization for Use Program in France), shall be deemed a &#8220;First Commercial Sale&#8221; of the Product in such country.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.63<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Full Royalty Term</font><font style="font-weight:normal;">&#8221; means, on a country-by-country-basis within the Territory, the period beginning on the date of the First Commercial Sale of Product in such country and ending on the last to occur of (a) [***] after the First Commercial Sale in the applicable country; (b) the expiration or abandonment of the last Valid Claim of the Patent Rights within the Atara Intellectual Property that Covers any aspect of the Commercialization of the Product in the Field in such country; or (c) the expiration of all Regulatory Exclusivity for such Product in the Field in such country.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.64</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">GAAP</font><font style="font-weight:normal;">&#8221; means the generally accepted accounting principles in the United States as generally and consistently applied by Atara.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.65<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Generic Competitor</font><font style="font-weight:normal;">&#8221; means, with respect to a Product, on a country-by-country basis within the Territory, one or more pharmaceutical product(s) (a) sold under a Marketing Authorization granted by an applicable Regulatory Authority to a Third Party (who is not an Affiliate of Partner or an Approved Sublicensee or a Distributor), (b) that contains the same or biologically similar active ingredient as the Product (whether or not in the same formulation or a similar formulation as the Product), and (c) is approved in reliance of a prior Marketing Authorization of the Product granted by the applicable Regulatory Authority, including for the avoidance of doubt, the Marketing Authorization transferred by Atara to Partner under this Agreement.. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.66<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Generic Market Share</font><font style="font-weight:normal;">&#8221; means, with respect to a Product in a country, the total unit volume of Generic Competitor(s) of such Product sold in such country, as a percentage of the combined unit volume of such Product and such Generic Competitor(s), in the aggregate in such country, for the current Calendar Quarter (i.e., the Calendar Quarter for which royalties are being calculated under Section 11.4) and the preceding Calendar Quarter.&nbsp;&nbsp;Such unit volumes shall be determined by the number of unit sales given for such Product and such Generic Competitor(s) in aggregate, during such period (as evidenced by data from IMS Health or other data service reasonably acceptable to both Parties).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.67<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Global Safety Database</font><font style="font-weight:normal;">&#8221; means the database containing worldwide safety data including Adverse Events, Serious Adverse Events, adverse reactions, Serious Adverse Drug Reactions, safety reports related to special situations for the Product as defined in the applicable Laws, and pregnancy reports for the Product.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.68<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Global Branding Strategy</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 8.9, hereto.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.69<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Good Clinical Practices</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">GCP</font><font style="font-weight:normal;">&#8221; means all applicable current good clinical practices, including, as applicable, (a) the standards detailed in the ICH Harmonized Tripartite Guideline for Good Clinical Practice and (b) similar standards, guidelines and regulations promulgated or otherwise required by other applicable Regulatory Authorities, in each case, as they may be amended from time to time.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.70<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Good Laboratory Practices</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">GLP</font><font style="font-weight:normal;">&#8221; means all applicable current good laboratory practices, including, as applicable, (a) the standards detailed in Directive 2004/10/EC and (b) similar standards, guidelines and regulations promulgated or otherwise required by other applicable Regulatory Authorities, in each case, as they may be amended from time to time.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.71<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Good Manufacturing Practices</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">GMP</font><font style="font-weight:normal;">&#8221; means all applicable current good manufacturing practices including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Articles 210, 211, 601 and 610, (b) the principles detailed in the ICH Q7 guidelines, and (c) the equivalent applicable Law in any relevant country, each as may be amended and applicable from time to time.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.72<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Government Authority</font><font style="font-weight:normal;">&#8221; means any federal, state, national, regional, provincial or local government, or political subdivision thereof, or any multinational organization or any </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.73<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">HLA</font><font style="font-weight:normal;">&#8221; means human leukocyte antigen.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.74<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">ICH</font><font style="font-weight:normal;">&#8221; means International Conference on Harmonization.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.75<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">IFRS</font><font style="font-weight:normal;">&#8221; means the International Financial Reporting Standards generally and consistently applied by Partner.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.76<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Investigator Sponsored Clinical Trial</font><font style="font-weight:normal;">&#8221; shall mean a clinical study of a Product that is sponsored and conducted by a physician, physician group or other Third Party not acting on behalf of a Party or an Affiliate, pursuant to a CTA held by such Third Party, and with respect to which a Party or its Affiliate, provides funding or other support for such clinical study.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.77<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Indemnitee</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 13.3, hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.78<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Indemnitor</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 13.3, hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.79<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Insolvency Event</font><font style="font-weight:normal;">&#8221; means, in relation to either Party, any one of the following: (a) that Party is declared insolvent or bankrupt by a court of competent jurisdiction; (b) that Party is the subject of voluntary or involuntary bankruptcy proceedings instituted on behalf of or against such Party (except for involuntary bankruptcy proceedings which are dismissed within sixty (60) days); (c) an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator or similar officer is appointed in respect of that Party by a court of competent jurisdiction; (d) a notice shall have been issued by a competent authority to convene a meeting for the purpose of passing a resolution to wind up that Party, or such a resolution shall have been passed other than a resolution for the solvent reconstruction or reorganization of that Party; and with respect to Atara only, (e) a resolution shall have been passed by that Party or that Party&#8217;s directors to make an application for an administration order or to appoint an administrator; or (f) that Party proposes or makes any general assignment, composition or arrangement with or for the benefit of all or some of that Party&#8217;s creditors or makes or suspends or threatens to suspend making payments to all or some of that Party&#8217;s creditors</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.80<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Joint Steering Committee</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">JSC</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 4.1. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.81<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Know-How</font><font style="font-weight:normal;">&#8221; means any and all tangible and intangible information and materials, including research and Development Data, regulatory submissions and correspondence, manufacturing information and processes, formulations, assays, cell lines, sequences, composition of matter, constructs, discoveries, improvements, modifications, processes, methods, protocols, formulas, utility, data (including physical, chemical, biological, toxicological, pharmacological, preclinical, and clinical data), results, inventions, know-how and trade secrets, patentable or otherwise, and all other scientific, marketing, financial and commercial information or data, but excluding any of the foregoing to the extent described or claimed in any Patent Rights.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.82</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Label</font><font style="font-weight:normal;">&#8221; or </font><font style="text-decoration:underline;">Labeling</font><font style="font-weight:normal;">&#8221; refers to such labels and other written, printed or graphic matter, (a) upon any container or wrapper utilized with the Product, or (b) accompanying the Product, including, without limitation, Package inserts and patient-specific information sheet.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.83<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Law</font><font style="font-weight:normal;">&#8221; means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order by any Government Authority (including, without limitation, any Regulatory Authority), or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law, including, without limitation, applicable Anti-Corruption Laws and GMP, GLP, and GCP standards.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.84<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Liens</font><font style="font-weight:normal;">&#8221; has the meaning set forth in Section 12.5(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.85<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Limited Period</font><font style="font-weight:normal;">&#8221; has the meaning set forth in Section 8.14.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.86<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Major Markets</font><font style="font-weight:normal;">&#8221; means [***].</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.87<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Manufacture</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">Manufacturing</font><font style="font-weight:normal;">&#8221; are used interchangeably herein to mean the operations required, as applicable, to (a) manufacture test, store, and ship Product for Development and for use pursuant to any Early Access Program in the Territory, or (b) manufacture, test, store and ship the Product to Partner, or Partner&#8217;s Affiliate for (i) Commercialization in the Territory, and (ii) Development and for use pursuant to any Early Access Program in the Territory, including primary Packaging, Labeling, and quality control testing (including in the European Territory), but excluding qualified person release and secondary Packaging and Labeling.&nbsp;&nbsp;For the avoidance of doubt, all secondary Packaging and Labeling (including accompanying patient-specific information sheet) of the Product for distribution and use in the Territory will be the sole responsibility and expense of Partner.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.88<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Manufacturing and Supply Agreement</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">MSA</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 9.1, hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk77771896"></a>1.89<font style="margin-left:36pt;"></font><font style="font-weight:normal;"><a name="_Hlk77771896"></a>&#8220;</font><font style="text-decoration:underline;">Marketing Authorization</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">MA</font><font style="font-weight:normal;">&#8221; means an approval by a Regulatory Authority for the placing in the market of therapeutic products in a country, region or other jurisdiction in the Territory, including, without limitation, a marketing authorization as granted by the EC and all amendments and supplements thereto.&nbsp;&nbsp;For the avoidance of doubt, Marketing Authorization does not include Pricing Approvals in any country, region, or jurisdiction in the Territory. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.90<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Marketing Authorization Application</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">MAA</font><font style="font-weight:normal;">&#8221; means an application for Marketing Authorization and all amendments and supplements thereto prior to its approval, including all necessary documents, data and other information, including, without limitation any application for Marketing Authorization filed with the EMA.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.91<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">MHRA</font><font style="font-weight:normal;">&#8221; means the Medicines and Healthcare Products Regulatory Agency, or any successor entity thereto performing similar functions.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.92<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">MSK</font><font style="font-weight:normal;">&#8221; means the Memorial Sloan Kettering Cancer Center.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.93<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Multi-Cohort Indications</font><font style="font-weight:normal;">&#8221; means any or all indications selected from EBV+ acquired immunodeficiency lymphoproliferative diseases (AID-LPD), EBV+ primary immunodeficiency lymphoproliferative disease (PID-LPD), EBV+ sarcoma, including leiomyosarcomas (LMS), chronic active EBV infection (CAEBV), EBV-associated hemophagocytic lymphohistiocytosis (HLH), EBV+ PTLD ineligible for current first line standard of care (rituximab &#177; chemotherapy) treatment, and EBV+ PTLD with central nervous system involvement.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.94<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">New Development</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 6.2(b), hereto.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.95<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Net Sales</font><font style="font-weight:normal;">&#8221; means the gross amount billed or invoiced on sales of the Product sold by Partner, its Affiliates or their Approved Sublicensees (including sales of Product by Partner, its Affiliates or their Approved Sublicensees to Distributors, but not by Distributors) to a Third Party in the Territory (other than sales among Partner, its Affiliates and Approved Sublicensees for subsequent resale in which case the first sale to a Third Party that is not an Affiliate or an Approved Sublicensee shall be used for calculation of Net Sales), less the following: [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross sales of Product shall be deemed to have been made on the date on which they are recognized in Partner&#8217;s financial accounts, in accordance with their standard accounting procedures.&nbsp;&nbsp;For clarity, Net Sales shall include [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Sales shall be determined in accordance with Accounting Standards.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that a Product is sold in the form of a Combination Product, then, for the purpose of calculating royalties due, Net Sales will be adjusted by multiplying by the fraction A/(A+B) where A is the gross per unit invoice price of the Product, if sold separately, and B is the gross per unit invoice price of any Other Component(s), if sold separately.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, on a country-by-country basis, the Other Component(s) are not sold separately in that country, Net Sales will be adjusted by multiplying by the fraction A/C where A is the gross per unit invoice price of the Product, if sold separately, and C is the gross per unit invoice price of the Combination Product.&nbsp;&nbsp;In each case, the gross per unit invoice price shall be those applicable during the relevant Quarter or, if sales of both the Product and the Other Component did not occur in such Quarter, then in the most recent Quarter in which sales of both occurred.&nbsp;&nbsp;If, on a country-by-country basis, neither the Product nor the Other Component are sold separately in such country, then the fraction by which the Net Sales value shall be multiplied shall be determined between the Parties in good faith.<font style="margin-left:36pt;"></font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.96<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Nordic Countries</font><font style="font-weight:normal;">&#8221; means Denmark, Finland, Norway and Sweden.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.97<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Observational Study</font><font style="font-weight:normal;">&#8221; means any non-interventional study for the Product.&nbsp;&nbsp;Observational Studies may include patient registries, surveillance studies, health economic studies or similar activities.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.98<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Option Notice</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 3.1. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.99<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Option Territory</font><font style="font-weight:normal;">&#8221; means [***].</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.100<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Orphan Drug Designation</font><font style="font-weight:normal;">&#8221; means orphan designation (EU/3/16/1627) granted by the EC for the Product in relation to the Primary Indication and any other orphan designation (i) granted by the EC for the Product with respect to an Additional Indication(s) or (ii) granted by any Regulatory Authority within a country or regulatory region within the Territory with respect to the Product.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.101<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Other Component</font><font style="font-weight:normal;">&#8221; means a product, component, or medical device, in each case, either as part of, or companion to, the Product, or co-packaged, or co-distributed with the Product. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.102<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Package</font><font style="font-weight:normal;">,&#8221; &#8220;</font><font style="text-decoration:underline;">Packaged</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">Packaging</font><font style="font-weight:normal;">&#8221; means all primary and/or secondary containers, including cartons, shipping cases, printed materials, or any other like matter used in packaging or accompanying a Product for Commercial Sale.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.103<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Partner Indemnified Person</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 13.1.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.104<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Partner Intellectual Property</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 6.6.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.105<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Partner Notice</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 3.2.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.106<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Patent Rights</font><font style="font-weight:normal;">&#8221; means any and all issued patents and patent applications existing upon the Effective Date and in the future, including, without limitation, provisional applications, continuation applications, substitutions, continuations-in-part, divisional applications, renewals, Patent Cooperation Treaty applications, and all letters patent granted thereon, invention patents, utility model patents, industrial design patents, all patents-of-addition, reexaminations, reissues, registrations, confirmations, revalidations, certificates of addition, utility models and petty patents, including extensions or restorations of terms thereof by existing or future extension or restoration mechanisms (including regulatory extensions), pediatric use extensions, supplementary protection certificates or any other such right, together with any foreign counterparts thereof.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.107<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Percentage Increase</font><font style="font-weight:normal;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.108<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Person</font><font style="font-weight:normal;">&#8221; means any individual, Entity or Government Authority.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.109<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Pharmacovigilance Agreement</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 7.3.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.110<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Post-Transfer Period</font><font style="font-weight:normal;">&#8221; means for Europe and the UK, respectively, the period from the transfer date from Atara to Partner of the Marketing Authorization or MAA, as applicable by (a) the EC, or (b) the MHRA, as applicable, onward during the Term.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.111<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">PPI Index</font><font style="font-weight:normal;">" shall have the meaning given in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.112<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Pre-Launch</font><font style="font-weight:normal;">&#8221; means all activities undertaken prior to and in preparation for the launch of the Product in the Field in the Territory.&nbsp;&nbsp;Pre-Launch shall include market research, key opinion leader development, advisory boards, medical education, patient associations, disease-related public relations, health care economic studies, sales force training and other pre-launch activities prior to the First Commercial Sale of the Product in a given country, region, or other jurisdiction in the Territory.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.113</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Pre-Transfer Period</font><font style="font-weight:normal;">&#8221; means for Europe and the UK, respectively, the period beginning on the Effective Date and ending upon the transfer date from Atara to Partner of the Marketing Authorization or MAA, as applicable by (a) the EC, or (b) the MHRA, as applicable.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.114<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Pricing Approval</font><font style="font-weight:normal;">&#8221; means the approval, agreement, determination or decision from a Government Authority establishing the price and/or reimbursement status for the Product for sale in a given country, region or jurisdiction in the Territory, as required by applicable Law in such country or other regulatory jurisdiction prior to the sale of the Product in such country, region or jurisdiction in the Territory.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.115<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Primary Indication</font><font style="font-weight:normal;">&#8221; means (as may be amended from time to time in accordance with the terms of this Agreement) EBV+ PTLD in patients who have received at least one prior therapy.&nbsp;&nbsp;For solid organ transplant patients, prior therapy includes chemotherapy, unless chemotherapy is considered inappropriate. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk77772873"></a>1.116<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Product</font><font style="font-weight:normal;">&#8221; means tabelecleucel, an allogeneic T-cell immunotherapy selective for the tumor-associated antigens expressed by EBV.&nbsp;&nbsp;Product includes, without limitation, a Combination Product.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.117<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Product Supply Price</font><font style="font-weight:normal;">" shall have the meaning given in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.118<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Product Trade Dress</font><font style="font-weight:normal;">&#8221; means trade dress for use in connection with the Commercialization of the Product in the Field in the Territory.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.119<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Product Trademarks</font><font style="font-weight:normal;">&#8221; means (a) the &#8220;tab-cel&#174;&#8221; trademark </font><font style="color:#000000;font-weight:normal;">owned or Controlled by Atara and designated by Atara for use with the Product in the Territory</font><font style="font-weight:normal;">, and (b) any other trademark </font><font style="color:#000000;font-weight:normal;">owned or Controlled by Atara </font><font style="font-weight:normal;">for use in connection with the Commercialization of a Product in the Field the Territory, each, as listed </font><font style="color:#000000;font-weight:normal;">in </font><font style="text-decoration:underline;color:#000000;font-weight:normal;">Exhibit G</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.120<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Promotional Materials</font><font style="font-weight:normal;">&#8221; means all written, printed, video, digital, or graphic advertising, promotional, educational and communication materials (other than the Product Labels and Package inserts) for marketing, advertising, promoting or otherwise Commercializing the Product.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.121<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Public Official or Entity</font><font style="font-weight:normal;">&#8221; shall mean (a) an individual or entity operating in an official or public capacity on behalf of a Government Authority (including physicians, hospital administrators, and other healthcare professionals working for or on behalf of state-controlled healthcare organization), (b) any official or employee of a quasi-public or non-governmental international organization, (c) any employee or other person acting for or on behalf of any entity that is wholly or partially government owned or controlled by a Government Authority, (d) any person exercising legislative, administrative, judicial, executive, or regulatory functions for or pertaining to a Government Authority (including any independent regulator), (e) any political party official, officer, employee, or other person acting for or on behalf of a political party and (f) any candidate for public office.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.122<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Publishing Party</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 14.9(b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.123<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Quality Agreement</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 9.3.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.124<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Receiving Party</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 14.9(b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.125<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Reference Price</font><font style="font-weight:normal;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.126<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Restricted Product</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 8.14. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.127<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Approval</font><font style="font-weight:normal;">&#8221; means, with respect to a Product in any country, region or jurisdiction, the approvals by the applicable Regulatory Authority in such country, region or jurisdiction necessary for the Commercialization and/or Manufacturing of such Product and including the approval by the applicable Regulatory Authority of any expansion or modification of the Label.&nbsp;&nbsp;For clarity, Regulatory Approval includes, but is not limited to, grant of a Marketing Authorization or a conditional Marketing Authorization. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.128<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Authority</font><font style="font-weight:normal;">&#8221; means any applicable Government Authority responsible for granting Regulatory Approvals for the Product, including, without limitation, any supra-national agency such as the EMA. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.129<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Data</font><font style="font-weight:normal;">&#8221; means any and all pharmacology data, chemistry, manufacturing and control data, preclinical data, clinical data, natural history data, including source data, pharmacovigilance data, safety data, and all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with regulatory filings for the Product in the Territory (including any applicable DMFs, CMC data, or similar documentation).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.130<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Exclusivity</font><font style="font-weight:normal;">&#8221; means, with respect to a Product, that Third Parties are prevented by an applicable Regulatory Authority or country, region or jurisdiction from legally Commercializing a product that could compete with such Product in a country, region or jurisdiction in the Territory other than through Patent Rights (inclusive of, for example, new biologic entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data or market exclusivity).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.131<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Filings</font><font style="font-weight:normal;">&#8221; means, with respect to a Product, any submission to a Regulatory Authority of any appropriate regulatory application specific to the Product and shall include any submission to a regulatory advisory board and any supplement or amendment thereto, including, without limitation, an MAA.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.132<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Interactions</font><font style="font-weight:normal;">&#8221; means (a) all regulatory actions, communications and filings with, and submissions to, all Regulatory Authorities with respect to a Product, and (b)&#160;interfacing, corresponding and meeting with the Regulatory Authorities with respect to a Product.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.133<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Regulatory Materials</font><font style="font-weight:normal;">&#8221; means regulatory applications, submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority that are necessary in order to Develop, Manufacture (subject to the terms of this Agreement), have Manufactured, obtain Marketing Authorization, or otherwise Commercialize the Product in a particular country or regulatory jurisdiction.&nbsp;&nbsp;Regulatory Materials include INDs, MAAs, presentations, and responses.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.134</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Representative</font><font style="font-weight:normal;">&#8221; has the meaning in Section 14.1. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk79075528"></a>1.135<font style="margin-left:36pt;"></font><font style="font-weight:normal;"><a name="_Hlk79075528"></a>&#8220;</font><font style="text-decoration:underline;">Right of Reference</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in 21 C.F.R. &#167;314.3(b) or equivalents thereto under applicable Law in countries, regions or jurisdictions outside the United States.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.136<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Royalty Report</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 11.9(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.137<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Royalty Term</font><font style="font-weight:normal;">&#8221; means, on a country-by-country basis, the Full Royalty Term and the Extended Royalty Term.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.138<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Safety Reasons</font><font style="font-weight:normal;">&#8221; shall have the meaning given in Section 16.6.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.139<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">SEC</font><font style="font-weight:normal;">&#8221; means the U.S. Securities and Exchange Commission.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.140<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Selected Manufacturer</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 9.5(b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.141<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Subcommittee</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 4.3. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.142<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Supply Price</font><font style="font-weight:normal;">&#8221; means, with respect to a Product, the price at which the Product is supplied to Partner.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.143<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Tax Documentation</font><font style="font-weight:normal;">&#8221; means, to the extent required to alleviate withholding on payments made by Partner to Atara under this Agreement, the applicable French tax forms number 5000 and 5003, as such forms may be amended from time to time in accordance with applicable Law duly stamped and validated by the relevant governmental entity with responsibility for taxes in connection with any tax reduction or exemption under any applicable international tax treaty between France and the U.S.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.144<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Technology Transfer</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 9.5(b).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.145<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Term</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 16.1. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.146<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Territory</font><font style="font-weight:normal;">&#8221; means:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Europe, the United Kingdom and Switzerland;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Eastern Europe and Asian countries (specifically and limited to, Albania, Serbia, Bosnia-Herzegovina, Kosovo, Republic of Macedonia, Montenegro, Turkey, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Republic of Moldova, Turkmenistan, Ukraine, and Georgia);</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>African countries (specifically and limited to, Tunisia, Morocco, Algeria, South Africa, Burundi, Republic of the Congo (Brazzaville), Benin, Burkina Faso, Cameroon, Chad, Democratic Republic of the Congo, Ivory Coast, Gabon, Guinea, Libya, Madagascar, Mali, Mauritania, Mauritius, Niger, Senegal, Togo, Djibouti, and Central African Republic); and </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Middle East countries (specifically and limited to, Egypt, Iran, Iraq, Saudi Arabia, Yemen, Syria, Jordan, United Arab Emirates, Lebanon, Oman, Kuwait, Qatar, Bahrain). </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.147</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Third Party</font><font style="font-weight:normal;">&#8221; means any Person other than Atara, Partner and their respective Affiliates.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.148<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Transition Period</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 16.8(b)(i)(1) hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.149<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Transition Plan</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 5.1, hereto. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.150<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">United States</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">U.S.</font><font style="font-weight:normal;">&#8221; means the United States of America including its territories and possessions.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.151<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Upfront Payment</font><font style="font-weight:normal;">&#8221; has the meaning given in Section 11.1, hereto</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.152<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;">Valid Claim</font><font style="font-weight:normal;">&#8221; means (a) a claim of an issued and unexpired patent which has not been permanently revoked or declared unenforceable or invalid by an unreversed and unappealable or unreversed and unappealed decision of a court or other appropriate body of competent jurisdiction, or (b) a claim of a pending patent application which claim was filed in good faith, has not been pending for more than [***] from the priority date, and has not been abandoned or finally disallowed without the possibility of appeal or refiling of such application. </font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000132"></a><a name="_Toc83283184"></a><a name="_Toc256000001"></a><a name="_Toc84000518"></a>Article 2<br /><br /><a name="_Toc256000132"></a><a name="_Toc83283184"></a><a name="_Toc256000001"></a><a name="_Toc84000518"></a>Licenses; Knowledge Transfer</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000133"></a><a name="_Toc83283185"></a><a name="_Toc256000002"></a><a name="_Toc84000519"></a><a name="_Ref81819064"></a>2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Grant to Partner</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to the terms and conditions of this Agreement, Atara hereby grants to Partner and its Affiliates during the Term:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk78984297"></a><a name="_Hlk78984023"></a>(a)<font style="margin-left:36pt;"></font><a name="_Hlk78984297"></a>an exclusive (except as specified in Section <a name="_Hlk78984023"></a>2.1(c) hereto), remuneration-bearing license with the right to sublicense only in accordance with Section 2.2 under the Atara Intellectual Property to (i) seek and maintain Regulatory Approvals for the Product in the Field in the Territory for the Post-Transfer Period in the European Union and the UK and during the Term in other countries of the Territory, (ii) Commercialize the Product in the Field in the Territory, (iii)&#160;perform Territory-specific quality control testing of Product not performed by Atara, and (iv)&#160;perform qualified person release and secondary Packaging and Labeling (including accompanying patient-specific information sheet) of the Product for distribution and use in the Territory; and</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>a co-exclusive with Atara (except as specified in Section 2.1(c) hereto), fully paid-up license with the right to sublicense only in accordance with Section 2.2 under the Atara Intellectual Property to Develop the Product in the Field in the Territory for Commercialization of the Product in the Territory subject, as applicable under the provisions of this Agreement, to JSC&#8217;s prior review and approval.&nbsp;&nbsp;Partner acknowledges that certain Know-How licensed to Atara by MSK under the Existing Agreement is licensed to Atara on a non-exclusive basis.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81820672"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reserved Rights.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Atara</font>.&nbsp;&nbsp;Partner acknowledges and agrees that notwithstanding the exclusive rights granted to Partner hereunder, Atara shall retain, on behalf of its Affiliates and Third Party designees, all other rights under the Atara Intellectual Property not specifically licensed to Partner under Section 2.1 including, without limitation the right to (i) conduct and complete the Current Studies, (ii) conduct or have conducted Development activities for Product in the Territory including, without limitation, any Clinical Study relating to the Product, (iii) the right to conduct or have conducted regulatory activities in the European Union and the UK in any applicable Pre-Transfer Period, (iv) the right to Manufacture or have Manufactured the Product for the Territory, and (v) the right to use or have used the Atara Intellectual Property for performing any and all of its obligations under this Agreement, each of (i)-(v) being subject to the terms and conditions of this Agreement and the Ancillary Agreements. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref83472585"></a>(ii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Third Parties</font>.&nbsp;&nbsp;The U.S. Government and Memorial Sloan Kettering Cancer Center have certain reserved rights pursuant to 35 U.S. Code &#167; 200 et seq., and section 2.4 of the Existing Agreement, respectively.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000134"></a><a name="_Ref81816768"></a><a name="_Toc83283186"></a><a name="_Toc256000003"></a><a name="_Toc84000520"></a><a name="_Ref427574418"></a>2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Sublicenses</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Partner may sublicense (i) the right to seek and maintain Regulatory Approvals for the Product in the Field in the Territory during the Term in the Territory (except for the Post Transfer Period in the European Union and the UK), if it is necessary under applicable Law for an Approved Sublicensee to hold any Regulatory Approval for the purpose of Commercializing the Product in the Field and in the Territory, (ii) the right to Commercialize the Product in the Field and in the Territory, and (iii) the right to perform Territory-specific quality control testing not performed by Atara, qualified person release and secondary Packaging or Labeling, solely to the extent necessary in countries within the Territory where Partner has no Affiliate responsible for, or capable of, the Commercialization of one or more products within Partner&#8217;s pharmaceutical oncology product portfolio (each, an &#8220;<font style="font-weight:bold;text-decoration:underline;">Approved Sublicensee</font>&#8221;); provided, however, that all such sublicenses with an Approved Sublicensee shall be consistent with the terms of this Agreement and that Partner shall be responsible for performance of Partner&#8217;s responsibilities under this Agreement to the extent performed on the Partner&#8217;s behalf by an Approved Sublicensee as if Partner were itself performing such activities.&#160; For the avoidance of doubt, an Approved Sublicensee may also have the right to perform Cell Selection services pursuant to Section 8.10.&nbsp;&nbsp;All Approved Sublicensees shall have the necessary financial, regulatory and technical capacity to carry out the portion of Partner&#8217;s obligations under this Agreement sublicensed thereto and shall be required by Partner to perform all activities under this Agreement in compliance with the terms and conditions of this Agreement, any applicable Ancillary Agreement, and applicable Law.&#160; Should Partner sublicense or assign rights to an Affiliate hereunder and such Affiliate subsequently becomes a non-Affiliate, Partner shall provide written notice to Atara within [***] of such change of such non-Affiliate&#8217;s status and such non-Affiliate shall only be permitted to continue performance under the applicable sublicense or assignment if approved in writing by Atara, such approval not to be unreasonably withheld or delayed.&#160; Countries for which Partner intends to use Approved Sublicensees are listed on <font style="text-decoration:underline;">Exhibit A</font> attached hereto.&#160; Any and all sublicenses to Third Parties under this Agreement shall require the prior written consent of Atara, such consent not to be unreasonably withheld, and upon Atara&#8217;s grant of </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent, and following such consent, shall be deemed Approved Sublicensees hereunder.&#160; Partner shall, within</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> [***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after granting any sublicense under this Section 2.2 to a non-Affiliate, notify Atara of the grant of such sublicense and provide Atara with a true and complete copy of such sublicense agreement, provided that such copies of such sublicense agreements may be redacted to omit information (including, without limitation, financial terms) not directly relevant to the performance of Partner&#8217;s obligations under this Agreement and in the case of an Affiliate, notify Atara of the grant of such sublicense and the identity of the Affiliate.&#160; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should it be necessary under applicable Law for an Approved Sublicensee to hold any Regulatory Approval for the purpose of Commercializing the Product in the Field and in the Territory, Partner shall provide prior written notice to Atara of such requirement.&#160;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160; If such Approved Sublicensee is otherwise acting in the capacity of a Distributor as set forth in Section 2.2(b), the financial provisions of Section 2.2(b) shall apply</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Partner may appoint any wholesaler, distributor or reseller for the Product and grant them limited rights under Atara Intellectual Property solely to the extent needed to import, distribute, market, promote or sell the Product in the Field and the Territory (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Distributors</font>&#8221;).&nbsp;&nbsp;When appointed, Partner shall use Distributors consistent with how Partner then Commercializes its other oncology products in such countries, provided that in such countries in the Territory where Partner does not book the sales of a Product and elects to use Distributors, Partner uses as a basis for calculating royalty payments due to Atara under Section 11.4 herein [***].&nbsp;&nbsp;All such distribution arrangements shall be consistent with the terms of this Agreement and shall require the Distributor to comply with all applicable Law, and Partner shall be responsible for performance of Partner&#8217;s Commercialization responsibilities under this Agreement to the extent performed on the Partner&#8217;s behalf by a Distributor as if Partner were itself performing such activities.&nbsp;&nbsp;Partner shall, within [***] after entering into a Product distribution agreement with a Distributor, provide Atara with a true and complete copy of such Product distribution agreement, provided that such copies of such distribution agreements may be redacted to omit information (including, without limitation, financial terms) not directly relevant to the performance of Partner&#8217;s obligations under this Agreement. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000135"></a><a name="_Toc83283187"></a><a name="_Toc256000004"></a><a name="_Toc84000521"></a>2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Other Rights or Implied Licenses</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except as specifically set forth in this Agreement, neither Party shall acquire any right, title, license, or other interest, by implication, estoppel or otherwise, with respect to any (a) information, Know-How or materials of the other Party or its Affiliates disclosed or provided to it under this Agreement or (b) under any Patent Rights or other intellectual property rights owned or Controlled by the other Party or its Affiliates. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000136"></a><a name="_Toc83283188"></a><a name="_Toc256000005"></a><a name="_Toc84000522"></a>2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Restrictive Covenants</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Ex-Territory Activities and Territory Activities</font>. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>To the extent permitted by applicable Laws, Partner hereby covenants and agrees that it shall not (and shall ensure its Affiliates, Approved Sublicensees and Distributors shall not), either directly or indirectly, market, promote, distribute or sell or otherwise engage in the Commercialization of Product into or within countries outside of the Territory.&nbsp;&nbsp;Without limiting the generality of the foregoing, with respect to such countries outside of the Territory, Partner shall not (and shall ensure its Affiliates, Approved Sublicensees and Distributors shall not) (i) engage in any promotional, advertising, educational, scientific communications, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical affairs, or similar activities relating to the Product directed to customers or other persons, entities or organizations located in such countries, or (ii)&#160;solicit orders from any prospective purchaser located in such countries, provided in each case that Partner, in alignment with plans discussed at the JSC, shall not be restricted from presenting the Product in international congresses, conferences or meetings outside the Territory organized by a professional society outside the Territory, conducting market research outside the Territory with prior consultation, and in coordination with Atara, or from interacting with key opinion leaders outside the Territory, each in connection with the Product. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>To the extent permitted by applicable Laws, and except in order to perform its obligations under this Agreement, Atara hereby covenants and agrees that it shall not (and shall ensure its Affiliates, distributors, and sublicensees shall not), either directly or indirectly, market, promote, distribute or sell or otherwise engage in the Commercialization of Product into or within countries in the Territory.&nbsp;&nbsp;Without limiting the generality of the foregoing, with respect to such countries inside the Territory, Atara shall not (and shall ensure that its Affiliates, distributors, and sublicensees will not) (i) engage in any promotional, advertising, educational, scientific communications, medical affairs, or similar activities relating to the Commercialization of Product directed to customers or other persons, entities or organizations located in such countries, or (ii) solicit orders from any prospective purchaser located in such countries, provided in each case that Atara, in alignment with plans discussed at the JSC, shall not be restricted from presenting the Product in international congresses, conferences or meetings inside the Territory organized by a professional society inside the Territory, conducting market research inside the Territory with prior consultation and in coordination with Partner, or from interacting with key opinion leaders inside the Territory, each in connection with the Product. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Ex-Field Activities and Field Activities</font>. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>To the extent permitted by applicable Law, Partner hereby covenants and agrees that it shall not (and shall ensure that its Affiliates Approved Sublicensees, and Distributors shall not), either directly or indirectly, market or promote the Product outside the Field.&nbsp;&nbsp;Without limiting the generality of the foregoing, Partner shall not (i) engage in any promotional, advertising, market research, educational, scientific communications, medical affairs, or similar activities relating to the Product directed to use outside the Field, or (ii) solicit orders from any prospective purchaser for use of the Product outside the Field.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>To the extent permitted by applicable Laws, Atara hereby covenants and agrees that it shall not (and shall ensure that its Affiliates, distributors, and sublicensees shall not), either directly or indirectly, market or promote Product inside the Field in the Territory.&nbsp;&nbsp;Without limiting the generality of the foregoing, Atara shall not (i) engage in any promotional, advertising, educational, scientific communications, medical affairs or similar activities relating to the Commercialization of Product inside the Field in the Territory, or (ii) solicit orders from any prospective purchaser for use of the Product inside the Field in the Territory.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000137"></a><a name="_Toc83283189"></a><a name="_Toc256000006"></a><a name="_Toc84000523"></a>2.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Existing Agreement</font><font style="font-weight:normal;">.&nbsp;&nbsp;The licenses and rights granted to Partner under Section 2.1 above include sublicenses of Know-How and Patent Rights existing and licensed to Atara under the Existing Agreement.&nbsp;&nbsp;Any royalty, milestone and other amounts payable to Third Parties in </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">relation to the licenses granted by Atara under Atara Intellectual Property hereunder, including pursuant to the Existing Agreement, shall be paid by Atara. </font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Ref81917902"></a><a name="_Toc256000138"></a><a name="_Toc83283190"></a><a name="_Toc256000007"></a><a name="_Toc84000524"></a>Article 3<br /><br /><a name="_Toc256000138"></a><a name="_Toc83283190"></a><a name="_Toc256000007"></a><a name="_Toc84000524"></a>Right Regarding Option Countries</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***].</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***].</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***].</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***].</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000139"></a><a name="_Ref81818907"></a><a name="_Toc83283191"></a><a name="_Toc256000008"></a><a name="_Toc84000525"></a><a name="_Ref424660464"></a>Article 4<br /><br /><a name="_Toc256000139"></a><a name="_Ref81818907"></a><a name="_Toc83283191"></a><a name="_Toc256000008"></a><a name="_Toc84000525"></a><a name="_Ref424660464"></a>Joint Steering Committee</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000140"></a><a name="_Toc83283192"></a><a name="_Toc256000009"></a><a name="_Toc84000526"></a><a name="_Ref81818883"></a><a name="_Toc519935528"></a><a name="_Toc519934762"></a>4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Composition</font><font style="font-weight:normal;">.&nbsp;&nbsp;As soon as practicable, but no later than [***] following the Effective Date, the Parties shall establish a joint steering committee (the &#8220;</font><font style="text-decoration:underline;">Joint Steering Committee</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">JSC</font><font style="font-weight:normal;">&#8221;) as more fully described in this Article 4.&nbsp;&nbsp;The Parties shall each designate three (3) representatives (or such other number as the Parties may agree to) of appropriate seniority and experience to serve on the JSC by written notice to the other Party.&nbsp;&nbsp;Either Party may designate substitutes for its representatives if one (1) or more of such Party&#8217;s designated representatives are unable to be present at a meeting.&nbsp;&nbsp;From time to time, each Party may replace its representatives by written notice to the other Party specifying the prior representative(s) and their replacement(s).&nbsp;&nbsp;A quorum of the JSC shall exist whenever there is present at a meeting at least two (2) representatives appointed by each Party.&nbsp;&nbsp;The JSC will be co-chaired by one representative each of Partner and Atara.&nbsp;&nbsp;The role of the chairpersons shall be to convene and preside at meetings of the JSC.&nbsp;&nbsp;The chairpersons shall have no additional powers or rights beyond those held by the other JSC representatives.&nbsp;&nbsp;Each Party may also, in its reasonable discretion and with reasonable advanced notice to the other Party, invite a reasonable number of non-member representatives of such Party to attend JSC meetings, as appropriate, to provide input with respect to matters on the agenda.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000141"></a><a name="_Toc83283193"></a><a name="_Toc256000010"></a><a name="_Toc84000527"></a><a name="_Ref81824948"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Responsibilities</font><font style="font-weight:normal;">.&nbsp;&nbsp;In addition to such other duties as specifically assigned to it in this Agreement, in order to facilitate effective Commercialization of the Product in the Field in the Territory by the Partner, the JSC shall:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>monitor the general performance of the Parties under this Agreement and decide on corrective action, where required;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>serve as the principal means by which each Party keeps the other Party informed about respective activities under the Agreement;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">act as the initial point of escalation for issues that cannot be resolved otherwise;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>monitor and coordinate the conduct of the Transition Plan;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>receive reports relating to, review and discuss the progress of, any ongoing or planned <font style="font-size:8pt;"> </font>Development activities of the Product in or out of the Field in or out of the Territory, and approve any Development activities of either Party, its Affiliates and their respective licensees or sublicensees of the Product in the Territory as applicable and as required under the provisions of this Agreement, including any proposed study protocols and proposed substantive amendments and updates and any activities conducted pursuant to Sections 6.2(a) and (b) hereof; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>review and discuss Commercialization activities <font style="color:#000000;">and plans as provided pursuant to Sections 8.3 and 8.7 </font>and coordinating with respect to the Global Branding Strategy, and<font style="color:#000000;"> receiving reports relating to market research and pricing and reimbursement status for the Product in the Territory;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="color:#000000;">review and discuss Product-related medical affairs in the Territory;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>receive reports relating to, review and discuss the progress of, and approve (solely as provided in Section 4.8(b)(ii) with respect to the Pre-Transfer Period) material submissions to, or material actions taken with, the EMA or the MHRA pertaining to the Product, including, without limitation, Regulatory Interactions, MAA, and Marketing Authorizations, either in advance or thereafter as determined by required timing for making such material submissions or taking such material actions; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">receive reports relating to, and review and discuss Manufacturing and commercial supply plans pertaining to the Product in the Territory including </font>any plans to ensure a continuous and reliable supply of Product in the Territory<font style="color:#000000;"> and </font>approve, as required by the provisions of this Agreement, substantive changes in the supply chain of the Product<font style="color:#000000;">;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>subject to Section 8.10 hereto, review and discuss a potential transition of Cell Selection services from Atara to Partner, its Affiliate or an Approved Sublicensee; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>review and discuss patent strategies and prosecution, defence and enforcement actions in relation to the Atara Intellectual Property, in each case solely as it pertains to or may have a material adverse impact on the Territory;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font>discuss and coordinate any action with respect to alleged infringement of Third Party Patent Rights by Commercialization of the Product in the Field in the Territory, or the Development or Manufacture of the Product for Commercialization in the Field in the Territory; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font>review reports relating to, and attempts to resolve disputes regarding Development, Manufacturing and/or Commercialization of the Product as it pertains to the Territory; and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)</font><font style="margin-left:36pt;"></font><font style="color:#000000;">P</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rovide a forum of exchange and discussion with respect to regulatory, medical and market access strategies, safety matters, pricing and reimbursement matters, marketing and promotional activities, Patent and manufacturing strategies for the Product globally.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000142"></a><a name="_Toc83283194"></a><a name="_Toc256000011"></a><a name="_Toc84000528"></a><a name="_Ref81819965"></a>4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;"><a name="_Ref81819965"></a>Subcommittees Establishment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;From time to time, the JSC may formally establish one or more subcommittees to review and make recommendations to the JSC with respect to particular projects or activities within their respective authority (each, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Subcommittee</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Each Subcommittee shall consist of equal representation from the Parties (unless the Parties otherwise mutually agree) consisting of individuals with relevant expertise.&nbsp;&nbsp;Such Subcommittees shall operate under the same principles and requirements as are set forth in this Article 4 for the JSC.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000143"></a><a name="_Toc83283195"></a><a name="_Toc256000012"></a><a name="_Toc84000529"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Meetings</font>.&nbsp;&nbsp;<font style="font-weight:normal;">The JSC shall hold meetings (a) [***], and (b) at the reasonable request of either Party upon as much reasonable notice as is practicable, but not less than [***] prior written notice to the other Party, to review, discuss, or approve, as applicable, an urgent matter within the scope of the JSC&#8217;s responsibilities, in each case, at such times and places as shall be determined by the JSC (including by videoconference, telephone, or web conference).&nbsp;&nbsp;The JSC may act without a meeting if prior to such action a written consent thereto is given by both Parties.&nbsp;&nbsp;Each Party shall be responsible for all its costs incurred for attending and participating in JSC meetings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000144"></a><a name="_Toc83283196"></a><a name="_Toc256000013"></a><a name="_Toc84000530"></a>4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Minutes</font>.<font style="font-weight:normal;">&nbsp;&nbsp;Minutes will be kept of all JSC meetings by the Alliance Managers and the minutes prepared by the Alliance Managers will be sent to all members of the JSC for review and approval within [***] after each meeting.&nbsp;&nbsp;Minutes for each meeting shall objectively reflect, in reasonable detail, the proceedings of such JSC meeting, including, without limitation, the topics reviewed and discussed at such JSC meeting, and the actions and decisions taken, authorized to be taken or approved to be taken by either or both of the Parties at such meeting.&nbsp;&nbsp;In the event of any objection that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute and such dispute shall be reviewed and discussed at the next regular JSC meeting.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000145"></a><a name="_Toc83283197"></a><a name="_Toc256000014"></a><a name="_Toc84000531"></a><a name="_Ref81816750"></a>4.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Alliance Managers</font><font style="font-weight:normal;">.&nbsp;&nbsp;As soon as practicable, but no later than [***] following the Effective Date, each Party will appoint a representative of such Party to act as its alliance manager under this Agreement (each, an &#8220;</font><font style="text-decoration:underline;">Alliance Manager</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Each Party may replace its Alliance Manager at any time by written notice to the other Party.&nbsp;&nbsp;The Alliance Managers will serve as the primary contact point between the Parties and shall be entitled to attend all JSC and Subcommittee meetings, except if the other Party specifically requests the exclusion of Alliance Managers (including its own Alliance Managers) from a particular meeting</font><font style="font-style:italic;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">Each Alliance Manager may bring any matter to the attention of the JSC or Subcommittees where such Alliance Manager reasonably believes that such matter requires attention of the JSC or Subcommittees.&nbsp;&nbsp;Each Alliance Manager shall be responsible with creating and maintaining a collaborative work environment within and among the JSC and Subcommittees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000146"></a><a name="_Toc83283198"></a><a name="_Toc256000015"></a><a name="_Toc84000532"></a><a name="_Ref81818446"></a>4.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Scope of Governance</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding the creation of the JSC and/or any Subcommittee, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JSC and/or any Subcommittee shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">so agree in writing.&nbsp;&nbsp;The JSC and/or any Subcommittee or any Party&#8217;s exercising its decision making shall not have the power to amend or modify this Agreement, and no decision of the JSC and/or any Subcommittee or a Party&#8217;s exercising its decision making shall be in contravention of any terms and conditions of this Agreement.&nbsp;&nbsp;The Alliance Managers shall not have any rights, powers or discretion except as expressly granted to the Alliance Managers hereunder and in no event shall the Alliance Managers have any power to modify or amend this Agreement.&nbsp;&nbsp;It is understood and agreed that issues to be formally decided by the JSC and/or any Subcommittee, as applicable, are only those specific issues that are expressly provided in this Agreement to be decided by the JSC and/or any Subcommittee, as applicable.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000147"></a><a name="_Ref81824274"></a><a name="_Toc83283199"></a><a name="_Toc256000016"></a><a name="_Toc84000533"></a>4.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Decision Making</font>.<font style="color:#000000;font-size:10pt;font-weight:normal;"> </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Generally</font>.&nbsp;&nbsp;Except as otherwise expressly provided herein, decisions of the JSC or any Subcommittee established under this Article 4 shall be made by consensus, with each Party having collectively one (1) vote in all decisions, with the goal being to leverage capabilities, minimize cost and maximize the chance of successfully Commercializing the Product first in the European Territory as a whole, and then throughout the Territory as a whole, in a manner consistent with applicable Laws and this Agreement.&nbsp;&nbsp;The Parties agree to make all decisions and to escalate all associated disputes in a timely manner, appropriate for each circumstance. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81818473"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;color:#000000;">Dispute Escalation and Final Decision-Making Authority</font><font style="color:#000000;">.&nbsp;&nbsp;In the event that the JSC is unable to reach a consensus on decisions expressly requiring JSC approval pursuant to this Agreement despite good faith efforts to do within </font>[***]<font style="color:#000000;"> after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue referred to the Chief Executive Officer of Atara or such other person holding a similar position designated by Atara from time to time, and the Chief Executive Office of Partner or such other person holding a similar position designated by Partner from time to time (collectively, the &#8220;</font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Executive Officers</font><font style="color:#000000;">&#8221;), for resolution.&nbsp;&nbsp;The Executive Officers shall meet within </font>[***]<font style="color:#000000;"> of referral of the issue to the Executive Officers to discuss the matter submitted and to determine a resolution.&nbsp;&nbsp;If the Executive Officers are unable to determine a resolution in a timely manner, which shall in no case be more than </font>[***]<font style="color:#000000;"> after the matter was referred to them, despite good faith efforts to do so, then except as specifically allocated under this Agreement:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Ref102466031"></a><a name="_Toc221533300"></a><a name="_Toc519935530"></a><a name="_Toc519934764"></a><a name="_Toc256000148"></a><a name="_Toc83283200"></a><a name="_Toc256000017"></a><a name="_Toc84000534"></a>Article 5<br /><br /><a name="_Toc256000148"></a><a name="_Toc83283200"></a><a name="_Toc256000017"></a><a name="_Toc84000534"></a>Transition Plan</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000149"></a><a name="_Ref81820472"></a><a name="_Toc83283201"></a><a name="_Toc256000018"></a><a name="_Toc84000535"></a>5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transition Plan</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Transfer</font>.&nbsp;&nbsp;A transition plan for regulatory affairs, commercial and market access, supply chain, medical affairs, and pharmacovigilance activities to be carried out under this Agreement and the Ancillary Agreements (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Transition Plan</font>&#8221;) is attached hereto as <font style="text-decoration:underline;">Exhibit B</font>.&nbsp;&nbsp;Each of Atara and Partner shall use Commercially Reasonable Efforts to carry out the activities as specifically set forth in the Transition Plan within the time set forth in the Transition Plan.&nbsp;&nbsp;Atara shall use Commercially Reasonable Efforts to make available to Partner all data and such other </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">documents as set forth under the Transition Plan as soon as reasonably practicable and in any event, within the time period set forth in the Transition Plan.&nbsp;&nbsp;Besides the Transition Plan, Atara shall provide reasonable assistance to Partner, subject to Atara&#8217;s available capacity to provide such assistance without incurring significant cost, to ensure a smooth and effective transfer of any </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Filings, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Intellectual Property, Development Data, medical activities and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> marketing materials developed by Atara with respect to the Product</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Subsequent Transfers</font>.&nbsp;&nbsp;Before the transfer date from Atara to Partner of the Marketing Authorization or MAA, as applicable, by (a) the EC, or (b) the MHRA, as applicable, Atara shall deliver as soon as reasonably practicable any and all Atara Intellectual Property, together with supporting documentation as each may become Controlled by Atara, and provide reasonable assistance to Partner which is necessary or reasonably useful for Partner to Develop, Commercialize the Product in the Field and the Territory, perform Territory-specific quality control testing of Product not performed by Atara, and perform qualified person release and secondary Packaging and Labeling (including accompanying patient-specific information sheet) of the Product for distribution and use in the Territory in compliance with Law.</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000150"></a><a name="_Ref81819478"></a><a name="_Toc83283202"></a><a name="_Toc256000019"></a><a name="_Toc84000536"></a>Article 6<br /><br /><a name="_Toc256000150"></a><a name="_Ref81819478"></a><a name="_Toc83283202"></a><a name="_Toc256000019"></a><a name="_Toc84000536"></a>Development Matters</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000151"></a><a name="_Ref81830042"></a><a name="_Toc83283203"></a><a name="_Toc256000020"></a><a name="_Toc84000537"></a>6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Responsibilities &#8211; Primary Indication and Clinical Studies</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Atara shall be solely responsible, at its sole cost and expense, to use Commercially Reasonable Efforts to conduct the Atara 302 Study as currently designed and ongoing as of the Effective Date and, if required by the Regulatory Authority to obtain Regulatory Approval for the Product in the European Territory for the Primary Indication, to conduct CMC and comparability studies.&nbsp;&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81819517"></a><a name="_Ref81830786"></a><a name="_Hlk82180045"></a>(b)<font style="margin-left:36pt;"></font><a name="_Hlk82180045"></a>Atara shall take commercially reasonable steps, at its sole cost and expense, to conduct any other Clinical Study or other Development (excluding Observational Studies) that is required by the Regulatory Authority to obtain Regulatory Approval for the Product in the European Territory for the Primary Indication.&nbsp;&nbsp;Such other Clinical Study or other Development shall be subject to JSC&#8217;s prior review and approval.&nbsp;&nbsp;If Atara determines that it is not commercially reasonable to conduct any such other Clinical Study or other Development, it shall promptly inform Partner without delay.&nbsp;&nbsp;Then, without prejudice to Partner&#8217;s rights hereunder, Partner may then elect to conduct such other Clinical Study or other Development, in which case Section 11.12 shall apply. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Subject to Section 6.1(b) hereto, [***].&nbsp;&nbsp;Partner shall promptly inform Atara of any Development Data generated therefrom and provide such Development Data to Atara pursuant to Section 6.6.&nbsp;&nbsp; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>For clarity, other than as set forth in Section 6.1(a), Atara shall have no obligation to conduct any Clinical Study or any Development for the Product for use in the Primary Indication in any country, region, or jurisdiction.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000152"></a><a name="_Ref81830138"></a><a name="_Toc83283204"></a><a name="_Toc256000021"></a><a name="_Toc84000538"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Responsibilities - Additional Indications and Clinical Studies</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81819155"></a>(a)<font style="margin-left:36pt;"></font>Atara shall (i) be solely responsible, at its sole cost and expense, to use Commercially Reasonable Efforts to conduct the Atara 205 Study as currently designed and ongoing as of the Effective Date, and (ii) have the right, but not the obligation, at its sole cost and expense, outside the Territory, to carry out any other Development pertaining to a Multi-Cohort Indication or to carry out all Development of the Product as it pertains to all other Additional Indications.&nbsp;&nbsp;Except for the Atara 205 Study, should any other Development activities to be conducted by Atara pursuant to this Section 6.2(a) propose to include one or more clinical trial site(s) physically located within a country in the Territory, inclusion of such clinical trial sites shall be subject to the JSC&#8217;s prior review and approval.&nbsp;&nbsp;Atara shall promptly inform Partner of any Development Data generated therefrom and provide such Development Data to Partner pursuant to Section 6.6.&nbsp;&nbsp; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81819187"></a>(b)<font style="margin-left:36pt;"></font>Except as set forth in Section 6.1 and if not Developed or elected to be Developed by Atara pursuant to Section 6.2(a), if either Party wishes to propose any other Development of the Product for (i) the Primary Indication or (ii) an Additional Indication, in each case, in the Territory, or provide support for any Investigator Sponsored Clinical Trial to be conducted in the Territory (&#8220;<font style="font-weight:bold;text-decoration:underline;">New Development</font>&#8221;), including potential sharing of the responsibility for the operation and/or cost of such proposed Development of the Product, said Party shall (1) prepare a reasonably detailed summary of the New Development and proposed activities and budget related thereto, including the roles and responsibilities of each Party with regard to such activities and budget, and (2) present such proposal to the JSC for discussion.&nbsp;&nbsp;The Parties agree to discuss any such proposal(s), including any associated Development plan and the allocation of responsibility between Atara and Partner for the associated Development plan, operation thereof, and costs associated with such plan.&nbsp;&nbsp;Such New Development shall be subject to JSC&#8217;s prior review and approval. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000153"></a><a name="_Toc83283205"></a><a name="_Toc256000022"></a><a name="_Toc84000539"></a><a name="_Ref81824211"></a><a name="_Ref82960330"></a>6.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding any other provision in this Agreement, in no event shall Partner be obliged to conduct Development activities and no such Development activities shall be deemed commercially reasonable to assess Partner&#8217;s Commercialization obligations hereunder. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000154"></a><a name="_Toc83283206"></a><a name="_Toc256000023"></a><a name="_Toc84000540"></a><a name="_Hlk78287849"></a>6.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Reports</font><font style="font-weight:normal;"><a name="_Hlk78287849"></a>.  The status, progress and results of the Development carried out under this Article 6 shall be discussed at meetings of the JSC, and the responsible Party shall provide the JSC with a written report with reasonable detail on the status and progress of such Development activities at least [***] prior to each scheduled JSC meeting. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000155"></a><a name="_Toc83283207"></a><a name="_Toc256000024"></a><a name="_Toc84000541"></a><a name="_Ref81818153"></a><a name="_Hlk78390777"></a>6.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Records</font><font style="font-weight:normal;"><a name="_Hlk78390777"></a>.&nbsp;&nbsp;The Party carrying out Development activity shall use Commercially Reasonable Efforts to maintain complete, current and accurate records of all Development conducted by it and all Development Data resulting from such work.&nbsp;&nbsp;The Parties shall cause their Affiliates, sublicensees and subcontractors (as applicable) to maintain complete, current and accurate records of all Development work conducted by such Affiliates, sublicensees or subcontractors (as applicable) and data and other Information resulting from such work.&nbsp;&nbsp;Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory purposes.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000156"></a><a name="_Toc83283208"></a><a name="_Toc256000025"></a><a name="_Toc84000542"></a><a name="_Ref81818255"></a>6.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Ownership of Development Data and Partner Inventions</font>.&nbsp;&nbsp;<font style="font-weight:normal;">All data (including, without limitation, pre-clinical, clinical, technical, chemical, safety, and scientific data and information, but excluding a closed portion of a DMF), Know-How and other results generated by or resulting from or in connection with the conduct of Development, including screening data, Regulatory Data and synthesis schemes (collectively, the &#8220;</font><font style="text-decoration:underline;">Development Data</font><font style="font-weight:normal;">&#8221;), shall be owned solely and exclusively by the Party conducting such Development unless otherwise agreed in writing.&nbsp;&nbsp;Atara shall provide Partner with all Development Data deriving from any and all Development for which Atara is responsible to the extent such is necessary or reasonably useful for Partner to Commercialize Product, seek and maintain Regulatory Approvals for the Product in the Field in the Territory and perform Territory-specific quality control testing not performed by Atara, qualified person release and secondary Packaging and Labeling (including accompanying patient-specific information sheet) of the Product for distribution and use in the Field in the Territory.&nbsp;&nbsp;Partner shall provide Atara with all Development Data deriving from any and all Development for which Partner is responsible, and, if Atara so elects pursuant to Section 11.12, Partner shall grant to Atara a non-exclusive, fully paid up, sublicensable, perpetual and irrevocable license under any such Development Data to Develop, Manufacture, Commercialize and otherwise use the Product outside of the Territory.&nbsp;&nbsp;To the extent that Partner, in the course of conducting any of its authorized activities under this Agreement, has developed and Controls Patent Rights or Know-How that are necessary or reasonably useful for the Development, Manufacture, Commercialization, or other use of the Product (&#8220;</font><font style="text-decoration:underline;">Partner Intellectual Property</font><font style="font-weight:normal;">&#8221;), Partner shall and hereby does grant to Atara a non-exclusive, sublicensable, perpetual, irrevocable license, under any such Partner Intellectual Property to Develop, Manufacture, Commercialize and otherwise use the Product outside of the Territory, subject to the provisions of Section 11.12. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000157"></a><a name="_Toc83283209"></a><a name="_Toc256000026"></a><a name="_Toc84000543"></a><a name="_Ref81830358"></a>6.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Right to Audit Development Activities</font>.&nbsp;&nbsp;<font style="font-weight:normal;">During the Term and subject to the requirements of applicable Law and Third Party confidentiality restrictions or obligations (provided that each Party shall use reasonable efforts to ensure that any Third Party agreements entered into after the Effective Date do not prevent the exercise of such rights), each Party shall allow the other Party&#8217;s authorized Representatives, to the extent permitted by applicable Law, during regular business hours and upon at least [***] prior notice, not more than [***] (except for cause), to (i) examine and inspect such Party&#8217;s facilities and the facilities of any subcontractor used in the performance of Development of the Product in the Field in the Territory hereunder, and (ii) inspect all data, documentation and work product relating to the activities performed by such Party or any subcontractor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000158"></a><a name="_Toc83283210"></a><a name="_Toc256000027"></a><a name="_Toc84000544"></a><a name="_Ref81824016"></a><a name="_Hlk82084009"></a>6.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Right of Reference</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to Section 11.12,</font> <font style="font-weight:normal;">each Party shall have the right to cross-reference the Regulatory Filings Controlled by the other Party under this Agreement relating to the Product (including each other&#8217;s, and their Affiliate&#8217;s or, in the case of Atara, its sublicensees&#8217;, and in the case of Partner, its Approved Sublicensees&#8217;, DMF), and to access such Regulatory Filings and any Development Data for (i<a name="_Hlk82084009"></a>) in the case of Partner, during the Term, any activity relating to obtaining or maintaining Regulatory Approval for the Product, or for Development or Commercialization of the Product in the Field in the Territory, including, to the extent allowed under applicable Law, inclusion of such Development Data in its own Regulatory Filings for the Product, and (ii) in the case of Atara, (1) any activity relating to obtaining or maintaining Regulatory Approval for the Product, or for Development or Commercialization of the Product outside the Territory, and (2) any activity relating to conducting Development of the Product or obtaining or maintaining Regulatory Approval for the Product, in each case outside the </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Field in the Territory, including, to the extent allowed under applicable Law, inclusion of such Development Data in its own Regulatory Filings for the Product.&nbsp;&nbsp;Subject to the provisions of this Section 6.8, each Party hereby grants to the other Party, its Affiliates, subcontractors (as applicable), a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) in the United States, or an equivalent right of access/reference in any other country or region, to any Development Data, including such Party&#8217;s or its Affiliate&#8217;s clinical dossiers, Controlled by such Party or such Affiliates that relates to the Product solely for use for the purposes specified in this Section 6.8.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000159"></a><a name="_Ref81824336"></a><a name="_Toc83283211"></a><a name="_Toc256000028"></a><a name="_Toc84000545"></a><a name="_Toc519935566"></a><a name="_Ref104969498"></a><a name="_Toc519934800"></a>Article 7<br /><br /><a name="_Toc256000159"></a><a name="_Ref81824336"></a><a name="_Toc83283211"></a><a name="_Toc256000028"></a><a name="_Toc84000545"></a><a name="_Toc519935566"></a><a name="_Ref104969498"></a><a name="_Toc519934800"></a>Regulatory Matters</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000160"></a><a name="_Toc83283212"></a><a name="_Toc256000029"></a><a name="_Toc84000546"></a>7.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Obtaining Regulatory Approval</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81824250"></a><a name="_Hlk77783789"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Europe and United Kingdom - Primary Indication</font><a name="_Hlk77783789"></a>.&nbsp;&nbsp;Subject to Section 4.8(b)(ii) hereto, during the Pre-Transfer Period, Atara shall be responsible, at its sole cost and expense, for all activities directed to, and decisions pertaining to, obtaining Regulatory Approval (including the preparation and filing of all Regulatory Materials, including, without limitation, any MAA, and all Regulatory Interactions) for the Product for the Primary Indication by centralized procedure or any other procedure in Europe and in UK; provided, however, that to the extent lawful, practical, and without causing any undue delay, Atara shall promptly submit to Partner all material correspondence received from a Regulatory Authority with respect to such Regulatory Approvals, as well as all relevant draft filings or draft material correspondence with the Regulatory Authorities with reasonable lead time, which shall not be less than [***] for correspondence with the EMA and the MHRA relating to negotiation of the Label, to allow Partner to comment on such drafts, and take into account Partner&#8217;s reasonable comments on such correspondence or filings.&nbsp;&nbsp;To the extent practical and without causing any undue delay, and to the extent permitted by the Regulatory Authority, Atara shall permit an appropriate representative of Partner to attend any meeting with Regulatory Authorities relating to obtaining such Regulatory Approvals as a silent observer under Atara&#8217; supervision.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81824309"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Other Regulatory Approvals.&nbsp;&nbsp;</font>Without prejudice to Sections 6.3 and 11.12, and with the exception of activities under Atara&#8217;s responsibility pursuant to Section 6.1 and 6.2 and other than those specified in Section 7.1(a), Partner, its Affiliates and their Approved Sublicensees shall be responsible, at their sole cost and expense, for all activities directed to or required for obtaining, holding, and maintaining all Regulatory Approvals (including, without limitation, for the preparation and filing of all Regulatory Materials and all Regulatory Interactions) and Marketing Authorizations for the Product in the Field in the Territory, subject to the oversight of the JSC, in accordance with Section 4.8 hereto; provided, however, that to the extent lawful, practical, and without causing any undue delay, Partner shall promptly submit to Atara all material correspondence received from the EMA and the MHRA with respect to such Regulatory Approvals of the Product, as well as all material draft filings or draft material correspondence with the EMA and the MHRA with reasonable lead time, which shall not be less than [***] for correspondence with the EMA and the MHRA relating to revision of the Label, to allow Atara to comment on such drafts, and take into account Atara&#8217;s reasonable comments on such correspondence or filings.&nbsp;&nbsp;Atara shall provide reasonable support, subject to Atara&#8217;s </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available capacity to provide such support without incurring significant cost, to Partner&#8217;s regulatory activities set forth in this Section 7.1(b).&nbsp;&nbsp;Partner, its Affiliates and their Approved Sublicensees shall own all regulatory submissions, including all applications, for Regulatory Approvals for the Products in the Field in the Territory, and shall not engage in any Regulatory Interaction in any country outside the European Territory and Switzerland, prior to receipt of an MA for the Primary Indication in the European Territory.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk78351672"></a>(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reports</font><a name="_Hlk78351672"></a>.&nbsp;&nbsp;The status, progress, and results of a Party&#8217;s efforts to obtain Regulatory Approval for the Product under this Article 7 shall be discussed at meetings of the JSC, and each Party shall provide the JSC with a written report on the status and progress of such activities at least [***] prior to each scheduled JSC meeting.&#160; In addition, a Party shall make available such information about such activities as may be reasonably requested by the other Party from time to time.&#160; In addition, Atara shall keep Partner reasonably updated with respect to matters pertaining to Regulatory Interactions and Regulatory Filings for the Product in the U.S. solely to the extent such matters are reasonably likely to impact in any material respect Regulatory Filings and Regulatory Approvals in the European Territory.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000161"></a><a name="_Toc83283213"></a><a name="_Toc256000030"></a><a name="_Toc84000547"></a><a name="_Ref81819574"></a>7.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transfer of Marketing Authorization for Europe and UK - Primary Indication</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Following the EC grant and the UK&#8217;s grant of a Marketing Authorization for the Product for the Primary Indication in Europe and the UK, respectively, Atara will file an application for the transfer of the associated Marketing Authorization, the Orphan Drug Designation and any other necessary Regulatory Approval for the Product in Europe and the UK, to Partner within [***] of receipt of said Marketing Authorization, unless otherwise agreed between the Parties and subject to applicable regulatory requirements.&nbsp;&nbsp;Pending such transfer, Atara shall hold the Marketing Authorization and [***].&nbsp;&nbsp;Subsequent to the transfer of the Marketing Authorization by Atara to Partner under this Section 7.2, Partner shall be responsible, at its sole cost and expense, for all activities directed or required to holding and maintaining such Marketing Authorization including, without limitation, for payment of all associated fees and taxes, if any, and will have no right to transfer, assign or grant any encumbrance or other right on, or under, any Marketing Authorization for the Product in in the Territory, except to Approved Sublicensees, without the prior written consent of Atara, which may not be unreasonably withheld or delayed.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Section 7.2, the Parties may mutually agree to transfer the MAA and Orphan Drug Designation during the centralized procedure in Europe and/or the UK procedure prior to the grant of the associated Marketing Authorization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000162"></a><a name="_Toc83283214"></a><a name="_Toc256000031"></a><a name="_Toc84000548"></a><a name="_Ref81819561"></a>7.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Pharmacovigilance</font><font style="font-weight:normal;">.&nbsp;&nbsp;Within [***] from the Effective Date, and before the transfer of the Regulatory Approval or MA for the Product in Europe and the UK for the Primary Indication, the Parties will negotiate and execute in good faith a mutually agreed pharmacovigilance agreement in customary form (the &#8220;</font><font style="text-decoration:underline;">Pharmacovigilance Agreement</font><font style="font-weight:normal;">&#8221;) delineating the processes and procedures for sharing safety information with respect to the Product that are customary for agreements of this type.&nbsp;&nbsp;The Pharmacovigilance Agreement shall, among other things, require each of Atara and Partner to inform the other as soon as is practicable of any observed significant safety issue considered likely to have an adverse impact on Commercialization of the Product.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000163"></a><a name="_Toc83283215"></a><a name="_Toc256000032"></a><a name="_Toc84000549"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.4</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Global Safety Database</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:normal;"> </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Responsibility</font>.&nbsp;&nbsp;Atara will establish and maintain a Global Safety Database that will contain all information and data arising from the Parties&#8217; activities with respect to safety matters that is required to be contributed by each party pursuant to the Pharmacovigilance Agreement, including information and data arising out of any risk evaluation and mitigation strategy (REMS) and/or risk management plan (RMP), periodic safety reports and safety monitoring activities.&nbsp;&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reporting</font>.&nbsp;&nbsp;Atara or Atara&#8217;s designee shall be responsible for collecting and submitting safety case reports to the applicable Regulatory Authorities for all countries outside of the Territory.&nbsp;&nbsp;During an applicable Pre-Transfer Period, Atara or Atara&#8217;s designee shall be responsible for collecting and submitting safety case reports to the applicable Regulatory Authorities for Europe and the UK, as applicable.&nbsp;&nbsp;Thereafter, Partner shall be responsible for submitting all safety case reports to the applicable Regulatory Authorities within the Territory.&nbsp;&nbsp;Each Party shall share all safety case reports with the other Party pursuant to the terms of the Pharmacovigilance Agreement. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000164"></a><a name="_Toc83283216"></a><a name="_Toc256000033"></a><a name="_Toc84000550"></a>7.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Early Access Programs</font><font style="font-weight:normal;">.&nbsp;&nbsp;Atara shall be responsible, at its sole cost and expense, for operationally managing and conducting the Early Access Programs for Product outside the Territory.&#160; Atara shall have the right, but not the obligation (unless required under applicable Law in any country, region or jurisdiction, as applicable, in the Territory), to conduct the Atara 902 EAP Observational Study and/or the Atara EU EAP/SPU Program in the Territory.&#160;With respect to the EU or the UK, as applicable, and unless otherwise agreed between the Parties through the JSC, Atara shall be responsible for operationally managing and conducting the Atara 902 EAP Observational Study and/or the Atara EU EAP/SPU Program in Europe or the UK, as applicable, [***].&#160; Partner shall be responsible, at its sole cost and expense, for any other Early Access Programs for Product in the Territory after the Effective Date, provided, however, Partner may not initiate or conduct any Early Access Program activities relating to (a) the Primary Indication prior to obtaining Marketing Authorization for the Product for the Primary Indication in the European Territory or (b) for a Multi-Cohort Indication prior to obtaining Marketing Authorization for a Multi-Cohort Indication in the European Territory, in each case, without the prior written consent of Atara.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000165"></a><a name="_Toc83283217"></a><a name="_Toc256000034"></a><a name="_Toc84000551"></a><a name="_Ref81830299"></a>7.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Audits</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Parties shall cooperate in good faith with respect to Regulatory Authority inspections of any site or facility, including, without limitation, where Clinical Studies, CMC, or pharmacovigilance activities with respect to the Product are conducted by or on behalf of a Party pursuant to this Agreement, whether such site or facility is such Party&#8217;s or its Affiliate&#8217;s or Approved Sublicensee&#8217;s, subject to terms and conditions of Third Party agreements (provided that each Party shall use reasonable efforts to ensure that Third Party agreements do not prevent the exercise of such rights), and shall inform each other of such Regulatory Authority inspection within [***] from its notification.&nbsp;&nbsp;Each Party shall be given a reasonable opportunity (taking into account the timing and notice provided by the applicable Regulatory Authority) to assist in the preparation of the other Party&#8217;s audited sites for inspection, where appropriate, and to attend any inspection by any Regulatory Authority of the other Party&#8217;s audited sites, and the summary, or wrap-up, meeting with a Regulatory Authority at the conclusion of such inspection.&nbsp;&nbsp;If such attendance would result in the disclosure to the other Party of </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Confidential Information unrelated to the subject matter of this Agreement, the Parties shall enter into a confidentiality agreement covering such unrelated subject matter.&nbsp;&nbsp;In the event that any audited site is found to be non-compliant with one or more GLP, GCP, or current standards for pharmacovigilance practice, the non-compliant Party shall submit to the other Party a proposed recovery plan within a reasonable period after such non-compliant Party, its Affiliate or its Approved Sublicensee receives notification of such non-compliance from the relevant Regulatory Authority and such non-compliant Party shall use commercially reasonable efforts to implement such recovery plan promptly after submission.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000166"></a><a name="_Toc83283218"></a><a name="_Toc256000035"></a><a name="_Toc84000552"></a>Article 8<br /><br /><a name="_Toc256000166"></a><a name="_Toc83283218"></a><a name="_Toc256000035"></a><a name="_Toc84000552"></a>Commercialization and Promotion Matters</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000167"></a><a name="_Toc83283219"></a><a name="_Toc256000036"></a><a name="_Toc84000553"></a>8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Responsibilities</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to Section 8.2 hereto, during the Term, Partner shall be solely responsible, at is sole cost and expense, for Commercializing the Product in each country in the Territory in accordance with this Agreement and with all applicable Laws, subject to the oversight of the JSC, as provided herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000168"></a><a name="_Toc83283220"></a><a name="_Ref83641412"></a><a name="_Toc256000037"></a><a name="_Toc84000554"></a><a name="_Ref81824779"></a>8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Diligence</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Partner shall utilize Commercially Reasonable Efforts to perform its obligations and to carry out its responsibilities under this Agreement with respect to the Commercialization of the Product in the Field in the Primary Indication and in any other indication, in each case if and when&nbsp;&nbsp;Regulatory Approval and Pricing Approval of the Product is obtained for such indication(s), [***]. Partner agrees to use reasonable efforts to assess Commercialization opportunities for the Product in the Primary Indication in all other countries in the Territory, and to incorporate the results of such assessments from time to time into the Commercialization Plan to be discussed by the JSC. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000169"></a><a name="_Toc83283221"></a><a name="_Toc256000038"></a><a name="_Toc84000555"></a><a name="_Ref81817603"></a>8.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Commercialization Plan</font><font style="font-weight:normal;">.&nbsp;&nbsp;Within a reasonable period of time of the Effective Date, but in any case no later than within [***] prior to the Parties&#8217; estimated Marketing Authorization approval date for the Product for the Primary Indication in Europe, Partner will present an outline of its Commercialization plans for the Product in the Territory including [***].&nbsp;&nbsp;Partner will provide an update of its Commercialization activities and plans on [***], for discussion by the JSC. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000170"></a><a name="_Toc83283222"></a><a name="_Toc256000039"></a><a name="_Toc84000556"></a>8.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Pricing</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner shall, at its sole cost and expense, be solely responsible for obtaining and maintaining Pricing Approvals in the Territory where applicable and subject to Section 8.2, Partner shall use Commercially Reasonable Efforts to obtain Pricing Approvals where applicable in [***], subject to review and discussion by the JSC under Section 4.2 hereto, taking into account [***].&nbsp;&nbsp;Partner shall also be solely responsible, at its sole cost and expense, for setting and managing local pricing and reimbursement, as well as Product launch sequencing, subject to review and discussion by the JSC. To the extent permitted by applicable Law, and unless necessary for the purpose of obtaining Pricing Approval for the Product in any country in the Territory, Partner shall not publicly disclose information on discounts and rebates relating to the pricing of Product in such country in the Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000171"></a><a name="_Toc83283223"></a><a name="_Toc256000040"></a><a name="_Toc84000557"></a>8.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Promotional Materials</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to Section 8.9 hereto, Partner shall, at its own expense, have the right to create, develop, produce or otherwise obtain, and utilize Promotional </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Materials to support the Commercialization of the Product in the Field in the Territory, it being specified that Atara shall provide existing Promotional Materials to Partner as part of the Transition Plan, including those currently existing and intended for use by Atara in the United States.&nbsp;&nbsp;Partner shall provide to the JSC for review and discussion a prototype of core Promotional Materials by Partner, without an obligation to provide any local Promotional Materials.&nbsp;&nbsp;Partner shall modify such Promotional Materials to the extent necessary to resolve any objections timely and reasonably made by Atara to such Promotional Materials on the grounds that such Promotional Materials are inconsistent with any legal requirements, and shall in good faith consider any of Atara&#8217;s other objections.&nbsp;&nbsp;The Promotional Materials, and any aspects of those uniquely tied to the Product, shall be used by Partner, its Affiliates and their Approved Sublicensees exclusively in connection with the Commercialization of the Product in the Field in the Territory in accordance with the terms of this Agreement, and Partner shall not use, or allow any other Person (other than its Affiliates and Approved Sublicensees) to use, any such Promotional Materials except in accordance with this Agreement.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000172"></a><a name="_Toc83283224"></a><a name="_Toc256000041"></a><a name="_Toc84000558"></a>8.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Ownership and Use of Product Trademarks and Product Trade Dress</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Ownership.&nbsp;&nbsp;</font>Partner acknowledges the sole ownership by Atara and validity of all Product Trademarks, Product Trade Dress, logos and slogans used or intended to be used specifically in connection with the Commercialization of the Product for the Field in the Territory.&nbsp;&nbsp;Partner shall assign (and shall cause its Affiliates and Approved Sublicensees to assign), and hereby does assign to Atara, all of its right, title and interest in and to such Product Trademark and Product Trade Dress, if any.&nbsp;&nbsp;Partner agrees that it will not at any time during or after the Term assert or claim any interest in or do anything which may adversely affect the validity or enforceability of, any copyright, trademark, trade dress, logo or slogan owned by Atara and used or intended to be used on or in connection with the marketing or sale of the Product in the Field in the Territory.&nbsp;&nbsp;Partner will not register, seek to register or cause to be registered any copyrights, trademarks, trade dress, logos or slogans owned by Atara and used or intended to be used on or in connection with the marketing or sale of the Product in the Field in the Territory or any variation thereof, under any applicable Law providing for registration of copyrights, trademarks, service marks, trade names or fictitious names (including as an Internet domain name) or similar Laws, without Atara&#8217;s prior written consent, which may be withheld in its sole discretion. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Maintenance.&nbsp;&nbsp;</font>Atara shall establish, maintain and enforce the Product Trademarks in the Territory and will bear all costs and expenses relating thereto.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Use.&nbsp;&nbsp;</font>All uses of the Product Trademarks and Product Trade Dress by Partner (and its Affiliates and Approved Sublicensees) to identify and/or in connection with the Commercialization of the Product in the Field in the Territory shall be in accordance with Regulatory Approvals and all applicable Laws.&nbsp;&nbsp;Partner (and its Affiliates and any Approved Sublicensees) shall use the Product Trademarks and Product Trade Dress solely pursuant to the terms of this Agreement to identify and in connection with the Commercialization of the Product in the Territory for use in the Field, and Partner shall not (and shall cause its Affiliates and Approved Sublicensees not to) use such Product Trademarks or Product Trade Dress to identify or in connection with the marketing of any other products.&nbsp;&nbsp;Atara shall also own rights to any internet domain names incorporating the Product Trademarks or any variation or part of such trademark as its URL address or any part of such address; and Partner shall not establish any </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">internet domain name or URL incorporating such trademark without the prior written consent of Atara, such consent not to be unreasonably withheld.&nbsp;&nbsp;The Parties hereby agree and acknowledge that nothing contained herein shall limit Atara&#8217;s right to use the Product Trademarks or Product Trade Dress outside the Territory</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000173"></a><a name="_Toc83283225"></a><a name="_Toc256000042"></a><a name="_Toc84000559"></a><a name="_Hlk77670537"></a><a name="_Ref81914822"></a>8.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Reports</font><font style="font-weight:normal;">.&nbsp;&nbsp;The status, progress and results of Partner&#8217;s Commercialization activities of the Product in the Territory shall be discussed at meetings of the JSC, and Partner shall provide the JSC with a written report on the status and progress of such activities at least [***] prior to each scheduled JSC meeting.&nbsp;&nbsp;In addition, Partner shall make available such information as may be reasonably requested by Atara from time to time.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000174"></a><a name="_Toc83283226"></a><a name="_Toc256000043"></a><a name="_Toc84000560"></a>8.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party shall, in Developing, Manufacturing, seeking Regulatory Approval and Commercializing the Product in the Territory, comply with all applicable Laws, including the Anti-Corruption Laws, as well as all applicable Regulatory Approvals for the Product.&nbsp;&nbsp;In addition, each Party shall not use in any capacity, in connection with its Development or Commercialization of the Product hereunder, any Person who has been debarred pursuant to Article 306 of the Federal Food, Drug and Cosmetic Act (or similar Law outside of the U.S.), or who is the subject of a conviction described in such Article, and each Party shall inform the other in writing immediately if it or any Person who is performing services for such Party hereunder is debarred or is the subject of a conviction described in Article 306 (or similar Law outside of the U.S.), or if any action, suit, claim, investigation or legal administrative proceeding is pending or, to such Party&#8217;s knowledge, is threatened, relating to the debarment of such Party or any Person used in any capacity by such Party in connection with its Development or Commercialization of the Product hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000175"></a><a name="_Toc83283227"></a><a name="_Toc256000044"></a><a name="_Toc84000561"></a><a name="_Ref81818626"></a>8.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Global Branding Strategy</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Atara shall have the right, from time to time during the Term, to implement (and thereafter modify and update) a global branding strategy, including global messaging and imagery, for the Product for use in the Field throughout the world (the &#8220;</font><font style="text-decoration:underline;">Global Branding Strategy</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;To the extent Atara determines to implement use of such Global Branding Strategy, Partner shall use Commercially Reasonable Efforts to adhere to the Global Branding Strategy in its Commercialization of the Product in the Field in the Territory including with respect to any Promotional Materials; provided, that, in the event that Partner believes that the application of the Global Branding Strategy in a particular country in the Territory would be inappropriate whether because of such country&#8217;s linguistic or cultural particularities, because it is against the Laws of such country, because of risk of infringing Third Party rights or because Partner reasonably determines it would be inconsistent with Partner&#8217;s obligation to use Commercially Reasonable Efforts to Commercialize the Product in the Field in the Territory, Partner will not be obliged to apply such Global Branding Strategy.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000176"></a><a name="_Toc83283228"></a><a name="_Ref83637529"></a><a name="_Toc256000045"></a><a name="_Toc84000562"></a><a name="_Ref81817437"></a>8.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cell Selection</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon grant of a Marketing Authorization, and prior to [***], Atara shall provide Cell Selection services for the Product in the Field for Commercialization in the Territory, to Partner and its Affiliates and their Approved Sublicensees, at the sole and exclusive cost of Atara.&#160; [***].&#160; If the Parties mutually agree that Atara shall continue to provide such Cell Selection services to Partner after [***], Atara&#8217;s provision of such Cell Selection services shall be at the sole and exclusive cost and expense of Partner, in accordance with </font><font style="text-decoration:underline;font-weight:normal;">Exhibit&#160;F</font><font style="font-weight:normal;"> attached hereto.&#160;[***]. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000177"></a><a name="_Toc83283229"></a><a name="_Toc256000046"></a><a name="_Toc84000563"></a><a name="_Ref81824970"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.11</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notification</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">Each Party shall promptly notify the other Party if such Party becomes aware of any information that is likely to have a material adverse effect upon Partner&#8217;s ability to successfully Commercialize the Product in the Field in the Territory or Atara&#8217;s ability to successfully Commercialize the Product in the Field outside the Territory.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000178"></a><a name="_Toc83283230"></a><a name="_Toc256000047"></a><a name="_Toc84000564"></a><a name="_Ref81817028"></a>8.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Order Handling. Order to Cash</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner shall be solely responsible, at its sole cost and expense, for order intake and order management, as well as invoicing and cash collection (order-to-cash) for sale of the Product in the Territory.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000179"></a><a name="_Toc83283231"></a><a name="_Ref83847877"></a><a name="_Toc256000048"></a><a name="_Toc84000565"></a><a name="_Ref81917248"></a>8.13<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000180"></a><a name="_Toc83283232"></a><a name="_Ref83847878"></a><a name="_Toc256000049"></a><a name="_Toc84000566"></a><a name="_Ref81917249"></a><a name="_Ref82901321"></a><a name="_Toc256000050"></a><a name="_Toc83905767"></a><a name="_Hlk83328077"></a><a name="_Hlk83913837"></a>8.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;"><a name="_Toc256000050"></a><a name="_Toc83905767"></a>Limitation on Activities Inside the Field and Territory</font><font style="font-weight:normal;">.&nbsp;&nbsp;From the Effective Date through the period that is [***] after the Effective Date (the &#8220;</font><font style="text-decoration:underline;">Limited Period</font><font style="font-weight:normal;">&#8221;), Atara, its Affiliates and their respective licensees and sublicensees shall not, other than the Development of the Product in the Territory as specifically authorized under this Agreement, Develop nor Commercialize any product comprising [***].&#160; For the avoidance of doubt, a chimeric antigen receptor T-cell shall not constitute an allogeneic EBV-specific cytotoxic T-cell but shall constitute a cell therapy product.&#160; Following the Limited Period and during the Term, [***]<a name="_Hlk83328077"></a>.  The provisions of this Section 8.14 shall not apply to any Restricted Product, Restricted Product candidate or development program of an acquiror of Atara, including its Affiliates or subsidiaries, in each case, existing as of the date of the acquisition by such acquiror of Atara, <a name="_Hlk83913837"></a>[***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000181"></a><a name="_Toc83283233"></a><a name="_Toc256000051"></a><a name="_Toc84000567"></a>8.15<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Partner Non-Compete</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the Limited Period, none of Partner, its Affiliates and the Approved Sublicensees shall directly or indirectly Commercialize, or enable any such Affiliate, Approved Sublicensee to Commercialize, any Restricted Product, other than Product, in the Territory. Following the Limited Period, none of Partner, its Affiliates and the Approved Sublicensees shall directly or indirectly Commercialize, or enable any such Affiliate, Approved Sublicensee to Commercialize, any Restricted Product, other than Product, in any country, region, or jurisdiction in the Territory, which Restricted Product that is the subject of [***]. The provisions of this Section 8.15 shall not apply to any Restricted Product of an acquiror of Partner, including its Affiliates or subsidiaries, in each case, existing as of the date of the acquisition by such acquiror of Partner, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000182"></a><a name="_Toc83283234"></a><a name="_Toc256000052"></a><a name="_Toc84000568"></a>8.16<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation on Pursuit of Generic Product</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the Term, none of Partner or its Affiliates, Approved Sublicensees, or Distributors shall (a) practice, or authorize any Third Party to practice, any Atara Intellectual Property for any purpose other than as expressly authorized in this Agreement, (b) take any action to seek, or engage in, the Development, Regulatory Approval, Manufacture or Commercialization of a Generic Competitor or (c) enable any Third Party to do the same. </font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000183"></a><a name="_Ref81819052"></a><a name="_Toc83283235"></a><a name="_Toc256000053"></a><a name="_Toc84000569"></a>Article 9<br /><br /><a name="_Toc256000183"></a><a name="_Ref81819052"></a><a name="_Toc83283235"></a><a name="_Toc256000053"></a><a name="_Toc84000569"></a>Manufacturing and Supply Matters</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000184"></a><a name="_Toc83283236"></a><a name="_Toc256000054"></a><a name="_Toc84000570"></a><a name="_Ref81819013"></a><a name="_Hlk79595448"></a>9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Manufacturing and Supply Agreement</font><font style="font-weight:normal;">.&nbsp;&nbsp;Within [***]<a name="_Hlk79595448"></a> from the Effective Date, the Parties will negotiate and execute a manufacturing and supply agreement (the &#8220;</font><font style="text-decoration:underline;">Manufacturing and Supply Agreement</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;">MSA</font><font style="font-weight:normal;">&#8221;) on mutually agreed terms and conditions for the </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Manufacture and supply of the Product that are customary for agreements of this type.&nbsp;&nbsp;Partner shall purchase from Atara or its Affiliates all of Partner&#8217;s, and its Affiliates&#8217; and Approved Sublicensees&#8217; requirements of Product in the Field in the Territory pursuant to the terms and conditions of the MSA.&nbsp;&nbsp;Key terms relating to Atara&#8217;s Manufacture and supply of Product for Partner that are to be incorporated into the Ancillary Agreements are summarized in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;"> attached hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000185"></a><a name="_Toc83283237"></a><a name="_Toc256000055"></a><a name="_Toc84000571"></a>9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Diligence</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Atara shall perform and carry out its Manufacturing responsibilities set forth in this Agreement and the MSA, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000186"></a><a name="_Toc83283238"></a><a name="_Toc256000056"></a><a name="_Toc84000572"></a><a name="_Ref81914236"></a>9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Quality Agreement</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Within [***] from the Effective Date and concomitant with the MSA, the Parties will negotiate and execute a quality agreement (the &#8220;</font><font style="text-decoration:underline;">Quality Agreement</font><font style="font-weight:normal;">&#8221;) on mutually agreed terms and conditions for the manufacture and supply of the Product that are customary for agreements of this type, including customary audit rights of Atara Manufacturing Facility.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000187"></a><a name="_Toc83283239"></a><a name="_Toc256000057"></a><a name="_Toc84000573"></a>9.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Return of Product</font><font style="font-weight:normal;">.&nbsp;&nbsp;All returns of Product shall be in accordance with a mutually agreed Product return protocol, as to be further specified in the MSA. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000188"></a><a name="_Ref81819903"></a><a name="_Toc83283240"></a><a name="_Toc256000058"></a><a name="_Toc84000574"></a>9.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Atara Supply Obligation</font>. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81915808"></a>(a)<font style="margin-left:36pt;"></font>The obligations of Atara under this Article 9, including the obligations to Manufacture (or have Manufactured by an Atara Manufacturing Facility) and supply Product to Partner hereunder, shall continue (on a country-by-country and Product-by-Product basis) through to the end of the Royalty Term with respect to such Product in such country; provided, however, as to be further detailed in the MSA, at any time after a period of [***] from the First Commercial Sale of the Product in the Territory, upon Atara&#8217;s delivery of written notice to Partner, Atara may elect to transfer its global Manufacturing responsibilities for the Product to a qualified Third Party facility that is not an Atara Manufacturing Facility (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Atara CMO</font>&#8221;). </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81819949"></a>(b)<font style="margin-left:36pt;"></font>At least [***] before Atara&#8217;s delivery of the written notice in Section 9.5(a), Atara shall inform Partner of its intent to deliver such written notice, at which time Partner may choose to assume directly, or through any qualified designee of Partner approved in advance by Atara, the Manufacturing of the Product for the Territory, or to rely on the Atara CMO (the supplier so elected by Partner, including Atara CMO where applicable, being referred to as the &#8220;<font style="font-weight:bold;text-decoration:underline;">Selected Manufacturer</font>&#8221;).&nbsp;&nbsp;If so elected by Partner, Atara shall use Commercially Reasonable Efforts to enable Partner to negotiate with Atara CMO for the supply of the Product for the Territory at terms and conditions substantially as favorable as those of Atara.&nbsp;&nbsp;Atara shall use Commercially Reasonable Efforts to (i) transfer to the Selected Manufacturer technology, materials, and other Know-How required to enable them to Manufacture Product for all of Partner&#8217;s authorized uses in the Field and in the Territory under this Agreement (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Technology Transfer</font>&#8221;) and (ii) complete the Technology Transfer within [***] of Atara&#8217;s written notice to Partner of Atara&#8217;s election to conduct the Technology Transfer.&nbsp;&nbsp;Atara shall bear the associated costs for such Technology Transfer, to be further detailed in the MSA. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Until completion of the Technology Transfer to the Selected Manufacturer and revision of all Regulatory Approvals related to the Commercialization of the Product in the </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Territory to reflect such Selected Manufacturer as the Manufacturer, Atara shall continue to (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;Manufacture, or have Manufactured by an Atara Manufacturing Facility, and (ii) supply Product to Partner pursuant to the provisions of this Article 9, </font><font style="text-decoration:underline;">Exhibit C</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and the associated MSA.&nbsp;&nbsp;In the event that a Technology Transfer to a Selected Manufacturer occurs, upon its completion, Section&#160;2.1 of this Agreement shall be amended to grant the Selected Manufacturer a non-exclusive, non-sublicensable, fully paid up license under the Atara Intellectual Property existing as of the completion date of the Technology Transfer to Manufacture the Product for all of Partner&#8217;s authorized uses in the Field and in the Territory under this Agreement.&nbsp;&nbsp;Atara shall have no further obligation to Manufacture and supply Product for any Partner, Partner&#8217;s Affiliate, or Approved Sublicensee use under this Agreement.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000189"></a><a name="_Toc83283241"></a><a name="_Toc256000059"></a><a name="_Toc84000575"></a>Article 10<br /><br /><a name="_Toc256000189"></a><a name="_Toc83283241"></a><a name="_Toc256000059"></a><a name="_Toc84000575"></a>Intellectual Property Matters</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000190"></a><a name="_Toc83283242"></a><a name="_Toc256000060"></a><a name="_Toc84000576"></a>10.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Ownership of Atara Intellectual Property</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner acknowledges that, as between the Parties, Atara Controls the Atara Intellectual Property. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000191"></a><a name="_Toc83283243"></a><a name="_Toc256000061"></a><a name="_Toc84000577"></a>10.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Prosecution</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner acknowledges that, as between the Parties, Atara, through MSK, has the sole right, but not the obligation, at its sole cost and expense, to file, prosecute and maintain the Patent Rights in the Territory constituting Atara Intellectual Property.&nbsp;&nbsp;Atara shall keep Partner reasonably informed of the progress of its prosecution efforts, by providing Partner with copies of all material patent prosecution documentation so that Partner may be informed and advise Atara on the continuing prosecution, and Atara agrees to consider in good faith all such reasonable comments.&nbsp;&nbsp;Partner shall keep this documentation confidential.&nbsp;&nbsp;If Atara elects not to file, prosecute or maintain a Patent Right in any country in the Territory, then it shall notify Partner in writing at least [***] before any deadline applicable to the filing, prosecution or maintenance of such Patent Right, as the case may be, or any other date by which an action must be taken to establish or preserve such Patent Right in such country or possession.&nbsp;&nbsp;Upon notification, Partner may elect to assume thereafter the costs of the filing, prosecution, or maintenance of such Patent Right.&nbsp;&nbsp;In such event, Atara shall file, prosecute or maintain such Patent Right. Atara shall reimburse such costs directly incurred with respect to the filing, prosecution, or maintenance of such Patent Right upon receipt of the corresponding invoice from Partner.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000192"></a><a name="_Toc83283244"></a><a name="_Toc256000062"></a><a name="_Toc84000578"></a><a name="_Ref81825932"></a>10.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Enforcement in the Territory</font><font style="font-weight:normal;">.&nbsp;&nbsp;Subject to Section 10.3(c) hereto, Partner acknowledges that, as between the Parties, Atara has the sole right, but not the obligation, at its sole cost and expense, to enforce the Atara Intellectual Property in the Territory against Third Party infringement, unauthorized use, misappropriation or threatened infringement thereof.&nbsp;&nbsp;However, Partner shall have the right to join such action as a party plaintiff if admissible by applicable Laws at its own costs and expenses in order to seek compensation for its own damages.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Each Party shall promptly notify the other Party in writing of any existing or threatened infringement, unauthorized use or misappropriation of the Atara Intellectual Property in the Territory by reason of the Manufacture, use or sale of a product identical to or substantially similar to the Product and shall provide all evidence in such Party&#8217;s possession demonstrating such infringement.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk78358175"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk78358175"></a>Partner shall provide to Atara reasonable assistance in any enforcement of the Atara Intellectual Property in the Territory against Third Party infringement, at Atara&#8217;s request, including joining such action as a party plaintiff if required by applicable Laws to pursue such action.&nbsp;&nbsp;Atara shall keep Partner regularly informed of the status and progress of such enforcement efforts, shall reasonably consider Partner&#8217;s comments on any such enforcement efforts.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partner shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but Partner shall at all times cooperate fully with Atara in bringing such action.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81825843"></a>(c)<font style="margin-left:36pt;"></font>If Atara, in its sole discretion, determines not to exercise its right to bring an action against Third Party infringement of the Atara Intellectual Property in the Territory, subject to Memorial Sloan Kettering Cancer Center&#8217;s secondary right to bring an action against Third Party infringement of the Atara Intellectual Property in the Territory as detailed in the Existing Agreement, Partner shall be entitled to bring such action at its sole cost and expense.&nbsp;&nbsp;Atara shall provide to Partner reasonable assistance in such enforcement, at Partner&#8217;s request, including joining such action as a party plaintiff if required by applicable Laws to pursue such action.&nbsp;&nbsp;Partner shall keep Atara regularly informed of the status and progress of such enforcement efforts, shall reasonably consider Atara&#8217;s comments on any such efforts.&nbsp;&nbsp;Atara shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but Atara shall at all times cooperate fully with Partner in bringing such action.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>A Party with responsibility for enforcement under this Section 10.3 hereto shall not settle any claim, suit or action that it brought under this Section 10.3 involving Atara Intellectual Property without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided that the other Party shall have the sole discretion to withhold consent in the event that such settlement would (i) restrict in any material respect the scope of the Atara Intellectual Property or its rights or interests therein or otherwise adversely impact the Atara Intellectual Property rights, or (ii) adversely impact the Development, Commercialization, any Regulatory Approval or any Regulatory Exclusivity of the Product, either in the Territory or outside the Territory. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>If either Party recovers monetary damages from any Third Party in a suit or action brought hereunder with respect to the Atara Intellectual Property, including in a settlement, such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amount shall be retained by the Party bringing such suit or action.&nbsp;&nbsp;[***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000193"></a><a name="_Toc83283245"></a><a name="_Toc256000063"></a><a name="_Toc84000579"></a>10.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Infringement of Third Party Patent Rights</font><font style="font-weight:normal;">.&nbsp;&nbsp;If a Party becomes the subject of a Third Party&#8217;s claim or assertion of infringement of a Third Party Patent Right granted by a jurisdiction within the Territory with respect to the Commercialization of the Product in the Field in the Territory, or the Development or Manufacture of the Product in the Field for Commercialization in the Field in the Territory, the Party first having notice of the claim or assertion shall promptly notify the other Party, and thereafter, the Parties shall promptly meet to consider the claim or assertion and mutually agree upon the appropriate course of action, but each of them shall be entitled to defend itself provided that it shall keep the other Party regularly informed of the status and progress of such defense efforts, shall reasonably consider the other Party&#8217;s comments, and shall not settle any claim, suit or action without the prior written consent </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">of the other Party, which consent shall not be unreasonably withheld; provided that the other Party shall have the sole discretion to withhold consent in the event that such settlement would impose any obligation or liability on the other Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000194"></a><a name="_Toc83283246"></a><a name="_Toc256000064"></a><a name="_Toc84000580"></a>10.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Patent Marking</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner shall mark Product marketed and sold by Partner (or its Affiliate and their Approved Sublicensees) hereunder with appropriate patent numbers or indicia, where relevant.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000195"></a><a name="_Ref81829846"></a><a name="_Toc83283247"></a><a name="_Toc256000065"></a><a name="_Toc84000581"></a>Article 11<br /><br /><a name="_Toc256000195"></a><a name="_Ref81829846"></a><a name="_Toc83283247"></a><a name="_Toc256000065"></a><a name="_Toc84000581"></a>Payments</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000196"></a><a name="_Toc83283248"></a><a name="_Toc256000066"></a><a name="_Toc84000582"></a><a name="_Ref81820488"></a>11.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Upfront Payment</font>.&nbsp;&nbsp;<font style="font-weight:normal;">No later than [***] after the Effective Date, Partner shall pay to Atara an upfront fee of [***] in consideration for the licenses granted hereunder (the &#8220;</font><font style="text-decoration:underline;">Upfront Payment</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;The Upfront Payment shall be non-refundable, non-recoupable and non-creditable against any other amounts payable hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000197"></a><a name="_Toc83283249"></a><a name="_Ref83409420"></a><a name="_Toc256000067"></a><a name="_Toc84000583"></a><a name="_Ref81826421"></a><a name="_Hlk80168596"></a>11.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Development Milestones</font><a name="_Hlk80168596"></a>.&nbsp;&nbsp;<font style="font-weight:normal;">Partner shall make the following one-time milestone payments to Atara for the milestone events set forth in this Section 11.2: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000198"></a><a name="_Toc83283250"></a><a name="_Ref83409421"></a><a name="_Toc256000068"></a><a name="_Toc84000584"></a><a name="_Ref81829393"></a>11.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Commercial Milestones</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Partner shall make the following one-time milestone payments to Atara for the milestone events set forth in this Section 11.3: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***].</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000199"></a><a name="_Ref81825978"></a><a name="_Toc83283251"></a><a name="_Ref83409424"></a><a name="_Toc256000069"></a><a name="_Toc84000585"></a>11.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Royalties on Net Sales</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81829557"></a><a name="_Ref83641455"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Full Royalty Term</font>.&nbsp;&nbsp;From the Effective Date and through the end of the Full Royalty Term, on a country-by-country basis solely with respect to the Full Royalty Term, Partner shall make the following royalty payments to Atara on Net Sales of Product at a rate of: [***].</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81818496"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Extended Royalty Term</font>.&nbsp;&nbsp;Following expiration of the Full Royalty Term in a country of the Territory, Partner shall pay to Atara royalties on Net Sales in such country at a rate of [***] until the termination or expiration of this Agreement (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Extended Royalty Term</font>&#8221;). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000200"></a><a name="_Toc83283252"></a><a name="_Toc256000070"></a><a name="_Toc84000586"></a><a name="_Ref81816932"></a><a name="_Ref81915032"></a>11.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party Licenses</font>. <font style="font-weight:normal;"> In the event that Partner determines in its good faith judgment with advice from independent legal counsel that it is necessary to obtain a license to any Third Party Patent Rights in the Territory, wherein Partner&#8217;s Commercialization of the Product in the Field in the Territory would infringe such Third Party Patent Rights absent a license thereunder, and Partner obtains a license under such Patent Rights, Partner may deduct from the amounts due to Atara during the Full Royalty Term under Section 11.4(a) an amount equal to [***] of any royalty payments on net sales actually paid to any such Third Party as consideration solely for any such license to such Patent Rights in the Territory; provided, however, that in no event shall the </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">royalties owed to Atara under Section 11.4(a) be reduced, in the aggregate, by more than </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner agrees to provide Atara a true, complete and unredacted copy of any license or other agreement subject to this Section 11.5 within </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;"> of entering into such license agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000201"></a><a name="_Toc83283253"></a><a name="_Toc256000071"></a><a name="_Toc84000587"></a><a name="_Ref81818565"></a>11.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Generic Competitor</font><font style="font-weight:normal;">.&nbsp;&nbsp;If during the Full Royalty Term, a Third Party Generic Competitor receives Regulatory Approval, enters the market for sale in the Territory, and (i) achieves a Generic Market Share of at least [***] in any particular Calendar Quarter in any country(ies) of the Territory, in lieu of the royalty rates specified in Section 11.4 hereto, the royalty rate applicable to Net Sales of Product by Partner, its Affiliates, and Approved Sublicensees in such country(ies) in that Calendar Quarter shall be [***], or (ii) achieves a Generic Market Share of greater than [***] in any particular Calendar Quarter in any country(ies) in the Territory, in lieu of the royalty rates specified in Section 11.4 hereto, the royalty rate applicable to Net Sales of Product by Partner, its Affiliates, and Approved Sublicensees in such county(ies) in that Calendar Quarter shall be [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000202"></a><a name="_Toc84000588"></a><a name="_Toc256000072"></a><a name="_Hlk83327916"></a><a name="_Ref81915118"></a><a name="_Toc83283254"></a>11.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Academic Hospital Manufacturer</font>.&nbsp;&nbsp;<font style="font-weight:normal;">If during the Full Royalty Term, on a country-by-country basis in the Territory, a product meeting the requirements of clause (a) and (b) of the defined term &#8220;Generic Competitor&#8221; is manufactured and sold by an academic hospital in a country in the Territory, Partner shall provide written notice to Atara of the sales of such product in such country and if the Parties mutually agree that the impact of such sales by the academic hospital is material, [***]. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000203"></a><a name="_Toc256000073"></a><a name="_Toc84000589"></a>11.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Milestone Reports and Payments</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Atara shall notify Partner (or Partner shall notify Atara, as applicable) in writing within [***] after Atara or Partner first learns of the achievement of each milestone set out in Section 11.2.&nbsp;&nbsp;The corresponding milestone payment by Partner shall be due to Atara within [***] of receipt by Partner of an invoice from Atara and issued no earlier than the notice of achievement of the corresponding milestone event.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Partner shall notify Atara in writing within [***] after Partner first learns of the achievement of each milestone set out in Section 11.3.&nbsp;&nbsp;The corresponding milestone payment by Partner shall be due to Atara within [***] of receipt by Partner of an invoice from Atara and issued no earlier than the notice of achievement of the corresponding milestone event.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>All payments due under Sections 11.2, 11.3 and 11.8 shall be payable, in full, in U.S. dollars, and shall be made by wire transfer to the Atara bank account specified in Exhibit E attached hereto, or to such other bank account designated in writing by Atara at least [***] prior to the applicable payment date, which account shall be opened in Atara&#8217;s name in the book of a bank in the European Union or the United States of America.&nbsp;&nbsp;Atara agrees to provide to Partner all information and documents required by Partner in connection with the relevant provisions of Laws relating to anti-money laundering/KYC and which are sufficient to allow Partner to comply with such Laws. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Any milestone payment made by Partner to Atara pursuant to Article 11 hereto shall be non-refundable, non-creditable, and non-cancellable.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000204"></a><a name="_Ref81829948"></a><a name="_Toc83283255"></a><a name="_Toc256000074"></a><a name="_Toc84000590"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.9</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Royalty Reports and Payments</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reports.&nbsp;&nbsp;</font>Within [***] after the end of each Calendar Quarter, commencing with the Calendar Quarter in which occurs the first invoiceable sale of Product in the Field in the Territory for which royalties are due and payable by Partner, its Affiliates or their Approved Sublicensees, Partner shall deliver to Atara a report (each, a &#8220;<font style="font-weight:bold;text-decoration:underline;">Royalty Report</font>&#8221;) setting out in compliance with the template attached in <font style="text-decoration:underline;">Exhibit H</font> all details necessary to calculate the payments due under Section 11.4, including royalty bearing Net Sales and the number of units sold in the relevant Calendar Quarter on a country-by-country basis, all relevant exchange rate conversions in accordance with Section 11.9(b) and the amount of any payment due from Partner to Atara, calculated in accordance with this Article 11.&nbsp;&nbsp;Partner shall provide a preliminary, non-binding, estimated Royalty Report (not including information on the number of units sold) within [***] of the end of each Calendar Quarter.&nbsp;&nbsp;The royalty payment shall be due within [***] date of invoice and issued no earlier than the date of receipt of the Royalty Report by Atara.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81829889"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Payments.&nbsp;&nbsp;</font>All payments due under Sections 11.4 and 11.9 of this Agreement shall be payable, in full, in U.S. dollars, regardless of the country(ies) in which Net Sales are made.&nbsp;&nbsp;For the purposes of computing Net Sales of Products sold in a currency other than U.S. dollars, such currency shall be converted into U.S. dollars using the average quarter to date rate of exchange as consistently applied per Partner&#8217;s internal accounting and reporting process.&nbsp;&nbsp;Such payments shall be without deduction of exchange, collection or other charges.&nbsp;&nbsp;All payments owed under this Agreement shall be made by wire transfer to the Atara bank account specified in <font style="text-decoration:underline;">Exhibit E</font> attached hereto, or to such other bank account designated in writing by Atara at least [***] prior to the applicable payment date, which account shall be opened in Atara&#8217;s name in the book of a bank in the European Union or the United States of America.&nbsp;&nbsp;Atara agrees to provide to Partner all information and documents required by Partner in connection with the relevant Laws relating to anti-money laundering/KYC policies which are sufficient to allow Partner to comply with such Laws.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Record Retention</font>.&nbsp;&nbsp;Beginning with the first invoiceable sale of a Product in the Field in the Territory, Partner shall keep complete and accurate records pertaining to the sale of such Products including the original data files used to prepare the submitted Royalty Reports, for a period of [***] after the year in which such sales occurred, and in sufficient detail to permit Atara to confirm the accuracy of the royalties paid by Partner hereunder.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Late Payments</font>.&nbsp;&nbsp;In the event that any payment due under this Agreement is not made when due, the payment shall accrue interest from the date due at the rate of [***]; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.&nbsp;&nbsp;The payment of such interest shall not limit Atara from exercising any other rights it may have as a consequence of the lateness of any payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000205"></a><a name="_Toc83283256"></a><a name="_Toc256000075"></a><a name="_Toc84000591"></a>11.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Audits</font>.&nbsp;&nbsp;<font style="font-weight:normal;">During the term of this Agreement and for a period of [***] thereafter, at the request and expense [***], Partner shall permit an independent, certified public accountant of nationally recognized standing appointed by Atara, and reasonably acceptable to Partner, at reasonable times and upon reasonable notice, but in no case no more than once for any particular royalty period, or more than [***] thereafter, to examine such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and the correctness of any </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">royalty payment made under this Agreement for any period within the preceding </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;">.&nbsp;&nbsp;Results of any such examination shall be made available to both Partner and Atara.&nbsp;&nbsp;The independent, certified public accountant shall disclose to Atara only the royalty amounts which the independent auditor believes to be due and payable hereunder to Atara and shall disclose no other information revealed in such audit.&nbsp;&nbsp;Any and all records examined by such independent accountant shall be deemed Partner&#8217;s Confidential Information which may not be disclosed by said independent, certified public accountant to any Third Party.&nbsp;&nbsp;Notwithstanding the above, if such audit reveals an underpayment by Partner in excess of </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;">, then </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;"> shall pay the reasonable costs of the auditors plus interest on the discrepancy as provided for late payments under Section 11.9(d) within </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;"> of the completion of the applicable audit. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000206"></a><a name="_Toc83283257"></a><a name="_Toc256000076"></a><a name="_Toc84000592"></a>11.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Taxes</font><font style="font-weight:normal;">.</font><font style="text-decoration:underline;font-weight:normal;"> </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Sales or Other Transfers</font>.&nbsp;&nbsp;The recipient of any transfer under this Agreement of Product or Know-How, as the case may be, shall be responsible for any sales, use, value added, excise or other taxes applicable to such transfer as required by law.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Withholding</font>.&nbsp;&nbsp;If Laws or regulations require withholding by Partner of any taxes imposed upon Atara on account of any royalties or other payments paid under this Agreement, such taxes shall be deducted by Partner as required by Law from such payment and shall be paid by Partner to the proper taxing authorities.&nbsp;&nbsp;Partner shall use Commercially Reasonable Efforts to secure official receipts of payment of any withholding tax and shall send them to Atara as evidence of such payment.&nbsp;&nbsp;The Parties shall exercise their reasonable efforts to ensure that any withholding taxes imposed are reduced as far as possible under the provisions of any applicable tax treaty and shall cooperate in filing any forms required for such reduction.&nbsp;&nbsp;Each Party shall cooperate with the other and furnish the other Party with appropriate documents, including Tax Documentation, to secure application of the most favorable rate of withholding tax under applicable Law (or exemption from such withholding tax payments, as applicable).&nbsp;&nbsp; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000207"></a><a name="_Ref81823608"></a><a name="_Ref82946988"></a><a name="_Toc83283258"></a><a name="_Ref83404793"></a><a name="_Ref83404817"></a><a name="_Ref83405208"></a><a name="_Ref83405332"></a><a name="_Toc256000077"></a><a name="_Toc84000593"></a><a name="_Ref83409026"></a>11.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Additional Studies</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>In the event that Partner elects to conduct a Clinical Study or other Development activities (excluding Observational Studies) pursuant to Section 6.1 (i) in order to obtain a Marketing Authorization in the Primary Indication in the European Territory or (ii) for any Clinical Study or other Development activities (excluding Observational Studies) upon which the grant of a Marketing Approval is expressly conditioned then, Partner shall be entitled to set off [***].&nbsp;&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>In the event that Partner elects to solely conduct and fund New Development activities pursuant to Section 6.2(b), and unless otherwise agreed in writing between the Parties, [***]. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000208"></a><a name="_Ref81817187"></a><a name="_Toc256000078"></a><a name="_Toc84000594"></a><a name="_Toc83283259"></a><font style="font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Article 12</font><font style="font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><br /></font><font style="font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><br /><a name="_Toc256000208"></a><a name="_Ref81817187"></a><a name="_Toc256000078"></a><a name="_Toc84000594"></a><a name="_Toc83283259"></a></font><font style="font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Representations and Warranties; Disclaimer</font><font style="font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000209"></a><a name="_Toc83283260"></a><a name="_Toc256000079"></a><a name="_Toc84000595"></a>12.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Representation of Success</font><font style="font-weight:normal;">.&nbsp;&nbsp;Atara does not warrant that Atara can successfully Develop or obtain Regulatory Approvals for the Product in the Field in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000210"></a><a name="_Toc83283261"></a><a name="_Toc256000080"></a><a name="_Toc84000596"></a><a name="_Hlk78295927"></a>12.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of Atara</font><font style="font-weight:normal;"><a name="_Hlk78295927"></a>.&nbsp;&nbsp;Atara covenants, and represents and warrants to Partner that as of the Effective Date:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Atara is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent Atara from performing its obligations under this Agreement;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Atara has full right and authority to grant the licenses to Partner as described herein; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Atara enforceable against Atara in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other Laws affecting creditors&#8217; rights generally from time to time if effect, and to general principles of equity;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk78295999"></a>(d)<font style="margin-left:36pt;"></font>The execution, delivery and performance of this Agreement does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Atara is a party, or by which it is bound, nor does it violate any Law applicable to Atara; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>All necessary consents, approvals and authorizations of all regulatory and Governmental Authorities and other persons or entities required to be obtained by Atara in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>The Patent Rights within the Atara Intellectual Property in Europe and the UK, and to Atara&#8217;s knowledge countries or regions in the Territory other than Europe and the UK, listed on <font style="text-decoration:underline;">Exhibit D</font> constitute a true, accurate and complete list of all Patent Rights within the Atara Intellectual Property in the Territory in existence as of the Effective Date Controlled by Atara relating to the Products in the Territory; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>Atara is the sole and exclusive owner or exclusive licensee (subject to Section 2.1(c) and to routine commercial licenses, and provided that certain Know-How licensed to Atara by MSK under the Existing Agreement is licensed to Atara on a non-exclusive basis) of all of Atara Intellectual Property in the Territory with respect to Product, including all Patents Rights listed on <font style="text-decoration:underline;">Exhibit D</font> and Product Trademarks listed on <font style="text-decoration:underline;">Exhibit G</font>, free from encumbrances, and has the right to grant to Partner the rights granted herein with the respect to the Atara Intellectual Property; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To Atara&#8217;s knowledge, all individuals who participated in the invention of any of the inventions claimed in the Patent Rights within the Atara Intellectual Property have made effective assignments of all ownership rights either pursuant to written agreement or by operation of applicable Law;&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>To Atara&#8217;s knowledge, all application and registration fees in respect of the Patent Rights within the Atara Intellectual Property listed on <font style="text-decoration:underline;">Exhibit D</font> have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of registering such Patent Rights within the Atara Intellectual Property;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>All application and registration fees in respect of the Product Trademarks listed on <font style="text-decoration:underline;">Exhibit G</font> have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of registering such Product Trademarks; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>To Atara&#8217;s knowledge, Atara has not misappropriated any know-how relating to the development, registration or manufacturing of the Product; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font>There are no actual, pending, alleged, or to Atara&#8217;s knowledge, threatened actions, suits or claims alleging the misappropriation of any know-how relating to the development, registration or manufacturing of the Product.&nbsp;&nbsp;Atara has taken reasonable precautions to preserve the confidentiality of the Atara Know-How within the Atara Intellectual Property; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font>Atara has not granted as of the Effective Date any licenses to any Affiliate or Third Party under the Atara Intellectual Property or Regulatory Approvals to be obtained by Atara hereunder which would conflict with the licenses granted to Partner hereunder;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:36pt;"></font>There are no actual, pending, alleged or to Atara&#8217;s knowledge, threatened action, suits, claims, interference or governmental investigations involving a Product (including with respect to the development or manufacturing of a Product or any Regulatory Approval or MAA related thereto), the Atara Intellectual Property, by or against Atara, or any of its Affiliates or, to Atara&#8217;s knowledge, other licensees, and to Atara&#8217;s knowledge, no circumstances that may give rise to any such action, suits, claims or investigation;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)<font style="margin-left:36pt;"></font>Atara has not brought a claim alleging an infringement by a Third Party of any of the Atara Intellectual Property.&nbsp;&nbsp;To Atara&#8217;s knowledge, no Third Party infringes or misappropriates any of the Atara Intellectual Property;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="margin-left:36pt;"></font>To Atara&#8217;s knowledge, none of the issued Patent Rights within the Atara Intellectual Property are invalid or unenforceable;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="margin-left:36pt;"></font>Atara has disclosed to Partner in writing copies of: (i) any and all material study reports, or synopses of the materials aspects thereof, from Clinical Studies or GLP preclinical studies of the Product in its possession, and (ii) all material filings and correspondence between Atara and its Affiliates and the EMA, relating to clinical or preclinical studies of the Products, and such information and materials are true and accurate in all material respects</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(r)<font style="margin-left:36pt;"></font>no information or materials provided by or on behalf of Atara to Partner including in the data room, when taken together as a whole, contain any untrue or misleading </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statement of a material fact or, to Atara&#8217;s knowledge, omit to state a material fact, in each case, that is likely to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have a material adverse </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Regulatory Approvals, Manufacturing</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and/or Commercialization, in each case, for the Product</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Territory</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)<font style="margin-left:36pt;"></font>All data with respect to Product that (i) is intended to be or was provided to a Regulatory Authority, or (ii) was provided by Atara to Partner, was generated in compliance with applicable Laws in all material respects;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(t)<font style="margin-left:36pt;"></font>In the course of the development of Product, Atara has not used any employee or consultant who has been debarred by any Regulatory Authority or was the subject of debarment proceedings by a Regulatory Authority, and to Atara&#8217;s knowledge, no such employees or consultants have been used by any Third Party on behalf of Atara in connection with the development of the Product.&nbsp;&nbsp;All studies conducted by or on behalf of Atara with respect to the Product or Product have been conducted in accordance with applicable Laws by persons with appropriate education, knowledge and experience in all material respects; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)<font style="margin-left:36pt;"></font>The Existing Agreement is in full force and effect in accordance to its terms as disclosed to Atara.&nbsp;&nbsp;No terms of the Existing Agreement material to the rights granted to Partner hereunder have been redacted in the Existing Agreement made available to Partner; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>No Third Party has any right of consent, right of first negotiation or similar rights under the Existing Agreement, that could materially interfere with Partner&#8217;s exercise of its sublicensing rights under this Agreement; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(w)<font style="margin-left:36pt;"></font>Atara has maintained and, unless otherwise agreed to by Partner, will maintain and keep in full force and effect all material agreements (including the Existing Agreement in accordance with its terms) and filings (including Patent Rights filings) necessary to perform its obligations hereunder.&nbsp;&nbsp;Atara and its Affiliates are in compliance with the Existing Agreement and have performed all material obligations required to be performed by them to date under the Existing Agreement.&nbsp;&nbsp;Neither Atara nor its Affiliates are (with or without the lapse of time or the giving of notice, or both) in material breach in any respect under the Existing Agreement;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)<font style="margin-left:36pt;"></font>Atara has no knowledge of any breach of the representations and warranties given by the parties to Existing Agreement; and</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y)<font style="margin-left:36pt;"></font>To the extent relating to the Product, Atara shall not agree or consent to any substantive amendment, supplement or other modification to the Existing Agreement or exercise any other right of agreement or consent thereunder, in each case to the extent that such amendment, supplement, modification, exercise or consent would materially and adversely affect Partner&#8217;s rights under this Agreement, unless Partner shall have consented in writing to the same.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000211"></a><a name="_Toc83283262"></a><a name="_Toc256000081"></a><a name="_Toc84000597"></a>12.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of Partner</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner covenants, and represents and warrants to Atara that as of the Effective Date:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Partner is a corporation duly organized, validly existing and in good standing under the laws of jurisdiction in which it is incorporated and it has full right and authority to enter into this Agreement and to accept the rights and licenses granted as herein described;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement has been duly authorized by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Partner enforceable against Partner in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other Laws affecting creditors&#8217; rights generally from time to time if effect, and to general principles of equity;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The execution, delivery and performance of this Agreement does not conflict with any other agreement, contract, instrument or understanding, oral or written, to which Partner is a party, or by which it is bound, nor does it violate any Law applicable to Partner; and </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>All necessary consents, approvals and authorizations of all regulatory and Governmental authorities and other persons or entities required to be obtained by Partner in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000212"></a><a name="_Toc83283263"></a><a name="_Toc256000082"></a><a name="_Toc84000598"></a><a name="_cp_text_1_59"></a><a name="_cp_text_2_60"></a>12.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations of Both Parties</font><font style="font-weight:normal;"><a name="_cp_text_1_59"></a>.&nbsp;&nbsp;Partner, with respect to itself and its Affiliates that have been or will be involved in the Development, Regulatory Filing activities and/or Commercialization of the Product in the Territory represents, warrants to Atara that, as of the Effective Date, and Atara represents, warrants to Partner that, as of the Effective Date, <a name="_cp_text_2_60"></a>to the knowledge of such Parties&#8217; compliance department:&nbsp;&nbsp;</font> </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>neither they or their directors, officers, employees, or any person authorized to act on its behalf have violated any Anti-Corruption Law in the Territory;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>neither they nor any person acting on its behalf, has offered, given, authorized, or promised anything of value (as defined by applicable Anti-Corruption Laws), either directly or indirectly, to any person, including to any Public Official or Entity, for the purpose of (i) improperly influencing any official act or decision; (ii) inducing performance or non-performance of any act in violation of a lawful duty; or (iii) securing an improper benefit or business advantage, in each case ((i) &#8211; (iii)) in any manner that violates the applicable Anti-Corruption Laws in the Territory;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>they have not received any written notice, request, or citation from any Governmental Authority with respect to any alleged or suspected violation of Anti-Corruption Laws in the Territory; and</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>they are not under investigation or being prosecuted by a Government Authority with respect to any alleged or suspected violation of Anti-Corruption Laws in the Territory.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000213"></a><a name="_Ref81830851"></a><a name="_Toc256000083"></a><a name="_Toc84000599"></a>12.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Rights and Obligations of Atara. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc83282009"></a><a name="_Toc83282551"></a><a name="_Toc83283054"></a><a name="_Toc83283265"></a><a name="_Toc83282010"></a><a name="_Toc83282552"></a><a name="_Toc83283055"></a><a name="_Toc83283266"></a><a name="_Toc83282011"></a><a name="_Toc83282553"></a><a name="_Toc83283056"></a><a name="_Toc83283267"></a>(a)<font style="margin-left:36pt;"></font>Atara shall not during the term of this Agreement (i) grant any lien, pledge, encumbrance, mortgage, or security interest (excluding any license rights or equivalents thereof) (collectively &#8220;<font style="font-weight:bold;">Liens</font>&#8221;) with respect to this Agreement or any of the Patents Rights within the Atara Intellectual Property in the Territory or (ii) permit such a Lien, to attach to this Agreement or any of such rights, in each case if such Lien would conflict with the rights granted to Partner hereunder. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon termination of the Existing Agreement, for the benefit of Partner and should Partner so elect, Atara shall assign to MSK the portion of the Agreement that relates to the Existing Agreement and shall use Commercially Reasonable Efforts to pursue enforcement of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 17.5 of the Existing Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc83282012"></a><a name="_Toc83282554"></a><a name="_Toc83283057"></a><a name="_Toc83283268"></a>(c)<font style="margin-left:36pt;"></font>To the extent relating to the Product in the Territory, Atara shall not agree or consent to any substantive amendment, supplement or other modification to the Existing Agreement or exercise any other right of agreement or consent thereunder, in each case to the extent that such amendment, supplement, modification, exercise or consent could materially and adversely affect Partner&#8217;s rights under this Agreement, unless Partner shall have consented in writing to the same, which consent may not be unreasonably withheld, conditioned or delayed (and which agreement or consent of Partner shall be provided within [***]<a name="_Toc83282012"></a><a name="_Toc83282554"></a><a name="_Toc83283057"></a><a name="_Toc83283268"></a> after a request therefor if such amendment, supplement or other modification would not materially and adversely affect Partner&#8217;s rights under this Agreement). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc83282013"></a><a name="_Toc83282555"></a><a name="_Toc83283058"></a><a name="_Toc83283269"></a>(d)<font style="margin-left:36pt;"></font>Atara shall not terminate the Existing Agreement without the prior written consent of Partner, which consent may not be unreasonably withheld, conditioned or delayed. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc83282014"></a><a name="_Toc83282556"></a><a name="_Toc83283059"></a><a name="_Toc83283270"></a>(e)<font style="margin-left:36pt;"></font>Atara shall at all times comply with the terms of the Existing Agreement.&nbsp;&nbsp;Atara shall promptly notify Partner of any actual or threatened breach of the Existing Agreement of which Atara becomes aware.&nbsp;&nbsp;Without limiting the foregoing, within [***]<a name="_Toc83282014"></a><a name="_Toc83282556"></a><a name="_Toc83283059"></a><a name="_Toc83283270"></a> after Atara&#8217;s receipt of any written notice, or otherwise becoming aware that such a notice may be forthcoming, relating to any alleged breach by Atara under such Existing Agreement, Atara shall notify Partner thereof, specifying the basis for the alleged breach, as set out in the notice or otherwise known to Atara.&nbsp;&nbsp;Without prejudice to any of Partner&#8217;s other rights under the Agreement or other remedies available to it, Partner shall have the right to take step to cure an actual breach of the Existing Agreement or prevent a termination of the Existing Agreement, at Atara&#8217;s costs.&nbsp;&nbsp;Partner may set off any reasonable payments made by or on behalf of Partner in connection with the performance of such steps against any amounts payable by Partner to Atara under this Agreement. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000214"></a><a name="_Toc83283271"></a><a name="_Toc256000084"></a><a name="_Toc84000600"></a>12.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Rights and Obligations of Partner</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Partner&#8217;s, and Partner&#8217;s Affiliates, employees, officers, contractors, and consultants performing activities in connection with this Agreement shall execute or have executed agreements requiring assignment to Partner or Partner&#8217;s Affiliate, as applicable, all right, title and interest in and to their inventions and discoveries invented or otherwise discovered or generated during the course of and as a result of such activities, whether or not patentable, if any, prior to commencing such activities; </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Partner currently has, and will maintain during the Term of this Agreement, directly or through its Affiliates, Approved Sublicensees, and Distributors (i) sufficient qualified and trained personnel and resources, and (ii) necessary financial and technical capacity to effectively fulfill its obligations related to the Product as contemplated in this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000215"></a><a name="_Toc83283272"></a><a name="_Toc256000085"></a><a name="_Toc84000601"></a>12.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Other Warranties</font><font style="font-weight:normal;">.&nbsp;&nbsp;EXCEPT AS EXPRESSLY STATED IN THIS Article 12, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF PARTNER OR ATARA; (B) ALL OTHER CONDITIONS </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT; AND (C) ALL KNOW-HOW, INFORMATION AND MATERIALS PROVIDED BY EITHER PARTY TO THE OTHER PARTY UNDER THIS AGREEMENT ARE PROVIDED &#8220;AS-IS.&#8221;&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000216"></a><a name="_Ref81817088"></a><a name="_Toc83283273"></a><a name="_Toc256000086"></a><a name="_Toc84000602"></a>Article 13<br /><br /><a name="_Toc256000216"></a><a name="_Ref81817088"></a><a name="_Toc83283273"></a><a name="_Toc256000086"></a><a name="_Toc84000602"></a>Indemnification; Insurance; Disclaimer </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000217"></a><a name="_Toc83283274"></a><a name="_Toc256000087"></a><a name="_Toc84000603"></a><a name="_Ref81817143"></a><a name="_Hlk78387705"></a>13.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification by Atara</font><font style="font-weight:normal;"><a name="_Hlk78387705"></a>.&nbsp;&nbsp;Subject to Section 13.3, Atara shall indemnify, defend and hold harmless Partner and its Affiliates, their subcontractors and Approved Sublicensees and its and their shareholders, directors, officers, employees, agents and representatives and insurers (the &#8220;</font><font style="text-decoration:underline;">Partner Indemnified Persons</font><font style="font-weight:normal;">&#8221;) from and against all Claims that may arise directly or indirectly as a result of: (i) the fraud, gross negligence or willful or wrongful acts or omissions of Atara; (ii) a breach by Atara of any of its representations or warranties under this Agreement; (iii) the failure of Atara to comply with applicable Laws; or (iv) Atara&#8217;s Development, Manufacture (provided that such indemnity will be placed in the MSA when entered into), Cell Selection services and Commercialization of the Products by or on behalf of Atara, in each case, except to the extent such Claim arises directly or indirectly as a result of any of the matters for which Partner is providing indemnification pursuant to Section 13.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000218"></a><a name="_Toc83283275"></a><a name="_Toc256000088"></a><a name="_Toc84000604"></a><a name="_Ref81816852"></a>13.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification by Partner</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to Section 13.3, Partner shall indemnify, defend and hold harmless Atara and its Affiliates and their subcontractors and its and their shareholders, directors, officers, employees, agents and representatives and insurers (the &#8220;</font><font style="text-decoration:underline;">Atara Indemnified Persons</font><font style="font-weight:normal;">&#8221;) from and against all Claims that may arise directly or indirectly as a result of: (i) the fraud, gross negligence or willful or wrongful acts or omissions of Partner; (ii) a breach by Partner of any of its representations or warranties under this Agreement; (iii) the failure of Partner to comply with applicable Laws; or (iv) Partner&#8217;s Development, as applicable, Manufacture, if and when transferred to Partner pursuant to this Agreement, and Commercialization of the Products by or on behalf of Partner, in each case, except to the extent such Claim arises directly or indirectly as a result of any of the matters for which Atara is providing indemnification pursuant to Section 13.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000219"></a><a name="_Toc83283276"></a><a name="_Toc256000089"></a><a name="_Toc84000605"></a><a name="_Ref81817076"></a>13.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notice of Claim</font>.&nbsp;&nbsp;<font style="font-weight:normal;">If a Party intends to claim indemnification under this Agreement (the &#8220;</font><font style="text-decoration:underline;">Indemnitee</font><font style="font-weight:normal;">&#8221;), it shall promptly notify the other Party (the &#8220;</font><font style="text-decoration:underline;">Indemnitor</font><font style="font-weight:normal;">&#8221;) in writing of such alleged loss and the Third Party Claim.&nbsp;&nbsp;The Indemnitor shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee.&nbsp;&nbsp;Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason in connection with such Third Party Claim, provided, however, that if the Indemnitee shall have reasonably concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action, the Indemnitor shall pay the fees and expenses of one law firm serving as counsel for the Indemnitee in relation to such Third Party Claim.&nbsp;&nbsp;The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party Claims covered by this Agreement.&nbsp;&nbsp;The obligations of this Article 13 shall not apply to any </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">settlement of any </font><font style="font-weight:normal;">Third Party</font><font style="font-weight:normal;"> Claims if such settlement is affected without the consent of both Parties, which shall not be unreasonably withheld or delayed. Each Party will not, without the prior written consent of the other Party, settle such </font><font style="font-weight:normal;">Third Party</font><font style="font-weight:normal;"> Claim or consent to the entry of any judgment to the extent that such settlement or judgment: (</font><font style="font-weight:normal;">i</font><font style="font-weight:normal;">) does not release the other Party from all liability with respect to such Third Party Claim, or (ii) likely will materially adversely affect such other Party or cause such other Party to incur any material obligation or liability. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Section </font><font style="font-weight:normal;">13.3</font><font style="font-weight:normal;">.&nbsp;&nbsp;It is understood that only Partner and Atara can claim indemnity under this Agreement (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000220"></a><a name="_Toc83283277"></a><a name="_Toc256000090"></a><a name="_Toc84000606"></a>13.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Insurance</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Each Party, at its own cost and expense shall, [***], carry and keep in force liability insurance covering such risks as are appropriate and in accordance with sound business practice and the Parties&#8217; obligations under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000221"></a><a name="_Toc83283278"></a><a name="_Toc256000091"></a><a name="_Toc84000607"></a>13.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation of Liability</font>.&nbsp;&nbsp;<font style="font-weight:normal;">NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF (1) A PARTY UNDER Article 14 OR (2) INDEMNIFICATION OBLIGATIONS UNDER THIS Article 13 FOR THIRD PARTY CLAIMS.&nbsp;&nbsp;FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS CLAUSE SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY. </font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000222"></a><a name="_Ref81817112"></a><a name="_Toc83283279"></a><a name="_Toc256000092"></a><a name="_Toc84000608"></a>Article 14<br /><br /><a name="_Toc256000222"></a><a name="_Ref81817112"></a><a name="_Toc83283279"></a><a name="_Toc256000092"></a><a name="_Toc84000608"></a>Confidentiality; Publications; Data Protection</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000223"></a><a name="_Toc83283280"></a><a name="_Toc256000093"></a><a name="_Toc84000609"></a><a name="_Ref81819871"></a>14.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Confidential Information</font>.&nbsp;&nbsp;<font style="font-weight:normal;">The Parties acknowledge that the Confidential</font> <font style="font-weight:normal;">Information include valuable trade secrets and is proprietary and the exclusive property of the disclosing Party and its Affiliates.&nbsp;&nbsp;Unless otherwise set forth in an Ancillary Agreement, during the Term and for a period of [***] thereafter, the receiving Party shall hold the Confidential Information supplied by the disclosing Party hereunder in strict confidence and shall use such Confidential Information solely for the purposes of performing hereunder.&nbsp;&nbsp;Notwithstanding the foregoing, trade secrets shall be treated as Confidential Information for as long as they retain their status as trade secrets.&nbsp;&nbsp;The receiving Party may only disclose Confidential Information to those directors, officers, employees, attorneys, contractors, agents, potential acquiror&#8217;s, potential sublicensees, bankers, and Affiliates (each a &#8220;</font><font style="text-decoration:underline;">Representative</font><font style="font-weight:normal;">&#8221;) who have a need to know and who are bound by obligations of confidentiality and non-use with respect to such Confidential Information that are at least as restrictive as those set forth herein.&nbsp;&nbsp;Each of the Parties agrees to: (a) advise their Representatives of the proprietary nature of the Confidential Information and the terms and conditions of this Agreement requiring that the confidentiality of such information be maintained; and (b) use reasonable safeguards to prevent unauthorized use by such Representatives.&nbsp;&nbsp;Each Party shall be responsible for any breach of this Agreement by its respective Representatives.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000224"></a><a name="_Toc83283281"></a><a name="_Toc256000094"></a><a name="_Toc84000610"></a>14.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Agreement Confidentiality</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Neither Party hereto shall disclose the terms of this</font> <font style="font-weight:normal;">Agreement to any other person or entity other than such Party&#8217;s Representatives, or as may otherwise be required by applicable Laws.&nbsp;&nbsp;In the event a Party reasonably believes it is required by applicable Laws to disclose any terms of this Agreement, prior to any proposed disclosure of any of the terms of this Agreement, such Party shall allow and reasonably assist the other Party in taking any action to lawfully prevent or limit any such disclosure.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000225"></a><a name="_Toc83283282"></a><a name="_Toc256000095"></a><a name="_Toc84000611"></a>14.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exceptions</font><font style="font-weight:normal;">.&nbsp;&nbsp;For the purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;">Confidential Information</font><font style="font-weight:normal;">&#8221; shall not include:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Confidential Information which is or becomes public knowledge (through no fault of the Parties or their Representatives in violation hereof); </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Confidential Information which is lawfully made available to a Party by an independent third party (and such lawful availability can be properly demonstrated);</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Confidential Information which is already in a Party's possession at the time of initial receipt from the other Party (and such prior possession can be demonstrated by competent evidence); or </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Confidential Information which is independently developed by a Party or its Representatives and such independent development can be demonstrated by competent evidence. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000226"></a><a name="_Toc83283283"></a><a name="_Toc256000096"></a><a name="_Toc84000612"></a><a name="_Ref81830932"></a>14.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Disclosures Required by Applicable Law</font><font style="font-weight:normal;">.&nbsp;&nbsp;Either Party may disclose Confidential Information which is required to be disclosed by applicable Laws or order of any Government Authority to be disclosed; provided, however,</font><font style="font-style:italic;font-weight:normal;"> </font><font style="font-weight:normal;">that the Party so disclosing shall, give the other Party as much prior written notice as reasonably practicable to permit it to seek a protective order or other similar order with respect to the Confidential Information and, thereafter, shall disclose only the minimum Confidential Information required to be disclosed in order to comply, whether or not the other Party seeks or obtains any such protective or other similar order.&nbsp;&nbsp;Notwithstanding the foregoing, information disclosed as set forth in this Section 14.4 shall not be disclosed to any other Third Party without the prior written consent of the disclosing Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000227"></a><a name="_Toc83283284"></a><a name="_Toc256000097"></a><a name="_Toc84000613"></a>14.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Injunctive Relief</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party acknowledges and agrees that its breach of the</font> <font style="font-weight:normal;">confidentiality and non-use obligations set forth herein may cause irreparable harm to the disclosing Party which would not be fully compensable by payment of money damages alone, and that in the event of such a breach or threatened breach the disclosing Party shall be entitled to seek equitable relief (including, without limitation, injunctive relief), without the necessity of proving actual damages or posting a bond.&nbsp;&nbsp;Such equitable relief shall be in addition to and not in lieu of any other relief available to the disclosing party at law or in equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000228"></a><a name="_Toc83283285"></a><a name="_Toc256000098"></a><a name="_Toc84000614"></a>14.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Ownership of Confidential Information</font><font style="font-weight:normal;">.&nbsp;&nbsp;All Confidential Information which either Party or any of its Representatives shall obtain or to which either Party or any such Representative shall be given access pursuant to or in connection with this Agreement, shall be and remain the sole property of the disclosing Party, and the receiving Party shall have no rights or interests (except as expressly provided herein) to or in such Confidential Information. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000229"></a><a name="_Toc83283286"></a><a name="_Toc256000099"></a><a name="_Toc84000615"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.7</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Return or Destruction of Confidential Information</font><font style="font-weight:normal;">.&nbsp;&nbsp;Immediately upon the expiration or earlier termination of this Agreement, the receiving Party shall, at the other Party&#8217;s option, return to the disclosing Party, or provide a certificate of one of its Executive Officers as to the destruction of all Confidential Information (including all copies thereof) then in the possession of the receiving Party or any of its Representatives.&nbsp;&nbsp;Each Party may retain one (1) archival copy of such Confidential Information, which Confidential Information shall be subject to the confidentiality obligations set forth in this Article 14.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000230"></a><a name="_Toc83283287"></a><a name="_Toc256000100"></a><a name="_Toc84000616"></a>14.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Data Protection</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party shall comply with their respective obligations under applicable Data Protection Laws.&nbsp;&nbsp;Where one Party discloses personal data to the respective other Party, the disclosing Party is responsible to ensure meeting all conditions that are legally required to allow this disclosure for purposes of this Agreement (including medical and diagnostic research and development purposes).&nbsp;&nbsp;If such disclosure may include transfer of personal data from the European Economic Area (EEA) to a non-adequate country as defined by the General Data Protection Regulation 2016/679 (GDPR) such a transfer will require the prior conclusion of a specific agreement between the Parties, which they expressly accept, </font><font style="color:#000000;font-weight:normal;">providing for the implementation of the most appropriate transfer mechanism in order to comply with the provisions of the GDPR related to export of personal data outside EEA. </font><font style="font-weight:normal;"> Additionally, this disclosure may include, e.g., ensuring that respective Data Subjects have given and not withdrawn their consents, or anonymizing or de-identifying the human personal data prior to disclosure.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000231"></a><a name="_Toc83283288"></a><a name="_Toc256000101"></a><a name="_Toc84000617"></a>14.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Publications</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Atara shall have the right to publish any information, data, or results obtained by Atara independently of this Agreement with respect to the Product in written, oral or other form and in any forum, provided that it shall provide prior notice to Partner with respect to any new Development Data that it intends to publish. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk95480821"></a>(b)<font style="margin-left:36pt;"></font>If either Party (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Publishing Party</font>&#8221;) wishes to publish any information, data or results regarding the Product in the Field in the Territory obtained from activities authorized under this Agreement, including any Development Data resulting from the Current Studies in any scientific journals or scientific conferences, a manuscript of the proposed publication shall first be sent to the other Party (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Receiving Party</font>&#8221;) at least [***]<a name="_Hlk95480821"></a> in advance of such publication for review.&nbsp;&nbsp;The Publishing Party shall consider in good faith the Receiving Party&#8217;s comments during this [***] period and unless the Receiving Party informs the Publishing Party in writing during this [***] period that the proposed publication must be delayed in order to protect a patentable invention or changed to avoid disclosure of the Receiving Party&#8217;s Confidential Information or adjusted (to the extent scientifically reasonable) to avoid any materially adverse impact on the Development or Commercialization of the Product, the Publishing Party shall be free to publish such results.&nbsp;&nbsp;In the event that a delay of the proposed publication is required, the Publishing Party shall withhold such submission for publication for one additional period, up to [***], or such other period as the Parties may mutually agree. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>If a Party intends to present any information, data or results regarding activities relating to the Product in the Field in the Territory, including any Development Data resulting from the Current Studies, at symposia or other meetings of healthcare professionals, or international and/or US or European congresses, conferences or meetings organized by a </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">professional society or organization, the provision of subclause (b) shall apply </font><font style="font-style:italic;">mutatis mutandis</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to (</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) all abstracts that will be submitted for publication (ii) all draft slide presentations for use in oral presentations, and (iii) all posters that will be presented at such Scientific Meeting, provided that the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review period referred to in subclause (b) shall be reduced to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000232"></a><a name="_Toc83283289"></a><a name="_Toc256000102"></a><a name="_Toc84000618"></a><a name="_Ref81819808"></a>14.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Publicity</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Parties shall agree on a joint press release in relation to the execution of this Agreement, following the public dissemination of which (i) either Party may make subsequent public disclosure of the contents of such statement, in a manner reasonably consistent with such contents, without the further approval of the other Party, and (ii) each Party shall be entitled to refer publicly to the relationship of the Parties reflected in this Agreement in a manner that is consistent with the joint press release issued by the parties.&nbsp;&nbsp;All other publicity, press releases and other announcements relating to this Agreement or the transactions contemplated hereby, including any announcement that discloses the existence of this Agreement or any Development or Commercialization activities with respect to the Product in the Field and in the Territory, shall be reviewed in advance by and subject to the approval of both Parties, which approval shall not be unreasonably withheld; except that:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>nothing in this Section 14.10 shall prevent a Party from promptly making all disclosures and filings with Government Authorities as may, in its judgement be required or advisable in connection with the execution and delivery of this Agreement or the consummation of and the performance thereof the transactions contemplated hereby, including, without limitation, disclosures required by the rules and regulations of the SEC, other Government Authority, or applicable stock exchange, provided that except where prohibited by applicable Law or exigent circumstances, the receiving Party takes reasonable best efforts to provide the disclosing Party at least [***] prior written notice of such disclosure (and the right to review and comment on the proposed disclosure), and discloses only that portion of the Confidential Information that the receiving Party is legally required to disclose in the receiving Party&#8217;s legal counsel opinion;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>to the extent that this Agreement and one or more of the Ancillary Agreements may need to be filed by Atara with the SEC, Atara shall, prior to making any such filing with the SEC, provide Partner and its counsel with a proposed redacted version of this Agreement (and any other Ancillary Agreement, as applicable) which it intends to file with the SEC and to give due consideration to any comments provided by Partner or its counsel and use reasonable efforts to obtain confidential treatment for such required disclosure;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>following the filing of the Agreement or any Ancillary Agreement with the SEC, Atara may describe or refer to portions of the Agreement or any Ancillary Agreement for which confidential treatment is not obtained from the SEC without the prior review or approval of Partner;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Atara may, only as required by the rules and regulations of the SEC or applicable stock exchange, disclose the Net Sales set forth in any Royalty Report in any earnings release, quarterly report or annual report, as the case may be, in each case without the prior review or consent of Partner; and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either Party shall be free, without the consent of the other Party, to continue to publicly disclose materials previously approved by the other Party to the extent such materials are substantially in the same form as previously approved.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000233"></a><a name="_Toc83283290"></a><a name="_Toc256000103"></a><a name="_Toc84000619"></a>Article 15<br /><br /><a name="_Toc256000233"></a><a name="_Toc83283290"></a><a name="_Toc256000103"></a><a name="_Toc84000619"></a>Subcontracting</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000234"></a><a name="_Toc83283291"></a><a name="_Toc256000104"></a><a name="_Toc84000620"></a><a name="_Ref81916049"></a>15.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Atara</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to the terms and conditions of this Agreement, including, without limitation, Section 15.3 hereto, Atara shall have the right to carry out all or any part of its obligations under this Agreement or any Ancillary Agreement through its subsidiaries, Affiliates or one or more Third Party subcontractors, with prior notice to the JSC with respect to the primary CRO responsible for operating the Clinical Studies and prior approval of the JSC with respect to Manufacturing entities other than the Atara Manufacturing Facilities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000235"></a><a name="_Toc83283292"></a><a name="_Toc256000105"></a><a name="_Toc84000621"></a>15.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Partner</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Subject to the terms and conditions of the Agreement, including, without limitation, Section 15.3 hereto, Partner shall have the right to carry out all or any part of its obligations under this Agreement or any Ancillary Agreement through (i) its Affiliates and Approved Sublicensees, and Distributors, or (ii) one or more Third Party subcontractor(s) that do not require a license under the Atara Intellectual Property to perform appointed activities under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000236"></a><a name="_Toc83283293"></a><a name="_Toc256000106"></a><a name="_Toc84000622"></a><a name="_Ref81830981"></a>15.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Responsibility For Subcontractors</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Each Party shall ensure that each of its subcontractors or Approved Sublicensees (as applicable), if any, accepts and complies with all of the terms and conditions of this Agreement and such Party shall be responsible for all acts of such subcontractors or Approved Sublicensees as if such acts were its own. </font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc256000237"></a><a name="_Ref81831001"></a><a name="_Toc83283294"></a><a name="_Toc256000107"></a><a name="_Toc84000623"></a>Article 16<br /><br /><a name="_Toc256000237"></a><a name="_Ref81831001"></a><a name="_Toc83283294"></a><a name="_Toc256000107"></a><a name="_Toc84000623"></a>Term and Termination</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000238"></a><a name="_Toc83283295"></a><a name="_Toc256000108"></a><a name="_Toc84000624"></a><a name="_Ref81820088"></a><a name="_Ref424658557"></a>16.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement will commence on the Effective Date and, unless earlier terminated under this Article 16 shall expire following the last Commercial Sale of the Product in the Field in the Territory by Partner, its Affiliates or their Approved Sublicensees (the &#8220;</font><font style="text-decoration:underline;">Term</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000239"></a><a name="_Ref424661752"></a><a name="_Toc83283296"></a><a name="_Toc256000109"></a><a name="_Toc84000625"></a>16.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Material Breach, Transfer or Assignment, Insolvency Event</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref83409063"></a><a name="_Ref81820184"></a>(a)<font style="margin-left:36pt;"></font>Either Party may terminate this Agreement in the event of a material breach by the other Party of any material obligation of this Agreement in the overall context of the Agreement on [***] prior written notice to the other, specifying the nature of the breach, unless such other Party shall (i) cure such default within such [***] period or, (ii) if not capable of being remedied within such [***] period, communicate to the non-breaching Party a written remediation plan reasonably designed to cure such breach or default within a reasonable additional time period, not to exceed an additional [***] following expiration of the foregoing [***]<a name="_Ref81820184"></a> period and diligently seeks to remedy the breach in accordance with the remediation plan.&nbsp;&nbsp;If the allegedly breaching Party disputes in good faith the material breach, this Agreement shall not be terminable by the non-breaching Party until it has been determined by arbitration under Section 17.10(c) that this </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement was materially breached by the breaching Party and then only if the breaching Party has not cured such material breach within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following such arbitration determination.&nbsp;&nbsp;If the material breach is due to an Approved Sublicensee or Distributor of Partner, the termination of the license or sublicense with such Approved Sublicensee or Distributor within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the notice of breach would be deemed to cure such breach for the purposes of this Section 16.2(a).</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Notwithstanding the provisions of Section 16.2(a), either Party may terminate this Agreement <font style="color:#000000;">on written notice with immediate effect upon the Insolvency Event of the other Party.&nbsp;&nbsp;All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to intellectual property as defined in Section 101 of such Code.&nbsp;&nbsp;The Parties agree that Partner may fully exercise all of its rights and elections under the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a Party or its assets.&nbsp;&nbsp;The Parties further agree that, in the event Partner elects to retain its rights as a licensee under such Code, Partner shall be entitled to complete access to any Licensed Intellectual Property and all embodiments of such technology.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000240"></a><a name="_Toc83283297"></a><a name="_Toc256000110"></a><a name="_Toc84000626"></a><a name="_Ref424662002"></a><a name="_Toc83283298"></a><a name="_Ref81915298"></a>16.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Patent Challenge</font>.&nbsp;&nbsp;<font style="font-weight:normal;">If Partner commences or actively participates in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts in writing any claim challenging or denying the validity or enforceability of any patent claim in the Atara Intellectual Property, then Atara shall have the right, in its sole discretion, to terminate this Agreement upon providing Partner [***]<a name="_Toc83283298"></a><a name="_Ref81915298"></a> prior written notice of termination. In addition to all other rights and remedies available to Atara for any breach of this provision by Partner, in the event that any such challenge is not successful, then Partner shall reimburse Atara for all costs and expenses, including but limited to attorney&#8217;s fees, incurred by Atara incurred as a result of defending against such challenge. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000241"></a><a name="_Toc256000111"></a><a name="_Toc84000627"></a>16.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Convenience by Partner</font><font style="font-weight:normal;">.&nbsp;&nbsp;Partner shall be permitted to terminate this Agreement at will (a) in [***], or (b) on a country-by-country basis outside the [***] with [***] prior written notice to Atara in the Pre-Transfer Period and [***] prior written notice to Atara in the Post-Transfer Period.&nbsp;&nbsp;During the period after providing Atara a notice to terminate pursuant to this Section 16.4 and prior to the effective date thereof, this Agreement will remain in full force and effect with respect to such terminated country(ies) and Partner shall continue (and shall cause all its Affiliates, Approved Sublicensees and Distributors to continue) to perform Partner&#8217;s obligations and applicable activities under this Agreement in such country(ies).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000242"></a><a name="_Toc84000628"></a>16.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination by Mutual Agreement</font><font style="font-weight:normal;">.&nbsp;&nbsp;In the event that by [***], (a) no Marketing Authorization has been obtained for the Product in the European Territory and (b) there is no ongoing Development for a Product for Commercialization in the Field in the Territory, the Parties shall discuss in good faith the terms and conditions under which the Agreement may be terminated by their mutual agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000243"></a><a name="_Toc83283299"></a><a name="_Toc256000113"></a><a name="_Toc84000629"></a><a name="_Ref81820286"></a><a name="_Ref82957940"></a>16.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination for Safety Reasons</font>.&nbsp;&nbsp;<font style="font-weight:normal;">Partner shall be permitted to terminate the Agreement for Safety Reasons upon [***] written notice to Atara, but only after consulting with Atara at least [***] on Partner&#8217;s assessment with respect to such Safety Reasons.&nbsp;&nbsp;In this regard, &#8220;</font><font style="text-decoration:underline;">Safety Reasons</font><font style="font-weight:normal;">&#8221; shall mean that, based upon all relevant scientific data, there are safety and public health issues relating to the Product such that the medical benefit/risk ratio of such Product </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">is sufficiently unfavorable as to materially compromise the welfare of patients so that use in patients is no longer justifiable</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000244"></a><a name="_Toc84000630"></a>16.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Alternative to Termination for Material Breach</font><font style="font-weight:normal;">. If Atara has materially breached or defaulted in the performance of any of its material obligations hereunder with respect to Regulatory Filings and Regulatory Interactions during the Pre-Transfer Period, and Manufacturing and Cell Selection services during the Term, or of its obligations in Sections 8.13 and 8.14, and such breach is not curable or has not been cured within the cure period in Section 16.2 after written notice thereof was provided by Partner, then, [***].</font> </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000245"></a><a name="_Ref81820326"></a><a name="_Toc83283300"></a><a name="_Toc256000114"></a><a name="_Toc84000631"></a>16.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Consequences of Termination</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Accrued Obligations</font>.&nbsp;&nbsp;The termination of this Agreement by either Party shall not release the other Party from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination, nor will any such termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement, provided that any milestone payment that is achieved under Article 11.2(b) and (c) during the termination notice period shall not be due. </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81820387"></a><a name="_Ref81915444"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Rights on Termination of Agreement</font>.&nbsp;&nbsp;In case of termination of this Agreement by either Party (unless as otherwise specified), this Section 16.8(b) shall apply:</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Wind-down Period</font>.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font>Partner shall use Commercially Reasonable Efforts to effect a smooth termination of the Agreement, including by performing the activities set forth in Sections 16.8(b)(i)(3), (4) and (5), for a period not exceeding [***] following the termination of the Agreement (&#8220;<font style="font-weight:bold;text-decoration:underline;">Transition Period</font>&#8221;).</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;"></font>Partner shall return to Atara, [***], in resalable form its remaining inventory of the Product in the Territory following the termination of this Agreement during the Transition Period.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;"></font>In the event Partner is the sponsor of or is responsible for conducting any on-going Clinical Studies of the Product following the date a notice of termination has been issued by Atara or Partner, as applicable, Partner shall be entitled to complete or wind down such activities, unless Atara requests that they be transitioned to Atara, in which case Partner shall use Commercially Reasonable Efforts to support such transition to Atara, [***].</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)<font style="margin-left:36pt;"></font>Each Party shall use Commercially Reasonable Efforts to cooperate with the other to effect a smooth and orderly wind down or transition in of the activities related to the Product in the Territory during the Transition Period.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)<font style="margin-left:36pt;"></font>Partner shall provide Atara with country-specific Promotional Materials for use limited to the Product, excluding any trademarks and logos that are specific to Partner.&nbsp;&nbsp;Partner agrees to provide Atara with country-specific Promotional Materials and to assign on reasonable commercial terms to be agreed by the Parties all worldwide rights in </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and to any Product Trademarks, other than Product Trademarks of Atara, specific to the Product that Partner or any of its Affiliates used in connection with Product(s).&nbsp;&nbsp;It is understood that such assignment shall not include the name of Partner or any of its Affiliates, nor the corporate logo, service mark, or trademark for Partner or for any of its Affiliates as a corporate entity.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:12pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Licenses</font>.&nbsp;&nbsp;Upon termination of this Agreement in all or part by either Party, subject to the provisions of Section 16.8(b)(i), all licenses granted by Atara to Partner, including any license to Manufacture Product in the Territory or use Atara trademarks and associated web domains, shall terminate, and Partner and its Affiliates and Approved Sublicensees shall cease all Commercialization activities under this Agreement, in each case, with respect to the terminated countries.&nbsp;&nbsp;Further, the following provisions shall apply to the terminated countries of the Territory: </p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk80276237"></a>(1)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment of Regulatory Filings and Market Authorizations</font><a name="_Hlk80276237"></a>.&nbsp;&nbsp;Partner shall assign, or cause to be assigned) to Atara any and all Regulatory Filings and Market Authorizations held in Partner&#8217;s name and relating to Product (or to the extent not so assignable, Partner shall take all reasonable actions to make available to Atara the benefits of) all Regulatory Filings and Market Authorizations for the Product in the terminated countries.&nbsp;&nbsp;In each case, unless otherwise required by any applicable Law or regulation or requested by Atara, the foregoing assignment (or availability) shall be made within a reasonable period of time mutually agreed between the Parties.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Approved Sublicensees</font>.&nbsp;&nbsp;Any contracts with Approved Sublicensees in the terminated countries engaged by Partner shall be assigned to Atara to the furthest extent possible.&nbsp;&nbsp;Partner shall use Commercially Reasonable Efforts, and cause its Affiliates to use Commercially Reasonably Efforts, to waive any exclusive dealing obligations of such Approved Sublicensee with respect to such Approved Sublicensee agreement, and to provide to Atara information relevant to the Approved Sublicensee agreement and make introductions to such Approved Sublicensee so that Atara may enter into direct discussions with such Approved Sublicensee to secure the relevant items or services.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Partner Trademarks</font>.&nbsp;&nbsp;Upon the effective date of termination, Partner agrees to assign on reasonable commercial terms to be agreed by the Parties all rights in and to any trademarks owned by Partner that are specific to the Product that Partner, its Affiliates, and Approved Sublicensees used in connection with the Product in terminated countries.&nbsp;&nbsp;It is understood that such assignment shall not include the name of Partner or any of its Affiliates or Approved Sublicensees, nor the corporate logo, service mark, or trademark for Partner or for any of its Affiliates or Approved Sublicensees as a corporate entity.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Partner Intellectual Property</font>.&nbsp;&nbsp;Partner shall and hereby does grant to Atara a non-exclusive, worldwide, transferable, perpetual and irrevocable license, with the right to sublicense through multiple tiers Partner Intellectual Property as it exists at the time of such termination of this Agreement and that are necessary to Develop, Manufacture, Commercialize and otherwise use the Product in the Field in terminated countries, and solely to Develop, Manufacture, Commercialize and otherwise use the Product in the Field in terminated countries subject to Atara&#8217;s making the payment set forth in Section 11.12; provided however, that </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if termination is due to a material breach by Partner under Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.2(a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then the foregoing license shall be provided on a fully paid basis.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000246"></a><a name="_Toc83283301"></a><a name="_Toc256000115"></a><a name="_Toc84000632"></a><a name="_Ref424662017"></a><a name="_Toc519934805"></a>16.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination Not Sole Remedy</font>.<font style="font-weight:normal;"><a name="_Toc519934805"></a>&nbsp;&nbsp;Termination is not the sole remedy under this Agreement and, whether or not termination is affected and notwithstanding any provision contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein.</font></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc519935630"></a><a name="_Toc519934864"></a><a name="_Toc221533306"></a><a name="_Toc256000247"></a><a name="_Ref424661910"></a><a name="_Toc83283302"></a><a name="_Toc256000116"></a><a name="_Toc84000633"></a>Article 17<br /><br /><a name="_Toc256000247"></a><a name="_Ref424661910"></a><a name="_Toc83283302"></a><a name="_Toc256000116"></a><a name="_Toc84000633"></a>General Provisions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000248"></a><a name="_Toc83283303"></a><a name="_Toc256000117"></a><a name="_Toc84000634"></a>17.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement and the Additional Agreements, together with the Exhibits and all written amendments, modifications and supplements thereto constitute the entire agreement between the Parties and all prior negotiations, proposals and writings pertaining to this Agreement or the subject matter thereof, are hereby superseded.&nbsp;&nbsp;No modification of this Agreement will be effective unless in writing and signed by both Parties. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000249"></a><a name="_Toc83283304"></a><a name="_Toc256000118"></a><a name="_Toc84000635"></a>17.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>.&nbsp;&nbsp;<font style="font-weight:normal;">In the event that any provision of the Agreement or the documents and instruments contemplated hereby is held by court of competent jurisdiction to be invalid, prohibited or unenforceable for any reason, unless narrowed by construction, the Agreement and the documents and instruments contemplated hereby shall be construed as if such invalid, prohibited or unenforceable provision had been more narrowly drawn so as not to be invalid, prohibited or unenforceable, or if such language cannot be drawn narrowly enough to satisfy such court, the court making any such determination shall have the power to modify in scope, duration or otherwise any such provision, but only to the extent necessary to make such provision or provisions enforceable in such court, and such provision then shall be applicable in such modified form.&nbsp;&nbsp;No narrowed construction, court modification, or invalidation of any provision of the Agreement and the documents and instruments contemplated hereby shall affect the construction, validity, or enforceability of such provision or of the Agreement and the documents and instruments contemplated hereby in any jurisdiction other than that upon which the decision of the court of competent jurisdiction shall govern. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000250"></a><a name="_Toc83283305"></a><a name="_Toc256000119"></a><a name="_Toc84000636"></a><a name="_Ref81915552"></a>17.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement may not be assigned by either to any person, firm, partnership, corporation or other entity (including by operation of law, judicial process or otherwise) without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, provided that each Party may assign this Agreement, or any or all of the rights and obligations hereunder, to upon [***] written notice (a) without obtaining the other Party&#8217;s prior written consent, to any of its Affiliates for as long as such entity remains an Affiliate, (b) in the case of Atara, without obtaining the Partner&#8217;s prior written consent, to (i) an entity that acquires all or substantially all of the equity interests, business or assets to which this Agreement relates, whether by merger, acquisition, reorganization or otherwise, or (ii) to an entity located in the USA, European Union or United Kingdom solely with respect to the transfer or assignment of rights to receive payments (or any portion thereof) due to Atara under Sections 11.2, 11.3 and 11.4 (and subject to set off rights as applicable), provided that, in connection with such a transfer or assignment, Atara may disclose to the transferee or assignee any reports or information provided to Atara regarding such payments under a written agreement </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">containing non-disclosure and non-use provisions no less stringent than set forth in this Agreement, and </font><font style="font-style:italic;font-weight:normal;">provided further</font><font style="font-weight:normal;"> that if Partner reasonably believes the assignment in (ii) would materially and adversely affect Partner&#8217;s ability to perform its obligations under this Agreement, the Partner shall be entitled to refuse such assignment; and (c) in the case of Partner, without obtaining Atara&#8217;s prior written consent, to an entity that acquires all or substantially all of the equity interests, business or assets of Partner or Partner&#8217;s commercial franchise within Partner&#8217;s organization in which the Product is operated, whether by merger, acquisition, reorganization or otherwise.&nbsp;&nbsp;This Agreement shall be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns.&nbsp;&nbsp;Any assignment not in accordance with this Section </font><font style="font-weight:normal;">17.3</font><font style="font-weight:normal;"> shall be null and void.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000251"></a><a name="_Toc83283306"></a><a name="_Toc256000120"></a><a name="_Toc84000637"></a>17.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts and by each of the Parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.&nbsp;&nbsp;Signatures of the Parties transmitted by electronic means shall be deemed to be their original signatures for all purposes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000252"></a><a name="_Toc83283307"></a><a name="_Toc256000121"></a><a name="_Toc84000638"></a>17.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Third Party Beneficiaries</font><font style="font-weight:normal;">.&nbsp;&nbsp;Memorial Sloan Kettering Cancer Center is a Third Party beneficiary of this Agreement solely to the extent required in the Existing Agreement.&nbsp;&nbsp;Otherwise, this Agreement and each and every provision hereof and thereof are for the exclusive benefit of the Parties hereto and not for the benefit of any other third party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000253"></a><a name="_Toc83283308"></a><a name="_Toc256000122"></a><a name="_Toc84000639"></a>17.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Force Majeure</font><font style="font-weight:normal;">.&nbsp;&nbsp;If the performance of any part of this Agreement (except for any payment obligation under this Agreement) by either Party is prevented, restricted, interfered with or delayed by reason of any cause beyond the reasonable control of such Party (including, fire, flood, earthquake, tsunami, embargo, power shortage or failure, acts of war, pandemic, insurrection, riot, terrorism, strike, lockout or other labor disturbance, acts of God or any acts, omissions or delays in acting of the other Party), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000254"></a><a name="_Toc83283309"></a><a name="_Toc256000123"></a><a name="_Toc84000640"></a>17.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Applicable Law</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Parties agree to conduct all activities under this Agreement in compliance with applicable Law.&nbsp;&nbsp;This Agreement will be governed by and in accordance with [***] without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000255"></a><a name="_Toc83283310"></a><a name="_Toc256000124"></a><a name="_Toc84000641"></a>17.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Waiver</font><font style="font-weight:normal;">.&nbsp;&nbsp;Neither Party&#8217;s failure to insist on performance of any term, condition, or instruction nor failure to exercise any right or privilege or its waiver of any breach, shall thereafter be construed to constitute a waiver of such term, condition, instruction, right or privilege.&nbsp;&nbsp;No consent or waiver, expressed or implied, by a Party to the performance by the other Party or of any breach or default by the other Party of its obligations hereunder shall be deemed or construed to be a consent or waiver to or of any other breach or default in the performance by such other Party of the same or any other obligations of such other Party hereunder.&nbsp;&nbsp;The giving of consent by a Party in any one instance shall not limit or waive the necessity to obtain such Party's consent in </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">any future instance.&nbsp;&nbsp;No waiver of any rights under this Agreement shall be binding unless it is in writing and signed by the Party waiving such rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000256"></a><a name="_Toc83283311"></a><a name="_Toc256000125"></a><a name="_Toc84000642"></a><a name="_Ref81818179"></a>17.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font><font style="font-weight:normal;">.&nbsp;&nbsp;Unless otherwise agreed by the Parties or specified in this Agreement, all communications between the Parties relating to, and all written documentation to be prepared and provided under, this Agreement shall be in the English language.&nbsp;&nbsp;Any notice required or permitted under this Agreement shall be in writing in the English language, and (a) delivered personally, (b) sent by air mail or express courier service providing evidence of receipt, postage pre-paid where applicable, or (c) by electronic transmission or facsimile (complete transmission confirmed and a copy promptly sent by another permissible method of providing notice described in paragraph (a) or (b) above), to the following addresses of the Parties (or such other address for a Party as may be specified by like notice):</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">To Atara</font>:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">To Partner</font>:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000257"></a><a name="_Toc83283312"></a><a name="_Ref83641437"></a><a name="_Toc256000126"></a><a name="_Toc84000643"></a>17.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Dispute Resolution</font><font style="font-weight:normal;">. </font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81818233"></a><a name="_Ref81915615"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Referral to Senior Executives</font>.&nbsp;&nbsp;The Parties recognize that a dispute arising out of or in connection with this Agreement (&#8220;<font style="font-weight:bold;text-decoration:underline;">Dispute</font>&#8221;) may from time to time arise during the term of this Agreement.&nbsp;&nbsp;Any such Dispute which cannot be resolved by good faith negotiations shall be referred, by written notice from either Party to the other, to the Executive Officers (or their respective designees) for resolution.&nbsp;&nbsp;The Executive Officers (or their respective designees) shall negotiate in good faith to resolve such Dispute through discussions promptly following such written notice.&nbsp;&nbsp;If the Executive Officers cannot resolve the Dispute within [***] of such written notice, or either Party concludes that the matter will not be so resolved, then, the provisions of Section 17.10(b) shall apply.&nbsp;&nbsp;If the Parties should resolve such Dispute pursuant to the procedures in this Section 17.10(a), a memorandum setting forth their agreement will be prepared and signed by both Parties, if requested by either Party.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81915602"></a><a name="_Ref81915656"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Mediation</font>.&nbsp;&nbsp;If the Executive Officers (or their respective designees) cannot resolve the Dispute during the [***] period pursuant to Section 17.10(a), the Parties shall first refer the dispute to proceedings under the ICC Mediation Rules.&nbsp;&nbsp;Such mediation shall take place in [***] and shall be attended on behalf of each Party for at least one session by a senior businessperson with authority to resolve the Dispute.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref81820154"></a>(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Arbitration</font>.&nbsp;&nbsp;Any Dispute not resolved under the procedures in Section 17.10(b) within [***] following the filing of a request for mediation or within such other period as the parties may agree in writing, such Dispute shall thereafter be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three (3) arbitrators, and the President </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Tribunal shall be nominated according to such Rules of Arbitration of the International Chamber of Commerce.&nbsp;&nbsp;The seat, or legal place, of arbitration shall be Paris, France.&nbsp;&nbsp;The language of the arbitration shall be English.&nbsp;&nbsp;The final award shall be rendered within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the constitution of the tribunal, unless the tribunal determines that the interest of justice requires that such limit be extended.&nbsp;&nbsp;Except as may be required to confirm or enforce a final award, or as may be required by applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:12pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Non-Disclosure of Communications with Internal Counsel</font>.&nbsp;&nbsp;Notwithstanding any rights to the contrary under applicable procedural or substantive rules of Law, any communications exchanged between members of each Party&#8217;s respective legal department and directors, employees or agents in connection with any disputes, investigations, administrative or other proceedings, shall not be requested, produced or otherwise used, to the extent such communications would have been covered by legal privilege and not disclosable, had these communications been exchanged between such Party and its external attorneys.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000258"></a><a name="_Toc83283313"></a><a name="_Toc256000127"></a><a name="_Toc84000644"></a>17.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Headings</font><font style="font-weight:normal;">.&nbsp;&nbsp;Any headings used herein are for convenience in reference only and are not a part of this Agreement, nor shall they in any way affect the interpretation hereof</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000259"></a><a name="_Toc83283314"></a><a name="_Toc256000128"></a><a name="_Toc84000645"></a>17.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Interpretation</font><font style="font-weight:normal;">.&nbsp;&nbsp;The captions to the articles and sections of this Agreement are not a part of this Agreement but are included for convenience of reference and shall not affect its meaning or interpretation.&nbsp;&nbsp;In this Agreement: (a) the word &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221; or like expression; and (b) the singular shall include the plural and vice versa.&nbsp;&nbsp;Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under generally accepted cost accounting principles, but only to the extent consistent with its usage and the other definitions in this Agreement.&nbsp;&nbsp;This Agreement shall not confer any benefits on any Third Parties and no Third Party may enforce any term of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000260"></a><a name="_Toc83283315"></a><a name="_Toc256000129"></a><a name="_Toc84000646"></a>17.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Further Assurances</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party hereto agrees that they will without further consideration execute and deliver such other documents and take such other actions as may be reasonably requested by the other Party to consummate more effectively the transactions and agreements contemplated hereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000261"></a><a name="_Toc83283316"></a><a name="_Toc256000130"></a><a name="_Toc84000647"></a>17.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Partnership or Joint Venture</font><font style="font-weight:normal;">.&nbsp;&nbsp;Nothing in this Agreement is intended, or shall be deemed, to establish a joint venture or partnership between Atara and Partner.&nbsp;&nbsp;Neither Party to this Agreement shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc256000262"></a><a name="_Toc83283317"></a><a name="_Toc256000131"></a><a name="_Toc84000648"></a>17.15<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Survival</font><font style="font-weight:normal;">.&nbsp;&nbsp;The following provisions of this Agreement, as well as the provisions of this Agreement which by their nature are intended to survive the termination, cancellation, completion or expiration of this Agreement, shall continue as valid and enforceable obligations of the Parties notwithstanding any such termination, cancellation, completion or expiration: Article 1 and Sections 2.3, 6.5, 6.6 (solely with respect to the licenses described therein), 7.4(b), 7.6 (solely to the extent that such audit relates to Product Commercialized during the Term), 8.6(a), 10.1, each of 11.8, 11.9, 11.10, and 11.11 (solely to the extent that such reports, records, payments and taxes </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">apply to the period prior to the effective date of termination), 12.7, 13.1-13.3 (solely with respect to Third Party Claims arising during the Term), 13.4, 13.5, 14, 16.8, 16.9, 17. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of page intentionally left blank; signature page follows.]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50.14%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: /s/ Pascal Touchon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Pascal Touchon </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: 10/1/2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.86%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PIERRE FABRE MEDICAMENT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: /s/ Jean-Luc Lowinski</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Jean-Luc Lowinski</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: 10/2/2021</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">List of Exhibits</font>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT A (Approved Sublicensee Countries or Distributor Countries)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT B (Transition Plan)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT C (Key Manufacturing and Supply Terms)</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT D (Atara Patents)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT E (Atara Bank Account Information)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT F (Cell Selection Services)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT G (Product Trademarks)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M442"></a><a name="_DV_M553"></a><a name="_DV_M442"></a><a name="_DV_M553"></a>[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT H (Royalty Report Template)</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Copy</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT I (Atara Officers)</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>3
<FILENAME>atra-ex1036_104.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex1036_104.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SECOND AMENDMENT TO LEASE</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS SECOND AMENDMENT TO LEASE (this &#8220;<font style="font-weight:bold;">Second Amendment</font>&#8221;) is made as of December 9, 2021, by and between <font style="font-weight:bold;color:#000000;">611 GATEWAY CENTER LP, LLC</font>, a Delaware limited partnership (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">ATARA BIOTHERAPEUTICS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Landlord and Tenant are parties to that certain Office Lease dated as of November 25, 2015, as amended by that certain First Amendment to Lease dated as of October 21, 2020 (the &#8220;</font>First Amendment<font style="font-weight:normal;">&#8221;) (as amended, the &#8220;</font>Lease<font style="font-weight:normal;">&#8221;), wherein Landlord leases to Tenant certain premises commonly known as Suite 900, containing approximately 13,670 rentable square feet (the &#8220;</font>Premises<font style="font-weight:normal;">&#8221;) located at 611 Gateway Boulevard, South San Francisco, California, as more particularly described in the Lease.&nbsp;&nbsp;Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, among other things, extend the Base Term of the Lease through May 31, 2025 (the &#8220;</font>Second Amendment Expiration Date<font style="font-weight:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-weight:normal;"> in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Extension of Lease Term</font><font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in the Lease, the expiration date of the Lease Term with respect to the Premises is hereby extended through the Second Amendment Expiration Date.&nbsp;&nbsp;Tenant&#8217;s occupancy of the Premises through the Second Amendment Expiration Date shall be on an &#8220;as-is&#8221; basis, and, except as otherwise set forth in the Work Letter attached to this Second Amendment, Landlord shall have no obligation to provide any tenant improvement allowance or make any alterations to the Premises.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Base Rent.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Generally</font>.&nbsp;&nbsp;Tenant shall continue to pay Base Rent as provided for under the Lease through May 31, 2022 at a rate of $3.90 per rentable square foot of the Premises per month.&nbsp;&nbsp;Commencing on June 1, 2022, Base Rent shall be $4.00 per rentable square foot of the Premises per month.&nbsp;&nbsp;Base Rent shall be increased on June 1, 2023 and on each June 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> thereafter (each, an &#8220;Adjustment Date&#8221;) by multiplying the Base Rent payable immediately before such Adjustment Date by 3% and adding the resulting amount to the Base Rent payable immediately before such Adjustment Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional TI Allowance</font>.&nbsp;&nbsp;In addition to the Tenant Improvement Allowance (as defined in the Work Letter attached hereto as Exhibit A), Landlord shall, subject to the terms of the Work Letter, make available to Tenant the Additional Tenant Improvement Allowance (as defined in the Work Letter).&nbsp;&nbsp;Commencing on the date Tenant Improvements are Substantially Completed and continuing thereafter on the first day of each month during the Base Term, Tenant shall pay the amount necessary to fully amortize the portion of the Additional Tenant Improvement Allowance actually funded by Landlord, if any, in equal monthly payments with interest at a rate of 7% per annum over the Base Term, which interest shall begin to accrue on the date that Landlord first disburses such Additional Tenant Improvement Allowance or any portion(s) thereof (&#8220;TI Rent&#8221;).&nbsp;&nbsp;Any TI Rent remaining unpaid as of the expiration or earlier termination of this Lease shall be paid to Landlord in a lump sum at the expiration or earlier termination of this Lease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;">Tenant Improvements</font><font style="font-weight:normal;">.&nbsp;&nbsp;Following the date of this Second Amendment, Landlord and its contractors and agents shall have the right to enter the Premises to complete Landlord&#8217;s Work (as defined in the Work Letter) pursuant to the Work Letter, and Tenant shall reasonably cooperate with Landlord in connection with the same.&nbsp;&nbsp;Tenant acknowledges that Landlord's completion of Landlord&#8217;s Work may adversely affect Tenant&#8217;s use and occupancy of the Premises.&nbsp;&nbsp;Landlord agrees to use reasonable efforts to perform Landlord&#8217;s Work in a manner which does not unreasonably interfere with or cause a material disturbance of Tenant&#8217;s use of the Premises and to cooperate and coordinate with Tenant to schedule any activities which are reasonably likely to cause a material disturbance with Tenant&#8217;s use of the Premises in order for Tenant to reasonably mitigate such interference; provided, however, that Tenant recognizes that construction noise and vibrations associated with normal construction activities are to be expected during the course of Landlord&#8217;s Work.&nbsp;&nbsp;Tenant waives all claims for rent abatement against Landlord in connection with the construction of Landlord&#8217;s Work.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Base Year</font><font style="font-weight:normal;">.&nbsp;&nbsp;For the period of the Lease Term between June 1, 2022 through the Second Amendment Expiration Date, the Base Year of the Lease shall mean calendar year 2022.&nbsp;&nbsp;For the avoidance of any doubt, Tenant shall not, during the period between June 1, 2022 and December 31, 2022, be required to pay any Excess.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Security Deposit</font><font style="font-weight:normal;">.&nbsp;&nbsp;The defined term &#8220;</font>Letter of Credit<font style="font-weight:normal;">&#8221; on page 2 of the Lease shall be deleted in its entirety and replaced with the following:</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Letter of Credit (Article 21)</font>: $145,750.17&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord currently holds a L-C in the amount of $194,333.56 under the Lease. Landlord shall cooperate with Tenant, at no cost, expense or liability to Landlord, to reduce the L-C currently held by Landlord to the amount set forth above.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">No Right to Extend</font><font style="font-weight:normal;">.&nbsp;&nbsp;As of the date of this Second Amendment, </font><font style="text-decoration:underline;font-weight:normal;">Section 5</font><font style="font-weight:normal;"> of the First Amendment is hereby deleted in its entirety and is null and void and of no further force or effect.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Brokers</font><font style="font-weight:normal;">.&nbsp;&nbsp;Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font>Broker<font style="font-weight:normal;">&#8221;) in connection with the transaction reflected in this Second Amendment and that no Broker brought about this transaction, other than Cushman &amp; Wakefield and Newmark Knight Frank.&nbsp;&nbsp;Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than Cushman &amp; Wakefield and Newmark Knight Frank, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Second Amendment.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">California Accessibility Disclosure</font><font style="font-weight:normal;">.&nbsp;&nbsp;For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project has not undergone inspection by a Certified Access Specialist (CASp).&nbsp;&nbsp;In addition, the following notice is hereby provided pursuant to Section 1938(e) of the California Civil Code:&nbsp;&nbsp;&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law.&nbsp;&nbsp;Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant.&nbsp;&nbsp;The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;&nbsp;&nbsp;In furtherance of and in connection with such notice:&nbsp;&nbsp;(i) Tenant, having read such notice and understanding Tenant&#8217;s right to request and obtain a CASp inspection, hereby </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="font-weight:normal;">elects not to obtain such </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection and forever waives its rights to obtain a </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection with respect to the Premises, Building and/or Project to the extent permitted by Legal Requirements; and (ii) if the waiver set forth in clause (</font><font style="font-weight:normal;">i</font><font style="font-weight:normal;">) hereinabove is not enforceable pursuant to Legal Requirements, then Landlord and Tenant hereby agree as follows (which constitutes the mutual agreement of the parties as to the matters described in the last sentence of the foregoing notice):&nbsp;&nbsp;(A) Tenant shall have the one-time right to request for and obtain a </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection, which request must be made, if at all, in a written notice delivered by Tenant to Landlord; (B) any </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection timely requested by Tenant shall be conducted (1) at a time mutually agreed to by Landlord and Tenant, (2) in a professional manner by a </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> designated by Landlord and without any testing that would damage the Premises, Building or Project in any way, and (3) at Tenant&#8217;s sole cost and expense, including, without limitation, Tenant&#8217;s payment of the fee for such </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection, the fee for any reports prepared by the </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> in connection with such </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection (collectively, the &#8220;</font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> Reports&#8221;) and all other costs and expenses in connection therewith; (C) the </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> Reports shall be delivered by the </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> simultaneously to Landlord and Tenant; (D) Tenant, at its sole cost and expense, shall be responsible for making any improvements, alterations, modifications and/or repairs to or within the Premises to correct violations of construction-related accessibility standards including, without limitation, any violations disclosed by such </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection; and (E) if such </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection identifies any improvements, alterations, modifications and/or repairs necessary to correct violations of construction-related accessibility standards relating to those items of the Building and Project located outside the Premises that are Landlord&#8217;s obligation to repair as set forth in this Lease, then Landlord shall perform such improvements, alterations, modifications and/or repairs as and to the extent required by Legal Requirements to correct such violations, and Tenant shall reimburse Landlord for the cost of such improvements, alterations, modifications and/or repairs within 10 business days after Tenant&#8217;s receipt of an invoice therefor from Landlord.</font><font style="font-weight:normal;">&nbsp;&nbsp;Landlord and Tenant expressly acknowledge and agree that the foregoing provisions of this </font><font style="text-decoration:underline;font-weight:normal;">Section 8</font><font style="font-weight:normal;"> shall apply only </font><font style="font-weight:normal;">in the event that</font><font style="font-weight:normal;"> Tenant elects to obtain a </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection.&nbsp;&nbsp;</font><font style="font-weight:normal;">In the event that</font><font style="font-weight:normal;"> Tenant does not elect to obtain a </font><font style="font-weight:normal;">CASp</font><font style="font-weight:normal;"> inspection, the terms and provisions of this </font><font style="text-decoration:underline;font-weight:normal;">Section 8</font><font style="font-weight:normal;"> regarding the allocation of costs for alterations and improvements shall not be applicable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">OFAC</font><font style="font-weight:normal;">.&nbsp;&nbsp;Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font>OFAC<font style="font-weight:normal;">&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;</font>OFAC Rules<font style="font-weight:normal;">&#8221;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;"><font style="text-decoration:underline;">Miscellaneous</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font>This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.  Reference to the Lease in this Second Amendment shall mean the Lease as amended by this Second Amendment.  This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font>Once executed by both parties, this Second Amendment is binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font>This Second Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.&nbsp;&nbsp;Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.&nbsp;&nbsp;Electronic signatures shall be deemed original s</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ignatures for purposes of this </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Amendment</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and all matters related thereto, with such electronic signatures having the same legal effect as original signatures</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.<font style="margin-left:36pt;"></font>Except as amended and/or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment.&nbsp;&nbsp;In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment shall prevail.&nbsp;&nbsp;Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">[Signatures are on the next page]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF</font><font style="font-weight:normal;">, the parties hereto have executed this </font><font style="font-weight:normal;">Second Amendment</font><font style="font-weight:normal;"> as of the day and year first above written.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:-46.15%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">611 GATEWAY CENTER LP, LLC<font style="font-weight:normal;color:#000000;">,</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:-46.15%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:-46.15%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">GATEWAY CENTER GP LLC,<br />a Delaware limited liability company,<br />general partner</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">GATEWAY PORTFOLIO MEMBER LLC, <br />a Delaware limited liability company,<br />managing member</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">GATEWAY PORTFOLIO HOLDINGS LLC, <br />a Delaware limited liability company,<br />managing member</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">ARE-SAN FRANCISCO NO. 83, LLC, <br />a Delaware limited liability company,<br />managing member</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">ALEXANDRIA REAL ESTATE EQUITIES, L.P., <br />a Delaware limited partnership, <br />managing member</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:38.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">ARE-QRS CORP., <br />a Maryland corporation, <br />general partner</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:53.84%;">
<tr style="height:2pt;">
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kristen Childs</p></td>
</tr>
<tr style="height:5pt;">
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, RE Legal Affairs</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC.<font style="font-weight:normal;">,</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:53.84%;">
<tr style="height:2pt;">
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pascal Touchon</p></td>
</tr>
<tr style="height:5pt;">
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">WORK LETTER</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS WORK LETTER dated December 9, 2021 (this &#8220;<font style="font-weight:bold;">Work Letter</font>&#8221;) is made and entered into by and between <font style="font-weight:bold;color:#000000;">611 GATEWAY CENTER LP</font><font style="color:#000000;">, </font>a Delaware limited partnership (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">ATARA BIOTHERAPEUTICS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;), and is attached to and made a part of the Office Lease dated as of November 25, 2015, as amended by that certain First Amendment to Lease dated as of October 21, 2020, and as further amended by that certain Second Amendment to Lease Agreement dated of even date herewith (as amended, the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), by and between Landlord and Tenant.&nbsp;&nbsp;Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">General Requirements</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant&#8217;s Authorized Representative</font>.&nbsp;&nbsp;Tenant designates Keith Kato, Andrew Arcuri and Tony Ma (any such individual acting alone, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Representative</font>&#8221;) as the only persons authorized to act for Tenant pursuant to this Work Letter.&nbsp;&nbsp;Landlord shall not be obligated to respond to or act upon any request, approval, inquiry or other communication (&#8220;<font style="font-weight:bold;">Communication</font>&#8221;) from or on behalf of Tenant in connection with this Work Letter unless such Communication is in writing from Tenant&#8217;s Representative.&nbsp;&nbsp;Tenant may change either Tenant&#8217;s Representative at any time upon not less than 5 business days advance written notice to Landlord.&nbsp;&nbsp;Neither Tenant nor Tenant&#8217;s Representative shall be authorized to direct Landlord&#8217;s contractors in the performance of Landlord&#8217;s Work (as hereinafter defined).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Landlord&#8217;s Authorized Representative</font>.&nbsp;&nbsp;Landlord designates Linda Rey (&#8220;<font style="font-weight:bold;">Landlord&#8217;s Representative</font>&#8221;) as the only person authorized to act for Landlord pursuant to this Work Letter.&nbsp;&nbsp;Tenant shall not be obligated to respond to or act upon any request, approval, inquiry or other Communication from or on behalf of Landlord in connection with this Work Letter unless such Communication is in writing from Landlord&#8217;s Representative.&nbsp;&nbsp;Landlord may change either Landlord&#8217;s Representative at any time upon not less than 5 business days advance written notice to Tenant. Landlord&#8217;s Representative shall be the sole persons authorized to direct Landlord&#8217;s contractors in the performance of Landlord&#8217;s Work.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Architects, Consultants and Contractors</font>.&nbsp;&nbsp;Landlord and Tenant hereby acknowledge and agree that:&nbsp;&nbsp;(i) the general contractor for the Tenant Improvements (the &#8220;<font style="font-weight:bold;">General Contractor</font>&#8221;) and any subcontractors for the Tenant Improvements shall be selected by Landlord, subject to Tenant&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed, and (ii) BRW Architects shall be the architect (the &#8220;<font style="font-weight:bold;">TI Architect</font>&#8221;) for the Tenant Improvements.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant Improvements</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant Improvements Defined</font>.&nbsp;&nbsp;As used herein, &#8220;<font style="font-weight:bold;">Tenant Improvements</font>&#8221; shall mean all improvements to the Premises of a fixed and permanent nature as shown on the TI Construction Drawings, as defined in <font style="text-decoration:underline;">Section 2(c)</font> below.&nbsp;&nbsp;Other than Landlord&#8217;s Work (as defined in <font style="text-decoration:underline;">Section 3(a)</font> below), Landlord shall not have any obligation whatsoever with respect to the finishing of the Premises for Tenant&#8217;s use and occupancy.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant&#8217;s Space Plans</font>.&nbsp;&nbsp;Landlord and Tenant acknowledge and agree that the plan prepared by the TI Architect attached hereto as <font style="font-weight:bold;">Schedule 1</font> (the &#8220;<font style="font-weight:bold;">Space Plans</font>&#8221;) has been approved by both Landlord and Tenant.&nbsp;&nbsp;Landlord and Tenant further acknowledge and agree that any changes to the Space Plans constitute a Change Request the cost of which changes shall be paid for by Tenant. Tenant shall be solely responsible for all costs incurred by Landlord to alter the Building (or Landlord&#8217;s plans for the Building) as a result of Tenant&#8217;s requested changes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Working Drawings</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord shall cause the TI Architect to prepare and deliver to Tenant for review and comment construction plans, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specifications</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and drawings for the Tenant Improvements (&#8220;</font><font style="font-weight:bold;">TI Construction Drawings</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), which TI Construction Drawings shall be prepared substantially in accordance with the Space Plans.&nbsp;&nbsp;Tenant shall be solely responsible for ensuring that the TI Construction Drawings reflect Tenant&#8217;s requirements for the Tenant Improvements.&nbsp;&nbsp;Tenant shall deliver its written comments on the TI Construction Drawings to Landlord not later than 10 business days after Tenant&#8217;s receipt of the same; provided, however, that Tenant may not disapprove any matter that is consistent with the Space Plans without submitting a Change Request.&nbsp;&nbsp;Landlord and the TI Architect shall consider all such comments in good faith and shall, within 10 business days after receipt, notify Tenant how Landlord proposes to respond to such comments, but Tenant&#8217;s review rights pursuant to the foregoing sentence shall not delay the design or construction schedule for the Tenant Improvements.&nbsp;&nbsp;Any disputes in connection with such comments shall be resolved in accordance with </font><font style="text-decoration:underline;">Section 2(d)</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hereof.&nbsp;&nbsp;Provided that the design reflected in the TI Construction Drawings is consistent with the Space Plans, Tenant shall approve the TI Construction Drawings submitted by Landlord, unless Tenant submits a Change Request.&nbsp;&nbsp;Once approved by Tenant, subject to the provisions of </font><font style="text-decoration:underline;">Section 4</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below, Landlord shall not materially modify the TI Construction Drawings except as may be reasonably required in connection with the issuance of the TI Permit (as defined in </font><font style="text-decoration:underline;">Section 3(b)</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Approval and Completion</font>.&nbsp;&nbsp;Upon any dispute regarding the design of the Tenant Improvements, which is not settled within 10 business days after notice of such dispute is delivered by one party to the other, Tenant may make the final decision regarding the design of the Tenant Improvements, provided (i) Tenant acts reasonably and such final decision is either consistent with or a compromise between Landlord&#8217;s and Tenant&#8217;s positions with respect to such dispute, (ii) that all costs and expenses resulting from any such decision by Tenant shall be payable out of the TI Fund (as defined in <font style="text-decoration:underline;">Section 5(d)</font> below), and (iii) Tenant&#8217;s decision will not affect the base Building, structural components of the Building or any Building systems.&nbsp;&nbsp;Any changes to the TI Construction Drawings following Landlord&#8217;s and Tenant&#8217;s approval of same requested by Tenant shall be processed as provided in <font style="text-decoration:underline;">Section 4</font> hereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Performance of Landlord&#8217;s Work</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Definition of Landlord&#8217;s Work</font>.&nbsp;&nbsp;As used herein, &#8220;<font style="font-weight:bold;">Landlord&#8217;s Work</font>&#8221; shall mean the work of constructing the Tenant Improvements.&nbsp;&nbsp;Tenant shall be solely responsible for ensuring that the design and specifications for the Tenant Improvements are consistent with Tenant&#8217;s requirements.&nbsp;&nbsp;Landlord shall be responsible for obtaining all permits, approvals and entitlements necessary for Landlord&#8217;s Work, but shall have no obligation to, and shall not, secure any permits, approvals or entitlements related to Tenant&#8217;s specific use of the Premises or Tenant&#8217;s business operations therein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Commencement and Permitting</font>.&nbsp;&nbsp;Landlord shall commence construction of the Tenant Improvements upon obtaining a building permit (the &#8220;<font style="font-weight:bold;">TI Permit</font>&#8221;) authorizing the construction of the Tenant Improvements consistent with the TI Construction Drawings approved by Tenant.&nbsp;&nbsp;The cost of obtaining the TI Permit shall be payable from the TI Fund.&nbsp;&nbsp;Tenant shall assist Landlord in obtaining the TI Permit.&nbsp;&nbsp;If any Governmental Authority having jurisdiction over the construction of Landlord&#8217;s Work or any portion thereof shall impose terms or conditions upon the construction thereof that:&nbsp;&nbsp;(i) are inconsistent with Landlord&#8217;s obligations hereunder, (ii) increase the cost of constructing Landlord&#8217;s Work, or (iii) will materially delay the construction of Landlord&#8217;s Work, Landlord and Tenant shall reasonably and in good faith seek means by which to mitigate or eliminate any such adverse terms and conditions.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Completion of Landlord&#8217;s Work</font>.&nbsp;&nbsp;Landlord shall substantially complete or cause to be substantially completed Landlord&#8217;s Work in a good and workmanlike manner, in accordance with the TI Permit subject, in each case, to Minor Variations and normal &#8220;punch list&#8221; items of a non-material nature that do not interfere with the use of the Premises (&#8220;<font style="font-weight:bold;">Substantial Completion</font>&#8221; or &#8220;<font style="font-weight:bold;">Substantially Complete</font>&#8221;).&nbsp;&nbsp;Upon Substantial Completion of Landlord&#8217;s Work, Landlord shall require the TI Architect and the General Contractor to execute and deliver, for the benefit of Tenant and Landlord, a Certificate of Substantial Completion in the form of the American Institute of Architects (&#8220;<font style="font-weight:bold;">AIA</font>&#8221;) document G704.&nbsp;&nbsp;For purposes of this </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work Letter, &#8220;</font><font style="font-weight:bold;">Minor Variations</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean any modifications reasonably required:&nbsp;&nbsp;(</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) to comply with all applicable Legal Requirements and/or to obtain or to comply with any required permit (including the TI Permit); (ii) to comply with any request by Tenant for modifications to Landlord&#8217;s Work; (iii) to comport with good design, engineering, and construction practices that are not material; or (iv) to make reasonable adjustments for field deviations or conditions encountered during the construction of Landlord&#8217;s Work.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Selection of Materials</font>.&nbsp;&nbsp;Where more than one type of material or structure is indicated on the TI Construction Drawings approved by Landlord and Tenant, the option will be selected at Landlord&#8217;s sole and absolute subjective discretion.&nbsp;&nbsp;As to all building materials and equipment that Landlord is obligated to supply under this Work Letter, Landlord shall select the manufacturer thereof in its sole and absolute subjective discretion.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Delivery of the Tenant Improvements</font>.&nbsp;&nbsp;When Landlord&#8217;s Work is Substantially Complete, subject to the remaining terms and provisions of this <font style="text-decoration:underline;">Section 3(e)</font>, Tenant shall accept the Tenant Improvements.&nbsp;&nbsp;Tenant&#8217;s taking possession and acceptance of the Tenant Improvements shall not constitute a waiver of:&nbsp;&nbsp;(i) any warranty with respect to workmanship (including installation of equipment) or material (exclusive of equipment provided directly by manufacturers), (ii) any non-compliance of Landlord&#8217;s Work with applicable Legal Requirements, or (iii) any claim that Landlord&#8217;s Work was not completed substantially in accordance with the TI Construction Drawings (subject to Minor Variations and such other changes as are permitted hereunder) (collectively, a &#8220;<font style="font-weight:bold;">Construction Defect</font>&#8221;).&nbsp;&nbsp;Tenant shall have one year after Substantial Completion within which to notify Landlord of any such Construction Defect discovered by Tenant, and Landlord shall use reasonable efforts to remedy or cause the responsible contractor to remedy any such Construction Defect within 30 days thereafter.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord shall not be in default under the Lease if the applicable contractor, despite Landlord&#8217;s reasonable efforts, fails to remedy such Construction Defect within such 30-day period, in which case Landlord shall have no further obligation with respect to such Construction Defect other than to cooperate, at no cost to Landlord, with Tenant should Tenant elect to pursue a claim against such contractor, provided that Tenant shall defend with counsel reasonably acceptable to Landlord, indemnify and hold Landlord harmless from and against any claims arising out of or in connection with any such claim. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall be entitled to receive the benefit of all construction warranties and manufacturer&#8217;s equipment warranties relating to equipment installed in the Premises pursuant to this Work Letter.&nbsp;&nbsp;If requested by Tenant, Landlord shall attempt to obtain extended warranties from manufacturers and suppliers of such equipment, but the cost of any such extended warranties shall be borne solely out of the TI Fund.&nbsp;&nbsp;Landlord shall promptly undertake and complete, or cause to be completed, all punch list items.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Changes</font>.&nbsp;&nbsp;Any changes requested by Tenant to the Tenant Improvements after the date of this Work Letter shall be requested and instituted in accordance with the provisions of this <font style="text-decoration:underline;">Section 4</font> and shall be subject to the written approval of Landlord and the TI Architect, such approval not to be unreasonably withheld, conditioned or delayed.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant&#8217;s Request For Changes</font>.&nbsp;&nbsp;If Tenant shall request changes to the Tenant Improvements (&#8220;<font style="font-weight:bold;">Changes</font>&#8221;), Tenant shall request such Changes by notifying Landlord in writing in substantially the same form as the AIA standard change order form (a &#8220;<font style="font-weight:bold;">Change Request</font>&#8221;), which Change Request shall detail the nature and extent of any such Change.&nbsp;&nbsp;Such Change Request must be signed by Tenant&#8217;s Representative.&nbsp;&nbsp;Landlord shall, before proceeding with any Change, use commercially reasonable efforts to respond to Tenant as soon as is reasonably possible with an estimate of:&nbsp;&nbsp;(i) the time it will take, and (ii) the architectural and engineering fees and costs that will be incurred, to analyze such Change Request (which costs shall be paid from the TI Fund to the extent actually incurred, whether or not such change is implemented).&nbsp;&nbsp;Landlord shall thereafter submit to Tenant in writing, within 5 business days of receipt of the Change Request (or such longer period of time as is reasonably required depending on the extent of the Change Request), an analysis of the additional cost or savings involved, including, without limitation, architectural and engineering costs and the period of time, if any, that the Change will extend the date on which Landlord&#8217;s Work will be Substantially Complete.&nbsp;&nbsp;Any such delay in the completion of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Work caused by a Change, including any suspension of Landlord&#8217;s Work while any such Change is being evaluated and/or designed, shall be </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a delay caused by Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Implementation of Changes</font>.&nbsp;&nbsp;If Tenant:&nbsp;&nbsp;(i) approves in writing the cost or savings and the estimated extension in the time for completion of Landlord&#8217;s Work, if any, and (ii) deposits with Landlord any Excess TI Costs required in connection with such Change, Landlord shall cause the approved Change to be instituted.&nbsp;&nbsp;Notwithstanding any approval or disapproval by Tenant of any estimate of the delay caused by such proposed Change, the TI Architect&#8217;s determination of the amount of delay caused by Tenant in connection with such Change shall be final and binding on Landlord and Tenant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Costs</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Budget For Tenant Improvements</font>.&nbsp;&nbsp;Before the commencement of construction of the Tenant Improvements, Landlord shall obtain a detailed breakdown by trade of the costs incurred or that will be incurred in connection with the design and construction of the Tenant Improvements (the &#8220;<font style="font-weight:bold;">Budget</font>&#8221;).&nbsp;&nbsp;The Budget shall be based upon the TI Construction Drawings approved by Tenant and shall include a payment to Landlord of administrative rent (&#8220;<font style="font-weight:bold;">Administrative Rent</font>&#8221;) equal to 5% of the TI Costs for monitoring and inspecting the construction of the Tenant Improvements and Changes, which sum shall be payable from the TI Fund (as defined in <font style="text-decoration:underline;">Section 5(d)</font>.&nbsp;&nbsp;Administrative Rent shall include, without limitation, all out-of-pocket costs, expenses and fees incurred by or on behalf of Landlord arising from, out of, or in connection with monitoring the construction of the Tenant Improvements and Changes, and shall be payable out of the TI Fund.&nbsp;&nbsp;If the Budget is greater than the TI Allowance, Tenant shall deposit with Landlord the difference, in cash, prior to the commencement of construction of the Tenant Improvements or Changes, for disbursement by Landlord as described in <font style="text-decoration:underline;">Section 5(d)</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">TI Allowance</font>.&nbsp;&nbsp;Landlord shall provide to Tenant a tenant improvement allowance (collectively, the &#8220;<font style="font-weight:bold;">TI Allowance</font>&#8221;) as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">a &#8220;</font><font style="font-weight:bold;">Tenant Improvement Allowance</font>&#8221; in the maximum amount of $246,060.00 in the aggregate, which is included in the Base Rent set forth in the Lease; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">an &#8220;</font><font style="font-weight:bold;">Additional Tenant Improvement Allowance</font>&#8221; in the maximum amount of $683,500.00 in the aggregate, which shall, to the extent used, result in TI Rent as set forth in <font style="text-decoration:underline;">Section 2(b)</font> of the Second Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant may only elect to use the Additional Tenant Improvement Allowance (or portions thereof, as applicable) after the Tenant Improvement Allowance has been fully disbursed.&nbsp;&nbsp;Tenant shall have no right to any portion of the TI Allowance that is not disbursed before the last day of the month that is 12 months after the date of this Second Amendment.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TI Allowance shall be disbursed in accordance with this Work Letter.  </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have no right to the use or benefit (including any reduction to or payment of Base Rent) of any portion of the TI Allowance not required for the construction of (i) the Tenant Improvements described in the TI Construction Drawings approved pursuant to <font style="text-decoration:underline;">Section 2(d)</font> or (ii) any Changes pursuant to <font style="text-decoration:underline;">Section 4</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Costs Includable in TI Fund</font>.&nbsp;&nbsp;The TI Fund shall be used solely for the payment of design, permits and construction costs in connection with the construction of the Tenant Improvements, including, without limitation, the cost of preparing the Space Plan and the TI Construction Drawings, all costs set forth in the Budget, including Landlord&#8217;s Administrative Rent, Landlord&#8217;s out-of-pocket expenses, costs resulting from delays caused by Tenant and the cost of Changes (collectively, &#8220;<font style="font-weight:bold;">TI Costs</font>&#8221;).&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the TI Fund shall not be used to purchase any furniture, personal property </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other non-Building system materials or equipment, including, but not limited to, Tenant&#8217;s voice or data cabling, non-ducted biological safety cabinets and other scientific equipment not incorporated into the Tenant Improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Excess TI Costs</font>.&nbsp;&nbsp;Landlord shall have no obligation to bear any portion of the cost of any of the Tenant Improvements except to the extent of the TI Allowance.&nbsp;&nbsp;If at any time the remaining TI Costs under the Budget exceed the remaining unexpended TI Allowance, Tenant shall deposit with Landlord, as a condition precedent to Landlord&#8217;s obligation to complete the Tenant Improvements, 100% of the then current TI Cost in excess of the remaining TI Allowance (&#8220;<font style="font-weight:bold;">Excess TI Costs</font>&#8221;).&nbsp;&nbsp;If Tenant fails to deposit any Excess TI Costs with Landlord, Landlord shall have all of the rights and remedies set forth in the Lease for nonpayment of Rent (including, but not limited to, the right to interest at the Default Rate and the right to assess a late charge).&nbsp;&nbsp;For purposes of any litigation instituted with regard to such amounts, those amounts will be deemed Rent under the Lease.&nbsp;&nbsp;The TI Allowance and Excess TI Costs are herein referred to as the &#8220;<font style="font-weight:bold;">TI Fund</font>.&#8221;&nbsp;&nbsp;Funds deposited by Tenant shall be the first disbursed to pay TI Costs.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in this <font style="text-decoration:underline;">Section 5(d)</font>, Tenant shall be fully and solely liable for TI Costs and the cost of Minor Variations in excess of the TI Allowance.&nbsp;&nbsp;If upon completion of the Tenant Improvements and the payment of all sums due in connection therewith there remains any undisbursed portion of the TI Fund, Tenant shall be entitled to such undisbursed TI Fund solely to the extent of any Excess TI Costs deposit Tenant has actually made with Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant Access</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant&#8217;s Access Rights</font>.&nbsp;&nbsp;Landlord and Tenant acknowledge that, pursuant to the terms of the Lease, Tenant is occupying the Premises during the construction of the Tenant Improvements.&nbsp;&nbsp;Tenant shall have the right to continue to occupy the Premises (except those portions of the Premises in which the Tenant Improvements are being constructed while Tenant Improvements are being constructed in such portions) at Tenant&#8217;s sole risk and expense, during the construction of the Tenant Improvements; provided, however, that Tenant&#8217;s occupancy shall be coordinated with the TI Architect and the general contractor and shall be subject to Tenant&#8217;s compliance with (i) applicable Legal Requirements, and (ii) all other reasonable restrictions which Landlord, the TI Architect or the General Contractor may impose.&nbsp;&nbsp;Tenant shall cooperate with Landlord in connection with the performance of the Tenant Improvements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">No Interference</font>.&nbsp;&nbsp;Neither Tenant nor any Tenant Party (as defined in the Lease) shall interfere with the performance of Landlord&#8217;s Work, nor with any inspections or issuance of final approvals by applicable Governmental Authorities, and upon any such interference, Landlord shall have the right to exclude Tenant and any Tenant Party from the portions of the Premises in which Landlord&#8217;s Work is being performed until Substantial Completion of Landlord&#8217;s Work.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Miscellaneous</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Consents</font>.&nbsp;&nbsp;Whenever consent or approval of either party is required under this Work Letter, that party shall not unreasonably withhold, condition or delay such consent or approval, unless expressly set forth herein to the contrary.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Modification</font>.&nbsp;&nbsp;No modification, waiver or amendment of this Work Letter or of any of its conditions or provisions shall be binding upon Landlord or Tenant unless in writing signed by Landlord and Tenant.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">No Default Funding</font>.&nbsp;&nbsp;In no event shall Landlord have any obligation to fund any portion of the TI Allowance or to perform any Landlord&#8217;s Work during any period that Tenant is in Default under the Lease.</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-5</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Space Plans<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> For the avoidance of doubt, the Tenant Improvements do not include any furniture, fixtures or equipment shown on the Space Plans, and Tenant shall be responsible for obtaining its own furniture, fixtures and equipment for the Premises, at Tenant&#8217;s sole cost and expense.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-6</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000012.jpg" title="" alt="" style="width:428px;height:649px;"><font style="text-decoration:underline;"></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-7</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000014.jpg" title="" alt="" style="width:523px;height:780px;"><font style="text-decoration:underline;"></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-8</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000016.jpg" title="" alt="" style="width:511px;height:771px;"><font style="text-decoration:underline;"></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50%;"></td>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-9</a></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2okx215f1r000001.jpg" title="" alt="" style="width:296px;height:63px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>atra-ex1037_103.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex1037_103.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 10.37</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><a name="_cp_text_1_1"></a>[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDED AND RESTATED RESEARCH AND DEVELOPMENT<br />COLLABORATION AGREEMENT</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BETWEEN</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:89.76%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DEFINITIONS</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">2.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">SCOPE OF THE COLLABORATION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">GOVERNANCE.</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">BUDGET; MILESTONES; PAYMENT</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">5.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">PRINCIPAL INVESTIGATOR AND PERSONNEL</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">6.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">CONFIDENTIALITY</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2<font style="color:#000000;">1</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">7.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">PUBLICATION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">8.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">REPORTS; RIGHTS IN DATA</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">9.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">INTELLECTUAL PROPERTY</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">10.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">EXCHANGE OF MATERIALS</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">11.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">SUPPLIES AND EQUIPMENT</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">12.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">INDEMNIFICATION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">13.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">NOTICE</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">14.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DISPUTE RESOLUTION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">15.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">TERM AND TERMINATION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">16.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">APPLICABLE LAW</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">17.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">WAIVER</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">18.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ASSIGNMENT</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">19.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ENTIRE AGREEMENT</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">20.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">INDEPENDENT CONTRACTOR</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">21.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">SEVERABILITY</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">22.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">CONSTRUCTION</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.12%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">23.</font></p></td>
<td valign="top"  style="width:89.76%;">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">COUNTERPARTS.</font></p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_3"></a><a name="_cp_text_1_6"></a><a name="_cp_text_1_3"></a>This Fourth Amended and Restated Research and Development Collaboration Agreement (&#8220;<font style="font-weight:bold;">Fourth Restated Agreement</font>&#8221;), entered into on December 17, 2021 (&#8220;<font style="font-weight:bold;">Execution Date</font><a name="_cp_text_1_6"></a>&#8221;), and effective as of the Execution Date, is made by and between <font style="font-weight:bold;">Atara Biotherapeutics, Inc.</font>, having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (&#8220;<font style="font-weight:bold;">Atara</font>&#8221;), and the <font style="font-weight:bold;">Council of the Queensland Institute of Medical Research</font>, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (&#8220;<font style="font-weight:bold;">Institute</font>&#8221;).&nbsp;&nbsp;Each of Atara and Institute are referred to in this Agreement as a &#8220;<font style="font-weight:bold;">Party</font>&#8221;, and collectively as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_9"></a>WHEREAS, <font style="font-weight:normal;"><a name="_cp_text_1_9"></a>Institute has conducted certain research and development, and possesses certain expertise relating to the research and development of, among other things, allogeneic and autologous cytotoxic T-lymphocytes (&#8220;</font>CTL<font style="font-weight:normal;">&#8221;), including in relation to the development of novel therapies targeting tumor and other cells infected with certain viruses, for use in oncology and autoimmune indications.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Atara is a biotechnology company developing novel therapies for commercialization for the treatment of human diseases and conditions.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_11"></a>WHEREAS<font style="font-weight:normal;"><a name="_cp_text_1_11"></a>, the Parties desire to collaborate in relation to research and development activities in accordance with the terms and conditions set forth herein.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Institute is uniquely qualified to conduct the proposed research and the research is within Institute&#8217;s mission and it is in the mutual interest of Atara and Institute that Institute continues to progress certain research and development activities in accordance with the terms and conditions set forth herein.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_14"></a>WHEREAS<font style="font-weight:normal;">, Atara and Institute are parties to that certain Research and Development Collaboration Agreement (the &#8220;</font>Original Research Agreement<font style="font-weight:normal;">&#8221;), entered into on October 20, 2015 (the &#8220;</font>Original Effective Date<font style="font-weight:normal;"><a name="_cp_text_1_14"></a>&#8221;), which was amended and restated as of September 23, 2016 (the &#8220;</font>First Restatement Date<font style="font-weight:normal;">&#8221;) pursuant to that certain Amended and Restated Research and Development Collaboration Agreement </font><font style="font-weight:normal;color:#000000;">and was subsequently amended on December 15, 2017, April 24, 2018 and May 9, 2018 (as so amended, the </font><font style="font-weight:normal;">&#8220;</font>First Restated Agreement<font style="font-weight:normal;">&#8221;) effective as of the Original Effective Date, which was, in turn, amended and restated as of August 28, 2019 (the &#8220;</font>Second Restatement Date<font style="font-weight:normal;">&#8221;) pursuant to that certain Second Amended and Restated Research and Development Collaboration Agreement (the &#8220;</font>Second Restated Agreement<font style="font-weight:normal;">&#8221;),</font> <font style="font-weight:normal;">which was in turn, amended and restated as of August 26, 2020 (the &#8220;</font>Third Restatement Date<font style="font-weight:normal;">&#8221;) pursuant to that certain Third Amended and Restated Research and Development Agreement (The &#8220;</font>Third Restated Agreement<font style="font-weight:normal;">&#8221;), and now the Parties desire </font><font style="font-weight:normal;color:#000000;">to amend and restate the Third Restated Agreement in its entirety to, among other things, [***], all as set forth in this Fourth Restated Agreement</font><font style="font-weight:normal;">; and</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_17"></a>WHEREAS<font style="font-weight:normal;">, the Parties desire that intellectual property rights and technology developed as a result of activities conducted under this Agreement be licensed to Atara for the further development and commercialization of CTL products based on novel allogeneic and autologous </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">CTLs for use in the diagnosis, treatment, prophylaxis and palliation of diseases and conditions associated with EBV, and to that end, the Parties entered into the that certain exclusive License Agreement (the &#8220;</font><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Original License Agreement</font><font style="font-weight:normal;"><a name="_cp_text_1_17"></a>&#8221;) simultaneous with the Original Research Agreement on the Original Effective Date</font><font style="font-weight:normal;color:#000000;">, which Original License Agreement was amended and restated as of the First Restatement Date pursuant to that certain Amended and Restated Exclusive License Agreement (&#8220;</font><font style="color:#000000;">First Restated License Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;), </font><font style="font-weight:normal;color:#000000;">which was</font><font style="font-weight:normal;color:#000000;">, in turn,</font><font style="font-weight:normal;color:#000000;"> amended and restated on the Second Restatement Date pursuant to that certain Second Amended and Restated Exclusive License Agreement (&#8220;</font><font style="color:#000000;">Second Restated License Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;), </font><font style="font-weight:normal;color:#000000;">which was</font><font style="font-weight:normal;color:#000000;">, in turn, amended and restated on the Third Restatement Date pursuant to that certain Third Amended and Restated Exclusive License Agreement</font><font style="font-weight:normal;color:#000000;"> and was subsequently amended on April 21, 2021 to </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> (&#8220;</font><font style="color:#000000;">Third Restated License Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;) </font><font style="font-weight:normal;color:#000000;">and </font><font style="font-weight:normal;color:#000000;">the </font><font style="font-weight:normal;color:#000000;">Third </font><font style="font-weight:normal;color:#000000;">Restated License Agreement is being amended and restated in its entirety pursuant to that certain </font><font style="font-weight:normal;color:#000000;">Fourth </font><font style="font-weight:normal;color:#000000;">Amended and Restated Exclusive License Agreement simultaneously with entering into this </font><font style="font-weight:normal;color:#000000;">Fourth </font><font style="font-weight:normal;color:#000000;">Restated Agreement (the &#8220;</font><font style="color:#000000;">Fourth </font><font style="color:#000000;">Restated License Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;)</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, <font style="font-weight:normal;">Institute and Atara hereby agree to the following terms and conditions in this Agreement:</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028550"></a>1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">DEFINITIONS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following capitalized terms shall have the meanings set forth in this <font style="text-decoration:underline;">Article 1</font>.&nbsp;&nbsp;Capitalized terms not defined in this <font style="text-decoration:underline;">Article 1</font> or elsewhere in this Agreement shall have the meaning given to such terms in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_21"></a><a name="_cp_text_1_19"></a><a name="_cp_field_47_20"></a><a name="_cp_text_1_22"></a>1.2<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Agreement</font>&#8221; means the First Restated Agreement as in effect from the Original Effective Date until the Second Restatement Date, together with the Second Restated Agreement as in effect from the Second Restatement Date until the Third Restatement Date, together with the Third Restated Agreement as in effect from the Third Restatement Date until the Execution Date, together with this Fourth Restated Agreement, which, pursuant to <a name="_cp_field_47_20"></a>Article 19<a name="_cp_text_1_22"></a> replaces the Third Restated Agreement as of the Execution Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">Alliance Manager</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 3.2(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_25"></a><a name="_cp_text_1_26"></a>1.4<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Allogeneic CTL</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">Allogeneic CTL Products</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Allogeneic Programs</font>&#8221; means (a) the research and development activities being performed by Institute and Atara pursuant to this Agreement directed to the identification and development of <font style="color:#000000;">Allogeneic CTL Products, including the Allogeneic EBV CTL Program, and (b) the research and development activities conducted under each New Research Program pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 2.3</font><font style="color:#000000;"> that is directed to the identification and development of New CTL Products comprising Allogeneic CTLs for use in any Indication.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Atara Forecast</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;">Section 2.7(c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Atara Forecast Quantity</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;2.7(c)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_37"></a><a name="_cp_text_1_38"></a>1.9<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Atara Indemnitees&#8221; </font>shall have the meaning given in <font style="text-decoration:underline;">Section 12.2</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Atara Inventions</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 9.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_41"></a><a name="_cp_text_1_42"></a>1.11<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Autologous CTL</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">Autologous CTL Products</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Autologous Programs</font>&#8221; means (a) the research and development activities being performed by Institute and Atara pursuant to this Agreement directed to the identification and development of <font style="color:#000000;">Autologous CTL Products, including the Autologous EBV CTL Program, and (b) the research and development activities conducted under each New Research Program pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 2.3</font><font style="color:#000000;"> that is directed to the identification and development of New CTL Products comprising Autologous CTLs for use in any Indication.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Background IP</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">BKV/JCV</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 1.19</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.16<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">BKV/JCV CTL Budget</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.6(d)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">BKV/JCV CTL Development Plan</font>&#8221; means [***].<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">BKV/JCV CTL Program</font>&#8221; means [***].<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">BKV/JCV Program</font>&#8221; means the <font style="color:#000000;">New Research Program including New CTL Products Specifically Directed to a Target that is associated with BK polyoma virus (&#8220;</font><font style="font-weight:bold;color:#000000;">BKV</font><font style="color:#000000;">&#8221;) and/or JC Polyomavirus (&#8220;</font><font style="font-weight:bold;color:#000000;">JCV</font><font style="color:#000000;">&#8221;), </font>[***].<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Claims</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 12.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_65"></a><a name="_cp_text_1_66"></a>1.21<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">CMV</font>&#8221; means <font style="color:#000000;">cytomegalovirus (including all naturally occurring variants thereof)</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_71"></a><a name="_cp_blt_2_70"></a><a name="_cp_text_1_67"></a><a name="_cp_text_1_69"></a>1.22<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;"><a name="_cp_text_1_67"></a>CMV CTL Program</font><a name="_cp_text_1_69"></a>&#8221; shall have the meaning given in Section 4.3.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_73"></a><a name="_cp_blt_2_72"></a>1.23<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">CMV </font>[***]<font style="font-weight:bold;"> Development Plan</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.6(e)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_75"></a><a name="_cp_blt_2_74"></a>1.24<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Calendar Quarter</font>&#8221; means each successive period of three (3) consecutive calendar months ending on the last day of March, June, September, or December, respectively; provided that, the final Calendar Quarter shall end on the last day of the Term.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_77"></a><a name="_cp_blt_2_76"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, with respect to the efforts to be expended by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken under this Agreement, those efforts that a company or institution developing technology within the bio-pharmaceutical industry of comparable size and resources would reasonably use to accomplish such objective, activity or decision under similar circumstances, and specifically means the carrying out of development activities using efforts that a company or institution developing technology within the bio-pharmaceutical industry of comparable size and resources would reasonably devote to a product at a similar stage in its development or product life, taking into consideration, among other factors, efficacy, safety, approved labeling, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.&nbsp;&nbsp;Commercially Reasonable Efforts shall be determined on a Major Market-by-Major Market and indication-by-indication basis for the Products being developed under the Research Collaboration, and it is anticipated that the level of effort will change over time, reflecting changes in the status of each such Product, including with respect to any Product that is the subject of Autologous Programs.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_79"></a><a name="_cp_blt_2_78"></a>1.26<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Confidential Information</font>&#8221; of a Party, means (a) information relating to the business, operations or products of a Party or any of its Affiliates, including any know-how, that such Party discloses, transfers or makes available to the other Party under this Agreement or the License Agreement, or which otherwise becomes known to the other Party by virtue of this Agreement or the License Agreement, in each case whether in written, oral, graphical, machine readable or other form, whether or not marked as confidential or proprietary, and (b) the terms of this Agreement and the License Agreement;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_81"></a>1.27<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">CTL</font>&#8221; shall have the meaning given in the Recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_83"></a><a name="_cp_blt_2_82"></a>1.28<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">CTL Product</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_85"></a><a name="_cp_blt_2_84"></a>1.29<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Data</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 8.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_87"></a><a name="_cp_blt_2_86"></a>1.30<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Designated Executive Officers</font>&#8221; means the Director and Chief Executive Officer of Institute, and the Chief Executive Officer of Atara.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_89"></a>1.31<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Development Plan</font><a name="_cp_text_1_89"></a>&#8221; means the plan, on a Program-by-Program basis for the research and development activities to be conducted pursuant to this Agreement for the time periods reflected in such plan, as prepared and updated in accordance with Section 2.2, including the budget for such activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_94"></a><a name="_cp_blt_2_93"></a>1.32<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Dispute</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 14.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_95"></a><a name="_cp_blt_1_98"></a><a name="_cp_blt_2_97"></a>1.33<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">EBNA1</font>&#8221; means Epstein Barr nuclear antigen 1.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_102"></a><a name="_cp_blt_2_101"></a><a name="_cp_text_1_100"></a>1.34<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">EBV</font><a name="_cp_text_1_100"></a>&#8221; mean <font style="color:#000000;">Epstein Barr Virus (including all naturally occurring variants thereof)</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_104"></a><a name="_cp_blt_2_103"></a>1.35<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Development Plan</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.6(e)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-4-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_106"></a><a name="_cp_blt_2_105"></a>1.36<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Existing Confidentiality Agreement</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 6.2</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_108"></a><a name="_cp_blt_2_107"></a>1.37<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Final Report</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 8.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_109"></a><a name="_cp_text_1_110"></a>1.38<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;color:#000000;">First Restated Agreement</font><font style="color:#000000;">&#8221; shall have the meaning given in the recitals hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_111"></a><a name="_cp_text_1_112"></a>1.39<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">First Restated License Agreement</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_113"></a><a name="_cp_text_1_114"></a>1.40<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;color:#000000;">First Restatement Date</font><font style="color:#000000;">&#8221; shall have the meaning given in the recitals hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_117"></a><a name="_cp_blt_2_116"></a>1.41<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">FTE</font>&#8221; means the equivalent of the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of 1540-1920 hours per year) in directly conducting activities under this Agreement.&nbsp;&nbsp;Any Party&#8217;s employee who devotes fewer than 1540 hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such employee on such activities by 1920.&nbsp;&nbsp;Any employee who devotes more than 1920 hours per year on the applicable activities shall be treated as one (1) FTE.&nbsp;&nbsp;For the avoidance of doubt, FTE shall not include the work of general corporate or administrative personnel, except for the portion of such personnel&#8217;s work time actually spent on conducting scientific or technical activities related to the Research Collaboration.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_120"></a><a name="_cp_blt_1_121"></a>1.42<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">FTE Rate</font>&#8221; shall mean the rates mutually agreed by the Parties for the engagement of specified FTEs, as set forth on <font style="text-decoration:underline;"><a name="_cp_blt_2_120"></a><a name="_cp_blt_1_121"></a>Schedule 1.15</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_123"></a><a name="_cp_blt_2_122"></a>1.43<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">HPV</font>&#8221; means human papilloma virus.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_125"></a><a name="_cp_blt_2_124"></a>1.44<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">HPV TCR Budget</font>&#8221; means the mutually agreed upon budget for the HPV TCR Program.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_127"></a><a name="_cp_blt_2_126"></a>1.45<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">HPV TCR Development Plan</font>&#8221; means the mutually agreed upon development plan for the HPV TCR Program.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_129"></a><a name="_cp_blt_2_128"></a>1.46<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">HPV TCR Program</font>&#8221; means the <font style="color:#000000;">New Research Program Specifically Directed to such Targets expressed in association with HPV, in such Indications as the Parties may mutually agree in writing from time to time.</font><font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_130"></a><a name="_cp_blt_2_132"></a><a name="_cp_blt_1_135"></a><a name="_cp_blt_2_134"></a>1.47<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">Indication</font>&#8221; means any disease or condition, or sign or symptom of a disease or condition.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_136"></a><a name="_cp_blt_1_139"></a><a name="_cp_blt_2_138"></a>1.48<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Initial EBV Indications</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.1(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_140"></a><a name="_cp_blt_1_143"></a><a name="_cp_blt_2_142"></a>1.49<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Institute Background IP Improvements</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 9.4</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_145"></a><a name="_cp_blt_2_144"></a>1.50<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Institute Indemnitees</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 12.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_147"></a><a name="_cp_blt_2_146"></a>1.51<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Institute Inventions</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 9.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_152"></a><a name="_cp_blt_2_151"></a><a name="_cp_text_1_149"></a><a name="_cp_text_1_150"></a>1.52<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Programs</font><a name="_cp_text_1_149"></a>&#8221; means, collectively, the CMV [***] Program and the [***] Program (each as defined in <a name="_cp_text_1_150"></a>the License Agreement).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_154"></a><a name="_cp_blt_2_153"></a>1.53<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Interim Reports</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 8.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_156"></a><a name="_cp_blt_2_155"></a>1.54<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Inventions</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 9.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_158"></a><a name="_cp_blt_2_157"></a>1.55<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Joint Inventions</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 9.2</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_160"></a><a name="_cp_blt_2_159"></a>1.56<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Joint Steering Committee</font>&#8221; or &#8220;<font style="font-weight:bold;">JSC</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 3.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_167"></a><a name="_cp_blt_2_166"></a><a name="_cp_text_1_162"></a><a name="_cp_text_1_165"></a>1.57<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">License Agreement</font><a name="_cp_text_1_162"></a>&#8221; means the First <a name="_cp_text_1_165"></a>Restated License Agreement as in effect from the Original Effective Date until the Second Restatement Date, together with the Second Restated License Agreement as in effect from the Second Restatement Date until the Third Restatement Date, together with the Third Restated License Agreement as in effect from the Third Restatement Date until the Execution Date, together with the Fourth Restated License Agreement effective as of the Execution Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_10"></a><a name="_cp_blt_1_169"></a><a name="_cp_blt_2_168"></a>1.58<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Licensed Products</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_12"></a><a name="_cp_blt_2_11"></a><a name="_cp_blt_1_171"></a><a name="_cp_blt_2_170"></a>1.59<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">LMP1</font>&#8221; means latent membrane protein 1.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_14"></a><a name="_cp_blt_2_13"></a><a name="_cp_blt_1_173"></a><a name="_cp_blt_2_172"></a>1.60<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">LMP2</font>&#8221; means latent membrane protein 2.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_16"></a><a name="_cp_blt_2_15"></a><a name="_cp_blt_1_175"></a><a name="_cp_blt_2_174"></a>1.61<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Losses</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 12.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_18"></a><a name="_cp_blt_2_17"></a><a name="_cp_blt_1_177"></a><a name="_cp_blt_2_176"></a>1.62<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Major Market</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_20"></a><a name="_cp_blt_2_19"></a><a name="_cp_blt_2_178"></a><a name="_cp_blt_1_181"></a><a name="_cp_blt_2_180"></a>1.63<font style="margin-left:36pt;"></font> &#8220;<font style="font-weight:bold;">MS</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.1(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_22"></a><a name="_cp_blt_2_21"></a><a name="_cp_blt_1_183"></a><a name="_cp_blt_2_182"></a>1.64<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">MSK Agreement</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_24"></a><a name="_cp_blt_2_23"></a><a name="_cp_blt_1_185"></a><a name="_cp_blt_2_184"></a>1.65<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">New CTL Products</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.3(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_26"></a><a name="_cp_blt_2_25"></a><a name="_cp_blt_1_187"></a><a name="_cp_blt_2_186"></a>1.66<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">New Research Information Package</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.3(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_28"></a><a name="_cp_blt_2_27"></a><a name="_cp_blt_1_189"></a><a name="_cp_blt_2_188"></a>1.67<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">New Research Programs</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;2.3(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_30"></a><a name="_cp_blt_2_29"></a><a name="_cp_blt_1_191"></a><a name="_cp_blt_2_190"></a>1.68<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">New Research Proposal</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;2.3(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_32"></a><a name="_cp_blt_2_31"></a><a name="_cp_blt_1_193"></a><a name="_cp_blt_2_192"></a>1.69<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">NHL</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.1(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_34"></a><a name="_cp_blt_2_33"></a><a name="_cp_blt_1_195"></a><a name="_cp_blt_2_194"></a>1.70<font style="margin-left:36pt;"></font>&#8220;[***]&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.1(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-6-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_36"></a><a name="_cp_blt_2_35"></a><a name="_cp_blt_1_197"></a><a name="_cp_blt_2_196"></a>1.71<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Option</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_38"></a><a name="_cp_blt_2_37"></a><a name="_cp_blt_1_198"></a><a name="_cp_text_1_199"></a>1.72<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;color:#000000;">Original Research Agreement</font><font style="color:#000000;">&#8221; shall have the meaning given in the recitals hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_40"></a><a name="_cp_blt_2_39"></a><a name="_cp_blt_1_200"></a><a name="_cp_text_1_201"></a>1.73<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Original License Agreement</font>&#8221; <font style="color:#000000;">shall have the meaning given in the recitals hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_42"></a><a name="_cp_blt_2_41"></a><a name="_cp_blt_1_203"></a><a name="_cp_blt_2_202"></a>1.74<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Other Work</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 5.2</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_44"></a><a name="_cp_blt_2_43"></a><a name="_cp_blt_1_205"></a><a name="_cp_blt_2_204"></a>1.75<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Principal Investigator</font>&#8221; means Professor Rajiv Khanna.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_46"></a><a name="_cp_blt_2_45"></a><a name="_cp_blt_1_207"></a><a name="_cp_blt_2_206"></a>1.76<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Program</font>&#8221; means, on a Target-by-Target basis, any and all preclinical development, clinical development, manufacturing and commercialization activities with respect to any and all products directed to such Target.&nbsp;&nbsp;Programs include (a) the Allogeneic Programs, (b) the Autologous Programs and (c) any New Research Programs.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_48"></a><a name="_cp_blt_2_47"></a><a name="_cp_blt_1_209"></a><a name="_cp_blt_2_208"></a>1.77<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Program </font>[***]&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.3(a)</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_50"></a><a name="_cp_blt_2_49"></a><a name="_cp_blt_1_211"></a><a name="_cp_blt_2_210"></a>1.78<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Payment</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;2.7(a)</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_52"></a><a name="_cp_blt_2_51"></a><a name="_cp_blt_1_213"></a><a name="_cp_blt_2_212"></a>1.79<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Capacity</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.7(a)</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_54"></a><a name="_cp_blt_2_53"></a><a name="_cp_blt_1_215"></a><a name="_cp_blt_2_214"></a>1.80<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Period</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.7(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_56"></a><a name="_cp_blt_2_55"></a><a name="_cp_blt_1_217"></a><a name="_cp_blt_2_216"></a>1.81<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Regulatory Approval</font>&#8221; means with respect to a country or region, any and all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a product developed or commercialized under this Agreement or the License Agreement in such country or region, including, where applicable: (a) pre- and post-approval marketing authorizations; (b) labeling approval; and (c) technical, medical and scientific licenses, in each case necessary for commercial distribution, sale or marketing of such product in such country or region.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_58"></a><a name="_cp_blt_2_57"></a><a name="_cp_blt_1_219"></a><a name="_cp_blt_2_218"></a>1.82<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Regulatory Authority</font>&#8221; means any Government Authority or other entity, in each case regulating or otherwise exercising authority with respect to the development, manufacturing or commercialization of a given product under this Agreement or the License Agreement in a given country or region, including the U.S. Food and Drug Administration (&#8220;<font style="font-weight:bold;">FDA</font>&#8221;), or any successor thereto, and the European Medicines Agency (&#8220;<font style="font-weight:bold;">EMA</font>&#8221;), or any successor thereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_60"></a><a name="_cp_blt_2_59"></a><a name="_cp_blt_1_221"></a><a name="_cp_blt_2_220"></a>1.83<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Research Collaboration</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.1</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_62"></a><a name="_cp_blt_2_61"></a><a name="_cp_blt_1_223"></a><a name="_cp_blt_2_222"></a>1.84<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Research Milestone</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 4.4(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_64"></a><a name="_cp_blt_2_63"></a><a name="_cp_blt_1_225"></a><a name="_cp_blt_2_224"></a>1.85<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Research Milestone Payment</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;4.4(a)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_66"></a><a name="_cp_blt_2_65"></a><a name="_cp_blt_1_227"></a><a name="_cp_blt_2_226"></a>1.86<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Rules of Arbitration</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 14.2</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_68"></a><a name="_cp_blt_2_67"></a><a name="_cp_blt_1_228"></a><a name="_cp_text_1_229"></a>1.87<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Second Restated Agreement</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Second Restated License Agreement</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.89<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Second Restatement Date</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Specifically Directed</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_70"></a><a name="_cp_blt_2_69"></a><a name="_cp_blt_1_234"></a><a name="_cp_blt_2_233"></a>1.91<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Target</font>&#8221; means an antigen expressed on or in a cell, including [***].&nbsp;&nbsp;For clarity, a Target may be a [***] (collectively, a single &#8220;<font style="font-weight:bold;">Target</font>&#8221;).&nbsp;&nbsp;Unless otherwise specified, where the antigen is naturally occurring, a Target [***].&nbsp;&nbsp;For clarity, (a) where a CTL Product is [***] antigen expressed on or in a cell in association [***] EBV, [***] (b) where a CTL Product is [***] associated with a single antigen expressed on or in a cell in association with the presence of, or infection of such cell by, EBV, [***] with EBV, [***].</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_72"></a><a name="_cp_blt_2_71"></a><a name="_cp_blt_1_235"></a><a name="_cp_text_1_236"></a><a name="_cp_blt_1_74"></a><a name="_cp_blt_2_73"></a><a name="_cp_blt_1_238"></a><a name="_cp_blt_2_237"></a>1.92<font style="margin-left:36pt;"></font><a name="_cp_blt_1_74"></a><a name="_cp_blt_2_73"></a><a name="_cp_blt_1_238"></a><a name="_cp_blt_2_237"></a> &#8220;<font style="font-weight:bold;">Term</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 15.1</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_76"></a><a name="_cp_blt_2_75"></a><a name="_cp_blt_1_240"></a><a name="_cp_blt_2_239"></a>1.93<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Territory</font>&#8221; means worldwide.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_78"></a><a name="_cp_blt_2_77"></a><a name="_cp_blt_1_242"></a><a name="_cp_blt_2_241"></a>1.94<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Third Party</font>&#8221; means any Person (as defined in the License Agreement) other than Institute, Atara or any of their respective Affiliates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Third Restated Agreement</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Third Restated License Agreement</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.97<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Third Restatement Date</font>&#8221; shall have the meaning given in the recitals hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_80"></a><a name="_cp_blt_2_79"></a><a name="_cp_blt_1_243"></a><a name="_cp_text_1_244"></a>1.98<font style="margin-left:36pt;"></font>&#8220;[***]&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_82"></a><a name="_cp_blt_2_81"></a><a name="_cp_blt_1_246"></a><a name="_cp_blt_2_245"></a>1.99<font style="margin-left:36pt;"></font> &#8220;[***]<font style="font-weight:bold;"> Milestone</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 4.4(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_84"></a><a name="_cp_blt_2_83"></a><a name="_cp_blt_1_248"></a><a name="_cp_blt_2_247"></a>1.100<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Period</font>&#8221; shall have the meaning given in the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_86"></a><a name="_cp_blt_2_85"></a><a name="_cp_blt_1_250"></a><a name="_cp_blt_2_249"></a>1.101<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Milestone Payment</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 4.4(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_88"></a><a name="_cp_blt_2_87"></a><a name="_cp_blt_1_254"></a><a name="_cp_blt_2_253"></a><a name="_cp_text_1_252"></a>1.102<font style="margin-left:36pt;"></font>&#8220;<a name="_cp_text_1_252"></a>[***]<font style="font-weight:bold;"> Budget</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section&#160;2.6(f)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_90"></a><a name="_cp_blt_2_89"></a><a name="_cp_blt_1_256"></a><a name="_cp_blt_2_255"></a>1.103<font style="margin-left:36pt;"></font>&#8220;[***]<font style="font-weight:bold;"> Development Plan</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 2.6(e)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_92"></a><a name="_cp_blt_2_91"></a><a name="_cp_blt_1_258"></a><a name="_cp_blt_2_257"></a>1.104<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Wind Down Activities</font>&#8221; shall have the meaning given in <font style="text-decoration:underline;">Section 15.5(b)</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028551"></a>2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">SCOPE OF THE COLLABORATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Scope</font>. Pursuant to this Agreement, as further provided in this <font style="text-decoration:underline;">Article 2</font>, during the Term:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Atara and Institute shall collaborate to conduct the Allogeneic Programs as set forth in <font style="text-decoration:underline;">Section 2.2</font> and the Development Plan, with the intention of identifying and developing CTL Products Specifically Directed to (i) Targets expressed in association with EBV, including [***], and such other Targets as may be incorporated in the Development Plan, for use in the diagnosis, prophylaxis, treatment and palliation of (A) multiple sclerosis (&#8220;<font style="font-weight:bold;">MS</font>&#8221;), (B) [***](collectively (A) through [***], the &#8220;<font style="font-weight:bold;">Initial EBV Indications</font>&#8221;) and such other Indications as may be incorporated in the Development Plan, and (ii) such other Indications as the Parties may mutually agree in the Development Plan;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_262"></a>(b)<font style="margin-left:36pt;"></font>Institute shall use Commercially Reasonable Efforts to conduct the Autologous Programs, as set forth in the Development Plan, with the intention of progressing the clinical development of Autologous CTL Products Specifically Directed to Targets expressed in association with EBV for the prophylaxis, treatment and palliation of [***]<a name="_cp_text_1_262"></a> MS.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing activities, as well as any New Research Programs conducted by the Parties pursuant to <font style="text-decoration:underline;">Section 2.3</font>, and activities conducted pursuant to the License Agreement, together, shall be the &#8220;<font style="font-weight:bold;">Research Collaboration</font>&#8221;.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_264"></a><a name="_cp_text_1_266"></a><a name="_cp_text_1_268"></a><a name="_cp_text_1_269"></a>2.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Conduct of the Research Collaboration</font><a name="_cp_text_1_264"></a>.&nbsp;&nbsp;The Research Collaboration shall be conducted at Institute under the supervision of the Principal Investigator and commenced promptly after the Original Effective Date.&nbsp;&nbsp;Institute shall use Commercially Reasonable Efforts to conduct the Autologous Programs, and the Parties shall use Commercially Reasonable Efforts to conduct the Allogeneic Programs, in accordance with all applicable laws, rules and regulations, the terms and conditions of this Agreement, the Development Plan attached as <font style="text-decoration:underline;">Schedule 2.2</font><a name="_cp_text_1_266"></a> and incorporated by reference herein, and in the case of the Allogeneic Programs under the supervision of the JSC.&nbsp;&nbsp;Institute will furnish the facilities, know-how, and technical skills necessary for performance of the Research Collaboration.&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, Atara and Institute may at any time modify <a name="_cp_text_1_268"></a>the scope of the Research Collaboration, including the Development Plan, by mutual written agreement in a document executed by duly authorized representatives of&nbsp;&nbsp;both Parties or otherwise expressly agreed to in writing by the Alliance Managers and representatives on the JSC of both Parties<a name="_cp_text_1_269"></a> that states that it is effectuating such a modification.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">New Research</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_94"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_94"></a>During the term of this Agreement, if either Party wishes to pursue a program of activities directed to (i) the research and development of pharmaceutical or biologic products comprising Autologous CTLs or Allogeneic CTLs, or [***], in each case Specifically Directed to Targets that are not associated with EBV (&#8220;<font style="font-weight:bold;">New CTL Products</font>&#8221;), or (ii) the research and development of the [***] arising from the [***] Programs (the &#8220;<font style="font-weight:bold;">Program </font>[***]&#8221; as further defined in the License Agreement), (such research and development programs in (i) and (ii), each </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-9-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a &#8220;</font><font style="font-weight:bold;">New Research Program</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), such Party may propose to the JSC that such New Research Program is included within the scope of the Research Collaboration.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_271"></a>(b)<font style="margin-left:36pt;"></font>If the Parties, through the JSC, agree that a New Research Program should be investigated with a view to inclusion within the Research Collaboration, Institute shall prepare and present a proposal (a &#8220;<font style="font-weight:bold;">New Research Proposal</font><a name="_cp_text_1_271"></a>&#8221;) to the JSC for discussion.&nbsp;&nbsp;Any New Research Proposal shall include, at a minimum: (i) the Target(s) for such New CTL Products or Program [***], as applicable, (ii) a description of the proposed research and development activities, including an estimated timeline for such development, (iii) a good faith estimated budget for such development activities, (iv) a description of any material know-how, data, results or information in the possession and control of Institute that is necessary for Atara (and the JSC) to determine whether or not to pursue the New Research Program, and (v) a listing of the patent rights (including any such patent rights owned or controlled by any Third Party) that (A) cover or claim such New CTL Products or Program [***], or (B) Institute reasonably believes may be necessary or useful for the conduct of the proposed development activities, including in each case the owner or licensor under any Third Party patent rights, and (vi) any other information that Atara or the JSC may request in order to make a decision as to whether or not to progress the New Research Program (the information and materials in (i) through (vi), the &#8220;<font style="font-weight:bold;">New Research Information Package</font>&#8221;).&nbsp;&nbsp;Any such New Research Proposal shall be presented to the JSC no less than thirty (30) days prior to the JSC meeting at which such New Research Proposal is to be considered.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The JSC shall discuss any New Research Proposal at the next JSC meeting following the delivery by Institute of the New Research Information Package, and shall determine whether the Parties should include the New Research Program within the scope of the Research Collaboration.&nbsp;&nbsp;A Party may withhold its consent to inclusion of any New Research Program within the scope of the Research Collaboration at its sole discretion.&nbsp;&nbsp;If the Parties mutually agree to progress any New Research Program, the Parties shall consult to prepare a formal development plan and budget for such New Research Program for review and approval by the JSC (subject to Atara&#8217;s final decision making right under <font style="text-decoration:underline;">Section 3.3(f)</font>).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_272"></a><a name="_cp_text_1_275"></a><a name="_cp_text_1_276"></a><a name="_cp_text_1_278"></a><a name="_cp_text_1_279"></a><a name="_cp_text_1_280"></a><a name="_cp_text_1_281"></a><a name="_cp_text_1_282"></a>(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">If the Parties agree to conduct a New Research Program, then within sixty (60) days </font><a name="_cp_text_1_272"></a>following the finalization of the development plan and budget for such New Research Program <font style="color:#000000;">(or such other timing as may be agreed to in writing by the Parties)</font>, such development plan and budget shall be added to and incorporated within the Development Plan and Budget, the Parties shall amend the License Agreement to provide that any New CTL Products and/or Program <font style="color:#000000;">[***]</font> shall be included within the scope of Licensed Products, and subject to the licenses granted pursuant to the License Agreement, and to make any other necessary amendments to the License Agreement in order to effect such change to the scope of Licensed Products, including, in the case of the New Research Program(s) including the Program <font style="color:#000000;">[***]</font>, amendments to the economic terms applicable to Licensed Products arising from such New Research Program(s).&nbsp;&nbsp;With the exception of such amendments, all other terms and conditions of the License Agreement shall apply equally to any New CTL Product and the Program <font style="color:#000000;">[***]</font><a name="_cp_text_1_275"></a> as to any other Licensed Product, provided that (i) the Milestone Payments applicable to any such New CTL Product shall be those set forth in the column under the heading &#8220;Research Milestone Payments &#8211; Licensed Product Arising Directly From Activities under New Research Programs&#8221; in the table in <font style="text-decoration:underline;"><a name="_cp_text_1_276"></a>Section 4.4(a)</font> <a name="_cp_text_1_278"></a>of this Agreement and under the heading &#8220;Milestone Payments &#8211; Licensed Product Arising Directly From Activities under Research Agreement&#8221; in Section 4.3(a) of the License <a name="_cp_text_1_279"></a>Agreement, and (ii) the Milestone Payments applicable to any such Program <font style="color:#000000;">[***]</font><a name="_cp_text_1_280"></a> shall be those set forth in the column under the heading &#8220;<font style="color:#000000;">[***]</font>&#8221; in the table in <font style="text-decoration:underline;">Section 4.4(b)</font><a name="_cp_text_1_281"></a> of this Agreement <a name="_cp_text_1_282"></a>and under the heading &#8220;Milestone Payments &#8211; Licensed Product Arising Directly From Activities under Research Agreement&#8221; in Section 4.3(a) of the License </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-10-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement.&nbsp;&nbsp;Except for (A) any funding that Atara agrees to provide for research and development activities to be conducted under any New Research Program pursuant to this Agreement, </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B) amounts payable by Atara for any New Research Program including the Program </font><font style="color:#000000;">[***]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, no other consideration shall be payable by Atara for the foregoing amendment of the License Agreement and the grant by Institute to Atara of exclusive license rights in New CTL Products and/or Program </font><font style="color:#000000;">[***]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> arising from such New Research Program.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>If Institute provides Atara with a New Research Information Package pursuant to this <font style="text-decoration:underline;">Section 2.3</font>, and Atara does not wish to fund such research and development activities, or include such research and development activities within the scope of the Research Collaboration, then subject to the terms and conditions of this Agreement and the License Agreement (including Section 7 (Certain Covenants) thereof), Institute may (i) pursue the research and development of such New Research Program independently or with any Affiliate, and/or (ii) shall be free to discuss terms and conditions for the grant of rights to any Third Party to participate in the research, development and commercialization of the New CTL Products that are the subject of such New Research Program, without further obligation to Atara with respect to such New Research Program.&nbsp;&nbsp;For clarity, this subsection (e) shall not apply to any New Research Programs including the Program [***], which shall instead be subject to <font style="text-decoration:underline;">Section 2.6(e)</font> below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Diligence</font>.&nbsp;&nbsp;Each Party shall use Commercially Reasonable Efforts to conduct the Research Collaboration by performing the activities allocated to such Party pursuant to this Agreement and the Development Plan (including any activities relating to New Research Programs that the Parties mutually agree to include within the scope of the Research Collaboration).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_285"></a>2.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Regulatory Activities</font>.&nbsp;&nbsp;Atara shall be solely responsible, at Atara&#8217;s expense, for preparing all submissions to any regulatory authority and making all regulatory filings in the Territory in relation to CTL Products arising from (a) activities conducted with respect to the Allogeneic CTL Programs, (b) activities conducted with respect to the Autologous CTL Programs, and (c) New CTL Products and Program [***]<a name="_cp_text_1_285"></a> arising out of New Research Programs conducted hereunder, in each case in accordance with Section 5.5 of the License Agreement.&nbsp;&nbsp;Institute was solely responsible at Institute&#8217;s expense, for preparing all submissions to any regulatory authority and making all regulatory filings in the Territory in relation to CTL Products arising from activities conducted with respect to the Autologous CTL Programs prior to the exercise of the Option pursuant to Section 2.2 of the License Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Specific New Research Programs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">HPV TCR Program</font>.&nbsp;&nbsp;[***].&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">HPV TCR Program Funding</font>.&nbsp;&nbsp;[***]. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">BKV/JCV CTL Program</font>.&nbsp;&nbsp;[***].  </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">BKV/JCV CTL Program Funding</font>.&nbsp;&nbsp;[***].&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_317"></a><a name="_cp_text_1_319"></a><a name="_cp_text_1_321"></a><a name="_cp_text_1_324"></a>(e)<font style="margin-left:36pt;"></font>[***]<font style="font-weight:bold;"> Programs</font>.&nbsp;&nbsp;Following discussion through the JSC in accordance with <font style="text-decoration:underline;">Section 2.3</font><a name="_cp_text_1_317"></a>, as of the First Restatement Date, <a name="_cp_text_1_319"></a>the Parties agreed to include the [***] Programs as a New Research Program within the scope of this Agreement.&nbsp;&nbsp;For the purposes of this Agreement the [***]<a name="_cp_text_1_321"></a> Programs shall be deemed to be Allogeneic Programs.&nbsp;&nbsp;The Parties previously agreed on a development plan setting out the research and development activities to be conducted for each of the [***] Programs during the [***] Period (the &#8220;[***]<font style="font-weight:bold;"> Development Plan</font>&#8221;, and the &#8220;[***]<font style="font-weight:bold;"> Development Plan</font>&#8221;, and collectively the &#8220;[***]<font style="font-weight:bold;"> Programs Development Plan</font>&#8221;. The Parties have agreed on a revised [***] Development Plan, along with a mutually agreed budget for such activities, as further set forth in subsection (f) below, which has been added to and incorporated within the Development Plan, and which the Parties may mutually agree in writing to update from time to time.&nbsp;&nbsp;If Atara exercises the [***] for the [***] Program pursuant to Section 2.6 of the License Agreement, such Program [***] will become Licensed Products, and such Licensed Products arising as a result of activities under the [***]<a name="_cp_text_1_324"></a> Programs shall be subject to the applicable Research Milestone Payments set forth in the table in <font style="text-decoration:underline;">Section 4.4(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>[***]<font style="font-weight:bold;"> Program Funding</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_326"></a><a name="_cp_text_1_328"></a><a name="_cp_text_1_330"></a><a name="_cp_text_1_332"></a>(i)<font style="margin-left:36pt;"></font>The [***] Programs Development Plan shall include a mutually agreed budget for each of the [***] Program and the [***]<a name="_cp_text_1_326"></a> Program (each, a &#8220;[***]<font style="font-weight:bold;"><a name="_cp_text_1_328"></a> Program Budget</font>&#8221;), which the Parties expect to cover all direct and indirect costs of the conduct of the [***] Programs during the [***]<a name="_cp_text_1_330"></a> Period.&nbsp;&nbsp;The Parties agree that Atara has terminated the [***]<a name="_cp_text_1_332"></a> for the [***] Program and that they have agreed on a [***] Program Budget for the [***]  Program of [***] (the &#8220;<font style="font-weight:bold;">Final </font>[***]<font style="font-weight:bold;"> Budget</font>&#8221;), and that other than the amounts contemplated by the Final [***]Budget, Atara will have no further costs or payment obligations associated with the [***] Program, including any incremental wind-down or close-out costs.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_334"></a><a name="_cp_text_1_336"></a><a name="_cp_text_1_338"></a><a name="_cp_text_1_339"></a><a name="_cp_text_1_340"></a><a name="_cp_text_1_342"></a><a name="_cp_text_1_344"></a><a name="_cp_text_1_346"></a><a name="_cp_text_1_348"></a>(ii)<font style="margin-left:36pt;"></font><font style="color:#000000;"><a name="_cp_text_2_334"></a>Atara shall pay an annual amount set forth in the [***] Program Budget existing as at the Execution Date, or after the time period covered by such [***] Program Budget, as otherwise to</font><font style="letter-spacing:-0.8pt;"> </font><font style="color:#000000;">be agreed by the Parties in accordance with subsection (iii) </font><a name="_cp_text_1_336"></a>below, to be allocated against the costs set forth in each <font style="color:#000000;">[***]</font> Program Budget (each, a &#8220;<font style="color:#000000;">[***]</font><font style="font-weight:bold;">Research Contribution</font>&#8221; and collectively the &#8220;<font style="color:#000000;">[***] </font><font style="font-weight:bold;">Research Contribution</font>&#8221;). Institute shall use Commercially Reasonable Efforts to ensure that any FTEs assigned to perform activities under the <font style="color:#000000;">[***]</font> Programs devote at least <font style="color:#000000;">[***] </font>of their total working time to activities under the <font style="color:#000000;">[***] </font><a name="_cp_text_1_338"></a>Development Plan, unless otherwise mutually agreed by the Parties.&nbsp;&nbsp;The allocation of the <font style="color:#000000;">[***] </font>Research Contribution to activities under each of the <font style="color:#000000;">[***]</font><a name="_cp_text_1_339"></a> Programs prior to June 30, 2019 <a name="_cp_text_1_340"></a>shall be at Institute&#8217;s discretion and thereafter shall be allocated solely to the <font style="color:#000000;">[***]</font> Program, and the timing of payments to be made to Institute out of such amount are as set forth in Section 2.6 of the License Agreement.&nbsp;&nbsp;The Parties may mutually agree upon changes to the <font style="color:#000000;">[***]</font> Research </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution (subject to </font><font style="text-decoration:underline;">Section 2.6(f)(iii)</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_342"></a> below with respect to </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="color:#000000;"><a name="_cp_text_1_344"></a>[***] </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Budget</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and to Atara&#8217;s final decision making authority under </font><font style="text-decoration:underline;">Section 3.3(f)</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_346"></a> with respect to any other increase thereto), or changes in the allocation of </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="color:#000000;"><a name="_cp_text_1_348"></a>[***]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Budget to activities under the </font><font style="color:#000000;">[***]</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Development Plan.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_350"></a><a name="_cp_text_1_351"></a><a name="_cp_text_1_353"></a><a name="_cp_text_1_360"></a><a name="_cp_text_1_362"></a>(iii)<font style="margin-left:36pt;"></font>Following <a name="_cp_text_1_351"></a>the Execution Date, the Parties shall discuss in good faith through the JSC and otherwise and may mutually agree upon an updated [***] Development Plan and an updated <a name="_cp_text_1_353"></a>[***] Budget, in each case for the [***] Program, to cover such period and such matters and expenditures as are not covered in the [***] Development Plan and [***] Budget agreed as at the Execution Date. Thereafter, the Parties shall update the [***] Development Plan and the [***] <a name="_cp_text_1_360"></a>Budget for the [***] Program at least annually.&nbsp;&nbsp;If, at any time during the term of this Agreement, the Parties are unable to agree upon either the content of the updated [***] Development Plan or the updated <a name="_cp_text_1_362"></a>[***] Budget, then (A) Institute shall have the final decision with respect to the [***] Development Plan, and (B) Atara shall have the final decision with respect to the amount of the [***] Research Contribution to be provided by Atara to fund activities during the applicable time period, provided that in no event shall the [***] Research Contribution funded by Atara in any twelve (12) month period for which the [***] Budget is in dispute be less than the greater of (x) the highest amount offered by Atara by way of [***] Research Contribution during such failed negotiations for the applicable twelve (12) month period, and (y) the amount funded by Atara for the [***] Research Contribution for the most recent twelve (12) month period.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7<font style="margin-left:36pt;"></font>[***]<font style="font-weight:bold;"> Manufacturing Support</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_368"></a><a name="_cp_text_1_370"></a>(a)<font style="margin-left:36pt;"></font>In addition to the funding provided by Atara for the [***] Programs set forth in <font style="text-decoration:underline;">Section 2.6</font><a name="_cp_text_1_368"></a>, Atara paid to Institute a one-off lump-sum payment of [***] (the &#8220;[***]<font style="font-weight:bold;"> Payment</font><a name="_cp_text_1_370"></a>&#8221;), which was used by Institute for [***] (the &#8220;[***]<font style="font-weight:bold;"> Capacity</font>&#8221;).&nbsp;&nbsp;The [***] Capacity shall be used by Institute to provide manufacturing and related services to support activities under all Programs included within the Development Plan, including the [***] Programs and any other New Research Programs that may be added to this Agreement from time to time.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>In consideration for the [***] Payment, until Institute has [***] necessary for the conduct of (a) [***]  (as defined in the License Agreement) and (b) all other [***] set forth in the Development Plan that are [***] the first Licensed Product (including, for clarity, the first EBV-Specific CTL Product) arising from activities under the Research Agreement (the &#8220;[***] <font style="font-weight:bold;">Period</font>&#8221;), Institute shall utilize the [***] Capacity for manufacturing activities required under the Development Plan and any other New Research Programs in accordance with the following protocol.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>During the [***] Period, on a calendar quarterly basis Atara will issue to Institute in good faith rolling forecasts (each, an &#8220;<font style="font-weight:bold;">Atara Forecast</font>&#8221;) of its requirements for use of the [***] Capacity for the following six months (the &#8220;<font style="font-weight:bold;">Atara Forecast Quantity</font>&#8221;).&nbsp;&nbsp;During the [***] Period, the [***] Capacity shall be used first to manufacture any amounts included in the Atara Forecast Quantity before it can be used for manufacturing services for any Third Party.&nbsp;&nbsp;If Institute wishes to utilize the [***] Capacity for any other activities during the [***] Period, including the performance of activities for Third Parties and/or outside the scope of the Programs included within the Development Plan, it may do so to the extent that such use is not allocated to the Atara Forecast Quantity, provided that Institute shall first obtains Atara&#8217;s prior </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written consent to the use of such excess capacity, not to be unreasonably withheld or delayed.&nbsp;&nbsp;Without limiting the foregoing, Institute may not offer the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Capacity to any Third Party for services outside any time period covered by an Atara Forecast without Atara&#8217;s prior written consent, which consent may not be unreasonably withheld or delayed.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028552"></a>3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">GOVERNANCE</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_381"></a><a name="_cp_text_1_382"></a><a name="_cp_text_1_384"></a>3.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Management</font><a name="_cp_text_1_381"></a>.&nbsp;&nbsp;The <a name="_cp_text_1_382"></a>Parties have established and <a name="_cp_text_1_384"></a>shall maintain a cross-functional, joint steering committee (the &#8220;<font style="font-weight:bold;">Joint Steering Committee</font>&#8221; or the &#8220;<font style="font-weight:bold;">JSC</font>&#8221;) which shall oversee the research collaboration between the Parties, including Allogeneic CTL Programs, Autologous Programs, and any agreed New Research Programs conducted under this Agreement and the License Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Alliance Managers</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Each of Atara and Institute shall appoint one representative who possesses an understanding of development, regulatory, manufacturing and commercialization matters to act as its respective alliance manager(s) for this relationship (an &#8220;<font style="font-weight:bold;">Alliance Manager</font>&#8221;).&nbsp;&nbsp;Each Party may replace its respective Alliance Manager at any time upon written notice to the other in accordance with this Agreement.&nbsp;&nbsp;Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.&nbsp;&nbsp;Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the JSC.&nbsp;&nbsp;Consistent with the Development Plan, each Alliance Manager, will also be responsible for (i) providing a primary single point of communication responsible for the flow of communication and for seeking consensus (both within such Party&#8217;s organization and with respect to activities under this Agreement or the License Agreement) regarding key strategy and plan issues, and (ii) identifying and raising disputes to the JSC for discussion in a timely manner; and</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_388"></a><a name="_cp_text_1_389"></a>(b)<font style="margin-left:36pt;"></font><a name="_cp_text_1_388"></a>Each Alliance Manager shall have the right to attend all JSC <a name="_cp_text_1_389"></a>meetings and meetings of any subcommittee thereof, as a nonvoting member.&nbsp;&nbsp;Each Alliance Manager may bring any matter to the attention of the JSC where such Alliance Manager reasonably believes that such matter requires attention of the JSC.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Joint Steering Committee</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Composition</font>.&nbsp;&nbsp;The Joint Steering Committee shall be comprised of two (2) named representatives of each Party (or such other number as the Parties may agree) in addition to each Party&#8217;s Alliance Manager who are members ex-officio.&nbsp;&nbsp;The JSC will be led by two (2) co-chairs, one (1) appointed by each of the Parties.&nbsp;&nbsp;Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Function and Powers of the JSC</font>.&nbsp;&nbsp;The JSC shall, in line with the terms and conditions set forth in the Agreement:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>define the scope of the research and development activities to be conducted under this Agreement, including by reviewing and approving the initial </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-14</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Plan, and each update to the Development Plan and associated Budget, and review progress against the goals in such Development Plan;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>discuss and agree upon the allocation of the Budget to activities under the Development Plan;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>discuss and comment on updates provided by Institute in relation to the Autologous Programs;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>review and discuss proposals for new Indications for Licensed Products to be included within the activities under the Development Plan;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>review and discuss potential Targets for consideration as potential New Research Programs;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>consider, discuss and make recommendations with respect to proposals for New Research Programs;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font>discuss Atara&#8217;s regulatory strategy for IND filing for CTL Products;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)<font style="margin-left:36pt;"></font>validate and back up the intellectual property strategy;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)<font style="margin-left:36pt;"></font>review and track publications and proposed publications, and coordinate review and comments on proposed publications by each Party;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)<font style="margin-left:36pt;"></font>establish subcommittees, as appropriate, and support the operation of such subcommittees, including by seeking to resolve disputed matters that may arise at the subcommittees;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_393"></a>(xi)<font style="margin-left:36pt;"></font><a name="_cp_text_1_393"></a>assume a general role of leadership in the collaboration; and</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(xii)<font style="margin-left:36pt;"></font>perform any and all tasks and responsibilities that are expressly attributed to the JSC under this Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing roles and responsibilities, unless expressly set forth in this Agreement or the License Agreement, the JSC shall serve solely as a forum for information exchange with respect to any matters that relate to (i) regulatory matters, including the regulatory strategy and filings for Regulatory Approvals in the Territory, (ii) commercialization of CTL Products (whether or not arising out of this Agreement), (iii) changes to the Budget for activities under the Development Plan with respect to Allogeneic CTL Programs or New Research Programs, and (iv) subject to Article 13 of the License Agreement, intellectual property strategy, including prosecution, maintenance and enforcement activities.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Frequency of Meetings</font>.&nbsp;&nbsp;The JSC shall meet at least once per quarter or more or less often as otherwise agreed by the Parties, and such meetings may be conducted by telephone, videoconference or in person as determined by the co-chairs, provided that no less than </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-15</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two (2) meetings during each calendar year shall be conducted in person.&nbsp;&nbsp;As appropriate, and provided that not less than two (2) business days&#8217; prior written notice has been given to the other Party, other employees of the Parties may attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting without the other Party&#8217;s prior consent.&nbsp;&nbsp;Each Party may also call for special meetings of the JSC with reasonable prior written notice (it being agreed that at least five (5) business days shall constitute reasonable notice) to resolve particular matters requested by such Party and within the decision-making responsibility of the JSC.&nbsp;&nbsp;Each co-chair shall ensure that its JSC members receive adequate notice of such meetings.&nbsp;&nbsp;Each Party shall be responsible for all of its own expenses incurred in connection with participating in all such meetings.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Subcommittees</font>.&nbsp;&nbsp;The JSC may establish and disband such subcommittees as deemed necessary by the JSC.&nbsp;&nbsp;Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties.&nbsp;&nbsp;Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute representative to any subcommittee meeting.&nbsp;&nbsp;Each Party&#8217;s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in <font style="text-decoration:underline;">Article 6</font>.&nbsp;&nbsp;Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC.&nbsp;&nbsp;Each Party shall be responsible for all of its own expenses incurred in connection with participating in all such meetings.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cooperation</font>.&nbsp;&nbsp;Each Party shall provide the JSC such information as required under the Development Plan, or as reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under the Development Plan.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_398"></a>(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Decisions</font>.&nbsp;&nbsp;Other than as set forth herein, in order to make any decision required of it hereunder, the JSC must have present (in person, by videoconference or telephonically) at least the co-chair of each Party (or his/her designee for such meeting).&nbsp;&nbsp;Decisions of the JSC shall be by consensus, with each Party having one (1) vote.&nbsp;&nbsp;If the JSC cannot reach consensus or a dispute arises which cannot be resolved within the JSC within [***], the co-chair of either Party may cause such dispute to be referred to the Designated Executive Officers for resolution within [***].&nbsp;&nbsp;In the event that consensus cannot be reached with respect to a decision after a meeting of the Designated Executive Officers, then, if the decision relates to (A) commercialization of any CTL Product, New CTL Product or [***] that has been included within the License Agreement pursuant to Section 2.3(d), including regulatory strategy for any such CTL Products, New CTL Products or [***]<a name="_cp_text_1_398"></a>, (B) changes to the Development Plan that would require a material change in the scope of activities for any Program thereunder, or an increase in the Budget for development activities relating to the Allogeneic CTL Programs or the Autologous CTL Programs, including any increase in the Budget pursuant to this Agreement (where Atara has not previously authorized such increase), or (C) the scope of research and development activities under, or budget for, any New Research Program, including whether or not to include such New Research Program within the Research Collaboration, the final decision will be made by [***].&nbsp;&nbsp;If a dispute arises which cannot be resolved by a subcommittee, the co-chair of either Party may cause such dispute to be referred to the JSC for resolution.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-16</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exceptions</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding the foregoing, (i) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not use its final decision making authority to require </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Research Collaboration, without </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior written consent, and (ii) neither Party in exercising its right to finally resolve a dispute pursuant to Section 3.3(f) shall have any power to (A) cause the other Party to violate any Applicable Law or to breach any agreement between such other Party and any Third Party, or (B) to amend, modify, or waive compliance with the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Authority</font>.&nbsp;&nbsp;The JSC and any subcommittee shall have only the powers assigned expressly to it in this Article 3 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement.&nbsp;&nbsp;In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JSC or subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Discontinuation of JSC</font>.&nbsp;&nbsp;The JSC shall continue to exist until the first to occur of (i) the Parties mutually agreeing to disband the JSC or (ii) until the termination or expiration of the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028553"></a>4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">BUDGET; MILESTONES; PAYMENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font>[Reserved]&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref5111578"></a><a name="_cp_text_1_401"></a><a name="_cp_text_1_402"></a>4.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Budget</font>.&nbsp;&nbsp;Atara shall pay Institute the amounts set forth in the mutually agreed upon budget set forth in <font style="text-decoration:underline;">Schedule 4.2</font> (the &#8220;<font style="text-decoration:underline;">Budget</font>&#8221;), incorporated herein, to cover all direct and indirect costs of the Allogeneic Programs and EBV Autologous Program and excluding the [***] Programs, for which budget and funding shall be subject to <font style="text-decoration:underline;">Section 2.6(f)</font><a name="_cp_text_1_401"></a>.&nbsp;&nbsp;The Parties may mutually agree upon changes to the Budget <a name="_cp_text_1_402"></a>or changes in the allocation of the Budget to activities under the Development Plan by mutual written agreement in a document executed by duly authorized representatives of both Parties or otherwise expressly agreed to in writing by the Alliance Managers and representatives on the JSC of both Parties that states that it is effectuating such changes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_404"></a><a name="_cp_text_1_406"></a><a name="_cp_text_1_408"></a><a name="_cp_text_1_410"></a>4.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Changes to the Budget</font>.&nbsp;&nbsp;During the term of this Agreement, the Parties may discuss, subject to [***] <font style="text-decoration:underline;">Section 3.3(f)</font> with respect to the Research Collaboration and any New Research Programs other than the [***] Programs, increases to the Budget for the Research Collaboration, which may include, without limitation, increases in the number of Institute FTEs allocated to perform activities hereunder.&nbsp;&nbsp;For clarity, any budget increases for the [***] Programs shall be subject to <font style="text-decoration:underline;">Section 2.6(f)(iii)</font><a name="_cp_text_1_404"></a>.&nbsp;&nbsp; For <a name="_cp_text_1_406"></a>the avoidance of doubt<a name="_cp_text_1_408"></a>, the Parties agree that as of the Effective Date, <a name="_cp_text_1_410"></a>[***].</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Research Milestones</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_107"></a><a name="_cp_text_1_109"></a><a name="_cp_text_1_111"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_107"></a>As additional consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration in accordance with this Agreement, Atara has paid, or will pay to Institute the research milestone payments (each, a &#8220;<font style="font-weight:bold;">Research Milestone Payment</font>&#8221;) set forth in the table below for each Allogeneic CTL Product and/or Autologous CTL Product (as applicable pursuant to the table set </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-17-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forth below) to achieve the corresponding milestone (each, a &#8220;</font><font style="font-weight:bold;">Research Milestone</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara.&nbsp;&nbsp;The Party achieving such Research Milestone shall promptly notify the other Party in writing of the achievement of any such Research Milestone and Atara shall pay Institute in full the corresponding Research Milestone Payment within </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_109"></a> of such achievement.&nbsp;&nbsp;For clarity, each Research Milestone Payment is payable once only for each Allogeneic CTL Product and once for each Autologous CTL Product, and each Research Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Parties acknowledge and agree that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_111"></a>as of the Execution Date</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Atara has paid the Research Milestone Payment for First Dosing in a Human Subject for a CTL Product Specifically Directed to EBV for a first Allogeneic CTL Product.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:88.13%;">
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research Milestone Trigger Event</p></td>
<td colspan="2" valign="middle"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:44.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research Milestone Payment</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CTL Product</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Specifically</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directed <font style="font-size:12pt;font-weight:normal;">[***]</font></p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product Arising</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directly From</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Activities under</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New Research</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Programs</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:9.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:45.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:24.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Milestone payable only once with respect to each Allogeneic Licensed Product to achieve such Milestone.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**Milestone payable once for each Allogeneic CTL Product and for each Autologous CTL Product to achieve such Research Milestone.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>As consideration for Institute entering into this Agreement and diligently progressing the activities under the Research Collaboration with respect to the [***] Programs in accordance with this Agreement, Atara:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_414"></a><a name="_cp_text_1_416"></a>(i)<font style="margin-left:36pt;"></font>paid to Institute <a name="_cp_text_1_416"></a>a fixed fee of two million five hundred thousand dollars ($2,500,000) within fifteen (15) business days following the Original Effective Date (which fee is non-refundable and non-creditable against any other amounts due under this Agreement), and</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-18</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:34.62%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_418"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will pay to Institute the following milestone payments with respect to research and development activities conducted under the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Program (each, a &#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-weight:bold;"> Milestone Payment</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) set forth in the table below for each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to achieve the corresponding milestone (each, a &#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-weight:bold;"> Milestone</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), whether achieved by Institute, Atara or an Affiliate or sublicensee of Atara.&nbsp;&nbsp;The Party achieving such </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall promptly notify the other Party in writing of the achievement of any such </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Milestone and Atara shall pay Institute in full the corresponding </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Milestone Payment within thirty (30) days of such achievement.&nbsp;&nbsp;For clarity, each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payment is payable once only for the first </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to reach the applicable milestone event, and each </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_418"></a> Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:87.95%;">
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="font-weight:bold;font-size:10pt;"> Milestone Trigger Event</font></p></td>
<td valign="middle"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:61.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:27.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Unless a Research Milestone Payment or [***] Milestone Payment is specified as payable for more than one Indication in the tables in (a) and (b) above respectively, each Research Milestone Payment and [***] Milestone Payment will be payable by Atara only once, following the first time a given CTL Product or [***], as applicable, developed under this Agreement achieves the specified Research Milestone or [***] Milestone.&nbsp;&nbsp;For example, with respect to the Research Milestone Payments, Research Milestone 2 in the table above shall be payable for a given Allogeneic CTL Product upon [***], but shall not be payable for such Allogeneic CTL Product for any subsequent [***].</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Each time a Research Milestone or [***] Milestone (as applicable) is achieved, then any other Research Milestone Payments with respect to earlier Research Milestones or [***] Milestone Payments with respect to earlier [***] Milestones that have not yet been paid will be due and payable together with the Research Milestone Payment for the Research Milestone, or [***] Milestone Payments for the [***] Milestone, as applicable, that is actually achieved.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>If, with respect to a given CTL Product developed or commercialized under this Agreement or the License Agreement and a given Indication, Atara elects to progress the development and commercialization of an Autologous CTL Product in lieu of an Allogeneic CTL Product for such Indication, then (i) following the decision to progress development and commercialization of such Autologous CTL Product, Atara shall owe all subsequent Research Milestone Payments due for such Autologous CTL Product, and (ii) subsection (c) shall apply solely with respect to any Research Milestone Payments that are </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-19</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable to both Autologous CTL Products and Allogeneic CTL Products, and have not already been paid for the Allogeneic CTL Product.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Other Payments</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_421"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_421"></a>Atara shall pay any amounts agreed to by Atara and included in the Budget to Institute on a Calendar Quarterly basis in advance, based on the allocation of such amounts to activities under the Development Plan for the applicable Calendar Quarter.&nbsp;&nbsp;Institute shall submit invoices to Atara on a Calendar Quarterly basis, no later than [***] prior to the last day of each Calendar Quarter, setting forth the amounts payable for the upcoming Calendar Quarter and the activities to which such amounts are allocated under the Development Plan.&nbsp;&nbsp;The first invoice shall be due under this Agreement no later than [***] following the Original Effective Date.&nbsp;&nbsp;Each invoice shall be signed by an authorized official of Institute.&nbsp;&nbsp;Atara shall make payment by wire transfer to Institute&#8217;s nominated bank account.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_426"></a><a name="_cp_text_1_428"></a>(b)<font style="margin-left:36pt;"></font>Atara shall pay the <a name="_cp_text_1_426"></a>[***] Research Contribution (and any other amounts agreed to by Atara and included in the <a name="_cp_text_1_428"></a>[***] Budgets) as set forth in Section 2.6(c) and (d) of the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_429"></a><a name="_Toc4028554"></a>5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">PRINCIPAL INVESTIGATOR AND PERSONNEL</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Principal Investigator.&nbsp;&nbsp;</font>For the purpose of this Agreement and pursuant to Institute policy, Principal Investigator shall be responsible for the administration, direction, and content of the Research Collaboration, including expenditures under the Budget, and revisions to the allocation and individual expenditures within the overall framework, and subject to the overall cap, of the Budget, in each case necessary to accomplish the Research Collaboration.&nbsp;&nbsp;Should the Principal Investigator leave Institute or otherwise become unavailable during the term of this Agreement, Institute may nominate a replacement.&nbsp;&nbsp;In the event that the Principal Investigator becomes unable or unwilling to continue the Research Collaboration, and a substitute reasonably acceptable to Atara is not available, Atara shall have the right to terminate the Research Collaboration and this Agreement by giving written notice to Institute.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_432"></a>5.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Other Commitments.&nbsp;&nbsp;</font>Except as otherwise agreed, it is further understood that Institute and the personnel performing the Research Collaboration may be or become involved in other activities and projects which entail commitments to other Third Parties (&#8220;<font style="font-weight:bold;">Other Work</font><a name="_cp_text_1_432"></a>&#8221;).&nbsp;&nbsp;The Principal Investigator and the personnel performing the Research Collaboration will use Commercially Reasonable Efforts to progress the Research Collaboration in accordance with terms of the Development Plan, including any timelines set forth therein.&nbsp;&nbsp;Institute and the personnel performing the Research Collaboration will each use their best efforts to avoid conflicts with the terms and obligations of this Agreement.&nbsp;&nbsp;The Principal Investigator will provide Atara with written notice as soon as practicable if he becomes aware of a conflict or potential conflict that may materially impose upon his ability to perform activities under the Development Plan and this Agreement.&nbsp;&nbsp;Nothing in this Agreement shall be construed to limit the freedom of Institute, or their researchers who are not participants in the Research Collaboration under this Agreement, from engaging in Other Work made under other agreements with other parties than Atara.&nbsp;&nbsp;Notwithstanding the foregoing, Institute and the Principal Investigator shall use all reasonable efforts to distinguish the research performed in connection with the Research Collaboration under </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-20-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this Agreement from all Other Work, and shall keep records pertaining to such Other Work separately from the records to be maintained pursuant to </font><font style="text-decoration:underline;">Article 8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028555"></a>6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">CONFIDENTIALITY</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Confidential Information</font>.&nbsp;&nbsp;Atara and Institute will treat and maintain the other Party&#8217;s Confidential Information in confidence using at least the same degree of care as the receiving Party uses to protect its own proprietary and confidential information of a like nature from the date of disclosure until [***] after the termination or expiration of this Agreement, provided that a Party may designate one or more specific, defined items of Confidential Information as &#8216;Trade Secret&#8217;, by giving written notice to the other Party briefly outlining its reasons why longer protection is warranted, and in such case the other Party shall protect such information indefinitely unless and until <font style="text-decoration:underline;">Section 6.4</font> applies.&nbsp;&nbsp;Confidential Information can be written, oral, or both.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Relationship to Existing Confidentiality Agreement</font>.&nbsp;&nbsp;This Agreement supersedes that certain Confidential Disclosure Agreement entered into between Atara and Institute, dated May 28, 2015 (the &#8220;<font style="font-weight:bold;">Existing Confidentiality Agreement</font>&#8221;); provided that all &#8220;Confidential Information&#8221; disclosed by the disclosing party thereunder shall be deemed Confidential Information of the disclosing Party hereunder and shall be subject to the terms and conditions of this Agreement and the receiving party thereunder shall be bound by and obligated to comply with such terms and conditions as if they were the receiving Party hereunder.&nbsp;&nbsp;The foregoing shall not be interpreted as a waiver of any remedies available to the disclosing party as a result of any breach, prior to the Original Effective Date, by the receiving party, respectively, of its obligations pursuant to the Existing Confidentiality Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Permitted Disclosure</font>.&nbsp;&nbsp;Atara and Institute may use and disclose the other Party&#8217;s Confidential Information to their Affiliates, employees, agents, consultants, contractors, and, in the case of the Atara, its Sublicensees, in each case on a need to know basis for the purposes of such Affiliates, Sublicensees and Third Parties performing activities under this Agreement or the License Agreement, provided that such parties are bound by a like duty of confidentiality as that found in this <font style="text-decoration:underline;">Article 6</font>.&nbsp;&nbsp;Furthermore, Atara may disclose Institute&#8217;s Confidential Information to: (a) Atara&#8217;s potential or actual collaborators, partners, licensees and Sublicensees, and (b) potential or actual investment bankers, acquirers, lenders or investors, and (c) advisors of Atara or any of the foregoing in (a) and (b); each of whom, prior to disclosure, must be bound by similar obligations of confidentiality and non-use as set forth in this <font style="text-decoration:underline;">Article 6</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Limitations</font>.&nbsp;&nbsp;Nothing contained herein will restrict or impair, in any way, the right of Atara or Institute to use or disclose any of the other Party&#8217;s Confidential Information:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>that recipient can demonstrate by written records was previously known to it prior to its disclosure by the disclosing Party;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>that recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than through acts or omissions of recipient;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that recipient can demonstrate by written records was obtained lawfully and without restrictions on the recipient from sources independent of the disclosing Party; and</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>that a Party is required to disclose pursuant to applicable law, rule or regulation.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Other Disclosures</font>.&nbsp;&nbsp;Atara or Institute also may disclose Confidential Information that is required to be disclosed: (i) to a governmental entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental contractual requirement; or (ii) by law, provided that the recipient uses reasonable efforts to give the Party owning the Confidential Information sufficient notice of such required disclosure to allow the Party owning the Confidential Information reasonable opportunity to object to, and to take legal action to prevent, such disclosure.&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, Atara may disclose Confidential Information it receives pursuant to this Agreement, to its actual or potential investors, acquirors, advisors, Sublicensees, consultants and employees who are bound by obligations of confidentiality with respect thereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Return of Information</font>.&nbsp;&nbsp;Upon expiration or termination of this Agreement (unless the License Agreement remains in effect), or the request of the disclosing Party, if earlier, Atara and Institute will destroy or return any of the disclosing Party&#8217;s Confidential Information in its possession within [***] following the termination of this Agreement and provide each other with prompt written notice that such Confidential Information has been returned or destroyed.&nbsp;&nbsp;Each Party may, however, retain one (1) copy of such Confidential Information for archival purposes in non-working files.&nbsp;&nbsp;If the License Agreement remains in effect as of the date of termination or expiration of this Agreement, then all Confidential Information disclosed pursuant to this Agreement, if not returned or destroyed at the disclosing Party&#8217;s request pursuant to this <font style="text-decoration:underline;">Section 6.6</font>, shall be deemed Confidential Information subject to the terms and conditions of Article 22 of the License Agreement.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028556"></a>7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">PUBLICATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Publication.&nbsp;&nbsp;</font>Either party, consistent with academic standards, may publish or present the Data (as defined in <font style="text-decoration:underline;">Article 8</font> below), provided such publication or presentation does not disclose the other party&#8217;s Confidential Information.&nbsp;&nbsp;The Parties agree that any publication or presentation of Data shall appropriately cite the contributions of both Parties, using customary standards of scientific attribution.&nbsp;&nbsp;Each Party shall provide the other Party with a copy of such publication or presentation [***] prior to submission for presentation or publication to permit protection of any Confidential Information and/or patent rights, if desired and applicable.&nbsp;&nbsp;The other Party shall have [***], after receipt of said copies, to object to such proposed presentation or proposed publication because it includes patentable subject matter which needs protection or because it includes Confidential Information of such other Party.&nbsp;&nbsp;In the event that the other Party makes such objection, the publishing party shall refrain from making such publication or presentation for a maximum of [***] from date of receipt of such objection in order to allow the other Party to seek patent protection on any patentable Inventions included in the proposed publication or presentation, and the publishing Party shall remove the other Party&#8217;s Confidential Information from such publication or presentation before submitting or presenting it to any Third </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-22</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party.&nbsp;&nbsp;Atara further agrees that Institute shall have the first right to publish any results of the Research Collaboration, pursuant to the terms of this </font><font style="text-decoration:underline;">Article 7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the case of Confidential Information of Atara being results of the Research Collaboration, Institute may publish a publication or presentation containing such information after taking into account any comments by Atara in good faith and after allowing Atara to seek patent protection in accordance with this </font><font style="text-decoration:underline;">Section 7.1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, unless Atara (acting reasonably) designates such information as a &#8216;Trade Secret&#8217;. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;"></font>No Use of Names.&nbsp;&nbsp;<font style="font-weight:normal;">Neither Party will use the name of the other Party or its employees in any advertisement, press release, or other publicity without prior written approval of the other Party.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028557"></a>8.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">REPORTS; RIGHTS IN DATA</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Reporting.&nbsp;&nbsp;</font>Each Party shall, in accordance with its established practice, keep complete and accurate records of the work performed under this Agreement, including all expenditures under the Budget.&nbsp;&nbsp;Institute shall provide Atara with a written report, prior to any meeting of the JSC, or at such other frequency as is mutually agreed to by the Parties (the &#8220;<font style="font-weight:bold;">Interim Reports</font>&#8221;).&nbsp;&nbsp;Such reports shall set forth, at a minimum: (a) the activities performed and to be performed under the Development Plan, (b) results generated during the conduct of the Research Collaboration, (c) any CTL Products or, New CTL Products or [***] identified, (d) the quality and quantity of any materials (including without limitation biological or chemical compounds or raw materials) transferred by either party for the purposes of progressing the Research Collaboration and (e) material expenditures of funds under the Budget, and (f) subject to any obligations of confidentiality to any Third Party, a summary of activities of Atara and its Affiliates relevant to the research and development of CTL Products outside the Research Collaboration, excluding information regarding Atara&#8217;s activities under the MSK Agreement.&nbsp;&nbsp;Institute shall provide a comprehensive final written report of all activities conducted, and all results and data generated (collectively &#8220;<font style="font-weight:bold;">Data</font>&#8221;) under the Autologous Programs, the Allogeneic Programs, and any New Research Programs within ninety (90) days after termination of this Agreement (&#8220;<font style="font-weight:bold;">Final Report</font>&#8221;).&nbsp;&nbsp;During the course of the Research Collaboration, Atara&#8217;s representatives may consult informally with the Principal Investigator at his or her discretion and convenience regarding the Research Program.&nbsp;&nbsp;Atara shall also be required to provide Interim Reports in accordance with this <font style="text-decoration:underline;">Section 8.1</font>, on a Program-by-Program basis: (i) for the Allogeneic Programs, following completion of Phase I Clinical Trials for the applicable Allogeneic Program(s), and (ii) for the Autologous Programs, in consultation with Institute.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Rights in Data.&nbsp;&nbsp;</font>Institute shall own all Interim Reports and the Final Report, and information and data contained therein or arising from the activities conducted under this Agreement and the Development Plan.&nbsp;&nbsp;Subject to the provisions of <font style="text-decoration:underline;">Articles 6</font> and <font style="text-decoration:underline;">7</font>, Atara shall have the unencumbered right to use the Interim Reports and the Final Report[s], and any and all information and Data contained therein for any and all purposes, including the right to reference such Data and information in any regulatory filings in relation to any CTL Product, New CTL Product or Program [***] under this Agreement or the License Agreement, and shall have the right to grant or sublicense to others the right to so use and reference such Data and information.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-23</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028558"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">INTELLECTUAL PROPERTY</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Ownership.&nbsp;&nbsp;</font>With the exception of the rights granted to Institute to perform its obligations under this Agreement, and the rights granted to Atara pursuant to the License Agreement, each Party shall retain all right, title and interest in and to its Background IP.&nbsp;&nbsp;Except as provided in Section 9.4, inventorship/authorship of all patents, copyrights, trade secrets and other intellectual property rights, in and to all tangible materials (including without limitation all biological materials), inventions, discoveries, and software conceived or first made in the performance of the Research Collaboration under this Agreement (&#8220;<font style="font-weight:bold;">Inventions</font>&#8221;) will be determined in accordance with U.S. patent/copyright law, such that all Inventions that are conceived or made solely by one or more employees of Atara in the course of the Research Collaboration and are not Improvements (&#8220;<font style="font-weight:bold;">Atara Inventions</font>&#8221;) shall be owned solely by Atara and all Inventions which are conceived or made solely by one or more employees of Institute in performance of Research Collaboration and are not Improvements (&#8220;<font style="font-weight:bold;">Institute Inventions</font>&#8221;) shall be solely owned by Institute.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Joint Inventions</font>.&nbsp;&nbsp;Inventions that are jointly conceived or reduced to practice by one or more employees, consultants or contractors of each Party, shall be jointly owned by the parties (each such invention, a &#8220;<font style="font-weight:bold;">Joint Invention</font>&#8221;).&nbsp;&nbsp;Ownership of all Inventions shall vest in the party to whom the inventor has an obligation of assignment.&nbsp;&nbsp;Institute will obtain agreements securing the assignment to Institute of all Inventions and intellectual property rights from the Principal Investigator and all employees, other agents and consultants who perform any part of the Research Collaboration at Institute that are necessary to enable Institute to grant to Atara all rights Institute purports to grant under this Agreement and the License Agreement.&nbsp;&nbsp;Subject to the terms and conditions of the License Agreement, including any exclusive licenses granted thereunder (for such time as such licenses have effect), each Party shall have all rights under any jointly owned patent, patent application or other form of intellectual property protection relating to any Joint Invention to use, research, develop, and commercially exploit such Joint Invention and to license and sublicense Third Parties (through multiple tiers of sublicensing) to do so.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_434"></a>9.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Inclusion within the License Agreement</font><a name="_cp_text_1_434"></a>.&nbsp;&nbsp;All Institute Inventions arising under this Agreement shall be automatically included, upon their creation, within the Patent Rights and Know-How Rights under the License Agreement, and shall be subject to the terms and conditions of the License Agreement, provided that for clarity, Atara shall only have rights to practice under any such Institute Inventions in relation to&nbsp;&nbsp;[***] of the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Improvements to Background IP</font>.&nbsp;&nbsp;Notwithstanding <font style="text-decoration:underline;">Sections 9.1</font> and <font style="text-decoration:underline;">9.2</font>, Institute shall be the sole owner of any Inventions that are claimed or covered by patents and patent applications claiming priority to any patent or patent application included in the Patent Rights, as such Patent Rights exist as of the Original Effective Date (such Inventions, the &#8220;<font style="font-weight:bold;">Institute Background IP Improvements</font>&#8221;).&nbsp;&nbsp;Atara shall assign, and hereby assigns to Institute, all of Atara&#8217;s right, title and interest in and to the Institute Background IP Improvements.&nbsp;&nbsp;Without limiting the foregoing, Institute Background IP Improvements shall be included, upon their creation by either Party (or assignment by Atara to Institute in accordance with this <font style="text-decoration:underline;">Section&#160;9.4</font>, if applicable), within the Patent Rights, and shall be subject to the terms and conditions of the License Agreement, including the licenses granted therein.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-24</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Option to License Atara IP</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In addition to such rights of reversion as are contained in the License Agreement, Atara will, prior to granting or offering to grant to any Third Party any license or other right to research, develop or commercially exploit any Atara Invention, first discuss with Institute in good faith for a period of not less than </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether, and on what terms, Institute may wish to use or license such Atara Invention in fields or applications not the subject of the License Agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Disclosure</font>.&nbsp;&nbsp;Institute will require the Principal Investigator and other investigators to promptly disclose all Inventions and Joint Inventions generated during the term of this Agreement to Institute&#8217;s Business Development Office in accordance with Institute policy with respect to ownership and disclosure of Inventions (and Joint Inventions).&nbsp;&nbsp;Institute or the Business Development Office of Institute, as applicable, will notify Atara promptly in writing following disclosure of a Institute Invention by any inventor, and disclose in confidence to Atara all Institute Inventions, including sufficient detail to enable Atara to evaluate such Institute Invention.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Patent Filings</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Joint Inventions</font>.&nbsp;&nbsp;Institute will use reasonable efforts to ensure that Atara has the first opportunity to file a patent application or application for other intellectual property protection on any Joint Inventions.&nbsp;&nbsp;Institute&#8217;s rights in any Joint Invention shall be automatically included within the Know-How Rights or the Patent Rights, as applicable, under the License Agreement, and shall be subject to all of the terms and conditions of the License Agreement.&nbsp;&nbsp;Atara&#8217;s prosecution and maintenance of any patents and patent applications arising from Joint Inventions shall be conducted in accordance with Section 13.2 of the License Agreement.&nbsp;&nbsp;If Atara elects not to file a patent application or application for other intellectual property protection on any Joint Inventions, or decides that it does not wish to provide financial support for the prosecution or maintenance of the protection for such Joint Inventions, Institute shall thereafter be free to file or continue prosecution or maintain any such application(s), and to maintain any protection issuing thereon in the U.S. and in any foreign country at Institute&#8217;s sole expense and with no further obligation to Atara, and such patent or patent application shall not be included within the Patent Rights under the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Inventions</font>.&nbsp;&nbsp;Section 13.2 of the License Agreement shall apply to all filing, prosecution and maintenance of any patents and patent applications arising from Institute Inventions and Institute Background IP Improvements.&nbsp;&nbsp;Atara shall have the sole right, but not the obligation to file, prosecute and maintain patents and patent applications arising from the Atara Inventions.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8<font style="margin-left:36pt;"></font>Except as expressly provided herein or in the License Agreement, nothing contained in this Agreement shall be deemed to grant either directly or by implication, estoppel, or otherwise any license under any patents, patent applications, or other proprietary interests to any other invention, discovery, or improvement of either Party.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-25</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028559"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">EXCHANGE OF MATERIALS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All materials, including any CTLs, including progeny and modified or unmodified derivatives, exchanged pursuant to this Agreement shall remain the property of the providing Party and shall be used solely for the purposes of the Research Collaboration, unless otherwise mutually agreed in writing.&nbsp;&nbsp;Upon expiration or termination of this Agreement, the unused portions of such materials will be returned promptly to the providing Party or will be disposed of as directed by the providing Party in writing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028560"></a>11.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">SUPPLIES AND EQUIPMENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that Institute purchases supplies or equipment under the Budget for the Research Collaboration, title to such supplies and equipment shall vest in Institute, unless the Parties mutually agree otherwise in writing.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028561"></a>12.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">INDEMNIFICATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Atara Indemnification</font>.&nbsp;&nbsp;Atara agrees to indemnify, defend and hold harmless Institute and its trustees, officers, staff, representatives and agents (&#8220;<font style="font-weight:bold;">Institute Indemnitees</font>&#8221;) against all damages, costs, expenses, losses and liabilities (&#8220;<font style="font-weight:bold;">Losses</font>&#8221;) actually awarded by a court of competent jurisdiction or agreed in settlement, as a result of any third party claims, demands, suits, or other actions (&#8220;<font style="font-weight:bold;">Claims</font>&#8221;) arising from (a) Atara&#8217;s use of the Data or Inventions in connection with Atara&#8217;s activities pursuant to the License Agreement, including the development and commercialization of CTL Products and any New CTL Products and Program [***] (in each case, if applicable), (b) Atara&#8217;s breach of this Agreement or the Development Plan (including without limitation Atara&#8217;s breach of its representations and warranties), (c) the negligent or wrongful acts or omissions or of any Institute officer, agent, or employee the negligent or intentional acts or omissions or breach of this Agreement (including without limitation Atara&#8217;s breach of its representations and warranties) by Atara and its officers, agents, and employees; provided that Atara will have no obligation to indemnify Institute Indemnitees to the extent that any such Claim is based on Institute&#8217;s negligence, willful misconduct or breach of this Agreement (including without limitation Institute&#8217;s breach of its representations and warranties).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_437"></a><a name="_cp_text_1_119"></a>12.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Institute Indemnification</font>.&nbsp;&nbsp;Institute agrees, to the extent permitted by law, to indemnify, defend and hold harmless Atara and its stockholders, officers, staff, representatives and agents (&#8220;<font style="font-weight:bold;">Atara Indemnitees</font><a name="_cp_text_1_119"></a>&#8221;) against all Losses actually awarded by a court of competent jurisdiction or agreed in settlement, as a result of any Claims arising from (a) any activities related to the [***] Program occurring after June 30, 2019 and (b) any other CMV-related activities of Institute following the Execution Date; provided that Institute will have no obligation to indemnify Atara Indemnitees to the extent that any such Claim is based on Atara&#8217;s negligence, willful misconduct or breach of this Agreement (including without limitation Atara&#8217;s breach of its representations and warranties).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028562"></a>13.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">NOTICE</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_440"></a><a name="_cp_text_1_440"></a>Except for the remittance of payments due pursuant to the terms hereof, whenever any notice is to be given hereunder, it shall be in writing and shall be deemed received, if delivered by </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-26-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">courier on a business day, on the day delivered, or on the second business day following mailing, if sent by first-class certified or registered mail, postage prepaid, to the following addresses:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:74.36%;">
<tr>
<td style="width:23.08%;"></td>
<td style="width:51.28%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Institute:</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Medical Research Institute</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Herston Road,</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Herston, QLD, 4006</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:74.36%;">
<tr>
<td style="width:23.08%;"></td>
<td style="width:51.28%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Atara:</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611 Gateway Blvd. #900</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, CA 94080</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: General Counsel</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028563"></a>14.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">DISPUTE RESOLUTION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Executive Resolution</font>.&nbsp;&nbsp;The parties shall initially seek amicably to settle all disputes (each, a &#8220;<font style="font-weight:bold;">Dispute</font>&#8221;) arising out of or in connection with this Agreement (including any Dispute relating to Development Plan and performance of activities thereunder) by negotiation, including discussion at the JSC, subject to the Parties&#8217; respective final decision making authority as set forth in <font style="text-decoration:underline;">Section 3.3(f)</font>.&nbsp;&nbsp;If, within [***] after written notice by either Party of the existence of a dispute, the Parties do not resolve such Dispute, then the Dispute shall be referred by the JSC to the Executive Officers from each Party for further negotiation.&nbsp;&nbsp;If the Designated Executive Officers of each Party cannot resolve such Dispute, then subject to <font style="text-decoration:underline;">Sections 3.3(f)</font> and <font style="text-decoration:underline;">14.7</font>, such Dispute will be referred to final binding arbitration in accordance with <font style="text-decoration:underline;">Sections 14.2</font> through <font style="text-decoration:underline;">14.6</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Arbitration</font>.&nbsp;&nbsp;Any Dispute referred for arbitration shall be finally settled under the Rules of the International Centre for Dispute Resolution (the &#8220;<font style="font-weight:bold;">Rules of Arbitration</font>&#8221;) then in force, by one arbitrator appointed in accordance with such Rules of Arbitration.&nbsp;&nbsp;The Arbitral Tribunal shall be guided by the IBA Rules on the Taking of Evidence in International Arbitration, and there shall be no depositions.&nbsp;&nbsp;The place of the arbitration shall be New York, New York, United States of America.&nbsp;&nbsp;The language of the arbitration shall be English.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Selection of the Arbitrator</font>.&nbsp;&nbsp;Each arbitrator shall have a minimum of [***]  of experience in arbitrating disputes in the pharmaceutical industry, or of pharmaceutical licensing disputes and be admitted to practice law in the United States of America.&nbsp;&nbsp;The arbitrator conducting the arbitration must and shall agree to render an award within [***] after the final hearing.&nbsp;&nbsp;The arbitrator [***].&nbsp;&nbsp;Without limiting any other remedies that may be available under Applicable Laws, the arbitrator shall have [***].</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Conduct of the Arbitration</font>.&nbsp;&nbsp;The Parties undertake to keep confidential all awards in their arbitration, together with all materials in the proceedings created for the purpose of the arbitration and all other documents produced by another Party in the proceedings not otherwise in the public domain, save and to the extent that disclosure may be required of a Party by legal duty or under Applicable Law, the rules and regulations of any stock exchange or quotation services on which such Party&#8217;s stock is traded or quoted, to protect or pursue a legal right or to enforce or challenge an award in legal proceedings before a court or other judicial authority.</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-27</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Continued Performance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Unless otherwise agreed in writing, the Parties will continue to perform their respective obligations under this Agreement during any arbitration or court proceeding seeking enforcement of an arbitral decision or award, and, unless this Agreement is in its entirety deemed null and void or is otherwise revoked or rescinded in its entirely, the Parties shall continue to perform their respective remaining obligations under this Agreement, and may continue to exercise their respective remaining rights and remedies thereunder, following any arbitration.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Preliminary Injunctions</font>.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any Dispute.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Patent Disputes</font>.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, any dispute concerning inventorship that is not resolved within [***]  following notice by one party to the other of the creation or reduction to practice of any Invention, and any dispute regarding any and all issues regarding the scope, construction, validity, and enforceability of any patent or patent application (including whether or not such patent or patent application should be included in the Patent Rights under the License Agreement) in a country within the Territory shall be determined in a court or other governmental authority of competent jurisdiction under the applicable patent laws of such country.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028564"></a>15.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Term</font>.&nbsp;&nbsp;This Agreement shall be effective from the Original Effective Date until all Research Milestone Payments under <font style="text-decoration:underline;">Section 4.4</font> have been paid, (the &#8220;<font style="font-weight:bold;">Term</font>&#8221;), unless earlier terminated in accordance with this <font style="text-decoration:underline;">Article 15</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Termination of License Agreement</font>.&nbsp;&nbsp;This Agreement will terminate automatically in the event that the License Agreement is terminated, provided that prior to such termination of this Agreement becoming effective, the Parties shall cooperate to wind down the activities being conducted hereunder as set forth in <font style="text-decoration:underline;">Section 15.5(b)</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Termination for Failure of the Research Collaboration.&nbsp;&nbsp;</font>This Agreement may be terminated by Institute or Atara at any time upon the giving of thirty (30) days&#8217; prior written notice to the other if either party determines, in its discretion, that the Research Collaboration is no longer academically, technically, or commercially feasible.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Termination for Material Breach</font>.&nbsp;&nbsp;In the event that either party materially breaches any of its obligations under this Agreement and shall fail to remedy such default within thirty (30) days after written notice thereof, the party not in default shall have the option of terminating this Agreement by giving written notice of termination with an immediate effect to the defaulting party.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Effects of Termination.&nbsp;&nbsp;</font>Following termination, but not expiration of this Agreement, the following shall apply:</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-28</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination of this Agreement shall not affect the rights and obligations of the parties accrued prior to termination.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">Promptly following any notice of termination of this Agreement, the Parties shall meet, through the JSC, to discuss and agree upon the steps to be taken to wind down the activities being conducted under the Research Collaboration, (the &#8220;</font><font style="font-weight:bold;color:#000000;">Wind Down Activities</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Unless requested in writing by Atara, agreed by the Parties to be included within the budget for </font>any Wind Down Activities, or already committed to be paid by Institute on a non-cancelable basis prior to the date of notice of termination, Institute shall not incur any additional costs or expenses in conducting activities under this Agreement following the date of notice of termination.&nbsp;&nbsp;Atara agrees to reimburse Institute for (i) any non-cancelable obligations actually incurred by Institute prior to termination in accordance with the Research Collaboration, provided such amounts have been incurred in accordance with the Budget, and (ii) any costs incurred in relation to the Wind Down Activities thereunder as mutually agreed by the JSC.&nbsp;&nbsp;Following wind-down of the Research Collaboration, Atara shall have no further obligations to make any payments to Institute.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>All materials, information and data, including any Confidential Information, provided by one Party to the other Party pursuant to this Agreement shall be returned to the disclosing Party as set forth in <font style="text-decoration:underline;">Section 6.6</font> and <font style="text-decoration:underline;">Article 10</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_450"></a>(d)<font style="margin-left:36pt;"></font>The Parties&#8217; rights in CTL Products, New CTL Products and [***]<a name="_cp_text_1_450"></a> arising from the conduct of activities under this Agreement prior to the effective date of termination shall be subject to Sections 9.6(b), (c), (e), (f), (g) and (i), 9.7 and 9.9 of the License Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_453"></a>15.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Survival.&nbsp;&nbsp;</font>Upon termination or expiration of this Agreement, any provisions herein which are intended to continue and survive such termination or expiration, including <font style="text-decoration:underline;"><a name="_cp_text_1_453"></a>Articles 1, 6, 7, 8, 9, 10, 12, 13, 14 </font>and <font style="text-decoration:underline;">16</font> through <font style="text-decoration:underline;">23</font>, and <font style="text-decoration:underline;">Sections 4.4</font> (to the extent that the License Agreement has not expired or terminated, and subject to Section 9.6(b) of the License Agreement) and <font style="text-decoration:underline;">15.5</font> shall survive any expiration or termination of this Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028565"></a>16.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">APPLICABLE LAW</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement shall be governed by the laws of the State of New York without regard to the conflict of law principles thereof.&nbsp;&nbsp;Any disputes arising hereunder shall be adjudicated accordance with <font style="text-decoration:underline;">Article 14</font>.<font style="text-decoration:underline;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028566"></a>17.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">WAIVER</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No waiver by either Party of any breach or default of any of the agreements contained herein will be deemed a waiver as to any subsequent and/or similar breach or default.&nbsp;&nbsp;No waiver of this Agreement is valid or binding on the Parties unless made in writing (identifying the provision that is waived) and signed on behalf of each Party.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028567"></a>18.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">ASSIGNMENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither party hereto may assign or transfer any rights or obligations under this Agreement without the prior written consent of the other party, except that no such consent shall be required </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-29</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for a party to assign its rights or transfer its obligations to its Affiliates or in connection with the sale or transfer of the majority of its stock or all or substantially all of its assets to which this Agreement relates, whether as part of a merger, acquisition, or asset sale.&nbsp;&nbsp;Any assignment in violation of this Agreement will be null and void.&nbsp;&nbsp;This Agreement benefits and binds the parties and their respective successors and permitted assigns.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref4537736"></a><a name="_Toc4028568"></a>19.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">ENTIRE AGREEMENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement, together with the License Agreement, any Manufacturing Agreement executed by the Parties, and any Exhibits to any of the foregoing, represents the entire understanding of the Parties and supersedes any prior or contemporaneous agreements or understandings between Principal Investigator or Institute with Atara with respect to the subject matter hereof, including the Original Research Agreement, the First Restated Agreement, the Second Restated Agreement, and the Third Restated Agreement.&nbsp;&nbsp;Furthermore, no modification, supplement, or new agreement may be executed, prior to the expiration of this Agreement, between Institute and Atara with respect to the subject matter hereof, without formal written amendment to this Agreement, signed by all Parties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028569"></a>20.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">INDEPENDENT CONTRACTOR</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In performing their respective duties under this Agreement, each of the Parties will be operating as an independent contractor.&nbsp;&nbsp;Nothing contained herein will in any way constitute any association, partnership, or joint venture between the Parties hereto, or be construed to evidence the intention of the Parties to establish any such relationship.&nbsp;&nbsp;Neither Party will have the power to bind the other Party or incur obligations on the other Party&#8217;s behalf without the other Party&#8217;s prior written consent.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028570"></a>21.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">SEVERABILITY</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any one or more of the provisions contained in this Agreement shall be held invalid, illegal, or unenforceable for any reason or in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028571"></a>22.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">CONSTRUCTION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The headings of the Sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.&nbsp;&nbsp;Except where the context otherwise requires, wherever used, the use of any gender will be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense.&nbsp;&nbsp;When used in this Agreement, &#8220;including&#8221; means &#8220;including without limitation&#8221;.&nbsp;&nbsp;References to either Party include the successors and permitted assigns of that Party.&nbsp;&nbsp;The Recitals are incorporated by reference into this Agreement.&nbsp;&nbsp;The headings of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement.&nbsp;&nbsp;The Parties have each consulted counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement will be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof.&nbsp;&nbsp;The official text of this Agreement, any notice given or accounts or statements required by this </p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-30</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, and any dispute proceeding related to or arising hereunder, will be in English.&nbsp;&nbsp;If any dispute concerning the construction or meaning of this Agreement arises, then reference will be made only to this Agreement as written in English and not to any translation into any other language.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc4028572"></a>23.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">COUNTERPARTS</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Fourth Restated Agreement may be executed in one or more counterparts, each of which together shall constitute one and the same Agreement.&nbsp;&nbsp;For purposes of executing this Fourth Restated Agreement, a facsimile (including a PDF image delivered via email) copy of this Fourth Restated Agreement, including the signature pages, will be deemed an original.&nbsp;&nbsp;The Parties agree that neither Party will have any rights to challenge the use or authenticity of a counterpart of this Fourth Restated Agreement based solely on that its signature, or the signature of the other Party, on such counterpart is not an original signature.</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-31</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, </font><font style="font-weight:normal;">the undersigned have entered into this </font><font style="font-weight:normal;">Fourth </font><font style="font-weight:normal;">Restated Agreement as of the date first set forth above.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed and Accepted By:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.:</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:86.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jakob DuPont</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:86.32%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jakob DuPont</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Head of R&amp;D</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Council of the Queensland Institute of Medical Research:</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="top"  style="width:13.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:86.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lee Bruce</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:86.32%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lee Bruce</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.68%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:86.32%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-32</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.15</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FTE RATES*</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-33</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 2.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DEVELOPMENT PLAN</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-34</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 4.2</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BUDGET</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-35</a>-</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>5
<FILENAME>atra-ex1038_102.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex1038_102.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 10.38</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0.96%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0.96%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0.96%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0.96%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0.96%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:7.69%;margin-right:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:5.13%;"></td>
<td style="width:6.41%;"></td>
<td style="width:87.23%;"></td>
<td style="width:5.07%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Article No.</p></td>
<td valign="top" >
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">1.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DEFINITIONS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">2.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">GRANT</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">3.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">SUBLICENSES</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">4.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">FINANCIAL PROVISIONS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">5.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DILIGENCE; REGULATORY ACTIVITIES</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">6.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">MANUFACTURE AND SUPPLY</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">7.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">CERTAIN COVENANTS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">8.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">BOOKS AND RECORDS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">9.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">TERM; TERMINATION</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">10.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">USE OF NAMES AND TRADEMARKS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">11.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">REPRESENTATIONS AND WARRANTIES</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">12.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">LIMITATION OF LIABILITY</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">13.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">14.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">PATENT INFRINGEMENT</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">15.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">INDEMNIFICATION</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">16.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">NOTICES</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">17.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">ASSIGNABILITY</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">18.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">FORCE MAJEURE</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">19.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">GOVERNING LAWS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">20.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DISPUTE RESOLUTION</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">21.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">COMPLIANCE WITH LAWS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">22.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">CONFIDENTIALITY</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">23.</font></p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">MISCELLANEOUS</font></p></td>
<td valign="top" >
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_8"></a>This <font style="font-weight:bold;">FOURTH AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT </font>(&#8220;<font style="font-weight:bold;">Fourth Restated</font> <font style="font-weight:bold;">Agreement</font>&#8221;) is entered into on December 17, 2021 (&#8220;<font style="font-weight:bold;">Execution Date</font><a name="_cp_text_1_8"></a>&#8221;), and effective as of the Execution Date, by and between the <font style="font-weight:bold;">COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH</font>, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (&#8220;<font style="font-weight:bold;">Institute</font>&#8221;), and <font style="font-weight:bold;">ATARA BIOTHERAPEUTICS, INC.</font>, a Delaware corporation located at 611 Gateway Blvd #900, South San Francisco, CA 94080 (&#8220;<font style="font-weight:bold;">Licensee</font>&#8221;).&nbsp;&nbsp;Each of Licensee and Institute are referred to in this Agreement as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and together, the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, <font style="font-weight:normal;">Institute owns or controls certain technology, including certain patent rights and know-how, and has expertise and knowledge relating to allogeneic and autologous cytotoxic T-lymphocytes (&#8220;</font>CTL<font style="font-weight:normal;">&#8221;) directed to antigens expressed in association with certain viral infections, for use in oncology and autoimmune indications, made in the course of research at Institute in the laboratory of [***] and are claimed in certain Patent Rights (as defined herein);</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee is a party to a certain agreement with Memorial Sloan Kettering Cancer Center (the &#8220;</font>MSK Agreement<font style="font-weight:normal;">&#8221;, as further defined below), pursuant to which Licensee obtained [***] at Memorial Sloan Kettering Cancer Center in the laboratory of [***], including [***]to targets that include, inter alia, EBV and CMV;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee and MSK consider the technology and patent rights owned or controlled by Institute to be complimentary and/or supplemental to the rights licensed to Licensee by Memorial Sloan Kettering Cancer Center under the MSK Agreement, and that such Institute technology will be useful for the development, production, or use of Licensed Products (as defined herein) specific to EBV;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee wishes to obtain certain rights from Institute to use such Institute technology and patent rights for the commercial development of (a)&#160;products based on novel allogeneic and autologous CTLs, and (b)&#160;[***], in each case directed to viral antigens expressed in association with certain diseases and conditions, in accordance with the terms and conditions set forth herein, and Institute is willing to grant those rights to Licensee so that such products may be developed and the benefits enjoyed by the general public;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee and Institute are parties to that certain exclusive License Agreement (the &#8220;</font>Original License Agreement<font style="font-weight:normal;">&#8221;), entered into on October&#160;20, 2015 (the &#8220;</font>Original Effective Date<font style="font-weight:normal;">&#8221;), which was amended and restated as of September 23, 2016 (the &#8220;</font>First Restatement Date<font style="font-weight:normal;">&#8221;) pursuant to that certain Amended and Restated Exclusive License Agreement (the &#8220;</font>First Restated Agreement<font style="font-weight:normal;">&#8221;) effective as of the Original Effective Date, which was amended and restated for a second time as of August 28, 2019 (the &#8220;</font>Second Restatement Date<font style="font-weight:normal;">&#8221;) pursuant to </font></p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">that certain Second Amended and Restated Exclusive License Agreement (the &#8220;</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second Restated Agreement</font><font style="font-weight:normal;">&#8221;),</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:normal;">which was amended and restated for a third time as of August </font><font style="font-weight:normal;">26, 2020</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">(&#8220;</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Restated </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</font><font style="font-weight:normal;">&#8221;)</font><font style="font-weight:normal;"> pursuant to that certain Third Amended and Restated Exclusive License Agreement </font><font style="font-weight:normal;">and was subsequently amended on April 21, 2021</font><font style="font-weight:normal;"> to change the HPV CTL Program to the HPV TCR Program</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">(</font><font style="font-weight:normal;">as so amended, the </font><font style="font-weight:normal;">&#8220;</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third </font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restated Agreement</font><font style="font-weight:normal;">&#8221;),</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="font-weight:normal;"> now the Parties desire to amend and restate the </font><font style="font-weight:normal;">Third </font><font style="font-weight:normal;">Restated Agreement in its entirety to, among other things, </font><font style="font-weight:normal;">[***]</font><font style="font-weight:normal;">, all as set forth in this </font><font style="font-weight:normal;">Fourth </font><font style="font-weight:normal;">Restated Agreement; and</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties further desire that Institute continues to carry out certain research and development activities already being conducted at or under the supervision of Institute, including certain clinical studies directed to the use of autologous CTL therapies in certain oncology and autoimmune indications associated with the expression of EBV [***]on or in tumor and other cells, and to that end, the Parties entered into that certain Research and Development Collaboration Agreement (the &#8220;</font>Original Research Agreement<font style="font-weight:normal;">&#8221;) simultaneous with the Original License Agreement on the Original Effective Date, which Original Research Agreement was amended and restated as of the First Restatement Date pursuant to that certain Amended and Restated Research and Development Collaboration Agreement and was subsequently amended on December 15, 2017, April 24, 2018 and May 9, 2018 (as so amended, the &#8220;</font>First Restated Research Agreement<font style="font-weight:normal;">&#8221;), which, in turn, was amended and restated on the Second Restatement Date pursuant to that certain Second Amended and Restated Research and Development Collaboration Agreement (&#8220;</font>Second Restated Research Agreement<font style="font-weight:normal;">&#8221;),</font> <font style="font-weight:normal;">which, in turn, as amended and restated on the Third Restatement Date pursuant to that certain Third Amended and Restated Research and Development Collaboration Agreement (&#8220;</font>Third Restated Research Agreement<font style="font-weight:normal;">&#8221;) and the Third Restated Research Agreement is being amended and restated in its entirety pursuant to that certain Fourth Amended and Restated Research and Development Collaboration Agreement simultaneously with entering into this Fourth Restated Agreement (the &#8220;</font>Fourth Restated Research Agreement<font style="font-weight:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the foregoing and the covenants and promises contained in this Agreement, and intending to be legally bound, the parties agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012473"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">DEFINITIONS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;">Technology</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.4(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Additional License</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Additional License Payments</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Additional Party</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Affiliate</font><font style="color:#000000;">&#8221; of a Party means any entity which, directly or indirectly, controls such Party, is Controlled by such Party or is under common Control with such Party.&nbsp;&nbsp;For purposes of the Affiliate definition, &#8220;</font><font style="font-weight:bold;color:#000000;">Control</font><font style="color:#000000;">&#8221; means: (a)&#160;having the actual, present capacity to elect a majority of the directors of such affiliate; (b)&#160;having the power to direct at least fifty percent (50%) of the voting rights entitled to elect directors; or (c)&#160;in any country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Agreement</font><font style="color:#000000;">&#8221; means the First Restated Agreement as in effect from the Original Effective Date until the Second Restatement Date, together with the Second Restated Agreement as in effect from the Second Restatement Date until the Third Restatement Date, together with the Third Restated Agreement as in effect from the Third Restatement Date until the Execution Date, together with this Fourth Restatement Agreement, which pursuant to </font><font style="text-decoration:underline;color:#000000;">Section 23.5</font><font style="color:#000000;">, replaces the Third Restated Agreement as of the Execution Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Allogeneic CTL</font><font style="color:#000000;">&#8221; means CTLs derived from cells obtained from one individual subject and treated, modified, manipulated or otherwise altered for the purposes of delivery to a second, genetically distinct individual subject.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Allogeneic CTL Product</font><font style="color:#000000;">&#8221; means a CTL Product or a New CTL Product derived from or incorporating Allogeneic CTLs.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_15"></a><a name="_cp_blt_2_14"></a><font style="Background-color:#auto;text-decoration:none;">1.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Autologous CTL</font><font style="color:#000000;">&#8221; means CTLs derived from cells obtained from one individual subject and treated, modified, manipulated or otherwise altered for the purposes of delivery back to the same individual subject.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_17"></a><a name="_cp_blt_2_16"></a><font style="Background-color:#auto;text-decoration:none;">1.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Autologous CTL Product</font><font style="color:#000000;">&#8221; means a CTL Product or a New CTL Product derived from or incorporating Autologous CTLs.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_19"></a><a name="_cp_blt_2_18"></a><font style="Background-color:#auto;text-decoration:none;">1.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Background IP</font><font style="color:#000000;">&#8221; means all intellectual property rights (a)&#160;Controlled by a Party prior to the Original Effective Date or (b)&#160;Controlled by such Party during the Term, but not generated in the performance of the activities contemplated under this Agreement or the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_21"></a><a name="_cp_blt_2_20"></a><font style="Background-color:#auto;text-decoration:none;">1.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Base Patent Rights</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_23"></a><a name="_cp_blt_2_22"></a><font style="Background-color:#auto;text-decoration:none;">1.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_25"></a><a name="_cp_blt_2_24"></a><font style="Background-color:#auto;text-decoration:none;">1.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Billion</font><font style="color:#000000;">&#8221; means one thousand million.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_27"></a><a name="_cp_blt_2_26"></a><a name="_cp_blt_1_29"></a><a name="_cp_blt_2_28"></a><font style="Background-color:#auto;text-decoration:none;">1.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">BKV/JCV-Specific CTL Product</font><font style="color:#000000;">&#8221; means a pharmaceutical or biologic product comprising Autologous CTLs or Allogeneic CTLs, in either case, Specifically Directed to [***]associated with BK Polyomavirus (&#8220;</font><font style="font-weight:bold;color:#000000;">BKV</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;"> and/or JC Polyomavirus (&#8220;</font><font style="font-weight:bold;color:#000000;">JCV</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">, including [***] BKV and/ or JCV [***] BKV</font><font style="color:#000000;"> and/or JCV</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_31"></a><a name="_cp_blt_2_30"></a><font style="text-decoration:none;Background-color:#auto;">1.16</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Calendar Quarter</font><font style="color:#000000;">&#8221; means each successive period of three (3) consecutive calendar months ending on the last day of March, June, September, or December, respectively; provided that, the final Calendar Quarter shall end on the last day of the Term.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_33"></a><a name="_cp_blt_2_32"></a><font style="Background-color:#auto;text-decoration:none;">1.17</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMO </font><font style="color:#000000;">shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;6.1(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_35"></a><a name="_cp_blt_2_34"></a><font style="Background-color:#auto;text-decoration:none;">1.18</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMV</font><font style="color:#000000;">&#8221; means human cytomegalovirus and any naturally occurring variants thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_37"></a><a name="_cp_blt_2_36"></a><font style="Background-color:#auto;text-decoration:none;">1.19</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMV-Specific CTL Product</font><font style="color:#000000;">&#8221; means any pharmaceutical or biologic product comprising CTLs Specifically Directed to one or more Targets associated with CMV, including any epitopes associated with CMV or expressed by a cell infected with CMV.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_39"></a><a name="_cp_blt_2_38"></a><a name="_cp_blt_2_8"></a><a name="_cp_blt_2_10"></a><a name="_cp_blt_2_12"></a><font style="Background-color:#auto;text-decoration:none;">1.20</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMV </font><font style="color:#000000;">[***]&#8221; means any [***], in whole or in part, or in any form, with or without [***], and in any formulation, including without limitation any such [***] that is also a [***], for use for (a)&#160;[***] or any [***] infected with CMV, or (b)&#160;[***] CMV, or any epitopes associated with CMV or expressed by a cell infected with CMV, or the expression of CMV, in each case of (a)&#160;and (b), [***]).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_41"></a><a name="_cp_blt_2_40"></a><a name="_cp_text_2_16"></a><font style="Background-color:#auto;text-decoration:none;">1.21</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMV </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Program</font><font style="color:#000000;"><a name="_cp_text_2_16"></a>&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section 2.6(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_43"></a><a name="_cp_blt_2_42"></a><font style="Background-color:#auto;text-decoration:none;">1.22</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Commercially Reasonable Efforts</font><font style="color:#000000;">&#8221; means, with respect to the efforts to be expended by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken under this Agreement, those efforts that a well-resourced and financially stable company developing technology within the bio-pharmaceutical industry of comparable size and resources would reasonably use to accomplish such objective, activity or decision under similar circumstances, and specifically means the carrying out of development activities using efforts that a company developing technology within the bio-pharmaceutical industry of comparable size and resources would reasonably devote to a product at a similar stage in its development or commercial product life and of similar market potential, taking into consideration, among other factors, Third Party costs and expenses, including the royalties, milestone and other payments payable to Third Party licensors of patent or other intellectual property rights, and the pricing and reimbursement relating to the product, based on conditions then prevailing, efficacy, safety, approved labeling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.&nbsp;&nbsp;Commercially Reasonable Efforts shall be determined on a Major Market-by-Major Market and Indication-by-Indication basis for Licensed Products being developed under the Research Agreement, and it is anticipated that the level of effort will change over time, reflecting changes in the status of each such Licensed Product, and the market(s) or country(ies) involved.&nbsp;&nbsp;Commercially Reasonable Efforts [***] that the Party [***].&nbsp;&nbsp;For clarity, Commercially Reasonable Efforts will not mean that a Party guarantees that it will actually accomplish the applicable task or objective.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-4</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_45"></a><a name="_cp_blt_2_44"></a><font style="text-decoration:none;Background-color:#auto;">1.23</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Comparable Third Party Product</font><font style="color:#000000;">&#8221; means, on a Licensed Product-by-Licensed Product basis, and a country-by-country basis, any pharmaceutical or biological product (a)&#160;that contains (i)&#160;an identical active ingredient(s) as a Licensed Product, or (ii)&#160;a &#8220;highly similar&#8221; active ingredient(s) as such Licensed Product, as the phrase &#8220;highly similar&#8221; is used in 42 U.S.C. &#167;&#160;262(i)(2), and subject to the factors set forth in FDA&#8217;s Guidance for Industry, &#8220;Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product,&#8221; (February&#160;2012), at Section&#160;VI, and any successor FDA guidance thereto, (b)&#160;for which Regulatory Approval is obtained by reference to Regulatory Materials of such Licensed Product, (c)&#160;is approved for use in such country pursuant to a Regulatory Approval process governing approval of interchangeable or biosimilar biologics as described in 42 U.S.C. &#167;&#167;&#160;262, or an equivalent process for Regulatory Approval in any country outside the United States, or any other equivalent provision that comes into force, or is the subject of a notice with respect to such Licensed Product under 42 U.S.C. &#167;&#160;262(l)(2) or any other equivalent provision that comes into force in such country, and (d)&#160;is sold in the same country as such Licensed Product by any Third Party that is not a Sublicensee of Licensee or its Affiliates and did not purchase such product in a chain of distribution that included any of Licensee or any of its Affiliates or its Sublicensees.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_47"></a><a name="_cp_blt_2_46"></a><a name="_cp_blt_1_30"></a><a name="_cp_blt_2_29"></a><a name="_cp_text_1_28"></a><font style="Background-color:#auto;text-decoration:none;">1.24</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Competing Product</font><font style="color:#000000;">&#8221; means any CTL Product that is listed on </font><font style="text-decoration:underline;color:#000000;">Schedule&#160;1.24</font><font style="color:#000000;">.&nbsp;&nbsp;For clarity, any [***] shall be a Competing Product and (a)&#160;shall be subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;"> during the [***] Option Period, and to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.4</font><font style="color:#000000;"> if the [***] expires without Licensee [***], and (b)&#160;if the [***] for the [***], [***] shall automatically be added to </font><font style="text-decoration:underline;color:#000000;">Schedule&#160;1.24</font><font style="color:#000000;"><a name="_cp_text_1_28"></a> upon the exercise of the [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_49"></a><a name="_cp_blt_2_48"></a><a name="_cp_blt_1_32"></a><a name="_cp_blt_2_31"></a><font style="Background-color:#auto;text-decoration:none;">1.25</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">&#8220;Confidential Information&#8221; </font><font style="color:#000000;">of a Party, means (a)&#160;information relating to the business, operations or products of a Party or any Affiliate of such Party, including any know-how, that such Party discloses, transfers or makes available to the other Party under this Agreement or the Research Agreement, or which otherwise becomes known to the other Party by virtue of this Agreement or the Research Agreement, in each case whether in written, oral, graphical, machine readable or other form, whether or not marked as confidential or proprietary, and (b)&#160;the terms of this Agreement and the Research Agreement;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_51"></a><a name="_cp_blt_2_50"></a><a name="_cp_blt_1_34"></a><a name="_cp_blt_2_33"></a><font style="Background-color:#auto;text-decoration:none;">1.26</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Control</font><font style="color:#000000;">&#8221;, &#8220;</font><font style="font-weight:bold;color:#000000;">Controls</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Controlled</font><font style="color:#000000;">&#8221; means, with respect to any intellectual property rights or Confidential Information, the ability of a Party, itself or through an Affiliate of such Party, (whether through ownership or license (other than a license granted in this Agreement or the Research Agreement, as applicable) to grant to the other Party and/or its Affiliates, as applicable, the licenses or sublicenses as provided herein, or to otherwise disclose such intellectual property rights or Confidential Information to the other Party without violating the terms of any then-existing agreement with any Third Party or misappropriating such intellectual property rights or Confidential Information.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_53"></a><a name="_cp_blt_2_52"></a><a name="_cp_blt_1_36"></a><a name="_cp_blt_2_35"></a><font style="Background-color:#auto;text-decoration:none;">1.27</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CTL</font><font style="color:#000000;">&#8221; shall have the meaning given in the first Recital.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_55"></a><a name="_cp_blt_2_54"></a><font style="Background-color:#auto;text-decoration:none;">1.28</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CTL Product</font><font style="color:#000000;">&#8221; means a pharmaceutical or biologic product comprising Autologous CTLs or Allogeneic CTLs, in either case, Specifically Directed to one or more Targets </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">associated with EBV, </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> associated with EBV or expressed by a cell infected with EBV (an &#8220;</font><font style="font-weight:bold;color:#000000;">EBV-Specific CTL Product</font><font style="color:#000000;">&#8221;), including without limitation any </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> to two or more of any of the foregoing Targets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_57"></a><a name="_cp_blt_2_56"></a><font style="Background-color:#auto;text-decoration:none;">1.29</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CTL Technology</font><font style="color:#000000;">&#8221; means proprietary rights Controlled by Institute with respect to information, know-how, concepts, ideas, techniques and data that relate to Allogeneic CTLs and/or Autologous CTLs, including methods of manufacture or use of such Allogeneic CTLs and/or Autologous CTLs.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_59"></a><a name="_cp_blt_2_58"></a><font style="Background-color:#auto;text-decoration:none;">1.30</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Data Exclusivity Protection</font><font style="color:#000000;">&#8221; means in a particular country with respect to a Licensed Product, any Law that prevents (notwithstanding any exceptions or provisos, save to the extent that such exceptions or provisos may be applied in the particular case) the use of, or reliance upon, clinical data generated by Licensee (or its Affiliate or Sublicensee) by a Third Party to obtain regulatory approval for a product, where such Third Party has not obtained the rights to market or sell such product as a licensee, sublicensee or distributor of Licensee or any of its Affiliates, licensees or Sublicensees with respect to such product.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_60"></a><font style="Background-color:#auto;text-decoration:none;">1.31</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Designated Executive Officers</font><font style="color:#000000;">&#8221; means the Chief Executive Officer of Licensee and the Director and Chief Executive Officer of Institute or such other senior executive officer of either Party notified in writing by such Party to the other Party from time to time.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.32</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development Plan</font><font style="color:#000000;">&#8221; means the development plan provided by Licensee to Institute that provides the activities, and the associated estimated timelines of when such activities shall be conducted (including in detail the activities that shall be conducted in the calendar year following the submission of such Development Plan to Institute), in order to develop Licensed Products for commercialization.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.33</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Diagnostic Product</font><font style="color:#000000;">&#8221; means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.34</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Dispute</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;20.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_63"></a><a name="_cp_blt_2_65"></a><a name="_cp_blt_2_67"></a><a name="_cp_blt_1_70"></a><a name="_cp_blt_2_69"></a><a name="_cp_blt_1_61"></a><a name="_cp_blt_1_63"></a><a name="_cp_blt_2_62"></a><a name="_cp_blt_1_65"></a><a name="_cp_blt_2_64"></a><a name="_cp_blt_1_67"></a><a name="_cp_blt_2_66"></a><font style="Background-color:#auto;text-decoration:none;">1.35</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Earned Royalty</font><font style="color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.6</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_72"></a><a name="_cp_blt_2_71"></a><a name="_cp_blt_1_69"></a><a name="_cp_blt_2_68"></a><font style="Background-color:#auto;text-decoration:none;">1.36</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EBV</font><font style="color:#000000;">&#8221; means Epstein-Barr Virus, also known as human herpes virus 4 and any naturally occurring variants thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_74"></a><a name="_cp_blt_2_73"></a><a name="_cp_blt_1_71"></a><a name="_cp_blt_2_70"></a><font style="Background-color:#auto;text-decoration:none;">1.37</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EBV Autologous Option</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_75"></a><a name="_cp_blt_1_78"></a><a name="_cp_blt_2_77"></a><a name="_cp_blt_1_73"></a><a name="_cp_blt_2_72"></a><a name="_cp_blt_1_75"></a><a name="_cp_blt_2_74"></a><font style="Background-color:#auto;text-decoration:none;">1.38</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EBV-Specific Autologous Products</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_80"></a><a name="_cp_blt_2_79"></a><a name="_cp_text_1_77"></a><a name="_cp_text_1_81"></a><a name="_cp_text_1_82"></a><font style="Background-color:#auto;text-decoration:none;">1.39</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EBV </font><font style="color:#000000;">[***]&#8221; means any [***], in whole or in part, or in any form, with or without [***] and in any formulation, including without limitation any such [***] that is also a </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-6-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">[***]</font><font style="color:#000000;">, for use for (a)&#160;</font><font style="color:#000000;">[***] </font><font style="color:#000000;">EBV, or any </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> associated with EBV or </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> EBV, or (b)&#160;</font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_77"></a> </font><font style="color:#000000;">EBV</font><font style="color:#000000;">, or any </font><font style="color:#000000;"><a name="_cp_text_1_81"></a>[***]</font><font style="color:#000000;">EBV</font><font style="color:#000000;">, in each case or (a)&#160;or (b), </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_82"></a>.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_82"></a><a name="_cp_blt_2_81"></a><font style="Background-color:#auto;text-decoration:none;">1.40</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EBV </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Program</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_84"></a><a name="_cp_blt_2_83"></a><font style="Background-color:#auto;text-decoration:none;">1.41</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Existing Confidentiality Agreement</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;22.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_86"></a><a name="_cp_blt_2_85"></a><font style="Background-color:#auto;text-decoration:none;">1.42</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">First Commercial Sale</font><font style="color:#000000;">&#8221; means, on a country-by-country basis, the first Sale of Licensed Product (or, solely with respect to </font><font style="text-decoration:underline;color:#000000;">Schedule 4.15</font><font style="color:#000000;">, any [***] Product) in such country to a Third Party by the Licensee, or any of its Affiliates or Sublicensees (or, solely with respect to </font><font style="text-decoration:underline;color:#000000;">Schedule 4.15</font><font style="color:#000000;">, by Institute, or any of its Affiliates, licensees or sublicensees pursuant to a [***] License Agreement), in each case after all Regulatory Approvals have been obtained in such country, if applicable.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_88"></a><a name="_cp_blt_2_87"></a><font style="Background-color:#auto;text-decoration:none;">1.43</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">First Patient First Dose</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">FPFD</font><font style="color:#000000;">&#8221; means the first dosing of the first patient in a clinical trial.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_90"></a><a name="_cp_blt_2_89"></a><a name="_cp_blt_1_94"></a><a name="_cp_blt_2_93"></a><font style="Background-color:#auto;text-decoration:none;">1.44</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Governmental Authority</font><font style="color:#000000;">&#8221; means any court, agency, department, bureau, commissions, council, or other entity or instrumentality of any supra-national, federal, national, regional, state, provincial, or local or other political subdivision.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_92"></a><a name="_cp_blt_2_91"></a><a name="_cp_blt_1_96"></a><a name="_cp_blt_2_95"></a><font style="Background-color:#auto;text-decoration:none;">1.45</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">HPV-Specific TCR Product</font><font style="color:#000000;">&#8221; means a pharmaceutical or biologic product comprising TCRs, Specifically Directed to one or more Targets associated with human papilloma virus (&#8220;</font><font style="font-weight:bold;color:#000000;">HPV</font><font style="color:#000000;">&#8221;), including [***] associated with HPV or [***] with HPV.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_95"></a><a name="_cp_text_1_93"></a><a name="_cp_text_1_96"></a><font style="Background-color:#auto;text-decoration:none;">1.46</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Indemnitee</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_96"></a>Section 15.3.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_98"></a><a name="_cp_blt_2_97"></a><font style="Background-color:#auto;text-decoration:none;">1.47</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Indication</font><font style="color:#000000;">&#8221; means any disease or condition, or sign or symptom of a disease or condition.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_100"></a><a name="_cp_blt_2_99"></a><font style="Background-color:#auto;text-decoration:none;">1.48</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Infringement Notice</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;14.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_102"></a><a name="_cp_blt_2_101"></a><font style="Background-color:#auto;text-decoration:none;">1.49</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_104"></a><a name="_cp_blt_2_103"></a><font style="Background-color:#auto;text-decoration:none;">1.50</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Institute Indemnitees</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;15.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_106"></a><a name="_cp_blt_2_105"></a><font style="Background-color:#auto;text-decoration:none;">1.51</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Issue Fee</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.1(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_108"></a><a name="_cp_blt_2_107"></a><font style="Background-color:#auto;text-decoration:none;">1.52</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">JSC</font><font style="color:#000000;">&#8221; means the joint steering committee established pursuant to Article&#160;3 of the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_110"></a><a name="_cp_blt_2_109"></a><font style="Background-color:#auto;text-decoration:none;">1.53</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Know-How Rights</font><font style="color:#000000;">&#8221; means the know-how and any supplemental information, including concepts, ideas, sequences, formulas, protocols, procedures, techniques and data (a)&#160;Controlled by Institute as of the Execution Date (including any of the foregoing Controlled </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">by Institute as of the Original Effective Date</font><font style="color:#000000;">, </font><font style="color:#000000;">First Restatement Date</font><font style="color:#000000;">, Second Restatement Date</font><font style="color:#000000;">), </font><font style="color:#000000;">and/or Third Restatement Date, </font><font style="color:#000000;">or (b)&#160;Controlled by Institute at any time during the Term and arising </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, or (c)&#160;Controlled by Institute and arising from activities conducted by either Party pursuant to the Research Agreement, in each case of (a) through (c), that (i)&#160;covers or relates to CTL Technology; and (ii)&#160;is not covered by a Valid Claim of the Patent Rights, or, if the subject of a patent or patent application in Patent Rights, does not issue as a Valid Claim.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_112"></a><a name="_cp_blt_2_111"></a><font style="Background-color:#auto;text-decoration:none;">1.54</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Law</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Laws</font><font style="color:#000000;">&#8221; means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of law of any Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_114"></a><a name="_cp_blt_2_113"></a><font style="Background-color:#auto;text-decoration:none;">1.55</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensed Field</font><font style="color:#000000;">&#8221; means therapeutic, palliative, prophylactic and diagnostic (including in relation to companion diagnostics) uses in all diseases and conditions and for all indications.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_116"></a><a name="_cp_blt_2_115"></a><font style="Background-color:#auto;text-decoration:none;">1.56</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensed Method</font><font style="color:#000000;">&#8221; means any process, art or method the use or practice of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights in any country were they issued at the time of the infringing activity in that country.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_118"></a><a name="_cp_blt_2_117"></a><a name="_cp_blt_1_123"></a><a name="_cp_blt_2_122"></a><font style="Background-color:#auto;text-decoration:none;">1.57</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Licensed Product(s)</font><font style="color:#000000;">&#8221; means any (a)&#160;CTL Product or New CTL Product or Program [***], including, without limitation, a CTL Product or New CTL Product or Program [***] for use or used in practicing a Licensed Method and any product made by practicing a Licensed Method, (b)&#160;a Diagnostic Product sold for use in connection with a CTL Product or New CTL Product or Program [***], or (c)&#160;any services provided using a CTL Product or New CTL Product or Program [***] set forth in (a), in each case of (a), (b)&#160;or (c)&#160;, where the manufacture, use, Sale, offer for Sale or import of which in a given country, (i)&#160;but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of a Valid Claim of any Patent Rights in such country, (ii)&#160;would infringe, or contribute to, or induce the infringement of a Valid Claim of any Licensee Patents in such country, and/or (iii)&#160;would utilize the Know-How Rights.&nbsp;&nbsp;For clarity, Licensed Products include Allogeneic CTL Products and Autologous CTL Products, but subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;">, do not include [***] unless and until Licensee [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.58</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Indemnitees</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section 15.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_120"></a><a name="_cp_blt_2_119"></a><a name="_cp_blt_1_125"></a><a name="_cp_blt_2_124"></a><font style="Background-color:#auto;text-decoration:none;">1.59</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Patents</font><font style="color:#000000;">&#8221; means any and all patents or patent applications Controlled by Licensee that cover or claim inventions created, discovered, conceived, developed or reduced to practice in the course of activities conducted pursuant to the Research Agreement, including the following forms of intellectual property rights anywhere in the world that fall within the foregoing: (a)&#160;issued patents, continuations, continuations-in-part, divisionals, substitutions, confirmations, reissues, re-examination, validations, extensions, renewals, restorations or any similar governmental grant for protection of inventions; (b)&#160;pending applications for any of the foregoing (including both provisional and non-provisional applications); and (c)&#160;all patents and patent applications claiming priority directly or indirectly to any of the foregoing, or from which </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">any of the foregoing claim direct or indirect priority, in each case including any joint interest in such rights held jointly with Institute.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_122"></a><a name="_cp_blt_2_121"></a><a name="_cp_blt_1_127"></a><a name="_cp_blt_2_126"></a><font style="Background-color:#auto;text-decoration:none;">1.60</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Development Plan</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;5.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_124"></a><a name="_cp_blt_2_123"></a><a name="_cp_blt_1_129"></a><a name="_cp_blt_2_128"></a><font style="Background-color:#auto;text-decoration:none;">1.61</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Major Markets</font><font style="color:#000000;">&#8221; means (a)&#160;the United States, and (b)&#160;[***] the following countries: France, United Kingdom, Italy, Germany and Spain.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_126"></a><a name="_cp_blt_2_125"></a><a name="_cp_blt_1_131"></a><a name="_cp_blt_2_130"></a><font style="Background-color:#auto;text-decoration:none;">1.62</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Agreement</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;6.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_128"></a><a name="_cp_blt_2_127"></a><a name="_cp_blt_1_133"></a><a name="_cp_blt_2_132"></a><font style="Background-color:#auto;text-decoration:none;">1.63</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Milestone</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.3(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_130"></a><a name="_cp_blt_2_129"></a><a name="_cp_blt_1_135"></a><a name="_cp_blt_2_134"></a><font style="Background-color:#auto;text-decoration:none;">1.64</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Milestone Payment</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.3(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_132"></a><a name="_cp_blt_2_131"></a><a name="_cp_blt_1_137"></a><a name="_cp_blt_2_136"></a><font style="Background-color:#auto;text-decoration:none;">1.65</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">MSK Agreement</font><font style="color:#000000;">&#8221; means the exclusive license agreement dated June&#160;12, 2015, by and between Licensee and Memorial Sloan Kettering Cancer Center.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_134"></a><a name="_cp_blt_2_133"></a><a name="_cp_blt_1_139"></a><a name="_cp_blt_2_138"></a><font style="Background-color:#auto;text-decoration:none;">1.66</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; shall have the meaning given in Schedule 2.1(a)</font><font style="text-decoration:underline;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.67</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; means any product or service, where the manufacture, use, leasing transferring, providing, furnishing for use, sale, offer for sale or import of such product or service in a given country would infringe, or contribute to, or induce the infringement of a Valid Claim of any [***] in such country. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.68</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Net Sale</font><font style="color:#000000;">&#8221; means the amount invoiced by Licensee or by any Affiliate or Sublicensee for Sales of Licensed Products, after deduction of the following in accordance with U.S. Generally Accepted Accounting Principles (&#8220;</font><font style="font-weight:bold;color:#000000;">GAAP</font><font style="color:#000000;">&#8221;) to the extent applicable to such Sales:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">trade, quantity and cash discounts or rebates, actually allowed or taken;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">allowances or credits given for rejection, recall or return of previously sold Licensed Product or outdated Licensed Product;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">rebates and chargebacks or retroactive price reductions made to federal, state or local governments (or their agencies), or any Third Party payor, administrator or contractor, including managed health organizations, to the extent specific to Licensed Product;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">payments required by law to be made under special medical assistance programs (including, but not limited to, payments made under Medicaid, Medicare or other government and other similar programs such as the new &#8220;Medicare Part&#160;D Coverage Gap Discount Program&#8221; and the &#8220;Annual Fee on Branded Pharmaceutical Manufacturers&#8221;), in each case to the extent specific to Licensed Product;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-9</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">amounts deemed to be uncollectible due to non-payment relating to Sales of Licensed Products during the applicable calculation period;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any tax or other governmental charge (including without limitation custom surcharges) borne by and not reimbursed to the Licensee other than income tax levied on the Sale, transportation or delivery of Licensed Product; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any charges for packing, handling, freight, insurance, transportation and duty charges borne by the seller.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Licensee makes any Net Sales to any Person at a price less than the regular price charged to other parties, and unless a cash discount within the meaning of this <font style="text-decoration:underline;">Section&#160;1.68</font> applies, the royalties payable to Institute shall be computed on the basis of the regular price charged to other parties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_136"></a><a name="_cp_blt_2_135"></a><a name="_cp_blt_1_141"></a><a name="_cp_blt_2_140"></a><font style="Background-color:#auto;text-decoration:none;">1.69</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">New CTL Products</font><font style="color:#000000;">&#8221; shall mean, for the purposes of this Agreement, pharmaceutical or biologic products comprising Autologous CTLs or Allogeneic CTLs Specifically Directed to Targets (including [***] associated with such Target or [***] with such Target) that are associated with any New Research Program that the Parties have agreed to include within the scope of this Agreement pursuant to Section&#160;2.3 of the Research Agreement, including [***] that are directed to the Target of such New Research Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_138"></a><a name="_cp_blt_2_137"></a><a name="_cp_blt_1_143"></a><a name="_cp_blt_2_142"></a><font style="Background-color:#auto;text-decoration:none;">1.70</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">New Research Program</font><font style="color:#000000;">&#8221; shall have the meaning given in the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_140"></a><a name="_cp_blt_2_139"></a><a name="_cp_blt_1_145"></a><a name="_cp_blt_2_144"></a><font style="Background-color:#auto;text-decoration:none;">1.71</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">New Research Patent Rights</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_142"></a><a name="_cp_blt_2_141"></a><a name="_cp_blt_1_147"></a><a name="_cp_blt_2_146"></a><font style="Background-color:#auto;text-decoration:none;">1.72</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">New Research Program Inclusion Date</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_144"></a><a name="_cp_blt_2_143"></a><a name="_cp_blt_1_149"></a><a name="_cp_blt_2_148"></a><font style="Background-color:#auto;text-decoration:none;">1.73</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Option</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_148"></a><a name="_cp_blt_2_147"></a><a name="_cp_blt_1_151"></a><a name="_cp_blt_2_150"></a><a name="_cp_text_1_146"></a><font style="Background-color:#auto;text-decoration:none;">1.74</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Option Notice</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_146"></a>Section&#160;2.2(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_150"></a><a name="_cp_blt_2_149"></a><a name="_cp_blt_1_153"></a><a name="_cp_blt_2_152"></a><font style="Background-color:#auto;text-decoration:none;">1.75</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Original Effective Date</font><font style="color:#000000;">&#8221; shall have the meaning given in the Recitals.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_152"></a><a name="_cp_blt_2_151"></a><a name="_cp_blt_1_155"></a><a name="_cp_blt_2_154"></a><font style="Background-color:#auto;text-decoration:none;">1.76</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Original License Agreement</font><font style="color:#000000;">&#8221; shall have the meaning given in the Recitals.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_154"></a><a name="_cp_blt_2_153"></a><a name="_cp_blt_1_157"></a><a name="_cp_blt_2_156"></a><font style="Background-color:#auto;text-decoration:none;">1.77</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Orphan Drug Exclusivity</font><font style="color:#000000;">&#8221; means in a particular country with respect to a Licensed Product, protection available under any Applicable Law relating to treatments for rare or neglected diseases or conditions, or otherwise requiring special incentives, that prevents or delays (notwithstanding any exceptions or provisos, save to the extent that such exceptions or provisos may be applied in the particular case) the approval, production, marketing or sale of a </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-10-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">competitive product by a Third Party, where such Third Party has not obtained the rights to market or sell such product as a licensee, sublicensee or distributor of Licensee or any of its Affiliates, licensees or Sublicensees with respect to such product.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_156"></a><a name="_cp_blt_2_155"></a><a name="_cp_blt_1_159"></a><a name="_cp_blt_2_158"></a><font style="Background-color:#auto;text-decoration:none;">1.78</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Participant</font><font style="color:#000000;">&#8221; means any one or more of:</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:22.22%;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_158"></a><a name="_cp_blt_2_157"></a><a name="_cp_blt_1_161"></a><a name="_cp_blt_2_160"></a><font style="Background-color:#auto;text-decoration:none;">1.79</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Patent Rights</font><font style="color:#000000;">&#8221; means (a)&#160;any and all patents and patent applications Controlled by Institute as of the Execution Date (including all such patents and patent applications Controlled by Institute as of the Original Effective Date, the First Restatement Date, the Second Restatement Date, and/or the Third Restatement Date) that cover or claim CTL Technology and have arisen directly from activities conducted by or under the supervision of [***], including the patents and patent applications listed on </font><font style="text-decoration:underline;color:#000000;">Schedule&#160;1.79</font><font style="color:#000000;">, excluding any patents and patent applications included in subsection (b), (b)&#160;any and all patents or patent applications Controlled by Institute that cover or claim inventions created, discovered, conceived, developed or reduced to practice in the course of activities conducted pursuant to the Research Agreement, and (c)&#160;any and all patents and patent applications Controlled by Institute during the Term that have arisen directly from activities conducted by or under the supervision of [***] to the extent that such patents and patent applications cover or claim [***].&nbsp;&nbsp;For clarity, Patent Rights include the following forms of intellectual property rights anywhere in the world that fall within (a), (b)&#160;and (c): issued patents, continuations, continuations-in-part, divisionals, substitutions, confirmations, reissues, re-examination, validations, extensions, renewals, restorations or any similar governmental grant for protection of inventions; (ii)&#160;pending applications for any of the foregoing (including both provisional and non-provisional applications); and (iii)&#160;all patents and patent applications claiming priority directly or indirectly to any of the foregoing, or from which any of the foregoing claim direct or indirect priority.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_160"></a><a name="_cp_blt_2_159"></a><a name="_cp_blt_1_163"></a><a name="_cp_blt_2_162"></a><font style="Background-color:#auto;text-decoration:none;">1.80</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Person</font><font style="color:#000000;">&#8221; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_162"></a><a name="_cp_blt_2_161"></a><a name="_cp_blt_1_165"></a><a name="_cp_blt_2_164"></a><font style="Background-color:#auto;text-decoration:none;">1.81</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase I Clinical Trial</font><font style="color:#000000;">&#8221; means any clinical study conducted on sufficient numbers of human subjects to establish that a pharmaceutical or biological product is reasonably safe for continued testing and to support its continued testing in Phase II Clinical Trials.&nbsp;&nbsp;&#8220;Phase I Clinical Trial&#8221; shall include without limitation any clinical trial that would satisfy requirements of 21 C.F.R. &#167;&#160;312.21(a).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_164"></a><a name="_cp_blt_2_163"></a><a name="_cp_blt_1_167"></a><a name="_cp_blt_2_166"></a><font style="Background-color:#auto;text-decoration:none;">1.82</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase II Clinical Trial</font><font style="color:#000000;">&#8221; means any clinical study conducted on sufficient numbers of human subjects that have the targeted disease of interest to investigate the safety and efficacy of a pharmaceutical or biological product for its intended use and to define warnings, precautions, and adverse reactions that may be associated with such product in the dosage range to be prescribed.&nbsp;&nbsp;&#8220;Phase II Clinical Trial&#8221; shall include without limitation any clinical trial that would satisfy requirements of 21 C.F.R. &#167;&#160;312.21(b).</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_166"></a><a name="_cp_blt_2_165"></a><a name="_cp_blt_1_169"></a><a name="_cp_blt_2_168"></a><font style="text-decoration:none;Background-color:#auto;">1.83</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase III Clinical Trial</font><font style="color:#000000;">&#8221; means any clinical study intended as a pivotal study for purposes of seeking Regulatory Approval that is conducted on sufficient numbers of human subjects to establish that a pharmaceutical or biological product is safe and efficacious for its intended use, to define warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, and to support Regulatory Approval of such product or label expansion of such product.&nbsp;&nbsp;&#8220;Phase III Clinical Trial&#8221; shall include without limitation any clinical trial that would or does satisfy requirements of 21 C.F.R. &#167;&#160;312.21(c), whether or not it is designated a Phase III Clinical Trial.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_168"></a><a name="_cp_blt_2_167"></a><a name="_cp_blt_1_171"></a><a name="_cp_blt_2_170"></a><font style="Background-color:#auto;text-decoration:none;">1.84</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Polyepitope CTL Product</font><font style="color:#000000;">&#8221; means any pharmaceutical or biologic product comprising an Autologous CTL or an Allogeneic CTL, in either case, that is Specifically Directed to at least two Targets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_170"></a><a name="_cp_blt_2_169"></a><a name="_cp_blt_1_175"></a><a name="_cp_blt_2_174"></a><font style="Background-color:#auto;text-decoration:none;">1.85</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Program </font><font style="color:#000000;">[***]&#8221; means any [***] developed in the course of the [***] Program, in respect of which Licensee has exercised the [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_172"></a><a name="_cp_blt_2_171"></a><font style="Background-color:#auto;text-decoration:none;">1.86</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Approval</font><font style="color:#000000;">&#8221; means with respect to a country or region, any and all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Licensed Product in such country or region, including, where applicable: (a)&#160;pre- and post-approval marketing authorizations; (b)&#160;labeling approval; and (c)&#160;technical, medical and scientific licenses, in each case necessary for commercial distribution, sale or marketing of such Licensed Product in such country or region.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_174"></a><a name="_cp_blt_2_173"></a><font style="Background-color:#auto;text-decoration:none;">1.87</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Authority</font><font style="color:#000000;">&#8221; means any Government Authority or other entity, in each case regulating or otherwise exercising authority with respect to the development, manufacturing or commercialization of the Licensed Product in a given country or region, including the U.S. Food and Drug Administration (&#8220;</font><font style="font-weight:bold;color:#000000;">FDA</font><font style="color:#000000;">&#8221;), or any successor thereto, and the European Medicines Agency (&#8220;</font><font style="font-weight:bold;color:#000000;">EMA</font><font style="color:#000000;">&#8221;), or any successor thereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_177"></a><a name="_cp_blt_2_176"></a><font style="Background-color:#auto;text-decoration:none;">1.88</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Research Agreement</font><font style="color:#000000;">&#8221; means the First Restated Research Agreement as in effect from the Original Effective Date until the Second Restatement Date, together with the Second Restated Research Agreement as in effect from the Second Restatement Date until the Third Restatement Date, together with the Third Restated Research Agreement as in effect from the Third Restatement Date until the Execution Date, together with the Fourth Restated Research Agreement effective as of the Execution Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_179"></a><a name="_cp_blt_2_178"></a><font style="Background-color:#auto;text-decoration:none;">1.89</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Research Agreement Patent Rights</font><font style="color:#000000;">&#8221; shall have the meaning given in Section&#160;13.2(b).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_181"></a><a name="_cp_blt_2_180"></a><font style="Background-color:#auto;text-decoration:none;">1.90</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Research Milestone Payments</font><font style="color:#000000;">&#8221; shall have the meaning given in the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_183"></a><a name="_cp_blt_2_182"></a><font style="Background-color:#auto;text-decoration:none;">1.91</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Reversion Product IP</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_185"></a><a name="_cp_blt_2_184"></a><font style="Background-color:#auto;text-decoration:none;">1.92</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Reversion Products</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_187"></a><a name="_cp_blt_2_186"></a><font style="Background-color:#auto;text-decoration:none;">1.93</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Royalty Term</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_189"></a><a name="_cp_blt_2_188"></a><font style="Background-color:#auto;text-decoration:none;">1.94</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Rules of Arbitration</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;20.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_191"></a><a name="_cp_blt_2_190"></a><font style="Background-color:#auto;text-decoration:none;">1.95</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sale</font><font style="color:#000000;">&#8221; means the act of selling, leasing or otherwise transferring, providing, or furnishing for use any Licensed Product (or, solely with respect to </font><font style="text-decoration:underline;color:#000000;">Schedule 4.15</font><font style="color:#000000;">, any [***] Product) for any consideration.&nbsp;&nbsp;Correspondingly, &#8220;Sell&#8221; means to make or cause to be made a Sale, and &#8220;Sold&#8221; means to have made or caused to be made a Sale.&nbsp;&nbsp;For clarity, a Sale excludes any Licensed Product supplied at cost: (a)&#160;for use in clinical trials; (b)&#160;for research or for other noncommercial uses; or (c)&#160;as part of a compassionate use program (or similar program for providing Product before it has received marketing approval in a given country).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_193"></a><a name="_cp_blt_2_192"></a><font style="Background-color:#auto;text-decoration:none;">1.96</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Specifically Directed</font><font style="color:#000000;">&#8221; means, with respect to a Target, the ability of a molecule, agent, or compound to selectively or preferentially bind to or interact with such Target (other than by non-specific binding).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_195"></a><a name="_cp_blt_2_194"></a><font style="Background-color:#auto;text-decoration:none;">1.97</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sublicensee</font><font style="color:#000000;">&#8221; means any person or entity (including any Affiliate of Licensee) to which any of the license rights granted to the Licensee hereunder are granted a sublicense or an option to a sublicense.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_197"></a><a name="_cp_blt_2_196"></a><a name="_cp_blt_1_204"></a><a name="_cp_blt_2_203"></a><font style="Background-color:#auto;text-decoration:none;">1.98</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Target</font><font style="color:#000000;">&#8221; means an antigen expressed on or in a cell, including [***].&nbsp;&nbsp;For clarity, a Target may be [***] (collectively, a single &#8220;Target&#8221;).&nbsp;&nbsp;Unless otherwise specified, where the antigen is naturally occurring, a Target encompasses all natural variants thereof.&nbsp;&nbsp;For clarity, (a)&#160;where a Licensed Product is [***] antigen expressed on or in a cell in association with [***] EBV and/or the virus associated with the Target of any New CTL Product and/or Program [***], and (b)&#160;where a Licensed Product is [***] associated with a [***] on or in a cell in association with the presence of, or infection of such cell by, EBV and/or the virus associated with the Target of any New CTL Product and/or Program [***], or [***] EBV and/or the virus associated with the Target of any New CTL Product and/or Program [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_199"></a><a name="_cp_blt_2_198"></a><a name="_cp_blt_1_206"></a><a name="_cp_blt_2_205"></a><font style="Background-color:#auto;text-decoration:none;">1.99</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_201"></a><a name="_cp_blt_2_200"></a><a name="_cp_blt_1_208"></a><a name="_cp_blt_2_207"></a><font style="Background-color:#auto;text-decoration:none;">1.100</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Territory</font><font style="color:#000000;">&#8221; means worldwide.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_203"></a><a name="_cp_blt_2_202"></a><a name="_cp_blt_1_210"></a><a name="_cp_blt_2_209"></a><font style="Background-color:#auto;text-decoration:none;">1.101</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party</font><font style="color:#000000;">&#8221; means any Person other than Institute, Licensee or any of their respective Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_205"></a><a name="_cp_blt_2_204"></a><a name="_cp_blt_1_212"></a><a name="_cp_blt_2_211"></a><font style="Background-color:#auto;text-decoration:none;">1.102</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party License</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.7</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_207"></a><a name="_cp_blt_2_206"></a><a name="_cp_blt_1_214"></a><a name="_cp_blt_2_213"></a><font style="Background-color:#auto;text-decoration:none;">1.103</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Product</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_209"></a><a name="_cp_blt_2_208"></a><a name="_cp_blt_1_216"></a><a name="_cp_blt_2_215"></a><font style="Background-color:#auto;text-decoration:none;">1.104</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Royalty Payments</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.7</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_211"></a><a name="_cp_blt_2_210"></a><a name="_cp_blt_1_218"></a><a name="_cp_blt_2_217"></a><font style="text-decoration:none;Background-color:#auto;">1.105</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_213"></a><a name="_cp_blt_2_212"></a><a name="_cp_blt_1_220"></a><a name="_cp_blt_2_219"></a><font style="Background-color:#auto;text-decoration:none;">1.106</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; means [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_215"></a><a name="_cp_blt_2_214"></a><a name="_cp_blt_1_222"></a><a name="_cp_blt_2_221"></a><font style="Background-color:#auto;text-decoration:none;">1.107</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> FPFD Date</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;5.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_217"></a><a name="_cp_blt_2_216"></a><a name="_cp_blt_1_224"></a><a name="_cp_blt_2_223"></a><font style="Background-color:#auto;text-decoration:none;">1.108</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Option</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_219"></a><a name="_cp_blt_2_218"></a><a name="_cp_blt_1_226"></a><a name="_cp_blt_2_225"></a><font style="Background-color:#auto;text-decoration:none;">1.109</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Option Notice</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(e)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_221"></a><a name="_cp_blt_2_220"></a><a name="_cp_blt_1_228"></a><a name="_cp_blt_2_227"></a><font style="Background-color:#auto;text-decoration:none;">1.110</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Option Period</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_223"></a><a name="_cp_blt_2_222"></a><a name="_cp_blt_1_230"></a><a name="_cp_blt_2_229"></a><font style="Background-color:#auto;text-decoration:none;">1.111</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Program </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Account</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(c)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_225"></a><a name="_cp_blt_2_224"></a><a name="_cp_blt_1_232"></a><a name="_cp_blt_2_231"></a><font style="Background-color:#auto;text-decoration:none;">1.112</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Valid Claim</font><font style="color:#000000;">&#8221; means any (a)&#160;claim in an issued and unexpired patent included in the Patent Rights that has not been disclaimed, abandoned or withdrawn and has not been held unenforceable or invalid by a final judgment of a court or other governmental agency of competent jurisdiction from which no appeal can be or is taken, and has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; (b)&#160;claim in a pending patent application included within the Patent Rights that has been filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or refiling, which application has been pending for less than [***] after its priority date; or (c)&#160;claim in a pending patent application included within the Patent Rights, which application has been pending for more than [***] after its priority date and which later becomes a claim in an issued and unexpired patent included in the Patent Rights as described in subsection (a), provided that for clarity, such claim shall be a Valid Claim only during the time period during which it otherwise falls within subsections (a)&#160;or (b).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_227"></a><a name="_cp_blt_2_226"></a><a name="_cp_blt_1_234"></a><font style="Background-color:#auto;text-decoration:none;">1.113</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]</font><font style="font-weight:bold;color:#000000;"> License</font><font style="color:#000000;">&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_229"></a><a name="_cp_blt_2_228"></a><a name="_cp_blt_1_236"></a><a name="_cp_blt_2_235"></a><font style="Background-color:#auto;text-decoration:none;">1.114</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***]&#8221; shall have the meaning given in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012474"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">GRANT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk33102857"></a><a name="_cp_text_1_231"></a><a name="_cp_text_1_232"></a><a name="_Hlk33102882"></a><a name="_Hlk33102896"></a><a name="_cp_text_1_239"></a><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">License Grant</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the limitations and other terms and conditions set forth in this Agreement including those reserved by Institute in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.5(a)</font><font style="color:#000000;">, Institute hereby grants to Licensee an exclusive, royalty-bearing, sublicenseable (in accordance with </font><font style="text-decoration:underline;color:#000000;">Article&#160;3</font><font style="color:#000000;"><a name="_Hlk33102857"></a><a name="_cp_text_1_231"></a>) license in, to and under (a)&#160;the Patent Rights and the Know-How Rights, and (b)&#160;Institute&#8217;s interest in any patents and patent applications owned jointly by Licensee and Institute, to make, use, Sell, offer for Sale and import Licensed Products, and to practice Licensed Methods, in each case with respect to (i)&#160;Allogeneic CTL Products in the Territory in the Licensed Field, (ii)&#160;solely with respect to<a name="_cp_text_1_232"></a><a name="_Hlk33102882"></a> EBV-Specific Autologous Products, <a name="_Hlk33102896"></a>and Autologous CTL Products in the Licensed Field, and (iii)&#160;solely following [***], [***]<a name="_cp_text_1_239"></a> arising from the [***].&nbsp;&nbsp;For the sake of clarity, the foregoing license grant in this Section 2.1 includes the exclusive right (subject to the limitations and other terms set forth herein, including those reserved by the Institute under Section 2.5) to: (i) </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-14-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">purchase and use, for any uses, including without limitation, clinical or commercial purposes, all </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, including without limitation, the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> that is used for the production and/or manufacturing of </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> (&#8220;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; and (ii) </font><font style="color:#000000;">optimize, modify, manufacture, or purchase any </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, including </font><font style="color:#000000;">without limitation, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, from any third parties, including without limitation, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, for any and all uses. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Assignment of Patents</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee hereby assigns to Institute all of its right, title and interest to the patents and patent applications set forth in </font><font style="text-decoration:underline;color:#000000;">Schedule 2.1(a)</font><font style="color:#000000;"> attached hereto.&nbsp;&nbsp;Notwithstanding anything to the contrary in </font><font style="text-decoration:underline;color:#000000;">Article 13</font><font style="color:#000000;">, from and after the Execution Date, Institute shall have the sole right, but not the obligation, at its cost, to prosecute, maintain and enforce each of the patents and patent applications set forth in </font><font style="text-decoration:underline;color:#000000;">Schedule 2.1(a)</font><font style="color:#000000;">.&nbsp;&nbsp;[***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Autologous CTL Option</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_233"></a><a name="_cp_blt_1_235"></a><a name="_cp_text_1_236"></a><a name="_cp_text_2_241"></a><a name="_cp_text_1_242"></a><a name="_cp_text_2_243"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">T<a name="_cp_text_2_241"></a>he Parties hereby agree and acknowledge that Institute has granted to Licensee, and Licensee has exercised on written notice to Institute (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option Notice</font><font style="color:#000000;"><a name="_cp_text_1_242"></a>&#8221;), <a name="_cp_text_2_243"></a>an option:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:37.04%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to obtain an exclusive, royalty-bearing, sublicenseable (in accordance with </font><font style="text-decoration:underline;color:#000000;">Article&#160;3</font><font style="color:#000000;">) license in, to and under the Patent Rights and the Know-How Rights to make, use, Sell, offer for Sale and import Licensed Products, and to practice Licensed Methods, in each case with respect to Autologous CTL Products that are Specifically Directed to one or more Targets associated with EBV, including any [***] EBV or [***] EBV (such products, &#8220;</font><font style="font-weight:bold;color:#000000;">EBV-Specific Autologous Products</font><font style="color:#000000;">&#8221;), in the Territory in the Licensed Field (such option, the &#8220;</font><font style="font-weight:bold;color:#000000;">EBV Autologous Option</font><font style="color:#000000;">&#8221; or the &#8220;</font><font style="font-weight:bold;color:#000000;">Option</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_237"></a><a name="_cp_blt_2_239"></a><a name="_cp_blt_1_249"></a><a name="_cp_blt_2_248"></a><a name="_cp_text_1_241"></a><a name="_cp_text_1_243"></a><a name="_cp_text_1_247"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties hereby agree and acknowledge that <a name="_cp_text_1_243"></a>Licensee has paid the Option Fee to Institute pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.2</font><font style="color:#000000;"> and the license rights as described in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2(a)(1)</font><font style="color:#000000;"><a name="_cp_text_1_247"></a>, are fully effective, without further action either by Institute or by Licensee. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_250"></a><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reversion of Certain Rights</font><font style="color:#000000;">.&nbsp;&nbsp;On a Target-by-Target basis, Major Market-by-Major Market basis, and Indication-by-Indication basis, if Licensee (a)&#160;ceases or determines that it will not pursue development or commercialization of an Allogeneic CTL Product for use in a given Indication under this Agreement or the Research Agreement, and (b)&#160;ceases or determines that it does not wish to pursue the development and commercialization of an Autologous CTL Product for use in such Indication, </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.3</font><font style="color:#000000;"> shall apply.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Technology</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_268"></a><a name="_cp_text_1_270"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to the terms and conditions of this Agreement, and the Research Agreement, during the Term, Licensee shall have [***] under any intellectual property rights (i)&#160;Controlled by Institute or any Affiliate of Institute not included in the Patent Rights or the Know-How Rights, (ii)&#160;[***], (iii)&#160;that [***] or to [***], and (iv)&#160;that either Party [***] for the Parties&#8217; activities under this Agreement or the Research Agreement (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;">Technology</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;For </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-15-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">clarity, this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.4</font><font style="color:#000000;"> shall not apply to any </font><font style="color:#000000;">[***] </font><font style="color:#000000;">Technology that relates solely to </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, which shall be subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;"> during the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Period, provided that if the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Period expires without Licensee exercising the </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.4(a)</font><font style="color:#000000;"> shall continue to apply, but Institute shall have no obligation under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.4</font><font style="color:#000000;"> with respect to any such </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Technology that relates solely to </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_268"></a> arising from the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_270"></a> </font><font style="color:#000000;">Program</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any [***] Technology, Institute shall provide Licensee, prior to any discussion with any Third Party, with (i)&#160;detailed information regarding such [***] Technology, including such additional information as is reasonably requested by Licensee regarding any such [***] Technology in order to enable Licensee to appropriately evaluate such [***] Technology, and (ii)&#160;[***] arising from the use of such [***] Technology in the Territory.&nbsp;&nbsp;Licensee shall have a period of [***] following receipt of [***] to notify Institute whether Licensee wishes to exercise [***], and the Parties shall thereafter [***] to Licensee.&nbsp;&nbsp;If the Parties agree upon [***] in such period, they shall thereafter proceed to an [***] for such a grant of rights to be mutually agreed by the Parties.&nbsp;&nbsp;In the event that the Parties have not agreed upon the [***] pursuant to which the Parties would [***] in the Territory within such [***] period after the initiation of good faith discussions, Institute shall be free to discuss terms and conditions for the grant of rights, to develop and commercialize such CTL Products and/or New CTL Products in the Territory to any Third Party.&nbsp;&nbsp;Notwithstanding the foregoing, during [***] following the [***], Institute may [***]  such a grant of rights with a Third Party, provided that Institute shall [***] (unless the Parties mutually agree to [***]), and provided further that [***], no [***] in the Territory [***] such Third Party [***]  with Licensee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reservation of Rights</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_277"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute reserves and retains the right (and the exclusive rights granted to the Licensee in this Agreement shall be limited accordingly) to make, use and practice the Patent Rights and the Know-How Rights (and to grant any of the foregoing rights to other educational and non-profit institutions solely by way of a grant of rights pursuant to an academic collaboration agreement containing provisions substantially equivalent to those set forth in </font><font style="text-decoration:underline;color:#000000;">Schedule&#160;2.5</font><font style="color:#000000;">) entered into solely for educational and research purposes, including publication and other communication of any research results, but excluding any sponsored research performed for or on behalf of commercial entities, provided that any such rights granted under such academic collaboration agreements shall be subject to </font><font style="text-decoration:underline;color:#000000;">Sections&#160;2.1, 2.4</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">11.2</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, Institute shall also retain all rights in and to the Patent Rights and the Know-How Rights for (i)&#160;all applications that do not directly relate to, or use or incorporate, CTLs, (ii)&#160;all uses or applications of CTLs for any Indication that is not associated with EBV and/or the Target associated with any New CTL Product and is not the subject of any activities being carried out under the Research Agreement, (iii)&#160;uses or applications of CTLs for use in any Indication for which an EBV-Specific CTL Product or a New CTL Product is being developed and/or commercialized pursuant to this Agreement or the Research Agreement, solely where such use or application of CTLs is in a patient or patients (A)&#160;that have been determined [***] (as applicable), and (B)&#160;that do not [***] associated with any [***], or [***] and/or the [***] </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-16-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">associated with any </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> such uses or applications of CTLs, and (iv)&#160;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">, excluding any </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_277"></a> included in </font><font style="color:#000000;">the</font><font style="color:#000000;"> </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Program, which shall be subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;">, or any </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> that is also directed to the Target of any New Research Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties acknowledge and agree that Licensee retains the right to continue all development and commercialization activities under the MSK Agreement, including any development and commercialization of products that would be Competing Products, and Licensee&#8217;s development and commercialization of products under the MSK Agreement shall not be a breach of </font><font style="text-decoration:underline;color:#000000;">Article&#160;7</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Licensee acknowledges that the Institute has notified Licensee that Institute has, prior to the Original Effective Date, granted to each of the Participants an identical perpetual, irrevocable, nonexclusive royalty free license under the Patent Rights and related Know-How but excluding [***], in each case solely for internal research purposes, with a right to sublicense solely for internal research purposes with Institute&#8217;s prior written consent, on terms to be agreed between the Institute and Participant, provided that Institute is not permitted to unreasonably withhold its consent to such a sublicense.&nbsp;&nbsp;Institute agrees that it will (i)&#160;provide Licensee with prompt written notice of any request by a Participant prior to any grant of such a sublicense, (ii)&#160;use its best efforts to ensure any such sublicense complies with </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.5(a)</font><font style="color:#000000;">, and (iii)&#160;at Licensee&#8217;s request, provide Licensee with a copy of any such sublicense, which may be redacted to the extent not necessary to demonstrate compliance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.5(a)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_279"></a><font style="Background-color:#auto;text-decoration:none;">2.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"><a name="_cp_text_1_279"></a> Program</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_280"></a><a name="_cp_text_1_284"></a><a name="_cp_text_1_291"></a><a name="_cp_text_1_296"></a><a name="_cp_text_1_299"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_2_280"></a>Institute has been pursuing as of the Execution Date, and proposes to continue to pursue during the Term, certain programs of research and development relating to the [***] (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Program</font><font style="color:#000000;">&#8221;) and/or the [***] (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Program</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Subject to the remainder of this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;">, Institute hereby grants to Licensee an [***]<a name="_cp_text_1_284"></a> Program (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">&#8221;), exercisable at any time prior to the earlier of (i)&#160;the [***] arising out of the [***] Program, and (ii)&#160;the decision by Institute [***]<a name="_cp_text_1_291"></a> (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;">Period</font><font style="color:#000000;">&#8221;), to include [***], arising from the [***]<a name="_cp_text_1_296"></a> Program <a name="_cp_text_1_299"></a>as Licensed Products pursuant to this Agreement.&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of determining the duration of the [***] Period, [***] shall mean the [***].&nbsp;&nbsp;The Parties acknowledge and agree that the [***] for the [***] Program as described in the First Restated Agreement has terminated effective as of the Execution Date and that the [***] Program (and Licensee&#8217;s obligation to fund the [***] Program) will continue solely as expressly set forth in the Second Restated Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_306"></a><a name="_cp_text_1_311"></a><a name="_cp_text_1_314"></a><a name="_cp_text_1_327"></a><a name="_cp_text_1_331"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In order to retain the right to [***] during the [***], Licensee shall <a name="_cp_text_1_306"></a>[***] commencing on the Execution Date and during the remainder of the [***] in the form of the [***] Contribution, in accordance with a mutually agreed [***] Programs Development Plan and [***] Program Budget, as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(e)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(f)</font><font style="color:#000000;"> of the Research Agreement.&nbsp;&nbsp;Licensee may terminate the <a name="_cp_text_1_311"></a>[***] at any time during the [***] Period by [***]<a name="_cp_text_1_314"></a> written notice to Institute.&nbsp;&nbsp;Following notice of termination of the [***], Licensee shall remain responsible for [***]activities that are [***] for which the [***] by Institute during the termination notice period.&nbsp;&nbsp;Licensee shall also be responsible for [***] associated with the termination of the [***], if any.&nbsp;&nbsp;For clarity, any </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-17-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_cp_text_1_327"></a>failure by Licensee to pay </font><font style="color:#000000;">the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">Contribution (unless disputed in good faith by Licensee) within the timeframe set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(d)</font><font style="color:#000000;"> </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> and upon written notice from Institute to Licensee shall </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_331"></a> for the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_338"></a><a name="_cp_text_1_344"></a><a name="_cp_text_1_346"></a><a name="_cp_text_2_347"></a><a name="_cp_text_1_349"></a><a name="_cp_text_1_351"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The [***] Contribution shall be payable by Licensee as follows: (i)&#160;no later than [***]during the [***] Period, Institute will present to Licensee [***] that Institute [***] during that [***] (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Program </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Account</font><font style="color:#000000;">&#8221;); (ii)&#160;provided that the amount of the [***] Program [***] Account does not exceed [***] of the amounts set forth in the <a name="_cp_text_1_338"></a>[***] Budget, Licensee shall, pay the amounts set forth in the [***] Program [***] Account within [***] of receipt of&nbsp;&nbsp;such account.&nbsp;&nbsp;Any amounts paid towards the [***]Contribution shall be [***] made or payable by Licensee under this Agreement, provided that any [***]<a name="_cp_text_1_344"></a> set forth in the [***]<a name="_cp_text_1_346"></a> Program [***]<a name="_cp_text_2_347"></a> Account will be adjusted in subsequent [***] Program [***]y Accounts <a name="_cp_text_1_349"></a>against actual costs and committed costs incurred by Institute in conducting the <a name="_cp_text_1_351"></a>[***]Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_353"></a><a name="_cp_text_1_355"></a><a name="_cp_text_1_357"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_353"></a>If Licensee fails to make a payment of any undisputed amount included within the [***]<a name="_cp_text_1_355"></a> Program [***] Account within thirty (30) days following the due date Licensee&#8217;s right to exercise the [***] <a name="_cp_text_1_357"></a>with respect to the [***] Program shall terminate.&nbsp;&nbsp;Licensee may dispute any amount charged in good faith by written notice to Institute, and the Parties shall promptly meet following any such notice to discuss and resolve any such dispute in good faith.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_360"></a><a name="_cp_text_1_365"></a><a name="_cp_text_1_368"></a><a name="_cp_text_1_370"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee may exercise the <a name="_cp_text_1_360"></a>[***] by giving written notice to Institute at any time during the [***] Period (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Notice</font><font style="color:#000000;">&#8221;) and paying the [***] Fee in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.2(b)</font><font style="color:#000000;">.&nbsp;&nbsp;Upon receipt of the [***] Notice and the [***] Fee, [***]<a name="_cp_text_1_365"></a>, arising from the [***]<a name="_cp_text_1_368"></a> Program will be included as Licensed Products pursuant to this Agreement, and the [***]<a name="_cp_text_1_370"></a> Program shall thereafter be subject to the terms and conditions of this Agreement, including the milestone payments due under </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.3</font><font style="color:#000000;">, and the royalty obligations set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.6</font><font style="color:#000000;"> set forth in the column entitled &#8220;Licensed Product that is a Program [***] Arising from the [***] Program&#8221; in the table in such Section, that are applicable to Licensed Products arising from the [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_375"></a><a name="_cp_text_1_377"></a><a name="_cp_text_1_379"></a><a name="_cp_text_1_381"></a><a name="_cp_text_1_383"></a><a name="_cp_text_1_385"></a><a name="_cp_text_1_387"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee does not exercise a [***] for the [***] Program during the [***] Period, or if the <a name="_cp_text_1_375"></a>[***] is terminated by Licensee pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(b)</font><font style="color:#000000;">, then subject to the rights granted to Licensee under this Agreement, including the licenses granted in </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.1</font><font style="color:#000000;"><a name="_cp_text_1_377"></a>, and to subsection (g) below, all rights of Licensee under the [***]<a name="_cp_text_1_379"></a> Program <a name="_cp_text_1_381"></a>for which the [***]<a name="_cp_text_1_383"></a> has not been exercised (or for which the [***]<a name="_cp_text_1_385"></a> has been terminated, as applicable) shall terminate, and Institute shall thereafter have no further obligations to Licensee with respect to the [***]<a name="_cp_text_1_387"></a> Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_390"></a><a name="_cp_text_1_392"></a><a name="_cp_text_1_393"></a><a name="_cp_text_2_394"></a><a name="_cp_text_1_399"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding subsection (f), following either (i)&#160;the expiration of the [***] Period without exercise of the [***] by Licensee for the [***]<a name="_cp_text_1_390"></a> Program, (ii)&#160;termination by Licensee of the [***] for the [***]<a name="_cp_text_1_392"></a> Program or (iii) at any time with respect to the [***] Program, as set forth below, if Institute grants rights to any Third Party to develop or commercialize any product (including any [***]<a name="_cp_text_1_393"></a>) arising from the  [***]<a name="_cp_text_2_394"></a> Program and/or the [***] Program, Institute shall [***] under any agreement for the grant of such rights, until [***] (i) with </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-18-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">respect to the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Program, the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Contribution&nbsp;&nbsp;paid by Licensee during the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Period (up to and including the effective date of termination or expiration of the&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_399"></a>) with respect to the </font><font style="color:#000000;">[***]</font><font style="color:#000000;">Program for which rights have been granted to such Third Party and (ii) with respect to the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Program, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.&nbsp;&nbsp;For clarity, Licensee may terminate the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> by (A)&#160;the giving of </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> written notice to Institute in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6(b)</font><font style="color:#000000;">, or (B)&#160;written notice in the event of (1) any issue relating to the safety or efficacy of the </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, or (2) a change in the regulatory framework or other laws applicable to the development and commercialization of the </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, or (3) </font><font style="color:#000000;">[***]</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_411"></a><a name="_cp_text_1_413"></a><a name="_cp_text_1_417"></a><a name="_cp_text_1_419"></a><a name="_cp_text_1_421"></a><a name="_cp_text_1_423"></a><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the purposes of this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.6</font><font style="color:#000000;">, &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Development Costs</font><font style="color:#000000;">&#8221; shall mean the [***] costs incurred ([***]<a name="_cp_text_1_411"></a>) by Institute in conducting the [***]<a name="_cp_text_1_413"></a> Program, provided that (i)&#160;[***] Development Costs shall also include [***]<a name="_cp_text_1_417"></a> Program<a name="_cp_text_1_419"></a>) associated with the [***]<a name="_cp_text_1_421"></a> Program, which shall be mutually agree by the Parties and set forth in the <a name="_cp_text_1_423"></a>[***] Budget, and (ii)&#160;[***] set forth in the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Other Rights</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party acknowledges that the rights and licenses granted in this Agreement are limited to the scope expressly granted.&nbsp;&nbsp;Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.&nbsp;&nbsp;All rights with respect to any know-how, patent or other intellectual property rights that are not specifically granted herein are reserved to the owner thereof.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012475"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">SUBLICENSES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Permitted Sublicensing</font><font style="color:#000000;">.&nbsp;&nbsp;Institute grants to the Licensee the right to sublicense, in whole or in part, as follows: (a)&#160;Licensee shall have the right to sublicense the Patent Rights and the Know-How Rights within the Territory in the Licensed Field solely to Licensee&#8217;s Affiliates and subcontractors performing work on behalf of Licensee; and (b)&#160;Licensee shall have the right to sublicense the right to make, use, sell, offer for sale and import Licensed Products within the Territory in the Licensed Field through multiple tiers.&nbsp;&nbsp;The term Sublicense shall include any grant of rights under this Agreement by a Sublicensee to any downstream Third Party, such downstream Third Party shall also be considered a Sublicensee for purposes of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Sublicense Requirements</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee shall (a)&#160;provide Institute with a copy of each sublicense issued within thirty (30) days after the execution of such sublicense; (b)&#160;collect payment of all payments due to Institute from Sublicensees through Licensee arising from Sales of Licensed Products; and (c)&#160;summarize and deliver all reports due Institute from Sublicensees through Licensee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Sublicense Terms</font><font style="color:#000000;">.&nbsp;&nbsp;Each Sublicensee must be subject to a written sublicense agreement containing all terms of the sublicense, which shall include at least the following terms and conditions:</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-19</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">record keeping, audit and reporting obligations substantially equivalent to those set forth in </font><font style="text-decoration:underline;color:#000000;">Sections&#160;8.1 </font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">8.2</font><font style="color:#000000;"> of this Agreement, sufficient to enable Licensee and Institute to reasonably verify the payments due to Licensee and Institute under such Sublicense and to reasonably monitor such Sublicensee&#8217;s progress in developing and/or commercializing Licensed Product, including the right for Institute (or its designee) to perform a direct audit of Sublicensee&#8217;s books and records on terms no less stringent than those set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.2</font><font style="color:#000000;"> of this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_255"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_255"></a>infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements imposed on Licensee and do not provide greater rights to Sublicensee than as provided in </font><font style="text-decoration:underline;color:#000000;">Article&#160;14</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">confidentiality provisions with respect to Confidential Information of Institute consistent with the restrictions on Licensee in </font><font style="text-decoration:underline;color:#000000;">Article&#160;22</font><font style="color:#000000;"> of this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a requirement of indemnification of Institute by Sublicensee that is equivalent to the indemnification of Institute by Licensee under </font><font style="text-decoration:underline;color:#000000;">Section&#160;15.1</font><font style="color:#000000;"> of this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_field_47_257"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">a requirement of obtaining and maintaining insurance by Sublicensee that is equivalent to the insurance requirements of Licensee under </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_257"></a>Section&#160;15.4</font><font style="color:#000000;"> of this Agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Sublicense that does not include all of the terms and conditions set forth in this <font style="text-decoration:underline;">Section&#160;3.3</font> or which is not issued in accordance with the terms and conditions set forth in this <font style="text-decoration:underline;">Article&#160;3</font>, shall be considered null and void with no further notice from Institute.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Effect of License Termination</font><font style="color:#000000;">.&nbsp;&nbsp;Upon termination of this Agreement for any reason, all sublicenses that are granted by Licensee pursuant to this Agreement will remain in effect and will be assigned to Institute, provided that the Sublicensee is in compliance with its sublicense agreement as of the date of such termination, and except that Institute will not be bound to perform any duties or obligations set forth in any sublicenses that extend beyond the duties and obligations of Institute set forth in this Agreement.&nbsp;&nbsp;Institute will have the sole right to modify each such assigned sublicense to include all of the rights of Institute that are contained in this Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012476"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FINANCIAL PROVISIONS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Issue Fee.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As initial payment for the rights received under this Agreement with respect to CTL Products, Licensee paid to Institute a fixed fee of three million dollars ($3,000,000) (the &#8220;</font><font style="font-weight:bold;color:#000000;">Issue Fee</font><font style="color:#000000;">&#8221;) within fifteen (15) business days following the Original Effective Date.&nbsp;&nbsp;The Issue Fee is non-refundable and non-creditable against any other amounts, including but not </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-20</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">limited to, Earned Royalties due to Institute by Licensee.&nbsp;&nbsp;The Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As initial payment for the rights received under this Agreement with respect to BKV/JCV-Specific CTL Products, Licensee paid to Institute a fixed fee of [***] (the &#8220;</font><font style="font-weight:bold;color:#000000;">BKV/JCV Issue Fee</font><font style="color:#000000;">&#8221;) within fifteen (15) business days following the First Restatement Date.&nbsp;&nbsp;The BKV/JCV Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee.&nbsp;&nbsp;The BKV/JCV Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As initial payment for [***], Licensee paid to Institute [***] within fifteen (15) business days [***]. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Option Fees</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_425"></a><a name="_cp_text_1_429"></a><a name="_cp_text_1_431"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Party acknowledges that Licensee has previously delivered <a name="_cp_text_1_429"></a>an Option Notice for the EBV Autologous Option and has paid to Institute a fee of [***] (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option Fee</font><font style="color:#000000;"><a name="_cp_text_1_431"></a>&#8221;).&nbsp;&nbsp;The Option Fee is nonrefundable and non-creditable against any other amounts once paid and is not in any way contingent on use or productivity of the underlying technology and know-how related to the EBV Autologous Option. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_434"></a><a name="_cp_text_1_438"></a><a name="_cp_text_1_440"></a><a name="_cp_text_1_442"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within ten (10) days following Licensee&#8217;s delivery of a [***] Notice for the [***]Program, Licensee shall pay to Institute a fee of [***]<a name="_cp_text_1_438"></a> (the &#8220;[***] </font><font style="font-weight:bold;color:#000000;">Fee</font><font style="color:#000000;"><a name="_cp_text_1_440"></a>&#8221;).&nbsp;&nbsp;The [***]<a name="_cp_text_1_442"></a> Fee is non-refundable and non-creditable against any other amounts once paid and is not in any way contingent on use or productivity of the underlying technology and know-how related to the [***] Program.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Milestone Payments</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As additional consideration for Institute entering into this Agreement and the Research Agreement, Licensee will pay to Institute the milestone payments (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Milestone Payment</font><font style="color:#000000;">&#8221;) set forth in the table below for each Allogeneic Licensed Product and/or Autologous Licensed Product (as applicable pursuant to the table set forth below) to achieve the corresponding milestone (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Milestone</font><font style="color:#000000;">&#8221;), whether achieved by Licensee or an Affiliate or Sublicensee.&nbsp;&nbsp;Licensee shall promptly notify Institute in writing of the achievement of any such Milestone and Licensee shall pay Institute in full the corresponding Milestone Payment within [***] of such achievement.&nbsp;&nbsp;For clarity, each Milestone Payment is payable once only for each Allogeneic CTL Product and once for each Autologous CTL Product, except with respect to Milestone Trigger Event 1, which is payable once only for the first Allogeneic CTL Product, and each Milestone Payment is non-refundable, and is not an advance against royalties due to Institute or any other amounts due to Institute.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:67.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payment</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone Trigger Event</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Product Specifically Directed to <font style="font-size:12pt;font-weight:normal;">[***]</font></p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Product <font style="font-size:12pt;font-weight:normal;">[***]</font> under Research Agreement</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First calendar year in which worldwide annual Net Sales of Product <font style="font-size:12pt;">[***]</font></p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First calendar year in which annual Net Sales of Product [***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:5.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:27.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First calendar year in which annual Net Sales of Product [***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:22.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Unless a Milestone Payment is specified as payable for more than one Indication in the table above, each Milestone Payment will be payable by Licensee only once, following the first time a given Licensed Product achieves the specified Milestone, for each Allogeneic CTL Product and each Autologous CTL Product to achieve such Milestone.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each time a Milestone is achieved, then any other Milestone Payments with respect to earlier Milestones that have not yet been paid will be due and payable together with the Milestone Payment for the Milestone that is actually achieved.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee, with respect to a given Licensed Product and a given Indication, elects to progress the development and commercialization of an Autologous CTL Product in lieu of an Allogeneic CTL Product for such Indication, then (i)&#160;following the decision to progress development and commercialization of such Autologous CTL Product, Licensee shall owe all subsequent Milestone Payments due for such Autologous CTL Product, and (ii)&#160;subsection (c)&#160;shall apply solely with respect to any Milestone Payments that are applicable to both Autologous CTL Products and Allogeneic CTL Products, and have not already been paid for the Allogeneic CTL Product.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_263"></a><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Milestone Offset</font><font style="color:#000000;">.&nbsp;&nbsp;If Licensee [***], that it is necessary to obtain a license (or a sublicense) from any Third Party under (a)&#160;any patents or patent applications owned or otherwise controlled by a Third Party that claim or cover [***], including without limitation any specific constructs or variants of such [***], wherever originating, including without limitation any such patents or patent applications owned or otherwise controlled by [***] and/or the [***] (the &#8220;[***]&#8221;), and/or (b)&#160;any patents or patent applications having a priority date prior to the [***] owned or otherwise controlled by any [***] in order to develop, make, have made, use, Sell, offer </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-22-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">for Sale or import any Licensed Product (such licenses, each an &#8220;</font><font style="font-weight:bold;color:#000000;">Additional License</font><font style="color:#000000;">&#8221;), and pursuant to such Additional License is required to pay any consideration (</font><font style="color:#000000;">[***]</font><font style="color:#000000;">) to such Additional Party for development and commercialization of such Licensed Product (&#8220;</font><font style="font-weight:bold;color:#000000;">Additional License Payments</font><font style="color:#000000;">&#8221;), then Licensee may offset </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> paid to such Additional Party against </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> payable to Institute under this Agreement or </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">under this Agreement in relation to such Licensed Product or </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> in relation to such Licensed Product after the effective date of such Additional License, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, provided that Licensee may not offset any Additional License Payments due under the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> for all Licensed Products in aggregate (the &#8220;</font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_263"></a>&#8221;)</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">For clarity, Licensee&#8217;s right to offset Additional License Payments under any Additional License falling within (</font><font style="color:#000000;">b</font><font style="color:#000000;">)&#160;shall be subject to the </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the foregoing, in no event shall the offset of Additional License Payments exceed </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, as applicable, and </font><font style="color:#000000;">[***]</font><font style="color:#000000;">due to Institute under this Agreement and the Research Agreement.&nbsp;&nbsp;Any Additional License Payments (</font><font style="color:#000000;">[***]</font><font style="color:#000000;">) in excess of such </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> may be </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> by Licensee and </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, provided that no offset may be taken by Licensee against </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> prior to the effective date of such Additional License.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalties</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.4</font><font style="color:#000000;">, Earned Royalties will accrue on a Licensed Product-by-Licensed Product basis and country-by-country basis, for the duration of the Royalty Term and will be payable to Institute when Licensed Products are invoiced, or if not invoiced, when delivered or otherwise exploited by the Licensee, its Affiliate or Sublicensee in a manner constituting a Sale.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Earned Royalty</font><font style="color:#000000;">.&nbsp;&nbsp;As further consideration for the rights granted under this Agreement and activities agreed under this Agreement and the Research Agreement, Licensee will pay to Institute the following earned non-refundable, non-creditable royalty on Net Sales of Licensed Products (&#8220;</font><font style="font-weight:bold;color:#000000;">Earned Royalty</font><font style="color:#000000;">&#8221;):</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;width:32.88%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Annual Net Sales</p></td>
<td colspan="3" valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:67.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Percent</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="font-weight:bold;font-size:11pt;"> CTL Products&nbsp;&nbsp;</font></p></td>
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Products <font style="font-size:12pt;font-weight:normal;">[***]</font>under the Research Agreement</p></td>
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:23.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Product that is a <font style="font-size:12pt;font-weight:normal;">[***]</font> Program</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:32.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion less than <font style="font-size:12pt;">[***]</font></p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:23.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:32.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion greater than or equal to <font style="font-size:12pt;">[***]</font></p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:20.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt;width:23.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, for any Licensed Product that is a Diagnostic Product, the Earned Royalty shall be [***] of the royalty rates set forth in the table above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Offset</font><font style="color:#000000;">.&nbsp;&nbsp;If Licensee [***], that it is necessary to obtain a license under patents or patent applications Controlled by a Third Party (a &#8220;</font><font style="font-weight:bold;color:#000000;">Third Party License</font><font style="color:#000000;">&#8221;) in order to develop, make, have made, use, Sell, offer for Sale or import any Licensed Product, and pursuant to such Third Party License is required to pay royalties to such Third Party (&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Royalty Payments</font><font style="color:#000000;">&#8221;), then Licensee may deduct [***] of all royalties paid to such Third Party against the Earned Royalty owed to Institute, up to a limit of [***] of the applicable Earned Royalty </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-23</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">in any given calendar year.&nbsp;&nbsp;Any Third Party Royalty Payments in excess of such </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> limit for a given calendar year </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Term</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to the remainder of this </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8</font><font style="color:#000000;">, the Earned Royalty will be payable, on a Licensed Product-by-Licensed Product basis, and on a country-by-country basis, from the date of First Commercial Sale of such Licensed Product in such country until the last to occur of the following: (i)&#160;expiration or abandonment of the last Valid Claim of (A)&#160;any of the Patent Rights existing as of the Original Effective Date that cover or claim [***] such Licensed Product in such country, (B)&#160;any patent or patent application included in the Patent Rights following the Original Effective Date that arises as a result of the Parties&#8217; activities conducted pursuant to the Research Agreement, or (C)&#160;any [***]; (ii)&#160;cessation of any Data Exclusivity Protection or Orphan Drug Exclusivity applicable to such Licensed Product in such country; or (iii)&#160;the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country (the &#8220;</font><font style="font-weight:bold;color:#000000;">Royalty Term</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding the foregoing, if in a country, (i)&#160;neither of the events set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(a)(i)</font><font style="color:#000000;"> and/or </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(a)(ii)</font><font style="color:#000000;"> have occurred in relation to such Licensed Product, (ii)&#160;one or more Comparable Third Party Products for such Licensed Product have been sold in such country for a period of [***], (iii)&#160;such Comparable Third Party Products do not infringe any Valid Claim of the [***], Licensee is [***], and (iv)&#160;following such [***] period, Net Sales during [***] Calendar Quarters in such country are [***] for the [***] Calendar Quarters, the Earned Royalty will be reduced thereafter to [***] of the amounts set forth in the table in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.6</font><font style="color:#000000;"> above (following any offsets applicable under </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.7</font><font style="color:#000000;">).&nbsp;&nbsp;Furthermore, if in a country, at any time prior to the [***] anniversary of the First Commercial Sale of such Licensed Product, [***] set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(a)(i)</font><font style="color:#000000;"> and/or </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(a)(ii)</font><font style="color:#000000;"> have occurred in relation to such Licensed Product, the Earned Royalty will be reduced thereafter to [***] of the amounts set forth in the table in </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.6</font><font style="color:#000000;"> above (following any offsets applicable under </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.7</font><font style="color:#000000;">).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Following the expiration of the Royalty Term, all licenses granted to Licensee hereunder shall become perpetual, exclusive and fully paid-up.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Payment Schedule</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee will pay to Institute all Earned Royalties payable to Institute quarterly on or before February&#160;28 (for the Calendar Quarter ending December&#160;31), May&#160;31 (for the Calendar Quarter ending March&#160;31), August&#160;31 (for the Calendar Quarter ending June&#160;30) and November&#160;30 (for the Calendar Quarter ending September&#160;30) of each calendar year.&nbsp;&nbsp;Each payment will be for Earned Royalties accrued within the Licensee&#8217;s most recently completed Calendar Quarter.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Currency</font><font style="color:#000000;">.&nbsp;&nbsp;All consideration due Institute will be payable and will be made in United States dollars by wire transfer to an account designated by Institute.&nbsp;&nbsp;When Licensed Products are Sold for monies other than United States dollars, the Earned Royalties and other consideration will first be determined in the foreign currency of the country in which such Licensed </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-24</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Products were Sold and then converted into equivalent United States dollars.&nbsp;&nbsp;The exchange rate will be the average exchange rate quoted in </font><font style="font-style:italic;color:#000000;">The Wall Street Journal</font><font style="color:#000000;"> for the purchase of United States dollars during the last thirty (30) days of the reporting period.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Royalty Reports</font><font style="color:#000000;">.&nbsp;&nbsp;Beginning with the First Commercial Sale of an Licensed Product, within [***] following the end of each Calendar Quarter, Licensee shall make quarterly royalty reports to Institute on or before each February&#160;28, May&#160;31, August&#160;31 and November&#160;30 of each year.&nbsp;&nbsp;Each royalty report will cover the Licensee&#8217;s most recently completed Calendar Quarter and will show: (i)&#160;the amount invoiced for Sales and Net Sales of Licensed Products that are Sold during the most recently completed calendar quarter; (ii)&#160;the [***] Licensed Product that is Sold on a country by country basis; (iii)&#160;the Earned Royalties, in U.S. dollars, payable with respect to Sales of Licensed Products; (iv)&#160;[***] the Earned Royalty; (v)&#160;a [***] to calculate Net Sales; and (vi) the exchange rates used.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;Earned Royalties on Net Sales of Licensed Products and other consideration accrued in, any country outside the United States may be reduced by any taxes, fees or other charges imposed by the government of such country, including those taxes, fees and charges allowed under the provisions of the definition of &#8220;Net Sales&#8221; in </font><font style="text-decoration:underline;color:#000000;">Article 1</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Late Payments</font><font style="color:#000000;">.&nbsp;&nbsp;If Earned Royalties, fees, reimbursements for Patent Prosecution Costs or other monies owed to Institute are not received by Institute when due, the Licensee will pay to Institute interest at a rate of the lesser of: (a)&#160;[***], or any successor thereto, at 12:01 a.m. on the first day of each Calendar Quarter in which such payments are overdue or (b)&#160;the maximum rate permitted by Law.&nbsp;&nbsp;Such interest will be calculated from the date payment was due until actually received by Institute.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Acknowledgement</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties acknowledge that the payments required to be made by Licensee to Institute under this Agreement are in consideration of all rights granted to Licensee and obligations undertaken by Institute under this Agreement.&nbsp;&nbsp;Such granted rights include use of valuable Know-How Rights, and the right to participate in the JSC and the conduct of the Development Plan so as to discover or develop Licensed Products that may not be, or may cease to be, covered by (a)&#160;Patent Rights, (b)&#160;Data Exclusivity, or (c)&#160;Orphan Drug Exclusivity.&nbsp;&nbsp;Each Party expressly acknowledges that it is their intention that royalties and other consideration be paid in accordance with the terms of this Agreement, and during the periods set forth in this Agreement, notwithstanding that a Licensed Product may be royalty-bearing at a reduced rate pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;4.8(b)</font><font style="color:#000000;"> in the absence of coverage by (i)&#160;Patent Rights, or after the expiration of such Patent Rights, or (ii)&#160;Data Exclusivity, or (iii)&#160;Orphan Drug Exclusivity.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Fees</font><font style="color:#000000;">. As further consideration for the rights granted and payments received by Institute under this Agreement, Institute agrees to pay to Licensee the [***] Fees as set forth on </font><font style="text-decoration:underline;color:#000000;">Schedule 4.15</font><font style="color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-25</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012477"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">DILIGENCE; REGULATORY ACTIVITIES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref5110263"></a><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">General Diligence</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee, following execution of this Agreement, will use Commercially Reasonable Efforts to proceed with the development, manufacture and Sale of Licensed Products in the [***] Territory.&nbsp;&nbsp;Without limiting the following, unless otherwise agreed by the Parties in a writing that specifically references these obligations, Licensee shall: </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref5110267"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***];</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***];</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided that, if Licensee&#8217;s failure to meet the applicable diligence obligation under <font style="text-decoration:underline;">Section&#160;5.1(b)</font> is the result of (i)&#160;Institute&#8217;s failure to perform its obligations in accordance with (A)&#160;the Research Agreement and the Development Plan (including any timelines set forth therein), or (B)&#160;any Manufacturing Agreement entered into by the Parties, or (ii)&#160;additional development activities (including any changes to manufacturing process or activities) required by the FDA in order to obtain regulatory approval for a Licensed Product, then in each case the target timeframe to meet the diligence requirements set forth in <font style="text-decoration:underline;">Section&#160;5.1(b)</font>, as applicable, shall be [***], to complete the required activities. The Parties agree and acknowledge that Licensee has met its diligence obligation as set forth in <font style="text-decoration:underline;">Section 5.1(a)</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_458"></a><a name="_cp_text_1_460"></a><a name="_cp_text_1_465"></a><a name="_cp_text_1_467"></a><a name="_cp_text_1_471"></a><a name="_cp_text_1_473"></a><a name="_cp_text_1_269"></a><a name="_cp_text_1_475"></a><a name="_cp_text_1_477"></a><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;"><a name="_cp_text_1_458"></a>Specific Diligence for </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"><a name="_cp_text_1_460"></a> Program</font><font style="color:#000000;">.&nbsp;&nbsp;Following exercise of the [***] for the [***] Program, Licensee will use Commercially Reasonable Efforts to proceed with the development, manufacture and Sale of Licensed Products that [***] in the [***] in the Territory.&nbsp;&nbsp;Within [***] <a name="_cp_text_1_465"></a>for the [***]<a name="_cp_text_1_467"></a> Program, Licensee shall provide Institute with a reasonably detailed development plan for the further development of the [***], through to Regulatory Approval (the &#8220;</font><font style="font-weight:bold;color:#000000;">Licensee </font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Development Plan</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Following Licensee&#8217;s delivery of the Licensee [***] Development Plan to Institute, the Parties shall discuss and mutually agree upon the date upon which Licensee will be required to [***] occurring after exercise of the [***]<a name="_cp_text_1_471"></a> for the [***]<a name="_cp_text_1_473"></a> Program (the &#8220;[***]</font><font style="font-weight:bold;color:#000000;"> Date</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The [***] Date, once mutually agreed by the Parties or determined pursuant to </font><font style="text-decoration:underline;color:#000000;">Article&#160;20</font><font style="color:#000000;"><a name="_cp_text_1_269"></a> as described below, shall be executed by each Party and thereupon constitute an additional diligence obligation for Program [***]<a name="_cp_text_1_475"></a> arising from the [***]<a name="_cp_text_1_477"></a> Program equivalent to the diligence obligation set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;5.1(a)</font><font style="color:#000000;"> for CTL Products arising from the Research Collaboration and be deemed to be a part of this Agreement.&nbsp;&nbsp;If the Parties are unable to agree on the [***] Date within [***] after Licensee&#8217;s delivery of the Licensee [***] Development Plan to Institute, then such dispute shall first be escalated to the Executives for resolution in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;20.1</font><font style="color:#000000;">, and if not resolved within the time period set forth therein, each Party shall, [***] following the expiration of the time period for the Executive resolution under </font><font style="text-decoration:underline;color:#000000;">Section&#160;20.1</font><font style="color:#000000;">, [***] Date shall be [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Governance</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties&#8217; activities under this Agreement and the Research Agreement shall be overseen by the JSC, as further set forth in </font><font style="text-decoration:underline;color:#000000;">Article&#160;3</font><font style="color:#000000;"> of the Research Agreement.&nbsp;&nbsp;In the event that the Research Agreement is terminated or expires, the JSC will remain in place and continue to operate as set forth in the Research Agreement to the extent applicable to </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-26</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">activities under this Agreement, including with respect to each Party&#8217;s final decision making authority as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3(f)</font><font style="color:#000000;"> of the Research Agreement.&nbsp;&nbsp;For the avoidance of doubt, the exercise of such authority by Licensee shall in no way define, affect or diminish the diligence obligations of Licensee hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Progress Reports</font><font style="color:#000000;">.&nbsp;&nbsp;On a [***] basis, but in any event no later than June&#160;1st and December&#160;1st in each calendar year, as long as Licensee continues to develop and commercialize Licensed Products, Licensee will submit a written report to Institute covering the Licensee&#8217;s (and any of its Affiliates&#8217; or Sublicensees&#8217;) activities related to this Agreement, including any updates or amendments to the Development Plan and activities being conducted pursuant to the Research Agreement (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Progress Report</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The report will include information reasonably sufficient to enable Institute to ascertain progress by Licensee toward meeting this Agreement&#8217;s diligence requirements set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;5.1</font><font style="color:#000000;">.&nbsp;&nbsp;Each report will describe, where relevant: (a)&#160;current schedule of anticipated events or milestones; (b)&#160;summary of work completed and in progress, including against the Development Plan, during such period; (c)&#160;summary of work in progress and progress toward commercialization of Licensed Products; (d)&#160;significant corporate transactions involving Licensed Products, including any Sublicenses granted.&nbsp;&nbsp;Licensee shall include in each Progress Report the date of First Commercial Sale of any Licensed Product in each country, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Regulatory Activities</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee shall be solely responsible, at Licensee&#8217;s expense for filing, obtaining and maintaining all Regulatory Approvals required for the development and commercialization of Licensed Products anywhere in the Territory where Licensed Products are manufactured, used, Sold, offered for Sale or imported.&nbsp;&nbsp;Licensee will obtain all such Regulatory Approvals in its own name (or that of a Licensee Affiliate) and shall own all right, title and interest in and to such Regulatory Approvals, and all materials, data and information included therein and relating thereto.&nbsp;&nbsp;Notwithstanding the foregoing, and subject to the terms and conditions of the Research Agreement, Institute shall be responsible for obtaining any Regulatory Approvals required for any clinical trials conducted by Institute or any Affiliate under the Research Agreement, provided that Institute shall provide Licensee with copies of all such fillings and correspondence relating thereto, and Licensee shall have a right of reference to all data, materials and information contained in any such regulatory filings and Regulatory Approvals.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute shall transfer to Licensee all of the data and information Controlled by Institute and arising from (i)&#160;the activities under the Research Agreement, or (ii)&#160;activities conducted by or under the supervision of [***] prior to the date of the exercise of the [***], in each case that is necessary or useful for the development, manufacturing and commercialization of EBV-Specific Autologous Products.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_483"></a><font style="Background-color:#auto;text-decoration:none;">5.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Abandonment</font><font style="color:#000000;">.&nbsp;&nbsp;If Licensee decides to abandon, or does in fact abandon, on a Licensed Product by Licensed Product and Major Market-by-Major Market basis the development or commercialization of Licensed Products (including an [***], solely following the </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-27-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">exercise of the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_1_483"></a> for the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Program), then Licensee shall forthwith notify Institute in writing and Institute shall have the right to terminate this Agreement, solely with respect to the Major Market(s) in which such abandonment has taken place, upon written notice to Licensee in relation to such Licensed Product(s) and Major Market(s).&nbsp;&nbsp;A suspension of a New Research Program or other activities related to the development or commercialization of a Licensed Product shall be deemed to be abandonment if Licensee does not have a good-faith intention to continue development and commercialization of such Licensed Product.&nbsp;&nbsp;Upon such termination, any such Licensed Products shall be deemed Reversion Products (as defined in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6(b)</font><font style="color:#000000;">), and </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;"> shall apply.&nbsp;&nbsp;Promptly following such notice of termination, the Parties shall meet to discuss in good faith and agree upon the process for transitioning to Institute the rights to commercialize such Licensed Product in the applicable Major Markets, and to coordinate the ongoing development and commercialization of such product in such terminated Major Market, including the sharing of information, regulatory filings and data relating thereto.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012478"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">MANUFACTURE AND SUPPLY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_271"></a><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_cp_text_1_271"></a>The Parties are parties to and intend to enter into one or more agreements that will govern the terms of manufacture and supply of CTL Products and New CTL Products and Program [***], including specific [***] CTL Products for clinical supply for use in development activities, including clinical trials to be conducted by each Party pursuant to the Development Plan and under the Research Agreement (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Agreement</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;As of the Execution Date, the Parties anticipate that any such additional Manufacturing Agreement shall incorporate commercially reasonable terms that are appropriate for a similarly situated manufacturing agreement, and shall include at least the following principles, as set forth below in </font><font style="text-decoration:underline;color:#000000;">Sections&#160;6.1(a)</font><font style="color:#000000;"> through </font><font style="text-decoration:underline;color:#000000;">(d)</font><font style="color:#000000;">, and other material terms such as pricing, as the Parties shall mutually agree upon:&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute shall be responsible for the manufacture and supply of CTL Products and New CTL Products and Program [***] (including specified [***] Products) for clinical supply through to [***] (which may include, subject to mutual agreement of the Parties, [***]), itself or through an Affiliate or mutually-agreed upon Third Party contract manufacturing organization (&#8220;</font><font style="font-weight:bold;color:#000000;">CMO</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The costs applicable to such manufacturing activities will be set forth in the Development Plan under the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute&#8217;s obligation to manufacture and supply as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;6.1(a)</font><font style="color:#000000;"> shall be conditioned on (i)&#160;the manufacturing entity shall have all Regulatory Approvals required for manufacture of Licensed Products for clinical supply, and (ii)&#160;the manufacturing entity shall have appropriate production capacity (including the ability to scale up as required) for the applicable CTL Products and New CTL Products and Program [***] to meet the timelines and specifications provided by Licensee for Licensed Product for clinical development.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-28</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties shall discuss in good faith the arrangements for the manufacture and supply of Licensed Products for clinical development activities following completion of Phase I Clinical Trials and for commercialization of Licensed Products in the Territory, including the selection of an appropriate manufacturing entity, which may include without limitation, either Party or its Affiliates, or a mutually agreed Third Party CMO.&nbsp;&nbsp;If Licensee requests that Institute continue to perform manufacturing and supply activities for Licensed Products hereunder, then Institute shall, subject to negotiation and agreement on the terms of the Manufacturing Agreement, manufacture and supply such Licensed Products to Licensee, with the further terms of such manufacture and supply to be set forth in the Manufacturing Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties acknowledge and agree that for the purposes of facilitating the manufacture and supply of Licensed Products to support the Parties&#8217; activities under this Agreement and the Research Agreement, including for reasons related to regulatory requirements or cost-effectiveness and economies of scale of production, Licensee may elect, or it may be necessary for the Parties to transfer manufacturing and supply to a different Third Party CMO, or to a different facility.&nbsp;&nbsp;Each Party agrees that with respect to any transfer of manufacturing technology, it will provide reasonable assistance to the other Party, at such other Party&#8217;s reasonable expense and subject to such arrangements as are necessary to protect confidential information and proprietary know-how, to effect such transfer in a timely fashion and without undue disruption to the manufacture and supply of the applicable Licensed Product(s).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012479"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">CERTAIN COVENANTS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">General Rule</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.2</font><font style="color:#000000;">, during the period beginning on the Original Effective Date and ending on the expiration or earlier termination of this Agreement, neither Party shall (directly or indirectly, and either with or without a bona fide collaborator) conduct outside the scope of this Agreement, or the Research Agreement, any programs that are intended to identify, optimize, develop or commercialize a Competing Product.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Exception for Certain Third Party Products</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.1</font><font style="color:#000000;">, during the Term, Licensee may acquire or in-license from a Third Party (a)&#160;rights in technology (including rights in patents, patent application and/or know-how) that Licensee [***] to the Patent Rights and Know-How Rights licensed by Institute to Licensee hereunder and are necessary or useful for the development and commercialization of Licensed Products hereunder, and/or (b)&#160;rights to develop and commercialize a CTL Product or New CTL Product or Program [***] that [***] (a &#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Product</font><font style="color:#000000;">&#8221;) if Licensee [***] that such [***] by Licensee or Institute (including any such Third Party Product [***]), including without limitation because such Third Party Product (a)&#160;[***] then under development, (b)&#160;[***] then under development, and/or (c)&#160;[***] then under development by Licensee.&nbsp;&nbsp;Licensee may negotiate the terms of such a Third Party license or other agreement at its sole discretion.&nbsp;&nbsp;Notwithstanding the foregoing, if Licensee acquires rights in such a Third Party Product, Licensee shall [***] the development and commercialization of such Third Party Product [***], for the Term of this Agreement, provided that if such Third Party Product is [***] pursuant to the foregoing shall be [***] of the amounts that [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-29</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Autologous CTL Programs</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">O</font><font style="color:#000000;">n an Indication-by-Indication basis, Licensee shall notify Institute in writing within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> following Licensee&#8217;s determination that Licensee (a)&#160;will not pursue development or commercialization of an Allogeneic CTL Product for use in a given Indication under this Agreement or the Research Agreement, and (b)&#160;does not wish to pursue the development and commercialization of an Autologous CTL Product for use in such Indication.&nbsp;&nbsp;Provided that such Indication is not the subject of an existing research and development Program under the Research Agreement, Institute shall have the right to develop and commercialize Autologous CTL Products for use in such Indication without such development and commercialization being a breach of this </font><font style="text-decoration:underline;color:#000000;">Article&#160;7</font><font style="color:#000000;">, and the license granted to Licensee pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2</font><font style="color:#000000;"> with respect to Autologous CTL Products shall no longer apply to any Autologous CTL Product for use in such Indication.&nbsp;&nbsp;Without limiting the foregoing, the Parties shall discuss, at least annually through the JSC, whether Licensee intends to, or is continuing to pursue development or commercialization of an Allogeneic CTL Product for use in the Indications that are the subject of research and development activities pursuant to the Research Agreement.&nbsp;&nbsp;Licensee will provide such information regarding its development and commercialization of such Allogeneic CTL Products as is required to reasonably inform Institute for the purposes of such discussions.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012480"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">BOOKS AND RECORDS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Accounting</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with GAAP.&nbsp;&nbsp;Licensee shall keep, and shall require each Sublicensee to keep, accurate books and records showing all Licensed Products manufactured, used, and/or Sold under the terms of this Agreement.&nbsp;&nbsp;Books and records must be preserved for at least five (5) years from the date of the Earned Royalty payment to which they pertain.&nbsp;&nbsp;Upon reasonable notice, key personnel, books and records will be made reasonably available and will be open to examination by representatives or agents of Institute during regular office hours to determine their accuracy and assess Licensee&#8217;s and, if applicable, each Sublicensee&#8217;s, compliance with the terms of this Agreement, provided that Licensee and any Sublicensees shall not have any obligation to provide access more than once in any given twelve (12) month period.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Audits</font><font style="color:#000000;">.&nbsp;&nbsp;In addition to the right of Institute to examine the books and records and interview key personnel as provided in </font><font style="text-decoration:underline;color:#000000;">Section&#160;8.1</font><font style="color:#000000;"> above, Institute, at its own cost, through an independent auditor reasonably acceptable to Licensee and, if applicable, a Sublicensee (and who has executed an appropriate confidentiality agreement reasonably acceptable to Licensee and, if applicable, a Sublicensee that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Institute), may inspect and audit the relevant records of Licensee or a Sublicensee pertaining to the calculation of any Milestones and Earned Royalties due to Institute under this Agreement.&nbsp;&nbsp;Licensee and, if applicable, a Sublicensee shall provide such auditors with access to the records during reasonable business hours.&nbsp;&nbsp;Such access need not be given to any such set of records more often than once each year or more than five (5) years after the date of any report to be audited.&nbsp;&nbsp;Institute shall provide Licensee with written </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-30</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">notice of its election to inspect and audit the records related to the Earned Royalty due hereunder not less than thirty (30) days prior to the proposed date of review of Licensee&#8217;s and, if applicable, a Sublicensee&#8217;s records by Institute&#8217;s auditors.&nbsp;&nbsp;Should the auditor find any underpayment of Milestones or Earned Royalties by Licensee, Licensee shall (a)&#160;promptly pay Institute the amount of such underpayment; (b)&#160;shall reimburse Institute for the cost of the audit, if such underpayment equals or exceeds </font><font style="color:#000000;">[***]</font><font style="color:#000000;">; and (c)&#160;provide such auditors with an audit right exercisable within six (6) months after Institute receives the audit report.&nbsp;&nbsp;If the auditor finds overpayment by Licensee, then Licensee shall have the right to deduct the overpayment from any future royalties due to Institute by Licensee or, if no such future royalties are payable, then Institute shall refund the overpayment to Licensee within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after Institute receives the audit report.&nbsp;&nbsp;Licensee may designate competitively sensitive information which such auditor may see and review but which it may not disclose to Institute; provided, however, that such designation shall not restrict the auditor&#8217;s investigation or conclusions.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012481"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">TERM; TERMINATION</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">.&nbsp;&nbsp;Unless otherwise terminated by operation of law, </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.2</font><font style="color:#000000;">, or by acts of the parties in accordance with the terms of this Agreement, this Agreement will remain in effect from the Original Effective Date until the expiration of all payment obligations hereunder (the &#8220;</font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Bankruptcy</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement will automatically terminate without the obligation to provide sixty (60) days&#8217; notice as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.3</font><font style="color:#000000;"> or </font><font style="text-decoration:underline;color:#000000;">9.4</font><font style="color:#000000;"> upon the filing of a petition for relief under the United States Bankruptcy Code by or against the Licensee as a debtor or alleged debtor.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination for Material Breach</font><font style="color:#000000;">.&nbsp;&nbsp;If a Party fails to perform or violates any material term of this Agreement, then the other Party may give written notice of breach to the breaching Party.&nbsp;&nbsp;If the breaching Party fails to repair the default within ninety (90) days after the date of receipt of such notice of breach, the other Party may terminate this Agreement by delivering a second written notice.&nbsp;&nbsp;If such second notice is sent to the breaching Party, this Agreement will automatically terminate on the date that such notice is received by the breaching Party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination for Convenience</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee has the right at any time to terminate this Agreement at will by providing written notice of termination to Institute, and paying to Institute a break fee equal to fifty percent (50%) of the amount of the next Milestone Payment that would be payable to Institute in respect of Licensee&#8217;s then most advanced Licensed Product.&nbsp;&nbsp;Termination of this Agreement will be effective sixty (60) days from the date such termination notice is received by Institute.&nbsp;&nbsp;Institute does not have any right to terminate this Agreement for convenience.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Termination if Patent Rights Challenged</font><font style="color:#000000;">.&nbsp;&nbsp;Institute has the right to terminate this Agreement by providing written notice of termination to Licensee, if Licensee or any of its Affiliates commence, pursue, encourage or support any administrative, judicial or other </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-31</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">similar proceeding to challenge the validity, enforceability or scope of any rights under any Patent Rights, including without limitation by (a)&#160;filing a declaratory judgment action in which any such Patent Rights are alleged to be invalid or unenforceable; (b)&#160;citing prior art pursuant to 35 U.S.C. &#167;301, filing a request for re-examination of any of such Patent Rights pursuant to 35 U.S.C. &#167;302 and/or &#167;311, or provoking or becoming a party to an interference with an application for any such Patent Rights pursuant to 35 U.S.C. &#167;135; or (c)&#160;filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against any such Patent Rights in any country.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Effects of Termination or Expiration</font><font style="color:#000000;">.&nbsp;&nbsp;The termination or expiration of this Agreement will not relieve the Licensee of its obligation to pay any fees, royalties or other payments owed to Institute at the effective date of such termination or expiration and will not impair any accrued right of Institute, including the right to receive Earned Royalties in accordance with </font><font style="text-decoration:underline;color:#000000;">Article&#160;4</font><font style="color:#000000;">.&nbsp;&nbsp;Additionally:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon expiration (but not termination) of this Agreement, the licenses granted to Licensee under </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.1</font><font style="color:#000000;"> (with respect to Licensed Products that are [***], solely to the extent that the [***] has been exercised prior to expiration) shall continue on a perpetual, irrevocable, exclusive, fully paid-up, royalty-free basis.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_485"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, all rights and licenses granted to Licensee in </font><font style="text-decoration:underline;color:#000000;">Article&#160;2</font><font style="color:#000000;"> shall terminate, subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;">, all rights of Licensee under the Patent Rights and Know-How Rights shall revert to Institute, and Licensee and its Affiliates shall cease all use of the Patent Rights and the Know-How Rights.&nbsp;&nbsp;Following the effective date of such termination, all Licensed Products that are EBV-Specific CTL Products or New CTL Products or Program [***], as applicable, shall thereafter be deemed &#8220;</font><font style="font-weight:bold;color:#000000;">Reversion Products</font><font style="color:#000000;">&#8221; and shall be subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the foregoing, in the event of a material breach by Institute of this Agreement permitting Licensee to terminate this Agreement pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.3</font><font style="color:#000000;">, as finally determined pursuant to a resolution in accordance with </font><font style="text-decoration:underline;color:#000000;">Article&#160;20</font><font style="color:#000000;"> or mutually agreed by the Parties (including by way of settlement), Licensee may, at its sole discretion and in lieu of such termination, elect to keep this Agreement in place and continue the development and commercialization of Licensed Products hereunder.&nbsp;&nbsp;If Licensee decides to keep this Agreement in place in lieu of termination, all payments, including all Milestone Payments and Earned Royalties, that would be due to Institute thereafter under the terms of this Agreement shall be [***]<a name="_cp_text_1_485"></a> for the remainder of the Term.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, all regulatory filings (including all INDs and BLAs) and Regulatory Approvals and all other documents necessary to further develop and commercialize the Reversion Products, as they exist as of the date of such termination, (and all of Licensee&#8217;s right, title and Institute therein and thereto) shall be assigned to Institute, and Licensee shall provide to Institute one (1) copy of the foregoing documents and filings that relate to Reversion Products, subject to Institute&#8217;s reimbursement of Licensee&#8217;s actual costs incurred in transferring such items to Institute, and preparing such items in connection with such transfer.&nbsp;&nbsp;For clarity, Institute shall have the right to use the foregoing </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-32</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">material information, materials and data developed by Licensee solely in connection with Institute&#8217;s (or its Affiliates or licensees&#8217;) development, manufacture and commercialization of Reversion Products.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, in the event that Licensee has inventory of any Licensed Product included in the Reversion Products prior to the effective date of termination, Licensee shall have [***] after the effective date of termination during which to dispose of such inventory (subject to the payment to Institute of any royalties due hereunder thereon) (the &#8220;</font><font style="font-weight:bold;color:#000000;">Inventory Disposal Period</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, Licensee shall provide to Institute the tangible embodiments of all know-how, data and information Controlled by Licensee and its Affiliates in existence as of the effective date of such termination to the extent necessary for the development and commercialization of the Reversion Products as such Reversion Products exist as of the effective date of such termination, subject, to Institute&#8217;s reimbursement of Licensee&#8217;s actual out of pocket and internal direct costs and expense incurred in transferring such items, and preparing and making such items in connection with such transfer.&nbsp;&nbsp;Licensee shall grant, and hereby grants to Institute, subject to Institute&#8217;s payment obligations under </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;">, and reimbursement of Licensee&#8217;s costs of transferring such materials, a perpetual, worldwide, transferable, sublicensable right and license under such know-how, data and information solely for (i)&#160;researching, developing, using, importing, selling and offering for sale Reversion Products in the Territory, which license shall be exclusive for purposes of this subpart (i), and (ii)&#160;making and having made Reversion Products anywhere in the Territory for use, importation, sale and offer for sale in the Territory, which license shall be non-exclusive for purposes of this subpart&#160;(ii).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;">, Licensee shall grant and hereby grants to Institute an exclusive, royalty-bearing (as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.7</font><font style="color:#000000;">), non-transferable license, with the right to grant sublicenses, under any patents or patent applications Controlled by Licensee or Affiliates as of the effective date of termination [***] and that are [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon termination (but not expiration) of this Agreement, Licensee shall provide to Institute all data generated during the term of this Agreement pursuant to this Agreement and the Research Agreement [***] Reversion Products and [***], subject to Institute&#8217;s [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither Party shall be relieved of any obligation that accrued prior to the effective date of expiration or a termination.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any costs and expenses incurred by Licensee in connection with the assignments and transfers made by Licensee under this </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6</font><font style="color:#000000;"> shall be borne by Institute.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-33</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Nothing in this </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6</font><font style="color:#000000;"> shall be deemed to limit any remedy to which either Party may be entitled by applicable Law.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties agree that CMV-Specific CTL Products, [***], and CMV [***] shall not be considered Reversion Products under the Agreement and accordingly clause (b) through (g) (inclusive) of this Section 9.6 and Section 9.7 shall not be applicable thereto.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Reversion of Rights</font><font style="color:#000000;">.&nbsp;&nbsp;If Institute obtains rights in any Reversion Product pursuant to this Article&#160;9, Institute will have the rights under such Reversion Product set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6</font><font style="color:#000000;">, provided that if Institute elects to grant a license or sublicense to any Third Party under patent rights or know-how Controlled by Licensee and relating to such Reversion Products (the &#8220;</font><font style="font-weight:bold;color:#000000;">Reversion Product IP</font><font style="color:#000000;">&#8221;) to develop and commercialize any such Reversion Product, then on a Reversion Product-by-Reversion Product basis, Institute shall pay to Licensee a specified percentage of all consideration of any type received from each such Third Party licensee or sublicensee paid for the grant of such license or sublicense, or sales of products that are claimed or covered by such Reversion Product IP, as set forth in the table below, with the applicable percentage being based on (a)&#160;[***], and (b)&#160;the [***].&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.19%;">
<tr>
<td style="width:44.45%;"></td>
<td style="width:25.85%;"></td>
<td style="width:25.88%;"></td>
</tr>
<tr style="height:82.8pt;">
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]<font style="font-weight:bold;font-size:11pt;">Effective Date of Termination</font></p></td>
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Percentage <font style="font-size:12pt;font-weight:normal;">[***]</font>.</p></td>
<td valign="bottom"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Percentage <font style="font-size:12pt;font-weight:normal;">[***]</font>.</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.75pt;padding-Right:5.75pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_272"></a><a name="_cp_text_1_274"></a><a name="_cp_text_1_275"></a><font style="Background-color:#auto;text-decoration:none;">9.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Surviving Provisions</font><font style="color:#000000;">.&nbsp;&nbsp;Any termination or expiration of this Agreement will not affect the rights and obligations set forth in the following Articles and Sections: </font><font style="text-decoration:underline;color:#000000;">Articles 1, 10, 12, 16, 17, 19, 20, 22</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">23</font><font style="color:#000000;">, and </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_2_272"></a>Sections&#160;2.6, 3.4, 4.12</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">4.13</font><font style="color:#000000;"> (to the extent applicable to payments accruing during the Term), </font><font style="text-decoration:underline;color:#000000;">5.6</font><font style="color:#000000;"> (to the extent applicable to Licensed Products that become Reversion Products pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;5.6</font><font style="color:#000000;">), </font><font style="text-decoration:underline;color:#000000;">8.1, 8.2, 9.6, 9.7, 9.8, 9.9</font><font style="color:#000000;"> (following expiration, but not termination), </font><font style="text-decoration:underline;color:#000000;">11.2(b)</font><font style="color:#000000;"> (with respect to the last sentence thereof, solely with respect to the manufacture, use, offer to sell, sale, importation or other disposition of the applicable Licensed Products prior to the expiration or termination of this Agreement), </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_274"></a>11.3, 13.1, 13.3, 15.1, <a name="_cp_text_1_275"></a>15.2&nbsp;&nbsp;</font><font style="color:#000000;">and </font><font style="text-decoration:underline;color:#000000;">15.3</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Section&#160;365(n) of the Bankruptcy Code</font><font style="color:#000000;">.&nbsp;&nbsp;All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section&#160;365(n) of the U.S. Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section&#160;101(35A) of the U.S. Bankruptcy Code to the extent permitted </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-34</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">thereunder.&nbsp;&nbsp;The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code.&nbsp;&nbsp;Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012482"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">USE OF NAMES AND TRADEMARKS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Nothing contained in this Agreement will be construed as conferring any right to either Party to use in advertising, publicity or other promotional activities any name, trade name, trademark or other designation of the other Party (including a contraction, abbreviation or simulation of any of the foregoing), except if such use if required by applicable law, rule or regulation (including the regulations of any securities exchange upon which Licensee&#8217;s shares are listed).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012483"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">REPRESENTATIONS AND WARRANTIES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Mutual Representations and Warranties</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party represents and warrants to the other Party that, as of the Execution Date:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or organization;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Certain Institute Representations and Covenants</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_486"></a><a name="_cp_blt_2_488"></a><a name="_cp_blt_2_490"></a><a name="_cp_blt_1_493"></a><a name="_cp_blt_2_492"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute is the sole owner of the Patent Rights licensed to Licensee hereunder with the right to grant Licensee the licenses described in </font><font style="text-decoration:underline;color:#000000;">Sections&#160;2.1</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">2.2</font><font style="color:#000000;">.&nbsp;&nbsp;As of the Execution Date, Institute has not assigned, transferred, conveyed, granted any license or other rights, or otherwise encumbered its right, title and interest in the Patent Rights or the Know-How, or other patents, patent applications or know-how specific to CTL Products, in any way that would conflict with or limit the scope of any of the rights or licenses granted to Licensee hereunder.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-35</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_497"></a><a name="_cp_blt_2_496"></a><a name="_cp_text_2_277"></a><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Institute hereby represents and warrants to Licensee that as of the Execution Date, to the best of its knowledge there are no patents or patent applications that if issued as patents, in either case, Controlled by Institute that are necessary for the development and commercialization of CTL Products</font><font style="color:#000000;"> </font><font style="color:#000000;">or the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> as currently conducted by Institute, or as contemplated to be conducted by the Parties pursuant to this Agreement (if the </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">was </font><font style="color:#000000;">exercised by Licensee) and/or the Research Agreement.&nbsp;&nbsp;Institute hereby irrevocably covenants, on behalf of itself and its Affiliates that it will not, directly or indirectly, alone or by, with or through others, cause, induce or authorize, or voluntarily assist, participate or cooperate in, the commencement, maintenance or prosecution of any action or proceeding of any kind or nature whatsoever, including, but not limited to, any suit, complaint, grievance, demand, claim, cause of action in, of or before any Governmental Authority against Licensee, or any Affiliate or sublicensee of Licensee, arising from, or in connection with any alleged infringement of any issued patents in any country Controlled by Institute in connection with the manufacture, use, offer to sell, sale, importation or other disposition of any</font><font style="color:#000000;letter-spacing:0.35pt;"> </font><font style="color:#000000;letter-spacing:0.35pt;">Licensed Product that is a</font><font style="color:#000000;"> CTL Product, </font><font style="color:#000000;">a </font><font style="color:#000000;">New CTL Product or</font><font style="color:#000000;"> a</font><font style="color:#000000;"> Program </font><font style="color:#000000;">[***]</font><font style="color:#000000;"><a name="_cp_text_2_277"></a> in accordance with and subject to all terms and conditions applicable to a license granted under this Agreement, by Licensee, or any Affiliate or sublicensee of Licensee occurring after the First Restatement Date. </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Disclaimer of Representations and Warranties</font><font style="color:#000000;">.&nbsp;&nbsp;Other than the representations and warranties provided in </font><font style="text-decoration:underline;color:#000000;">Sections&#160;11.1</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">11.2</font><font style="color:#000000;"> above, NEITHER PARTY MAKES ANY REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE FOR THE INTELLECTUAL PROPERTY, PATENT RIGHTS, LICENSE AND ANY PRODUCT.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012484"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">LIMITATION OF LIABILITY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">NEITHER PARTY WILL BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY OR ITS SUBLICENSEES OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012485"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">INTELLECTUAL PROPERTY; PATENT PROSECUTION AND MAINTENANCE</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Intellectual Property Ownership</font><font style="color:#000000;">.&nbsp;&nbsp;With the exception of the rights granted to Licensee pursuant to this Agreement, each Party shall retain all right, title and interest in and to </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-36</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">its Background IP.&nbsp;&nbsp;Ownership of intellectual property and inventions arising as a result of the Parties&#8217; activities under the Research Agreement are set forth in Article&#160;9 of the Research Agreement.&nbsp;&nbsp;Except as set forth in the Research Agreement, ownership of intellectual property rights arising out of this Agreement or the Research Agreement shall follow inventorship.&nbsp;&nbsp;Inventorship shall be determined in accordance with United States Patent Law (without regard to any conflict of law principles).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref4418753"></a><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Patent Prosecution</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Institute shall have the first right, and shall use Commercially Reasonable Efforts to diligently prosecute and maintain the Patent Rights existing as of the Original Effective Date and licensed to Licensee hereunder (the &#8220;</font><font style="font-weight:bold;color:#000000;">Base Patent Rights</font><font style="color:#000000;">&#8221;) at Licensee&#8217;s expense, using United States based patent counsel of its choice reasonably acceptable to Licensee.&nbsp;&nbsp;Institute will provide Licensee promptly with copies of all relevant documentation so that Licensee will be informed of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response.&nbsp;&nbsp;Institute agrees that it will incorporate any reasonable comments by Licensee in relation to such prosecution activities, provided that with respect to any claims of the Base Patent Rights that relate directly to Licensed Products or the manufacture or use thereof, Licensee shall have the right to make the final decision regarding prosecution of such claims, including the filing of any new claims relating to Licensed Products or the manufacture or use thereof.&nbsp;&nbsp;Licensee agrees that all documentation relating to the prosecution and maintenance of the Patent Rights shall be the Confidential Information of both Parties.&nbsp;&nbsp;Without limiting the foregoing, Institute shall use all reasonable efforts to amend any patent application to include claims reasonably requested by Licensee to protect the products contemplated to be sold under this Agreement and the activities being conducted under the Research Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_502"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee shall have the first right, and shall use Commercially Reasonable Efforts to diligently prosecute and maintain any patents and patent applications arising from activities conducted under the Research Agreement that relate to (i)&#160;Allogeneic CTLs or Allogeneic CTL Products, and (ii)&#160;Autologous CTL Products that are EBV-Specific CTL Products, and (iii)&#160;New CTL Products and Program [***], in each case of (i), (ii)&#160;and (iii), provided that such patents and patent applications do not claim priority to any patent or patent application included in the Base Patent Rights (in which case </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2(a)</font><font style="color:#000000;"> shall apply) (the &#8220;</font><font style="font-weight:bold;color:#000000;">Research Agreement Patent Rights</font><font style="color:#000000;"><a name="_cp_text_1_502"></a>&#8221;), at Licensee&#8217;s expense, using United States based patent counsel of its choice reasonably acceptable to Institute; provided, however, that Institute shall reimburse Licensee for fifty percent (50%) of all prosecution and maintenance costs (including attorney&#8217;s fees) incurred by Licensee for the filing, prosecution and maintenance of any patents and patent applications claiming priority to, or having common priority with, PCT Application Number PCT/AU2013/001216 (&#8220;Improved Human Herpesvirus Immunotherapy&#8221;) (including such patent application itself).&nbsp;&nbsp;For clarity, any Patent Rights Controlled by Institute as of the date upon which the Parties mutually agree in writing to include a New Research Program within the Research Agreement, and New CTL Products arising from such New Research Program within the scope of </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-37-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">this Agreement (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">New Research Program Inclusion Date</font><font style="color:#000000;">&#8221;) that relate specifically to such New Research Program (including the Target thereof) or such New CTL Products (the &#8220;</font><font style="font-weight:bold;color:#000000;">New Research Patent Rights</font><font style="color:#000000;">&#8221;) shall be considered Research Agreement Patent Rights as of the New Research Program Inclusion Date, and shall be subject to this </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2</font><font style="color:#000000;">.&nbsp;&nbsp;Promptly following any New Research Program Inclusion Date, unless the Parties otherwise agree in writing, Institute will transfer to Licensee, or to counsel of Licensee&#8217;s choice reasonably acceptable to Institute, all relevant documentation required for Licensee to assume responsibility for prosecution and maintenance of such New Research Patent Rights.&nbsp;&nbsp;Following the New Research Program Inclusion Date, Licensee will provide Institute promptly with copies of all relevant documentation so that Institute will be informed of the continuing prosecution and may comment upon such documentation sufficiently in advance of any initial deadline for filing a response.&nbsp;&nbsp;Licensee agrees that it will incorporate any reasonable comments by Institute in relation to such prosecution activities, provided that with respect to any claims of the Research Agreement Patent Rights that relate directly to Autologous CTLs or Autologous CTL Products, or the manufacture or use thereof, Institute shall have the right to make the final decision regarding prosecution of such claims, including the filing of any new claims relating to Autologous CTLs or Autologous CTL Products, or the manufacture or use thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Party agrees that all documentation relating to the prosecution and maintenance of the Patent Rights shall be the Confidential Information of both Parties.&nbsp;&nbsp;Without limiting the foregoing, Institute shall use all reasonable efforts to amend any patent application to include claims reasonably requested by Licensee to protect the products contemplated to be sold under this Agreement and the activities being conducted under the Research Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties agree that as of the Execution Date, Institute shall have the sole right to prosecute and maintain, and Licensee shall have no obligation to pay any costs or expenses incurred after the Execution Date in relation to the prosecuting and maintaining of, the patent applications listed in </font><font style="text-decoration:underline;color:#000000;">Schedule 13.2</font><font style="color:#000000;"> or any patent or patent application claiming priority thereto, or having common priority therewith.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Effects of Termination</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee will be obligated to pay costs incurred in relation to prosecuting and maintaining the Patent Rights in accordance with </font><font style="text-decoration:underline;color:#000000;">Section&#160;13.2</font><font style="color:#000000;">, even if the invoices for such costs are received by the Licensee after the delivery or receipt of a notice of termination.&nbsp;&nbsp;The Licensee may terminate its obligation to pay the cost of any given patent application or patent under the Patent Rights in any or all designated countries upon three (3)-months&#8217; written notice to Institute.&nbsp;&nbsp;Institute may continue prosecution and/or maintenance of such application(s) or patent(s), and applications in foreign countries where Licensee has elected not to pay costs, at its sole discretion and expense, in which case the Licensee will have no further right or licenses thereunder.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-38</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012486"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">PATENT INFRINGEMENT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Infringement Notice</font><font style="color:#000000;">.&nbsp;&nbsp;If Institute or the Licensee learns of infringement of potential commercial significance of any Patent Rights licensed under this Agreement, the knowledgeable Party will provide the other Party with: (a)&#160;written notice of such infringement; and (b)&#160;any evidence of such infringement available to it (the &#8220;</font><font style="font-weight:bold;color:#000000;">Infringement Notice</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;During the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, neither Institute nor the Licensee will notify a possible infringer of infringement or put such infringer on notice of the existence of any Patent Rights without first obtaining consent of the other, which consent will not be unreasonably withheld, delayed or conditioned; provided, however, that Licensee may notify any then-existing Sublicensees under the relevant Patent Rights of such infringement without Institute&#8217;s prior consent if such Sublicensee is bound by obligations of confidentiality with respect to such information.&nbsp;&nbsp;Both Institute and the Licensee will use their diligent efforts to cooperate with each other to terminate such infringement (with or without litigation).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_503"></a><font style="Background-color:#auto;text-decoration:none;">14.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Enforcement</font><font style="color:#000000;">.&nbsp;&nbsp;If infringing activity of potential commercial significance has not been abated within [***] following the date the Infringement Notice for such activity was provided, then during the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, Licensee shall have the first right, but not the obligation, to Institute suit for patent infringement against the infringer after providing Institute (a)&#160;[***], including an [***] and (b)&#160;[***]<a name="_cp_text_1_503"></a>.&nbsp;&nbsp;Institute may voluntarily join such suit at Licensee&#8217;s reasonable expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Licensee&#8217;s suit or any judgment rendered in such suit.&nbsp;&nbsp;Licensee may not join Institute in a suit initiated by Licensee without Institute&#8217;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.  If in a suit initiated by Licensee, Institute is involuntarily joined other than by Licensee, then Licensee will pay any documented costs incurred by Institute arising out of such suit, including any documented legal fees of counsel that Institute selects and retains to represent it in the suit.&nbsp;&nbsp;Licensee shall be free to enter into a settlement, consent judgment or other voluntary disposition, provided that any settlement, consent judgment or other voluntary disposition that (i)&#160;limits the scope, validity or enforcement of the Patent Rights or (ii)&#160;admits fault or wrongdoing on the part of Licensee or Institute must be approved in advance by Institute in writing, such approval not to be unreasonably withheld, delayed or conditioned.&nbsp;&nbsp;Licensee&#8217;s request for such approval shall include complete copies of final settlement documents, a detailed summary of such settlement, and any other information material to such settlement.&nbsp;&nbsp;Institute shall provide Licensee notice of its approval or denial within [***] of any request for such approval by Licensee, provided that (A)&#160;in the event Institute wishes to deny such approval, such notice shall include a detailed written description of Institute&#8217;s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (B)&#160;Institute shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within such [***] period in accordance herewith.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-39</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">14.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Step-In Right</font><font style="color:#000000;">.&nbsp;&nbsp;If, within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> following the date the Infringement Notice was provided, infringing activity of potential commercial significance has not been abated and if Licensee has not brought suit against the infringer, then Institute may Institute suit for patent infringement against the infringer.&nbsp;&nbsp;If Institute institutes such suit, then Licensee may not join such suit without the prior written consent of Institute and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Institute&#8217;s suit or any judgment rendered in such suit.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Recoveries</font><font style="color:#000000;">.&nbsp;&nbsp;Any recovery or settlement received in connection with any suit will first be shared by Institute and Licensee to cover any litigation costs each incurred and next shall be paid to Institute or Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other.&nbsp;&nbsp;Any remaining recoveries shall be allocated as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For any portion of the recovery or settlement related to the infringement of the Patent Rights, other than for amounts attributable and paid as enhanced damages for willful infringement: for any suit that is initiated by Licensee and in which Institute was not a party in the litigation, Institute shall receive [***] of the recovery, and the Licensee shall receive the remainder; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">for any suit that is initiated by the Licensee or Institute and that the other Party voluntarily joined (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily joined, the non-initiating Party&#8217;s percentage of such recovery shall be [***].</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any portion of the recovery or settlement related to the infringement of Patent Rights paid as enhanced damages for willful infringement:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">for any suit that is initiated by Licensee or Institute and the other Party voluntarily joined but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily joined, the non-initiating Party&#8217;s percentage of such recovery shall be [***] and the initiating Party shall receive the remainder; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">for any suit that is initiated by Licensee and in which Institute was not a party in the litigation, Institute shall receive [***] and the Licensee shall receive the remainder.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any portion of the recovery or settlement received in connection with any suit that is initiated by Institute and in which Licensee was not a party in the litigation, any recovery [***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will reasonably cooperate and assist with the other in litigation proceedings Instituted hereunder but at the expense of the Party who initiated the suit (unless such suit is being jointly prosecuted by the Parties).&nbsp;&nbsp;For clarity, such requirement does not require a Party to join a suit unless otherwise specifically required under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-40</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">If Institute is subjected to Third Party discovery related to the Patent Rights licensed to Licensee hereunder, or to Licensed Products, Licensee will pay Institute&#8217;s documented out of pocket expenses with respect to same.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012487"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">INDEMNIFICATION</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_504"></a><font style="Background-color:#auto;text-decoration:none;">15.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Indemnification by Licensee</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee shall defend, indemnify and hold Institute and its respective trustees, officers, faculty, students, employees, contractors and agents (the &#8220;</font><font style="font-weight:bold;color:#000000;">Institute Indemnitees</font><font style="color:#000000;">&#8221;) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys&#8217; fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage to the extent arising out of Third Party claims and suits related to (a)&#160;this Agreement or any Sublicense, including (i)&#160;the development, testing, use, manufacture, promotion, sale or other disposition of any Licensed Product (including any product liability claim), excluding any activities relating to Autologous CTL Products prior to the exercise of the Option, or following reversion to Institute pursuant to </font><font style="text-decoration:underline;color:#000000;">Section&#160;7.3</font><font style="color:#000000;"> and/or </font><font style="text-decoration:underline;color:#000000;">Section&#160;9.6</font><font style="color:#000000;">, (ii)&#160;any enforcement action or suit brought by Licensee against a Third Party for infringement of the Patent Rights, (iii)&#160;any claim by a Third Party that the practice of the Patent Rights or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent, copyright, trade secret, trademark or other intellectual property right of such Third Party, (iv)&#160;any breach of this Agreement or Laws by Licensee, its Affiliates or Sublicensees and (b)&#160;Licensee&#8217;s negligence, omissions or willful misconduct, provided that Licensee&#8217;s obligations pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section&#160;15.1</font><font style="color:#000000;"><a name="_cp_text_1_504"></a> shall not apply to the extent such claims or suits result from the negligence, gross negligence or willful misconduct of any Institute Indemnitees as determined by a court of law. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_302"></a><a name="_cp_blt_2_301"></a><a name="_cp_blt_1_279"></a><a name="_Ref4928222"></a><a name="_Ref4928286"></a><font style="Background-color:#auto;text-decoration:none;">15.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Indemnification by Institute</font><font style="color:#000000;">.&nbsp;&nbsp;Institute shall, to the extent permitted by law, defend, indemnify and hold Licensee and its respective stockholders, officers, representatives, employees, contractors and agents (&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Indemnitees</font><font style="color:#000000;">&#8221;) harmless (or shall cause each [***] to defend, indemnify and hold Licensee Indemnitees harmless) from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys&#8217; fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage to the extent arising out of Third Party claims and suits related to any grant of rights to any Third Party (&#8220;[***]&#8221;) to develop or commercialize any product directed to one or more [***] associated with [***] after the Execution Date, provided that Institute&#8217;s obligations pursuant to this </font><font style="text-decoration:underline;color:#000000;">Section&#160;15.2</font><font style="color:#000000;"> shall not apply to the extent such claims or suits result from the negligence, gross negligence or willful misconduct of any Licensee Indemnitees as determined by a court of law.&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_281"></a><a name="_cp_text_1_283"></a><a name="_cp_text_1_285"></a><a name="_cp_text_1_287"></a><a name="_cp_text_1_289"></a><a name="_cp_text_1_293"></a><a name="_cp_text_1_294"></a><a name="_cp_text_1_297"></a><a name="_cp_text_1_300"></a><font style="Background-color:#auto;text-decoration:none;">15.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Process</font><font style="color:#000000;"><a name="_cp_text_1_281"></a>.&nbsp;&nbsp;As a condition to an Institute Indemnitee&#8217;s or Licensee Indemnitee&#8217;s (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Indemnitee</font><font style="color:#000000;">&#8221;) right to receive indemnification under </font><font style="text-decoration:underline;color:#000000;">Section&#160;15.1</font><font style="color:#000000;"><a name="_cp_text_1_283"></a> or </font><font style="text-decoration:underline;color:#000000;">Section 15.2</font><font style="color:#000000;">, as applicable, an <a name="_cp_text_1_285"></a>Indemnitee shall: (a)&#160;promptly notify (not to exceed thirty (30) days) the indemnifying Party <a name="_cp_text_1_287"></a>as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b)&#160;reasonably cooperate, and cause the individual Indemnitees claiming indemnification under this </font><font style="text-decoration:underline;color:#000000;">Article 15</font><font style="color:#000000;"> to reasonably cooperate, with the indemnifying Party in the defense, settlement or compromise of such claim or suit; and (c)&#160;permit </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-41-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_cp_text_1_289"></a>the indemnifying Party to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel.&nbsp;&nbsp;In no event, however, may </font><font style="color:#000000;">the indemnifying Party </font><font style="color:#000000;"><a name="_cp_text_1_293"></a>compromise or settle any claim or suit in a manner which (i)&#160;admits fault or negligence on the part of any Indemnitee; (ii)&#160;commits any Indemnitee to take, or forbear to take, any action, without the prior written consent of </font><font style="color:#000000;">the other Party </font><font style="color:#000000;"><a name="_cp_text_1_294"></a>(which consent in the case of either (i)&#160;or (ii)&#160;shall not be unreasonably withheld, delayed or conditioned), or (iii)&#160;</font><font style="color:#000000;">where the indemnifying Party is Licensee, </font><font style="color:#000000;">grant any rights under the Patent Rights except for Sublicenses permitted under </font><font style="text-decoration:underline;color:#000000;">Article&#160;2</font><font style="color:#000000;"><a name="_cp_text_1_297"></a>.&nbsp;&nbsp;The Indemnitees shall reasonably cooperate with </font><font style="color:#000000;">the indemnifying Party </font><font style="color:#000000;"><a name="_cp_text_1_300"></a>and its counsel in the course of the investigation of, preparation for and defense of any such suit, claim or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information and witnesses, and provided further that no Indemnitee may compromise or settle any such Third Party claim without the </font><font style="color:#000000;">indemnifying Party&#8217;s </font><font style="color:#000000;">written consent.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_304"></a><a name="_cp_blt_2_303"></a><a name="_Ref4928320"></a><font style="Background-color:#auto;text-decoration:none;">15.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Insurance</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee, at its reasonable cost and expense, will insure its activities in connection with any work performed hereunder and will obtain, keep in force, and maintain Commercial Form General Liability Insurance (contractual liability included) with limits as follows:</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.41%;width:68.28%;">
<tr>
<td style="width:56.24%;"></td>
<td style="width:12.04%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Occurrence</p></td>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products/Completed Operations Aggregate</p></td>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personal Injury</p></td>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Aggregate (commercial form only)</p></td>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_field_47_306"></a><font style="Background-color:#auto;text-decoration:none;">15.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Certificates</font><font style="color:#000000;">.&nbsp;&nbsp;After receipt of Institute&#8217;s written request, the Licensee will furnish Institute with certificates of insurance evidencing compliance with all requirements.&nbsp;&nbsp;Such certificates will: indicate Institute as an additional insured(s) under the coverage described above in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_306"></a>Section&#160;15.4</font><font style="color:#000000;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012488"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">NOTICES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any notice or payment hereunder shall be deemed to have been properly given when sent in writing in English to the respective address below and shall be deemed effective:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">on the date of delivery if delivered in person;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">on the date of mailing if mailed by first-class certified mail, postage paid;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-42</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">on the date of mailing if mailed by any global express carrier service that requires the recipient to sign the documents demonstrating the delivery of such notice or payment; or</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">in the case of notices, if sent by email, on the date the recipient acknowledges having received that email by either an email sent to the sender or by a notice delivered by another method in accordance with this </font><font style="text-decoration:underline;color:#000000;">Section&#160;16.1</font><font style="color:#000000;">, except that, automated replies and &#8220;read receipts&#8221; shall not be considered acknowledgement of receipt.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of Licensee:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">For notices<font style="font-weight:normal;font-style:normal;">:</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611 Gateway Blvd #900</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, CA 94080</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.A.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: General Counsel</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">With a Copy to:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2430 Conejo Spectrum St.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thousand Oaks, CA 91320</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.A.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Global Head of Research &amp; Development</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of Institute:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">For notices:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Medical Research Institute</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Herston Road,</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Herston, Queensland, 4006</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AUSTRALIA</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Operating Officer</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">For remittance of payments:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Medical Research Institute</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Herston Road,</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Herston, Queensland, 4006</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AUSTRALIA</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.81%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Financial Officer</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-43</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">17.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012489"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ASSIGNABILITY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Licensee may assign or transfer this Agreement, and the rights granted to Licensee under the terms of this Agreement, without Institute&#8217;s prior written consent, only to an Affiliate of Licensee or in the case of assignment or transfer to a party that succeeds to all or substantially all of Licensee&#8217;s business or assets relating to this Agreement, whether by stock sale, merger, operation of law or otherwise, provided that Licensee gives Institute written notice within [***] after the effective date of such assignment.&nbsp;&nbsp;This Agreement is binding upon and will inure to the benefit of a Party, its successors and assigns.&nbsp;&nbsp;Any assignment not in accordance with this </font><font style="text-decoration:underline;color:#000000;">Section&#160;17.1</font><font style="color:#000000;"> shall be null and void in its entirety.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">18.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012490"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">FORCE MAJEURE</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties shall not be responsible for failure to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible, including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national or state emergency; power failure and power outages; acts of terrorism; strike; and war.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">19.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012491"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">GOVERNING LAWS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">This Agreement will be interpreted and construed in accordance with the laws of the State of New York, United States of America, excluding any choice of law rules that would direct the application of the laws of another jurisdiction, but the scope and validity of any patent or patent application will be governed by the applicable laws of the country of such patent or patent application.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">20.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012492"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">DISPUTE RESOLUTION</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Executive Resolution</font><font style="color:#000000;">.&nbsp;&nbsp;The parties shall initially seek amicably to settle all disputes (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Dispute</font><font style="color:#000000;">&#8221;) arising out of or in connection with this Agreement by negotiation, which may include discussion at the JSC, subject to the Parties&#8217; respective final decision making authority as set forth in </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3(f)</font><font style="color:#000000;"> of the Research Agreement.&nbsp;&nbsp;If, within [***] after written notice by either Party of the existence of a Dispute, the Parties do not resolve such Dispute, then the Dispute shall be referred to the Designated Executive Officers from each Party for further negotiation.&nbsp;&nbsp;If the Designated Executive Officers of each Party cannot resolve such Dispute, then subject to </font><font style="text-decoration:underline;color:#000000;">Section&#160;3.3(f)</font><font style="color:#000000;"> of the Research Agreement and </font><font style="text-decoration:underline;color:#000000;">Section&#160;20.7</font><font style="color:#000000;"> of this Agreement, such Dispute will be referred to final binding arbitration in accordance with </font><font style="text-decoration:underline;color:#000000;">Sections&#160;20.2</font><font style="color:#000000;"> through </font><font style="text-decoration:underline;color:#000000;">20.6</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Arbitration</font><font style="color:#000000;">.&nbsp;&nbsp;Any Dispute referred for arbitration shall be finally settled under the Rules of the International Centre for Dispute Resolution (the &#8220;</font><font style="font-weight:bold;color:#000000;">Rules of Arbitration</font><font style="color:#000000;">&#8221;) then in force, by one arbitrator appointed in accordance with such Rules of Arbitration.&nbsp;&nbsp;The </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-44</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Arbitral Tribunal shall be guided by the IBA Rules on the Taking of Evidence in International Arbitration, and there shall be no depositions.&nbsp;&nbsp;The place of the arbitration shall be New York, New York, United States of America.&nbsp;&nbsp;The language of the arbitration shall be English.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Selection of the Arbitrator</font><font style="color:#000000;">.&nbsp;&nbsp;Each arbitrator shall have a [***] of experience in arbitrating disputes in the pharmaceutical industry, or of pharmaceutical licensing disputes and be admitted to practice law in the United States of America.&nbsp;&nbsp;The arbitrator conducting the arbitration must and shall agree to render an award within [***] after the final hearing.&nbsp;&nbsp;The arbitrator [***].&nbsp;&nbsp;Without limiting any other remedies that may be available under Applicable Laws, the arbitrator shall have [***].</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Conduct of the Arbitration</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties undertake to keep confidential all awards in their arbitration, together with all materials in the proceedings created for the purpose of the arbitration and all other documents produced by another Party in the proceedings not otherwise in the public domain, save and to the extent that disclosure may be required of a Party by legal duty or under Applicable Law, the rules and regulations of any stock exchange or quotation services on which such Party&#8217;s stock is traded or quoted, to protect or pursue a legal right or to enforce or challenge an award in legal proceedings before a court or other judicial authority.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Continued Performance</font><font style="color:#000000;">.&nbsp;&nbsp;Unless otherwise agreed in writing, the Parties will continue to perform their respective obligations under this Agreement during any arbitration or court proceeding seeking enforcement of an arbitral decision or award, and, unless this Agreement is in its entirety deemed null and void or is otherwise revoked or rescinded in its entirely, the Parties shall continue to perform their respective remaining obligations under this Agreement, and may continue to exercise their respective remaining rights and remedies thereunder, following any arbitration.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Preliminary Injunctions</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any Dispute.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Patent Disputes</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, any dispute concerning inventorship that is not resolved within [***] following notice by one Party to the other Party of the creation or reduction to practice of any Invention, and any dispute regarding any and all issues regarding the scope, construction, validity, and enforceability of any patent or patent application (including whether or not such patent or patent application should be included in the Patent Rights under the License Agreement) in a country within the Territory shall be determined in a court or other governmental authority of competent jurisdiction under the applicable patent laws of such country.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-45</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">21.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012493"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">COMPLIANCE WITH LAWS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Licensee shall comply with all applicable international, national, state, regional and local laws and regulations in performing its obligations hereunder and in its use, manufacture, Sale or import of the Licensed Products.&nbsp;&nbsp;The Licensee will observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">22.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012494"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">CONFIDENTIALITY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Confidential Information</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee and Institute will treat and maintain the other Party&#8217;s Confidential Information in confidence using at least the same degree of care as the receiving Party uses to protect its own proprietary and confidential information of a like nature from the date of disclosure until seven (7) years after the termination or expiration of this Agreement, provided that a Party may designate one or more specific, defined items of Confidential Information as &#8216;Trade Secret&#8217;, by giving written notice to the other Party briefly outlining its reasons why longer protection is warranted, and in such case the other Party shall protect such information indefinitely unless and until </font><font style="text-decoration:underline;color:#000000;">Section&#160;22.4 </font><font style="color:#000000;">applies.&nbsp;&nbsp;Confidential Information can be written, oral, or both.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Relationship to Existing Confidentiality Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement supersedes that certain Confidential Disclosure Agreement entered into between Licensee and Institute, dated May&#160;28, 2015 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Existing Confidentiality Agreement</font><font style="color:#000000;">&#8221;); provided that all &#8220;Confidential Information&#8221; disclosed by the disclosing Party thereunder shall be deemed Confidential Information of the disclosing Party hereunder and shall be subject to the terms and conditions of this Agreement and the receiving Party thereunder shall be bound by and obligated to comply with such terms and conditions as if they were the receiving Party hereunder.&nbsp;&nbsp;The foregoing shall not be interpreted as a waiver of any remedies available to the disclosing Party as a result of any breach, prior to the Original Effective Date, by the receiving Party, respectively, of its obligations pursuant to the Existing Confidentiality Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Permitted Disclosure</font><font style="color:#000000;">.&nbsp;&nbsp;The Licensee and Institute may use and disclose the other Party&#8217;s Confidential Information to their Affiliates, employees, agents, consultants, contractors, and, in the case of the Licensee, its Sublicensees, in each case on a need to know basis for the purposes of such Affiliates, Sublicensees and Third Parties performing activities under this Agreement or the Research Agreement, provided that such parties are bound by a like duty of confidentiality as that found in this </font><font style="text-decoration:underline;color:#000000;">Article&#160;22</font><font style="color:#000000;"> (Confidentiality).&nbsp;&nbsp;Furthermore, Licensee may disclose Institute&#8217;s Confidential Information to: (a)&#160;Licensee&#8217;s potential or actual collaborators, partners, licensees and sublicensees, and (b)&#160;potential or actual investment bankers, acquirers, lenders or investors, and (c)&#160;advisors of Licensee or any of the foregoing in (a)&#160;and (b); each of whom, prior to disclosure, must be bound by similar obligations of confidentiality and non-use as set forth in this </font><font style="text-decoration:underline;color:#000000;">Article&#160;22</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-46</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">22.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Limitations</font><font style="color:#000000;">.&nbsp;&nbsp;Nothing contained herein will restrict or impair, in any way, the right of the Licensee or Institute to use or disclose any of the other Party&#8217;s Confidential Information:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">that recipient can demonstrate by written records was previously known to it prior to its disclosure by the disclosing Party;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">that recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than through acts or omissions of recipient;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">that recipient can demonstrate by written records was obtained lawfully and without restrictions on the recipient from sources independent of the disclosing Party; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:22.22%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">that a Party is required to disclose pursuant to applicable law, rule or regulation.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Licensee or Institute also may disclose Confidential Information that is required to be disclosed: (i)&#160;to a governmental entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental contractual requirement; or (ii)&#160;by law, provided that the recipient uses reasonable efforts to give the party owning the Confidential Information sufficient notice of such required disclosure to allow the party owning the Confidential Information reasonable opportunity to object to, and to take legal action to prevent, such disclosure.&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, Licensee may disclose Confidential Information it receives pursuant to this Agreement, to its actual or potential investors, acquirors, advisors, Sublicensees, consultants and employees who are bound by obligations of confidentiality with respect thereto.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Return of Information</font><font style="color:#000000;">.&nbsp;&nbsp;Upon termination of this Agreement, or the request of the disclosing Party, if earlier, the Licensee and Institute will destroy or return any of the disclosing Party&#8217;s Confidential Information in its possession within [***] following the termination of this Agreement and provide each other with prompt written notice that such Confidential Information has been returned or destroyed.&nbsp;&nbsp;Each Party may, however, retain one (1) copy of such Confidential Information for archival purposes in non-working files.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Additional Confidentiality Obligations</font><font style="color:#000000;">.&nbsp;&nbsp;Upon written request of Licensee, Institute agrees to cooperate in good faith with Licensee and Memorial Sloan Kettering Cancer Center (&#8220;</font><font style="font-weight:bold;color:#000000;">MSK</font><font style="color:#000000;">&#8221;) in order to enter into a mutually agreed tripartite confidentiality and non-disclosure agreement with Licensee and MSK, which agreement shall provide for the obligations of non-disclosure with respect to information shared between the Parties and MSK for the purposes of furthering the activities under this Agreement and the Research Agreement. </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-47</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">23.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Toc4012495"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">MISCELLANEOUS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Headings</font><font style="color:#000000;">.&nbsp;&nbsp;The headings of the Sections&#160;are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Binding Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Third Restated Agreement is not binding on the Parties until it has been signed below on behalf of each Party.&nbsp;&nbsp;It is then effective as of the Execution Date. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Amendments</font><font style="color:#000000;">.&nbsp;&nbsp;No amendment or modification of this Agreement is valid or binding on the parties unless made in writing (identifying the provision that is amended or modified) and signed on behalf of each Party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No waiver by either Party of any breach or default of any of the agreements contained herein will be deemed a waiver as to any subsequent and/or similar breach or default.&nbsp;&nbsp;No waiver of this Agreement is valid or binding on the Parties unless made in writing (identifying the provision that is waived) and signed on behalf of each Party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement and the Research Agreement embody the entire understanding of the Parties and supersedes the Original License Agreement, the First Restated Agreement, the Second Restated Agreement, the Third Restated Agreement and all previous communications, representations or understandings, either oral or written, between the Parties relating to the subject matter hereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Invalidity</font><font style="color:#000000;">.&nbsp;&nbsp;In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement and this Agreement will be construed as if such invalid, illegal or unenforceable provisions had never been contained in it.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Independent Contractors</font><font style="color:#000000;">.&nbsp;&nbsp;In performing their respective duties under this Agreement, each of the Parties will be operating as an independent contractor.&nbsp;&nbsp;Nothing contained herein will in any way constitute any association, partnership, or joint venture between the Parties hereto, or be construed to evidence the intention of the Parties to establish any such relationship.&nbsp;&nbsp;Neither Party will have the power to bind the other Party or incur obligations on the other Party&#8217;s behalf without the other Party&#8217;s prior written consent.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;Except where the context otherwise requires, wherever used, the use of any gender will be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense.&nbsp;&nbsp;When used in this Agreement, &#8220;including&#8221; means &#8220;including without limitation&#8221;.&nbsp;&nbsp;References to either Party include the successors and permitted assigns of that Party.&nbsp;&nbsp;The Recitals are incorporated by reference into this Agreement.&nbsp;&nbsp;The headings of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement.&nbsp;&nbsp;The Parties have </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-48</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">each consulted counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement will be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof.&nbsp;&nbsp;The official text of this Agreement, any notice given or accounts or statements required by this Agreement, and any dispute proceeding related to or arising hereunder, will be in English.&nbsp;&nbsp;If any dispute concerning the construction or meaning of this Agreement arises, then reference will be made only to this Agreement as written in English and not to any translation into any other language.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:14.81%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Fourth Restated Agreement may be executed in one or more counterparts, each of which together shall constitute one and the same Agreement.&nbsp;&nbsp;For purposes of executing this Fourth Restated Agreement, a facsimile (including a PDF image delivered via email) copy of this Fourth Restated Agreement, including the signature pages, will be deemed an original.&nbsp;&nbsp;The Parties agree that neither Party will have any rights to challenge the use or authenticity of a counterpart of this Fourth Restated Agreement based solely on that its signature, or the signature of the other Party, on such counterpart is not an original signature.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- <font style="font-style:italic;">Signature Page Follows</font> -</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-49</a>-</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, <font style="font-weight:normal;">both Institute and the Licensee have executed this Fourth Restated Agreement by their respective and duly authorized officers on the day and year written below.&nbsp;&nbsp;The Parties acknowledge that the signature date may not be the Execution Date.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:6.84%;"></td>
<td style="width:9.86%;"></td>
<td style="width:33.75%;"></td>
<td style="width:4.33%;"></td>
<td style="width:6.84%;"></td>
<td style="width:9.81%;"></td>
<td style="width:32.43%;"></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A<font style="font-weight:bold;">TARA BIOTHERAPEUTICS, INC.</font></p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Jakob DuPont</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Lee Bruce</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Jakob DuPont</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lee Bruce</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Please Print)</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Please Print)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Head of R&amp;D</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/20/2021</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/22/2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Bookmark"></a><font style="text-decoration:underline;">Schedule&#160;1.24</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competing Products</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule&#160;1.79</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Rights</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule&#160;2.1(a)</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assigned Patents</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule&#160;2.5</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:15.38%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:15.38%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule&#160;4.15</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Fees</font><font style="color:#000000;">.&nbsp;&nbsp;Institute will pay to Licensee [***].&nbsp;&nbsp;[***] Fees are non-refundable and non-creditable.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">[***] </font><font style="font-weight:bold;color:#000000;">Fee Payment Period.&nbsp;&nbsp;</font><font style="color:#000000;">Subject to the remainder of this </font><font style="text-decoration:underline;color:#000000;">Schedule 4.15</font><font style="color:#000000;">, the [***] will be payable until the earlier of the following: (i)&#160;expiration or abandonment of the last Valid Claim of any of the [***] Patents existing as of the Original Effective Date, or (ii) the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) anniversary of the First Commercial Sale of such [***] Product.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Payment Schedule</font><font style="color:#000000;">.&nbsp;&nbsp;The Institute will pay to Licensee all [***] Fees owed or payable to Licensee quarterly on or before February&#160;28 (for the Calendar Quarter ending December&#160;31), May&#160;31 (for the Calendar Quarter ending March&#160;31), August&#160;31 (for the Calendar Quarter ending June&#160;30) and November&#160;30 (for the Calendar Quarter ending September&#160;30) of each calendar year.&nbsp;&nbsp;Each payment will be for [***] Fees accrued within the Institute&#8217;s most recently completed Calendar Quarter.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Currency</font><font style="color:#000000;">.&nbsp;&nbsp;All consideration due Licensee under this Schedule 4.15 will be payable and will be made in United States dollars by wire transfer to an account designated by Licensee.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">[***]</font><font style="font-weight:bold;color:#000000;"> Fee Reports</font><font style="color:#000000;">.&nbsp;&nbsp;Beginning with the earliest of: (i) First Commercial Sale of a [***] Product; (ii) execution of a [***] License Agreement; or (iii) any other exploitation or commercialization of the [***] Patents, within [***] following the end of the Calendar Quarter such event occurred, Institute shall make quarterly reports to Licensee on or before each February&#160;28, May&#160;31, August&#160;31 and November&#160;30 of each year.&nbsp;&nbsp;Each report will cover the Institute&#8217;s most recently completed Calendar Quarter and will show all information used by Institute to calculate the [***] Fees owed to Licensee for such calendar quarter. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;[***] Fees and other consideration accrued in any country outside the United States may be reduced by any taxes, fees or other charges imposed on the [***] Fees by the government of such country.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Late Payments</font><font style="color:#000000;">.&nbsp;&nbsp;If [***] Fees are not received by Licensee when due, the Institute will pay to Licensee interest at a rate of the lesser of: (a)&#160;[***] or (b)&#160;the maximum rate permitted by Law.&nbsp;&nbsp;Such interest will be calculated from the date payment was due until actually received by Licensee.</font></p></td></tr></table></div>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_311"></a><a name="_cp_blt_2_313"></a><a name="_cp_blt_2_315"></a><a name="_cp_blt_2_317"></a><a name="_cp_blt_2_319"></a><a name="_cp_blt_2_321"></a><a name="_cp_blt_2_323"></a><a name="_cp_blt_2_325"></a><a name="_cp_blt_2_327"></a><font style="text-decoration:underline;">Schedule&#160;13.2</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>6
<FILENAME>atra-ex1039_101.htm
<DESCRIPTION>EX-10.39
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex1039_101.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.39</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">ATARA BIOTHERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">for</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">[NAME]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Executive Employment Agreement (this &#8220;Agreement&#8221;), is made and entered into as of [DATE] (the &#8220;Effective Date&#8221;), by and between [NAME] (&#8220;Employee&#8221;) and Atara Biotherapeutics, Inc. (the &#8220;Company&#8221;). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Employment by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Position.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee shall serve as the Company&#8217;s [Senior or Executive] Vice President, [JOB TITLE], reporting to the Company&#8217;s [SUPERVISOR]. During the term of Employee&#8217;s employment with the Company, Employee will devote Employee&#8217;s best efforts and all of Employee&#8217;s business time and attention to the business of the Company, except as permitted in Section 7 of this Agreement and excluding approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#8217;s general employment policies. Employee further agrees not to usurp, for Employee&#8217;s own personal benefit or gain, any opportunities in the Company&#8217;s line of business. Employee shall be expected to work on a full-time basis [and travel as part of his/her position]. Employee&#8217;s anticipated start date will be [DATE] (the &#8220;Start Date&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Duties and Location.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee shall perform such duties as are customarily associated with the position of [JOB TITLE], and such other duties as are assigned to Employee by the Company. Employee&#8217;s primary office location shall be the Company&#8217;s [LOCATION] office. Subject to the terms of this Agreement and applicable law, the Company reserves the right to (i) reasonably require Employee to perform Employee&#8217;s duties at places other than Employee&#8217;s primary office location from time to time and to require reasonable business travel, and (ii) modify Employee&#8217;s job title, reporting line and duties as it deems necessary and appropriate in light of the Company&#8217;s needs and interests from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Policies and Procedures.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  The employment relationship between the parties shall be governed by the general employment policies and practices of the Company, including the Employee Handbook, as well as by all other rules and policies applicable to the Company&#8217;s professional employees, except that when the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">At-Will Employment.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee&#8217;s employment relationship with the Company is at-will. Either the Company or Employee shall have the right to terminate the employment relationship at any time, with or without Cause (as defined below) or advance notice.  Should a Company policy exist now or in the future which contradicts this at-will provision, this at-will provision controls the relationship between Employee and the Company.  The at-will nature of Employee&#8217;s employment may only be changed in an express written agreement signed by Employee and a duly authorized officer of the Company. Nothing in this Agreement is intended to modify the at-will employment relationship between the Company and Employee.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Compensation</font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Base Salary.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  For services to be rendered hereunder, Employee shall be paid a base annual salary at the rate of $[_________] (the &#8220;Base Salary&#8221;), less all required and applicable standard payroll deductions and withholdings for federal and state taxes and for any authorized voluntary deductions and payable in accordance with the Company&#8217;s regular payroll schedule.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Annual Discretionary Bonus.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee will be eligible for an annual discretionary target bonus (the &#8220;Annual Bonus&#8221;) of [##] ([##]%)] of Employee&#8217;s then current Base Salary (the &#8220;Target Bonus Amount&#8221;).  Whether Employee receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined in the good faith discretion of the board of directors of the Company (the &#8220;Board&#8221;) (or the Compensation Committee thereof), based upon the Company&#8217;s and Employee&#8217;s achievement of objectives and milestones to be determined on an annual basis by the Board (or Compensation Committee thereof).  No Annual Bonus is guaranteed and, in addition to the other conditions for earning such compensation, Employee must remain an employee in good standing of the Company on the date the Annual Bonus is paid in order to be eligible for and earn any Annual Bonus.  For the calendar year of Employee&#8217;s Start Date, Employee&#8217;s eligibility for the Annual Bonus, and the amount thereof, will be prorated based on Employee&#8217;s Start Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">[Signing/Retention/Relocation Bonus.]<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup></font><font style="font-family:Times New Roman;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Standard Company Benefits.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">  Employee shall, in accordance with Company policy and the terms and conditions of the applicable Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive officers and other employees from time to time.  Employee shall also be entitled to paid sick leave, paid time off, and holidays as outlined in the Company&#8217;s employment policies and as otherwise required by applicable law.  Any such benefits shall be subject to the terms and conditions of the governing benefit plans and policies, as well as the Company&#8217;s policies and may be changed by the Company in its discretion.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Expenses.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">  The Company will reimburse Employee for reasonable travel, entertainment or other expenses incurred by Employee in furtherance or in connection with the performance of Employee&#8217;s duties hereunder, in accordance with applicable law and the Company&#8217;s expense reimbursement policy as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="color:#auto;font-family:Times New Roman;text-transform:none;">Equity</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Options.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  The Company will recommend to its Compensation Committee of the Board that Employee be granted an option to purchase [##] shares of the Company&#8217;s Common Stock (&#8220;Option&#8221;). Grant of the Option is subject to the approval of the Compensation Committee. If granted, the Option shall vest over four years of Employee&#8217;s continuous service with the Company, with twenty-five percent (25%) of the shares subject to the Option grant becoming vested on the first year</font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Certain executive officers may receive retention, sign-on, relocation or other similar cash bonuses.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> anniversary of the Start Date, and the remaining shares becoming</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> vested in equal monthly installments over the following thirty-six (36) months of Employee&#8217;s continuous service. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">The exercise price of the Option, as well as all other matters related to the Option, will be governed by and subject to the terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Plan or 2018 Inducement Plan, and the stock option agreement Employee will be required to electronically accept.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Restricted Stock Units.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  The Company will recommend to its Compensation Committee of the Board that Employee be granted [##] restricted stock units (&#8220;RSUs&#8221;). Grant of the RSUs is subject to the approval of the Compensation Committee. If granted, the RSUs shall vest over four years of Employee&#8217;s continuous service with the Company, with twenty-five percent (25%) of the RSUs becoming vested on the first year anniversary of the Start Date, and the remaining RSUs becoming vested in equal annual installments over the following three anniversaries of the Start Date of Employee&#8217;s continuous service. The RSUs will be governed by and subject to the terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Plan or 2018 Inducement Plan and the applicable grant documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Proprietary Information Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Proprietary Information Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  As a condition of employment, Employee shall execute and abide by the Company&#8217;s standard form of Proprietary Information and Inventions Assignment Agreement (the &#8220;Proprietary Agreement&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Third-Party Agreements and Information.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee represents and warrants that Employee&#8217;s employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Employee will perform Employee&#8217;s duties to the Company without violating any such agreement.  Employee represents and warrants that Employee does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Employee&#8217;s employment by the Company, except as expressly authorized by that third party. During Employee&#8217;s employment by the Company, Employee will use in the performance of Employee&#8217;s duties only information that is generally known and used by persons with training and experience comparable to Employee&#8217;s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Employee in the course of Employee&#8217;s work for the Company.  In addition, Employee represents that Employee has disclosed to the Company in writing any agreement Employee may have with any third party (e.g., a former employer) which may limit Employee&#8217;s ability to perform Employee&#8217;s duties to the Company, or which could present a conflict of interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Outside Activities and Non-Competition During Employment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk15662614"></a><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Outside Activities.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Throughout Employee&#8217;s employment with the Company, Employee may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Employee&#8217;s duties hereunder or present a conflict of interest with the Company or its affiliates.  <a name="_Hlk15662614"></a>Subject to the restrictions set forth herein, and only with prior written disclosure to and written consent of the Company (including in the discretion of the Company, the Board), Employee may engage in other types of business or public activities.  The </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Company may rescind such consent, if the Company determines, in its sole discretion, that such activities compromise or threaten to compromise the Company&#8217;s or its affiliates&#8217; business interests or conflict with Employee&#8217;s duties to the Company or its affiliates.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Non-Competition During Employment.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Throughout Employee&#8217;s employment with the Company, Employee will not, without prior written disclosure to and written consent of the Company (including in the discretion of the Company, the Board), directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint ventures, associate, representative or consultant of any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its affiliates; provided, however, that Employee may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. In addition, Employee will be subject to certain restrictions (including restrictions continuing after Employee&#8217;s employment ends) outlined in the terms of the Proprietary Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Termination of Employment; Severance and Change in Control Benefits.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Termination Without Cause or Resignation for Good Reason Unrelated to Change in Control.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  In the event Employee&#8217;s employment with the Company is terminated by the Company without Cause (as defined below), and other than as a result of Employee&#8217;s death or disability, or Employee resigns for Good Reason, in either case, at any time except during the Change in Control Period (as defined below), then provided such termination constitutes a &#8220;separation from service&#8221; (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#8220;Separation from Service&#8221;), and provided that Employee satisfies the Release Requirement in Section 9 below, and remains in compliance with the terms of this Agreement and the Proprietary Agreement, the Company shall provide Employee with the following &#8220;Severance Benefits&#8221;:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.1.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Severance Payments.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Severance pay in the form of continuation of Employee&#8217;s final Base Salary for a period of [##] ([##]) months following termination, subject to required and voluntarily authorized payroll deductions and federal and state tax withholdings (the &#8220;Severance Payments&#8221;). Subject to Section 10 below, the Severance Payments shall be made on the Company&#8217;s regular payroll schedule in effect following Employee&#8217;s Separation from Service date; provided, however that any such payments that are otherwise scheduled to be made prior to the Release Effective Date (as defined below) shall instead accrue and be made on the first regular payroll date following the Release Effective Date.  For such purposes, Employee&#8217;s final Base Salary will be calculated prior to giving effect to any reduction in Base Salary that would give rise to Employee&#8217;s right to resign for Good Reason.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.1.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Health Care Continuation Coverage Payments.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">COBRA Premiums.</font><font style="color:#000000;">  If Employee timely elects continued coverage under COBRA, the Company will pay Employee&#8217;s COBRA premiums to continue Employee&#8217;s coverage (including coverage for Employee&#8217;s eligible dependents, if applicable) (&#8220;COBRA Premiums&#8221;) through the period starting on the Separation from Service date and ending </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">[##] ([##]) months after the Separation from Service date (the &#8220;</font><font style="color:#000000;">COBRA Premium Period</font><font style="color:#000000;">&#8221;); provided, however, that the Company&#8217;s provision of such COBRA Premium benefits will immediately cease if during the COBRA Premium Period Employee </font><font style="color:#000000;">become</font><font style="color:#000000;">s</font><font style="color:#000000;"> eligible for group health insurance coverage through a new employer</font><font style="color:#000000;"> or</font><font style="color:#000000;"> </font><font style="color:#000000;">Employee c</font><font style="color:#000000;">ease</font><font style="color:#000000;">s</font><font style="color:#000000;"> to be eligible for COBRA continuation coverage for any reason, including plan termination.</font><font style="color:#000000;"> </font><font style="color:#000000;"> </font><font style="color:#000000;">In the event </font><font style="color:#000000;">Employee </font><font style="color:#000000;">become</font><font style="color:#000000;">s</font><font style="color:#000000;"> covered under another employer&#8217;s group health plan or otherwise cease</font><font style="color:#000000;">s</font><font style="color:#000000;"> to be eligible for COBRA during the COBRA Premium Period, </font><font style="color:#000000;">Employee </font><font style="color:#000000;">must immediately notify the Company</font><font style="color:#000000;">, in writing,</font><font style="color:#000000;"> of such event.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Special Cash Payments in Lieu of COBRA Premiums.</font><font style="color:#000000;">&nbsp;&nbsp;Notwithstanding the foregoing, if (a) as of the date of Employee&#8217;s termination of employment Employee is not a participant in a Company group health plan under which Employee would otherwise be entitled to continued coverage under COBRA or (b) the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Employee or Employee&#8217;s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Employee, on the first day of each calendar month following the Separation from Service date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Employee&#8217;s eligible dependents), subject to applicable federal and state tax withholdings and required or voluntarily authorized deductions (such amount, the &#8220;Special Cash Payment&#8221;), for the remainder of the COBRA Premium Period. Employee may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums or toward premium costs under an individual health plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Termination Without Cause or Resignation for Good Reason During Change in Control Period.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  In the event Employee&#8217;s employment with the Company is terminated by the Company without Cause (and other than as a result of Employee&#8217;s death or disability) at any time during the Change in Control Period, or Employee resigns for Good Reason at any time during the Change in Control Period, in lieu of (and not additional to) the Severance Benefits described in Section 8.1, and provided that Employee satisfies the Release Requirement in Section 9 below and remains in compliance with the terms of this Agreement and the Proprietary Agreement, the Company shall instead provide Employee with the following &#8220;CIC Severance Benefits&#8221;. For the avoidance of doubt: (i) in no event will Employee be entitled to severance benefits under Section 8.1 and this Section 8.2, and (ii) if the Company has commenced providing Severance Benefits to Employee under Section 8.1 prior to the date that Employee becomes eligible to receive CIC Severance Benefits under this Section 8.2, the Severance Benefits previously provided to Employee under Section 8.1 of this Agreement shall reduce the CIC Severance Benefits provided under this Section 8.2:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">CIC Severance Payment.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Severance pay in the form of a lump sum payment in an amount equal to (i) [##] ([##]) months of Employee&#8217;s final Base Salary, payable within sixty (60) days following the Separation from Service date and subject to required and voluntarily authorized payroll deductions and federal and state tax withholdings; provided, however, in the event the Change in Control is not a &#8220;change in control event&#8221; under Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) [or the Separation from Service </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">occurs more than two years following the Change in Control]</font><font style="font-family:Times New Roman;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">and the </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">s</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">everance </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">payable under this Section 8.2.1 </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">is considered nonqualified deferred compensation within the meaning of Section 409A of the Code, then the severance payable under this Section 8.2.1 shall be paid in installments in accordance with Section 8.1.1. to the extent required to comply with Section 409A of the Code</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">For such purposes, Employee&#8217;s final Base Salary will be calculated prior to giving effect to any reduction in Base Salary that would give rise to Employee&#8217;s right to resign for Good Reason</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">CIC Health Care Continuation Coverage Payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">COBRA Premiums.</font><font style="color:#000000;">  If Employee timely elects continued coverage under COBRA, the Company will pay Employee&#8217;s COBRA premiums to continue Employee&#8217;s coverage (including coverage for Employee&#8217;s eligible dependents, if applicable) (&#8220;CIC COBRA Premiums&#8221;) through the period starting on the Separation from Service date and ending [##] ([##]) months after the Separation from Service date (the &#8220;CIC COBRA Premium Period&#8221;); provided, however, that the Company&#8217;s provision of such CIC COBRA Premium benefits will immediately cease if during the CIC COBRA Premium Period, Employee becomes eligible for group health insurance coverage through a new employer or Employee ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Employee becomes covered under another employer&#8217;s group health plan or otherwise ceases to be eligible for COBRA during the CIC COBRA Premium Period, Employee must immediately notify the Company, in writing, of such event.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Special Cash Payments in Lieu of CIC COBRA Premiums.</font><font style="color:#000000;">  Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the CIC COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Employee or Employee&#8217;s dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Employee, on the first day of each calendar month following the Separation from Service date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Employee&#8217;s eligible dependents), subject to applicable federal and state tax withholdings (such amount, the &#8220;Special CIC Cash Payment&#8221;), for the remainder of the CIC COBRA Premium Period.  Employee may, but is not obligated to, use such Special CIC Cash Payments toward the cost of COBRA premiums.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Bonus.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee shall also receive an amount equal to the Target Bonus Amount, payable in a lump sum within sixty (60) days following the termination date and subject to required and voluntarily authorized payroll deductions and federal and state tax withholdings; provided, however that, if the period for satisfaction of the Release Requirement (as defined below) begins in one taxable year and ends in another taxable year, payment shall not be made until the beginning of the second taxable year.&nbsp;&nbsp;For purposes of calculating the Target Bonus Amount for purposes of the payment pursuant to this Section 8.2.3, Executive&#8217;s final Base Salary will be calculated prior to giving effect to any reduction in Base Salary that would give rise to Executive&#8217;s right to resign for Good Reason.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.2.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Equity Acceleration.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Notwithstanding anything to the contrary set forth in the Company&#8217;s 2014 Equity Incentive Plan or 2018 Inducement Plan, any other equity </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">incentive plans </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">or any award agreement, effective as of Employee&#8217;s employment Separation from Service date that occurs during the Change in Control Period, the vesting and exercisability of all unvested time-based vesting equity awards then held by Employee shall accelerate such that all shares become immediately vested and exercisable, if applicable, by Employee upon such Separation from Service and shall remain exercisable, if applicable, following Employee&#8217;s Separation from Service as set forth in the applicable equity award documents</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">and, if applicable, distributable within sixty (60) days following Employee&#8217;s Separation from Service (or such other date as required to comply with Section 409A of the Code; </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">provided, that the performance conditions applicable to any outstanding and unvested equity awards subject to performance conditions will be deemed satisfied at the target level specified in the terms of the applicable </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">equity </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">award </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">document</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">; provided, further, that any awards that are unvested as of the </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">d</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">ate of </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Separation from Service </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">but would vest upon the </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">satisfaction of the Release Requirement</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">, shall remain outstanding and shall not be exercisable or distributable until the </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">satisfaction of the Release Requirement in accordance with Section 9 of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Termination for Cause; Resignation Without Good Reason; Death or Disability.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Employee will not be eligible for, or entitled to any severance benefits, including (without limitation) the Severance Benefits and CIC Severance Benefits listed in Sections 8.1 and 8.2 above, if the Company terminates Employee&#8217;s employment for Cause, Employee resigns Employee&#8217;s employment without Good Reason, or Employee&#8217;s employment terminates due to Employee&#8217;s death or disability.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Conditions to Receipt of Severance Benefits and CIC Severance Benefits.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">  To be eligible for any of the Severance Benefits or CIC Severance Benefits pursuant to Sections 8.1 and 8.2 above, Employee must satisfy the following release requirement (the &#8220;Release Requirement&#8221;): return to the Company a signed and dated general release of all known and unknown claims in a separation agreement acceptable to the Company (the &#8220;Release&#8221;) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following Employee&#8217;s Separation from Service date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the &#8220;Release Effective Date&#8221;). No Severance Benefits or CIC Severance Benefits will be paid hereunder prior to the Release Effective Date. Accordingly, if Employee breaches the preceding sentence and/or refuses to sign and deliver to the Company an executed Release or signs and delivers to the Company the Release but exercises Employee&#8217;s right, if any, under applicable law to revoke the Release (or any portion thereof), then Employee will not be entitled to any severance, payment or benefit under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Section 409A.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">  It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A&#8209;1(b)(4), 1.409A&#8209;1(b)(5) and 1.409A&#8209;1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A&#8209;2(b)(2)(iii)), Employee&#8217;s right to receive any installment payments under this Agreement (whether Severance Payments, CIC Severance Payments, reimbursements </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder </font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">shall at all times</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;"> be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Employee is deemed by the Company at the time of Employee&#8217;s Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section 409A(a)(2)(B)(</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">i</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">i</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">) and the related adverse taxation under Section 409A, such payments shall not be provided to Employee prior to the earliest of (</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">i</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">) the expiration of the six-month and one day period measured from the date of Employee&#8217;s Separation from Service with the Company, (ii) the date of Employee&#8217;s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">i</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Employee, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the Company determines that any Severance Benefits or CIC Severance Benefits provided under this Agreement constitutes &#8220;deferred compensation&#8221; under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective date of the Release will not be deemed to have occurred any earlier than the sixtieth (60th) date following the Separation </font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">From</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;"> Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for Employee to execute (and not revoke) the applicable Release spans two calendar years, payment of the applicable Severance Benefit or CIC Severance Benefits shall not commence until the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A, amounts reimbursable to Employee under this Agreement shall be paid to Employee on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Employee) during any one year may not effect amounts reimbursable or provided in any subsequent year. The Company makes no representation that any or </font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">all of</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;"> the payments described in this Agreement will be exempt from or comply with Code Section 409A and makes no undertaking to preclude Code Section 409A from applying to any such payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Section 280G; Limitations on Payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">If any payment or benefit Employee will or may receive from the Company or otherwise (a &#8220;280G Payment&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;Excise Tax&#8221;), then any such 280G Payment provided pursuant to this Agreement (a &#8220;Payment&#8221;) shall be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#8220;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Reduction Method</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;)</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">that results in the greatest economic benefit for Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Pro Rata Reduction Method</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Notwithstanding any provision of Section 11.1 to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Employee as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Unless Employee and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control transaction shall perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section 11.  The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Employee and the Company within fifteen (15) calendar days after the date on which Employee&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Employee or the Company) or such other time as requested by Employee or the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">If Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 11.1 and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 11.1) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 11.1, Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">Definitions.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M14"></a><a name="_DV_M17"></a><a name="_DV_M21"></a><a name="_DV_C24"></a><a name="_DV_M24"></a><a name="_DV_M29"></a><a name="_DV_C29"></a><a name="_DV_M32"></a><a name="_DV_M33"></a><a name="_DV_C32"></a><a name="_DV_M35"></a><a name="_DV_M36"></a><a name="_DV_C34"></a><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#auto;font-family:Times New Roman;">Cause.</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">  <a name="_DV_M14"></a>For purposes of this Agreement, &#8220;Cause&#8221; means the occurrence of any one or more of the following: (i) the Employee&#8217;s refusal <a name="_DV_M17"></a>(after written notice<a name="_DV_M21"></a> and reasonable opportunity to cure) to perform <a name="_DV_C24"></a>duties properly <a name="_DV_M24"></a>assigned which are consistent with the scope and nature of the Employee&#8217;s position; (ii) the Employee&#8217;s commission of an act materially and demonstrably detrimental to the financial condition and/or goodwill of the Company or any of its subsidiaries, which act constitutes gross negligence or willful misconduct in the performance of duties to the Company or any of its subsidiaries; (iii) the Employee&#8217;s commission<a name="_DV_M29"></a> of any theft, fraud, act of dishonesty or breach of trust resulting in or intended to result in<a name="_DV_C29"></a> material personal gain or enrichment of the Employee at the direct or indirect expense of the Company or any of its subsidiaries; (iv) the Employee&#8217;s conviction of, or plea of guilty or nolo contendere to a felony; (v) a material violation of any restrictive covenant with respect to non-competition, non-solicitation, confidentiality or protection of trade secrets (or similar provision regarding intellectual property) by which the Employee is bound under any agreement between the Employee and the Company and its subsidiaries; or (vi) a material and willful violation of the Company&#8217;s written policies or of the Employee&#8217;s statutory or common law duty of loyalty to the Company or its affiliates that in either case is materially injurious to the Company, monetarily or otherwise. No act or failure to act will be considered &#8220;willful&#8221; (x) unless it is done, or omitted to be done, by the Covered Employee in bad faith or without reasonable belief that the Employee&#8217;s action or omission was in the best interests of the Company or (y) if it is done, or omitted to be done, in reliance on the informed advice of the Company&#8217;s outside counsel or independent accountants or at the e</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"><a name="_DV_M32"></a>xpress direction of the Board. An event described in clauses (i), (ii), (iii), (v) or (vi) of this definition herein shall not be treated as &#8220;Cause<a name="_DV_M33"></a>&#8221; until after the Employee has been given written notice of such event, failure<a name="_DV_C32"></a>, conduct<a name="_DV_M35"></a> or breach<a name="_DV_M36"></a> and the Employee fails to cure such event, failure, conduct or breach<a name="_DV_C34"></a> within 30 calendar days from such written notice; provided, however, that such 30-day cure period shall not be required if the event, failure, conduct or breach is determined by the Company to be incapable of being cured.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Change in Control.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  For purposes of this Agreement, &#8220;Change in Control&#8221; shall have the meaning described in the Company&#8217;s 2014 Equity Incentive Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Change in Control Period.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  For purposes of this Agreement, &#8220;Change in Control Period&#8221; means the time period commencing [##] ([##]) months before the effective date of a Change in Control and ending on the date that is [##] ([##]) months after the effective date of a Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#auto;font-family:Times New Roman;">Good Reason.</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">  For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean, without the Employee&#8217;s prior written consent, any one or more of the following: (i) the Company reduces the amount of the Employee&#8217;s base salary or cash bonus opportunity (it being understood that the Company shall have discretion to set the Company&#8217;s and the Employee&#8217;s personal performance targets to which the cash bonus will be tied); (ii) the Company adversely changes the Employee&#8217;s reporting responsibilities, titles or office as in effect as of the date hereof or reduces the Employee&#8217;s position, authority, duties, responsibilities or, after a Change in Control, the Employee&#8217;s status, in a manner that is materially inconsistent with the positions, authority, duties, responsibilities or, after a Change in Control, status, which the Employee then holds; (iii) any successor to the Company, as described in Section 14.7, does not expressly assume any material obligation of the Company or any of its subsidiaries to the Employee under this </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">Agreement or </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">any </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">other </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">agreement or plan </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">pursuant to </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">which the Employee receives</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">benefits or rights</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">;</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> or (iv) the Company changes the Employee&#8217;s place of work to a location more</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">than fifty (50) miles</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> from the Employee&#8217;s present place of work,</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> provided, however, that </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">the occurrence of any</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> such </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">condition shall not constitute</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> Good Reason</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> unless (A)</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> the Employee </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">provides</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> written notice to the </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">Company of the existence of such condition not later than 60</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> days after the </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">Employee knows or reasonably should know of the existence of such condition, (B) the Company shall have failed to remedy such condition within 30</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> days </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">after</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> receipt of such notice </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">and (C) the Employee resigns due </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">to </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">the existence of such condition</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> within </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">60</font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;"> days after the expiration of the </font><font style="color:#auto;font-family:Times New Roman;font-weight:normal;">remedial period described in clause (B) hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="color:#auto;font-family:Times New Roman;text-transform:none;">Disput</font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">e Resolution/Agreement to Arbitrate Claims.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;color:#000000;">  To ensure the rapid and economical resolution of disputes that may arise in connection with Employee&#8217;s employment with the Company, Employee and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Employee&#8217;s employment with the Company, or the termination of Employee&#8217;s employment from the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1, et seq. and to the fullest extent permitted by law, by final, binding and confidential arbitration. Except as provided below, the Company and Employee agree that confidential arbitration is the exclusive, final and biding method for resolving all such claims.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Claims Covered By this Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Disputes that are subject to arbitration under this Agreement include, but are not limited to, claims for wages or other compensation due, including claims for overtime; meal or rest break claims; claims for breach of any contract or covenant (express or implied); tort claims, including, but not limited to claims for defamation, intentional infliction of emotional distress, invasion of privacy, and all negligence-based claims; personal injury claims; claims for discrimination, harassment and/or retaliation in employment including, but no limited to claims under the California Fair Employment and Housing Act, the California Labor Code, claims arising under Title VII of the Civil Rights Act of 1964, the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act, the California Family Rights Act of 1964, the Family and Medical Leave Act, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Older Worker Benefit Protection Act, the Sarbanes-Oxley Act, all as they may have been amended from time to time, claims for misclassification, and claims for violation of common law or any other federal, state, or local laws relating to employment or separation from employment or benefits associated with employment or separation for employment.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Claims Not Covered By this Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Claims for workers&#8217; compensation, unemployment insurance, claims for injunctive relief, and claims under California Private Attorneys General Act of 2004, as amended, are not covered by this Agreement.  Nothing in this Agreement is intended to prevent Employee from filing an administrative claim with the Equal Employment Opportunity Commission or the California Department of Fair Employment and Housing.  Moreover, both Employee and the Company may bring an action in any court of competent jurisdiction to compel arbitration under this Agreement and/or enforce and arbitration award.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">13.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Arbitration Rules and Procedures.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">The arbitration is to be conducted in or near the city in which Employee is or was last employed by the Company by JAMS, Inc. (&#8220;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">JAMS</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">&#8221;) or its successors before a mutually selected single neutral arbitrator, under JAMS&#8217; then applicable rules and procedures for employment disputes (which will be provided to Employee upon request); provided that the arbitrator shall: (</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">i</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">permitted by law; and (ii) issue a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions on which the award was based and a statement of the award. Employee and the Company shall be entitled to all rights and remedies that </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">either would</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> be entitled to pursue in a court of law. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Questions of whether a claim is subject to arbitration under this Agreement shall be decided by the arbitrator. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. To the maximum extent permitted by applicable law, all claims, disputes, or causes of action under this section, whether by Employee or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">The Arbitrator may not consolidate the claims of more than one person or </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">entity, and</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> may not preside over any form of representative or class proceeding. </font><font style="font-family:Times New Roman;color:#000000;">BOTH EMPLOYEE AND THE COMPANY ACKNOWLEDGE THAT BY AGREEING TO THIS ARBITRATION PROCEDURE, THEY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTE THROUGH A TRIAL BY JURY OR JUDGE OR ADMINISTRATIVE PROCEEDING.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law (that is, costs that are unique to arbitration) and shall pay the arbitrator&#8217;s fee. Employee and the Company will pay for their own costs that are not unique to arbitration, including their own attorneys&#8217; fees and costs such as, without limitation, costs to subpoena witnesses and/or documents, take depositions and purchase transcripts of hearings or deposition, to copy, facsimile or messenger documents, etc. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Any dispute as to whether a cost is unique to arbitration will be exclusively resolved by the arbitrator. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Both Employee and the Company have the right to be represented by legal counsel at any arbitration proceeding. The arbitration proceedings will be confidential to the extent permitted by law. </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">Employee and the Company will maintain all information and documents exchanged in connection with and </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">in the course of</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> the arbitration as confidential, except to the extent the disclosure of such information or documentation is necessary to enforce any award or challenge any award as permitted by the applicable law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">No Change in At-Will Employment.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  This agreement to arbitrate claims is not a contract of employment, expressed or implied, and Employee and the Company acknowledge that Employee&#8217;s employment with the Company is at-will and that this agreement does not change the &#8220;at-will&#8221; status of Employee&#8217;s employment.  BOTH EMPLOYEE AND THE COMPANY ACKNOWLEDGE THAT THEY HAVE READ AND UNDERSTAND THE TERMS OF SECTION 13, AGREEMENT TO ARBITRATE CLAIMS, AND AGREE TO BE BOUND BY ITS TERMS.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-family:Times New Roman;font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;text-transform:none;color:#000000;">General Provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.1</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Notices.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by email upon </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">confirmation of receipt) or the next day after sending by overnight carrier, to the Company at its primary office location and to Employee at the address as listed on the Company payroll.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.2</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Severability.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the Company and Employee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.3</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Waiver.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.4</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Complete Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  This Agreement, together with the Proprietary Agreement, constitutes the entire agreement between Employee and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment of the Company&#8217;s and Employee&#8217;s agreement with regard to this subject matter.  This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations.  It cannot be modified or amended except in a writing signed by a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company&#8217;s discretion in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.5</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Counterparts.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but both of which taken together will constitute one and the same Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.6</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Headings.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.7</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Successors and Assigns.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  This Agreement is intended to bind and inure to the benefit of and be enforceable by Employee and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Employee may not assign any of Employee&#8217;s duties hereunder and Employee may not assign any of Employee&#8217;s rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.8</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Tax Withholding.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">  All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities.  Employee acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Employee has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to this Agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">14.9</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Choice of Law.</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.10</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Clawbacks</font><font style="font-family:Times New Roman;color:#000000;">.&#160;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> The payments to Employee pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules&#160;and regulations thereunder, or as otherwise required by law.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#010000;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.11</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Company Policies</font><font style="font-family:Times New Roman;color:#000000;">.&#160;</font><font style="font-family:Times New Roman;font-weight:normal;color:#000000;"> Employee shall be subject to additional Company policies as they may exist from time-to-time, including policies with regard to stock ownership by senior executives and policies regarding trading of securities.&#160; </font></p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Witness Whereof</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company and Employee have executed this Agreement to become effective as of the Effective Date written above.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td style="width:3.85%;"></td>
<td style="width:41.15%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Name]</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:9pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Employee</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[NAME]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>atra-ex211_9.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex211_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ke70601_consent_of_independent__ke702314"></a><a name="toc_ke70601_2"></a>LIST OF SUBSIDIARIES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of subsidiaries of the Company as of December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary Legal Name</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">State or other Jurisdiction of Incorporation or Organization</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics Australia Pty. Ltd.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics Ireland Limited</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics Netherlands B.V.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics Switzerland GmbH</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times,Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>atra-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="ke70601_consent_of_independent__ke702314"></a><a name="toc_ke70601_2"></a>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in registration statements No. 333-199508, No. 333-204076, No. 333-209961, No. 333-214431, No. 333-219763, No. 333-223254, No. 333-229861, No. 333-236704, No. 333-249976, No. 333-253734 and No. 333-259882 on Form S-8 of our reports dated February 28, 2022, relating to the consolidated financial statements of Atara Biotherapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) and the effectiveness of the Company&#8217;s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Atara Biotherapeutics, Inc. for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/<font style="font-style:italic;"> DELOITTE &amp; TOUCHE LLP</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California <font style="margin-left:276pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 28, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>atra-ex311_10.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex311_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Pascal Touchon, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Atara Biotherapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 28, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pascal Touchon</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pascal Touchon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>atra-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PURSUANT TO</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Utpal Koppikar, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Atara Biotherapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 28, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Utpal Koppikar</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utpal Koppikar</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>atra-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
atra-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and in connection with the Annual Report of Atara Biotherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Pascal Touchon, Chief Executive Officer of the Company, and Utpal Koppikar, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 28, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pascal Touchon&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pascal Touchon</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom"  style="width:50%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Utpal Koppikar&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utpal Koppikar</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_131"></a><a name="_cp_text_1_132"></a><font style="Background-color:#FFFFFF;"><a name="_cp_text_4_131"></a>This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed <a name="_cp_text_1_132"></a>filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gbn5n5jlnzog000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbn5n5jlnzog000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,_!?(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TOPUX:TC4
M_#]M>7EJ9;B4N7<RN,X=AV/M6M_PA?A__H'_ /D:3_XJCP7_ ,BE8_\ ;3_T
M8U;U &#_ ,(7X?\ ^@?_ .1I/_BJ/^$+\/\ _0/_ /(TG_Q5;U% &#_PA?A_
M_H'_ /D:3_XJC_A"_#__ $#_ /R-)_\ %5O44 8/_"%^'_\ H'_^1I/_ (JC
M_A"_#_\ T#__ "-)_P#%5O44 8/_  A?A_\ Z!__ )&D_P#BJ/\ A"_#_P#T
M#_\ R-)_\56]10!@_P#"%^'_ /H'_P#D:3_XJC_A"_#_ /T#_P#R-)_\56]1
M0!@_\(7X?_Z!_P#Y&D_^*H_X0OP__P! _P#\C2?_ !5;U% &#_PA?A__ *!_
M_D:3_P"*H_X0OP__ - __P C2?\ Q5;U% &#_P (7X?_ .@?_P"1I/\ XJC_
M (0OP_\ ] __ ,C2?_%5O44 8/\ PA?A_P#Z!_\ Y&D_^*H_X0OP_P#] _\
M\C2?_%5O44 8/_"%^'_^@?\ ^1I/_BJ/^$+\/_\ 0/\ _(TG_P 56]10!@_\
M(7X?_P"@?_Y&D_\ BJ/^$+\/_P#0/_\ (TG_ ,56]10!@_\ "%^'_P#H'_\
MD:3_ .*H_P"$+\/_ /0/_P#(TG_Q5;U% &#_ ,(7X?\ ^@?_ .1I/_BJ/^$+
M\/\ _0/_ /(TG_Q5;U% &#_PA?A__H'_ /D:3_XJC_A"_#__ $#_ /R-)_\
M%5O44 8/_"%^'_\ H'_^1I/_ (JC_A"_#_\ T#__ "-)_P#%5O44 8/_  A?
MA_\ Z!__ )&D_P#BJ/\ A"_#_P#T#_\ R-)_\56]10!@_P#"%^'_ /H'_P#D
M:3_XJC_A"_#_ /T#_P#R-)_\56]10!@_\(7X?_Z!_P#Y&D_^*H_X0OP__P!
M_P#\C2?_ !5;U% &#_PA?A__ *!__D:3_P"*H_X0OP__ - __P C2?\ Q5;U
M% &#_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5O44 8/\ PA?A
M_P#Z!_\ Y&D_^*H_X0OP_P#] _\ \C2?_%5O44 8/_"%^'_^@?\ ^1I/_BJ/
M^$+\/_\ 0/\ _(TG_P 56]10!@_\(7X?_P"@?_Y&D_\ BJ/^$+\/_P#0/_\
M(TG_ ,56]10!@_\ "%^'_P#H'_\ D:3_ .*H_P"$+\/_ /0/_P#(TG_Q5;U%
M &#_ ,(7X?\ ^@?_ .1I/_BJ/^$+\/\ _0/_ /(TG_Q5;U% &#_PA?A__H'_
M /D:3_XJC_A"_#__ $#_ /R-)_\ %5O44 8/_"%^'_\ H'_^1I/_ (JC_A"_
M#_\ T#__ "-)_P#%5O44 8/_  A?A_\ Z!__ )&D_P#BJ/\ A"_#_P#T#_\
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M .*H_P"$+\/_ /0/_P#(TG_Q5;U% &#_ ,(7X?\ ^@?_ .1I/_BJ/^$+\/\
M_0/_ /(TG_Q5;U% &#_PA?A__H'_ /D:3_XJC_A"_#__ $#_ /R-)_\ %5O4
M4 8/_"%^'_\ H'_^1I/_ (JC_A"_#_\ T#__ "-)_P#%5O44 8/_  A?A_\
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M3_XJC_A"_#__ $#_ /R-)_\ %5O44 8/_"%^'_\ H'_^1I/_ (JC_A"_#_\
MT#__ "-)_P#%5O44 8/_  A?A_\ Z!__ )&D_P#BJ/\ A"_#_P#T#_\ R-)_
M\56]10!@_P#"%^'_ /H'_P#D:3_XJC_A"_#_ /T#_P#R-)_\56]10!@_\(7X
M?_Z!_P#Y&D_^*H_X0OP__P! _P#\C2?_ !5;U% &#_PA?A__ *!__D:3_P"*
MH_X0OP__ - __P C2?\ Q5;U% &#_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
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M7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5O44 8/\ PA?A_P#Z!_\
MY&D_^*H_X0OP_P#] _\ \C2?_%5O44 8/_"%^'_^@?\ ^1I/_BJ/^$+\/_\
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M^*H_X0OP_P#] _\ \C2?_%5O44 8/_"%^'_^@?\ ^1I/_BJ/^$+\/_\ 0/\
M_(TG_P 56]10!X6+FX50!/( !@ .>**BHH ];\%_\BE8_P#;3_T8U;U8/@O_
M )%*Q_[:?^C&K>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /!J*** /6_!?_(I6/\ VT_]
M&-6]6#X+_P"12L?^VG_HQJWJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '@U%%% 'K?@O_D4K'_MI_P"C&K>K!\%_\BE8_P#;3_T8U;U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8.E?\C;XA_[=O_19K>K!
MTK_D;?$/_;M_Z+- &]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X-1110!ZW
MX+_Y%*Q_[:?^C&K>K!\%_P#(I6/_ &T_]&-6]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6#I7_(V^(?^W;_ -%FMZL'2O\ D;?$/_;M_P"B
MS0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >#4444 >M^"_P#D4K'_ +:?
M^C&K>K!\%_\ (I6/_;3_ -&-6]0 4444 %%%% !1110 445B>+]<D\->$=4U
MF* 3RVD!D2,YP6Z#..V3D^U &W17FVBR^)[@76I6GB)M0D4VDK6SVZ&WDC>-
M6<1A0&7AB1\QSCD'.:ZSQ%8^(M1CCM]"UFWTA<%I+IK47$F<C"JC$*!UR3GZ
M=Z -VBN,\$ZWK;Z)JX\5-$TVDW<L#7T:;$N$0 E\=/7.../8UB#Q7X@;P.WQ
M %R?L@8S+H_E)L-J'V\OC?YFWYL[MO;;0!Z=17(^*/%K6>GZ)'H[QM>:]<1P
M6<CC<L:,-S2E>^U>WJ13+'6K[1_'$/A;5+Y[]+VT-U9WDR(DFY3AXV"*JGCY
M@0 <9!SUH [&BBB@ K!TK_D;?$/_ &[?^BS6]6#I7_(V^(?^W;_T6: -ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;9YB?3>K#]/I@\URT/@!9]5NIM9U6^U.R::*:*VN'C"NR* #*$C7?@C@$D'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJP=*_P"1M\0_]NW_ *+- &]1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !113)98X(FEFD2.-1EF=@ /Q- #Z*YBY\=:2LQM].6XU6Y'_+.QB+@?5NF
M/<9J'=XSUC[JV>A6Y[M^_FQ_Z#_6LG6CM'7T_JQJJ,MY:>O]7.HN+F"TA,US
M-'#$O5Y'"J/Q->">/M0M-3\7W5S93K/ 510Z="0H!Q7K%OX$TPS+<:K-=:M<
MCG?>2EE'T7ICV.:XKQGX$UF_\233Z1ID9LC&@01R1Q@84 C:2,<UR8R-6=/X
M>OJSKP<J4*F_3T1YM7H/PB_Y&:\_Z\V_]#2L?_A7'BS_ *!7_DQ%_P#%5V7P
MY\)ZUH.MW5UJ=F((GMC&I\U&RQ93_"3Z&N+#4:BJQ;B_N.S$UJ;I22DOO/2Z
M***]T\,**** "BBB@ HHHH **** "BBB@#P:BBB@#UOP7_R*5C_VT_\ 1C5O
M5@^"_P#D4K'_ +:?^C&K>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K!TK_D;?$/_;M_Z+-;U8.E?\C;XA_[=O\ T6: -ZBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBD)"J68@ #))[4 +17.W_ (VT.RF^SQW#7UT>D%DAE8GTXX_6
MJGV_Q?K'_'EIMOI%N?\ EM>MOEQZA!T/L:R=:-[+7T-51E:[T]3JW=(T+NRJ
MJC)9C@"N<O/'.C03&WM'EU*Z[0V,9E)_$<?K4*>!X;MUEU[4KS5I <[)',<0
M/LB]/SKH[.PL]/A\FRM8;>/^[$@4?I2O5EY?B%J<?/\  YK[3XRUC_CWM;71
M+<_\M+@^=-CU"C@?0T^+P+932K/K5Y=ZO.#D?:9"(P?9!P/IS7544_8Q?Q:^
MO^6P>VDOAT]/\]R&VM+:RA$-K;Q01#HD2!1^0J:BBM4K&3=PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /!J*** /6_!?\ R*5C_P!M/_1C5O5@
M^"_^12L?^VG_ *,:MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L'2O^1M\0_P#;M_Z+-;U8.E?\C;XA_P"W;_T6: -ZBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK$
MU/Q=H>DL8[B_C:?.!!#^\<GTPO3\<5F_VYXEU;C2-"%G">ESJ;;3_P!^QS6;
MJP3LM7Y&BI3:OLO,ZVL#4?&>A:;)Y+7@N+DG @M1YKD^F!P#]2*I?\(=<ZE\
MWB'6[N^!ZVT)\B'Z$+R?KQ6]IVC:;I$?EZ?906X[E$Y/U/4_C4WJ2V5O7^OU
M':G'=W]/Z_0P/[6\5ZOQIFCQ:; >D^HM\^/:,<@_7-*/!1OV$GB'5[S5#U,.
M[R8?^^%_QKK**?L4_C=_Z[![9KX%;^NY4L-+L-+A\JQLX;=.XC0#/U/?\:MT
M45HDDK(S;;=V%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBO+/BE\4D\.12:+HLJOJ[KB64<BU!_\
M9_0=NIKJP6"K8RLJ-%7;_#S9,I**NSU.BOG;X9?%B?1[E=)\0W,D^G2O^[NI
M6+- Q/<GDJ3^5?0Z.DD:R1LKHP#*RG((/0BM\RRRME]7V=35/9]'_784)J:N
MAU%%%><6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_R*5C_VT_\ 1C5O5@^"_P#D4K'_ +:?^C&K>H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K!TK_D;?$/_;M_Z+-;U8.E?\C;XA_[=O\ T6:
M-ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!J***
M/6_!?_(I6/\ VT_]&-6]6#X+_P"12L?^VG_HQJWJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *P=*_P"1M\0_]NW_ *+-;U8.E?\ (V^(?^W;
M_P!%F@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.'(^9P,NWU8\FL^:<_A5EY_Y?YFG+"'Q.[\O\_\ (P?L7B?Q%S?W']B6#?\
M+O:L&G<?[3]%_#\16YI'A_2]#BVV%HD;'[\I^9W^K'DUIT54:44[O5DRJ2:L
MM$%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X-1110!ZWX+_P"12L?^VG_HQJWJP?!?_(I6/_;3_P!&
M-6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#I7_(V^(?\
MMV_]%FMZL'2O^1M\0_\ ;M_Z+- &]1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNS^^S$GK9G2T445PE!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDECG Z"N@HH **** "L'2O\ D;?$/_;M_P"BS6]6#I7_ "-OB'_MV_\ 19H
MWJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HI"0JEF(  R2>U<%?>*-3\67TVC>#&"6\;;+S7&7,47JL7]]_?H/UKHP
M^&G7;MHENWLO7_+=]!-I&EXD\9C3KY=$T2U_M3Q!,/DM4/R0C^_*W\*CKCJ?
M;.:3PWX,-C?MKFO77]J>()1S<,/W=N/[D2_PCWZGVR:TO#?A;3?"UBT%BC/-
M*=]Q=3'=+._=G;O_ "K;K>IB84X.EAM$]Y=9?Y+R^^_1)-ZL****X"@HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X-1110!ZWX+_ .12L?\ MI_Z,:MZL'P7_P BE8_]
MM/\ T8U;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8.E?\
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MS16AZ=17 :1\5-/U'4%MKJS-E$59C/),"JX&>>!UQCZXK1/B;5-=)C\,Z<3
M>#J%Z"D7U5>K?YXIK$4Y*\7<'AZD7:2L=/=WEM86S7%W<1P0KU>1@HKF6\57
M^M,8O"^FF>/.#?W8,<"_0=6J6T\%V\EPM[KUU+K%X.1Y_$2?[L?3\ZZ=5"J%
M4 *!@ #@4[5)[Z+\17IPVU?X'+VW@Q+F=+SQ%>RZM=*<JDGRP1G_ &8QQ^?7
MTKIT1(T5(U5$48"J, "G45<81AL1*<I;A1115D!1110 4444 %%%% !1110
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MH4A@B4*D<:A54#L *EHHKSVVW=EA1112 **** "BBB@ HHHH **** "BBB@
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M2?X5XF)A-U9-H]K#3@J229I?#ZU@O/&MA#<PQS1'S"4D4,"0C$<'WKWX
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MR%XSR,9].GTQ79T5G3P_)+FN3&E)24FPHHHKH-@HHHH **** "BBB@ HHHH
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MJSMO$UYJ%_X4V+"MQ!.X6V;L)4R3M[ @_P"%>FZ/HVAV-O%-I-G:+&ZADFB
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MTX1V1,JDI;L****L@**** "BBB@ HHHH **** "N*\1^$+N+5&\2^$Y4M-;
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M +YSFMBN2=.=-VFFGYE)I[!1114 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X
M-1110!ZWX+_Y%*Q_[:?^C&K>K!\%_P#(I6/_ &T_]&-6]0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6#I7_(V^(?^W;_ -%FMZL'2O\ D;?$
M/_;M_P"BS0!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%JNT6&LV%RQZ+%<*6_+.:RJ8+$TE>=-I>CM]X*2>S-6BBBN8H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&HHHH
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M]]$UMP6UO:ILMX(H5_NQH%'Z5+15**6R&%%%%, HHHH **** "BBB@ HHHH
M**** "J]]8VNIV,UE>V\=Q;3+MDCD&0PJQ133<7=;@>:B34OA;*%F:?4?!S,
M LA^>;3<G@'^]'_+_P!"YIOCTH\8[5LP?#H_=EMO[X\_ZSZ?[/I[UO?&S0]?
MU;P]%/I<SR6%KE[NSC'S/Z/_ +07T[=?I\W5][DV6X3,:#Q&(M*;NG;3YO\
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M1L^)E]]Z7PYID9_NK+-(/S^6NXHH^N0C\%**^]_FVOP#E?5G#_\ "'>*KO\
MY"7CZ^(/\%C:1V^/Q&31_P *KT*X_P"0I?:UJWK]NU!VS_WSBNXHH_M+$KX)
M<O\ A2C^20<D3FK+X?>$+#'D>'=/)'0RQ"4C\7S6_;VEM:1^7;6\4*?W8T"C
M]*FHKFJ5ZM7^))OU;8TDM@HHHK(84444 %%%% !1110 4444 %%%% !1110
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MP_J\0_ZZ6\K?^RBCZG3E_#JQ?K=?FK?B',^J.YHKA_\ A-]?L?\ D,>!-6C
MZMI\B78^N%P:DA^*OA-I1#=WEQITY_Y97UK)$1^.,?K0\MQ5KQAS?X;2_P#2
M;ASQ.THK.L-?T;5<?V?JME=$]H;A7/Y T[6-8L- TJ?4M2N%@M85RS'J?0 =
MR>PKE]E4YU#E=WTZCNMR_17BF@_'9;OQ7+#JULEMHT[!;>0<O!Z%SW![XZ>]
M>THZ21K)&RNC ,K*<@@]"*ZL;EV(P4E&O&UU?^O-=11FI;#J***X2@HHHH *
M*** "BBB@ HHHH **** /!J*** /6_!?_(I6/_;3_P!&-6]6#X+_ .12L?\
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MNC?X$'_"8^(+XLNE^#KTC&5DO'\D?DP _6L^YUCQ=(%-WK?AW15_B4S*T@_
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M\WU]-XI4G%W84445\H;A1110 4444 %%%% !1110 4444 >#4444 >M^"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#P:BBB@#UOP7_R*5C_VT_\ 1C5O5@^"_P#D4K'_
M +:?^C&K>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!TK_D
M;?$/_;M_Z+-;U8.E?\C;XA_[=O\ T6: -ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#P:BBB@#UOP7_R*5C_ -M/_1C5O5@^"_\ D4K'_MI_Z,:MZ@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L'2O\ D;?$/_;M_P"BS6]6
M#I7_ "-OB'_MV_\ 19H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!J***
M /6_!?\ R*5C_P!M/_1C5O5@^"_^12L?^VG_ *,:MZ@ HHHH **** "BBB@
MHHHH ***;)(D,3RRNJ1HI9F8X"@=23Z4 .HI%97171@RL,A@<@BEH **** "
MBBB@ K!TK_D;?$/_ &[?^BS6]6#I7_(V^(?^W;_T6: -ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '@U%%% 'K?@O_D4K'_MI_P"C&K>K!\%_\BE8_P#;3_T8U;U !111
M0 4444 %%%% !1110 5GZSH>FZ_I\EEJ=G!<PNI \V)7*$C&Y=P.".QK0HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \&HHHH ];\%_P#(I6/_ &T_
M]&-6]6#X+_Y%*Q_[:?\ HQJWJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *P=*_Y&WQ#_ -NW_HLUO5@Z5_R-OB'_ +=O_19H WJ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /!J*** /6_!?_ "*5C_VT_P#1C5O5@^"_^12L
M?^VG_HQJWJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P=*_Y
M&WQ#_P!NW_HLUO5@Z5_R-OB'_MV_]%F@#>HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \&HHHH ];\%_\BE8_]M/_ $8U;U8/@O\ Y%*Q_P"VG_HQJWJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P=*_Y&WQ#_V[?^BS6]6#
MI7_(V^(?^W;_ -%F@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHK!_X2?_ *@6M_\ @)_]>C_A)_\ J!:W_P" G_UZ -ZBL'_A)_\ J!:W_P"
MG_UZ/^$G_P"H%K?_ ("?_7H WJ*P?^$G_P"H%K?_ ("?_7H_X2?_ *@6M_\
M@)_]>@#>HK!_X2?_ *@6M_\ @)_]>C_A)_\ J!:W_P" G_UZ -ZBL'_A)_\
MJ!:W_P" G_UZ/^$G_P"H%K?_ ("?_7H WJ*P?^$G_P"H%K?_ ("?_7H_X2?_
M *@6M_\ @)_]>@#>HK!_X2?_ *@6M_\ @)_]>C_A)_\ J!:W_P" G_UZ -ZB
ML'_A)_\ J!:W_P" G_UZ/^$G_P"H%K?_ ("?_7H WJ*P?^$G_P"H%K?_ ("?
M_7H_X2?_ *@6M_\ @)_]>@#>HK!_X2?_ *@6M_\ @)_]>C_A)_\ J!:W_P"
MG_UZ -ZBL'_A)_\ J!:W_P" G_UZ/^$G_P"H%K?_ ("?_7H WJ*P?^$G_P"H
M%K?_ ("?_7H_X2?_ *@6M_\ @)_]>@#>HK!_X2?_ *@6M_\ @)_]>C_A)_\
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MCSMF_P O[,-VW.,XW9QGO0!T5%8/_"3_ /4"UO\ \!/_ *]'_"3_ /4"UO\
M\!/_ *] &]16#_PD_P#U M;_ / 3_P"O1_PD_P#U M;_ / 3_P"O0!O45@_\
M)/\ ]0+6_P#P$_\ KT?\)/\ ]0+6_P#P$_\ KT ;U%8/_"3_ /4"UO\ \!/_
M *]'_"3_ /4"UO\ \!/_ *] &]16#_PD_P#U M;_ / 3_P"O1_PD_P#U M;_
M / 3_P"O0!O45@_\)/\ ]0+6_P#P$_\ KT?\)/\ ]0+6_P#P$_\ KT ;U%8/
M_"3_ /4"UO\ \!/_ *]'_"3_ /4"UO\ \!/_ *] &]16#_PD_P#U M;_ / 3
M_P"O1_PD_P#U M;_ / 3_P"O0!O45@_\)/\ ]0+6_P#P$_\ KT?\)/\ ]0+6
M_P#P$_\ KT ;U%8/_"3_ /4"UO\ \!/_ *]'_"3_ /4"UO\ \!/_ *] &]16
M#_PD_P#U M;_ / 3_P"O1_PD_P#U M;_ / 3_P"O0!O45@_\)/\ ]0+6_P#P
M$_\ KT?\)/\ ]0+6_P#P$_\ KT ;U%8/_"3_ /4"UO\ \!/_ *]'_"3_ /4"
MUO\ \!/_ *] &]16#_PD_P#U M;_ / 3_P"O1_PD_P#U M;_ / 3_P"O0!O4
M5@_\)/\ ]0+6_P#P$_\ KT?\)/\ ]0+6_P#P$_\ KT ;U%<[-XNAMH6FGT?6
M(HE^\\EL% [=2U2?\)/_ -0+6_\ P$_^O0!O45@_\)/_ -0+6_\ P$_^O1_P
MD_\ U M;_P# 3_Z] &]16#_PD_\ U M;_P# 3_Z]'_"3_P#4"UO_ ,!/_KT
M;U%8/_"3_P#4"UO_ ,!/_KT?\)/_ -0+6_\ P$_^O0!O45@_\)/_ -0+6_\
MP$_^O1_PD_\ U M;_P# 3_Z] &]16#_PD_\ U M;_P# 3_Z]'_"3_P#4"UO_
M ,!/_KT ;U%8/_"3_P#4"UO_ ,!/_KT?\)/_ -0+6_\ P$_^O0!O45@_\)/_
M -0+6_\ P$_^O1_PD_\ U M;_P# 3_Z] &]16#_PD_\ U M;_P# 3_Z]'_"3
M_P#4"UO_ ,!/_KT ;U%8/_"3_P#4"UO_ ,!/_KT?\)/_ -0+6_\ P$_^O0!O
M45@_\)/_ -0+6_\ P$_^O1_PD_\ U M;_P# 3_Z] &]16#_PD_\ U M;_P#
M3_Z]'_"3_P#4"UO_ ,!/_KT ;U%8/_"3_P#4"UO_ ,!/_KT?\)/_ -0+6_\
MP$_^O0!O45@_\)/_ -0+6_\ P$_^O1_PD_\ U M;_P# 3_Z] &]16#_PD_\
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MK;7-4O79#%=^5Y8!.1L4@YXK3HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-9TZ;4/[/\
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M[_4?*GX&NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI,'/S!0#^M &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN"MD'Y<@$@8/'6M.BB@ HHHH S+;0K:V\17VM^;-)=7<4<!$A&V)$R0J  $
MEB3DGFM.BB@ HHHH **** "BBB@ HHHH **** "BBB@#P:BBB@#UOP7_ ,BE
M8_\ ;3_T8U;U8/@O_D4K'_MI_P"C&K>H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!J***
M /6_!?\ R*5C_P!M/_1C5O5@^"_^12L?^VG_ *,:MZ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \&HHHH ];\%_P#(I6/_ &T_]&-6]6#X+_Y%*Q_[:?\ HQJWJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5/%=QJ8N-$MK"WT^ZDLY76_,S-*F,X7RU&WGKG\*["@ HHHH **** "BBB@
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M_P"VG_HQJWJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE];\:#1=3>R_X1KQ)?[%!
M\^PL/-B.1G ;<,D=ZZBBM:,Z<97J1YEZV$[]#A6^)3;3M\$>,2V. =+P"?\
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MF_=<?.I#+C_9(/O639>+]7TWPWJNF?:[R[N(O$QT6TN"ZO<")B#PTA"LX 8
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M4=>.U>GUP?A_1?B%:?9],U?6](GTJWVC[5#%+]LF12,*22%7(&">3CWYKO*
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M %HR@"'&"<,PSFO5;/\ X\;?_KDO\J /-VEU2+XZZL=+L[.ZE.BP[UNKIH%
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M_HQJWJP?!?\ R*5C_P!M/_1C5O4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#
MX@\&Z)XHDA?6+>XN/((:)%O9HD5AG#!4<#=R?FQGWK>HH BMX$M;:.",R,D:
MA5,LC2,0/5F)+'W))J6BB@ HHHH **** "BBB@"/R(?M'VCR8_/V[/,VC=MS
MG&>N,]JDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YZP\$Z%IFO3:
MY:07:ZE-_KIFO[A_-XQAE9R& [ C P,8P*Z&BB@ HHHH **** "L_6=%LM?T
MY[#45G>U?[Z17,D.\8((8HP)4@G(/!K0HH S-#T#3O#>G+I^EQS16JG*127,
MDP3V7>QVCV&!6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /!J*** /6_!?\
MR*5C_P!M/_1C5O5@^"_^12L?^VG_ *,:MZ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^*H_X6'I'_/O>_\ ?"?_ !5 '6T5R7_"P](_Y][W_OA/_BJ/^%AZ1_S[WO\
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M =;17)?\+#TC_GWO?^^$_P#BJ/\ A8>D?\^][_WPG_Q5 '6T5R7_  L/2/\
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M]\)_\50!UM%<E_PL/2/^?>]_[X3_ .*H_P"%AZ1_S[WO_?"?_%4 =;17)?\
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M3_XJC_A8>D?\^][_ -\)_P#%4 =;17)?\+#TC_GWO?\ OA/_ (JC_A8>D?\
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MD?\ /O>_]\)_\50!UM%<E_PL/2/^?>]_[X3_ .*H_P"%AZ1_S[WO_?"?_%4
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>H_X6'I'_ #[WO_?"?_%4 >9T4\1.1D#K[T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gk2okx215f1r000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2okx215f1r000014.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" RD!F,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!@#8'S=O04N&_O
M?H*4=!]!_*EH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?W
MOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH
M ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH ;AO[W
MZ"C#?WOT%.HH ;AO[WZ"C#?WOT%.HH CWD9&,X)]N_THIAZGZG^=% $PZ#Z#
M^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH @/4_4_SHH/4_4_SHH F'0?0?RI:0=!]!_*EH ****
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MJ<  RHQQ[#Z9Q7[[']@K]E(DG_A3_A09).!I=E@9).!_HW3GBOQV_P""5?\
MR?9^V5_V/VL_^E4]?TF4 ?'G_#!/[*7_ $1_PI_X*['_ .1J/^&"?V4O^B/^
M%/\ P5V/_P C5]AT4 ?'G_#!/[*7_1'_  I_X*['_P"1J_)+_@MW^QQ^S?X)
M_P"">GQ<U_PU\,_#VC:Q9-I M+ZRTVTCF0O>HK#>D*'##C Z\C%?T85^-?\
MP7G_ .4;GQE_ZZ:)_P"ER4 =7^PW^Q-^S'X@_8U_9GU#5OA+X5NM0N?A-X7O
M+N]DTNT-S=W-Y81RS27#M"V]MQ.T@*<'YBQ.:^IO^&"?V4O^B/\ A3_P5V/_
M ,C5-^P%_P F5?LQ?]D<\&?^FR.OKV@#\Z/CC^PM^RQ8?!_XB7-O\)/"T$UO
MX5UNXBFCTJR\R*5+"=E92(%Q@C.<\8SUK\E?^"#O[(_[/?CC]F?XNW?BGX:>
M'-;NT^-_BBPAN[[3;62XAM;6XE:&*)FB;:H!P0=PQP #DG^B+X_?\D8^)?\
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M2$_8*_921HV'P?\ "9,;*P!TNRP2IR V+<9!Z$ C([BOYY=-_95^ -W_ ,'
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M]JMOIFN7<%E;WFG6TD=K&UXZ?NPT9VD*3M P.^#7]2'C7_D3_%'_ & -6_\
M2&>OY^_^"-'_ "7S]J[_ +&&X_\ 2]Z /UG_ .&"/V4?^B/^%.N?^078^N?^
M?:OYV_VEOV8?@59?\'"O[&O@>R^''AJU\(ZQ\#O$&I:GX?ATZW73;N]LHKGR
M99H-A#$^2C/DDDEMI7C']=%?S)?M/_\ *Q_^Q'_V0#Q9_P"BK^@#]K9?V#?V
M4Y9993\'O"2F61I"J:59!07.2%!MR0H[ DGW-?C+_P %J?V0?V=/!WP)\ WG
MA[X:>'-'N#XSM+1[BSTZUCDEA>6%F61EB&<[B,# (X*\9K^EJOPY_P""Z/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ((T?\E\_:N_[&&X_P#2]Z_H$\:_\B?XH_[ &K?^D,]?S]_\$:/^2^?M7?\
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M *;YZ_,K_@@!_P F*K_V5#QQ_P"EXH _<*BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @/4_4_SHH/4_4_SHH F'
M0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^-/&#,H\(>$WBCN=9O[KK;QV<3QMAW;:JD-G)Q@<5_.3\*?B*O[5G[>?P?\
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M^]?@1_P7;_Y)K\*?^QQTO_TYPUR'6?L_\"/^2,?"W_L1?#7_ *:[>NB^)/\
MR3_QE_V+>K_^D4M<[\"/^2,?"W_L1?#7_IKMZZ+XD_\ )/\ QE_V+>K_ /I%
M+0!^#G_!$K_DHO[7'_8Y_P#M[+7]#-?SS?\ !$K_ )*+^UQ_V.?_ +>RU_0S
M0!_-9X5_Y6"=7_[(Q??^BC7]*=?S6>%?^5@G5_\ LC%]_P"BC7]*= 'XS?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(*%TE_4-H$,EOH6BP2@B6#2=-AE!ZB2.SA1\^^Y3FOR!_P""\_\ RC<^,O\
MUTT3_P!+DK]D8V1XXWB(:-T5HV7[I1E!0CV*D$>U?C=_P7G_ .4;GQE_ZZ:)
M_P"ER5XFJT>ZWTMKU/4]-NGH?:_[ 7_)E7[,7_9'/!G_ *;(Z^O:^0OV O\
MDRK]F+_LCG@S_P!-D=?7M 'D'Q^_Y(Q\2_\ L3M>_P#3=<5^-W_!OE_R:_\
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MP-_X3E/AS^S9I_B/7?&UOJ1L?M+VEDKR:0T*N//+%=NT@YSTK]!?^"[;;/V
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MD_Q0_P"SF/BK_P"G)*_HDK^=O_@VJ_Y,G^*'_9S'Q5_].25_1)0!\Y?M<_\
M)MOQD_[$3Q!_Z;YZ_,K_ (( ?\F*K_V5#QQ_Z7BOTU_:Y_Y-M^,G_8B>(/\
MTWSU^97_  0 _P"3%5_[*AXX_P#2\4 ?N%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 0'J?J?YT4'J?J?YT4 3#
MH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !14%S=
M6]G!)<W<\-M;PHTDL\\B111HHRS/)(510!U)(%?)'B[]O/\ 9-\#>(CX5\2_
M&CP;8ZXLODO:?VQI\NR7>$*.\=T55@QP03Q7JY7D><YW4G2R?*LPS2K2@ZE2
MG@,'7Q<H06\I*C";BE=:L\G,\]R7)53EF^:Y?EBK-JE]=Q5'#>T<;7Y%5G%R
MM=7M>W4^OJ*Y3P?XY\(^/]'M]>\&^(=*\1:3=(LD-[I5];7L)5QE<M;2RA3C
M^$D$=Q70WM]9Z;:S7NH75O96=NC23W-U-'!!%&HRSR2RLJ(H Y+,!7!4P]>C
M6EAJM&K3Q$)^SE0G3G&M&HG;D=.24U.^G*U>^ECNHXS"XC#0QF'Q-"MA*E/V
ML,32JPG0E3M?VD:L9.FX6UYN:UNI:HK\C/%__!93]DW2?VR?A9^Q3X0\76'C
M;XI?$757TJXCTB87-IHTR/LV27,$K0O+D,=O/"DC(!Q^N==V9Y-F.32PU/,L
M.\)6Q6'CBH8>I*"Q-.C.4HP>(PZE[7#2J*//"G7A3G.DXU(Q<)QD^3+,WP&<
M4ZU;+JSQ-"C6]C]9C3J+#UIJ*DY86O*,:>*IQYN5UJ$JE+G4H<_-%I%%%%>6
M>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'X<?M\_%WQGX,^->M?9UU+PU8^$? Z^(O!VN:;%^]\3>)%C!7
M0G?:WF!G&WRQSZ8ZUY+^QQXW^+]O^U7\';[7O'OB[Q+9?&OP-?\ B;QKX7U)
MY)-,\'ZI#&[068C#LMNS<$*RI[5^M7Q"U_\ 9X^(_P 8+/X,?$&#1K[QKX=T
M^/Q796VJR06JQP;?,219II(Q,.A\G+#/;[V?2O!_PX^"VA>)Y-?\(VWAC_A)
M94V>=8:A8W5W'$!M*0113R/$F."$4+5_6^*\(W1H8/"8?+\1"$JE;#U%3>-P
M=6/L6\52AEK<I4\.YRM/%U)5<2H5/:4(JS4,-P[BE[>IBL?/&TG.FL/7P<9P
MP^(P\E44<+BZ^-5;V-?$\M9SI8:$*5%2PU.-:$G(]MHHHJ!A114<P9HI%1MC
MLC!7Z;21][\.M $E%?SI?MQ?%GXX_#KXB:EX/^#G[89G^*>L2.N@?"WS(A!:
M-,Y$23S!\1",,,F0Y!SP":_2+_@G!X6_:<\.?!.XG_:I^)]I\2_B'K>J_P!I
M+-9W<=Y'H-G*LC+I7F1NX!3>A(//R^U=-?\ LN@J5"6:-9M6IPKT\GJ95F]'
M%K"R2?UNO4K8*&&PN&G%IX6MB*U..-_YA?:V=LJ526(4ZV&@JV"IS=&>.5:C
M"A.NOBHX2,ZD:N.=*7N8F6$A5AA9^YB'3=K_ *%T445S&H445CW7B'0+&7R+
MW7-'LY_^>-UJ=E;R_P#?N:9'_2FHRE\,7+T3?Y ;%%9=AKFBZI)+#IFL:7J,
MT(!FBL-0M+R2('H94MYI&C![%P*U*<HRB[2C*+T=I)IV>J=G;?H)--7336UT
M[K3?;L%%%%2,*_%C_@I5;Z_HWQ'\(>*+O4;*_P#"NH^%[WPSIOA:[G""3Q9J
M'FQ:9J,4);YI()7C8, ,$=>U?M/7Y8_\%,I/"=WX(T[1[+PK)XF^,-XRCX?_
M "S"*PU!B1;73S!A"K1S;652 Q]>E'M*U).I2Q"PL8J^(K2JX>C".&6M;VD\
M7B\!AN3EU<:N-PT9V4/:IM)U&C2Q#]C6HUZZG94Z>&I5JM=UFTJ3IRP^'Q=?
M#OG:4L52PN(EAX.57V346U\(_L[?LP?%'PY\8OV6]=N?!ES9>,O"M]J.J_%;
MQD\$R)J^D:B[3Z5;^>SE)EAA9 H!(  Q[?T>5^.G[$W@;]N[1)_ T_Q]\>6%
M]:6\9?6?#\4D+W<&FNJFQ@F 9I0(H]J#<.<8XK]BZY\/B:&)4YX;B&7$5+GN
M\3+(\\R-T:TTIXBG['/*5.>*]K5E+$?6<"ZF7R]KR8>K-0;-*U"MAY*GB,HI
MY/6BN6=&EGN69_3J1A[E-T\3EDG"A2I4U&A2PV)4,53ITTZL(\R0F0.I%-$B
M$[0ZEO0,,_E7YD?\%%?AG^U'XQ\-:;K'[-_QLMOA=J6D*9;VQO+V.RAU58RS
ME-\CJ,L,(  22.E?FM^PM\?_ -H"Z_:O\+_"KX\?'/5]6UM$FA_X1:VMI[K1
MM9>'Y3*^H(&@4$C<,MT]J];#4\MQ-#$N&95(8S!PY\3AJV68_#TDYM*C3PV/
MKT:>#Q]2HW>4<'5K.BOXJCK;S*U;%4L30HN&!E#%-O#4J&/CC,TJPIN*Q-6I
ME.#I5L7@\/A^9.>*Q:I8?E?,JG*FU_3'1117"=H4444 %%%% !1110 4444
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MSP5\'K#P]9:!X?\ @%H>O74FOS);7FL3VUE$JVMJDA7S25R$10<\$\U^@_\
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MM5_R9/\ %#_LYCXJ_P#IR2OZ)*_G;_X-JO\ DR?XH?\ 9S'Q5_\ 3DE?T24
M?.7[7/\ R;;\9/\ L1/$'_IOGK\RO^" '_)BJ_\ 94/''_I>*_37]KG_ )-M
M^,G_ &(GB#_TWSU^97_! #_DQ5?^RH>./_2\4 ?N%1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@A^V?\
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MO<O/;7D;Y5*VO*WTYMK]+W,;7T;<4]')*[BGU2>C:W29^(/P_P#^"GWQ.O\
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MC#$T9UL[EE49WYL/AYYW*57,Z5*7--_6Y<E7VDHJ-KI\9IFE_LG^,#X>\/\
MCC]I#7/%?PQ;4='73]#&JWTL5U#%<P_V=!,5,H9.$4Y1N.V>*\C^+>H?#CP-
M_P %?OB5)JVD#5?AKI7[)^F16&AVHW2:GI2Z:H@@A8_,S,F "W))YYQ7]#WP
MK_8*_9C^%OA+2_"=C\+/">K6^D70N[.]U328)[U)$D$D'[UB[;8"%\M<X&.0
M:_#+QC\.- ^*/_!>3XC_  OUN'R- UO]G&QTT&S5(GT^W%J HLT7:D94 ;0H
M4#@# JW6Q6+=3&9F\VSJ3PZI0IY]Q#F><XRK@_C_ +.E4S-\N$IMN2G&@[3G
M.3D](M*.%R[+X4L+D^/GAJ;Q'MJDL+PWD'#N$PV+:C"6:4,-D%*E/$8FI92J
M3Q7/5C"G!4FIN5_F[P!KNFM=Z_I7P+_9]^)OP\_X2/P_JWB*ZOKZ[NDTW4/"
ML'FR7\%N>(5,T0<JN>=PXZ"O7_VQ]=\%^)_V!?V;[OP%HESX:TB/QQ8V]YI5
M^<WL6I1:FB7TLLA&YEDFWL">W?CG^@JT_8_\&Z7\&4^#^F:OJ4$4.E7.AP>*
M]L7_  D,&EW0(EMH[D,"$96*[=XK\9_^"KGP8\-_L\?LR_!#X6^$9+FZTK2?
M&FG3?;[]@;RZFEU.(RR3,N1N=V9N_7J36>%Q.(J>RPM; 83#86A3J3RZCA,(
ML/1RFC4=-U,.\54E/$XVOBVH*I2O+#X582,J+3KR1IBJ.$O5Q5#,\XQ.*JU(
M1QKS3-<?F7]IS@FH8JG1Q#5#"4<-:?L>9/&5%B90J3<*21[?HO\ P4^UGX.?
M&KP!\ -9^%NNZU\.]+^$GAK4]2\:Z5"[6VD9L8%:ZO'2*0&.-0202.%XK])M
M!_:Q^ GQ]\%^,])^&'Q#T7Q+KL?A+5KFYT6T:<7]NGV.4,'CEAC7*-\K?-U!
M[5QWP$_94^&DEIX4^+FJ60UK5/%OPG\/:!K&EZG#%=:9+:R:= Q(BD!P2IVD
M$$<D@YQCKA^RA\#_ (0Q^//B'\.? ^C^$]<NO">LVTQT>V%K"Z-:S.Q*!B"S
M'.>G7T&*[?[;K5W]7QG#$)0A;!X+,LJQE++L32Y$K8W.L%BE6PV.PZU4'ECH
M8VM?FKOF3.'^RL'07ML%G>/]K.V(Q6"S"E]=P,Y3M*K2P&(O#'86NY/DC"M.
MKE]&$?W5..S_ !8_X)7_ !D\!_ 6\_;,^(OQ+UB'P]X4T?QB[7VIW0?R82M[
M)\K>6DC G.!E<>]?JA8_\%2_V2M2M+6_L/B!975G>+$UO<0I<21R"8@1X98"
M/F)QCJ#7YA_\$G?ACX*^,VH?MI?#[XC:#8>)O"^O>*KFWOM,U&(30,+FZF1I
M IZ2*2&1AC:1^?[ _"7_ ()^?LN_";PFOA'3OA9X5U>QBO9+N";5]*AN;F(,
MVY($D<L5BBX"*#Q^5"QTJ#^KPR?#XNHU[6..Q.,Q5+#N-U&6'='#+GIU8Z3C
M4DY1J1DXI1<'<_LK!8RV(Q/%'$.4N/[MX#*,KR+%0GLUB/K.:4ZD[[QE1M%+
M246[L_$SPG\0O#(_X+B:A\4YK^.'P;/\ ;[7/[6D#"*/31;&5KAU"LX14Y.%
M+<?=K]9[#_@JM^R!JUO<W>E?$;3]0M;:>YMY)K=;B15DM9&BE! @W+AD;A@,
MX[5^67A?PQH#_P#!>#6/!+Z38MX3/P*O],_L%H%.GK8-;M&UJ+<@IY)0E2N
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M%K$TU@&MC&[R,BG YK])/^"UG@_PQ\/O^"<7C[PUX*T33_#?A^UO-,,&D:5
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M+]J>]CU+]ESXJZC""(K_ .'&KWD8/4)<Z3),H/N X!]Q7YK_ /! #_DQ5?\
MLJ'CC_TO%?I;^U=;16?[,?Q;M(5"0VOP]UJWB4# 6.'2Y8T '8!5  K\TO\
M@@!_R8JO_94/''_I>*5[ZVM?6U[V\K];;7ZCVTNW;2[5F_-KHWN?N%1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX6QV:*#<JDI5<=F%2MGF%E2HTZD82HQPL:>)GA98%32JW_>"BBBMSF"BBB@
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M?_!M5_R9/\4/^SF/BK_Z<DK^B2@#YR_:Y_Y-M^,G_8B>(/\ TWSU^97_  0
M_P"3%5_[*AXX_P#2\5^FO[7/_)MOQD_[$3Q!_P"F^>OS*_X( ?\ )BJ_]E0\
M<?\ I>* /W"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** (#U/U/\Z*#U/U/\Z* )AT'T'\J6D'0?0?RI: "BBB@
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M(2WU?6K#39G)NY^%6]G@#'Z$GT'-?T6_\+7^%O\ T4KP!Z?\CCX=[?\ <1H
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M^RJ3_P#H^ZK]B?BS\4_AA-\,O':1_$CP"6;PSJJ<>+_#[X9K5PHVIJ#,2>P
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M_&[1S0.)(I$-^-KQN.&5AR"* /W&HHHH **** "BBB@ HHHH **** "BBB@
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M#Q/H]P\B1W^IVTOFPR%0IC=5?!.[/3'2OV.K\&?B!I^D_M2_M1_$7P3^T/\
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M]?S4:)_RL7>*O^R!6/\ Z3"@#^E>OP(_X+M_\DU^%/\ V..E_P#ISAK]]Z_
MC_@NW_R37X4_]CCI?_ISAH _9_X$?\D8^%O_ &(OAK_TUV]=%\2?^2?^,O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]U2::;3333LTU9IK=-=QIW2:U3U36J:>S3/Z"J_FHT3_ )6+O%7_ &0*Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?@M_P %.?\
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MC[]KCX5?MT?#/PM\3/BG%X@^'OQ0$RP>$[.[%W':^0=HG?RW<()2N\$@<'T
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M?PA\7/\ "K6]?TE?$5[\199&A@2S7=OL()&94>=@,>4I+LQ &<XK]4*_'?\
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M5^R/Q^_Y(Q\2_P#L3M>_]-UQ7XW?\&^7_)K_ ,7?^R]>+_\ T=)0!^^%%%%
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M]DL=0O+=M6DLL0&'RL(CY*$%23W.:_57_@NR-W[ /Q(Y(\NXTV4XY+!;I"5
M]2!^/:OS$\'?M&6EM\-/A;#XKT_P':#0_P!FNQM_AWX9\2:+#=:WJ_BE+)4M
MI;>22(M)')(5("Y)SCMSV8/^T?:M9;./MN24IX?DQ-6I6A!>T<U#"U*514L+
MR_6<15E)PHTZ;E)7:.;%0P,Z2CF$,3]7YX+V^'QF#P$J,IR4(TU7Q^!S##RJ
M8N4EAJ5!X=3K2FU&K3Y6S](/^">W[>?P]^,WP,\._!;4]>U'4/C-#X&\0SZ[
M:7EC=QR1R(ERR_:9I0RHQC=0 ^T\< <9\'_X(UHT?Q__ &L4889/$=TK#W74
M) ?U%>,?L<_\)/\ "GX_?">RUG3?"5MXC_:#^%WBGQ'XVL['2TBU#19U@G>V
MAMI!"AM4*E?EX/85[;_P1S3R_P!H;]K>,$D)XHO5R>2<:E+U-9U\13QGLL5"
M=6H\1352K5KX>KA:U>MS253$RHU<3BY*GBI)XG#3]M+VN%JT:LHTYSE"+PV'
MCA83P\/:>SI590IQJ8_!9G&C&*BOJM+%8#+<JHN.#DI86K2EAI5:6(I582K5
M%%,_HCK^9+]I_P#Y6/\ ]B/_ +(!XL_]%7]?TVU_,E^T_P#\K'_[$?\ V0#Q
M9_Z*OZYSH/Z;:_#G_@NC_P F_P#@'_L?++_T."OW&K\.?^"Z/_)O_@'_ +'R
MR_\ 0X* /TW_ &1?^3;_ (1?]B=I?_HD5ZG\4_\ DF/Q'_[$/Q?_ .H_J->6
M?LB_\FW_  B_[$[2_P#T2*]3^*?_ "3'XC_]B'XO_P#4?U&@#\%_^#:K_DR?
MXH?]G,?%7_TY)7]$E?SM_P#!M5_R9/\ %#_LYCXJ_P#IR2OZ)* /G+]KG_DV
MWXR?]B)X@_\ 3?/7YE?\$ /^3%5_[*AXX_\ 2\5^FO[7/_)MOQD_[$3Q!_Z;
MYZ_,K_@@!_R8JO\ V5#QQ_Z7B@#]PJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _FW_P""W]_JOQH^+O['_P"S
M'X;NIE,/Q=\/^-/&%C SL-1T+SK0R6US'&,FW:&, K(&0DD]^/Z*?"V@Z5X7
M\.:+X?T.QM]-TK2=-L[*RL;6-8H+>""!$5$10 .F2>K,222237\A/_!5'XI?
M'+X??\%C/A?+\&_!UUXWU*'X9:3<1:4D33Q+.+:$ATC".-X)ST)_7/V1)^W-
M_P %4 RC_AFK5D BCP%TE@"-B\X%KC.,$GN230!_2;17\V'_  W/_P %4/\
MHVS5_P#P5/\ _(M'_#<__!5#_HVS5_\ P5/_ /(M &I_P=.?\HF_BI_V']#_
M )S5^;7_  9J?\FZ_%[_ +"EOV/_ #W/3UKQ[_@N'^T1_P %!OCC^P3K_P .
M_BC\!M2\->'->\2V=O\ VFVG&%[J\#XMK3S?LZ$N2Q6/+=6QTKQG_@A+X?\
M^"F?["7P4U\:!^SCX@N]$\>HE[IS7^F&8F.4"6&9 ;>502I#(RMGNI&>0#_0
MGHK^:\?MS_\ !5#'_)MFK_\ @J?N?^O6E_X;G_X*H?\ 1MFK_P#@J?\ ^1:
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ML%23E%\Q0??MP3GZMKY!_9RU[]HG5=9\0I\:+2SM]/6*)M&:TB5 79TW9**
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MNC7ULM_9-,"8Y+*"]M99?*S\K+Y8.<#!["O[J/\ @BA\1/ WQ(_X)W_ G6/
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MI#"BBB@ HHHH **** /YK_\ @H[_ ,I/OV(_^QRL/_1L=?TH5_-?_P %'?\
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M_P#['?Q1\>Z'8_\ "5^%/A?X4GTZ=A&HO6-G%+Y4R-(HD56 !^5R1GIU./\
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MQLW/%ISRIQR"O''_ 'UGCZ]J /P_MCF"(CNHJ>JUID6T0888+AAZ-DY_6K-
M!1110 5V_P +?$">%?B+X>UZ5_*CM;F)&?D &211[9_,X&>*XBHI0?D=<[HI
M%E4#N5((].F* /Z'=*ODU/3+#4(V#1WEI!<JR\@B6-7R/SK0KXR_9.^,MKXL
M\.1>$=7NMNO:3&!$)9% FMP,(D8)R6 '09YR.#@5]FT %%%% !1110 4444
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M:_3D]#QQ@5^6!Z'Z'^5?I5^PA*X\+^(8L_(;YFQ[AN3]>0,]Q],4 ??]%%%
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M';F678C"TJ=#ZG'W54JQIRE&I&M*HZDKW_KXW \ @GTS7\DO[2?C?Q7\-_\
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MBS=>&-<\7V7AWQ?/))H_AZU:\U25([R5MZ1*&RJ _.=IQZ&ON'P5_P %?O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML03:SF](' 1@#_/_  KRCQ#^W3HT$<D&C^';F2<Y"3M)^[!Z XZ]3]/>@#]
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M,J#@LXXZSS'\8K X:$K-/!Y+D68*MFF(A3<*48X/"4</"=I5*M2I"I$^[?\
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M714^WGQOBLJ#X:> +6XBNK?P?X=AN(&#PS1Z18I)$XZ,CK &5AV(((K^>?\
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M#VU54U252?LHR<XT^9\D9-).2C>R;22;6]E?8_</]K@?\8V_&-5!/_%">(
MH)/&G3]AD]*_,K_@@!_R8JO_ &5#QQ_Z7C]:^"_VA_VI/^"M%[\#_B3:Z_\
ML_:I9:-/X6UJ+4+L6SYAM6LIA*Y(CW853TSC^GVA_P &Z-YJ]_\ \$[M!O-?
MMVM-:N/B!XODU.V<'=#>->*9D.?[K''X&MS,_>:BBB@ HHHH **** "BBB@
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MC!M/^*_@W[6?#^JV6I^3OU*%UWM:2S*N5E13EA@G'6O[U]"_Y >C?]@K3O\
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MO-(=['X]^,"21_TVDK]D/C]_R1CXE_\ 8G:]_P"FZXK\;O\ @WR_Y-?^+O\
MV7KQ?_Z.DH _>_ ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH
M3 ]!^5&!Z#\J6B@#^;/_ (*.SS?\/.OV(H0_[H>,[$A-HP,RQ9K^DO ]!^5?
MS8?\%'?^4GW[$?\ V.5A_P"C8Z_I0H _$7_@O[E?V ];*X5A\0_ Y!QT/]JK
MS7Z2_L>2/-^S'\$WE;S'_P"%?>'!N(&<#3H,#\*_-K_@O]_R8%KG_90O _\
MZ=5K](OV./\ DV'X)_\ 9/\ P[_Z;H* /4OBX2OPP\=LN%9?#&K$''0BU?FO
MP]_X(7N\O_#5[2MO;_A:DPR5&<>?=5^X7Q>_Y)?X]_[%?5O_ $E>OP[_ ."%
M?3]J[_LJD_\ Z/NJ /Z"<#T'Y5_-9H,LB?\ !Q9XM1&VI)\ ;$2+@8<?9N]?
MTJ5_-1HG_*Q=XJ_[(%8_^DPH _I6P/0?E7X&_P#!=B66+X:_"L1/L#^,=+#
M#K_Q,H1S7[YU^!'_  7;_P"2:_"G_L<=+_\ 3G#0!^SWP)&?@Q\+B0"3X%\-
MY.T#_F%V_:NC^)''@#QD1@$>'-6(.!U%G+7._ C_ )(Q\+?^Q%\-?^FNWKHO
MB3_R3_QE_P!BWJ__ *12T ?@_P#\$3I))?B-^UN96#X\9\?*!C_39?2OZ%<#
MT'Y5_//_ ,$2O^2B_M<?]CG_ .WLM?T,T ?S8>&)99?^#@G51*^\)\%[T)D#
MY1Y1X%?TG8'H/RK^:WPK_P K!.K_ /9&+[_T4:_I3H _&K_@NU++%_P3]^)
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M<4 ?F;13$?<.X924=2,%77AE([$'J*?0 4444 %%%% !1110 4444 %%%&:
M'(\D8Q'))&#U".5!I_GW'_/Q/_W\;_&N<U7Q5X8T&2.+7]?T[1I)_P#41WDT
M<3S =U$C+GVK1L=1L=2MUN].NX;ZSD($5U;N)(9,]@ZDJ3]#@]NAKHEA\73H
MT\1/#XF&'JOEI5YT*L*%1]J=:4%3J.Z:M"4MGYF$<1A9UIX>%?#SQ%-)U*$:
MU*=>FG:SJ4HR=2"=U9SBEJC2\^X_Y^)_^_C?XT>?<?\ /Q/_ -_&_P :3RI=
MN_RVVXSG*]/^^L_I48.1D<BL%-O:5[=G?^OZ\S=QMO&U]KQM?\![2S,"KS2L
MIZJSD@_4'K3!QP.@XHHH;;W#;;0*9(VU21U[#GD_ADT^N_\ A9\/M1^)OC+3
MM"LHI&LTN(I+ZY082!$8$K(Q'&X#GGIC@YS2 ^X_V*?AI+86-[X]OX#'+J*F
MVMTF1@P0#AU#C XZ%>G;K7Z#5@>&- L_#&AZ=HMC$D4-C:PP?(N [1H%9S[L
M<G\:WZ "BBB@#\WOVY=)RVD:QMQLC$&_C([8R>_^>,5^>Z_='T'\J_5#]N#3
M!)\-(=012TL.H1J<8)VL"3P<<#G//0XK\KD^XO\ NK_(4 .HHHH **** "F,
M'<K#$"9IF$<*KU:1CA1QD\GC@&GDX!/IS7T-^S;\)+OXE>,K;4;N!_\ A'M'
MG2:>4J=K31MN5>@!&1CKZ\CB@#[O_9-^&'_"$>"5UF\A:+5M>19;B-UPZ)PR
MDD@')&,>U?6=06MO%:6T%K"JI%;Q1PQJHP L:A!@#CH*GH **** "BBB@#^?
MC_@MA_P1R^'?_!3*Z^%?COX@_%VV^$MA\'[>\C.K7,XLT:*[E>9V^UN!%"RE
MOE9G5@RAEY K^>KXG_\ !MI^Q5\*/"6B?%7XM_MYII7A#5[LV/AGQG?:TUU'
M)>1\>58:A)*8E96Z>5,2".!7V#_P= ?M!_'SQK\:OV7?V"O@-XOU'P@OQGU.
M"+Q=J&GWLUC,\-Q=^4-LL+QL4CA<%EWC>5VC&=P\<_X+7?\ !/;XQ?#C_@F/
M^P-^RU\/K?QG\5-5T[QWI4OCG6],-Q>:C +Y+*2^N9IT\R4PK'>MM9F.7C8G
M( KS<QRWA'"U\//->*O$C#5,7&&;YUAL@X@CD7#V6X2A^YPF'CB<3[2A#-Z]
M54ZU!NC.G%2J)J-35^QE6<\;U*=7#Y3E? $L+0G_ &9E$<WX8PN=\18S$U+5
M\3C:D?91K5<LI4_:TW3G6IU'*,'&JZ<N6/ _LA?\$)OV!/B/^TA\,?$/PC_;
M^M/C%XX^&?BC2/&<7AJ[UA=2N;N/1[N*[CABS--* SPK@*!G X/2O[\[*W^R
M6=I:@Y%M;06X/KY,21Y_';FO\QO]H+]A?Q'_ ,$8?VJ_^"?WQO\ @MXP\5VF
MD?%V_P#"%I\1M*U/4)A=17NHS6AO[22-GSY9\V1=A7KC.1G/^F7X1UF+Q%X5
M\-Z_"2T6LZ%I6IH3G.+VQ@N"#GN#(0?4CCBNO!T<CJX6.;Y+CN.\1_:-2<,;
MA/$'-J6<YU@Z^&;C3E'&4(0HRP^+I35:GR*7NJ-ZDM%'FS+'9[6Q;P.=+A*L
ML#3@\'CN#\AAP_@,1#$)2K4L1@DY55B<+5A[*4JL]5?DC&)T5%%%;G %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@ '(
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M<:[H6A:[?SR7+SZ9;M+##"DSEMT:(BE/G8X'4\UTRQW">98?'2R;AG.^'ZN
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MY(Q\2_\ L3M>_P#3=<5^-W_!OE_R:_\ %W_LO7B__P!'24 ?OA1110 4444
M%%%% !1110!_-?\ \%'?^4GW[$?_ &.5A_Z-CK^E"OYK_P#@H[_RD^_8C_['
M*P_]&QU_2A0!^(O_  7^_P"3 M<_[*%X'_\ 3JM?I%^QQ_R;#\$_^R?^'?\
MTW05^;O_  7^_P"3 M<_[*%X'_\ 3JM?I%^QQ_R;#\$_^R?^'?\ TW04 >I?
M%[_DE_CW_L5]6_\ 25Z_#O\ X(5]/VKO^RJ3_P#H^ZK]Q/B]_P DO\>_]BOJ
MW_I*]?AW_P $*^G[5W_95)__ $?=4 ?T%5_-1HG_ "L7>*O^R!6/_I,*_I7K
M^:C1/^5B[Q5_V0*Q_P#284 ?TKU^!'_!=O\ Y)K\*?\ L<=+_P#3G#7[[U^!
M'_!=O_DFOPI_[''2_P#TYPT ?L_\"/\ DC'PM_[$7PU_Z:[>NB^)/_)/_&7_
M &+>K_\ I%+7._ C_DC'PM_[$7PU_P"FNWKHOB3_ ,D_\9?]BWJ__I%+0!^#
MG_!$K_DHO[7'_8Y_^WLM?T,U_/-_P1*_Y*+^UQ_V.?\ [>RU_0S0!_-9X5_Y
M6"=7_P"R,7W_ **-?TIU_-9X5_Y6"=7_ .R,7W_HHU_2G0!^,W_!=W_E']\1
MO^OO3/\ TJCK[C_8-_Y,U_9M_P"R2^$O_3>E?#G_  7=_P"4?WQ&_P"OO3/_
M $JCK[C_ &#?^3-?V;?^R2^$O_3>E 'T?XU_Y$_Q1_V -6_](9Z_G[_X(T?\
ME\_:N_[&&X_]+WK^@3QK_P B?XH_[ &K?^D,]?S]_P#!&C_DOG[5W_8PW'_I
M>] ']%=?S)?M/_\ *Q_^Q'_V0#Q9_P"BK^OZ;:_F2_:?_P"5C_\ 8C_[(!XL
M_P#15_0!_3;7X<_\%T?^3?\ P#_V/EE_Z'!7[C5^'/\ P71_Y-_\ _\ 8^67
M_H<% 'Z;_LB_\FW_  B_[$[2_P#T2*]3^*?_ "3'XC_]B'XO_P#4?U&O+/V1
M?^3;_A%_V)VE_P#HD5ZG\4_^28_$?_L0_%__ *C^HT ?@O\ \&U7_)D_Q0_[
M.8^*O_IR2OZ)*_G;_P"#:K_DR?XH?]G,?%7_ -.25_1)0!\Y?M<_\FV_&3_L
M1/$'_IOGK\RO^" '_)BJ_P#94/''_I>*_37]KG_DVWXR?]B)X@_]-\]?F5_P
M0 _Y,57_ +*AXX_]+Q0!^X5%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z
M#^5+0 54O[*#4;2>SN8UE@N8I(94< JT<JE'!!R.5/'H<'M5NB@#\:/VD/@Q
M>?#7Q1/J^F6<K^&-5E>6*6.,E()78%_-*@A ._ ''/'-?-H((!'(/0U_0!XO
M\(Z/XTT2\T36K2.ZM+N)T8.@+(S*562-B"59?;&?K@C\;?C9\%-<^$NNSE()
M[SPS=2N]E>QH\@@#'*0MM'R@ X.>F,= < 'B5%(&##(((]N?Y4M !1110 44
M44 %%%% !0!N=0>@R<>I&,?AR>**5?OK]&_I0!_(5_P<A_%OXE_#KXQ_!.Q\
M#>,M<\+6LWAVXO)H='O9+5)[B,Q['F5.' WME3E>>AP#7[P?\$D->U_QI^P;
MX \1>*M3N=:UQK6[N)M1NW,MQ,;>RFE0.[$D_.@P,_AVK^=K_@YW_P"2W? [
M_L5+K^<-?T(?\$:YK,?\$]?A^LNI:5 _]G:C^[N-1M890?[/G(S&[A@>1CCK
M79/'8^OA:6!J8K%UL'AWS4<)*K6J8>@[OWJ5#F=.F[MW<(QNV[[N_+'"8*CB
M*F,AAL)1Q5?2KBE2I4Z]9:+EJ5K*=1/EC[LI/9)))'X5^(?^"RO[2%A^WE9_
M ."STU/!A^+-KX.G,CN+E["XOQ:^8@52@ 7!)+<X. .*_L"EB$0MBIR)K"PN
M3W :XMHY6Q]68U_G#^-F3_A[+9L)82G_  T)I7[T2H8<?VV/F\W.S;CG=G%?
MZ/5U<6&VP_XF^B?\@?2?^8M9_P#/C#_TTZ^U;YAFF-S7ZLL4J4OJ=)T*/U?"
M4:'+3?+I4^KTH.K*\5[]7FGO[UG8Y\#EN ROZP\*G2^N5?;5O:XNO6YZEFKP
M6)K5/9QL_@I*$/[MR"BH_/LSQ'J6E3OVBM]1M9IF_P!R-'+-^ ]NM6;*UO-4
MO+?3=,MY;R_NY%B@@B1W)=B  Q0'9C.<MBO-::W37JFOS2/14HR^&49+O&2D
MOOBWJ2:?IM_KFHVNC:7!)=7U]*L,442,[ N=H8A>@!QG-?L=^SI\%[?X6^&(
MYKV)&\0:I&DU_)@'R]P5@BDY8'J&&1Z>M>??LU?LXV_@6UA\5^*($N/$EU&L
MD,<J!A8HPW; K*?FYZY!'6OM(#   P!P!["D,**** "BBB@#YL_:GTK^UOA=
MJ,6S?Y#B?&,XV*>>?\]#VK\983\K#^Z[I]-K8Q_B.Q]J_>/XN:8NI_#_ ,31
M, 3'I5U*H/K'$S<?KGUX]*_!N(G=<@YRMW<KSU^65ASZ>P],4 34444 %%(2
M%&2< >O'\Z['P%X \3?$K6X-&\/64SQF11=W9C=8[>/(W,6QM/!)^]]<T -\
M!> ]<^)7B*T\/Z)!*Z22H+RZ5"4@A)&Y@PP,[2?XN/U'[7_"OX<:3\,_"UCH
M6FPH)4B0WEP%P]S/CYG<]2020">?PQ7,?!3X+:)\)]"BMX(XY]6G16O+XH/,
M9F'S(#UP#^'8<=?<J "BBB@ HHHH **** /X^?\ @YK_ &+/CYKWB#X _MY_
MLW:)=:YXH_9RU*'4?$.BZ;;O=7VI6-M="Y_=V\(,CJ84V.0"?ESSDBO(OA+_
M ,'8G[/G_"K_  WH7[1OP-\3Z3\3O#.D66G7NC7.@SRH^K:?;1V[S+'=)^[:
M22)<E .><YS7[W?\%!O^"HGPK_8N^-GP!_9Y^(?@U/%5Q^T9=_V5IIG*O:P"
M:\:Q*SV\F8Y5)!)#(U?''[5/AK_@CWX%_:9^#OPE^-'P/\(R?%WX\SZ?/X;2
M+2[&%)KK5&C>,.JQ#)\R1>B__7Z,-@^,,OA/"4.#N /$3ASB"&)S6AE7$^>R
MRO'9//!**Q48U,#*KS87$2I*M]3S&%*K*<4\+"2<&<^+K\&9HH5,SXA\0."<
MYR6KA\MJ9MP;E?U^.;TL9-/"QKX?&TO9WPRJNG+'8*52G"$G#$2I\LK_ ,X^
MH_%']IO_ (.(/^"BGP-UGPK\*=<^&_[-?P-\2Z3XC-UJ>G7EE8:A::5<QS;S
M/.BHSNL?RJK.!Z !:_T7M TJ#0M#T?1;9%2WTG2[#3844841V5K%;K@?2/-?
M@G^UU_P4#_9]_P""1GQ8_9Y_9M\"_ W1[6V^-_B;2?#.GW>BVUMI[:>=2N5M
M5EF>!(6F"$Y(;.< \DBOWXL;G[996=V!M%U:V]R!Z">))0/PW8KG=#B+$.GQ
M#Q%2X=RZ><TE'+>'^&,0J^69#E^!?L:>#BJLWC_:U&_:3K8ZG2J5M)0BXJYU
M.MD5!/(\@I9Y6PV4S?UK.N((/^T<]QN*2G5QU2I"^&M%15-4,+*=*AK'G;E9
M?GM_P4+_ ."G?[,__!,[P3X9\=_M(ZGK>GZ1XNU&;2]#CT/3GU*[N[N!4:1!
M!'E_E5P>%-=1_P $_O\ @H9\ ?\ @I)\&KKXX_L[76OW/@VRUV?P[=?\)'I4
MVCZA#J=NK/+$UI.%D"A5SN*C.1Q7\O7_  >H(K?LR_LXN5!9/'^H[6(R1F*V
M! /49SSCK7TI_P &<G_*-?QKQ_S6C6/_ $F>@D_J_P#%'B+3?"/AS7?%.LRF
M#2/#NDW^M:G,!DQ6.FVTEW=2 =RD,3MCOBOY^;[_ (.A?^"3>FZIJ^CWWQ?U
M>VOM$U2]TB]BET54 N["X>VN/+9KM?,C$L;J'4;201G(('[F?'?2)_$'P5^*
M^AVP9KC5_A[XNTZ *"S&:[T.]@CV@<EM[C&.<].:_C?_ ."0G_!%G_@F3^TE
M\,/B1X?_ &C?@HGC7]H3PO\ $GQ9>^+=0U#5KBVNETZ]U65[)8[9'+P0J9,[
M&B",7!4CG< ?J;_Q%'_\$D?^BSZE_P""B/\ ^3*5?^#H_P#X)(%@#\:-24'J
MW]D1G &.WVSGKTS7;?\ $,Q_P1U_Z->LO_![>_\ QNC_ (AF/^".O_1KUE_X
M/;W_ .-T ?.GPR_X.B?V,_C=^U5X/_9W^$FE>+?%NF>+KZ+3[+Q5;:+<[&GE
MD5 510T+* VYMDKD#GZ_TZV5W%?V=K>PB18;N"*XB$J&.4),@=1(AR4<!@&7
M)P<BORE_9B_X(C_\$WOV0/B!9_%'X%?L^Z)X8\<:>0UEK=S,=4N+9AR##]KB
M;RR#R-I&#R*_6.@#^:[_ (.7/V\?CE^Q'^R%8:Y\!M9?POXM\1ZU;:<?$<)<
M3V$=Q((0T01D9BFXL '3)_B'4?C7\,O^#D;]I']DW_@GO\$?B3\7?!VG_%SQ
MGXZCG&GZYJMTT=SJ!4<F?]\C$ KD;F<J. <=?L+_ (/%F _8T\%J2H)\6:<0
M"PW$?:5Y"]3S7\N_Q=\-:EXG_P""5'[*$-A\+)/B.(([KS=1CF$?]@<OC\3U
M[8QUQ0!^G7B#_@]/^/5]H-_:Z+^SAX4TW6YH0ME?/J$ABMI<\NP%Q)E>G_+-
MC["G:'_P>H?'BTT33[76/V;_  G?ZQ!!LOKV._D$=U,/^6BAKE, _P"XGTK^
M3O4OAW>^']&N-;UCX'36^EV$0EO;MKH$1H3]XD]?\]*L:1\-M0UW3['6-*^!
M4UWIFHQB:SG%TJB:,]#Q^GKGU% ']LOBS_@Y4^.O[4W_  3=_:0^,OPX\%67
MPD^)/PJO-/M([VPGED4+>[/+DCD664=) Y"LK8X)!''ZV_\ !MC^WU^T;^W)
M^S#JGB'X_7$.N7^B:A/:6GB7>S75_)!.T#^:K%F16\LN$);;G;N;&:_@Y_9C
MTR]T?_@EW_P43L;_ $J;0Y(?$.AJ-+N1(&M=KPKY4;R "81 >6&0L&"YS@BO
M[$/^#/<D_L4^(AN)QXCU+Y<C@?;I^W7K0!_8?7Y._M]_\%!_%W[(WC;P1X8\
M-^#=/\36WB38VH7%Y(R/:1E\.8@K+N*ISCGFOUBK^9W_ (+2+YGQC^%47 \T
MPQX(SN+.HQ]3]#F@#]^/V??BU%\;?A9X;^(<5J+(ZU;B26U'W89E53(BGNH9
ML ]\5[57R5^Q%I8TC]G/P':!-@%BLF NT?O$C.> !^7I7UK0 445EZUK.G>'
M]+O=9U>ZALM.T^WDN;JYG<1QQQQJ6.68@9., =2>!0!;N[RUL+:6\OKF"TM8
M$,DUQ<RI!!$B\EI)9&5$ ]68"OCSXC_MR?!KX?ZC_8T,FL>+=39S$B>%K(ZK
M;^;T >XMV= ,]<9-?-U_X@^+'[;?C/4_#_@[4;_P1\"=$O)++5]:C\Y)/$S0
MN5DM;:1 .)0C;74A0"3NK[D^%7[-_P *OA#IL-EX7\.6K3HB^=?ZBJZA>32]
M7D\ZX5V0LV2-O(_O=Z /BCPE_P %%V\2_'CPE\)9_!ESI%EXID*PW=_%)!>Q
MJ2 I,+X(SD9^7'4=1S^J%?@Q\>+2VB_X*3?")(+:WMU%RC;8(DC!^9.H55'.
M>O7@5^\] !7P]X#_ &QM)\5?M,>-_P!GB\TT6NH>&WVV%['D_:L'DR9.!_\
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MQ2V"WIN'B-L;EH5E"G .X*, $C&:_NM_;RT;3_$/[(GQXT75?&C_  [T_4O
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M&4F(*K!5RW8FO]3#X._LU^&/AM/+K%]#!J>O2OE;AD#PVXP"/)1T&&!SSC'
M_#-^&/[#_P"RK\']4TGQ!X ^"G@?0/$NB<Z?XCL](ACUBW? RZ72X*L3SD**
M^KJZ_P"V>*<[D\3Q77PM?&4OW.%GA:]>O%86RG:;K4*#A)U7-J$%**C9\S;9
MQSRSAG*E&APOAL9A<)47M,3#&4\-3E+%7<>:'U64HRC[)03E.TW)/HDQ
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M 22)\H.)44@C 8A<[N*_OPT+_D!Z-_V"M._])(:_@U\<_P#!"S_@G+_P3_\
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MZ51U]Q_L&_\ )FO[-O\ V27PE_Z;TH ^C_&O_(G^*/\ L :M_P"D,]?S]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"NA]<=%[=/T]Z_I1H **** /B__@H9X(^%GQ&_8W^.W@OXU^+AX#^%^O\
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MPJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@" ]3]3_.B@]3]3_.B@"8=!]!_*EI!T'T'\J6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _AB_X/93_Q9#]D<=_^
M$]\4?^FN.OL__@SOD1_^"9_B558,T?Q@UQ9 .J,1<, ?0D'-?T$?M=_L#?LH
M_MV:)X;\.?M3?"70OBOHWA*_DU+P_8ZX)O+TZ\F54EFA,+HV750&!)!'%=M^
MS#^R5\ /V-_A\WPM_9S^'FD?#7P*]^^IMH&C*ZVIO9 5><[V9B[!B,D]* /I
M"BBB@ HHHH _FO\ C9_RF;^"_P#UT/\ ):_I0K^:_P"-G_*9KX+G!P)#D@$@
M<+W Q7]*% !1110!\2?\%&OC9'^SK^Q;\>_C1+X3TGQPG@+P;/K1\*:[$LVE
M:UY=S!']DO8G#(\1\S<592/E%=/^PC\5T^.G['W[/?Q>C\-Z9X/3X@_#G2?$
M:>&-&B6'2]$6\DN +"QB0*J01>7E54 #<<#%</\ \%,/@?XI_:1_8=_:$^"?
M@J6R@\3_ ! \$W&BZ1+J-PEI9+=27-O(OVBXE(CA0B,C>Q !Q75_\$__ (2>
M(O@-^QA^SC\'/%LEI-XE^'?PTT?PUK,MA.ES9O>V<ER9#;SQDQRQXD7#J2#V
MH ^P:*** "OYI?\ @LS_ ,EP^#O_ %]6O_H:U_2U7\TO_!9D_P#%\/@][75K
MGV^=: /W3_96_P"2%^ _^P1;_P#HJ.OH>OGC]E;_ )(7X#_[!%O_ .BHZ^AZ
M "BBB@ HHHH **** /)/CU_R1?XG_P#8E:]_Z0RUX!_P3S_Y-6\ ?]=M:_\
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M,<33DXUX1I3HJ$UO'V-2I6G2<;VE3E5JRBTTZDF?2'C0$^$/% '7^P-6Q_X
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M/&5L*_8XG'1JYC",:V(KU_:1Q4<++DH3IPI584ZL91/Z<:_#G_@NC_R;_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>DZU:/8ZC:Z5;K<6T@.^)O*3Y3D#D8(/TKW.D4!0%48    '8# I: "BBB@
MHHHH **** /D+]N#Q#\3-!_9^\7Q_"KPO<^+/$^LVLNC#3;5&>9;.]A>*XF
M56("JV"<=#7G?_!.3_A8&E?L_P"C>$OB#X/OO"FJ:%+<,B7BLIN1=R^;*%#
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MP^=X.II"CA\ZI8:A4V5:=6C3H8FO/D<:U.E.4^6#G1:@Y250Z"BBB@04444
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M/!YW[7!5HR5*O&HH8R=*JE>2K5LKC7PG+'K6A*-%]6F^4_9[XO?\DO\ 'O\
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M/VA/A1H/PY^ NAZD\^G_  VL]/L-,\1W9MIV\MII(XXF='VC<@3G/0U]H_\
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M>N_6VNOJ=BV5MNA^X5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #X56:VWA[PW8$W$_EK')J&I-!MNKV4*.7F8%B3SDFOL.H;C_CWG_P"N,O\
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M[X4>--(_X)__ !Y_:+^)*P:+??'OXP>$?%5EX9@*M)X=TZ74HR([R6,!9I
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M2Z,?$26L7A2V4,?)AAFS]G,)&T$!0N.M>*_MU3VOAS]MC_@G++JTH2TT;0]
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MO&GQ.O@GPO7]FK3M>N;T9 ETTV:S*PY_C4_PD_CQ7E_CSXN?'3Q/XE_:&1_
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M/VRO&&EZZ;O48M1@MO&,MM:VMS-=2*T44&X>6$8C':JWAQ[/0_\ @LS(?C)
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MG?LDW_@J*9]=?]FKQ3");<%KNQ@:"Z$EW;JOS>=%G<H4CD?G7]ET<JDJ=?\
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MAXX_]+Q73>^NFO9<J^26B7ETV.;;373N^9_.75^?7<_<*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_-+_ (*]_P#*/;]HG_L4+G_T7+7Z6U^:7_!7O_E'M^T3_P!BA<_^BY:
M/\57Q;_R-'B'_L,ZC_Z52U_IN?\ !G!_R8!\1_\ LI[?^B;VO\R/Q;_R-'B'
M_L,ZC_Z52U_IN?\ !G!_R8!\1_\ LI[?^B;V@#^ONBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@" ]3]3_ #HH/4_4_P Z* )AT'T'\J6D'0?0?RI: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#2J>OZ3* /X_\ _@O)K/Q.^&?[2WPN^+_B/0?%WB+X<>&9(!X$LO#DFHF
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M:WTP0/<S8:/<[EF/KS@?CI\;/V$OVJ_ NE^&E^)'[0OP>\+>!_AC\0KKX@>
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MJ&X_X]Y_^N,O_H#5-4-Q_P >\_\ UQE_] :@#^;G_@E7_P GV?ME?]C]K/\
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MC]DWXQW_ ,=?@O\ M#>/]"^#&A?"GX27_A/7D\$ZM8P+:ZSKQBTZXW+J-O\
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MHH **** "BBB@ HKE=1\;>%])U<:'J6LV-CJ;6C7RVUU<0P,;9!EI1YLB9
MSP#7P=\?/^"F'P!^#]CJUIH.LP^._&.EN\;^&=*+O*73(8;X\EL,"/D[]^]
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M#Y1T)[?_ *NU?L-7XZ_\$5'9_P!ER^9N2?%E]G\L?_7^M?L50 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF_L"T:\M"+M-#U6. (LS,V(GBD^\<@^E?TF?\%=/V[?V<OV9].\*?#WXF?!
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MY2J,VJ57#592<H1PV$359+D<9XB?-'WWI_5I^UJBQ?LT_&"-!A(_ .O(H P
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MT ?N!XN\<^$/ 6F/K/C+Q#IGAS3(P2]YJ=PMO",>YR3^ K\KOV@/^"M?PF\
MZC>^#?AK8W7C?Q/<0O%I&JV!\_1VNCD(<K$0X#8QE\'TK\:/$$_[0W[0&N6&
MH?$SQ?XF\3^!O%SOG0?#4LUXND22D[(Y(K=SY:(QVGY<C!/85]T_L_\ _!,O
MQ9J6F16'B/3=/TCP;-,MUIVONP7Q;!$Y#(&CD;S0Z@\\C!QF@#\R/VB/VD/V
MA/C5\1-,UKQUJNL>%=?N<:9H&GZ))/:+/:S$+%#Y=N &R"%/&.<&OLKX!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '&?$;_D0/&O_ &*VN_\ IMN:_FR^&/PE\0?%;]F3X&Q>'O'$7@%M
M"^/_ (LO+S5Y=C@1KJ$COB)^),!<XP>1^%?TF_$;_D0/&O\ V*VN_P#IMN:_
MF^^'OPH\4?%']BGP"O@CXB6?@#Q1H?QU\47.G"\E6)-98ZE+YUJJD@R%DX
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MQE7*\?#ZT^;V=25+VF'O4EB<-*3Y3&I@L,[4_P"P</BJ>%4O99;F>>4LOQF
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MU*^,Q="A4HX3"PA2S.G5A*Q_HPVC2M:VS3?ZYK>$R]_WIC4R<]_FSS7XY_\
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M6'XEUI/#GA[6M>D@DN4T?3+S47MX03+.MI \QBC !)=]FU>#R>E?RK_LG?\
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M\6?$_P"&GA*W\.>)9)'2^2*.SMS*+2<,)8MT6060X'.170_&7Q=X;N/^"?\
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M4W5RSA]9+P/BL4[N<\'F&8NMQ%Q3FU.\E_;N/KQIXBC.H_9\TDXS?"#]C/\
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M^%?P?\56-[J4.LB^O+IKNWG=&>!IGD& PQ\BCOGU^1?AM\&-<^+GQE_:*O\
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MEIEI/?ZA=0V=G;1M+<7-PZQPQ1J,L[NQ   &: +=1RRQ0H9)I(XHUY9Y76-
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M]8O@5_P3/U&">W\0^))X_ =C=QJNK^!(8%NHKM6 \W=/M(0MD@X;//2OU_\
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MZ* )AT'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN+:YMUU/5+16U&_>4,JRV[,!O8[L@KG).:]W_8G^)FC_ ![_ &K[GXU:S"?
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MLY_C%\'KSX4'X*WNB0,_B/2[?PK#NMRG]FB\N)TL>02 GG=0,=:_4B;X;_\
M!&R265W\??LVB0R7/(\8^'<Q_:&9IT0B\X5RQSM.&'KFK(_X-\_^"6@N!=K^
MS^JWN,?;5U^^6](_NFZ"B?:<GC?BK7_#@'_@F%_T0V[_ /"JU;_XJLL?D&59
MG*C+&4*S>'IQI4OJV.Q^!Y:<'%PBU@<3AU/V;A%TW-2=-J\'%MWK#9GC\)S^
MPQ#BJLG.HIPIU>:<K\TOWL9VE-.2G):S3]YNQ\9?\%6/C9^PM\/_ /@FWXY^
M$GP.^-GP7LM+AN]/N-.\+^&O%&E7CSRM=HTKQV]C.[;SRS%ATY..M>W_ +/%
MY_P2Y^)_[+W[-VK_ !;^(W[/6H>*K+X4>'].NY-7\7^'TU-&%F@NK2\B>[6>
M,H^08YD7V!')]8G_ .#?C_@ES=(8KOX!M=PG&8;KQ'J-Q"<<C,4P=#^5/C_X
M-_?^"7T2+%%\";B*)!B.*+Q/JD<4:]ECC0A$4=E4 #L*TKY+EN(P-#+:M"H\
M)AHPC0A3Q6+HU:<:>D;8JC7ABFVKJ3E6;J)M5')-IQ#'XRGB*F*A7DL16;E5
MJ.,7[1R:<N:#3@U=)I<MHM)JS2.F\(ZS_P $K?@LOB#Q=\+OBM^SQX<\0VWA
MC5K2TNM-\:^'XY8(I;64;(46\Y+O@;44LQ/0YK\=/^":WC_]@SQ]^T!^T5J_
MQI^*'P4UR"#7;ZYT)O%?B'3+:S97O7>22U:]N((Y^#D&-GSV%?K.?^" '_!,
M%@0?@9=D,,$'Q5JI!'H1NP1['(/<5!#_ ,&^O_!+6V+-:_L_BU=_]9):^(+^
MW>7G/[QH@A?_ (%FGA\GP&&P?U"C'%+"^TC44)YAF%6HG%P:C'$5L34Q$:*Y
M$OJ\:JH<MXNFXN2<U,;B:M?ZS.I>O;^+&%.$K_S+DBDJEVW[1+GN[\U]3ZW\
M'_M0_P#!.WX?VRVG@OXX?L]>&[90%$6E^,/#ULH X ^6ZSU]Z_G]_:K_ &BO
MV9_%G_!P%^QWXED^,WPNU;X=V/P+\1:7KWB*+Q=HMQX;L[N[2[,%E?ZK'=M8
MP/,'C!269<;L.5PV/U3_ .' /_!,+_HAEW_X56K?_%56;_@WT_X):/<)>2?L
M_K)?1C;%?R>(+][Z%/[D5VP,\:_[*N!751P>$PT:L<-AJ.'5=\U;ZO3C0E5D
MX\O/.5)0E*IRZ>T;YU;21%?%8G$U?;8G$5\357*O:XBK.M4M'X5SU92DTK62
M;LEI8NZAX2_X)"W=]J=Q<?%#]G8S7]W=SWH_X37P\X>:Y=FN 66^*,&9CRIV
MGMGK7Y]_\%1_BS^PG\-/V5?A]\,_@5\8O@OIGA^'QU;ZF^C^%_%&DW@+&XB=
M[J:WL+B1T8ON)>4+]",FOT _X< _\$PO^B&W?N?^$JU;)^IW<FH)_P#@WV_X
M);W05;OX!&[1#E8[OQ%J%S&I]0DP=5/N #^0K@P>0Y;@,2L9AXXR6(C3J4HS
MQ6:YICXPA6Y745.ECL9B*5-SY5>4(*=DDI);[ULQQF(HNA5J0]BY0E*%.A0H
M\\J:M!S=&G"4^6\FE)M)N^^HSP)\4?\ @G)\;OV:O@]I7Q:^-/P%U34M*\)Z
M?;VE[J7B[0(]7TZ1($$D:&6Z2Z@(X^67;Z@<FNJ\,^+?^"8WP/\  OQ*O/AY
M\:?V?[;Q%?>!/%4$FM#QEX=EU5DET2]C6*!S>O*[-(4"Q0$RR-A5&2:YQ/\
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M7[-7PZTCX4_!KPM9^#O NA*5TW1++<88,@!F+-\S.^!N8\DC)KU#A/9:***
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MK?\ )K5Y_P!C9?\ \A7[$4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M38$<TLT+JB,S<*"3R>U>E5X?^T1)91?"OQ*^H12/:"RF\Z2($M;IY;9G^49
MCZD\?44<L9>[.$JD):2IP:C.:?V8.5DIO[%VES6U6XTI-I0LIMVBVI-)].;D
M][E_F<;R4;M)NQ^/_P"R5X*\>:_\6?$6M:OIF@W_ (3\&Z+XK^P0_P!HQRS^
M&?M-M<&);*$,QWR \A>G.2 N:^1O^">D.DW^B_ML6VKWMQ::?<>*?%(>6VW"
M5T%W<$\IR"1QD$98#!KZ@_8"U?X2WWQ4^+$'A'XAW$FO1:)XE%SH%U<R.NLG
M[+<;_+CD;:&MSG SGCY03@5\U_\ !./3M9U;0_VWM-\/:2=5UVZ\2^*DTW3P
M Q:Y6ZN"B@8/._ .!DY QC@77P]3 5)3EAL_RV<H4ZU/_6FO%8J*IQC"&)CB
M88K&1> BX<[FZD.5QJ4ZL%R2F]%2FI4\/4I</T)<R4H<(T<3'#)5))N<\/F&
M%PBCF=I.3Y(5*55NG6<W.4H+PO\ :3T+X51^%FU+X>>*?$>F7-C\/]1M-3\#
M:H+J*SUJ;8^_5(UN#MF)Y;<H/K[5^_G_  2G_P"3'/@P<8SI5V=O]W_3)>/P
MK^?3XS?#']I9_AIXC^)'QW\(IH]KX;\,:EH6@7EK:BTCBL<.L<5RJ1H)9-N,
MNVXGW)K^@K_@E.0?V&_@NPZ-I5VWYWDW]*PHXKZY357ZYA\<HN5)5L)F<LWP
MRY7=PH8N45)4^:3FJ$IUG1Y^557#EC'7&82."KNA&MB*Z<85%4Q>%P^%Q+YX
MKW:RPT:=.O.-O>Q/L:$ZDG:=.\>:7Z+4445H<H5^&/\ P5&_X\O%)PV/[,QG
M:V,^6>^,5^YU?S)_\%6/&_Q7N/B[XA\,Z;H\UOX%M=.3[5J;JWEW V88*PP!
MTX.>AP<T ?<G_!%;_DUJ\_[&R_\ Y"OV(K\=O^"*RA?V7]0"D%!XLO<>N=H.
M?QS_ %R<U^Q- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)W[
M9'[)'P\_;*^#FL_"3X@VQ%IJ)BDL]3ADFBN].EB?>7@D@DC;Y_ND$GU'?/SE
M\+?^"3_['W@WP#H?@O6_A;IWB*;1;*"Q.JZA=WTES=K;A0LLC+<H-[$;CD'I
MUK]/J*XJN!C6K.I.OB_92@E+!QQ5:&$=2+O'$*C"<5#$6]R56'+*<%&,^915
MO3PV<9C@Z$:&%Q57#*%252%2A.5*LN=)2INK!QE*E>*E&E)N$)N4X)2E)O\
M!7_@O/X0T#P#_P $IOB5X/\ "MA%I7AW0K.SL-+TZ'<8K6UAM[ORXD+LS$+D
M\L2>>M?X_5Y_Q^7?_7S/_P"C6K_8K_X.&?\ E&;\8O\ MW_]$75?XZEY_P ?
MEW_U\S_^C6KLBE%**VBDE=MZ)66KNWZMMOJ>=*<IRE.<G*<Y.4I2;<I2D[RD
MV]6VVVV]V?ZSO_!JC_RBC^'G_8T:W_Z*LZ_I2K^:W_@U1_Y11_#S_L:-;_\
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MA.%4<DGL!7\Y_B_3O'7B#XPWWQ1U[4;+5_#ND_%?3-+L/AY>7"BYEB:]5!J
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MX:?"WQ'\4/B3:?"71VCTSQ#=W]SIT$E_\D<?V>9H \F_'#;0>>H..IK]KO\
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MK'^V7^R*_P"QKX]AC^/WPSB-S#)%;+;ZU;S2RS>61Y:1( X))'89)&*^J_\
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M%#K=[J,OC=GDFM+ARR6ADE$NU%/"[2,?+QS7P1^WO\%_VW?$/[1'PZOO@?\
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M[B?\/9?@!_ST?_O[1_P]E^ '_/1_^_M?B'_PR_\ #3_H*'_R)_\ $4?\,O\
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M_P#O[7XA_P##+_PT_P"@H?\ R)_\11_PR_\ #3_H*'_R)_\ $4 ?MY_P]E^
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M&883O^;GGDJ /\]3BO(?@=\.?#7Q'UB^L/$$@LX;:U$\;@$9?&0. >#Q^.:
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MA/O/_ FOYF3=Z:AV2;U<=08IOS^X._7]:?%<:=._EQ;B^,@%'4>W+ #KZ9H
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MJ.F#&FZ>/2QM!^4$=7J "BBB@ HHHH **** "BBB@ HHHH ***^;OC%^U?\
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MI+<9ZU\(_MD^./&'Q!^(\_[/>E^#4L=#7QUJUX^N:;9&+7[16FD)>[N5CWB
M \;CC'>MJ6*CAE.-7%8*A3G%.6'Q.=3RC$XV<;1IPP*I4Y_6:E&4N:M0FXTJ
ML7&%UH8SPV&Q,H.MAJE>LI-8;$?ZKX3B+#X5NTIU,5+%4YSP"FHJ-*OAYT:T
M9MU>9^RL>U?\$E_&'QJ^)FF_M9_"3X$62Z-I&I_$W4#J/Q,=08+%II9EDMX)
M<?)(Z$J&C()!QV(/._$OPKK5CK7Q=^!?Q*U._P#&OQ4\/R22^#[BZ::4M&^6
MGDMWE).WJPV9%?;W_!O-X2M?!'PN_:*\.09DET[XLW$=Q=.,RW,FV?,DK]7?
MMD\_K7JG_!4KX1ZQX%\6^"OVD/AUI5G;WMI/_9?B^_> %9+>]D\DRS. 22L;
M%LDK@UCMH:?UW_'J>=?\$<?V@+_3+[Q)\ /%NIQ6-KH^YM&M+N0*TFK;U6X@
MB+D'>?F&%&#\N:_5G]NP9_9M\?\ _8*N.Y_YY^U?RRP^)K3]GG]I#P3\0]%U
M@:I:M<6/BC6&L7S;S7.H2QR36S;24(4NPVDDX7&!CG^F']J#QK:?$7]C'5?&
MUBJK;>(_"4>I(B-O$9N+8,R9&?NMD'/(X!YH Y[_ ()A*)?V8]"CE'FH;FY7
M9( Z[?-?C!R,' R#UP*^B_C?^S!\./C1I)34-*ATGQ%9AIM&U_2U6QN[*\7+
MQ2R-;(K3('QN5LDCO7SM_P $OO\ DV70?^OJY_\ 1LE?HY0!^:_P ^,7CWX1
M?$-_V=?CG</<LJ[O!7C.Z,B6M_8YQ:V;2R?+)(R[57!+9QV.*_2<$$ @Y! (
M(Z$'D$?6OB[]M?X3P>-/ALWC;3U%KXD^&TW_  E=E>VRA+VXBT_9*UGYRX9H
MVVGY&)Z\<UZU^S5\2Y?BS\&_!WC*Z 2_OM/$5]"?]9%/;$PGS!U#,J!B3R23
MF@#WBB@G')Z"HXYHI@3%(L@4[6VG.".H/O0!)1110 4444 %%%% !1110 44
M44 %?AC_ ,%1O^//Q3_V"Q_Z+-?N=7X8_P#!48_Z'XI_[!?_ +3- 'HW_!%;
M_DUJ\_[&R_\ Y"OV(K\=_P#@BM_R:U>?]C9?_P A7[$4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45P_C7XE> _AS;6UYXZ\5:1X7MKR40VL
MVK7!@2>5CM"1G:V6)XQ72Z1K.EZ_I]MJVC7T&HZ=>1+-:WELV^">)QE7C; R
MK#D'%=,L'C(8:GC)X7$PP=:<J='%RH58X:K4A\=.G7<52G.'VHQDY1ZI&,<3
MAYUYX:%>C+$4HQG5P\:L)5Z<)?#*=)2=2$9?9E**3Z,_$[_@X:_Y1E_&3_=M
M_P#T1<U_CI77_'S<?]=Y?_1C5_L6_P#!PT<?\$R_C)_NV_M_RPN?7BO\=*Z_
MX^;C_KO+_P"C&KF-C_6?_P"#5'_E%'\//^QHUO\ ]%6=?TI5_-;_ ,&J/_**
M/X>?]C1K?_HJSK^DFWO+6[,HMKB*<POY<HB</Y;_ -U\=&XZ'WH _/7_ (*G
M?$SQG\(OV./'OCKP#>OIWB?3-4\.0V5W%$TLD<=U?%)PJ*"3N0?AUKY__P""
M>/QU^)_Q/^*&JZ/XUUFYU'3H/AEX<U:&&5)45;^YAM6G?YOER2QXZC/->5?M
M&_%;]I3XG_ME1_LN:MX1TS5?V:=8O[675KJ>QB>[86TVZ,B=TR0IR1A\ G/L
M?U\^&WP&^'OPPU$ZWX2T>/3M0N-)M-)GE  +6=JJ"./ 4$8V#&21@"MZ^/QF
M&]EEV QN49GEF(IJMC99=FN&Q%?+\55TKX/'X2%.57#XNE&CAW*G4J)M2TMR
M.\TL#EM>,\?BJ-?#YI1E*GAUB,LKP5:A3Y94:M#&5E14Z4W6KVE2A4A&S]Y\
M^GME%%%8%!1110 4444 %%%% !1110 4444 0'J?J?YT4'J?J?YT4 3#H/H/
MY4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'D?Q[_ .2+_$[_ +$O7O\ T@FK^)/P[N_X1+QM
MA1M_MW4MQQSG[9+CMZXK^VSX]_\ )%_B=_V)>O?^D$U?Q"Z'>O#X<\8VJVTL
MPFUS4F:6-798P+R0_,%R!QUSW]!@T =A\&_BI9?"35+O5M0\":1\0%O8E1;#
M6(UEAMN,!H]P*YSSTSGTKM/C+\>=/^+>CVVGV7P?\._#IH9A+_:6BPQQ23 '
MB-F5!D$=L\]*\,TWP_XFO;9+G2] U:^M2 BW-K87$T)8=E>.-EW ]1GKVZUI
M7^E>./L2P7_AC7OLL1W#9HUX6&.G(B'/OSGOC@@ J>#;-;_QQX*LI<F&7Q+H
MT<RGI-&UR@=&&1@,,AO4?A7]L/AGX!_!V;PSX;>?X>>&Y)?[ TC<YL\,S-8P
M.[,0XW,SLS%FR<GKBOXH_!7]JVOCWP1<MX=\1;%\4Z,7+:+>JL:"[4.S'R^,
M#.3T _7^[3P9<1W?A#PM<1$E)?#VCL,J5(/]GVX964\JRL"K ]""* ."_P"&
M?O@Q_P!$Z\-_^ A_^.4?\,_?!C_HG7AO_P !#_\ '*]BHH \>'[/_P &%! ^
M'7AH ]?]"Y/U;?D_G2?\,_?!?_HG7AO_ ,!&_P#CE>Q44 >._P##/WP8_P"B
M=>&__ 0__'*/^&?O@Q_T3KPW_P" A_\ CE>Q44 >._\ #/WP8_Z)UX;_ / 0
M_P#QR@?L_?!?(/\ PKGPT2.F;+=C\"Y%>Q44 >/']G_X,$Y/PZ\-Y_Z\R/Y2
M4G_#/WP8_P"B=>&__ 0__'*]BHH \=_X9^^#'_1.O#?_ ("'_P".4?\ #/WP
M8_Z)UX;_ / 0_P#QRO8J* /&9?@#\&HX9V3X=^&PWD3+G['G@QL#U<@'!.".
M1U!!Q7\AUQHVF+^W5!X=%G -$;XN?8SIH3_1C:B\(\C9G_5XXQZ=Z_M1N/\
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M5.F3VFI6J6L7B:UM<Q)J%G/+.GVJXN-N_:BMN!X.>*_37_AG[X,?]$Z\-_\
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M]#6@#Z^_X9^^#'_1.O#?_@(?_CE'_#/WP8_Z)UX;_P# 0_\ QRO8J* /'?\
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M^T)\+-,^,OPD\8^ ]453#JFE7+PL4#%+FW@ED@*GJK;P ".AQ7Q9_P $P/\
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M?\/FOV;_ /GG?UU?_#I/]GC_ *!Z_P#?I?\ XFC_ (=)_L\?] ]?^_2__$T
M<I_P^:_9O_YYW]'_  ^;_9O_ .>=_75_\.D_V>/^@>O_ 'Z7_P")J"X_X)'?
ML^2QE8K7R7/1A$O'O]V@#G!_P69_9PR/W.HD C=@<@>W8'Z]J_.;]LK]M_X6
M_M VNNIX6%W$U_8F"V\T ;F5"/F.".O' SUK]#K[_@CK\&KALV^IM;#D<6X.
M![?+_6OS9_:V_8<\(?L[P>))M,U+^TUM['S[16C6-H6*G!QMSP/P)[\4 ?I;
M_P $5MP_9=OXVQN7Q9?'C/0C_P"M_7O@?L57X[_\$5RS?LNW[MC+^++[/KD*
M <GOGM[5^Q% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?D=_P
M59\5:!:>$O '@F+2K'5?B-XLU*5O L&L2FWT47-BXEF-]/E51?EXRPK\V_ _
M_!1;]M.Y\*>)="^'?@CX9#3_ ( Z,ESXV']IP!'M=.(2Y6U_>_. JMM."22.
M>,5^_'[3G[+G@7]IOPM;:+XIA^SZOI3M)H&NPLR7>DR2']\T$B?./,'!"D9[
MFOS7U+_@C%X6TYI8_AS\3=7\'67B2)+/XB6Z2W<O_"6Z>S*;BWG89QYP# E\
M]<]:YX\05LJQ,Z5+(<PQ#JTXJ6.H8/#9QA^6#]JITJ6:<38+#X'$5I1^IUZ>
M&R9\V'M7>+E4FXPZ'D6'S;#TW7S3)%"$Y/ZEFM7,\NDY2M"<*N(R'**V,Q6$
MHPMB\&ZV8\ZQZ=*6'6&2E+X=_P""\?Q]\8_%S_@A9+\8O#^@W5QKGCV3PVVJ
MV&BVUQ>KI\5Q<WMEJ5P$M4E8VEN8C*S\)LP2P%?Y6SVUV \LEO<!0Q\R1X9
MH;/S;F*@ YZ@D&O]VW0?V:/A5I_P(T?]GC5_#.F^(?AQI>AIH+:)JEM'=6MQ
M:@/YC,DJL!([R2,' #*6)%?A/_P4Z_X)!?\ !/;X7_L1?'GQOX+_ &>O#&A^
M)]*T*]U73]8LT;[7;7LB2,S1_P  3<-P7;P>^,"NCVTL1_M$\.L+*O\ OI8:
M*2CAY5/?=&*C.I%*DWR*,:DU%*RG-+F>#I1H?N(5GB(4?W4*\N9RK1A[L:LG
M*,9.51+F;E&,KO6*>B_(O_@@;_P7 _8*_8D_X)T:#\*?CIX]U30_'7AG6M3O
M[G1;73TNWN(KB) /*D,\;+@P*/\ 5R9WD\;2#_0]_P $6_V]O"7_  4$\#_M
M!?%GP)>:G=^$K#XKS:5H?]K1O!=Q63)>21*T$@5H@R*C ;5RI!Q@BO\ '2\1
M6T5EK^M6ELNRWM]4OH84_NQ1W,BHGT50%'L*_P!,+_@S(T633?V$OC-?O*KC
M6?BXMRJ*/]4L5I>0JI. 22H#'.<$D#@<@C[&_;R_:2^+=C\:OB5?>$;*W\$S
M?!>1(=!DG"VL_CA90V9K8OM>[\OKE20,#M7A_P &_P!HOX\Z%XU_9L^+UU\>
M+WQQJWQH\<1>&_&/PA&J1W47AG3FGC3[3_9ZW+RP'!/+0J <9R:_2G]M#_@G
MYXJ^./Q9B^,'_"80:M;:)EM-\"*XL(I$ ),-Y(N%N3(/ES)NQUQ7S[\ O@7H
M'PE^.GAC5O$7[(\.BZK)J*QZ?XR_X2!;ZVM+@.H^W6VGEGCB9R-WR*#VSP*C
M"<38_".IE^78_"Y=*=27UG 4J67Y!D[JR2HJ&8YAGO#N"HX[#XO#.6(J++\W
MS+,J^:25.ERTIQ4-<1D&58ET\;5I8S,J?LH4:F,48YAF%&RCB/JF'PU+BF>9
M<U+$J"IUX9#A<'0P<>62J.E)U?Z'(FWQQO\ WT1N_P#$H/?GOWI]1Q,'BC8#
M **0/3@<?A4E69??\]_GMK\D%%%% !1110 4444 %%%% !1110! >I^I_G10
M>I^I_G10!,.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110
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M<.OZ'<3QVT&KZ;-<2DB."*]MWED(ZA(UD+,1W &1WH UJ*** "BBB@ HHHH
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MW_H:U^>G_!<?_D(_"O\ Z]+[^;U^A?\ P2H_Y,[\!?\ 7:^_]#6@#](****
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MA4C_ #)IR@_>IRO"6L69X2O+$8>E6EA\;A9SC>>'S##/"XNE*[3C4HNUE?\
MA3M:K2Y*JTFF?A__ ,.]_P!J?_HL.@_]^YO_ (W7&>._^"8W[2GCOP]+X?UC
MXLZ'=64TH=H0L@ P>&^= O [>E?OG16)TG\RW_#DCXS[=G_"V/#^S PIMFX&
M.G^I/3USWI\?_!$[XWPJ5@^,.B0*>T4#KUZ](<?I7],U% '\SO\ PY3^.W_1
M9])_[]/_ /&:D/\ P1:^/;)Y;?&S360?PE92/UBK^EZB@#^6_P >?\$@?C1X
M"\'>(?&6H_%[2[ZS\/:?-J$]@D3!KN&!"S(K& *#VPS+GJ.:^/\ ]BRR8_M*
M>%+)_FDL]5@20C W-'/M+<9QDJ3V]?05_6]^TK_R0KXF_P#8JZE_Z)-?R,?L
MD^(]/\+_ +3_ (>O=1!\FZ\1PVD6T'/FR7>T9/.>2,\4 ?VHVG%K;#TMX?\
MT6M6*KV;A[2U=>CV\##Z-$I'Z&K% !112$A068@*H))/   R23V ')- "T5\
ML?'?]L3X)?L^:=%J'C3Q/97+2.R-8:/=VM[J$17.?-M8Y&=.01\^TCG(%?C]
M\=?^"NOC;Q5/<Z1\ ?"3-X1U.)]/;QA?0^5-832C9YOF-\D90G)YXQZ&@#]X
M_B!\6OAS\+;+[?X^\7:-X8@9&>(ZI="!I]H)VQ+M9F8XP..M?D%\>/\ @KYX
M=M=0U3P!\"/#M]K_ (S^>/2M8GC6?2;J120&A!B"L#@'DGC\:_*1OAW\;?CQ
MXDM=/^+7B/Q=X^L-=5IM(N-(DN;W3M/GF.Z*&:2)G6-$9L'H,#IR#7Z5_ ?_
M ()?>(KW2=&M_B-%8>&+/2I1<Z7K.ALG_"12P$AHUN0SB0.5P'WL.3S0!^<?
MC+QY^U#^U7K-S>^,?&6I:3XBLP8F\!:+-/:-?P;L>4D$2K&VX<  $'->@:=_
MP3;^)?C1?"FNZ'X9U#P3!<7%LOB<:] 3/>.S@23#(W'>"3SGK7](WPS_ &8?
MA/\ #.*SFL/#EAJNO6:JH\3:E:I)K$K+CYWFW, Q(R2.]?0,MM!,BI+&KJN-
MH8 @$=#TZC'!H ^&OV??V$_A)\'M*TV[ETW^W-=:U@:__M K<Z69_+4N8;&:
M-D WYZ^G3N?M^PTVPTJ!;73;.VL;9,!+>T@CMX4 XPD42HB\>@'05<4!0% P
M ,"EH **** "BBB@ HHHH **** &2()$>-ONR(R-_NL"I_0U_)]_P4Q^$%Y^
MSO\ M*Z3\4/ >BW%KI-W<1>(UU5@?LR:\\RR,A?8 6#=3G..W:OZQ*_/7_@I
M/^S^GQV_9YUQ(ITM;WP8EQXFCD "S316<6]X%D W8.W)3/)/ )H ]H_8_P#C
M/;?&_P"!G@OQ5)K%GJOB#^R;6#Q&EM('>UU!4VF.90 0S*H()Y/.>:^GY8UF
MBDB<925'C<>JNI5A^()%?S,_\$;OVA'\)^/-:^!.H1HUOXIN+B_AO;N4QM:S
MV32QI%'O;:=Y4J%XW9X7.*_I*U_Q5X;\+6WVOQ'KFE:);%699M4OK>RC<(,L
M$>XDC5C[*2?:@#\T=' _9S_:SU?P[=;K#X5_%.U(L;?;BWD\17V/-&W"H[EW
M()Z\GVKN/$'_  3(_9K\4?$&+XG:C8Z^_B)-8AUZ!TU0BVCNXI!-'LB\O BW
M ?(.,5\6?\% _P!N/X ZM'HFB^%=7FU3Q_X#UT:SI=Y;1QG3C<6[#;&M[&[;
MXV9-QZ+STR2:_/37?VY?VROVC?$?A9O T/B2T@M;NTTB1O!\<DNG%F98UEU!
MX %7CF1F!R<Y.017)B\!A,<J<<70C65*7/34G)<DU;WERRCKHM3KPF.QF!<Y
M82O4H2J1<)N%DY1>\7=/34_JM\7_ !(^'OPGT:WG\:>*-,\.V%M;QP0-?SD/
M(D*".-510[LY50 2 ">]?@Q\0?VJ]<TW_@H+X0\7?"W2[N[\'>-/L7AO4M3^
MRR&/5H \<9,#"$C#+D@-G&1R37Z#_!C]B8ZOIFC>,?V@/$^M^/\ Q)J%I;7=
M]X:UN5I]%LI619%C2(S$[T)PX*#!R.#T^TK3X(?"6QDTJ:T\ >&X)M#=)-)E
MCT^,26$D>"CV[\LC @$')/K76M-%LM#D/3+68W-M;W!C>(S0Q2F.08>,R(&*
M..S*3@CU%6*0 * !T  'T' I: "BBB@ HHHH **** /SJ_X*0_!G2?BI\&6O
M=5MS-'X:F%P'4 O$DS[793U''&1W//6NU_8!^%OA/X5? '0M'\(1SQV.H.VI
M7 G;<S7<RKYA!],] >>>GKZA^UM_R0'Q_P#]@U?_ $:M4_V1?^2)>$_^O-/_
M $%* /IRBBB@ K-DUC38M1BTF2[B349HS-%:$GS7C49+*,8( !/7L?2O$?VD
M_&>L_#[X9:SXPTCS,:)#)=W?E$^9Y,:%L*.^<8Z?XC\]?V"OV]O"?[0_Q'UC
MX?\ BU?)^),"W-UX=6=?]*DT:W\SS,Y((^5"?NGI@<'-;THX6<*B^LQEC(Q<
MHX&-XUI4E\5=3<90=.DO>J1?+)K2+NS"I+%PJ4[8'$3PDVXSQU.*G1HU/LTZ
MD4^=.;^U9J*]Z2Y=3]BJ***P-PHHHH **** "OPP_P""HP_T/Q2<<_V7_P"T
MS7[GU^&/_!4;_CS\4_\ 8+'_ *+- 'HW_!%;_DUJ\_[&R_\ Y"OV(K\=_P#@
MBM_R:U>?]C9?_P A7[$4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?FE_P5[_Y1[?M$_P#8H7/_ *+EK]+:_-+_ (*^?\H]OVB?^Q0N
M?P_=RT ?XJOBW_D:/$/_ &&=1_\ 2J6O]-S_ (,W_P#DP#XD<?\ -3V_]$WM
M?YD7BP@^)_$)'(_MG4>?^WN6O]-W_@S@_P"3 /B/_P!E/;_T3>T ?IM^WI^S
M_P#MI>*_VC/ASKWP)\<WFG_"C56*>.=,MIY8YK8AR%="HP%QAN".,>E>H_#'
M]B']H+P]\1?!7C3Q/\99]?T/1+V*_O-$N[JYG\R/<K&WVNNTLH!!YZ\'I7Z6
M_%+XE:%\*?"TOBSQ#;WESI\-U;VK1V$/GW'F7+^7&1'W4$_,>PK!\5_&SPOX
M/_X5V-0L]4F'Q)N;6UT3[);>8+=[N&&>,WV/]2H6=0Q_O!ACBM5#B_&1I4GQ
MEQ/_ &8JE2E@<LH9O1PV!IX:C!5J^"K8>46J]'WI<M2O:;I3^K4YM0C97X2P
MTIU?]1^$9YFX4YXO-J^1O%9C4Q$W[*EC:>*U]AB(VB_W"2C4C[>I'WI-^QH,
M(HQC"@=.^.:=2 Y (Z$ _G2UD,**** "BBB@ HHHH **** "BBB@" ]3]3_.
MB@]3]3_.B@"8=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \C^/?_)%_B=_V)>O?^D$U
M?R/?LV_\DS^,_P#V$=9_]'S5_7#\>_\ DB_Q._[$O7__ $WS5_(]^S;_ ,DQ
M^-#94*NHZSDLZK_RWF^Z&(+=.P/MDT ?T,_\$KO^35="_P"PUJ?\TK])*_-O
M_@E:<_LJ:%_V&M3_ )I7Z24 %%%% !1110 49KC?B!X^\*?##P?K_COQMJ]M
MH7ACPUIUQJ>K:I=EQ!;6MLA=V;RT=R3@*H"G+$?6OQ3^'?\ P7)_9!^-^H:]
MJOAKXEV'A?PG\/\ Q!<Z?XEUG4_-DLY+6RD9);Q98X@5@(0G'E,X'% 'YD?\
M'-'_  5F_:5_97\2_"C]C?\ 91N+_P -?$SXT6,%\WC#2B#J<4-U?+IZ:9:*
MVX*\QEC8R%"B*6D<$)Q_-WJ^D_\ !Q'\+O#</Q9U+QMXTMK'PY:IXD:X&M&X
MO#:&/[:TDL M5CE66,;I$5D') 8=1[C_ ,'%O_!0/]FGXB_\%(/V5OVB/V>?
MB#X>^.GA7X9>%X)_$)\.M,UJEY!J&YK&*2]AM6\\0N6!94"S1$!BN&.K\4O^
M#GCX;^,_A7KG@?1OV??$UIJFI^%6\/PW5YJ=K-9QR/I[6AF>)K]AMW-N "G
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M/[6K?%GX$? K]D?QG/X!O/B8FF:A<^)[;+%;'4/+;JK#< K]NO3/(%1?M7_
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MNW>J:9;W5P/PDD:O8:^;/V.?^35/V>_^R2>"/_3':5])UR':%?C]_P %BO\
MDA6A_P#87?\ ]!%?L#7X_?\ !8K_ )(5H?\ V%W_ /010!SW_!$G_DW/Q/\
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MZ^%>EII'@KPU8:19H!A4B660, .1-(&D'N 0#Z=*]/    & . *6B@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R/X]_\
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M[/D2];\=?L\WOQ'^/_Q#OOLEO:RZ1JFFW4(U+*3310HCLU@"063CL,&O,_\
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M2_[-<_\ PBGQU\''^T[NSL<6UCXWM;8F>XM]41&47%TR*5B!0[B<]2:^"O\
M@BJ5/[4'_!04H<@?&755/NXNI@Q_[Z#=?6OZ1:X\XRC!YW@YX/&1ER\T:M"O
M3?)B,+B*;YJ6)PU6W-2K4I6E&2M?6,DXMH^T\.?$;B3PPXEPW$O#=>GSJG4P
M6:97CJ:Q64<09-BDJ>/R3.\!-NCCLMQU"]*M1J)N+Y:M&<*U.%2/PC^Q;^V;
MH'[27AR;P[XBA/A7XQ^$@=.\9>#=2_T;4!>6@$5Q?VUM)M=K:61692 1@Y%?
M=U?E/^V=^QKXFD\2P?M0?LPROX9^-WA0C4-6T?3-]O:^/K&V(DET^[A@V1F5
MXT8$D$O]<U[I^QY^V?X4_:-\)S6/B%H/!WQ6\)M_9?CGPAJ\L>GW5KJEMF.Y
MEM(KJ1))K=G1FWHI7!R..GAY-F^-PF,7#O$,E_:,8MY;F2CR8?.\+!6YX?9I
MX^E&WUK#7NW^]IWA(_5/$KP[X:XBX<J>,O@[1J?ZF5:U*GQKP5*K]9S?PNSS
M%._U:O\ \OL9PECZW,\BSODY(1M@,;*GBJ=G^5/_  7*=AXD^#:CHUO>9]_W
MCU^F_P#P3)_Y-+\!_6Z_]"6OR_\ ^"X=U;7?B7X--:W$%ROV:[.ZWECF&"[D
M',;,,'L>]?J!_P $R?\ DTOP'];K_P!"6OL#^;S] Z*** /DS]LK6M%L?@WK
MVF>(/L\>F:M;R17,]V=MK$B#<3*QX [@GTK\\OV/?"/P\3X3_&OQQX(U[1-8
MD;PEJNF36ME<I-J,"QV\PY3<9%@/1. !C;7W=^W-+HMO\&]5N_%.D?VMX7MX
M9GU>+)4+'L.,N,%0V,9KX"_8C\3_ +/FM_!3XV6OPL\.P^&/&47AG5S?V,<L
MD@GT_P"SS>5.OS^7N8AB^4S@\$GBLI5\.ZM/#NMGJKV=2-#+\TP=#)YI*\IY
MMEE>4<1C;1T56A&I.BG2=.R=1%QPR<98EY,J[7NQSFK@J]98.[5J.'QE.LJ6
M$G/EDDJM%QFW/G;;IL_/7]C/P?'XT_91_:LTB73Y=0BO/BS);OY*EI(5DOW4
MR/MP1&H)+' &!S7+?MS?LVI\ ?\ @F_\8+R&XMKFP\1Z[X/EM5M9-Z0L]];L
M5/S'#KT?WZBO7?\ @GOX+^*OC[]FG]K+P[\'9XE\67OQ,NHT@E945XS>2[]A
M)7Y]N2 HW8!(Z<\+_P % _@O\?O@[_P35^*]K\<-5:\2^\3>%6TNT:9IA;2-
MJ$&Y1EFQSGI@<$=!DQ+$818F&&E*E'%->T@X\/PK59P:UA5SV6,C7PO*TG1C
M2P-2DX^TINI'GDUUQ_M?ZE/V>(PRRCGMB,+/.:D,1*M[KC4H9.L)*C43DU[2
MK/&0E*RE[-<BO_29^QS_ ,FJ?L]_]DD\$?\ ICM*^DZ^;/V.?^35?V>_^R2>
M"?\ TQVE?2==!PA7X_?\%BO^2%:'_P!A=_\ T$5^O4]U;6R[[FX@MT'5IY8X
ME_[ZD91^M?CS_P %@M1T^\^!6B"SOK.[(U9VQ;7,,YQM'.(G;CWZ4 97_!$G
M_DW/Q/\ ]C=-_P"@/7[15^,'_!$Q"G[.GB;/?Q?/CZ!&_P :_9^@ KYT_:'_
M &?M)^.N@:=8S:SJ'AK6-&OTU'3-8TEUANTFC.X1M)O0^62 3\QQV'-?1=?)
M_P"UC>VUEX0TZ2Z^)6O_  RC^W#_ (G.@6DUW<OQS&ZP@L$(X)/'\Q4,)B,=
M.&%POUQ8FK.*P\L!!3QL*T9*5.>&A*,XRK0DE*"E"46UK&2T&JOL+U7*C",4
M^=XER6'Y&K359PA.7LW%M2M%NWWGDOPJ^$_@7X-> ?CE_8/C#6/%GBO5+*^7
MQ??/.;F^L+T6LD<3*X+>6$8AF;/&WH<9/Y/_ +,OP8UOX??'3P7\0_$'C;2?
M%\/B^_\ &/\ 9T*W:7&LV*M;7)$5TNYG3RQA3N (P,"OLG]A'Q%I+Z#^UI?Z
M/XJU?XGO8WMW]IOM7CE2YOB+6X!C\F3Y@75F.T8.1QD\U\T_L^?#S0?!/QI\
M%_$:TN]4U^X\=W_C&'_A$K@S/#X-D^S71:Y6%F(@#'G)5?3ZW6P=/#U7A\SP
M^<2QU"M*I!8S#O-)O,*D7*KB>(I8>K0PN%H5;U:U&H\-.5/&.G",(>QFREF-
M;")4UB\'4>.C##PK86.%P7/24(RIX?)I8R"Q?MJ5!*C74:D:5;!QJN:=2K13
M_.3]ESP))\0-&_:=T<6LTL=W^TMXB22>)25ME?49AYET1PL8_BSV_3]$OVE?
M@L_P6_X)M_$C2Y18NNH^);&XMKBQ(9)48J2S,,@G)P>>O<U\4?L1?#CXU_$W
M1?VO="^",L9UUOV@_$W]HB1MBI:G4)\NCDC#8[J:^W/VFOA5\:/A'_P3;^(.
M@_&S5SJ&JR^);.7386F,K6T#.O!W%B 2"%!ZC..,5P?6,(\4L/)T7BU3O"4<
M@I3K.DU&4HSXA^NK$P?,DXT/J3H2IW@IINYTI9LL%>.(PZRAU$IX5YS56(]L
MFN6=/)/JOL%"^LZSQGM)-<[A=)'ZA_\ !,[_ ),Z^$__ &"?_B:^^*^"/^"9
M_P#R9U\)_P#L%?\ Q-?>]=1QA44\\-M#)/<RQP01*7DEE=8XXU49+.[$*H Z
MDFJL^JZ7:R+%<ZE86\K,%6.>\MXI&8]%5))%8L>P R:_EU_X*"_M9?M%^&OV
MCO&GPO\ "GQ'O-.\$RO;V5EIMI*WDS/>L(EB$D;<!B^TGMGJ#0!^N_[=7[5O
MP4\*_!#QYX/?Q?IVL>(_$^BWFC6.G:+<07TD5S,I3-T8I"(0AZ@@GW&*_D4T
M^)YHSIMM%)>WQ>5A:6RNTSK)*S@ *,G((X!YQZ5^PGP&_P""2/Q8^,,1\4_&
M?Q/>^$K/7+:'5["ZM+V:_GNX[M1,C/$\C^6\BMGEEX;TXK]CO@C_ ,$ZOV??
MA!H4%E=>&-/\7>((HPA\2ZM;EKTL /F5=^P'(_B!H _&#]BS]@7XC?$70?[>
MOO#NG:?X5UIE-]-XA3R]2A5NLFF><0Y8 [E*C /<=:_<'X-_L*?!_P"%=C%!
M?6LOC:6,K-"/$L<=W#83]3]D4LP55;[F<< <5]?>'M!L/#.DVNC:9"D%E9KL
M@AC141%SPJJH  '2MN@"CI^FV&E6L5CIUI!9VD"A(;>WC6.*-%& JHH   Z5
M>HHH **** "BBB@ HHHH **_&'_@K!\;+[X/VO@:ZT'X]>)_A)XDNVE.E:-H
MUI++8^)9UW".WO9TPL89P$.3CD'&:^F?^":OQ/\ BC\6?V<=-\5?%F^FU/Q'
M)J]Y;1:A/GS+RPB"^1.<D_?!SG/.:Z7A,1'#QQ4J,X492M&=2/(IQ>D:E%RL
MJT')2A)T^;V<HM34;HZI4*/U:.(ABHRGS*$Z$J->DU/5RC2J5(1I8GV<>655
MT)35/GBI-,_06BBBN8Y0HHHH **** "BBB@ HHHH _G/_P""W!*^*?A:1U&G
M7'_HQJ[/_@B;9^5;?$VZQS,;;GCD[QTQ^([_ )"N,_X+<_\ (T?"_/\ T#;K
M_P!#>O7_ /@C!9^5X3\:76!F<P GGG##% '[HT444 %%%% !1110 4444 %%
M%% !1110!_.M_P %<1GXM_#3 Y.HV@Z<_P"M2OV5_9/1T^"WA,,I4_883R,=
M8TQ7XW?\%;O#OB+Q?\6OAQX:\'H)?%&I7<*:1&S;0TZL-F6XQ\^ ?3\J_4O]
M@KP?\:? WP,TW0/CC;16OBFVNG^S1Q2"4?V=Y:>020S $CG!.: /MJBBB@#S
M3XN_#JR^*?@'Q!X,O)'A&K6<D,,Z-M:*?K&^[L W7D5^;T'[.&J?#>YU+QU\
M2_'$=KKG@WP%J_AOP-#HE[&VJ1:9)!(L=ZT22,_FQ##!B.".M?I?\3DNI/!.
MNI9:Y)X;NC:/Y.LQ'$EBVT_OEY'*]17XGK/?>'_VH([[Q;\6]9^+SM\,]8CM
M?#ESYLEFY,$NW>F=@P>"Q7MU[UK2H4YJ=3^ULZPE:/+4I8#!X#%SRS%U:+4J
M<L=FOU.M@, K^Y*-?$T)5(67)--M85<RR[#U:."Q5+*IXS$>TC@JV(E*>:T/
M:I4ZT<NPT*T?:.M#W)U*E&K"FKRO"VOSO^R)\"]9^&?Q\T/XB_$GQK=?$!OB
M#IGCB;P-J>IW N=6M$>&Z;R;DY9D$8;:H;'0 <<5QG_!/^U?4=#_ &W]/2UN
M+VZO_%?BF.&W@4D22->7 VRA1D@YV\?B:^BOV=_#/C#PA\9/"WB+Q<UIK^@^
M-=+\;OX4T**\2X;P$A@NB D0<F+?G!!"GC&3BO&O^":-CXJU2#]MO3/!$2W/
MBF]\4^*X])5P/^/DW5P$;D]0^#UKFCBL54IRQ&(Q^(Q%2$JLH8S.,'0RV-!P
MFY3]IA,!*<:.$P]92;K0M]8IQEB8+V4XM],:6(YU3Q4\,ZLO8Q:RC,*>98>G
MAY0C]76'KU*-"C]:5#DG6P[@H+%<T&];GS1^T9H6C^&?"8T6Z^&^I>"O$LGP
M^U&4:A%:/!I6I)L8^=*Y 1Y6!'N<X[U_0+_P2HS_ ,,.?!C/_0*O.G_7[-7X
M>_'GX4?MAZ%\#/&OC#]HFX74=#L=%U*QTF1XE273X'\SRH V-Q7:!R">!GZ?
MN#_P2F.?V&_@L1T.DW9'T-[,16>%QGUVDJJQF4X^,92IQQ625L56P%2UI-P6
M+<IT9\TY.=&G4K48W4X5+S<8]>/P\<-B'2A6Q]=<D).68_5_K$).*3IWPZBI
M0BHIIU*=.I&3E3<7&$92_1:BBBN@X@K^9/\ X*K>'/B]J7Q?\1:J+_[+\/;'
M3D,=M&Y5KC"=)!NY'!SP>/:OZ;*_#+_@J,?]"\4CH/[+!_'RSZT >C_\$64"
M_LOZ@5SM;Q9?%0>WRCIP/7_ZPK]AJ_'S_@BU_P FMW?_ &-=_P#^@K7[!T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A[_P<,*S?\$S
M?C'M4L0+=B!Z""Y_QK_'1O#F[NCZW$YY]Y6K_9(_X+W_  %^,?[2G_!/CQ[\
M)O@5;37GQ \1ZQI<&G6<.X&Z0B9)(790WEHY90SD$+U(/2O\\OXK?\&T_P#P
M44^"?P%\1_'?XF>%]$T33?#-DVIZOI<>J0WEU!:>691*<>7(Q(X8>6N&R"<\
M4 ?W%_\ !JDI7_@E'\/ 5VY\3ZV>F,CRK0?T-?TDP7=K<F06UQ#.86V2B*19
M/+?^Z^TG:W!X.#P:_P 7K]F;_@LW^WY^Q3\);G]G_P""'Q8O_!W@_3]0NS#9
M6Y<_9+P,\,CHH=0<$<?,,X%?WP_\&H?[1W[07[3W[(_QM^(_[0OQ!U[XC>)+
MKXM&/3=9U^9)KA+(V]Z988@B($A$P^10#\H4DDDD@'ZU_M+^./\ @H[HOQ!O
M;7]GCP?\.]6\!1$>1>>(1:_;M@&79_-8-P.>!_6OR6^,/BS]L?XZ?M7?L?>'
M?CEK_P $="M_ 'Q+@UN_T+P_?VZ^(KJ07$ 95@CD+!]L:KM4!>,@9)S]$?\
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M] '\L/\ P2N_Y/%TK_L):[_Z5SU_7=7\B/\ P2N_Y/%TK_L):[_Z5SU_7=0
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MM9R49*%DOS*N_P#@O-_P2V_LRXC'[3.B.W]F%P$T;6CN+V^1&N;0?O!D @@
M'/S8&:_./_@A?^T;\(OVE?V[_P!OOQQ\&_$%SXF\+S3::\.J/IMW8P2A[^,
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M'\._$[2?'_Q1\;_&O24\/^,(M!UK2?"GARY=+ZXM=(F$R+>@IN.(T(?Y<GC
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M_O?^)A8:5;6UU^_R9OWD:J?WA)W#H<FOE[X@_P#!-?\ 8H^)_C*_^('B_P"
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MH%N+31O#VB6PM-,T^W'/E6UNI(C7/. >M:QC&*M&*BELHI)+Y+0PN=I1113
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M+RK(K*1SE2H(Y^AI]-10B(HZ*JJ,>@  Z?2G5L0%%%% !1110 4444 %%%%
M!1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >1_'O_DB
M_P 3O^Q+U[_T@FK^1S]FW_DFOQG_ .PCK'_HZYK^N/X]_P#)%_B=_P!B7KW_
M *035_%Q\./B]'\//"WQ#\-'19M2D\2:EK"I=PH[BUW7$RY8J.!SGGU.#WH
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MB/XJ0L+G7+.:6PM[LG&!Y;J "#TVA1SR#V /W8HK\TO^&O?VI=H/_#'OB Y
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M^+9?&6HV**K:Q,92\N%QEO-56Z\]* /#_P#@I%_R9_\ %K_L$Q_^CEK\DO\
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ME@WQ3^)GQ0_:$U;,FIMK&H>#;8S EE@L9F0&($%5VJF,KM.".>37Z6U^7_\
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MK4L%C\;@Z6)CRXBGAL36H4Z\=N6M"E.,:BMI:::MH-5550BJ%4#:%  4#I@
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MXYXE5:T\PS"?UW$YG6HJI1I4:&#6&KJG"M'V),[$SUVKGZX%.HHKL.4****
M"BBB@ HHHH **** "BBB@" ]3]3_ #HH/4_4_P Z* )AT'T'\J6D'0?0?RI:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'+?#3P4Q)SD^'M-)R#D')@SG->HT4 <]I'A/PQH"+'HF@:3I2(,(MA86]L%
MZ "*-<8[>E=#110 4444 130Q7,,MO<1I-!,C12Q2*'CDC<%71U.0RLI(8'@
M@X-9FB^']#\.6IL=!TFPT>S,C2FVTZUBM83(YRSF.%54LQ)).,DUL44 %%%%
M &;JVCZ5KUA/I>M:?::IIURNVXLKZ!+FVF7KB2&4,CC/J#7 +\$OA B[5^&O
M@M5(QA?#VG 8^@@_^O7J-% ' Z1\*_AMH%VM_HG@7PMI5ZG*W5AHMC;3K])(
MH58?G7?#C@# '  [444 %%%% !6%<^%_#EYJ4&L7>AZ7<:K;$&WU&:R@>\A(
MZ&.X9#(N.V&XK=HH **** "N,\1_#KP'XOF%QXH\(^']>N%3RUGU73+6\F5/
M[JRS1LZCV5A79T4 >90_!?X2V\:Q0_#GP<B+P%&@Z><?BT)/YFI?^%/?"K_H
MGG@__P $&G?_ !BO2** /-'^#/PGD!#_  Y\',#P0= T\C\O(KFO%7[/OPGU
MSPOX@T2U^'?@VVFU;2KVQBGBT#3HY(9)X72.6.00!XW1V#*R,I!'6O<**F<(
MU(3IS5X3C*$EWC).,E\TV;8;$5<)B,/BJ$N2OAJ]+$49K>%6A4C5IR7G&<8M
M>A^6'[%W@WX;66J^/_@7XB^'OA6\UKX:ZM)/%J.HZ1:7-[=)<7!9&1YX7;$(
M(VE&P ,]Z_4FWMX+2"*VMH8[>W@C6*&&%!'%%&@PB1HH"JJ@8"@  5^9OQJM
MI?@E^U3\.OB!I*/:^&_'UPUIXVO/NQHX81Q&0]""2",^X'-?IC:W,%Y;07=M
M(LMO<Q)/!*OW9(I%#HZ^S*017@\/3E2H8G*ZK_>Y5B)8:-WOA9)5<))=XQHS
MC2<M;SIR3U3/U7Q:PU''YCDO'6"@HX/CS**&<8CE3?L\^H-X'/Z=5J\85:N9
M8>MC(TKIJAB:4K<K3,KQ!X9\/>*['^S/$NBZ;KNG^8LOV+5;2&]MO,7[K^3.
MKIN7L<9%7=,TO3M&LH--TFQM=.L+5!';V=G"EO;0(.BQ11A41?90*OT5] ?D
M@4UT25&CD4.C@JZ,,JRG@@@\$$=13J* /-KOX.?"F_NI;Z]^'?@^[O)V+37,
M^@Z?+-*QY)>1X"S$^I--3X-?">-=J?#KP<J^@T#3O_C%>ET4 ><#X/?"L9_X
MMYX.Y!# Z!II5@1@AE-N5((XY!K\A/VQ/V&O^%3^.[/]K/\ 9M\$:%=ZWX=;
M[5XQ^'[Z;;R:7K.E1DRWLUM8+ 8?/\L/L4(<' QBOW"IDL4<\<D,T:RQ2HT<
MD;J&1T<%65E.058$@@\$5X^=Y+AL[PJH5I3HXBA-5\#C:/NXG XJ.M/$8>>\
M9)I<T?AJ1O"::9^D>&'B;GGA?G]3-,MI8?,\IS3#3RKBKA?,HNMDG%608CW<
M7E&;8:_+4I5*;;P]=+V^#K\F(P\X3AK\%?LJ_$']F7]JCP+#XE\/_#OP3IWB
MBP5;7Q=X2O-!TQ-7T/4X@J7*W-O]DB81//O\I]G3@^I^IC\$/@^PP?AGX)(]
M#X=TW_Y'K\K?VJ?V8/B!^SA\0Y/VN?V3X9K>YMYQ>_$OX<61=--\1:>'#W<T
M5HDH620QARRK'D&OT&_99_:D\!_M0_#ZS\5^&+J.TUVU1+3Q1X8N'2+4]$U:
M)0+N"2T>1K@0)+N5)&4#C!/<^5D>=XKZU+(<_4*.>8>#G2K17+ALYPL798[!
MWT53_H)PU^:C4NTG!IK[[Q3\+LA618?Q;\)*F)S/PMSC$QPV8997G]8SOPVS
M^M'GGPQQ&H7E+".7,\BSII4,RPBC&<HXJ%2#^B])T72=!LX].T73;+2K&$8B
MM+"WCMK>,>BQ1*JC\!3M6T?2]>L+C2]:T^TU33;I=ES8WT$=S:SI_=EAE5D<
M>Q!K1HKZT_GDQ- \->'_  K8+I7AK1M-T+348NECI=I#96JL>K+# J(">Y Y
MK;HHH *X/6_A=\.?$E^VJZ_X(\,:SJ3J$>^U'1[*[NF4=%:::)G('N:[RB@#
MS./X,_":(;8_ASX-0>BZ!IP'_HBI/^%/?"K_ *)YX/\ _!!IW_QBO2** /-6
M^#GPI;[WP[\'G'_4!T[_ .,5!_PI+X0$DGX:^"R3U)\/::2?Q,%>HT4 >7?\
M*2^$'_1-/!7_ (3VF_\ QBKFF_"+X7:/?P:II7P_\):?J-JVZWO;30[""Y@;
M^]%-'"'0^ZD5Z+10 5RVM^"/!_B2]LM2U_PSHNLZAIS!K"\U'3K:[N;-@=P-
MO+-&SQ$'D;".:ZFB@!JJJ*J(H5$4*JJ,!54850!P    !T%.HHH IW^GV.J6
MTEGJ5G;WUI,"LMM=0I/!(IZAXI R,/8@U^"W_!73]EK3H/!NA?%+X<^%],\/
MVOA^263Q++H]E%:QDDDP3ND"!4D!Y# 8)'2OWUKRSXU?#71_B[\,O%G@'70Y
MT[7-+N(G\L;F$L<3R0$#(S^\"\ @^E 'Y;?\$>OV@-/\:?".?X3:IJ^K:QXR
M\*O+J,]QJ,QN%&FS;5A@B=L,J0@#:H+#!(XQ7[.5_(#^RMXY\5?LA_MF-X1E
MB&C:-KOBF70-4EU'_1XTT);GRXIG\S "E-I!.?KGFOZ]+&^M-2L[:_L;B&[L
M[N&.>WN;>1989HI%#(\<B$JRD'@@F@"U1110 4444 %%%% !1110 4444 ?A
MM_P5O^%^O>--/T'4I?$=OX>TS3I$EM[^280^2D?S2QA]P(:0*5 [D]Z_,K]N
MAM E_9._X)VVOAFWECMK;]H#2K2\FGRO]HWJ7L"S7:NV%=9FRP8=1UR:_6C_
M (*M?#[0OBYIW@WP1'XGUVT\5F22_P!-\.Z0DLEOJ:V>9V2^$1RJ,%P<X&,Y
MKY%^*7[%7B3_ (*.?L(_";P5X)U63X6>/OV?/'?VK16LW^S_ &O5='D4EYV!
M3#NT:LV]MQ).#QQFG3=9T_;<^*HQ6)GAJ^5X.E/#X?$6HT<5@LRPC]M5ABE2
M=#$TLP2FUAZ3H*RE)]#G5GAH.-+-:>&A.5'V\,RQ+R3$UHR]I*A5RO&0C!XO
M#.;J4:^52E1I2J57BI-RC%?NMX'^!_PNM['PUXF/@K03K_\ 9FE7K:B]A;O<
MBZ^QPL)O,*'+JQR&.2#WZ5^%OA2"2/\ X+/^*7*@1>6JQX*X"A1@!0<@#TQ5
M'PU^R;_P5\\/:=H^FI\9O.CT>.&WA=M63<\5N@BC+?O_ .ZHK$_X)]?\$K_V
MS_A?^W?XX_:V_:>^*<GB>TUDO_9.C+?_ &E(PV?O())-O7G[O3O7/@\OP67^
MV^IX>%#ZQ4=6LX\S=2HW?FDY.3W;:2:2N[)79-7$5Z_+[:K4J\BY8<\G+ECV
MC?9>G8_IUHHHKL,0HHHH **** "BBB@#^;O_ (+>2[?'_P ((N[:=<G'_;1N
M3Q_G\:^IO^"0G_(C^)?^V']*^4/^"WW_ "4CX._]@RZ_]&/7U?\ \$A/^1'\
M2_\ ;#^E '[/4444 %%%% !1110 4444 %%%% !1110!^*__  6:\'^)/$OP
MP\#W>@Z;+?QZ5J=S+>>4A9HU;&P@@':2<>F??I7-_P#!,7]E'P1XP_9W.K_%
MGP$K^(+S6I_LTVIVZB<V2\Q.GF1Y9'!QVX[FOTR_:]LK2[^ GCB2YMH9WM;)
M)K=I8U=HI1(N&0L"5/KCKQZ"E_9)=I/@GX39MN?L:#Y45>B)_= _.@##_P"&
M)/V>/^A$TS_P'A_^(H_X8D_9X_Z$33/_  'A_P#B*^M:* /DK_AB3]GC_H1-
M,_\  >'_ .(H_P"&)/V>/^A$TS_P'A_^(KZUHH ^2O\ AB3]GC_H1-,_\!X?
M_B*KR?L.?L[2')\#Z>/I!$.V/[O]*^O:* /C.7]@W]G.7.?!MH,GM%%TY_V>
MO/7]*SW_ ."?G[-[Y_XI&)<]=JQ#\L(!GCJ037VY10!\)R_\$[/V;)<Y\+ $
MY'RB(8'TV_UK/E_X)M_LSR]?#4HXQ\IC'MV7'X8_*OORB@#\]'_X)F?LQR-N
M/AZZ'/19(UXZXSMZ^_Z5^5O[<G[*_P */@?:>*I/!&GRP-_9V]$N,/Y1*<[&
M 4#\!U&:_I=K\,?^"HW_ !Y^*?\ L%C_ -%F@#TO_@BWS^RY>'N?%=]G_OE:
M_8.OQ\_X(M?\FMW?_8UW_P#Z"M?L'0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >1_'O\
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MW?\ V-=__P"@K7[!U^/G_!%K_DUN[_[&N_\ _05K]@Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (#U/U/\ .B@]3]3_ #HH F'0?0?RI:0=!]!_*EH
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MO+[3?"FI0IFWT^:4SMGH&.1QW_'WY% 'YPU]7?L5D_\ "Y+@>FB77K_SS?\
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MKQU;=V?:_2NR;P%ROC3AK$?1XXCP&?<$X_@W*%C*6%H9KA\9E^?X*,L/F?\
M:D,WHT,2\9CJC6(YHP5-TU%Q2O8U**S/[;T;_H+:9_X'VO\ \=I&US15!9M8
MTM5'4MJ%H /J3-BOMS^6S4HK,36M'DYCU;3'!Z;+^U;/_?,IJ==0L&^[?6;?
M[MS"?Y/0!<HJK]NLO^?RU_\  B+_ .+H^W67_/Y:_P#@1%_\70!:HJK]NLO^
M?RU_\"(O_BZ/MUE_S^6O_@1%_P#%T 6J*IMJ-@BEGOK-%499FN8551ZDEP /
M<U8BFBGC66&2.:)QE)(G62-AZJZ$JP]P30!)1110 4444 (1D$'H1@_C7\I7
M_!3SX*I\ /VC]!^*_AFSNKBRU;48O%]W<LI6WCU.*82BW=P0 =XZ$X/7O7]6
MU? __!17X M\=_V>_$6GZ?#;KK/A^*36H;ID7[3]ELXVEG@B?[QW!<A1GOB@
M#V']D?XR?\+R^!/@?QU<26@U6^TN&/4[6VD5VMIX$6("5 =R,ZJ&Y')SS7TO
M7\U/_!'G]H2/PCXY\1_ SQ-=74]UX@O9H] AEDD"63:>[(ZB-\JH<H<X )['
MU_I6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)UW6K#PYHVI
MZ[JDOD:=I-G/?WDQZ1V]NADD;\ *_,CX-^$;_P#:K^,^O?&?Q^C7WP_\(:BU
MK\.=+G5I+"_CCE8)=NFX1,8F7=G!.<<8)KZ9_;.\73>&O@UJFGP2^4WBV4>&
MV8<,4O5"NJG!(W X..<5V_[,7@R#P%\$_!'AV",1_9]/,TIQAGDN':4LYZLQ
M##D]NG% '1_&KX8Z9\5?A5XL^'=XL<-EK.C7%I%A/EA>.%O(V ?=VD!5V]!T
MK\B?^"6GQ4N? /COXE_LG^(!<QW/A36K^YT6?4"R-/:QR.$2V\PDNK(!@>@'
M?@?N@>>",@\$'O7X$?\ !0CP-KO[/?[2GPQ_:C\)7!T/PQ<ZK8Z?XMBT]#&M
MWF6,3FX\H*!O&3\W8YH \I_X+??\E(^#O_8,NO\ T8]?5_\ P2$_Y$?Q+_VP
M_I7P7_P5L^*'@[XMZ]\#_$O@W6+?5K630!+=")U+VTDR"1HY@&.UU9RISUQF
MOO'_ ()"2P-X)\2HEQ;R2#R"T4<J/(@&WET!W+^(H _:&BBB@ HHHH ****
M"BBB@ HHHH **** /C7]NSQG=^$OV>_&2Z=H>HZ[?ZI8R6L%MI]NUPZ#!+.R
MJ"?Q. /?.*_%W_@D-J4VJ?M1>.[FYM)["Y_X1(B>TN8S%+$^Y"RLAY!!X([5
M_2YJME9W^GWEM?6MO=V\EM.DD-S"DT;*T3 @I(K#D'TSZ5^ _P"P=;6]G_P4
M-^/=M:016UO#97Z10PH$C11,,!57@#V% ']!%%%% !7D7QWBEF^$_C=(; :C
M)_85\5M]A=LB%OG0 $[E[8_I7KM>5_&C79/#_P .?$M[&=A?3KFW,^TO]G6:
M)E,Q0?>">AX_2CD=3W(QA*4O=C&HW&$I/X5*2E%Q3=E=233U3N',H>^](Q]Z
M3M>T5K*ZM*\;7YERN\;JS/P?^"?PU\!>%_B_\(_%W@ZPN;SQ=K>B^-6\9'RR
MSZ21;7.!<8=VB&>%#HH]ZP/^"27C#3/ ?C#]KOQAK:W<FE:/XW\37EZ+&$W-
MQY45_+*WEP@KO.$/&1CKZ9]B_8AT#PQK?Q;^)?B+3_B;<ZAJ^D:+XF-UX?EM
M,+J!N+:Y+&#S %C2 GYO+Y('0\@?,G_!-&XUK[-^VI%H=I#/>W?BGQ5$//VF
M*WWW5PF6W97:,Y.X< DU,,%5R><Z.-R_^SJ<)+%.CC\ZQ>84YPJ)5*U6IF4Z
M-6O1P[GSQE[&A6=%1DXTYU$Z8+&8?-(JI@LUP&=2_P!WEB,CR:GE?LYQM"E@
MUEEZ5.IB\/2=.%*4JD?K<%2E*<?::?0_[?G[=?P2_:#_ &;?'OPZ\ S:]+XB
MFTNZNY$O]--M:V\<",K)+/O;$A(/R%1CWS7W=_P2E!7]AGX*J>JZ1= _47DH
M-?@Q^T7X&\;?"OP;XBT/6O"^C_V9XN\(ZEK4_BK3I[:XECGD5W$#"#+19/&S
M(Z<U^]/_  2HX_8<^"XZXTJ\&?7_ $V;FM)9AE^9VQ>64</A\+)<JHX?,*N9
M*%2&D_:U:^%P=>C5D_>6'K8>G4A1E2J32=7E3>&QF$?L<=2Q%*NDI+ZS0A0E
M4IR7N581I5:U*<);.5.K.,:JJ4N9NFS]%:***D05^$__  5*O]/A@\36\U]:
MQW4NF 16KRJ)I"8S]U"<U^[%?S/_ /!5+X-^)-2^*_B3XAWGB:X;1+33E-GH
MB.ZPQE5SRH.T\#N,_6@#[<_X(M'_ (Q<O!W'BN^R/3*KC^1K]A*_'K_@BV/^
M,7[^3&"_BR^]^ HX]>,U^PM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS?H#7\H7[5'_  =H_L<_LW_&+QA\%M+^$_Q'^*'B;P5X@O/#.KR>&WBM[?\
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M^'?&&CV?B#PKK>F>(=$OXUELM5TB\@O[&YC8 AHKBW=XVX(X#9'<4 ?P5_\
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M^(SX"_";_@I98_!_X<W'B3PC\78O%LF@V[Z]!J5[>"\BOS&ID2XCW3*C[LY
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MCW_R1?XG?]B7KW_I!-7\CG[-O_)-/C/_ -A'6/\ T=<4 ?L]^R7X:\5>+/\
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M:MJ>I?$KQU_;=H89=-U)X=&NKA<SM;;B/]&D;E4*G.$X//K7A_[4?[3?P?\
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M8C]LJ[_:,T#4-?\ "?PTFU*"V\)-J-S+I]TMI=2*"8@SQ)N"\C: .WI7I_\
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M2: .CJG>ZC8:;"UQJ%[:6," L\UW<16\:@<DEY71?UKX \;_ +<]GJ5X^@_
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M9B*CYY5J=5Z*-.G#D<I/:JL2XT:]?-XYA/$P<ZL9Y+D6$JS<&H4?J^:Y?/\
MM#%X/"4DJ$:&*@U3JRG.I4G4:Y>J_;?_ .36_B__ -BO<_S6OQ]_X(F?ZWQ)
M_NW?_H^2OV"_;?\ ^36_B_\ ]BO<_P UK\??^")G^M\2?[MW_P"CY*DQ/Z,*
M*** "BBB@ HHHH ^?/B]\(3XKN;+Q1H-Q%I^O:8RM+YI2*RN;526G:XR5!D"
MYPQSG')K^4'3_P!F_P :_P#!5#_@J;X^\ _%36"O[//[*%Y8W=SH?G,;/Q'>
MBY39!!"#MF4RC8259%!); S7]?\ \1_'/A/P7H<C^*=3^P0:J?[,A6$++=O+
M>*T*M%;>8DKJI;YG4$+WQ7\S7_!.#XY^%_@E_P %5_VOO@=\2+VV\+M\2IK*
M_P#A9JFJA;3_ (2PO<K.UO%/*5,DNT[40;OGP-U ']/'@3P'X2^&GA71_!?@
MC0[#P]X;T*SAL=-TW3[>.W@A@@0(F1$JAY"!EW8;F/M@#Q7]K+]DSX-_ME_!
MSQ3\%_C3X5TWQ)X<\1Z;=V44M[:QSW&E7-Q"T<=]9NPW1RQ,0PVL#QD$$5],
MU%//#:PRW-S+';V\$;2S3S.L4442 L\DDCD(B(H)9F(  R30!_F'^./^"/\
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M">-/B'^R!\3-*^$OQ,U"Z\2?"OQ7>&V\%>+KMY2-,W.%CM;J5V(C6$$1D/U
MXYQ0!^IE%5X[NUEMDO8[B%[22)9X[E9$,#0LNY91+G9L*G.[.,5\]?%G]J?X
M/_""VW>(/$*ZA>ON2#3_  ^L6L7+3=%CE2UF8Q9;C+ X]* /HVO,/'OQD^&_
MPUMII?%WBS1M*N(XV>+3KB]B6^NF4$B*"WR9&D;HHV]>*^#KGXO?M3_M#2MI
M_P ,/!S> ? EZ=L7C>X>6#4S;N2%E2VFD!5BA#;5 P1[9KT?P!^PKX5BN8=>
M^,_B#4?BYXB1UN8KK6Y)XXK2<G<0D:R_,JGH#P: .(UC]K[XJ_%S4)O#7[./
MP\U**Z21H)/$7BZQ$6DNA)4W%M*ZJFW'S*Q)XP<U=\,?L5^+?'>IP^+?V@OB
M!K>JZJT@FF\*Z3?%_#;9.YH9(A*%9!]S:%(*]Z_0W1M"TCP]86^F:+I]KIUE
M;1K%#!;0I&JH@"J"54%C@#EB2>YK6H X/P1\,? 7PYM!9^"_"VD>'XRBI*VG
M6B0/.5 !>5QEG=CRQ)Y-=Y110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?BA_P6AU34[+X6^![2SADDM;[4[F*^=!E8XS@98]A
M@GT..]?C[^SI^U9^T=\#/!+^%?A'H%_JWA>6[-W)-;1/+"+C))7A6&>?6OZ
M?^"D?P \8?M">#/"?A/P;*ZZB+^4F(*?*E5^/WKC[@7J.0.N:Z3]AS]C:Q^
M'P83P5X^TO2]=UVYOY+ZZN+JWBN9(0X!6%)7WL%0DXVGIP>E 'XX1_\ !2S]
MN")0@^'UZ^!]XV<GZ_*.33_^'F'[</\ T3N\_P# .3_"OZ5/^%3?#C_H3M#_
M / *+_"C_A4WPX_Z$[0__ *+_"@#^:O_ (>8?MP_]$[O/_ .3_"D/_!3#]N
M=?AY=J/4VD@ _2OZ5?\ A4WPX_Z$[0__  "B_P *:WPD^&S JW@[0R#_ -.4
M0_I0!_-0W_!3?]ME/O> YQWYM9/TXY_"H#_P5!_;/3/F>"G3']ZWD_PQ^N?4
M"OZ4G^"GPLE_UG@G0F^MG'S]< 51?X!_""4$/X#T%L]<VB_TP/\ /.: /YM&
M_P""I?[8J?>\) =^8'']/TZ^U0_\/5OVO(V1V\,P?*X.&BDQQS@@KWZ8)'7\
M*_I#D_9Q^"<HP_P\\/G/4_9%!/\ GVJFW[,/P'=@S_#7PZY!!PUKD'!!P1N
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M-?F[_P $T[2"P^%_C>RM46.WMO'>I10QJ %5% P  !_(5^D= !1110 4444
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M$5PEI<?&[1;>ZEP8H)S'"\@.>561PS=#T'M[U?/[=7['H4D_&O0?E7<Q\R$
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M$\(>)?"M[<_$3PQI']K^'K6SFN_$6A:>ADUK4;I S*+-%4M(6   Y.2?:OQ
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MZ 'ZE5R.M_#_ ,!^)IEN?$G@CPCX@N%^[/K?AK1M6F7_ '9;^RN''X-7744
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M^<G_  3>_P"2<^/O^Q_U3^E?HW0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2?'K_ )(Q
M\3?^Q,U[_P!()J_D>_9O./AI\:3Z:EK7_H^:OZX/CT<?!CXF_P#8F:]^/^@3
M<5_%[\-?B_!\._"_Q%\.2Z0VH/XDU+60ERF?]&W3S+DGV.#Z^QH _>']FA]
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MHW 5_0_:V=K91^5:01P1YSLC&!GUJP % 50%4   #  '0 #@ =@*6@ HHHH
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M-+-,-C^+<=G6&RB51>TPV#IY57P="C@9UX<^(A)U76A2:I052DN==/\ MO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU_417\Q?_!-=+!O^"UW_  4X=-QO$GTT$[?E 9XP>>Q(Z?\ UZHS/Z=****
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M165IFNZ)K:-)H^KZ9JL:'#OIU];7BH?1C;RR!3]<5JT %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,%,/BA\8/!7B^S\ R77@C3?#JZE'97=K)-$UVL:R".<NA5N<!N>1^%?.O\
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ME_9T^(]M_P $Q]1_9_6_N[SXBV'P,N]!/E.TD^J:K'I4KC3G*Y+&<D6^T=7
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M,O/U&[A0LEC%YZ'?*<' QSVXH _18?Y_SS_,T444 %%%% !1110!^<W[22?
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MZ&G*D,/NKW%?+/\ P53^(?BWP3\!9K/PW<1V]OK;RPZDQXE:.(%D"-UQGMD
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M0 4444 %%%% $!ZGZG^=%!ZGZG^=% $PZ#Z#^5+2#H/H/Y4M !1110 4444
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M<3EF;&-S$X]*"2>I)^O/\Z2@ HHHH **** "BBB@ HHHH **** "BBB@ /\
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MK0?!NH:WHESH]]#?Z=>WMG8M-!;2RPLP53(JK(&VG;G''-?G5^T3_P $8_\
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M%N_\'+V/^3>OV5,_]A_3_7_K^_#]:_IDHH _CJ^+7[,/_!8+X]^)D\;?&/\
MX)V?L/>._&"/'))KVK:MI;7D\D9!C:1C<G?M('WF(R*^@_ ^M_\ !P_\+_#M
MCX/^&G[)O[('@OPIIB".PT/2-:TV&TMU QA$2[C4< #.TD@=:_J2HH _EO\
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MY\/_ #VB_P"_B?XU_)')XT_X*4Q@EM4UX8]+:[/^?2J;_$3_ (*/QX+:MXA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_#S0++PUX2TFUTG2K&)(HXK>)$>38,>;.Z*IEE;JSL.3774FX>H_.C(]10
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M34O">DZ8^J:C81&V>^MX8EW36S1'I<0@X=<9!X .. #\R_VRO^"X'P.\=_\
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MUW6;Z&"??YL2S2*X1]_S9&[G//K7[/W]Q]ELKJY\LR^1!)+Y0&2^Q22H!XY
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M_*/KP#_V,WBW_P!.-?L=7XX_\$)_^4?7@'_L9O%O_IQK]CJP **** "BBB@
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M^)_[5W[27PN\3?M4?"#Q)X1^)L%_X4TC5+*36;[3;FX73(HHY(_,:=7B1V4
M'($7;UK]D=*_:;^!6I^"[WQWIWQ(T"]\(:,\5IJ>OPR7/V*TN2@'DREK99-^
M<@A8R,@\U^27[6'[/G@G1OVJ/@YI7A/X3:7:^$K_ %6Q76HM+TO9I4L;R1^8
MMVB?+M()W9('.*_8K3?@)\&M/\*77@ZR^&_A:T\+ZH\5SJ.@P:<L>G75P%'[
MV:!6"L^?XN,GDYH \O3]N/\ 96D>"-/C'X69[F:.W@427F9)I7"1HO\ HG5V
M8 9P.:[+QG^U'\!_A[=6-EXR^(^A:#=ZE9Q:A907CW(>XLIP&BN$\NW<>6ZD
M$$D'GIFJZ_LF?LV(T3K\&/ JO#*DT3#25S'+&P9)%/F9W*P# ^H!KIO%'[/W
MP5\:W-I>>*_AKX5U^ZL+6.RLY]1T\3R6]I$ ([>-BXQ&@  7GI0!SG@O]JGX
M!_$/4[O1O!GQ)T'7]3L+*34;NTLGN3)!90@M+</YENB[$4$G!)QT!KE[G]MW
M]EJSGN;:Y^,/A>*:SDDBN49[S,4D3%9$;_1.J,"#C/3C->D>%OV>_@EX)O[G
M5/"?PS\*:!J%Y:O8W-YING+!//:2@K);R.'.8W!(9>^:Y^?]E#]G"YEGGN/@
MWX&FFN7>2>1])5FE>0EG9R7Y+,23ZDYH GF_:?\ @1!X,L_B!/\ $?08?!VH
MS/:V6O.]R+*XN%SF*,K;F3>",<H!GO7PU\ /BWX.^)?[8'B*?P7XS_X232CH
M]U(D=O+*;,<'#(CA>G&,@'IVK] IO@#\%YO"UKX+E^&WA:3PI82M<6>@MIRG
M3K>=OO2Q0;L*Y]<U\+_!#X5:#X _:\\0-X5\"6WA?1CH]U''/86K063C!PJ9
MR 3V&3TQ[T ?J11110 4444 ?EI_P5/^!FL_%[X/:=J&E736J^%KJ2>Y;>1'
MLN#M#2*.J@^HQ^5=;_P3*^"<_P '?V<-/T+5[NRUB;5M0FU;S4BB=1%.%*1/
ME23L)X#="3BOH[]K;_D@/Q S_P! U?\ T8M4OV1<?\*2\)@?\^:<8Q_"G:@#
MZ0_LW3O^?"R_\!8/_C=']FZ=_P ^%E_X"P?_ !NKM% %+^S=._Y\++_P%@_^
M-T?V;IW_ #X67_@+!_\ &ZNT4 4O[-T[_GPLO_ 6#_XW33I6EGKIM@?K9VY_
MG'5^B@#,.BZ,WWM)TP_6PM3_ .TJC_X1_0B,'1=*(]]/M3_.*M>B@#$/AKPZ
MWWM!T8_73+(_SAIA\*^&6^]X=T,_72K$_P#M"MZB@#\SO^"B?A_P_:?"J>2V
MT#1X)?LESMEAL+:!UPC8P8HEZ8'6OYQO@D,?%;P  ,#^U;_@=!\IX'L.WM7]
M*'_!1O\ Y)/-_P!>MS_Z ]?S8?!/_DJ_@#_L*W__ *": /Z3O^";W_).?'W_
M &/^J?TK]&Z_.3_@F]_R3GQ]_P!C_JG]*_1N@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^6?VT_CQ%^S9^S)\7OB^EQ#'K'A/P=JM_X=M)& FU'6TB
MQ96EK']Z29G;< HRN,_>V@_F3_P0M_9]N_#WP4\9?M;^+()8/B%^USKT_P 0
M==M;Z,&^TV(W=TD=N)702I%*<-Y1;_EFI(^[7(?\' _Q#O/#_P )?V9?ASIO
MF7$_Q<^/VA>$+^RA)+/IEW)81R231CK &=@2P*Y!K]MO@A\/+'X4?"?P'\/M
M-CCBM/#/AW3[!$A4+&KB%9)0@7C E=\8X/6@#U6BBB@ HKS'XT>/?^%6_"CX
M@_$<P-<KX'\*:QXF>V52S7$>D6<EV\0 Y)=8R!@$Y[5^?W_!,C_@J9\#O^"C
MWPXU'Q%X'URPLO&GA[6M3T;Q%X/N)XH=2LI=/NGM_-6U=EF>.3;N!$>-N&!(
MKT\+E.-QN!QN88:$:U++W3>+I0FI8FG2J72Q/L%[[PT)6A5K).-.<X*5E*Z\
M[%9KA,%C,'@\4ZE&6/<X8:O.FUA9UX6:PKQ'P1Q-6+E.C2E9U8PGRMM6?E'_
M  7YEOX?^":7QYDTZ6\ANU\.WWEO8O)'.#]G8C:\1$BG(X*D?6ORC_X,W;G5
M[C]@GXK-J]QJ=Q(OQ<NUMSJ3W$A2$'4,+ ]QEBF<$@,P4\9'W1_6-\2/AYX%
M^)_A/4_"/Q&T+2_$7A/4()$U/2]8B26PG@VG>)TD(38%SDD],U_/C^V]_P %
M7/\ @GI_P1G^%'BCP!\#=(\'_P#"?7<=U<Z7\/OAXMC)9CQ"59+=M56SEE$1
M\V3]X7VA1N+G;G'+E. XKSK-XY3E>6^TR)8>IB\RS:KF<<+@LNG2M:>,H54J
M,**C><L3.K'EY;1A.31OFF:\-9/EKQ6/K8AY]4K1H9;E^&PM*O7Q\9-7I891
ME];J5V[QC"$/9+FO4JTXIW_I*HK\^/\ @ES^UIXC_;@_8I^#W[3'BK3+;2-7
M^)6EW.J2Z?:@K#;Q)=RPP*%(!!,:*6X^]FOT'J,316&Q%?#JK1Q"H5:E)5\-
M/VF'K*G)Q]I0J67/2G;FISLN:+3MJ:8>K*M0HUIT:F'E5IPJ2H5DE5HN<5)T
MZJBY152#?+-*32DFDV%?C]_P6G_96U/]HS]D37M:\!:=&OQ8^%VI:9XU\,^(
M+=%34]/TK099M2UF&"X"F18WBB#%5(ZN>_'[ UR_CC2_[=\%>+]$*>8-8\+^
M(-**8SO&H:3=VA3'?=YV,=\XK$V/B'_@F)^U#I/[6/[(?PX^(6G2>9=Z'9IX
M"UYBV6?7?"-I::;J,K _,&DD4%\CE]Y[D#]!J_G&_P""'6H+\'/''[2?['Y_
MT9_ GC/6_&4>FM\K6RZYJ:EI%C8[U619AGC!.W(X&/Z.: "BBB@ HHHH ***
M* "BBB@" ]3]3_.B@]3]3_.B@"8=!]!_*EI!T'T'\J6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PO$_\
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M>/\ 0_$]W#>Z1.]MILSR&W"&$N\V^.,J8]IWX! P,&@#@/''[/'P5^$_QO\
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M$XOVRG^*FLW_ ,";KPL-)NO!NE_:4U,.3]KBC*K]S.WY@<DA<^M???[6/_)
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MW4JO\-N6B4W=63;LW=-;IW0<RA[[NE'WFU>Z2U;LDVTEJU9W5U9WL?A;\%?
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MBPA&:]#H \!_X9@^!W_0A:/_ . \7_QNC_AF#X'?]"%H_P#X#Q?_ !NO?J*
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M(&WGMT-?H17PM^U-\5?%/@3XL?L\^'=", T_QEXJ%AK'F_?,'G*O[OWP?SH
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MHHHK8YS\Y/\ @HY_R2:?_KTNO_0'K^>KX4_\AWX2?]A[4OYR5_0K_P %'/\
MDDT__7I=?^@/7\]7PI_Y#OPD_P"P]J7\Y* /Z%?^";W_ "3GQ]_V/^J?TK]&
MZ_.3_@F]_P DY\??]C_JG]*_1N@ HHHH **** "BBB@ HHHH **** "BBB@
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M'ZK80BO0*X3X7_\ ).?!'_8L:-_Z0PUW= !63>Z[I&G,4OM0M;5ADD3SQ1$
M=SO=<#W/%:U?DI_P41T;QYJVK^%/#WPT\0W5AXC\6O)9"V@GDB\M44DN-ASG
M'.,<<FKA4P5)NKF-:KAL'!.5?$4L/6Q4J,%]IT*$9U9IOW4H0DW*45I>ZB=+
M'5TJ66T(XK&U)1C0PSJ4:/MI.23BJN(K4*%-)-SG.I5A&,(RDWH?3'[97[;G
MPL_8Y^!6J?'+QA</K&@VET=-LXM'9+N2[U(C$=L@A9]S%\*54[L\''2OR&\*
M_P#!>#Q'XTT2R\2:!^S=XZN-'U5F;3ISHFI9FA)_=MQ_?4J1Z[AVKY4_:>T[
MQ)I7_!.^+PI\0-5?Q+K^A_M#:?8Z@VI$WRHRW\>^%TG##8>A5ACV]?Z2?V5-
M \%#]GWX5%O#_A2!F\,:65C32-*B43FVCX1?(SYIX/'SGCMBG.6&J3=3 U*E
M?!U+3PU:K1J4*E2C))QE.C5C&I2EK9PG&,DUJA4XXJG!4\=25#&4[PQ%&,Z<
MU3JQ^*,9TJE:E..SC.G5J0E%J49--'YG_LE_\%M/ 7Q^_:)'[-GC/X?>)?AW
MX[O-BZ3'JVGW-K!>2.<",-.,'KV(/XCG]WJ_F@_:<TC1M._X*]_ HZ=HND:>
M[ZA8F2>QTVUM)I23'D2201(7 /.3U/KS7]+]9F@4444 %%%% '\^/_!<;_5?
M!3_L,'_TI%?I_P#L$?\ )M_@S_K@/_1<=?F!_P %QO\ 5?!3_L,'_P!*17Z?
M_L$?\FW^#/\ K@/_ $7'0!]GT444 %%%% !7Q[^T9\,?#'C?XD? _7];\1+H
M^H>$?$GV[2K(R*IU2;S580JK<L0>,#U_/["K\IO^"B'CC2?AQ\2?V9_&7B*^
MNK#P]H_B\SZI-;&5ML(G4EI+>(@S+@8QC\?0 _5@=!WX'/K[TM?*>A?MH_ #
MQ'X6O_&.E>+)YM"TUF2ZNFTN\C8.HRP2)DW/CGTZ?C7G<'_!2#]E:XN8+5/&
ME^9;BX6UC7^P[SF9W$:KG)&"QQF@#[PHKY,\<?ML?L_?#V/3Y?$GBJYMEU.)
M)[40Z5=SEHY%W(S!54+D'D9.*I^!?VYOV=OB)J5UI/AGQ9=7-[9P-=3I-I-W
M BPJ"2P=@V3@'@"@#Z_H)P"3P!R3Z"OAS5?^"B'[+^C:G>:3>^,KU+RRD:*9
M4T2]9-Z\$!^,\@C.!7EGQG_;[^&^M?"+Q=J/P6\375WXAL(HHGO)=-N+4:;'
M,VV6<>;@NRH3@(<CUR10!#^TO\./A;XL_:#^&/C?5OB)I.F:YX;U6T9-'.I6
MJEVAD3 F'FXC)(Y$A0@]1UK],[.>WN+6":UFBN('BC,4T$BRQ.FT;621"592
M.A4D&OY&OB7J_P 'M?\ B=\-];O/'WB/79];EM;_ ,::WOOH1I\\I5[A((2-
MSB-\XV<$#\1^IG[+'[9W@KP!<^+?"WBKQY>^(?AYI5TH\,:]<V5T]Q86B# M
M)(B#*YZ+N([ Y)Z@'[145\(1_P#!1_\ 96DN8+5?&M]YES=1VD.=#OL/+,XC
MC&0#@,Q R1WS[5Z)\2?VSO@+\)[W3-/\9^)[FPN]7T^'5+*&+2[NY:2RN$5X
MI24 "[E8?*3D?S /JNBODWX:_MK? 'XL:UJ&@>#/%%UJ&IZ9ITNJW<$NE7=L
M([&!2\LN^0$':JGY1SQ7#7__  4:_99TV\O;*Y\:WHFL)IH+C;H=\RK) Q21
M=V!G:RD=.<4 ?=1Z'MP>?3CK7R#X3^&7A?2_VA]6\;V?B)+C6;O3YH9M(\Q2
MT0?.Y@@)X'?ICMP:V;K]LCX#6GPXT[XJ7'BBXC\&:M<O9V.H'3+OS)KE<AH_
MLVWS%Y&,GCUKXF_9F^-/@GXP?M>^(]4\%:O>ZCIYT>[D19DN((MN"0P@EX!Z
M=^O3(H _7^BBB@ HHHH _-/_ (*;_%SQ]\)O@K_:/P^UJX\/ZQ>M/&NJ6K%9
MK?8I(*X93GTZ]^*Q/^"3'Q-^(OQ5_9K/B7XF^*KWQ?XA_P"$AO;;^U+\DS?9
MT *19)8X7MS^&>:XG_@L#>00?!'3(97"R37%P(E+8+G:1A1_$?:N=_X(X>+O
M#>B_LNR6&KZUINFW<?B6\D:WO+R&"79( $81R,K,"0>0#COC- '[/T5RJ^./
M![C*^)=%(]?[2M/ZRT[_ (3;PC_T,FB_^#*T_P#CU '445R__";>$?\ H9-%
M_P#!E:?_ !ZC_A-O"/\ T,FB_P#@RM/_ (]0!T^!SP.>O'7Z^OXUY+XF^ _P
M=\9:FVL^)OAWX7U;57&)+^YTV$W,@Z_/(H4MGN3SWZUV?_";>$?^ADT7_P &
M5I_\>H_X3;PC_P!#)HO_ (,K3_X]0!Y4?V6OV?&>-W^$W@Z0Q.)(_,TN*0*X
M.0P5\C(/M7M>DZ/I>@V%OI>C6%MING6D8BMK*SB6&W@C7HD<: *BCT Q63_P
MFWA'_H9-%_\ !E:?_'J/^$V\(_\ 0R:+_P"#*T_^/4 =117+_P#";>$?^ADT
M7_P96G_QZC_A-O"/_0R:+_X,K3_X]0!\&?\ !1S_ ))-/_UZ77_H#U_/5\*?
M^0[\)/\ L/:E_.2OWW_X**>*/#EY\*;B*UUO3+F7['=%4M[ZVF8DQOM&(Y&Z
MY'!_&OP%^$[HVN?",K+$<Z]J7 8%E'SG+ '/3Z>O2@#^AC_@F]_R3GQ]_P!C
M_JG]*_1NOSC_ .";IS\./'W0_P#%?ZI@CH> <C^7U%?HY0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7E'Q@^!WPG^/OA2Y\#_&#P/HGCSPM=
MAA-I&MVYF@;>NTE61XY4..A1Q@\UZO10!_/9\6/^"$^FZ+KLGBG]BK]H;QY^
MRC(CM<CPIX,GNSH-VX)?R&S=F1$=N#E6XXS7F)\$_P#!<7]FM?LWPN7PW^TA
M%:@1QR>.M82V-\$RHDF::Y1@SX#%LA@3G)K^F&B@#^4U_P#@HA_P7R@\=R_"
MN;]A[X"GQY%:I>&P7QH[(;9QE904U0KAE(8$MCVKU-+#_@NS^T2J6/Q+\+^"
M_P!GBUG C>?P3KD%Q):I)UD62*Z=F:/).69V/K6M\2[W4H_^"X&F6T6JZG#9
M/X&T7?8Q7MQ'9OF& $M;JXC)/?*\YK^D@=!]!_*BX'\Z_P -_P#@AGXA\;>(
MD\4?MK_M2_$?]H[2;F1;J7X:^(+FZ'ARS?=O-M'(+P%HP24)6/[O0FOVV^!G
M[-7P._9K\,Q>$?@E\.?#W@#0HHTC-KHML4>;8,!IYY7DFE8XR<OC/.*]SHH
M**** "BBB@ HHHH **** "BBB@ HHHH @/4_4_SHH/4_4_SHH F'0?0?RI:0
M=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /(OCW/-;?!GXE3V[M%-'X0ULHZG#*38RKD'!P1G(XZ
M@5_"M=,]W/K=S=NUU<G5=6S/,=\K?Z3)U8]>G^><_P!TG[07_)%/B;_V)^M?
M^D<E?PM-UUK_ +"NK?\ I3)0!_05_P $\(5C_9\T^=2=[WLP(/W0,L.,'J=O
MIP".O(K[L'  ]!BOAG_@GI_R;MI?_7[-_.2ON>@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!'-<-(@YSN4/D8QSG'X53GUOQ3>RI9W&I:G=775+-Y)GEW*3P$+%N"/[HY%
M']LO@;XV?":V\&>%HI_B!X;25=#T]65]2A#AEMT5@RY)4@@C!Q75?\+S^$/_
M $4+PQ_X,HO\:_AT/BGQ? 4MO[;U:.4?NXX#<3 AAC]V!YF1CTQVZ'%2MXG\
M;+DG6M8"H=LC>?<8C;T/S\>^<<B@#^X;_A>?PA_Z*%X8_P#!E%_C1_PO/X0_
M]%"\,?\ @RB_QK^'I/$OCB=6>UUC6KE(\^:T4UPXCQC[Y#\#GD\X-.C\1>.[
MC<+/5=<NVC&95@EN9#'_ +P5SC'?VYYH _N#_P"%Y_"'_HH7AC_P91?XT?\
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MBJ%?X@V"O?K0!_;A9?M)? C48?M%C\4_"%U#NV^9%JD;+N_NYQU]JUA\=/A
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M_#GP.1R#X7T8@^O^@P^E=Y7GGPD_Y)AX ZG_ (I+0^3U/_$O@KT.@ K\N?\
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M5_5U10!_*+_PP!^W%_T/WBS_ ,#YO_BJ/^& /VXO^A^\6?\ @?-_\57]75%
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M1N@ HHHH **** "BBB@ HKP?XQ?M,_ _X!2:5#\7/B)X;\#2:V2-+77M2M[
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M4C+_ )B'1JXBG2DFI0G6P]&OA:U>E&<8RE2IXFC*=DN>UT_Y>/VN;2P\+_\
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MSHFE7%O&04AFL+:6)".A5'C901VP..U:\44<$:0PQI%%&H2..-0B(BC"JBJ
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M#U_/5\*?^0[\)/\ L/:E_.2@#^A7_@F]_P DY\??]C_JG]*_1NOSD_X)O?\
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M87_E_P!_[*9?.QW^YTKH0<\CH:_@UO\ XY_%OX?_ /!Q7-H?Q_\ B%XB\"^
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M 4444 %%%% !1110 4444 >._M!'_BRGQ-_[$_6O_2.2OX6CUUK_ +"NK_\
MI5)7]SO[1?F?\*/^)WE@%O\ A$=7Z^GV5\U_#$<8UC'_ $$]4S]?M$G7WQB@
M#^A#_@GI_P F[:7_ -?LW\Y*^YZ^&/\ @GI_R;MI?_7[-_.2ON>@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** / OVH_P#DW_XC?]@BX_\
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M/]J:^^&'AGQGX.\1^'+;Q<OC6:>[GN[DQ--#=W&[$ZR2$LK*6R".>.O6MO\
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MG =3N!#=\#O5WXZ6-MI7[0OPFTJSC\NSTS^SK2TCZ[(HMB*.@'W?3N37S?\
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M"S%B3S7:5^3'_#V7X1_]"YXA^G]FW?Z_)UH_X>R_"/\ Z%WQ#_X+;O\ ^(H
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M2@.@^@_E7\U_Q._Y3C:3_P!B-HG_ **@K^E =!]!_*@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** (#U/U/\Z*#U/U/\Z* )AT'T'\J6D'0?0?RI: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#QW]H+_DBGQ-_[$_6O_2.2OX6CUUK_L*ZO_Z525_=+^T%_P D4^)O
M_8GZU_Z1R5_"TW76O^PKJW_I3)0!_0A_P3T_Y-VTO_K]F_G)7W/7PQ_P3T_Y
M-VTO_K]F_G)7W/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '@7[4?_)O_ ,1O^P1<?^@M7S!_P11'^D>)#CGR[CG'/WVKZ?\ VH_^3?\
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M]"[I'_@%#_\ $T ?RW?\-A?\%(O^@'>?^ ]U_P#&*/\ AL+_ (*1?] .\_\
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M_P J^1?"G@+P)I_[0NJ^+--UQ;CQ-=6$T5SI?F*7C1\[GV9. /TH ^NZ***
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MZG^=%!ZGZG^=% $PZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444
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M^#_V6/'DWPVO_&MA\0_@)XO>06,[31WL/ARWNR0+2XD96W1A'VLNQ1@=OE-
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M3]E?]LWP]\#-+^*/PZ\1V7]M?#GQA>ZK;^']. RNGV]P9E@>93\K1[6'X>]
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M;G.T^GK7\W_QAN;"\^*?Q*U'PM)')HM[XJNY] EM0%MFLFNB8VM@O"QE",8
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M!7PCUKXZ7/Q#^&GCVXMK2;2;NZN9GA5V0%@EQAD)5CU48/ITK^N6L"PHHHH
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M?\*R>)/MUG:F[F_M#0;JSB\I5W';)(<,VWD 9-?4%[X7\,ZDL:ZCX<T*_6$
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MX<M_^"D?[.]S=VUG')XQ\VZNHK2,MX7O53S97$:;F)X7<1DD<#GI7JWQ3_;
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M2:(AHW 96'((/(((ZBOQ#_;>_P""B/B3X _%?Q'\&8M&?48+C2H+NSOXT.^
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MA=W$<*6\!E $TSN0$0XR"?Y'-?2/_!9+P9_;?C'X=20W#^<;>:58<L !$K9
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M_P#'QXD_ZYW'_H;5]/\ [4?_ ";_ /$;_L$7'_H+5\P?\$4?^/CQ)_USN/\
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M PO;TIY^&OQ#8!3X%UL@#:!]DEX'7'W*_1O_ (>MG_HB?A+_ +XL/_B:4?\
M!5IB<#X)>$R3V"6.?_0: /SC'PU^(8*D>!=;RO"_Z)+Q_P".4C?#7XA,P9O
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M[:\9N[>4?9%M4FP"P; 0!3C/8&O]#^WCBAMX8H$1(8XD2)(U"HJ*H"JJKP
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M;C<RS/)\RR'AK"S@\JEG5-X;%9MG#44WA<OE)U:,:%%M5JDU&HM/;0A#DO\
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M 4#@!0%51V50.%4=@.*=1R"P/521QT-% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@7[4?_
M ";_ /$;_L$7'_H+5\P?\$4?^/CQ)_USN/\ T-J^G_VH_P#DW_XC?]@BX_\
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M36ZNG0JXF<:-' K,:DOAP=ZRJ5[6;IT%0Q&$J2KS2<:<5B:*N[RE9-/\AO\
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MZ/>7\E_H=E!9"&"1UGFVIF-7"XSGL,^E?%9_9M^/@X;X>:L" "1]GEXS_P
MK^Q;Q;\(/#WC+XA:3XHU+P_ILMYHDB3Q:C-;(\\H4CY"Y4Y^AX'?->PGPWH#
M'+Z-IA8@!C]B@YP,?W* /X7_ !/\(/BAX*MC>^*?"-]H]JRY$TUO(H88)R6*
M#C\\=\5Z7\!B#\1_AGZ_;;K/K_JCU_2OZ0/^"C&@Z''\*I9%T;30XM+@*ZVL
M4;+A'Q@H@/&!W^M?SB_!%0OQ6^'X   U6_  Z ;3P/0#L* /Z3_^";W_ "3G
MQ]_V/^J?TK]&Z_.3_@F]_P DY\??]C_JG]*_1N@ HHHH **** "BBB@#_/\
M?^#SJX63XL?L.6UV1]AAN;]I0_W!%)K-N9MP)VE2ADR".F<\&OZ'/$OQ5_8[
MMO\ @E))\.[#QA\-HX+W]G/2+>70HY=*%T^KS>';9KAG@"_\?8NUG <MY@Z
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MI8,4O6TR[%JXX*S^2WE'/LV*W:QO$5TMEH6KW;@LMMI]U.P7.2L<3,P&.<D
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MN8GAN88KB&0%7BFC26-U/!#(X96![@@BN8_X0/P223_PB7AW).3C1[ 9)ZG
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MP_H]NMKIFD6<%C90(JJ$@@0(@.T*"V!ECCD\FMF@ HHSCK1F@ HHHH ****
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M;SPY8/8Z?J%[&'MH_)7]RT\T@\UU/).XD@@GKD^I?\))X>_Z#VC_ /@SL_\
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MTOS6TYK<M_.UW:^]KNVUV%%%% !1110 4444 %%%% $!ZGZG^=%!ZGZG^=%
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MO-64?\,KP-M4-_PF$PW!5W$?:LX+;=W<\9H _:WX#X_X4Q\-\<C_ (1^V_\
M12Y_6O6:\E^ W'P7^&^/^A?MO_1:UZU0 4444 %%%% !1110 4444 0W'_'G
M??\ 7O)_Z+K\'++:W[6GB0$*W_$SCX."/^/D?_KK]Y9$#QRQL2(YD9),=0&7
M:2/8#DC_ .O7Y&^/?@/K?PX_:)C\<7DR2:-XKOXGTO8V78F8$AQGISP>W)&,
M4 ?K5IO_ ""]*XQ_H,?'X#CZ#H/;BKE4M-.=*TH^MA$?T%7: "BBB@ HHHH
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M=4NM7TO7-0_M&VT^_?YI84L+D2*%BDRHP2..@K]*=*T?2-$M4L=&TVQTRSB
M5+:PMH;:! !@ 1PJJC ]J^*/B1^PQX$UN=]9^%^K:E\)-=#FY,GA0O;PWMP"
M6 N!YP(5VZX!QD]J\EC^)G[5G[.4B6WQ%\-0>//AW8D1)XATPM>^(7MX\#S9
MHXG9BY0;FW*?FSZB@#]1**^9?A/^UA\(_BM;1FQUM?#^I$A&TCQ.\&D7YFX!
M2.*YE0RD-\H  8GH*^EHI8YD22)TDCD4.CHP=64\AE920P/8@D'L: )****
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MM0!_191110 4444 ?@S_ ,%QO^1'^$7_ &'KO^<=>"?\$6?^2Q^./^Q<D_\
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MOVMP&^ /C[/;3D8?42BJG[(Q)^"7A//)^QIV_P!E*N?M;'_BP/C_ /[!J_\
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M9GD>'>?O;0P%?>U%;&(4444 ?G+_ ,%&_P#DD\W_ %ZW/_H#U_-A\$_^2K^
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M ?\ O@?X4 ?;VX>H_.C</4?G7Q#_ ,/ OV??^A@/_? _PH_X> _L_'IKY/\
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M +9-\R[)UT2.YFN/*SU=;7YPON>!Q0!_=A_PL7P)_P!#=X>_\&UCV_[;4?\
M"Q/ G_0W>'O_  ;6/_QZOX>_^$Z^-W]WQ_\ ^ 6K_P"%3V_C'XZ73;(5\>YS
M_%9:N ?IWZ^U ']OO_"Q/ G_ $-WA[_P;6/_ ,>IK?$+P$ZLC^+?#K*P(93J
MUC@@]0?WU?Q017O[1%PFZ*/QQCMFUU8'/U/_ ,3^=2^=^T=_SS\;_P#@/JE#
MUT:NGHT^H)M:K1K5-=#^SMM9^$#2>:VJ>#VDW;]YU"P)W9SN_P!?USS6^GQ!
M\!1HL:>+/#JH@"JHU:Q 50,  >?T Z5_%+YW[1W_ #S\;_\ @/JE'G?M'?\
M//QO_P" ^J5C2PV'H.3H8>C1<[<[I4H4W*VW,X17-:[M>]KFU7$XBNHJO7K5
ME#X%5JSJ*%[)\JG)\NB6UMD?VN?\+$\"?]#=X>_\&UC_ /'J/^%B>!/^AN\/
M?^#:Q_\ CU?Q1^=^T=_SS\;_ /@/JE'G?M'?\\O&_P#X#ZI_A6QB?VJR_$_X
M>0 F;QKX9B [OK-@H_,SC/X5G/\ &7X41G;)\1/!Z'.,-X@TQ>3GUN/:OXJK
MO3_C]?\ %U;>.7!&"!!JJ\=^<G/Z?TKF[GX>_%F[;=<Z1X\D.<YQJZ].1P#V
M^O;I0!^H?_!9OQ5X9\6>// 4_A7Q!I7B*.+3IEN&TB\AODMVVL-LDENSH"0<
MCD]17W5^P5^T;\+/@C^Q1X/OO&?B2RCO+.>\5]$LYHI]8W.P*_Z$)!(H./O.
M%YX .:_F^E\ _$"VE6"Y\,>+KF1U+*;NPU"Z(5>6PTP<CUX(^GK0L[?QOIEP
MTMGX>\9Q/$^!"=,U-K57!.2MOL\L<YY S0!_4%+^U3\7OVB9Y;+X(3>&O"GA
M"8F&]UGQ1<QV6KQV[</);K(P97V_=V]3W-=[X _98^#UE?#Q!\6_BM;_ !3U
M:X87%QI?B+6;.;2;*Y)W%+6)KXN$1\@9C3@ =LU_+@OCKXU1($@M?&MH@_AM
M-+U*V7 ]?*1<^^?>G#QO\<3R(OB"<\Y%AK!_DM ']LWA_7_A+X5TZ'2O#FK^
M$=&TZ!0L5G8ZA800HJC &T39.!P-Q)K<_P"%B>!/^AN\/?\ @VL?_CU?P]GQ
MU\;P=I3X@!NF#9:N#G\1Q^-6X?%GQWN/]4GCSM@-9ZL#^?3O[?C0!_;S_P +
M$\"?]#=X>_\ !M8__'J/^%B>!/\ H;O#W_@VL?\ X]7\3<.I_M"3_P"KC\<?
MC:ZMT_''/I_*K)F_:-XQ%XW]_P#1M5']3_2@#^UO_A8G@3_H;O#W_@VL?_CU
M'_"Q/ G_ $-WA[_P;6/_ ,>K^*/SOVCO^>?C?_P'U2CSOVCO^>?C?_P'U2@#
M^US_ (6)X$_Z&[P]_P"#:Q_^/4?\+$\"?]#=X>_\&UC_ /'J_BC\[]H[_GGX
MW_\  ?5*/._:._YY^-__  'U2@#^US_A8G@3_H;O#W_@VL?_ (]1_P +$\"?
M]#=X>_\ !M8__'J_BC\[]H[_ )Y^-_\ P'U2CSOVCO\ GGXW_P# ?5* /[7/
M^%B>!/\ H;O#W_@VL?\ X]1_PL3P)_T-WA[_ ,&UC_\ 'J_BC\[]H[_GGXW_
M / ?5*/-_:./ B\;D^@MM5)]\  DT ?VN?\ "Q/ G_0W>'O_  ;6/_QZHW^)
M7P_C^_XR\-I_O:Q8#\\S\?C7\1]GXG^-^HWMQIEAJOB:[U2T.VZTV%K][Z%L
MG(>V5FE7&#D%>O>K\T/[0UQN$T'CAL\$?9]5XQSZ@Y]1^5 ']BWCT_LY_$>T
M:R\<ZC\/M=CV%(WU'5-,DD@)Z/%(;E2K*>1SP>HKX;U_X':!\/\ 4IO%GP"_
M:+TG3+R!C-;>"M5\2V!\/,02RPB.*\EPG12'C!QD<YK^;>;PY\<+G/VBP\=.
M",?ZK5A]?S^IK+D\ _%N;_6:1X\8]\?VRN??AL_KB@#^F+PK_P %&-)^'NM6
M7@K]H74/#Z:_=7$=I;:GX-GBO-,P7$2R3E&V <Y;#+CKQTK\?/\ @JCXT\,?
M$#]I;2O$?@_6+/7=&F\*6JB]L95FB1S'_JV*YP_3*GD'/7%?"[?##XCOS-X6
M\6W#]!+<V6H3R@\8(ED#."#T(88K#U3PQXH\.Y.OZ+KEA&^0EQJUM=QJ3_=2
M:YSD <;5;K0!^@_PV_Y1A?&7_LH$'_H=?G!IG_']X5_[#>A_^E4-?H_\-3G_
M ()A?&4CH?B!!_Z'7YP:9_Q_>%?^PWH?_I5#0!_=Y\)/^28> /\ L4M"_P#3
M?!7H=>>?"3_DF'@#_L4M"_\ 3?!7H= !7,^(?&7A7PFL+^)O$&DZ$EPVRW;5
M;ZWLEF;^[$9Y$WD=]N<5TU?E)_P5&T>R\4>"O"/AJSTZ[O?%NH7\JZ(]O-/:
MQPM@$F6:-E4 X[GCU%;X=X=58O%PQ$\-%.5982K@J-=4XIN4X3S'$87">XES
M.-2O&4XIPI*564(O&O45*C.HZU##J"3=;$QKRH05TKU?JU*M5C%WY5-0<(2:
ME4<::E)?/'_!<;Q-H7BO]D[P%J?A76=-UZSC^,'A]3>:3>V]]!')')&&1Y+=
MY55PW!1L'KQ7Z2?LP_%#X?V'P/\ A3H^J^-_#-IK4GAK2K8:;=:UIUO?-<-;
MQ[8A:/.DH9LC *#)/4FOYT/VCM/B\-?\$X/#FA7%G>Z?JVF?'C38];%W/-<>
M;=K>1[I(99F8LF<XVDCCIUKS[0_ *'QCX/\ BCXMU+Q7I_AO2]:\+6]C=V+Z
MB]HTKO;K&KI&WD*I)&>WTQ6BEE+KRY\56P^&K5*=/+U5^K5,3BJE5I4J"6&K
MU</*O4B^:*IU916D92C)22=*M"5*-23E*$J52K[3#T,16BHTX<[JN,:?M/81
MC[TZG*K0O-<T;,^X?VIYGD_X*Z_ 3:X:!KZP>(@*0X)B^97499""-O)'IP*_
MI-K^9G]H(H__  5-_9;FAD::WGT[0)K:5_OO \,)C9QU#LI!.>>2#SS7],U<
MK5FU9JS:L]U;H_/N:K9/1W2=U>SNKIJ]G9]+I/NDPHHHI %%%% '\^/_  7&
M_P!5\%/^PP?_ $I%?I_^P1_R;?X,_P"N _\ 1<=?EY_P7&D7;\%8_P"(:OG\
M#< Y/I7Z@_L#LK?LW^#=I!Q ,X[?NXZ /M&BBB@ HHHH *^0OVB?&WP^\-?$
M;X):3XNT:/4M:U[Q&+?PS<O'N:QNS*JF1&VG:<\YXKZ]KX%_:S^'/B_QC\7_
M -F[7?#U@MWIGA?Q:+O6YB<&UM_/5_,'8G;0!]\C@ >@I:** "BBB@ HHHH
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MSR*@+(X;"[B,M@$X&?IBN)_82\9Z=XS^!.AW>FW$=S#9,UBTD3;DWQ*H89'
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MP-^R_P##>R\ ^"X&;=Y=UK6J3!3=ZMJ6P^;=7$@RSL[LYR6.<CTH ^C:***
M"BBB@ HHHH **** "BBB@#\*/^"K\0F\>?#1&) %A>,,<$%5D/7_ #CK7XW:
MS\)M 7X,K\2H05U^Y\23V5R[8P\'GE /<XZ_G@YK]E?^"K7_ "/_ ,-?^P=?
M?^@2U^7VKC_C%:#C_F<)NW_3R* /I?X<?\$\/ OC+P'X5\5W5VBW.O:;%>SJ
M=G#NH;N">,^OX9YKM?\ AV9\/?\ G\C_ /'/\*^W?@,!_P *7^&_ _Y%^V[?
M],EKUK ]!^5 'YD?\.S/A[_S^1_^.?X4?\.S/A[_ ,_D?_CG^%?IO@>@_*C
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M7A6>2.+4;.WO8HW X=([F.548=BH!%?67_!<7_D2?A#_ -A^Z_\ 0HZ^7?\
M@BQ_R<;X^_[%*?\ E0!_2U_P@/@7_H2_"G_A/:3W_P"W2G+X#\#H<KX-\+*?
M5?#^D@_F+05U=% '-#P9X0 P/"OAP#T&B::!^EM2_P#"&^$?^A6\._\ @ET[
M_P"1JZ2B@#F_^$-\(_\ 0K>'?_!+IW_R-1_PAOA'_H5O#O\ X)=._P#D:NDH
MH YO_A#?"/\ T*WAW_P2Z=_\C4?\(;X1_P"A6\._^"73O_D:NDHH YO_ (0W
MPC_T*WAW_P $NG?_ "-1_P (;X1_Z%;P[_X)=._^1JZ2B@#F3X*\',06\)^&
MV(Z$Z'IA(^A-KFH/^$!\"\_\47X4Y.3_ ,4]I/)]3_HG6NMHH Y+_A / O\
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M@#]84O;-T9X[JW>.,?.Z3(R(,9^9@Q"\<\D<55&MZ,Q 75M-))V@"^MB2?0
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MN_$6BZ?XN\0>*%31+I#-KL\DUQE0>79F8$],\GW-4(_9ZBBB@ HHHH _#/\
MX+;"<?#?X<R117+HFJW9D:#?L4  CS0O!'7&<?6OD3]@K_@GU\/OVI_@O+\1
M?%<\EOJBZM-IT,<D3#*0]6RR'&5(QCCKS7[B?MO^ ?#/C+X&>)+W7]-AOY]
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MX5U2TUK0-=L;?4-,U*RE6:VNK:XC$D<D;H2""#@CL017\ '_  <7_P#!%?\
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M3_"6+4/B)KGC/POXC?4I5_LRUUF[MXE@0\.T<;8!;G&%Y[XKZ4O?^"0_P?\
M+,5W\2/&T$;_ "-O\27L1(/&%+.OS>F.?H: .*^ 7CJXL?\ @HG\4/#O@#Q?
M+XJ\&Z_<[M;M[.X^WZ3IS+)D".>*26!<'.-I !VX[5^X5?('[+G[%WP6_96L
MM0?X<V%S=:QK6&U7Q!JET;^^NV)SE9Y 74'GHQX)%?7] 'S]^TS\<-,_9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB3)WH>WID4 ?J_17FGPG^*GA7XP>#].\8>%+Z.[L[N-!<PJ?WUA>;<S6=PI
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M)X7TVWTG0=,L]+L+9%CC@L[>&W4A0!N<0H@=R!\S$9)ZUM4 %?C;_P %H_\
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M4@*'C.0:Q-3W:BBB@#\Y?^"C?_))YO\ KUN?_0'K^;#X)_\ )5_ '_85O_\
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M** "BBB@#P+]J/\ Y-_^(W_8(N/_ $%J^8/^"*/_ !\>)/\ KG<?^AM7T_\
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M/GP[M=33PMX.M)7CN-1O[%)I+>6]@'E!B1&'9W!Y.<Y//>?"3X9_'#_@I?\
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M>2(>#;:UCU:-(R!.]ZPR=X')&>.>H&,U_237\PG_  6/'_%[=&X_Y@D7;VH
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ME%%% !1110 C=#]#_*OAGP/\4O%.K?M0ZWX%NWB.B66G7$T(4C?N0'&1R?\
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M-99@@6XU"X1=K7=VP)\R9\L2Q)/)YYH ]?HHHH **** "BBB@ HHHH ****
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M?F'^UOYWQ8_:%^$W[.=Y>W-OX<UZV'B35(H'VI<"RD+^3<*"-\3JF&5C@@T
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M_7__  97/_Q5'_#I#]HG_H?]?_\ !E<__%5_4710!_+I_P .D/VB?^A_U_\
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MF1UXR*_ODC_;V_9&FTH:U%\<_ KZ88?M NAJ\&PP[2^_!(;!49'&?:OY_/\
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MCO\ X*B_L>_#WQ//X4UOXBF?4[.X-M??V7IT]_;VDBOL823PGRSM8$$@\8H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '@7[4?\ R;_\1O\ L$7'_H+5\P?\$4?^/CQ)_P!<[C_T
M-J^G_P!J/_DW_P"(W_8(N/\ T%J^8/\ @BC_ ,?'B3_KG<?^AM0!_191110
M4444 5KS_CSN_P#KVG_]%-7YS?L2?\CI\8/^QJU+_P!'25^C-Y_QYW?_ %[3
M_P#HIJ_.;]B3_D=/C!_V-6I?^CI* /TBHHHH **** /DO]M_POXL\8_LU?$?
M0?!5J;WQ#=Z9_H=L%9FEV'<ZJ%();;G '6OX[;/X=?&30];BBB^'_C*UU_3[
MLJMY!HMX4CNT?F1&"_.N[D')!XYXK^\1E5U*NJNIX*LH92/0@@@_C69_8>B%
MBYT?2BY.XO\ V?:;B3U);R<Y]\YH _B$\8>,/VD-#\B+QWKGB[2D 5K1=1CN
MK157 $>P,X  P.@['!STX^X^+'Q3OXPM[XXU6YCA38D3SRL@C*\KM,I!XX],
M=J_;K_@K%\.]1\:?%WX2^'+._M=(T3Q"UKI-PL%M'$\=Q<R^4+DM&@+%-P..
M3@ >@K\[/VT/V)E_8ZA\$31>-YO&*^,K83$7$#V[6,@5"ZKN^5HQN"H?O$=5
M!P* /B2::>YE>XNI6GN)26EF?EG8\D^P]OSYJ(]#]#_*@'(!]1FEH _5S_@E
M1K.B:/XB^(\FMZKIVF12>%]:2-=1N8;99V:RE'E*TS*&+YP IR<XZUYC\+?V
MZOB5\!H?C)X0TO4&;1M4\4ZP_A*SA8-!83->R$SP-G_EH.=PX(]<5^>L-S?6
M;,^GW][82/P[6=U+;;QT(;RB-P(Z@Y![U&V7.^0F20\L[G<S,>2Q8\DD\D]3
MWH _9CP]^W#=_M8:O\*?A1\2/LOAJTT/7--U"[\1"=(WU*[@=<QW+NXC1"!A
MF^4-RQ/&*_1#_@I?XK\*V?[(VJ67AK7O#^HZEI]QHQTBWL]5LKRY2:U4>3<)
M%;W$DA9& 8DJ1D]>@/\ *NIDB=);>66VFC;='-;R-#*C=F61,,#[@YJ]/K/B
M"\C$%_K^LWUOW@N]2NKB$D  'RI'*''NO';CB@#]._"G_!4;XN>$_!_PNT6:
M]DU;4_":Q+K[3$!=1LHHUCAM9B2<JB@+SR ./6OO#]C?X]^&/VG/CWXC^,WC
M/4=+\*ZQI_AQ].L] N=0@M;/RXXBHG1[J9#))C+$!F8XZ#H/YQ=H]!SUXJ:"
M[U&R9GTW4K_37<;9&L+N:T9UQC:3"02.?\Y- 'L?[6L\%W^T5\9;BRN(;ZTD
MUNZ^SW=JXE@G3S6^:*1?E=<8P0<$<^E?N;^R/J'A^3_@GIK&E7^LZ=!-)$^^
MVGNX(IUPO_/)F#DY[ 'KSC(S_.2V^0NT\LMS+*299IW:665CU,DCDNQ/J2:Z
MFR\<^---T>7P]8>(+ZUT24$-8Q7,R18;@C8K;#Q[ T ?UZ?L:^(?".E_!6PL
MCXFT%##-/\DFJ64,@&P]8Y9T?MUQCWKYC_9FUC0('_;*G&MZ6OVS5]=>%GO;
M<+*ABNP&B8R!958D &,MDX_'^:"S\9^-M.A-MI_BG6;2#DB.+4+I%!.<_*KA
M<9/859TKQ[XWT.*_ATOQ%J%O'JN[^TMMW.#=%_OF4J07W<YW$GGK0!^^W_!.
MK5=$B^&G[2-OJ&K:=;+=2^( HN;N"'?N\_!C#R*[@]M@).:^P/\ @GUXB\+Z
M9\$-5M;CQ%HMLR^+M>(2YU6S@D"M*VUO+FG5PIQP<8/.*_E&TCQQXQ\/P7MK
MHNO7MC;ZD6-['#<S1B;S/O[PC?-N)/)]?SALO&7C/2XY(=,\3:M902.TKPP7
M]S$AD<Y9MJ.!DDG)(S0!_3Q\$+_PG;?M#?&'4XO$.C_Z3;:F1)]OMA&Q99<;
M9&D$;Y[>6QSVKS']@/5](A\6?MDFXU33XDGU#4WB>6[@B6:(0WP:2/S'7>@W
M %ERH)'J*_G;TKQUXUT2XN+W3?$>I0WEV"MS/]LN T@;[P)#$G/^UFI](^(/
MCCP_)J<VB^(;^PDUK?\ VJT-U-&;O?G=YI4YDR"1\] ']3O_  3L\1^%-)^%
M'BBVN?$NAVDA\<:Y-]ENM4L[>1%-S(=^V>6,E6_A*Y'7I6!X4U;PQ)_P4#UK
M4;37])N(9?!DR">"_MFAW[<E/,$GENWR\A6)QVK^7"S\7>,-,\T:9XDU:R2=
MVEEC@O[F)'E?)=RL;J,LQR<^]7-,\=^-M&U-M:T[Q+JD6K.OEO?&]N#.8SU4
M29+XZ\$]* /WZ_9;UG1[?_@H+\?;J?5]/BMI=7N?)N);N".";<[CY)G=8VYX
M!5L'MFOVLN_&WA"RMY[JZ\3Z!!!;*SS2R:OIZH@12Q+$W'8#Z^U?PLV/CGQC
MIFJW6O6&O7UOK-ZQ>[ODN)4EG8G.7D4[R?0DG%:^I_%OXGZQ8W&FW_C+6I+.
MZ&)T74;I68=P&W9&>_(_P /[#?\ AL_]GX7%Y;'QWI@DLKAK:8B6(H70X8QL
M)<,H[$=>/6O@3XC_ +1/PAU']N_X0>-++Q38R^'M*\)WMGJ&J+*A@BFE1]BR
M MA2NX <@\9 -?S6*UTHQ_:&I$G[S&]G+,3U9COY)[DTA\\_,;V^,G\,INI3
M,H]$DSN4>P- ']/?[;G[1GP4\<>$=$LM'\66.I2VFJV\[^1,@VB.X1R>')(&
MW/0?2OC3_@IK_P *I\<_L\?"3XK>#=8TK4_%45MIWA^Y6UO;:6^2UAAC5Q<6
M@E:XB*,"I+)M88.0<U^)Y\]OOWM_*/[LMW*ZY]0&8X/T^M!>[*&*34;^>V )
M2TN+N::V1L?>2%W,:GZ+^- 'Z+_#(D_\$O\ XQ$]3X]ML_7<,U^<>F?\?WA7
M_L-Z'_Z50U^C_P ->/\ @F%\91Z?$"W'_C]?G!IG_']X5_[#>A_^E4- ']WG
MPD_Y)AX _P"Q2T+_ --\%>AUYY\)/^28> /^Q2T+_P!-\%>AT %4Y]0L+4[;
MF\MK=O2::.,_D["KE?DS_P %$/$?Q5\,W_AG3OA7:7>M>(?&3RV%AIUI-*KQ
M2HAW.5CY QDY/'IFM*3P\9.6*EB(4(Q<JD\-AY8FK",5>4O91:;BDG=]';N1
M..)J)4\'3HU<3-J-&E7Q%/"PJ2;2Y?;56H1>M_>:T39]??M6?M@_!W]C[X.Z
MI\;_ (K:K<?\(9IDIMV?1(TU*[NKK&1;6L44F))21MVABP; QG-?C?I?_!S#
M^QGK5G'J&F?"7]I"\L9W9;>ZA^&VIO#<*IP'B=8B&5N"I!Y!%?(_[4>N^-/$
MG_!.RSTWXHVTS>*=!_:"T_3M4TW42UVBRK?1B2WECGSNC/0HPQP<XR:_HS_9
M8\%_#:3X ?"QIO!G@2.9_#&EGRU\.:"A$YMX_NJ;0MYI..?ODX]J<U2G.3PG
MUB>'=I4I8C#RP]=TY).,JM"5Y4I._P +>UGUL$57IQ4,9"E1Q,7R5Z=*M#$4
M854[.-.O!\E5=I1T?0^%_P!D7_@NA^R+^V%\8O\ A1O@S2/B9X.\?/@6NG^/
M/"]QH:W;'&$A:X\LLQR/NAJ_:6OYF_VEM!\/Z-_P5W^!,>B^']"T8-J%BTDN
MD:39:;+.=T1(F>SAB,HSU+=<^YK^F2LBPHHHH **** /Y\?^"XW^J^"G_88/
M_I2*_3_]@C_DV_P9_P!<!_Z+CK\P/^"XW^J^"G_88/\ Z4BOT_\ V"/^3;_!
MG_7 ?^BXZ /L^BBB@ HHHH *^%/VJ/A5XM\=_%G]GCQ%X?C@?3?!WBH7VM-*
MX5TM_/5\QCJQV@^U?==?GA^V/\1]=\#?%O\ 9LL['6UT?1==\7"VUPRN(H)[
M?S@"LLC.B* N>7.!Q[T ?H?16'#XE\/7%O+=6^MZ5/:P &6XAU"TE@CX!P\R
M3-&I .2&88K,7Q_X(9@J^+/#S,S;%4:O8%B^=NT 3Y+9XQ0!U]%8%]XJ\-::
MD3ZAKNDV23@&)KK4+2 2 ]"ADE7<#V(R.:CL?%_A;4Y3!I_B'1[V91N:*UU*
MTG=5[L5CF8@#N<<4 ='17*3>.O!MO+)!/XHT&&>(XDBDU6Q61#TPR&?(/'0B
MO)OC;^T!X6^%?PWUOQK87VE^(;NQC2.STVQU&UG>XN)SLC#>1,Q1%)#,S;>F
M,]< 'Q3^U?\ !#QWXP_:?^#GCO1DM#X?T35;!K]YI LH$4B%PBYR2,8Z<]#T
MK]5H1MBB'7$:#/KA0*_F<^,GQ4_:3U_XO?#K4)OBM;:&WBZ]MK[0M$@O4,&D
MV\[+)#'<,CE%*+A2'(/TK]??V7/VE;_QC+K_ ,/OB==Z;9>+O",J6@U=KVW6
MUUZ%4&;Q93+Y08XS]X9SCDXH ^ZJ*Y$>/O!)?8/%?A\N7V!1J]ADOG&W_CXZ
MYX^O%7[_ ,5>&]+\K^TM=TFQ\Y0\0N]0M;<R(>CH)95+*1R& *D=Z -^BN>L
M/%OAC5)6@TW7](OID7>\5IJ%I<2*@ZNR12LP0=VQ@=S527QWX+@E>&;Q3H$4
ML9*O&^K6*NC#J&4SY!'<=1WH ZL\@CU!KX8\$?"OQ;I'[4>N>.KQ(/[ O=,N
M(H9%<&0L^=H903CVZ9XX[5]E_P#"2^'FL/[2&MZ5_9S!@M\=0M1:,0#D+<&7
MRBPP<@/D5\#_  N^)^J>)_VK_$/A^U\1V^J>';73;IXK:UN%N(ED3.U@T;NA
M'<8/K0!^BM%%% !1110 UU$B.AZ.K(?HP(/\Z^.OA9^QIX%^%/QR\7?'/0]4
MOY-=\802P:AI\J*+1/-;+.A#GG_@(ST-?6>LZOIVB:==ZCJ=[;V-K:V\LTL]
MS,D,:JB,Q)>1E&>.F<^@KR3X(?%?3_BUH^MZSIEQ%=6FG:W=Z5'/"X>.06[8
MW!E)!SCJ/2@#V^BBB@ J"YMH+RWGM+J)9K:YB>&>)QE)(I%*NC#N&4D'VJ>B
MDTFFFDTTTTU=-/1IIZ--;H:;333:::::NFFM4TULT]F>->&/V??@_P"#=:U#
MQ%X9\"Z+I&M:G%<Q76H6T+"=DO PN I=V5?,W'=M S7Y"?$__@A)\&O&?Q@\
M4?&'P7\5_'?POUCQ?/<7.LV/AEC%:SSW+F260^7=0?,[$Y.WO["OW@HK*C0H
MX>+C1IQIQDU*2CU:BHJ[=V^6*4(J]HP2C%**26E:O7Q$E*O5J5I132E5G*;2
M<G)I.3;5Y-R?>3<GJVS^;CXH?\&Z?P[^+OAN/PGXS_:=^+NI:$+M;J:RDED:
M.?:P)C=3J)!5@,'CI7[B_LN?L\^&/V5_@?X%^!?@V\N[_P .^ ]+32].N[[_
M (^YXE8L7F^9OF8DD_,>2:^@J*V,@HHHH _.3_@HY_R2:?\ Z]+K_P! >OYZ
MOA3_ ,AWX2?]A[4OYR5_0K_P4=_Y)-<<'BTNB?8;'YK^>KX4G_B>_"3_ +#V
MI?SDH _H5_X)O?\ ).?'W_8_ZI_2OT;K\Y/^";W_ "3GQ]_V/^J?TK]&Z "B
MBB@ HHHH **** .;\6^,/#/@70K_ ,3>+M;TWP_H6FPO/>ZGJMY!8V<$:*6)
M>>YDCC!P#@%LFOA7PQ_P4_\ V'?B!XUD^&FE_&WP3?:Y+</I_P!DN=4TX6ES
M*6\IHDEDN3$ZL2!SP<U_-C_P>$?M6_%GX4_#G]GWX _#?Q)>Z#IWQJGU*+Q*
M-/N9[2>XC@O'M88_-MY(W&_?$F-W1BV#TK^=[XO?\&^W[5_[.G[#^A?M[6GQ
M1U/^UK31--\=7^B6MS>17FE:7<Q+J$%V;I'$A8QA77=(0WR[@17J5<Y\.LDP
M>7X3BS"<1YMC.()SPW+D^'Y\'E-)U8454QD/J..ABE-34YPQ%3 8=1E"#K-S
ME*'F+)..,[Q&-Q'#^9\.Y/@\I4*D:>;*,\3FM10]LX8:I/'X-T97A4IPC1IX
MBJO9RJ;N$'_HE_M3?\$O/V#_ -K7PQJ6H?$WX4> A)J5G+<-XWM+2SBGCBFC
M+?;%O?.CMF0*=XEW!3U#5_*)^RA^P7^P/^Q-_P %T/@)X9_9N^/%WXZ\3S6?
MB"XN/"%C-97VDZ9/-#*L\)N[03 &-411&+E@-O !)-?D7XV_X."?VUOV@OV5
M/A7^Q+\"8O$C^/'T:Q\+ZMXET6*:X\0ZL@"6C6YE1S<!G3<%G?<B [ONC!_;
M/_@W[_X((_M&?"#X_>"_V^OVJ?$>IZ/XRTVVO;W2?".KM/>:I>-K4 ,EQ>74
MY=\[6!VEE"DMM7G ^7S;AOPMX(S3"PRW,\VK\6YO5A+!9/P7BZF%RNAE]1I1
MQ/$&#IPQ.#]G&F_]LHT,/@Z-*3E!9E5J2C2G]-E&;^)7%.5XBIFL,#E_".7J
MI&OB^):4<9F6-S"A#E6'R/&UDL91@ZO+&@H5*]65-WKX7"T>:H?W74445ZAY
MAQWQ$N=1LOA_XYO-(\S^UK3P=XFN=+\H%I?[1@T6]ELO+5<L9/M*1; !DM@#
MFOX=?^"?/_!S/XM^$?QS\<?LT?\ !0KP]JWAN"V^(GB#3/#'CB_L;Z"\BL?[
M6GM;**_2ZCA00B-$=9MS1-&0R/UQ_=TRJZLCJ&5@596&596&"I!X(()!!X(K
M\+/^"G__  0@_90_X*'^'M7UE_#>F?#_ .,36\TFE>.]%LHK:<7H1FB>XCMX
M0&9Y"-SD'J2:/]:LTX9UAPU@^*^'<4U_K!E3FJ.<1ITFO88S)*_(I1Q6'C4K
MR=.->FZBM:EB6E1D?ZMY-Q%[F+SK'<-YUADWD6=T.>IE^'K3:=;#YMA(N2K8
M3$\E.,I.A7Y$I+EAS^VI?L/\*?C%\-_C;X0TKQS\,O%NB^+/#FLVD-Y9WNDW
M]K>#RID#J)DMYI3#( <-&Y!!'>O3:_S%=*O_ /@K1_P;K?%PV][:>,/BA^S*
MNL$%0+[4M)U#2TF.2FYF-@K0YP,K$#PNT#%?V=?\$ZO^"Y/[('[>7P_T_5;;
MQKHW@'X@P6L0\0^"M?O8K.ZL+P*JSHC3R $"3< K-G //%?18++\GXNP$\[\
M/,PGQ!@:;:Q^2SINEQ/D-5/WL-F>566(FJ3NGB:-*T4N;$4L-*2@>'F6+S;@
M[$T\NX]PE'*G5CS8#B3#S53A?.J*TCB,-F//.EA:E1[T*]5T^=^SHUZTDTOV
MPHKY_/[4_P"SV"0?BUX)!4X/_$^T[J/^WBNO\%?&KX5_$74;C2?!'CCP]XEU
M&TC$US::3J5K>3PQ'@2/'!*[*ON17)7R#/<-1J8C$Y-FE"A2CS5:U; XFG2I
MQNH\TZDZ2C%7:5Y-*[2W9GA>+.&,=B*6$P?$&38K%5Y<E##T,QPM6M5G9OEI
MTH57.<K)NT4W9/L>HT445Y!] ?S7?$[_ )3C:3_V(VB?^BH*_>;]HW7O%7A?
MX"_%GQ%X(@EN?%^B^ ]?U'PY;P(SS3:O;6,DEE'$B@LSM*%"@ DFOP9^)W_*
M<;2?^Q&T3_T5!7])DB120NDZ1R0LA$J2JK1LA'S!U<%2N.H(Q34ZM-JI0<%7
MIM3HNI'G@JL?>IN<'=3@II.46FI*ZZARTI^Y7C*="7NUHQFZ<I4I:5(QJ+6G
M)P;2FM8M\RU1_F+W/_!6;_@O=#JNN0VWPV^($EO!K>J06[?V!K*X@BO)HXD7
M_1/F54 PRDJW4''%97B/_@L?_P %V/!FBW'B'Q=X,\6^'-$M4:2;4M8TK4+*
MU5%!)/GW4$:'A3_'G\:_MU_X*&?\%5/V%?\ @GKX4U2\^(>H> ]6\>I;S2:1
MX(TZRTBXU&_O%1F2*7R8G,.YP%.><DYP,U_"3^TC_P %&/\ @H9_P7&^*%W\
M%_V8OA;%X6^%6H7IL(=%T71;:!([%YFB^TWFK(K("8SYA169BF<XR*^RGQGX
MV9%E2XBXXXT\..%L@4%4I?6>",MEG&94WR*G_9N7U*5.<U5<HQIXK$*CAJCO
M&E5J5K0?S='ASPDX@S%Y)P3X<<7\29JIRAB<5_Q$/.*.297R?Q:N.QT:485)
M4;.4J&%]I[%Q_P!KEAX-S/"KW_@YJ_X*63/<:9#XN#:B9#;H(IKBX?SPX0A(
MXHV,C9&T*F<\ 5_I-_\ !)CXU_$[]H?]@3]GKXP_&*WNK?XB>-?"$>I^(H[V
M">WN?M37$R R17$<4RYC52-Z D'(XK^?'_@E-_P:Q_!SX +H'Q8_:_ET_P")
M?Q#"VVJQ^%;A4_L_0[\A9?*EWQLDQC<X=3RQ')'-?V%>%/"_A[P7X?TOPOX4
MTRST?0-&M8K+3--L(HX;6UMH5"QQQ1Q*J*H [ #.:^1GXF<7\>>YF6 A0X;H
M/V^ QV*RK+<FS''XO2FJ]++\%@*&)H8&5&4[?7Z\*DY\CAA5%*H_HH\"<(<'
M-_V3C)8K/ZJ]ECJ>$S''YGEF#PVDGAUC,9C:U/%8N-6$.:IA:#P\8IJ&)J\U
MET-%%%9%!1110 4444 %%%% !1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#
MZ#^5+0 4444 %%%% 'Y\_P#!3#XA>)OAW^R]XGO?"MY)8:GKEY9>&_M<3E)(
M8=5$T,C(X((. .X' S7CW[$G[!'P$T_]GW0;[QOX'TCQEXL\8VD^I:YK^NVL
M-[?2/J2+(WE32(S(4,C%6)8AL'J.>M_X*SK<K^REJ5W;V=S?#3_%&A7T]O:1
MM),T%N\S2;549) Y'N!VS7@GP*_X*L?LW>"_A9X/\,:SI_CBUU+2=+M+.[B3
M0I)462."-78.70D;EX!4?44 ?GU\9?V/X? G[?WPU^#OA_5]0;X$7>KV7B2?
MP9<7#/IWVJZ>*=[8VO\ JC"I=E4;-N.@&>/Z?(_A=\/(?##>#H?!WAZ+PXUB
MVG?V6FEV8M_LK1^48\>23RO4]<\U_-+\:?V[?A+XO_;(\$_%S1M%\8W'@_1(
MK&*[O)-(>*8&V6)&(@R_#;2<;^.>>]?J O\ P6 _9:,@4P^.EC.-TO\ PCLG
MR\ M\GFC.TDC[PSB@#YY_8-CA^#?[>?[57P6T!7M_!DVI1W.D:8N%M;&0W'F
MO]FB'RQ9(P0@QC..,BO:?^"N?BG4[+X4>!O MM=W-KIGQ&\61>']8^SNR&6S
M9K;=&V.&4B1@5/\ >-?*O["WQ+TOXW?\%!OCC\5/">DZQ:^$M?G1].NM4M'M
MFE"L3G#97IT /IZC/NW_  68OI-%\!?!GQ$^G7NHV&B?$!+R_CL(FFG2!#9L
MS!5!Q@*3D\?E0!^@_P"S5\"OA=\/O@I\/= T7P3X;CC@\-V!N+A](LI;B]G=
M-\D]S+)"[R.Y/.YB..F<D_E=^VGX$\,?L_?MO_LV_%CX;Z9;>%[WQ'/);>);
M/2(4LK/5"]Z\ >>" (CL0 S9!YSCC KVKP%_P5M_9ET/P3X7TB[LO',=YIVD
M6MI=1#0)"(Y($", ^\;^<_PJ?8U^>/[<W[=GPC^-7Q<^!?BGP3HOC#4-)\#W
MBSZY+/H\D#Q(UV\["- SE]H;'49Z\$XH _J*TRZ-]INGWI&TWEE:714= ;B"
M.8@?3?BKM?DEI/\ P5Z_9?LM'TFUEM?'(EM=+LH)U_X1^3$<L%O'$R ^9\W*
M9S@8S@BOL+]F[]KSX9?M0VE]>_#R'6XH=/9EG_MBQ-FV5!^Z-S \CUH ^JZ*
M** "BBB@ HHHH **** "BBB@#\(?^"L[JOC?X9[VVJ;.\7=Z;D<9K\2-1^*-
MBGP]G^'<%I+]O@UV:[EO"I$+QB8N IY&X@].YX [']MO^"M*+)XU^&BL,C[%
M>'\0CD?K7X\7GA'0Y?@R_B(VBKJX\020M=*OS/$;C;M)QT QT(QB@#Z_^'/_
M  4B\+^"?!7ASPC>^&M1GFT#3HK%Y(XY=KM&%&X$*P_AZ_7VKN/^'I7@K_H5
M-5_[XF_^-5Z_\)?V/O@[XC^&7@G7M2TV)]0U32(;B[=H02TCHI.3M.>><Y)]
MZ]$_X8E^"'_0+A_[\C_XB@#Y<_X>E>"O^A4U7_OB;_XU1_P]*\%?]"IJO_?$
MW_QJOJ/_ (8E^"'_ $"X?^_(_P#B*/\ AB7X(?\ 0+A_[\C_ .(H ^7/^'I7
M@K_H5-5_[XF_^-4?\/2O!7_0J:K_ -\3?_&J^H_^&)?@A_T"X?\ OR/_ (FJ
M[_L._!%\'[!&G&#B(Y[=R&QT[?G0!\R?\/2O!7_0J:K_ -\3?_&J7_AZ3X+/
M_,J:I]-LN?R\NOHU_P!A/X*N<^0%Y[1MG@G SM'^>*J-^P1\%7X^=<G.1$<#
MV^[Q[>IR: /G[_AZ1X,_Z%/5?^^9?_C5'_#TCP9_T*>J_P#?,O\ \;KW9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >!?M1_P#)O_Q&_P"P1<?^@M7S!_P11_X^/$G_ %SN/_0VKZ?_
M &H_^3?_ (C?]@BX_P#06KY@_P""*/\ Q\>)/^N=Q_Z&U ']%E%%% !1110!
M6O/^/.[_ .O:?_T4U?G-^Q)_R.GQ@_[&K4O_ $=)7Z,WG_'G=_\ 7M/_ .BF
MK\YOV)/^1T^,'_8U:E_Z.DH _2*BBB@ HHHH **PO$GB+2_"FC7VO:S<I::=
MI\+SW,\A 5(T!+$DD#MZU\+2_P#!3#]F&'4KG3)/$]R)[2X>VD<6Z&/S(VVM
MM;S0",].Y'84 ?+W_!1WGXX_ 7&,_P#"1:7P6Q_R]1]CQ7@G_!:U@;+X( =K
M-L_BD9&,=>ASZ5X]_P %,OVG_AY\7?$7@_4/A5XAO)M6T2*.:"]A41?9IT;>
MDJA7<!T/3D'(SGH*_,7QS\5_BC\4O[-/Q+\:ZKXP.CPI!I?]IRO)]BB10JQQ
M;G;:% P,=<?6@#@UZ#Z#^5+103@$^G- !17NGP'_ &;/B7^TGJ>H:3\-C9"\
MTV"6XN%OW$:LD*DE(BV,R,!\H/4].V?+O&G@SQ/\._$VJ>$/%&GS6FM:-<2V
M]]$\;+M:%BC.H(&8V(.UAP<T <Y16EX;T74/%7B+1O"VF^7'J>OWD5AIQE.V
M(SRL%0NS8PI)&?\ ]=?<OQ _X)F?M/?#?P-<?$/6$T34M#M;=+N6UTFXBN=0
M6V>,2B4V\;-)M"GD[1P,]C0!\$44QUN86>.6!U:.1H265AF6,X=>G4'@CL:]
MK^ W[/OQ!_:3\57?@SX<26$>N65L;J9-1D6*,Q*N\[2Q&YL=ASC'>@#Q>BM_
MQ[X3UKX9^+_$7@7Q-Y8UWPM.UMJ@BYB$R-M(C(_AX.._.<5[CHW[)7Q<U[X3
MQ?&RT?3(? TL\< >:4).'E<(K'=T4$\]. >: /F^C..M?I?X;_X)-?M)^*O#
M^C^)M&UCP?=:5K=A#J-M*FI0$QP3J'59090?, /*]J\GF_8&^+EE\1M2^%UW
MJWAZZ\0:9H=SX@F^RWL;PI:6D;2R*QWY\S (P3R: /BC-%?2'AW]ECQYXF\!
M>-_B+:W-A%I'@+4_[)U4W$RQR>?YQ@#Q@GYE#C<3R,9]*^E/!W_!*7]I#QQX
M;T?Q3H.J^$KK3-:LX;ZV==2ARD4Z!U5\R?>7=AAV]AT /S;SCK29'J*^YM2_
MX)[_ !BT7XL1?!N\U7P[?>*)=(DUO%C>)/##;QJ69)2C';( /4X/&,U0^$/[
M!OQ3^,FH?$K3/#]YI-K/\+3<1:V+RX6/SG@$DACM]Q&\N(W(QG\N* /BFC..
MM?>7PD_X)N?M _&G1K_Q%X3ET2+2[+4[K22U[=)$SW%FY238690RY'!7H,9I
M=$_X)R_'/4_BY/\ !F]N=%MO$D&G-JIGDN42S%L@W9\PG:?3.[OUH ^"\CU%
M&1ZBOL;P'^P_\4/B#\8/%OP8TB;38_$G@RX>UU*6:9%M=R,<^7*S!2I(]2 ,
M$&OI#5?^"/O[2EG87EU:W?AZXN+5'DBACO(G:4QJ6(0!SN+<A< YH _*JBOI
MK_AC']HI;J_LV\%:H9=.NGM)G^R2!)9$8J7A/ 9#C@]^M<G??LU_&+3?%VG>
M [SPW?P^*-8@-UI]@UM()9H!R65,9( [_0T >(TAZ'Z'^5>\>+/V8/C3X'MU
MN_$?A;4;.&1A'&6MG7+DX &1R2>./IUJ;X@_LO?%GX6?"?1/C+XULHM-\*>(
M[L6.F6TQ\K49)'P%D,)PVPY)#8P!0!]-_#;_ )1A?&7_ +*!!_Z'7YP:9_Q_
M>%?^PWH?_I5#7Z._#,[O^"8'QC;^]X^MC^; U^<6F?\ ']X5_P"PWH?_ *50
MT ?W>?"3_DF'@#_L4M"_]-\%>AUYY\)/^28> /\ L4M"_P#3?!7H= !7Y=?\
M%"]<\7>"G\#>,OA?HLFN>.=,U!S' ZB>UAB<! SQ."BL06&2#^'-?J+7Y%_\
M%&+WQS9O8_\ "O==L=+U&1H%OGU*>.&.%-ZE6@,AQN/W3CL?7%73=13C*CA*
MV-JQ<94\-1>)4JDE)-*2P;6(G3:NITZ=_:)\DERN1,YN$)/FRZ,6G&3S6=.E
M@;/K5JU?W=-Q?OPG)KEE%-.Z2?Y?_MJZ;XI'[ F@>*?&WAZZ\,>*_%GQYT[5
M=0@ND\N&XGENXW:XA3"KY1Z_*N,?2M'PGK7Q"72O"FKV/Q U:UTS1]6\+6SP
MVFH/'96\;FW!@,0<###@J!BO4/\ @I3=?$*Z_P""=_P5F^*)T>YUM?B9X<6W
MN=#F$\5Y:*\8MYIV7Y!,\1;<$QSC=@]?D71+W5!X]^'N@:;8ZK+X0U74O#,^
MNVT,,C*TZFV*L1CH,<Y!XZUMA,9FF%E.>$S:AP_6FI?67B,XQ.64JMI<RP,:
M^.C4QN(E&I;V>&Q%J34>7$<M%6,\32RK&>R_M.DYT7R?5XY-E=/.J"J2@HNK
M1CA9.A3HN'-4CBZ=YJ3YZ3]J['U-^T%+)/\ \%3_ -EZXEE^T2SV.A323\DS
M,\4),A/<L3DYY[]:_IGK^9K]H184_P""J7[,,=NC1PQ6>@Q1Q, &1%BAVJPZ
MA@!TK^F6N:[>KW>KU4KMZMWC[KN];QT=[K0VVLELDDKWO9*RNGJG:UT]4[IZ
MA1110 4444 ?SU_\%QIACX+1D?=U<-GV,X/U)X[5^H/[ DJ2_LW^#2A)Q" >
M".?+3UKYH_X*E_ 3PS\7?#OP\UC6]3N=/N/#6MP/;K '*W*O<J61]IQCM@_6
MOT,^!'@_1_ WPH\$Z%HD/E6<6@Z=*>-K22RVT;/(P&<,2>>: /7J*** "BBB
M@ K\F/\ @H_X(T?XD_$']FOP+KLU_;:;XA\7&UN+C37:"]B#3A=UO<J"87P?
MO9'XYK]9Z^0_VA_&WP^\,_$;X)Z3XNT.#5-:U[Q%]G\,W4L8=["[\U5\R-B,
MH=W.1S^M &%X;_84^%WA;P;J?@?3/$?CPZ1JCL\\MSK\D]ZI<8<)<%05!YP
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MEPPXR"?K7JOQ;_87^%_QCU'1]2\2>(O'-G+HNE6^D6T6DZY):0O;VR*B22H
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M#X=_X?A?#/\ Z$'7?^^)_P#XFC_A^%\,_P#H0==_[XG_ /B:^XO^';?[-?\
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M)'U_[^CD<<XH _-_]IO_ (*A>#/C[X/F\+Z/X2U339Y+:6'S;A)0@:5",Y;
MQSGJ3_3X.^"_C2UU+QS\-?#L5I*U[IFIWUY,VQ@DJR(Y4(2,9Y'K[^M?J7^U
M]_P3J^#GP;\#3>(O#&I:F+R.VF=4N4 WM&A(QL>3.6!ZXS]>OYK?![1M/LO$
M_P )[^WMT2]FUB^@FN0,22QQAE ;\L^WT&* /Z)?^";+%_AIX[<J4+>/M38H
M>JYQQ_C[U^C]?G)_P3>X^'/C[_L?]4_I7Z-T %%%% !1110 4444 ?Y^_P#P
M>;W45I\7_P!B&ZN)!';6EQ>7,[L?EBBBUBVEE<^@$:,Q)/05^GO[<G_!3/\
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M@7SG.*_L/\*>$?#/@;0M/\,^$=$T[P]H.EV\=K8:7I=M':VEM!$H1$CBC
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M7_\ 7GM_5U^UA\?/@U>? KQS8VWQ#\.SW=YIDL-M;0WFZ:>0J2%C0JI)[@Y
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MKQ7X24\+^^PN2X'(,LPO#6<5,-90HXG'82^74*-5KDCBXU/KU9/]XNJ]'+^
M,9PO"KF/A[P[P5X@2Q%.%/&X_,L=F-3B_ 4JM6WM84\QJ5JV+K0IRDW@YX;'
MTTTE1KP5.#7WU_P:1_LL? KXJ^-_BWXC^)7@'2/&/B'P5K5Y:Z-?:O;17,,
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M0 4444 ?A'_P5F_Y'?X:_P#7C>_^@/7Y.3?\F^2?]C+)_P"E5?K'_P %9O\
MD=_AK_UXWO\ Z ]?DO<3VZ?L_M$UU;"8^)9/]'\P>>/]*'6/.1]<>_2@#]V_
M@1_R1GX<?]@"W_\ 1:UZS7DOP'/_ !9CX<?]@"W]_P#EFM>M4 %%%% !1110
M 4444 %%%% "'H?H?Y5\=?M0_P#(V?#+_K\A_F*^PW8 ,2<*BEG_ -W!S@]C
MWK\Z_CO\8/ _C3XL>#_!?A_4'NM<\-7L2ZK!M^6!O, Y8'!QDY[\>@H _0K3
M/^05I/\ UX1?R6KM4M,XTK2AZ6$7\A5V@ HHHH **** "BBB@ HHHH ****
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M)SX^_P"Q_P!4_I7Z-U^<?_!-TY^''C[!!'_"?ZI@CH>!R/Y?4&OT<H ****
M"BBB@ HHHH \F^+'P6^$7QIT9O#_ ,6? _AGQKI;QO%':>(K&"]2,2 AO)\W
ME"<D_*1SS7\X?[;?_!K)^Q/^TDVJ^*/ADEY\)_%]PLT]E;^'HH;/1S<L"R!U
M25=J;R.JX"^^*^6_^#I']OK]J3]COXH?LA:'^S[\4-7^'VG>,]6$_B:+3&"#
M5([;5H(/L]SNR# \<A$H #$8PRXY_K$_9Y\:_P#"3? ;X-^)M?UVPO-8\0?#
M;P?J^I7K7D -U?W^B6=Q=S9,G+-<22!^I#[@>:\K/. ^&\TIX'.,+B\70XDJ
MJK'$8O)(X[*\TRQPE%49O'4U]5QLZL(^[[2G7=.$>2R2T]')^,N)<HK8O U)
M83^PK4HX?"X^O2S#"8Z#?M,12JY=BJ/+A(*H]7AJRG4OS.4)-'^7O^VI_P &
MWW_!1']E>^C\6^&-_P 6/"/A.\&H>'GT:YN=2U.SBLY%F@VVL3SA9 (E&%4'
MKC'(/[+?\$&O^"S7[<.I?M5?"3_@GC^T;\-9])T&^TN_LK+5M<TK4=/UNQCT
MBV'E M>6L2O#)M"H\<KJ620#!R#_ 'GS:EH%S&T5Q?Z3/$X*O'-<VDB,#U#*
M[D$?45\YG]EC]F*[^,6B?'&V\ >#$^+&@QRQ:3XGT^*QAU.".4,)0GV;:S;P
MQW<'KS1EN.\3,BKXG#U\;EW&N39JH8?,*G$N!=+/,'0C!4J6,HX^%'$0QF+P
MD9.K"JW@)N48I\Z?*[S"'AWG\:.*KY57X<SK+W6Q.75.&L<XY77QM249.A4R
MRIB**PN&Q#7+64:N,3C.5J'-+F7U)1117JGEG'_$.?4;;P!XYN='\S^UK?P?
MXFGTOR03-_:,6BWLEEY0&29/M*Q;  26QBO\>#XX?$WXM_%+]KCQQH?_  4;
M\>?'70?A>/'VOVZ6]U%JUO:0Z<FM7*0I9)-&D<EL+-8V1X]ZX8MT&!_LG,H9
M2K ,K JRD9#*1@@@\$$<$'J*^$?VG/\ @FQ^QW^UMIM]9_&3X->%?$%W>12)
M_:G]GP6][')("/.$D*(6<$[LMDD]37%C\]XPRG#RP_#D:E?*\==9]@L!GF(X
M;SK%T:2?L*>59O0P]94*KYZL91KSI4)<T7)OE.[ 99PKCZ_M>(85J6-PL>;)
MLRAEV"S:C@<1*2<IXC 8UQ4Z;E&G-U:$_;P5.4(QDJCM_.3_ ,$E/V8?^"!7
M]BZ)JWPR\3>"_'?C&2*WEDA^*U[:'4DO"%/[N+49$.XOT4#L!SDX^F_^#GK0
M/ /AS_@C'X_T[X;:9H&E^%HO&O@C^SX/#<=M'IOEM>29,36I*.& 3)W'(4 G
M&!7Y\?M=?\&D.GZ=J6I?$?\ 8K^,OB#P!XAMY9+W2?"=K+/;6Z3(WFQ11W$8
MR%# */WBY&,@U^!7[?GPF_X+B?!;]G;6OV5OVD[7QK\0/@3_ &M!J5O<PI>Z
MXN--D1X)<Q0O(% B#@$M@$XW$FO&RO$^!]#V]98+B#PZXOJ2]K]4X_A//*.9
MXSV2<</EG&<N:&(QV)JVM"BOJ\=YU(L]/'Y9XN9C6H0AGN2>)?#JFH<_#[>1
M9IEM"FHJ%6MPDH156C@Z;E&KBE1HSGO"=1WO_=1_P;<8_P"'2'[-&!_S!KGM
MCO%7[O5_GZ?\$0_^#BC]G3]D;]FKX:_LA?M)^&M7^'4_@(2::GB>\M+F)9DE
M=%)FM;DQ;&5ESDK'QG(XK^U3]F']N/\ 9G_;!TC^V/@)\2]%\;1+;1W5Q:V5
MQ!]NMHI I#3VJ3221J-P&6 YK]*K\)Y[1RNGG=/"0Q^45,/1Q,\QRO$X?,\)
MA85TG3ACJN"JUXX*O=J,J&*]E54M''57_/H<3Y3_ &I/)L34Q.6YHL3/"TL'
MFN#Q.6U,76@G)K /%TJ5/'1Y4Y\V%G5]SWG9'UO1117S9] ?S7?$[_E.-I/_
M &(VB?\ HJ"OZ3BRHA=V"HJ[F9B JJ!DDD\  <DG@"OYL?B=_P IQM)_[$;1
M/_14%?NQ^U#XGO?!?[.'QN\6:=.UMJ'A_P"&'C#5+&X0E6AN[71+N2VD4@@A
MEF"$$$<U=-1E.$9RY8RG%2DE?EBVDY6NKV5W:ZOW)FY*$W%*4E&3C%NR<DFT
MF[.R;T;L[;V9^>'[7O\ P7'_ &#OV,?&;^ ?B=\1H;[Q/;R^5>Z;X>EM]0EL
M7R05N1&[["""""!C'-?2O[*W[;?[)?\ P42\!7>J?"GQ%X<\>:48L:MX:U'[
M)=:A:0R +_IM@VYT1MX7. .>O(K_ #9/^"1W_!+75_\ @N+^T-^TC\0?B[\3
M-3TBW\(ZS>7>JWS;KN>ZN=3N&DT^W7S!(RQQ+*B!58  .V.M<3XH^)7QZ_X-
MX/V[/CI\%/A%XHO]?O+W14L--N2\B@6VHO<QV,HLT(C>YRI =8]^5C"\CCW9
MYGX<9]C<5P7/AO.,OG"DDN+\YK/%Y!C:E&-.I66)P$\$\/&E*%2$W"A4J5*<
MG&%*5><:D5XRRGC7*LOPG$]/B?*\RQ+Q$IU.$L!@OJF98>G4E*.'CA\S56+C
M4ISC-1K2E.4U&-2K1HQJ1/ZR?^"\'[/_ /P17^''P?\ &VM?&73/"7@SXJ2Z
M;<G0M,^&T=FOBF?66*^09K2R:64%I64%7C!ZY&*_9'_@AP?!9_X)C?LPGX>-
M?/X,_P"$0E_X1]]21H[UM/\ [1NO),Z.JL)-N,Y&/2OX//V(_P#@C%^W5_P6
M=^+4O[2?[5.O>)_"OPM\2:G_ &O/KNN27)N;VTFD$OV+2[6Y7]Q&Z94.@+%3
MD,*_TH/V3?V;?!O[(W[/_P -_P!GSP!N/A;X<:#!HFF.Z[6D2,L\DA4<#S)'
M9L<=:^"P$_#S#9EC<K\.,LS2>78>56>;<15J]7^Q\QS-3A3E2RK!SJO#X:$4
MIMPP"K4XQIQ6)K0K-48_98O#\<_4,+C>/>(</6S&KRQP'"U-4JN*R? 5(^UC
M/'XJ-#ZU5Q#=DY8_$1K3]JW1PL**C4G]&T445[IY 4444 %%%% !1110 444
M4 0'J?J?YT4'J?J?YT4 3#H/H/Y4M(.@^@_E2T %%%% !1110 4444 >9?&3
MXE:7\(/ACXS^).M%?[.\(Z'>ZQ<HS!?,6WC)$8)(R6<J, Y(SCU'^<]^U/\
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M/"6H^+/%NIP6-K:PO]GA9LSWET5/DV\$:Y=VDDVKD @9]>*^ ]*_;1\=^+-
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M7V)7Q#^T_P#"'Q)\0OBI^S_XFT6\M+>R\$^*1?ZK%<.JR30><KX@!(R^,]*
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M)G@'7KR\>XL-5U2^ABLQ(V(9%# NJ$X7)SV&/7%?TK_\%'/^233_ /7I=?\
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MLX>!KR[U#PO\--%71=*O+]M]W/ LLDN^9LG+%G/>O8H<9\.Y]0I93D?A;G'
M<<#"-2.,Q]?&5,/7P\(QHQP5*&(QE>G&HFU5O"G&5H2]ZSL<"X8S/**U7,,Q
M\2:7&TL7*4)85971P-6E5E+VDL9.K3P.%E.]G3Y74FFYWY(\O,_J&BBBM#0*
M*** "BBB@ HHHH **** (#U/U/\ .B@]3]3_ #HH F'0?0?RI:0=!]!_*EH
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M[0H_@W\.DEU6SCD70;<.C742,I$:C!4N"#Q7IEYXN\*Z? UU=ZY8Q6Z'#/\
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MY^KS.^_['938EBLP268>6"%VY& O>OMZD "@!0  ,  8  Z  < 4M !1110
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MAURI'>OCNW_X)U?LWVUU;WD6F^+!/;7,5W$3XHNBHFA<2(2OE<KN7E2:]/\
MB;^R/\(/BV^DOXPM-=F;1;&'3[+[!K4]B!;P($C\P1HV]]H&YVZGM0![CI?C
MOP;K<[VVC^)]"U.XC0RR06.J6=S*D8Y,C)#,S!!W8C ]:I3_ !-^'MM-)!<>
M-/#,,T3%9(I=:T]'1EX8,K7 (*]P>G>O#_A?^QS\&/A#K=YX@\&V6OP:C?V$
MFFW#7^N7%]&;:52KA(Y$4(Y!X<<@CI7$:S_P3W_9UUW4[[5M0T[Q4]YJ$TL]
MRT?B:ZC0O*Q9]J"([1N)( .!F@#Z['C#PJ^E_P!LKXBT;^R6W!=2.I6:V3$
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M /QRC_AV/X*_Z+'X?_\ !S;_ /QR@#]+O^'O_P"S7_SZ^(/^^$_^-T?\/?\
M]FO_ )]?$'_?"?\ QNOS1_X=C^"O^BQ^'_\ P<V__P <H_X=C^"O^BQ^'_\
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MI573IYG0R?%8S!9AB)?!!X:KR8S"T)_%#W'7DU[.$)71[G^U'-]H_P""N7P
MGCD+VUQ=:=/;D'*/')Y1613W##D<D#\L?TH5_,E\>=J_\%1/V4XHV>2.#2/#
MD*22@K+*(X(!YD@/.]L9;)/UXY_IMKF>[MM=VU3TOIJM'IU6CW6AV+9:WT6J
M32>GQ)/57WY7JKV>J"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M7\Q!_P""S'QZ'WOAE OUA4?^S9IH_P""SWQT1E8_#>S^5@2&10#@\J>>X[4
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M?^RMXB\.:;I[K;WVL66A&S+*AV-(96MP<\%B3P2>">M?T@_\$T?^"VO[+?\
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MH/ 'C_XE^(G\/^&9O"/AC4M2F_L#22OVB5(7E8QX1<DB0$, H)Z#&>G9^(O
M'A7Q2^GOXGT-I8%>*Z,;P&TFN+?>K$9<1MAU[G^5?N%_P3<_X(<^'?AY_8GQ
M=_:5BAU[Q:B6]_HWA<J&L[ MMD":A _RET^Z5*DYR..H_1[]KS_@FO\ #SXV
M:4^L_#W3['PAXQL+/RK%+.)+;395B4F-'ACVC)*A<<>WI7]7_P#$SWAWEN?X
M7A&=3'8W):-". Q'%//*K0I5X*-&+DY7Q.*I**O5QZDI\]YJ,K<S_P Z^)OH
M,^)6*R?$>)?!4L+DO%#Q$LUI\%4TL-6Q%*3=>;P?)RX7"5IR;5/*ZD?93IM4
M_P!VGRG*?\$R?B;^R?8_#+1OA[\*](T3P1XOM;6%=7T^YCM8M2U"Y"A7G2\/
M[UPQY\K>!R&&[BOUR0@J""&!&00<@@\@Y]QS7\.7COX;_&3]E_QXT.L6VL^%
M=;TB]Q9:S:B>VMK_ ,J0['CF3;OB?;RA)X/KAJ_I'_X)A?M/>.?VA_A]X@MO
M'+13WW@V6VL(KU!^\ND;"JTKX!9L#/.3DFOY\\=O!&GDF#Q/B9PMG\,_X6S*
MO2Q&)EB,9];Q>&J8^I&-*5'%MS^N8:4ZD8Q4VJU!6C/FMI_3'T4OI3X[BW-L
M)X*>(W"U7AGQ RG#8C#8.IA<OE@,'CX970E/$4\;E\E3_L[&PHT9U)2I1EA\
M3;F@H-V?ZD4445_)Y_H*%%%% !1110 4444 %%%% !3'C21=LB)(IZJZAU/X
M,"*?10!_.)_P6ITK3X?&?PF%I8VEH]SO^T26UND#S_.ZCS#$%WD<=1R/4U^3
M?C9=-M_ .@6UO'''<K=DS=/,VCIDCYL]^2?S%?KI_P %K25\9?"%AU <C\)'
M-? /A;X!+\0]+^'U[/>B*V\3ZPNFRQ[P"@W ,R@C/XX'YB@#XI=H9%*LXP>N
M#71ZGXNUSQ+;^%]"U>\CN-+T2X@M=)B4<P122*K GD'(Z_3IZ_L#-_P3)\,1
M2M'_ &M(0",'SCT*Y]?\YK@M9_X)L2R:G;V_AS51#Y,JRO/.Q,:LISU/KUSS
MT]Z /LO]GWX*?#67X3>')[_P[9WEY<0032SM!&[,SQJQRVT\\C_/7V?_ (4A
M\*_^A4L?_ :/_P")JU\(O!5_\// NE>$=0NUO+G3DC1YU.Y65 0 IR??'Z]J
M],H \I_X4A\*_P#H5+'_ ,!H_P#XFC_A2'PK_P"A4L?_  &C_P#B:]6HH \E
M?X&?"F3.[PI8_P#@-#_/9G\\U4D_9^^$,OW_  G:_A!'D]^24S^O2O9:* /#
MW_9P^"\F=_A&!L\?ZJ,<>PVG'3U)]ZJO^S%\#9/O^#XN_14P0?\ @(_0?B:]
MZHH ^>)/V4O@)*<OX-3KGA4Z\?[)]*K?\,C_ +/ID$Q\%J9$8,I^3&0<C(V^
MOL3[]J^D** /)(/@5\*+>&."/PI9;(E")NMXR=HZ9.WDX[U*?@A\*\'_ (I2
MQ_\  :/_ .)_SZ'I7JU% 'YD?MJ_LN>&M2\'0>(_!.G0:/+I^(;TQ(JARX/9
M .03SD9_2OH']BGP'=_#_P"!6D:3>W/VFXFN3<%LMA5D']T^@/YX[&O0_P!H
M_P#Y)#KO)Q]IAXZ=S^/I^0K4^ __ "2_0_\ <A_]!6@#U\< #TXHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-UJ_@#XUZ%81ZMJJ^-(],D4/'>1:AJ<T)5NC>:C,@!'<D<YIT/P]^-=SI/\
M;UJ/&5WH_E-.;JUU+4I]D:C)+B-VV'&?E8 \>O _HW\$ZE!\ -?N/V<_VAO#
M.DZM\//$$C6O@_QS/8PSP""?,=M:W%W)$WE3*K*&(=74J&YQMKAM>UK1/V$_
MBI:Z3>Z78>,?@7\3)/M@22WAU"?2!=.64QF6*:(6D8;<P4*"F#D@BKA"=1\L
M(N3LW9*[LM6[>1,YQIQYIM1C=*[VNW9'\_FA^ OC)XGM9;[06\7W\$.\S+'J
M6HFXC,?#AX0WF*5P1\RCD"J^D>#/BYKU_<:5I4OB^;4K0D7%G+J.HPSJ5.&V
M1NRL_<# Y/'U_H/OX/#WAGQKJO[0G[,6E6/BWP3;^1=?$/PE%;K/#Y$V'G;3
M+-1((S$A9I55,+R, <'TKQM\-?!WQYT'2OVD?V<H-*L?B#X>"7FL^&8H884N
MYH 'N=-N[&&&-?/7#)\Z#?R0-V5+JTJE&?)4BXRM&5G9Z2BI+:ZU30J=2%6/
M/!\T6Y*_G%V?XH_FDD\'?%R#6T\-W3^,;76I%W1VMSJ&I0*X]%>5E!;V!-.U
MOP5\8?#-Q:VNO#QII\M\56U:6^U)89"W"YF+;%#$C&2,YX)K^F"+3/AC^VIX
M%GTQ]'T_P!\?O!#"1[06\&GWK:O8J=KNJ10&:QEE09!#LH.264G$?@75O!_Q
M@TG5?V8/VC?"NE^%OB;H\;6.B:\MG;VQUPVX,=G>:7=F$2,P 0NBR['YP >:
MS+/YK-7^'_QHT#3X]6U6/QI%IDJJZ7<-]J<T15_NGS$9D QC)S@<Y-2I\.?C
M7-I)U^V3QC=:.(?M#7=MJ.HSA8@,DMY3/M8#'R$9K^C7P1JUM\"M>N/V;OVB
MO#&E:EX"UR1[7P=XXN+*&:!H9OW=M#/>21-Y<J*ZX82JR,,D'&# VBW'[%?C
M)[F;0++QU^SEX[N_,DNVMH-2ET!KP[A*[O#<1BQB#@D !2O(/< '\X>F^"?B
MYKFFS:MIDGBVZL+8,UTPU+4/-@$>?,\R+=O7;C!+*.,\5SFBVWC3Q'K4'AO0
MM7\27NN7<K6]MI\6J7GF/.C;&1$5RP;/!_*OZ/\ X\_"*W^&NCZY^T/^SS:Z
M9XE^'_BW2+F;Q+X;MD2XA!NX6_?Z7"JD1K%N.]$5?+*D'W_ [X#ZGXKM_P!H
MGP[KW@738KOQ@?$MUJ.GZ-/'OC+-<&66T>(\91>-A!Y&,4 8S?#3XWQ>)1X-
MN8_&%KXD9=RV-SJ6H0!P>1L>1E5B1V4D^U<;XATSQIX7U2XT7Q5>^(['4K0X
MGMKS4+L_-S]WS&P>!D%0!UK^G_6[OX0_M7>$3+J5QI/PO^/W@:7<T-R;;3=0
MDUFRBW9E79;FXT^:5<8;>RJ1RR\U^"W[7FM>,/$'Q"BTOQ;IFG)KVA$V4VJZ
M5$B6NM^63'%/$R "3**"3D\G(.10!\M)<>)4@69/$.OI;L0(UBU>Z 7..B"7
MCKVX^F:FFN/%-MY8G\2>(E,HW)C6;HY3J"?WO!]C5JSM;[2;F"36K&Y6R<C;
M$PX._IY8P"3Z8[9HUK3[^29KRWL+V+3]I:-I\G:O;!/1=O('(XX% %!=0\0L
MI;_A*/$. 2#_ ,3F[SUQ_P ].GKW]C5BW?Q;=+))!XB\1-%#_K6.LW8Q[KF4
M9_*HO[*U*Z@26QT^XD@129Y #MXQD[AV&>G7ZU?2#4[RQ\G3+2Z9XCB8Q @$
MCJ&Y)./I]>] &3<7WB"!]MQXB\0ABO ;5[INO3!,@P2#SZ"MRT\/_$.86TEE
M+XKCAU&1([>XCO-0BM[F1R F^;*QL2?XMQ^M8L.AZQJMY%I=M;37.I2R($@Z
MR%@00@!(S@\'UR,Y-?O_ /LAZU\(_B;\$;CX$?'"PT3P+XQLXB-!U.]CMK&]
M)1,0W2WCKO8HX5R-P#C^(8R0#\2/$_PL^.G@O2QKGB>/Q=I^C,@E74/[4OVM
MBC#*D3;_ "SD<YW=\>@KF/#V@_$SQ?;:A>>%[SQ=K%OI,)N=1>TU+4)C;P#.
M9"L;DD8';-?LO^U-XZ\1_"K]G?QG\"?'VD6WB?1[J0CX<?$&RA$J7%H,A!)>
M*I5RJ <[_>OG'_@FC\1Q\%-<U'6?%/A7_A)O /BNV32=8U#[,ES!H<#862[O
M/,CD18L;MV\=,@$$T ?!UO\ #_XQW^@7'B>T?Q9<:%9LPN[A=4OVE@*'YO,@
M5F= N"&W@8S]37 )>ZS*Y*Z_K@F1BN\ZG<++$Z\%58ON7G()'&:_H>_:*\*>
M'/AGH7B?XL?L\Z_X;\3^#/'6FW,.L^$?/@NUM)[R-C)=6ENHQ L>_H(^&!'1
M2:_GMFTC5;B^OVMK)Y))+JXFD\@96)I)&=E4 8 4D@ ].V* '1R^+)6,<?B+
MQ%O'/.M7>W!&0<^8,Y].#WJN^H^(HW\M_$WB-6#;#_Q.+O ..?\ EKZC%='9
M9ETU].&GWKZW;Y.8MP9<@\/@\CVP./;%<\-/OHK@P7UE.+F0%DB8D,SYR"01
MR>F,?C0 -?\ B,.J#Q+XD9G( "ZQ>'.>G_+3TJY<+XN@A\Y_$7B(18RS'6KK
M.".W[WKST_2H[>SU'2KI)M1L)DC?Y$63=\V[[NSHN>1@ @GWY%2:C9ZVJF62
MUO(M/^_^\SL*GGOG@=, _CB@"MIL7B?7KR'3M,U/7]3O9F M[87]W*QE/0J@
M8D.3SN !R1SS7H'ASX7_ !Q\57U]I6A1^+KG4=-D$5Y9/JFH17"MV$<3,'D'
MH55ACG.*[3]FI_$OA3XH>'/B#!X>.J>&?#^HV]YK3R1))"]E$X,JIO#+OVYQ
M\K >W4_T$^,-%^'GQ,N/#/[1/[-6N>'[/XD:/!;7VJ^"(7M475+.W4->6UYI
M\)'^ELJLBDP[7SN7G*T ?S'>(]*\:^$];N/#_BN^\0:?KUIDSVMWJ%T9X>3C
M!D8.HX]L5DF^UDHR-K^MO&W^LC?4;ADE7^[(N_#KVVGBOHK]L+Q_-\4/VA_%
M/C"\\.3>$K^:&.ROM#FB,#1WEOE+B9(MJ_NY)%9E..0<@U\WM]UOH>OTH C#
M.#\MO<-#_%<)"YMD/H\P78K<=&.2?K4MJ<ZOX=(Z?\)#I'_I;%7T_P"$?'OA
M_3_V0_'GPZN/!WVWQ'JWB5+ZT\;?9HW_ +.MU;+6INVB:6,GD;%E45\MZ<-N
MH^&%SG&O:,,^N+R(9^IZGWH _NZ^$G_),/ '_8I:%_Z;X*\I_:V_Y(OXD_ZY
M'_T!J]6^$G_),/ '_8I:%_Z;X*\I_:V_Y(OXD_ZY'_T!J )_V2O^2#^"O^O>
M?_T97D7[;'B7X+>'M"T&7X]Z))-X+:[?9KT%T;632YSC:QE0B0*S[5(''.>Y
MKUW]DK_D@_@K_KWG_P#1E?G%_P %A-;\$/X#\.:;XWN+A-!L+T3ZOI\;.KZE
M#(Z^6EN!PSHV"2.W7CDZ4:4*U2$:M/"5::E&4J>-JXJA0ERR3C^^P<9XFC5Y
M^7V%6G"2IUN2I4BZ<9#3JJZH5LQP]6:<(5LJP]+%XZFY)INCAJ\H4JUU>,Z=
M245.G*45*,G%KX^_X*)ZKX+U;]@;P#J/P^\)-X/\&/\ &G23H-S)<+=-XBM/
MM2"+5&FP6/FC)(<YZ8 Z5YYX(_8X_:0\?^.?AI\1-$\,7R^%H)O#UY!J"32+
MI]Y:1>1))-+;KB*3:@SEQQC)KEOVM;.R\*_\$IOA_P"((_$CZQX$M_BMI6MV
M4LC27#>%/#\=S'(T5YMWF(0(I+CM@]^*_4C]F3_@K)_P3?T?X%?#72K_ /:_
M^$%E?6'AW3[*[M+S7)8;FVNH8426&>(VK&-D<$-EB!Z]AP8W".M&-+"U,-E\
M(5)-QP%+$RP_))OVE"F\>J6*E"IS..(E7A;$3=2:A[.<&=^%Q/U.K4EC<//,
MZLJ:IR>;PY,2JBM:K5I4:U2G3KQLK0C5FJ2M!2T:/C3]HV&>T_X*N_LV6-UM
M^U64.BV]R%Z":)(5< >@/ Z\=SU/]+]?R,_$;]LK]EC]H#_@KY\!8_@U\:_"
M/Q$FDU.RBC'AJ[EO(GD1XU*)+Y4:D@^@QT.3FOZYJZU>R3=VDE>R6R2V6B]%
MHC@;NWI;5NVKM=WW>K^84444""BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)G_ (*I? CQQ\=O!W@+
M0? EI)?:K;ZI.?LT:LQ=9.,Y4$@KU'3..M=#^PI^PYI/PH^"D?ASXO\ AG3M
M9\5WE^][-->0I+/:Q. 4@5V!((SA@0PP !@@Y_3V6UMIY(I9H8Y)(#NB=U!:
M,^J$_=/N*GR/44 >$_\ #-'P3_Z$/1O_  %A_P#C5'_#-'P3_P"A#T;_ ,!8
M?_C5>[T4 >$?\,T?!/\ Z$/1O_ 6'_XU4<G[,?P1E!5O FCX(QQ;0#U_Z9>]
M>]T4 ?.DG[*'P%E&'\ :2??RHP?TCQ^E9TW['?[/4_\ K/A_IISZ*@_]IU].
M44 ?*$W[$O[-T_\ K/AYI_/IL'_M*L^3]A+]F.4@O\.;$X(./,X/L?W?(/<9
MZ<5]?T4 ?QS_ /!2+X=^#OA/^U%J/A#P-ID6A^'X]&MKI-/B8F-)I0I+*3@@
M'/ YXZU\-&2(]77J#U]*_HW_ &TOV"-6^//[3VD>-SJ<<6AZU!;:9?P)_K88
MHPBLY*\C."<DY]/:%_\ @C#X!R?+\13E,#8?,<9X]SGKZT ?SVZWXOUSQ-9:
M7I>L7D=Q9:' 8=,B4 &&/&.O?@$9P/:O9O@1:PM\2OANSQ12K)=W*O'+&KHX
M$9(#*PVD?4'M7Z"?M4_\$SM"^!_@\^(_#VM_:)4ADED6=@P.Q<M@/EN".P [
M9/%? GP*1H?B=\.8&(;R=1O8RPYR40@X]LYQ_AS0!_2C_P $VT2/X;^/4CCC
MB0>/]4"QQ($C0<<*J@ #Z >GO7Z/5^<G_!-[_DG/C[_L?]4_I7Z-T %%%% !
M1110 4444 >;?%?XN?#WX(^"M7^(7Q.\3:;X3\)Z) UQJ&K:G.D$$,:J6."[
M#>V%/RKSCFORM\#_ /!>_P#X)G^/_B)#\-="_:&\+R>(+J^_LZT62=8H9[KS
M!$$$K/M 9R "<9S7X&?\'D?Q[^)'A'PO^S%\#/!7B34=$T;XJW.J1^)(+&YF
MMUO56^-K!'-Y3*64F6('G[N1UQ7XZ?M ?\&UGCWX _\ !.[2OVV-+^),H\;Z
M1X3TGXBZS86]Y.C6NF7MJFHP-;[91Y<Z1LKK)&0RL5).>*]:6?\ !'#]#*:&
M=Y)Q3GV.S:O*.)K9'4IT,-DN&]HJ4:M:,\+7=2W/3G.M*?L_WT*:I7C.HO-C
MP]Q1GU?,<1E_$V1\-X3*J,:F$PV/I1K5LZK^S<YTI.HK\O-&4(4,/+#U/=<Y
M8E<T4?Z=TGCGPG#X4'CB?7],@\*-IXU4:[+=Q)IQL&B\Y;D7+,(S&8_FR"3U
M&,BOQMT3_@N5^R]\1/V^/ /["WP>U2V^(?B;Q5%J/]K^(]*G$FGZ)<Z>DCRV
MQ=6*RR (I9>H# \ @G_/SNO^"NG_  4)_;4^ 'PI_8!^!D7C"]DL-.L= O[S
MP_->3>(+^*,I;L;J]MCYHM=H8LSR@JK-@$YS_43_ ,$%_P#@W9\8_LG?%'PE
M^VI^TSXGNKSXOVEG<7GA_P /17,[MI[:O HN9-5\Z1Y);I@0K^:Q8%1@ 'FL
MYS[@3A>O#)</]9XRXGS>">&P>"53ZIP]EV*]R&/S1T94G+%X>,XU).I7I86$
MH25.EC=5!95P_P 99_AO[:S&MAN$>'\MEK*K.#QO$6/PUF\)@U*G7Y<'7DI-
M4Z4)5N3_ 'C%8>W)/^T"BBBO'/3.8\;:1/X@\&>+M!M9_LUSK?AC7](M[G=L
M^SSZEI5W913[^-OE23+)NR-NW/:OX>?AI_P:,0^.OB5XR\=_'S]I9_%UEKOC
M+6M<_P"$<L+Z[O98K'4-0ENX[>YG#3*9523RF)8<*H &VO[<OBE=W%A\,OB-
M?6DC0W=EX$\77=K,A*O%<6_A_4)H9%8<JR2(K*1T(!K^*_\ X-6/VE?CG\;_
M -K#]OW1/BM\1O$WC72O#VIWESH=EKNJ7-_!I+MXMFLS#8QS.RP1+;QHBA !
MUXY)K'&Y/1SC+L53K\7\3Y J2@X9-D%L-A\^E.7++^T<TIU:>,R_ZE3YY8>6
M$?/6=6=.3C'5=> SG'Y-CL-6P62<.YDI2E[;'YU0AC<3EL8Q?)_9V!Q-"O@J
M\L1)I5Y8B,94XTXRHRYKQ?[8_LZ_\&[?_!-;]G^/3[VV^#6F^)?$-B(F.KZN
MT=SYDL>"6,<]L_5AGD\]^O'Z_P#@/X&?![X:Z?;Z7X(^'OA'0K6U1(X5LM#T
MM)5" *O[U;8/D #G(Z ]:7X\^*-4\%?!GXF>+=$*KJWAWP?K6K:<S<*+NSM7
MFA+>V]1G^E?R[?\ ! [_ (*E?M/?MP?M$_M$^ ?C5J>GWVA> _$FJZ?HD=JK
M+)#!:W=Q%&&))#D*B^V17D9-X=<%8.C7S*5'!/-\$H/"5LWABLYSC&N;][DS
M/'2Q5:')O^\JQ72&NCVSGC3C+'U\'@9U\3BLGJSG/$PI8^&7X'+W%?N_893A
MZ4*$XR>BC1A2C3WM;;^MY4AMXR(XXX8HU)VQHL:*JC)P%    ],5Q.@?$WP%
MXIUF_P##WA[Q5HNL:UI98:CIEAJ%M<WEF5.UOM$$4K21[3P=RC%=-KK,NAZR
MRDJRZ5J)5EX*D6DQ!![$'D'UK^ __@W+^)?Q&\3?\%L/V_\ P_XH\<>)O$6C
MVC^-WMM-U75[R[L+9K;QEJ=K:FVLIIFMK?[/:P0P+Y,:96-206))^KP<,JCA
M,<L7];ABE2@LLIX2G1^KNMS?O/KCFXN%)0LH^QYIN;^'E3:^?QBS26)P,L'5
MP4<*JTWF<<53KU,15HN/N+!SIU84Z=53UG*M&K%QT45+4_T!:***X3O/YKOB
M=_RG&TG_ +$;1/\ T5!7[S?M&:/XN\0_ 7XLZ'X!>6/QIJO@/7['PP\!*S+K
M5Q8R1V)C9>5<3%<$<@\BOP9^)W_*<;2?^Q&T3_T5!7](M]?V>EV%SJ.HW$5G
M865O)<WEU.XC@M[>%"\LTKMA5CC0%F8\  FJBZRE%X><J>(4DZ%2$7*<*R?[
MJ<(KXI1GRRC'JTD)NDDW7A"I02?MJ=5VIU*7_+R%1W5H2A>,W=6BV[G^9)<_
M\$UO^#B&35M<DM=:\?"WN-;U2>V#:S?_ #6\MY,\+1@ [86C*F,=0N,\UX5^
MT%^S1_P6Y_9<\#W_ ,0/C=\7M<\&:#8PO,SWGBB0W3!%+8^RO*DN2!CH<\]#
MQ7]:_P#P50_X.5_V9?V+K#6O 'P8U&R^*_Q?$5S:VCZ+-;W^BZ3?H'B_TXA6
M!\J4<@D<C@=*_D.\'>&/^"GG_!?WXR/K/C[XBZGX'^$^H7X#&]U&XTGP=;:8
M\VXV]O:+>6\4LJPG@O'Y8(QM;O\ 5XO./%WA/!1S7CKQPXHPO-&,\)PKE&63
MQG%&9<ZA[&"PU"KBY8"G4<TDZ]&IB'RS7U>*]]>!AJ/AKQ-B7@>$O!;P[HX>
M+DL9Q7Q!C,?EV08.G!VKU<+/$X[#K,:M)1G*\)PPT91C*,JZ:IO\H]#_ ."@
M/_!0OQ]KJ^"?!WQB^(WBC6M1NO[.L[/0I]1NKRZE:3RT\A4F?&]A\K,-N.3@
M<U_K2_\ !(*R^,NG_P#!/+]FZW^/R:I'\5O^$*@E\5KK)9M1^V2SS2(;HN6;
MS#$R9R2>W4&O@W_@FA_P11_8(_X)[:'I>L7=WX0^(?Q72""75O$_B2[T[488
M-150TDNGQ7;2&$)(3M(..AK^@S1[G2KK3K:31)+273/*46C6)C-IY(&%$'E?
MN]@Q@;>.*^7GQ=XH<5)5N+7G>%X:@W/*L!Q#7QE?-:N*:C&.-Q-.;6#P$G0]
MI!86*JXA\_/.I!+V9Z]')O"[)I.AP94R3'Y[9_VGF.1+ T< L-?7"8:G2B\=
MB:,:\8R^MUY4Z4[+V=%.\Y:=%%%9'2%%%% !1110 4444 %%%% $!ZGZG^=%
M!ZGZG^=% $PZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% 'P=_P4"_9F\1?M7?
M!U?A9H-U'8+J%\3J%Z[;6@M7$:L\>>KX5L9X'UKXU^&_P6_8J_X(^?!Z+Q;X
MZN](NO' MMTFLWL=I<^)+NX.YVBT^%I3)Y08\S;1C. "2=OZZ_%SXC:3\)?A
MOXP^(VN$?V7X2T2]UB[4N$WQVT>0@9B!EG*CCG!..>:_SJ/VQ/VG/BC^W1^T
M5J.I2:CJ>NZ=J/B"31? 'AVWEG-K%;2W!@MH_LRLT9+<?O-A 49R1BOZ-\%.
M%.)/$3!XWAJOG6*R;P_RS$/,<^^JR5&6.Q%17CA'5>CO2CSS]I>G2I)S<)2:
MM_-?C;Q7PUX=8_!<34<GP^<>(6:8;^S\B6*BZ]/+\-2ERO%QH+52]I)0I\G[
MVK4;BI0BI'[3?&S_ (.0/%\&M7MI\%_AQI%]H(E=;74M9=XKAHU8A7*N6Y(Y
M^[@=B>*X7X<?\'(7QHCU6W@^('PR\-2Z(TJ"XO+&7=<QQDC>RJOEY(4$@<Y/
MT)/N'[&?_!OSINH>$-"\=?M$ZZZZGK=I#?2>"A P^PPSQK+$)) N S*X.&RV
M#TQBO;OVC/\ @WK^$OB/PO?WGP6U]_"GB+3[6:XL;!HGDBU&>-69+8MM*H9"
M HW87WR17Z35S'Z*^ QO^K4\GGBHTY/"5>(8QQU6E&K%^SE4>+C6C.24]76I
M8=TOM*\=3\VIY?\ 2HQ^"_UFCFLL-*I%8NED3K8&A7=!VJ1I+ N@Z46X:*C5
MKJK;25IZ'VE\)?VE/V-/^"I?@*;0!)IZ>,EL?(GM-32"#6-/NBA#-IYEE224
M*YPBA2PP-I.0#[S^PY^R+J/[)]W\3-&.H?VEH'B#5([K0[ER3.T"/D+)GD;4
MX7(YQDDL37\%K?\ "[OV"?VAO]9JOA/Q?X'UQ3-"C3VD.M6-I<?.IC4JDL<R
M+C<1QNZU_H)?L*?M.:=^U9^SQX'^)L<L*ZW?Z7 FO6"$>;:WL4:(S2+DX\T_
M,3UW;L@9&?D?%[A///#GAAX3A?B#$YMX7<7U<-5IX/$55BX8#%TIPQF&]A57
MNQA65-N%:FH1DE*E5BZEF>YX2YGPEXF<=83B/BOA?!Y/XP\$T,=1CFN$I/ U
MLSP.(HRR[&4\;27\>KAU6Y94JSJ2IWC.C4C3YH'V11117\KG]@A1110 4444
M %%%% !1110 4444 ?SI_P#!:_\ Y''X1?[LG_H;UXO\"P/^$3^"W _Y&\]O
M]JO:/^"U_P#R./PB_P!V3_T-Z\8^!?\ R*?P5_[&\_\ H5 '[$W0'VF3@=(^
MW^P*KA%7.U0,G)QQD^_K]#QVJS=?\?,GTC_] %04 '3@# HHHH **** "BBB
M@ HHHH **** "BBB@#PS]H__ ))#KO\ U\P_S-:GP'_Y)?HG^Y#_ .@+67^T
M?_R2'7?^OF'^9K4^ _\ R2_1/]R'_P! 6@#U^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \"_:C_P"3
M?_B-_P!@BX_]!:OF#_@BC_Q\>)/^N=Q_Z&U?3_[4?_)O_P 1O^P1<?\ H+5\
MP?\ !%'_ (^/$G_7.X_]#:@#^BRBBB@ HHHH _!/_@N3_P B9\'O^P]=_P#H
M4=?AU\%?$T7@GXT?#?QE/!+=P>'/$%OJ$EI;H7N+A8V!,<2#EF.. .<^M?N+
M_P %R?\ D3/@]_V'KO\ ]"CK\1?@+J6CZ)\=OA;K7B3RQX>TWQ):W&KF9/-A
M%JKC<9(CPXQG"GKGVH Z3XY>/?\ A.?VIM9^)VDZ?<0RW_BK2=3T_2;N-DNF
MFM9$9()(CAPS,I4#.>>,U_15IDO@K]M3X<Z/9SY^'W[0'@;2+&737)%IJEI-
M;0QFW%L7E6::WG9 6X*H&)'RDX_GH_:"\4^&;[]K[6_'/A8QOX/M_&.BZG9?
M9H1'&]K:21R3>5;C(P1D;0"#CT)K^A37_!NB_'CPAX3_ &C/V9]732/B=X8T
MC3SJ&E6A-M<:REE!'YUG>VD15O,?:P5W39(I[,,$ L>#O&&F?&/3-1_9<_:B
MTV+1/B3HL36OASQ%=+Y*:@(4$=GJ6G73R1*VH-M5RJR'S"?7!/SYK<=[\,_'
M;_L\?M%P0^(_#E_I5U#\,_%]ZPEE\AP\=G#-,S/Y9X52-P9<$<'./H2";P?^
MVIX/.FZ@O_" ?M&> ,F&7#66I0:I9 8N01'')-:R2)]W>P7.1E>!X1XTU71/
MBE:GX4_M0:HO@#XK>!8'MO#7BZ>/RFU^"WRL.H1W$FT@D('"JWS$YQSFLJU*
M%>"I5*52K&<X+EI*O*<'>ZJJ&&E'$5/9O5TZ/-.:=N22O;:A6E0J>VC5A2E3
MC*5ZD82A-6]ZD_:TZE-.HO=4I15F[J29YY^SKXB\7_L>^-?$\>L:$NN_"#Q1
M?,OB&>T5KQ=&M+J0BW9 7(\LQMND0_*5Z@CBOJ?QCX-U;X*ZQ;_M-_LR7(U[
MX<:^J:CXU\$:?(+BS2SGVR7-Y:VT4TBBX +%X\!XV^@)\)_9F\?:;\--<\0_
M"KXV ^*_AU\07?3O#7CV_MVELKJ-B8HP\LBLL1P?E=64@X*DXQ7MN/%G[%'B
MP7%O]H\:_LS>-+C=)$?-U"'PS'?<M<! 7C,&Q\*AS&8^U53G[2$7>+Y5[-N,
M903E3]R5Z<IU)4Y)JTJ<I<T&K247>*SFDI-J#I1G^\C3::Y(U/?C'6,&[)K7
MEUW3:U-CQEX/T?XWZ/IO[3?[,>I+H7Q,T5$O-?T"UE%M+J!@!DNK'4[99@1<
M,5=0#%F3TW9%2J?!W[:_@\+(W_"OOVCOA\ $D0K9ZK!J-EC"P;IA-/:W,J?.
MVW"!L_=Y&9XS\%ZS\%]7MOVG?V8K@^(/AQX@VZGXT\$6$CS6TMO-F2ZU"&VB
M)2(Q*6+0@!XW'(^Z3?\ %_@_2OCAH^F?M.?LP:E_8OQ,T5%NM<T*U8P3:G)!
M^\O+*^M(SO,[$.BEDQ*.0 V0;)%\(>+])^..DZE^S'^TYIT>@_%'0(S:Z#KU
MT/).H&!0EGJ.F7+O&)+Z0JCN%D._(R-V"<SP9XQUCX+:S=?LR_M,6W]N_#S7
M@]AX.\7WZ^?;-93[DMK:YNF=XX7564 [MR,,@]5K54^#_P!M?P<L;8^'W[1W
MP]RT;@&SU&VU.R"@RM\B2W%K-+'T9CLW<#9T;X/\7Z5\<=)U+]F']IS35T/X
MI:#$\'AW7KM3;R:L;=&2VU>RO)<?OB523RT/[SH/FQD \W^(%OXY_8ST[Q;;
M6$EQXS_9T\;Z9J#VK*/MO_",27L3F**TRTJ+#\X(8<'@J:_!;]GSQXO@+]IW
MPW\2;#3[G58K3Q==:A#IEO&[74UG=71; BC&[Y8CE@HSQDC&:_>W4O&_B7X&
M>'?%_P"SO^T1:R^(?!.H:3J(\!>-+N%YH9(5BD%K')+* O[L85=YX.2!C-?A
M)^S1XI\,^ _VLO"WBOQ(T9\'6'C&]CG9H!=0?8)[KRXB;<AE9-N/X1@9QSB@
M#[+_ &U-7B^-?[46A:W\";J?1]6U+PS;RZ[:V#/;W3:H\:>;!=PPNJ_:1RK9
M0%C\Q4$FO5?AO^P?X5_:+\-:A)+\3=6MOC%X8MW6[\/:VYMY1?HF8E@BD*R/
M"7 &X9 !R?6N5_:CE\)?";]N/P/\1O@_907WAK5[*S\6:_;Z9)YT3)*%EF\N
M!<O#PW^H90021C&#7Z5>,O!]A\8=,TK]I[]F'5/['^(VCVL-SKV@V;&WDU18
M$#7-E>VJ,N9Y K*,HN]<D#.5H _-3X4_L*>%/'/B[6/A)\9/&NJ^$/B5H[S)
MIL4ZF#3]4"\6GV"5L).S$*3L8D@\9X-5$_84L?!/Q9_X51\=/%^IZ+X;U9GA
M\+>);3/]G7 (/D+<70)16/RA@_()/88'Z>$>#_VUO!R7-HW_  KW]I#X>#<H
M7?9ZA::G9[<LQ $UW;7$L9ZYV;L?<Z+X+\7Z7\=M*U']FO\ :1TP>'_BYX<@
MEM]!UJZ5H)=0,$;);ZM8W3;"9I,"0QHV7'H_+ 'XCZ!^S?\ V9\1_'^EZGKF
MHW/P3\'>(4\/W7B?1D-S*))WVI,[Q[@L !!D<X"@$_3ZB^+'_!-X^ O"&D?%
M/X0>-;KQCX"NXX+SQ"UE)]JO+>SF"M*]M&A9F,:MB3:,HPP<9%>G_L9>,_!?
MP<^(7QZ_9D^*T#ZWX5UKQ1<64GC"_#SV<DUR[PQ0332HX1]K+LD&V5&"L"<8
MKZJBD\6?L3>*A;71NO&O[,?C2X(1F$NH0^$(K]AR5.Y7@9'P0?D*=..@!\)P
M?\$Z/#_C7X:1_%[X ?$*\U?Q980"YU#1[IP;VTN8U#SP&WR&21<-A' 8L/E!
MQSX3\1_V>O#6H_!+6/BG%\3-;@^,/A.5M,UKP]J4LMG=QSQ_(S6=OE6>$;#\
MXR,<\BOUH\9>#M;^!&M6W[2/[-UP_B'X8>(A'J'C+P982-=6JV=QMEN+Z""+
M,<1"DEXOOQ'@X.#7S9^WIX0^'/Q@_9\NOVCOA!=#2O$3QBV\0:/:R>1_I$BG
M[2M]:)M'VB-RVYWC^?[RD$-@ ^?=1^/?A'X@_P#!.R\^'WCBPF7QYX3A-OX?
MU?5DVR:D5SNEL9I=\DI !7:KE<<X!Y/E/[$OQ4\.^#_@?\5/ _Q"L"FE^+?#
MLUCH6J?9Q)NOVB88>=AF'#D$D'WYQ7K^N#X-?%'_ ()JZ?<1-9_\+-^%UNR7
M058[*\^UR9W[R"IO8]I'S?,V[.05^:O/OV([_P"&?C+]G3XJ>!?',=G#XAT_
MP_<7GAV]NPL$@O&A=A]FE8?.X.,(&R.!UH \5^!'PS\8:WIFI^(_$?BC7M/^
M",.NR>'9M0TI[BY-I+-,R[IP&81VRAL/*0  "1ZU]:?&#_@G$?A_X9T;XJ?"
MKQI=^,_A_>I#=^(9[)C=7T%M/AYY;>-3N8("=^W=M=2#COO?\$S_ (M^"_"W
M@OQQ\ ?BOH_F^"?%.O7ELGB:[0O827EV[Q):O(ZO'"X!5DE4+*C[6#'&*^W4
MF\6?L3>*?[-U,7/C7]F+QI,4AGD\R_B\(PZ@W$+9!5X6213G[A7D8XP ?"C?
M\$W_  YXY^%G_"U?@#\0KO7-?CMA/JFA7<@^U)/&-UU \()973Y@$=0Q(X4X
MKP7Q+^RKX)U/X8V7B7P[XROT^+UOJZZ'JOA75=UO/%?A]C/;P,%=K?<#M;&#
M@<^OZS^+O"&O?L]ZY!^T3^SK</XD^$OB3RM1\8>#K&1[JU@LKC;+/=P0Q[TC
M(#$F,?/&000".?"/VS="\ _$+X>^#?VI/@B4@\6Q:S9+JF@V<GE"XN-ZM/:W
M=G$J 7*N&1G906^]Z@ 'RC\#?V)?!/Q9U"[\ ?$_QMJWA'XDV<._2K:[7[/9
M:A*4S$UJ[E?/5CC[A.<X S3[?]AG3O"/Q3D^$OQX\6ZGH6CZO*+;PAXBMP1I
MEWN(6'[5=DE$!&.IX)YQC _2'P[IO@O]LCX4:'J/AN\C\#_M!_#JPMP7A3^S
M]0M[^UC!%K*J;9;V"X9 "_.UF^8D<UI^%/%6C?M#:)J7[.7[1NG?\(U\7_#:
M-;:-K-RC6UQ>R6X"6E_I]RPC+2RLJ.P5R7![.,D _.WX@_L,:S^SMXKTO3=2
M\<:Q+\"O%#Q6H\0Z.&N6AFGQM>[EC+>7:X8$N3MVG()'->;67A2X_9!_:6\#
M:Y\+/%-]XW\*ZI+:WFH[)Y+J.33'8/=2%!(R$JA(88P".3FOU5\"^-M4^&^J
M77[+?[4MM_;/A'64DTWP9XUU&-YK:ZM)08[2S:ZE#)"\:$>7,IW(XZ]17YU^
M+= TO]F/]M/PUI^NWQU_X6ZK=QV.C6\Q_M"+3M-OY>8_-)=?+\MN7S\H^E '
MQ'^W'XY\-?$S]ICQ1XU\(IY>CW]E;(\?E+!LO@H^TJ8D^4$2;AGJ<?E\IGH?
MH?Y5]8_MV:;X,TO]J#Q5%\/$M8_"ES8VU];)92+);B:Z7S)-I4  Y8[E !!)
M!Z5\G-T/T/\ *@#[,\#>+O ME^PK\3/!5]]G'Q U'Q?#<Z5NA!N?L0D&0DI;
M<HP<@!3D9R:^+].!74/"ZMG<-=T4'/7(NX02?KUK[1\#^$/ -[^PE\3/&=^M
MN?B+IWC"*TTEWN42Z%B[\B.U^^Z8/+*:^+=-)-_X6+?>.NZ+N_WC>0Y_7/'X
M4 ?W=_"3_DF'@#_L4M"_]-\%>4_M;?\ )%_$G_7(_P#H#5ZM\)/^28> /^Q2
MT+_TWP5Y5^UJ&/P7\2!5+'RCPHR?N-0!-^R5_P D'\%?]>\__HROAW_@I;X1
M\"?$C4?AIX ^(L5OI/A_6]2DCD\1EECF@91N1-[;5P6P &<9)K[B_9*R/@1X
M+R"/]'GX/_72OA#_ (*X)K4GPX\)KIG@6;Q%;G4'^V^(;:5DN/#<>0?MD:1D
M22,@&_:O4+4RULN?$4KM0]K@\;1RW%TN=J//AL=B)*GAZL4]'R59U%>C3I3G
M4BB*G-[.:A6HT*DDHTJN)C*>'A5<H^R=6C"I2EB(\_+RT%6I>TJ<BYUL]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP3E)J,7)I+9-G+C<;A,NPU7&8ZO3PN%H*+JUZKY:=-2DH1<GK9.4DKVW:/\
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M@&RSK(5\OYE8"@#["\9>$-&^,.G:=^TY^S+J]KHWQ(T2-+WQ#X?M9HHUU%H
MLEY97]I$ CRJ0R,T@(8\D%LBI[J]^'O[7G@:37KJ^M?AO\?/AM#+/<W#3P6>
MH0ZA8PMNEN"BPF33II$X7<VT?[.,?(_Q#_8LUKX/^%M)^+'[,_QB\7ZK\.-1
MVWWC*'3KPW5VUC<E7GFM8H)Y=SA&/FKM#(00RJ,4^^_8;\/_ !&^%VI_%O\
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M[C'!K^H'X"^+]8\??![X?^,O$!A.L^(_#>G:IJ)MU"P_:KF%6E\M0  N[D
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MW@72NGR+^.GS>UZ6_1:BBBLRS\Y?^"C>?^%3S8Q_QZW/4X_@>OYI/@G?6O\
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M)/5IA1117X:?NH4444 %%%% !1110 4444 %%%% '\Z?_!:__D<?A%_NR?\
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M%S8W%Q)<[)9M[+L,A8Q(<\!<#';C)_8[_@E*=W[#/P5(Z'2+HC\;R4U^(/\
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M/_CE?T4#_@A__P $YQ_S0K0^I_Y86?<Y_P"?2C_AQ_\ \$Y_^B$Z'_WXL_\
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M^&_CS7/C+\%?B<\":P-3U'3= UV^D6*_DU2&:1/M6FSL5)N3(!(5W;F;C.2
M?T+\&^)/$?P3U>[_ &;_ -I"P?Q'\,=>$ECX0\9W:I<VJ6<Y9+:VN[IF=(9U
M!7[S!HV&0.H/\WOB[6/$?PZ^)EU=>!_$.LS:E8ZI-J]OK2P2V]X]_+*9'N)(
MT*2.&8[OGR/8]^H\>_M4_M._%'2+30_'WC76M>TVPF2XLXY+.99X9HR/+9;@
M_.-N ,9Q@=Z /WD\>Z9\0/V/-,\8)HJ7/CC]G;QIIFH-%Y12^;PY)>0NT4=L
M?G$<0W@@J=I'*]*_ GX$_$:S^&/[2&C_ !7-M)=6&D^)M1U2.S0,97AFF>1(
MF5?F&00K@?IQ6QJ'[7'[4.J>#?\ A7>K>/M7O?!BQ"W&D7MK)(!"%VA \N3@
M)P>>F?Q^>H+J\M+A;N"&9+LLSK(8QAY'R6P"<G))./?J: /NKXU_&O3_ -H7
MX]7_ ,7H?"\^B_V:#_9UOH<+!Y+B, +-=;06,IQEBS9)Z\Y->X:OX_\ V2_'
MGA"QO=;OOB1:_'32;0F&2U2=%CO84Q%&NW'[EG #C.,>M?F/HOB[QIX>EFN-
M)%[;&X<R2DV98.S')(SP 3R.O%"^+?&:ZHVN0I>KJ+YW3BSW YZ\!0#Z\CKR
M30![_I?[2_Q+\+CQIX?U;3H/$G_"1#[+IESK_P U]H$,)Q!<Z>S_ #Q3[0&9
MEP=W2O=_"_\ P4P^/'A+X<R_"S7?"^B>,]$N+9K%;S7]L\\-NZE/+5G)X13E
M2V2N.#GFO$OV>/AOX!^-\WCJ]^,'C35_"FM:-:/-X>:PLGF_M.Z5"R0RJ@.T
M.X"GIP:]F^$'P)_9_P#'2ZSH?Q9\?>)?!>KZ?<31:5]FTJ5EO;*,L(+MB$8[
MI,#()/7\@#B?@#^W3\4_V;(?&5KX,\':#J.B^-M2EU'4](OXU-G \Y;S(X,\
MB,JY4XX*\8Q5WP=^WO\ &SX=^-O$OC_P9HFDZ;:>*(;A+OPE:A#H<$ERI#RQ
M0%6C$BLV\-L!!R3@]-3PE\#O@FOQ'U'P/XZ\;^)--\!F61='\6II4[2W463L
M9AM8 $8/(^N:3QG\"?@SX%\;VNE:#XW\2^(/AS>P3O>^(WTN<RZ>RJYA 39_
MRT.U>@X/6@#A_!_C70-4TW7/B&][XHB^,FK:Y<:M>0Z/O.F^3/*TC6I",L81
M0QP#QCC'->_^-O$W['OQ<^&YM_$TOQ"/QLATF6-E6&<1+J(3"Q@@#,#.!N([
M9'K7YVQ^*M<\'^(]>M/!=U=/I46HW$.G3M:[IKNR1R(II(SC8SK@D'&,XQDU
M37Q;XR35&UJWBNX=3<8DN%LB<YZY  ^OOZT ?HII7[1GA[Q7^P]XW^!/C[1[
M*V\2^ 7>'P'<SQJNI&URRH<[0^\KR<X)YSD8KR_]G/\ :57X/?L^>// 'B'1
M(]0L?&NE-INE74T8;R[J52CG+*<,,\;><^@Z?#FHW>L:C=RZCJ<%^]S.V;F5
MHWBB;O\ .HPI_'C'6G-J.LW-A!I0AN;C3K:4SP010%_+DSG<67W'XF@#[I^!
M7C7X?_#*[LK#Q7'XPM?A=KEF]QXF&GPR\WTS%G6+ YAYZ[<8 P<XQ/\ '/Q9
M\)_#:VOB']DS7/'EAI]Q<Q7VM_V@;F.T\Y'\QHDW,$*.1AP..?>OC*7QQX_E
MTQ='E:\;3%C\E;<V)XC/ 7<5Z^I^GO56#Q3XO2SM/#LS7D.@W-Y#%<Q-9D;(
M9) )7#;<EE4D@"@#ZKL?VU_C%8^+?#GC[P[IVG:-KOA^*"*_?3]J'Q$L 7Y=
M452%E#X^;?GK@FM/X^_MV?$S]I)=#E\2^"/#F@>(?#MW#<V7B#245-3986#"
M%G7D1,1DJ.!D_C;\4? ?X2^&/#/A'Q/X-\:>(_$%[JJ6S>*=*?2I]FD1RA3-
M)"=GSA03@ D\>]=WXT_9M_9RA\!6OC3X>_$_Q/K/C+[.MQ<^&YM*N(XQ/@%H
M%/EKWR.N",DCM0!@>+?^"BOQ>\>_#C3OA9XD\#^&[A-(ABBTSQ-*%.LV[P(J
M1S0R%0RNI7=N0Y) .3C \W\<?MC_ !D^)/@+PG\)_'+K<^&?#US&)+]R&O;^
MT+!?(FDP9'$<>1&#W^E>U^%/V=/V:O''P\?7]7^)_BC0?B-9VL\DWAQ=)N!"
MM["I,-L&\OD2N-N1QZU\A_$?P[X<T'P[IYMKS5?^$IAOI(9["[LG@B%I$^(+
MD2. &:155MN<Y)7DT ?6GP_^)/PN\!ZWI^FZU>^/)O@WJ&D1G6CLG=X-0=%\
M^"W#9 M Q)4@;<>AK.\1^/?A#\)_C9X$^+/[*]IXGU7PNNHVC^+AXA@D>*"T
M:96O/LJR94J%W9 V\GIS7PK<_$#QG<:<NCW^H,NG[/*2UEME5FA& "I(R0!R
M#SQWXI;3QMXHM-+;1K;4D73&4J8/*4]>O../KUH ]U_;,^(WA7XO_M"ZY\0?
M!2>7H>IZ78H\8C2+9?",&Y'EQ_*/WF[!_P#K5\R'H?H?Y4BJ%+$9)=BS$G))
M)R?YTZ@#['\#^,O UE^PQ\2_ U\ML/'^I>+HKK2R8U-W]B#@GRW9MX49SP",
M5\7V@=;C0$&?._M/3$BSC_7^<@C)]<OCIR:F*]3O<+U9 Y$9([LG0D8ZUZ9\
M$?A=K_QN^+7@[X>>&K>>6]OM6LKLW,:.UO;QVDZ2R&>91MB&U3]\@&@#^S#]
MF.#Q-'\%? +^+&#:F?#VG"+'\%G]FC\@$#."4QU/3''K[_7+>"-$G\->#_#/
MA^Y8/<:-HFG:;,ZG<K2VEK'"Y##((+(<$<&NIH **** "BJ&JZG9Z-IM[JVH
M2B&QT^VEN[J8](X(5+R.?]U037P7JG_!3S]CW1]3O-)OOB,R7MC-)!<(E@75
M98F*NH<3X.&!% 'W#XE\)>&O&-@VE^*=$T_7=.?.ZSU&!;B Y&#E&XZ&OE;Q
MO^PC^SWXUC6W;PE:Z':>9YDEKI$*PQ2MUR59B%YZX4_X>>1?\%2/V-IG")\1
MY"Q]=-91^;3CCWZ5H+_P4V_8_8@?\+'P#_$;$[1]<3D\_2@#^=?]K/P9I'PW
M_:K\,^!/#T9BT/P_XVT>VL(VP&6,7B8! R.A['\*_L%\)?\ (J^&_P#L!:3_
M .D,%?QV_M5_$?PE\6/VM])\9>"-0.IZ%?\ CS19+:\*;!+&;R/D)N.. .YZ
M^]?V)>$O^15\-_\ 8"TG_P!(8* .AHHHH **** "BBB@#^7C_@L]_P E<TG_
M *]M,_\ 1T5?T"?LI_\ )NWPB_[$K1O_ $F2OY^?^"SK _%[2E!RWV;3/E'7
M_715_0-^RG_R;M\(O^Q*T;_TF2@#Z#HHHH XSXBSZ1:^!?%=QKZN^BPZ)?2:
MHL8R[62Q$SA!@_-LSCCK7E/[,VI_#S5?AQ9W7PUAGA\/-//Y:7"[9%D\QMX/
M _B!(/IVKT/XO6=SJ'PP\=V5G&TUU=>&=4@@B0%FDEDMV5%4#DDDUX#^Q+X;
MUKPQ\';+3M=LI;*]%W<L898VC8*9I"/E8 ]^.* /L2BBB@ HHHH *X3XH2:-
M'\.O&LGB(2'0D\-ZLVK>5_K/L M)/M&S_;\O.T=S7=UY=\;;6XOOA%\1[.UB
M>:YN/!^N10PQJ7>21K*4*BJ.K,> * /(OV,+CX=77P*\/R_"S[:?!YO=4%B;
M\$7'F"\D^T!@1P!+NVCT(Z=*^KJ^&O\ @G;I&IZ'^S%X3T[5K*>PO8M1ULRV
MUQ"T$B!M0E*YC8 C(Y!Z$'(-?<M !1110 4444 ?+_[76K?#+1OA#=WOQ:M[
MFY\(KK>CQRQ6JEY3>O<XLR% 8[1)R>#TKWSP;+IT_A/PY-I"LNE2Z+IKZ<K@
MAQ9-:Q&V# X.[R2F?>OD#_@H1X6U[QA^SS?Z/X<T^74M2;Q-X=G6VAB,KF*&
M]#RL% )PJC)...*^L/AU;3V?@+P;:7*-'<6WAG18)HV&&26.P@1U([%6!!'7
MCF@#LZ*** /F[]K?/_"@?'^!_P PY,_3S!G'J?:J'[(4D<GP2\*>6X<+:("1
MCKL7@XZ&O)/^"BOQEL_A1^S_ .(XYK)KV\\16LMG9H/NJZ MN/OD#'([]37!
M_P#!*KXEWOQ*_9KM]8U&/[/+::S<V2Q,<E(XP ON!V''/;(% 'Z;T4T,I&00
M1]:7</4?G0 M%)N'J/SHW#U'YT &!SP.>#P.?KZ_C7D?B7X!_!?QCJ3ZSXI^
M&?A#7-5D&'O]0TBWFN7'^U(0"W/KFO7-P]1^=&X>H_.DDEHDDKMV2MJW=O3J
MWJ^[ \ D_94_9PEV>;\%_A_)Y;B1-^@VKA7!R& 8$9!&<U[7HNAZ1X<TVUT;
M0=.M-)TJRC$5I86,*P6UO&.B11)\J*.P' K4W#U'YT;AZC\Z8"T4FX>H_.C<
M/4?G0!^<W_!1O_DD\W_7K<_^@/7\V'P3_P"2K^ /^PK?_P#H)K^D_P#X*-D'
MX3S_ #*/]%NCSW^1^!CO7\V'P2S_ ,+6\ 8!(_M6_P"1T/RGISZ\4 ?TG?\
M!-[_ ))SX^_['_5/Z5^C=?G)_P $WO\ DG/C_L1X_P!4R#U' /\ (@U^C= !
M1110 4444 %%%% '^?W_ ,'F!"_&;]ALL=JB\N"S'HH&MVI))/' YYK]8_\
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M^E^,_"WP[UV>2WCL="-[9:-]FE;:5&IM;-%(%C8!O*8X'W6)Z?T;_P#!O?\
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MTZ2WMU<\;RI ],CZ&M+_ ((LW<<>K^(]/;F=8)VSCLSLPY_$#\: /Z,Z***
M"BBB@#!\3P:#<:#J<7B:*TFT)K24ZE'?!3:M;*A:03!_E*[0>#^1K^17]L^S
M^#WCSXR^)&^!NF#1K+P^LZZM:+&8(+JY@)#S6J$*&1B#M"D\=.E?OK^V;\0=
M?\2:MX2_9X\#W$D.H?$*]BM?$&I6Q*RZ58"5&(9QS'YBYWYQD8YZU\Y_M@?\
M$][-/A7HOC'X-:=;VOQ#\":5'+KL=NN!XN@LX=]SYZ?*9KB4JV<AB^<X&.0#
M^:-2WS*ZE71BK*<Y&TXYR >H/:GUHZ]=WUWKNKS:OIAT36HKAX=2T9HC"]G+
M$QC*F(A=I=E)'&"2?6LXG R>!0!#/,L,9=C@#\3D\# ')Y_.OV6_X)P?\$][
M7XP6\GQ7^-6DSIX3#;-#\/S!X3JP/S1WRRM$<1 8.!P>GT^(?V+OV7O$O[4/
MQ>TO2+6%(/"/AZX@U'Q/=7("Q7.G1N&>&W=OE:4C^$$D'MS7]C_@SPCHW@/P
MOHOA'P_;BUTC0K&&PLH>,B*%0H+%0 68C)X]NU 'R_-^P9^S/-IXTUO 5N+9
M2N '0.-O0;_)W'WSUKTSPY^S+\%O"^E0Z/I7@K3$LH,>6LL$,K_+C&7,7/3T
MKWNB@#R'_A0_PH_Z$S1__ 2#_P"-4?\ "A_A1D'_ (0S1\C_ *=(/R_U?2O7
MJ* /DC6/V'_V<]=\2S^*[_P-;-JES&(Y/+:-+?:/2$0E0<=_QJ7_ (8D_9S_
M .A#L_\ R%_\9KZRHH ^/+W]A']FN^SYW@2WY!'R/&O\H?\ /K6$?^">/[+K
M/;.? HW6LGF1XN% W=?F'DG/X]17W!10!\D_\,0_LY! @\"6> NT']T>./\
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MW_@I5_SXWW_@)<__ !BOZF/^$/\ "O\ T+^D_P#@%!_\31_PA_A7_H7])_\
M *#_ .)H _EG_P"&K?\ @I5_SXWW_@)<_P#QBC_AJW_@I5_SXWW_ ("7/_QB
MOZF/^$/\*_\ 0OZ3_P" 4'_Q-'_"'^%?^A?TG_P"@_\ B: /Y9C^U=_P4I7D
MV-]C_KTN/T_<<U5;]KO_ (*01_?M;Y3SUM)__C7^>G6OZH_^$.\*_P#0OZ3_
M . 4'_Q%0-X&\',26\-:,Q/!S8P'_P!EH _E:D_;'_X*+QYWQ7HP?^?.X_\
MC7^?QJH_[:O_  4-CSO-VN/6SN/_ (S^M?U5-\/? [YW>%-#;)R<Z?!_\3^G
M2H6^&O@!\[O!_A]L^NFVY_FF: /Y4G_;C_X* 1<22W6<_P#/C=8'&?\ GC_^
ML]A55_V\?V]4SONKI1SG_0+S/X#R.:_JP;X6?#AOO>"?#;?72K4C\MF*@;X1
M_#!\AO ?A<@G)SI-K_\ $4 ?R!_$[]K?]JOXC:4VD?$:\G?2VC:,A[:>(;&7
M#<O&!T/&1[YZUY?\!9-4G^+O@6)F\NW^U74D$Q!'[YD.[)((Z_3!Y^G](?\
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MLO8X6638B5:O+%:3_>)X[%+V+I<SYE!>_P JYNC_ $&HHHK4H**** "BBB@
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M+_Y%/X*_]C>?_0J /V*NO^/F3Z1_^@"H*GNO^/F3Z1_^@"H* "BBB@ HHHH
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MZJ?LD/B+3+%]'>7Y$NI%,;ND). S\]%SZ9Q7Z<T ?SK_ /!4[]D'P_INH/\
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M-O[R-RI_$<U^*?B?X7:W+XLLQ:>/)SX3TC7FNKO78GD6!B]SN-O,X^60*?E
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MX.> +;X:?#SPWX5AA6*ZLM-M?[49<?OM2,*_:Y3CC+29'?IUKU"BB@ HHHH
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M/?%.+Q8M]/J=SK?ANXU]]+N;:1OLRVP@MIS;/(5R)&("GD]<5_.U%_P<R_\
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MP[X>\5_\'#/POT'Q3I-AX@T2^UJRCNM+U*$7%G,&N6#"2%U*NI&!@]N,FO\
M2(K\+?C7_P $._@[\:/VY?#?[;VK^-M;L_&'AV]BO8-#@@0V$LD,AD >3?N
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MNX\B2\E:)X\SKLC=-K(@R%0@!B.!7/[ 7_!?]/G7Q+\8"5Y _MC5CG_R9_\
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MGUNYN_&&C3:4\DT,;N4C$R*2&V$  ]<#WK]-S\._AV?^:?>"^_\ S+&A]_\
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M0!^_<OQN^$4$C12_$;P@DB?>4ZY8Y'?J)B#U[$XZ=:C_ .%Y_![_ **3X/\
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M8X   R23@#K0!^7_ /P50\?6/A_X!R^'&N[=;K7-6TY6@,J"81PW2,S>7G>
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MZ<9[?R^H/A_?76I^!O".HWL@FO+[P[I%W=2@8$D]Q90RROCMN=B: .OHHHH
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M* /Z%?\ @F]_R3GQ]_V/^J?TK]&Z_.3_ ()O?\DY\??]C_JG]*_1N@ HHHH
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MN\#_ (^8>0,'J>XYK5^ _'POT3_<A]3_  +ZUE_M'_\ )(==_P"OF'^9K4^
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M  +@_P#CE?RB+^SE_P %%4&%\9^*A_VTN>WUD-._X9T_X*+?]#IXJ_[[N/\
MXN@#^KG^U]*_Z"=A_P"!<'_QRC^U]*_Z"=A_X%P?_'*_E&_X9T_X*+?]#IXJ
M_P"^[C_XNC_AG3_@HM_T.GBK_ONX_P#BZ /ZN?[7TK_H)V'_ (%P?_'*/[7T
MK_H)V'_@7!_\<K^44_L[?\%%@,_\)GXK/T>?^L@JA+\!?^"B<60?%_B\D G@
MW!''OYG?UZ?7C(!_63_:^E?]!.P_\"X/_CE']KZ5_P!!.P_\"X/_ (Y7\D\G
MP6_X*'19SXI\:,?0&Y_'!R,]._Z5G2?"G_@H1$2&\2>.3@]%%T21Z_>XY/O0
M!_73_:^E?]!.P_\  N#_ ..4?VOI/_03L/\ P+@_^.5_(/+\.O\ @H%""6U_
MQ^<>BW1'YUGR>#/V_HOO:S\1&QG.([K/7'7=CWP!S[4 ?OC_ ,%&M1T^3X37
M CO;:1A9W1VQ3Q.Q^1\#"L3@^H%?S[?"@YUOX1N&0@Z]J6.>?^6AYZ].AXZ]
MZXOXAZ-^UE8::S_$G4/&\^D^6<KJ<=P(-FTYR78\$=>!Q[UE? W1_$"_$;X<
MWNH7DW]AW=[=)8VX)_<SA&WL%Z@D]AR/<4 ?TO?\$W3GX<>/O^Q_U3W';H?\
M\U^CE?G!_P $V4\OX:^.XP2P3Q]J:[F^\V,<GWS7Z/T %%%% !1110 4444
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M'\+>,-5L81<7=AH>HQWEQ;PG&)944 JAR.:_@X_XA2_VY?\ HZ#5/_"DE_\
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MQ1X?\7RQ2:):V_AO7;GP'?W%F+V%8P\D>GD+%%,Q3/F#<Q8[CDDY_53]E?\
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MSPL/W<T; ADD7HRD'N#^5>6S_!#X63S37,OA/3EEG)=U2Q@"!CR2,9!)/)-
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MQ9U;_P!))*_EE_X)[?\ *0JS_P"NFL_^C9Z /ZVJ*** "BBB@ HHHH ****
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M.,_5%_PI##">L,1^L:_X5+10!$8(#U@B/UB3_P")IIMK<];> _6*/_XFIZ*
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M4E4XARR6&AC\MPV.M&ERX+%++\W56I)T^6&'ITL-/X*56-2JI3E^!W_!4O\
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M_P#)+]$_W(?_ $!:R_VC_P#DD.N_]?,/\S6I\!_^27Z)_N0_^@+0!Z_1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >!?M1_\F_\ Q&_[!%Q_Z"U?G-_P2X_X_-6_[>/_ $9)7Z)?M43>
M5\ /B$I'S2:1-MST)9&X'T)Q7YI_\$O-<L4\3ZEH#28U*2&:=8N<>67D.3]
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MX:\;7?B">W;4E?[/+#J5G<9ED1\C"R2H<'."".<U]7>$O&6N:5^V=\5_BK\
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M>U_L._ .;XG?!OQG\<? $@/Q+\,^++BXBT*[*^1J-C:R-+-:M'NR))51L9C
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MT =S1110!\W_ +6O_) ?'_\ V#5_]&K5/]D;_DB7A/\ Z\T_]!2K?[6V?^%
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M.?\ ))I_^O2Z_P#0'K^>KX4_\AWX2?\ 8>U+^<E?T*_\%'/^233_ /7I=?\
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M!I/BUX;\-V=]X7L-=-E_9VJVOVA(K^W+$2&&Z$F'4H1R,C%?DG\(_P#@N?\
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M#-9PSY<1>?;O,6G4@'>I4$KMQ7M__!O=^S;\0_V[?^"F?C[]M?QWHFL0^%/
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M3BOI/_@MY"G_  E?PG?',@<-VX#,.W7( ZUX_P# ."*'P?\ ! 1QJ@/BF,G
MP22222>_./I0!^R5U_Q\R?2/_P! %05/=?\ 'S)](_\ T 5!0 4444 %%%%
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M_P"4A5G_ -=-9_\ 1L]?U-?%;_DFOCC_ +%G5O\ TDDK^67_ ()[?\I"K/\
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M$.,9YZ#)Z_6OZ1O^"D,$<WPEN!*N]?LER=K<KD(Y''3J,U_/#\(M-LK;Q/\
M"F^@MTBNY]<U%9;A>)'5=X"L<#C XYXZ8/< _H@_X)LNS_#7QX[*49_'VILR
M'JI('&.W '\^]?H_7YR?\$WO^2<^/^Y/C_5"2>IX _D *_1N@ HHHH ****
M"BBB@#_/\_X/+_\ DM'[#0_Z?9^O_8<M*_87_@M*@;_@AEX4^:(E/@MX%YW
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M^=%!ZGZG^=% $PZ#Z#^55KC[R?C_ "-61T'T'\JJ76<H1T7+-VPJ\D_RX]Z
M.0\7^+- \#^%M<\9^+M0ATCPWX<L+C4]3OIF$<<%I;(7DE+L5'&!A21R1R.W
M\O?Q:_:T_:A_X*H?$_7/@U^R3JFJ?#;]G;PWJ3Z5XK^*UDTL-UJ4$<S6UT+6
M6-U\V-PIR4R!D=!7L'_!4O\ :)^(7[4WQP\+_P#!._\ 9MU2>-]4E@OOB[XB
MTN60P0>&Y-OV_3'G@+1JRQB12&(.23C)('Z/_LY_LW_#S]E'X5Z%\+OAWIUO
M:6VD64+:QJ421I<ZI?/&DMU+<3(%:4F?>V6!['/3/Y)XI<?SX3P,<'EE2/\
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ME_M'_P#)(==_Z^8?YFM3X#_\DOT3_<A_] 6@#U^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \"_:C_Y
M-_\ B-_V"+C_ -!:OSF_X)<?\?FK?]O'_HR2OT9_:C_Y-_\ B-_V"+C_ -!:
MOSF_X)<?\?FK?]O'_HR2@#]ENY_WF_\ 0C11W/\ O-_Z$:* "D/0_0_RI:0]
M#]#_ "H _+#_ (*F_P#(I_#O_KZ;^5?F3^S?;Z!>?';X;Z9XK6)O#>J:];V^
MK+.XCMFMG(#>=(PQ&H'WF/'YU^FW_!4W_D4_AW_U]-_*OS!_9Z\-V'C/XT^
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MO>./ ^GZ]XH\206L$E]J^I7#/YLDMR$W$!DSC.=Q.<\5_,Y^TY_P<(_L7?\
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MDK_@X!_: ^#OP2O3=?#K7SJ<=]H>FN9=+TE+BY>5K8P1L(T,+RL%)7<@50"
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M]2*6BBH&?S7?$[_E.-I/_8C:)_Z*@K^E =!]!_*OYK_B=_RG&TG_ +$;1/\
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MQ<RQQ*7 PK9!S\V><_C_ &E^'-677_#_ (>UY3QK.D66I<<9%W;QW /'& '
MZ8Q@5S9I0CA\?B:</AYW.*ZI32E9^B?0^]X3S&IF61X2M6UJTHQH5)*[YW%)
M1E?5M6M=O6]^QE?$#PY)XP\$>+/"<=Q+9OXCT2^TJ.[@)6:V>[MWA$L;#E70
MMN5AT-?DWX*_X(Y_#[3-+C76OCI\;FU>2ZN[N\2R\5W$=@C7,SRB."(S8C10
MP !Z<#'.3^R9(]0H7DN>D?'4^G!.*_(#_@H-_P %+M*^!;V_P,_9_2#XB?M'
M^-LZ7HFC:65O[70YKH&W-[JLD#,+:6W=EE7>%V%<]17GGTI\ _MT^ OV<_V/
M-+MO!'@_XT?&SQS^T+XL=-/\&^"-+\47FHZC:W=R5B@N[^T@9UCA#R*2'8,%
M5L@<9^Y?^"3'[%GQR^!_AV\^+_[1/Q0\7>+?'7CJV-UI_A?6-2EN+3P_I=ZC
MM'!<VTC'9>1(RC!4,I&<  ;L#_@G_P#\$Z8/ASKTW[47[77B*Q^(W[1OC3&L
M1#Q!=+=VO@U;P+.EMI\=S<%8WMR0B8C 7:2<# /[*:?XV\*WWB$^&[+7-,OM
M;6W-RUE:W<,TZ0 9+^7&[;4 Z>@Z^P!VM%%% !1110 4444 %%%% !1110!_
M.5_P6[&?%/PB&<9+C/IEVY_"OA/PC\<T^&OA_P"'!U/3I9]*\.:NE^7B!)F
M.0BXSSC(';Z'%?='_!;J6,^*_A(L<J-(A<R(""8P)&.6 Y&5YY]1BORB\<W5
MM-\.?#$,4T<DBW(+1H58J,8 8#)!SZX% 'ZCR_\ !47X<R2O(/#.J@-M &UO
MX5 S63J?_!3_ ,%/:[-+\-ZDM\\BK$95.S!;OR,GG@$XK\9YG6&-I&7(7DX
MX]Z[#Q!X \1>$M.\'>(M;CC32?%LT4^DNA!9H%8%_-[+QCGT)]C0!_39\&_B
M#_PM+P!IGC5;=K0:@R+Y,@PPR"3QQZ<=<#H3G->HU\C?LY?$KX;Z'\)/#FCS
M^)])M;F*"!I(9[N)&C?9\VY2?E]#_M9!KW7_ (6U\,_^ANT'_P #XO\ &@#T
M2BO._P#A;7PS_P"ANT'_ ,#XO\:/^%M?#/\ Z&[0?_ ^+_&@#T2BO._^%M?#
M/_H;M!_\#XO\:/\ A;7PS_Z&[0?_  /B_P : /1**\[_ .%M?#/_ *&[0?\
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MJ/P]9^&%O+W58_[(L55;> P7LD990H !?&YN.O<U]:4 %%%% !1110!\#?\
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M:V_^*H ]=HKR+_A?/P?_ .BA>%O_  ;6W_Q5'_"^?@__ -%"\+?^#:V_^*H
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M[02@[?[8;KC_ (F%SSU[!R?Y9[5_0QY]Q_SWE_[Z_P#K4>?<?\]Y?^^O_K4
M?SNO^PO^T2,!+;6F)./^0C<X_,/UP,^U>=ZO^RC^T9IFLP:'_86NW,L\B1H_
MVZZ:-E)PSEB>"H.?3\:_IG^TW/\ S\3?]]U5*H\B3NB-.!E+AUS*!G!P3@*>
M2!UQZ4 ?@Y:_\$[_ (OR6-O<R:_JMO<3P)+);#4)U\F1@"T0PP^[[&LN\_8
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M+7_0T:M_X'W'^-?NUOD_YZR?]]4;Y/\ GK)_WU0!^$O_  [H^+7_ $-&K?\
M@?<?XTO_  [I^+8X'BC5P/\ L(7'^-?NSOD_YZR?]]4;Y/\ GK)_WU0!^$W_
M  [J^+?_ $-.K_\ @PN?_BJ/^'=7Q;_Z&G5__!A<_P#Q5?NSOD_YZR?]]4;Y
M/^>LG_?5 'X3?\.ZOBW_ -#3J_\ X,+G_P"*H_X=U?%O_H:=7_\ !A<__%5^
M[.^3_GK)_P!]4;Y/^>LG_?5 'X3?\.ZOBW_T-.K_ /@PN?\ XJC_ (=U?%O_
M *&G5_\ P87/_P 57[L[Y/\ GK)_WU1OD_YZR?\ ?5 'X07/_!._XMV]I>W3
M>*=7V65G/>/_ ,3"YY2!"[#[WHI^OM7Q+X/\(^(O&?Q#M_AS8ZQJ\>I3ZM+I
M E%_.2)H7\LGKU)R:_JJU>27^PO$?[V3_D :G_%_T[25_./^S1:^=^U=#("2
M8/&^HMP3E?\ 23T[@G.<_P @* /<9/\ @G/\78I&C;Q3J^5QTU"Y[@'^]UIG
M_#NKXM_]#3J__@PN?_BJ_>&\>7[5-^]D_@_B_P!FJ^^3_GK)_P!]4 ?A-_P[
MJ^+?_0TZO_X,+G_XJC_AW5\6_P#H:=7_ /!A<_\ Q5?NSOD_YZR?]]4;Y/\
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M@AKT&O-/@TMPOPI^'HN65YO^$2T3>R#"G-C"5_';C/O7I= !1110!Y_\5O\
MDFOCC_L6=6_]))*_EE_X)[?\I"K/_KIK/_HV>OZFOBM_R37QQ_V+.K?^DDE?
MRR_\$]O^4A5G_P!=-9_]&ST ?UM4444 5+ZPL]3M9K*_MXKJUN$:.:"9%DC=
M&!!!5@0<@GJ*\<;]G/X,L\DC>!M&+RNTCM]FC^9V.6/"8Y)KVZB@#Q#_ (9R
M^#/_ $(NC?\ @-'_ /$4?\,Y?!G_ *$71O\ P&C_ /B*]OHH \0_X9R^#/\
MT(NC?^ T?_Q%'_#.7P9_Z$71O_ :/_XBO;Z* /$/^&<O@S_T(NC?^ T?_P 1
M5>Y_9G^"=VACF\!Z.RG(XMXQU_X!7N]% 'RAJ?[$G[->KDM??#G3926#G&U?
MF!# \1]B!^5?1WA;PMHO@S0[#PYX>M!8Z1IL*V]G:J<K#$@PJ X' 'M70T4
M%%%% ',>-/#P\6>$_$/AHS?9QKFE7>F^?C/E?:8C'YF.<[<YQ7YU_!C]EO\
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MP4YCTWXM?LYZOX3\/^,O"L.IR_:+:.*_OK:W47&''ED_(=P(P1GC/?%?E_\
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MAUS6I?AMKG@C]G:V\+W+Z)/K]A+87]UJ:QN;9GCE522[!<G!X[GFOE/]B7X
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M?D=1)98^N]J^-O\ @B=HR6WA?Q?JP #7EM: G^(X"=>,]/>OLG_@JY_R9O\
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MPVU7_@JI^WY^TE\;F^$/[8=[\#OAMX#\0:MHFF>&HK::5<V-TT$<H*DC<^T
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M4C42,,XR=F>@Z\^M?HN. !Z 4M% !1110 4444 %%%% !1110 4444 %%%%
M!1110! >I^I_G10>I^I_G10!,.@^@_E52Z4,T9[KDK]<'^H%6QT'T'\JK7'W
MD_'^1H _)O\ X*C?L%)^UU\-+;QE\/V70_CM\,)3XB\&:]:*(KV^N]/ EMM,
M>8#>T3>5A4W%2"5QGK\7_L#_ /!0I?';K^S?^TXK_#[]H?P-*-#GAUT/:#Q5
M]E<6<-S927 B1@R1@Y7((/IG']%0CPVX,01T/!(]1SD8(R",8K\N/VZO^"7?
MPE_;"B'C'199?AC\:-)5KG1/'OAM38ZG+?1!FMUNIX'C+1-)@,3SSDC&:^)X
MUX(P/&> HX?%U/98S!RJ5,%BHPC>+G9^QJ*WO4[K=W:U9ZV4YG/*\4JT.:5*
M6E2'=2M=VVYD9_ABQO;;XT_$F::$BSNK.)K6="&BE0CAD=25.X=@>OZ>B7WR
M/\IVLB@YYSD?3GIWZ9-?A\?BK_P49_X)[7+>%/CI\.)?C%\,K%S;6/C+PI:/
MJ_B6^TV$[(&O)(O.<MY2[V!/#<DYKW/P;_P5V_9U\66Z+XB\'>/_  /J8 2>
M#Q-I\MAY;9PW$B+T///MWZ_RWGWA?QCEV.BWEM;'86#<98G!Q]M&LKKD?LX^
M]JEO+2]GI<_8\FXJR3$8*M2>,A1J6O*C6]R:BHQO[K>R>]K[KN?7'Q.\+WVC
M:K;_ !%\)1F+5++C5;2 ;8+NT W333Q@'S)  6#')'X5TNB^)M-\6Z);:KI[
M[_.PMQ$/OQSKD2[@3N4A\\G'7'0XKY)U?_@IK^RU:6\TO]J7&J1O&PDL[5A+
M--$1\T10*<[A\HSD]J^,=1_X*)C4?$^KZ5^RC\$?B5XC\1^(F,%K'J&BW3^&
M+&ZE)19ED\ORE5I"&)R/E.>G-?K7 F5YM%8?Z[@<70GAXV7M*;A)I*R5:._,
ME91OTMT/Q+C>=/&U:]/ N-:-924)T[.FKI)WMMJFM?(_4CXF_$GP7\&_#.I>
M-OB!XAM= T"PMI9G:YG5/M!1&Q&D6\.79ACA22<=^:_(OX#_ +/OCK_@K'^U
M!I_Q O-(U?P=^R;\/M8AOS"Z36UIXSO[&8F.\\J146>&;8I/WMVX],YKZ<^"
M?_!*K]J']LCQCI?Q8_;X\52>&O!MG<Q:GI7PN\.7+#3K^'>DL=OJ=HLBC' #
MJZ?W@>]?TM_#+X7>!?@_X/TGP)\.O#NG^&/"^D6T5O:Z=IT"0(XC14$LH099
MVP6.2>3^?]"4,96>#IT.7D@HI6LXRZ/RW\]/T_,.&>!L+EN*GG&/_?YA.<G1
MI:^PP\&[J45?6H[:M][HW_"OA;0O!?A_2/"_AK3X-,T/0["VT_3[*VB6&"..
MUB6'>L2C"LX0%CT))*\<GHJ**R225DK+LC]##K_.LO5-%TG7+=K36],L-:M6
MSNMM3MHKJ$@C!!BEC>,_BO\ C5Z2=8R%(.3^7YU*"#C'?I[_ $_SFF!\3?&C
M]@/]GKXSR1WM[HEWX*U.+#"_\#LF@SNX(*-,;-8Q(,XRN5';(ZUXE^S3^RM\
M<O@/^T[J%Y=>/[WQ-\"U\*3V&BZ;J%Y)=WD%]Y;B!YV<G+JP7<2QS@G)-?J,
M>A!YSV]>V/UQ5>TN+=;HVP?9-@MY+%=V.3N&.Q__ %T ;-%%% !1110 4444
M %%%% !1110!_.G_ ,%K_P#D<?A%_NR?^AO7B_P,(_X13X*_]C>>QQ][UZ5Z
MU_P6VNBGB[X5>6I,D,<IP1][!9N.1_>Z^WXU\T_LUZGXIO[#X1IJ5K%%H$?B
M<-9R*/WTDV_!W#KCOW QQZT ?N/=?\?,GTC_ /0!4%3W7_'S)](__0!4% !1
M110 4444 %%%% !1110!#<?\>=]_U[R?^BZ_GX\0?$'XI> ?VE_%US\+%C?4
M[W5[>&\BD3<7A:Y"RXQD?=)Z?S%?T#W)_P!#O_\ KWD_]%U^#VGN1^UKXD*,
M01J<?(Q_S\#J"/3../6@#]S?#=Q>WGAOP[?:H,:M>Z/:W.IJ%VA;R6-&F  ]
M&)'0=*VJIZ=_R#-+)Y)L8LD]3T_QJY0 4444 *OWU^C?TKXFUC_DZWPC_P!>
ML_\ 2OME?OK]&_I7Q-K'_)UOA'_KUG_I0!]MR_ZZ;_KJ_P#.F4^7_73?]=7_
M )TR@ HHHH **** "BBB@ HHHH **** *&K_ /("\1?]@#4__2:2OP%_8W_Y
M.:\1?]C7?_\ I2]?OUJ__("\1?\ 8 U/_P!)I*_ 7]C?_DYKQ%_V-=__ .E+
MT ?T'3_Z]_HG_H-15+/_ *]_HG_H-14 %%%% !1110 4444 %%%% !1110!R
MOC?_ )%#Q%_UXR_^BVKY^_9)_P"12\7_ /8=E_\ 0VKZ!\;_ /(H>(O^O&7_
M -%M7S]^R3_R*7B__L.R_P#H;4 ?5=%%&<=: "FL>".^.@]^GY]LUDZYKVC^
M&].GU;7]2M=*L+=&<S7<BQ))A?N M_$3T YQ7R/JW[55_P")-3ET/X0^$M4U
M.]A9H_[4O;5CI,S@D;XIB-I4G!R"0 >.* /FW_@J[QX7^&>01FZ;&>_)->Z?
M\$Z#G]GZ?'_06;_T*O#OVAO@-^UO^U!IFB1>)-/\,Z39Z$[2Z<ENZK*Y.<"3
M!X]2,_7J17UI^QY\'O&7P-^$\W@OQRUL^MRZ@UTGV1@8?))R <$C(! /IVH
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M?V'/AS<W>D:Y\=/&D(G\>^/M0O&FEG3>UO81SDV_DLY;9O4@Y0 X[CD']!Z
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ML:,IQ2A%Q?,Y.3<G?H?HK1116))^<O\ P4;_ .23S?\ 7K<_^@/7\U_P3/\
MQ=?P!U_Y"M_V/]P^U?TD?\%)+E+;X2322(SJ+:X!"C+<JPSCCUZU_,O\#-1U
M&X^,O@ZT2()%#J-[);.?XBP;"D<<^@R>F.>X!_3?_P $WC_Q;CQ]_P!C_JG]
M*_1NOS@_X)L^9_PK7QYYO^M_X3[4_,XQ\V!_3 'M7Z/T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA:.36\OB?67KW"*45RQ2BNR5E]R&*@48X(R<  !5'H%' Q[#]*?110,****
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M$?CCJ"?#OPJ\'A7XAZ7IGVS5_AJUHMG=Z!%"O[V%H8H+>(>3M.=D2KM''/%
M'VQ1110 4444 %%%% !1110 4444 ?SH_P#!:]%_X3+X2':,LL@;CJ-S#^0Q
M7C/P*4+X3^"H4  >+B!@=MU>T?\ !:__ )''X1?[LG_H;UXQ\"_^13^"O_8W
MG_T*@#]BKK_CYD^D?_H J"I[K_CYD^D?_H J"@ HHHH **** "BBB@ HHHH
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M_L:[_P#]*7K]^M7_ .0%XB_[ &I_^DTE?@+^QO\ \G->(O\ L:[_ /\ 2EZ
M/Z#I_P#7O]$_]!J*I9_]>_T3_P!!J*@ HHHH **** "BBB@ HHHSCK0 4#)&
M54E>[ 94#'4^P[UQ_C;QSX:^'FAS>(O%6HQ6%E$#Y*.X$ES,!\L*(#O+.3C
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M*K_DV^U_["'_ +(U?FS_ ,%6?^2=_#O_ +#"_P#H0K])O^"57_)M]K_V$/\
MV1J /TVHHHH **** "BBB@ K#\2ZW#X=T+4]9G!:/3[.>XVJ"2[QQLR)[;F
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M:%GTGQ/HNL2%0<K#8W ED;.. %7D]J /K#X;:1::%X$\*:=91)##%H6F/M0
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M_P#222OXLO#?PH\6?'+X[ZS\-/! D/B34]3U&:V\JY>U<(MQ*2?/0JR# YY
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M2^%6#_Q<?PST/_+]#Z?[U?@?_P ,"_M4?] 4_P#@UG_^/4']@7]J@<_V*?\
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MP!]K3$_.5V9SP>G'2_&HZPO_  <&_#L>'0C:\W[.6L?V69PIB6[-E-Y6X/\
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ME^+WAYF%HTJLJB6++2>40?*'\63CUH _1NS18K.TC0[DCMH$5AT94B55(^H
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M* "BBB@" ]3]3_.B@]3]3_.B@"8=!]!_*JUQ]Y/Q_D:LCH/H/Y56N/O)^/\
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MBH(_CIG_  Z[\/?]!,_]]_\ V= 'V%_PVG^S_P#]#E9?^.__ !='_#:?[/\
M_P!#E9?^._\ Q=?'O_#KOP]_T$S_ -]__9T?\.N_#W_03/\ WW_]G0!]A?\
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M_P#V/O!_[.VBZ3K?B)KK4H=<N_LEE!8!VE,Q.W& 3GGKQ^!)P "3_A,?%/\
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M*<%#Y:$9XR/7I^/2@#^F7_@FTXD^&WCQU.5;Q]JA4^HX]/\ ./>OT>K\XO\
M@FXH7X<>/@ %4>/]4PJ_=4  8'MQGZFOT=H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH @/4_4_SHH/4_4_SHH F'0?0?RJM<?>3\?Y&K(Z#Z#^55KC[R
M?C_(T 0T444 %%%% !1110 4444 %%%% "$9Q['(],].1WZTO//+<G/WF _
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MC[-<?\\9/_'_ /"OB7_A$/VK/^BA1_\ ?IO_ (FC_A$/VK/^BA1_]^F_^)H
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M]4Z<[/I]@['<SV=JS-_>9H$)/XDYJY5:S$8L[41',0MH!&?6,1+L/XK@U9H
M**** /R[_P""I'P1M?BW\(]*OKB2:'_A&;UIUEB5CL\\A2S8!''49_\ KUZ1
M_P $X_@YI?P8_9YTC0]+U6;5XM4NI-7EGF5E,<MPB[HAGJ%[>@KVK]K=5;X
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MBVBZC.QRTUWY:><Y/0DONR1UK;H **** %7[Z_1OZ5\3:Q_R=;X1_P"O6?\
MI7VT@+2(!C)R!G@<XZU^>6J^.=&?]L#P[I*P7;7=C%+%,3"VPLQQ\K?Q >H.
M * /T.E_UTW_ %U?^=,I6;=)(0,!FW@>@?D*?<8YI* "BBB@ H[Y!((Z$<&B
MB@!=S_\ /1_S_P#K4;G_ .>C_G_]:DHH 7<__/1_S_\ K4;G_P">C_G_ /6I
M** %W/\ \]'_ #_^M1N?_GH_Y_\ UJ2B@!=S_P#/1_S_ /K4;G_YZ/\ G_\
M6I** %W/_P ]'_/_ .M1N?\ YZ/^?_UJ2B@!=S_\]'_/_P"M1N?_ )Z/^?\
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M>\_\$YH)Y/V?9VCB9U_M9N1G^][ T ?=5%3_ &6Z_P">#_D?\*/LMU_SP?\
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M.-FO>2Y7T=SFHXS"XBK7H4*].K5PTHQQ$*;YG1E)749M>ZI6UY;\RZI'R?\
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MOK31MTZP7KMLK49]<01C-7:J:>C1V%E&_P!^.TMD;/\ >6%%;]0:MT %%%%
M'S?^UK_R0'Q__P!@U?\ T:M4_P!D;_DB7A/_ *\T_P#04JY^ULI;]G_XA$''
MEZ5YISW6-PS#'<E0>.]?+'[ O[6?PF^)FFQ_!CPS<ZA_PF?A'3%GU6UN+8I
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M* "BBB@" ]3]3_.B@]3]3_.B@"8=!]!_*JUQ]Y/Q_D:LCH/H/Y56N/O)^/\
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MI<PLL)GM4VJLL0=<DID%<<=: /VIHHHH **** "BBB@ HHHH **** /YD_\
M@L[K.J7OQ+\%6%Y;^3:::C+I\NX_OV;)R.QYYX'7/4\#QG]FBP\3K8?"+4]4
MU#S-(F\3!+/3L8\J3?\ ?R0 >,FOI+_@MO:00>+_ (57$0(EN WF\<?*S* #
MWX'KP3WXKRGX#_\ (H?!#_L:(OZT ?L;=?\ 'S)](_\ T 5!4]U_Q\R?2/\
M] %04 %%%% !1110 4444 %%%% $%R?]#OAW^SR<=S^[_P ^U?@W8.#^UMXE
M4G:XU2,;,X;_ (^ <\'IC-?O0P&&)&01A@>ZY)(_4GWP*_./XY_!7P/X&^+_
M (5\>^'X[J+7O%MY$VK^9Q!N$@8>6N>_?^F: /T3TW_D%Z5_UXQ_TJY5+3,_
MV5I6?^?"+^2U=H **** %7[Z_1OZ5\,ZMIUDO[6GA6X6VB\^6WF:23RT+,1S
MR2N3R<]:^YE^^OT;^E?$VL?\G6^$?^O6?^E 'VW)Q--@?\M7_G3*?+_KIO\
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MO_!?'_\ $T?\(=X(_P"A*\-?^"^/_P")H _GL_X:^_:\_P"AAU;_ ,%5S_\
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MP_YF[4CR.NCW7XXQ&/\ ]=(__!1?]NI!EO%NIX]M'NCTY_YYU^YW_"'>"/\
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MJLH#%3P>O0U]'5X/^TQH.D^)_@CX]T+7=2ATC2M1TAX+S49R%BM8BZDR.6(
M QZT >9_L.>/O%'Q'^ GA?Q'XNO8[_5YH%CDGC01J0!G[HX';MQ^-?7\THAB
MDF8$K&C.0.N%&3^@KY3_ &:=$\)?"CX Z0GAC68?$^BZ7IQN6O+&17CF"*2P
MC;+ $8/7CGDGK67\/_VU?A#\2?B2GPETJYD7Q=/#<,VF2.LC[8=RR*=J@'(!
M'WA]*ZZ&"Q&)HXBO15%PPL/:5E/%8:C.,+I*2I5:T*M2+;44Z<)WE[B]YI/C
MQ&.H8:OAL/5CBG4Q<_9T71P.-Q--R6LE.M0P]6C1Y8^_)UJE.,8)SDU%-K\J
M?VW/A%\,=:^.6E?'NU^+)\.^*M!U6T6/PM<:@#:Z@ZW" QM8/)Y9R0 /D)Z<
M5^S&G?&[X<^!?AWX&U+X@^-?#?AN;5?#VFSPQZCJ5G927&ZWC!>"VDD1RA/0
MJFWMG/%?S2_MW^$_AKXJ_;!'@_4/$^JZ5=^*]?TZWT.&.>>*QT"\AU"+S)K\
M?+&L<C@CYCT(KF?VG_V5/#7[4'_!8+X*_LY?%/X@>/(?AUX3_9YT>XM--\):
MU/8Z?J=_#8PD74D<4GEYD89\W:W7/)S6%5X1R@Z%3,ZM=THNO+,L#B7[.UHN
MA@LXQ:J5<5@Z,TXTL%3Q#P]%7K4*,*<U)^@XXKV5.5>G6I4(\U/"1^JX7 X6
MI3TG.M3P^#FHUJU2<KU\;7H1Q%6?NSJ3<;'].7_#77[.H&3\5O"('&2=8L@
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M)R;BL:(S?./O%1DG'J3ZU^R'[= ^)<_[/_B^P^%^B2:_KM[9R1MI\$7FW$L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@" ]3]3_ #HH/4_4_P Z* )AT'T'\JK7'WD_'^1JR.@^@_E44D1D93G
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MKF 2#,;MT!YX/&/Z4 ?H1+_KIO\ KJ_\Z92NP:64C.&<NN><JQX/^?8]Z2@
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M225_++_P3V_Y2%6?_736?_1L] '];5%%% !1110 4444 9^K G2]2 &2=/O
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M "BBB@" ]3]3_.B@]3]3_.B@"8=!]!_*EI!T'T'\J6@ HHHH **** "BBB@
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M+*$D=1R(V,:=L(N !]>!FDI\O^NF_P"NK_SIE !1110 4444 %%%% !1110
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MPVEE9ZK806UM;HL4444<T:*JQH%084 <+VSWK]"*^ OV]/\ D3_#7_8;L_\
MTHCH ^SOA_\ \B1X3_[ &E_^DD==?7(?#_\ Y$CPG_V -+_])(ZZ^@ HHHH
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MM7C_ ,!_^1/^"'_8T1?UH ^G9O\ @GU\&HYI$%O"<;3DXSRH..G;G\^E1_\
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MUA,TA(! 58VR<8)ZC'0_K7S7^Q9XCT[Q!X+\77&GOO1M<F8?*02/,<9P0.M
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MIWVS3L9_M;2\=,_:X\?^A5^"<0_:CCBBC7P1XLVQ1K&N;BZZ*,<_+R<_3O\
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M0 4444 >?_%;_DFOCC_L6=6_]))*_EE_X)[?\I"K/_KIK/\ Z-GK^IKXK?\
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M?L_ZCI.N:1 9H-)OK&SDU7564$A(9WL1-NR!UW<GMUKRG2_VX/B7=W5C9?\
M#,/CJTCN)E@WDL(H%+!<X%HJA5!!QP,>E8PGCYU9_6:E*="R]BE*JJR:]U*=
M+#SPV5*,::C&-2GEE/,)6MB\=B[)KIK/!.G3E0HUZ6)>F(E4JT\13GRQBE*E
M6KT:F9PYI*4GAZF8U<#2NEA<)AU=/](O(A_YXQ?]^T_PI4BBC.8XHT)ZE$52
M?R KX]^+G[3'C;X;6_A>;2?@MXH\7OK]FMU=Q:<S!]*<J&,,X$#Y8$XR=O/;
MBN%\#?MC_$3Q;XLTSPY>_L[^-="M-0?;)J]VS&VM1G&Z3-LHQ_P+M6QS'T?^
MTE'X7F^"'Q$A\9W)L_#<N@7*:I=*,M! 2N9 .Y']:J?LP1>&8/@5\/(?!UVU
M_P"&H]$B72;MAAI[;>Y5RO;DD8_'O7QM^V5\</B3JO@SQQ\'?#GP*\4>(I/$
M^B2V%OKL(9].B>7!WNJQ#)&!C]YP<\-TJ/\ 8Q^-GQ(T+P3X"^#'B'X&>+="
MG\-Z*+.[U^YRNFL8BS*(T-LN#R0<RX] .X!^I-%? 'CS]L7XB>#_ !3J7A^Q
M_9W\::_:V.?+U6S9OL]SC_GGBV;KVYKT;PS^T;XTU[X:ZCX[N?@YXGTK4+$2
M&/PS<;C?W10$@1Y@4Y;C VGK0!]<T5^;NE?MP_$S4-1TZQF_9E\>6D=]>1VL
MER[/LMD=]AFD_P!%QM ^;D]*]:^+O[3/C?X:G11I7P4\4^,#JD,<MP--)!L&
M= Q27;"_*GY2<#F@#[(KY)_:X3X4/X;\"#XL79M-.'CK2CH3A=V_7=Z?94.>
M@+;>?P[UA_"+]J'QU\2M5U/3]6^!_BOP=#I]NTZ7FIDF.Y(4L(X@T$>2Q&!S
MU/>OBK]JOXD_%O\ :"UGP%\,M#^ GBNRM_#?Q/TC5K[Q-> R6'V&RG3=<0J+
M==J[!N8^8P/8B@#]GK/R_L=KY7,7V:#RCZQ^4NS_ ,=Q5FJEA&T5C91.,/':
M6T;#T9(45A^8-6Z "BBB@#\.?^"V2VA^&GP]DN)IHI8M4NV@6/<%D8 '#D$#
M@@=?7\_ ?^";W[$_PB_:-^ L_CCQQ;&YUL:W/81RHB2(D4(!P2<GD' QT[CI
MC]./^"C?PCTKXF?!A[O5+/[5'X>G$^\*I>!)F"LP)Y&1GH1GZXKM/V!_AIX0
M^&/P"\/Z3X.M);6QOR=1N1*02]W,B>8XP3P3].: /%?^'4G[.?\ T#O_ "!%
M_P#$T?\ #J3]G/\ Z!W_ ) B_P#B:_4*B@#\O?\ AU)^SG_T#O\ R!%_\31_
MPZD_9S_Z!W_D"+_XFOU"HH _+MO^"4?[.AQMT['OY"?R Y_'ZU1D_P""37[/
MKDE(608Q@0)_AQCUY.*_5*B@#\FY?^"1_P !GSLDD3/I;)P?P /XYSQTK,E_
MX)!_!!_N:C<QYZXAS@^WM[5^N]% 'XZR_P#!';X,.#LUNY0^OV?/^'UZ51E_
MX(V?!]U(3Q-?(3G_ )=E.,^^/Z?ETK]F** /YLOVJ_\ @FE\/_@AX,E\2Z'X
MFN+B>*VFE$4T"QEFB0D ;5.06''.<9/?C\__ (->'=.T_P 7?"O5[>,#4+K5
M;ZVN)\#=)'&&7!X]CUSZ5_1E_P %'/\ DDT__7I=?^@/7\]7PI_Y#OPD_P"P
M]J7\Y* /Z%?^";W'PY\??]C_ *IV ].PP/TK]&Z_.3_@F]_R3GQ]_P!C_JG]
M*_1N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@" ]3]3_ #HH/4_4_P Z
M* )AT'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /YR?^"WG_(T?"/_ +:?^AM7C_P'_P"1/^"'
M_8T1?UKV#_@MY_R-'PC_ .VG_H;5X_\  ?\ Y$_X(?\ 8T1?UH _8VZ_X^9/
MI'_Z *@J>Z_X^9/I'_Z *@H **** "BBB@ HHHH **** $/0_0_RKXZ_:B_Y
M&SX9?]?D/\Q7V*W0_0_RKXY_:A(_X2SX8\C_ (_(?YB@#ZZTS_D%:3_UX1?R
M6KM4M,_Y!6D_]>$7\EJ[0 4444 .CV^8FX$KSN ZXXS7YSZF?B.?VQ] 61=/
M_P"$?$<@TX@?OS#GY_,/7<!T.<<^QK]%U^^OT;^E?$NL ?\ #5OA'@?\>L_;
MZ4 ?;3;O-EW==YW=_GR=V/;IC\:2GR_ZZ;_KJ_\ .F4 %%%% !1110 4444
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M $?DQ?\ /*/U^XO^%.9$;&Y%;'3<H./ID4ZB@!BHBG*HBGU50#^@% 1 2P1
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MJ?YT4'J?J?YT4 3#H/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110
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M/_4_ZITY';H>]?HY7YP?\$V4$?PU\>1@DJGC[4U4M]X@ <GWSFOT?H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH @/4_4_P Z*#U/U/\ .B@"8=!]!_*E
MI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#^<G_@MY_R-'PC_P"VG_H;5X_\!_\ D3_@A_V-$7]:]@_X
M+>?\C1\(_P#MI_Z&U>/_  '_ .1/^"'_ &-$7]: /V-NO^/F3Z1_^@"H*GNO
M^/F3Z1_^@"H* "BBB@ HHHH **** "BBB@"&X_X\[[_KWD_]%U_/MK_A7XE>
M*/VG/%2_#.V2XU"UU>%[HN2-D*7*M,5.01\O7G&>IYK^@FX_X\[[_KWD_P#1
M=?E?^S<2/VK_ (H8('^D/U&?XZ /T]\.)>P^'?#]OJ2!=3MM(M8=1 Y NUC7
MS1G)_BSCV].*V:5OOR?[Y_I24 %%%% #D!,B@=3D#ZG%?GWJOB[2'_:]\-Z8
MK2_:K.&6*8%6"JS<##=P>.GM^'Z!K]]?HW]*^#=5T+3$_:W\+WJVH%S<02R2
MR?)\S YY[]3W)/O0!]Y.V993ZN6'T)./Y&DIT@ EFP,?O6_G3: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .!^*%
ME/J7PZ\6Z?;W36,]QITRQ7J'#PLR,=P[Y'('MBOF3]A_P]?Z#X)\6PW^M3ZQ
M(NMS@23[LG+L<DD?-Z]\?I7U?XW_ .10\1?]>,O_ *+:OG[]DG_D4O%__8=E
M_P#0VH ^J@, #K2T44 "_P"L7@'Y6V@]"WH?QQCUR>U?C+\39/$GQ'_:BF^&
M/Q?\23>$_!%].1H! %O%=1[R$C64%2^_(Q@DG([C%?LR1D>AZ@^A'0U\#_MW
M?!&3QYX*L_B5X;L9)_&_@.XBOK)+(M%-+!:D2R%V0;F'R9(Z=SGK0!WW@C]B
MWX2> M<TKQ%IL<EY>Z:PN+.=YIW\[G*R@%BIW8#9Z<CL*^N0  ,#  PH[*N!
M\H]N*^8/V3?C7;_&;X7Z7->2K'XLT&*/3=9T]B!/;FT01MYJD[LG:020.3D\
MU]0 Y /J ?SH 6BBB@!#T_$?S%?B1_P5,_Y*U\/?^P6?_0*_;<]/Q'\Q7XD?
M\%3/^2M?#W_L%G_T"@#]-?V4_P#DW_P3_P!<E_\ 0:^@Z^?/V4_^3?\ P3_U
MR7_T&OH.@ HHHH **** "BBB@ HHHH *_/\ _P""CQ_XLCI@[_V@W%?H!7YX
M_P#!2R;R?@EH7;?JA4_WB-W;UST_$<4 <3_P2J!'PR\?Y &=67&#G/SFOU#'
M0?0?RK\PO^"6( ^&/CG@#_B; _FY_+(/ZU^GHZ#Z#^5 "T444 %%%% !1110
M 4444 %%%% !1110 4444 6+3_C[MO\ KLO]:_FY_;&_Y.]U;_L8-&_]+4K^
MD:T_X^[;_KLO]:_FY_;&_P"3O=6_[&#1O_2U* /[#_A5_P DT\!_]BIH?_IO
M@KOZX#X5?\DT\!_]BIH?_IO@KOZ "BBB@#S_ .*W_)-?''_8LZM_Z225_++_
M ,$]O^4A5G_UTUG_ -&SU_4U\5O^2:^./^Q9U;_TDDK^67_@GM_RD*L_^NFL
M_P#HV>@#^MJBBB@ HHHH Q-2\2>'M&=8]7UW2-+D;E4U#4;2S=@3@$+<2QL1
MGN!BFR>)_#D-HNH3:[I$5B^-MW)J-HELV?2=IA$?P:OR=^)W@*+XX?M^W_PX
M\6:GK$/A'2_AY!JL-G87,]O&UWM5M^48(7!.<=<'FON;7?V7? ^N?#VQ^'<M
MSJL>E66T),E],MPVS &91\Y..N2?QH ]RM_&O@^[F2WM?%/AZYGD.(X;?6-/
MFE?_ '8X[AF;TX!J2\\8>%-/F-M?^)="LIP ?)N]6L;>7![^7+.C?I7R1X-_
M8;^&G@SQ)IOB2QU#79KG36#11SZG<R1L1T+*QVM]"".OK6Q\1_V-?A[\2?$C
M^)-6O]:@NFB$6RUU&XACVCI\J';G'?VH ^I;3Q1X;OXI9['7]'O((03+-;:E
M9SQ1@=2\D4S*H'0Y(P>*H?\ ">^",[?^$O\ #6[=MV_VYIN[?TV;?M.=^>-O
M7/%>&?#_ /98\#_#WPYK?AS3+K5)[;7$DCN)+F^GEE591@['<DI@$XQP.U>1
M_P##OKX5_:!<_P!J>(=_VO[7C^U;O;O\SS-H&[IGMWY'?- 'V]=^*/#=A#%<
M7NO:/:6\X!BFN=2M((I 1D%)))E5L]MI.3TK.7Q_X%9TC7QEX7>1V"I&NO:8
MSLQ. JJMT6+$]% S[5XCX_\ V7/ ?C[P]H^@:M<ZM%9:#;%+9K6^FBF=HXBL
M9D=6&[!"DY].F:_,?]B/]ECP+\0/$?QGNO%&H^);V7P+\3+G3-"5]5N1''!:
M3.4W*3\R$(!C'?GW /VSOO%WA72_+&I>)-#L/.&Z(WFJV-L)!V,9FG0/D<C;
MGCFFV/C#PGJCO%IOB;0=0DC7=(EEJUC<LBCJ76&=RH'?.,5\]_$_]DGX:_%3
M^QO[=?6(1HL*06OV/49X"410HW["-Y. 23WYJO\ "[]D#X9?"G4=1U'07UF:
M?48&@D^V:C/.J*ZE6**['!Y[?GTP ?0,OC_P-!(\4_C'PQ#+$Q62*77=,CDC
M8'!#H]T&4Y[, :OMXK\,)9+J3^(=%73V^[?-J=F+0Y[BX,PBQ_P.OC'7?^"?
M_P '/$&JZGJ]Y<^(EN=4N'N9Q'J]TL8=SN.Q0WRC<>G/%>J7W[*_PZOOAQ#\
M-';55T6$*!*NH3BZ8J."9L[L\<CD'ZT >VP>//!%U+';VWB_PS<3RG$<,&N:
M;++(3V1$N69OP!J>^\9>$=,F%OJ/B?0+"<@,(KS5["VD(/<)-.C$>I P*^1/
M"O[!GP@\)^(-+\0V%QXADNM*D$D"3ZM<O$67!&Y"V#R/3L.,\UQ_[87[+?P]
MU_X:?$CXBSSZ[;>(M \(7UUIDEEJ5S#'#):QAE)CC<98^OMD]30!]T6OC?P;
M?SK;67BOPY>7#<K!;:UIT\K <Y5(KAF(]P*EOO&'A/3'$>H^)M L7;HEYJ]A
M;,?^ S3H:_,G]@W]EOP#<_"+X;_%B^N]>O?%&HZ=--<276IW,D;$3O&I9'<@
ML GTQ@=L5]3_ !)_8]^&7Q.OXM0UR76HYH3E?LNHSP#'7&U&QU_2@#Z0L/%W
MA757ECTSQ)H>HO ADG6QU6QNC#&.KRB"=S&O^T^![U2D^('@2)WCE\9^%HWC
M.'1]>TM&0C^\K70(_$5X)\+/V1OAK\)KS6K[P])K$DVNV+Z?>?;-1GN%\AU*
MMY:R$A&P>&7! ]37G&J_\$^O@UJ]_?ZA<W/B,27\KRRJFKW2KER2<8;CDXX
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MG*,:%*,*?M%B8^VE%U72A*3.X_X*O?%_X"K^QG\08K/XK_"RVW6THB%OXO\
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MM/%OPO\ &.C^+M"N\-%=Z5?6UYE6&1YD<,C/%QR-X7(Z9KU6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@" ]3]3_
M #HH/4_4_P Z* )AT'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH
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MBBB@!5^^OT;^E?$VL?\ )UOA'_KUG_I7VROWU^C?TKXFU@X_:M\(YX_T6?\
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MR[60O.S#(//(.: /H^BBB@ HHHH **** (YD\R*6/^_&Z?\ ?2E?ZU^:_P
M/V)O%'P>_:J^(_QVNO$%A?:!XUM;B.WTR( 7=M-,^_+X'*]1WS[<U^CFJ:I8
MZ-8S:CJ5Q':65N-T]Q,P2.-?[S,> /K46CZWI6O6:7^D7UMJ%I)]R>UE66,X
MZ@,A(R.,CWH U:*** "BBB@ I&8*I9CA5!)/H!R:6D(# J1D$$$'N#P1^(H
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M%?I)_P ,Q_!G_H6;;_P&6C_AF/X,_P#0LVW_ (#+0!^;1_X*@^)1U^'%Z/\
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MB'8ZI?\ A'P7<ZV-"+KK,$42I+831??CF1P#N4@Y[\<$CB@#]V?^&V/V7_\
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M:/&05((8@8!Q0!)2VW_(8\._]C#H_P#Z6Q552YC==P#@=LJV3^&,_I5FV/\
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M !R=G)XY- 'XP6__  6I\>QX\WX5:A+];.8']4/\A6G_ ,/M/&7_ $2#4/\
MP%E_^(K]CO\ AC']GW_H1M-_[\1?_$4?\,8_L^_]"-IO_?B+_P"(H _'$_\
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MC&   <]>W>@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (#U/U/\ .B@]3]3_ #HH F'0?0?RI:0=!]!_*EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_G4_X+6G;XS^$+8S@.?KB1SBOSMT'X":C\1=-\"7(O/*L_$VJKIRJ2?W9R 6
M&6 !Z\A<_G7Z(_\ !:__ )''X1?[LG_H;UXO\#!_Q2GP5Z_\C>>Y_O?6@":7
M_@F')'(T?]N/QMQ\Q/5=W/(]^WI7":S_ ,$W_%$6IVEMX<U 3S0SQRO),3L3
M8P;@\<\=<_C7[?W0_P!)DZ](^Y_N#WJLJ*I)7Y2QR2N03^/7^OO0!YC\'/"&
ML> OA_I'A77)%GU'3TB2:0-GA%"X!&>,CY03S@XKU&C_ #GN?J>IHH ****
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M#\??V4/'NH>%?B[HRXUSP/=3PV\4-S;C=-8BU,BR+!N4HA:$ G !SBN.UO\
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MX;^+/B-X]O\ X.?MQ^.+J?5H[7[)X)M;I3%!(XC\NW^SW\A"YC."I1P7[$T
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MI(9<8';L*]D^%O[67@GQ'^S=9_M'>/+VW\&>$#:2WFI7FHR>7#8PQN4!=I6
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M_P#^"2?Q*T7XA'Q1X9\=.1=Z_J6JI<_,O]FK?S.Y"A>NU7X./;'!% 'Z ?\
M!-\$?#GQ^",$?$#5 1^7^?K7Z-U\E_L@_L\ZM^SGX!U/PMK?B%_$NHZKK=QK
M-SJ+C!,EP &0CKP1U//7FOK2@ HHHH **** "BBB@ HHHH _";_@X8_:Z\>?
ML>_\$\O&WC7X<2S6OB7Q9?+X+@U&T/ERZ>NJQ^6;L.,,GE&3)((Y&<U^1O\
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M4 %%%% !1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z#^5+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_.G_P6
MO_Y''X1?[LG_ *&]>,? O_D4_@K_ -C>?_0J]E_X+8L$\8?"-F(4;9/F/3[[
M_P!*\)^ VJZ=<>'?@S8VU]!/?1>+!)+:(ZF2-2_WF R0 .0?PH _9NZ_X^9/
MI'_Z *@J>Z_X^9/I'_Z *@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?AO]J?PY8?'3X%WR>#OCKX-59M3TR!A;7$EU;<W&G:K#'''YTDSHR0R,&W9
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MZQ@U2#3"+8:I-9PJUQI]];)&#+-*4Q'*^=^XC(;@^BV=YX/_ &T?!T_A/Q7
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M9P1VUM;QK%!!"@2.*- %5$4<    58H \V^,7_)*_B!_V*FL_P#I')7\K?\
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MX\)^,Y5L_$&BW^IBXU_2;V>811&. LS1(,AN@XXZU^U4_P <OA-86]C-JWQ
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M/\J /RA_X*L_\BU\,?\ K[/\S7Y=?!GQ%-X/^,?PZ\6VUHVHW/A_7K>^ATY
MQ>[9&!\I%0AF+8Q@$>WI7ZB_\%6?^1:^&/\ U]G^9K\Q/@7KFE>%_CC\,/$V
MNJC:)HGB.VO-361!*C6R."P:)E8...A5AUR!UH M?M.>++GXD?&OXC>,KO3W
MT>]U^=)9-,D#I):,$50CB3YUW=@V37[A?L6:?\(/VE_V4?#OP8N+]="^*/@0
M2W6B:RZ"TOK>^!#V\EA.&22Z0$8D0;VYW#."*_$O]K#Q+HGCCX]_$_Q=X2$:
MZ#K4Z2:8D48A0*J#.R%0BIENP1237[1_LH?!G0_BK^R;X"\5_"'7K;0_CO\
M#R22_DELIO*EN'B.\6>HQ(H:<W"@JA.]02%."0: /H_P1XW.I#4?V3?VLM.5
M=3\IK+PGXLOU(BU:U \NSN(KV4D"YP(V5D<,#C/&,5/#GB3Q+^R=XDE^#7QE
M2;Q=\ _%[O9>&_$MVC7D&D6]Z62+3YB\AC6(HRJ68_*!N7D#&[I&J^$OVQO"
M=W\,/B79_P#"#?M">!E86=S*OV/4&U"S&V+5;:?RA+/;321AV@5B #N3/(K.
M\#^-QJ?]H_LG?M8Z>BZF(Y+'PAXNOXML.KP#,=I<VMW*@"7 &QD??D\<X^8
M%35](\4?L;>*5^(?P[>?QC^SAXQF6?6]&MI)+^#PS#?,&,UJ(VD0PLKD[DP%
M&X''S"K7CKP+=:%<V7[5W[*5\MU9WL<=_P",O!NGRG[/J5JP62ZC>VCF)6X
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M+;9;I([*,!8YU&[S 5#AL^QJ_P")/#7AW]I[PY8_'_X WR>$OC;X219=:T>
M_99Y[FV!>YTO4;9(XS+<2NK)',^=^0"=W+ %?P#XX@\:P:C^RC^U;IT4/BBU
M5K3PKXGO\QIK2Q92SNH;^5L1W$85"A1@'QM/J/Y]/VW?A]K'PD^/&L>#M8UJ
M;Q&+=X5TJ]F<LT&E/,JVUNCL276.-AM<=<=0*_H5TZ_\'?MF>$;CP?XRMO\
MA!/VAO (*H[*;/4TO[+A)X9!&LL\$SH"8T8D;LCC(K^=_P#;,B\?Z=\:]0TG
MXJ2/<>)-'6#2;:YDR))[*"5(K:=]X#,2-KDGD]P<T ?M3\%T^(G['OPZ^%_C
MFUFO/''P1\=:'8W'BRQ<2W1\/W%]&I>98=V%A568X9=A4'((KV3QIX+U#P/?
MV?[5?[*EV-5\/:J$U#QMX)L9&>UU*W?$EY,;5&VQ3PJ6W1!=RL,CC!KS/]F[
MXF>+/@U\.OA]\,_VD;6/Q!\*/B3X?@_X1SQ7/")]/TN&]B58=+G:2-XU8;P
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M_"?]A[X*?"&?Q!<>&M+NQ+XET^33-2:>\GFWVLBE&10Y(4[3U SGO7EVI?\
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M+3X;ZUXCD$^ORK(#]E_L^>\>23)^7:8AGD=L5_6#;.7R2C)PH"L,-A0 "0.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4CUP:^IJ^4OV)?$.L^*OV9_AGKOB"_?4]6OM+FDO+QQAIG%U*H)'^Z!7U;0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0]#]#_*EI#T/T/\J /RA_X*L_\
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M))2 /N  _,/3\* /[<K+_CSM/^O:#_T4E6:@ME,=M;HPP4@B0CW6-0?U%3T
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M^A4 ?L5=?\?,GTC_ /0!4%3W7_'S)](__0!4% !1110 4444 %%%% !1110
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MFTOP1XLFO#=1:?!.S+:Q,69HT*!D_>9[=>HKV[P58?$/]C"Q\/>+;.6Y\<_
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M[%7PQU[X=ZM\>+C6_*V^)_B1?ZO8".993]EEDE*[PC,$/S#@G([T ?>E%%%
M!1110 5Y%\?-<_X1GX,_$G7S8Q:F-)\*:G?'3Y\>3=^3&&\B3/&U^AKUVO'_
M -H#0;OQ1\%?B7X>L2JW>K^$]3L;<NP11+-& I9B0 ,]R: .,_9&\8?\)Y^S
M]\/O%(TFVT,:IILLJZ9: ""U"W$B;$ X .W/X^E?2=?-'[('@[4/ /[/7P\\
M*ZHT;WVEZ;+'.8G$B;FN)'&UU)!X(Z5]+T %%%% !1110!Y7\:?%<W@OX<>)
MO$4-C%J3:?IUQ,;.<*8IPL9.Q@_RX.,<].N#7-_LV>-9?B#\)/#?BJ72X-';
M4EN&^P6P40P^7.Z?*$ 7D $X'4XKI?C1X4G\:_#?Q/X<M[B.VFU#3;B%)9&5
M$!:,C)9B .O<XKF/V:O!-W\//A'X;\*WMQ'=7.G+<*\T4BRQMOG=QM=20>#S
MCN* />J*** "BBB@#^7W_@K].MQ^US\-+!8$N//T"RBE@^SPRS3*3&K)&71G
M(8'  ZD_2OV&^ ?[(W[.NM?"#P-J6N_!SPO/JM[HUM<WEQ?Z>XO9)709,WSI
MC=UQL'7WKP3]NOX/>"=;^/7P7^(6JZ>MWKL&M:;IR;\%#;K)$-C(00PQ@\CZ
M"OUJTVW@M-/LK:UACM[>&U@CBAB0)'&BQ*%554   4 ?-_\ PQE^R_\ ]$8\
M&?\ @ W_ ,=H_P"&,OV7_P#HC'@S_P  &_\ CM?3M% 'S%_PQE^R_P#]$8\&
M?^ #?_':3_AC']E[K_PI?P7G_L'M_P#':^GJ* /F'_AC']EW_HBW@O\ \%[?
M_':/^&,?V7?^B+>"_P#P7M_\=KZ>HH ^8?\ AC']EW_HBW@O_P %[?\ QVC_
M (8Q_9=_Z(MX+_\ !>W_ ,=KZ>HH ^8?^&,?V7?^B+>"_P#P7M_\=H_X8Q_9
M=X_XLMX+Z@_\@]NQS@_O>A[^U?3U% '\]7_!2GX%_"#X<Z-)-X'\ Z-X:N/*
M0^9ID0A4').0#O8=,_>]!T%> _\ !(^"*#]JJX\J,)YO@>>23@$L_E.,Y'0\
M<GOGUS7VK_P5?_Y ;_\ 7&/^9KXP_P""2G_)U4G_ &(D_P#Z+DH _J-HHHH
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MJEFTCLQP J+,6)/& !DT =E14<4GFQK)C 8 CN"",@CV(-24 %%%% !1110
M4444 %%%% !1110 4444 0'J?J?YT4'J?J?YT4 3#H/H/Y4M(.@^@_E2T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?SI_\ !:__ )''X1?[LG_H;UXQ\"_^13^"O_8WG_T*O9_^"U__ "./PB_W
M9/\ T-Z\8^!?_(I_!7_L;S_Z%0!^Q5U_Q\R?2/\ ] %05/=?\?,GTC_] %04
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4AZ'Z'^5+2'H?H?Y4 ?E#_P59_Y%KX8_]?9_F:_,GX"0Z)/\>/A7%XG\
M@>&Y/$ELNM&[P;3['O&_SPP92@&=V5/!XK]-O^"K/_(M?#'_ *^S_,U^8'P1
M\/6?C#XV?#3PEJ4[6VF^(/$-M8WMPAVO#%(P!=6+* >3@EE QUH Z']K5/#E
MG^T+\54\$&T_X1:"YB_L8V  LMH0%A"%"@+G@X ]>E?JU\"?V<=>N?V.?#'Q
M<^$U[<WFM3PW-UXX\)&3S8]:M[<9VQVP+#=&<':P#%<G;@9'Y-?M1^%-,^'/
MQX^)O@W1IGOM(\/W"1VMQ*XD>960,=S[G#''^TW;K7ZZ?LD:G\4_V8_V</#?
MQXTZ]G\5?"KQ/!=Q^+- N)78>'5*-%'<6,*R J%<C<P7 /RL><4 ?.G[-_A'
MQC^U#\6/$$FE1VGA_P"(OP@#:QH0N4$82YLG+1V,H.1E2@3:<C) QDUP?_!1
MSXPZ_P#%?QKX'L/&OAVZ\/>,O FEOI&O-/$\<.I749(:XLE(4>5(VZ0[1SN/
M;@=?\%];^)'@#XM:_P#M'?#F6,Z)XPU^>[72K9R[:M:7,Q<V!0$;YMK'<F,]
MC[9/_!3?XI^#_C+XV^'/B3P[IW]D>(+?0EC\7::\(@N+74ROSI.H^9CO+ %@
M&V@9R1F@#U#_ ()9:K\)[^R^)/PE^*D-E"WQ"41:)=7J(I20C:K6]S(A,,JL
M08V#;0P!QSQ^C'AG7/$O[)OB2Z^#_P 78IO%WP"\6K<P^'/$ES"+ZWTR*XC;
M9;7SR(V;94(7;O11@,I! %?G7_P3*^&OP[^-_A#XG^"_$&H6VB^/K4I+X+U=
M9U@UBUN8_G1K(;T>2,2 -*%8G:#A3TK])/ GC:6\75?V3OVKM/A34DL[BT\)
M>+;X*EKJMHD++:RQ7\C "]*!74*_S'@G^Z ?&G[,7C?QQ\$_%WQL^)G@*P@\
M3_LX_P#">W&GZAHFEPK(EK;S3OYNH)"$<+;1!R&)P" 0<@XKZ>^->B6O@OPW
MJ'[7_P"S#JT#:?J6E3_\)=X7M'3[#?&[B*W -I&@B2>$N5DCVE@03]VOFW]C
MCXHZ?^SUXR^,_P (/%6@C5_@1?\ C:[T8>)FB,\,=Q>321"*ZDW*GV<HX5BS
MX ^8$$ U[5\>OA3XI^"'A[7]7^%6H7/B+]GSXBHT^MZ7ILOVY?#@O@2)-,1'
MF3R</N9E^Z,JV"&P ?BYX!_:"3PKXP\0_$33HM3TKQY->WM_8_V<[06[7UX7
M,D&H+& KP@O]T^G([UT_@']H;PE%X=\<V_Q*T"YN/'/BC5[CQ!9Z[I2^7<0Z
MK(S-&K3#!\C<067/'.!VK*\%?LJ^(OBQXR^(=I\-+Q=5L/!]A+XBU-4;??&"
M13,8$B!!-P@!5D&2.F.E2_ /]E+7_P!H3Q?XH\'>&K[[%XB\-V=S.]E?,()S
M-;B3,3HY5@^4(P3D?E0!WW[.7[5_@KX8^#?B_P"#/BQX3D\5-\36G:QO3%]H
MGM'(9;5C(02"F5.0<Y&:L?LD_MBZ1^S;=_$K3O%'AF3Q)X,\=QWUO::=+&)5
MAMKA76".:,A@517'!Z=.HXP_@+^QEJGQ@^(?CCX4^)M>AT#QUX,-VD6FRR^5
M)=/;%E39&?F<,8Q_/I5?X1_LG6GC+XV>+/@;\1_$T?AS7-$-VFCSM*(X+HVP
M;RP[%AG)3'4$GK0!?^ '[96M? 'Q?\1M1TK1HY? 'CNZO98M :)3#:6]X9,1
MK"RD1A X^Z!CT&.>6^&W[5?B/X3^-OB%X[\!Q7%HOC;[;"VC D:4UO?;Q*TU
MOS&74.=I*9.!SD<XGA?X!Z;-\:M9^%?C/6+NVT*TU>71;+6[+FU$L;%5GN)P
M<+"2/F8D#W'6J][^SU<Z3XH^(:V^H2:O\//A[=&VO=5TDFZFE."0Z-'G*J!\
MY!..>XH L?#SXZIX1U3Q#XUT6WU6R^(-R]]<Z9)IIDBLY+B_#F87R1C]Y&"Y
MVCGISBNF^'W[0W@RP\ ^*_#_ ,0?#M\WQ UK5;O7;+7;")X9X]4N"SC?*55S
M"'(XS@<],U[A^RQ^RUXKM]/OOVEM$TK2_&G@'PPSW-OX?U)EDDU-(/WDD4\#
M9)954AAL..1S3+SX96W_  4'^,OBS4?A-X;T?X<7OA#07^U>&K,Q6UL]_;H=
MXVKY0RSKMQC.2 <GF@#@_P!G;]K7P3\+OA7\6/AA\4?"4GBF?XBSW=U9:@\7
MGO:7$N\6[EW#%6CR#DD<\\]*E_9)_;,TW]F_3OB3X:\5^&3XF\)>.XK^*TLI
MXA*D$=RCI;I*K!@5C#C"GT&#GFL+]G[]C#4/C3XQ\?\ PX\0>(;;1/B!X':\
MC&EO*(VGEMBZJ$C.-P)09/OZ5G_!G]E/3?'OQ8\:?!GXB>*$\.^(_#AO3I4C
M2B*UN#:;PH>0MC+[>.<Y_*@"[^S]^V3K_P  =8^(AL-)2[\$>/+J_E719(UD
MALK6],FR..$HP38CXX P!C ZUTO[(GQQ\=>'OC1XG\2?":UOY[_4[R;6]1\.
M)^\TZ71=YFN46TV,IN-A<*0F<\YSS7C?@?X$:9J?Q:UCX;>,M5N[/0[75+K2
M+'7+,,UJKVY=5GNIAE4@;;G<2!],5]"_LB:'JW[/'Q\\4?$S3[7_ (2_X=>$
MM3/A?5+JPC^VJ]K(Q66[< ,K0HA)<G(ZYQ0!^P7B+0="_:D\-6/QN^ ^ICP=
M\;O!N)M4T:-DM9KB[MB#<66L0(L7FO,Z,L#N&#Y"GYL;O*/%7QG^'7[07AD>
M!_BAHE[X%^/'@\^4->$*64UE?6F!_:4MSLBF-G-(@95WE,'Y,"O1?'/@BZ\/
M7UC^U=^RI?1WVGW8CU#QIX-L9@;/5+<D27F^TBE(%Q&I?=#L#*1E3@YKY\^.
M?@.S_:WM)?C9\)M3TKPGXKTRP2#Q7H6HW"V-[>7=J@-S9W4!97, 9&57;);/
M))S356A1:GB:%'$4K\KI5Z[P\9-J]H349N51I-0I\MI2DN;W4R9PG.G-4\3'
M"3BN959TG5CHU=22:LE%N5];\JCU/9O@I\9_#_Q=TN\_9K_:)AM9M4@5K+PA
MXRN%C6VU>%4,=G=65W(H5;P#:RR^;\S8!/I\V? [4M)_9"_:*^)/P.^(F[6_
MA1\1;QX)-?UA?M-M MX[) ES(XD&0' 1CD*.5Z MZI^SCH/@K]I#X5:E\-?$
M[6OA/XU^!KV0^'M0A9;>_$UGD0364GF1M/9F1!EE^ZI+#<,X\A^"@T;QE\>?
M'G[/_P"TG=VU[X@TIIK2#7I[B*.+=&&CL[IKN215,L0"LF9<9'!QTF+ND_9T
MZ2:O&G1J*K3IQ?P0C4C[LN6-DVM.9-="W'D]WVWUFRC_ +0J4Z*K/E3=14JE
MITU)N_+))KT/JC4]+\4_L7>+5\9>#3/XS_9N\:S"?4=,C;[:/#T-\59[A $9
M4L]LF58*$*=1U ^:OV^OAEX5L_A3_P -#? _6XX/#?BW":QX?M95&F2SW:[I
M9FMHSL2=22'#*"K#CKFO0D_:6T;]DO6?%7P,^+^H)\4OA#=1RQ^'-;M94U.2
M"*Z.V+3KYU:8+!""$'.%*@J?7X+_ &D-%^,-[\.KP_#;2M=NO@+XCU-M8L[8
MP3/;Z8DS;T"9RJVT8;[P50![4Q'RQ^Q1H7Q!\1?'W1H?A7?QZ;XUT^VFU:WD
M=]HN8+8M--:+V+3;2JKC//2OZ$8;SP;^V3X6U#P7XMMSX#_:"\!">&*9U6RU
M2.]L@5%Y%((UFEBGE0$ <+G<,+D#\:_V0O@G^T3\(_&^B?M$^!_#]IXFT;1H
M&_M."$>>8]-QF\) _P"6RQ;@HQD'C&:_9/Q1X;\-_M.>'X/C]^S_ *B/"OQL
M\,P2MJFD1RI;76HW=N@\ZQU:$2+(RAU*PR-&/,'!^;[P!^;5Y8^-=>\3Z]\#
MOC/J\YU>QGEL/#NN:K*TD<[(Q6"6UED.!<'"'<#G^GW)\'O&?C+]GC3=&^!G
M[3EK'XC^%_B^V-GX:\77,2W5CIUK=@I#9WLSQR(KLKJ48G<APRXQS\V:3::/
M\?\ PEXFL_B1JZ>'/C;X=UJX2.X:7R+V/4;:0\Q#Y7:'>@P22"#G-?4WP@^(
MNC_$GPLO[,'[3>FPVNL+;-;>#?%%X%CBU*.,;+2^AO))51;U,(T>TY<\'L14
ME5E^]5-RH7=.IBWA,3A55Q$$DJ<'6?)6C2IZ.K"*NWHVKC;MRTYUZ+J**E3P
MM*>#J2I46]:M25!*O"52;_A56^6S<ES6+%_IWBW]BKQ:/%'ACS_&?[-OC699
M;ZPA8WR^'X+X[S*GRNJ6Q1\_(H0Q\<#(&AXU\%ZAX"U"T_:K_95O8M2\.:HD
M=]XW\$Z>ZO9WED^);HP64>5CNP"P<; P;V(--\*^*/$7[-OB"3]G[X_0OXM^
M#/BQY++P;XQOD:YMX;:Y;9%:ZE.2WEPQ(5"!B-I&5(P<\1XL\5Q?L#^+H_$&
MG^)K+Q5\ /',QFF\-K>1W=WHZ79RTMG9K/(#;JKD)G 8<$#D"1'7_%/PAX/_
M &H?AAKGQT^!NK0^#?BGI7AZ]A\4:=$Z6L@$<$C7]CJ\*1Q$W!"/Y<C@[\8)
MW9S_ "YQ^8/%%I'.=US#XWMH;I^TES'JB+/(#W#ODY[U^Z7C/XM:AJNM>,?B
MW^QMX=UV\\,>(-%OK'Q=H!LI(]*O6O(7%Q>-""8EE4L67[QR/4U^/UI\&?B+
MJ%]:^)CI$L"2^,;6^U&U:-UFLYIM16:994(^0*QP#TQ0!_;)\)/^28> /^Q2
MT+_TWP5Z'7G_ ,*(WA^&?@.*08>/PIHB.,8PRV$((_ UZ!0 44A( )/  R2>
MP'4U\L?&K]K?X8?!UETVXN[GQ-XDG)B@T+PU&NJ7D<Q^51=I;R,T #$9^4L,
M<XH ]1^.I_XLW\3/^Q,UW_TAEK^4W_@EO_R>UX=_W]>_]*+BOVO\9?%;]LCX
MQ^#?$UIX#^%_AZP\(:]I%[:-?>()'M=1AL+F%DD9899$#3>62<;,@YP 17YY
M_P#!.#]C[XN^&?VI9/B1J']F1^&_!\M_;ZXOG*MQ]LNY)#MMT+9==[_P@Y&<
M'J0 ?TS4444 %%%% 'Y3:S\6=*\!?\%%]9L_&WC<^'O"TWPS@>TLM5NW@T=[
MTJI\R,$>4)_?()Z=Z_0R\^,OPPT_08O%%[XTT6V\/SX\K5I+@BTDSTVR;#G\
MJY3XD_LU?!WXL:S'XA\:^#]/U;7(H5MDU.1,70MUQMBWJ0=HQTSS5S5?V>_A
M7K/@VU\"7WAJUD\.6840V1W[0%QC/S=>/;CZ"@!VD_M%_!#7=0M]*TCXD^&M
M0U&Z(%O:6UX7FE)X 1?+Y)/O5SQ#\?/@[X3U#^RO$?Q \/Z/J(4.;2]NFCF"
MGHVWRSQ^-<%X:_9"^!/A/6K'Q!HO@RSM=2T\AK:8&0["._W_ .O-:/C7]ECX
M+?$#6V\0>)O"5I?ZBT8B,S;P=@X X8=O;]: .[T'XT?"WQ/87FJ>'_&VB:KI
M^GJSWMW:7#20VRH,LTK;!M"@'/':N5_X:?\ @#YGD_\ "T_"@E\WR-AO6#>=
MNV^7@Q_>W<?6K/@_]G;X4>!=%U30/#GABULM-UA72^B7?^]6088$[NXR#ZYK
MSK_AB3]GCSOM!\#67G?:?M6\%Q^^W^9NQOQ][F@#V77_ (Q_##P]IEOJ6M^-
M=$TNPU&%FL;N[NO)AN5,;,#$[+ALCE1U/& <BOS._83_ &A_AY9^(/C[!XO^
M*-@9-2^*-ZWAN'6+]QYVGR22+"-,5UPT+%EVJG08XQDU^B/C#]G?X4^.=&TO
M0/$/AFUN],T=42QMVW[8EC&% ^?/3 ///YYX73OV*_V<-+N[:^MOASI2W=K.
MMS#, 599D.5D./O,#_>)H ]2\4?'3X1^"_L?_"5>/-!T/^T$$EE]NN6C^T(P
MW*T>(VR".1TJ+PO\>O@]XUN;BS\*>/\ P_KMS:QF6XAL+II7AC49+./+& !S
M69XV_9Q^#GQ$.G'Q;X,T_53I4:PV/F;E\F-5"A5"G' '^14/@C]FKX+_  ZO
M+N_\(^"=.TJZOHS#<RQ;B7C8;2O)& 1G/KWH BO_ -J+]G[3+NZL=0^*OA2T
MN[*0PW5O->LLD$BG!1QY7!!XZFNIF^-GPJM_#B>+IO&^AQ^&I.4UEKAA9,#R
M")-F3D<CBO,=4_8V_9TUF_OM2U'X<Z7<7FHS-/=S,7W2RL<ESSP2:[FY_9]^
M$EYX/C\!W'@^P?PM" $TSYO+&.G.>?RY[YH HZ5^TU\!=;O[72])^*/A:_U"
M]8+:VEO>,TT[$X C4QC)S[UY;^U=\<_AGX<^#7Q1T*?Q_I&D^*;GP9J8TNQ%
MX8M3>XDB'D&U0*6:0G[I7IW(S77Z%^R!^SUX;U:RUO1_AYI=IJ6G,'M+A2Y,
M3*<@@$\XK9\:_LO_  0^(6JKK7BWP-INK:BD0A$\VXGREZ(5)(('H: /G+]A
M7X]?#74?@!\,O#FH?$?3-1\9C2YA?6%Y=NVK^;]ID($T;KO.$*88G!![8('U
M=XE^/?P>\'SI:^)_B!X?T6>3[D5[<O&S?0",\UR7A3]E#X"^"M9AU_PUX TO
M3-3MUVPSP@CRQZ*HP!6GXR_9H^"WC^Y2\\5>"M/U2XC^Y)*7!'X X_3^9R ;
MWA7X[?"+QO/?6WA/Q[H&O3Z;;FZOX]/N6E:UMU!8RR_NUVJ "<\]*YN[_:E_
M9\L9Y[:\^*WA.WN+5F2XBEO75XF4X97'E<$&KG@?]F_X-?#B?4KGP?X+T_2)
M]6MFL]0DAWDW%LZE6B;)QM(..!_*N.O_ -C+]G'4KNZOKSX<:7-<7CM)<.2_
M[QF;<Q/.?F).>: /4;KXV?"JQ\-VGC"[\;Z'!X9O\FSUF2X865P!U,<FPD_]
M\USVD?M+_ ?7M2LM'T?XG^%]0U349!%965O>,\]S(>B1(8QN;VS5S4/V??A)
MJ?@^P\!WG@^PE\+:8"+'2CO\FWR #LY)[=^/UKDO#W[(G[/OA;6-/U[1/A[I
MEGJNER":QNU+E[>53D.G(&X<=?04 <-^U/\ 'OX6>&/AUXNT"\^(^E:%XH?3
M;B.RLDN674FN6B.Q(D"CYR2-IW=>173?L9WU]J7[/O@F_P!0O+G4+BZAN9?M
M=X[//,AN'*.[/R05/R^@X[5TGC3]EGX%_$'6QXA\7> M+UC51*LOVBY#'<Z8
MVEEZ'&!^5>U>'_#VC>%M)L]#T"P@TS2K")8;2RMEV0P1KT1%[ 4 ;-%%% !1
M110!^;O[:O\ R/WP;_[&K3__ $9'7Z-VO_'M;_\ 7"+_ -%K7YR?MJ_\C_\
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M"_\ 9-_9@TWQGXLTO2;ZZ^"7@&2"VGNH4ED6/0K* [$9P2QD! 7@]NM?E/\
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M\ZY" 2R!CG:7'S$# ZF@#]IKK_CYD^D?_H J"I[K_CYD^D?_ * *@H ****
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MC[XF?'[]I=/%L?PT\0:1JI%C=P7>/,>%F$]HD2OF9;EPR[E!^]6K^R"_P_\
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MV// 6@?'_P ;_M'Q_$:^M_#/Q(BM)T\-ZU%J2Q31O C9O(,.K2QR$>9)L<L
M> <5\9_#K]E'5?BGKGC_ ,8?##59[_PGX!U1HYK?3W9-6O=.@8FY>)LF3*J&
M!(Y)[@BO:/V8?V8++]I&X^/1\"^)O$_@WQ#X'M"FB2?;YX+R>]A5A<07;[@T
M@D=61=Y*Y(!.,&@#TC]AZZ^&UM\5OC7\*/CEJFFBV:/4M(TO7]0N(XGN[B+S
M$%Q!=/N>.9P-P/4L "PR<<#\#_VD-%_9-\:?&GPE:^#H/B/\-;_7+VPA>ZFC
ME%U!/)(H"R2[PV5; =>0.XZUD_L:?LM^!_C]XU^+7PV\9ZWJFF_$?PM9WT&E
MZK]M:*:36;8LK7+G.^<%P"P4'Y23S@D?/EIX2\$?#S7?'?PK^*UW?ZCK6E^*
M9- CURVD<6UO.\S1PZE<NIVM'"N&<DG@=^: /O3]E[]KCQ_X/^('B;Q'HG@-
MK#X W]^?[7\-"Y^URZ&EY)\SP6XW[DVL2=B[0,@Y%>\?M,?!WP_XV-U\:/V9
M_&BP375C%J?B[P5IMXUK$\# 33"2VBD39,5W!UVYR<=*^+?V6)OA5^SM^T/H
MOA#QY\0[?XA^%?&R"!+RV,LV@6(OP$B@U!/G@,L>Y4WMG:1D@D5]-?%W1_#_
M .RC\>=4U[0)M4UWX2^,;3^TKO2M/NVEAM8KP;I=C1'9]F 9A&ORC&..2IWP
M_M%4<Z*KJM3BYTIX>K&E.E)67M'*49\T(Q<N>"BVXOLF14CSQY>>%.+:YW/#
M/%*45KR1I*=)JI)I*%15(<DK.ZZ^C>%M)\*?$[X$CXV_#K5H_AC\8_A/;O!J
M,\=TEO+JYTY=TMG-") \KW!4JKE&+L< ]<_&'PFMM3_;!\5>*/#^CVYTGXD>
M+GN#KGC9[C['=:9<619 L,FY99!<,FXD' !SUR:\V_:$\6Z/XJ#^+_V=;/Q'
MX=\!WT@@UUX[J6/3KW69#A[5X58AY7;=P<$D\]Z_1CX%?L\Z!XQ^!GA;XE?
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M - %04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_BWX-@BM9O$*&*"QLO(&V>.QND5&9+AAEE,I'H,,:_&30=:\5Z!<MJ/A/\
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M*Y!Z<=O2J)/V3TS_ (*3>&/%?PGN_A3^T#X0FU&6VMFMM"UR>)FU%O+!6VU
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M#9^[SV["@#^P:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPW\+;6\OM;\,:S'XKOM-LDD:>_TO3HA)/:^7$V9!*J,,$$'TQ7QS_P $8?\
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M<"4MT?.&(XZ#GH:]V_X=C?M!_P#04T+_ +Z'^-+_ ,.Q_P!H/_H*Z'_WV/\
M&@"K\6_VJ_@'X_L-*U#PM\(YO#_CG2_*D_M+R0EA+.FTL7B VLK8/!![=!5[
MQ+^UM^S[XV^'=IX<\5?!^9O&UG:Y37-/@$$#:BB@13,%ZQA@"P(Y!.<9J/\
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MKX1_M<_"7P$-=T;Q=\+8O$7@V[,RZ%:+:JU]91S9!668CDA21DYP>GK77_\
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M#?D*%@NK2*27SL<DL\;''7GY<]A7W310!\?_  Q\/?M1VWA?Q$GQ"\6Z+?\
MB-XI1H<MM;1QQ0R%3Y9D544'!Q][KZ5XC_PB7_!0+[5N_P"%@>%_LWVW<5%C
M!G['YN=H/E9SY7&<XSWK]+J* /D/XD^'/VH;KPOX?A^'_B_0]/\ $45N'UVZ
MO((FAFDCCWN(U:/:-S#:H4#/;FOA3]G7Q_\ MU_''7_&D:_$+PK8:=\//&#>
M'=7@:RA$EZMO(RS>5B+ABB'&.G%?M)+@QR ]"CY^FTYKX<_8V\ Z3X)U3XX2
MZ;K=IK#Z_P#$.^U*[2UE20V,SO)NMYMI.V12>0<?3K0!M_%[PC^UGJ/]A?\
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ME_@;P'^W9;>*]"N?&?Q,\*WOAB"X5M:L[:RA2>YM\\I$RH"&QGH?KBOT+HH
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M_P#'J/\ A?\ \%/^BH>"O_!_8?\ QZ@#U^BO(/\ A?\ \%/^BH>"O_!_8?\
MQZC_ (7_ /!3_HJ'@K_P?V'_ ,>H ]?HKR#_ (7_ /!3_HJ'@K_P?V'_ ,>H
M_P"%_P#P4_Z*AX*_\']A_P#'J /7Z*\@_P"%_P#P4_Z*AX*_\']A_P#'J/\
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M4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?S@?\%O)7/BOX5QE<*D<FQAW8DD9XX[U\U_LT:+K]OI_
MPBUC4=4EGL+GQ,L=KIC?ZN$[AAQR/0]O;K7T[_P6\_Y&CX2?]M/_ $-J\?\
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M?0!_*I_PY_\ V@_^?NY_\'EY_P#)%'_#G_\ :#_Y^[G_ ,'EY_\ )%?U5T4
M?RJ?\.?_ -H/_G[N?_!Y>?\ R11_PY__ &@_^?NY_P#!Y>?_ "17]5=% '\J
MG_#G_P#:#_Y^[G_P>7G_ ,D4?\.?_P!H/_G[N?\ P>7G_P D5_5710!_*?+_
M ,$@/VAU7,=S<L1GY?[<N^?3/^D?SK"N?^"1W[4D7%M%+,.2-VNW?X#_ %PQ
MZ?\ ZZ_K-H/((Z>_I0!_(=>?\$GOVQ8N+71A*!G!.OW63Z=;@_7H>W2LT?\
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M4 ?W7VSF2W@D;K)#$Y^K(K']34U5K/\ X\[3_KV@_P#12U9H **** "BBB@
MHHHH **** "BBB@#XK_;Q^&7[/7Q5_9M^('AO]J34+32/A*FE7=WK.L7=ZEB
M=-6.%MUU!.S)^^B7YHU7#$CTR:_SI/V<OVF_VQ_@/^V!XF^$W_!(#X@>/OVA
M?@9%K%_'IFAZQ'J5QH$2I<RK)$FHNY@$<9 1>=I4#!K^\/\ X+.Z?\%=1_8Z
MUV']H+Q-=>%_A8NJP/XHNK6Z:U:[L @\ZR:167*S)E<'Y>3GK7PO^SA\=O\
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MZOX9T;5C9BR?4+.&Y>Q! 2S,BAC"@!*@)]W@#H>.E '94444 %%%% !1110
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M/'DD^-O[1K2,SL==@R2<X_?/TP!7Z-U^<7['/'QK_:,'7_B>P<^O[YZ_1V@
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M0<>]?4=?)W[$&N:MXD_9D^&6LZW?/J.IWFESO<W<GWI6%U*!G'H /KU-?6-
M!1110 4444 >0?'7PQJ7C#X8>*M THJ+Z_TRYA@#$ ,[1D <]\GVZ]1UKF?V
M7/"&K>!/@QX6\,ZV,:EIZ72S@=,O.[# !. 0:U/VB]8U'0OA'XOU32KUK"_M
M=*NI+>Y3[\;K&3E3D8((%<M^R'K^L>)O@3X0UG7=0?4]2NTNVGNY,[Y"MPZC
M)[X  !R?K0!]-4444 %%%% 'A_[1GQ+U+X2?"#QEX[T:"*YU?0]*N+K3H9UW
M0/<QKE!*#QL]<UYS^QE\=O$7[07P;TGQUXJM;6SURYDFCO(;)0ML"LC!#&%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0]#]#_*EI#T/T/\J /RL_X*I_\
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M$_:1^(8=/ G[,_C7PRL\,WE?\)/I<@*90[3)OA4AEXX4#GMT!^*_V/\ 5_\
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M(KJSOM6M+_P6]Y>6&TPW+3ZUYWG!EX9I%()8$DYZ^F?LJ%*JK8VI5Q-2#4\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I#T/T/\J6D/0_0_P J /RM_P""J/\ R*'P]_Z^
M6_D*]3_X)KJ4_9ZO%/7^VW/ QU8G\?\ .>:\L_X*H_\ (H?#W_KY;^0KU[_@
MG"NW]GNX]#J[$=L9;./P!'\NU 'WK1110 4444 %%%% !1110 4444 %%%%
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MFXG;S;N#7YI/L^6.YX$_TIB8^J]!D=NAK\XK']A/_@O:][#]L_X*(VL=L?\
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M;.VU^Q_6M17\PNK_ +!?_!=PF#^SO^"C5N!M'FC[ >N.<D(/U]L4FC?L%?\
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MXQTS]E[7;?P[\3M=D.EVE_<7:6*&UN8BDL8NG9!$S%AAMV:_@Q_9F_X)7?\
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M10 4AZ'Z'^5+2'H?H?Y4 ?E/_P %5)2GA3X<*.2UVVX<9P OJ>*]K_X)T_\
M)OT__86;_P!"KPS_ (*N,1X7^&?I]K)('!)R1US]/RKW/_@G3_R;]/\ ]A9O
M_0J /NZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^-?V\)_LWP$NI 2-]RR$]NW'MGV_&OF+_@E#G^P_B>3WN\_FQ->^_\
M!1&Y^S_L^;AD;]35<\C.<<<]?;W_ %\$_P""3T<LF@?%!T1G5;@%VP1M'&2Q
MQ@=1DT ?K(.@^@_E2UR^I>-?!>C1RG5?%NAV$D"DO!<WL*2_*.5\O.<]1CUK
MY4\:_M[? +P7<7FG7%]=W^H6^Y8I+(;[=I1D [@#QGG).,=^* /M+/0<\G X
M('XG''UJ1HY$"E@GS] )$)&>F[#'&??&._&37XH>-?\ @J/XJ>YN]/\ !OA[
M2YK"8O#;W%RR"Y7?D)MSU;GOW/:F_LV?$/\ :P^*OBCQ++8Q:FFDZBFZ2;6(
MWBL[*.7DMIKLRJQ (QMX/7.>H!^RGB>_TW1= U6_UN\MK.PCM)6FEDDC*A!$
M<YPY/4 =!7PK^QC\3?"FN^+/BSH=EJ<!N[G6Y9-)MPXW7ENLIR\('WE ZX!Q
MZUUEK^R?KOB)WN_'_P 5/$5T+E-MUH*SR&P96R6CVAF7:,[3G@CZUL?!_P#8
MP^'OP4\>3_$#PSK-]=ZA,'"6$QD\B(/DD*#A?KGGH: /K\9'RD8*\$>A &12
M,H;.Y5<$%61QE74]58=P1_GFG$DLS'JS%C]3U_6B@#\_?C?^P9X;^,OQ.TCQ
M79O::3H;NH\06:*L=Q<R$@R-&<=3S@YXSD=:_(?]I?X<>'OA-\8=:\!>%%E_
ML?3VABM4F^9Y)W(7: <\,W3'<\#U_I_MP/M-O_UV3\>>_K^-?SA?MM@']JJ]
M!Z'Q!HP(YP0;R'(([CV- 'H/P0T^\^!^L>!OBG=?#O5=5U>"_ANKW39K.659
MM.RKB2!#$0-\?0CCGGBO3OVK_P!I.'XR_%*PU_P)\,-3\*7LGAV33KO238I;
MW6HNZ%6N9T@M;8S-DD*[1D[0,D\L?Z0_AK\._ VK?#CX?W>H^%=%N[D>$=$7
MSI;*,N0UC"S;B -Q+$DELGMG'%?'GCSP-\*XOVW/!>GW/AZP6[E\#S31:=#:
M1I9RXC;$KHJ%=P]@.F3CK0!^2G[.GA^RO?V9/C+H/BB'4M"U[4]1CL[2]A,D
M,VFRWT@C0RNH!55+Y.<<#\O9_@7X"U+X'?!#]J+X.ZOXQU#Q=<CX;CQ'#)+=
MO<:?!;7ML\BJBDLBS@-ALX/K7M$%UI>A7/[2NBQ:#9365YXBM+9&G15LM+AE
MN0C7&\@+&\*G<ARH!4$G@U0A@T[1O"?[3G@;PS]G\7VY^$46I#Q992Q7U[).
M]BSR:4)X'E'DVWS (6!&.E5#$9M2<J&'QN*I977BUC,%2Q>7?4<1.\)*6*H5
M[YBL2G"#I4<+:G6BN=6E";%*E3J<DYUX<U*5.<<+.GCEBIRM+DK82I1A]0>#
MI\U18KZS+V\YRA&*481/EG]COX>?$3XH_P#!.[QEX0^'ZRS76H>-[B*YAM01
M<B(W4@=P5YVX)...Y(-?+G[<7P!^(/[/G[&^BZ%XXDF*ZA\4/"$MBEP<RKOU
M&W+ D\YZYP,BOLC_ ((X_MT?LP?#?X"^-_"GCWXI>&O"'B30O&M]%?:/K>H0
M6M\&\V2,@12.K#!&2&V@ YR:\>_X+O\ [?'[*/CGX%?#/PQX3^+?A7Q%K=_\
M4?"*VUEINIVTTSM+J=N%7RUD9B<G'&.N.:XY1S&6+IS69SCEU.$H_P!EK"83
MV<JDM9598KV?UKF<E&5O:65N56BVCH2RY49-Y?*692DDLP>.Q?+&BK6I1P'/
M]43MS*5504Y<R<O>@F?TZ_!'_DCOPN_[$+PK_P"F:SKU&O*O@9(LWP8^%4L9
MRDGP_P#"<B'U5]$LV4_D:]5KJ,#/U;4(])TO4=4F!:+3K*YO9%'!*6T+S, 3
MTRJ'GG'H>E?B7^S%X)C_ &K_ -L#XE_'WXF0KKWAGP-??9/AGHMZ$FM-%O+2
M<QFY2WE5U5AL#+@ D\DCBOVXU"RAU*PO-.N03;WUK/:3 =3%<1-$^,\9VL<5
M^'?PB\97'[$?[:'C7X7_ !-_XD_PI^+UZC_#/Q%<%(-/&IW5P&>*\NIF2&/=
M(^S+.N">-V*^&XM]E',>%ZN8:Y-#-7]9<E^XAC94I1RZIB[KE]@JS<8N?N+$
M.BW9V9_5/T>5C:_!GCM@>#VX^)>*X#@\CC0;6;8KABCF-"KQCA.'^2U9YI/+
MHPJUX89JO/*:681CS0YXOY<\'DG_ (.9OB$#T7]E&R51V51'!@ =OH*_ISK^
M5U?'_@;X?_\ !RKXSUCQSXQ\->$-(U;]E:QBTW5?$NMZ=HNFWLK00N([>^U"
MXM[65BJDC;*V1^%?T,G]KG]ET$C_ (:!^$&02#_Q<#PSU!P?^8EZU]S_ ,/]
MY_*W==4VFGHTT[--=&GHT]4]&?1-%?.W_#7/[+O_ $<#\(/_  X'AG_Y94?\
M-<_LN_\ 1P/P@_\ #@>&?_EE0!]$U_-=^V+G_A]1^QIR3B"_P,G _=R< =/T
MK]R1^UQ^R\Q"C]H'X098X _X6!X9'/U.I8'XU_.K^UW^T-\ ;_\ X+'_ +'G
MB"P^-7PWO=(M(KQ;[4;;Q7I$FGV+.KJHNM1^T"RB!+ 9:XX_D ?U945\]2_M
M:_LP0RR0R?M _!\21,5<#X@^%V (XX9=396'NI(]ZC_X:Y_9=_Z.!^$'_AP/
M#/\ \LJ /HFBOG;_ (:Y_9=_Z.!^$'_AP/#/_P LJ/\ AKG]EWC_ (R"^$')
M _Y*!X9ZDX'_ #$J /Q#_P""G7_)_P#^S!R?^0CHN1G@XFCQ_D?C7]'5A_QX
MV7_7I;?^B4K^67_@I5^T+\ M5_;P_9MU*P^-7PUO++3M0T@W=U9>+-'O+2#;
M-%GS;NVN9K:/ Y)>4 8/3I7]"MK^UI^S!#9V22?M _" -]BM6Q_PL'PP?E,$
M9&=NI$ \\J<$'@@4 ?2%%?.W_#7/[+O_ $<#\(/_  X'AG_Y94?\-<_LN_\
M1P/P@_\ #@>&?_EE0!]$U^*__!P22/\ @EM\>\$C-SX3!QQD?VS'P?4=./:O
MT?\ ^&N?V7?^C@?A!_X<#PS_ /+*OQW_ ."\_P"TA^SYXM_X)B_'72O#GQM^
M&6M:I=7'AC['IND>,M"U/4+N2'5HI'CALK*]GN6Q&2YD\KRU"D,P) H _5[]
M@[_DR_\ 9>_[(A\//_4=LJ^LZ_-+]A[]J7]F[2/V-_V8K35/CM\)["\A^"_@
M2VGL[OQYX;@NK>>UT*TAGAN+:341-!+%(C(Z2HC @\5]2?\ #7/[+O\ T<#\
M(/\ PX'AG_Y94 ?1-%?.W_#7/[+O_1P/P@_\.!X9_P#EE1_PUS^R[_T<#\(/
M_#@>&?\ Y94 >&_\%-R?^&+?C?@D?\4=JO3_ *]GKPG_ ((]^'M'\5?\$V/A
M+X=UZPMM3TC5]*\06-]97D$=Q!-!<WUU%(#%*KIN <E3CY6PRX--_P""DG[4
MW[,VK?L<?&6PM/C_ /":6\OO">J06-M;^-] N[B\N&MW"006]M>S3O(YX4"/
MDGK63_P2/\>^%?A[_P $QOA)XV\6:UIVC>'=-T?7M0?4;^[BM;>>*.]NIHEA
MDE*J\EPJ@0HFYG+952 :SK2I1I5)5W"-%0DZLJK2IJFD^=S<O=4>6_-S:6W.
MW+:685\PP5'*J>*JYG4Q>'AE]/!1J2QD\:ZL5AHX6-&]5XAU>7V7L_?Y[<NI
MQ7[)MM?_ ++?[<GQ6_9GT>^N7^#FLZ=_PD_A33Y6W?V=K&H.L\L:QC*I""[1
MJ$  !ST%?M]7XE_L3V'B#]IW]K7XI_MD7&FW&G?#&6V?PGX)M+U&5[NYTYUA
M_M"'=CS(9$7S%=1M((SP0#^VE?'<!K_A(Q,J*G'+*F;YE4R:,E))99+$-X=T
M5+6.&E[TL/&RM3:6UC^D?I85$_$7(Z.95,/7XXPGAYP3A/$JMAW3E.7'5#)J
M,,YCF,Z3<:N=4FJ-/.*J;]ICE4;?/S!1117VI_,)^<'[:D<C>//@Y(-NT>*M
M/ZNH/^MC!XSN&#['MTS7Z,6O_'M;_P#7"'_T6M?S6_\ !6_XF>// _[5?PLE
M\.Z[>1V>E:58ZQ;Z$CL+2ZOHV1E9T!P68@Y..<^N:_>_]G;QMK7Q$^#'@'QC
MXBMUM=9UO0K:YOH$!"I,!L/'JP4,?4G- 'M5%%% ',Z_X,\)^*C"?$GAW1];
M-N08#J=A;WAB(Y'EF>-RO//&*X;XM_ OX:?&OX7:Y\'?'?ANQU'P#XAM%L]0
MT-;>)+5H4R4"1!/+4H3E?EX->OT5FJ-*-25:-*"JS5I5%%*<EV<K7>R^Y=D6
MZM1P5-U)N$=H.4G%6O:T;V5KNVFEWW9^.</_  0]_8KM8EMK/3/%EI9PC9:V
M<&L!+>UB!^2*",182-.BJ, "NM^"?_!&W]COX#_M$Z%^T]X,T7Q#)\4?#FD/
MHNEZAJ>IBZM8+)AC:(#&/G /#!ASBOU?HK0@**** "BBB@#\0?\ @J__ ,@-
M_P#KC'_,U^-'[./_ "7_ .$?_85T[_T:M?LO_P %7_\ D!O_ -<8_P"9K\:/
MV<?^2_\ PC_["NG?^C5H _M/M_\ CW@_ZXQ?^@+4U0V__'O!_P!<8O\ T!:F
MH **** "BBB@ HHHH **** "BBB@#XF_;T^"OPK^/GP%U_P'\9/B+JOPJ\'7
M#-/+XQT;46TR\L)D3".+I7B:,*/FR''KVK^,CXP>!]3_ &*9+N[_ &&_^"GL
M?Q0UO3Y+BYL/!?B'QH^KZ@\L19DLVA>[F+'<!&$*$=L5_:-^W/\ #3X/_%OX
M!^*?!?QT\=VWPV^'NH03)JGBBZU"+34M4,94[;F2:':Y7D!6W'L,@5_GJ?M)
M?L>_\$G/V1O&VI?$O]GOX[>.OCK\0-/OKN^T[2-"N)M8M)=2,C2K$Q@,AF1I
MP$.[>,#Y1CJ ?K;_ ,$K?^"N_P#P67^-'[2W@7X-_M ? :YUSX1ZGJW]G:W\
M2+3PTD$%E8QRK&MZ^HK;L)8IH_WJR><K<\J#7]O\ VDJ  -J-M . Q S\W?G
M/%?P=_\ !'+_ (+!?\%"/'O[07P]_9\OOV2KO0_@7K>JIIMYXYO/"FHZ==6.
MDJRI#=7%]-IUG!*YC^<E+FX&0/I7]XD&0S#  VHV .[*I8YZ?>)X_&@#\@?^
M"CS?M4V/COX?:W^S5\2_@K\-;VRM)8]4U+XFV-C/K#[L[1HT]TK/''M(WA?E
M)R:^$#XZ_P""O(A,O_#8?[+PRIVDP:03NQQE%3Y1WQCI7["_M:?L)^ /VM]9
MT'6/%_B;Q!H-QX8MI(+.+1W*1S;LD-,!/$2>>,!CC'X_S@_L9?\ !/[0OB;_
M ,%"_P!KGX*>+OBEXUNO!/PTTBUF\/V:74Q:![JXCMPP1[A%^4RAFY&0,9X%
M '[[_L$>)/VI=6\/7C?M-_%?X=_%/6S>%;*[^'T=LEA!$V=JRK   X[[AN&#
MFLK]NVS@M/B!\-O%7Q1CDN_V?=,,:^+K%E:2T_M$R$PS7,8!5HD4KYFX$8&#
MG&*]\_9?_8Z\&_LJ:9<:3X5\1:OKD-W<&<MJ\A>1&.2 I,DN ,^HK?\ VP_$
MFF>&?@SXCU?5_ 4GQ-L+:VED?P?#9&]>^F6/*;854N^2"HP.2<>U 'P-\=OB
M!^R+XXT?P=X>_9J3P5J/QDN[C3E\&7?@O3XK:\TJ-)$WK?S6\$)#",8?>6;<
M#EB3Q^JFG::@^$%EI7Q-DB*_\(E;6OB^:[(,1D%G&MZ\Q;.X>8#GN2 !SBOY
MX?V.OBCK7Q*^+6G3>$?@5\*/@=-!JKQV]CXADATKQT\2S ;[#3[HI,[R+S\J
MYS]:_I"\1^'(/%/@C4_#7B"X\N#5]':SU.=2JA/,C4S.",*%5USUQCN10!_.
MAKWQ0^)GPP^+VJ?#[X)W?B+X??!#Q-J[6=Q\0_$%Q,/#"R74K*8M)<@QP;BW
M[L J<$=*_5+]B/P[\*/"NK^/=*\)ZY)XK^(#_9+OQQXG>X%RFI37'[Q&CD#,
M2N]LKDCCM7!>#],_9VT'P'\0/@]\8OB=\/=;\,6^I7(T:RU#5[(W^D*/.*3H
M/,\Y+R&38R<\%3A><BS_ ,$^?V:/A]\%O$'Q6\9_#CXJ'XD>'_'U]'-:J]^;
MR32HXI=Z6^-[;(T7$<?^R/I0![)^W?\  G6OV@O@_?\ @>R\>_\ "O-&F#/X
MBUP7@LGCL."P$V]#M&#D;L'D=>GXK>#]=US]G'QO\+O@+\#OB!8_&"V35K"'
M6=.\$S&2]-D)E\_4-9,._P YHQDR2L2>,DDYK]Q_VT/A)X+^-7PIO_ WCSXL
M7/PAT+4LQS^(;;4[;2VE5L?N&N+F[M$VLWRE1)D@D '.#^.'PM_99\??L9_M
M"?#SXN_#<^ _$'P7>RA\&R^-+O58;C5?$/VUO+-XTRW$@EGE\PD,DK'+<-G!
M !_16]Z]GX>AO[@&$66C&_NHW^^JVMF)YXV;^^$5@>.HSVK\;?C5_P %"-5U
MOPKXTUBS^$'B7Q%\$-$O;C1O%6N6"#<BVLYBN9$=0LA5=K.<<$)G/2OV8N8X
M]6T&02<1ZGI4RW 3+ Q7=J1.%Z\['95/<<9SBOY\OB+\//@7X3^(7B'P"?C?
MXUTGPC<ZG=ZIXI^%MBS&VU#S93+<K+:G+&.3YEZ<J3R<Y !^JO[&'QA^ WQ7
M^%>BZC\#?$"7NG3VD<UWH[NYOM(G*DO;78<95XV)4@$^ORUX_P#\%$/"WP9U
M/P9IFN_$Z+Q)J'B32G5/#FE^"[IK/Q/);,2;BXM9XG618X<EWQW!_NX&G^PK
MJ_[*VO:?J\/[,OAC_A&[/P[,=*UT?9WMGNKY 5DFG5F.9&8%B<*,GH170?MH
M? OX7?&2#0_^%C?%"X^$MUI\4EM8^)(;V'3R(Y@1)'Y]U/;0#?N/#2*??I0!
M^%_@7X>_LB^'OB[H'Q"T#X3_ !T:6^GM$UWXO3ZG,\&ER^8N8-8O/,+R+$^$
MD5FQV/H/V8_;]TCQIXL_8MG?X/WFJZQID6EV]YJO]ERRG5=9\+I;H)8H'3,C
MSRQY!/4L<^M?$?B_]@WPG\(O"'AQ?!WQ\^)GQ"\">)M6B?4-.T62+5=)ORTR
M2>;<3V-Q=1K'(22WS#@G XK]R/AUI&A:%\)_#6CR(D7A_3_#=M;2)J.V-$L8
MX0'%V9"%50N?,+L .<XZ4G+%P3E@*GLL99K#S:;7M&K*,N5.:C4NZ<I4_P!Y
M&,G*FU-194/JW-'ZW357#*2=:#:5X1=W)-^[S0LIQY_<<HI33A=/^>;X<_L3
M^'OB7^SC\./VA_V1#XG^%?[0GPMDBU"\TG5IY+8>(!ITKW.I:=JMOM1KBYO/
M(?R'D#EF8KG( -/_ ((\_&WXJ_'K_@H9^V]XO^*O@'Q'X US3O#?A_P_<V&L
MP2P6U[>:9>65O<:A8H\<:^5=.K2*4!X([<G]O+3]IG]C_P"'NJW/AG3OBC\+
M?#VH2S,UWIUKXCT>!S,"P=I8OM9P0Q?><#&6)YS7,_ :RU+6OC_\6_B/H>F_
M#V\^%OB;3[*/PMXT\)75E=ZIKMS')"UQ'J<UF6#+&H9E)8Y(4U$,#Q-D>%H8
M2K@Z.59)C:[KU<NQ;S_%PP&,J1E4K4N'LPQ2==4,?5C[;$X;-9RP_P"X4Z2C
M6WF6:Y!GN+KU88QYMG.74HX>GF7UG)LOQE?!Q:]E#-\!1A3H9A/"1E*.#GEL
M%BZ4:M5N4J#J*'W!1116@!1110 4444 0'J?J?YT4'J?J?YT4 3#H/H/Y4M(
M.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445BZY!J\]E(FBW$-M?%<123KOC5N>67OV_*@#^>/_@MZ=GBCX1-
MP?\ 6-CN LC_ 'O8G^?-?DUXROK2\^&OAI(S$TR785E&UI._WOXAR._?K7Z*
M_P#!5?P3\8(?'_A.[^(6OZ?X@T^[\U_#\&G1[#8QHS965 JX.,CD<X'48-?E
M%>:5>VND0:G+.7M9+EH%MRQV1RJV&8KSTY/?% &')Y,2%W1 HZG8./TKIM4\
M%>(/#47A'6M=L$M]*\37EM)HTP5?]*B\Q<G&W/X#/US7+W:LUO(JJ68@@ ?2
MOI;XP^)-%UOP!\ M+TK4X[^^T5H(]4M(WRUB[.IV.O9N<>GO0!^^/[/5O#:_
M"'PI%;QB*/[);L44  L8ER< #J>?RSTKVJO'/@%_R27PI_UY6W_HI*]CH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_
M0_RI:0]#]#_*@#\GO^"KO_(K_#/_ *^C_P"A&O=/^"=/_)OT_P#V%F_]"KPO
M_@J[_P BO\,_^OH_^A&O=/\ @G3_ ,F_3_\ 86;_ -"H ^[J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBD^@)([ &@!:*>D3R9VF)<?WY8U_/<RX_7
MVKSGQ-\6OACX,FEM?%GC+2]&N4!S'/<("#CA?E<\GMGGUH ]"+ =2.*<%D(R
ML;L..57(P3UX[=Z^!/B%_P %$OA!X%NY+/3[2?Q8BEE%S8'<C8S@C8<<\=3Z
M^]?$?CO_ (*6?$[6-1>/X;V2Z3:7+LEO;W=M*\A#=%W"/&X9QUZ]: /W/DNK
M*$,;C4M.M2@+,MS=0P.%7EOED<'..PY/:O!/&'[4_P "/ EQ/8^(_&$$5[#O
M!C@*7"[US\NY">,CC./SR*_$75[']L+XT7<6L3Z7XL2WORO^E:;/<V]J%E/+
M!4  7&.2N"!7N?AG_@F=\5/%UII^M^*/&=M'YS))=V.I,);L!B"ZLS_-NZCM
M\V>!0 O[9/[9OA;XU>#C\-?"UE&]C%J(N8]8#*'F56&%V@@Y;'MSZDU\7_#'
MXN?&/X66M_I'PSGUO2(O$+QQ7I@T^XDBN&<",?O$3&&Z @^^<U^SGA3_ ()R
M? '2K.P?7K._O-;L]DDLUN^+>293DDA?E92PY'(QQZBOL70?AK\/O#FFVVE:
M?X,\/O;V:JEO-<Z?"]SA!@,TFTMN[\G@YZ4 ?@(_[,7[7/Q1:U\1:II>JW=K
MJ965KLW]U#A)B#O,>X;=H.[''Y8!^JO#7_!+%KZQTS4_$7Q$EM;]UBFU#2Y=
M\Q1L O%O<-GN/QS7[%0O);QB&W<V\*\)!!^[AC4=%1!P !P/;\:9@$DGDGDD
M\DGW)H ^3/#?[$G[.NC:7IMIJ'@J'5=4T[RVDU,L 9YXL%9",;?OCH>._ -?
M4&CZ-I6@:=;Z5HVGVNG6-LB1PQ6\$44@1!M57EC"E\ #KG/.<UJ44 &,?Y_K
M1110 4444 36W_'S;_\ 79/YU_.7^V5 +S]K:\MR/^9@T;(QT(O8^_H<8Z>A
MK^C6U -U; C(\Y/ZU_.9^UEE_P!LG4E<EE&O:1P?:\0CICT'_P!>@#^OWX5)
MY7PU\"1CHGA71%_*PA%?&?Q!U&SB_;D\#V3Z&;B[E\"3/'JVTD0+LD_=EN@[
M\&OM#X7_ /).O!'_ &+&C?\ I%#7QSX]F\0K^VYX*BM;2*316\#3&YN613)'
M+Y;X4,2"!QGCIG)STH \\_9J\'^'O'WQ(_:;\*>*M/CU/0]3UB..[LY<KE9)
M6!VR+AD('W2.AK[.^'?[-OP@^%VGZUIGA'PM!96OB&VELM76:5[IKRTF1HW@
MD:;)\LHQ&WMGBOE?]CG/_"Z_VC,]?[<@S]?.?-?H]6$L-0G5C7E3BZL'%QEK
M\4%)0FXKW93IJ<U3G).4%.7*US.^\<5B8498>%>K&C/F4J2G)0DI\G.G&]FI
M\D.9;2Y8WO9'Y5ZY_P $6?\ @G5X@U_6_$U_\![%=7\0WLNH:M-9ZM?V<=U=
MS.7DF:&!E0,S$GICFOYG_P!JGXH_\$DO@9^W=IG[&=S^P->_$7Q;X5U.WU>V
MUV+4[J^-E>:=*LT-W#;L6DD,+H'QMR2#]:_NTK^!.XTG2]3_ .#L?PO9ZCIM
MC?VDVC:K)-;7EK#<V\TBP3E7E@F1XG92 064^M;F!_23^SO_ ,%JOV&/'.LZ
M-\&'\1:M\-/&&DP6FA6WASQ1H=[I6FV$5G'':6UJNJW02WQ$B)&"V!A17[':
M-KFC^(M.MM6T+4['5]-NXTEMK[3KF&\M9D=0RE)X'>-N"#PV1W%?&'[27_!.
MG]D_]J#PSJ'A[QY\+/#ND75^)&_X2;P9I&E>&?$L-PP.RX35=.L8KAG1\2'<
MV78<MR37X5R7O[6O_!#GXF:.FL:OKGQU_P""?WB;68M,0W#SZIXG^&:7,BI_
M:FJ:C)"\J6EHK9<LRQ%%.<C!H _JXKYS_:0_9B^&G[3?@\^&?'VE)-=V6Z?P
M]K<9:._T/4!\T%W:S)AU,<H63:#R5XKTOX6?%#P7\9O /AGXE_#W6K7Q#X0\
M6:9;ZIH^JV;^9!<6\Z!L!L#YXFS'(.SJP&1S7H-<^+PF&Q^'JX3&4*>)PU>#
MA5HU8*=.<7T<7IH[-/=-)III,]GA[B'/.%,YR_B'AS-,;DV=Y5B(8K+\RR^O
M/#XK#5H;2IU:;3M*+<*D'>%2G*5.I&4)2B_Y _VDO^"9VE_#_P"-*?$?]J7X
M3Z[^T5X5L-.71M-^,^FZC?VNM>&O"T7RPZ3*ENPGF^S0@+ACR%Y%?0_P*_X)
MD_\ !&O]HFS$G@,>)H=5C5?MVDZUXOU+2[R"XZ21+!>/;E]KY4;2Q('KR?Z9
M]0TS3M6MI++5+"SU*SE!66UO[:&[MI%(P0\$Z21N".,,IK\_/CM_P34^ /QB
MOO\ A(=,M=4^''BB%C/;7W@>Y70K9[D9*M<VMDD*."V"W//7':OD%E?$>0KE
MR+%T\WRR#;AE&;U91Q-"#=_98/-;3G[.*OR4\53K-64552/Z+J<>^"WBY+VO
MBOP_C?#OCBO"$<5XC^'> P];)<VQ$$H_7.)> G/"X>6+KM)XC%Y#C<MIN7-6
MG@:E1R;^18?^#??_ ()TW""2W\*>*IHVZ21>+]1D0_1DG(/X&I?^(?#_ ()X
M?]"?XN_\*S4__CU:TW[/W_!1WX"R>?\ "SXP>'/&/@#2\'_A&M9@^VZY<6D1
M^6**:XB9FF9!MRI)WX/>K^D?\%*?C9X%O%\.?%W]E#XDK-:L(KOQAIMNT>BS
M;#M>55-I)QG+#! .<"M(\:87#-4\\RS-LCJ745/$X.IB<+4EI?V6)P2Q$7"[
MTE5C2\TCDJ_1ESW/*<\9X6<<>'_BE@U%U98?)>(L+DN?82EO&./R3B>6458X
MFS7-0P%?,'=VC.:U.:_XA\/^">'_ $)_B[_PK-3_ /CU>,_$3_@AC_P2E^'V
MNZ'=^-O!>O6-W=),]EKEYK]\?LGDAB__ !,'<FVSCIN0'KS7Z,>%/^"GG[+>
MI"*#QKXTM_AQJ<I5!8^)EN(F61L#RR\=MD,"2.4QGO4'[0OB+X._M>?#Y_AS
MX0^+WA :5KT3+<ZO;3XU"$,I"?8;B80O!N)&XKC=G!Z5[F$XFX<JVK+-,!BJ
M4+.KAZ.+IK%U(NW[FC23=2.*J74:$:E-0=5Q55QAS27Y9Q!X-^*G#G-3SS@3
MC#)(-N-/,Z^09A++%.+3C5>80PE;!8C"1E9XAX:M*;H\WLY1GRL_(+5/^"='
M_!&ZUL+_ %*PM_$NHPZ;<20WTL?B[4I(P8V*$Q2+-MD.1_"6)K.L?^">O_!'
M&?4+'2;W3_$UKJ.L6XN-&M5\6ZD9;X-]Q0HF+;F..,9.>E?7D7_!+/6],^$=
MMX*\$^.M'U.YAOVNK;6))X)FE4OE3=RAV\_C[P))ZYQ65HW_  2C^)2>.O!O
MCN]\;:,=1\&QP3P0$*UO<7EM@HHC"L/)) RI&/SKUUQ+PQ97I3IU*BYZ>62P
M>;U\Q]E5M&C4>84<+_9RE"WUK$T+.5/#)TX3G5LW^<3X;Q,*DH5>(\U^M4O=
MJ5H5,JPV32G3=ZM/ZC6P-3,TY4[TZ59UXJ6*Y9.FJ2DCSSX4?\$??^"6?Q?C
M\6_\(]X7\9+<>"1(=?MW\3ZI%):HL<DN]D:8-\R1,5S^E>*#_@G]_P $:X-)
MU[Q'J>F>+['PYH6H3:4VI2^)M647&H02^1)#'\Y5RK@YVYQUSFOW!_9F_9U\
M>_#?5OC)X@\>:GHEWJ'Q,00P1:/#'!;VL26LULN]$55)(D&3CL<]Z^-O$O\
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M)_98\%-;_P#")_ >PFG5-6L82#;O<S1[ JO&%\SS,;N00><_JU\"?V)O@%\
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ME^SE\0/ ]M\$_A_%)XGT*W>+0[:)X9-1M4DB<*"4:-I RD;AU&.>O6OX;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/PB_X*SHK^./AF& (-I=9!Z=&YYXXK\%-8GN[W2?[(MK2:=H]9N&B2)2QE^?
MA4"CGCMQ^%?O5_P5H_Y'7X:_]>-[_P"@/7YW_L]>&="U.3X?SZAIL5U)<>-;
MB*=I K&1!+C#!@000. <@8Z4 ?!7_"-^*O\ H6]5_P# 27_XFJZ>']?L+RQN
MI]!U*VB6_MGEDDMY50 2*>XP,X/ZU_5-<_"_X>BXD \+6 &$X\BV_NC_ *9U
MF7WP?^&.IPFVO_"%A- 2&VB*!3N!SGA!^/>@#EOV<KZ+4?@]X6GARJI:VT95
MA@[A$H;(//!!/XU[C6/HF@Z3X<L(M*T6RCL-.@QY%K']V/'IV[#&,8R?;&Q0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(
M>A^A_E2TAZ'Z'^5 'Y/?\%7?^17^&?\ U]'_ -"->Y_\$Z3_ ,8_3]?^0LW0
M$]_85X;_ ,%6QN\,?#)>F;L\_P# C7(?L7?M(IX*^'-S\/=)T.36]=6\:[>"
M-"[+&2<$@<[>.3]* /V/R/?\C_A2U\:I^UC/IA67Q;X.U#3+4',LMO:S2$)D
M;CM&[) SCK]#D"O;O /QQ^&GQ+3_ (IC6EAG7 :UU4K8SM)W1(I2K/\ -D#;
MN(]J /7**3GN.OW3V<8!W+ZCGCVI: "BBB@ HHHSCKQ0 44JJ[_<1W]U7/\
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M^CBFC_:/MXX9AN$DVCS($'K(HG9U^FTGKQ7\QO[+W[3GP=_;!_X.?O GQD^
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M;7]I(")+>ZB6:)@1@Y1P1TXK@?\ A=7P=_Z*K\.O_"T\._\ RQH_X75\'?\
MHJOPZ_\ "T\._P#RQI-*2<9)23T::NFNS3T9=.I4I3C4I3G3J0DI0J4Y2A.$
MEJI1E%J49)ZIIIKH>;^+?V._V8_')ED\4?!;P-JMQ)EOM4^E 7".?^6B21R(
M0X/(/0'M7S1XE_X)>_ O5&E_X1K5?$?@5&),47AV4PK;]@(LW"8"@\#V_&OM
M_P#X75\'?^BJ_#K_ ,+3P[_\L:X+XG?M9_LZ_"'P/K7Q#\;?%WP'9>%] A,^
MI7=KXHT2^EC106/EV]O?M+*X )V(":\7%<-Y!C6WB<HP$Y/>I'#PHU7ZU:*I
MU'\Y'Z;D/C9XM\,J$,F\1.+<-1IV]GA:V<XO'X.FH[*G@LQJ8O"07=0HJZT9
M^>M]_P $D[RRNCJ'A+]K7XYZ5*I+1:<^J,NG9'*J0EZ[8R /N=/TK?\ #$W[
M7?A?]SX9^/6MZU##@02:OJ;>8X7[N_?..?7O]:^Z?@+^W+^RU^TCX"B^)7PM
M^,7@K5/"<UW+9)>:AX@TC2IO/A.&5K:\ODE0'^!F #8..AKV?_A=7P=_Z*K\
M.O\ PM/#O_RQKRGP+P]"[PM'&X%R=V\)F6/IIOORSQ%2"^44O(_0H_2Q\9Z\
M84\\S;A[BBE3BH0AQ!P9PMBN6*MHZN&RK"5IM]95*LI:[GY7?\*:_P""EF@C
M_B1>,_#.IF/_ %9U'4H?FV] VZ;\^#GUJ-U_X+%Z;B'3K#X/:A$O"R7M]8LY
M P!G?*3GOU]22<<_JK_PNKX._P#15?AU_P"%IX=_^6-><_%[]JCX*_"OX9>,
M?B)>_$?P1?V7A?1[N^D@L/%FA7-Q+*D3>3%''#?2.SM(5(4*6(!P.XQK\*87
M"4:V(?$?$V"H4:<ZU:=/-VHPITX\TI2=2C4TBHMZW^9Z>4_2#XAXAS3+LG7@
MSX'\39KFV.PN78##8SP]C4Q&*QN-K0P^&HTUA,TPEZM6M4C&-DO>>VY^=[:Q
M_P %IDQM\,? :0'^]?Z66'N0)LC\1QW% U7_ (+0.,2^'/@7&#U,=YIIQT/&
M)#R/_K<U\"_\$Y/^"K_CKQC^T?X]T#]H#XF:=-\)O&>LW=S\-]3UO6+)5TF*
M:=Q9:<F^X!2V6/8-[H"ON!D_TH?\+J^#V%)^*?P[&]5==WC/P\I*L 5.#J(.
M""*^=X5I8#B[+I9CEO%7&M.%.O5P]2AB,UHPKTW"5H5)1CA9?NZ\(JK1G?WX
M/NFE^Q^/V8<7?1UXQP_!O&O@']&+%8K&93@<WP>:Y-P#FE?+,53Q>'I5,3A*
M6(KY_3?U[*L1.6"S/#.'/AL5!Q=X3IRE^5J^&/\ @K/KW&NWOPVTM6SG^S=1
MM1MSZ!90,@<#\OH[_AFW]O\ \09_M[XHVFF"3&\:;J2\9Z[0LW7MZ\?G^J/_
M  NGX/G=M^*?P[;:K.0/&?AXD*@RQP-1)P!R3VK\I/V@/^#@7_@E[^S1\1+[
MX7_$_P"/MM;^*].!-Y#H>G-KME#@D8:^LKAH,D@@8)![$U].N#,*_P"/G7$F
M)[^VS:IKLM?9TZ?16TL?A?\ Q,WQ!0URGPV\&<BM\/\ 9?A_A8\FWP_7,9C+
M6\[]+IZWL/\ \$V_CCXZ&/'7[4OQ(T"-OOKX<U2428[A<3J.>P9EQ6WHG_!(
MOP_83+)K7[37QO\ %$>06M]6U$21-SEAC[>^ >1T[GZ5\X_\10?_  1Z_P"C
MAKS_ ,)>\_\ C]:]A_P<T_\ !(/46*6_[1JA@,[9M$FB./7#7&:<>!.&.93K
M8&KBJJM^\Q./Q]63MWB\2J?RY#.M]+/QU=*6&R_BS!9'@I*RP62\*\)X&C#_
M  5%DL\5%]G]8NELT?>?A7_@FE^S5HSQOXG\/-\0=F,Q^*5-S%(P[R*)FW9/
M) *\]Z^FO"'[-OP'\ &,^#?A5X-\.F''EG3M*CB*;>A&YGY'KUK\B?\ B)._
MX)(_]'&6_P#X*9/_ )(J&X_X.5?^"1MK#)/+^T; (XE+OMTB4G '.!]HY/M7
MLX3(,DP-GA<JP%&2VJ+"TI5?_!TXRJOYS/S+B#Q:\3^*5.&?\?<69E1J)J>$
MJYYCZ>!:>_\ L%"M2P2O?6U!76FQ^\\<<<2+'$BQQH,*B*%10.@55   [ #%
M/KXT_9P_X* ?LD?M5?#RQ^)_P?\ C5X*U?PKJ!(AFU/7=*T:]4KU\VROKR.5
M,>O(]Z]^_P"%U?!W_HJOPZ_\+3P[_P#+&O7/SUMMMN[;=VWJVWNV^YZ;17F7
M_"ZO@[_T57X=?^%IX=_^6- ^-/P>) 'Q4^'1). !XS\.Y)] /[1Y- CYF_X*
M,?M-R_LG?LF?%;XL:0T4WB_3- N+?PAI9*M<:EK5WBVABMH6.9'C$I?(!VD*
M1SBOB/\ X(J?L?VOPO\ @M<?M0>/<Z[\:OVF)C\1-<U;5XFFUCP]9ZR7G30K
M>XE9C#;J'RT<? 7:,@$K7Q+_ ,%P_P!J;X6^-?C[^PA^RKX.^('ASQ-KOQ(^
M,EC!XKT71-7M-3AM=&>YM51]0>SFF@PQ!/EN6&T\X;BOZ<? OA;3?!/@_P .
M>%-(C6+3=!TBQTZT1$5$$5O B#:B *H.,@#@"@#JZ_DB_P"#O/\ Y,8\$?\
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M<XP: /NJBJ/]IZ=_S_V?_@3#_P#%T?VGIW_/_9_^!,/_ ,70!>HJC_:>G?\
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M/_\ @N[^T%X\_9N_8 ^(WB_X=ZI+HVOZINT$:I$YBEM(;Z%E>5) 0R%<DC#
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M:I5H)U84\/0GB:U3D5W"GAZ<9SKRDKKV482<U>/*[V/%?@!^QSI/PI^!%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7I/@"ZT/187EDU/QUI>CZA%8PHI>1H6U6WG*J%Y*Q#WP:_GV_;!_X+&?L/?
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#R"/6BB@#\7/
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MG^%_@231/@+XBA\+V$&N0?%G3DBO]/@6TN2#+:R?O# J>:-Q;.X$\@>F*?\
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M@'^>M1T4 ( !T 'T&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_:&^ ,EOI_CA[60R6VHV\C^1:7V[+9GG"AWP1UY!KZN_X*<?M[^#_P#@G?\
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MZ<#I[F@#]Y+K_CYD^D?_ * *@I\TB2S-)&P>.1$:-QR'7:/F&.,'(Q^/I3*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OG3]JK51HGP8UG4S$T_DSD^4O). <#
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M#=5TV?3+I=6TV_O[0O=1Y>PD6=YX6 Y8PX) QTQ7M\7_  21\!_$ZYU[X/\
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M[8%>?:;_ ,$.?VW?V,?A;;Z'\-_V@%\8ZUIE@QBT^RU-Y;%)1 0(H(-YV)N
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M?"#P#\'=8^,W@'X@QZG;HR-?7NFZ;(D[(JI&H2U@:5-P\S:H;U S7V'^QO\
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M^T5\.]!^)WPK\3:7XH\+Z_9P7EM=Z9>0W8A\Z-9/(N/*8^7,F[#*P'MFO8:
M/Q!_X*O_ /(#?_KC'_,U^,O[-W_)P'PE_P"PMIW_ *-%?LS_ ,%7S_Q(Y.G$
M*$Y.. 6R?_K5^+O[-EW;M\?_ (3%)@X&L:<C8QA7\U?ER._^% ']K=O_ ,>\
M'_7&+_T!:FJ&V.;> CH88O\ T!:FH _)_P#X*QLJ?#KX*,^ J_&'1R<]/^6
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M-?\ Y2>\6=;_ /&01^7^Q8;3^ON/ES]D$G_A<&ED'GRV/K_=ZYQ[^_\ *OW
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M=% $PZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'X._\ !6U7;QI\--C%6%G=L"/97XYK\L_V
M=/A-IM[\0? 'CVZN97FN/%TEO+9[F\IMDHR=H..Q^O;!K]4/^"M'_(Z_#7_K
MQO?_ $!Z^#?V:_N_#GC_ )GBY_\ 1M '[AS11Q3-'$@CC1(U1!T1=@X'Y#/;
M(XIE3W7_ !\R?2/_ - %04 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4KQE!-,\VE'$J%\3/+IN;YZ3RS&_7Z+HM+E<ZWLJ251ZODBI)1<?>N?T+_\
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MPSX#8P?ND@]*^<K_ .-_Q=OKR:[3QKJ=HLS,X@CE?;'N.=H(<<#H*\O  X
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M'04U[PI-JVGPPV[1"4QW;W4:PN%96'RR8/0=QWK]%*_'7_@M)\'_ (A_&/\
M9CBT'X=: WB#5;?Q#I5S+:HNYEACO8G=P,$_*H_PYH L?M:Z[X3\0? /]GGP
M]H/A.VU+PCXOTC0YM,N;F/\ =Z)H;V4'V9HSCY)$C"X4#. *^3="UO0(OV?O
M'VG:-X>;0?$7@'Q[8VG@U-/BP_B>^253:O<*H!D223 9CNX.>]?27[13>+/
M?[*W[/\ IDNA6=WJ&E?#GP_ITUG>3Q6K6NKV]A#$8T>4H=RE0 !@C'(]/E3X
M?>)=<L?V4?'WB?QAI>G^&/&FF>+8M2TJ\>2*2*VL;>3?]O);Y)3"H##))X%<
MD882IC'&GC<ECCZL%3C@GQ+3HY@E!)O'5\@Q>'6$J4Z7PUYXO%_5*N#NU2]H
MU(;RN'*LRQ&#SJ.'UIU<>N&\R663C47LOJM/BG"XNJJ=6I3YJ=.EA<KGBJ->
M24:CF[+ZD_8TU36/$6D?M1Z[\0H+G2_BI=^ =9C\1:&ZLEI:6B>'+];22%3Q
MND0 N1@Y)[5\^_\ !N=J>DZ+^QE\7[W5;VQTNR7]I3XD>9<WT\%I;Y>_(3=+
M,R1Y<@A03DX/I7T/^PYK.K^//AE^T3\3-3O[3Q+%X@\#^(+>#Q?;&)3J@MO#
MVH*T#11\KY.W )ZX%?CA_P $W=3T?1O^">GQ U'Q'KE_:Z-!^U5XV>;1K%Y8
MFU+&K7.87DBP0,CC)Q].*]#"TOWT*%=8C,)1J2I55P_A,)CZV(J0=IK+<!ET
MUAX0YOAPBJ*6$IIQKOGIR3B=)0I1AEE&-*'LJ3P.$S/&8C!NE1E&+IX;$X_.
MJ>'JJM"#Y/;8Q4XU:EK3Y919^D__  <)ZQI^H_L9?#?6-#O;+4X(/CSX'EM;
MNPF@O+<317:_<DB=X]Z'@@'*G@XS7\-]EX,\._M%?\%T=#\'_&:P3QIX9OET
M@7>AZTS36\D-MHEF(;41R&18T#2-(%0#DY !R:_J2_;KUC0=4_X)U>$M8\.Z
MY>:[H<G[4_A-O[)OGEE;2H_[2@W6*R3$[EYQP>/;DU\E?\% /^#?#]I;Q;\5
M_ _[=_["/Q"73OB=XD\.>&]4N- =%M4TBZ_LFV5GCG9 3O4A&"2%/DY 89IU
MU3C5FJ5+'T::DU&EF>$>!Q].V\<5A)3FZ-1.]ES-3ARS6DDAJ&(II0Q<*%/$
MQ_BT\-B:6-H0DU=1IXK#RE1K6BUS2I2E!3YHJ4K7/C[_ (+??LU_!']EJ[_9
M*\8?L]_"S2/A%XGO_B7:V5WX@T. 6US>VJW\:"-G1$W @$#G&.>E?T8_ 7QO
MXVTCX3?#W5M(\2W]CJFH^'+"6_O8Y7WW,IMXR[O\_4^QZ^F:_CH_;8_96_X*
MY^'?&WP4?]O7Q'_PD?@3PYXHL+[11%=B6*"Y%S&6)7RR68G)W&8A>?E)K^O7
MX+LC?!OX:&/_ %?_  C5B%'^[ JG]5K$9];Z=^T=\5M/LGLWUZ\NW*E1<O(W
MF9(Y8?,/PX_&N9D^-/Q?DDDD'CS5HQ(<[%ED 4'/R\2=LX]\5YO10!K:YXD\
M3^*9!+XFUN[U=U^Z\TLH(QT ^<_S/%8/V:+@_O,CI^]DX^F6Q5BB@!H4+TSG
M !)))./7)I<#T^OO]?7\:7-1F6,$@NH(ZC- #7@CD^\&Z8PKLHQ]%(_(<5TV
M@^,O&GA-0GA?Q)?Z/$6!:.WFD 8 YQG=G'4=>G>N:\T$X0;\#)*D<>Q]^] F
M3G<0A!P0Q&?K]#0!]P?#C]M+7]&:STKQMIXN].BVI<ZSO9KMAP"Y )#GKP?;
MH2:_0?P+\5/!GQ"L$O\ P]J]O,CA<03R10W>2.?]',A<C.1D C/%?@V"CCC#
M#\Q6IHFNZ[X7OX]6\/ZG<V%_!\T3K/((E(Y'[I3M//MVQ0!\J_\ !T1\,? ?
MCGX1_"'5O%OA&R\17ND>)M/CTJ\NT#M8I<7P6=8BRG9YH=@V.H)R.37YC?M[
M_L+?LFZ9_P $U;CQ_:_!;POX5\8:7\)M/UG3?$*6R17=QJ?]G&7SXG\H%I3(
M%;@@YQ[&O=O^"\6B_M3_ +:?@?X'^ _@WXOM])\4:'?6[WVC/,MM)XIN4<-!
M+'NZF.7:[80EL$$[B2/SFU[_ ((\_P#!>K]HSPEX ^#OQ3^)\1^#VI6FFZ9J
M$8O%0:/H8\M'BEBX$X6#<-I],8)H _83_@S1\3^(->_88^,5AK.L7^J6F@_%
ME[#1H;VXDG6PLFLWD^SVQD9BD(;E44[4&%&  !_8Q7Y9_P#!)7_@F?X%_P""
M8'[-5G\%_">I2:UK&KW46O>,=8D4 ZAKTD.+B4' ) 9G4<8   X K]3* /PS
M_P""M-M+/I =9#&L<*953C>.>&Z5^+?[,&DQV?Q_^%HSN\[7=/GYZJ3,AQ],
MYX^E?ME_P5?_ .0&_P#UQC_F:_&7]F[_ ). ^$O_ &%M._\ 1HH _M2MN+>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-O&_@S1/!<4YM+I!)?V]HEEOA2=(S.'EY"Q!ASSQT_JF_P"#5[]E7XP_LO\
M_!/^]L_C)X8O_"6M^.O&EYXHTO2-2A,-Y'I-VADMWE4CN)!T)'N<U^S.F_\
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M2T;PU\7/CYJ?B_P3<:A;-!_:NA7!N_*O("RKYD3AD*NORD-VXK^H^@#\0?\
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MP_\ !2S]J_4_AEIQL-?T7QM8^&7U338;AM,1XKORTTYV#F(PHZ[6A;"<<Y%
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M\$_$WPI_92O?BWHVG:XEW%>V$T\Q6XA997BNHH 1MC"9)D4<#=P*^ _V(O\
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M@.5"&5SDEB23[ 8 _P _;2=WV>0!N?M-R>1_TWDZ\#K^!Z5Z/&/#-/A;%X#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_%NH0^&O'#^)?&NO0S1R^$]2T..6\\.0,6#1PW,Z QK$I(1LM]WJ*_6#X/\
M_!.GQ1K,.E7GQ)DTWP$VFB)K67P64BU"^ME V)?A&7YW4 2!W##GKV_6GP-\
M,? WPWTR/2/!OA^QT>QB "QPQAVX&,F63=(2?]ZN]H _#3_@J'\'_AU\'?V6
MM.;PWX=L_P"V?[>MK2?Q(\"?VS>&53O>XN%R3N(&1@X&?F.:_++_ ()VVA?X
M]:7=GGR[-\G/(R,D9Z\G.!WSC' K]E?^"T4FS]F+3OGV ^+++/O\OK^-?D)_
MP3D /QBMFQG_ $9L'_@ Y'^- '[Y2D&:<C.#,YYZ]?\ ']*CI\O^NF_ZZO\
MSIE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>&?M&_\ )*]0_P"OD_RKW.O#/VC?^25ZA_U\G^5
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M/P#H7B/PHED;/1XKNPBGE\/XA$$4^D;R!;2PQA50@X 5>X!'U!10!_*I;_\
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M3]H7X<^)GU;7$^,VN:WJATW3(6D.B[/M+F-,<I\H(!'..O?%?TR?$_PKX/\
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MQ[>WTR3STK]F?^"5OQ2T#]G#_@G=XT^,]_;(1HMG+-(4"AIKQ(M\&]@#D;B
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M $U_AI_R(O@G_L 67_HB.O\ ,H_9C_Y.8^#W_8R6O_I7'7^FO\-/^1%\$_\
M8 LO_1$=?O/@O_N.:_\ 83_D?XB?M9/^2K\*O^Q%F7_J:STVBBBOV\_R*"BB
MB@ HHHH **** (#U/U/\Z*#U/U/\Z* )AT'T'\J6D'0?0?RI: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /PA_X*
MT?\ (Z_#7_KQO?\ T!Z^#?V:_N_#G_L>+G_T::^\O^"M'_(Z_#7_ *\;W_T!
MZ^#?V:_N_#G_ +'BY_\ 1IH _<>Z_P"/F3Z1_P#H J"I[K_CYD^D?_H J"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **,TJJ\AVQJ6;L.G\_P_P : $I,YX')_3KC
M)/05PGBWXE^"/!4<AU[7[&&^B#$:09E%Y.5YV1)D%B2,+W-?"7Q/_;I,=OK=
MK\/8+?1[_2 ?M<.O[8YKF+D,]H&')V?,I ].2: /N'QS\4_!GPWDM3XSUBUT
MFUO7$45P\J$[F[;0VX<X& ">WM7S/\3_ -M#PQX8L9)O">G_ -OZ695MG\21
M/B"P>3@22)NR%0X+9Z]<C%?C1\0OB9XT^+OC*S\5Z>-9\2VE@RS76ERL\^G1
MW@/[PK'T\I3GHN".G<UZCX?^"/B37YH-7U[4;O7_  IXD*-J/@KP4SS7VG7#
MC 6XMT+,I!ZY4<CVH Z_XG?M.^(O%VLS:%KNMWGC+2]4Q_8R>'VGM_L4TO\
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M_P"T#_T#-$_*+_"LK6OVOOCKH>F76JW]CHD-K;(Y=V6(#< <#.#C)'''OTH
M_4<\=05],T;AZC\Z_*'X3?\ !233WAUB7XM:<%CM-S60TL?-,1G& !SGL>F?
M>O5[#_@IA\!=08(FEZU <@%IE91[Y!'']* /T(HKXHA_;Y^!<Z"16NE#<X9\
M$'Z9R/H?K4O_  WG\#/[]Q_W\H ^TJ*^+?\ AO/X&?W[C_OY5.\_;^^!MJD;
M*+R9YIEMXXXVW,7D.T''I^6.?P /MZBN9\(>)+;Q?X>L/$=C&\=GJ*)+ DO$
M@C=5*\>P.>_YUTU !1110 4444 %%%% !1110 4444 %%%% !7AG[1O_ "2O
M4/\ KY/\J]SKPS]HW_DE>H?]?)_E0!R?P]^&G@_XE?!_PU8^,+!KR*U.;62,
M S0$C^!S\RGW!'7V-<Q\9/V=_AEHWP1\=&PM]4!T?2+B\LA)<,RB<(Q4N"Q!
M ..I_''%>Q_ /_DE>@_4?RJ[\>/^2(_$W_L7[C_T6U 'Y$_\$A69OVOH"QR1
MX?U11]%$RC/O@<U_6Y7\@G_!*?Q1X>\'_M60:QXIUC3M TK^Q=4A_M#5+J*S
MM!*S3*J-/,4C5B2!@MWYK^I,_M%? P%E/Q4\%94E3C7K$C(]")<'ZCB@#VBB
MO%O^&B_@9Q_Q=3P5R<?\AVQ_^.U.G[07P3DSL^)_@Q@.XURR(_ ^;0![%17B
MEY^T9\#[)8C-\3O!Y,TB11)'K-H\DDDA"HB(LA9F9B   >:]BL[N"_M;>]M9
M%FMKJ))X)4.4DBD4,CJ>ZLI!!]#0!9HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /%_VB[8WGP*^+%KC/G^!]>CQZ[K.08KXN_X)63^7^SM;Z1R/
M[+U2]CVYX7=<R' [?Y_+[Q^,-M]L^%OCZUQGS_"VKQ8]=UJXQ^-?G?\ \$MK
MG9X+^(&CY_Y!7B*:+9V7=<2\ >WTZD].E?&YA[G&N0U/^?N59GA_6U2C6M_Y
M)<_I;A"^*^C!XLX7=8#Q X&S:W;FPF89?S6_[F.6_FT?JQ116;J^L:9H.GW.
MJZQ>P:=IUI&TMS>7+B."&-1DN[MP !7V1_-)I5^</_!2;PK^SWXL^$FFV'[0
MFKKH_AY-8LI;"X>0(#>K<H8E^\I.9 HZX'>OK)/VD/@3(N]/BKX**Y(S_;ED
M.5)!!!D!!!!!R!S7X@_\%T/B_P#"#Q+^SOX9M].^(/A74Y5\3:5+Y%EJEO=O
ML^W1')%O*67H<[NF.<<T ?O#\'+30K'X5?#VS\+S"X\.6OA'0X-$G'(ETR.Q
MA6SD!'!#0A#^->DU\:_LU_''X.V/[//P5BG^)'@^ CX<>%XQ&^MV(=6@TJW2
M173SB\;*RD$.%)ZC((->]>'?C-\,_%^MKX?\+>,="\0:DT9E-OI5_!>,B+R2
MWE.VW'?- 'J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445S7B
M?QCX8\&67]I>*=;L-"L,[?M>HSK;P9ZX,CX4$ 9Y(XH Z6BO%%_:.^!3#<OQ
M4\%$>O\ ;ME_66K2?M!?!.10R?$_P:RG&"-<LCU.!_RU_P B@#\HO^"K_P#R
M W_ZXQ_S-?C+^S=_R<!\)?\ L+:=_P"C17ZT_P#!3[XA>!/%FB2+X9\7Z'KL
MJQ(&BTV]ANB,$YYB8@XSV)Y'>OR6_9NS_P - ?"7((_XFVG<'_KJ* /[4K?_
M (]X/^N,7_H"U-4-O_Q[P?\ 7&+_ - 6IJ /R?\ ^"L;;/AS\%&VEMOQAT<X
M]?\ CW'.>W-?#\G[,L^M_$+XE>(-3^*MAK'PN\1:"[^(O"4KI*V@ZO)8CR)F
M5BRQB!B">G0\<U]Q?\%865?AW\$V<X4?&'1RWN,0#'YX/X5^,GQKNOVN/ 7C
M;XLZ1\/O"4UYX/\ ',$<D>J26[O!!;R6BAIY),$"*-3N8YX'/;CX[+,/1Q7&
M?%%&OG,<EI5,OR>-6I5JY71HXNC+#UE6PE2IFGN0=6&E*6'M7C4BG&239_2O
M&DG#Z-7@9)83"XMPXJ\39Q6)>-BZ4XYIELH5J3P*E54Z+7-+F7*Z;::D[(_<
M;]FNQN/@1^P[>+X<\86GB";0(M=N-'\0Q*);>(/.YM(RHRK?9L*C#D<<]*_(
MGX)_&WX\Z]^U!X6\7^*/C3HTWB+7O%4>C75E%;&-+OPTTRJFGI'L"A]@VYQP
M>17[!_\ !.[P3>7W[%'AGPIX_N-+UV[OX=675Q8.);/?,QD\@]1OB8X=3T(Q
MP,5^17C;P/XD^'O[6GPUC\&>&]#U2W;XF0VU[:VD*/?:7I7VM0;EU4'8%4D[
ML_K7VV'Q>=X9?5,MP& S; 0BJV,S/,*N787%4E#]U#$NI-PA3C&#<TL)&2J5
M*BARV<3^8,9AL%C)4L5_K/A\BKUJWL,-EKP$<;@<SISY:L\+A*F*PM6LZM;D
MY.7$.@XPIQJ1E[1-'])/Q<N=33X;>(;?3-%N/$-WJFC76F?V=:_++,M_:O!*
M0<' V.P/'&<Y&*_%C]DKX*_&3X9_'SPS9/\ !J?P]X#CU>_OY]=NHXS+:M=S
MM*6,H&YMV[J&SDGIP#^SOQF/C5/A9XEN/ 5U9V'BBUT.YNK*XOR$MXG@M&D=
MF9OE4KM)!/0CBOPO_9(_;+^//Q$_:*\#_"SXB^(K6:.SUC4K6\DL)4,.JK#<
M.BHQ4?.J8Q@\]^W-X?!8K$NI7PF99Y@WAJ<_K.&RJE7>'Q>&G:4H8YPKT:52
MC>"C.,XS=.G*I-*W,I:U:F$I\D,7DG"^9*M-?5L5G><K"8_ XBFTHU<LP'L:
MCJ58>TYX24XJM65*G):*2^\O^"B'_(S?LJ_]EDL?_0K.OTVA_P!5%_US3_T$
M5^9/_!1#_D9OV5?^RR6/_H5G7Z;0_P"JB_ZYI_Z"*^0RK_DHN*?\>4?^H"/W
M?Q _Y,[X"_\ 8+XC_P#K6Q)*8W4?1OY4^F-U'T;^5?3]5_BC_P"E(_#>C_PR
M_P#26?Y_O_!=R/SOVPIXAU>TG7/IDG'Y^W^%?07_  3G_P""N?PP_8O^#;>!
M/$_A"^US420PDM)"NXJ.A&#E2.&'MU'?P+_@NIQ^V43G'^C3_P VXX]?2OQA
MCAFO[R.SL=/EU+496"P65JC2SS.QP B*"22>,XZGJ.:_E+'9_F7#_&&>XS+H
M_O'BZU-S]FJFLYQY8J#NVV^J6B9_TA^%W@YP+XX_1!\&^#_$2GBI\/X3(,'G
MG^R8N>"DL1A:E2G&5;$PE!4J:4K7G+EUNTS^PF7_ (.6_A#;OY4/P<UZ0*>6
M660+CUQMQW_O?H,T'_@Y>^$3*3_PI?7F/8^<^/7GY>OIS@U_+-9?LL?M+W^D
M?\)!9_!+QI+IQC\T2)I,S!X,%@X.P_*5^O'>O&M4T_5] U"31_$>C7?A_5(>
M)K'4H7@N$9>"&1@O(Z<?XBO2Q/B)QE"$*^*E]6YE^Z_V&*C.R3;;J0:6]EYV
M/G,G_9^?1!SRK5PN0T<3G&)H?[SA,NXYAC<104;1DZ]&E7E."3ONN]_+^O<?
M\'+GPD3YA\%M='?_ %CCOWXS^'\JNP?\'+7P;G;9/\'==AZ?,97S^&5SZ_3!
M/O7\H_P?_9_^+?[07B2+PW\+O"&J:Z[-MGO[.TDEM+9B<?O7"[5'T)^G6OJ;
MXA?\$K/VP_AKH$GB34_ FIZU:PQ&:2#3K*22>.,(6.5 )RJYSG\/:L'Q_P =
M8[#?7*6'Q%>@N9QJT\OBZ=H:R;:AY.[5[KKHDOFLY^AA]!7A_-X\-Y[G&&R/
M/*\_8QRO'<<QPN,55VY8SI3E>#=_=Y[7;/V7_;0_X+4_!7]J+]GSQ%\-])\(
MW^D:QJUM,EO]JDW".61"JD#Y2!]W@YZD5_+I8P&")E)W;III!QCAY'8 >V"/
MY=JBO=/O]'U*;2M=TBXTG6K-VBN+&]C>*ZA=#M8.K8Q@@Y]N^:N)OV#'IQG'
M_P"NOD,^XAS/B2O1Q6:.FJU"FZ,.2G[*T+IVE&R?-<_L'P1\"O#[P+X>QV1^
M&L<;_8F=8^EF]66,S%9DJM94U3C6PU=7YJ-2F[JS:=DUT)1T_$_S-+0/\_CS
M17SY^Z!1110 4444 %%%% !1110![)^S'_R<Q\'O^QDM?_2N.O\ 37^&G_(B
M^"?^P!9?^B(Z_P RC]F/_DYCX/?]C):_^E<=?Z:_PT_Y$7P3_P!@"R_]$1U^
M\^"_^XYK_P!A/^1_B)^UD_Y*OPJ_[$69?^IK/3:***_;S_(H**** "BBB@ H
MHHH @/4_4_SHH/4_4_SHH F'0?0?RI:0=!]!_*EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _"#_@K20/&OPU!8
M+FRNP"W3)5P,U^9W[/?Q+\*:=XA^'_A.:XE;6[;QE--/;QKGY'G(W+CJ2.?P
MYP,5^C?_  6##-XG^&^UBA6UN6W+D-T?C/I_6OS0_9B\#:!<^._A[XJFMUDU
M4^*#&TC!3N42#J/R^M ']"C3I<.)XP1'-&CIN!#[=J_>!Y!.1_/N**FN0!<R
M8 '$8PHP -@X [?_ %JAH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,\X')]!U_S]:AN;B"T@DN
M;NX@M8807D,\J1-L )) =E.<>@./TH F) Z__K^E9=[K.FZ==V]IJ-Y%8/<K
MNAENI%AA(Y/+.0GZ]!GTKYX\=?M3^ ?#/VVR\,.OBW7[*-Y)](201D;!R5=L
M!L$<%3R:_'S]I7]J3QQ\1M9LS;:P^F:;$S&YT6UD>.XTY%/,)E1LDD9';KWH
M _;/XB_M ?#+X9VKS:WK"7KC*HVELEW&'Z+YSQ;@@W'J>W7G./S[^+_[<6LS
MSR:';3P>%]&OK9Y=(U_394EO9 XS&'1<L';COD9QBO@[P[HGQ3\1Z7_::O<6
M7PTU_%KJ&N:A(=0EM< *TL<3[Y$ZEL\?I7U/\'?V-[_Q%=Q6&F^$M6^+&EW\
M:M8>+P98[31Y'Y5FCF& L3<X' QC'(H ^;)O$7Q1^,6I-X>M;6ZGUXN;O2/&
M6O/-I\=PB'<"LD[)&YP  J^O<$UZ=X%_9IUGQ[K47]JOK?B3XI64D<<NBBTG
M_P"$?U!4("HUY'F)E)'5F(P<\YK]MOA/_P $ZHCI^EQ?&37;;7].T\))I>E:
M1"VEWFGHN&C@FNXHAYNP#8WS-G'OQ^CO@OX9^"? &FVNE^&- L+*&T18XKAK
M:":_8*  9+UHO/=L#DE_PH _(;X2_P#!.'7->FTS7_&,47PJ-JD7VG0- 6.Y
MAU%5 W>>0Z[3(,DY]?PK]0/AC^SC\)OA/MN?"OA33[;5G5?M>JM'YEQ=2A<-
M*PD+(C,>?D4$$]:]UHH 0      <  8 ^@I:** "BBB@ HHHH **** /R>_X
M+ W @_9E3./F\06XY/4%",?Y'\J_G!^!_P  ?'_[17B2/PA\.X8I=5>,R?O;
MIK2-57J3*K)C').3@#\Q_1)_P6:G\C]F*S.<;_%%FN/^ GT&<8SGGC\Z_-7_
M ()!_P#)P$7OI\YXSMYB;\* /B/]H#]E;XH?LS7&GVGQ-BDMIM3?9:-:ZE<R
MQ/S_  L)6#9Z@@G(QR:Y7P+\'/%/C;1;G6]#U2WMK6W8HT=[JTD,Q*]?E:7<
M1]!^=?KW_P %L[?48M4\ 731W-Q8O,/+6&WDDCA(^\9712%YY&3VK\T_@9^R
MA\<?CWX?N->^&5EKDFF03F&5;66ZM86<'GY %4\CL#WZ#- '@7BWPQK_ ('G
MCM]<U!W>93)&UGJ$TR[%ZEBLOR].<CJ>O:NIU7X-?$'2/ .B_%+5(';P?KK,
MNE73W,LCR,O.#&[D*1GOT]:M_'OX)?$OX#:E!X?^)>E:M#J=_:R26@N([J[&
MS!)"R>60N?3=T^F*^QOB+#?)^PU\)9;@SI;RSRF&"9)8C&2#GY'"_AQSD ]<
MT ?*/[/GP#^*O[1GBVYT#X/V]K-K^A0#4+N6]G6WCMH1@^8&=E7=[9')'?&?
MOC_AW5^WF>3J%EG !S>-GCCM)CZ5N_\ !$S_ )+K\1_^Q5_JE?T\4 ?RU?\
M#NG]O/\ Z"%E_P"!C?\ QRC_ (=T_MY_]!"R_P# QO\ XY7]2M% '\M)_P""
M=/[>>#C4++/;_36Z_P#?RN/\7_\ !.W]NU="OWUB*SU/2;>)Y[JVCO \CQQC
M<[A!(6X7)X4^F".*_K&K,UL9T;501D'3KW((R/\ CWDH _@E\2Z#J?A/5Y/#
M^L0>3J=C>1V5U&,8C/G"&4?5,G@\GD?3V3]H?X0^'?@V?A^GA?6KC7O^$R\+
MV^O:G]I1D-C=W$:N]M$2!E 6(!&1GG/05B_M%_\ ):?&H/(/BRX&/][4%'?Z
M]/RKVK]M6"[TVY^";W<5Q,DOP^L98Y$MI#$J>1'M7>%VLW/8Y/;- 'M/P._8
MT_9;^('PWTCQK\2_CQ=>#]:U!%-UH]O/M-KG&5";CCN2<?B*^*/C]X%\!?#+
MXGWG@_X9>)Y_&?@Z%K5;7Q!-(3).9YE1QG_9!8]3^->Y?#/]A;]HGXM>$+'Q
MEX,T;6KK0[^/S;90\T413&=PB9>..^#VVG%?,7Q2^'GBWX3^,G\#>,=*U2WU
M^QO+(SQ/;7,I.ZX086418?!_ND]Z /VK^#__  1T^&_Q0^'7A;QU<_%+Q':W
M'B+2[>_N;6T3=#;R3QAVB4F5?NECV_&OSG_:O_9ET3]EKXQ>$O ^C>(+SQ+:
MW6KV9>>]+"15\U<@JQ(&>G!]<$5_5#^QU:W5K^SS\.?M1??+H-DZJZ-&R(84
MPI1P&!^O6OY^?^"KTD<7[2_A&ZD<"WMM1M9KAQUCB24%W/(X4 GZ4 ?JS\,X
M(;?P!X6C@C$2#2K$A1T!,*9/'&?>N[KY4^''[3OP"_X1+0=,/Q!L5OK+3;.*
MY@9@#'+'"H=/O8^4@C\*]!_X:/\ @9_T/MC_ -_%_P#BJ /:J*\;L/VA/@OJ
MSR)IOC:SNGB8+(B,-P8GL Y) ^G/M6W_ ,+@^&7_ $,T'YG_ !H ])HKS;_A
M<'PR_P"AG@_/_P"O1_PN#X9?]#/!^?\ ]>@#TFBO-O\ A<'PR_Z&>#\__KT?
M\+A^&0Z^)[<#N2V /J2P_P : /2:*\V'QA^&1Z>)X"/7/!]QS1_PN#X9?]#/
M!^?_ ->@#TFBO-O^%P?#+_H9X/S_ /KT?\+@^&7_ $,\'Y__ %Z /2:*\V_X
M7!\,O^AF@_,_XTG_  N'X8YQ_P )1;D]P'!*\9^;#<4 >E5X9^T;_P DKU#_
M *^3_*NJ_P"%P?#+_H9X/S_^O7BW[0'Q2^'VI?#/4+6P\017%RUP66)2<D=/
M7_\ 50!Z?\ _^25Z#]1_*KOQX_Y(C\3?^Q?N/_1;5YG\#_BG\/-/^&6AVE[X
MAB@N8V_>1,>5XQZ_YXZ5:^-WQ6^'=_\ !OXC6-EXBBGO+K0KB*V@4DM)(8VP
MHY[^_7I0!_/7\%?@MX]_:%\8#X<_#.!+CQ1(+N["2W3648MXY7+LUPKH5 "Y
M.3@ '. "1[?\7/V ?VDO@3X9N/&7Q%T[[+X?M.)[FSUJXN-N.,DQW#=>WKD<
M>ON'_!(,,/VOH RE2?#^J'!ZX/G$?H1^-?M9_P %4[:_E_9B\136QE:"+_CX
MAAC:5Y!U'RHI88[GTSCF@#^53P+\.M;^)%])IWAN^D2XAC\YSJ&L7-O&4Z@J
M[3J#TXP>3Q70>*/A=XU\!V<MYJ^J8MH9/(9;/6;B>0N.X"S<C/ QQWYK2^ _
MP<^(?QRUE_#7PXM-7.KVUJDLOV%9[9@I!P'E50!UQ@D$>@KU3XW?LC?'KX#^
M'!XF^).CZ\NCR3I 'F-W>!I3RI,81\Y]3^8QP ?+^FQ7-WXF\(9OM3FD'B31
MBB?;KML W<1(*&7!R,]OP[U_=[\,D\OX=^"$P05\+Z*"&)+9^P09R3R3[GGU
MK^%SP1=VMGXQ\+:AJ'^CV=OK.G7%PTZ[/*BBG1F=T<94*O.2 1C!K^Q?P1^V
M#^SA;>"?"Z-\4?#JM!H>FPS1B>3=#-';1QO$X,>-ZL#G!(]Z /L6BO!-/_:;
M^".JQI-I_CS1[F)P"LD<C,N#TSA<C\JU/^&@OA%_T.FE?]_'_P#B* /9Z*\8
M_P"&@OA%_P!#II7_ '\?_P"(H_X:"^$7_0Z:5_W\?_XB@#V>BO&/^&@OA%_T
M.FE?]_'_ /B*0_M"?"!>OC;203V\ULG\ F?TH ]HHKQC_AH+X1?]#II7_?Q_
M_B*/^&@OA%_T.FE?]_'_ /B* /9Z*\8_X:"^$7_0Z:5_W\?_ .(H_P"&@OA%
M_P!#II7_ '\?_P"(H ]GHKQ?_AH/X0CKXUTD =S*P'YE,4+^T)\(6&5\:Z21
MZB1\?@=F#]10![117C'_  T%\(O^ATTK_OX__P 11_PT%\(O^ATTK_OX_P#\
M10![/17C'_#07PB_Z'32O^_C_P#Q%'_#07PB_P"ATTK_ +^/_P#$4 =]XXMC
M>>#_ !):XSY^C7T>/7= XQ7Y8_\ !,&YV:_^T/H^<?V7XQ,83/W=T\Q( _#_
M .MZ?H->_'OX07EG>6A\:Z03/;31E?-8DAXV'0+^A(K\E?\ @F]\8OA[HWQJ
M_; M+_Q+8VEHGC=)[&2=RJSVXFFW/'@'U7@98].0.?CL[3AQ3PA47_+VKFV'
M\W;+YUK?^27Z^A_2?A?*.(\!/I'85NRR_ ^'^;N^T>;B["9>I/M_O'+?;5J^
MI^[=>&?M,65O?_ /XKV]RNZ/_A#-8D&&92LD=LS(ZLI4AE/0YJX/V@_A$>?^
M$TTKG_IH_P#\17D7Q_\ CC\+=4^!_P 5+2Q\7Z9/=3>#M6MX($=S)+--;L(U
M0;,$Y_+\L_8G\V'\6MAI?FWWV".\U R7FL7-I"S:E=JBO)=NJ[SYN O./3@]
M*^OO$'_!+CXD?$[PE8W>L:CX2U32KNV34K6UOO%"LZ)'&+@;DEN6*R*!@=/F
MZU\D68;=.Q)C+:A=,)!PR![J1ED![$=1SP#G/>NJCU;Q(+@6B>//$\-J% 0Q
MZU>K"BXSY:J)L 8^7:.PP!0!D7.AZCX-N9_!CZA>Q'PLSZ0(;;4;B2UC^R_N
MMMNZS;6B&"%V_+CGCC/[*_\ !&;PU#<_$?Q!XFEO+N2ZMH+BW$4]Q-,KAE92
MV'<@8^]7XS2EVFG9YI+ERS;KB5C)+.QZO)(Q+2.2,[B>]?LE_P $AO'7A3P9
MK_B1O$^L6^D"=I/*:Y;"D-D#.T$G.>P./RH _IFHKQC_ (:"^$62/^$TTK@X
M_P!8_P#\11_PT%\(O^ATTK_OX_\ \10![/17C'_#07PB_P"ATTK_ +^/_P#$
M4UOVA?A I /C;203_#YK$CZ@)0![317C'_#07PB_Z'32O^_C_P#Q%'_#07PB
M_P"ATTK_ +^/_P#$4 >ST5XQ_P -!?"+_H=-*_[^/_\ $4?\-!?"+_H=-*_[
M^/\ _$4 >ST5XO\ \-!_"$9)\:Z2 .YE8#]4_P ]Z%_:$^$+#(\:Z41_UT?_
M .(H ]HHKQC_ (:"^$7_ $.FE?\ ?Q__ (BC_AH+X1?]#II7_?Q__B* /9Z*
M\8_X:"^$7_0Z:5_W\?\ ^(H_X:"^$7_0Z:5_W\?_ .(H ]GHKQ?_ (:$^$&[
M9_PFND[NN!*Q_DE+_P -!?"+_H=-*_[^/_\ $4 >SU\)?\%%-%T[5OV:/&LE
M] TLEE9336KI*\3PR^6WSJRD'/ QR,$=QFOH;_AH+X1?]#II7_?Q_P#XBOC[
M]N?XS?#/Q#^SIXWTW2?%5C?7UUITJP6T#MO9MCC&&"Y[=,^W>@#^2+PYH5QK
M>I:+H5K>7PO=<U%=.M'EU.[2%9IYBD9F<R[43)Y8D  5]C>/?V'_ (Y?#+PY
M<^*-3\1:#/HUA;0W-REEXH:XNQ'-&LJK'''<,S-M;D<$'@D]:^.;#S8H(V5W
MBFCE=HI8SLEB/F';)&Z\HZ_>#+^%=$=2\07EK/\ ;?&?B.ZBC 4V5WJ]W-#.
MO8-$\NUE P ,< @#- &.L]V#(IO;N7YPLOG7,DP89Y 5W<#ZGKZ9S7U1^SK_
M ,G"_"C_ +"^F_\ HQ:^5Q]T'&,[<^IY')[Y^O-?4_[.AS^T+\*>G_(7TWH<
M_P#+5?84 ?VG6_\ Q[P?]<8O_0%J:H;?_CW@_P"N,7_H"U-0!^37_!6D*WPU
M^"P?<%/QAT;E1D];?M],BOFK]H;]KWQ[\+8_^%>M\.--\1:#K_AM-(_MW3((
MKZ?3+*]L!#)>:D\0)M6@1BY:;[NW=V!'TW_P5B8+\.O@HQZ+\8='/3.?^/<=
M/Q]Z^)]&\2ZA\&+W]H/3M8^&6I?%FS^)^DW-O9:PLL5S'X3COM*EM_+'GQW'
MV>*(3^:%B\IA)%$P8;2#\=EF%P6+XSXHI8O*L#G$_J.2/#87-,=E^4Y?"I&C
M5<ZM;-LTR_,L'@JRI\RP<94(SQ>)<<-3GS32?]'<=^S_ .):O B=>-.6'I<6
M>*+J1E5S"%5RGF.6QA["EEN:97B:W++EEB%[2M"G0YISII)S7Z'_ +$UUHGP
M[_8]GNO!-^WC*2S76=85+:4W:MJ6H*9OL,<J%@?)E(1D4Y4@@ =3^1G@GP'^
MTWJWQQ\(_$:X\.:UINO:E\63=:O#)9W!MHO"$EX&4EI 50"'OGW[5^HO_!/C
MX1Z[X _87/A'P;K']CZ_J%[XGUG2K_5#]M&G75],;F."X+!O,2$KL QA1TQB
MO@_PC^TO^UEIWQ'\%>&?$'Q4\'ZGXA?XI#PUKO@RVTZV2]E\-+="+^T8Y H=
M=\>".,@FOJZM3"58TZ2S+AS**,9K$4,-QKP_F>=9R_9N,85*>,RZ&&R_#2HW
MY*JJ8:G25:M1J5*7LHTU'^?:,IX>6(E/#<0YCB*U.6&K2X2S7!8+)I0;4U&K
MA,;A,VQ%6-:2<H5J>/\ ;*C2J0IXA3E.I/\ H4\;7-O9> O$]U?IYEM;^%]4
MENXS_'$FFS&9?Q4,*_FJ_8:^!/BJ_P#VO=.^.&D3Z"_PZOO$>KK8::^I1#5-
M.D2\E$K1V9?>2Q&2 G'-?T4_&NUO+[X3>+8X-;@T#/AV]DO=0N%#1BT%F[72
M="5,B;E!'KCI7\TW[&G@G6?"O[8_PWU\ZEJ</@;Q'KVJIX;=-2=M,UBX6Z<7
M#+8JXC3<V3R@)S6D\#6Q:ISIX++JT*52\\7C*\Z5:GR1]LJ.$I?7\)"HYJ#K
M2FZ=>494J5-1DJKISXXXZ.%<Z:SO!Y?.I!)X#$X&.-GC:4Y>R?LI/#U)X:OS
MRC3H3IUE?GJU)PY://']??\ @HA_R,W[*O\ V62Q_P#0K.OTVA_U47_7-/\
MT$5^9/\ P40_Y&;]E7_LLEC_ .A6=?IM#_JHO^N:?^@BOFLJ_P"2BXI_QY1_
MZ@(_<O$#_DSO@+_V"^(__K6Q)*8W4?1OY4^F-U'T;^5?3]5_BC_Z4C\-Z/\
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M?US^-?VCK[]LS_@D3J7C[X@1+<>)- 9[*XN9(R#<WD"%&G&_!+?(,$Y( ';
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MP3_Z&_Q#_P!\+_\ ': /YD(Q;P,7MB;=F.6:+(+?7G^E6/M<G_/[<?\ ??\
M]>OZ9_\ AS)\$_\ H;_$/_?"_P#QVC_AS'\$_P#H;_$/_?"__'?Y8H _F_\
M!OC.;P9K"ZE"[RH<^9#)N*,3CDYR-QSZU[J/VE3WLH\_]<V_PK][O"?_  2
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M%?T-_P##J/\ 9]]+O_OTG_Q5'_#J/]GWTN_^_2?_ !5 '\\G_#2I_P"?*/\
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M&G("QL!GZ>H^F._7FH[[]HI+ZSN;*6RC\JZC,;_NVZ,,>F/T_G7]$W_#J/\
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M[Q_]\O\ _$U_0'_PZC_9]]+O_OTG_P 51_PZC_9]]+O_ +])_P#%4 ?S^?\
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MFOZN?^'4?[/OI=_]^D_^*H_X=1_L^^EW_P!^D_\ BJ /Y11=6Y+;F)X!3AL
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M&"PV#C5DIU(X:C3HJI)+E4IJG&/,U'1-W=M#Y+B7C/BWC*MA<1Q9Q+G?$E?
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MY/R<G]Z.2.]?LY16?^K/#RVR7+O_  F@>A_Q,!XY?]':X]_\2/,/+_I]Y/\
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M18_R_P"GGDC\>/#'_!$3]A[P9XIT3QEX>\"2VVN^'[I+S3KAI01',CAU..>
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MYP"/QK]:?^"P/_(S_#K_ *\[G^3U^?W[+@_XFOP\Y/\ R-C<=/\ EH/3G]:
M/WC,)MV$/F-+Y4<:>8WWI#M7+-ZDD9!]#14]U_Q\R?2/_P! %04 %%%% !11
M10 4444 %%%% !1110 4444 %1NF]98RQ02Q.@<=8W9"J,._4K@#N#4E(1G@
M^WZ'- '\\W[:,?QG\#?$K5/"OBWQCJNH>%M=FDU#2[ S2?98;-\LL?#_ "L
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M)6EWNC^#8[\^)M.?4M1GDN&E,6IR-G[5'')GRBK<C:3CM@5]<L%6PE3ZK[+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 7D^CZ[X.TN2#5[.].U9M,@)\_4(D( *!0Q!&[@#DU]X_P#!,;7H=(U7Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0'J?J?YT4'J?J?YT4 3#H/H/Y4M(.@^@_E2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@;_P6!_Y&;X=?
M]>=U_)Z_/W]EL_\ $\\ ?]C4_P#Z,K[Q_P""RVH+I>M_#J\9&D58)HRBC)._
M?SC!QCUZ'H>F:_+C]FSXHVUCX_\ AWX8CTNXN;UO$8N0Z*P5Q)(#L!VE<C/<
MC^E '](-U_Q\R?2/_P! %04&5YF$LD;1/)%&[Q, &B)52$..^#^E% !1110
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M RP"X) .<5^!W_!/JU\60?M1_#V\^)]M9Z?<Q:%JD'A34K;RX+77;5O.7ST
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M^+NK_#/QE<ZM<P6_@NVUG07O[E[A5TN38UNKL=P,NQADD[N#[5ZM_P %1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (#U/U/\Z*#U/U/\Z* )AT'T
M'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /PK_X*LZ /%'Q!^&>C>3]H,NG7LWED;@?*61LD=.,
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M_P""/_I*/YZQG^^8O_L)K_\ IV044459S!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 0'J?J?YT4'J?J?YT4 3#H/H/Y4M(.@^@_E2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C;_P %!?\
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MR20Z[-K?B1?!1@U%M.N&D^WRAU1ADLNWN!G=D#BOV:_: _Y(A\5_^Q"\3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUTV*35O %IXALSIETMS'#IUR(WBAE",5CD57 <$ Y]":]/\ ^"H__'_\&/\
ML==&_P#2R*NR_8>C_8WG^(OB>\^!6NG7/',.G_9;MY+QKF6VT-'58HHPP)$2
MC:!@JN.W2N-_X*C_ /'_ /!C_L==&_\ 2R*OFN/5F$>&<PAF4L^G7A]5A3GQ
M+6P]?-Y8>->DJ/MY83$8K#Q@E>-&%.O-1I*-U%MQ7[_]$B&4P\<.#_[%HT\/
M@YK/*CHT5C_8PKSR;'.M[+^T_P#;7&4O?O5M>4I./NV;_6[P[_R+^A_]@C3O
M_2.&MFL;P[_R+^A_]@C3O_2.&MFOJJ?\.G_@C_Z2C\!QG^^8O_L)K_\ IV04
M4459S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 0'J?J?YT4'J?J?YT4 3#
MH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?.GQ<_9@^&'QL\5^$_%OCO3Y-2O?![E]-MFVFSD
M)<R8N8F_U@W'IZ5[1X=\(^&?"5HEEX:T+3-$MD14\K3;2&U1@H RXB5=Q..2
MV2:Z.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ,.6,L36XCQ/]KPYVHN%+(VHX58*=E[WO5(M2K*7+&2?Y'?\%/?V@/"WP?\
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M@%<\]A7Z4_MS7'AFV_9>^*DGB^&YGT$Z&\=Y':Y\\^82L97'/RN03[5^#_\
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M=T\35K5H4_CD[Q/Z7/V/9K!OV1/!TEM#+:62>$]5!AED:26)([>?S TC$LS
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MOB\4UJGB:[377][(****LY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (#U
M/U/\Z*#U/U/\Z* )AT'T'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (;BWANH);:YB2:WGC:*:*0;DDC<%71QW5@2"/2O*)/@'\&999)
MG^''A<RRN9)&_L]5W.QRS$*P7)/).*]=HK&KA\/7<77H4:SC?E=6E"HXWWY>
M>+M?K;<]+ 9SF^5*HLKS7,LM59Q=98#'8K!JJXWY746'JT^=QN^7FO:[MN>0
M'X _!@XS\-_"_'3_ $ ?T>@? 'X,#I\-_"X_[<!_\77K]%9?4,#_ - 6$_\
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M]<.+?^BHXB_\/>9?_-)Y ?@#\&&X/PW\+]<_\> [?1Z3_AG_ ."__1-_"_\
MX __ &=>P44?V?@/^@'"?^$U'_Y /]<.+=O]:.(K?]CO,O\ YI/(/^% _!@_
M\TX\,=,?\>/;_ONKVF_!/X3:/=Q7VF> /#=G>0L'BN(;!1+&R_=9&9FVD8XQ
M7J-%-8' IJ2P>%33NFL/133[IJ%TR9\6<4U83IU.)>(*E.I%QG3GG.8SA.+W
MC.,L2XRB^J::8BJ%4*HPJ@*H'0 #  ^@I:**ZCY^X4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110! >I^I_G10>I^I_G10!,.@^@_E2T@Z#Z#^5+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $!ZG
MZG^=%!ZGZG^=% $PZ#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 0'J?J?YT4'J?J?YT4 3#H/H/Y4M%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 0'J?J?YT5/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gk2okx215f1r000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2okx215f1r000001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X0 B17AI9@  34T *@    @  8*8  (
M   !          #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?
M'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_VP!# 0D)"0P+
M#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C+_P  1" #P!$,# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%0/R1:A\<3R:9\:/"]_!_K)+22)UQ]Y1O_\ BJ .M7QA<:IKFH:9X>TR*_\
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M'NQRO8\CI7HM 'G7AOXCZKXJEOX]-\+9:QD$<_F:@JX;)X'R_P"R:U[7Q3K
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M;^=>E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8QY^\,Y!.3G&YF; ["NZT72H-$T6TTRW+-%;1K&K-U8CJQ]R>:T:* .)\?\
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MODVJ<G);VQCFJW@S5$T_X=^+XM1M[JR:ZN;N6%IX65'+Q!0BMT9LJ>!7M]%
M'GWPFU.T?X<:?;F9$GLHW%Q&Y"M&-['+#L,<YK#\ ZK8GXJ^,'^T($OI8_LK
M'@3;2V=I[UZ[10!X/H&MMJ5KXEBUW3=1O/&,HGAAB^S,XAC*8"Q_PQJ&SGIG
MWKM_A#J$=SX L;%8KA)K(-'-YD3(NXNQP">O&#QTW"O0:* /*_CEJ%M_PAAT
MM9-U[--'(L*J6;;EOF^G%5=5\*VGCSP!H]_HEP%UW2K6%89$.QMRHI,3?W3G
MH>Q^M>O44 >7^%O%<GCGPCJ'AS51)9:^]K-9RK+&4WDHR[Q_4=C61X)^(T/A
M?28O"OB:QO[;5+ F&)(H&<SKN^4*!W[>A'.:]GHH \C\?Z_XBB\,:5<WEI=V
M6G7E_G4([3(FAM<C",P/#,NXGIS\OUS;[5]*M?B+X/U73]+O;;0K>&>*.2.P
M=1(S(R_*FW<>67G%>W44 >/R:Q82?'^WNQ<I]G73OLS3%OD$OS';NZ9Y_/BO
M8*** /"+KQ+I:?'R+6C<$Z;%:F(W*1LR;O*(XP.>M=GK_P 4/#%K8&XL_,U*
M^@R]K"EK)_K,%<[F4!>&()SG!->B44 >5ZZ/#_B&8Z'XZ6"UN[:TADBU!OW/
MSLG[P*Y^7[W\)Z^E4-'T_7+CX+^(]/F>XNXD,R:9)*C"2:W7&TA3S@X.T?TQ
M7L=% 'ALWBZ_D^"EK#X86_\ MEG;PP7D\=NR^0H^5MK=SQU7.T==M0>(=4T1
MH/!MYH6F7R:39ZK#<7-VUHPRV03N.-TCX#9(S]:]YHH \A\<:E#8_$3P7XCN
MHKB+3%CD#R- VZ,LIP&4#<#\PXQFJ+>(G\!_$/4=<O\ 3[P>'O$*1RB?R2'B
M=1QN';JWR]<,/I7ME% '+>'_ !/+XHO/M.FV<L>B1H0+FXB*-<29&/+!/W ,
MY8]3P.];]]>VNG6KW=Y,D-O'C?(YP!S@?J:M44 >$?"GQ/I&@WOB5]4N)+5;
MN[66 M;R'>N7YX7W%=I<?$#3K_Q!INF>&E:ZOKV>..XN3:LJI A+MEF49.W=
M@=!N)KT.B@#Q'P#XCB^',FH>$/$4-U%.MVTMG)% T@N%( ^4*,G.W(^O;%:7
MPJ=K[6?'[B*2%KC4F/ERKM:,LTO##L17JMQ))%"TB0R3LHR(XRH9OIN('YFO
M._A[I.O:/XC\3W.J:%/:P:M>M=0R&>%P@+.V&"N3GYAT!H Y;P%XEAT+P)J7
MA:[L-0_MR$SC[&ELQ8AA]XM]U5'<L16IX1U.'3/@3-:W\=Q:31VMU$JW$+)Y
MS.9&41[OOYW=J]@HH \<T>1=1_9YNM/M!YU[;V4JRVZ_ZQ3YC-RO7D#(]:U/
M#_C'29?A9%'OF06>E+:R/)$R*9EBV^4I;&]OE)PN>*]/HH ^?+.UN[_X,Z!-
MHX,NL>'KYKR2T&3(!YKL#MZ]U/TS7=Z;\5K;Q););:!IU]-K,ORFW>$B.W/3
M?(_38/;D^E>D44 >>>+_ /A'-6UAO#OBY88K<64=Q;W\A\H)(S.K@2'A3A4(
M4]>>M9/@:^OO"_@[Q!<7)O=3T;3KEAIC;#YDT0X.W/\ #TYZ?>KUFJ]RDTMK
M*MO*(9F4A)"FX*<<''>@#)\*>)K;Q;H,6JVL4L*N[1M%,,,C*<$5SGQ>U2TM
M_ 6I:<\H-Y=1H(8%4LS?O%YP.W!KK]'TJ'1M/6TA9W^=I)))#EY)&.YG;W))
M-:5 'DFDZWIO_"A[BS-V@N8M)FMWA.0XD9'55QUR3TK/M=3LA^SL]D;A!=BV
M> P'[^\R,0-O7D<_2O:Z* /![Z+4/^$+\#^*=#B:]E\/J([RWC!+@;4W CJ/
MN\^S9Z5WFB_$2+Q9-!:^'M.O&?<INIKJ'9%;("-P)!Y8C(4#OST%=Y10!S%K
MXO@O/'-]X66RNTN+2!9VN&0>6P.WI_WT/UKIZ** *6HZC:Z5837UY*L5M",N
MY!..<=O>O./!^C^'?'D.I:]K%E!>ZC=7;.T,ZG?;0YV1(1_NIGWKU2B@#P;X
M@:?I?@+QAH.L^&;:.&YMW(NK.WSDIZGTW*67\JU/C'XATS6_ 5K!IUR+F:>Y
MCF2.,$N%VN"2.W/'->RT4 <)IGQ(\)VNB6<<NIL&CMXU=1:S$@A1Q]RLZ7QO
M'K/A+Q/J4^ZUTQTDLM.CEC*R3,(CN..OS%@ /]FO3** /&?A-XOT/P_X&CL-
M4O6MKI;B1C&UO(3@GCHM==I7CB+Q-XPBTW0UEDT^W@DGN[J6%D#'A51=P!ZG
M)/M7<44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 96OZQ;^'] O=6N?]5:Q&0CNQ[#\3@5Q/@73+RSMG\5:IIEU?
MZYK8\]WB\L?9XC]R,;W7'&/T':K'Q8#7FE:'H@8[-5UBWMY@.\>26_7::] "
MA%"JN%'  [4 9OVS69.8=(@0>ES>;#_XXCC]:K3SZC#);F^NM.MXY9D18!$\
MK.V>BMN7GWVG'7M4]_JOV>86=G%]JU!QN6 -@*/[[M_"OZGL#266DF&=KZ]D
M%UJ3*1YS#"(O]Q%_A7]3W)H \"^(GBZ^TOXCW\<1=I+*0"WE9P7B#*"0A*Y4
M?,>E>]3RW*Z@+2SO[,2B%7,-Q S2.,XW;PXR/^ G]:^;M>\06&L:[>:C<S6'
MG3R$L%0.!V'S-:DG@=S7T'HDJ>+_  AINH7)4RR)YB36[G=&PRNY6*J0?7C'
M48(H TOM&NH?FTZQD4=3'>,&/_ 3'C_QZL'Q9HQ\8Z++I=UI%W:S#]Y;7A>(
MB"4#Y6RLF['8\?TK8M]0GL;B.RU<C<Y"6]XHVQS'LK?W']NC=O[HW: ..^'7
MB.X\0>&MNHJ4U;3Y6M+Y3P?,3O\ B/US78UYUH2_V7\:?$UC'Q'J-A#?[>P9
M3L)_$L37HM !1110 4444 %%%% !1110 4444 %%%% !7)7?Q%\,V&J_V7=7
MMU'?=H#I]P7;Z 1\CZ5UM>,>,[NWL?V@?#-S=SQ001V +RS.$11F?J3P* /0
M;'Q[X:U#4UTR'4]E\V L%S!) ['V$BKG\*O:YXBT[P[:_:]3DGBMP,M*EM+(
MB\X^8HIV]>]>3?$^]M/'&J:-I7A,KJ6JP3EFNK0[D@4XZN.,9YZ\;:]%^)G_
M "3?7O\ KU/\Q0!I:#XFTSQ);"YTF::XMSG$K6TL:-S@X9E ;\*I:KXZT+2M
M3_LQ[F6ZU+O9V4#SRCZJH./QKB]*UZ;PU^SM;ZG;$"Y2V9(3Z.\I4'\-V?PK
M6^#NB0:?X(MM28;]0U,M<7$[?,S?,<#/TY^I- &K_P +'\/)<Q6MU)>6=Y*Z
M(EK=V<L4C%F"C 9>>35[7O&>A>%RG]LW,UJKG"R&TF=">N-ZJ5S[9K)\=/X5
MU*.'3]:UBRL;RVFCN('F=0\;*0W )'4<5S'QUO+>^^'&FW5K-'-!)J4;)(AR
M&'E2]* /3+?6K2[TS^T81=-;XW#-G*'8>H0KN/7L*R-,^(7AK6)[B'3[RXG>
MW!:?;83@1#G[Q*87H>M-M/'WA);.!6\1Z8&$:@@W*\'%>?\ PFAM]8U;XB0B
M7?;7MPJ"6-ADH[3C*GZ'B@#NE^)_A)[%[Y=0N3:+]Z<:=<E!SC[WEXZT3?%#
MPE;VD=U-?W,5M( 4F?3[D(P]CY?-5/B190Z=\(-4L;9-D%O;111KZ*KH!5CP
MSI5OK7PETO3+M28+K3(XGQC(!3J..HZB@#8UWQ7I/AT6ZWLTC3W3;;>WMXVE
MEF/^RJ\FJ5EX]T.^U:UTK?<V^I7#%4M+JUDAD'RLV2&4<86N$^(HU?PCX[TC
MQE;637VEVMH+24#K$,L#D_PY#<-Z\5U6F:KX<^(LNEZKIEV%OM+G$_ENH$R*
M059&&?NG/49'% '=UR5W\1?#-AJO]EW5[=1WW: Z?<%V^@$?(^E=;7C/C2[M
MK']H'PS<W=Q%;V\>G@O+,X1%&9^I/ H ]!L?'?AO4-3&F0ZELOFP%@N89('8
M_P"R)%7/X5;UWQ-I7AJV^TZM/-;V_&95MI9$7G RR*0/QKRGXHWMIXXU'1M*
M\*%=3U6&Y+-=6GSI O'60<8SSUXVUVWQC_Y)3K7_ &P_]'QT :$'Q \.W,"3
MP2ZC+$XW))'I5T58>Q$?-:.A>)=*\2V]Q-I5RTT=O(8I=\+QE6QG!#@'O7(>
M#_'7AK2_ 6C17NK1126]C&LH*,2I"C/1:U='\KQ3X'U+4]-A^Q7.O0S'<6)P
M^TQ(Q].%6@!W_"Q_#SO,T/V^XM87*37MO82R01D=<NJXXK5L?%&E:IHCZO83
M37-DDC1[X+>21B5.#A%4L?RKRCX>^/8_!447@WQ7:2:;+:N_E3NORD,Q;YO;
M).&&1C\Z]4\-Z-;:/;WAT^9&M+VZ>[A6-?D0.%R <\C<"W&/O>U &=9?$SPI
MJ*NUC>7ETJ'#&#3;J0 ^^(ZN6?CC0;[4_P"S;>XN?MOEF402V4\3E1U(#(,U
MY?\ !SQ)I&AVFO1ZE?1V[R7NY0P8Y&#Z5Z#H/B/1?&/BJ\?3U6?^Q8T6*[&X
M9:8-O7! X'EK^- $B_$GPM+J$UA'=WCWD.?-@73;DNF#@Y7R\BK^C>-/#WB"
MZDM=,U));F/.^!D:.08Z_*Z@UYUH>IZ=H_QT\73ZA?6ME"\"*)+B98U+$1G&
M6[U7O)$\8?&O1M4\,(TUK8(OVW4(D*QG!;(W?Q$J=OO]!0!Z;X@\9:'X7\LZ
MS=2VJ2<+)]EE="?3<JD9XZ9S5_2]5M=9L4O;(S-;R ,CRP/%N4C((#@$C!ZU
M0\8^'8_%/A:_TB0@/-'F%C_#(O*G\ZY3X,>(9-2\)OHUYN6_T>3[.Z/U\O)V
M?E@K_P !H ZH^,M%&O+H9ENO[2(W"#[!/DKG&[.S&W/\6<>]4F^)/A==3DTT
MWMW]OC^];?V;<F0<9^[Y>>E0>#D&L:YKGBIAE+J;[%9-_P!.\)*Y'LTF\UQ-
MUJEEI'[1EW=7\X@@%DJEV!(SY2^E 'H$OQ#\-V[0K/<WD!FD$<9GTVYB#,>@
MRT8%/UCQ[X=\/Z@ECJEY/;7,G^K4V4[!^<?*50AN?2LZ[\7>&_$VLV/AB&1-
M0^V%I90NX"(1#S%;./[RBN9^,G_(W> /^O\ ?_T9!0!VK_$3PM%/'#<ZC)9O
M)]PWMI-;J?\ @4B**Z2*6.>)98I%>-P"KJ001[&H-1TVSU:PDLK^VCN+:48>
M.1<@UY3\*[F[T+QQXB\#O.\ME9EY[7>>47>!^H=3]?K0!['1110 E<E+\1=
M-Y+::>;W59H3B4:;9R7 C^K*,?K7.?''Q!<Z-X-BL[21HY-1F\EV4X/E!26
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M6T*QL;NQL]+M;:VO$,=Q'#&$$BD$8./8F@#*U/3O"WQ#\++<W)@N+)HC)'=
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MU.^U*QTR 3:A>6]I"6""2>144L>@R>]7*\UUSQ-X,U[P'I6I>*US:7(6Y2V
MD+"8!E(&SGKO'/!KL]9U^ST5+<7'F-/=2^5;P0INDE;&<*/;N>@H UZ*Y?\
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MW1C;R\DDX*HI[]\UJW<$ES;/%%=S6KL,":$*77Z;E9?S!H \J^#?_(W>/_\
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M\"KUNZO8-2\(W-]:OO@N+%Y8V]59"14/B?PQ%XKTF32[N_N[>TEQYJ6WE@R
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M$,47PX\0E(T4O;EF(4#<V1R?4URD]]I$'PS\$V^H:9_:5]<"V73;8R-&#/@
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M_P  V?AM;<VNG7MQ%:"89"6PW;C*Q'4C;NP>IZUD3^&-(TZU6[LOBEJT0/\
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MQ&UM\#K>XL8@+R'2IY;=D49$NUSD>^:L6WPKTJRTR^TNTU;68+*]+^; DZ%
MK8RJAD.!P.?O<=:Z#PSX;C\,:2NF6^H7MU:1C$271C8QKD\ JBY'/?- '!^
M/#T'B;X9VD"^(]72TEBDM[BTA: (IR=Z\Q%AG.>N?FKMO!^FZ7H.@KI&DWDU
MU:V4SQ%YF#,'SN9<A0#@MV^G7-<__P *AT>#4Y[O3=5UG2X;@YFM;&Z\M&YZ
M=,[?:NXTW3;32=/AL;"!(;:%=L:*. * +M%%% !1110 4444 %%%% !1110
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M+/?:Z7)&YP;D8+7''8$!5]M_]ZO26170JP# ]CR*;%#'$"(XT0'LJ@4 <EX
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MCE7;)&KKUPP!%*D:1H$10JCH%&!0!P'@;Q47\ S1W1635]"CDMKJWW_,6B!
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MAC15L[-T"J  Q>/)_')_.NBNO <UUX(C\+/K<HLT18C(MNN]HU(*K^G6C4?
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M1:C(TMS'/ HW.<Y.1]>E8MG\)#I=W/\ V-XJUC3-.N&W/9V[XQ_NMV^N,^]
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M\2-;O)9,TQCACA93F63VQNP "3^59/A'[;'\=/%4=[+%)<&QA,C0H40G;%C
M+$\ XZUTOB/P!!KOB&QUZVU.[TS4K6/REFM=OS+SQ@_[Q_"H+/X=1:=XIDUZ
MQUO4DN)81',)'63SF&/F<GDC*C@8].!Q0!0^'_\ R4KXA_\ 7U;?REKTJN,\
M.^"9O#WB#4=676I[EM3D$EW') H#,,[<8^[C<:ZB^BN9[-X[2Y-M,V-LP0/M
MY]#UH \3^%?AG2_$&I>*FU"&=S#? )Y=U+%@%GS]QEST[UZ'HWAS2O!.L:E?
MPS-#9:FUK#''+*\K^<"ZXRQ+'=O7')[]JS=#^&5]X:DNGTGQ??V[7CA[@FUA
M?>PSS\RG'4]*T(_ MY-X@T_5=7\3W^IBQE,L5M+%'''OP0&VH ,C- ')ZBWB
M3P)K.LZ[HT,.N>&KZ[DN+V!6R\$F2LO3T(([@8Y QFF^+;_3=3\)_#ZYT=63
M3SJULD"-]Z-5!7:?<;<5V2>#KVV35+>S\13Q6NISS32Q/;HYB,I)81GM][ON
MJ+6/AQINI^$=/\/6MQ/8QZ;(LMK/'AG5QGD^N=Q/;F@"'X@3Z/'>Z EW8SW^
MK_;@^EVT4QCW2@KRS= H^7)Y_G6 YU./]H'1O[1FMS/+I#96V1E15S+\N6.6
MY&=WR_05OZQ\-H=:M].>XUW5/[4L)VFBU#>N_<=O;& /E7 7&/Q-#_#6%]?T
M_7/[?U9M0MHS'-.TBL\R\\=,(.2/E'Z\T 9G@+_DJ_CW_KK#_P"S5F_#6+5-
M=L=<N(?$$EG=/JDQNX/LL<AW$#!.X9QC@#_9KJ_^%?HGC.\UZUUF_M8[\+]K
MM82%$I7'\74#CMSR<$52U'X71OXDGUS0]?OM$NKIBURMM@I(2>3CC&3SWYH
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MI_PCNH:Q<_VI=WO]I7'G[)VR(N6X7U^]U]A744 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '*77PY\'
MWE\UY/H%HTS$LQ (!/J5!P?RKHK2SMK"UCMK.WBMX(QA(H4"(H]@.*LT4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M;JNCV>M6;6=_'));/]Z-9G0,/1MI&1['BH=$\.:9X<MFMM*MVMK=CN\H2NZ@
M^P8G;^%;%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gk2okx215f1r000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2okx215f1r000016.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" R1!C\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HIH4')([GU]31L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\
MC1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/
MY_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;
ML7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T
M.HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT
M .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_
MG_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&
MQ?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\
MC1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/
MY_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;
ML7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T
M.HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT
M .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_
MG_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&
MQ?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\
MC1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/
MY_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;
ML7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T
M.HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT
M .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_
MG_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&
MQ?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\
MC1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/
MY_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;
ML7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T
M.HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT
M .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_
MG_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&
MQ?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\
MC1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/
MY_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;
ML7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T
M.HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_G_C0 ZBF[%]/Y_XT;%]/Y_XT
M .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^-&Q?3^?^- #J*;L7T_G_C1L7T_
MG_C0 ZBF[%]/Y_XT;%]/Y_XT .HINQ?3^?\ C1L7T_G_ (T .HINQ?3^?^--
M8!1D<'/]#0 \=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ IC]/Q_H:?3'Z?C_ $- #AT_$_S-+2#I^)_F:6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4TLJXW,JYX&2!GZ9KEO''B)/"?A36_$$FT+IEE+<9=@B@J,*2QX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,?I^/\ 0T^F
M/T_'^AH <.GXG^9I:0=/Q/\ ,TM !1110 4444 %%%% !1110 4444 %%%%
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MC;]H"X_:+^$4'C&^\,VWA'4--U6\\/7FA64_VFTLY=,/D[+><,P>,;=J[3@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4Q^GX_P!#3Z8_3\?Z&@!PZ?B?
MYFEI!T_$_P S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ,D"M'(LF-C(ROGIL*D-GVQG-?E;\1_P!A:3Q#XYUCQY\ _B?J
MO@Z#7)Y8_$.A:/J9BT;[=(?])N!!#M1;MLL6)&[)P>>:_4G4<_V??[=V?L=U
MC:,MGR'QM'=L]/>OY^OV;O$?_!0FTL_B['\./"V@ZKX1A^)VN_8+WQK>_8=3
M6#SY-HAAGE1WM H&Q]I4#[O4YERA1G'$T,_S?AO-J5X8#,\EJ^RQ2HUG&.-H
M2<:.)J2IU8*E>,:$XMQ7/*&EZ4,564J"R?)<\RZHN;,,NSZMAL/@*KI^]AYR
MJ8RKA\/S4Y\\DG7A5WE34E&:/U>_9-_94\,?LN^%]<TW1]1U'6=;\7ZF=<\3
MZMJ<QGN+O4GW;V5SSL)=C@DGISUKZSKY;_98U3]H?5?".JW'[1&C^'](\1?V
MCC2H_#UTMW:3:=A\2/(COAP=HQQWKZDJ*-.-*FH0Q-?&ZRE/%XIU98G$U9R<
MZU>O*M&%5U:E64Y5.:$/>;M&*LE52IB*LN?$TL+0K.,$Z&"KX;$X2C",(QI4
M\-7P<I8:K1A24(TY492CRI+F;384445J9A1110 445Y7\0_C-\/OA=]G/C77
M[/11='$!NYHX1)G/W=[#/(/\ZUHT:N(J1I482J5)?#".[MO:]CFQF,PV H3Q
M.+JJC0@TI5'&<DG)V6D(RD[OLF>J45^95]^VKIWB?]M'X2_!+X>:K;:_X7\2
M^&K_ %37[NRFCFCM+F 2O$CF-FP2JKP>^>AXK]-:UQ6&>%E"G.<75=-3K4DF
MIX>;;_<U$_M\G+/33EG'K<SP&.I9A1EB,.F\.ZDH4*VO+7A%1O5@I1C)1YW*
M'O+5P;3:9SGBT>'#X<U=?%IL5\.O9RIJIU(*;(6KKMD^T;P5V8/.0:_+74?^
M"7/PJ\;:O>>*- ^+7Q&M?!7BBY.I/X8T77I(_#%S9S.6-K;VJ.L?V*494HJ[
M2.U?:G[8UAJFJ?LT?%ZPT6*>;5;GPE?QV,=L&,S7!"[-FSYL@CMTK\C_ (0^
M$OVJ-&^ _@&ZF^.'A_0-,33DL8HM1UZ&W?3KEI#Y=E=;YP\4ZC@HZALXKDOE
M4)<U?..)LES&K&6'^L<-95FN:UL3EU96K8/%4\HHUZT*-6=U^_C&G.[C1G&J
M=TI9]&DYY;ALBQ6#A.%2K'.\\RG)*=+%4FITJM"KF\O8UIJ/Q1H+VD4DZG-3
MT7[E?"_X;^&OA)X'T'X?^$;46>@>'K46MC#QG;U9W*@ N[99CCDFN_KRGX)6
MWB*T^&7A:#Q7K-MXAUY;!3?ZQ:3K<V][(W(EBG4L)%*XPP)KU:IITJ%"$*.%
M558:E&,*'MJ%;#5O915J?M</B+8BC4Y4N>E62JPE>-3WTRJE2O6G*KBG3>)J
M-SKNC7I8FC[:6M3V6)H?N*]/F;Y*U']U4C:=/W6@HHHJR HHHH **** "BBB
M@#YW_:A\3?$_PA\)/$6O?"+0K/Q'XTL;:273=+O85GBG=(V8#8X*D@CCZFOY
MB-$\7^.OCI^US\(K/]L#_A(?@_H<UV+W4%@N)-+T&[UNVN<Z?:*T<;0KY\@1
M=K #!Z]:_H _X*(?%3QA\,OA'HB>$KB\TQO%_BO3_"^KZ[8INN-#TO4,I<:B
MA_@, ^8,< $"OR__ &3=1^!]I\2O'_PN_: \5I\:[2/Q#IM_X'\7^,!&UQ87
MDSK/';V<I*O^ZE8("L@VD#@\"KE0Q->E*EA*>58YXB+HXG!O"4\)F$L)>,L1
MAIYU[&LZ]7$4.>I@<OQ/L</&5*56%7VO*CE>.RS+\7#%9A+$X&I02K8/,:;Q
M>/JTZD7:E6P>62<,MH488B4</F.)G*>*J4ZT8TZ:@I3/WS\=6WBF/X8ZE:_#
M"2PE\1P^'XH?"\NIXFLI6CM$2S>9B"KK)$$.\C!W;L<XK^2C]H7PM\>=0^+/
MP\O?VI?"_CRX@A^(*?\ "7ZCX/W_ /""CPO]L&TW<=N#']W&X./Y5_3S^UO\
M0M<^$O[-7C'QAX#M9)]1TC1]/M](CM%,CPVEP8;5)H0"2?(MF#J<GA1R<U^*
MW[._Q;T;X??'.XTKXO\ Q:U'XM_#OXF^$+35]5T3Q8D,^G>&-8U!%>:RB,H8
M(;>5RH7<.!]:BIA,5BL-4P^"Q&73E64L/5R3&Y?2Y,RIRBHK"9CGU.E4Q^6X
M3$0=:G0IX51C6Q,+SE&RNYYAE^ Q-'&9A1K473_>X7.L-B,=]>P3O_M%; Y9
M3C4RO,9X=>QKUZ&:PY'!P5%M\Z/V6\?^(-<\(?LP6.L_LW:%8Z]+IWA>VE\&
MZ3<0++;S626Q,*F-UP7! !!7[V>M?S;1^-/B'\=OVK?@]IW[8*>(/@[X<N]3
M%QJ[VDS:7H-QJ5I= Z?;[XHVB7[1(J( R@'<,D U^]G[:?Q1N_A7^S1X4O/@
M\7TS0/%&LZ-X:M]3T=-ZZ%X=U4,KZA; ;@JVZ;F4DX7!YXK\T?V5]2^"FG_%
M/Q_\,?V@O%Z_&_29]5TO4O!_BCQ@J/+I=_<-'.+:SEW*V8IB47;("I P*(8*
MNL-'!X'"Y15<J7U.ME7U:-#&TL'!0A7P']O2H5:F(=7#QFL!@<9&C1<J,JZJ
M*JU$)9EEF%Q<,?F&)QL)I+%X/.W#$8K$U*EU*GC<-D\)1RK#+ZQ*G',ZSE/$
M>SQ'LJ%+V<7(_HTT."QM=&TFVTR47&FV^G64-A.'\P36<=O&EM)Y@X??"$;=
MQNSG S6I6?I,5C!I>G0Z8JKIT5E:QV"IDHMFD*+;*AR?E$(0+R> .36A1;E]
MU1<4M%%ZN*6G*[:76SMH=/-S^_?FYO>YDK*7-K=+I>][=""ZN$M+:>YDSY<$
M3ROCKM0%F_05\)?&N#]CO]HS3&\*_$CQ)X.&I:3J,%Y+'//;V^MV%U82AXRT
MC1&10'49^9N,=S7W/J-Q9VMA>7.H/'%8P6\LMW)*0L26Z(6E:0G@($!+'L,F
MOA'QU^R_^RY\5;ZV\4VS:-I>I:]]HN!?Z5=!9=96V+/<E0+E1-LPWF&,$#O6
M.)PV"Q&'E',^'<VX@P+ERSHY)BL%@\QIU.5RBZ5;,:E'"QARJ4JMJU.KR1:C
MS0<TJHXJ>&Q-*6%SW"9+CU:=">88:MB< XJI!.IB(X3FQ;<:CA3ITZ=.I3G*
M?OQ5DSZ$^'OQ@^$.I'3/ 'P_\7Z3XFFT'3[331;:5="YDM;6SA2WA\_"* 0B
M*"1QUX KW>OEK]GCX,? /P387.N?"72]+GN&GEL-0U^U<S7%Q<V[%)HI9#)(
M Z,,,O8\>Y^I:Z)23DU'+<9E,(6C# YC7H8C,*$4DE#&3PKEA?;1V?U>4J=K
M/F;O;.#C**JQQ\<Q]M^\EB*6'>'PSD_B>%A/]\Z$G>4'B+5=;2C&U@HHHJ2C
MEO&UUK%EX5URZ\/VT=WK5OI]Q+IMM,H>*:[2-FACD4@AE9@ 17\DO[7/QF_:
MB^)'B?3O#'Q^\):Q\-/!O_"P(-&O?$GAJ/[!9)X7:ZV2W5U);H2H$(R693@=
MJ_J,_:9\<Z_\-O@9\1?&OA>UDO-=T'P_=7FG01(7D:<#:"BC)+(&+C'<>E?S
MT?#+QMX5LOCCX8USXZ?$?4/BOX&^*OA5]2\4^"/%"1/I'A+5;IFWVZ*^1&T#
M-@+\K<=1UJXT\5*$OJ#RFKBYWHT\/B\%&.*_>QY6WG4:->M@L+B8.>'CAG3^
MK8G$.*Q$Z:2;Y*V(RW#5J5;-(8BEAX?O(8VG5QE=T94FISG@<JIRA@L1C\*E
M3Q'M\=-*E1;C0IU)MH_H@_9RT#P)X8^"_@'1/AKK;>(_!MEH5HFD:R]U]M>^
MC:)&DF>XVJ79I"Q;*@J>#R*]NKS;X1V/@'3OA]X=M?AC:V=EX(6S#:%:V!S:
M16SG=MA^=_ER3P&(!X&.E>DUG&E&A&-&%"6&C22IQP\Y1G*A&"Y51E.'NS=-
M+D<H^[*UUH=CQ'UMO%>V>)^L/VWUB5/V3K>U]_VKI+2FZE^9P6D;V6P4444Q
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Q^GX_T-/I
MC]/Q_H: '#I^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %>\9TM+IXTWNEO.R)C.]UB8JN/]H@#\:_F8\?
M_M+?&EO&LW@O2O%FM>%M?\<?$O4?!^M^#;#2;B&+P_X5$KJGB@R0J!\R /YA
M'S8R3FOZ9KR;[/:75QC=Y%M/-C&<^5$SXQWSMQCO7\HOQX^/WQ;G\;7GQ]\'
MWW@NTN?$OQ)O?A#:>%+C283JMMY,[6@U9G,8D3(.[S3QCG/%=6$EBZ57VV$A
MA7-)TG7J<\,1@O:IWQJJT<#C\1' T*<:GUNGAZ<:LJTL%4@Y2HJ#X\9+!JFH
MXV.%E2<HRY,?B</1PF(Y91?U2E3Q4H8>MF5>7)+!JM.E!T:6,I3JTX5I27ZV
M_P#!+SQM\0M>T+XV^$/'/C*_\=6_P]^(+:#X=UZ_259)]-\N9R%,N2P#*HR.
M.*_5:O@+_@GY\)/%'PO^'&OW/C'Q5H?B?Q!XPUA-?OFT6..-=.>XB,GV2Z,7
M#3+YO/<8Q7W[7//$UL7)XBO'%*K.U_KL*E/%3C!*%.I656G2JRG5IQA4=2M2
MI5:RDJM6E3G.45T4H8:%.,<'++)X?XJ<LGJT:V6>][TXX.6&C'#PI1FY1]C0
MYJ-"2=&G4JPIQJ2****DT"BBB@ K\-/VX_$?@S4/VDO%'A?XJVDUUX/T#X+7
M_B714DDF@MGU^WCE:)8I$=4:8LHPO))/3C(_<NORM_X*"_LL^*OC!/IGCG0I
M[!].T"S9==T@%(-1U?3X\O-:)<2 !DD0%1$7YSP*RJXFEA8<^)I8*KA9N-'$
MQQWMO8>SG)6UP^6YK6C-U53C%T\%5>K3Y4W);X;VWM.?#9EBLIQ5.,IX;&X2
M,9UJ=9*RBH5,QRJE)3@YQ_>X_#4XNTI3LK/X$_9$U7X+?\-.?LGZG\.--2W\
M1^-/ VNW/B8B5[FX@DMS,L:7!9G,)*@87Y?\/Z3:_G__ &#/&_['5Q^T5IG@
M3PW\-?$/@SXY^'--NK6S?5EFDM!;QADNS92%6AC64JS (PR#]*_H K>>%Q.$
MG*GBLDP60SGRUXX3!XS"8U58UX1J_6:\L)A,%["K4E*2CAL10AB:5&-)5%'W
M8J:F+EC.2K//<PXBJ*$:<\?F&7XC 2CR>[##4/;9AFE+&4J-/EC+'8/&UL+B
M*[JNG)M2/%OVB-/\9:K\%_B#I_P_56\877A^\CT-67<K7A3Y00>N5##ZU_-5
M-X(UOQ_JNMZ1XJTO7(?A[X:^'NJ1>+8;/4+Q(S\8XED^RSXB=1;1"XV$\!1[
M#-?TC_M->/-;^&7P)^)7CGPZN[6O#OAN\O[ >69/WR*!G8H);:I)P >F:_E]
MMOBQXEU'XK^$/ASX3^/'A3PYH_QS\,R>+?BO<:K;AUTNZN6;[79Q"1/W%X 6
M"L5#*1QWKLPE+,JD*RP..S/#PG'DK4\IR7-<UK12M+]]4RG,,)5PWUYJ.$P'
M/AL:YXQ<M+ZK)RKKCJPPTJE.I6P>%G5I-2HXG%YQ@\IIN[M*WUW+,QC7^H1<
ML9/DJ83V<).53ZS%JD?T6_\ !/\ L?%.F?LH_"VP\8LSZY:Z==13%[DW;_9T
MNY!9AIV9B["W\L'+$CO7V97A'[-/A?PWX-^"W@GP]X3\0GQ7H=AIP6UU\R-*
M-19FW33*[ $J9"P48X& ,CFO=ZXYRQ$IREBUBEBI2;Q"QV'EA,9[9N]3ZUA9
MUL3/#XCGO[:C+$5Y4ZG-"56;3D]HJC&*CAO8_5TDJ/U:K[;#^R2]SV%;V5#V
MM+EMR5%1I*<;25."?*BBBBI&%%%% !1110 4444 ?-W[4OPSF^+'PLU7PE;R
M6D-Q<_-#->-'''$^QP'624@1LN<AL@YQ^'\_?CW]EC5?V48/#?Q?\36^E>/-
M,M?&.DV,VD0ZW;-/YEW>(([G"3&20P9W;=O;'M7[M?MJ>*_"?A/X-:E<>*=2
MOK(7]PEAI%KID[6U_JFIS*P@L+:5"KB28D!0#UQ7Y&_$+X _#[X<^ OA?\5O
MC;H_Q*UKP=XD\0Z5<S>'[O7;N:/P[J-Q<QOIS:C%)( 4=F5P&R"N0,UE5<:%
M3"OFSBI7QM7DPN6X;@W@;-\JS*K3:A[/,<_S[$4L[RFA>:IU<3@X^SPZE>E/
MVK43OP>)Q;HXNE2Q=#"X/#Q<\;7CQ)Q9EN88:$Z<JGM,%E63U*678^MRPYX4
MZLW4K-.G4BXV3_<#Q5I47Q)^!XL+:&&WB\2>$M.>"&ZV^5;K<V$+QQN9/E_<
M[@H9NZ@CG%?SX?%;]A7Q'\)M \8?%W4KO1_$VF>%'?6[G0$UJU62\M8YBWV5
M/WY*C'W44< 8QUK]YOC9XV\(>"/V;=7\5WDL]GX5M?"&FFS-FYCN$M[FS@CT
M^*)TY63YHTR,?,.O>OQ!\3?LS:UK'[-6O_M ^,[OX@R^&&N6US4/!+>(+IWU
M?PFTRO%,J;]OENA#;21@?2BO/"X7V.(Q>,S? U*]=4*.%RW@?A'BS"8VK2<9
M/#X[&Y^WC\KPT)584ZE?!1M"G6=>#<XRMCA,7F<?;4<MI1KT(4E7Q5>7%/$&
M08JE3J/DISPV&RK%X3#X[%U(TZDZ4:\[<]+V=6=.-2'/^IFGZ+;_ +1O[$O@
M:WT?3;;P]%KGA2Q>VT^]EC\K3&B1X@BSRMMRA;*R!L\G!QFOQP^(O[)^K?LL
M:;I?QD\1Q:3XZTO3/%>EV\^BQ:W:F=VN[R,1S#;.7D,)YVKV%?K'K'C[X4Z5
M^P9X!UVS&I>&/"&H^&-.LO#.CV]R]OJLMY(LT=OI2S(5=KF:4-ELDDG-? ?Q
M ^ 7@+P)\,?A[\7OC5HWQ,UCP5X@\0Z7<WGANYUV[E70;J>ZCDTV:_C=PIBD
M)5UW9!Y7/>G7:PU;#RJ1S6EB<76]G0R? <'<"9WDV,KTW&'U;&9]GN)I9OE6
M%A*HJ,\5@(^QP].2G1J>U:3UP6*Q4J.*IT,=&E@J$/:XS%U^).+<KS:C2J4W
M4^L4,MRBK# YAC'"FZGLL16G6K58NG4<DS^@'X?:M#KO@;PAK-M;FT@U/PYI
M%[%:G.;=)[&%UAYZ^7G9GOBNOKEO \VDS^#?"TV@Q^5HLN@:2^E1?\\[!K*$
MVJ'U*1;5)[D$UU-:OF3:E!4Y)^]3B[QA+K"+3::B_=33::5[G"FFDXRE.+UC
M.2:E.+VE)/7FDM7?6[U//_BMH]]X@^&GCS0],R-0U;PIK=A9$,4/VJZL)HH,
M,.5/F,N".AK^7:/XJ_M+?"[6OA5H$'PFO?$&F_ VV\8Z?XMO[?5KB9;IM:^T
MI9O<F.8A0GF _-C;]*_J;\?6VLWO@GQ7:>'G,>NW.@:I!I#@[2NHR6DJVA![
M8F*5^'GP2^*WP?\ @IX!^+GPY_:#2XTWXS^)AK\6O/K%PT[>(I;A9DTQ-)+"
M0QR;V0*!LY(Y[$CF&9X*3CE%7(:N+G!3EEW$+Q5#"5,-3J0]OB*&)PV9Y;)U
MW%_5*E!>WFL/B*F(Y%"C*252CAIT?:8ZCG'U2%3D^L9%@*N:8U8FK"4:%*I@
MZ&$QE2GAX.^*6)=)4W7P]/"RG%UU)?87_!*F#QI_PS1-JGCK2UT;6/$'CKQ/
MKD>GK=F\^SV5_=F:V0S%G.51@"N?EQT%?I?7YI?\$K] \8:!^S?<1>+=.U/2
MUO?&FOW^@VFK3M<7(T2XG+6<@D8D^5(A4QKP .@%?I;4QK+$)5U7P^)]K[_M
ML)&4<+4<M9/#QG7Q,E13O&G?$5FXI/VD[W=SI3H2=&=.I2G3M%TZT>6K&R5O
M:PY8<E1JSG#ECR2;BTK!1113).,^(6B?\))X,\0Z'B(_VEIMQ:CSPIBS)&R@
MOOPN <9R:_G0^*O[ 7B7PA:^.OB=<ZIHFL:?X;BO/$,FB#6;2-KFUMF>9K)!
MYX,8=1M5% R2 !WK^AWXM:SH7A_X=>+-8\2ZBVE:)8Z1=3:A?JYC:"$1D;E<
M$%6)(4$$$$BOPCD^!NB?$7X1?$+XYZG:_$ZZ\ 6EW>R3Z%%K]X#XD\.1NQGU
M.UCWX-H8P6(!P%YK'$NEAZ=/%5L1G>'4ZT<-3AE/!?!/%5/&54U..&Q5;BJO
M2Q. I7DO:5<N4E2ISE7J2C**9W9?B,;[2KAL'5P=-*"K8EXGB3BC(:E.@WR.
MKAXY!*G1Q59<LE3IXJI&3FHPAI(_6K]AKQKIWC[]F7X;>(=+T/\ X1RUETU[
M4:.)#,+1[23RG"RY(D5R-P8$@YKZWKY;_8RN_AQ>_LY?#J?X4:=<Z5X'_LUX
M])L+Q_,NK?RY"LZ3R$DO()<[F))/?UKZDKHDIJ353#T\)43]_"TG3E3P\NM&
MG*C*5%PIOW8NE*5.R]R4HV;X>>$_?I5ZV)IR]Z&(Q'M?;UXO:K6]NW6]K4^*
M?MFZO,WSMRNPHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IC]/Q_H:?3'Z?C_0T .'3\3_,TM(.GXG^9I: "BBB@ HHHH ****
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M^'_Q \(-=:]<^-O!7BIM'\<-K;.P.KPK)&[:?O\ ^73*$#;QRO%?J-7YU?\
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MD/&'_!5CXG?M7W6IZ);>&/A[\-+W3&\ :;(8A?\ ]F7MTBBXNG!RQ:W_ 'C
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MSXZ^%GPG^&\NI^/?[*TWX?I FFS1300C3([66,JL(@VF+RRF<(JGT S7S?\
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MHQ<,'RKZK%J,7&A;]TG&,81BU"UXQA",7HHQ2LBBBBI*"BBB@ HHHH ****
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M7MVA?MO> IPD>N6EY;3.!DVZ!E4\@EL\8S[_ $K\M\ ]0/RIABC((V@9].*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !3'Z?C_0T^F/T_'^AH <.GXG^9I:0=/Q/\S2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445R'C3QOH/@71[C6-=O(
MK:&&-W2-V DF91D)&#U).!GH"1F@#I[JZM[.&2XNID@AB4O))(P554#)))('
M0&OBKXS_ +7&A^%OM.B^"W75M6&Z)KV(Y@M9N>.IW$8Y.#CT!KY)^,G[3/BS
MXCWESI>BW$ND^&XY'2+[.[1SSCH&D*D9!'&2>1[=?F<)\S2.3),Y+22O\SNQ
MZLS'DGZT =IXP^(OC3Q]?-?^(]9N9F9F(AAEDCAVMNPK1C:IP"!R/Q]>+6-$
MY50#R<]SGU]>M/HH **** "BBB@ J:W.&D/H.W)^Z*AI.02RY!(P<=QS^O/7
MKQBFMU?;J!_FT_\ !3/7=9\*?\%%_C1XET-9H]4T;QI!J-C((I&*36Z(T<FT
M#)4.O7ID8SFO1->_X+/_ +<_B+P1+X U'Q=)+X?ET>/0VMO[/E!-C%"853<.
MXC) ./KFO[CO&W[ _P"RU\1O%>J^-_&'PZT/5/$NM.)-1U"YTZ"6>=QSEW=2
M2<^O/7U-<S_P[5_8W_Z)9X<_\%5M_P#$5Y.$XKX[RB6,HY=PKD];#UYRA[;%
M9OEM6I4I1;C"<8XG+JL\.YP;;A"=XMI.3:N>KB.&N!<SCA:V99WC98BC",E"
M.28IJA4DH2G",Z>/IJJHS5N=Q2ERWLE>W^=+\%OVB?BQ\!_BA/\ %OP%<36'
MB^XGN+A[QK65E\RYF:>0A<<9=CW/%?HTW_!<S]OYB6;QK)G:JY.GR<!1@=?:
MO[0/^':O[&__ $2SPY_X*K;_ .(H_P"':O[&_P#T2SPY_P""NV_^(J\OXU\1
M,LI3HX7A#(N2I4=63KYKE&)GSNU[3KY74FHK6T4^5:62)QO"7AYF-6-;&9WC
MJU2$(TXR>1XR-HQM9)0S"*T[VN[:];?FW_P0:_;=^/G[9S_'=/CGX@_MW_A#
M;:SGT-OLYM_LSW" LG4[F0G!Z-@<BOZ#AT'T'\J\'^"7[-/P<_9U.MCX1>%=
M.\,#Q'C^V#I]K%;?:MO(\SRU&[I_$>:]Y'  ].*])9CF>;)9AG&$P^!S&O\
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M"@M*,;4_LA1114E!1110 4444 5;ZSM]1L[JPNXUFM;R"2VN(G&5DAF4I(C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:M:QQPZG;[EWI.%PS;<[CD@Y.,<]:]LH **** "BBB@ HHHH **** "BBB@
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M<'_!03X8^(=6T'P1X^L-5\,WEMX-MK>WU#P'XSO8K;PSKQ95W378E<+(T."
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M2EAXU:DJ\+65G.M.4MZCF[M^0_ GX0:-\"/A?X9^&&@75Q?:=X;MGA2\NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:T.QUJ;XAZ%JUS=W;Z5/"DHNWTZSG*+*\3><%= SC!YR30!_4#17YC_LC?\
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MX_T-/IC]/Q_H: '#I^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444
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MRCGVIA=?NOF)N"!( ASU'!/Z=QFC1Z-73T:[I[K[AIM:IV?1]GT?R/\ /_\
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MJN'P^>UJ^'Q.(QD(RC2_LZO#-,DPU%\DYT\36Q>:0I4J51SCAL3448+]@_\
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MT$UJJ+KUG3^%U:C7,RBBB@D**** "BBB@ HHHH **** "BBB@ HHHH ****
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M)NI@XJ:CA9M^]02J?O$J3O!*?OI+WDI7044459(4444 %%%% !1110 4444
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M8[G/3C$TIY[\],?7-?I97YH_M[+C5? !&#E+DGH"/WLOXF@#X%HHHH ****
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M._&+PQ:3OX0\46\44,DL^QF2WOY\*[QLQVG<Q!0[3P./\Y?]H#_@BG_P4O\
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M?]W)N'0S=DVE3ITDG94J-_94TOL4[Z\D=H7UY4@HHHIB"BBB@ HHHH ****
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M85.=/GBH02E=**V%&49)2IJ"A))P5-)04&KQ4$M%!*W*EHE:P4445 PHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS^6&Q]2E2E7H8;,\C]G'+L)2G"52M4C@I1E3O.-%SC*3.6>,R:EAZ>%J<?\
M$^9X6-6<_J];*\CP7U2FIPPM?%Y7GL%/-YU\-*,*6'EB;TYVC4KQ4K-_SJ?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4Q^GX_T-/IC]/Q_H: '#I^)_F:6D'3\3_,TM !1110 444
M4 %%%% !1110 4444 %%%% !44\8FAEB/W949&'JK J1^()J6B@#\2_VDO"#
M>#_BIJL4,'E:;> W$$H&U7DE(<C@;<C/(['OC->%U^G'[:GP[N-9\.6/BK3(
M3YFC2[]2D1,LT PR;FP?<'ID#FOS$C<2(K@$!AD ]: 'T444 %%%% !1110
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M9M.G/,,-E=&MF$\.DI1_V6'M(U94Y.2@IFE"ACL155/+\7F&#KV;E5RG%X'
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M=:,7/SW@:TZ5/#8W#XRLH*,L5F6+S/'9IBZ=.G+FJ8J4<ERWA?$8J.53M&&
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M>C35H4ZU2"4V4444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF-/L+73+*VL+*%(+:UB2&**-0JJJ*%& ,#)QDGN>30!<HHHH **** "BBB@
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MM7WQQTGP[I_A[0+J%9=#BUW6[5U@#QLOEBT21" " JKC' K\D?@UX;^*6O\
MCJ?]GCX=_!?PAH7Q-\!>)],O_$OB;3M/@B\):=I;3I<R1M*JE%N6MSE0#DMV
M.:_9+PO^Q>WQ!_85_9]^ GBWQ&VC^(_AWX2\+O%XET*5;@6VN:3;RA;JRF#
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MV^"37-+EA2@N9VA0O["*OI&C>,/W:VA[L?=MH@HHHJB0HHHH **** "BBB@
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ME96&&4@]00<$5^=W[0'[*!N);[QC\/X?+N#NGOM(B'^OQEV,2C P,D\?,.E
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M[4=I$=U;1(" <%L*,^A/Y<GO7S-7W#^W!I9M==T74]I'VLJF1@;MK ;2>Y&
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M ***X+XE>/\ 3/AGX1U7QCK,<DFFZ/;O<W7E_>$2 LQZ'& /0]: .]HKX_\
M@C^VU\%/CSX@M?"O@O6XYO$%Q;S7/]FM(C3)'!D295><J0<_T[_8% !1110
M4444 %%%% !1110 4444 %%%% !1110!X=^T=_PC7_"G?&G_  EVCW>O>'O[
M+F.I:58O)'<W=N%.](WB(=3C/(K^-;]HS0/V1_&?PZ^(?A;]GO\ 9D^(EC\=
M]6O%@\#:VGB+5TAM]<%VA,ZNL@!8-\WE@YQQCG%?UR_MQ>/?&OPU_9D^)_B[
MX?Z&OB#Q-IVAS"STZ2 W,;1S QW$SQ!6++!&QE( Z+GM7\W5]^TW\)M*_P""
M=^H>+O"WQ:^&W_#6OA7Q-)XCTGPY!IR1Z_>:Y/>IYGA\1BW$[21EF1OWC*I0
M@KDUM2P>-Q5ZF5X/+L9C,);$XC$RPW%V,QW#V"IN\L]JT^'>),DPM#"86IRU
MH2QU'$QJJAB7*<(4?9U=(YA/!1]E7S3B#+L%CG]5HX3 9ODN699Q#CJC2CDM
M>&9<.YUB*]7%T[T*BPU;#S]G6IPITYRG*=/]L?AE\8_&7[)W[%W[)=E\5],N
M-0\=:Y9^$? _B&"\G?S]-U"^20.UU/,V]VMUV!WD/)/)QBOH'P_\6?AW^TWK
M/Q'^%\MS;VQ^&NLZ2NH2V^JPJ\]RZ+<1E3'-D(C?*V#CD#.>*^8?&7A7Q5^U
M-_P3V^"_B'X@>&=3U3XCZEX2\.>+K[3-)<VU[:^(1;3,9(F;:8@A"'G!7(Z5
M_.YI&N:E\%_V@-+\&^!_ ?Q>\4?$CQGXSTAO&>EZ1JM[(]I''>1QM/J#Q%DD
MAAC&7#';M!'/%70S?)4J^#SBOG$L0H*K/B7),LK8BCR56I_VG+,'FF7T,%/$
MXF,:.'C5J.<J>)<X3G5C&+Y:N4<05)TL1D>1U\3%R]F\F>-RV'L)TK0E@EA,
M3-XJK2P=&4ZN)Q%'"JE3=&*K.$&W'^ROXP>#[/Q5\)O$'A&318_$EG=:.EDF
MDRNJI>I#$JQ*TK':OW V\MQUS7\C'Q_T+P;\'OB'_P (AX?_ &6-;\8?%K6]
M0CL[#2M#\17%TK6S7 ")+>VLCB"-5.3$S +C&*_K/^*6IIIGP#UF^U/7!X,<
M>";<3ZI=R^4^F74VEQ*8WER"MPLS&+<#GS1FOY'OAQ8?M8_!OQ/XS^)_A_P)
MXF\2>";KQ/<7TOQ6\5+<:C!IVG2W;$:E8W<R.8;,H2T05P ,8]^27L\,Z.+A
M4S.GBZ^(HX3+ZL*6 CEDL3S<U.MCZU?'8;&XNIAU-N.!P4J5W652ICJ$7:IT
MPP.*S-5L/2PN!Q5'"4)XK,*$^+^(.&<PCA7RJI]4EE<)Y>J<Y4U&M7Q5'%XB
M=.$J6%PDI\LX_P!='[-MIJ]C\"?A?:Z]X:F\':Q%X2TQ;_PQ/.US-HL_EY:Q
MDG8EI'B& 6)SD\U[?7C_ , ?$\WC+X-_#SQ-<:G%K-QK'ANQO+C4H3F.ZFD0
M^9(I]-V5^HKV"M)QJ0G.-9WK1E*-5\O+>HFU-\JJ55&\KNWM:EMO:3^)Y0<'
M&+IJ*IN*<%"M5Q$%&RY5'$5XPKUXI62K5H0JU$N>I&,Y-+.U;5M/T/3KO5=5
MNHK+3[*%Y[FYG=8XXHT!9F9F(4<#C)&3QUKY!\7?M^?LR>#-)CUO6/'D<=B^
MK?V.SQVDLDB7/F"/S&B4EQ;[O^6^/+(YS78_MD:/%KW[.7Q*TR?Q&OA2.XTA
M,ZXTAB6T9+B-T4ON7:)F AZ\[\5^'?AO]E?XR>.=/\3_ ! U#P-8ZMX:\3?#
M-? '@K2W6S>&35 GE0^-5BDROF2_++YXP^2>:IYGDF74E+-*.*JUJM1QPZA7
MJ8:C5Y8J<J2G3R_&)RC352I6G.I2]A'V+C"NZKC&?J&:X^JX9?."I0A!XAPC
MAG6H<TW&FW+%XO#TV\1-QIT*=.G6;]G7E5=&*A)_T1+XGTOQS\.)_%'A"_AO
M],U[P]<WNBZ@&"PS1SVSF"7<20JYQG)XP>]?B5^R=^V%H'PL^)GQT\)_M,^(
M88ET_6Y#X5D@\,R7ULEF+DF0'4;>%ED/EC!R6 .=S"OU3_9N^$^O>"_V7? _
MPE\8W3C6[#P9)H&K7-O)B2*2X29"T4BDX:))0$*G@J,=*_*KXR? ;X^_LR>'
M?&.I:?X@^%NH_"V_NIK&WU7QCH46H^(++^WI# IN+V>%G=T:4"(AR00,8Q7+
M/%934K4.>2P]'&R3P>*S"5:G@H4:CC*EA\34PV68_%?6<1S4X45]5P]%23J5
MJD%'V;[*5.&%A5KX[#X3%5,#"2G*A-T\SH5U%PJ8G+9NJ\/*@O?CB*;]K5G2
MDE1YGJ?LG\+/%GPG^+>@VGQ%^&DFEZGI5TTD<&K6%G%:R/(HQ)')L59 R]&1
MSP>HQ7\O?_!5W7OA\O[2C^!->^&FM:_/>6ZW;:YIMM<26.YG7]W.\*&)3Q@[
MCD5^R'PT\->*_P!B;]@KQ/XDMM9L?$7B6*UD\;0W=E PTX#6Y()$CMX-@VQ)
M%,64*F NWW(^<=>_:3^&/B"[UK2O$.E>#]3US6?V?IOB%>:UJEC:WEY;:XUL
M9&MK>XGB8P,K\"-2&!QZ<=$,OGC*%7$\/93%.O7E)Y?BLTQ^58G#TYJ'/5Q.
M,R7#4L75G5UC1I4ZF&HXBI!?7:-2C"5&7#6S3!Y;6I4\_P PH.FH6ABX0PM?
M"UZU[\U"CFU7V#IT.:,ZU2MAJU>E"IS865#$.%6'ZA?L66EA8_LQ_".UTNR;
M3K"'PM9K;63##6\>W(C.><COG!YZ"OJ2ODS]AWQ/_P )C^R_\*_$0"!=2T9Y
M4$:[8PBW,J($7LNU1@>G85]9TI0=-NG+FYH-Q:G5C7DG'1J5>%*A&M)-:U8T
M:2F_>5.%^5:QE&<8SCR\LDI1Y/:<G*U>/+[6K7J\MK6]I6JSM\52<KR?D?QV
M^)\?P:^%'C+XERV1U"/PII;ZBUF"5,X1E78".1][/'IWZ5\Z^#_VLO _Q;UW
MP3\*;U;6QU+XH_#B7Q6ZC4H%EL[2XB^>WQYN1+M;C@.,=/3Z.^.7@ZR\?_"C
MQMX/U&QEU*TUW1+NREL8/]=<AXR5CC)X#%@,$_F.M?QM?M#^'A^S1\0XM9N?
M!OQ4E^(MM"_A[P3X=TO5KF2_N-+>3;%!:BW9S"CC "8  QWK?#9ID^&J2P>;
M87-N6K3E5AC\IRRKF$\'1LJ>(Q.)J1S#+Z6"I8&%L13K5ZL:<JDN6=2"Y695
M\LSK%1CB<EP=;,*T)JE+!PQF P_MYQM4HX>CA\955;%U,5-NG5CA:-6K3I1Y
M]%=']J'@?PQI7@[PUIWA[1)C/IM@KK;RM-]H+!W+',NYMV"2.M=;7R-^QEK^
MM2?LJ?#3Q%XWT/6_"6ICPM_:.K:1XFDDDU?38T1IF^WR2X=G$0\PEL'!KZ"\
M _$/PK\2O#Z>)_".JVVK:,]U<6:WMNX:(W%J_ESQ;L_>1^"#@Y.,5FJ:J4YX
MC#5,1B\&IQC3QF)UKUHU%)T:F(E[6O>O6A%SG^^K7GS?O)_$W*I.C5AAL926
M$QKA.57":.-"I2Y(UZ2G37L?W,Y*"Y6DTKQ5D=O12!E;E2&'L0?Y4M9FMPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^!Q!/<6JZY?P;2MU>IDAEZ,!N.3^7TQP?I&&&*WB2&"-8XHU"HB*%55'0
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M &*GA_\ ]-5K0!V-%%% !1110 4444 %%%% !1110 4Q^GX_T-/IC]/Q_H:
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MX;36(-'6(2_;8)[59X+?RMK*P9'4%=I&.@K^.'XH_M=:S^U!XQO]$U3X-/\
M#OPW'X@-JB^!]-.C^);\+= !VN(8XF+OC).<<FM\/A<5B:<I/@[A+C%4:L:L
MJ&;RSW^VL-7A[T\7E.&RW$X7!8VE12YZ^$Q&)PE6?,O98E)-&%:$)RC&GGF9
M<.RDE&ECI8K),-P^HJ2DJ.83QT99C#%5(WAAJF&ISP\96=6/0_M0^'OB.7Q;
MX*\->))M,&CR:SI5M?/I:NLJV)F7/V=9$^1PG3*\=ATKLJ\-_9HT^WTKX"_"
MO3[2/58;>U\(:7%#%KDC2ZM&@BX6^D8EGGYRS$G@BO<JXF^9N7LU2NV_91IS
MI1I7=_9QI5*M>=-0^%4YUJTX)<LJM1IS?2M$ES^ULDO:\\:GM/\ IYSPC&$^
M?XN>$8QE>\8I-(^>OVJ/&FG?#_X%>//%.K)-)IUCI\<=VEO(T4IANYX[9@DB
MLK(<2_>!&/I7Y3^(/AW^R"_PY\2^ K;P G_"6)\-4^,Z^)IKJ-O$$-Q<Q_:L
M1ZLP^V(%?_EF)=H_(U^O'[0'PGM?C?\ "3Q?\,;R;[-#XGL!:_:.?W,D<BS1
M/QR,21KDX-?BOK/_  2P_:1OM7UK5+3XO:5"=4\&I\/E4M/F/PQ&/+2(YBP9
M!%CCU]<FO.QU?(W[&AG>3YQF2H5%B\#5P&&Q6-I83%\T>3%TJ=+,,)#"X_"N
MC&5#%1A*LO;+EFN1)=V#PO$$_:5LAS?),NE.U'&TLTS6.42Q-"/PT)3_ +.Q
MTL7A*ZK58UJ,I0IQY7>,G49^M7[+=WI/BW]E[X=RSF:ZT75/!_V>;[;,US++
M8-YUO(LTSEFD_= J6)/'TK@-"_9"^!C^$/B=X%*Z9J/@GXC1WD4^DO<P,VF2
M7:.LS6K-B2V<,Y(V8'J#7M?[/OPD;X-? KP-\);Z^74&\*>'(]%NK],A;@C>
M995R 0#YAZCKGM7QC\2_V-=#U3Q5J/B#P)\:-?\ #E[J<SOJ.FS>(9190[V)
M<6T" "+&3VXZ>]=-2&78W_:LTP_%E3"5J4U7>38.MG68RIXFTE1S++WCL+4Q
M;YU"K.O5Q<YT<1256TJJYUPSQT\FY:-'-^&,OKTZL%A(9MC*65X"6(P[M]9P
M&9RHU8X2,*?/2BJ6";JT*OL_<IMP?M/[,O[+?PR_9<^"-]^SUX$UH-H][>:W
M>62"^%Q=6LNK@L%#(WFJ(F*[>!T&.:^+O O_  3F\4^'[3XE:[\9/C!KNHVM
MUK]]K&D746HWJ#2-!\UI4M]J9SL3@X[ ]*]SMO@I8?LH?";XA_&G0O&6O>//
M&FGZ-)=6TNKZI+J>D+=*0BK#;LIP/-8$^@&,<UXA\-?V\/C3I/A2V?\ :+^#
M>L^*=#\76_VNS\1>$K2%-$MM)N<J(+]#"V7V, X(!X.3V.^%A6]GAL+DO''%
MG#-.<E0HY=C.*<5PEG7$*H0C.-7,*[Q4Z>#KX9;SQN:\[;2G*M;V:TE.-=5L
MRQ'#V0\3QE'ZS+'X'AW#9UE^30J_Q5@:=2%L92K[VP6!?M(\KIX>G=L_5GX,
MZ=HFD?#7PMIOAW59=;T:RT](++5)F=Y;N.,D>8[2?.6)R"6YKU"O/?A7K6@>
M(? 7AW6O"^G_ -E:'J-BES8:?L$9MHI/F\LH%4 @YS@ 9KT*G+G4FJLJTZB;
M52>(QBS&O.=_>E6Q\6XXVK*5W4Q<6UB)-U5I,RC*,HQE""IPE%2C".&>"C"+
M5U".$E&$L*HK18=QBZ*7LW%.-CQ+]HP>/#\%?B"/AEO_ .$X.@7?]@",D2&Z
MV<A".0QCWXQSGIS7X@Z;\9/V/M!_9;^('PV\;W*1_M":AINI7&NZ?J&CW=QK
MT_Q$99?LYT[4%@=XU^U;<%94PI.03@5^_'Q"\;Z)\.?!VN>,_$;^5HNA6;7=
M^^0-L (5N3D<[L?C7Q_?7G[(6M:G#XKO? /@F]\1WWA.7XBQR2:)I<FH7.EP
M(9GO&D>W+O* ,^8<^_:M53S1TE.CECS? \U3V>%IYK#*)X;,8Q@Z>83J2I8B
M.*I8>#A*5"=&%16<L-B:575$<7EV%JMU<5BL!CI*G"=?"T55>(P-2;4L)4YH
M/DO)3E2G"HDIMJO3J4[1$_8DU'Q5I/[$W@[5O',5Y%K-AX6UJ_GBO6D-VMC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"O\ /E_X/-O^1C^$/_8/M/YBO]!JO\^7_@\V_P"1C^$/_8/M/YBN@YC^(O\
M9N_Y.#^"/_95O /_ *D^F5_NN_#S_D0?!7_8J>'_ /TU6M?X5O[,%J;W]HWX
M&6PSF3XK>!>G!^3Q'I\G_LM?[J?P^4KX#\%J>J^%= 'Y:7:_2@#L**** "BB
MB@ HHHH **** "BBB@ IC]/Q_H:?3'Z?C_0T .'3\3_,TM(.GXG^9I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'X4U)I(&) DB$)\U3]4S_P#KQ0!_.+_P28\86>N?M0Z/H2^'M.MWTW1M7/\
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M^H*^9/V._$_BKQA^SG\,_$'C2TDL_$-_H<;7L4UL;.5MAVQRO;%5,32H Y7
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M1P-!5O8X6FOAI4_K%6O7Y(K;VM6I.WQ2;"BBBD,**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]#0 X=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#*G5DYQ_J'^!7@S6_AW\ ?!O@Z?2]*MM=T#PHEI_9-BZOI4=ZD3O':1.#L,
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M_FZL?&7Q.\"?M%>*]3^(MO<?&WQ2?$\R^'_%FL6JW7AKPF!<-Y,8OF1[>.&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ IC]/Q_H:?3'Z?C_ $- #AT_$_S-+2#I^)_F:6@
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MI-8N8S;F1+ZUN(GO)8Y-IBYE,A#XP.O%?@1X^^&_CGX6:MI6H:1^TS;V&@_
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MGE;FZ*'[H5'9N<9 R<5_,/X\\!^&?#?Q7M?"FB?MEP^#-$^&&K>(-7\&6O\
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M2I4PT\)*3DDU_LU3#82=&"BTJ<'AJ*5-1Y8*+5RBBBJ)"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$):QHSYO>YZ::A+FUNG?4P?$]KJ][H&JVN@W45EK$UE.FG74P+1071C;R7D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#^R_^R5!I4*ZK'\6/$&H7DMG=^'?!&IVDE_H_EYS/J'VA1&D>0<JK%B!P<D
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MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^?!_P><_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVK^TIX ^%D_B?1OV:_AW_P *Y\%V<=E8!O$*C4GT^U/E1Q1V7VH$W(C'^I1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY^"MKXXMI/B3:,5G\-_9;D7"D'!_>&/RB!@\A\?I7T<DT4G"2(Y')"NK$?4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'I,LI:V*B14(BP<* H QP,5^H%9NEZ1IFBVPL])L;>PM0VX06L2Q1ACU;:H
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MM0[)N4#A2H(P ,=Z_6C]GS_@DM\%/A7J>G>*?%LEQXSUA($-YHNKH+G18[@
M?ZI6E9F"'^+&#TP17[)E^5Y=E.'CA<LP.%P&'@E&-'"T848)1T2:@E>W1N[/
M\U^,>.^,_$'.,1G_ !QQ1GG%6<XFI4JULPSW,L5F.(=2JTZCA+$5)JDIN*<H
MTE"+:6FB/QOOK_\ ;H_;H\3:-I>I:?XGT[P[XHD2&YU&S\^+PK$C$$M=QL@C
M$.#P&^@Z5]]?#W_@E5\)?@3H]EX^^/FJMKUYHMQ'>+#HV]+%I(\,5NHSM5HS
MC! R#SU[_O'X=\*^'?"6G0Z1X;T>PT?3;<8AL[&WCAAC &,*JCCC _"O$/VK
M[>:Y^!OC>.#3?[2?^RI_W:J6DC7;\TL8 )+J#QZ<UZ,9J$HRE!58QE%RINI&
MESJZO!5)^[&4MHN5H\S2EHV?(R@ZD94XS]E*:<8U'S6IM[3ER^]R1>L^5-J'
M,UK8^8O@9^UG^S?K_B_6_AA\(/"NDZ7K_A_PS?:HMQ9Z?:PF86$#$)+)# DK
M99 6+2.3G')-?AW\)_&'_!63]N+]I']H\_#[XS>"O OPY^'VO3:7X7TB?>DR
MHES)&BND4;%6=5QN90!MZC(S]N?LW_#CP+X&^.'AS6/A]9W%]<Z[\)->N/%]
M\4++IVHM;R[K>X;>WEOGHK%#QR.:\T_X)9?%+PK\&_%O[:OCOQC/<PZ+IWC.
M627[)";BXD87TNV..+>-S.S *<\>]=%:?UJO&-+)\5DU2RIO+L7B\/C,3SK:
MJZN&E*DE6BU)0O>.J?1OGP<.6BG'-\%GM.I.]/,<NIXJGAJC?+"5"G3Q<(8A
M2HU8S@^:-I)<Z=I'SA^V+X4_X+,_L9_!76?VB3\?O GB#3O EQI]UJ^D"1]U
MU:S7:1RHJRH S%-P 7/8GIS_ $P_LB_$KQ!\8OV9O@E\4/%8B_X23QQ\/?#W
MB'6O)&(CJ-_9)+=&,?W#*6V].*_'/_@JQ^UA\*/VA_\ @G[\?/#G@'4;L^(-
M)TG2M2U#1=0A%K?06<EU&R3/"6+A&4Y#8'7-?J9_P3PX_8A_9C'I\(O"?O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT3IWQ2^"=GX O;UKCQ9X"C%KJ,ES<JT]S&Y^1EC=O,;R^!E 5"XR!@U\^_\
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MQJ^.7CRQT+P'!J?P_P!)TZVU&POFTJWGOSK-]$\D,+OL+>2691@*!UZUF_\
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MMN?YJ/\ P>*?\G,>!O\ L'VW_I,]?S6?\$N?^4@_[)?_ &67PK_Z4M7]*?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT7 5%4  #H*[3 NT444 %?R]_P#!9 D_$2+//^BG''8-'BOZA*_E[_X+'_\
M)1(O^O4_^A1T ?MM_P $^_\ DTCX/_\ 8OI_Z%7V=7QC_P $^_\ DTCX/_\
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MCZ HHHI@%%%% !1110 4444 %,?I^/\ 0T^F/T_'^AH <.GXG^9I:0=/Q/\
M,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\"?\%"/VF/%/[+WPKT3QMX5L_MMW?:\NGS1^D(2-R2._#'
MCN>O K\@A_P61^+! /\ PCQ_R<&ON_\ X+0%E_9U\-D=/^$L /3O%"._;!.:
M_FGUO1&T*'2)99%D74[47(&!^[R,XSZ]21TQP!DT ?K;_P /COBM_P!  _0#
M)_($FC_A\=\5_P#H7V_[X-?F;X&^!7QB^)=I+J7@#P1=>(K.W.UYK=T0!F(
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MV#Y1D@YSR3Q7PAI6E:CK^I6>C:):&_U74)TM[.TCP&GFD.U(U)P 6/ R?4T
M?KC_ ,/C_BT74C0#C'*8Y[?R]>HJ;_A\?\5AUT CV(P3],D9_"OS>\7_ +.G
MQW^'6B3>*_&GP[OM"\-VOE"YU6>2-H8C* T>54D_,K!A['!SCCQAIO.DLB"N
M)KJWCC"J 9#+,BJHP!R^[ 'J1SVH _8@?\%C?BXW*^%KMAV*V[$'Z$'!I?\
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MO^'Q?Q>_Z%2\_P# =O\ &C_A\7\7O^A4O/\ P';_ !KM/^&8?'O_ $1#4/\
MP#/_ ,31_P ,P^/?^B(:A_X!G_XF@#B_^'Q?Q>_Z%2\_\!V_QI#_ ,%C/B\!
MG_A%;S\;=J[7_AF'Q[_T1#4/_ ,__$U6O/V8O'JV6H2?\*2OT\NRFD+FRX0*
MK$O]W^'K0!QK_P#!8_XN;EV^'9,CK$%)<Y]$&,_C4W_#XSXO_P#0J7?_ 'X?
M_"OSR\%>#=7O/VA]-\%_V!+>ZM-JEQ"OAU(PTLK++@Q>7@9QT  S]*_4>?\
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M&0!@61[#_=')H X__A\1\6_^A9O/_ <__$T?\/B/BW_T+-Y_X#G_ .)KL/\
MAF'Q[_T1#4/_  #/_P 31_PS#X]_Z(AJ'_@&?_B: ./_ .'Q'Q;_ .A9O/\
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M:9X;MC>^*=,GL=8U.<?:&DEN(V22X@AD_=1-N8L H&/45];@8  & . /844
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M*C4@IOE=?'5JSDJ. H7]I6JPHUZT)1@\/&-?V=2'-BJF$A&'UVKD=*CSJ?\
MPOPKO#5)TVIQI82I0JTIT<RG:V#J-RIJ?NUHNE*1E?\ !56ZMI?BC_P3=O\
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M,-F5;]VI5JV6Y_2R.O@L-+E3KJ<VH8[=4WA^2M2LW)TFI19\P?\ !-[0=?\
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M14L=^=XRHXFZD>F>HI@_X*F_LAK:FZF\::A;)C<%N-+:)V7^\JO,"R^X'TH
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MW#A$C@985)))  ^0\DC.#Z5^1$?_  29_:M**7TW1@Y4;@M[$0#[$R$_K^-
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M87$$4AVQ^7!YF[<V1@?,,\U^#FG_ /!)G]K,V=M]ITK18YO*0.BWD1VX0?\
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MFSCS'Y(/4<''0'K7\YGCW5?CC\6-?N_'7Q*T#QEK6NQVRQ7FM:CH]W'MM8^
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M_P#@##_\35.X^!7PEN@?/\"Z"^<];*/^6,4 ?S<R_P#!6C]KR YF\(6L6/\
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M%A_^2]:%_P!=]#_]*8* /Z//@+_R1?X8?]B5H/\ Z0Q5ZW7DGP%_Y(O\,/\
ML2M!_P#2&*O6Z "BBB@ HK*UO7-(\-Z3?Z[KVH6VE:/I=O)=ZAJ-Y((;6TMH
MEW2SSR-PD:*"6/H*^1G_ ."B'[$D<LL+?M*?#'S(9'BD"ZQ(X61&*NI9+9ER
MK @@'J#0!]G45\R?#_\ ;-_99^*GB*V\)?#SXY> O%?B6\.+31=*U4R7]R1U
M\B"2&-I,=#MS7TW0 5E:[_R!=6_[!UY_Z3R5JUE:[_R!=6_[!UY_Z3R4 ?RC
M_!G_ )2?^%_^QGU#_P!*C7]9M?R9?!G_ )2?^%_^QGU#_P!*C7]9M !1110
M445YA\4OC3\*?@EHL/B+XL^//#W@+1+B;[/!J/B&]%G;S3GI%&=KL[\CA5/4
M4 >GT5\6_P##Q3]B$+O_ .&E/AGM SG^UI^@_P"W2O=_A5\>?@Y\<+.\U#X2
M?$7PSX_L]/*B^F\.WPO!:%SA1.I1'C+'@;E&>U 'K=%%5_M5MY_V7SX_M.W?
MY&X>;L_O;/O;??&*:3=[)NRN[+9=WY#492ORQ;LG)V3=HK=NVR75O1'Y4_\
M!8%F'[+&IC<P7[<A91T.!W'>O-O^"-%B8?A'J]T% $ZVV3@C.-F,?EUSZ],U
MZ1_P6"/_ !BSJ8[_ &U/_0:P/^"/D"1_ 7S%^]((=Q]>%_P_SQ2$?K]1110
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M_P""@?[%VD:E?:/J/[1WPTM=2TVXDM;ZT;6':6UN8CMDAE\NV=5D1AAAG@T
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M,BE5YR0#D9(/-?H!#;P6R".WAC@C&,1Q(L:#' PJ@ ?@*FHH **** "BBB@
MHHHH **** "OFS]K/X-CXY_ SQQX"A^SPZEJ.E3/IUY/&&:VG@1I28F*DHSJ
MI48(R2,Y.*^DZ:Z+(CQNH9)%9'4]&5@58'V()% '\F'_  34^,<G[.'[3VJ_
M##71=ZA!XAU23P6BO*\<%M>0S^4;L1L1&,LN=Q7D9]Z_K0!# $<@@$$<Y!Y!
MXK^4/_@J%\&]:^!G[1=A\4? FA7&@>'=0:WU"TUF'Y('UZ29'N#'*JC$A;=P
M6)]>F:_8#X4?\%"O@CH?[.'A?Q7XP\:6U[XLT;0;6WUOP_\ :E.NWE];P!9'
MA0JX<2%<@M@X[$T =S^W/X&U"TTGPU\</"4$TWC+X?:E9B!8%;<=,FG!O&8Q
M@L0B;B0>,=_3U23X]? /3?AQX5^(GQ"UCPI91:S8V<<UYJ%O8W5RNI>3&+B%
M\J\RLDVX?-C'?%?B7^T)_P %??%7Q,$G@_X(>%#:Z;K"2Z9=6^MV;7%]<F;=
M"#"Z0D*S$_N]NWGG!ZU\I?"+]A_]K;]I/4+O3-97Q)X,\.27)U.&X\2FX;1"
M+I_-D-C!(H50=Q*!.F1U-3.$*BM.$9KM.*DON:9492B[QE*+[Q;3_ _HM\9?
MMV?!O1;*WT_X<77_  L+Q)<P(VE>']"MYFCE1A^Z3[1"IBBSP!&,%1Z=*_-K
M]JOX3_MD_M6S^#_B-HO@J^\$RZ#J]H=)\.B659[:(3(Z:E*_+.L8.\AB?3/>
MOTS_ &1/V./!O[-?P\T_PY?66E^)O%,4@GO/$MW90W%WYI S':SS1F6*)&'R
MA-O&.M?:H 4    #  &  .PJEIHE9+1)=";GE?P3TCQUH/PO\(:3\2=676_&
M5EI5O#K&HHI42S+&H"D'DM&H",3R2.>17JM%% !1110 5^&O_!>CPCX0\1?L
MCR:EXCEFAU'P_?RW_A]H;AH#]O$7RAL$&13@ IGGH>*_<JOPE_X+[^"[[Q5^
MR0E]:ZQ'ID7A_5'U"ZAD8*;Z-$!^SKW);!& >IKX?Q)7-P)Q.O81Q'_"76?L
MI6LVG%J6NEZ;7M%YQ5M;']3_ $)*BI_2N\#)/-*V3+_7S*XO'T%-U*?/[2/L
M4J:<W'%W^J325G"O+FM&[/E#_@AR%?\ X)R_M*(Q*L=5\5-NY4D#2692'X_B
MXR#^HJ]_P1KUGP_:_%[Q5I6JF8>([R_U>33#)$^)(!<RDL)F/S  =O\ OGC-
M-_X(C73:C_P3;_:(MI42);.^\5VRO"NV1T73))=SD9+.2<9QTP!75_\ !'O5
M[+7_ (A:U#J=OI$&HZ%>ZO!I3K B:C/!]IE#$OC<1CKGKG)SFN7PHM_Q#OA2
MSNO[,AK:W_+VK=?)Z>>Y[G[0!R?TR/']SAR2_P!>:ZY>;GT67X!1=[+XHI2M
M;W;\MW:Y^Z/[3F@VGB#X.^*[6^1);>.R>62*1%=9  <!@P/ /;ODUYG^PQ:V
MUG\%;>VM+6"UBAU6ZC5+>)(D(7 !P@'/J3^'%>U?'[_DDOC'_L&2?R->._L1
M?\D=7_L,WG\Q7Z$?QX?8M%%% &1J^O:5H42SZK>16<3DA7E8*I(Z\G_/ZUSF
MC^,AKVMO::5;1WVAK!O77+>3S(&GXS;\$C>._IT(KY[_ &VM*\1W7P,\4:MX
M2E>+7]&LY;BR97*@$HVXM].OX5^8O_!)7XX_'[Q'X]\<?#'QQHE[?>!=.M9=
M3@\7S;I8#JY<[[&.5ACC)R V./PKJI^PE0J+V&(A73:6)K*,<ODDHRE1I57.
MDWC6I)TZ475?*IR=*46FL)0QGMXRISP4\*HWJTE72S"FWI&K[!W_ -GYM.=J
M'/)\E.4I0DC]^***\=\2?M!?!/PAJT^A>)OB9X2T;6+4@7.G7NIQI=0$]!+&
MH8H>V#R#UKE-SV*BO"[']IKX :G>V^G6'Q:\%W-[=.([>W35HP\KDX"KO"+D
MDX +<GI7M\$\-S#'<6\J303()(I8V#QR(PRKHRY#*1R"#@CI0!+1110 5_+W
M_P %C_\ DHD7_7J?_0HZ_J$K^7O_ (+'_P#)1(O^O4_^A1T ?MM_P3[_ .32
M/@__ -B^G_H5?9U?&/\ P3[_ .32/@__ -B^G_H5?9U !1110 4444 %%%%
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MG7J2A3B[NQR8UY>J/-F?+]54H\Z]O6HU)<SY5"C[&\YSDVKK[,%*71GYT?\
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MVO@*;E_LM2M6PE58RFMZL(8:O6G1M>+Y,1&G.TE9/6W],=?&/Q5^#'BSQ/\
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MLF#')N*E3Z\YSQ_7SX7=Y/#/AV21B\DFA:0[L>2SMI]NS,3W)8DD^]?R!?\
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M]:_.G_@K]=W]KXO^!$MI>7-L8]2E*K#/)$CEI#N\Q%8(XP.C U^B'["TCR_
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MYK7S#"U,-F$8T\XRJLL!FE%62]M32]GB:<5:U#&4G"O2:3BE-T[\T))9^.?
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M.0>>PXK[5!RSC.?*8VX'H+<F(#\E'% %_P#M/4O^?ZY_[^R?_%T?VGJ7_/\
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M@'O7XR_\%#_VH/ ?[4/P0U35/ =OJ%M#X3OC8ZBFHJHD,I<CY JI@9]0?UH
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MQ6*J0E&OAU.48052G0YE.G*9%+#T:4J<)5_[2H5)J4\7C,##+%C8W4:BJX;
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M9)^$)4 %] 1FP.IW=:^T:^,?^"??_)I'P?\ ^Q?3_P!"K[.H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _S._P#@\0UG39_VK/!.D07:
MOJ%MID$MU:@<Q1_96VDGW)![]1ZU_,[_ ,$ZO&'ASP#^W!^S)XQ\7:I;Z)X:
M\/?%?PUJ6LZK=MMMK&R@N"9;B=OX8T')-?ZIW[=W_!![]F#_ (*)_M#V/QL_
M:"N/$$D>C6MM!8:9H%\;);LP #;J/!66,@8PRL,<8P:_BC_X.3?^"77[+_\
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M/4O#.H64</@?5K.\O(]1N$D\I!%#=2OY>YP"2N<9'T_J)I&954LQ"JH)9F.
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M6NI9X;9V6=I)&=A(6^8E<9/!R*^YH88K>*.&&-(HHE5(XXU"(B*,*JJH 4
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MP" 23Z5]_?\ !1#XT?#[XR_L+?&/4/A]KHU>'2S9V^H1F-K>YMG$F[]Y"^6
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M_$"_^%7P4\#:U\4/&.C2/#KLVFV$MWI.D7,9(:VN[B$%8IL@C:[ ]ZI? ?\
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M4:+J9\F>: G[1'RT+E"1A",$CU-._P"'PGP,Y_XDFJ''7%PG_P ;Z^E9Z_\
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M7!=/%;V]W( T5]-;[E#;=XW9!P1UK\:O"G[+WQ.^#GQ<USXP_LX>+OA]XO\
MAEIEV&35_%;6]Q9>%M5CF7[7#J#R;C (2K+VP0!QV_6Z]UGX ?M;^*? ?@'X
MI:^VC?&&'PS;7=S=Z/=QVWAS76"@NVB.S"*6WE8'RU4YP0!UKDQG%M;/<OJ8
M7#X7,\AS:GCL/]2E#'8:FL;:JX0GE^/BXTZJJ-.2CRPYHWBIN5XGMY'X%+P6
MXLR[BJMQAA_$3@?$\-YI_K-7X+R7,Z7$_"L:F H8K$X?B/AS')8O*EA>:%+%
MU8XJI5C=R]C'#R567S]_P4C^(FC7O[)7P^T#5-?M[KQ9KUH+JSL@?WMW"!\I
M3DD[1QT(X.371?\ !,']H[X(?"OX*IHOQ ^(NA^%]7'E[K'4YO*<;5&<;5<D
M]N@Y'.!7N/[;/_!.K4/CSX5^'FD_#74[+2]0^'VG_P!GZ?<:H_\ KX2N-TKY
M^8D8]?TK\U[;_@BQ^T+<.QU3Q/X49D'RNLPVL<=@''KCL!VS7Z;A56CA<,L3
M*<\2L/16(G4DJE2==4XJK.I-:3G*=W*22NVV?Q#G^*PN-S[.\;@4XX'%YMF.
M)P473C1:PE?%U:F'4J4;QI25*4;TXMQB]$?O7_PW'^RIC/\ PNCPAZ_\?;__
M !NK4/[:O[+LZ[HOC'X28>OVQO\ XCO7X,_\.3_C=_T,_A;_ +^G_P"+IK_\
M$5OCY%&1:>+_  NC]OWF%]L_.>@K<\D_>[_AL[]F+_HL'A+_ ,#3_P#$4Q_V
MT?V8(P"WQA\)#<RH/],/+,0H'W.Y(%?@)_PY;_:6Y_XK'PAUX_>CI_WWU_+^
MM,D_X(L_M+L!CQAX0)#J1^]'&"#D'?U&,\>E ']/WAWQ;X;\6:3;:YX=UFPU
M72;M%DM[VUG1X9$<94ALC&1ZX-<=\9/&6C^#/AAXV\1:CJUIIT-CX=U66&YE
MN(T!N!:2^2D9W9:1I-H4+SDYZ<U^8_P2_P""8>OZ#X&M=+^(OQN^(5GK\+ "
MW\*:W);:1!"/NK'#N()!]_S&*3XY?\$O=7\2_#S4]'\ ?&SXB7WB.X!6"W\5
MZX]SHTJE3D30EL=<#N"#Z#% 'TG_ ,$^]-MM2^$T_P 2P(WOO'6IWUQ<7(PT
ML\<%R?+:23[S9R",D_A7WS7RM^QK\$?$?[/WP*\+_#GQ9J4.IZ]I2/\ ;IK5
MMUF'.,"W X /))'4U]4T <#\4VV_#KQF2"?^*>U/@ DG_19.@')-?Q9?$'6;
M1-,^+&@M-B_OO$5U+!:/E7D G<GY3SVX.".W2O[@[NV@O;:>TN8DFM[B)X9H
MI%#))&ZE61E/!# D$>]?SA_'7_@D7\=/'OQF\?\ C?P;XC\*:5X8\0:K)=Z)
MITK(DEK [LVQTS@$;AUH ^K/^"=G[47[/_PU_9G\)>%_&GQ.\/\ A_7[,,;S
M2]1G,4]NQ50J@*KEAP>3@\>]?=:?MP?LK2':GQF\(LWH+QO_ (WC/XU^#L?_
M  14^/4RB2^\5>%9+@CYF67C]& _SUJ3_ARA\< 0R>*?"RGU\S.?3J_'- '[
MUC]L_P#9B(!'QA\)8/\ T^'_ .(I?^&SOV8O^BP>$O\ P-/_ ,17X$W'_!%K
M]HL<6GC'PHH'\,DHQ^'S\?\ U_6J_P#PY;_:6_Z'#PA_W]'_ ,70!^_9_;1_
M9@5XXS\8?"6Z:1(D_P!-/+NP5%^YU8G KZ+TO7M&UK3K35=*U*RO=.OH4N+2
MZ@N(GBFAD&4=&#8PP['GL0#7\NK?\$6?VES) X\8>$/W<T3,?.PRJK@LR?/]
M]1DK[XK]//AU_P $S)M+\(:3I_BOXZ?%&+6K:VACN(M$UR2'382B@&*WB+$;
M%Z)@_*,4 ?<W[3/Q!\._#_X)>/M<UO6;;2XIO#NJ6-A<O,B[K^YM)([=8SDY
M8.03C./:O*/V M*@M_V<?".M$QW&H^(&OM0OK]0-]WON"869^K@)@@YQR37Q
M3^TG_P $L?$GC+X:SZ'\,OC+XXU7Q*]RA6V\<:RUWH;0Y&YVA+#;*H'RG)R?
M3%?I'^RG\*_$'P5^ _@'X:^*;NVO==\,Z6MG?W-H=UO+,#DM$>Z^E 'T37@/
M[4S;?V>OBX3DX\$ZUP 2?^/5^@')->_5SOBWPY8^+O#6M>&M3C$MCK6GW5A<
MQL,J\=Q$T9!!ZCY@<>U '\#5Q(L^E$1?,WF7HVXPP/VAQ@Y^AQT'2OZH/V%O
MVKOV>? /[+WPU\,^+_BIX8T/Q!IEE+!?Z3>73I>6SL^\>8@C*@8Z_-G/;'-?
MGQX__P""-OQYU#QUXHU+P=XI\*6/A6]U&:?1+*5T6:"VEE=]L@/1L,,YYS7/
MI_P13^/$JB2\\5>%9+EO]8XEX/TPP'7\Z /W?'[<7[*A( ^-'A#)Z#[6_P#\
M;J['^VE^S!*NY/C#X2(_Z_#_ /$5^"I_X(G_ !O[>*/"P(Y!\TG!^F_FF2_\
M$6/V@44BT\7^%T..,R@#\<N?Y?UH _6[XF>,OV"/BYXDLO%7C;XB^%-1U.PL
M9M.B7^T=EL\$P*NTT)MW$D@!^1RV5P,"O1OAO^T/^QW\*?"EEX+\'_%;PI9:
M#IK2O:6[7Y?R_.<NX#>4IVYZ+M&T8 K\/1_P1;_:7_Z''PA_W]'_ ,7_ (?U
MH_X<M_M+?]#CX0_[^_\ V=<E/ X2EB:F+IT(0Q-:+C5K134YQ;4K2UL]4FM-
M.EKLZZF.QE7#T\)4Q%6>&I-.G0E*].#5TG&/1^\]5W9_1U\//V@/@]\5;Z[T
MWX?^/-"\2WUBGF75M872M)$G]XJVTD?3/O7KJW%NQ"K/"S'HJRH2?H V37\]
MW[-'_!(OXM>"?%6IWGQ%^*-SX=T:: +!+X#OVMM1N),<K/(KC" \C=G'/7(K
M[K3_ ()N:"KJQ^/'QHV@YPOB-U;GT8-P>IZ=_:NLY#F/&/BCPM\4/V_OAUH]
MCK%O>R_#S3+R#4M(#JZK<L';S)$W$%E8\$CC;D=!7ZI@8  & . /85^+O[./
M_!.?XG_!#]L&_P#C/=>-QX@\ )%<P6 U*Y^T>(KQ9MP5]1DWDNPW DGJ<U^T
M5 !7\Z?_  51US3="_:7\(SZI<"WAN? -W;Q2-D RNDH5 > 3DC^+)/&*_HL
MK\G_ /@HO^PAXO\ VJ[G0/$?@'4M+T[Q%X?LVME.I$!98LLY1&;C<<_+SC/:
M@#\=?^"69W?M@^'& X==3=3D<JSR%3UST(SZ=*_KJK^-']GKQ'+^Q5^V5H<?
MQ2AN)IO#5]'H.J6^GK\TEU?RBWCE0$$,H9@QX)QWYK^QW2-3@UG2M-U>U#BV
MU.QM;^W#C#B&[A2>+>.S;'&1V- &C1110 4444 %%%% !1110 4444 8WB&P
ML-3T74K'5"!I]Q9SI=DD*! 8V$AW'@84DY[5^,7P=^%W[%WA/]IQ?&_A,ZQ9
M^,KO6[_3[3Q+<:C(+#4=9VRJ^F#:_P RJ=P"<#@=.:_8GQVML_@_Q$MY.]M;
MMI-Z)9HR5=08' P1SR<#^>!DU_,+\$_$4_Q _:N\*_!K1-,G,G@[XEZCXHN;
MX(RQ26@,KB5V. 68#DY)]AW<:=%-XFJ\YIK#)U95,LKYO2IJE%QC+VT<KJTX
MU6IU*:Y,="MAO93J7I2NW&)RS)N%' XBG3A5?)6ISQN3X/VBDTU&I_:T'*O"
M4:<U&C@)TL1*2UJ1]Q2^7/@;:ZQ>?%_]ON'0K!KOQ%_PT,[:9$S 6D\XO&,$
M,JL-C!_ESNXYSDU]=ZU>ZA??L:?M@V7BC2!H7CO3+W3$U[3X-JV:*441-$D?
M[OYEP25Z_6OG_P#9@^$7Q(^-_P 7_P#@HCX2^%>IQZ1XEC^.,US!J.X)+:M%
M.P\V)CR'0KE2#CC!-?9GQ-_9D^*'[.'[ /[1,GQ6UZ+Q)XI\6W-C/<ZNS^;?
M7**=B?:903D _* 3D#'&*X'B,,LPAAI9AA_K<J2E'+$LR6(IPM?V\73ME\Z5
M6SYHUY-+D3A%346_06"R^6"ECW@XK,J=14Z>/YL-*I/#WBOJW+5O7I4X:RE[
M&,:TIN/--T^>)^CW_!*'_DS+X;_]<)/Y+7Z2U^;7_!*'_DS+X;_]<)/Y+7Z2
MUW'$%%%% !1110 4444 ?/\ ^U.<?L]_%@^G@_5#_P"037\Z'_!':+=^U5K\
MP X\/ZB",C/,CDYX]#^-?T4_M7N4_9U^+;C^'P?JA/T\KU[8Z_A7\[G_  1O
M;?\ M,ZX^"-VA7[<]>99#S_A^% ']5-%%% !1110 4444 %%%% 'SS^U-X&N
M?B/\%/%OA"S\5V_@J[U:&&&W\17;B."QDWG:SL2/O$@  Y/8&OY>O^"C'[''
MQU_9T_9ON_%MW\2X_B1H>M6WV/4UMA,!:V;1EA<EW0*\9C.X%6(]#7]*O[<'
MV5?V<?'$]Y'JDD-K]@N=NC[S>[X;C>A0)\VP, 9/11FOYYO^"@7[:UOXT_9K
M\._"+Q#X5U^\T2#1X(=7U[0(I&6&TBM1#$+Z4+A+A44><"5&X,>O-?B?BOAN
M&,5ALUEF.;8O+<]P>0^VRZ@\YGAL'F,*M>M2C2HY5!26*Q%&7/+$5*JTH3CR
M+]W)K_43]GY6\4L-G7 $N#:.79QPE7\67_KIDF-R7)ZU>G@L'E>6XA8W 9MB
MG#,5B)7488/"UZ*5>C0E#VCK5%'U+_@B,;23_@F[^T/_ &=&]O>+?>*H[N1V
MW++.-,<F15R=H9,+] *V?^"0?A_PQK7Q4U/Q'I5G?6>K:%=ZQ;:G-YY%I=R-
M<3*7$0."1_N]>OOB?\$/6LH_^"?'[3#()WT4:YXJ,(DV_:C#_9D@/F;!MW^7
MM^Z<<$XR:7_@C[;7,GQR\3W6C272>'TO=7#Q9(C9S<RY\X=,@XQ^E?5>%+_X
MUYPKMIED5HK)VJU5=6[VO?KOU/Y^^G^K?3'\?=9OFXWJS_>-RG'VF79?/DE=
MMIPYN7EO[MN5:(_H._:)^->C?L__  I\3?$O6[&ZU.TT2SE=;&R8+<7$K1MY
M:H2&Z-C.!GGCFODK]@G]LKPU^T-X-UJ^U6\CT35_[6NKNWT_4[J..6.PD=O*
MC+2,OS(!^//>H?\ @J7KCZ;^S1X@L1$7344>-FP2$ '4]A[>]?S?_LX? O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'/\
MX+2?\FX^'/\ L;HO_0;>OQH\'_\ (S_!O_KXTSMC^)/U]Z_9?_@M)_R;CX<_
M[&Z+_P!!MZ_&CP?_ ,C/\&_^N^F?^A)0!_7MX$_Y$[P[_P!@JT_]%+76UR7@
M3_D3O#O_ &"K3_T4M=;0 C*&!4@$$$$$9'(QR#UK\-/C-I&H_L _M;Z)\=_#
M5M>0? /XR:O%IWQ/L;0E88/%.J3O##>,BGRHU#2K*',84#[P;!S^YE>,_'WX
M-^'/CM\+_%'P]\1V4%U'JVG70TN:903I^L+!(-.OXB0VR2WN&5MP&0N<8."/
MG>),HJYI@J=3!S5'-LMK1Q^58C^3%4=?93[T,5!/#UX:*=.;3/V7P2\1,%P)
MQ/B<%Q)AYYEX?\:Y?5X4X^R=/_>LAS"2BLPPZD^6&:9%B?99ME6):<\/B\,I
M0UD[_A?\4I_ TW[6'Q;\2>'(A;7WB[3]*U"35)&VP:Y'=0QS1"PD^[=/&K*'
M$><-D$ UXY^TMXDTKP1\!?B%XL\1W!L="T;34FOKAV"")&E"H,G&,$\\]C7N
MW[.7@'0O%VH>,/V1?CE>0^&?C-\&[ZY/P[^)5[(+6Y\06,\Q6WACEF9/[0CM
MH2N!N;:JX4'&*^;?^"P7[!GB31?^"?\ \>_$K_M(6XM?#7AVWU+4M&$MK"->
M2._MT>Q#_:%83R%]R0JI9D65N-I#=>1YO2SO+:&.IP=*J^:AC,+/^)@\=0?L
M\5AJB_FI58R2>TXVG'W6F?/^*GAYC_##C7-.%L5B*>8X&*HYGPYGN'7^Q<1<
M,9I2CC,CSO!35XRI8[ 5:-2<$W+#U_:8>KRU:<XK],_^"8WC\2?##X>1VMTL
MWA#Q;X6M]7T>]##RIO.4F+YL[2<GMD\]Z_5'QYX5T[QEX6U;0]3M5O(+FTF\
MJ%AD&Y$;?9V'7D/@?0G&#@C\@OV"O!0\/_\ !-']CGQ)X=5X+K3_  %X:U6^
MN0VZ1[$M()E=^NS$ (S_ 'CQD5^Q_AC7+;Q'H.FZS:-O@O;9'4Y!!8#:_3C[
MX;CMTKUS\Z/P/\2^']1\*>(M6T#58?L]U:7D^R':5VP>8WE#![[ /RSWK&KZ
M]_;+\!R>'/'D/C-YP\'B;$"PCCRY(]NXGMGC.0.A[U\A4 >X?LV>+U\%_%73
M[Y\%=3*:9M;@$S$H>"<'KU ZXYK[/_X*(:6NM_LQ>)H6175-0T:]PX4HH@G,
MF]MP(PG?/'/)K\VO"<ZVOC3PG<N<);ZU9RR'T1),MSV[5^H/[:LD.L?LB?$^
M^M3YD8\$WU]"P_A:&PDD#!N2-C+]X?6@#^)WX'_&GX:?#G_@IM\7-<\4^//!
MFDPZSX5TG3Y)K^_TZ&)1:0QJT8WX570+C;@'(Z&OR[_X*_\ Q4^&_P"T1_P4
MH^!$?P"FL?'_ (SMM>T+37;0GAN+&Z<75L8[82V8"LP,3/@$L!&3VS7[0_L)
M_P#!OO\ LS_MW?"V']JGXF?%/5;/Q=X@\9^(K#5-/M=;\D);V5SA89I1=*\3
M'>!$C+\ZH_S#;7[>_L8?\&^G_!.S]D_XHV'Q2TK3M-\>?$W1[V/4-"U+6M9M
M;^\TZYB*M#-%"T\D[.K $'&#@9)Z4 <?_P %6]-US0_^"0'PKT?Q9ICZ1J]I
M)\.8-;T\ F6PG$=RQC19,$NN]" Q .>2!BOQO_9Z\.>%_!7P6GLK[Q?X@UKX
M>?$73_.TV]NK-D&B7H@!DAB!0"$&7*G8J9YSUK^B#_@OE::9<_L%>((=0OUT
MU8?%GA^>S.S<)[FW>9H+4*/^>C;5 &#_ '><5^"O[ WP%_:(_:!_9J\3Z;X,
ML;;Q7HN@N/["L+@+;FT##++'-(!SG@!3VZ&OPG$J'_$?<N4Z?/)\,QE2J*23
MHRC#&1DIQYU>G.,]I0G[_(XV2;/]8,BGB?\ BD=QI]7QRPU"'CA5HYA@J^'Y
MH9E1KXGA6K1^J5982JUC<+5PZFIT<3AXK#O$4ZKJ2G"!^^/['?P+_9<^.W[#
MGA+X9_M$:#\/?B+X-L=9U)['1_'5WI^R-2RK;2A)[J">*1@SD;2,Y)YQD>'^
M*/\ @WO_ ."1>MZG<Z_%X&\$^'[*\E>2*RTW7]/M=,@$A)$< _M%%VKD[=Q9
MO4] /C/P=_P3K_;,E@TM=5\/ZM8Z+9.6ETBSU^>V@#!25.(Y F W.<<@C@BK
M5Y^P5^WAXFFU#P[<Z9K%CX:M[AI=,\KQ+<&4(OW$+"5CVS]3ZBOW>W]?UZ_U
M9G^3U_7[GY;Z:;H^JQ_P;H_\$EWB\Y?"_AQH2"?,7Q%9F,KC).\:GMQCOFL^
M3_@W<_X)(?8]0N;7POX:OFL;&YNGBMO$MC,\8@A:4LRIJ3D ;1N#!1V++FOG
M;4?V-_V^YK33O#.CZ#J-K8Z= ;2YN5\3S23W(QMWN%GW!N^#WSBOG+X^>!_B
MO^R%=_#GPEXX\0ZKHGC?XH7/V+3K&'Q#/J,^I37#^3Y4\$<[O;@LVTAU'7;V
MQ2^[[U_77\^S'OTEM>W)*]N]K;>>VW<]C_X(7_LH? _]GO\ ;Q_:P\>_!R&V
M\)> +[26\(6&EWVI>7$TNFW:!I+=;J81%"5=P8\Y+,<]2?ZRIO'_ (&MY%BG
M\8^&(97.$CEUW3(W8GH%5[D%C] :_E.\'?L0?MB^"M+N?$WA_P *VWVSQKI\
M=Y;2Q:^FG3C[6N];EHQ*CR2,K!F!&2?KFKFD?L$_MH:C+<Z_XVANUO8+63^S
M8Y?&+VT!N@"8R'>X",W0X#9/ ]*/FOO7XZZ;]05WM&;OM:G-\W^&T?>?32^J
M:Z,_JIG\=>"K8H+GQ=X:@,H!B$VMZ;%Y@.,>7ON5WYR,;<YJ23QKX.AC\Z7Q
M5X<CBQGS'UK3E3'KN-R!CWSBOY/O^&$?VZ?%/V?4O$[SV_\ 85P'L(U\8>5#
M<0Q/E5DE^U!,.H !)[]JUM;_ &.?V[_&5\UG]A?2_#K1PVS+;^,O,3;"0&D$
MR7) +C/\7'?(P:-%UC_X$O\ ,/>_DJ::/]U4LGM:_+:_EN?U30^._!-Q"UQ!
MXO\ #,T"<O-%KFF21H!SEG6Y*KCODC%.M_''@R[4M:^+?#=PB]7@UO395!]V
M2Y*C'0\\'@\U_*IJ?[#?[:NEW4?AKP=(#H%Y9K!J<B^.$GF5V7$C$"[9T8?,
M<8ZXX[":S_8Q_;:\%>'+OPKX9M4O[^ZN_M!U=_'$<DT"GDPF/[677N #[\4:
M=X_^!1_S"T_^?=;O_!JZ)[-^YHGWV/ZH?^$^\#&?[*/&/A@W/3[/_;NF>=UQ
M_J_M._K[4Y_'?@F.;[-)XO\ #*7!QB!]<TU9CGIB(W(?_P =K^5*W_80_;&L
M-+U#Q'<7,<GC21U>R27QVB+"1C< CW@_B/3;ST[4W2_V'?VU4U>Q\>>(7CO=
M6MLB32&\=QQ13@#Y< W05\''3@_4@T:=X_\ @4?\Q\L_^?5;R_<5=;=O<U^1
M_5C<>./!=H@>Z\6^&K=#T:;7--C7\WN0*1O'7@I8!=-XN\-+;,<"X;7--$!^
MDIN=G_CU?RIR?L1?MM>.=7<^+)HM(T(W;7$%J/'*1%(OO)"'^U+NQP,\^F?F
MR:5]^PW^VUK$M_X2&HVMIX2B8FTN%\>0A_ER%S(+LG.!ZC/.*-.\?_ H_P"8
M<L]_95VNZH5FM?\ MP_J]B\:^#IX_.A\5>')8L9\R/6M.>/'KO6Y*D?C4,'C
MSP1=2-#;^,/#$\J$AXX==TR1U(&2&1+DL"!V(S7\KM]^R/\ MPVNAZ1X3\-6
M=O#%I68K_5SXZBD%\D@VY9Q=\84YY/3IC.3G3?L.?MD>$-.L;[PU?V]QXCU"
M9O[0>3Q]%( LOWE"F]XQDGH#S1=?S1_\"C_F-0JMV5'$-[V6'K-]]O9]M3^K
M1/'?@F65K>/Q?X9>=#AX5UW3&D4^C(+G<I^H%)<>/?!%HRI<^,/#$#.0$6;7
M=,C9B>@4-<@L?IFOY5M&_8I_;%\#7E]XCD,&O:OKMLT(M?\ A/8BMI>2_P#+
M0)]K/W2<[0,\8&*HVO["O[9WB">35?&NIP02:?%+-:6Z^/(XB6&6B#)]L'3C
MZ@>PHNOYHZ;^]'_,%"J^6U#$/F^&V'K^];3W?W>NO8_JYF\=>"K81M<>+O#4
M"R\Q--KFFQ"3C(V%[E0V1TVYSVJ0^-/!XB,Y\5>'1"!N,AUK3@F/7<;C&/?-
M?R0?\,;?ME>,U UW68+>TT&X\S3XX_'<:-/%;ON5&(N@6W*NWIDYP/2K7B'X
M"_M>>*KFVTS2]FA^'TMTTFX)\9J!--" CW"SBZ&2_)ZYZ=L"LW6HJUZU%<VJ
MO5@K[7M[W2ZOV.R&69I4Y_9Y9F4_9\O/RX#%/EYOA4OW6C:3:6[29_6A!X[\
M$W2/);>+O#5Q'&"7>'7--E1 .I9DN2% [DFE@\=>";HD6WB_PS<%3AA#KNF2
M;3Z'9<G!]CS7\ANL?LX_M+^![RS\,:!XC!MM3@$.IRMXT60AY!\Q5C=Y!!W8
M(Z$?2H_^%+?M!_"RPNO"UE?3:GXA\1M]LT_44\8&X^R)C?(H NF*C)/7C]*R
M>-P<4W+&86*4E%WQ%)6D[63][1N^SUZ;G;2X9XEKNFJ/#F?575ISK4U3RG'2
M=2E37-4J0M0?-"$?>E->[%7;=D?UZ/X]\#I/]E?QAX86Y/ @;7=,$QST_=FY
MW<]N.:67QWX)@F6WG\7^&89V^[#+KFFQRM_NQM<AC^ K^.#4/@K\<='TZ7QM
MXG\8S0Z^1BRMT\8%E,J=0T/VG@[@,@@>X!X.=:^ ?C#/:P_%[Q;XLGN;+PTP
MFO;!/%I4SP1_P>4+G+$X'J3^0.4LTRR+DI9C@8N,7.2EBJ"<8)7<FG/2*6K>
MUE?:U^^CP+QQ7A2J4.#.*JU.M7CAJ,Z609G.%;$SDH0P].4<,U.M*;4(TU>3
MD[)7/[,Y_&_@RVC$UQXL\-PQ'I++K>FHG_?37(7]::/'7@HV_P!K'BWPW]E'
M_+S_ &WIWD?]_?M.S_QZOXQVT?XQ_%22?4IO$E[HG@>\1M2MED\326[QV,6=
MQ3?.I<$#)VGN.#UKE=-@^(7BJ\NO 7AWX@WC^'"'1+F3Q))&YDCRK8D-QV8$
M9!R<]Q6;SK)DZ:>;Y8G5UI)XW#KVBTUA^\]Y:K:^ZZ-';'PR\2IK%RCX>\;2
MC@)<N.E'AG-Y1P<O>]W$N.%?L9>Y/2=G>$ENF?VR0>-O!MTNZV\6>&[A>FZ'
M6]-E4_0I<L,>_2OQ9_X*D?MOV/A"72_V?O"\NG:YH_BJ!3\5;G2[ZWO+_3O!
MUSA;MK46TCE95C)8KN#8Z@8K\/8/B!XKL+F7X.>"?$VJS^+_  I(T^OZF==N
M)(7MG; 5K@3E, <@E@,?CCXJ^,9U[PY\;K&VF\4N?%VJ:>D]]?7>IMJ5O>6D
M@RUF6D>1!D;A@GJ<$<<?"<?\1X+_ %=E3RK/<M57&9EA<MK3HXO#59*C5J2C
MB::_>*FI6CR58U9TX^S=2'/&;BC^K?HB^"W$_P#Q&6CCN/?"CC.IE_#?!F>\
M:Y=A\SX=SS!8>698#"X>OD6.J<F#EC)T.:L\3@JN"PV-JK%QP>(CA:U"%5Q_
M:OX/_!OP'KMYX9^%$'B_08/A3XEDA\3?#3XOG4[6'Q9X%DC83KI%Z6DCEB4S
MG:5G=5Z[L"OHWXA_$W0O"6LZ]\(OA?XSTVU^/FD6$:'Q@;RVAT7XO:/;18N;
M34KU&6"25[8&,@._S-@,>#7\W=Y\4/"OPPN+^_AUK4]=MM1@>P\0>'[;4YE&
MF7]PI7[58JL@$*Q,Q95A S@8Y!%>O_#[X%?'+Q7X#L_C%>0ZSK/PHTV]5O"G
MBI+JY6^LY;Z4&*VN;P-YC1*S!&WL$V@\8''YWE;RV=>&2Y5CLLEBTH_VGC\-
MC%.C@,&H^ZJ$TXRIT*4'5=#'<M3$86K; XE2P\E)_P!E<<TN-J&4U_$[CWA?
MCBCD5255<$\)9WPW4P^9<7<2U*M&-:IFV#G3J4L7F^/Q4,!3S;A9U,)E/$&7
M*?$^32HYQ1J4:?[0_!G2OAY?^#_B!\7[K7(- ^&TT-QHWQN^":7X6%M0AW)J
M&N:% 9=]Q-+<!IE,*_-D$$@YKR+Q!X#^"OPU\,^&/C[?_%K6(?@QIWBBVU;P
M1XETR[$GCK0K2.X#P^$YK!)#<+8!L(Q<;=O)SSGXZA^$_P 7+7QQHW@>YBU"
MT\8>)M/@O?#>E6=U++HWB&&\C5H%NGB8VUS/(&RZ2$N#DGO71^)_V4OCYX5L
MO$-OXX\/2VD>B02Z]K_A.]OF-I;:?"#)+>6VESG:0$^9?+A/&,<U]G4X,R6I
MA4H9SEE7^SX5J=7$2@W['-.98A.5*GBX06'G&*JRP,944JO-B:%2DI2B?S5@
M_I,^)F"SUSQ?AMQQ@(<78K+,5@,FI8E1_M+@54Y91.G1QN,X?Q%:IG.&J59X
M'#\4UZ&/J5,#[+),UPF/E1I5E_77\#?VA/A9\6?A7X8\>^'?&>ERZ)?Z;;A+
MK6-2LK*]_=1(F^\CGFC*3. &;(!))SSR?7D\:^#I(?M,?BKPZ]OC/GIK6G-%
M@=_,%P4_6OXT_@7^S;^TS\>O",DWP:L=:;X97<[1O-::G<V4<$T3E'2."-U$
M>&W#:!R!D# KVX?L-_\ !0C25/A/3M&\1R^'<;%O&UF]+X(*\-YF01QSGZ'D
M5^HY;6]O@,'5^L4,7SX>DWB<,TZ%9\BO4I<LZBY9/5)5)I;*4K7?\'<:Y?\
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M;;Q;X;N(UZO#KFFR(/\ @27)'ZU$OC[P.\WV=/&'AAY\X\E==TQI0?0QBY+
M_45_*;#^PY^W[X.LCX?\-^'?$MW:W+^9-?R:W>R,@8Y9 3)G&<XY_'J!JV7[
M"7[;F@^']4U"'PMXGO\ QG=W"RV=XVN7I2U7.YD\OSL<GTR!F@#^I\^._!*W
M'V1O%_AE;G_GW;7-,6;_ +]&Y#_I2W'CKP5:8^U>+O#5OGIY^N:;%GZ;[E<G
MVZU_*)#^P7^WL]U'XVOM$\2S>)(4 %@-;O1&Q S]SS.>?UZ9)J_8_L,?MY>*
M-7L]0\9^'?$HL;6X,TEA'K5['YR9R(SMDSZ=NW!Y- ']5C^.O!4<"W4GBWPW
M';-]V=];TU(3GIB1KD(?SIZ^-?!SQ>>GBOPX\'7S4UK3FCQZ[UN2N/?.*_E*
MU?\ 88_;U\3WU_X?E\.^)=+\(>=YE@J:W>B2)%^ZID\W/TY[X(]$F_8H_P""
M@UO;0>%=.\-^)(]'M4:'[>=:O"\RMQNW>;G('N/QS0!_5E;^._!-VS):^+_#
M-PZYW+#KFFR,N.NX)<DKCOG&.<]#1%X[\$SRO!#XO\,RS1Y#Q1Z[ICR)CKN1
M;DLN/<"OY8;O]AW]N3POX>TJ'PAX3\2MXA:9VUC4I-:OI/.BDX*A3+@%0Q[=
M.V:QK7]@[]O3PI)/XATC0O$U_K.K*3=0MK5XRP2.#N8*9<+C/8?0"@#^K6;Q
M[X'MW$<_C#PQ%(QVJDFNZ8CL?15-R"3] :?/XZ\%6HC-SXN\-6XEQY1GUO38
MO,STV;[E=V>VW.>U?RNZ!^P?^VY<ZA-X@\8>&?$^H7*6<JVEDFN7J(EVP/ER
M%5E_A8\YQ]!6"_[!G[??C%E/B71?$UE'H\[2Z7'%K=['O1'+1(W[PY)&!CZD
M<] #^L23QKX/AC$TOBKP['$1D2/K6G*F/7>;@+CGKG';K4</CGP7<1O-!XM\
M-S0QY,DL6MZ<\: =2SK<%0/<G%?RE7O[%/\ P4)\2,NE7WASQ'8:3"(X%*:S
M>J\D4; %MWG='49X_2MCQ!^Q-^W58RZ?HG@SPEXELM%FLDM-9E?6[YWFE( D
MF#^:3SR>/K] #^IZW\<>"[M6:U\7>&KA4.&,&N:9*%/H=ERV#[&HQX^\#&86
MX\8^&//)P(?[=TSS2?\ KG]IW?I7\I5M^PO^WWX(MI=,\,>'_$M\FHN);FZD
MUJ\D,)8Y=03)G )XZ=P#6MIG[!_[;FE:9K.KW'A?Q-J/BN["MIDAUV^V64@&
MXX3SMN,YP0?0>N0#^J&3QWX)AF6VE\7>&HKAONP2:YIJ3-GTC:Y#G\!3KCQQ
MX+M!NNO%OANW4_Q3:WIL8_-KD"OY0H/V"_V]]2N8/%^M:+XE;7[ #RK)-;O
MDNS&T%?, /0=.<_G5Z']AS]OCQ=JEK/XM\.^);;3(;Q)I;*/6[U&DA0C]UN$
MHQN&>><].: /ZK6\>>"%B$[>+_#*P'I,VN::(C_VT-SLQ[YQ6MIFNZ+K4?FZ
M/JVFZK%_SUTZ]M[V/_ONWDD7]:_D>^)7[&/[=4,>NFW\)^)['P/86\DZI'K=
M[YL%M!&3-,6\S)"JI8^PY%?</_!(K]I+P[I-_K/P,\;7VHV/BI;IK30I]6DN
M[DZO=0MLN+>.:4L%9"".<Y8#)&<@ _H5HHHH _FP_P""PO[/Q\)^,/#OQO\
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M8?\ L2]6_P#1)K^=_P#X(R?\G':K_P!B_?\ _HQZ /ZL**** "BBB@ HHHH
M**** /!_VE?',7PZ^#OBSQ7<:-8:]:V%O&EWINI%%M9;:=C',S&0%=\:G<@(
MY;IS7\VW_!13XQ?LRV'[).IV?PI*CQCXSM)'US3)88R=/N+M#YR6Q<;A$DC,
M(V0_< (]*_H@_;(L?[2_9\\<V/\ 8/\ PDCW,%M%'HYF^SBZE:7$8,N1M"L0
M>HS7\M_[6WPADTOX:>(-%\9?#K3])\5:IX8#^%)4U6V,:,T#-%$"'(,B<<]2
M1]#7X7XMYC@*2Q673R[#5LUQ.25%EF8SI2<L%4JSK1DIU84)\M2M"G4IX*C.
MJE5G*M;D<;R_U!_9^9#PCB\SX6SK.L?G.%S#+?%'"8QY?E>>8'!T,\P>7X;+
M)T89GE>*Q<:V,P655\3/'5:^'H4948MWJUU>G3^LO^"(EK/IO_!-[]HFZN0A
MM[R^\57,/E.'DV-I<D>'7C8V1D ]N16Q_P $@K#QKX:^*FII%:V%SX4\1W6L
M74]S'(KWEK(+F5DC=,EE+'&0<8R.N,UD_P#!#JVN1_P3U_:5TB5#]M@UOQ7
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M8_3\?Z&@!PZ?B?YFEI!T_$_S-+0 4444 %%%% !1110 4444 %%%% !1110
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M;CO(FN;;5+<2?OHQ(&5A(#U((/2OW&_:G\/Z_P"&_P!H'X@ZQXLT.<>!_%\
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M[]J_4WQPP\6_L9ZU!?Y:/6_!=[87/KY5Q!+"^#QSM/7L<XZ5^5=[_P >TO\
MNFOT_P!9U"+2_P!B._U6[)-OIO@R^OKC;PWDVL,LCA/]K"\=>: /Y_\ ]D/]
MGW1O@5X U;2/!WBWQ;;VNI^)]6U":QDU2;[%!-=S.[^1"'VQY)." .#VZ5\S
M_MWZ)\7?V;O$'@;]LWX%?$[QV_BSP3KMG=>.?"6HZ[=S^&]:\-07$?FVL6G,
M[1&=X\@,4R<^N17U[^S#\;? OQ4^&TGB70K];&R/BG5=,6'4&V3/<6DTB2;
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ME$J&7YC".6>VE.I4J82DI>SIUY5:DINNDJCOR-\NA_ YXF\)_P#!7[5[+4_
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M#^S;B9?*L(9)9-T<418A?DR NT9ZX[9 /U\_:\_Y-K^,/_8EZM_Z)-?SO_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F/T_'^AI],?I^/]#0
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M1Q1J,M)*ZQHH]69R% ]R:R3XD\.J<-KVBJ?0ZI8@^G0SYZT :[HDJLDB+(C
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MH,C!'/4YZU^9G_!R3X^>R\6_";P%)I)GM]4\.76IKJ+,Z1V\\5S(B!2$9))
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M&902INU!4]P1[4 ?UPT5_)#_ ,1=G[#O_0!U+_P,6C_B+L_8=_Z .I?^!BT
M?UO45_)#_P 1=G[#O_0!U+_P,6I])_X.UOV0/$WBCP]X4\,>"=8U?4O$%XMG
M$$O-J0NY 7>V, G)/)' Z>@!_6O17XN^&/\ @LW\'];MX;C4/#%WI0GB65!)
M=JW# '!)X. 1T)KK_P#A[W\"O^?27_P)6@#]<Z*_(P_\%>_@4.?LDO'_ $\I
M7QK^V[_P<9_L_?L<?#?3/'$_@?4_'.HZU</:Z7X?TZ]2">ZG7/R^<Q$:#H2S
ML !R<#H ?T>T5_#7H'_!ZS\$+]8_[;_9<\6Z*['$BG7(;L)SC[]N9%/'.<^Q
MQBO<?#__  >,?LB:IL_M/X8Z]I&XC=YMZ3M]>J]1Z''K[4 ?V1T5_) O_!W;
M^P\5!.@:F"1R#=KD4O\ Q%V?L._] '4O_ Q: /ZWJ*_DA_XB[/V'?^@#J7_@
M8M'_ !%V?L._] '4O_ Q: /ZWJ*_DA_XB[/V'?\ H ZE_P"!BT?\1=G[#O\
MT =2_P# Q: /ZWJ*_D9?_@[J_8TNKW2=,T/P;K&JZCJ^I6VFVUO%=]);F18D
M9BJG:I9L G Z<U^CVC?\%LOAMJ-O97%Y\/=2L%O;2WO$WWJG$5Q&)4)/^ZPH
M _<BBOQ^L?\ @L)\$;F(//I<]LY&2C72\?K5[_A[W\"O^?27_P "5H _7.BO
MR,_X>]_ K_GTE_\  E:/^'O?P*_Y])?_  )6@#]<Z*_(S_A[W\"O^?27_P "
M5KE?%G_!9SX(^&+*PU1M(EGTG[;%'KM^UVD<.BZ:2/.U*9F959(5)8IE2<=:
M /V=JAJEA;ZIIM]IUU#%<6][:SVTD,R"2)UFB:/#HP(8?-W'N.17%?"CXJ^!
M_C7X \.?$SX<:Y:^(_!WBJQCO]'U>S;=;W4+@;BA!(RCY1L$C<#@GK7HE '\
MCOQ?TZ7]BK]LVQOM:T:2WT>3Q4/%,VLV@>.VDTRZN=ZVHDB(5@J,,I]05'-?
MU5_#CQWHOQ,\$^'?''AZ=+C2?$6FV^H6KI(DA59D#-&Y0D*Z$D%3AAQD#-?F
MC_P5>_9Z;XI?!E?&&C:)!=:KX,G.IZM<Q0J;R72;==[QD@>8Z)M)X/RCOT%>
M+_\ !'G]H[0?$/A/5_@_JNHW4?B6RNI+O1-*NW9G33+?=&ZHCMF)5VYVJ.@&
M1SF@#]S:@NH$NK:>VE57CGADB=64,I61"A!4\$8/(/6IZ* /Y#_VN_ -U^QW
M^VAI?C2Q>XGTBZ\0)XR>2(21V[I+.)#:;E(7 SMV' ZY'I_5#\&?B+:?%CX9
M>$/']DB10^(](M;[R4=9!$[QC?&2I;#!NJDY&>@K\[O^"KO[.<OQ;^"4OBKP
M_I<#^(/"$C:C?WZJ/M)TB!3)+&>,NJD?09Y[5\Z_\$:OVBAK/AS7?@YXJUF>
MYUVTNY)_#EC(Q(@TVU+1/&J,WR@!<Y4=1TQ0!^]5%%% !1110 4444 %%%%
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MD<'/-?UM$;@1Z@C\QBOY9_\ @L#HFEZ9\23/86<-K+<6[/<20Q+&\TA9,L[
M?,3GJ>M '[B_\$]FE/[)7PD$B;0NA((_5EW=2>YSQGT K[4KXQ_X)]<?LD?!
M_P#[%]/4_P 7O7V=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:5E11[DBJ&@>*_#/BJW-WX:U[2M=M0<&XTJ]@OH01V,EN[J#[$YH Z"BBB@
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MDJEY-,EU&Y@2YM_+!93"))$P#AFQP ?KS1110!^;/_!7C_E'7^TW_P!B./\
MTYV-3?\ !)C_ ),+^ '_ &)NG_\ HH5#_P %>/\ E'7^TW_V(X_].=C4W_!)
MC_DPOX ?]B;I_P#Z*% 'Z04444 13?ZF7_KE)TS_ '#Z5_(#^U?\-_ #6W[1
M_P 1)K/Q3_PGD7BC5K2+1/[)O?[-^P>9(#J37/E&)85&6+EMH /'I_7_ #-M
MAE;&[;&[;?7"DX_'I7\VO[9'[4GQ#U7X=?M'^%M)3PA8V$L.M^%+J!_#T)U8
MVLJ21-.MWY/F"<*21.&]\FJ6&J8E>YB,LH>Q_?M9A@:V-;=*S52FJ.%Q/L:=
M&[=>=;V5!J4/:5%9&U&M.BY<E'-ZKJ1=*?\ 96,I8-*G.RE&NZTH^T<UI1C2
MO74E+V*NV>N?\$/?'7@/1_V=-8AU+Q[X)M)_[4W/;7'B?1[:>#$DF5EAN;R*
M1"IX8E< \$Y-?MK_ ,+5^%__ $4CP%_X6'A[_P"6-?P-?\$UO^#?.;]IKX?>
M,_B->_M+_$;PFFJZY=SVVDZ1XFU6W@A>ZN9964Q6S%$0$D<YQC 6OTE_XA9X
M\?\ )WGQ:SCI_P )=KWY=*DQ/K/_ (.#/%7PL\3_  7^ =I/X[\*W:CXN6,L
M4.G:_I6H3N1)9 ,(;.ZFE*%AMW[=F01GKC]T/V7$M8_V>?@^ED_FVB^!]'%O
M(.0\?E':<U_!;_P5(_X(9S?L4Z'^S]\3M/\ C]\0?B.7^)VGV%WHGB'7M4U&
MU11=6TF^**[)CY5Q\^ V[<,$8K^\7]DN+[/^S5\%8-K)Y/@'1(]K_>&R$J=W
MN<9_&@#Z'HHK@/B;XRO/ /@[5_%-EHLNORZ5 UP=.AF2!Y8T!9L2.0JX [U4
M(^TG"'-3@YRC%2JU(4J<7)I)SJU)1ITXJ^LYRC&*U;2)G.,(RG-J,()RE)[1
MBE=M^26K.-_:$OO#$/PUU[3?&6GG4O#>LV<NGZI )#%_HTJD.3(,;!CN#G\J
M_'[]@6'X>_#[]IG7O!/P<\0PVO@>_L=0U+4/#+/'<M!.'ED:07C[I-B/\Q^;
M'&,\X/L.M_MLZ7^U'X'^*_PYL_A_K/AN+3_#=\EWXHFE^TV^FWL<<FY4$:Y+
MH01N#'J3VK\^?^"9OP[T.+Q]\8?'L?C=D\2>%/ _BG3K30+@LE[KJF.Y/]IP
MB4K)MCP.0"1Z=P\PP^%P&,IT<34R7$9C2]S#*CGM3'SC[>*^L>QP.73Q>4SQ
MM"G_ !:F*E3Q.&HNT9PDTG="IB\1A*DJ5;,L/EE2=.I653(8SPE:I2:>&DLR
MQ$(8G"4L5)NE1JX6]/$STDW2NS]B_'O_  5*_8J^''C36O 'B/XL6O\ PD_A
MZ9H-7L=-M?MXLY58JRRR13@ A@1R!R,5B:-_P5J_88UO6=.T*V^+D-O?:K<)
M;61U"P-E;R32,J(IGEN-HRS =^M?C;_P2:_8E_9]^.?CK]I[QU\4?#%QXN\2
M7_B^_CFN=6N?/$2R:C(N(/,61E*9X&0%;J#7HG_!9/\ X)[_ ++_ ,+OV1];
M\>>!O!\OA?Q7X>O["XTK5-,N!!<12I=PL&+QQQMU.#@X(QP,9,"/Z9-)U73]
M=TRQUC2;J*]TW4K:*\L;N!@\-Q;3*'BEC=259'4@@@D&OEOXT:5\*[WXJ^ +
MCQEK+6'B:%!_8-F!Q<@2L<DD8^_D#GUSCK5C]AB:XN/V/OV=)KJ>6YN)/A5X
M7,MQ.[233/\ 8P"\CMDL[8Y)ZGTKQK]J'0]5U'X^?!^]L=.FNH+10)[A(W9(
M?](D;YF52%P.Y(Z_C0!^AEN%$$ 0Y00QA#ZJ$7:?Q&*FJM9@BTM0001;0 @]
M01$O!]ZLT %%%% !7X!?MM:Q\:%_;5CT[X4KX=UQK?P1:W%YH&N2V<2HC0#]
M^OVG&[)(.,'GO7[^U^#W_!0OX<:9X(^.&H?M&^(/ WB?Q+I</A"#1Q-H6L2:
M?YDD2>6(!''*CR/T& "?0&LZG++DH2>)C]9G&A&6'5-PBY._-BXU<+C%+!J,
M6ZZ5%M*TG*,5)BEA)8NG4BL#A\P]C!UWA<1&,W-0:BOJT)9OD:GBN::5"*S&
ME*4G:,:DFHOZH_X)E^'/C'H?@;XCW?QBAT>UU36?&+WNE6>BS6\UK:V!67]V
M3;DHK E1CCIVZ5^CGBC_ )%O7O\ L$:A_P"DLM? O_!->=]5^"UUXEC\ ^)?
M .G^(-3-[IUCXFOY;^[O+<JW^E1M,S/'&<@!<XYXK[Z\4?\ (MZ]_P!@C4/_
M $EEITTHPC&.*CC8QO%8F$Z52%51;2<*E&CAZ4H1MR1=.C3CRQ5EU;]A+#6H
M3R_^RYTTE+ >P>&>&DTI.G*@\PS5TIZWG"688J2DWS5+WC'^/G]F'_E(9X6_
M[*/K'_I6:_LCK^-S]F'_ )2&>%O^RCZQ_P"E9K^R.K _D5_X.3O!-C=>*OA%
MXW757&IV&@SZ8-'5"XDM)+MY'NC@93RR 2Y^7 (/48_;#_@CS?3:A_P3\^!=
MS.@20Z5>1L NT'RYU0-C ^\!N/'>OQD_X.-+'Q7HOC?X1>/-(U*W32;;P]=:
M1>Z7/$DPFDN9Y5$WER(RL%# '!4C.[<-N#^SW_!'W43JG[ /P/O6B2%Y=.O_
M #$C&U/,%P S*H^Z&/(':OP'A>,8^.7&UH2I2ED].4H-7C6]_+E'$1ES/?6#
MCRQM;NV?Z[>.]:O7_97?1AY\31S&CAO$;%4:.(A+EJY;)T.,95,HJT?84[^S
M]VM&LJM9S51*32C%+]-Z***_?C_(D*^4OCWXLEOGB\(Z'JP8,'C\1V5O+B5+
M:5<!9"AW)N7N<=<@^GU;7Q+\>OA%KFDZS<_%7P!'/>7SH#XIT/>9/[5M(\<V
MR%3L:-<DA26X&!B@#Y'\7?LM?!3XA>"M9^'GB;PS<7N@:[YTETGVR;STNY06
M^U1W )>,K(PD&", =AQ7Q'^S[^UWKG_!,;XK^)/V>/VCOBAHGC+]ENTT>]\3
M^"_B/-K::GKGPYM8$D>#P;-I:W1NI844)&7:-F4KD#/%<S_P4L_X*"ZW\$OA
M]X)^&/[.NG3^)/V@OCIK4?@C0;.VBD>X\$ZG>2"V:[OH44R+';[R=[(!A0<]
M379_L7_\$"/AS<^&C\6OVZ=;\4?&#X[>/+'[5XGL[KQ!<'PYIRWZ^=)9QZ;*
MDL&Y!(8R@1=I'/(Q0!\Q_P#!63_@X8\!3?!7PG\,O^"?WC"V\4_$OX]>;H&A
M^+YG;2FT-;PO9,L,$DX=I)?,PSX.. N!DG\UOA'_ ,&UWCSXX? N^^-'Q^^/
MOBO1OVEO'EA-XOM)++6M19-.NYX&U&WDB83$%9)PGR@D '' X'[:_M__ /!M
M;^R5\;?@SYG[.&B7?PG^-_P]MY-6^&>O6.H,ME%JEEF[M;.:WAAC!$UU'%M)
M.T,!G& :_![X4?\ !=OX_?\ !/+P%\4/V/OVX/ &MZO^T5\+;&Y\-_#W6I(9
MV;Q1#Y;:?I#6SR;3+YC&(C;GJ,>P!^@?_!OA^W]^T3\,/VB_B1_P3$_;"\3#
M6[KX;+<0?#7QOK5ZLE]K<%H[Q6=B&FD$I,D0CZ@G<<$<9/\ :?7\.W_! W_@
MEA\?/C9^T%KW_!5+]LZ/4_#E_P"-[R;6/AA\/[AI;6^BL[F1KBQOKOJWV5(C
M'A-RA\G[V1L_N)H **_,/]K?Q7^U5XRU\^%?V9_'&E_"VX\.DC5M6\16T5U;
MZTSGC[('B8(L?3@G)ZGL/R^^/GQW_P""E/[%GPN\0?M$?%_]HWP#XU\'^"[=
MFO/ MEI-NFI>)'O0;>WALB(@_F12NC QDL"ON<@'XQ_\%S?&GAG]G?\ X+I_
M ?\ :&^*FLP0?"W1O"VDB_>QN(]0U&TEA6/S%_LL,[*ZE?\ GGGD$GM7W%^U
M?_P<!?\ !.#XC?L^_%?P3H'BSQQJ6H:[\/\ 4=)TBWN_"UU]GFO9=+-O&H\R
M'RU#2?*& Z'-?0?[ O\ P1K\#_MA:>_[=?\ P4,%Y\8?B-\9+U/'/PV\/7U_
M)_9/@SP7JV^XT[2[BQECD1IDC*+Y952% 8G!&?V(O?\ @D1_P3]O],?2;C]G
M?P1]D>'[.PCTBPCD,>W:?WBVH8,1_%U[DYH _#C_ (-'O#6I6/[+/Q.\63V>
MDV6D>+_&&H:CHD=OJ,,NIO:37[31/?::KF6R/ED':Z+R:_KSK^2']LG]F"?_
M ((A^,/#G[:'[&UYK>C_  'FUNWL/C1\'KG4;C4=/U-]2N5BMFT6S""*V4E_
MNQQ*1@C)ZU^F^G_M\?M%ZE\-_#7Q=T;X,ZGXATSQ)X<L_&%CX8M$>.\NM,OK
M<7,=K$VTLLBQ?CGZ\@'[3U#<3Q6L$MS.XCA@C>661N%2- 6=B?10"37PW^PI
M^VSI/[:7@3Q#XF3P7JGPY\1>%=<ET+7?!^N29U2SN82ZO(498W,.Y,!PI!R.
M:^W]0LH=2L;O3[D%K>]MY;:<*2I,4R&-P&'()5B,CI0!^>GQ<;2OB_K-];:C
MJ<GB#P1'($L+:TG>&.*[@;$FV2%R#AQSEN< ''%?%/[1_P"Q1\/OC#X=M==\
M,ZF_PW^*7@:%;_P'\1/[1ELDT&^LE$L$EU/N59$RBJ3(W.3ZYK[ \9> KOX#
M:M*D$5S<?#74+J6\%T0\\FARSN9)I9V"DE5R2.< =>#7\^_[8'QX_:(_;^_:
MPL_^">O[&&JW?AWP7IMM#JGQ:^+=AYL5JV@R,/MEA#>PKM@N%C+J2&5U;C&<
M  'Z+_LU?\%IOA5\(?AS?>"OV\?'VA^$O'G@3Q5#\/=-\7:5<GQ##\0Q&[6]
MOKLS6MS(+6>;$?FJP4$$G[PP?PU_X*6?\%&/VA?^"MW[5-I_P3__ &&_%:^&
M/@_8W5JGCSQ'8ZJ]I?\ BO3;A\S7 BAG,D(2W8[8P<*!R"Q8G^ACX-_\&_?[
M!O@'X:Z5X0\;>$=;^)&NF:WUC7_$'B?7)=3GO?$ Q)/=VYNX)'@3SRYC .0#
MG@\5^-7_  5+_P""%OC7]D;Q-9_\% /^"6,VL>&/B1\/0NK^._ "WT]T/$FC
M6)\^]^QHB*OS6\91D5 1_$2N* /AK]JG_@WX^(?[$_P8M_VI?V4/VA_&5E\:
M/A%9VOB?7[-=:U06^J7]FJW=_:S*93&58Q,A,B8(/)Z5_4!_P04_X*.^(?\
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M_P""@_QJ\;_#+_@E=_POK1[KXB?$O78K7XU?$#PM;/:3:;X*NITWQ1R6*>;
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M"CQ[)'#X6\9:5J<LO^KC64Q.WL%E"'/MUKUM75QN1E8'H5(8'\1D4 .HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#\;O\ @M/&7_9U\+L#CR_%ZGZYC@&".^:_#+X6^!].T'QY\,=5
MAS)-JM_IUS,LGW5=I$)QR>_7MQQBOW3_ ."T?_)N7AW_ +&U/_0(*_&/P7_R
M,_P<_P"N^E_^A)0!^_7[=&JSV/[(L=G82PV.K7&D:?<6.L7"@1Z>;6 R'RY<
M929UVJFTCH.X%?F?^R7HWB3Q1^SW\9/B?KWCW3-9U,:0EEI6@W=R)=5N9K->
M%OXV.][29EQ$K#!!QBOV"_:3T7QQKO[+<]G\// NB_$3Q0="LS9>']<*BUE
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MW8X)(.>/+/$?[ GASX7?'KX:^(?AO9:G=:7:^6VJ><998XVCD."S;W"\ $C
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MUW^R-X>\1_LGZ_XT^V:2[2Z_%#J[PVK)XIG9OM-G9QL$P^2R;$ SC'U_K<H
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M_P!I3]H.>.^^._CD^$?#4C+/8:-X)N#97@MV.]8+X1F,;BIVMDDCG(SU^O\
MX9_LT_"CX7VUN-'\-6%]JL 7=K^IVT-UJTKCK(]U(C/N)YR#G//6O?NG044
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M_P"35/A;_P!@J3_T>]?9= !1110 4444 %%%% !1110 4444 %%%% !1110
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M':=X&^'/AVP\/:#IT2((;*WBBEO)47:;N^EB1#<W<OWI)I,LS$UZ70 4444
M?F[^UQ\)?A?\:?&$?@SXF>$M$\3:7=:*RRQSV%I+JB1,&!,5V\;7,"<Y!1@
M<GH:_/KPK_P1\_X)XZ5XPTG7+'X/W[:C'J<-S''/K%Q<6IF\T/AK5V:-E+=4
M*$8XP.*_6+]HSX#>-O&VL:/XZ^%WB6W\/>*M-98-66^5YK?5-'7F2SA14?RY
MW&45C@$D<YXKXA\6>+?VE;F\UOP%X$^#>O:%XK%M+9:!\1KV.631;3560I#J
MLJ;"&MTFQ*R@'Y>.O0 ^(/\ @C7967A7_@IC_P %./A]X?LK+1_"7ABZ\,0Z
M)HEC;P6J648O(D^>&%$PS)_$5R3UY-?U!5^1O_!,S_@G5XJ_9'USXQ?'+XU>
M.;/XB?M&?M!:A#??$3Q)I4,MOI36UM,+BPM+:"1(RKP#:CLJE20<'DY_7*@
MJEJ-E'J5A>:?,66*]MIK:0KPPCF0QO@^NUCBKM% 'YKZCX:T_P"%VOZCX17_
M $'14N);ZUU74)!%!))<OYCK)<2D(JC=CEB/?BOF3]K_ .+G[-_@+X,:^_QJ
MN?"7Q TC5;.>QTOP987>FZ[JVK7TR-'%;VUK$TUQ;R-(RA940-GYA@U^M'QB
M^"W@SXW>$-1\%^,8+H:9J<9CGN=,G^Q:D@(QF"\5&DC(!]P..,9K\TOAU_P1
M)_9!^'WQGL/C27\>>+=7TJ1)]-T'Q?XBDUSP];7,;!TF.GW<<D$A# '!C H
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M5[3M.L-(L;33-+L[;3].L8([:SLK.&.WM;6WB4)'#!#$JQQ1HH 5$4* , 4
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M6$S6MA<7RJ,<3FM+"T(87$4%%JEB<DP>557S-SE-J+C]B?"?]G'X'? ;0(M
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MUOX@T.VU#0+?3-.:!],GOK9)HTN"85\P1>8I)!8'& 3R* /N.BOS5UCX9_\
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M?"W_ +!4O_H]Z^RZ^-/V O\ DU3X6_\ 8*E_]'O7V70 4444 %%%% !1110
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MU&SU72]$GTUK>TE>*-K*:XD,DKF-E8%<D$]"N5(()KZ$_9S_ ."C?@']A/\
M8#_9 U'XHZ3K&M6/Q AU.*6;1(1->QPVYDEED",-A;";VS@GHH).*^7O^#DW
M1?&2^,OA!XBM+R1?!R>'KG3[^R2?8LE_+=2;))(1CS4*90YR!N!QQQ\!?MM>
M%7N/^"?/["6O66HWUW'>6VJ16/AV.%I?LQ:"6.8VT<89W);/*J,\BOY&XBSS
M,N&O$#Q,SC)J?L,=@\GP$X.O%5*4W5QN4TZF(]E-I5(SIMTN6.K>VS/^B3P;
M\*N"O&SZ(/T(/#CQ)Q;S;A;B+Q'XKH8JGEE:I@\?A8X+AGC_ !>$R=X^A3E/
M"U\-BZ<<=[2JG25).,WK"_[UK_P<5_L:S2"&S\)_%"ZG=ML,,>DQ[Y3V  1B
M"1GC!ILO_!Q;^QI 6CF\)?$^*>,E9('TJ,/&XZHV4'(]<?A7\DOA?XY>!_A_
MI.E:?IOP>TB^\7:=][6M4AV7R7#*5;$1B9RP8<*5!^M7?!WC^#PYX<\3>-O%
MWP1\.^+;?Q-KLHBU+5T:"YM;F8G;;VD;0EVC4GY62/'&>E>+#QPXWGR)9QDK
MER2J5W#(J\Z>&A&$96G*+<I3YVX/EBX1W<C].Q'[+/Z+>&^M5)>''B9[".(P
M^$RF%?Q6RO#8W.\17Q,J;>%IU81H4:$<-'ZS!5ZT,35;=.%'2Y_6Q<_\'$W[
M%=O#:RC0_B)<-<+N>*WTV-WMO]F;*+AO;ZU W_!Q-^Q[%%'=7'@OXIPV<^?L
MMT^DIY=R5SN"9B XQS\Q_P ?Y"/"?Q(\'^&?&%YXB\8_!&RN= O(9A#H]U:W
M,5K!)(/W1C:>UB4KSQCIVSQCI;KXGZA\3_$W@BQTKX/:5#X7\.W=S=:9X<6U
MD32K^$$R;;BX:VBBVJ@(.976B'CCQO.%UFN3NO*HJ5+#4\BKRF_WE.'M:C;7
M+"492G%*\VX\BA<JO^RO^BSAL2HRX!\2/[,I8.>-QN=XOQ5RNAAJ;6&Q-?ZC
MA8TZ<G6Q=.M2I8:I.HJ>%A3JO$2KVB?UL6?_  <3_L677VDOH7Q$M1!$9$\_
M3HU:X8#_ %<2B/ECT&3^'3->'_@XH_8\NR5L/!GQ2O)%5I)(XM*3='$OWI&V
MQ/\ *O4]!CJ17\B7Q(^)&B^*[EX=$^!&B^'3I-XT-])HL%S<6[2P28EBD>"T
M:)1E2#ESQSZ8ZRY_:(\+P:)_8WP[^".D:5KLV@2:1KFK6UJ\M\6E3RY9Q'%:
M2N#G)W/L/;(Y%->./&BG4C/.<E4:2]V<<BQ#GB)-ZQI0DXI2A;7F<59WN[&;
M_98?1B>%P5?#^&OB;5Q.-FU7PM?Q7RB&&R>G&,'&OC\7AXU7.EB82=2FL/&M
M4YU&'+&,KG]7W_$1A^Q?N51X8^)@W,JDMI<2A,G!+'8<!>_'3TJU>_\ !Q1^
MQ7:3B&+0OB-> HK>;;:9&T6YAGR]Q3[PZ'CK7\E]GXWTSP1\/="T/Q!\ ?#>
MKZGX@BN;C3M=G5SK-UYK%G=[9;>6=70ME5V*<CL17-^ ?BIX#\#1>(/^$R^"
M6FZOJ&H8?0X]2MIHELYU.Y,?:+96(5L8VJ<_W12_XCAQS&5*-3-LCI>TA&=6
M53(\3%8=NFI^SE_/*=THN-T[IIV=RO\ BEI]%6K1S#$X/P^\4L='!XNIA<!1
MPGBID=5YW3CBUA:F,P\FU]7IX9PJRJT\1[.<5&I&4>>%C^O";_@XE_8^LRJZ
MCX*^*=C)(HDACFTJ/,L+?=E7,:_*W;K_ (RQ_P#!Q-^Q8]A+>MH?Q#CDCDV+
M9'3HS=2C/^L5?+'R^O\ ]8U_)MI/Q(U?QK\0+[Q_K?P9T76M*T'PX(U\/:E;
MO:Z7::? F%F@>:VA620*,KA'SU'&:\^USXC>']=\2:7XH@^"&G:3X?M[J.:X
ML;*UNFT^ZMXY,R+YHLDA;@'/S$9X) HGXX\<1BYQS3*)1E5E"DJF0UZ<YTDX
MQ>(O&4J:49-MPYF]+-="L-^RQ^BOB*T<+6X$\1*5>C@</BLPJ8'Q8RK%4,-C
MZM.=:.2J-:%/$SK5:<$HXCV*I2<G*G4Y8\S_ +!$_P"#B?\ 8\FCDN(/!GQ2
MFLX OVJZ72H_+MBPRHDQ&1S_ +P^E+:?\'%?[%MS=16[>'OB/;1R,0US<:;&
MD,0'=SL)Y[>_%?R6>-_CMI?C#1=4\(?#3X.:9X:T+6;FP%_+IMI)-/--&R*8
MYC%:ND2S'A@9%X)X[B_XW\?:3I>DV7@&;]GCPU:>([32;5I=2TR.2XOY(VC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ_V7_P#HJ.A_]_XO_CM'_#=?[+__ $5'0_\ O_%_\=H ^O**^0_^&Z_V7_\
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M?#+]HFYB^".IRZ[=6VL^(H?%)NI3%- JR2[E3E0NW)P.G?'?]2?^&Z_V7_\
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M@AA:&!CXG\>+!X6N\3A\+_K3G/L*.(<7%UJ=+ZYR1J.+:<DKM-I[L_6CP?\
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MR\9JKS&53Q4X_G+-Z<:.9REQ7G4I8^E&5*<:>*;QEZT%.A1ERS;5Z4':\4?
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M-6D:2W.NZ7#')S&[WL 5OH0YI9?%7AJ&U^VRZ[I:6F0!.UY#L)/3'SYY[<4
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M*]6^(6D7&AZMXE^)7B/7;73;B[:\-OI][*'@6.5F;]V 2%4' QQ7Z95^9O\
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MYIMS8MM\]YI4D4.@SN*Y;D@'OF@#[7HHHH **** /'OCVVWX3>,3ZZ7*!G@
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M!_2)^P%_R:I\+?\ L%2_^CWK[+KXT_8"_P"35/A;_P!@J7_T>]?9= !1110
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M\_AU_P &Q/PF\1?\$J+C]ISQ!XBUBQ^.EU\,IOBII[-<S+8K9IIYU!+*6'>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BY_P6V_Y-X\&_\
M8ZQ_^BX*^ _^"=?CWPK\-O OC#Q5XKU""QT_3KN2=@\@2>?RR6,<0)!+'TYS
M[@U]^?\ !;;_ )-X\&_]CK'_ .BX*_FUMM1U<68\/VMW,EA>S(QLHG95FG9A
MMWJ" =S<'/;/X@'J'[1?CK0?BE\8_&?CSPJMQ_8^MW#+;I= K)^[<@DCWZY
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M]]?ITIO_  ZXUK_H+K_X$R?_ !5?M=EO[S?I_A1EO[S?I_A0!^*/_#KC6O\
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M0,I4ZO%@YZ2L.ON#FOVCRW]YOT_PHRW]YOT_PH _%'_AUQK7_077_P ")/\
M&C_AUQK7_077_P "9/\ XJOVNRW]YOT_PHRW]YOT_P * /Q1_P"'7&M?]!=?
M_ F3_P"*I#_P2XUO'RZLA/HUS+C]&!K]K\M_>;]/\*,M_>;]/\* /P+^)O\
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MM.^ZV;F-L*<J>_KUK\E];TOX<?MS:=\<[O6?@?X4U*W\#V]\W@_5IKB.UO\
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M><8]<8]: /Z"**** "BBB@ HHHH **** "BBB@#\:_\ @KY_R)?PT_[&!?\
MT<M?D)XP_P"1PG_[)U-_Z)%?KW_P5\_Y$SX:?]C O8_\]E[U^0GC#_D<)_\
MLG4W_HD4 ?TB?L!?\FJ?"W_L%2_^CWK[+KXT_8"_Y-4^%O\ V"I?_1[U]ET
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M&@!PZ?B?YFEI!T_$_P S2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXR\<_P"E?$#QS<2:OJ-[(,W$.G7F)[2Q=C\_[D, 5;D8'K7V?35545410B(
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MGX \&>%[^3XS^&Q)J?A_PYI>CWTB"_@'EO<:?;V[.A'!5@>,\^O].%?S@?\
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M)TJKNJ=2UG9WY3^U"BOXJK[_ (+3?\%0M"V:KX@^&FA6>GQ(O[N;PDME',9
M#&YR\C2#G( 3D'&?2U8_\%E_^"I.M/9F+X?>&;#3]39C::A-X06WM50*6!:[
M+LH  ^\R<D] ,FFO'/@YRY/J?$G/I[G]C5.9)M*,FG522<M$[[HF7[*CZ2,*
M2Q$N)/!186TO]J7B7A)495()SJ4:<EE[=2K3IKVDX*/PM6OK;^TNBOXJ8?\
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MP_\ 1)]3'UAN!_,#-'_#\&'_ *)1J7XQ3#^8K]+)O^">?[-LW7PC$H]%$?\
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M/_A;^&?_ )9T?\+A^$G_ $5+X<_^%OX9_P#EG0!Z-17G/_"X?A)_T5+X<_\
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MCRL$>U:R\$,SG3J4GQ]F#A7FZF(B\LP]JTW*,N9I8E<K7+:\;-K3171Q8?\
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M>_C_ /\ !,+]@#XN^./$OQP^.?P@\%ZKXJU6(W'B'Q7K[P6WG16Z$[YYIW1
M$49Y:OY)_P#@J3^UY_P1'_9)LM=^%/[._P"SAX+^,'QD<7.F2-HUM!/::)>D
M-"KQW"_:#,ZR?=\L?.0H7.<UZ_"V8\44(9A2R#P-\,WE5#$2Q.;<2YMG.9X6
MC6F[1GFF9UZN+=*GC,5"G[66%H*,JE2]/#T'+W3S<_PG!LI8/^U_%3Q?Q6=5
MZ$*6 X;R?!Y+CZE%:-8#+*55RJT,MPTY.G3Q.)]EAZ,'%U91N[^LO_P>6_#^
M$[+CX.7=O(.L4MO<AQ]1QC\:_?S_ ((R_P#!7+1O^"L/@'XI>--)\(R>$?\
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M HHHH **** "BBB@ HHHH XOQ_X'T;XD>$]4\%^(D>31]8 2[CC.&=.X/(
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M^B[0X,X^\.LKXU\*N/\ .^*<XI<69E_;W#_UFMEW$N59KP_AJN1XO#U(UJ6
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M\5_L8>*_^$H\,+<>-/V:/&LXEU#382VH1>%X;]@QD#E'3[*4D^0#*[ 02"&
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M"B@#^>__ (AI_P#@GC_T%?VAO_#QZW_\9H_XAI_^">/_ $%?VAO_  \>M_\
MQFOZ$** /Y[_ /B&G_X)X_\ 05_:&_\ #QZW_P#&:/\ B&G_ .">/_05_:&_
M\/'K?_QFOZ$** /Y[_\ B&G_ .">/_05_:&_\/'K?_QFC_B&G_X)X_\ 05_:
M&_\ #QZW_P#&:_H0HH _GO\ ^(:?_@GC_P!!3]H;_P /'K?_ ,9KTKX*?\&^
M7_!/OX&?%/P[\8/#VE?%+Q%XP\*7L.H:'+XV^(-_XDL;*[MV5X9H[.]MR@=&
M4$$$?I7[C44 -1!&B1J,*BJBCT50%'Z"G444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !3)8XYHY(9462*5&CDC=0R.CJ5=&4@
MAE9200000<&GT4#3:::;33NFM&FMFGT:/XB/^"\?[*?A[X3?&&V^*/AS6;?2
M]#\93P;/!,"F.WAOG;=>7=E#'MCA>8LSN0IW>H.370_ #]J']G73?A[\(/@%
M\8_">O6WA?5)+";3_$R6MX^N:'K95"NJ1ZLB"2+3T<!A$LNS;GC'-?2?_!R-
M>6-P_P %-/AAB;4(=3?S=B_Z1.) =B=/FZA5'N,<5^O7["/P1^ _Q0_94^$.
MJ^*/@WX3O-8L/#6G6EU<ZWH5K/?M=16T>^83RQ^:-W!&'XXP:_EBAPM5QOBI
MQG@<AQ&79?R4,%B:U+&X2>,PV*CB)TZV*H<BFO91G)ZQ@XJ%DX1O'3_>_-/'
MK+^&OH"_1GXK\6,HXRXO6*S7B3),MS#AGB'"<-Y[D6(R?#8G+\@S>.*J8>M]
M>JT*=-.%7$0J5:W-4AB*CC5=_P":W_@I-^TG\,_&NK:?X(\%7TNBZQ\-K2/3
M_#_C2UAFM5\7Z<$!7^U755:_E9,(S2[SUR<D&NP_9<_9E_:+_:8^$6C^'?@]
MX4U7P#X'\7V-V_Q4\3:^LT_A[Q-]FA=E.DVDR-%!)/V9 ""P^E?=G_!8?]E?
MX9^!K[PEX]\*>#?#6EZ5;VCB^L([9$:2=2=AA4#=LX /)]N<8_7?]@+4U@_8
M<\#:MI]E;V36WA?5[BWMX$$<2O;P.\>  !R5&2/?VK](I^&^9YEB9U.(\YP\
M\)SVCA<HH5</.I0B[4Z-2M6<O8I47+#SJ890K8BC)PQ$IZ27\58SZ:W W!.1
MX;!>"_AKF]#B!X;VF(S_ ,0\SP.<87"9K7IPJ8K,,'EF7TJ']IS>94J.;X/!
M9W/%9=D^9T5B,IHT%*=-Y/\ P2^^#NH? G]FBU^'.KZ8^F76A^(]6MG$H"_:
MXT?8MTG"XCF +(.PKV+]I'X@> /@A;^"_$UY\*-&\8WOC#QEI_A@7-IH.GW-
MY92WKJO]H37 M9)-D1;+L6XP22.M>:_LZ?%'4?B7^S?\0_$WCV^.CI9ZUXHT
M^>_TYC'-;65FTB1R1.@4B8 #!&#N/!YKX8^ /[:7P*^&'A?XLZ5X\MO&VM^&
M?"&H:AXGTOQE\1XVOM+O;NW=VBL=%GNHY-DN]1Y/E.K=.@K[;-JF7X.G@<EH
MT,MPU>I0E')ZF;86G5R>@\(J;G1JR<XRIU/JZFZ45RNI*/NN33B?SUX5<$<6
M^)N)XH\1:F"XGX]Q^ S_  3XCX>RMXS"X[BB?$E6M1E4>>X;%472Q-+'U\/7
M^HT<-BJV(I)J,*=)2E']T;D:9_PCTYO(XK327TJ22[C51'%#9O;%YUV@!558
MBP( P,=*_EQ^.'P7^%7Q/^,'C/5/@U^SY\2?'FE>&;NZN]6\4:!JMU#I[M%(
M[W[V*PL5A,05VRN.F>,'/]%GP5^+?AO]HWX$:'\3=+MI[;PSXYT&\FBMV!69
M;!TEMW"C .6C#%.!P1Q7X=OXV^.7P(^)GQ"\!? 3QQ\,?#W@3Q)>7L7E?$5[
M87]H]Z\B7,L1N?F4J)&:/GK@G()KY+Q&HY?C<-DBKXG"8#!5*DW3X@5"EF,,
M.N2G/#X;#9=.?+BHX^4::IS6'Q#I\D/9QA.4:D?V?Z(]/BS@KB7Q8P.7XFID
MW'610HY97R;/.(L\X<X<C]4S2KA,]AG&/X=]KCJ^:8!0J4\%A91E0J-XF<I\
M\8)_J%_P3?U;X8ZE^S[;V_PPM-?T[3M*UJ[L-9TSQ+J$NI:I8:U%Q=V\L\SR
M.%1P5"DX!4\"OT KX6_X)_\ P1L?@G\&+FQA\6:3XRU/Q9XBOO%6NZQH<R3Z
M8=5U$F6YAM7C9E$:2.V #@#%?=-?=<-/$O(,I^MX.OE^)^I455P>)5:->C)*
MR56.(G4KPE.*51PJ3E*'/R7T/Y9\=,3E&,\7_$/%9%F./S;*<1Q-CZN$S'-)
MXFICL7&<HNK5KU,9"GBZG[_VL:53$TX5JE&-.=2*DVC\^O\ @I%X7U[Q7\!K
M.Q\/Z6^JWD/C+0;F2! 2R0I=1EY, 'A<9/I@5]K?#^&6W\#>#X)HS%-#X;T:
M*6,]4DCT^!'4^ZL"*^1/^"@OC_7OAY\$+;5_#XC^V7'BW0[)S( 0(9;I ^,]
MSGMCI7V!X%NI;WP7X4O)_P#777A[1[B7'_/2:P@D?_QYC7N'Y0=51110 444
M4 %?GKX^\%>)[K]O7X5^,+?199O#=CX,O[:[U@?ZN"X>.4")CM.#E@ ,CMGM
MG]"J^'/&OQ7\3Z;^VA\./A?;I#_PC>L^%+S4;MB!Y_VB*.1EVG&=N5YY''K0
M!]QT444 %%%% 'D'QY/_ !:?QEVSI4P_-2,_@.?Y\5^!_P#P3G@BA_;6\=/"
M CO8R!Y% W-R<ACU(]B:_;O]KK7]=\-? 'Q]JOAO1KK7]8BTQEM=,LXVEGGW
MY#[$56+;1VQWYXK\)/\ @EWJFL:W^UGXHU+7M(NM"U2?2M]UIMY&8IXG<$D-
M&0",'^= ']-]%%% !6'K_B/2/#-G]OUF[BLK7.TRRL%4'&>2>*W*^9/VN8;)
M_@AXOGNFGCDMK"62TF@R##<;2%D9@00HR"3[=>QJ#@I1=2-2<%)<\:*4JKC?
MWO9Q;BI3M\,;WD_=6K2)E&I.,HTI1C5DFJ;F^6'._A4I--13=DYR3C!/FEHF
M=EI?Q_\ A=KNIZGHNB>*-.U36=*TNYU:XTVUG1[DV]M&TDFU03SA<8[=Z_GH
M;_@LK^V1\7/C]\9_AI^SE^R%XK\8^$_A-J,VGR^(H(I)8K]H9FB=U98V7&1D
M'C QBO1_V6/@_)\)_P!H33?$&H^*)]?NOB+\)]>U:.#SS+';*]O*PC;D@$ X
M(."#@5I_\$<];T[1?BA^V5J&MZC::;IEEXSGFEN[V6.WMX(DO9V=FED8 !0<
M[2<\\ UK5J8/$SA++</FM&C*/)['-L'+!XYUHMJ<OJSE.2I3MS4GO*/G<RHT
ML;AZ<HYC6RZM6YN95LLQU#,,"Z;44H0Q="$*52I3GSTJL;*4:D9)W5F>!_&/
M_@L3_P %!OV;O"R?%#XM?L1^,+3X>Z7>6:>(;[R9D2TMKJ=(3*\GDK@(&+?>
M[=":_I"^ 'Q8M?CI\%OAI\7[*QDTRU^(GA'1_%,.GRDF6S35;5+@6\A/.Z/=
MM.?2ORJ_X+/?%/P)XU_X)V_':Q\#>,M!\175O9Z:;ZVT6^@O)88OMD?,JQG*
M+SG)Q^E?='_!._\ Y,A_9B_[)%X3_P#2!/UK*<)TY.,X2A);QG%QDO5-)FZ=
M]M?0^S:***D#\:_^"OG_ ")?PT_[&!?_ $<M?D)XQ_Y'"X_[)U-_Z)%?KQ_P
M6 D2+P3\-I)'$<::^K.[9VJHF7))Z<?6OQ8^(?C/0K/Q*+VWU2TN[>;P0]B\
MD3J4CG:(#RB>S9Z#.?Z@'].?[ /_ ":I\+/^P5)_Z/>OLNOC3]@ ?\8H_"IN
M?GTF1NN009W(([<@]N]?9= !1110 4444 %%%% '^:-_P<I?\%:?VRV_:^^+
M_P"Q?X \1ZSX0^%'@B6VLF'A^*[MM0U9+NW$DC&\M2C"(@A&.22<C@_,?YW_
M -B#XZ?!GX"_$W_A9_[1?P2\5_&G5K*\34-)BNQ-=0_;(W$BR7JW\G[\EQDE
MRV>?6O\ 2<^)W[67_!+'XF_\%.M4_8>^(_[/>A>*OVEM7N8[34O&&K:#:W=M
M>77E+*D$MW)"6:01,K[2_"$'D9KVG]JWPQ_P2"_8RU/PUI/QR^#_ ,)?#E]X
MLN;>ST>*YT+3XFN)KB011*H<#)+N!@'O59Q6\8\YQF5<.U_#_(N(,IEA8XC)
M,DEQ5@\/EN/RV,=,1C,OP%&G2IUL72A[3&T,;5EB:LY26(<^9&."K>%N38',
MLWCG7&.09@L2Z>:YU@\L=',:>/E**D\#F%6M]>J8>G4?L\'7P_[FG2484E!1
M/YI/"/\ P=Z6OP]T'3_"_@7]D.Z\,:%I5M%:V=CI&GV=E%Y4*!%+QPNJER%&
M3WZ]2:_I8_X(??\ !6W6?^"KGP[^+/C76/AY>?#Z;X<^)+'1$M;HHPO8[V!Y
MDEC9"1E%4"0=F)'.,U['\1OV5_\ @G%\//V=O$?[2TO[-OPWU?P-H'@B;QVH
MLO#EFT][I,=J+M/((C.YI(R-N ?QKQW_ ((@?MP?L<_MI_#_ .,.L_LB? V/
MX(:-X+\6PZ1XHTI-/MK#^U;Z42M:WVVU4(XDB0R+DEU$F'"-D5K@LYXRQ^68
MC!8KPP\.N$<BR^K##8C$Y%F>#CFN$JP<?9TL#EOLX5Z]"=51HXBK0O3HPDG-
MNZ."ID_!N7YGA<5EW$'B?GF;8ZE5Q-*MGM?%8[(YQG%>UEF6)GCJT*>)E3DY
MX:%2E*4ZFL7"VO[K4445@>J%-9=RLIZ,I4X]",&G44 ?S7_\$^+MO#?_  6G
M_P""B/@2^7[/*/#VB:A8/)\OVU);R"5O() $A2,[CM.<*3T%?TH5_,]^T;.O
M[)G_  61^#OQ'NX3IVG?M5W=MX6FU;/DVLQM'CA\JXGQM)4C!5V!!P*_I@!!
M ((((!!'((/(((X((Z&@!:*** /$?CKXF^"&F^$;KPW\==6\+6/A/Q;;W&E3
M6?BI[=;+4(YHVBDC5;A65G57)!"DJ>:_S1/^"\G_  2H^%G[,WBS6_VF_P!B
M3XJZ5??#_P 7W%U<>*/!7A/7%BN](>ZE:6Y>(6-S"YLR78M"8]C <+GK_7M_
MP<(?\$V/VI_^"BOPY^#'AK]F/QNO@W4_!7B.\U+Q S:M=Z2M[:SHRQ+YMI<0
M.YB=DE"DD$QA3@$D?RT:M_P:U?\ !5_6--DTK6?CM9ZII=RI2>PO/$]_=VLJ
ML.5D@>_92,=0R\UX.9\1^%.48JCB\=FG&N2^(&64Y+ZYDV%4\IQ.%K/GHX+'
M.GE]6M7PTJ4^:3A7=?#U;RP\Z5Y*7HY?E?'^,C6P^%K<!8O@[,91Y\LS[&RH
M9K1KTTH3QF&OCJ<:&*A-/V;^KJE6HN,:RK1TC7_X-CO!_P#P2[\=:_JUY^T_
M%HJ?M#:)?B[\-GQI>12Z5>0(X<W*QW9E621L#(:(@X(+9&*_T1/AU\=?V:;J
M^TOX??#3QQX!-Z\8@TKPWX;N+& O' H4+;V=HL:850!PO:O\X_0?^#23_@HS
MX4OHM9T#XF^#?#6I("L6HV.M_P!G7BANJI+'?PR\X^8 _P"-?J+_ ,$L/^"!
M'_!1S]DO]O#X-?'_ .,WQBB\4?#GP7<7<NO6*>*=0U(WL,T16.#[(VH36[JK
MD2!V1OF./>C)N*_ J<JF,^J<64^,LVOAEF,,/C,5@L9C:C4<*YXK-<MGBL+A
M95I)UL'0Q,,/1CS2IN%[DYMDGB=[6E@Z7%'!&-X:RRU:.55<TPCS' X5VGB:
M&%PV78^C2J3E&$G1KUL+4KSJ2Y:GM4DS^[FBBBO>. *_$#_@X/OK6[_X)L?%
M?P-'*'UWQMJGA33M(L4P9KDQ:S#--L7.6VA0/E![].,_M_7\W_\ P68\53?$
M/]JS]A/]EG1#_:Z_$?QL\OBVRM6\]=+L[:\#6\VI1H&$:OC*^9C YZX% '[1
M?L5:9<:+^R-^S;I%TC1W.F_!CX?64\;##));^'+"-E(/(*E<<\^O-?3U<YX0
M\/6_A+PMX>\,6@ M= T?3](M]HP/*L+:.W3 [#;&,#M71T %%%% !1110 4Q
M^GX_T-/IC]/Q_H: '#I^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\9_MZZ%<:U^S3\0
MW@OI;/\ L[2+B[<19_TA%7#1/C^$Y';USV%?R<_#[P9#H?B?P!J0F:<ZM>PW
M)CD+$1,;AOND].?0'\ <5_7;^VE_R;-\6?\ L6+S^0K^4WP__P A+X4?[]OZ
M_P#/RU ']$OA//\ PC6AY_Y\;?\ ]$+_ )SWKHJYWPG_ ,BUH?\ UXP?^B5K
MHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,LI#J<,O(/TY_3
M'%?F5^W-\+-?\&Z]X2_:R^%MK+'XA^'MY WBS2K '?XAM))E::2Z1 !*L,66
MRX;;ST'%?IK5'4M-LM9T[4-&U.".YT_5;.XL;F&5%DC*743Q,Y5P5)0-D$CC
MKGBO(SS*:6=Y;6P,YNC5O"O@\5#2I@\;0DJF&Q--Z-2IU8Q<E=*<+PE[K9^B
M^%7B'C?"_C7+.*L-AJ>8X",<1E?$N1XC7!\1<+9K2>#SS),9#6,J>,P-6M&G
M-QE+#U_9XBE:K2A)<%\(/BEH'QE^'GA[X@>';J.ZCU2PMFU=(W5A8ZNZ W5H
MX7A9(GW*RG!&.:]+K\BOA'JM[^Q)^TKJWP5\1S3K\&?B9J,MWX%OYV<VH\17
M\@9[99'S%&BO)P  !QP>WZ[NAC8IN5QA2KH0R.K*&!5APPP1R/;UKFX<S>IF
MN!G#&05'-\MK/ 9OAE_R[QE)?Q8=70Q4+5Z$]IPDVG:Q[?C3X>8'@+BC#8GA
MK$5,S\/>-,NI<6^'>=25_KO#F8-/^S\0XWA#-,@Q,IY5FF&OSX>O1C&:NW9M
M%%%?0'X^%%%% !1110 4444 %%%% !11UZ GZ G^0-*RM&-TN(8^\DY\F,#U
MW. ,>_\ 2C4+_CMW?HMV_):B49QUKE/$OCOP3X0LGU#Q#XLT&TMXU+.B:K9O
M<8 R1Y E,F<#(&.<@5\?^,?^"BW[-?ARZ?1M!US5O$OBA6*1Z;;:5<2P2.#P
MHGC1EP3CG)]R<YKR\PSO)\J5\QS/!8-OX85\13A4G?94Z;ESU)/I&*<GT1]W
MPCX7^(W'LW'@W@;BGB2,':MB,KR;&XC!X:*?O5,5C%26&PU*&\ZM:I&G!:R=
MC[K'S'"Y8GH%Y-/GCDMH3<7*FUMQDM<7 *0J!SEGZ ?C^=?EC??M@?M7_$24
MZ;\+OV:[I-#N#MB\72M+$T2MG;+Y;8]<\ <=?2J\/[.7[;7Q7D6_\8?M 2^!
M]"FPUSX22*3<T;<F,2!CMX^3KSWZ<>'_ *WT\4^3),ESO.9;*=/!O 8;_$J^
M8O#0JT^KE1<[K6-S]47T<L9D4(XCQ.\3_"_PUH_%+"8OB*'%V=R6C]C_ &1P
M7'.\1@\9+X8T,SCA%"3_ 'SA'WC]#O$WQ?\ A1X0M)KK7/B+X3@>!26L!K%L
MM\Y7.4CA\S>S>VWG\Z^._&?_  4G^!F@73:+X>T+QMXGUYW,=L^EZ1/=Z>\F
M<+F=$*[,_P 7;/O1X:_X)N? U+F'6/B6^M>./$43+)]O_M>Y2W:8'<6:W,FT
M@GG!'&:^P_!?PC^&GP^M4LO"W@_1(H44*LE[IUG>3  $#]]+$SY'J#UQR*/^
M,XQ__0DX>I/K:MG&,Y7_ #0E]4HTJG2\:E6*W5QV^BUPEHUXH>,684_B@YY?
MX;<..K'EUH8NC_;V9X_"-VYHXG!8"K47NVA>Y^?#_M&?MU?%7_1OA/\ !G0[
M7PY=9']K:UBUOX(6SB14?:Q<*0>!G/ YZ4IOV._VE_B=9:KK'Q._:!\3^!HX
MM+O+JZ\-Z+-*UE.4A=VMV*/]QN5^F#R:_5B)4@&+6&&S7LMG&MNH']T+$J+C
M''Z=,BJFJECHOB#+,<Z%J.<D'/\ H[]>*/\ 4^GBK2SO.LZSK5-T*N,E@L'%
MZ/EIT< J%10WO&I7J)WL[H:^D=C>'HRI>%WAGX8^&:47"GF>!X<I\3<1U(V2
M4L9F7%4\WP=3$<K=J^%RW"2C)<T5&5K?R[?LG_L\_#O4_P!M'P+X4\9Z9%XR
MT]_&%W:7HU3S&74##< >=.JLK%GQN;#9YZX%?VR>"/A1\.OAO:+9>"/".C>'
M+95""/3[54P@& N]R[X _P!KZU_(?^R: /V^? V /^1[U'M_T\5_9E7N8'(\
MGRRSP&68/"S2LZM.A#V\O.==IUIOSG.3MU/RSBKQ3\2..%*'%G''$V>X=RYH
MX#&YMBWE='9\N%RFG4IY;A875^3#X6E"^JBMCAO'?PT\"?$W2!H7CWPOI/BC
M2%E69;#5;5)X%E3[KJ#@AA['L/2N/M/V=?@A8R:;-:_#/PK#)I "Z:RZ<A^R
M < 1!B1QV!!'%>TT5U5,#@JM3VU7!X:I5M%.K.A2G4:@^:"<Y0<FHR5XJ_NO
M:Q\]@^*.)LOP<<NP'$.>8++X3K5(X'"9KCL-@XU,1!4\1..&HUX45.O!*%62
MA>I#W9MK0\HU3X&?"+6YC/JGP^\,WDQ !DDTZ(,0I! .P*, @8&*_.G_ (*F
M76F?![]F1I_ _A_1](DOM5M]%<V>GVT)6QN$8/'YBQ[R/8ECP,<5^MM?D)_P
M6;!/[+]IA6;_ (JFR^ZI.!M;DXIK!8-.36$PR<U:;^KTO?3W4O<]Y/JG=,4N
M)N))0H4Y<0YXX862GAH_VKCK8:I&RC4PZ]O:C4C9<LZ?+)65F?A)^R+\-=<_
M:*^-N@_#I?%$OA[4;/3;C4]!UBV!MYK"[B!FA17A"R8WC)&[..GI7ZQ_#;X1
M1ZG\1M9^"'[9_C/5?$6K@2V7@34-48QZ9=PC]W9/!>RL59E4JZCS%)/'7-?D
M]^Q#X3\=>-/V@=$TWX9ZZWA[Q=I^F/JUI>HQ!NELX_,_L\E2,"YQY?)QD]>U
M?T$6>I^%?VOO#NI?"SXG6@\ _M#> 9)(;*ZD#6U]'>63[(+ZRF8H\Z7+1^9)
M''O/S%@"20VU.G3I14*5.G2A%)1A3A&G!))+2,4HK1+9'FXS&XW,*\\5F&,Q
M>/Q55N57%8W$5L5B*DI-RE*I7KSJ5)RE)N3<I-N3;>K9R7@J[G_9"UBX^ GQ
M:TN/7_@%XUN9X/#/BJ:)9X;8WY"I9ZA+D[+5 ZA6:3*XW(PXS<U"Q\4?L7^*
M!XM\)M-XW_9H\;3K+J&GP/\ ;H?#RWS-F2UB221?L2HY(<X4J"" 0P&AX)\<
M+K2:A^R=^UGIZIJOE-8^$_%U\I5=8MU 2RE@O) ?+N0H0J\9!/3)ZBMX<\1^
M(/V7-?E^!GQS23Q;\"/%SO8>$_%U[&]Y;Z3;W@:.#2KB20LHC"R(/-8_(<,K
M [6JSE'^,/!NH_#S4;7]J?\ 96O(]8\*ZLJ:AXU\#V4H>SO;:3]Y>3?94D*+
M<0J6_=[0RL..!5_Q1X6T3]H71M._:2_9MU!?#GQ@\/!9O$'AV*1;:YUBXM0A
MNM-U:V216W ATBDD0";&#B3!?&U'3_%/[&'BG_A+?"7G^-?V:O&DZR:GID#M
MJ$'AJ&^;=OB*[XS!L<G<HP%!!Q@@6_&/@_4/A_?VO[5'[*]W_;'A;5UCOO''
M@BPE=[;4+5RLET$M8VQ%+&I;S%5 0RDC Z '*_%'5OAS^UW\ ?',_BVP7PC\
M;OAGHET^KV;[;'4Y+RRA?=Y2,\3W-C+*G4;L%@5!!-?S%3;Y!>+=#=*L]Q')
MG^+RY70<G&<X[]R,^M?TX?'SP=X)_:7^"GBCX_?!?6O^$-\>Z1H$X\;Z?:YM
MYKE+:$F[TF_LXSGS<JR1W$J_O?7>!G^:GPU9/XB\8Z%HIB(FU[Q!#I;09QNE
MEN_*;/'5S^'/6@#]#?V;OVF;#P[\&[WX/>(/$FK>)K_6=?TH>&_!\ZL^E:>@
MN8U;9R0%7'4# [U]-?M'W<-Q^US^S<B_9XYDL=#\RS@8;K<[(,J<8P%R?P]J
M\M^(G_!-GXE?"3P^GQ0T&]MK>:(Z7-9VIDCD^RRW7ENKLV<@HS9P<XZ'T&_>
M?LU?%KP)\8OV=OBA\4==;7+OQ)J6GQPR>89%AB8Q%(<%B%*(58 <A2K=""0#
M^EU+5+W18K209CN+".)O]V2 *<>^#Q[U^5'C7_@E'X-\:?%J#XK77Q0\5VUW
M:Z_;:Y;:1%&OV.)K>?SQ; _: =C'Y2<9Q7ZQ6&!8V87[HMH,?]^U_3T]JMUQ
M8W+\+F$:4<5"4U1J>UI\LYPY9[<RY6K.VEUK;2]CLPF.Q&"<WAW33J1<)^TH
M4:UXOHE6IU$O5),JV-L+*QL[)6+K:6MO:J[=6%O"D08^[!,GW-6J**[5HDNV
MAQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61K^M6?AS
M1-5U[42RV&CV%SJ-VR#++;VL332E1W(120.]:]><_%X _"WX@ C(/A+7 1_V
MX34 ?F-XA_X+$_L^Z;K$]CIJ7US9V=U-:7=U.GE%)8)#&X4$#^)3US_6IK?_
M (+)?LRLG^D3WZ/GD*H./PQT]#SGWZU^$/[(/P@\-_'']JBU^&?B>%?[#U;5
M-<EN0BKN/E74I]#G@' /&<>]?OC)_P $B?V>2\GEVS>47.S=$H8)VS@8S[ X
M]Z *O_#Y#]EW_G[U#_OC_P"M1_P^0_9=_P"?O4/^^/\ ZU6/^'1'[/?_ #[M
M_P!^A_C1_P .B/V>_P#GW;_OT/\ &@"O_P /D/V7?^?O4/\ OC_ZU'_#Y#]E
MW_G[U#_OC_ZU6/\ AT1^SW_S[M_WZ'^-'_#HC]GO_GW;_OT/\: *_P#P^0_9
M=_Y^]0_[X_\ K4?\/D/V7?\ G[U#_OC_ .M5C_AT1^SW_P ^[?\ ?H?XT?\
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M;I_@7PG8II/A_2=/.G:;9P<+;0%"@VD8RPR3G@DU\6ZK_P $V/V;O%WBZ_\
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MP)8+N/05]-E^99Y7P^%RC(<!E_\ J^JE2MQMF=3!?6<;5IT7[:CA(XF5"I/
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MM#LD/V1!<.$NM:NHU 0,F]F:1A[Y[U\5G\)9%F5#BS#QD\*XT\!Q+1IIOVF
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M^U_\;==_9_\ @=XK^)'AJQM-1US1K<R6%I>C-M+(!G][["OEW_@G7^W'XO\
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MU^#M];Z'^V-^S)\0O#UC92I;WM_;>'K^"5D0A9)=[VXR<9)P3SW.0U<&7U/
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M:5J5M+9W^GWT$=S:7=K,I26"XAE5DDCD4E65@00:_"[]I#_@AU\,O%OBV_\
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MK95B<RPGM:^75JC4ING*$Z:KTG)<WL,4JU)2;M%*4D]__@J#_P $Z_BKI?\
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M^FFE>$_"6B6\5OH_A+PYIZ0J%BDMM'LH9L+]UFD2(.6]^I[XKH@\@4()'5
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M:DL54EC)3:Y72=9RI0C34??A2E;WHM12,[XD>)O''[*/P[^)7P>^)T=[XO\
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MES1NK_FY_P %L?!8O[;P;XPMKR\?4M'T^:.'2;:-I4F3>Q,\BJI'R9/)X'?
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M"?CS_P %-P"2-6 '4_9;K_XW55_VA_\ @I;&"7?5E [_ &2Z.?I^[ Q[YZT
M?UD;AZC\Z-P]1^=?R5O^TM_P4CCSOGU<#U^PW?\ /RS_ "]ZIO\ M3?\%%X_
M]9>:NHY_Y<;O/'MY7]: /ZX-P]1^=&X>H_,5_(I+^UI_P4,B^_J&L+SC_D'7
MGKC_ )Y\?C^54I?VQO\ @H!%P^IZR,'MI]X3D>G[GJ#CK@>] 'ZQ_P#!7_\
MY$KX9]/^1CB&,_-_Q\ISC'3WK\N/BV"/%^EY5AGX6.1E2,C[*O(XZ5\Y_&+]
MH#]I3XF66F6OQ@U"_N++3[E9M,%S9W-OMN0RE=OF1JI)?& .^!WJSH>I_$K7
M=6U*7QY(T-Q;^!IUT-I$9#+I:QX0 ,%SE,>O;VH _J5_8"_Y-4^%W_8,G_\
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M?*OGSPW_ ,$>_P!OG]N+Q[=^-_AG^SE!\--#UR?SX=+N#<:1:V4<S[LK%+;
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M%%%% !1110 4444 -95<8958'J&4$?D0:^?/VI'_ +(_9X^,>JZ;!:0:A8^
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MFA^*]/)DT^WDD8!)=0N5)6.)MP(+MW!XSR ?-?\ PU]^T#@D>/-;./2_G/\
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M_P##:U\0?"+5+C1OC'X) .L>$=4=8$NK^UQOMKBUD:.3RY'4J&VLO//WJU/
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MA5"KBL:W)2J8F<U4JRY>=['A2RJ,<-C,%3SW/*$\?BY8OVBSBK+%X=R:E[#
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M -&"@#^ISX8_\D^\*_\ 8.M__1"UW=<)\,?^2?>%?^P=;_\ HA:[N@ HHHH
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M8H S_P!BOP\OA#XG>(/"@38_AWP^FERC&/FM\)D].<KU(SG(-?FS_P %L?\
MDNGPM_[%E_\ T*6OU3_9KD,W[1WQ6E_OBZ;CH/WO2ORL_P""V/\ R73X6_\
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ML/V/OA$NH*5,_ARPGMU))Q ]M%LQGMV'TK\)_P#@Y N+^?4/@G87"-;Z<=4
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MOQ/A\.74>CP;@-^GE)/,8KG).TMV/3IP* /KNBBB@ HHHH \<^/W_))?&/\
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MM]+?Z>OFV]FLH.XQNR ;>0<CCI7UI2H_E.LN VTY*GHW08(/'0G_ /57'F.
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M62<\N W'2+XT>//%_P"T?9?\*X\<^#K/PQ\3_!<PT_4-6M8Q%K-Q=P?NDFL
MJ^;/&VW<[AF&6;.:'5]BO:SQ%'#4H-2G4K.NG[1-?5U1]A=^VE5LH.:<([M/
MI<8U9\T,/1E6Q$XRA3C&&&JVA*RK2=+$M1J1C2YI.%.4:LDK19ZU\//BAXR_
M90^'DG@#X\:3/X\^#/B#3+N#PKKRPB]AT]7A8)'J,DD<L?DLR@J"<K@$$$!J
M_-/]F#]L;0?V</B)\7=3OM!'B/P!XZO-4AL=,>+S(DL[DRB%-NTKY*!AA-H4
MKP1SQ^G_ ,,/%%KXU^%UU^R'^T)8SZ)>ZC8R67@CQ5K,)ACU*;85M_,N)O\
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M/!.GSVUAJ%FEM!K&M7UBCI%,S%H7F6YF15=&8E00RY^96_,?P]^SI&NK^/O
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M)Z>([B3]GW2_ ^O%8/%W@Z*XLM7L20)(U";(W9<Y&=F#F@#!_9E_Y.)^*?\
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MKUKZ*_8__;7T_P#:MOO%>G6W@O4O"5UX6M[:YF%\79;F.Y:-4:+<.G[P'O\
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MI=?&'0/"&N3M-9WOC"VTB]NF8HYMI[TQEMY/!"'AMP]217](/Q N/A_^V/\
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M(%\6_%GQ1XL1@P\2:&NJ9!R/WX#=.H/3/?H*_-/_ (+8_P#)=/A;_P!BR_\
MZ%+0!\G_ /!-[0M*\3?MA^!]&URRM]1TR:SNGEL[E!+#(R*2NZ-LJ<8Z]<<5
M_5Z_P#^$<DCR'P-H(+L7(6QA !/7 V]*_E9_X)@?\GK> O\ KPO/_0&K^P>@
M#QS_ (4#\(_^A'T+_P  8?\ XFC_ (4#\(_^A'T+_P  8?\ XFO8Z* /'/\
MA0/PC_Z$?0O_  !A_P#B:/\ A0/PC_Z$?0O_  !A_P#B:]CI"P'4@?4@?SH
M\=_X4#\(_P#H1]"_\ 8?_B:/^% _"/\ Z$?0O_ &'_XFO8=Z?WE_[Z'^-.S0
M!XY_PH'X1_\ 0CZ%_P" ,/\ \32'X ?"(@@^!]"P>O\ H,/_ ,37LE% 'A<_
M[-GP6N<^=X"T-@?^G2,8^A !_6L:;]DWX!W&?-^'FBL#V\A?TXR/P.*^C:*
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M[N..:VGCEC26-H9 T<BAT8;&X96!!![@@BOPO_9WCCB_X*2?$A(88;>--/E
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MI?BU^R@FL^&(=2+WEQXF\'1:BLL4<P,CVU_,6$2LH8IN4 9ZDC-,_P""JO\
MP5M^''_!3+]HO]E[XD:)X#E^%L'P[U70+?Q+;3K!'!#Y%W:^?-$D 55C7#$
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MO9>*M0?$ES(@&U(UDD^]P!QUQ@?KM'+;SQ07-G/'=6=U#%<6UQ"0T4L<L:R
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MBB@ HHHH **** "J6J?\@7Q!_P!@+4?_ $G>KM4M4_Y OB#_ + 6H_\ I.]
M'\]?[)W_ "?SX&_['O4?_2BO[,:_C._9._Y/Y\#?]CWJ/_I17]F- !1110 5
M^8G_  5>LM.OOV9[M-1,0CCU:"2+S>GFA&VD>^0*_3NOR0_X+(W\MC^S! 8Q
MDS>)[*,GV96!&/ZGB@#^6W:08U3]YLG(0=F"G"K].GY5_17^S==_ G]H+]F+
M0/AUK/B'2_ /Q0\ P&]TG7IYH-.O+6ZA42Q26EPS1R21EE E0$R'.5)P5;^=
MB)?DC;^,8=3TPV!@CT['Z\UH1ZMK5M,EQ::E=VTR J&@N)8<J000VQAD8[4
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MSE<*3QCBHXM$UV4":#0=?FC/.^*"=XG4Y/RA?EYSG.S\^P!^W_[1/[;/[/\
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MSZKI-QNWZC;,-T"--'\N\$DN@ "Y.>U?QJ#Q3\83A1)XR!VX!$=]PJ]!G>>
M#QC\,5!<^*/BU' [WMWXL@M<%9YIQ?)"BD8/F.TF,'H=V<CB@#][_P#@G#\4
MO!6D>/?B-HVO>+-'TQ/#TUUH>FM?WL5O'<6EM*4B>!I2%*%5!&&QC%?)?_!9
M7Q)H'B7XV_#.Y\/:QI^M6\'APQS3Z;<Q7<,3L9"%>2%F0$Y'&>_-?DG;WNHV
MMP][9WUS!<SG,TT%S+&9#W+,CC>6.223C//-37FI:IJKI)JU]<7\D("P/<S2
M3-&H'0&1F(Q[&@#[H_X)@?\ )ZW@+_KPO/\ T!J_L'K^/C_@F!_R>MX"_P"O
M"\_] :O[!Z "JUY<?9;2YN=I;R(9)=H')V*3C]*LU#<9\B7$8E/EM^[/1^/N
MGV/2B_I_V]I'_MY]%W?8/6]O+?Y>?8_,CXI_\%,?A/\ "WQ98^#=:U*SCUR\
MURUTC[$Y_?1-<W*VX+J!D<MQ]>M?E9^W?\8_VUOCW^WKX4_9A_9Q\=6W@7P2
M_A72/%%[J'VLVTT\5_$DO# KP5?N>3@<5]!_'32_V==4\9?%SQ%XT^'?AZ;X
MD^&O%VA+X?L[J94O+V1]0B FMH6=2Q5OF^56((KP#4?&&C^%/^"N&C>*_$#K
MHNBV7PB\,W,X)"QV, M(F\LEN"$QM4<'VKMK5:N)6'I?V%B\JEHJ%>O]6E#-
MU4C3_?X+ZO5J-X=3;5-58QJ.+4]I-+S\-/"*IB_8XZKBIT9>RQE.IB\/B(X"
MM'WE0E3H^_0K.E*%2HJFBYO9?%3D;?Q)_8'_ ."F?A;P'XQ\2:9^TQYE_H6B
M7>IZ>C:Q)MEEM83*5;+=/EY#8SV)XK[$_P""*?[17QY^-WP5\9:!^T'J-MK'
MC;X;^(7\/SZI;R-+]L6.22/S'D).2=F>OZ8KZVN_VP_@C\>?"_QB^'_PYUZ[
MU/Q!H?@O69KF.:S-O!)$;20%H9O,<.,@CCJ.1[?G_P#\$,,_\(_^T5G);_A8
MMP#GDC%Q<<=NF3^=<]:A6P\_9UZ<Z51)/DG%QE9[.S[G>G?;LG\FKI_-.Y^^
M]%%%9#"BBB@#/U;_ )!6I_\ 8/O?_2:2OY3OV,?^3^O'?_8\WW_I4]?U8ZM_
MR"M3_P"P?>_^DTE?RG?L8_\ )_7CO_L>;[_TJ>@#^L =!]!_*EI!T'T'\J6@
M#^3;_@Y"MK^*]^"MY?M_Q(IM3(_=D>>BQY^T&,=G\O=M)&,[?7G[>_X)Q?\
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M^RZ^-/V .?V4OA8^20^E3,..QN'(QZ@@\5]ET %%%% !1110 4444 ?P,?\
M!7#_ ()6_P#!7#X__P#!0#XS?%?]G7XF>(="^$OB2:RD\+V5EXLU;3[6T@CA
M5)H$TZ"Y6V4M("_FJ%;DK@X)K\Y#_P $2/\ @O ?^:U>*O\ PL]9_P#DNO\
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M_P""96AZO<Z!X<U2?0]2\9>'[2:34$NX+B2SNII+V!0L,,<L;C<7(STR <>
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MX_T-/IC]/Q_H: '#I^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444
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M_@+#_P#$UF2?\%(OAQ)=K+%\ +!+9>&@-I -S$<-]W\\]O:OV-_X=:?LI_\
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ML%!'YTW3/^"C'P;T>TBL+#]G&R2UA 6)7MHF< =-S;><<=S7[%?\.M/V4O\
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M%.+4HW:?YG?\%DM)^'USK_@RQU2>'P]KD^AWES::I!:I&)F0L%BFEC0;F8@
M;VR ?>OT#_X)D>$] T;]E;P'JECIMK'J6I17+7NI+!&+B]\N0*DIFQO*LO.W
M(SDDCICX2_X+:7OAPZ!X5TN>&U?Q)<V<KZ<[(OVH1AF&(G/*@G.1@U^AG_!-
M2&XM_P!COX4074;Q31Z?.&5_O<R Y^GIWQU%?N!_EF?>-%%% !1110 4444
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ME/%FOR8SC&K71X]P7Y_P]*RIO^"4O[3J ^7KGB"4@X _M>[7/_D3]17]5U%
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M/W(Z'^M '])G_!/M3'^R?\*8R<^7H[19_P"N<K(?Q)!/XX.<5]H5\:?L _\
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M:8BC0IQQ^94]:.-Q]FZ]:BW&+E3NXP4VESN#E&\6FRBBBO3//"BBB@ HHHH
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M)'OQBO%OVW@#^SMXNSTVP=>G6K7[& "_ #PSA2!LM^QP3M'?&/UH ^IZ***
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M1110 52U3_D"^(/^P%J/_I.]7:I:I_R!?$'_ & M1_\ 2=Z /YZ_V3O^3^?
MW_8]ZC_Z45_9C7\9W[)W_)_/@;_L>]1_]**_LQH _.C_ (*0^"X=>^$V@ZW_
M &1%JSZ/XOT8WT$T9EB.E-/NNS*O3RU1<G.!@G)Q7MG@/]G[]FGQ=X.\.:]I
MOPK\"7EM>Z18'SX]%M<&9;:(3JQ51N=9=P+'+'N>U>]>/_!]AX\\'Z_X5U".
M)X=9TR[LD>5-_P!GFGA>.*X3C*O$[!P5^;C'()!_/S]E'XEWGP8\6:Q^R_\
M$ZY^PRZ-?7+^!M>OV,<&N6]U/YGDK=3.J'8I 3!(S@9 Z 'UO_PRU^SS_P!$
MA\$?^"6W_P *?'^R[^SW#*DT7PC\$I+&VZ-UT:W#*PZ$<5[R"& *D$$9!!R"
M#T((X(I: /RZTWPMX;\-_MP^'+30-#L=(@AT>[6.*RA2)%4(XVA4'';\@*_4
M6OS9N?\ D^G0?^P3>?R>OTFH **** (;@%H)0%#$QL K?=;(Z-_LGO[9K\IO
MC/?>*[OXI:3X3\0> K;2? M[J2?:?%.D6Q5T F4J\\R_=W'&2S?6OU-UGSSI
M.I"U.+DV5R(#TQ+Y3;#GV;%?G[J/Q;TP_##7OA_XJO)+KXC/J<Z6MLUL6#1M
M>1F I<9R L88=NOIFM*<<3-R6#6'G6C"52K3JX=3JK!PM]9JTL3RU'A8PA*T
MYJC4YE)72M<I2C'6K]84)-0I3H8FK14<6W_LSG0IRA'%6E>4:-2I"#DDF]3[
MY\-VMI8Z!H]GI\IGLK;3[:*UF8[C) D:B-R>Y*XS6W7'?#Z.XA\$>%X[L$7"
M:/9B4'LWE@XSU.!@9KL:S5K+E=X]&M4UT:=E>ZZV7HMA/FN^=MSO[S:LW+[3
M:3:3;NVDVEM=A1110(*_FK_X+??\E3^#?_8#O/\ T?-7]*E?S5_\%OO^2I_!
MO_L!WG_H^:@#U#_@AY&5M/C*Y &ZXL 1U^[*@'Z'%?O1KWAO0O%%A+I?B#2[
M/5M/G4I+:7L*30N&!!RK ]B17X/?\$0/^/'XQ_\ 7S9?^C4K]_: /@GXA_L+
M>%+^Z;7OA1XBUGX6ZU"[7,5IX:F:UTV\G7YECNHUD7]V[?>!! SR>]>;V_QL
M_:>_9UDCM/C1X/C\;>"K8BWL-7\)Q"^UI[=3M6:^,/FMOV ,Q?OQSUK]/JKW
M%K;W<;PW$,<T<B%'21%=65A@JRL"""."".10!X%\+_VG?A+\4[6 Z7XBM-(U
M:;:&\/:W<0V6L1N?X&MI61BP/! '6OH165U#*0RL 58'((/0@BOC[XG_ +%_
MPJ\=7$VO:#8_\(5XS<F2'Q-HC30W$<W+*[0K,L9^;!. ,XZ>OS]Y?[87[-<_
MEV@D^.O@R(EKK4-3G>*_TVR3&?*B5R[,B9QUR0 <T ?J'17R!\*/VT?A+\2+
ME="O;VY\)^*(,0W^G^((/[-MDNP=LD<-W=/&CJ'! )XQ_%R*^MK6]L[Z%;BR
MNK:\@< I-:SQ7$3 \@K)$SH0?4&@"S1110 4444 %%%>8?$'XQ_#OX8Z9<:I
MXM\26%I'; F2T@N;:YU(X[)8).+AC_P"@#T^N6\4>-O"7@JR;4/%GB'2O#]F
M 2)]4O(K2-L#.$,K#>Q[*H))Z"OSYUC]KKXK_%^ZET;]FOX<W.KZ9*S6UQXI
MUV*73?LBGY&GACF<1MLSO7&X].?70\*_L5>(O'%XOB#]HGX@ZOX\CNG%PW@Z
M:66/3--D+;_)CDCE^=$/  7!'X4 :'C3]N%M:U6?P;\#/!FM>,/$KL8K36Y+
M)I?"Y<G:K_:U4*Z<@[M^,=O7EK#]F3X^_'2\BUW]H+Q_>>%K4.)HO#'@N["V
M,T).[[/=(DH505^5P<GKGFOT"\$_#GP7\.]*@T7P?H%AHMA;J$BCMH1O"@8
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M^4!'GC<._'2OS'_;'_:$O?V$?^"H?@_XN?%#X/\ Q2^(7A+5/ 'A_1&U_P
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M_IA!^N;;FNPTC0]&T"U6RT32M/TFT3A;;3K2"S@'_;*WCC3/OC-=)B:M%%%
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M\8?'_P"%7AOQ%I[%+[1=7\8Z19:C:,#@K/:S7"R1'(QAE!K\QOV7?VW/B/\
M&OXT>+?!VHC6;/P_!X*UJ]T]K^T>WBN);>&;9<0NX ;:5R"/KZFOR]_X)_?\
M$WOV8_VS/VEOVP_B!^T7X8U#Q_XAB\7S6EG/<ZYJ,,=G$;V91Y$23F-2H7C:
MH7U!S5U?J?-_L6/P^8T;6E7PRJ*G&JOCHOVL(2<Z;TDTG&^S)A'&P5L?EV+R
MNNW>.&QD8QK2I.W)6Y8N24*BNXW=]-4C^F.R_;B_8]U*^M=,L/VD_@Y=W][(
ML-I:0>.-%DGN)7.U8XHQ<Y=F/  Y)KZ?LKZSU*TM[_3[F&\LKJ))[:ZMY%E@
MGAD4,DL4B$JZ.I#*RD@@Y!K^43_@K%_P1Y_8C_9V_8R\?_&3X/> =0\'_$7P
M0^EWWA_Q!;>(-1,UG<K>QG>B^8N[H."<?3-?T"?\$_\ 4M1U?]BW]FG4M6O)
M;_4;OX2^$Y;N\F9GEN)CIT8:61V)9G;&2223W)ZUF6=3XI^!WA?6_CAX9^)4
MWAW39KS3=/FMKB\>TB9Y6<?*TIV?.1D#<<Y[YYS[:? OA!B6/AW226;<3]CA
MY).<\)C\N*ZK ZX&?I2T ?B=_P %;_#'AS3?!OPV>QT2QM97\0('EMX(XF9/
M.7Y&*@$\\YS[5^3_ (M18_%TR(,*OPYF '8#R0?ZU^OO_!7S_D2_AI_V,"_^
MCEK\A/&'_(X3_P#9.IO_ $2* /Z1/V O^35/A;_V"I?_ $>]?9=?&G[ 7_)J
MGPM_[!4O_H]Z^RZ "BBB@ HHHH **** /\W_ .)_PE\ ?'__ (.OO%'@#XM6
MMMKOA*+Q-#?1Z)JI$EK=7&GZ9:26UN$D)3:)6:78!R3D#BO]%_PYX4\.>$='
ML- \-Z-I^CZ/IEM%:6-A8VL4%O;V\*!(XXXT4 !5 ]3[U_GH?\'$W["_[4W[
M)G[>5G_P4^_9MM]>U5=:U>SUK5[OP];7-W=:%=Z>J(PFBMHI)O(GA013L#MV
M@.HR"#Z5\"O^#Q[Q!H'@G2/#_P ;?@,\WB_1["WL;_4P]]'+J-Q;Q+&]S/$5
MA,<DKJ68&-<'.<G-='#?#^0\:XG&8["YGD%+B;+JT\LQN"XCQF%RS&8?"X:S
MH3PV(S&4*,:555'-4HU(5:E.5*HO:0E%0RX@QV?\-4<%0Q&49QC^&<;1CF.$
MQN18:OF.'>-JI0K0KX/#1=6=6%E2=:$*OL:D:E*HJ?,I3_03_@Z#_9!_:@_:
MM\#:;:_#W3-)M_@G\,]!;QIXGUIXH1>QWMG$TT\>?E?RAL; SCC..A'Q/_P9
M<^*?$%EHW[3G@5/,N/#T?B&TN9I /W,5[;Q"-)%..#)DGKT?U-?GA_P4+_X.
M2OVI_P#@HQX*N/V9_P!FKX2:KX0TSQW.NB:E<:!:ZAJ.J:Q;7Q%NUE(!!-Y4
M4BOAG9U15.XYQBOZH?\ @VP_X)H^*OV!/V3=1U_XEV[6OQ(^-=S9>*-:T^=?
M])TJ+RR8[23*(R<,F4*ALIEN:X\UH4N&<[I9&^(,BSK,<="I)Y5P]@L"\#D.
M7T(KFGBL?@6X9CB\34DW5S"3;=:=*E&<FI6Z\NCB<YR:KFM?AO,>'\NP56$*
M&-S?$XE8_/<;6<9<U+!XAR6!HT(>]# P:E&C&=6I3I^T2?\ 211116AB?FC_
M ,%4OV"?AE_P43_9KD^!'Q5\:W'@/PW_ ,)#9:\NNVUY'92QW=C@Q()I98DP
M2,E68@]P1P?YTM/_ .#.?]E;4+2&ZT[XX^-M0M)5#0WEOJ!EAG7^\DD=PR,/
M4J2.>M??/_!U7\6/B3\'O^":-SXF^&'BW5?!FO3_ !'\.Z;/J^BW+VE^+&ZE
MC2:&&="&C+@D%AD@$[<-AA][_P#!#+QSXM^(_P#P2W_9/\9>.-:O/$/BC6O
M@GU76-0E,]W?3K>3H)9I6Y=]BJ"3W%>?FO#^%S'"TL9AN-/$+)\U]M[&KE62
M9N\KR"&#BG*.)I2HUIUI8^K4TKQEAH4^10DJLI)I=N6<09UEN+JX7^RN%<5D
MWL/:4<3CLLHX_./KLIQ]I3J/$85TXX-4U>ERXB4U/FO3BG=_@Y_Q!M?LQ_\
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M/'[6G_)M/QM_[)YX@_\ 24U[YXA^8W_!"[_DV[Q-_P!C5/\ ^CKJOW K\/\
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M#A!; +$;3D<?A0!^H@[C.=IQGUX'7W]<<4M(OW1]!2T %%%% !1110 4444
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M<'&:_!;_ ()Q6EI8_MG>-K:QMHK.VCL)%2W@54B0 G"JJC  ["@#^E&BBB@
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MHTHT\IEB*F7IMX>IB<QJ9M6J)N[G+'584YU;O:+A%4_A6A]F4445S&Q^-?\
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M.S7'8C*\-2Q5/),\S>-6LZ*IY+E\L=5BU%R<YIU*48TU91<E)VDTFM3]F/\
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M6^,W[2I89/\ PL72!^'VX<?ICZ<5SMLB1_M1>#5C4(O]D:/PH !S;1'H/?\
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M 0,D\=<U^['_  3>O-#N_P!D#X/C1%D1(/#&G0WJRH4<7BVT?F_*><>F0/\
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MZ]US3BWI+W6RHPA4:IU>3V<WR3]K&4Z3A+W9*I&+4^1Q;YG#WTM8)R2/PO\
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MB#_TE-?0]?/'[6G_ ";3\;?^R>>(/_24U]*>0?F-_P $+O\ DV[Q-_V-4_\
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M /!6C]F:PO+/PGXX\':OI-[,UPNE:[<VT]EIX<DK;6D#R,([>/A47:,8Z=Z
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MO-=3VSRL^5GEW;3$F.-QQC;U'3M0!^G@Z#Z#^5+1C!8<C!& >P*@@#';THH
M**** "BBB@ HHHH **** "BBB@!#R"/45\*_\%$?"-QK/[.6N^+M)BW^)/!M
MYIUSI)7_ %J*+E&E,9&6^51R0" !T[5]UUR'CWPK9^-O!/BCPQJ"*]M?:1J$
MI5L%3)#;2R1<'G.\*!CGCC.:\O.\O6:Y/F>7;2QF"Q%&G+K"M*F_95$^DJ=1
M1G%]XH^\\+N+GP'XC\#<8M.5#AWBC)\RQM):K$Y;2QM%9CA)K[5+%X-U</5C
M]J$Y+N<3^SUXOM_&OP0^&6L12"6ZB\*Z7:ZJ2P+)?K"@F5R/X@X.<X/L.WLM
M?F[_ ,$T_%5Y-\-OB)X#U]RNN^&_B!JUM8V[D[ET>&>18"$." 5 Q@8'KCI^
MD(.17/PUCWF>093C7I.K@J4*L7\4:M!>PJ1DND^:G>2Z7/8\;^$5P+XM^(/#
M%-J>&P'$V/Q& K1UI5\NS64<VP56A):3H>QQJITI1]UJDTOA%HHHKW#\K"BB
MB@ HHHH * Q1ED7AD.[TZ<]>O4?A111<--FKIZ-/9KJOF?EO^VO\/=;^$'CG
MPI^US\+K26.7PW?6Z_$?2K%6$FOVDTP4M,D0S*L4>3\_]TYP,U^A_P -?B'H
M7Q6\#>'O'WAZZBN;37=.M;N[CA96^PWT\:O+:2 ,=KQ$[2#@YZJ*Z/7=#TOQ
M-HNJ^'-;M8K[2]8L[BSN+:=!)$6N(WB27:>-T98,/3'45^5?[/>O:C^QW^T%
MXA_9M\;7,W_"L_&E_-K'@+6+QF\I]7OWW)IEO(Q*E8BP58U;&!T%?$5O^,8X
MA6*5H9#Q+7C2Q2VI9=GKC&-'$VVIT,QBE2JO2,:\5-IRJW/ZERV_CIX02R&5
M\5XL>"655\?P^_CQ_&?A5&HJV9Y+=KVF+S/@JO4>.R^"<JU7*L14P\.6A@&E
M^M5%*R-&YC;[RX.?4$ @_D?\YI*^W/Y:332::::336S35TUY-.X4444 %4M4
M_P"0+X@_[ 6H_P#I.]7:I:I_R!?$'_8"U'_TG>@#^?;]D<$_MZ>#."<>.[\\
M=O\ 2<<U_9-7\;G[(?/[>?@_'_0\ZA^ER<_RX]:_LCH **** "OS?_X*A_\
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M*7Q.U*QF2YL-0\:W-U9749W1W%O)?%DE0C(*L"",$]>IK[X_X*(_\B[^R/\
M]DML_P#TEBH Y3_@F!_R>MX"_P"O"\_] :O[!Z_CX_X)@?\ )ZW@+_KPO/\
MT!J_L'H **** "OY\O\ @H#_ ,%2OVAOA#^U9HW[)7[,_P %M3^(?C"6PL]3
MU;4[.-Y8[:WNT6100$8 A7' QW^E?MGK/QX^#GA[5Y=!USXC^%-*UF">*UFT
MZ^U.*"ZBN)G$<43QOC:[N0H!/4@5^ 7BS7].T/\ X+9:QK]]J=MI^A_\('HM
MS/JD\J+8?9OL\7[XSD[/+(&0X.&'*GUZ:V#QF'5)XC"8F@JZ4J#K4*M)5DTI
M)TG.$543C*,DX734D]FC.%:E4YO9U:<^5N,N2<9<LDW%J7*W9J2::>MTUN9_
MC+]MW_@K?X/\+^(_$]Q^R_K4T'AS3I-2N(A9N#)%$F]ESY/=0>@'X5^DG_!+
M/]O'Q#^W5\&M3\5^-? UWX"\;>%-2.C^)-&NPP=+Q&9&(4@8^9#V'N,]/JSQ
MY\7?AGX_^%_Q1T_P+XX\-^)]1T_PAK+75KHNHP7L]N#:2#<\<9SCKR,@=Z_*
M#_@ADSR:%^T7)(=SM\1;@,2,'BXN.N._/-82A.#M.$H-I.THN+L]G9I:/HS2
M^K75.S75/LUT9^^U%%%2 4444 9^K?\ (*U/_L'WO_I-)7\IW[&/_)_7CO\
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M,UI%&(U>[MYV6:?: ,F1LG/>OJF@ HHHH **** /SC_X*>7-Q;?L^6#V\]U
MQ\;^'E+6HD+D?:X\@^6,[?7/'-?='P\)/@#P:S9<GPMHA;((9O\ B6V^00><
MGH<\YZU\R_MS^,_#?@CX-1:GXFTF/6;.;Q/HMI%:R1"55GEN4"2[6!P4)&#Z
MU]4>"[B*[\(>&+J",107&@Z5/%&!@1QRV4+H@'8*K 8[8Q0!_/W^W7\,O#?Q
M!^/_ (GU?5/&\WPXO/!^@KJ^G:3)%,&UJZA96#VC1@+YDK*,;0<;@!BOEO\
M;;A@^(G@_P#9XN?$.LW-C&FB6NE)'J#R?:M^4BCUW,OS@0[1+DXP!US7].GC
M7X(?#+X@:M;:WXI\)Z1JNJ6^%%Y<VD4D\D:XQ%([*2\8Q]ULU^/7[=O@CX::
ME\9]&\-_$+PIJ5]96?@^ZA\#6'A"W\J&&\$3+:0311J$7+A00 ,GOBL,*L=6
MJ8G"9?E. PM>K^\=?%T,#C\)F%2E&U.=/"^SP_U.E0PRJ/%5,RQ555:T8U4V
M^5'IRQ>'Y,%+,<TS:&#P,9Q53"XBEAL1E]*M).K^^JW^MRGB.2-!4X1J4:$G
M32=VU\2_MU^%$\/ZQ_P3D\'0>*V\7F33%MK;Q8LOFF5KJ-5C"2J6.VV) P6#
MX7E17Z1?L_\ _!-;7OA[\4] ^-6O?$MM;EMH)-2%HJS^<T5S;F2*U>1T4,J;
M@#EL#'>OS"_X*(>'_C'\+?A3^Q-\<?#?P,\=_$S2_A!=R2Z[X%\)V$UWXEBL
MEG#VY\F%'8/Y0&/E.3GZ5[?I'_!P[Y&AZ=:3?\$W_P!LM)(M)B@E5?#$I"W"
M6ZQ[%#:*3LW#!RS$ ]3CF,1AJ6*>&J1Q>(G3H5%5I5:,EAH8B44N6K*E#F4%
M*/V(345&7*FTC*AC:^$6)@J.'YL3%TZJKT,-B)P6MXTZB@X0>NLJ'+%R2DEH
MCI/V%9!)_P %5OVBW Q_Q+-1&/I(PZ=LXK]&/B)=7B?\%$/A':K<WR6K^![]
MI+=#+]C=O*FVF0 >46';<<CIU%?B[_P1Y^,?Q2_:#_X*#_''XK>)/V7_ (N?
M WPEK>B7UQI>I?$32KBP2[,\A*6ZO+#"C2X.<*!]!T']!GB[XA>#+']J_P !
M> KO08I_%^I^&[J]L-<,0,MM:I&[- )<94$ _+[]N_4<)]?T444 %%%% 'CG
MQ^_Y)+XQ_P"P9)_(UX[^Q"<_!U<<_P#$YO/YBO5?VC]3TW2/@SXXU#5KZ#3K
M"WTF9YKNY;9%& K$ MQRQ& ._->!?\$]_%6F^+?@<VHZ5=0WEHOB"_ACG@<,
MD@4\.,<@$8QGTH ^[:*** "BBB@ HHHH **** "BBB@#\:_^"OG_ ")?PT_[
M&!?_ $<M?D)XP_Y'"?\ [)U-_P"B17Z]_P#!7P_\49\-/^Q@7_T<M?D)XP_Y
M'"?_ +)U-_Z)% '](G[ 7_)JGPM_[!4O_H]Z^RZ^-/V O^35/A;_ -@J7_T>
M]?9= !1110 4444 %%%% '^8G_P4M^#%_P#\% O^#CW5?V2_'?B/4E\$W/BW
M3-&MK5[N7[/8Z>+"&]NTMXPVV)I5<H2H)*@>M5_^"ZO_  2W^'/_  1=\;?L
MU?M%_LN:KJ6EW%YK:VZ6TMY,)!J^FQ2327.X,& D\MB..<KGH0.>_;W_ &L/
M"/[$/_!S'\1_VE/'>F7VL>%_A_XQL;W4;#3%+7LT<VB0PCR0,_,K+D94CU!&
M17$?\'!__!;SX"_\%5?AW\%_!_P@\)>*/#]Q\//$M_K.I3^((O*$\-S:SP+'
M#M1!D&52<Y/'7M74N',RS#&8;CJ.9XR-3A[V&&ITO[<5##\M%0C3A/)98B,<
M;!QJ4US/#U8Q5-).*C)/G?$$,#0J\(?V/.K@\Z56M7Q<,EI5Z,)5FY2=3-^7
MVV#J1=.3485(2O7<DIN=X<_^RO\ L(_\%%/^"_WQ;TSXH?&+Q'XBTCX/:3):
MVDOBG6CJ(T<V$3+FWTZW:4P23O$I7[0JACU7U/\ HF?\$U/^":'P+_X)G_!N
M3X8?!RQE%WKKVE_XQUJ>5I)-:U>"+8;GYU#JH+.%5B<# & *_D^_89_X.COV
M%/V2OV6/@W\$;#X.>+]/UKP;X/TO2?%,^BZ?%%:ZEK=K;)'=W_F&!WF-Q(I<
MEF.W(5>*_IO_ ."3W_!6WX3?\%7/!7Q'\:?"OPMXA\+VGPXUVTT34K;Q (A-
M-+>QO-!+#Y2(I1HUW8R2H(#!6R*K,>#^-,5C:G''&V=X?,L6U_L&7X/.L%+
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M%NJ6MU;^!O"RS1Q76M:DJ.B^4'9<K%+MS@XX.<"O"/\ @A=_R;=XF_[&J?\
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M>>0I!?ZY+J&G;W8,WGOO0<GK\P!'Y\U]G:E_P2^\-K9W<MIXM4W$4$LD$8C
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MK_P%U"O[;_[(TK_H&6'_ ("0?_&Z/[(TK_H&6'_@)!_\;H _B0_X5S^TU_T
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MP]IS.L<:H'8RQY9@H 8]\GG/?FN?_P""B/\ R+O[(_\ V2VS_P#26*@#E/\
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M=3_[X'_Q-2M_P2(_9_(P(L'U\A?\*HR_\$@/@0^=DC1YZ8B'M[9'X9H M?\
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MOB\TJU<=1X+RZ&*HP4:=52JNI4QF9X"E@<$Y7C3GBLLHTZB_=0H5I<R?V_\
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M_#O_ ()L>)O[:_:!^/+?#[6-2U_X4WOB'4[Q-1:5IM)DOV:<HUG(25*%BI7
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M7](W@7_@I'\(?'4,&H6WACQII&AW+A8==U73S!IK*3_K/.$94*%^8_-QZ]2
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M5^F__$9O\*\?\FS_ !!S_OP8S_WSTK])?V ?^"9O_!,']C7X$VWPG^-GBO\
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M9TXM-0A>4I.S7SQ^UI_R;3\;?^R>>(/_ $E-?0]?/'[6G_)M/QM_[)YX@_\
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MVG,$7</#E[SCG[DG>@#^MRFNVU'8C(56)'K@$X_&G4UQE'!&058$>H(/'XT
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MKS$<'H @  ZY_.OIO_@HC_R+O[(__9+;/_TEBH Y3_@F!_R>MX"_Z\+S_P!
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M.\*-#*ZJ+IGC&YO*G4?4@FOZ+O\ @Z\N?%EM_P $LO%G_"*F_!F\7:1#K/\
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M1YRR&0)D0G).,]C7AO\ P:R^(/&6K?\ !-/P38:^]S+H.DZA>VOAB6X$A5K
M3.$\J1^J% A^4[?;D9]2.=\0YGE,*/&E;"YIG&&K\F4<54L%3R_%9WEZ7[S"
M9I1H_NL5C\))J;QRO*HFU)I24*?C2RK(<)F4\1PE@WD^ JT.;.>&Z&(J8C+<
MLQCDE1QF61JN4L#AL3%.#P2?+%WGS3:4G_2W7SQ^UI_R;3\;?^R>>(/_ $E-
M?0]?/'[6G_)M/QM_[)YX@_\ 24UYYV'YC?\ !"[_ )-N\3?]C5/_ .CKJN8_
MX+0?\%GM&_X)0GX2P:K\/!X\7XH_;U,3+<,EK%9,Z2EA"0"2HX4YSG'UZ?\
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MNA7T-T8['4(COBDCB4F&1XWPT;L#CU%?LI7-7QV,Q<W2QO F5>'=;+O^$_\
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M.0/MDG7_ +^4 ?.7A#Q_\</!?AO2_"VC?M*^#(-+T:$VUF@NT4^2K'87PXY
MQ_\ 6[])_P +F_:"_P"CG/!W_@:/_CE>L7?_  1/NAG[)XI#'G!>\8$=/65?
M\]:Y^Y_X(J^+ADVOB:U)[;[Q<_\ HWT]^M '"2?&C]H)(Y'_ .&F_!Y\N-I
MHO1ER@W!%^<_,Q&!^ YS6U^Q]^W_ /'2_P#V@='^'?B_5+/Q!H>KZO'HWVT?
MO?,#.(_/B9MWRMR001C-,U+_ ((O_$ZVMKFYM_$.EO\ 9H)9]KWX^;RHV<J
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M+<2FKXG 8J"ERR:5Y4:D72E.,9M*2U_S5/B#_P %6O\ @X)_:W\-7/P8\/\
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MPF9TE"2BM$[XO#XB<FNL]>Y_2/C')\4^%_@+XDK]YB*W#6;>&7$-=>\ZW$'
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M("BBB@#\V;K)_;IT')./[)O..W ?'O\ KS7Z35^;-S_R?3H/_8)O/Y/7Z34
M%%%% !56^_X\KS_KUN/_ $4]6JKWBL]I=(HRSV\ZJ/5FB8 ?B30!_$?=^+6\
M ?MB^)O'$=LM[-X:^*%]J$-G(VV.>1+N3:K-@]\'VQ[U_0#\#_%OPPN?$EY^
MTO\ 'OQSI-SXNUQX8_"FD37<=TGAS3BBA+>&W9RH=01A\)M.#V%?CC\7?V#O
MVN-3^+OQ)UW1?A-JE]I6M>+M1O\ 3;V)V >TFG=TF4@#;E6![#&#7DGQ5_91
M_:5^#/@M?''Q,TCQ!H?AA)TMO,NM1F:&"=^$58F/RX/ [^AXX /Z*?VI/&O[
M-_Q4\'0^++/XAZ;HWC?PE)#>^%O$%E<1QZA!<1.)DM/D9F:*9AM(RH&XDM@B
MOYY_VN_BYK?QA\;VFK>)5B&O:;9P::9H9!*NH6=LH2*_=@?]9,J[V!/5C@ Y
MKY42_P!2N%CC.N:A+$5#>4;Z1D)P"I*;B,C/&>E.9Y9F$D\TMQ*,KYLSEY-H
M) &X]AV'8<=J %7JW^Y_4U^BG_!*>ST^[_:PMY-5MH;RRL?#%_>20W$2SQCR
M8F;(A<%7;C@'J>.]?G6O5O\ <_J:^Y/^"<OQ%\)?"W]H2]\4^-=:M- T@>$=
M4M8+Z]R('O9+=UAAP <EF(P#P: /V/L?A]K7[5_Q8\:2#Q+;_#[X>>%+Z6TT
MS1K&WM!/K3Q3-$[SP[H2@!!<G!P/K4/B/X?>(OV0OB9X!N9==C\?_#[X@ZU'
MH4^B:I:P+_8Q9HP;FW5@WF':^0%).>^.:_$+Q5^T]\2O"GQ:\9>)? OBJYBM
MM0UN]GLFM9I([)[<W3/&P@3" ,N#TYY^E?47PD_;<U'XQ_%'X<V7[2.NP'PE
MX2U.WO=-N9-T,5M>1%,W%T<9=#M!.<DA?I0!^W/[77CCPS\'OAAIFI^'/#&C
MKJWCC5K+PSI&H-96\:Z;<:HH$-X[-'B,1%LGL,'/K7BWAO\ 8'U'5O#T&H^*
M_BU-<>,=:M1?0WEM;V[1VCW"B:(6F75IEA#*NY$(P!AN]?.O_!4/]IGX-_$K
M]GVS\,_"GXB:-KOB.'Q!974$.DR2-/:00#F9&*QF-DX*E#G /(&,_E[HW[?7
MQW\,-X#31_$EV7\":8+"*2YEEF%\0@53<@D^;M P-P/!P>.H!^YW[/MY?^'/
M%7Q:_9[^),.G^*[WP9H=Y=:/XMFM+=[N^ADMG9(YEV%XV52-I;HV<D5_+Q\5
M(E@^)GQ)A0!8XO&&H(B  *BB\;Y5 P !@  #C\:_=/\ 8J_:V^$NKS_%?XC?
M'#Q?IVA?$GQ-I%S:SW=\6"7<;6[K'#9Q;"JR8PJ#A<G!QV_"7XE7D&I_$'Q_
MJ>GR?:K#4?%5Y=V-RO2XMI;IGCE '3<AW<9]\4 ?T\^#?&<G@C_@GKX?N8W>
M)M?T1-"\^,D/$E[ L$C*P(V_*Y!.> <C'6O6_A1\ OA_<?L=/X8O-&M;N/4M
M"U37KJ]9%^VW.I+#+=PW,MT0TQ:.0# W]!Q@G(^-++XS?"(_L+^!O">H>,-.
M&L6:6ANM,9D-S$RB/<=F<<8]<^N,5]??#;]JK]GC3O@%#H<WQ,T&"^A\*:C:
MBRFE=+@RO92*L(4(1O9CA1N&2>M '@'A#69/&O\ P3F^)EEKP:];P]-K^D0"
MX+2/%;65R(K55+[B-D2E0<XP2>G%<W^RK=VW@+_@G-X_U31$^P7<]OJ4,4T
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MOPWU?PX^O0>(3<>+M:U3[9;LCHGVR=G^SDH2-T?0C_\ 4/K2@ HHHH ****
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MT_=O^QZ7IT*P6MOOPN[RXT SM&?2NM*VRMZ(X;MZO5G;T444 ?C3_P %?O\
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M^5O]0OIZ+[U+AO[K?I_C7X5P?\%"_C_!%'%_PK^601H$#&V.X@>I(Z>U2_\
M#Q'X_P#_ $3R7_P'_P#K4 ?N?AO[K?I_C1AO[K?I_C7X8?\ #Q'X_P#_ $3R
M7_P'_P#K4?\ #Q'X_P#_ $3R7_P'_P#K4 ?N?AO[K?I_C1AO[K?I_C7X8?\
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M!E%E0HQ' .?FS[>HKRW]D#4EO_V@[/5;U/\ 2-9U;[7(J]$FE<%NW3=W]^:
M/Z.W4I(ZD#.5;C_:4?KQG\:2I)LB9LYSM3.>?X?ZU'0 4444 %%%% !1110
M4444 %%%% !1110 4444 >!_M._#^/XG? WQIX7EB65;6PN=<6,KOS+I<#7"
M,!_>S'D8Y&..U>2_\$_/B _Q$_9NTV]NY6^W>']>O?#CV\N3-%!ICM;Q@@C(
M0! 1^G'%?9UY;?;[#5-,."NJZ==:>P(SD7<30'CN,-S7Y@_L27!^'O[1?QV_
M9[D)MK3PZ+CQ':1'*PR27SF4F('C<3)STSU/<#Y#,E]1XOX?Q^U+-<-C,BQ#
M_FQ"C'&8"[_Z=QHXNR=T^=VL]#^D."'_ *U_1V\7^$W>ICO#_/.&?%;*8_%+
M#Y-4JRX=XN<(]/K5?'\/\THZI4/>NC]1J*1>@]N/QI:^O/YO"BBB@ HHHH *
M*** "BBB@ HHHH *\S^,?PW\-?%KX7^,O _BVSCO=)N]#U"Y2.1%<+=P6TC6
M[@'G<KJIR.G;GKZ95+51G0O$AZ$:!J9'_@-)_A6=:C2Q-&KA\13C5H5Z<Z-:
ME-7C4I5$XSA)/1II[,[LLS/,<ES++\XRC%ULOS7*L;ALQRW'8><J5?"8W!U8
MU\/B*-2%I0G3J03372Y_+W_P3-UB7PU^W1X=^%^M2^5+H/C?4(='EFW 2V4-
MQLM[>(L1]U%4 #GL!7]T-?P*VL7BGP?^T39_&;X=6$NH>,_ 'CN]OXM-MT:2
M34XEOLS1M&F"X2($X((P#G!'/]L_[,GQYT#]H?X3>'?'ND7=O+J4MG;VWBFP
M@P&T?Q"D0-]I\J D1O'(&^7C XP,5\APY7K95BL1PGCJDJD\!#ZQDN)JMN6-
MR:I)^S@Y/XZ^ E?#U=YRC&-66DM/Z)\:LKRWCW(<F^D'PIA:6&P_%F)_L?Q.
MR3!4U&CPQXE86C!X[%QHTXVPV5<7T7#.<O=H4*6(JXC P;JT9(^@Z***^S/Y
MH"BBB@#\V;G_ )/IT'_L$WG\GK])J_-FY_Y/IT'_ +!-Y_)Z_2:@ HHHH **
M** $P/0?E7YA?\%6=%M]>_9^T+2+V>:/3]5\?:!I5[%&Q5'M[V4I(Q4<%U7[
MA[9/K7Z?5^:__!4)XXO@9X4EFD2"&+XG>%GFGE.V*&-9V+R2-T5%')- 'Y6_
MML?L'?!']G;X/>&_''@$ZPNLZEIFGSS&^N#-#+)/:0SLR+QY88R<+@[<8R>1
M7X^0.7BC=A@LN3CWK^C/_@I_XR\(:U^SGX+L]%\5^'M6NX]%TK_1M/U2UN[@
M[=/MDYA@ED>,DJ?D<!UQ\PSQ7\Y5K_Q[P\$?(.#U'M0!87JW^Y_4U7>)94&[
MLR?CD#K].U3@X+9[K@8]>>OH/>FC[I]0T>?K@4 * !@#L,>O%1RPI,,./\_U
MJ6B@"M':QQ.'3(/X\_7G_/>K  '08I:* *TMI#,P9USSDCL3[U,$4*$ ^4=O
MY?E3Z* '-<:@T7V=KV9K7M;L[^7Z_=#8_3Z5"/M"J46XD5.@4,P&.XQG!)[G
MWJ2DW#U'YB@"1;F_2+[/'>SI:G[T"NRHWN0#@GZBA;F_1#!'>SI:L?FMP[>6
MWU7../I41900"0">GO1N4L5R-PZB@!H^T*NQ;B0)DX7<V,'J" <?Y[U/'<WT
M"&*VO)H86^_$KMM?/!W $9X]>W%1[AZC\Z-P]1STY'- $JW>HI&UO'?3):L2
M6ME=A$Q/=E!VD^O%5U^T*I5)W53GY0S;>23R,\]<'],4ID0-M+#=Z4[<!U('
MX^O2@"2&YO[9&CMKV:")QB1(W91)D<[\'YAUX(Z4Z*\U*VRMI?W%LC'++$[K
MN8]2<$#_ ".:@9T4X9@#Z?CC^M!= <%@"1G'MZ_J* %NY+O451-2NYKV.-MT
M:3NT@C;'50Q(!SS5<VL!&TPI@\>_\NM3AU8X# D=:=0!7-K P4,@(087/;Z#
M\:06D 4H(P%(P0.X]ZLT4 95Y!%;VFV) BFXMC@=,^>G3TSWK],?^"B/_(N_
MLC_]DML__26*OS4U+_CV'_7>V_\ 1\=?I7_P41_Y%W]D?_LEMG_Z2Q4 <I_P
M3 _Y/6\!?]>%Y_Z U?V#U_'Q_P $P/\ D];P%_UX7G_H#5_8/0 54OHHYK.Z
MBE;9')!(DCCC:C*0QS["K=0W+Q1P3/, 8DC=I W38 2V<\8QUSQ0KO17OTLV
MG?R:U3\^@)VU?Y7_  >C]'H?S/\ [27PY^-_B7XB>-_&OACQ%;VOP\^&/C/1
M/,LWD87&I)+J<6\1CJ< G/&,#O5*S\0VVG_\%?-!UV^OX]/L3\'_  M-JEY<
M.(X(PUG 6,TC8VCKG/'TKWCXP?#?XV>//VD[^P^'>M:38^!M<\0Z==77A9[J
M-(=4BM+Q))Y)8BR[F"*S8"DYQ@'@'X6_:YM[;1O^"DGC33[R62P73_A/X?M+
MI++<(TE6WC5@A7!\O&",'IUYS5*I2C42K8RMC(P4*N*PU+.(YE5P4%+DGAJ-
M&K&%/#5)QA*I&K.;A*HW2J-.E*Y+ZM4H\V7+*Y8F\Z+>!RZKA*F)KM1J0GCI
M:NK4YZBI<M).THN4?<E!+^EOXD?$KP)XN^&'Q-T_PEXLT37-2M/!NL2RVNF7
MD5Q<1(;.3:Y12#CW&<'KBOR2_P""&;-)H7[1DLA+2O\ $6XWL>IQ<7'7W[5R
MO[,FEZ/H7C'XFVMAJ<UTVI?!S4KTF*9YH,/9RG;.6=U63G!!&>..HKJO^"&7
M_("_:-_[*/<_^E-SS]3T_P" BKJU\OQ+5;*UB8X244HK%5\'B:OM%\=L1@6\
M-4IZKE<-4U*,M5<SIT<PH)TLRHJCB8N[BJ&(PUZ;2<)O#XJU>E?5<M35I*2T
M:/WVHHHK(T"BBB@#/U;_ )!6I_\ 8/O?_2:2OY3OV,?^3^O'?_8\WW_I4]?U
M7:TY31]5<#)73;T@>O\ HTE?RE?L63&?]OKQV((WN&7QS?&40#S/* NI.9 ,
ME0.^??&<4 ?UCCH/H/Y4M(O0?0?RI: /Y/?^#D+3K.RNO@AK,-SYE])JQ\ZS
M<[HPL)WQED)P5;'((Z9!-?O'_P $[;:UB_9*^$MU;+:H=1\-Z?>3I:*%B262
MVC++M7H02>#_ /6K\(O^#C];NT@^$IFM+::UU/4T%M=-DW%LUN=S+&.WF8*,
M3QM.,$$5^YO_  39TJ^TK]C_ .$*WV UUX;L+J$ DXADMHRHY].E?A_#"MXR
M\<I4[)Y7ETI.S]R7+22=WNZD=;K2SMW/]3?'1N7[-+Z*DYXM2G'CSC2C3CSQ
MD\325;%3=-*%N58.=Z?+-<Z]G=NTD?G?_P %K?#\<6G>$_&EKK-[8:OING7%
MI%:6TQ2.XMY"V\2)NY^\>@K[F_8#G9_V#/!]Q&P6=O">OR%T)#><;:5@Q/4,
M6Y]>:^ /^"W&@Z\Y\#^)X[Q%\.Z;I\T=]8.^/M$Q=BIVY^;@GM^=?H5^P=<+
M?_L)^#I[6V$1F\)ZV(K>(;LN+>0*$  RSMP/5L5^X'^61Y#^P3^TW\+-%\#Z
MYX(\;?$:Q@\;/\0_$$$.DZI<2&_9'NG$*H&!'E@#@9  [&OMWQ;^UM^SSX(U
M0:/XD^)N@6&HE=QMVG+,HQGYC@8(&"1[_7'Q=^P9^SC\+->\!:YXR\;_  MT
MN3QHOQ!\02Q:OJ]G-'J?EK=,89$(E3"8)*G9AL\YK[:\0?LH_L[^*M0.J>(?
MA3X8U74",&ZNH+AI,>F5N%'Z4 6/"_[47P(\8Z7J>LZ!\1="O=-T@,=0NA.5
MCMPHR=QP>0.<=2.E<4W[<G[+BS>0?BSX>\SS_LVWS3S-OV!0<8Y;@5W>A_LQ
M? 7PUIM]H^A?#+PYIFFZGG[?9VT-PL5UG@^:#.2<CCJ/Y5RY_8N_9<,GFGX+
M^#S)YHGWFVN<^:&W!_\ CYQG=SZ9[4 ='XH_:@^!/@W3]/U3Q%\1="T^SU.-
M);*22<DS1R ,K !>A!'?OQ7$3_MI? '4=$\3W?A+XAZ%KNKZ#HEYJT>F12OY
MMR;>)G2.,;?F+,N",CZYXKO=?_9C^ OBFUL[+Q!\,O#>J6MA&L-G#=03LEO&
M@PJ1A9UP   ,YZ5QNI?L<? &WT#Q+8^$_AIX:\-ZMKNBWFE1ZK8V\RW%O]IB
M9$=&>9]NQB&^4<XYS0!^"_[0OQ6TKXZ> KSXE^*?C#-8:_>^*K>UT7P%H^H3
M0KIVEK=B.>XO+9751)''D@X!! /I7V;^SC^TOX;^"OQ!\&_#>'XK6GC[X?\
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M'H01[5_5=^P;^R3H/[#G[+GPQ_9F\-:U>^(=%^&VE/IEGJ^H "[O%DF>=GF
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M;H?[1L/[-NJ6EKH^GVEA_8$D=[(\@M5C3?YY!?+!/X2!SGW']4'_  CV@?\
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MO_PI_P"&)X/A/3R/^O6+_P"(JN_P6^%C_>\)V&.N!;18ZY_N?ITY/&37J%%
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MH_X9]^$'_0C:'_X!Q_X5[-10!XP?V?/@^PP? VA_^ <?^%5)/V;_ (+R_?\
M >AG_MTCY^O%>Y44 > /^R]\#),[_A]H9SU'V91_+G]:IR?LG_ .7[_P[T,_
M]NR_ETQ^E?1=% 'S/)^R!^SS+]_X;Z&?;R<?C5"3]B[]FZ7._P"&FBG/_3,_
MSSG_ #Q7U/10!^ '_!4#]GGX/?#'PCX O/!7@^RT*\U#7XH;N2SCXG@\^,;'
MSDY/(/;&..N?A/XF:;8:9XITR#3[:.UA;X6.62*-8]Q%LIR=H7)R>IR>U?JK
M_P %?O\ D2OAG_V,47_I2E?EQ\6O^1OTO_LEDG_I*M ']"7[ 7_)JGPN_P"P
M9/\ ^E,E?9=?&G[ 7_)JGPN_[!D__I3)7V70 4444 %%%% !1110!_'M\0_^
M">7PN\"?\%U=2_X*!>-/VE_"7ARTT_5H=:U#X?7U[IUOJ=M=K91V2Q2/*RR+
M T<88J1N+$_/M^6OZ3/^&\OV2_\ HMW@C_P=6'_R17\DG_!47_@WO_:O_;?_
M &\/C3\>?A1^T=;^'/#GBF>RE3PK!K6H)?:*8HA&;=[6SU*-88G(+[#;*2YS
MGG%?! _X-+_V^_\ HYV_'_<5UW_Y85Y>#XX\)<@GC,%GG_$6,QS+ZU*>(=3*
M9+"X6<E!2PV6/#<*T^?+8RYIX6I5JXNI4I24GBJR:9KC>%_$?/5AL7D^<>%.
M6X"%"-&C3HUG/%5HPDTJN:.KQ1)1S*W[O%PITL-"%6+7U>F[Q/[TO^&\_P!D
MO_HMW@C_ ,'5A_\ )%>R_"OXX_"OXV66H:C\+_&>B^,;+2IQ;7]QHU[;WD=M
M.V<1RM!)($8X/#8Z5_GE)_P:6_M]LP4_M07<8Y)>76-;CC4 9)9VU$*H]22
M!DDBOZ0O^#=K]@;Q;^P%X#_:&^&_CCXX:3\8_$NH^-;"XU%-)U&348O#4MK%
M+"UG*\E]?,D\Y_>2C>NZ0,=M>K2XV\-.(85<'PIE?B!',HQA56*SC+,92RG#
MTE).;Q>(ED.$HTG45Z=#VF+I<]9QA!5)/E/.7"W'>2UZ6(XBXFX!Q>":G%X#
M)Z]!9KB9M6A+"TO[<QE2I"E+WZ_)A:G+3NY2@ES'])=%%%([#\0?^"^_[:'Q
ML_8A_87U;XD_ &PU"]^(WB'Q+8>#M)?3+.>]NK,ZJOE_:TAMT>0^46SD+VQF
MOY$/V!?^"!_[:'_!4#X@V/[4'_!0/Q;XHT3P7KU[#KD5AK\EQ+?:]9SNMPUL
MMG.H^PPNC;56/##HS>G^C3\2/A3X!^+>E66A_$/PUIGBC2=/U&#5;6PU6T@O
M+:._MR##/Y-Q')&70C@E:[;3=,T_1[*VT[2[*UT^PM(D@MK2S@CMK>"*-0J1
MQ0PJD:*H& JJ /2O-S3&<89GA9<+X;.%D/"$Y+$9C_9-J.=YY5J-.6$Q&-C3
MA/#8.BH)1;GB:O[R4L*\)-.I+TLKI\-95B?]899/'->++?5\)B<SM7RW)\-3
M7N5<'@YN<*N+K3DY3YU##^Y'V]'$^[R?*7[)/[#_ .SK^Q9X TOX?_ OX?:)
MX5L+&TAM[B]M;*$:A?RQQJCW%S<[/,9Y67<P!QDX]<_7=5;R]M-/MY;N^N8;
M2VA1GEGGD6**-%&69G<A0 !DDFORI_; _P""SO["?['.E:J_COXQ>&-4\4:;
M'*1X2TC48IM3EFC!_<_+N56+#;CD\U[/"O!>(J4(Y;PMDE66'HR3JRP]-JA3
MG4?O8C,,?6:IQJ597E5Q6-Q"E4DW*=1MW/!XDXPPE"O+&\19PIXVO%.%.K.>
M)Q]>,;1C#"X*A&IB:L(*T84\/0<*<5:,8Q6GZODA02Q  &22<  =22> *1)$
MD&Z-U=?[R,&'YJ2*_P ZC]LO_@Z[_:._:#O-6^&/[!?PKUW1;C4A/IEIK?V#
M^V[^<3$QI<6D-LX=7(P8\^7R<'O7]E/_  2$\5?'OQK^P!\!O%/[3$&I6WQF
MUO0)[_Q?#JT#6U\ES/=RO%YT+22M&3"5^4N<=!Z#U,YR[*<EJ0RVIQ/DF/XD
MY?;8G(,JQ4<=7P&$B^2=;%XFFUA^9594Z:CA98FD^>[KQ:Y7SY7B,]S*E_:=
M3A?-LKX=FYT<+G&:TGA?KV+3BXT\+AE&I^ZE1YZCE7JT:\7'EEAHWYE^F%?/
M'[6G_)M/QM_[)YX@_P#24U]#U\\?M:?\FT_&W_LGGB#_ -)37B'J'YC?\$+O
M^3;O$W_8U3_^CKJOVXN;JTLXFGO+BWM84!9YKF6.&)%'5FDE954#N20*_$?_
M ((7?\FW>)O^QJG_ /1UU7Y'?\':O[:_[5'[+?@OX$>%_@%XIU?PAX:^($.N
M1^--3TBWN3,WD/(MO";V!T^S>8OR\_-@94KG-=F7T\LK8NC3S?,/[,R^<K5\
M6L.\74AI[D*6']I25:M5GRTZ4)5:<7.2YIQ5V<V,6:O#5GDN7QS/,8QYZ.$J
M5IX:G*,6G6J5*].AB9TZ=&ESU925&>D+:)W7]"7[6'_!5G]B7]CC3+RZ^+_Q
MB\-V.HVT,CQ:3IU[9:C=S2(K$1%;:Y8QLQ&TY&5ZD<8K^1/]N#_@\&U*_GU;
MP1^R#\.C&TSRV6E^.;F>3SY)')B@E@M&=BSL2I553)) ':OYU?\ @G)^SO\
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ME2I-RFRBBBF(**** "BBB@ IC]/Q_H:?3'Z?C_0T .'3\3_,TM(.GXG^9I:
M"BBB@ HHHH **** "BBB@ HJA=ZKIE@0+[4+.S+=!<W,4&?IYC+3[34+"^#&
MQO;2\"\,;6XBG ^IB=@*?+*W-ROEVYK.WW["YE?ENK]KJ_W;ERBBBD,****
M"BBB@ HHHH **** "BBB@ I#T/T/\J6D/0_0_P J /Y3/VK?^2K?M2_]CUIW
M_I4:\O\ AO\ \E^\&_\ 7K8?^BHZ]0_:M_Y*M^U+_P!CUIW_ *5&O+_AO_R7
M[P;_ ->MA_Z*CH _>^'_ %-O_P!<%_DM2U%#_J;?_K@O\EJ6@ HHHH ****
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M5]2?@84444 %%%% !1110 4444 %4]5_Y /B7_L7]3_])I:N53U7_D ^)?\
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MM?%<\DGQWJ9)/4G[9(.?P % ']@O[!?_ ";-\//^P5;_ /HI*^R:^-OV"_\
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M*5D?<%.2OL <FOI_]B3]MW3_ -IW1;ZS\7:=;^!_B-I]S(L_A*Z(M[G[.K,
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MK\N/BU_R-^E_]DLD_P#25:_4?_@K]_R)7PS_ .QBB_\ 2E*_+CXM?\C?I?\
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MH\52A_:5+#S48J,*,:U=X?"\T9>RH5)\\)<]X4TU3B4445YIZ(4444 %%%%
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M[P_33=1\/9O":CQ'P;C:BORXO(<RE5I4.?D>*P$L/B:4'2?,?S'G[EO]8O\
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M@QW=C;_"%XK]3;:OJ@6YLMJ[U^S_ #QMN(RH+*#\I!..3C@_NG_P3AT<:/\
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M/C#0;N2%FV[;>*ZC,CCUV@'CZ8K[-\ V\UIX(\(VMPGESV_AS1X)D'\,D5A
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M=24W%>)?M 1Z'>?L9?M0ZUI7BO6]5#>%M%LFTC6&NP4$5Q&HO(X;D\"3&X,
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M/^+\]_XH_9LU>\^ OBPM)=VYTB:;[,]YN:1"!"BA/WA!&>G7(QFOY>OVB/\
M@B=_P5<_8-^-WAG]HKPC8:_\99_A7J5MJ?A[QND]QJ-[%;Z2[26R&-Q)*4"
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M444 %%%% !3'Z?C_ $-/IC]/Q_H: '#I^)_F:6D'3\3_ #-+0 4444 %%%%
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M?<?[/W[6?PW^(7A6RT?1['Q5;7OA+PQIJ:NNIZ+<686:SL8XYHH6D $K!HR
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MKP^$OVT_@=J'A36;7;%>KH.F.MS\C!))1$(SGG)&<#^O]D_[(7[47@']LO\
M9^^'_P"T5\,1>+X+^(FE_P!IZ.M_&8KM8@YC=9HR%*LLBLN"!TK^-+X5?\&E
M'CWXS:K!XY_;-_:#U;5O$MSMDU"RT^WCD^9R'FC60$;<GC<I&3QD8VU_91^Q
M[^R]X*_8V_9[^'O[.WP\:63PE\.]*&EZ7+,-LLJ%VDDD=06PS.Q)Y.>]<O\
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M#3Z8_3\?Z&@!PZ?B?YFEI!T_$_S-+0 4444 %%%% !1110!\#_MW_LT_"O\
M:B\&:9\//B;XCM_#L%U*1IT]Q*D*RRECE=\F%R#TYZ]!FOR^M?\ @WF^ KVT
M#P^+'GB:-#'-&KR)(I'#JX0A@?4$BOL3_@KC<ZKI_P ']+U329KVSN;&Y,RW
MUDTD<ENRON4^9'AEYYZ_7BOA#]BS_@J-X@^'ITCX?_&9Y=;\,,MO9Z?KC'=>
M60X027<K98H!]XDE3@GVK^JO#_A;Q8J^%G^L_ASQ-C'1P^98Z&.X8P_LHU_W
M2IN6)P,G&7MJDXM<^'ERS:5Z<I-J)_"WBEXO^"N2^.\O#[Q;X7PN%^N91E5;
M*^-:[K3P:GBE)0P>:0BT\/1C.,HPQD.:G&_+6C!7F=E_Q#Q_ G_H9YO^_3__
M !NC_B'C^!/_ $,\W_?I_P#XW7[_ /@/X@>$_B3X?M/$O@[6;/6M+NXXW$]G
M*)1&SKN\J3'W77H1CM7.?%_XU_#;X%^$=1\:_$OQ1IOAK1=/MIKCS+ZX2*2Z
M:)"X@MD8@R2OC:H'!/?(Q7YJO%[Q@>,_LY<2YZ\?[;ZO]2]DOK7UCF4/8^P]
MC[7VO-[O)R\UWMM;^@(>#W@S/+XYM#A_(IY7+#K%QS&.(4L%+#.*FL1'$JLZ
M,J4HZJHI\K3=GJ?@Y<_\&]OP!LH);N[\7&VMK>-Y9YIP8HHXD4L[O(Z*BJH&
M2SL !G)KE?!G_!"/]E?XB6%UJW@GXAQ:]IEG>SZ;<7=I^^C2^MVQ-")(E>,[
M#UPWIQZ?G+_P4=_X+:>/_CN^N?#+X 75[X/^';2SV%]K2$PZOJ42,\9>VGBV
MGRY@?EP""IP,_=K]R_\ @@G-JMS^PQI%YK,]]=7UWXKU:>2ZU RO<W'F!&$K
MO-\[[L_>.<]222:_6^):OCAP;P%1XQXEXTS+ 8S&9CA,'A,DO1G7IT,12J5)
M5\9-0Y:=7W(J-"-W"[YY7:BOR;AG!^!W&7'M7@_AO@K+\=@<'EN+Q>)SQNM&
MC6KX>=&$:6#I\]YTOWDG*O4Y5-V]G&VK^>;C_@W>^!4\+Q#Q1,N\8SY<JD \
M'!6/.?I7[)?LC_LP>'?V3_A9IOPN\,W1O-.TT ).006P .A (SCTKZFHK^>N
M(O$;C3BS!4\NXAS_ !N9X*E6CB(8?$.#A&O&+C&JN6$7S*,FM[6;T/Z(X:\-
M>">$,=4S'AW(<)EN-JT)8:=>CS\SHRE&4H>]*22E*$6VE=VWL%%%%?$GW044
M44 %%%% !1110 4AZ'Z'^5+2'H?H?Y4 ?RF?M6_\E6_:E/8>.M.R>P_TINM?
M/WASQSH'A+XV^&=6UNY%MIUC9V+W$YY55\N/)^F.M>]?M87=O'\6OVI+=YD6
M>7QQIYCB+ .P6Z;) SDCGT]<U^?/Q02*7Q3&I"LITJS!QZB*/(XH _?J/]MC
M]GI8H0?%UOE854CC@X''WO;G^55&_;=^!]QJVE:+I.NPZA=ZM>PV5N$^]YLS
M;4 (;L<#H3CKFOYUK'0Y=6OK72M(T[[?JE])Y5E8Q*#+<RGD)&H'+'TZUV7@
MCPY=:5\6O!NDZK8MI6IZ7XHTW^TK2=0DEHZSJY64'&T[0221V/I0!_5NA+)$
MQ'$D,4RGU25 ZD^^",_G3JRHM<T1K;3PFKV1VZ7IZG,L>=RVR@C[PY&,'//3
MI4RZIIC8VZE9L3T'FH/_ &<D?4B@"_157[;9_P#/]9_]_D_^+H^VV?\ S_6?
M_?Y/_BZ +5%5?MMG_P _UG_W^3_XNC[;9_\ /]9_]_D_^+H M4'G@]#Q57[;
M9_\ /]9_]_D_^+H^VV?_ #_6?_?Y/_BZ /+/CA\,'^,?PWUGX?QZD-)GU7R]
MFH$;A$L;9.1_M=/;-7/@Y\.$^$O@+2O T=X-0_LR*%)+L# F:/(:3GGYO3V^
MM>@R:GID?$FHV:'MF5?3/9QCIV//KVJE_P )+X=#^5_;=@)>@0RKU]SD'KGO
M^/6@#=HJFNH6+J&2_LRIZ$3I@_\ CP_SZT[[;9_\_P!9_P#?Y/\ XN@"U17'
M>*_'WA'P5ICZMXDURPL;52$0/,A\UW(55 #Y)9L8P01GFM?0M9AU[2[35[6-
MQ9WT4<]I(W2:"7E)4SR5(/7)'3!YH VJ*** "BBB@ HHHH **** "BBB@ HH
MHH **** $;IGN",?B<?_ *Z_+7]M2(?#']H[X-_M$@?9H[)[+P>UR 5C+7SI
M$%=N S-O_B/],?J7UX-?$W_!0#X?-\0?V?)5AA9YO"&MV_BYI47,D::64G+%
MNH50O..WOBOF.,L-5Q/#N.GAX\V+R]T,UP:_ZBLOK1KTWW5K2U/W?Z-6>X+)
M?&3A3"9O5]ED'%\<TX!XC;MRO(N,,!5RK&Q=]'S2G2BHRT;>FI]JP2>?:Z?>
M9!_M#3;._P @YS]JA28'(_O;\U)7@_[,7Q 'Q3^!'@;QJDHG66U32!*#N!.F
MQ+;%<G)W#RSD?B/?WBO?P>*I8W"87&47S4<7AJ.(I2_FA5IQG%Z=TS\BXDR+
M&\+\19]PWF5-TLPX?SG,LEQM)IITL3EN+JX6K3:=FN65.VNOYLHHHKH/%"BB
MB@ HHHH **** "J>J_\ (!\2_P#8OZG_ .DTM7*IZK_R ?$O_8OZG_Z32T ?
MSY?L2?\ )\GAO_L?=2_]*C7]E-?QK?L2?\GR>&_^Q]U+_P!*C7]E- $4\*7$
M,L$HS',C1N/56&&'X@U\.?M!Z3\;[/Q#X&^'?P T&W\.Z!XNN95\=_$"WMOG
MT2S+;7$SQQF222>,ML9F.UL<CBONBJ6HFY6QO&LE5KU;:<VH8<&X$;&$'@\>
M9MS[5P9C@HX[#RHNM7PS;BW6PK4,1[.,XSJ4J=2SE!5HQ=.;@XSY9/EDGJ?6
M\&<45>%<YHYC'+<LSF$8UXT\LSRG4Q&4/&UL/5P^#S#%8-5(4L5/+*U6.-PU
M/$QJX9UZ,/;4JE-S@_E_PC^S9X?^$?AC6[_P-$^H_$C4K,M+XEUEO[0GFU9^
M9;JV6X5_L@=MS*(VW+_>'-?GK_P57L/%,7[%VEV/Q"OH=5URX\36WVUU0(I5
M]V(R/XR$X(QWQQR!TOPY^.O[:_Q(^+OQ"^%#>(? /A'7O!]S=WL>GZKIT9N6
MT)7/V><X@.<Q88MSCEF('-?GE_P5$^,OC9OAE;^'?&'CW1/B$='UY/[9;PKD
MV6E747$L$H0",,AR./ICDU\C@^(LEPM.%:A@<?@L#&5; N->G3H83VD*O+B7
M4H*M.K4JP:?MIRI2FH7<VD[G]%\1>#7B?G>+Q>69KQ3PIQ+Q36HY7Q5&ME>-
MQN:\0+"8K QK9)2P>:2R_"X#!9?B(SI_4*-+'TZ$\0H0P\9RA&!\$?\ !+CQ
M?I/[/?[>7AJ7Q7J,>E^"?%NG36MMJ%RP6SLKZ[&RWM]S85-[L!@'IG -?W#Q
MZKILL4,\>H6;0W$23PR"YA"RPR*&CE0EQE&4@ANE?YZ&O6$'C[PE#?:+=RV=
M[%&M]I.HVCF.[@NK= T024892K@=/XAQ@G-=%\+_ -H7XSZKI4_AS5_BUXYB
MUS0 ;6>(ZQ<[EM8LQPA!NZ! ,8' Y'>M,EJ0R+-GD2JJ>2YQ&IF?#.(4N:C"
M52U;&95&>UH\[Q6#6KE2G4BK1I(X_$[!8CQ7\/8^*DL%/#>)GAO4P7!'CAE,
MJ7L\?B:6#Y<LX<X]Q&'2YU.K&A'(>(9M*.'QV&P%2HY5<;.1_H+0W$%RN^WG
MAG3.-\,B2KGTW(S#/MFIJ_CW^ ?_  4=^.7P$\*OX8T[5V\5K+.9S=^)"^H7
M";C]U6G5]N.P  X^N?=O^'R?[08'_(,\.^G_ !X1$_I#7W)_*9_4E17\MO\
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M@?\ H'>'?_!8/_C-'_#YC]H'_H'>'?\ P6#_ .,UL9']2U%?RT_\/F/V@?\
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MUEO8]]R\<;A8Q"IWE2,$#'T^4_VU?A9\0?VQO^"FG@_]GO5/B%X@\ ?#G0_
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MI+$8+&X"M"<H3PV/H/#XB#C;7EO*,X2O[E2G.=.5GRR=G;]]Z***R- HHHH
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MX)Q?M"-J.KMX"D\ ZY<B61+_ ,+31Z5!!,^2',<$<8"JV#C)Z#BOYX_VDO\
M@WM^(7[(<]_XP_9Q_P""A<'PPTS2C)=6NA^(O&4]K*B0Y=8?*6_A9N% ^:-A
MV ZY]'A_,/#S"\^$Q/@IQ9P!BJG+7Q.8>'N%I<;\-X7X5*O7H4J+XAJRU<IM
MR]W5^1XV>9?Q%*K]9P_C=P_Q.ZDHM8+Q04N&<\Q:22CA,OQF'K_V;5MI",ZD
M9M/5I*T3_0KBN()U#0313*>0T4B2*?H4)%2U_E3Z5_P7O_X*/?\ !/?QFGPU
MNOC1X.^/&D:8=C:AN&J),L#!"IG?S%WN.Y8D]R<U_HM?\$P?VKO$7[;/[$_P
M4_:2\5Z9'H^O_$;0&U+4;"&-8HH9XYWA;9&N JL4W# Q@\5]CF>5Y-1P5',\
MEXCP^:X7$5%"G@\7EV99'G]*+@Y.KC,FS'#QJ8:FFN1WKSFI2A>"4TSY_+,?
MG5?$5L+F^0RRZ=&,I+&X+,L)G&45;348TX8[#>SDJU1-U(0EAU"4(3<*LG"2
M7W]7SQ^UI_R;3\;?^R>>(/\ TE-?0]?/'[6G_)M/QM_[)YX@_P#24U\\>X?F
M-_P0N_Y-N\3?]C5/_P"CKJOPU_X.^_V;_CW\<]6_9*U/X*_#OQ#XYE\+S:TU
M\V@VANFT^YDN?-M))QD;4#HK$YST^4YK]RO^"%W_ ";=XF_[&J?_ -'75?M/
MJOA[0]<\LZQI&G:GY/,7VZSM[KRR>I3SXWVY[XQ7GYI'-98*JLDK8"AF5Z;P
M]7,J&(Q&#C:I%S]K1PU?#5IWIJ2CRU8VDTY75T^_+)99'&4GG%'&8C+_ 'U7
MI8"M2P^*E>$E#V=6O1KTHVGRN7-2E>*:5FTU_DT_&+XL_P#!=OXZ_ FQ_9P^
M(G@GQ]J_PKT_0[/P[;Z)_P (\\6-,L(%M;:)YA.68QP*L:L4X50N !BJ?[)/
MQ*_X+I?L1?#6?X3?L_>!?'OA3P7<7SZB^G#P^]R5NG;+R+(9H]A;.#M'(ZU_
MK&?\(!X(_P"A3\/?^"BP_P#C%'_" >"/^A3\/?\ @HL/_C%<2XC\;ECZ69+/
M_#OZY1PWU2G/_4_$>R5!I*TL,\?]7G5T3]M*FZM]>:[=^Q\/^"CP53+7PAQ)
M]0JXCZU5PO\ ;&5>RGB-/WLE_8^LUK]UMM#^''_@B;^V/_P6C^+/_!0#P5X+
M_; M?&L7P4NO#FMW&N_VQH?V/3%O(;?=I[K<>?(XD:3<'4@CY4P!GG^[VN<L
M/!_A;2[E;S3?#VCV%VH*K<VFG6EO,%/51+%"K@'TS71U[%'-.+<VA]9XQQF2
MX[-(MTJ=7(LK>4X-82.M.$L,ZE6]93E4<JG,DXN$4ERZ^14ROA'*&L-P9E.+
MR?*Y+VM7"XROA\15EC)Z5:JJ8;#X6')*,:<4G3<KQ;<G=6****U,PHHHH **
M** "F/T_'^AI],?I^/\ 0T .'3\3_,TM(.GXG^9I: "BBB@ HHHH **** ."
M^(GPV\(?%'P[?>&/&6CVFL:7?0R0R0W42R;-Z%1)&6!VR)G*GD9[5_-U^V3_
M ,$P/%OPNGU3QI\(+>Y\1>#MTMY<:4B&2_L%8ES'#%'N81H,X ^7T)R*_IIU
MWQ%H?AC3+S6?$&JV.D:780RW%W>W]S%;00Q0H7D8O*R [5!.!DGH 37\PG_!
M27_@N3H&@0>(/A#^S++:Z]J<@N-)U7QHRJUO83+F.86RLTD;J"3M<#+=RHP1
M_0'@#GOBEEW$M/"\ TJF/P-2M2EG. QKJ+(E0YHJ5;%5?APM>,+NE4I/V\FD
MHPJ62/Y4^E+X;>"_''"52MXE>RR[.L-0K1X=SO+8TO\ 62GB%!N%##4M'CL(
MZG*ZN'Q'[B/Q*I2?O'R/^SS^U[\:/V7=:F;PW=W5[86S-!<^$=7FD^Q1SQ[E
M9)8'SLD!Z@K@^H'7\\?VZOVE?VI?VJOB5)_PFD^LW/AW5;M(]$\&Z$\\NEH[
MG;&OV>%MI)X XZ]<UB_LKI^TA^TK\3+KP]X6\-ZCX]U?7[U[[5=3:UEBL())
MY':21KE4:!&'.$!W  >QK[.\<_#CXC? 'QS:VGB_0)M%\2:%=075O/<6AEM3
M-&PE41RRQ^6V&4#;SGH#UQ_H<\DX!QG%%3,Z&"X9AXC_ -E^UE#GHK&VY4U4
MG15ZG(ZJY?K:PZQ/LG=WV/\ ):AQ5XT^$^1T,CSC%<3YQX,5LV=*A7C#$SRZ
MG[ZYH8;$3;I8;%0H_O/[-J8CZM*HGRJ*]X]O_P""</\ P0W\4_$UM%^+/[2L
M<_AOPB&M[_1?"H39?Z@J[)%_M"WD*D1./E(8 8]6P!_7O\,_ACX*^$/A'3/!
M'@'0;#P[X>TJ!(K>QT^%88V9$"M-(JCYI9,9=B>O0 5^0O[%7_!4CPUXNM](
M^&_QD^S>']:MX8-/TO6XT2*VO]BK%$DJ*4CB. !G"GIU&#7[6:=J=AJ]G!?Z
M9=V]]9W,:RP7%M*DT4B. P*O&S*>",C.17^<OCKF'BA6XHK8/Q!HU\#2HU*C
MRK!8;VG]AO#7M"M@*B_=XEM6YZU1NNI-J<:=^4_V#^C9C_!O.N#</F_A9C\/
MFE6K2IQSNOB^2/$6&Q<HQE4PN9X9I5<&HSO[.G2BL-.*4J<ZJ]YWJ***_"S^
MD0HHHH **** "BBB@ HHHH *\_\ '%S\0(+)O^$%L]*N[_:^U-5D$4&0#MRV
M5./^!9]NP] I#T/T/\J /XG_ -JF7X@:G^U%\3-(\0^5;^+-3UZ./4].TQB]
MD;MIF$3QA&VL <$^XZ=J\.\8^'/$'A7Q"^A^*)?,UF.UBG+,<X@D5613DG!
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M4GZLXY[\$X[]:_I* B''V.Q/UMH3_P"T\G\<TFV+^"ULXO>*"-#_ ..H,^M
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MQ]!0!]8?\$P/^3UO 7_7A>?^@-7]@]?Q\?\ !,#_ )/6\!?]>%Y_Z U?V#T
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MUR,#UJ:__:H_9_TVSCO;OXH>%4AD8HNW5;1I PZAD\W*D>AI_P!JY7[Z_M'
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MN)F9O]E0,MVQ7VW_ ,%$M3GU;]J7QW8Q64SM8:B\4,%O;$R2KDC<D:J&9?\
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M]@:_UOPC\4OB!!-\2](@9_\ A"K2/SKPS%"T4<YCE#Q"0@ $H#S7\A?[5_\
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M444 %%%% !1110 4444 %%%% !36Z9Z$$8/IS3J*!IV:/S _;VTW_A$?BS\
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MDTM '\^7[$G_ "?)X;_['W4O_2HU_937\:W[$G_)\GAO_L?=2_\ 2HU_930
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MGB'P]:L;>2]GMEWW6C7UA"BL]TS*Z)/*N9?7=PV+XBNO!/[9GPC\6VNO1R^
MOCM\/M!U :S$A-GJ@:Q@D$RG"K-/;7#1G(C#X##(*]+7C+P=??#[4+/]JK]E
M2[CU3PMJL:WWC?P38NLEG=V4G[R]DCLHRX2]4%\H4W!N1D50^*/A#PU^TC\.
M-:^/W[/NK1>#OBAIWA^^A\5Z0DB6KN%@E:_M=:A B)N@JR>7(RDR=#\YRP!_
M+W;6K/XI;3D<&]M/%AL[:5A_K+^WO_*AE<GJQE )!'4G(ST_H,@_;#\+^'/
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MQ*LEU8K9[,Q7L:[E="&R1N&>5%R]^"7P)_:^^'L/B7X<^&M&\&?&7P7B>_\
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M\3F.)4KNM.MF^98*OBZ,:L6_K+A6B\1K[:4NGZW_ +)'_!;']A']KSXQ:/\
ML_? OQ]IVK^-=1T^>]TW1[,PI']DLX]\HBCBPJB*, E5' (XP0:_8FOY+?\
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M(]4\0:GJ$<;9WQ)=7#R+&X/(9 <$'D'/K7WC\'OVOM%_97\0_%'0=/\ "?\
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M2,?^*BTDX!48/%UU]NH/!&:_E*_X=??MEMS)X?U*9A]UYM;N)70YSE':4LK
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ML?\ GKKG_@_OO_CM'_#JO]K'_GKKG_@_OO\ X[0!_49_PM3X9_\ 0_\ @_\
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MY S[\F@#ZJ_X+*:5IWB33O#6A6_]E0>)?[*NKVTNKZ5(IQ;1;B\<&2&).W@
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MXTQD:<L;GU:O#V&7P2C*6!RZC&]_=DZ==4(8;"TVK*&)E:LMBBBBI*/Y;/\
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M]_P4\^#>B?"/7_V;]5\&VVD:E!J)OK'1=5EDFEBF64Y!MB?FV@<;1Z"OJ/\
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M1@Y!_,3588;3Q#XFT^UQ]AT[7M2L=/(.X&RMKAX[<AL#<-@&&P"1R0*_7_\
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M+R1AC(:49?! P1^N<5P/@C]BC2_"'B73O$!\;^)[_P"P21RBUGU&Y:&1HR"
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M%]\._P!B#X:/;1:M)+8Z=J%]I+77B&7S28HY+.*.V>7S,LI4X7![\'/[C_\
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MU<JGJO\ R ?$O_8OZG_Z32T ?SY?L2?\GR>&_P#L?=2_]*C7]E-?QK?L2?\
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MM(.AP!@=?Z_I=_P3<@MK?]D#X51V<[7%N-/FV2/G<?W@SV'&<XXS^&*^ /\
M@LIK/AZ^A\+^!]:U==$DU#2+J_MKIK</YDD6[;!YQ4[-Y &W(]3[_>W_  32
M0P_L??"Z#[RPVEW&D@.1*BS *XY_B SQQSCGK0!]Z5^?_C[P/XHO_P!L?PEX
MKL],EET*T\-I!<7PA9HDE4X*&3[H8<=2/RK] *^&/&WQ4\9Z1^UQX6\ 6=Y;
MKX6U#PZEW<V;Q*9'N"3\XD/(X]/U'( /N8=!]!_*EI <@'U I: "BBB@ JGJ
M(+:??* 26L[I0 ,DDP. ![DU<JI?NT5C>R)PT=I<NI/9DA=AUXZ@4 ?E1_P3
MZ^'_ (N\,?$7XXZMKVBW6FV.I^,-5EL9KFWDB%PCW3LK1L^ P(&01USFOUBK
M\Q?V%OC=\0_B3X[^,N@^,+ZVO+#P[XKU.TTI+>W2%HK>&X9(U=E"EB .2<D^
MM?IU0 4444 %%%% 'YC_ /!8:VDN_P#@GU\>((]F\Z19.-[*@/EW0D(!;C<0
MI S^8K\?_P#@V\\9:Q<6OQ+\&3Z-;Q:39VHU&UUE"#/<22RQY@?!/"ACCM^/
M _7?_@L@,_\ !/;X[G)!73-/*D$J<F\"D9'JK-D<Y%?D3_P;=^,/!=S9?$OP
M?:I*OC.RMOM]\S1,(WT^29/+\N7&UN2,J#QMQ@<X_!N(Y*/CCP<O;*@Y9#6C
M[TE:NG5QMJ"BXOWVTY+EDI6CIHG?_6?P7H3J_LKOI'R>72S.G3\6\NJP]G3J
M<V53A@.%8RS6K.%6*]C34H4'SPE3C*JE*,I2BX?U;T445^\G^3!XY\?O^22^
M,?\ L&2?R->._L1?\D=7_L,WG\Q7L/Q_*CX2>,V=XXD72YF9Y7$:*JJ6)9FX
M'2O"_P!@[5+35?@NT]G)')''K]_"SQ,KH60X.&7@CN#0!]L4444 %<3\0_ ^
MF?$3PCK/A/51BVU6TEMA,%S);/(,+/%R/GCZCG!Z&NVHJ9PC4A*G--QFG&5F
MXNS[2333[---/5-,J$Y4YQG&RE%J2NE)77>,DXR3V::::T::/A/X2?L6Q_#S
MQ+=^)-?^(.M>-)TT*^\/:'#J42)'H^G7B2(8X"KDDHK #IT_+\1=$_X)Q?\
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M7XD^'OPH\*SV-A86VD-<68U.WO;=6EF-PZ"-HLLR$Q;AN!^;C%>?_P#!*/\
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MC_0T^F/T_'^AH <.GXG^9I:0=/Q/\S2T %%%% !1110 4444 %%%% !1110
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M ,JGJO\ R ?$O_8OZG_Z32UI?9[C_GA)^0_QJGJMO<?V#XE_<R?\B_J?8?\
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MM/@WW[(F=QB9 S+ZGCCTP.>-O/V4?C)K7B"Z\+>$?!]UJ7B?3G":OX+2R?\
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MG5=.\/V-Z;!]7>WD%O)-G&Y=JM_WUP/?C!_N+VCT'Y5YY\3OAEX7^*O@G7?
M_B?3+2^TS6K*YMMMQ DOV:>>)HTO(0<%9X6;>K*0<CG- '\(T<<:C<@'S=^O
M;_.:EKW_ /:A_9_UK]FGXMZ[X$U""Z307O9Y?#>H74;H-0MI9&=?(=A^\55(
MQSPOX"O * "B**>YN(K.R@>ZO;AUCM[:%29)9&("JH /)SQQ4<K^6F2#R0O'
M4%C@'WQUKZM^'7A^Z\%GPI;>%]&M?B'\8]?O+76/#NC:=']NAM+#<K@:@@5E
MC=?X@<?E0!^RG_!*O]BO4?ASILOQJ^)-@G_"2:RBR^%()%V7&E6<G+^8I <E
ME/RYV@DGK@BOV[KX^_9'^/#?%'PF?"GB?3X?#_Q(\%VMM9^*=!C1(8[:4(J
MP1 *=J]&P",]\"OL&@ HHHH *_.__@HK^TO\1?V:/ACI'B?X<6]G-J^HZBUH
M[WT/G01( "'92".YZ\5^B%?E)_P5MCMW_9_B>4(72[F,6_&=PC!&WOUZD=*
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MG//:@#Z6_P""VE[X>.A^%-+GAMG\27-G,^G,T:FZ$88Y$3GY@,YX'ZU^AO\
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M#0__ (%/_P#':/\ AR38?]#0_P#X%/\ _': /U9_X;O_ &7?^BI:#_X$Q_\
MQ='_  W?^R[_ -%2T'_P)C_^+K\I6_X(DV../$[D_P#7TX_'F6J,O_!$D\^5
MXG4_[UVPQ_X__/\ /I0!^M'_  W?^R[_ -%2T'_P)C_^+H_X;O\ V7?^BI:#
M_P"!,?\ \77Y"R?\$2]5&?*\2P$<D?Z9C/U_>@?C^>:H3?\ !$WQ-SY/B.Q]
M@U\V!_Y&!_,G^= '[$C]N_\ 9>/3XHZ"?I<Q_P#Q=+_PW=^R_P#]%0T+_P "
M(_\ XNOQEE_X(H>.@/W/B+2_8&] 'T'[_I^OOZ9TO_!%'XF_\LO$&B8]&OQD
M^QS/C]?QQ0![%_P4V_:1^#OQ7\*^ ;+P'XPT[7[G3M:6XO4LY%=H(?-4DL%)
MX YZ_A7YN:[XDT/6?%-W=:9J4%W#%X FMY7CSMBG\H#RV[[L]?Z9K8_:5_X)
M]>._V7]+T/5]>U'3KVW\07HL(/L=R9BDC.J8?$C*N 1CI^/?S31?AW:> ];U
M>QRURVI>![B^F#L6$<S1ACL+=,9QW^O' !_4G^P#G_AE/X6<?\PJ7GL?W[]*
M^RZ^-/V <_\ #*?PL!Z#2I<#T'VA^">YQBOLN@ HHHH **** "BBB@#^5;4?
M^"V_QLM/^"Z#_P#!-F/P_I#?"Y=9BT4ZJ8(_[3%P]FEYO\W&_9Y3@=<[\@C
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MI5LQS^HHK&>PM[B3KQ<VVY)+E>^"R7POG##9GD>.QWB%F]+$0KRXDX@KT:V
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M'_I*:^C/ /S&_P""%W_)MWB;_L:I_P#T==5^X%?A_P#\$+O^3;O$W_8U3_\
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MZ)_L^_\ )P?Q9_[%RQ_]%+0!]J#H/H/Y4M(.@^@_E2T %%%% !1110 4444
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M&3C_ (2!3C) SYR\\=Z_(3QAQXPG_P"R=3>I_P"6(]:_7O\ X*^?\B7\-/\
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M2SU"&%(Y$D5&8,"-W? [<#\*^=O^#<O_ ((Z?L6_MN_L/W_Q5^.WPXL/$WC
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MQ6\??\%J/!7C#Q9J7P?_ &3O ^N_$GXL6LTULD=[I\AT5+A 5"23HO=L$DR
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M4]&5ACK_ "QS0 N,G)R3^GY=,>WYTM*RNAPZ.A.<!E(SCT)&#^!I* "BBB@
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MQ.%JTZM*?VH-/8****]<_.0_BC_ZZ)_.ON7P5QX<T[_K@GJ?X1ZU\-#[\?\
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M_:X_9(@F DA.NSN8V *[O-ZX/7H.HZU^J-?EE^U__P G>_LD?]ANX_\ 1IH
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ME<<YZ<TUJTM%=[MV2\V^B\^@.]G9-OHDG)WZ6BM6_):O9'0I>6LC!$N(F<G
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MV?@/_P %1?V+_@5KG[1FC_M(:7KA\ W&GWE_I,U[.R7=M+=QI+'M<;6RFX
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MFJ?"W_L%2_\ H]Z^RZ^-/V <_P##*?PL)Z'2I<'U_?O_ )]#VXK[+H ****
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M-= O=^J:[J.F:KJFEZG'#*IDDEU*"SD7!6/[Q&WDY/!-?Z,?_!#?_@KC=?\
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M'VGS?;-(6YL-'@T*PU1&F&J7$16*X>XM596@PW+Y=@1MK]Q?^#P/XM:QX?\
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MWM\9/AQ\+OAY\/K?]G;3KZ/P5X1T/PRFH-::CNO8]&L8;&*<A;<QY:*% 2@
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M/%^"_AGX*\$ZMXBUWPQH&FZ-J/BFX6ZUR33[2&T%W<*Q8/*L*(K.#DECSDT
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M^(6BBBOL#^;P'WX^N/,7IUX/ ]L^O3\Z\C^,;_MXR^((?^%'64?_  APT]!
M[SA&,^T8(4D?R.#WKUP?>C_ZZ)_.ON7P5G_A'=.R2?W"=?\ =% 'X%Q?\+_M
MO$T1_;TU37$\#SSJ+?3],CNIH&3?P)FMFP(RN-Q)]\]:_;?X%Q?".+P+I:_!
MY=)3PQY*M EBT)NER <WRAWN%F.1D3X.>@SFO2M>\+^'O$]E<:?K^CZ=JUK<
MQ/#)'?V=O=#9(,-L,\;E#CHRX(/(K\Q_B=\*?%W['OB8?&7X*R:CJ'P^N;Y#
MXY\!O--<J(9YLR75A$J[8H84R?D"A,$$ $4 ?JM17!_#7XA^'_BCX/T?QCX;
MNX[JPU2UBD=4)W6MT8T:XM)0>1) [%&'/;G.:[R@ HHHH ***X[Q]XXT/X=>
M%-9\7>(+F.WT[1K*:[E#.$>8Q(66&$'):20C:  ?6@#@/CY!\(Y_ 6JK\8%T
MMO#:P2/*MXT0N]P4X-D-ZW!FX) ASDC)!P*_$VU?]I5]>#?L2ZUK=U\.4NI5
M72]6CNHDVJ^"L<EP0#&%QL.X<#@DBOLCX7_#'Q)^V-XRNOC#\77U.W^&-E?L
M_P /O"J336UO?6L,Q"SW<;+LEB.!N#*=V<8ZU^G^A^&]"\-6-OIV@Z3I^E6=
MM$D,4-C:06R!(UVKN$*)N;'5FR2><T ?B!XNE_:_;PZX_:/LX[?P\6B733%.
MLN+W>APP#DY]_P 0:_8[X-Y_X5=X(S_T ;/\L''Z5\W_ +<__),]._["T?\
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MJ2-Y<K+''&08^C N-O /?%9/[-FJ_#*;5;[2?!7BFYUZ_P!-T](;I+AR3Y*
M#SMISC)YSDY]ZP_VQ)? ,'A_PBWC:RN[LB7_ (E]M:[P%F$<8V2!.,9P,MZ8
MSCIY5^Q??>!KOXD>*1X>T&ZTC4UTD>:TJL(Y;;C:,D*"V,'ODD],<=$:<_8R
MG]3S[EDF_K%#%8:GE,M5[V)H4*]&O6<%[KECJ->3?+[%1C&RB4FY1C[; R4'
M9TIT(U,92;Z0J8FC5=*,_LO+JU%1]Y5KN5W^G5%%%<Y84444 %%%% !1110
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MX?$.[^)W["J:_>^&[SPQ+#\2]!A^Q7LJ3M*D<R8DC9%'W@PXY]/I^H7[$?\
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M#^(K\%/^"=:JO[:GC@)&D8%C)A8UV(.>R@ 8],#'I7[U?'MMOPG\9?\ 8+F
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MJ[\0ZUX#\/V+7^DWD5S;?9$EB6.-H[<^6C*!S\H;*Y/(-?T>_P#!/'_DR/\
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M7[5>RG['"\DU4]R<N>\6HPYI:6*/_$,W_P $S_\ HG]__P!_8O\ "N=\4?\
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M "BBB@ HHHH 3:-P8###HPX(H P21D$]2.I^M-\Q<L RY4$MN8*% Y))/ P
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M]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH 0J&Z_0^X[@^H/3\::(K<?\
M+C8Y[G[.F2?4_+R3W/>GT4 -\NW_ .?&Q_\  =/_ (FE5(-\?^@V/WQ_R[I[
M_P"S2TJ_?C_WQ_6@#X/^(.AZ-+^U!X0OGTVU^TK<)@BW0)G>!R-N",\Y(/K7
MWG, )Y< * Q"JHPJKA3M4= *^(O'G_)RGA'_ *^5_P#1JU]O3_Z^;_?_ /95
MH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P[]HK3=3U
M/X0^+(]-U"334MM+N)M2GBD:&0V@3YU$BX*$C/S9X/XX_-;X$_L,^)/%S^'/
MBYX*^)USH%I-97=C-INIF35H-3AG9DFV"X$L8+;R%(!V_AS^NOC+PY!XR\(>
M)O!]V[16OB;2Y],GE0X=$F3864CD$9SP>W/%?GOX"\,?M6? 2RO/AMH%S:^(
M/"EK-,O@N^CB,G]EQS2LT9O'VD,8SC.<@ <\'CX+B;*L'B<[RW'9EEF/Q^!I
MX6<%4P$ZOM<-CJ=>%2A[M*K3J0IU*?-><6XRJ<L:B4=5_7'@?Q_Q-DWACQIP
MOP3QMPGPGQ5B\_PN)J8+BS#X'^S\]X5QN5U<%FO+5Q^"QN#Q6,PF*E2:H8B$
M*M#!JI6PM1U8*$NK_92\26?@GXI_$C]GV]T,Z?=:&)2NN*Y:+6Y+YL2D0 @0
M!R['[JC!P1BO,OA2W_"H?^"AGQ*\%W'^B^$?$7AD7>E,/D@FU6X'SJ@X1GWD
M X&1^%?3O[/GP%\1>!O$?BGXL_$_5[36OB-XQQ)J5U&T<=M9PI^\C2$/M"O&
M!S@ ]><U\L_MQF+PK\7_ -GKXN>%;B.YBU+QQ!I/BJ\MCN6&S2>-'6>1,Y4
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M<;+5M$TK4(?^$TU(;KNR@FE +MG#NA9>O9A^=?B%\&.?VMK-CRQ\3ZYD^O\
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M#_B/QUI%WIGQ^_94:6+Q_;RPZ7XW^&Q;S(_$5TQ"S7]K9#<IA.6;/ED#)/U
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M6SS"XNK0Q^*A4G5I8VI';%TI5*M:?+4UBXRJU.6<)J-24;,****YSH"BBB@
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M?\G*>$?^OE?_ $:M?;T_^OF_W_\ V5: (J*** "BBB@ HHHH **** "BBB@
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M$OX9_P#8Q1?^E*5^7'Q:_P"1OTO_ +)9)_Z2K0!_0E^P",?LJ?"[C_F&3_\
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M]!);7EC>P1W-K<P2J5DBFAE5D='4D,K*017\#/\ P7Z_X)/_ /#%7QD\'_\
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M]??'/X?UH"@?F3GH>3G''8=/PI&; )!7Y?F<DX"(.K'G@#OZ=3Q7Y0_M4?\
M!77]G[]F[Q?)\.=%TW5?C)\0K8E+[PMX'#7>H6DBG:8YRD4RJX; (QW[9H _
M6#:.>O/!Y/(]#S5FWSM;))PQ ![#)X'M7XI_!_\ X+-?#SQ[K5IIGQ&^"/Q$
M^!^G7LJ0Q>(?&\#P:<K.<*2XM(MHQR<M@@BOV-\(>)]#\8:'8^(_#.J6FM:%
MJL"W6GZI9/YEO=1. P9".XW88>H]* .GHHHH **** "BBB@ HHHH *0]#]#_
M "I:0]#]#_*@#^0C]HG_ )2.>/O^QHMO_2HU^B?[/O\ R<'\6?\ L7+'_P!%
M+7YV?M$_\I'/'W_8T6W_ *5&OT3_ &??^3@_BS_V+EC_ .BEH ^U!T'T'\J6
MD'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH *5?OQ_[X_K24J_?C_WQ_6@#
MXE\>?\G*>$?^OE?_ $:M?;T_^OF_W_\ V5:^(?'G_)RGA'_KY7_T:M?;T_\
MKYO]_P#]E6@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N=\56]Y=>&=>M[+5?[$EDTN[$^JYP+*#RV\RXW#!7RU^8= .A/.*Z*LG7]-
M&M^'O$.@,QB&O:1>:5YHZQ_;(3#O![;=Q//_ -<143E2JQ2;<J=112E*#E)P
MERQYH^]'F=H\RU5[G9E]6-''8&M4E&G3I8[!U:E2=*%>-*E3Q-*52JZ%12IU
ME2IJ57V4XRA4<%&2:;3_  W\*?!W7O%/C/Q78>&M"U?XCZ7<7MV;[XBV%Y/
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MV,JV68ZE]7E5AC<'B,-5HT85Y5:CI^Z_KSX$?M4_%?\ ;4_:]\%>!%\2Z/\
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M\D=7_L,WG]*]B^/W_))?&7_8,D_D:\=_8A.?@ZN/^@S>?S%?HY_&9]BT444
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M$GPQ\,:IK-TQ+-<7]Q81FXE9CR2[@L3WSFL38^IZ*** /QI_X*_?\B5\,_\
ML8HO_2E*_+CXM?\ (WZ7_P!DLD_])5K]1_\ @K]_R)7PS_[&*+_TI2ORX^+7
M_(WZ7_V2R3_TE6@#^A+]@+_DU3X7?]@R?_TIDK[+KXT_8"_Y-4^%W_8,G_\
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MX9^$-*T7Q)I5GK&BZK::/8M/-87D:SV\T4[6_F)O1@P8," >M?8H 4    #
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MY_R<IX1_Z^5_]&K7V]/_ *^;_?\ _95H BHHHH **** "BBB@ HHHH ****
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MU:L,/Q7P_F%.I">'S_*L5E-2I3O[.KC,(H8W#U+NSTHT:U*',N;W[-7T/S3
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MFW^#O[2W[*?A+X9RZ[;>$?B[\-XWETC7IY(;#4H]1B/F))97#R12SP2. DJ
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MYT\7VOC/X4>+F1(-)2]BO[3PW97LI+6HV231QP&-\L%883J%.57WOX_?#,>
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MY0 4444 %?C[_P %B_\ DA>B?]A2;_T6M?L%7X^_\%B_^2%Z)_V%)O\ T6M
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MOQP_X)N&Z'Q2^/PEDOVB/C/5RGVEIGC_ ./M_P#5^8651[+@8K]CZ "BBB@
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M3_9]_P"3@_BS_P!BY8_^BEH ^U!T'T'\J6D'0?0?RI: "BBB@ HHHH ****
M"BBB@ HHHH *5?OQ_P"^/ZTE*OWX_P#?']: /B7QY_R<IX1_Z^5_]&K7V]/_
M *^;_?\ _95KXA\>?\G*>$?^OE?_ $:M?;T_^OF_W_\ V5: (J*** "BBB@
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M5;W_ (^Y_JO\J_FT_9U=+G]KW3'QG;XTU+'7K]I;(Y]/TST%?TE7?_'U<?\
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M:?\ %C3M1_9;_:DTU=(^(&EQ/9^&O$EY$8&U18ALM;^PN7B4K<R%8V5@X+C
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M5M+@S:W-S?6H#7&G7]LJB24M(KQH[H0Q.UCDY9]A?>$OVSO"4O@KQG;_ /"
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M;,\"CKBPNAGZ(]?U^U_(%_P2\R/VS/ H/)^P763ZG8]?U^T %%%% !7X^_\
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MKR7.G>(M7-HEY=>'-/@W>7>-'$&G7.!\VU<]03V_I*_X+)F8?\$]?CJ8MO\
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MG^\B.#CAE==RL/J.<=J=21C_ $73L%#_ ,2O3LD..6^S+DGWI<-Z+_WT/\*
M"BC#>B_]]#_"C#>B_P#?0_PH **,-Z+_ -]#_"C#>B_]]#_"@ HHPWHO_?0_
MPHPWHO\ WT/\* "BC#>B_P#?0_PII91U>('^Z9%#>^%ZG^M #J5?OQ_[X_K2
M8;_9_P"^Q3D#&2, +]\?Q=!TR>.* /B3QY_R<IX1_P"OE?\ T:M?;T_^OF_W
M_P#V5:_+SXT?&KPEX5_:I\-:9=769].NHC?HO"H))54$,>O)';CTXK]-[:^M
MM2MK;4K:: VVHP)=VY,J@^6ZKM!'_P"KTQ0!/1297IYL&?\ KLM+Q_STA_[^
MK_A0 44?1HC])4X^O3^M)GW3_OL4 +129]T_[[%+AO1?^^A_A0 448;T7_OH
M?X48;T7_ +Z'^% !11AO1?\ OH?X48;T7_OH?X4 %%&&]%_[Z'^%&&]%_P"^
MA_A0 448;T7_ +Z'^%&&]%_[Z'^% !11AO1?^^A_A1AO1?\ OH?X4 %%&&]%
M_P"^A_A1AO1?^^A_A0 448;T7_OH?X48;T7_ +Z'^% "-V'J<?Y]Z^ /VV/B
M;XR\*2>"_#>D-XETOP_J^HB'5-<\*6+76I6Z$C);8C.JAL _[(/6OO\ (;!X
M7H?XA_A7RW^U3;?$BW\/>&?$GPSCL;F^\.Z@;S5=-OH(9H=3MMW_ ![L\H*H
M#T!.,G'/6O!XFA6J9)CE0K8FC)1IRE+"4W5KRI1K4W5A&FJE*4TX<SG&%2$W
M%-1=[(_6O W%9;A/%'A6IFF R?,:$Z^-H4:&?8R.7Y73QU;+\3# 8BOC:F$Q
M]'#5(8ITXX>KB,'B,/&O*#K0]GS27S#\"?CS^T1_8'BG3=,TBU\2Z1X=O7D@
MUWQ/!'#J']@QDEY[PLNZ.54SP<$8]*^F?C'HD/Q\_9?UN>7[+<N-+O=?*VY6
M6W%YI,#3E8G Y(DC(&/3'M7Y[^)/&OQN\'6_B#6?B+X=M_ 7@GXH64VCDZ2X
MGF6XO@8_.@A@/W1NW95<=@>HK[0_8EU3P+JOPGUWX2^$_&USXRN]#M+W3=96
M_C>*;3FU8$&)EES(P/F8&>HSC@5\7P_F#QLZG#>.Q&-Q%/%Y9C</*GFDXX>M
MSN7/A5AL%64<5.G6PSG4<I.HU&G[VUW_ $]XN<'0X8P^%\:N&,FX:RG&</\
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M)>_\GF^!O^O&[_\ 07K^OR@ HHHH *_'W_@L7_R0O1/^PI-_Z+6OV"K\??\
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MG^"KJ\NI8YH5=Y8]7@LF=U5OERL_Y]3^=_\ Q$%?\%J/^A.\<^I_XI?6^O\
MWYI8;A;P^S95,1QGX@>$WU^-24,+AL3E^;8W'8'!^[*.#S"KBLFJQAC*-5SC
M7IX6I+#*:;A*2;D>C/'>)V$C1APGX9^)M++YTH3GBL+FN!C@\RK/E7U_!TZ.
M*P;IX7$4_9SI1K0J5E!J,ZC2T_TH_P#AG?X'_P#1+O!O_@FM?_B*[;PC\/\
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MO$W_ &-4_P#Z.NJ_<"OP_P#^"%W_ ";=XF_[&J?_ -'75?N!0 4444 %%%%
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M4?\ #1?[;'_/A<_^ \__ ,17[S?\(YX<_P"@#8?]^8_\*/\ A'/#G_0!L/\
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M_P! &P_[\Q_X4?\ ".>'/^@#8?\ ?F/_  H _!G_ (:+_;8_Y\+G_P !Y_\
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M%BE((4G;]?PYKY7\%? #XH_%'1I-=\#^!M:\2:);S?9WO=.MI)X$F7K&SH"
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M .BDK\?O^"GW_);K+_L"0?S6OV!_9M_Y-]^%G_8#C_\ 124 >T4444 %%%%
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MO@_Z[1_SK]"/XZ/BSX7?\GJ?&O\ [%J'_P!!%?9PZ#Z#^5?&/PN_Y/4^-?\
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M9PZ#Z#^5:GG"T44#).U068]%'4_Y]30 5\E?MJ3Q0? [5O-8)O$JKG !)CP
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M-7Z_5^0/_!%S_DUF_P#^QPO?_0&K]?J "BBB@ HHHH **** "BBB@#Q3XV?
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M.S_^CHZ_H)K^?;_@N7_QY_ K_L.S_P#HZ.OK#^>S]*O^"?'_ ";9X0_W#_Z
MM?;]?$'_  3X_P"3;/"'^X?_ $!:^WZ "OA/]H/]J'6M)\2Q_!GX(:;_ ,)3
M\4-2_P!'O+J!#<V'A59?E%SJ&U'4%,Y.3\O89KUO]J?XQ#X,?"G5O$%M&9]6
MU)TT/28(SF<7FI P13QH#D^2S!LD$ XZ]*X']D'X#)\.O"C>./%*?VE\1O'
M_MC6-;NL2WGV6^ N+>S\QBQ58D< KD'  - 'A:_L)7OC+PSK_BGXY>,M>\5?
M$'4=.N9A::;J,UOH5I*87<1"R(V2%6&T@* /?H/P_P#%NH)X*_9E^-OP@5R/
ML'Q+D,<+\2!(KEMORYR" .N/<8K^P"50T<BD9#(ZD>H*D$?C7\8W[;.DZ[X&
M^/WQ4\.7!\O1_$_B2YU6W@7(3F1F'RXP<9R3S0!W?_!+/C]L7P*/33IQ^49K
M^P&OY O^"7 V_MD^"5'1;*Y ^@5A7]?M !1110 5^/O_  6+_P"2%Z)_V%)O
M_1:U^P5?C[_P6+_Y(7HG_84G_P#18H J?\$5/^38]8_[&^Z_] :OV-K\<O\
M@BI_R;'K'_8WW7_HMJ_8V@ HHHH RM<FB@T;5)IXUEABL;F22-AE758F)5AW
M!Z$5_+A\ I$N?^"GVLZW9:7NTI=2G22.!0$@<W##=MX!]?NGN#G/']2&MI%)
MH^II/GR6L;D28&24\IMPQ[CBOY?_ ( PSZ9_P5 U*U476G:)>7UT\(F7RXKH
M^>W3LV3WQG!ZXZ ']2:D,JL.A (R,<$9%+167J^MZ1H%H]_K6I6>EV4?W[J]
MF2WA7ZR2$*/SH U**XO1_B-X#\0).^B>+="U1+5&DN&LM0@G6&- 2SR%&(55
M .2>!BL4_&GX3*[1GXA^$PZN8V3^V+3<) =I0C?G<#QCUH ].HKC-0^(O@32
M=/M=5U+Q9H5CIMZ<6E[<ZA!%;7!/:&5F"N?8&J>E_%3X;ZW=I8:1XV\.:C>R
M'$=K::G;S3.?]E$<D_A0!W]%>=ZA\6_AEI5Y/I^I>.O#-C?6IVW%K<ZK;13P
MMZ21LX93]:TK?XA^!KO2Y];MO%>ASZ1:_P#'QJ,=_ UI#_UTF#;%_$T =E17
ME3_'+X/1X#_$KP<A/0-KED"<].#)GGMQ6]/\2O %KHZ>(;CQAH$.AR.(TU63
M48%L6<]$%P6\LM[9S0!V]%>:V'QC^%>IW45EIWQ \*WEW.0L-M;ZQ:2S2,W"
MA$60LQ)Z #O5C5_BS\,] OGTW6_'/AK2[^-0[V=]JMM;SHAY#-'(X8*1T)X-
M 'H5%<1IGQ)\ ZS97>HZ5XOT'4+"P0RWEW::C!-!;1KR7FD1BL:@=2Q%82?'
M'X/R,J1_$CP@[NVQ%76K0EFSC:!YF2<\8]: /5**X;6/B;\/O#\-G<:WXQ\/
M:5!J*>98RWVI6]O'=(?XH&=P''N*Q[;XV?".\GCMK3XC>$;BXE8)'##K5G)(
M[$X"JJR$DD\ 8ZT >HT5P6M?%+X=>'+B*TU[QIX=TBZGB$\,&H:G;VTLD+#(
MD1)64E".A'%2Z-\3/A_XB%P="\8:!JPM(VFN38:C!<B")!EY)3&S!%4<DG@"
M@#N**\K/QP^#ZNT;?$CP>)%<Q,AUNS#+(#M*%?,SN#<$8R#6[J'Q*\ :3IMI
MK&I^+] L=*OFVV>H76HP16ERWI#,[!'/T- ';T5YWI?Q<^&.MWD>GZ/X[\,Z
ME?3'$5I9:K;7$\A/9(XW9B?8"FWWQ>^%^F:F^C:AX\\,66JQRK ]A<ZM:PW2
MS.<+&8G<-O8\*O4]J /@+_@LC)Y?_!/;XZ@HSB33=/0X'W ;L-O/!X!4=L\\
M<U_/A_P2$^+FH?LNZ%JOBKQYJ>A^+?@QXNLH\V/DK=1Z#?R_\?!N4E63YHSD
M2*4!&&X'&/Z&_P#@KM!'KG_!/KXY):7=J(KC1;*:*YEE"6[)'<"8%9>GSJOR
MG."#FOY\_P#@B=\(!^TMH7B7X7>.K6S;P#X6D;6D>';))J4TL@)M;@@_/%N;
MD9 Q^O\ .7'U7%4/%OAVK@L*\;CO]7I1P.%E356AB*WUK%1G0Q5*35.IAYTY
MR=1U;1IM1FG>)_L[]$^OPW3_ &='C94XQC"IP=A?&&E4XNHTXT_[364U<BX<
MA1Q61UIKVF'SFAC84?JD\-*,N5U55O2<T_WD\1?'C]A/XWI\.M)T'Q]X$T7Q
M&_B33M3TJVTK28;2_FU!9$*6(FAM87R\@Q\TA]_?]6+4*MM;JC;D6"%4;^\H
MC4*WXC!K\Z?B+\(/V*_V7;+X=ZUXA^#OA>/4;SQ+IOA_PW>:=I2OJ$.L3.BP
M7F3)N 61D9I<?*>F,5^BUJ\<EM;R0C;%)!"\2^D;1JR#\%(%?LO#F'QE'ZW/
M&Y3@<FJUEAI+"9=B95<-94VG55#V%&GAZDI7C/V;J>T<+RDG%'^:WB]B.&L7
ME/!V)X(H^)2X/G6XFCE>*\0J^3XJ&)Q,,?AECXY)B,JIPE.C0;P\<;'%.<X5
MY0Y)6<K^1?'[XPZ-\!OA3XK^*.OZ?>ZII?AJR,]Q8Z?_ ,?4PDW(HC^1^AY.
M%)QZ=:_"_P#8$^,.D_'G]MWQC\2M"TNYT?3=8TII8K*\W&X19,E=^[!R/]T#
MGI7[D?M$Z9INL?!WQK8:M90ZA8S:7)YUK<*'BDP#MW*00<'GD<=>U?@S_P $
MW[&RTW]LSQI9Z=:QV5G#8.L5M$H"1J.BKC& !QTKZ@_"S^E*BBB@ KYT_:EL
M!>?![Q3)#J,>FZE:V,TVE2R, K7NW$28/J3G\!7T77S_ /M.6D>I_!OQCI"-
M!%J&J:7<6NE3SX"V]\R$Q3!N"I0\@@CZTUOULM7:K*AI'5WJP3G35E[TH>^H
MWY?>L'-&.LY0A!?%.I25>$8O1N=&7NU8I/6$M)+1Z'XW?LP_!KXG_"CX[/XB
M^(WC.VUV/Q]\+]=U.SL(')-I&UO,5C*XY.TCD9%9_P#P1=BL8/B_^V1+Y$$.
M?&TIEF*HNY3>SYWN<9&.O./7/%==^QK\$OCJOC#Q-\1OB=XRTSQ1X9\'>"=>
MT+3H8KI;FYM=\,[1Q%59BFU!W&!MQG!KXX_8FN/#\7A7]ON?Q!XB\1^%K+_A
M([PVVI>%)'CUK[4;J0VT5OL(8B20A3S@YQGM51J8&M5:P.,Q6:X:%3DEBH_7
M\3BJTWRSJTZ5#,W2Q"E1<W1HT%+V4XPA4A.]25B\:L(3H_V7AU5@E26#PM+"
M8&D[^RC*JL%&2J.3BJE:LH.JG)TVOW=S])/^"Y%WH>H?\$Z/C;:V[V%[)';:
M:S0QM'(T2_;$^8JIRHY]*^Q_^"=JJG[#_P"S"JJ%5?A#X2 4#@ :>F /8=!7
M\PGQBUB^U#]BG]JY-?\ $WCK5]870=,%MI?C)YCLTP72?9;R..5C^]E3#,P[
M^]?T_?\ !/'C]B+]F3C'_%H_"?'_ &X)55O8J?[B-=4FER_68TXU)62YI6I3
MG#D;?NM2>F[N"H8K#_NL95PE;$1UE/ JO]6Y9)2C&/UA1JN44[3;23>L58^S
M****R _&O_@KY_R)?PT_[&!?_1RU^0GC#_D<)_\ LG4W_HD5^N/_  6*NXM/
M^'_P\OKC(M[;7!)(5SNPLH8@ >PZYK\4&^(V@>-_$6IW^B+</#8>!Y["Y#Y+
M"81!25P"=O!.??B@#^H+]@+_ )-4^%O_ &"I?_1[U]EU\:?L @_\,I_"PYR#
MI4N.N<?:'QGU.,5]ET %%%% !1110 4444 ?RH:C_P %M/CA:?\ !=1O^";<
M>AZ0?A8NLQ:*=2,$?]IBX>SCO=_F_?V>6^!R3N!!]:_JOK_*3_X*S?M%_%/]
MD[_@X9^,WQW^"^A+XF^(O@WQ5IUUH.BM:SWHO)I-'BBDC-M;QS2OE!T6-O<5
M]82_\'/_ /P5W>5V/[.%HG)^3_A$=;^7GH=VED\8[\]:^EJ8O)LWIX5YSQ1P
M1PI6P6'I8*CA,8Z648G%T*45R8VM"A1?UNI4DY0J8NM+VE2<&I2=E;Y_ZCQ-
M@*E?_5WA+B'BG#XJM/%5\7#,U6HX;$5'[V$I1QDIRP\(1Y)0H4;4(QE[L8M-
MR_TO**_S0/\ B)^_X*[?]&XVG_A):U_\JJ_J4_X-[/\ @I%^U1_P45^%OQI\
M5?M/^!HO!>K^"/%>GZ5X=CAT6^T5;VRN899)R8;ZWMY)# Z+&74,K$%N,@5P
MXK#<.4Z$IY=QWPEGF+3CR9=E.83Q.,JIM<\J</8QC:G%N<DY)\D9-)\LN7IP
MLN-/;P6<< YQD6 :E[7,L7B<-4H496_=0E"FE-NK-JG%K12:OV/Z*Z***\@]
M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F/T_'
M^AI],?I^/]#0 X=/Q/\ ,U5F^_\ @*M#I^)_F:JS??\ P% $1YX/0\5%/!#=
M6\MI<P0W-M.C1RP3HLL;HPPRLC@JP([-D9^@J6B@#\\/CA_P2R_8L^/U[=ZW
MXR^$NDIXFN"TBZWIY;3ITG;)\W9;[$9@WS< <]Z^$]:_X(-> %N''@?XW>,O
M!FF9(@T^TGN)D@3^%%+7/.U>,U^_>,]1G\*3 ]!^53.$*EO:4Z=6VWM:<*EO
M3GB[;= C>,90C*I"$[<ZA.4;V\D[7/P,T+_@@K\)WNH7^(7Q;\7>/;)7!GLK
M^XGA2=/XD;;<GANGX_G];_!__@D)^P[\&=93Q%H_PHT_5]>MYDFLKW599;X6
MK(<Y6*5S'][YL'<,G&#BOT\P/0?E2].@J*="C1BH4Z5.$4V[1A%:O5[+37M8
M+*RNDVM+R5Y?^!.[_'U,W2=*T[1=.M]+TC3[32["VC2*&ULK>*VC2.,;541P
MJB#"C (&<8SDUI445J 4444 >$?M$?%27X(?"7Q5\4AIMWJW_"-1QSOIME"U
MS<7$1D42>3"H+.P3.% [<5S_ .SC^U'\-OVD?!.E>*/"6I+8ZE=6T/V[P[K9
M33=7M[PH#*BV,[B9D#9&57TP#UKU?XB>(_!OA#PAK7B/XCSV$'@O387FUB74
MHXI;%(5&2TT4W[MUQ_"V>AZYX_G(_:=_:M^'GQ%^).GV/_!-;P3J?CKXY^9]
MEO?$WAJVN=-\+:"G"BXDMH EI,8^"6"G(!./0 _H)^-_[0WPC_9Y\*WWBWXK
M^,-(\/V%E;M.;"6]M?[5N@BEMMII[SI/<,1]U53!; !S7R1_P3[_ &Y;?]M;
M6_C1K?AKPUKVC_#WPGKT6G^$-3US3IK!]:MC(R/<0>: )(\*&#*2"#G-?B;\
M*O@+XQ\1?%RS\6?\%@=9UN[U:;4(3X+BCN+Z'0'G=LVD%Y;11/ 8P"B2>9'C
M SG=7]2WPET;X7:#X4T_3?A1:>&+/PW;VMNMM%X;CT^-?)\M?*:\6Q529RFT
MEIQO))S@Y% 'J-%%% !1110 4444 %%%% !2'H?H?Y4M(>A^A_E0!_'I^TUI
M-IJW_!0SX@:;?QBXMF\4V;-&W1BMT?O#G(^O8D5^C7[-MA::9\>?BK9V,*06
MT7AO3PD:*%48@5<@+@#OVYSZ8K\^?VB?^4CGC[_L:+;_ -*C7Z)_L^_\G!_%
MG_L7+'_T4M 'VH.@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4AY!'J,4M% '
MS]^U!X$\1_$SX+^*/"?A.".YU^^A'V2VE.U',0)?G(XXX.>W'>OE7]@[PUX@
M\':YK7AOQ1:QV>LZ9IRV]S!&VY0T:D'!Y[U^E1)"3E25/V>3E>#]Q^]?&/P'
M)/QN\>%B6.R?EN3T]: /LX=!]!_*EI!T'T'\J6@ HHHH X#XJR1Q_#'Q^9)8
MXE/AK4@&E8(I)MF  )P"2>@&<]..M>4?L=9?]G/P@5&X+J&I[BAW[?\ 2&QN
M '&>V?Y5;_:E\!^+_B3\(=2\*^!;^33M;NI<R21DJTUL% >WRO/S#*XY'/IU
M^3?@I\+_ -J/X0>$8].M]9^U6$)9H= 8$R*>"^"><R'TQDGCCB@#]/,_Y[_E
MUI:^+-*_::\5^%+N/3?C#\/;[PQIR,J?\).4EDBDR0N[8H(Y]QQ[U];^'O$>
MB>*M*M];\/:C!J>EW2*\4\4B,X#XV^9&IW)CON&0>OK0!N4444 %%%% !111
M0 4444 %*.70>K@?SI*5?OQ_[X_K0!^"W_!3)L?M!Z7'C(_L: CJ>FWDYX[#
M^?K7[%_L^?\ )"?AE_V!(O\ T6M?C=_P4Q_Y.+TT_P#4#A]?6/MTK]D?V?/^
M2$_#+_L"1?\ HM: /7:*** "BBB@ HHHH .0=PX8=/KP?Z5X-\1/V<OAA\2M
M;M?$^MZ-&OB6Q4I!K,;-'<(ASN4,F&Y'<=_J*]X)P":\K^*OQ"UGX>Z)_:F@
M^%)_&.HLZK%I5ONW,&P.2 0.G4D#!Y YQPYE3P%3"5'F5"G7PM*U64:E%U^5
MP::G"G&,INHG\/)%R['UG!6,XLPG$&#AP7F>+RK/<<YX##XC"9E#*?:T\3'D
MJX?$XRM7P^&CA:L&U6CBJL<.XW]IH>6VOP]_9Z^!6O\ A^6]T40>+?$T_DZ7
MJTSFX$TV>=_G[PF6Z8QGJ?6O7OC!X3'Q$^$?CWP4$2>/Q-H4]JBA05=3&SC;
MM''3C;COCG%>/>.?'?P]O/!7A3QG\<=!;PUXEDD67PUX9#":[,X^<"+;N;.[
MY2%!/<UUOP4_:+^'_P 5-?G\$:),;'Q;H]C)/-X>NHRDT>G&)E6XE$F#@K\Q
M+ =J\C#ULIC4KY/[7+<+A\RI*GA,%1A]7Q52&+P_+6ABJ+4']8J1E.<(32JR
MIK6+LV?HF<9;X@UL)E?B1]3XVSW.."<PJ8OB'B7,<1+.<BPF*R#.:=3+\1D>
M94JM>+RC!5:6'P^*Q&'E4P%#%6Y:\>:,#YR_X)R^+CJWPR\:_#EI#GX0:_-X
M;2!S\T2I.ZD*I.<<<<\8Z&OT/@#-/!M5VQ*A.U20 #R2>F/QZ<]*_%+P%\4K
M']E_]KCXD_#[2[+_ (2&Z^)=Y=^)!HMFV\3WA=V5?W.5!+-CH23^GV0WC3]I
MGX@K<MI'AB;X>VUTDT<)NLL41\A).A(RI!_A/3'6L>"Z]2>0TL'7_P!YR?%8
MS*,0M?=>#K2]A'7:V%G0LNWE8]+Z3N6X2AXLX_B/*XI9+XC9'P]XBY/-)<M:
MEQ'EE!YI637NRY^(,+G#YEN[W?,F7?A9*C?MJ?&LI)$X_P"$<A7*R*PSM' Q
MU;/&/UK[27H/H/Y5^5/P7_9S_:%\'_'N3QUKGB1Y=-N[AI=?O'WG^UK=CG[,
M,] !P <X[=3C]67*&20Q B,OE1[8'3\<_7K7U9_/HWDD*/O,<*.>O;..WJ:^
M4/C5\:]6L]7A^%7PMMVU?QWJK""\N8OG315D.UY79#^[,88L"<=ABO9_BMXV
M@\ >!=;\03.([A[:6TTMF."-0FCQ;@9(R=Y!P.037C?[+GP[ETGP]>_$SQ/&
M;GQOXTN)9KV>Z7S)(;=V+V_D&0%HP59?F&!F@"/P!^RSX>LFA\0?%6[G\>^+
MYMMTUS>RR%;"=_F:!(V)!2)N!D'('%?3^F:3I6CP"VT[2[""W4;54VL!(&,#
MYO+ST]?7ZUH#/4G+'[S=R?\ )./:EH 0JF<I#;P#N((4B#?[P15SZ\Y_Q6BB
M@ HHHH **** "BBB@!#T/T/\J_.7_@I;_P DNT#_ *ZO_P"SU^C1Z'Z'^5?G
M+_P4M_Y)=H'_ %U?_P!GH ^K?^"+G_)K-_\ ]CA>_P#H#5^OU?D#_P $7/\
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M#[].:_L"K\4/AE^R[\(?@5^VGX0@\ Z/+I\UK;7"H[N6^5E(_( XS@<U^U]
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MY)+XQ_[!DE>._L19_P"%.KDD_P#$YO.3^%??G\?GV+1110 5\Q_M:"W;X/\
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MTAY92UX@VI##<;R3T  R?2OO7_@G7)'-^P[^R_+$XDBD^$'A%XW'(=&T]"K
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MC76B>/\ POI6O6T]M+#'<W=I#-<V3.I FLY6C:2VF0G=')&1AQTQ7RQ^Q?\
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M$S?'?BWQAH?Q&B\3>(+K7!8>+=6AM#<R!S!$EW*JQIC. %  YZ4 ?JE1110
M4444 %?+'[7GP^UWXE?"U/#OA_;]N.O:;=_.%(\JWEW/][C.#]?2OJ>OC7]N
M3Q'K?ACX-+J6@:K-H]]_PDFD0_:X&*R>7)-\\8(YPPX- 'S'_P %-H]2\%?\
M$R_BC:RQV\E[IOA72;2X2:-7A)9DB<[#\I(9@1S^/:OY[?\ @E5^SQXZ^+'P
MUUCQQ\+7TB+QOH$UU'#$\<(=EVM&IE3LIR"!MX.,=*_?3_@IYJ%[J'_!+3XD
M7US,;VYN?"NA-=SR'+N'E4N^>[[MOYFOP6_X)8:KXO\ @-\,O&7QH^#\OC'Q
M=/K.FPZ;J'AB&T:6&RU$.([F6"*$;#M.X[U!R!DL2:_F[Q$I4ZWBKD4:]7$4
M*%/AJ=6>)PN'6,Q.#<,5BIQQ6'P-F\;*$X0A+#Q3E*,WHU=/_:OZ'-7.<+]
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MOG_(E_#3_L8%_P#1RU^0GC#_ )'"?_LG4W_HD4 ?TB?L!?\ )JGPM_[!4O\
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M/Q_H:?3'Z?C_ $- #AT_$_S-59OO_@*M#I^)_F:JS??_  % $5%%% !1110
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M,%_'_P#Z&_6__ Z7_&@#]O?^$]\%?]#5H_\ X&V__P 51_PGO@K_ *&K1_\
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M .AOUO\ \#I?\:/^&"_C_P#]#?K?_@=+_C0!^WO_  GO@K_H:M'_ / VW_\
MBJ5?'O@K>G_%5:/]\?\ +[;^_P#M5^(/_#!?Q_\ ^AOUO_P.E_QI#^P7\?\
M_H;M;[?\OTOKU_#K0!F?\%(-6TW6/V@],N])OK?4;7^QH4-Q:R)+&&^3Y=T9
M*Y^OO7Z]? 7QKX1M/@C\.+2Z\2Z5;W,&C1)-!)=P+)&PC&592V017XY:Q^PA
M\=([F+SI+W7)'(!N[ES/+$#UP[ D#OC';CG%=!;?L%_'P01!/$^LVJ;<K;I>
M2I'#T&Q$& H[X % '[B?\)[X*_Z&K1__  -M_P#XJC_A/?!7_0U:/_X&V_\
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MDDG/)SCFOZ?+S_C[G'H5''3I7V+NM'TT/YK34DI+9I->C5T5J***!A7$>//
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M]NC0M5\0_!A;#1].?4[O_A)-(E^SQ@EO+CF!=L '[O!_"@#YP_X*BV_AI_\
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MO(J7#BQ57,*&.P%:5.MB^&*&%R_,,GP\<2J&18JMA:&,=*&*A6C+D4G\#?\
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M_P!$VT;_ +XH_P"%O_M-_P#1-M&_[XH ^S_.D_YZ+_WR/\:/.D_YZ+_WR/\
M&OC#_A;_ .TW_P!$VT;_ +XH_P"%O_M-_P#1-M&_[XH ^T!/*,XE SUP /Z_
MK2>=)_ST7_OE:^,/^%O_ +3?_1-M&_[XH_X6_P#M-_\ 1-M&_P"^* /L_P Z
M3_GHO_?(_P :/.D_YZ+_ -\C_&OC#_A;_P"TW_T3;1O^^*/^%O\ [3?_ $3;
M1O\ OB@#[/\ .D_YZ+_WR/\ &CSI/^>B_P#?(_QKXP_X6_\ M-_]$VT;_OBC
M_A;_ .TW_P!$VT;_ +XH ^S_ #I/^>B_]\C_ !J>VFDWR_O%_P"/:?\ A'_/
M*3WKXI_X6_\ M-_]$VT;_OBG)\8_VG(RS#X;:,=T<D9&S^^I4?ENH K?L6NX
ME^/NU@,_$&])^4')\^3)]J^U_-E_O#_OD5\D?LC> _'/@G1/B+J/C^QM].U7
MQGXEGUJ"SM6S'''-(S[3D9R-W 'XGK7UI0!YI\9]#E\7_"WQ9X<;=,E]:2EX
MPN=R1J[,-O7HO7TZ<9-?#O[.O[,'P2^(/@.]U/4--BEO]*U673+K$8R'A<JP
M(.22<'G@'O7Z5.BR)-$X!2X@DMWR,C;*C(20>.C=>O:OA#PW?-^SE\:M1\,Z
MN#:_#GQO<O=:?J#$I;IK5V<LCNWR*-S#/J3ZT =ZW[$_P*QC^R%'0?ZL<<X]
M/2OSU_;:_95^%GPN\;?"CXI6&GFU\-Z1=VVEZTP4+&\E]*(DWDC&[YLKGIP>
MM?M\NUHXWCD2:"5%>&>,[HIHV&Y2CC(;Y2,D$]Z^1?VZ/AXWQ-_9M\3:%!"9
M+S3[ZTUM)$7=)&FEO]I9D8?,  F#CH.3C KYOB_"5,9P[F2HQYL3A*=/,L(N
MKQ>75(XO#I:-J]2G'8_;OHY\0X3AWQFX)J9G55'),_QF*X+XBJ/X8</<98.M
MD&;SDF[24<)C)NTE:]OEZ5\*/@E\+?!/AGPWJ/A[PSIL]UJ&G6FMV>L3V\;7
MT7VV)9@T4Q4LH^9<8/3.">:]QY))8EF8Y8GN< ?TKYL_9%^((^)OP#\(ZVDP
MN!H5O;^%Y)%8-B32XEMV4E>^4Z''XXKZ3KV<!BZ>/P&"QU*7-3Q>%H8B,OYO
M:4XMO3^]S(_,N+N'L7PEQ7Q+POCZ7L,9P_GV:917HNZ=*6#Q=2G"+3U7[GV3
ML^C"BBBNL^>"FLP568D*B F1V("QJ!DLQ)' &"?:G5\O_M=:WKWAWX,ZOJ'A
MW49M+OBDBO<PL5DV!,X!&#UY//T'3 !]+M>6B0&Z:[MA:C/^D>8GED#J0=_;
MOD\8/7BO'?'7[0'PR\"VDS3Z]::[JR*1#H.FR%[Z:7HJ+&N<Y8 #))#9]L?F
M)^Q-X0\=_M$:)XGOO%?Q9\0V5MX>OG@M]/AEF,4Z&0@AR&Z$?3CTXK])_!W[
M-?PR\*W:ZI>Z5%XCUN,AH]6OPTDJLIR& ?<,DX/?G\30!X7H/A#QY^TIXIM/
M&7Q!@NO#WPWTBX6XT/PY*&BN;R16W1_;82%W0G ^\#D?E7W5:6MO96MO96<*
MVUE9QI%:V\8VQQ(B[ %4= 1T'_UJG555(XU5$CB79%'&JHB( 0!A0 >/4<'I
M3J "BBB@ HHHH 0]#]#_ "K\SO\ @I_*T?PU\(+G'F7C@?FPY&>>?\YK],3T
M/T/\J_+S_@J=.8OAWX#48_>7\HZ_[1]>/3]: /MG_@C!_P FMW__ &-][_Z"
M]?KW7Y"?\$8/^37-0_[&^[_]%&OU[H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OY]O^"Y8S9_ K/_ $';C_T<E?T$U_/M_P %R_\ CS^!7_8=G_\
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M,"_^CEK\A/&'_(X3_P#9.IO_ $2* /Z1/V O^35/A;_V"I?_ $>]?9=?&G[
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M3Q/ G_8.F_\ 19K^P&OX_O\ @EG_ ,GB>!/^P=-_Z+-?V T %%%% !7X^_\
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M GPGTOPG>>";+P=I$/AS4,?;M/6T@$=S@YQ*!& P/?(S[T ?B#J7[7/P5?\
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M* /Z1/V O^35/A;_ -@J7_T>]?9=?&G[ 7_)JGPM_P"P5+_Z/>OLN@ HHHH
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MG5>.Q-'!55[F';R_'*.'CS*51X?$1AB(2G+GC%61_E_?\0]?_!:G_H<O%?\
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M%% !1110 4444 %1SP?:[6^L"=HU&RGL"W<?:4:,D>X#5)4D/^O@_P"NT?\
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M_P!"[H/_ 'Z/_P 11_P\]^/G_0NZ#_WZ/_Q%?KE_PS?\ O\ HF^D_P#?"_\
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M<F[L/[)C*>?,S!F,I[@^F<#TK]QO^&6?V<?^B6Z/_P!\K_\ $T?\,L_LX_\
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M!EN]0UG1[7,=OJUPR7T)62=5#ONBR<G/?/V+'^T-_P $GUDCD'PJM 4?(/\
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M3S+B#6]\,>"=SB0%00/5L5^$Z^-/B%XCU;4;[4-%&G7]OX3EM(HIH]BS:<$
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M"Q;[Q/DKDMZDUN5GZ3-!<:983VJ&.WFM8)(4( *QM&I53CN!Q^%:% !1110
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M% !2'H?H?Y4M(>A^A_E0!_(1^T3_ ,I'/'W_ &-%M_Z5&OT3_9]_Y.#^+/\
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MA<13?6%2+"BBBO2/B HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+P7BI;T\1P_F-24,+3J<M6KE-?+\5)?OC4HHHKZ@_!PK\??^"Q?_ "0O1/\
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M^THXYVTV)8&E"PS)'\VPDL!DY).37SYXN^,G[<G[9O\ P4E^ FN2?LJS>!_
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M';@'W'6OR\_X-P?!44&G?$KQV(K6*748/[.(AXD813)RR[N!QCIV')K]+?\
M@J'JFH:I_P $N/B9J-[)]LN[WPMH4EY.< MOEC+R ;L9W;>,\[NW6OS8_P"#
M=;P%<:2_C[QAI7C/4-9\,ZOH5O!)H$]O)!;:9K"RQFY,88E=ZE2I*_>'S9/4
M_@_$<7+QPX0_<^VC3R&K+XH1=%RK8V/MDI6E4C&RC)0NUS7>A_K)X-588?\
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M]:^*7_),OB!_V+.I_P#I,U>2_L>?\FY^#_\ L(:G_P"E#4 ?2U%%% !1110
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M'!5AC&?K7QW!U\+0S?))-WR3.L90HIW;EA,7)8ZA43_D<\15IQZ+V=EHE?\
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M6FNY47*Q1J =S,>!CGFOS3'[9_[0S^9M^#FOHN^145[.3<%5B!G]WT(P1^5
M'ZD7=]9:>@DO[J"TC)"J9Y$BW$]-N]ESSQP#GM5M#&Z*ZW%L5=0Z$3QX93T(
MYYK\)?C_ /%O]I+XUPZ+#:^ O%WA[^QY8Y'_ +/BE@%QM.[#X5>,=\UC6OQ
M_:2@M;2#_A$_'C?9[:. M^_^8HH&[IWQZ\]: /WUP@Y-Q; ?]?$?_P 528C_
M .?BU_\  B+_ .*K\(]!\7_M+^(/$WAW0E\.^-K"WU348K6^OKCSQ!:V[L \
MLAV\*H.<GW)Y%?H:_P"S9\1U*@>/[X@Q0OQ=28#.@9E^^?ND[?PH ^S\1_\
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MU_X69\/?^AGT_P#\"8/_ (ND/Q.^'H*K_P )1I^YV"(/M,'+'@#A^YK\7O\
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M )$KP;_OR?RKU#_@FS_R;6/^PS+_ .A&@#[WW-Z_R_PHW-R,]?8?X<?A3:*
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M_/J5G;7$=K//'%-,,QK(RH& ]V('X=?TH O456DO+2)/,ENK:./^_)/$B?\
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M\G\J]0_X)L_\FUC_ +#,O_H1H ^]:*** "BBB@ HHHH **** "BBB@ HHHH
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M!/4^PK\%/^"=P(_;5\<*^,BQD&.#C!/' [?B?>@#^DBBBB@ KP+]IFWTZ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIC]/Q_H:?3'Z?C_0T .'3\3_ #-+2#I^)_F:6@ HHHH **** "BBB@ HHHH
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M>GIGTS7DW[&]G;0_L\>%)8HE1YK_ %$2LH WA;AL9P,XP<<_7KS0!]04444
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M-:DGXT_\%?\ GP5\,_\ L8HO_2E*_+CXM?\ (WZ7R3_Q:R3K_P!>J^E?J/\
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M(!ZY56SZAAE6'L13J5$86VG  9.EZ>2<\D_9TR3QU.<GZT;7_NC_ +Z_^M0
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MI?\ T&OD3_@JO=>5-X#M3TGLI#MS_LG./QR3GU_"OKW]@3C]E[PH/34)A^E
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M7VEVM0S"(OVW%<=N#7"?\-T_&PZ=XCTJX%K=VGBB":WNUF8/]FAN 5=( 20
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M"O*_V,O!&O\ P[_9W\!>$O$T#6^LZ7;WJ7<+#:4,EW*Z#'NA!_&@#ZDHHHH
M**** "OA_P#;1\5>!?#$/P?/C?0;C7$U'XCZ79:,+=2WV+5)'C$5S)Z(A()/
M;%?<%?GS^WKX*\1^,K?X'+X?LI[TZ3\5-(U&_$*[O)M8GB+2OZ 8.3[?6@#[
M_M6#6UNRC"M!"5![ QJ0/P'%3U7M 5M;96ZK;P@_41J#^M6* "BBB@ HHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,?I^/\
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MJ$?^S9_*FG_@IC\3UZ^ T'U!'\S7ZH/^S3\$I"2W@^#GCB.,?R3G\<]*I/\
MLL? B4?O/!T9.<G"I_\ $C^5 'Y:S_\ !3'XG20S1KX(BC:2)XEDS_JF92!)
M][JA((]P*YO]G#X[?&WXH?&:QTWQ)\2-:M]&N]2^T1Z9$K-#Y<C@BT<ARIC7
M.T'';//%?K%)^R3\ )00W@X8/IL'IQG;GMZUN^$OV<?@[X$U9-=\+>&%L=5C
MP4G;:VT@\8) QCUZ]N] 'MRQ&#;$7\PQ1HI<]9&(&7;W)7C\:?2 =SR3U/X8
M_*EH **** .+^(UI/J'P]\;V%JADN;KP]J$4$8!+/(UN0JJ!U8GH.<X-?!?P
M%^-GBOX;_"W1_!-[X(U"6XTG4-1+2FUE^=7G<J>0.N!V YK])F4-P0#ZAAD$
M="&!Z@@G(-5Q8V SC3M.&3G'V*'OU_A&>>2<<T ?('_#4/B'_H1;_P#\!9?\
M*/\ AJ'Q#_T(M_\ ^ LO^%?8'V*Q_P"@=IW_ (!0_P"%'V*Q_P"@=IW_ (!0
M_P"% 'PGXR_; \7>&](CU*P^'-_?3M<Q0F#[)(<1R$!GQ_L]R,5T%C^U5XDN
M[.VN7\!:@CSQ)(Z?99/D9D#$<9Z'BOL>73-,G79-I6ER)D-M>QA(W Y!P1C@
M\].?:I!8V &!IVF@   "QA"@#L!C@4 ?('_#4/B'_H1;_P#\!9?\*/\ AJ'Q
M#_T(M_\ ^ LO^%?8'V*Q_P"@=IW_ (!0_P"%'V*Q_P"@=IW_ (!0_P"% 'QQ
M<_M3>(X;:YF7P'?L\%O),B_993O= 2%QCG)'3^74<;X;_; \9^*=&U)KGX>:
MCIMWBYMK=OLDH*OM9(I1P!]X@\9SQFOO@V-@P(.G:<0PPP^Q0\CN#QTJ.+2]
M*A7;#I.E0KDDB.Q@&X^I(4<_AU[T ?A/=R?M6:EJNLZ@_C'Q/9PW>HS365I'
M;76R"T=R8U&&Z!3@?R]6?9?VI?\ H>?%?_@-=?XU^\7V6R_Z!^G>G_'E!V_"
MC[+9?] _3O\ P!@_^)H _G_\0ZC^U+H5E#=_\)GXMG\^^M[((MK=-@SR+'N.
M2<*,\GC'7L:^K="_9P_:TNO[!U2X^+.JP6EY!9:A(OF2;XX9=DK1.I8X8*2I
M!!Q^%?J=+IVFSILFTO3)4W!@K6,. PZ,,#A@>0>N>A%6QD*J MM50JJ"P55'
M157.%4=E' H RM!M;JPT/1K"^G:\OK&PBM[R]<Y>ZN%51)*W7EF!SZ'KD]-5
MB0"?I^ SR?P'/X4M% 'R_P#'CX\^(OA!XL\$>']'\)7/B2P\6!C>WL$+RC3R
MI/WBH^0MC.>^?I7+M^U#XA#.H\"WY"L5!^RR\@=^E?7L]C974B2W5C9W<L7^
MIDNK=)WASU\LN#MSZ]O>G?8K'_H':=_X!0_X4 ?'_P#PU#XA_P"A%O\ _P !
M9?\ "F/^U'XA5'8>!;\E$+@?993DC.!C')XXZ\]J^P_L5C_T#M._\ H?\*0V
M-B1C^SM._P# *$_TH ^"_#/[8_C'7=4U>RN_AOJ%K'IQ(@F-G(/.&?PS7:C]
MJ+Q"0#_P@M_S_P!.TO\ A7UTFE:5&[R1Z1I4;R??9;&'+?4[1G\N?7M4WV*Q
M_P"@=IW_ (!0_P"% 'Q__P -0^(?^A%O_P#P%E_PH_X:B\0Y'_%"W_)QG[-+
MQ^E?8'V*Q_Z!VG?^ 4/^%'V*Q_Z!VG?^ 4/^% 'P+K'[97C'3O$6DZ)#\-M1
MFM=0DVRW0M)2(5SW...Y[ #G'2N[;]J#Q"K,O_"#7YVMC/V67G@>U?7+Z5I4
MC([Z3I321G*2&P@WJ?7.W).?<8J;[%8_] [3O_ *'_"@#X__ .&H?$/_ $(M
M_P#^ LO^%.3]J/Q"DD;_ /""W^$=7/\ HTO1>?2OK[[%8_\ 0.T[_P  H?\
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M6K#5;SP#X;O-6FT*1X-4LVN6ANK>>,D-']G.)2 PV[MG.,9P<T ?MI_PU_\
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M]PV><YKV3]AS]H3X6?#;X&?\(WXPU@6.KC5I)?()4?NR3A@"<\^GOFOS_?\
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MDC);\*\]_9>TKP/HGP4\'Z;\.=476?"-M#=+I6HI]V=&N9&D(Q_=D++^%:G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/#_[4/AZQ^.GP*OAX-^._A$)+J^BATL[S4+NT53<:;J]L)$D>%G1UBD="LG
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M^8_V</\ @H[H/C3X6_%WXS?&,6_@/P-\-+P6\NHW>(HY 02(U,A4-*_RA%)
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M! >0I(3J<>F<\5^8W_!/&,VW[</@&P/33=5U73P>H(M99(@0?<*/;]:_KO\
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M0/B7HVA'7_V6/VN8;"UTU4FMO!GB.^F!6[TE!ML(XKMBQCGAB$?ERH26QM;
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M.?C.5[?0=<N U[%H,%\^%MI@TCHD)1USN;*KADQ@&MCPYXBT#]IK0+_]G_\
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MI-2^$OP;U;X1?M'>";O7_'>C79L/"FL+"Q?4[>([(-6@N60E2%"MN249X/N
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MGCTK]H:_%K_@M-)L^"O@T%2<Z_-C'_7-1^'XT ;/_!%7_DV36?\ L<+O_P!
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MW;CG%?I?&3L7/)Q0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IC]/Q_H:?3'Z?C_0T .'3\3_,TM(.GXG^9I: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]#]#_*EI#T/
MT/\ *@#^.?\ :K\.VGB;_@H#\1-#U EK2?Q19^:.N[%T=P/U'RYST)K]%_V6
M/#FE^%/C9\4=$T6V2TT^W\.6)2&-=J[S"H9\#C).23WSUKX)_:)_Y2.>/O\
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M +3?A_3_ -H']GR_'A3XV^%0LVMZ''(MI=ZG=VH1KG3=5MQ*CE2T;)%(R 2
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M7[9WA&'Q1X7G_P"%??M&>  #-$A6QU0:C9??BE0RI-);W$J';(RD88 Y4YH
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MN@P_;0^'@;EAI=P&)[D0\_K7]AE?QY_\$N26_;0^'C-U.EW!/U,.3^M?V&4
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MUQM9CT9H9/D$<YDDC!W#:P4\] :_>&/[B_2OPV_X(7_L7_!?]FG]DCP=\1O
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\$_P#!1O\
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M -HOX? /-;H39W\%_:9,MI/#A7N8;F92J2N6VJP5R00:9H>O>'/VJ?#E_P#
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MC3XM?"-IO&'[/'C*1;WQ)X:M'FO;?0X;XAIM4ME7*A,.Q"* N 5*YR*^0O\
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MP/XS\/\ _!)_XG^$_%+G5?%5EHL7VR51N>8IJ(D\Q=PY)C!.>I4G&<U\ ?\
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M 4444 %%%% !1110 5\$_P#!1O\ Y(#:?]A8?^S5][5\$_\ !1O_ )(#:?\
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MC[N/;&.:BN1JDL*1:@;R>UE_U8F,AC?9P2&/&%Z\'CD"OV#_ &;_ ("?"_\
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M/%X#_:.\ <S0M'':ZDFHV6&EADCED\Q[:62,A7(R-W7;@C L_FE\4? WXO\
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M5215B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*8_3\?Z&GTQ^GX_T- #AT_$_S-+2#I^)_F:6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_0_RI:0]#]#_ "H _D(_
M:)_Y2-^/O^QHM?\ TJ-?HG^S[_R<'\6?^Q<L?_12U^=G[1/_ "D<\??]C1;?
M^E1K]$_V??\ DX/XL_\ 8N6/_HI: /M0=!]!_*EI!T'T'\J6@ HHHH ****
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MF-0ZA!@NR&0#S-F>#DB@#]-+'QEKOP$76?V<?VE%FU[X:Z_!+8>!_'MQ&]Q
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M_P#!+G/_  V?\/-W7^R[C/U\GG]:_L,H **** "OPS_X+A_\DB^&W_8T3?\
MHI:_<ROPS_X+A_\ )(OAM_V-$W_HI: /0O\ @BQ_R;-K7_8X77_HMJR_^"RE
MSJ"_!.VM C?V5/+_ *7,,XB[9/&.@S]:U/\ @BQ_R;-K7_8X77_HMJD_X*_/
M#J/P4_X1^?4K;35N4DN%DN1@2&-2?+1B0,DC'XT >R?\$L;?[-^RCX/CAO?M
MMD 3;MC[A**64'H>V>O/I7Z15^:O_!*:<M^R7X0M-GRV<DL22 #;*H  <'ON
M !&1GU-?I50!Y=\;=<U'PU\(_B+X@TB58-3T?PEK.H6$SC*175M:220NPP<A
M7 .,5Y7^QCXX\1_$;]G;P%XP\67<=]KVK6][)?7,2>6DC1W<D:X0=,(H%>S?
M%72],UOX;^-M(UJ\33])U+PYJEGJ-](0$M+2>V=)IW)X"QH2Q)["O//V7?"_
MA?P;\$_!_AWP9K,'B#P[I\-TEAJMNRO#=*]R\CE&4D?*[%3[B@#Z"HHHH _,
M;_@HY^SAK7CSPAI?QP^%H;2_BY\);F'7H=4LR4O=1\.Z8?M5]I(\L>;)YJ(0
M$4\J<$$5]&_L=_M&Z1^TK\&?#WC2W\JS\000+IGB;1&D_P!-TW5+$+;3_:8&
M/FQ>?)&TB[@!R0,# KZFN+>"\@FM;J&.XMKB-X9X)D$D4L4BE7CD1@5964D$
M$8(-?ACK\6H?\$\/VR8_$MH9(_@!^T-J8/B1U1QI/@_5GFVPJD80QVYDF8$$
M%0P)Y.:^&S5/AK.Z?$%-6RK-94<#GT%90P^(;5/ YKRVLDI2^K8N6EZ<X59N
MU(_JS@":\;O"_&^$&,E&KX@< 4,RXI\),34;>)S?*8P>+XJX 51MRJ2G0I2S
MKA^@W)QQ>&Q&!PM/FQMC]U*^ ?V[?B)XL^']M\$W\+7T-F==^*.D:3J?G1"3
MS;&:2(2(F0=K$,<$8^M?>6G:A::K86>IV$R7-E?VT-W:7$9RDUO<1K+%*A[J
MZ,&!]#7QA^V;X+\->,8/A GB+Q):>'1I'Q'TO4K W3*O]H7<3Q[+.+<1F23'
M &?ZU]PFFDTTTTFFM4T]4TUHTULS^59PG3G*G4C*$X2E"<)Q<90G%N,HRB[.
M,HM---)IIIGVG:,S6MLS<LUO"S'U)C4D_G5BH+4!;:W53E1!$%/JHC4 _B*G
MIDA1110 4444 ?GEX9^(GBRX_P""@'C3X>S7T3>%;+X?6FI6UB(@)ENY A9S
M+U*Y.<>GYU^AM?#/ASP9X5M_VW/%_C*/Q':2^)[OP/;6,WAT,OVN"V55 N63
M=N",!G.,8K[FH **** "BBB@#%\27$MIX=U^Z@;9/;:+JMQ"YZ++#8SR1L?]
MUU!_"OCO]@OXC^+?B?\ "'6->\9:A'J.J6_C?Q#ID4T2"-5L[2Z98(\#'*J<
M9QSBOLK7(H)]%UB"Y<16TVEZA%<2'I'!):3)*YSQA(RS'/I7S3^R)X.\"^"/
MAOJ6D_#_ %Z'Q#H\OBO6KV>]@<.B7]Q<%KBW)#-AHFX(S0!]55\!?M'?$WQ)
M\,?C9X(UO3H;O6M(BT&[DOO#D6\17+)YG[_>/D61  5R#RHZCBOOVOC/]I7Q
MY\.-,U_P]X-\736FAZMJL#7=CXDOD0006\;?/:M*5S^\P<J6QT&!S7C9[4Q%
M+ .IAG/VD*^'E[.&+>!=>"JQYL/[?V=6'+57NRIUJ<J-2-X5+1=S]2\'E"?&
M=/#ULAK<1X7%Y1G.$QN6T(2G5^I5\#4AB<5&-*,L1_LM.]:^%2Q2Y;T)*:1\
MG_\ !2+XF6/Q'_X)C_&#QQ/H4T5KJ6D11RZ1.QCDA=+PPJ2YVGY'VON ]=HR
M./R__P"#;WP7-;#XG^-E2>*TU"S%@L9N'>#S8YH\LD;$@,0!DX!XK]-?^"GU
MUHC_ /!+[XMOX<GM+_2FTFPBAN=.4+;./MOSS*%)SEE!/5B6'%?F[_P;J^&O
M'6B2^/KJ7Q1IFL_#[4]"@N]/T^R):73]6EDC,\<Q90P9>5=3T8=!G _&,Z=2
MMXT<$5,1A[U5PY[2I##2A.GAJU6>,][G;3J4(6<>:',M8M*TC_2[PY>&P7[,
M_P"E-1RRI#(</B?&IX?#Y9F57&U*E3+L+A^%Y?V51<J?*LQC&4'&6)C1G6A0
MGS2E."1UO_!:&TUG5/VB_AOI&G6UU-_:?AR"UMDB201SW+N%$ D0@;F/R[<Y
MR?2OW-_8\\")X=_9N^%NB^(O#EA:ZK:>'X/M=M=Z? \J2O\ ,&D,T1<NRX.Y
MN2,<U\U_\%*/#&A3Z?\ !'Q-)I=K)KUO\5-"L8M1:)//6T>:)FA,A!)4DG@Y
M'YU^FNE@+INGJH"JMC: *HP !!&  !P .P%?T ?X_E7_ (1[0/\ H!Z/_P""
MRR_^,4?\(]H'_0#T?_P667_QBMBB@#'_ .$>T#_H!Z/_ ."RR_\ C%'_  CV
M@?\ 0#T?_P %EE_\8K8HSCK0!C_\(]H'_0#T?_P667_QBC_A'M _Z >C_P#@
MLLO_ (Q6ON'J/S%&X>H_.@#(_P"$>T#_ * >C_\ @LLO_C%'_"/:!_T ]'_\
M%EE_\8K8HH Q_P#A'M _Z >C_P#@LLO_ (Q1_P (]H'_ $ M'_\ !99?_&*V
M** /Y_O^"H=C8V_QX^$\-MI^GVT?V>/>+>R@B\W<P/[T(BA\9P,@U+_P341%
M_:2^*82.*,?8X,+'$J*/DQ\H7A>G..M2_P#!4G_DOOPG_P"O:+^:TS_@FK_R
M<E\5/^O.#_T&@#]^J*** "BBB@ HHHH **** "BBB@ IK_=/4=.0,GKZ4ZHY
M?]6W...OIS[T ?S+?\%&/^"F/Q2_9N_X*@?L_?LU:7J/]A?##QSIFF7WB75K
MYOLNF1_:-C3"2[E9;=6QD;6.2*_-#_@I_P#ML_M:_P#!1']L:#]C7_@G1X]G
MT#P[\.M!.H>.?&>C73RV$FJVUOYIWW]D[6ZH)5/#.,*!G)&3^]7_  5]_8%_
M8H_:C^%G_"Q?VK?&7_"IY?!L#2Z7\1;*^CTK48&MTWQVR7ADBFY"C"JQQP/2
MOP;_ .">G[6W_!$C]@"\^('PK^&GQ2U/4_%GQ5AOO#OB/XN:_/=74^^_#VIF
MMM6E#"(("'#K(IR 0V,@@'Z%?\&]_P"W=\>OBQJ?QK_8Y_:4O'\2?%']G28V
M=]XR69KJ'5UBE^S8-P"REAMW,,Y!&2,FOZBD)*@G&2.<<BOQW_X)??L%_LP?
MLTV'CKXZ_L[>,_\ A9,?QXNKC7M3\:S7BZE+??;YC>-$+D22OMB:3;L+<*0"
M!P*_8>+B-?IZ8H ?1110 4444 %%%% !113)"0CD<$*3G&>@ST]<=* 'T5\6
MZI^W]^RSH7B/7_"&J_%/2+?Q!X7NFLM<L6CF\RPNTR&BDP"I;(QU _#FO6?@
M_P#M$?"_XZOJ3?#7Q1:^(X=(95OFM591"20 &WYSNSVQGMQ0![S1110 4444
M %%%% !1110 4444 %,?I^/]#3Z8_3\?Z&@!PZ?B?YFEI!T_$_S-+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H?H?
MY4M(>A^A_E0!_(1^T3_RD<\??]C1;?\ I4:_1/\ 9]_Y.#^+/_8N6/\ Z*6O
MSL_:)./^"C?C[/\ T-%K_P"E1K]$_P!GP_\ &0?Q9_[%RQ_]$K0!]J#H/H/Y
M4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]XY^"6B:K^TC\,K"Y\6>#-1UR[M_%^CQ1223V7A\3'RI4@0[G<0#<PV\8)/
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MY>>OSH@/- 'R'X^_;=\#?#[Q/>>%M2\&>.;Z\LDWR7&G:2TUJPYP$D .>G?
M],UV/A3]JKPKXM\":KX^L_"_BRUTW20YGL[S3FBOY-F2?*A."V0..*^B+KPQ
MX>O9VN;O1=-N;A_O336D,CM]6923^-68=#T>VM'L;?3+*&SE_P!9;1VT20OV
M^:-5"G\10!\*:=_P4(^'>HWUC8Q> _B)')?W:6D;RZ*ZQH[OL#2-MP%SR?:N
M+_;K\:?"OX@?".\^&WCOP=XNU*7Q)IXU3PY/I.EM<36.L6T9N-.+2IF2!C.$
M#[=I(X-?H@GA#PLC(Z>'](5XVWHPL;<,K#D,IV9!SWJ]>:%HVH/%)>Z78W3P
M8\EI[:*0Q[>FS<IQCL.E<^*PN'QV&KX/%4HUL-B:4Z-:E-7C.G4BXR37H[KL
M[,]?(,^S?A?.\JXCR#&ULMSK),?A<SRS'8>3A5PV,P=:-:C4C)=IP2DNL6T]
MS\7O^"7W[<5QXST#7/V=?BII^O6'Q5^%@NH[:UU* I+=^%;7*Z4%$A#F80*H
MQE@<]JS/VX?VD-(^)MY\,M&\-?#_ ,>WUW\/?B;8ZUKG_$GE6+[)82IYAMI$
M)\TD(2,@#M[UV?\ P4 ^".I?!WQAX4_;2^#FEKIVJ>!-0@N/BEI^EPA7\3>'
MA*B;);>#89 BY\P[6 X/M7Z/?!+QI\./CK\.?#'Q0\.Z9H5S%XFTRUO[J..W
MM)I[&]FB5KBSN@%9HYX7)4J_S8P3DDU\MPSBZ^#JXKA;,:DJF-RF,9X#$5'[
M^8Y--\N%Q%W\5;#V^K8FW_+R'-91:O\ O7CEP_EG$F7Y%X\\&X.CA.&O$"I4
MPO%F38.*5#@WQ*PM.-7/LI4(W]CEV<<ZSS)5+18/$>QYG4ISC'@_AC^U?X5^
M(GAO5M9TKPAXTTZW\.6:M=0:KI3VUQ-Y$(WI;1DDR8*E5.?FZX';R1O^"BWP
M^6[-I_PK;XGEQ>_8MXT%_+,GF^5O#$#]WNYR1TK] +?2M,M$>.UT^RMXY?\
M6)#;0QJ_^^J( W![YJJ?#F@$Y.B:5G=NS]@M<[NN?]5U]Z^Q/YN/FGXB?M9>
M%_AQX;T'Q-J7@[QIJ-MKZ1R6]KI>E/<75NL@!'VF,#Y",\US_P ,/VU/!WQ2
M\1MX:TKP-X]TNY6 SFYU?1WMK3: 3M\S&-W'3-?8$^EZ;=1I%<Z?93Q1\1QS
M6T,B)Z;%="%_#%,M]&TBSD\ZTTNPMI2,>9!:01/C_>2,']: /A[QA^WSX%\'
M>(M5\.7GP]^(][<Z5(T<MS8Z(\MK,5SDPOCYAP<'G\*])LOVK?#%[\-)OB</
M"'C*+2H?O:;)I;_VJ1WVVP&2<?\ Z\<U]*2Z#H<\C2S:/IDLC\N\EC;.[D]V
M9HR6/N<U.NEZ:EO]C73[(6O_ #["VA\C_OULV?\ CM 'X2>'_P!J71=-_;0\
M6?'2X^&/Q(?P=K7@JV\/V-P-#F%XMY&$4LUODIL)'=P5SDG@5^GWB?\ :O\
M#'A?X?:9\1+KP?XRNM-U39Y.GVFF-)J4>\ CS8.JX!YX[5])'PWX?(P=$TK&
M2<?V?:]_^V7_ .KM5R32]-E@2UET^RDMH_N026T+PI_NQLA5?P H ^*? 7[=
M7@GQ_P"*+'PKI_@'XAZ?=WX!CNM2T5X+-,_\]),8!J?XB?MQ^"_ASXHN_"NH
M^ _B#J5W9Q^9)=:7HSSV;>R2XP3^/<5]D0:%HMM(LUOI.G02I]V6*SMXY!]'
M6,-^M+/HFC74AFN=*TZ>4]99K*WDD/U=HRQ_$F@#YG\'?M7^&/&?@;6/'=EX
M/\9V6GZ,DCSV-]I;Q:A,(P21!#U<D#CCGBO'[#_@HE\/]0OK&PC^&WQ.CDOK
MQ;-))-!D6.-V?9OD8KP@/)/I7W[%I>FP0O;0:?9Q6\GWX([:%8GS_>C"!#^(
MJJ/#N@*P9=%TI6#;@RV%J"K=<J1$"#GN,4 ?)?QQ_:P\+_#GPV]MJ7@WQMJD
MOB?P_J"6*:1I+W1CEN[&6.**YVG,9)D 8X.,=.:\]_X)H:9J]A^S[<W&L:'J
M/A^;5_&OB'5;?3]5AD@O4M;NY\R%I4D^8;E8<=!R!7W_ '6E:7=A?MFG6-R(
MQ\AN+6"78!_=,B-@>PJQ;1VL,8CM(X(85Z1P(D<:_18PJCISQ]: +%?F!^W_
M /"J_P#'EWX<U2WT#4=6ATZPGC\^RB9TAF)8JLC*1@$GG)&/UKI/VU_^"B?P
MY_9(&F:!#:/XW^(>K2JD'A;3 ]P;&"3Y5N]5EM9=UE$KD;C,%"J"2RG(K\6_
MBK\<?VU/VD_%I\,ZE\3+WX%2>,],FU;X5Z7X:']HZ%K:E"]G9WVIJSQP7$Q*
MH8R^_=P1FORWCKC#+J.%Q>2X"G1S?.(U*$98&>%6+P=.K*2E3HXRK+$86C0J
M5G:%+]_[6-5Q2ISD^5_W3]%_Z/?BG4S7(/%FK7R7@/A%X;,<1E^?\6UL=2EF
MN!I0]AF>*RC)\JH8K/<?A<%0G+$8C&4,&\)2P].I6G5=*$VOT!_;%\*:A:?\
M$C/B)X?O5CTR]A\/HSI>,8EB2._#JLA)8J2J]^IZU\#_ /!N#XD\3F+XF>$K
MJSL#X;M+7[?9:C;D//+<23('BD<#E1DXY[=/3SO]NWP5^UCI?_!/71=*^*?Q
MLETC7?"L[CXC>!+VZ%M+XMLBV+.XBA=HWN!(H5_D1NA(SFO.?^""_P"V+\*O
M@KJ?C'X=_$>*;0)-6B2>Q\21V;W%N_G2*5CU"92HM( >!*^5)P>AS7Y7//J;
M\5^!JV94I9%]7X:P^&K2Q'LJ%&K5JTZU1T%2A4J+"TX59RI<E:<9PJ4^5NW*
MY?Z 8#PKSNI^SZ^E%@>&\7D_BIF/$'C1FF?PH<(87,L1#+5@\;E&'J9E@)XN
MCAZN9JMA:%/'X2>!ABJ4L!C*<E*57VL:?]#O_!2'_D4O@O\ ]E?T#_T9%7Z+
M:;_R#K#_ *\K7_T1'7YH_P#!0O7]'USX;_ SQ)I>H6EWH=]\5/#=];:G%-&U
MH]K*T+I/Y^[RQ&5(R2P"G@^WZ2:%?65_I6GS6-W;7D+6-H1+:SQW$1!@CP1)
M$SH0>V#S7]2QDI14HM2C)*49)W4HM7336C36J:W1_@U5I5:%6I0K4YTJU&I.
ME5I5(N%2G4IR<9TYPDE*,X23C*+2::::N:]%%%,S/G+X\_M#^%_@/9IJ?BNX
MBL=.:'SC=7#^7#\N<H&./G]!S^5?D#^WC_P4=U;Q3_P3U^-WQ6_9NUI+3Q?X
M:\6:/X0M-4M9\/:IJLZV[W*2*1M=?,^7&,[>O-?=G_!1;2O!6J>!O"47Q+TD
MW'@8^)K%=8U" .T\<!=?,MW6/#>4ZY)R0",_,*_!_P#;,\-_"SP[^P+^U3!\
M%-*;3O 5S\5? ;6K[72.5OM=L9#"'9LDL<G#'GC)KM5=/ SI_P!CXUQ]M&D\
M[A2IO+:=?2K2P+K>V558RM052I->Q=.*BH7YIQ.?V$/K"J_6<7[7E<XX3VM#
MZO*C=0J8B5)_OO9PJ2A"/+[W/+FMR(]B^ __  2[_;0^*?PD\"?$C6_VT_B9
M9:GXWT'2_$=S9PZ]<"*U_M2WCN7AC'VE<)&9"%&,X'2O/_A#I/[7?[#W_!3C
MP?\ !KQ9\>?%'Q>^&7C71;)WM?$>HS72037.Q6DBCED8J1N)&0#[=,_IA\*_
M^"C/PD^!/PA^!7PSU^.[EUUO '@VVC41OL+7%C;1?,W\(^;(R!V.>:^3OVG]
M6M_$/_!5G]GKQ%:$_9=9\+:+>VZD=(IEB=3[G:<9_P#U#.MA9T*=&K*IAI*L
MFXTZ.*P]>M!*U_;T:52=6AJ^6U:,'S)QW1-#%>WJUZ7U3,,/["27M<7@,5A,
M/7N])82O7I0I8J+7O*5"4XN#4T^5W/Z6XV+1HQZLBD_4J#3ZCA_U47_7-/\
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M  YX'8'\.GM0!-1110 4444 %,?I^/\ 0T^F/T_'^AH <.GXG^9I:0=/Q/\
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MH48PIQC"*44HH^S/VX/A7^Q3\5UTF[_9S\$>"_#E_;E4U!;>TCTRWD1<;F,
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M^'NO2_M!?#;7[-/"]Y?0W^N:=!/!93:7<P/YL;6"Q3;ITD;G,:]/^^1]^_\
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MIH6KZ<DFL"Z@-U#;W#@>9$T!5D8=3A@<_P#?0K^<7X]_\%C_ /@H#^R?9?\
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M3=IX;^"AUS]H[5O&%\+:^^&7V6\&B^%[65P!>?VE"=B/&",J'##&#P30!_0
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MK:GHM]#J6GR>'[*-+NW;?$TBPKN0,."1@Y].GI0!]T#H/H/Y4M(.@^@_E2T
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M^!$U>%_#'BMI'U>SD&_!D)++; C]V/F(&TCCMCBOV?\ ^'=_P _YZ:I^9_\
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MB/PA_9-\;Z-X%\?:1X@O]4UO3AJ5K+I,:/ L!Z"0NA^?'4 U\TG_ (+9?LS
MD'P[XTR/^G>/_P"-8K^@C_'P_9:BOQI_X?9_LS?]"[XT_P# >/\ ^-4?\/L_
MV9O^A=\:?^ \?_QJ@#]EJ*_&G_A]G^S-_P!"[XT_\!X__C5'_#[/]F;_ *%W
MQI_X#Q__ !J@#]EJ*_&G_A]G^S-_T+OC3_P'C_\ C5'_  ^S_9F_Z%WQI_X#
MQ_\ QJ@#]EJ*_&G_ (?9_LS?]"]XT_\  >/_ .-4X?\ !;']F@X_XISQIST_
MT>,'\C%F@#]E**_&S_A]?^S3_P!"YXT'L8(@?R,8I?\ A]=^S5_T+?C3_OQ%
M_P#&Z /&O^"I)_XO[\)_^O:'^:TW_@FN?^,E/BI_UYP?7[GIUKXT_;-_;<^&
M?[1GQ(\$>,_!.D:O:6/A>(1WJZFFV:9P<Y554*!GC@<@9]:]Q_X)?_%[P]J7
M[1WB[[1FVN_%L*0Z7#)P[>4!G@]>F?\ #J0#^E.BBB@ HHHH **** "BBB@
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M\-/#WQ-\'ZU9W^@:U8Q3&X6XA(MKD(HN+>X*N5BDCEW+M8JQ R%YQ76KX_\
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M2[.RO-<UB^N8$ FNWB3?*V.2<R<^F2!QT K]>G=(T9Y&5$0%F=R%50.I9C@
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M^M7];U]C[%>;AE?LMQD>WDOG]* /QV\*6$-E^SE^TPT6L_VP9O&&M2$&0O\
M9#]JD_<\LP7:> !TK]"OV3\_\,^_#3(Q_P 2"'CT^=^*_.[P<WAX_LY?M.#0
M$N%;_A,M:-ZTX('VC[3(&"C RNXY'M[U^B/[*&1^S]\- >3_ &!#D^IWO0!]
M$T444 5KN[MK"UGO+R9+>UMHVFGGE.V.*)!EG=CP%4<DU_.U_P '!?BW0+[]
ME_1K.SEL+YM2U.VN+*_A*3%HTF0E8IE)QG!R,Y[=:_:']JSQ3IGA_P" 'Q=D
MGUNUTB^3P-K1M));J.WG$[6S"(P!F#L^[IL!(ZG K^3;]M3XN_##QK_P3?\
M!&B7/Q'TCQ9\3+/5CG31?I<:M:0K>#<)8]S,NU1CGMP.U?D/BUGE.AP]GF1N
M6'A/%\/XO&1JU:T(MNCB*-)X>%)R4IU:D:G-!1UO'8_T7_9Z>%F-S/Q@\+/%
M2-+-L1A<@\8>'^&ZN"P.6XNO3C#,LHQV84\WQ&-I0E1P^#PE7#1I8AUI1IN-
M5+GO9/\ 0_\ X)U?%*'X>?\ !/OX/Z'XATNW;1K^^O9M1L;FV\VYU2%G:2/[
M&V&"$J00>N#C/:OW,_9R\;>&_'?PZM-7\+:1)HNE1W$EK'8RJ59&BX+8P.&[
M8' %?RE_LY_MX? SX1_L'_"GP9XGFLM:\6:1<7SZG;7#B74+&$%_*2V7E@Q4
M +@=>!SG'[C?\$V?VV/@/\7_ ('R:AIVO6'A&2RU>ZBETWQ#=1:?=2 $CSD6
M=D+(<=>2>M<'AUQADDX</\/_ -HX26+H\-8*2@JD4Z<:>&HN="M)<M-8B$I/
MF4FYN,;7:6GW/TSO KCFG'Q;\1'X;\6X;"U_''B:+SJE2Q,\IQU+'YWFGL<;
M'+X*52I]:A3IK#XRI3FU245&<:4H(ZK_ (*T0ZK>?LLZAI^DZY/X?FU'6K6T
MFOX)F@"6\BXE$S*1NBQ]X'BO@[X*?'_2!H/P;^''A/Q'<MXC^'/@35(+N9)7
M2SU.[-JQ2\C0*HE\J0;F8%N<\C&*_0/]OFY^%OQV_9R\9^&](^*/A*&^TFSG
MUR&./5K:66Y>TA8BWB1)"[228PH4<GOQ7R=^S-\#/V:/&?@#X#_%C5O'7AGP
MAXK\*^%M4\.:WIT6H6MN^KK<>9;O/?QO.KF<)^\1G0+SUSC'TF>8/'8K,L7C
M<MS+#1A5EDU&6'J8ZC"C6P]&K5GB*]*U3]WB<-/DDIM>_3<J:W3/PCPJXDX7
MR/@KA[AGC;@O.JV*P%/Q)S##YO@^%LPQ&99;FV:8'+,/E&69A)X-O&9/G=".
M*H^QC)O!XJ-/%R2C%WZ/X-?L9>#_ (\?!7Q%\4?'OC+Q!+\3=:UK5KP>*;37
M9(;+3ETVZ>6VMHXB-L8!15<^:H4C!!SFODC]CSXL^/O'/_!0/]H?POXD\2ZK
M?:?\.O@R_AG1X_M]VUC/'I\+11Z@+1Y/LK7+!%8W"1;V/._FOJ";X2_$[P:V
MM_"CX4?M _#B#]GSQ3J\FI:G>:EK%L/$^EQW5P)[N+3G$[,BLI* (X!X/09K
M$T?]ES3OAU^TUXV^+_PL^+OPTL_"7BGX31^!FGO];@;5KWQ"MN8Y;^Z4/LVR
M2%CN8EB#]ZOC:V!Q"Q'#E7 Y;4P<\KS&A_;LXXNA)YK*.'QL?K$&J[6)I4JM
M2-5XF=G*590:]T_I/+.*\GJY3XSX#BGC;!\14./.#,V_XA1A:^19G3I\ TJN
M;<*UGD^(4\K4LDS#,,!A*N7T\APOM:=*EEM3$J:59)^N?$O2?B-<?LU:1XS^
M&VOWEAXXTKQ;!]IUBYN6DLK'24N<S7%X@R&@C3+/O(3 .??RGP1J7B[XJ^$O
MC%XV_:0^(J^(-#^'O]GGP%KGA.X:PT_4M7AC1K>R1H2L<DCW 6)@K<EL$YP#
M]+?L^:,WA?X1>/OA;\</C+\.-0B\76&IZ98SZ5JUN3:P7Z21>:=TF-Z+(&&,
M,'52I&,4^Q^!O[.>B_LM2_LUZ7\7?"A5-1?6X=<DU>W^T7&J1W;7EJ]R3)YC
M(K[(R"?N9XP<5[LLOQ&+>&QL)JG!Y-5^L99C,QITZ53,L/3G0PE&MA(UG3FZ
MWM?K#KMODE1IK[6GY72XPR?A^.=\-8C#3QF+I^)>7+)N-^'.#<7C,=A>",WQ
MF"S/B#,LKX@JY=3Q>'AEZR^.41RNG!0KT<SQ=3>E=_GO\-?$?QS^)]Q\8OC%
MXC;7O _Q ^$VA03^ M#O[B<VMUHT( L=2GM@0)8Y8%61B5(8$DUCZGKWCCXB
M^*?A;^T/^T9\3M)U?P=X2GL[^TM]%*6NFOX@M\%=*\A,0B]WC;\R[MW8FOTC
M^ 7A;P[X4U7QMK?QI^+?PZUNX\3^&H?!T-K9:K:"W.AVD!MK9I07 \_R=I8\
M,&'<U\*_M?\ P;^"?@3X">#_ (.>#/B/X?UBW\:?&F'7!<1:C#,VC1W5RL@S
MLD9TMXMPR6"H . 5.:RRC*,=0E@<4\PDY4XX_%XBEB\QHTI5\PH574RVKC,+
M3K.A4=:$U1MM35.'\SOW^(7B+PIFU'BKAZ'"-.E2Q=;A#A[*,?PYP=C\PHY7
MP=F>7X?"\:9?PYGN)P$,SPD,MQ.'EF$*C7M,94QN*L[TTCU[0OC+X;_:"'Q%
M\0_$KPIXST#X=I=B+3+*"\FBO-4BB0)%=6;1A=L;*H<;0!C%?)DWANVU#QN-
M:T:R\>ZQ^SQX:>6W\2Z.-2NI+RRBG)1;F=<EB+=,N2<<+GG&*^W/ ?PL\1>
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M<-X_#X#+.&<T\0.'/$V618''<.X;B#,,ZQ;_ -1>),/!975QG$V7Y_P_@Z&
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MYIBP0PPPX(R>GU9_P3_^+FN_&S]FGPE\0/$ZR1ZQ<V[VES)+PS_8X54W!/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OE#]L__ )(=K'^Y-_Z+-?5]?*'[9_\ R0[6/]R;_P!%F@#Y._X)5_\ (I_$
M7_L*-_Z&U?J^.@^@_E7Y0?\ !*O_ )%/XB_]A1O_ $-J_5\=!]!_*@!:***
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M=<UXGU-Q<?\ R31_PZX^#O'_ !/=>XZ?Z3<<?3_2:_3ZBC_4WAC_ *$^$_\
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M@(/]MZ[QZSSD?B#<$&G?\.N/@[_T'=>'L+BX _(7('_UNE?I[17L?ZF\,?\
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M<O@[PSICZSXE_91\=:#ID0^>XUA-0TT$D9 3[5&F_/;'MUSB@#]T_P#@F_\
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MR_'GA+X$_$R_T?\ 9R_:!/AKXXZY<*\_P>\0[[RQ\7S%]S647VHF!/.(\H
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MP5^UMX NFT[XH:5>ZV-!U:\9X=+BDC\Z2_'V-"ELN&W[LDC.%(KY-_X(D?\
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M; X*^);<@D="+NN<^-/QP^)GPG^.GB6[\":NNFS:MH]E%?E@V)$$:@  _P!
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MI\Z YR<<YP1S0!]<9Y &22<#@XS]<8Q[U*890C2$(L:J69S(FU5'))Y!Z?\
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MO9/^V?I$YPQ%SK84X_Z;2\C^5?UOW_-C>#.,VMP,^G[E^?PZU_(__P $M/\
MD\C2/^OK6_\ T=)7]<%]C[#>9Z?9;C/T\E\_I0!^/'A:QELOV<OVF&EUH:PT
MOC#6715D,AMD^TR'R>O!4X7GTP.M?H1^RAS^S[\-,@#_ (D$)QCH=[U^=W@Z
M/P]'^SE^TY_8,MQ(S>,M;-X9\D)<?:9-RID?=#?RK]$?V4,_\,_?#3/7^P(<
M_7>^:&KJS5T]TU= ?1-?&O\ P4&\5^*? _[&_P ?O%?@O5)]%\3Z'\/]:O\
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M*H_I*\#22G.E3]NY\(YS2EA(3JIP4\3""A!/E?->TTVDOV>_X(=7=K>?L(^
M9T:R%XUQ=17,5J4#H(#Y<9G0$L'=06)8 MSZ5^P]?PJ?\$[?BY^T!_P3?L/@
MW\?/$>LZIXK_ &1/VB->_L7QN+OSIM+^%\WVD6T-Q:%Y3';&23+_ ,.[)!.#
M7]QOA?Q+HWC+PYHGBOP]>)J&A>(M,L]8TF^BYCNM/OH5N+:=.O$D3JPY/7J:
M^_X YO\ 4GA5R5F\CR]M/=WH1][_ +>^+YG\@?2[Y%]*#Q[C3J*K"GXH\6PB
MXNZBEFE;]U>[UI7]D[.UX:&]41@@8EFAB9CU8QH2?J2,U+17UY_.A#]GM_\
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M*]5N?VG_  =^R[\7/$GPT\5^*?A3IOA#2;3Q"NOZ3<W&ES:HDMPC^1#,I59
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M 'ZN/_B:/^'WGPC_ .A,US_OU<?_ !-?9'_#M/\ 9J_Z%J/_ +\I_P#%4?\
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M[,NO?'[Q?K-OHUZ;1=#T:RF=R"2^Z!#M/.>,9_,5[Y^U=_R5+]JG_L>-._\
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M^5-/B_X+B_MHO+%'_P .@_VE6\R14VI=?,=QQA<Z21N/;((]J /Z7J*_@O\
MC'_P<Q?MU^&_V]/!/P4L?V/?''@O3KR^LK>_^ VN6\<GQ \0&ZY2+3KIK)&#
MRA6 *VY ;IWQ^N]W_P %POVT8+F6'_AT#^TQ'Y97Y)KK,JY&<.5TA1GOPHX(
MH _I9HK^9[_A^/\ MH_](A?VD_\ P)/_ ,J:/^'X_P"VC_TB%_:3_P# D_\
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M/!'!_P"83Z]#1_P_(_;2[?\ !(3]I/)('_'R>Y _Z!-?<'\L?KJO1['ZL?\
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MT=]%CUZQ@D\B.XBMS'&I#0!9 44A@00Q[_N@Y#VS%N!Y98^P4;N_TYK^?O\
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M--Y2B1XMOR[&.2NWC'2OYA-#^%.B>"]2T;Q)\0_@'\?_  [X7TJZM7O->O\
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M&;@DE9'W%2#CZCD?HMJ?A[PUJEY;ZAJ>F:7<W]H1]GO+B"V:[AV\@1W#J9D
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MJNW)!@1I,YQD$'H1ST/6OMS_ ()[^-H=:^%-UX%6427/@[4+NWF4MF2)87*
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M<IS*1&SLO4MC (P>!S@_2_PY_P""?GP8\ 7 FU(MXU15 $6HQ_*?4DLN,?7
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MD5K.6D.Z0EVSG<W)I** #IT%%%% !1110 4444 %%%% !1110 4444 %%%%
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M^:C)9)F[C*7)&2RW&M2G_)%^QLY?W5KY'E'_  QI^RG_ -&__"W_ ,)/3O\
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M)S-XIATZ.TU2ZW%GN+A(/+EN<Y)WR,6D8YR2?Q/SK'_P3]_9XUC6=:\0^/\
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M$'PVXG<!T"]CR,=^5_:N_P"2I?M4_P#8\:=_Z4M7M_[ G_([?$'_ +%ZP_\
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M ,VXXWZ?\TOFW]U?] _F_O1^B">4AW#.<>G?N<^I[_TYJ7S4]3_+^=?G2?\
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MH _30=!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "CKU%%% !1110 4444 %%%% !1110 4444
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MT[[7OB1\.?BAKFD:7_96OFY6RL(-6O(;=Y+:4QQQQW$"S>8L#3E]J,59L8H
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M_@I=\)/$/[5WQK^.OB[P[XQ\9^(+[4+>'[*FH-JB74DDOVJ26[M;R6 R-G;
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M  -H7PDN;G2)M#TC41IMMK<]@L;7.K7]SY-RV%,A1%,<;,XX<*HS\*^*KO\
MX+F?\$W)M"_:-^(OQ0\6#X?:%XETB#Q),-?^WVLUL;N,W5I<V\EO$Q66'>F4
MGRS$#:>< '^K>S!068@  DD\8 &3^E<HOCKP:UP+1?$VB-=&?[,+<:E:&4W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?%/B?Q1XVU"^N=0^']M#=1MHZ3H-B)?1QC>R OYG."=IZ<5]&_\ !5;X\?\
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MSIWMM?DCMY=C_,G&66,Q:BIJ*Q>)2]I\=O;3MS_W[?%HO>OH?N]_P4^^%?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP"<#&/EY':OJCQ=??""P_P""4L&B^&M9^&"VB>$[,PVRRZ"=8\TZ</,!PHN
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M_#G]E&\US2OV0M)^'GB/4;[['X>\0>'=-@N;J#4FF7RGN!;6Y:*$.0QD8*H
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MX8I\0TM(PJ8*C4P^+BVTN=2C)T92^U)U$K[W/Y%SSZ,G"G@-5S'/?!KZ0<_
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M8HHHK[(_E4**** "F/T_'^AI],?I^/\ 0T .'3\3_,TM(.GXG^9I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]#]#_
M "I:0]#]#_*@#^4S]J[_ )*E^U3_ -CQIW_I2U>W_L"?\CM\0?\ L7K#_P!)
MQ7B'[5W_ "5+]JG_ +'C3O\ TI:O;_V!#_Q6WQ!_[%ZP_P#2<4 ?IH.@^@_E
M2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<<UA?$'PIX;\1?"[XC:%K>A:3J6BQ> O$TD>G7]G#/8P/!I5QY,L44H*+)"
MK1.!E>"""!C\XO\ @H3^U[?_  4\7_"?X4>#_&WAWPEXD^(&MZ?Y5[K5PB1R
M6<LR))@@L IR3R>0>G3/Z"?%;]C#]O/XW?!'P[I'[/?CWP#:'QSH5C;>(_%]
MZZ?V=-HNJ6J1ZH+*4X/G/!))Y9 SO/7(Q0!^+/[#_C"^N?\ @F_:>%_$-[=Z
M]H.C?'WQ;!X?AEFFE73$CU2=8;>!Y&8+!%@!(HVVJH"CI7*^(H-0U/\ ;9^
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MSXK? 2[C0QI/X?TEUC88* VD)QCL!G:/I7R#^S-_RDA\ _\ 7#_VFU?M-/\
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MB$EB%#LJRC%2_P *9'%EERQ+')!+8)&.,?A4M &.@Q]!169UW"BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/S[\&/^"%?_  6;_;-_:0^$I_;S@UCP;\*_AUK6EZS+KFKZA;7<'DZ5=P7
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M^*_#-UH6H":UUBTU34([[6HY&WQ!@+C+LT9#F,$\MN(]/L3_ ()O>(/VIO\
M@K'_ ,%9OAA^T78?#[6?A?X+^%TUO>WNI2VUW#96T%I,LQLWN98569I%7!59
M& .!DL2!^NW_  7+_P""&O[5OQ"_:BT;]O'_ ()]2ZCJWQLO8;1/$^CVDT=I
M<"ZL8?LXNX))%,;^:ASAFR1PZC 8 'Y3?\%/O^"1WP7^$W[,'B3Q]+\=M2U#
MQ+\-TCO]-L=>U&0W.L&)U$D$<%T[B5Y$#* !N&00PX(_KM_X( _%#P=\<_\
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M_P ">!I-3TRW\0ZKJ$UO+/+&6D2$SNZRJ0C( %89Y49XS_K05_&M_P %R_\
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MW4?=_:^BBBOM3^80HHHH **** "O*OC7_P DL\>>WAW43^5K*:]5KRGXV?\
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MG?\ I2U>W_L"?\CM\0?^Q>L/_2<4 ?IH.@^@_E2T@Z#Z#^5+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1144DL<2EY'6.-?OR-PJ#U)Z#Z]!WZT 2TA(K+U
M36]'T*R_M+7-5L]*TXJ76]N952!D R3N)XQZC_#/RE\2OVPO!/@]OL&A0RZG
M/<-Y=KXBC(DT2.8_*AFF&5"AC\QR.O(R1D ^OY'2*)YII(H(HP6=Y9$3 "EB
M<,RXP!W_ $KY[\=?M,?#OP@+FSTB[C\6>(K59/,T*S<"?*@DC=DICTQU_"OR
MJ^+/[57BWQGJ^J>$M7UNZ?7&19/#J^#96:"\+<I#,8R S'(#CKR2?0^/:9X1
M^*OQ*EWWMQ9> ==TN(/LO&:WU[68%_AC'66211[DDX]< 'L?[47[5OBWXF>&
M+FPTC7(_#VF6=[_I?A2$-_;,,X/$BM'N<*I'4]!Z]*^>/""?%_5- BG:.Y;P
MGJ^R/4O$NNL]]':!MJB2*.16>/8/F&T \<>M?<'P5_8G\2^.]1L]:\ >$=0@
M\1.BQ>)K[XB6\BZ7?$\2W%DTP5&S\SJ0/NG(/&*_7#X,_P#!/'P1X+6'4O&6
MIWNL74^V2^\+12*WA=)>&98K<L5*;LC 7!'3% 'XA?##]D*_\47W]ES:#KOQ
M<T_4PDVE>(].\X:5H5U(0P>2)UV*D3D%E_N@Y%?KA\)_^"<LMU8:7'\9-8LK
MFRTM(GT:T\,Q#2]0MHEPT=M>W42*9-H #GYCG(QR:_4GPSX.\+^#;)=.\+:%
MINA62JJBVTVVCMH\*,#*H!D^YKI: /-_ _PD\ ?#VPM['PWX<TZ![=0HU">T
MMI]3EVC :6^>'SV;CJ&%=CK_ /R =9_[!6H?^DDM:]9'B#_D!:U_V"M0_P#2
M26@#^*[X4?\ )ZB?]E2U7_TJ:OZ8K[_C\F_X!_Z *_F=^%'_ ">HG_94M5_]
M*FK^F*^_X_)O^ ?^@"@"K1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(>A^A_E2TAZ'Z'^5 'QW^TSC
M_A+_ (?[ON_;;/./3SAG]*M?#R76G_:&\91/%$NF+H5@89OD$A;RUR&.<D#\
MJI_M.,4\6^ 7 SMO;,X/?$R\54\7_ _XL2^/E^(?PY\0PVB:QI=BM[8WDP$2
M*B)G8I[D9YXY]>X!Y!_P5,&/@[X0.X,/[< X^]G<#T'^%?.GP$L]+F_X)^?$
MF2[\,7_BF_F\:QVUG9Z:DCW$,KN D[A%9FC0D$\=JZ/_ (*%:%\5--\!>%K[
MQM?V=UHANTAA@MGW2"\[N5!/!//3U[9K[G_X(MZ-I6N?L^^.;/6-/M-2M7\7
ML6@O(4GC)VR'[K@@'('(P?7O6&)A*IAZL(4:.(FXODHXFOB\/0G-?#[6M@*E
M'%P@GJW0JPF[<K?*Y)]&%G3AB*4JTZM.BIKVLZ%#!XFLJ;=I^SHYA2KX.I/E
MORK$4:D+V=DTFNG_ ."0'PDUGX<>#_B)JFL7D1D\47]I=Q:4L!AN-+C!WK#<
M94%I "%)/?UY-?LW6'HWAGP_X=$PT/1[#2A<$&<65ND E*]"X0 $CM6Y48*E
M5HX:G3K*DJL4^?V$J\Z3DVVW!XF=2JHN]U"4VH?#'W4D5C98:6)JO!RK3PUT
MJ,L1AL#A:_(HI)5:.6TJ.#YU:SJ4Z<956O:5+U)284445U'*%%%% !1110!E
MZSHFC>(]-NM'\0:3INMZ3>QF*[TW5K*VU"PN8V&"D]I=QRP2K[/&PKXU\4?\
M$X_V+O%VN:;XAU;X _#_ /M#2[X:A;BU\/Z=;6S7*OO#2V\=L$9=^#L78!C
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MN)IEI<_L6>+]2DU*>QO=.YM(X7*?:?,^5T8 \C!P1Z5\?X@7_P!2N)O=4O\
MA'QETVEI[)W:;TYDM8]W9']'?1"L_I.>!R=6I1?_ !$;AOEG3ISJ/G>/I*$9
M0IM3=*<K0JM/W:<I-Z)GS[_P;M3:8_[*NOHLY?58_%%XDD+,28K4.Q78#T4D
MC@=,\<&OV=_:D\9Z3\.OV<_C5X[UW2$U[1O"?PY\3Z[J>BR*KQZI9Z=ILUQ-
M8NK_ "LMPB&,AN"&YK\8O^#=NTLS^RMKM^I@%Y_PDUW;.B?ZUHU=R'D'X8S]
M!]?V&_;#\":S\4/V6OC[\._#S1)KGC3X6^+?#NE/.=L*WNIZ7-;0&5NR!W&[
MVKSO"N__ !#[A:_+_P BRE\/;FE:^K][O^2/L?I\<G_$X'CQR.J_^,XQBE[7
M>,U0PZE&&B_=)_!Y;ML\)_X)<?&SPC^T/^Q/\(?BUX%\&P^ ?#/BBVU>73O"
MUO%'%%IJVVJ7%M(J)%^['F21F0[>[5^@]?F=_P $A/@)XS_9F_8#^"/P9\?R
M6LOBKPC::W#J3V3;[9FNM7NKJ/RV!;CRY!GDX.17Z8U^@G\@![XYHHHH ***
M* "BBB@ HHHH *CFABN(9;>>-)H)XWBFBD4/')%(I1XW4Y#*ZDJRD8()!J2B
M@:;BU*+:::::;336J::U33U36Q^&7Q&M-6_X)]?MA:=\2=$CD'P&^/VI16'B
MRUB5O['\%WAG :Z$*J(K5I9&W"0%-V?O')K]O-)U73]=TRPUG2KF.]TW4[2"
M]L;N$[HKBUN8UEAFC/&5=&##@<&O&/VDO@9X;_:(^$7BOX9^)8@8-7L9'L;I
M(U:YL]1MT:6RF@<X>,^>$#%&!(/? KX,_P""<OQS\4:1=^*/V1OC/-+;?$[X
M77-S'X=CNL*]_P""[9C%ISKO(9W6%5?C=P2/>OA<#?AC/YY5-N.2Y]5JXK*9
M/^'@\S:]IC,NO>T(8G7$X6.EYNM3@DHH_JSBB,?'+PCP_'^'4:WB;X28' 9%
MX@T86>,XFX%@H83ASC*4$N>OB\B4:>19Y55^7"QRW&5YNI7FS]:Z***^Z/Y2
M"BBB@ HHHH _#/\ X+:WKZ3X ^$NK6_E&[@\5&*)9QF(AWCY93G.TG/0#'?T
M_FB^+*>(1^UO^SGX>U:ZTN6#4/$?A?6K=]/@ABEB>^OXHS').HR H'"Y&"23
MFO[:?VO_ -C_ ,#?M=>$-*\/>,;S4;*7PY>-J>CRV$@0?:QM($X)&Y/E&/?\
M:_*;Q+_P18\#>)/$O@+XHZ9XI\60^.O 7B.P>2">8'2[C3--N%EB\E')E#J5
MW!DVY/#'&5K\R\5.&\TXER'!8?*::JXC!YQ@L;5I2K>Q53"TZL/;I)Z5)I)2
MC%M/1M.Y_<OT!?&S@7P0\6>)\W\0L9/+\FXE\.^)^&<!CZ>6/,G@\^QN!K1R
MRI.4&JF!P\YSG2K8B*:?M(PFN76-G_@I-;&R^*GP$M"Q<P>'=)1F8Y+,+2(,
M<]_N\&OD']F3_E(]\/\ _KBW_HLU]@?\%++9[#XO_!#3G>61]/T:PM7DF_UC
M&"".'+')))V\=.GOBOC_ /9D_P"4CWP__P"N+?\ HLU^E4]*=-6M:G!6WM:"
M5K];6/XCQDN?&8N?-[3GQ6(FIVY>=3K3DI\OV>=/FMTO8_K.HHHJSF"OQ[_X
M*>>$KOP7XE^!O[56FH;:V^#'B6*;Q'<0#:+BTO;E$A6["C,BCD GMQVK]A*\
M&_:9^$FG?'#X)>//AQJFS[-K6CSR 2+N4SV4;W5N,8/)EC4*>Q(Z=:\'B?+9
MYKD>.PE'_>E3CB<$[VY<=@YQQ.$E=[+V]*"E_=;74_6_ OC;#\ >*?">?Y@W
M_8=3&U,CXFIJ+G[;A?B+#U<DXAI*&TIO*L=BI4N9-1K1ISM>*/1_AYXNM?'O
M@;PGXTL2IM/%&@Z;K<&W)41ZA;1W  SSQOQSR,8/.:[*OS!_X)9_%O4?'7P4
MUSP1K[O!K'PI\6:EX*M[&Y8+<+I.E.;>TE2-CYAA;RR <;0>A&[G]/JZ,BS*
M&;Y/E^8P_P"8K#4YS3T<:R7)6BUT<:L9JQXWBOP3B/#KQ&XPX,Q$4ED>=XO#
MX649<\*N7U9?6<MK0GM.-7 5L/-3BW%MNS>X4445ZQ^>A1110 5Y3\;?^25>
M/?\ L7=1_P#226O5J\J^-G_)*_'>>G_"/:A_Z2RUCB?]WK_]>:O_ *1([,N_
MW_!?]AF$_P#4FD?YFWB @?MAZHSML)^*K>AP!?@$\_3IWY]Z_HS_ ."NGP&_
M:3_: ^"W[-FB_ SP-KWC;P_!X1L5UR/2"[6RS?9(P//C1&5F)X'<?7I_.1XS
M,4?[6VNSSNL,%O\ %!Y)IF.U8U%]RY/8#OGIUK_03_9T_:8^ 7A_X'?#FQU;
MXP^"],NK?0+&.XAN=5MTFCD6)-R.A+$%?[WKQ[5_/_A_E>!S;"\29=CL4\-2
MQ==J356%.=E4DUR.<E>WSL?[:_33XTXH\,<P^BEXB\)\.+B?->'.&:DZ.7U\
MOQ688)3JY9@Z=.K7AA82E&4;N5+9\R3UL[?P:M_P2^_;IB@1$_9S\3%BF/\
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MVZ].<G&>@'M0!^FXZ#Z#^5+2+T'T'\J6@ HHHH **** "BBB@ HHHH ****
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M!6H?^DDM '\5_P )@S_MJQJ@W,?BEJORCK_Q]-T R:_IHOK2[^V3?Z-+_!_
M_P#<'^Q7\HNN:YKOACXX^-_$/A9Y(O$FE^/=9GTJ2&)II5G%U)@K$@+.<\8
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MX2\/V>]I3'I]L3*[%F8M I.2WS$\]30!T]%%% !1110 4444 %%%% !1110
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MK':WB#5%+'@G5;Q3)Z 9N,>A&#[>E7?M-ZPW+K&JE5'RO_:=]CW.?M'3U_\
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MU,;;+3H1! ,<#Y 3S[G)H _+7X4_\$Z+R\MM*F^,>K6"'2A&^G1>#U&F78B
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M57XG?\-.-_T.^H_^!3?_ !='_#3C?]#OJ/\ X%-_\70!^V/DR?WH_P#OH?\
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M4X9S&=5N,\MGG=/ZG@<WPLE**CC,!CI8:="4GRKGE?>Q]'?\%@-!\-:)\2/
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M:B_[&^T_]'5[=_P3B_Y&#X@?]@BV_P#2>O$?VO?^2P_M1?\ 8WVG_HZO;O\
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MM[^_OIT@N$CW$&:&-BOF&-?FP >>W'/Q3X[_ &C/$GC#4/M%O>ZU\1=$U/\
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M(]EN  ?<@'KQUH_X<Z?&+_H*Q?\ @3_]>OZ?Z* /Y@/^'.GQB_Z"L7_@3_\
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M_P#UZ/\ ASI\8O\ H*Q?^!/_ ->OZ?Z* /Y?!_P1V^,HD*_VC R'G<TX./4
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M7DV[6?<Z<%4A2QF$JU&XTZ>+PM2I)7]V$,12E*6FME%-NVMC_,+^)5]:Z?\
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MT5$4#H%50% '8  4^@"K:V5G8Q)!96MO:0HH5([>&.%%4   +&JCH/2K5%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG3PKZ(])HHHK[4_F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI,@=2* %HK%N_$&CV-[#IU[J-G9WET=MK#=7$4#W#]D@65E,KGLJY)]Z^+
MOC/^VAH/PK\0Z?X&GL);?QCJVN0:7ID&IQ-;V%Y%/($5X;AY%#R-D%4')SP.
MI'!CLTP.6TG6QF(A2IJ2A=N_[R5N6%EM.5URQ=G+I<^OX4X#XJXUS&&5\.91
MB,?C)T)XOV<8\B6#I*3K8QN=D\-049.O6C>-))N;BC[I=UC1Y)&"HBEW8\!5
M49))[  9)/05X/??M/\ P!T_6KGPW<_%;P?%X@MA*)-)?5(ENQ)$K%HMI&WS
M,KM";MQ;@ UZSIPN]:\-Q#5$-K<ZIII%RD?6'[7!A@N#U57XYZU^/NA?LV?L
M_7_Q<^.GP\\:^%-.LM0T2T?Q!8?$;4+U[2_6>?-Q_H\TUQ%%B-_O+DY''L?+
MSS,LRP?]GK+J."G]<JSIRECZE>E&,HT95X4H^RC+EJ5(PJ+FJVIQ<4I.[/N?
M"S@G@CB7_6^?&N9<48;_ %:P.%QM&APE@\LQ]6K1J9G0RS%8RLLPKT57P^$K
M8O"OZO@O:8O$0J2=*-H-GW/=?M.V?B/X*?%CXC^"=-G;5/A]9ZI):Z;>X+ZB
M]@N8KF!-JE[:Y(;RVPP..N<5\#_%[]HN[_:@_8S\%^*--EOM"UR]\:Z1I_CK
M2+=OL\\5@EWY&H!T3:QL9(N7.W:!NW=B?!_A1XR\;:?HW[06K2VFHW?@<Z'?
M_#[P.+")IUU6\BWVT-X@CW1SF3(;>,D]CUKU7X&_L->+/ ?P\\)_%"W\9WE[
M<^*-.*>+O ?B^2/3_#VFV6HR.9KY#<3)''>VT;EAYBQ@%5*L<<?G];.L\S^G
M3P^'I5JN%Q.48VAF<(\E)4VL=&E0S"E%N,IN<(SBJ5-N52AS3U1_8&6^&GA9
MX1XK&9OF^/R[+\]R;Q$X8S/@/$UY5\PGCHRX6J8W->$,?6C&='#*A6JT*U3,
M,7"$,)FGLL+)WN>\_'>?P#^RE\#_  YXY^!/PO\ !N_7=.L]"O\ QA9V%L1$
M-9MX[:XN;V[0,7FE>1W.[YEDRI 88KRCX&?'_7OV4?#D_@[QC\.?%7B+PIXF
MM9O%NC>(?#FG/<07&I:\AGDM@X3:8VED"#<Q* 9"GOXE\;O G[._PKN;2#QM
M^UCXW\=_#VTO8M3G^#?@VZA\16B:C'()_LHBL)[T+$LH\L+OW!0 R@\5ZW_P
MU;^T_P#'O1=-\*?LI?L[Z?)\/K"SMM*BUOXB6TFG7EC96\:0PW<$-XZPB5(P
MK I$K9 QR:YI9E*EFE6I"O\ V9C,'AJ-#+LHRBAA\[J2G-<N.E]3P%HPPV)Y
M*#YZ\XUXRIWERJ-CV,/P53Q_ >!PN+RQ\=<-\1YUF&;\:>(OB+FN<^%^#AAL
M/4IUN%<.^(N+9K$8G.LF>(S6$</E6%Q&6UJ.,Y:,JE2K%K1^"'PG\5^.O VH
M_%7Q<(O@Q:1_%:7QG;'7V2PFOM!^TF?_ $EG,0):+.>FX'@&NE_: _:)_83T
MKQK8_$'2]#M/C'\3M'A2W:'X86R7NIS74(VJM\]I"1-+N4+D[FR1EC4'AS_@
MG5\:/BE>VGB7]H;]H/QA]DD"_:?AAHDN/#,,9P6M\Q31*4 R@VACQS7WK\(_
MV,_V<O@FT5YX%^&7A_3M:4*UQK;0RW&H7<PP3/*]Q+*GF,WS95!@]*];+LFX
M@Q&$AAJ&5X/+:,O8SK8_/O9X['5:U%RE3Q>'RS#_ .RX:I%SD^2M4C)*W,KH
M_/.-/$GPARG/\1G>9\=\3<;9G068X;+^$_"CZYPIPM@<OS*&&I8W(,WXXSA0
MS[.\%4CA*5\5EN%K49RYW2:A)'YT6_QS_;__ &F+=+7X _#G2_A'X%D"V\TO
MQ(LA9ZQ!9YP&MWF2-UD"<J5Y)&/45WOA+_@E]<^+]4M?&O[17QE\?^,?$;LD
MM[X7L]9=O" ?AGBCMC+M,1;*X\OE:_7P * H      P !P !Z 4M?24N#,'6
ME&KGN.Q^?UHN,E#&UG2P%.4;6=#+\.X4::72,G4CY'XMCOI+\2991K9?X5<+
M\*>$66U8SI2Q'#&74\=Q7BZ%16G#-.+\VAB,SQM2:MS5J4,'4TT:/%/AU^SI
M\$_A3% / GPV\*>'[J%$5M1L-)MX;^X=  9I[G!D>5R-S-NZDX KVNBBOK,/
MAL/A*:HX6A1P]*.U.A3A2@NGPP45?SM<_G[-L[SG/\94S#/,US'.,?5;=3&9
MIC<3C\3.[O9U\54JU+7VCS66R204445L>8%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4Q^GX_T-/IC]/Q_H: '#I^)
M_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(>A^A_E2TAZ'Z'^5 '\B_[97B+1M.^.O[2^B7ESY6JW_BJ
MVGM+;('F1)+EF(SGCV!SVKV?_@F]XHT67Q7XZLTG>2:XTRWBA$89@9%B",&8
M<  D?CGWKQW]L/X?:;XA^.O[2?C6ZBE:\T+Q?9V$4HSY:Q3W!1@Y'&<$^GXU
M[_\ \$[/".D>&?&GQ$@L8$DWZ)9W*R3 ,\<DL(=O+;JN6[YX[<T ?JH,CY3U
M4[3Z9 '2EI!T'T'\J6@ HHHH ***,T %&:%!;IM48)W.P1>/=B,_TKR[QM\8
MOA[X W0>(/$-G#JF";;3?,4R74@R1&A5BN6(V@DY!//L >G*X9_+4AI.<Q@_
M.%&?F(ZA2!P<5S'B?QKX5\&V,VH^(]9M;>WA4N\<$T<MT%498?9D9I&/'3;7
MXX_'?]N;XDV7Q/CF\!V+^$]--J;"2'4095O(\!/MD*C<,%?F!7/49KR*Y^*/
MC#XE3+KO@30_$&O>--,93J^H7<LKZ 1G,K_8YAL95)8D!3P!R#Q0!^D'Q'_;
M-AM-&U'4_ &CQ:EX=L3Y>I>(KF1;:YTM6^7SQ:NP=_+'SC@]/6OS_P#'/[0>
MH^+-=CTV?4M3^+6C^(+=?[/\E9K.UTF\EQMADN5Q'B,GG)P<8)S4OAOX)>(_
MB!K4/B74Y[WX@?VSMMO$7P\\')+:):O]TB6VC548HQ.3W'I7Z:? S_@GAXKN
M].CM=4ATSP?\-=0;S3X:N[-?^$JL@QW,BW6W?$R@XY<<Y [B@#\KK7X<_$'Q
M<!X(^)?B*Y\)Z1<.+SPOI6D6[WT\W\4$$E];@R(6RHR7XYSC&:^[/@E^P#\0
M_%=QH>H6?A5_A=<Z4%">/KX/?3>(+;C][+;RJ[DR+SA@0"W7GG]I/A1^RU\)
M/A)90VVBZ&NKW$(4I?\ B)8=6ND9<',+7,3^4-PRH4 C@9KZ*CBCAC6*&-(H
MT 5(XT"(BCH%50%4#T H ^,/AA^Q#\*?!-U:^(_$5F/%7C2,*;K69=T-I/(N
M"7%CCRSE@&PRX'I@U]CVEA9:?$D%C:6UI$BA%CMX(X5"@8 Q&JBK=% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >3_'3X<P?%OX1>/_AS<JC1^+?#>H:2-^ %DGB/EL"?NL& VMQ@]Z_/O_@E
ME\1;B3P1\0/V?M09DN_V?_$T_A&&.?(N&M?.E*L"WS21*5 5N0,XXS7ZN5^)
MFNQG]F'_ (*4>&_L&[2_AS\;='N]3\27V#!9'Q%*TB0I<-Q&\C2X(RVX\8!Z
M5\5Q'_PF9SP_Q!'W::Q']B9C+:^$S*26&<GTA1QJIU)R>BC>]KW/Z<\&+<<>
M&OB_X0UK5,9+)X^*/!M.2NJ?$/!=*4\[IT8_%4Q69\+SQF"P]*'O3J*-D[6/
MVSHIJ.LB)(A#(ZJZ,.0RL RL".""""#W%.K[4_F-W6C5FM&GT"BBB@ HHHH
M**** "BBB@ HHHH ***,T %%<)\0/B9X%^%FA/XF^('B73O"^A1R"*34M2D9
M(%=NB_(CN3Z[5.*^??#O[3NF>(/B/HGA[2(X]:\(>,%+>%O%.GB1[&]"KEBK
ME P]<.HX([XK@Q&9X'"UJ>'K8BG&O4E3BJ*E&56/M9<E.<Z<6ZD*<YVA&HX\
MCDTKW/K<FX'XIS[+L9F^79/C:F5X.ABZ\\QGAZM+ 5G@*2KXS#X;&5(QPV(Q
MF'P]\14PE*I+$1H1G4]GRQ;/KVO'_BK\=_AC\%H-/N/B'XDM]$35+E+6T5@9
M96DD8*K/$AWQQ9.#(P"CGTKQ;]L+6?C5X,\-Z!\1?A=XETW1] \%:@FJ>/M*
MO8FDGUW1!+&LEK:81@)-I88R#SW[?+/Q7TGP3\3_ (Q?"GXE_%:TGE^$GQ.\
M#VVAZ?97<A-O;:]?1A49/E/D7!E8[9-I88!P>_C9QGM?"2Q.$P>'4<;2G@N2
MKC;QP7U?%U/9O%N5.3FZ%&K^YJWY'&I)-*43]+\./"C*L_IY+Q%Q)FU3$\+8
M_#<32Q.7\,257B:.;<.X:.,7#T:&,H1PT,TS+ 3>9X#V;Q5*KA*4U-TJKY5^
MGK^,]*O/!5YXUT*XAU;3(]&NM8LYK9PZ744%L]RH5E/!<+C&>,U^7WCO_@H/
M'??"ZT^)W@2+S=:\+^(I=+\5^"AO:X-M%=>1)/@DNP"*6. < ?C7IW['ZZII
MFH?'SX(/>RW/A7P??3Z?X*@NIQ<7$>E7T$P"._<;7C '3&.!TKXZ/[&GB75_
M&VJ)X A&DG0M7N;GQGI5ZH2V\16MY.2WV=9 (V=$/!&<$#M7S^<YOG^,P&75
MLIIRI2Q=/&87%T:4>>K1QN'KP@JV'D[<\:,Z5:IR3LJM"]X\S2/V#PT\._"3
MASBSC+*_$#&T<71R#%<-9]P_F..F\/E^8\,9QEE;%SRW.:*YWAZN98;,,NPK
MQ&&4Y8#-5!QJJBIS-O\ X*%_&.TU7X;_ +/7QR\*^+;W0K]-2T[5HK71_.N&
MN=09HI9-(N(H"6+QMN0K)DYSR>:Q/VFO&O@[]L']F;X8^.=$LKB'XL^'O'&@
MVD$[64ECJ]OK,+Q#S#&%$SVS2 /DKM4E@/EP*]?\5_!7X3? I_!UQ\6?BKX4
MT+X9>&[Z+Q5_PC'B98;^Y@U5R)98(X6$C"+?\JJL;*.W!P?/O'O[:GPMU_Q/
M#/\ LU?LW:]\8;[S%CL=<\+:5]D\,0W*X6+4Y+.&WBMR8R PD,6<*2?6OFLQ
MY_:YS_;68X+"+-\+@,+B<H4*F.QE3$T*--/,<+0PLZU6$HSC^[_V:GS77-.+
MBF?MG!<</_9WAI_Q##@WB;B*IX=Y]Q1GN3>(KK8+ACAO!Y-FN/Q-2'!N?YGG
MN'RS+\31JX:KS8UK/,9[+D?L</6A7<5]E> /C7^T'I^E:+X2UCX8MJFK^'K7
M3+37_$%Y.]C9SPM#&IN5=_+B+*@W.2W)SN.<UX5^WG9?LZZVWAGQ-\0/C5#\
M-39-#<>,M-\+7"7^I>)(%"M_9EPM@SR\$-$2Q((X*\UQ-M\&/^"B7[2$BW?Q
M#^)>B?##X:ZJJK<^$=+M6L?$@L7 'D27,$*%98XOW8+,,;>O-?2GP;_X)C?L
MZ_"J^37-0MM=^(6NR,)[R;QQJ)URQDN2=\C)97:2*J>9DJ"YXZCM7N<F?9Y@
MYY?1RJO6R^K[-1QO$]2.%Y(TFO95*."P/^V5U**2J.MB</.HE)224VG^6K$^
M$OA7Q-AN,,QX^RK+^+\%]=J5N&/ W"UN((XNOCZ:CCL)FG$_%*_U>RJ=&K*K
M/!T\NR3-J&$FZ<Z%253#TJD?C;1OVM_$>M>&]&^'7[%W[+E]\2O"E@8U@\4:
MM:RV:03K\HU:6":,"63/[TEP"2/6N_T[]CC]L_X\W4>L_'7]H+4/"?@^^V_:
M_A5I,%S!'#;/]^V%Q;@1QA4/EXW#! XQFOV$T'PIX8\+6RV?AKP]HV@6J@*M
MOH^FVFG0A0, ;+6*)2..X/KUK?KV:'!LL1&FL\S;%XZ$(PC' 8+_ (2LKIQ@
MN6-.-#".%>M22TY,5B*T6MXGYKFGTE:64U\3+PM\/N'N%,37K8BM5XNXG7^O
M_'>,JXF?M*V,K9KQ%#$97EV/J5/WCQ>0Y/E=:,TI1FG&+7Q!\%_^">O[,GP1
MNX]7\.>"5U+Q P#WFJZ_=2:N;JY)W/.;>\$D2EG^8#!_I7VG9Z?I^GQB*PL;
M.QB  $=G:PVT8 X "0HB@#L ,"KE%?58'+,ORRBJ&78+#8.C':&'HTZ2N]V^
M2*;;ZMW;ZGX#Q7QSQCQSF$\UXQXGSSB;,:B47BLYS+%8^HH+X:</;U)QITX;
M0ITU&$(I1C%))(HHHKN/E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F/T_'^AI],?I^/]#0 X
M=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I#T/T/\J6D/0_0_RH _FH_:#M+:2#]MJYDA1[B+XC:0
M(YC]] ;L9P<9YR>A&*V_V#?^1Y\?_P#8M:;_ .DHK-_: _X\?VWO^RCZ/_Z5
MK6E^P;_R/7C_ /[%K3?_ $E% 'Z6#H/H/Y4M(.@^@_E1G)P.6/11R3^% "TF
M>">PZ_EG@=_PJEJ.HZ9I432ZQJ5EID0&<WEPEON&#D*SD9<8R /U) K\UOVC
M/V\K'X;^)M.T'P#:#7KO39B=664CR)(M^/D<X#QXYR.._(H _329TMX7N;F1
M;>UC7=)<.P"(!U+DXP ,9]#Q7S]\0OVE?AQX"M)YH+EO%L\ <2IH++=&T=0<
MFX53\BK_ ! YVXS7Y/>._P!L7Q5\3+ 7^G:OJUAK*3;Y?!6BQR7$%W:Y'[N1
M8,E0?7&3GZD^:V'AOXG^,A)XRTV%/!?AVY;[/XETZVF,^MSQ2\3RKI['S=Y!
M)&$)SV.,4 ?4OQ@_;9UV[%C'+JME:>#-=\V&#^Q)@->M'.Y8XYPGS(^2 <X.
M<^O'RA%+\3/B%<2>'[BW?3M*U*9I=%\:^-28Y@KDF+R+A\C/3'S9SC\/KWX%
M?L3ZMXBN'G\ ^")?'?AC5W4ZAK?C".6QNM$N)#F6>TBNMO*.2R #YB./?];?
MA/\ \$]_">@6=HGQ-UN?QY:PE+BU\/WL/EV&F/@,L$;HRNZQ, !T&!C/2@#\
M,_AU^R?XG\;:U8Z;+IWB+Q7XYTVZC.F^()8)9_"-S&&&Q)9Q^[,+#"M\V"IK
M]?OA-_P3NOKB33]?^)VHV_A+4[9(Q-HW@62.+3M0C4#Y+Y4* [\'S ?FR<8K
M]2?#'A#PUX,TR'1O#&CV>D:;;JJ16UK'M554  ;FW.>F<ECS724 >8> O@W\
M./AM#&OA+PII&EW:H!-J-O:1QWUTXZRSS#YF=CRV" 3S7I]%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=,UN;>]O>6K7D\,,SV[$%""<[?>O.;#XO?LV_LI_$&?4=>^+GC;]HGQK!=7
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M<&OU0^%G[/WP>^"NG)I?PT\":)X8M(U"J+2W\R48&,^=.9)<GN0PKV,  8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8_3\?Z
M&GTQ^GX_T- #AT_$_P S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I#T/T/\J6D/0_0_RH _FQ_: _X\?V
MWO\ LH^C_P#I6M:7[!F3XZ^(&T$X\-:;G'0?Z*.OI[UB?M&RB#1?V[)N?,M_
M'>GSH/\ :BGW#/XC'YCO7PS\ OV@_&'@:W\;>(=$US2]%O;S1K6V:'4!F6\B
MB@52EJ!EO,*@8P,CK0!_0)XH\:>%?!>G/J?B;6K2RLHD)D,4J2SKM'.8$8RY
MSQC'O7Q-\4OVXM$T.P,_@_3TO]#DN?LC>*FD$9L79MOF20$[FV$%L$ G:?09
M_.E_&/Q4^+=S#XO\#Z'X@U>,R"#Q#J.IO)+X=M\\3S+;RC;L R1A2 .AP./1
M_!W[,^D3ZLUSXKNM2^,NG^(D\VY\*?#X2HFAZE+T%U!&K)MB; ?@#@]0<T <
MMXH^-WC_ .+/B:X\(1RZK\09-5Q+X=N+,S:;9VK'E4:Y^2)A&S<G<<^^.?F[
MXO\ PY^('@E[&^\>6=PWB*\N8XFTVPADOS;6OF*(EDN+=6W9'R$ENO/H:_?/
MX0?L-?$37-"TW1];@T/P3\.X<2:7;VMHEMXWM[=\$1SWJ1K*LBIA<LP(/7-?
MHAX!_9+^#G@;2?[,FT"/Q<[ %]0\6+'JUX7&/F669=R\@$8.1@8- 'XC_LJ_
ML7^+OBGH'A_QAX6\(+\)[H00&Z\3ZM +M=8@X+,EO(I<,XRVW;D\#UQ^OWPM
M_8?^%'@6\@\1ZY9?\))XPRDEWJ3N\>G33+R6&FNABQNY&X8QU6OKC0/#^F>&
MK!=,TBW2TL8SF&VB4)#"O9(D4 *H' 'H!6W0!3L]/L-.B6#3[*TLH5 58K2W
MAMHP!P!LA1%X^E7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\3OVAK>
M7]FS]O[X.?$?1$DLO"7QDN);'XAZDJM%!#/&XBA-U(F$96)4@R'/7 %?M5;7
M,%Y;PW5M(LUO<1)-!*ARDL4BAD=3W5E((/H:_/K_ (*7_"/4OB=^S7XANO"]
MM_Q67A2ZL-=T:_C7_2+:*QN%GNPCCY@IA1B<8.>^,U[!^Q=\7M-^,G[/O@7Q
M!83^?<Z3I=KX:UE\[O\ B;Z/;QVMYD^I=<D$DYR3UKXK)_\ A*XFSS)W[N'S
M)4\]R];14JB6'S"A26SY*U.&)J6V>)\S^GO$A?Z_>!GA;XD4[ULXX*JXSPGX
MOFK5*\J&";S?@_-<=-:Q6(RW&8C)<)S6O3R7E7PGU91117VI_,(4444 %%%%
M !136=4!9F50,DDD #'N2*^7OBQ^V9^SE\&FGL_&OQ/\.6.N1AU@T!;LRZG=
M3KG%M%'%'(HD9L+\QX)Z&N7%X[!X"DZV.Q6'PE%;U,36IT8>BE4E%-]DKM]$
M>]P]PMQ+Q;CX97PQD&<<09C4LXX+)LNQ>8XCE;MSRI82E5E"FOM5)J,(I-RD
MDFSZCJI=W]E81M+>W=M:1HI9I+F>.! JC)):5E7 '4YK\</$'_!1;XT?%K49
MO"'[.'[/?C59KES#I_Q#\0632^&U9CMCG^:U2(PD$.=Y?Y>>E9]I^Q'^U_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC?G]'3ZYF]7_ %)X%IXB&L*^&P-!8OB#.<)*2]_#9C'*)2CI[NI^/J_L_?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM('V83ABFP-CL0.E?JS7XODOA1E?$6%I8[C/&Y]G&8X>57 U<-CL9.AAL/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !3'Z?C_0T^F/T_'^AH <.GXG^9I:0=/Q/\S2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4Q^GX_P!#3Z8_3\?Z&@!P
MZ?B?YFEI!T_$_P S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4Q^GX_T-/IC]/Q_H: '#I^)_F:6D']3_,TM !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %,?I^/]#3Z8_3\?Z&@!]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gbn5n5jlnzog000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbn5n5jlnzog000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (E!7@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JC>?ZX?[M7JHWG^N'^[6=3X2H[E>BBBL"PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .O
M^%__ "472O\ MM_Z*>BCX7_\E%TK_MM_Z*>BO*QW\1>AUT/A.0HHHKU3D"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M +%G_KC_ +M7JHV?^N/^[5ZMZ?PD2W"BBBM"0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH R:***Y#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** )K;_CX7\?Y5H5GVW_ !\+^/\ *M"MZ>Q$MPHHHK0D**** "BBB@ HHHH
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M=5^G_M"N>I5E"L^RC>WS-(P3A\SRNBO7O$_C4>&?%K6UGIMJQ?8]Y,X/F29
MX!'3 QUS]*H?$O0K:37]&DMHEBEU!S#(47&XY7#'W^:B&*;<5*-E+8)4K)V>
MQYA7:+X0T\_#8^(_.N?M@'W-R^7_ *W9TVYZ>]==XH\10^ ;:ST?1=/MBSQ[
MW,H)!7ID@$%B<'DGM3M8O+74/A!/=VELEK%*H8PI]U6\X;L>V<UE+$SFH-*R
M;1:I15TW=I'G0M/#/_")FX.HW/\ ;O:VVGR_OXZ[/[O/WO\ "L"O5$_Y(4WT
M/_H^G6"VO@7P!;:W':17&IWFPK)(,[2X) ]0 H[=35QQ%KZ7?,TOZ[$NG>WI
M<\IHKN]9\=Z?XA\.O;ZGI"MJF3LGAPJIZ$$Y;ZCOZ^D_A3Q(=-\/M;Z%X;FN
M=6#?O+@1&16R>K%<$#L!T[Y]=76FH7<-?7]2.2+=KGGM=7HW@X:CX4U#7IKO
M9';))Y<*+RS*N>2>@Z?_ %J[GQC:/J?P[;4]7TZ*VU:$(QVCE#O"XSD\$'."
M3^8JWX?\3WMQ\.[K5GBMQ<6:.L:A6VD(HQD9S^M<\\5.5-2@NMC6-)*5I=CR
M[PW:>&KK[3_PD.H7-IMV^1Y"D[NN[/R-[>G6L)L;CMY&>*]=^&>IS:QJGB'4
M+A8UFG,+,(P0HX<<9)K%^'N@:?/%J6OZI$DT%F6"1NNY00-S,1WP,8^OTK3Z
MQR2FY=+?CV)]GS*-NMSSNBO4M)^(HUW6HM)U+2;/^S;IQ%&FW<4SPN<\-S@<
M 5%9^'X?#OQ>L;:VS]FE1YHE)R5!1QC/?!!JOK+C=3C9VON3[).SBSS*BO7O
M$_C4>&?%K6UGIMJQ?8]Y,X/F29 X!'3 QUS]*R/BSIEK;7UA?V\21R7*N)=H
MQN*XP3[_ #=:*>)<I14HVYMM1RI))M/8\XHHHKK,0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH R:***Y#4**** "BBB@#UO3O '@.^AM5'B5VNIE7]RE
M] 6WD#Y0-N<Y[5;O?AEX&TV80WWB&XM92NX)/>P(Q'K@ITKS3P=_R.>C?]?D
M7_H0KJOC-_R.%O\ ]>2?^A/7$XS]HH<[U-TX\M['"ZI!;VNK7EO:2^=;13.D
M4FX-O4$@'(X.1W%5*]8T#Q==VOARTL_!_A&9KD$+<3R0F2-CCJ77&23ZX Z5
M;^+.G0R^%=-UB>QCMM3:5$FVXR-R$E21][!'7FM%7:DH27XDNFK73/'**]^U
MG7AX:^'.C:G':PW%VD,$=OYRDJC-'R>.?N@]".M8?@?R=?N-9\<:[;PRS6YQ
M&BI\D>Q,DJ"3SC&,].:2Q+Y7)K0/9:VN>.T5[/X4^(*>+/%]O::EI-JC@N]C
M-'DO$0I)!)ZY7/3 ]JJ7OA^W\1_&Z\M[L;K:"*.>5/[X"( OTR1GVS3]NU)J
M:M97#V=U=,\CJ[I&G2:OJ]IIT3JDES*L:L_09/4U[Z9_$HU[^S1X5LCX:#>3
MGS(]VSIOV[L8[[=N<5RD:'P/\6(]/TR&(66K^7E'4GRU9CD+@CN#C.:E8GF3
M26MK[C=*QPGC7PS%X4UJ+3H[E[@FW61Y&4+EB6' [#@=S7-UZU\7_$MY'=GP
MZ(H/L<D4<Y<J?,W;CWSC''I7DM:T)2E33D1424K(****V("BBB@":V_X^%_'
M^5:%9]M_Q\+^/\JT*WI[$2W"BBBM"0HHHH **** "ND\'Z1HFKW=S'K>H_8H
MXT#1MYZ1[CGIE@<US=%1.+E&R=AQ=G=GKL/PV\(W%H]W!K-S+;1YWS)=1,BX
MY.6"X&*Y7Q=X>\,Z3ID4^BZQ]MN&F"-']ICDPN"<X4 ]0*Z+P?\ \DGUOZ3_
M /HL5A_#+P]:ZSJ]Q=7L:RPV:J1$PR&=LXR.X&#Q]*\^$IP<Y3FVHO[SI:4K
M)+<X:BO>+.3Q!J>HR6.M^&K1-&D!5#YJ,4 Z;AN.?P Q7+^&_!%DOCO5H;E/
M.M-.*M%%(,AMXRN?4 9^IK6.-C9\RV5]'<AT'=6/+ZZ;P-X=M/$VMRV5[)/'
M&EN9086 .0RCN#QS73K\4XFU">UO=)A?1QN2.-$R^!TR"=I!],#&>]1?#>>T
MN?'NH36-LUM;/;.T<);=L&].,TZE:I[.3<>73N*,(\RL[G"ZS9QZ=K=]90L[
M1V\[Q(7.20"0,X[U1KUQ?&J6'CM]%L]-M4LYKSRIY0#YDDC-@L3G'4]"#P.W
M;)\4:7:Z9\4M(-I$D27$L$K(@P WF8.!VSBG#$2NHRCTN$J:W3ZGG-%>S^.O
M%7_"+ZM:O9Z?:RWTT67GG4DK&"<*,$'KGO65\2;:TU'PQI7B"*W2.XG*!B!R
M5="V">^,4J>*<G&\;*7F$J*5[/8\MHKUR[DL_AIX9LFMK*"XU>YX::5><XRQ
M]<#(  (HL9+3XF>'KT7EG!;ZM:XV31+Z@[3ZX)!!!)_P/K>G/R^[W_X >QUY
M;ZG+^&_"&GZQX.U/6+B:Y6XM?-V+&RA#M0,,@J3U/K7%UZIX'!'PQ\0 ]0;C
M_P!%"J_@S2].T;PA=>*]0MDNI5R8$<#"X.T8ST);OV_.DL0X.=]=;)#]GS*-
MNQYG17K'A[QE%XTU%M$UW3+1HIU8PE >"!G')/.,_,,=*J^%O!-I%XZU2VO$
M%Q;:=M:-9%R&+\J6]<#/XU;Q7+=5%9I7%[*]N5WN>8U8L4MI+^W2\D:.U:51
M,Z#E4SR1P><>QKTV#X@PZSXI@TR[TNV?3FN5CMWP3(CAL*^>G7' QCU-)XX_
MY*?X>_[8?^CC2^L2YN24;75]P]FK73N<'XCM]"MKZ-- O9[NU,8+O,I!#Y/'
MW5XQCM6/7JWC;25USXDZ/ITC%8Y;<;R.NT,Y./? -=%>OK^E7T5CH7AJTDT>
M, .?-1"_KM!88_$'-9K%J,(K=M7U=OQ*=&[9X/17J?B/PMI-IX^T5VB2&QOW
M/FPXPF]>WL&)48_QKJM2G\1Z;J,<>G:+8W.BK@-'"0LH7'. 2%^@ -5+&JRY
M5NKZNPE0>MWL>!45N^+I[6X\0SO:Z5+I@X#P2#:=WKMQ\N1CC\>]85=D)<T4
MS%JSL%%%%4(**** "BBB@ JC>?ZX?[M7JHWG^N'^[6=3X2H[E>BBBL"PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -M?Y)7EE%4J%G!W^'_(3J:2TW"BBBNDS"BBB@ HHHH **** "BBB@ HHHH
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MQ_J%OI]VUW;1VKJDQ7&[YDSCU'OWKS2BAT)RBXRG>ZML"J1332.JD_Y*J?\
ML,?^U:ZKQQ_R4_P]_P!L/_1QKRNBJ="\E*^RL)5-&CT#XN?\C-:?]>:_^AM6
MIXR_Y)3H/_;O_P"BC7E=%)8:R@K_  C=763MN>NWL=E\2O#-DMK?00:M;#+0
MRGG.,,,=<' .0#3;&.S^&7AZ]^V7D-QJUU@I#$?0':/7 )))(%>245'U33DY
MO=[?\$?MM>:VIZIX')/PQ\0$]2;C_P!%"H/!FIZ;K/@ZY\*:A=):S-N$+.0
MP)W#&>I#=N]>9454L*GS:[N_H)5;6T/5_#_@Z+P5J+:WKNIVBQ0*PA"$\DC&
M>0.<9X&>M5O"OC6UF\=ZI<7;?9[?4MJQ,YX4IPH/ID9_&O,:W/"VIZ5IVHO_
M &SIZ7EG,FQ@4#-&<\,O_P!:IGAFXRE-\S:MV*C5U2CHCN;?X?0Z/XKM]2NM
M4MUT\7*O;IR)'<M\J8Z=<<CTZ"D\<?\ )3_#W_;#_P!'&JMM_P *VT_5$U2W
MU"\+PN)8[;8Y0,.F,IGKZM7)^+_$ \2Z_)?)&T<(41Q(W4*/7W))-94H5)U$
MY7T5M58J4HQC9=SN?&FJIHGQ+T;4)03%%;C?@9.TLX)_(UI:UH>L>(=0CU/0
M/%#0Z?,J[U2YD"I@8)4+Q]0<<UXM16OU2RCRO5*VQ/MKWNMSK]7L%'B:UTS6
M/%;7MJ"=UP':7R,]B"2%S@9P3CO7>6>@^)+*]ADT;Q/'<:-E2?M;^<VT=0#M
MQCTP1_6O%**J>'E))<WX(F-1)WM^)W7Q1U6PU+7K=+*5)GMXBDLB'(SG(7/?
M']:X6BBMZ5-4X*"Z$3ES2N%%%%:$A1110 4444 %4;S_ %P_W:O51O/]</\
M=K.I\)4=RO1116!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '7_"__ )*+I7_;;_T4]%'PO_Y*+I7_ &V_]%/17E8[
M^(O0ZZ'PG(4445ZIR!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVX_(4?\ "JM,_P"?VX_(5']HT?,V^K3/):*]:_X55IG_ #^W'Y"C_A56F?\
M/[<?D*/[1H^8?5IGDM%>M?\ "JM,_P"?VX_(4?\ "JM,_P"?VX_(4?VC1\P^
MK3/):*]:_P"%5:9_S^W'Y"C_ (55IG_/[<?D*/[1H^8?5IGDM%>M?\*JTS_G
M]N/R%'_"JM,_Y_;C\A1_:-'S#ZM,\EHKUK_A56F?\_MQ^0H_X55IG_/[<?D*
M/[1H^8?5IGDM%>M?\*JTS_G]N/R%'_"JM,_Y_;C\A1_:-'S#ZM,\EHKUK_A5
M6F?\_MQ^0H_X55IG_/[<?D*/[1H^8?5IGDM%>M?\*JTS_G]N/R%'_"JM,_Y_
M;C\A1_:-'S#ZM,\EHKUK_A56F?\ /[<?D*/^%5:9_P _MQ^0H_M&CYA]6F>2
MT5ZU_P *JTS_ )_;C\A1_P *JTS_ )_;C\A1_:-'S#ZM,\EHKUK_ (55IG_/
M[<?D*/\ A56F?\_MQ^0H_M&CYA]6F>2T5ZU_PJK3/^?VX_(4?\*JTS_G]N/R
M%']HT?,/JTSR6BO6O^%5:9_S^W'Y"C_A56F?\_MQ^0H_M&CYA]6F>2T5ZU_P
MJK3/^?VX_(4?\*JTS_G]N/R%']HT?,/JTSR6BO6O^%5:9_S^W'Y"C_A56F?\
M_MQ^0H_M&CYA]6F>2T5ZU_PJK3/^?VX_(4?\*JTS_G]N/R%']HT?,/JTSP^B
MO7/^%6Z1_P _5U^8H_X5;I'_ #]77YBL/KM(T]A,\CHKUS_A5ND?\_5U^8H_
MX5;I'_/U=?F*/KM(/83/(Z*]<_X5;I'_ #]77YBC_A5ND?\ /U=?F*/KM(/8
M3/(Z*]<_X5;I'_/U=?F*/^%6Z1_S]77YBCZ[2#V$SR.BO7/^%6Z1_P _5U^8
MH_X5;I'_ #]77YBCZ[2#V$SR.BO7/^%6Z1_S]77YBC_A5ND?\_5U^8H^NT@]
MA,\CHKUS_A5ND?\ /U=?F*/^%6Z1_P _5U^8H^NT@]A,\CHKUS_A5ND?\_5U
M^8H_X5;I'_/U=?F*/KM(/83/(Z*]<_X5;I'_ #]77YBC_A5ND?\ /U=?F*/K
MM(/83/(Z*]<_X5;I'_/U=?F*/^%6Z1_S]77YBCZ[2#V$SR.BO7/^%6Z1_P _
M5U^8H_X5;I'_ #]77YBCZ[2#V$SRFV_X^%_'^5:%>EVWPMTDW"@7=R#SZ>E7
M_P#A56F?\_MQ^0K6&/HI:W)EAYL\EHKUK_A56F?\_MQ^0H_X55IG_/[<?D*K
M^T:/F3]6F>2T5ZU_PJK3/^?VX_(4?\*JTS_G]N/R%']HT?,/JTSR6BO6O^%5
M:9_S^W'Y"C_A56F?\_MQ^0H_M&CYA]6F>2T5ZU_PJK3/^?VX_(4?\*JTS_G]
MN/R%']HT?,/JTSR6BO6O^%5:9_S^W'Y"C_A56F?\_MQ^0H_M&CYA]6F>2T5Z
MU_PJK3/^?VX_(4?\*JTS_G]N/R%']HT?,/JTSR6BO6O^%5:9_P _MQ^0H_X5
M5IG_ #^W'Y"C^T:/F'U:9Y+17K7_  JK3/\ G]N/R%'_  JK3/\ G]N/R%']
MHT?,/JTSR6BO6O\ A56F?\_MQ^0H_P"%5:9_S^W'Y"C^T:/F'U:9Y+17K7_"
MJM,_Y_;C\A1_PJK3/^?VX_(4?VC1\P^K3/):*]:_X55IG_/[<?D*/^%5:9_S
M^W'Y"C^T:/F'U:9Y+17K7_"JM,_Y_;C\A1_PJK3/^?VX_(4?VC1\P^K3/):*
M]:_X55IG_/[<?D*/^%5:9_S^W'Y"C^T:/F'U:9Y+17K7_"JM,_Y_;C\A1_PJ
MK3/^?VX_(4?VC1\P^K3/):*]:_X55IG_ #^W'Y"C_A56F?\ /[<?D*/[1H^8
M?5IGDM%>M?\ "JM,_P"?VX_(4?\ "JM,_P"?VX_(4?VC1\P^K3/):*]:_P"%
M5:9_S^W'Y"C_ (55IG_/[<?D*/[1H^8?5IGDM%>M?\*JTS_G]N/R%'_"JM,_
MY_;C\A1_:-'S#ZM,\EHKUK_A56F?\_MQ^0H_X55IG_/[<?D*/[1H^8?5IGDM
M4;S_ %P_W:]H_P"%5:9_S^W'Y"J5Y\+-*$HS=W)^7VJ9X^BU97*6'FF>.45Z
MY_PJW2/^?JZ_,4?\*MTC_GZNOS%9?7:17L)GD=%>N?\ "K=(_P"?JZ_,4?\
M"K=(_P"?JZ_,4?7:0>PF>1T5ZY_PJW2/^?JZ_,4?\*MTC_GZNOS%'UVD'L)G
MD=%>N?\ "K=(_P"?JZ_,4?\ "K=(_P"?JZ_,4?7:0>PF>1T5ZY_PJW2/^?JZ
M_,4?\*MTC_GZNOS%'UVD'L)GD=%>N?\ "K=(_P"?JZ_,4?\ "K=(_P"?JZ_,
M4?7:0>PF>1T5ZY_PJW2/^?JZ_,4?\*MTC_GZNOS%'UVD'L)GD=%>N?\ "K=(
M_P"?JZ_,4?\ "K=(_P"?JZ_,4?7:0>PF>1T5ZY_PJW2/^?JZ_,4?\*MTC_GZ
MNOS%'UVD'L)GD=%>N?\ "K=(_P"?JZ_,4?\ "K=(_P"?JZ_,4?7:0>PF>1T5
MZY_PJW2/^?JZ_,4?\*MTC_GZNOS%'UVD'L)GD=%>N?\ "K=(_P"?JZ_,4?\
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MZY_PJW2/^?JZ_,4?\*MTC_GZNOS%'UVD'L)GD=%>N?\ "K=(_P"?JZ_,4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@A1J5+\D6[=D9%%6[/3;R_NFMK> M,H)9"0I&.O7%:'_"):Y_SX_P#D5/\
M&IE6IQ=I22^94,-7J*\(-KR3,2BK-]I]UIMQY%W%Y<A7=MW \?@:?9Z5?7\,
MLUM 7CB&7;< !W[GFJYX\O-?0A4JCGR<KOVMJ4Z***HS"BBB@ HHHH ****
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M[_7K_N_U-:%9]]_KU_W?ZF@"M1110 4444 %%%% !1110 4457O;C[-;,_\
M$>%^M14J1IP<Y;(3:2NR"^O_ "#Y40W2G]*BATQI3YMVY)/.W-.TVUX^TRC,
MC<C/:M*O-HX>6*M6Q&W2/1+S[LQC%S]Z?W&-XAE.E>&M0O+-4CGAA9T?:#@C
MZ]:X2#Q9K44FF2OJLMTMS-%'+#<:8((P&Z_O,]NWYUZ3J=A%JNF7%A.SK%.A
M1BAP0#Z5P&@V&A:WJ[Z;_:FN74=@PDBAN[D-#,$;;N4 <@$8_&O8I1A&-DAS
M3NDCT":PMY@<H%/JO%9T@N=*??G? 3R>WX^E;=(RJZE6 *D8((ZUQU,)2J/F
MM9]UH_Z]15*-]8:,CM[A+F(.A^H]*EKG_FT?4UCR3;R_ZO/ZK_GVK?!! (.0
M>E:4W-/DJ;KKW71_YKHTQ8>M[5-/22T:%HHHK4Z HHKBKWQ5JVLZI<:3X1MH
M9?LYV7.I7'^IA;T4?QL/2@#M:*X<>"_$-P!)>^.=364]1:HL:9]A22:)XXTC
M]]I?B*/554\VNH1!2X_WUZ4 =S17.>%O%L/B$7%K/;O9:M9G;=6<OWD/J/53
MZUT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 6=/_ ./Z/\?Y&BC3_P#C^C_'^1HH \RHHHKZT_,SHO!MB+G6?M#_ .KM
MEWGTST']3^%;FH2KXD\*W,\8!DMYF91[*3C_ ,=--T&&UTSPI)<7LK0+=DAG
M )(!X&.#[GIWJQX<.AP2S6FFWTT[3#<T<JG''I\H]:\>O4O4E42?NM6[:;GU
M&$HJ%&%"32YT[JZOK\-D<;9:_J>G6XM[6Y\N($G;Y:GD_45V.NZM?6?ANQN[
M>?9/+LWML4YRI)X(QUKB-4LFT_5+BU(QY;G;[KU'Z8KJO$W_ "*&F?\ ;/\
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MO8?%R_DNYXH(Y+50C2N%!.U.,GZ&@"NFIP:7\5-6FF2:0O;A(XX8R[NV(S@
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M^ISO+8RF4'RT D)7;R ..">GK51/!<2PVT+:C</'!<RW&UD3Y_,SN4\=/F-
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MM([Q[M+6!;IQM>81@.PXX+=3T'Y4+8VBWC7BVL NG&UIA&-Y'H6Z]A^53T4
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M*Z%!X9U5+B&&.*9Y8=JX0C[@^\Y.!P!QGVH E^(5_+JGPRT>_G5%EN)H9'"
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M1+N55*SJ3M!#$C@CD$8ZU5UKQ?XF\/Q6FJ:AI>GC3+B0*88Y':>/(S@MPN<
M] :S/%?A>_L?AOH^D6MM->7$%P&E%O&TF"0Y8\#.,G&:V?BA87FH>$[:&RM)
M[F5;I&*0QEV VMS@=J .Y1@Z*Z]&&12U';@BVB!!!" $'Z5)0 4444 %%%%
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ME<P_@VZT]M#OH?M.H"V9&NK"XNLJK ?>3) ^4YX[\5T\OA:U;/E321Y['D5
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M_@A[3#_R/_P+_@&O_P (Y>?\];7_ +_BC_A'+S_GK:_]_P 5D44<M7^;\/\
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M:<']R;_OV:NT4 4O[3@_N3?]^S1_:<']R;_OV:NT4 <_]J3T?_OFC[4GH_\
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MU)Z/_P!\U/10!!]J3T?_ +YH^U)Z/_WS4]% $'VI/1_^^:/M2>C_ /?-3T4
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M)Z/_ -\U/10!!]J3T?\ [YH^U)Z/_P!\U/10!!]J3T?_ +YH^U)Z/_WS4]%
M$'VI/1_^^:/M2>C_ /?-3T4 0?:D]'_[YH^U)Z/_ -\U/10!!]J3T?\ [YH^
MU)Z/_P!\U/10!!]J3T?_ +YH^U)Z/_WS4]% $'VI/1_^^:/M2>C_ /?-3T4
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MFQR)-$DL3J\;@,KJ<A@>A!]*=0 4444 %%%% !1110 4444 8U%%% !1110
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MZK<;JRA_$6G<VZ*9%*DT8=#D&GUW1DI+FCL;IW"BBBF 4444 %%%% !1110
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M-L8NMF\$$>[_ &"JC)/TY)H P_A?_P B%8_[\G_H9IWQ,_Y$'4/K'_Z&M6O
M>E7NC>$;6QU"'R;F-G+)N#8RQ(Y!(Z4[QSIEYK'A&\L;"'SKF0IL3<%SAP3R
M2!T% $WAVWAN_!.E07$22PO8Q*R.N01L':O.?"3O#X6\;Z<K$VUNDABYX&5<
M']%%:MF_Q,MM*@TN#1K"".*%8$G,BET & W^L(S^'X5K:3X,GT3P+JNG*XN=
M3OH9#(5. 7*D!03CCW/J: .&\'SS^$&T?7)'8Z3JH:"Z/:-P[ $_@ ?^^JZ3
MX<D'7O&!!!!N,@C_ 'I*U]'\)2W'PTC\/ZM"(+@K)U(?RWWLRMD''<=#[50^
M&OA?6/#PU==3M!#YXC$1$JMNQOST)QU'6@#D_!OC*]\+Z!=B/0+B]M?M)D>Z
M5RB(2%&TG81G@=^]=-X&LKS6_%=WXRFMX+2UN(RD444@8LW )./ISG!R>E:O
MP]\.WND>&KW3]9LUC,]P[&)G5PR%%'.TD=C5+PQX;UOPCXMNK>UA:X\/W1SO
M\U08CV.TG.1T.!R,'VH ]"HHHH **** "BBB@ HHHH **** "BBB@ K/OO\
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M*QZ%CN8GMS@=,D VZ*R/"TTD_A;39)6+N8%^8]6 X!_$8-:] !1110 4444
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MKG4;D0PRN(T;8S98C(^Z#Z5GKXY\,OJ(L%U> W!;:,!MI/IOQM_6@#H:***
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MOXG@V]]X;U&16^RVMWF:0*2$&4/./]TU5\>7L=W)X7\2VBR7&EV]P9))4C/
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MN/K2VV-0=/+:;>W*\<8SCL.U,LO#NE:>;\VMKY?V\EKG]XQ\PG.>IX^\>F*
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M.%7*D9)]!7G&@:>L%W86T5SX*N7B=,.A+7#8/4'NW]:]"\0\^&=5QSFSF_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?]^?_KT?\)-=_P#/K9?]^?\ Z]8M%'U>E_*'U[$?SLVO^$FN_P#GULO^_/\
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MLJ'_ )ZS_P#?=']E0_\ /6?_ +[J]10!1_LJ'_GK/_WW1_94/_/6?_ONKU%
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M/[\G_?53T4 0?9$_OR?]]4?9$_OR?]]5/10!!]D3^_)_WU1]D3^_)_WU4]%
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M_94/_/6?_ONKU% %'^RH?^>L_P#WW1_94/\ SUG_ .^ZO44 4?[*A_YZS_\
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MX_RK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L^^_P!>O^[_
M %-:%9]]_KU_W?ZF@"M1110 4444 %%%% !1110 4444 %%%)N&['>IE.,?B
M=AI-["T4450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIMS"Q*O&H=&!ZAD/#>V>E1Z)H,NFW%Q>W^I2ZCJ%PJH\[QK& BYPJJ. .<T
M>9PSRWEA::(/$MTTZ-&!I::"HDA8$?Q9 &#R6W"N_P!+@B?QOXC=XT9_*MDW
M%?X2AR/H:Z>B@#R.2&Y@\->&;^*[DLK2S>Y5[E+47(@)<[6*'M@$;NU7](=]
M0_MW4UUJ;5HSICQ-<?V:+:-C@D#.068<_P /0]:]-HH \[MK^TT"^T;5]65T
ML9-&B@BN1$76*0<E3M!()!'Y5V.@W=G?:8+FPLGM+:1V9%>$1>9S]\*.S=<G
M!-:=% !1110 4444 %%%% !1110!C4444 %%%% !1110 445C^*KZ73?#&H7
M4!*RI%A&'522!G\,T ,U#Q?H&EW+6UWJ4:S+PRHK/M/H=H.#[&M&QU*RU*U^
MTV5S'/#W9#G'L1V/L:Y?P=X7TC_A&;2XN+"WN9[E/,>2>,.>>PSTX]*V-*\-
M:;H)O);".1#<#+*9"5 &< #\3[T 4_\ A8'A<'']I_\ DO+_ /$UM:=JMCJU
MO]HL+F.>,'!*GD'T(ZC\:X;X<:3IM_H-U)>:?:W$@NF4/-"KD#:O&2*-/@C\
M/?%0V%BOEVEY#DQ \+\I;^:G\Z .WU36+#1;87&H7 @B9M@)4L2?0  FK,MS
M#!;-<S2K'"J[V=S@ >M>8>/]#NH+-M6O]1DN97N_+@B'"0QG<0![\+Z?CUKH
M/B%%<2>"5\@,41XVF _N8_QQ0!N:;XIT35[HVMC?I+..=A5E)^FX#/X5L5XU
MKFJZ!OT.;P_$L-U;LIE*1%",8P&./F.<\\U[*.1F@ HHHH **** "BBB@":T
M_P"/E/Q_E6G69:?\?*?C_*M.@ HHHH **** "BBB@"KJ6I6>D6$E]?SK!;1X
MW.03C)P.!R?PJ&36]/BT0:RTY^P&,2^:(V/RGH=H&>_I7!_$CP]>7&G:IK%[
MJ<CVMOY?V.S3A$)*J6;U/+?GU[5U_A2-)O!.E12('C>R165AD$%>0: +EKKN
MF7NC'5[>[1K!59C,05 "]<@C(Z>E4AXST Z,=7%Z_P!@$OE&;[-+C=]-N?QZ
M=J\AU>TNM)\07G@RSU"-=-OKN)CN.1'GH#Z8R,^NU:]HC\/Z<GAT:%Y.;$0^
M45/4CU^N><^M #Y]=TRVT4:Q+=HNGE%<38)!!Z<8SGGIC-3Z=J-KJUA'>V4C
M26\HRCE&3</7# &O#+&RNK_Q!;>![C4D?3;:^=MRG[V,Y /KP<#L6/6O>H88
M[>".&% D4:A$4= !P!0 ^BN8\4>*+C2;ZPTG3+6.YU2_)$2RMA$']YL<_P#Z
MC2:3K'B)->.E:[I<6UX]\=]8)(8,_P!UBW0\'J1^HH ZBBN'B\5:_P"(-0OH
M_#-E8&TLG\MI[YV_?-Z*%Z?C[=,XK7\)>*%\2V5P9;8VM[:2F&Y@+;MK>H/H
M<'\C]: .AHK-\0:NN@Z%=ZFT33"W3(C!QN)( Y[<FN+LO&WB.6&UOQ9Z5J5G
M,P\VVTQGDNH ?[R\\CZ?E0!Z([I&NYV55Z98X%4-2UW3=(N+.WOKGRI;Q_+@
M78S;VR!C@''4=:\_^),VK_\ "0>'TA>V6VDN%:U1MX)D!3_6CT!(QCGK6KXH
MU:\TV[\+PZAI^D75W<W&R5VA+B([DYB).5Z]3Z"@#O**XB^\5:Y_PG-QX=TV
MSL9<0!XY)RR[#@$ER"<CM@#/(YK.T[QOXHU6UU.&VTW3!>Z86-S)([^60,_*
MJ@YW':W);'% 'I%%<,?'-U+\-Y/$D%M EW&P1HGRR9WA3T(.,'/6M#4_$MY9
M?#M/$$<4!NVMH92C*?+RY7/&<X^8]Z -G6-;T[0+1;K4[CR(&<1AMC-EB"<8
M4$]C5]6#J&4Y!&0:\O\ B%?RZI\,M'OYU19;B:&1P@(4$QL>,YXKK-:UC5[)
M-.LM&TS[1<7"C=<3JWV>!0.KL/Q[]J .EIN]/,\O<N\#.W/./6N)\.^,-3U+
M7M0T&]CTU[VWA:2*XLY&:%B,<'.3U;GZ$8K"\#2^()?'.NEWL7*W 6^+&0X
M9L"+VSG[W;% 'HEAKNFZI?7EE9W/FW%FVRX38R[#DCJ0 >0>F:T:X#1?%$%O
MJWBV:YT^QMH=.D):6U@V2S?,P^<Y^9CCVY--'BWQ8VAGQ&-(T[^R0/,^SF5_
MM'EY^]N^[COT_"@#T&BN)\2^.9-/\):=KNE1Q2)=RJI6=2=H(8D<$<@C'6JN
MM>+_ !-X?BM-4U#2]/&F7$@4PQR.T\>1G!;A<X!Z T >@44B,'177HPR*6@
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MK**S@U9/L[B.?S 95^Z2<#!/ _.NBT33[^QEOI+Z6WE>ZF,Q>($$< !>>P
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M% !1110 4444 %%%% !1110!T?@O_D,3?]>Y_P#0EKNJX7P7_P AB;_KW/\
MZ$M=U7@9C_'/M,C_ -T7JS.UW1K;Q!I$VFW;RI#-MW-$0&&"#QD$=O2N._X4
MYX>_Y_-4_P"_L?\ \17H5%<)[!EZ%X?T_P .:?\ 8].B*1EMSLQRSMZDUH30
MQ7,$D$\:R12*5=&&0P/4&I** .._X5KHV/(-WJAT\/O%@;L^0#],9_7-:VM>
M%-+URVMHIXW@:TQ]FFMF\MX<8^Z>@Z#MVK;HH PM#\)Z?H-U/>12W5U>SC$E
MU>2^9(1Z9P..!^5/TGPQ9:-JFI:A;RW#3:C)YDJR,I53DGY< ?WCUS6U10!B
M^&_#-EX7LYK:REN)$FE,K&=@2#@#C ''%">&;*/Q5)XB$MQ]LDB\HH6'EXP!
MTQG/'K6U10!@Z9X2L-*.K&":Y;^U&9IM[*=N=WW< 8^\>N:JIX"T8>&/[ D^
MT2VHD,J2.X\Q'/<$ #]*ZBB@#CC\-]*=K666_P!5FN;617BN);G>ZA>B\C;M
MSZ#\:U[OPS97OB:SU^26X%U:1^7&BL-A'S=1C/\ $>];5% &+#X9LH/%5QXA
M66X-W/$(F0L/+ PHX&,Y^4=ZX*_N/!L/B34'O7US19F)%Q N8XKODYX3)(/7
MJ <^]>KT4 ><_#S0'E\+:Q%=P36MKJ4K+$I&UQ&5QD9SCKQ]*ZVQ\-6>G^&&
MT"*6=K1HI(B[L-^'SGG&,_,>U;-% '-?\(+H[>%D\/2^?+:1N7CD=QYB,23D
M$ #N>U4S\-]*=K666_U6:YM9%>*XEN=[J%Z+R-NW/H/QKL:* ,6X\,V5SXIM
M?$+RW N[:,QHBL/+(PPY&,Y^8]Z+OPS97OB:SU^26X%U:1^7&BL-A'S=1C/\
M1[UM44 <[JW@S3M5U+^TDN+W3[XKM>XL9O*=QZ'@U+8>$=*TS1KS3+9)52]1
MEN)V?=+)N!!)8]^?3'MR:W:* .:7P-HW_",1Z!,LTUK$Y>-Y''F*Q).00!ZG
MM3M(\%Z=I6IC4FN;Z_O539'-?3^8T:^B\#UKHZ* .:U#P1IUYJ4NH6UYJ.FW
M4_\ KGL+CRO-^O!_2M'0] L/#UFUO81L/,??))(VYY&]2:U** "BBB@ HHHH
M **** ,:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH FM/^/E/Q_E6G69:?\ 'RGX_P JTZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K/OO]>O^[_4UH5GWW^O7_=_J: *U%%% !1110 4444
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ME_\  <T>VCV?W/\ R#ZI/O'_ ,"C_F9%%:_V/1/^@M+_ . YH^QZ)_T%I?\
MP'-'MH]G]S_R#ZI/O'_P*/\ F9%%:_V/1/\ H+2_^ YH^QZ)_P!!:7_P'-'M
MH]G]S_R#ZI/O'_P*/^9D45K_ &/1/^@M+_X#FC['HG_06E_\!S1[:/9_<_\
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M/^_HH NT52\^_P#^?-/^_HH\^_\ ^?-/^_HH NT52\^__P"?-/\ OZ*//O\
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M_OZ*//O_ /GS3_OZ* +M%4O/O_\ GS3_ +^BCS[_ /Y\T_[^B@"[15+S[_\
MY\T_[^BCS[__ )\T_P"_HH NT52\^_\ ^?-/^_HH\^__ .?-/^_HH NT52\^
M_P#^?-/^_HH\^_\ ^?-/^_HH NT52\^__P"?-/\ OZ*//O\ _GS3_OZ* +M%
M4O/O_P#GS3_OZ*//O_\ GS3_ +^B@"[15+S[_P#Y\T_[^BCS[_\ Y\T_[^B@
M"[15+S[_ /Y\T_[^BCS[_P#Y\T_[^B@"[15+S[__ )\T_P"_HH\^_P#^?-/^
M_HH NT52\^__ .?-/^_HH\^__P"?-/\ OZ* +M%4O/O_ /GS3_OZ*//O_P#G
MS3_OZ* +M%4O/O\ _GS3_OZ*//O_ /GS3_OZ* +M%4O/O_\ GS3_ +^BCS[_
M /Y\T_[^B@"[15+S[_\ Y\T_[^BCS[__ )\T_P"_HH NT52\^_\ ^?-/^_HH
M\^__ .?-/^_HH NT52\^_P#^?-/^_HH\^_\ ^?-/^_HH NT52\^__P"?-/\
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M 4444 %%%% !1110 4444 ='X+_Y#$W_ %[G_P!"6NZKA?!?_(8F_P"O<_\
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M* "BBB@ HHHH **** "BBB@#H_!?_(8F_P"O<_\ H2UW5<+X+_Y#$W_7N?\
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M&TE>0H/IWKU&WU"RO)9HK6\MYY(#ME2*4,8SSPP!X/!Z^E>7Z+IPTKXM6%F
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MV#@X(0&@#U6+6-,G,XAU&TD, )F"3J?+ [M@\?C4MI?V5_"9K.[@N8@<%X9
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M'-OIMN7B8OVE-02Z[[':Z?:^#]4E:.PL]-G=!N8) .!^54OB4 OA(*H  G0
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ML[6C121%W8;\/G/.,9^8]JV:* .:_P"$%T=O"R>'I?/EM(W+QR.X\Q&))R"
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MAYI6W.1Z=@!]!6S110!SVN^#-'\03?:+F.2*XX!F@8*S >N00?RS1H?@K1]
MG^T6T<DMP,A99V#,N?3  'Y9KH:* .4U?X?Z3K6J3:A<W%ZDLN-PC=0HP .,
MJ?2I]$\#Z-H5T+J!)9KA?N23L&*_0  ?CBNDHH Y76/ .F:YJ<M_=W5\)9,9
M5)%VJ ,8&5-3^'_!FG>'+R2ZLYKJ1Y(_+(F92,9![*/2NCHH Y&X^&_A^XU
MW12XC5FW-!'(!&?PQD#Z$5UD<:11+'&BI&@"JJC  '0"G44 %%%% $UI_P ?
M*?C_ "K3K,M/^/E/Q_E6G0 4444 %%%% &5XA\/VGB72CI]Y)-'"7#[H6 ;(
M^H-9^J>!]*U=M+:Y>XSIJ*D6QE&]1C ?Y>>G;'4UTM% &*WA>Q;Q6OB/S+@7
MBQ>5LW#RR,8Z8SG!]:H77@/2[C6)M3@NM1L9KC_7K9W'EK+GKGC//L174T4
M8'A_PAIGAJZO)].,X%UMW1R.&5 ,X"\9[]R:CTCP98:)JTM]8W>H1I*S.UH9
M\P$D8SMQDX[9-='10!Q-S\*_#5SJ;7A2YC5FW-;Q2!8B>_&,@>P(KIM2T/3M
M6TDZ7=6R-:;0%11MV8Z%<=,5H44 <IX?^'NA^'+[[;;">>X PCW#AO+SUV@
M#\:Z+4-/M=5L9;*]A6:WE&'1N_\ @?>K-% '(V_PZTB*:W-Q=:E>V]LVZ"UN
MKG?#&>V%P./;\ZT]<\*Z;KTL-Q/Y\%Y ,175K)Y<J#T!_P 1Z^M;=% &'H?A
M33=!GFNH#<7%[.,2W=U)YDKCTS_@.P]*W*** .3G^'^F-<3R6=]JFG1W#%IH
M+*Z\N-R>N5P?RK43PQI,?AQ]!CM]E@ZE64,=QR<YSUSGFMBB@#EXO UC'X=N
MM#?4=3FL[C8/WTZL8@IR GRX4<>E2W?@K3;VST>UDGN@FE%3 5=<MC&-WR\]
M!TQ71T4 8LOAFRF\50>(6EN!=PQ>4J!AY9&".1C.?F/>C3O#-EIFNZAJ\,L[
M7%]_K5=@4'.> !G\R:VJ* .17X=:-'=7$D-QJ,%M<',UE#=%(9/8@<X]LU=T
MKP=IVCZ)?Z3;2W)M[[?YA=E++N7:=N% ''J#70T4 <U_P@NCMX63P]+Y\MI&
MY>.1W'F(Q).00 .Y[53/PWTIVM99;_59KFUD5XKB6YWNH7HO(V[<^@_&NQHH
M P->\(V/B"\M;V6XO;2[M@1'/:2[' /;.#[]*63PI93:_I^LR7%VUU8PB&/+
M@AP 1EN,D_,><BMZB@#GM7\':;JVHC41->6-_MVFYL9O*=AZ'J#^6:M:)X:T
MWP_;316,;[YSNFFD?=)(?4G\3[<FM>B@#&\.>&K/POI\ME92SR1RRF5C,P)R
M0!V XXI/#?AFR\+V<UM92W$B32F5C.P)!P!Q@#CBMJB@ HHHH **** "L^^_
MUZ_[O]36A6???Z]?]W^IH K4444 %%%% !1110 4444 %%%% !69X@TC^W=%
MFTXS^3YI4[]N[&&!Z9'I6G5:]F>*)!&0'D<(&(X7/>KI\W,N7<BIR\CYMBOH
M6E?V+HT&G^=YWE9^?;MSDD]/QI=;TS^V='N+#S?*\X ;]N['(/2IX;>6&3)N
MI)$(Y5P#S['M4%]>/#,HC(VQC?)D]1G&/YFK2E*I>+N]S.3C&E:2LMB/P_H_
M]A:/%I_G^=Y98[]NW.3GIDUE^(? VG:],;E6:UNSUEC&0W^\.];]Y,\=NLD.
M"2RXST.:BANS-?J@RN(SOC/56R*J$JJ;JIZZDS5)I4I+L<0/AE<RE4N]<DD@
M0\*$)P/;)P*[/1="L-!L_L]C%MSR[MRSGU)J0"6\GF G>)(FV@)C)/J:==M-
M;Z9(WFYE5?OXQ5U*E6I:$I;]":=.E3O.,=NOH8VN^$AK6O66I_;?)^RA/W?E
M[MVUBW7(QUKI:I6(9\R&2Y..-LR[?QZ55FN<7=PKWDD14@(JKD=/I4.,YODO
ML4IPIKGM\1K$9!'K7.^&?"@\.7%Y*+S[1]I(X\O;MP3[G/6MZW:1[>-I5VR%
M?F&*CNY)%,443!&E;&\CH/\ &HBYJ]-/??Y%SY&E4:VV^99K'\2Z%_PD6E?8
M3<>1^\#[]F[IGC&1ZUHP020N=UP\J$=' R#]:HAY9K^:(RW2@/M7RU&T#'<X
MITXM2YHO;4522<>6:WT+&DV']EZ3;6/F>9Y"!-^W&?PJGXFT'_A(]+6R-Q]G
MQ*)-^S=T!&,9'K5Z\FE@$'DC>S/M*G^+@TVVN_M%ZX1CL$8RI'W6SSGWIQ4T
M_:KU%*5/^$_0=I=E_9NE6MEYGF>1&L>_&-V!UQ5NL[RIO[1,7VN;9Y>_''7/
MTHU"61;F%%>9596)$*Y)Z4O9N4M]]1^U487MHM#,\1>$QK^I6=V;SR/LW\/E
M[MW.>N1BNDJMAHK%R))&;86#/U'%4+:Z=I+<174D[N1YL;+PHQR>G:JM.I&U
M](D\T*<KVUE_7]6-&\M_M5C<6_ \V-DR?<8KQ+PO?_V#XN@>X^15D:&;/& >
M#GZ'G\*]TKRSXB>%Y(+M]:M(RT$IS<*H^XW][Z'^?UK? SC>5*6TC''0E:-6
M.\1OQ4(.K6.#G_1__9C6#KUA<C1]%O\ RR;9[01AQT#!FX-9=]JMWJ4-K'=/
MYGV:/RHV/7;G(!]<5[%X9LK?4? =C:740DADAPRGZG]:[)R>%IPOK9_YG%"*
MQ56=M+K_ ".#NK"YU#XD^7;1%RDL4CGLJA5))JC9G_BXP(_Z"3?^AFO8[/2[
M6QGN)X4_?7# R.>2<  #Z<5X;>7DNG^*[J[AV^;#>2.NX9&0YI8>K[:\5T5B
ML12]C:3ZNYU7Q0U9)[^VTR)LBW!>7!_B/0?@/YUT'PSL&M?#CW#C!NI2R\?P
M@8'ZYKSW0]%OO%FML79RK/ON9SV!//XGL*]QM;>&TM8K:W4+%$H1%'8"L,6X
MTJ*H+?J;X12JUG7>W0EHHHKS#TPHHHH **** "BBB@ HHHH LZ?_ ,?T?X_R
M-%&G_P#']'^/\C10!YE1117UI^9A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '1^"_^0Q-_P!>Y_\ 0EKNJX7P7_R&
M)O\ KW/_ *$M=U7@9C_'/M,C_P!T7JPHHHKA/8"BBB@ HHHH **** "BBB@
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MWG_?AO\ "C^Q]4_Z!MY_WX;_  H_MC5/^@E>?]_V_P :/[8U3_H)7G_?]O\
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M^T/_ 'P*/L=M_P ^T/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV*/L=M_S[0_\
M? H^QVW_ #[0_P#? H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW_/M#_P!\"C['
M;?\ /M#_ -\"@ ^V6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_ 'P*/L=M_P ^
MT/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV*/L=M_S[0_\ ? H^QVW_ #[0_P#?
M H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW_/M#_P!\"C[';?\ /M#_ -\"@ ^V
M6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_ 'P*/L=M_P ^T/\ WP* #[9;?\_,
M/_?8H^V6W_/S#_WV*/L=M_S[0_\ ? H^QVW_ #[0_P#? H /MEM_S\P_]]BC
M[9;?\_,/_?8H^QVW_/M#_P!\"C[';?\ /M#_ -\"@ ^V6W_/S#_WV*/MEM_S
M\P_]]BC[';?\^T/_ 'P*/L=M_P ^T/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV
M*/L=M_S[0_\ ? H^QVW_ #[0_P#? H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW
M_/M#_P!\"C[';?\ /M#_ -\"@#)\Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H
M\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\
MB@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?
M0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0
MH\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H
M\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\
MB@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?
M0H\Z+_GHG_?0H\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0
MH\F+_GFG_?(H\F+_ )YI_P!\B@ \Z+_GHG_?0H\Z+_GHG_?0H\F+_GFG_?(H
M\F+_ )YI_P!\B@"6VGA6X4F6,#GDL/2M'[9;?\_,/_?8K.MH(6N%!BC(YX*C
MTK1^QVW_ #[0_P#? H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW_/M#_P!\"C['
M;?\ /M#_ -\"@ ^V6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_ 'P*/L=M_P ^
MT/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV*/L=M_S[0_\ ? H^QVW_ #[0_P#?
M H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW_/M#_P!\"C[';?\ /M#_ -\"@ ^V
M6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_ 'P*/L=M_P ^T/\ WP* #[9;?\_,
M/_?8H^V6W_/S#_WV*/L=M_S[0_\ ? H^QVW_ #[0_P#? H /MEM_S\P_]]BC
M[9;?\_,/_?8H^QVW_/M#_P!\"C[';?\ /M#_ -\"@ ^V6W_/S#_WV*/MEM_S
M\P_]]BC[';?\^T/_ 'P*/L=M_P ^T/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV
M*/L=M_S[0_\ ? H^QVW_ #[0_P#? H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW
M_/M#_P!\"C[';?\ /M#_ -\"@ ^V6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_
M 'P*/L=M_P ^T/\ WP* #[9;?\_,/_?8H^V6W_/S#_WV*/L=M_S[0_\ ? H^
MQVW_ #[0_P#? H /MEM_S\P_]]BC[9;?\_,/_?8H^QVW_/M#_P!\"C[';?\
M/M#_ -\"@ ^V6W_/S#_WV*/MEM_S\P_]]BC[';?\^T/_ 'P*/L=M_P ^T/\
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M_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H
M/.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/
M.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)
MB_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B
M_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H
M/.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/
M.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)
MB_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B
M_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H
M/.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/
M.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)
MB_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B
M_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H
M/.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/
M.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)
MB_YYI_WR*/)B_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B
M_P">:?\ ?(H /.B_YZ)_WT*/.B_YZ)_WT*/)B_YYI_WR*/)B_P">:?\ ?(H
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MNV\IKA$+B!@ .<=/NC\SZ&@#HM#\6KJ>K3:/?Z?-INJPKO-O(X=67U5AP?\
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M0&DC5LE >F?3I0!8HK%TCQ-9:UJNI:=;17"S:?)Y<K2* K')'RX)]#UQ6U0
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M:YI=RMPT.H6SBW_UQ$@^3Z^E1V6O6&HWTEI:2-*\2@NRH=JYZ GUH TZ***
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MNL6GS>7"8U(9AN8?-DGT'3%:/ANYU^YLYF\06-O:7 E(C6!@0R8')^9N<YH
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M_(4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 8U%%% !1110
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M 'F5%%%?6GYF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLV?_ )_/_(0_QH_LV?\ Y_/_ "$/\:** #^S9_\ G\_\A#_&C^S9_P#G\_\
M(0_QHHH /[-G_P"?S_R$/\:/[-G_ .?S_P A#_&BB@ _LV?_ )_/_(0_QH_L
MV?\ Y_/_ "$/\:** #^S9_\ G\_\A#_&C^S9_P#G\_\ (0_QHHH /[-G_P"?
MS_R$/\:/[-G_ .?S_P A#_&BB@ _LV?_ )_/_(0_QH_LV?\ Y_/_ "$/\:**
M #^S9_\ G\_\A#_&C^S9_P#G\_\ (0_QHHH /[-G_P"?S_R$/\:/[-G_ .?S
M_P A#_&BB@ _LV?_ )_/_(0_QH_LV?\ Y_/_ "$/\:** #^S9_\ G\_\A#_&
MC^S9_P#G\_\ (0_QHHH /[-G_P"?S_R$/\:/[-G_ .?S_P A#_&BB@ _LV?_
J )_/_(0_QH_LV?\ Y_/_ "$/\:** )K2RGBNXW-UN /(\L#-%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gbn5n5jlnzog000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbn5n5jlnzog000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (9!$L# 2(  A$! Q$!_\0
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MG??\+<U__GTTW_OU)_\ %T?\+<U__GTTW_OU)_\ %UP-%'U2C_*'MI]SOO\
MA;FO_P#/IIO_ 'ZD_P#BZ/\ A;FO_P#/IIO_ 'ZD_P#BZX&BCZI1_E#VT^YW
MW_"W-?\ ^?33?^_4G_Q='_"W-?\ ^?33?^_4G_Q=<#11]4H_RA[:?<[[_A;F
MO_\ /IIO_?J3_P"+H_X6YK__ #Z:;_WZD_\ BZX&BCZI1_E#VT^YWW_"W-?_
M .?33?\ OU)_\71_PMS7_P#GTTW_ +]2?_%UP-%'U2C_ "A[:?<[[_A;FO\
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M_P"?33?^_4G_ ,77E=%'L:/\@<\^YZI_PMS7_P#GTTW_ +]2?_%T?\+<U_\
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MGE_;["ZM/,R4\^%H]V.N,CGJ*%),+,J4444Q!1110!IQ?ZE/]T4^F1?ZE/\
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MRGW!J_%_J4_W17C9U_#AZGDYK\$?4],^-'_(G6G_ &$$_P#1<E>%5[K\:/\
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M%\.L]?./_H-<#=^+_%-YI[:=+KLYM&0(R[%#E1V+@;CGOD\\YSFH5\0ZTO\
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MY4>5)_SS;\J+,!E%/\J3_GFWY4>5)_SS;\J+,!F >U%/\J3_ )YM^5'E2?\
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MH_X1K7/^@1>_]^6_PH]I#N'*^QE45J_\(UKG_0(O?^_+?X4?\(UKG_0(O?\
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M%[_WY;_"CVD.X<K[&54UM_Q\+^/\JO\ _"-:Y_T"+W_ORW^%2VWAK7/M"_\
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M*** "BBB@ HHHH K7W^H7_>_H:SZT+[_ %"_[W]#6?0 4444 %%%% !1110
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M*V/_ ($)_C7B%%']F0_F#ZT^Q[?_ &[H_P#T%;'_ ,"$_P :/[=T?_H*V/\
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M_;NC_P#05L?_  (3_&O$**/[,A_,'UI]CV_^W='_ .@K8_\ @0G^-']NZ/\
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M[/8P^8ZKZD9'O0!T-! (((R#U!KCO WB*Z\07FO/+=>?:PW96T_=A-L1+8[
M] .O-5/&'B#7$\3V/AW1;NTT^6>,2_:;K&')+ (,@CDCL,DX]\@':VEE:6$'
MD6=K#;0YSY<,81<^N!4]<7X=UGQ%8R:I:>*H"Z6,)N%OXXL1R*!D@$ *3CZ'
M@YK&L[_X@^*X9-5TFZL]-L'8BWAE5274$\Y*-D]LG ]!0!Z+:Z?96,<D=I:6
M]NDC%G6*,(&)ZD@#DU1_X1;P]_T =+_\ X_\*YW2-?U[Q+X>U.Q@$.G>)+&5
M8G9QF,?-UQANH5AT(SR.O'/6UW\1+KQ->Z#'K]D+JSC621VA3800I&#Y6<_,
M.U 'H\OA[1)DB271]/D6)=D:O;(0BYS@<<#)-6++3;#349+&RMK57.6$$2H&
M/O@5)9K<)96ZW;K)<K&HE=>C/CDC@<9SVJ:@"*XMX+N!X+F&.:%QAHY%#*WU
M!X--^Q6ILOL1MH?LNS9Y'EC9M]-O3'M4]% %6TTVPL('AL[*VMHG.72&)45C
MC'( YXJ/^Q=*^R):?V99?9HW\Q(?(78K_P!X+C /)YJ]10!5O=-L-214OK*V
MNE0Y43Q*X4^V14HMX!:_9A#']GV>7Y6T;-N,;<=,8XQ4M% %(Z-I;6*V+:;9
MFS5MRVY@7RP?7;C&>34LMA9SR0236D$CVYS SQ@F(\<J3TZ#IZ58HH K1Z?9
M0M<-%9VZ-<G,Y6)09>OWN/FZGKZUBZ_H%W/H0L/#SV-B ^6MY+5&@E4GD,-I
MQZY _P 1T=% '%:'X3U.+Q'!J^J_V5 MG 8;6UTR)EC&XL6)W8Q]X].N>W?M
M:** "BBB@ K,N_\ CY?\/Y5IUF7?_'R_X?RH AHHHH *X3QFL[^)=)6VMH;J
M8HVV&8 HYST.2!7=USVO^&I=:O;:[AU%[.2!2JLB$GGN"&&*Z,-.,*EY>9G5
MBY1LBKH%KJL>J*]]X?TNRB"'$UO&@<'TR&)]:Y?0K?59;29K'0=-OXO/8&6Y
M12P/''+#CI^==?I?AS4K#4HKFX\0W=W$F=T$@;:V01W<],YZ=JSX? ]_;!EM
M?$ES!&S%BD4;*,GZ/75&M33E[RUMT=NOS,7"6FC_  ,[2=-CO_"&L6(C9;^*
M8R21%<!''0+^ (_&D?43XDL?#VCALL[9N@!R G&?Q 8UU^@:#%H5K(@F>>>9
M]\LSC!8]N/\ /4U4T7PG!HVL7-^D_F>:&$<93'E@G/7//IVI/$PYI.^VJ];6
M'[*5DOO.A "J%4  #  [4M%%><=(4444 9^N_P#(O:G_ ->DO_H!KQ"O;]=_
MY%[4_P#KTE_] ->(5[.6?!(XL5N@HHHKTSE"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHIR;2ZAR0N?F(&2!]*0'JGAI+[PUX#M;ZST^ZN;N_NTDD2
M"(NPA!]NQ53C_?K+\6Z0--^)>GW,:;8+ZYBF7C'S[P&'USS_ ,"J+6OB1=B2
MUM_#4DMC800+'LE@C+$CCONXQC]:9>^.+/5]*T<ZG'</JUA=+,\R1(%= W('
M(P2 O;&17G0IUE/VC6]_77;[CI<H-<M]BO\ %#_D=9O^N,?\JTO"O_)+O$O^
M\?\ T%:FU3Q7X"UF]:\U#1=2FN&4*7SMX'3@2@57TCQ=X5TZTU;3GTZ_.FWD
MVZ.%<$A-H!!)?.<@]Z?ONC&'*[JWX![O.Y76MSB]$_Y#VG?]?4?_ *$*]?\
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M/J:\G,94W9?:.S#*6_0W****\DZPHHHH **** "BBB@ HHHH **** "BBB@
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M7XT6 0/'\GF#CH#N]]N,]L]Z]0HJ!F>DMS/X?\Z]@6WN7MBTL*MN",5Y&?\
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ML=0>?6/$&HVIM7U68/% V0RH"W)'OGC/7&>AJ+1O^2R^(_\ KTB_]!BKO:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S+O_ (^7_#^5:=9E
MW_Q\O^'\J (:*** "BBB@ HHHH **** "BBB@ HHHH HZU&\NA:A'&C.[VTB
MJJC))*G  KR'_A'-<_Z NH_^ K_X5[96S77A\7*@FDKW,:E%5'=L^>O^$<US
M_H"ZC_X"O_A1_P (YKG_ $!=1_\  5_\*^A:*Z/[3G_*9_55W/GK_A'-<_Z
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MOO\ P'?_  KV^BC^TY_RA]57<\0_L+6/^@5??^ [_P"%']A:Q_T"K[_P'?\
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M?\(YKG_0%U'_ ,!7_P */^$<US_H"ZC_ . K_P"%?0M%']IS_E#ZJNY\]?\
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M]&H&7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
MOHT 7**I[M0_YY6__?1HW:A_SRM_^^C0!<HJGNU#_GE;_P#?1HW:A_SRM_\
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MC>C8.TD[/KW- 'J]%8?AFU\0VMG,OB*_M[RX,F8V@4 *N.APJ]\UN4 %%%%
M!1110 4444 %%%% !69=_P#'R_X?RK3K,N_^/E_P_E0!#1110 4444 %%%%
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M[+_O_A_P0^M>1]'V/^H;_>_H*LU\ST4?V7_?_#_@A]:\CZ8HKYGHH_LO^_\
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MLG<KL"L8+;B%P 0,XZD]!6S=6=K?1K'=VT-Q&K!PLL8<!AT.#WJ>B@ HHHH
M**** "BBB@ HHHH **** "LR[_X^7_#^5:=9EW_Q\O\ A_*@"&BBB@ KS[Q_
M]E_MO3?MOG?9_+;S/)QOQGMGBO0:Y/Q-I^L2ZYI^H:5:).ULI^^Z@9/J"0:Z
M<))1JW;[^1E65X6,CPC'X>?7XVT[^U/M"(S#[1Y>S&,'[O/>N:M/[!VR_P!I
M_P!I>?YK8^S>7MV]OO<YZUZ)I=YXKEU*)-2TRTALSGS)(V!8<''\9[X[5B:3
M;^,-$MY;:TTFV>-Y6DS+(I.3@=G'I7=&K[TFVKZ?:7GU,'#1:=^A2MK&74/
M%S()C)]EG,MLNX%XU'4''3C)Q[ UIZ[JKZUX>T>S@;]_J;J'P>FTX;\-W\JU
M?"VBW=C;7TNI)&LU](6>!,;5'/'''.3P.V*S/#7A6]T_Q!)/>I_HUL'6U.\'
M=D]<9R.">OK6;JTW*3;^%W7W?YE*$K)=SL[>!+:VB@B&(XD"*/0 8%2445YC
M=SJ"BBB@#/UW_D7M3_Z])?\ T UXA7M^N_\ (O:G_P!>DO\ Z :\0KV<L^"1
MQ8K=!1117IG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 /BED@F26)VCD1@RNIP5(Z$&O9/!7
MC1-?A%E>E4U*-?H)@.X]_4?B/;Q^RLKC4+R.TM(FEGD.%1>__P!:O;?"7A*W
M\-V>YMLM_(/WLV.G^ROM_.O.S!TN2TM^ATX92YM-CI****\0[@HHHH ****
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MRZM$FLU4(L;Y.T 8&#U! [YS571?"NB>'I99=+L$@DE7:S[V=L>@+$D#V'7
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M??\ @._^%']A:Q_T"K[_ ,!W_P *]OHH_M.?\H?55W/$/["UC_H%7W_@._\
MA1_86L?] J^_\!W_ ,*]OHH_M.?\H?55W/$/["UC_H%7W_@._P#A1_86L?\
M0*OO_ =_\*]OHH_M.?\ *'U5=SQ)?#VML,KH^H$>UL_^%+_PCFN?] 74?_ 5
M_P#"O?+'_4-_O?T%6:/[3G_*'U5=SYZ_X1S7/^@+J/\ X"O_ (4?\(YKG_0%
MU'_P%?\ PKZ%HH_M.?\ *'U5=SYZ_P"$<US_ * NH_\ @*_^%/B\,:]+*D:Z
M/?@L0 7MV4#ZDC %?05%']IS_E0?58]SF_"7A*W\-V>YMLM_(/WLV.G^ROM_
M.NDHHKSYSE.7-+<Z8Q459!1114#"BBB@ HHHH QJ*** "BBB@ HHHH ****
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MSN/'.P#M6U69=_\ 'R_X?RH I^7-_P ]_P#QP4>7-_SW_P#'!4U% $/ES?\
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MQDUI!=-$2MX5&[IY8-3_ &>\_P"?\_\ ?I:?8_ZAO][^@JS2 I_9[S_G_/\
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M** "BBB@ HHHH ^A?#G_ "*^D_\ 7E#_ .@"O']/TNZ^S:OXBTS/]H:3J;R
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M#H* /&8I9$^%<\"NRVQUWRI<$\1; ?RW8KI?$.FZ-IWCSP@NE0V\+.^72
MID;&..N?FY[X]JZ?5/#:Z?X5O=/\.Z99R_:)#)+:W;NR2Y !P2P(;A<'( QV
MZUS6C>#[Y_$&D7#>'+?0[33V::5ENQ.\[D# !R2 "HX)XR: .;TS2=1UW1M;
MFF_X1Y&:[875UJ+.MQ V1T;HJYX'KR*W[Y)M2UW1=%,.E7>HQ:8&EU"\+31%
M2/O1ID*QQ\V6!S[8KL[WP1X;U'4CJ%UI44ERS!F;>P#$=RH.T^^1SWJ?5_">
MAZZ\#ZCIT<S0+LC(9D(7T^4C(]CTY]: /)+7Y?A9XDB642QIJ*!6484_,G(
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M5VMM?Z<DSV\5_K$D,MXQXB7CY1Z$_P"- 'K59EW_ ,?+_A_*K=E9Q:?90VD
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MV?YC59VO8[Z.1)8UDC=71P&5E.00>A!IU-CC6*-8T4*B *H'8"G5Q&X4444
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M]?'_ /%5'_PA/B+_ *!__D:/_P"*H^L4OYE]Z#V<^S.?HKH/^$)\1?\ 0/\
M_(T?_P 51_PA/B+_ *!__D:/_P"*H^L4OYE]Z#V<^S.?HKH/^$)\1?\ 0/\
M_(T?_P 51_PA/B+_ *!__D:/_P"*H^L4OYE]Z#V<^S.?HKH/^$)\1?\ 0/\
M_(T?_P 51_PA/B+_ *!__D:/_P"*H^L4OYE]Z#V<^S.?HKH/^$)\1?\ 0/\
M_(T?_P 51_PA/B+_ *!__D:/_P"*H^L4OYE]Z#V<^S.?HKH/^$)\1?\ 0/\
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MQ_X!G]5?<Y2BNK_X2"X_Y];#_P !4_PH_P"$@N/^?6P_\!4_PHYZG\OX_P#
M#ZJ^YRE%=7_PD%Q_SZV'_@*G^%'_  D%Q_SZV'_@*G^%'/4_E_'_ ( ?57W.
M4HKJ_P#A(+C_ )];#_P%3_"C_A(+C_GUL/\ P%3_  HYZG\OX_\  #ZJ^YRE
M%=7_ ,)!<?\ /K8?^ J?X4?\)!<?\^MA_P" J?X4<]3^7\?^ 'U5]SE**ZO_
M (2"X_Y];#_P%3_"C_A(+C_GUL/_  %3_"CGJ?R_C_P ^JON<I175_\ "07'
M_/K8?^ J?X4?\)!<?\^MA_X"I_A1SU/Y?Q_X ?57W.4HKJ_^$@N/^?6P_P#
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M1U)(KC 8QJCN5!Z9V@X_&@#=HJO97MKJ5E%>6<Z3V\HW)(AR#_\ 7[8[58H
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M7G_?"_\ Q5'_  G>E_\ /"\_[X7_ .*KG]#\%:MKUF;NW\B* G"/.Y&_J#C
M)XQWJEK'AW4=#OX[.ZAW/+_JFBRRR=OE[YSVQG\Q0L+AG+E3U]0.M_X3O2_^
M>%Y_WPO_ ,51_P )WI?_ #PO/^^%_P#BJXK5-*NM&O!:7BJLVQ7*JV=N1T/O
M5*K6!H-70'H7_"=Z7_SPO/\ OA?_ (JC_A.]+_YX7G_?"_\ Q5>>UK:YX>N]
M :V%U) _VA-Z>4Q.![Y I/!4$TGU ZS_ (3O2_\ GA>?]\+_ /%4?\)WI?\
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MY5A^.17L^F61T[3H;0W-Q=&,8,UQ(7D<YR22?K7,OX#263Q(SW^1K.,#R?\
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MLQ'"CT'J:]@T_3[;2[*.TM(PD2#@=R?4^IKS\=6@H^SW?Y 6J***\<84444
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M>SQ-" )4/S=F%4?,3^^OYT?7ZP'G_P#P@FJ?\][/_OMO_B:/^$$U3_GO9_\
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M8?\ PFFG?\\;K_OA?_BJ/^$TT[_GC=?]\+_\51]4K_RL/[3PG_/Q&Y]BM?\
MGWB_[X%'V*U_Y]XO^^!6'_PFFG?\\;K_ +X7_P"*H_X333O^>-U_WPO_ ,51
M]4K_ ,K#^T\)_P _$;GV*U_Y]XO^^!1]BM?^?>+_ +X%8?\ PFFG?\\;K_OA
M?_BJ/^$TT[_GC=?]\+_\51]4K_RL/[3PG_/Q&Y]BM?\ GWB_[X%'V*U_Y]XO
M^^!6'_PFFG?\\;K_ +X7_P"*H_X333O^>-U_WPO_ ,51]4K_ ,K#^T\)_P _
M$;GV*U_Y]XO^^!1]BM?^?>+_ +X%8?\ PFFG?\\;K_OA?_BJ/^$TT[_GC=?]
M\+_\51]4K_RL/[3PG_/Q&I>6MND(*P1@[NRBJ7DQ?\\T_P"^:I7/B_3YHPJP
MW((.>57_ .*JM_PDUE_SRN/^^1_C1]4K_P K#^T\)_S\1K>3%_SS3_OFCR8O
M^>:?]\UD_P#"367_ #RN/^^1_C1_PDUE_P \KC_OD?XT?5*_\K#^T\)_S\1K
M>3%_SS3_ +YH\F+_ )YI_P!\UD_\)-9?\\KC_OD?XT?\)-9?\\KC_OD?XT?5
M*_\ *P_M/"?\_$:WDQ?\\T_[YH\F+_GFG_?--M[B*YA66)@R-T-2USM-.S.V
M,E)76PSR8O\ GFG_ 'S1Y,7_ #S3_OFGT4AC/)B_YYI_WS1Y,7_/-/\ OFGT
M4 ,\F+_GFG_?-'DQ?\\T_P"^:?10!:L[6W>$EH(R=W=15C[%:_\ /O%_WP*;
M8_ZAO][^@JS0!!]BM?\ GWB_[X%'V*U_Y]XO^^!4]% $'V*U_P"?>+_O@4?8
MK7_GWB_[X%3T4 0?8K7_ )]XO^^!1]BM?^?>+_O@5/10!!]BM?\ GWB_[X%'
MV*U_Y]XO^^!4]% $'V*U_P"?>+_O@4?8K7_GWB_[X%3T4 0?8K7_ )]XO^^!
M1]BM?^?>+_O@5/10!A^3%_SS3_OFCR8O^>:?]\T^B@!GDQ?\\T_[YH\F+_GF
MG_?-/HH 9Y,7_/-/^^:/)B_YYI_WS3Z* &>3%_SS3_OFCR8O^>:?]\T^B@!G
MDQ?\\T_[YH\F+_GFG_?-/HH 9Y,7_/-/^^:/)B_YYI_WS3Z* &>3%_SS3_OF
MI;:WA:X4-$A'/!4>E-J:T_X^4_'^5 %S[%:_\^\7_? H^Q6O_/O%_P!\"IZ*
M (/L5K_S[Q?]\"C[%:_\^\7_ 'P*GHH @^Q6O_/O%_WP*/L5K_S[Q?\ ? J>
MB@"#[%:_\^\7_? H^Q6O_/O%_P!\"IZ* (/L5K_S[Q?]\"C[%:_\^\7_ 'P*
MGHH @^Q6O_/O%_WP*/L5K_S[Q?\ ? J>B@"#[%:_\^\7_? H^Q6O_/O%_P!\
M"IZ* (/L5K_S[Q?]\"O$]< 7Q!J2J  +J4 #M\YKW.O#=>_Y&+4_^ON7_P!#
M-85]D>!G_P##AZGJ_CO_ ) </_7RO_H+5Y[7H7CO_D!P_P#7RO\ Z"U>>U]-
MEW\#YGE9Y_O;]$/BC>:5(HUW.[!5'J3TJUJ&E7NEM&+V'RC("4^93G'7H3ZB
MM7P;8_:=9^T,I,=JN\\9^8\#^I_"K=Z;_7?!]Q>7UG<6UU:7+S1I/&48Q9)Q
M@^BG_P =JJN*Y*RATZ_,C#Y<JN&E5=^;6W;3?_@&3!X8UBY@CGBL]T<BAE;S
M4&0?QJ*^T'4]-M_M%W;>7%D+N\Q3R?H:O^#IKN3Q)"'U"[> 1,!;M,QC'''R
MYQ6;;6E[KOBN6UN=1O9K87\A,#SL8U57/;.!P,"I=>M&HXRM9:_+[RXX3"SH
M1G#FYI.RVW^[8+G1=0L[)+RXMBD#XPQ8=^F1G(_&H+.QNM0G\FTA:63&2!V'
MN>U=S*UYKEWKVD3V<T-HJ*MG,\+!6=1R<G@_-C&.PKA;:YU:..2TTV>2WFN/
MW4@5 6/48&1D'D]*=#$SJPEHN9?<+%X"EAZL-6X/3SNB>_T;4-,57O+9HU8X
M#9##/U!-3Q>&M8G@$R6+[",C+*"1]"<U;U>)?"O@>WT:6<RW]W.KHA;=LPP+
M=>W&/JU/\/V.JZOKL6OZIJ#FVLE(1FPB@<Y'&!CU/M4?6JCIN:MI^/H:_P!G
M4575)\VJ3MI==[NW3T,RRT34=1\W[+;%_*;:X+*I4^F"13[SP]JFGVK7-U:^
M7"N 6\Q3C)P.AJE<^3XM\0W/D*3!<76V$],C@;OH<$U<\63H-1MO#FGYBT_2
MT4R*O\<A&1GUP#GZDUI[>JYQ2MKK;M^)BL)AU2J2DW[NE[JS?32WWZD%GIEY
M?QS26T!=(1ND;<  /Q-5*[;1]9CU#3=9M+6P%K:6MK\A/WI&*MN)_(5P=I_Q
MZ1?[HJZ%>52<HR5K&.+PE.C2ISA*_-?TT[$U%%%=)YX4444 %%%% 'IUA*(=
M M92CN$M4;:B[F.%' '<^U<@^D:];Z-#K :%[R*Y_M,VB6C>>6?AXM^_GY"5
MQM_A ]Z[+2O^0/8_]>\?_H(K)U+QUX:TF]>SO=41+B/[Z+&[[3Z$J",^U?*U
M/C9^CT/X4?1&%K*7(M?$EHFGWTLE_/%/;F.U=E=-D8.6QA2-C9!P?8U9U*SN
M7U#6O]#N)8A?VEXT8A8B>%$C#!3C:Q!4G;G)V].E=E#/%<P)/!*DL3C<DD;!
ME8>H(ZU)4&IPVHVUSJ#ZQ?6MG=+;W$U@J*\#(\K1S*7?8P# !2!DC^'T%(;2
MY.GMHXL;G^TSJQN1<^4WE[?.\SS?-QM_U?RXSN[8K>_X3#0?[,N=1^W?Z);3
M>1-)Y+_*_'&-N3U'(&*VHY$FB26,Y1U#*<=0: //YU^R0:;IMS87'VZ/7EF>
M<P'RVW3%@XDQAB58#&=PY!&!5F2TN38W6D"QN3J4NK&YCN/)81A?-#B7S<;1
MA!MQG=QMQ6MIMOX;N-;NX;'<]Y8S>9-"7E\N*1L_,$8[-W7E1W/K6W<7UK:3
MV\,\Z)+<OLA0GESC)P* .)O8KI8;G3A87K3MKJ70*6[M&8C*C;]X&W&.HSD<
MY& 35J.*>#7XX[*WO)(GOWEFM;ZQW1Q%B2T\4X&!P3@%F/S8P*[2B@##UV*:
M*_TO5(K>6XCLY'$T<2[G".A7<%ZM@XX'."<57O\ 7K^:UO?[,TJ\95AV132P
MO$QF8X4!&7<5&<EC@#'?MTE% '&0Z/J?A[4=%N$DBN[>)/L$RVUHZOY;<AV^
M=\X< DX'WFJHNC:P/![>7<WY3SYFN-,*(GFPF5]R*=F\%AR#DYS@=1COJ* (
M+-XY+*%H8WBB*#9&\91E&. 5/(^E9GA^"6&36#+$\?F:C(Z;U(W*57!'J/>M
MJJ3ZAC6(M.CC#N83-*Q;'EKG"]N2QSZ<*?8$ NT5D:3K\6KZGJ=I!$1'9,B"
M;=Q*2#D@8Z @C/>B'5+ZZUF[M+:QMVM;25(I9Y+EE8DHKG:H0@X##JPH UZ*
MS-2U26UO+2QL[9+B\N0[*LDOEHJ(!N9F"L>I4#@\FBWU65KVVM+VR-I+<P&6
M,&0/\RGYT...,J0<\C/3% &G1110 4444 %%%% !6;;C[9J4UPW*0G9&/?N:
MTJXK41?-!9&T^U>7YLOG>0)#V&,["#6-2//4A%[:O[MC.;U2.UKCM2O57Q0M
MP-.$EI;.L<\WV0-ECU;?C(V?+^OI3'/B.;1]/MH(;P7,:--+*7"$L&(C5BQY
M!ZD=<8S5_P O4;J_M@LMS!97BB>X1LAX&7&8P?X0V?T..M=*5AMW.EK*U=3;
M/#J,8PT;!9,=U/\ G]:P=,&H_P!O3_:/MNWSI]@<3;=OS;>^S&,8J#3[?5K>
MRG_M-KCRY+%6 =W<%\C.[<?E8>@ZY]J<*:E+E?4QQ$OW3:W6OW'<J0RAAT(R
M*S;O_CY?\/Y5;L23I]L3U,2Y_(54N_\ CY?\/Y5FTT[,WC+FBF8UKX@TN]U!
M["WNM]TA8,FQATZ\D8I7U_2X]5&F-=#[86"B,(QY(R!G&/UKSRQ?[#XANM6+
M;4@U(12'T1S(&/Z4ZS+7/BK3-2=<&]NWE7_=#8 _0UZ3P<$WJ[6_'<P5:5OZ
MV/4Z*\R35]6U.&XU"!M;-UYO^CK:Q[K90".&'<X_IG-:6O:AJ?FZ?=7BZG:Z
M:UL'G^PY1TD/4,3TYQP?7UK%X.2DHME^V5KV.[HKAU\0R6?@N:YM-2>^F601
MI)-%MDAW<X;).XCGGI^5+<'4/#<FDW9U2ZO$NG6.XBG?>IR.J^G^>U3]5E>U
M_3SL/VJ.N:_M5FGB,RF2W022J.2BGIG\NE%C?VVIVBW5G+YD+$@-M(S@X/!Y
MKA-'L-FM^(C]KNF^S*X^:3/FY#CY_P"]CJ/>J=LE[8^"8=6M]3NHGBGQ'"CX
MCV[NZ]SG/7MQ6CPD=E+73\41[9[M=SU"JNH:E::7:_:;V7RH=P7=M+<GV -<
M;JNLW5]KL=GNU1;:.V25DTM?WC,P!R3V7YJI:I=:E/X'FCU**Y5X;I%C>XC*
M.Z8XSGJ?>IAA&W'F>]OQ'*MO8[U=5LGU+^SUFS=&/S/+V-]WUSC%7*XXWET/
M&4EN+F80#3]XC#G:&V]<=,UB0MJ;^"Y=:;6K_P Z"4!$$QVD;E'S=R<GO0L+
M>VMKV_$?M;=._P"!Z'J'_(-NO^N+_P C7"5V?G-<^'//?[TMIO;CN4S7&5W9
M8K1DO,^:X@UJ0] HHHKTSYX**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"]INI2Z?-D9:)OOIZ^_UKL;>XBN85EB8,C=#7 5L^'3=_:R(O\ 4?\
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M"H.#AASDCCFL>U!6UB!&"%&14M%.--1FYKJ3.O*=*-)[1O;YA1116A@%%%%
M!1110!ZCI7_('L?^O>/_ -!%>5PZ//8'6)H- T[Q3IES([K>6TR-,A;^$'YC
MD YPHZG.:]4TK_D#V/\ U[Q_^@BN+NOAI,E]<RZ)XDO=*M[AM[V\08C<?<.O
M'L<_6OE:GQL_1Z'\*/HC)_M^+2OAS96_AJ>[C:XO39[[O:9+9B2S#@ =^/9L
M\&M5O[1\'>+M$L_[8OM2L=5W12I>R>8RNN/F4G[H^<<>QSGC&HOP^TI?"(T
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M[?,)0_E?ZLAB?7GK[5*OA-(Y=&=+L@::N"/+_P!:<Y)Z\<Y]:Z.BMOK%7O\
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M )[77_?:_P#Q-=F"Q4*2?/U/%S;+ZV*G%TNB.%HKNO\ A"]._P">UU_WVO\
M\31_PA>G?\]KK_OM?_B:[?[1H>9Y']AXOLOO.%HKNO\ A"]._P">UU_WVO\
M\31_PA>G?\]KK_OM?_B:/[1H>8?V'B^R^\X6BNZ_X0O3O^>UU_WVO_Q-'_"%
MZ=_SVNO^^U_^)H_M&AYA_8>+[+[SA:*[K_A"]._Y[77_ 'VO_P 31_PA>G?\
M]KK_ +[7_P")H_M&AYA_8>+[+[SA:*[K_A"]._Y[77_?:_\ Q-'_  A>G?\
M/:Z_[[7_ .)H_M&AYA_8>+[+[SA:*[K_ (0O3O\ GM=?]]K_ /$T?\(7IW_/
M:Z_[[7_XFC^T:'F']AXOLOO.%HKM+GPAI\,899KDDG'++_\ $U6_X1FR_P">
MMQ_WT/\ "C^T:'F']AXOLOO.4HKJ_P#A&;+_ )ZW'_?0_P */^$9LO\ GK<?
M]]#_  H_M&AYA_8>+[+[SE**ZO\ X1FR_P">MQ_WT/\ "C_A&;+_ )ZW'_?0
M_P */[1H>8?V'B^R^\P=.TZ74)]J_+&OWW]/_KUV5O;Q6L"PPKM1?UHM[>*U
M@6&%=J+^M2UY>*Q4J\O(^BR[+H82%WK)[O\ 1!1117(>D%%%% !1110!H6/^
MH;_>_H*LU6L?]0W^]_059H **** "BBB@ HHHH **** "BBB@ HHHH QJ***
M "BBB@ HHHH **** "BBB@ HHHH *FM/^/E/Q_E4-36G_'RGX_RH TZ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "O#=>_P"1BU/_ *^Y?_0S7N5>&Z]_
MR,6I_P#7W+_Z&:PK[(\#/_X</4]7\=_\@.'_ *^5_P#06KSVO2?&-PMMI4$C
M013C[0!LE!(^ZU<7_;,7_0)T_P#[]G_&OH\!*2HZ*YP9S"$L4W*5M%T9E45J
M_P!LQ?\ 0)T__OV?\:/[9B_Z!.G_ /?L_P"-=G//^7\4>5[*E_S\_!F516K_
M &S%_P! G3_^_9_QH_MF+_H$Z?\ ]^S_ (T<\_Y?Q0>RI?\ /S\&95%:O]LQ
M?] G3_\ OV?\:/[9B_Z!.G_]^S_C1SS_ )?Q0>RI?\_/P9E45J_VS%_T"=/_
M ._9_P :/[9B_P"@3I__ '[/^-'//^7\4'LJ7_/S\&95%:O]LQ?] G3_ /OV
M?\:/[9B_Z!.G_P#?L_XT<\_Y?Q0>RI?\_/P9E45J_P!LQ?\ 0)T__OV?\:/[
M9B_Z!.G_ /?L_P"-'//^7\4'LJ7_ #\_!F516K_;,7_0)T__ +]G_&C^V8O^
M@3I__?L_XT<\_P"7\4'LJ7_/S\&95%:O]LQ?] G3_P#OV?\ &C^V8O\ H$Z?
M_P!^S_C1SS_E_%![*E_S\_!F516K_;,7_0)T_P#[]G_&C^V8O^@3I_\ W[/^
M-'//^7\4'LJ7_/S\&=YI7_('L?\ KWC_ /015RLRQMFFT^VE%Q-&'B5@B$!5
MR!P/858^Q/\ \_ES_P!]#_"OFI_$S[^C_#CZ(MT54^Q/_P _ES_WT/\ "C[$
M_P#S^7/_ 'T/\*@T+=%5/L3_ //Y<_\ ?0_PH^Q/_P _ES_WT/\ "@"W153[
M$_\ S^7/_?0_PH^Q/_S^7/\ WT/\* +=%5/L3_\ /Y<_]]#_  H^Q/\ \_ES
M_P!]#_"@"W153[$__/Y<_P#?0_PH^Q/_ ,_ES_WT/\* +=%5/L3_ //Y<_\
M?0_PH^Q/_P _ES_WT/\ "@"W153[$_\ S^7/_?0_PH^Q/_S^7/\ WT/\* +=
M%5/L3_\ /Y<_]]#_  H^Q/\ \_ES_P!]#_"@"W153[$__/Y<_P#?0_PH^Q/_
M ,_ES_WT/\* +=%5/L3_ //Y<_\ ?0_PH^Q/_P _ES_WT/\ "@"W153[$_\
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M>TGYT>0?^>TGYT 345#Y!_Y[2?G1Y!_Y[2?G0!-14/D'_GM)^='D'_GM)^=
M$U%0^0?^>TGYT>0?^>TGYT 345#Y!_Y[2?G1Y!_Y[2?G0!K6/^H;_>_H*LUF
M6EHSQ$BZG7YN@8?X58^Q/_S^7/\ WT/\* +=%5/L3_\ /Y<_]]#_  H^Q/\
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M7QB:%)5ZK_"X(_2NLO-9UO4?$6G^'=&O8M/VV*W-S<F!7/(^ZJGC'*^G7VY
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MO'U[5C:M;B^GTVW:T9V)C&#)G!QR Q!Z<Y'% &M8ZS::CJ.H65N6:2Q94E;
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M@U>\'B>2Q:^V01W0B2'=&N5P.-I7)_ BF6&I:O<WWE7LC_9)UN0/,5-K!20
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M\[RO]K/W<_UK3ZS"Z;?\O3RU)]E*VW<R-5UFZOM=CL]VJ+;1VR2LFEK^\9F
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M76WY1-C'3KMQQ]>?:K5GX:US4?$-CJWB6[L7_LY2+:"R5MK.>KL6Q@_=X''
MZ8Y[*BH-3SD^ -5_X1#5M(^T6?VB\O\ [3&V]MH7(X)VYSQZ5I:CX5U:'6[#
M7-#N+)+Z&U%M/%=AO*D &,Y49ST].@]P>THH Y#PEX9U71=:UC4-3N[:X>_9
M&#0[@<@L3D$<#GCD]*=XH\.:KJ&O:5K.CS62W-B&&R[W;&S_ +O/KQQ76T4
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M **** -"Q_U#?[W]!5FJMC_J&_WOZ"K5 !1110 4444 %%%% !1110 4444
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M^?C^]FK_ ,)'J_\ S^M_WRO^%'_"1ZO_ ,_K?]\K_A6511["E_*ON#ZYB/\
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M =5+J PY'(SUJO8^*K>XAFGNHQ:PPV5M=LY?=_K@V%  R2"H QR21@4 :O\
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M2A;VX;MQ4GAWQ+IWBC3VN]/=\(VR2*48=#[C)ZCN"1^(-;%0:G(:+I&HV[Z
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M*** "IK3_CY3\?Y5#4UI_P ?*?C_ "H TZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "O#=>_Y&+4_P#K[E_]#->Y5X;KW_(Q:G_U]R_^AFL*^R/ S_\
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M4_'^50U-:?\ 'RGX_P J -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^^C1]HG_P">TG_?1HM5[K[O^"%\/VE]Z_R/1M/NH(--M899522.%%=2>00
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M9GD\QH?LZ[&?^\1C!/O0!PKW-KIGQ9ANM6DBA@DTP"UFG8*B-@9PQX!^^/\
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M5EZ/KD&KQMM'E3+]Z(MGCU![BM2N:<)0ERR5F=]*K"K!3INZ84445)H%%%%
M%:^_U"_[W]#6?6A??ZA?][^AK/H **** "BBB@ HHHH **** "BBB@ HHHH
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M9+.]:!0DA0OAE4 ]@"3R<9JW>V^B69T:?^S)7_M/:@M_M!"Q X+-GJ2,@8R
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MG::7-AI]K:E\;S!"J;L=,X'-7** ,S0M%AT.RDMXF4F69YGV1A%W-V51]T
M #VHN_\ CY?\/Y5IUF7?_'R_X?RH AHHHH **** "BBB@ HHHH **** "BBB
M@"MJ'_(-NO\ KB_\C7"5Z&RJZE6 92,$$<$5>_LK3O\ H'VO_?E?\*[L)BXT
M(M-7N>/F>6SQDXRC*UCRZBO4?[*T[_H'VO\ WY7_  H_LK3O^@?:_P#?E?\
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MR7=S<W+19\O[1,TFW/7&3QT'Y4M%)QBW=K4M5)J/*GH%%%%,@**** "BBB@
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IUK1=5EU[49(],O7C>ZD966W8@@L<$'%>R45$X<QPX[ QQ<5&3M8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gk2okx215f1r000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2okx215f1r000012.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" J;!3P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD SZ]3W/J?>C'U_,_
MXT +128^OYG_ !HQ]?S/^- "T4F/K^9_QHQ]?S/^- "T4F/K^9_QHQ]?S/\
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M "T4F/K^9_QHQ]?S/^- "T4F/K^9_P :,?7\S_C0 M%)CZ_F?\:,?7\S_C0
MM%)CZ_F?\:,?7\S_ (T +128^OYG_&C'U_,_XT +128^OYG_ !HQ]?S/^- "
MT4F/K^9_QHQ]?S/^- "T4F/K^9_QHQ]?S/\ C0 M%)CZ_F?\:,?7\S_C0 M%
M)CZ_F?\ &C'U_,_XT +128^OYG_&C'U_,_XT +128^OYG_&C'U_,_P"- "T4
MF/K^9_QHQ]?S/^- "T4F/K^9_P :,?7\S_C0 M%)CZ_F?\:,?7\S_C0 M%)C
MZ_F?\:0<YY(P2/7^>: %'3\3_,TM(.GXG^9I: "BBB@ HHHH **** "BBB@
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MEY=SMXI\1%[BYN])M;F>:0F^Y>265R2 ., Y(R0#],O^&IOV:_\ HO7PC_\
M"_\ #/\ \LJ=_P -1_LV[=__  OCX2;?7_A/_#'_ ,LJ_/S_ (<4_P#!,O\
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M[-?_ $7KX1_^%_X9_P#EE7Y_?\.*?^"9?_1OT7_A4>(?_DZC_AQ3_P $R_\
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M^N:_'7]BC_@E'^PYX\_X*/\ _!1'X5>*?A/<:SX#^&<'P_3P/H-YXH\1&VT
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M>?A&3_V4#PQ_\LJ#^U+^S8#@_'GX1Y_['_PS_P#+*OP!_P""FW_!';_@G_\
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MWLHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "FK_ !?[QIU-7^+_ 'C0 HZ?B?YFEI!T_$_S-+0 4444 %%%% !1110
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MC_TY75?H!^T__P FW_'K_LC_ ,1?_43U6OS_ /\ @B'_ ,H_/A3_ -=-8_\
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M)_F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA/\ Y,Y_9O\ ^R3>%/\ TA6@#\[/^#@C_DP_0/\ LY[]G_\ ]26]K]H/!O\
MR*'A7_L6]#_]-EK7XO\ _!P1_P F'Z!_V<]^S_\ ^I+>U^T'@W_D4/"O_8MZ
M'_Z;+6@#\3O^"W'_ "+'[.'_ &6'P]_Z<[.OV^\/_P#(!T3_ +!&F_\ I'#7
MX@_\%N/^18_9P_[+#X>_].=G7[?>'_\ D Z)_P!@C3?_ $CAH J>+_\ D4_$
M_P#V+^L_^FZXK\5/^"('_)._CW_V5W7?_3AJ%?M7XO\ ^13\3_\ 8OZS_P"F
MZXK\5/\ @B!_R3OX]_\ 97==_P#3AJ% '[FT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !35_B_WC3J:O\7^\: %'3\3
M_,TM(.GXG^9I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ _7E=?SAKTS_@H;_R97^T3_V3Z\_]+;&O,_\ @E)_R8[\'_\ KRNOYPT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "FK_%_O&G4U?XO]XT *.GXG^9I:0=/Q/\
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MMIGAS5KS7UCW>8^E06DKWB)M(;<\095P0<GK7XC?\&ZW_)EWQE_[/;_:=_\
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MQ.H^HO\ @I]_R8Y\>?\ L68?_3A:U:_X)H?\F5?!#_L6U_\ 1AJK_P %/O\
MDQSX\_\ 8LP_^G"UJU_P30_Y,J^"'_8MK_Z,- '1_P#!0W_DRO\ :)_[)]>?
M^EMC7F?_  2D_P"3'?@__P!>5U_.&O3/^"AO_)E?[1/_ &3Z\_\ 2VQKS/\
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M?[QIU-7^+_>- "CI^)_F:6D'3\3_ #-+0 4444 %%%% !1110 4444 %%%%
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M]D^O/_2VQKS/_@E)_P F._!__KRNOYPUZ9_P4-_Y,K_:)_[)]>?^EMC7F?\
MP2D_Y,=^#_\ UY77\X: .B_X*C_\H]/VN/\ LC7B/^=M4G_!,+_DPC]E[_LE
M'AG_ -(8ZC_X*C_\H]/VN/\ LC7B/^=M4G_!,+_DPC]E[_LE'AG_ -(8Z /.
M/^"O_P#R8C\8/^O&'^4M?1/["?\ R9S^S?\ ]DF\*?\ I"M?.W_!7_\ Y,1^
M,'_7C#_*6OHG]A/_ ),Y_9O_ .R3>%/_ $A6@#\[/^#@C_DP_0/^SGOV?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:O\ %_O&G4U?XO\
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M"BBB@ HHHH **** "BBB@ J&X_X]Y_\ KC+_ .@-4U0W'_'O/_UQE_\ 0&H
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M#_P5,Q_SS^%W_HN6@#][*_!G_@BG_P A?]LW_LXCQQ_Z=VK]YJ_!G_@BD?\
MB;_MG?\ 9Q'CC_T[M0!^XWBS_D5_$/\ V!=3_P#2.:OQ4_X(3?\ )%OVF?\
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M !1110 4444 %%%% !1110 4U?XO]XTZFK_%_O&@!1T_$_S-+2#I^)_F:6@
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M5M/C(WI<1>9=,!QQ*1GD<_7]/J?P1^V_X4U66*T\6Z1<Z W"R7S/OMRYP,A
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M6:+XJL[&TNI[C6+J2:%H9[69C);O(T+,I0%E)QBOZV?C1_R1WXL?]DT\=_\
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M>FOP6\:_\IN_"G_9+-$_](8J /WIHHHH **** "BBB@ K\%OV=/^4S'[6?\
MV+VD?^FJ2OWIK\%OV=/^4S'[6?\ V+VD?^FJ2@#]Z:_!/_@GQ_REB_X*F?\
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M*3_DQWX/_P#7E=?SAKTS_@H;_P F5_M$_P#9/KS_ -+;&O,_^"4G_)COP?\
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M?\$0/^2=_'O_ +*[KO\ Z<-0H _<VBBB@ HHHH **** "BBB@ HHHH ****
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M;_E#_P"">7_!?_Q7J?CC0?@]^USI]HFGZO>6VD:=XUMHFM[FUOYY$@B76!,
MZ"24@!_NY(!/K_6]8W]EJ=E9:EIMU%>Z=J-K!>65W"XDBF@N8DFB974E6RCC
MD$]QZ5_'+_P<'_L&_"WX,+X%_:1^#6C6OA&Y\0ZBT/BW2=-1;6RCNUG;[)=6
M,$6$@DCE6-\J.3GG.*_>_P#X) _%G6/B]^P)\$]4\0W$U]KFA^'XM-U'4;B1
MI)[R2,HL3NQY;8JA1GL!BNEYO4SS!K%9CE]#+<[H572QL<+[-8?&1T7UA*C"
MG1G4YN6<:]&C1]K2JVJTH5*4D<D<LHY1BY8?+<77QF35J2J86.(<Y5L'5M&]
M+][5JU(0DN>,Z4ZE6,:M-2HR5.MI^FU%%%<1UA1110 4444 %%%% !1110!U
MO@7QMK'P\\3Z=XHT:>2*2TF0W<*L52YM-P,Z.O1FV [<@^AXK]P?AUXZTGXA
M>%M,\1Z3,CQWENC30A@9;:?;^\AE7JK*0<>WT-?@C7UU^R+\59/!WC ^#]4N
MW&A^(I1]D20_+%J;L1&%)P%7G!Y^[QCK0!^MU%(#D CN ?7]12T %%%% %:\
MB$]G=0E@HFMIXBQZ*)(F0L?89S7^?E>?\$:/BY\*_C+\>?$/P*_X*V?#OX(V
M/Q(^*'BWQ5K'AC0O&,%C-;3ZOJUQ>/8ZI +R,"[M/-$$@VK@1H"I(W'_ $$I
MHQ-#+"V0LL;Q,1P<2*5.#V.#7\-?_!3#_@FK_P $9/V,+WXC_%_X]?'3XEW?
MQ*\?>)->\5V/PS\-^/KV]UG5=?U:>2[;3K?2[2Y::SAEN7\J)"B@%MH&<UKA
M%CWC\++*\'XG8C'Q5=TZWAKF7"65U<'14$\17SO%<6PEA:6!5-7A6HSI*CRU
M98B?LW%$8C$X*A@Z\,QQ7AS1PE>="F\+XA\.9]Q+1Q]?G;H4,GP&12]K/&J5
MW*%2E5=1.G[&*E&3/E/XM?\ !'']HWXW^"+[P%\6/^"SW@/QYX)O)8I[OP_X
M@\:Q7&E3S1RQ,K31F^97^X  01NP"".*_NV_9!^&]K\'?V7O@+\+++7+'Q-:
M?#_X6^#_  I;^(=,D$NGZS%HVCVUFFHV4JDK);W0C\V)P2&5@<FO\S?]C+_@
MB%^U-_P4P^*EWX[^'>F_$G]F/]D"YU,#3-:^(.O:Q<:U>:7'/NC-E937$$LK
MW,*I*DA#JNY6YQFO]/?]G_X56_P-^"7PL^#MIJUSKUM\-/ _AWP;!K-XS-=:
MG'H.FP6 O;AF)8RW'D^:Y8DY;DDURSSG)\YQU>>!X@\1.(\=@X+"8_%\89CP
M_FV5X6=.<E+ 99F>0Y5@<+C,9AZJJ+%SPN+S#!15E"JIOFJ=7]G9KEN#HT\=
ME'AOD.&Q$WB<)EW!618S(,SG&I"-L9F^!KYCCEAZ-:"C]7HXFEA,=S7G.DZ;
MCR^OT445J8!7X2?M0W'CWXQ_M%^(_#'PPNOB)\1_#O@9GMO'?A"P$-Q\/X+E
M SSZ!>QR LNI31I)M4 @@<=,5^[=?S>?MA_M!7?[-'[5/BSP]^S[\1]3^%'B
M+XA2OKOQ"MM;\$W>N>&-;UW#1G5X-3EMWLX)5C=PH#!@3G!4X.D*E11K4XYA
M0RJG7HU*>(S#&)5L#0PUN:K'&8*+CBL92K)*DH8+FKT:DH5^24(2M$X4FE7K
MX#'YI3PTHU)8'+<+CJ^+JMM0C*G6P&!S&>&]DY*HY5L.J%6WLI5J,I1D?K=^
MP;XL^$?BKX'QGX/?#U/AAHNB>)=;T/7/""V_V<V/BFPDACUF9HQ)(";J<!]P
M(SLQM&!G[5K\^?\ @FKHWAG3?V=(]2\.ZT?$=QXG\8>(_$7B37-NQ-2\1ZC-
M#+J<\,?_ "R@,IS'$.$!(]:_0:L*<:$(0AA<-2P>'C&,:.&H24Z-*FDE%4I*
MMB/W<E[\$Z]5J,E&4Y239K-UG*3KUL3B*S=ZE7&0KT\5*3UMB(8FAAL1&M#X
M*GML/1FY1;E3@W9%%%%62%12SPP+NGFBA7INED2-?S<@5+7XF_M9?$;1_'/[
M4.M_![XT?$+QA\+_ (3>"/#^C:OHS^$[?4H)_&.H:O$AN89-3L4)C6Q9R67+
M<+C;G%=>#H1Q-=4G2S#$R<9.G@\IPE+'9IBYJW[G X7$8O 8>K54>:K-5L;A
MJ<*%.K4]HW%0EAB*LJ-/VBEA:4(R3K8C&UZF'P>&I:N56O5HX?%UE=I4J4:>
M'J.=>I2A+V=.4ZL/VO21)%#QNDB'D,C!E/T920?SI]?E1_P3#^*NH>/8OVB_
M"5IXJUSQA\/OA;\3[;PO\.-8\06EU!J<N@2V%W.Z3W%VB37A62*/]Z0<$8SD
MG/ZKU&+HQP^(J48K$14&DX8NA'#8JE)Q3E1Q-"G6Q%.EB*4FZ=:%/$5Z<:D9
M*G6JPY9RJA.=2E"=3V/-)7OAZLZ]"<;ODJ4:M2CAZDZ=2'+4BYT*4TI)2A&2
M:"BBBN<U"BBB@""Z5WM;E(Y/*D>"94ESCRW:-@LF>VQB&SVQ7\Q/[3OC[]IG
MX)?%3Q;<W7[6_P#PFWAN^U5CHGPL^'FKQ2^/-/BDG;;:-"TNU'4$)M8@_*:_
MI>\5WJZ;X7\2:B\;RK8:!K%ZT49*O(MKIUS.8T8?==Q&54]B0:_E\;X4_L)>
M([Z7XFZQX?UW3OB1\1/AM\0?BS?WMW\0O*O-(U#PAJ,\2:9$LDV^UENV1FAC
M!X# <=*[,)B<[PO/4R/%9WA\1*T*BRB.1UJ/L_B<\QPF;T95ZU#W73IRRO$8
M7&T:U2$X5)65.7/7HY97<(9K0I5,-JW45+$K'0DY0BHY?C*6/PU#"57?GK?6
M\+C*5;#PG!*C+WW_ $E_ O5K[7O@[\-M9U./6(M0U/PAHUY>1Z^0VM)//:H\
M@U,J2IO,G]Z02"W2O5Z\'_9?URQ\2?L\_!W7M,2XCT[5? >@W=DEW<_;+E;:
M2U'E">ZRWVB0(!NER=W7->\5RR<W*3J2YZCDW4E[WO3;]Z7O-RUE=^\V]=6V
M;QY>6/+&48V7+&22E&-M(R47*/,EH^64E?9M:A1114C/Q*_X*K^'_AM%J>F>
M*]4\5>.M*\7W'P]U;PQKVF^ 71=1A^&]Y=R2:KK.H*W/]GV\Y9)&'<5PW_!)
MBP\/_P#"X_B?J,FJ_$VZ\30_"7P5I&BVWQ =&AN/AU:W5O\ \(_JVD!2?W-T
M F#U*DU]E?MR_LE>'OC5=0^/+[XM:?\ "2Y;P=J'P[UC5=6,(L=0\-:K.]Q=
M6 ^T21QB>1W)3DGC@5D?L)?LIZ=\'?%_BCXEVWQST[XRG5/ GAWX<Z6=,,!@
MT/0?#4T3V5N3"\@W 1!""1]36:Q.+5\/#"<21P+JMRJ+$<V33K:2E4G'ZSRP
MHPJ6<:4,/SRJSBJFD86U=&#M5EF7##K*E[F%E4Q%//U2]V/LX8:.5RH5I-/E
M]K4S&*C0C*<%SN4)?IW37W;'VXW;6VYZ;L'&?;/6G54OY?(L;V?!/DVES+@=
M3Y<+O@>YQQ6AE\K^7<_GB_:]_:/_ &[?V:_B9XEU3Q)X^^&EY\*M2N)%\&Z-
MX=O%?Q5:19;:-4MA)YB':!\Q0 D'TK]M?V9_&6L?$+X#?"_QKK\AEUCQ)X7M
M-3U"1NK7$LDRL3^""OYN-1^$W[-WQ(^(0^*?BKQ-KL7C'XMK\7K^\T;Q/XT-
MUIGAV3X<M=M#';Z;<SE;0:B80(U"J #\O2OZ$/V(==L?$G[*?P4UG38TBL+O
MPDHM$CD6:,06^HWULA25<APPAW CU]*[L3BL55I1H5Z.?J%"2C2Q6<9=D&!P
MV)A'GA!Y9_8&-JQG0C"*;GF6&_M#$0E2Q,Z\8U/8G)0P>78>I*MA<!DF$Q6(
MBYXJ>48G.*M1N7LYNECJ.<.LZ&(A)\L_[-KK+YUJ=>4:$'[-GU51161KVNZ7
MX9T75/$.MW<=CI&C6-QJ.HWDO$=M:6L9EFE?V1%)]^E<<8RG*,(1<ISDHQC%
M-N4I.T8I+5MMI)=6=4I1A&4Y-1C%.4I/1*,5=MOLDKLUZ*_+&]_X*/:IITU[
MXVN_@CXFB_9]T_5X],N/BXTKK;/#/=1V=OJ,&FF 22V<TSJJRJVWYASFOT]T
M?5+36])TO6K!_,L=7TZRU2RDQCS+34+:*[MWQVW0RHV.V:UJTJ<(\U''Y5CX
MQJU,/6>5YKE^:+"XJBHNKA,9]0Q&(^J8NFIQ=3#8CV=:%US01G"K.4N2IA,?
MA9.G3K06.P&,P+JTJG-R5*7UJC2]K%\M[PYK)Q;LIQ;T:***P-0HHHH ****
M "H;C_CWG_ZXR_\ H#5-4-Q_Q[S_ /7&7_T!J /P4_X-UO\ DR[XR_\ 9[?[
M3O\ ZE5C7[F>,A8'PGXC&J7\NE:;_8VH&^U*!BLUC:BVD,]U$PY$D,89T(YW
M 8YK\,_^#=;_ ),N^,O_ &>W^T[_ .I58U^V/Q6U"'2OAKXZU*YFBMH++POK
M%Q-<3P_:((8X[.5FEE@/$T:#YGC/#*"*<=916NK2]V4H/?I.*<HOM**;B]4F
MU83=DWIHKZQ4EIKK&2E&2_NN+3V::T/\[#]KWXU_#/XR_M3>+_@'^RM^V)\7
M?AFFF>*+Y?B)\7/BI87 \-Z?%'< 7]IX5OC:-.'@0R"!@_+( IR./[E?^"8W
MA7PKX*_8J^#/AOP=\;M5_:)T73M&FB'Q;UF66:]\4WIG)OYR\W[PPPW.^* -
MTC"XXK^;'P+^Q/\ &K]IVU\<_$WX;?M4_LE:7X6U3Q?K=G%IVM_#;P[!J5G-
M&[!H=1^T*KRRKGYG;)?:^:_J"_8)^$WBCX(?LN?#CX;>,?%O@OQQX@\/VU['
M?>)?A]IUII7A34#-=/*C:98V7^C0JB$(XCZN"34+&XFM5Q&'JT^(,'3C5YE@
M:U7BRID<JE-*F\97Q7$7"V6?VOF]6.D<=/.,1*CA_:4<%A7A7*I#*EA<+24*
M]*OPWBL16@GB,1AEPL\_;=I1HSI9)@,!B,MRZBO=>7NDJ7MW&KB)2Q#C;X>_
MX+>_\F]?#3_LK.A_^CK2OUG^$_\ R2[X<?\ 8B^$_P#TQ6-?DQ_P6]_Y-Z^&
MG_96=#_]'6E?K/\ "?\ Y)=\./\ L1?"?_IBL:HV/0*_!;QK_P IN_"G_9+-
M$_\ 2&*OWIK\%O&O_*;OPI_V2S1/_2&*@#]Z:*** "BBB@ HHHH *_!;]G3_
M )3,?M9_]B]I'_IJDK]Z:_!;]G3_ )3,?M9_]B]I'_IJDH _>FOP3_X)\?\
M*6+_ (*F?]<_A=_Z+EK][*_F:_9O^.FE? S_ (*J?\%*;W5=,GU,>)=1^$6D
MVJPRI#Y-Q>W"V<3R%E.8T:;<V.3C'?-:4J4JU2-.'*I2=ESSA3CM?6<Y1BOF
MU?9:D5*D:4)5)W4(*\FHN32[VBFW;K9:+4_IEK\&?^"*?_(7_;-_[.(\<?\
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M_43U6OS_ /\ @B'_ ,H_/A3_ -=-8_\ 3E=5^@'[3_\ R;?\>O\ LC_Q%_\
M43U6OS__ ."(?_*/SX4_]=-8_P#3E=4 ?I3\:/\ DCOQ8_[)IX[_ /46U6OR
MN_X(1?\ )AGA;_L;O&'_ *?;^OU1^-'_ "1WXL?]DT\=_P#J+:K7Y7?\$(O^
M3#/"W_8W>,/_ $^W] 'U%_P4^_Y,<^//_8LP_P#IPM:M?\$T/^3*O@A_V+:_
M^C#57_@I]_R8Y\>?^Q9A_P#3A:U:_P"":'_)E7P0_P"Q;7_T8: .C_X*&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAJ% '[FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT^PN+( 6<]G:S6@ P!;2P(\  [#RF3 ["KE101Q0P0Q6ZHD$44<<"1@!%A1
ML:H!P$5 H7'& ,5+72MEHHZ?"M5'R3ZI;7.?YM^;W?F[:7>X4444P"FK_%_O
M&G4U?XO]XT *.GXG^9I:0=/Q/\S2T %?!W[='B(V?A'P[HEO)^^O=2D>YC!Y
M%N8U"DC.3\RGCZ8K[QK\I_VXM5>3XAZ1H^[*PZ1;W0C)X#/W[@''L#^= 'Q9
M&-J*!T &.,<?_6Z4^BB@ HHHH *LV-E?:K>P:;I=I/?W]RP6&UMD,DK9.,[5
MR<#N:;9V=YJ=[:Z9IT#W-]>S)!;P1J69FD;:&P,G:I(+'L*_7C]GC]GK1_AM
MHMKK6M6L5]XPOXHY[FXF17%B'4,(+;=DQD9R^ ,-D=<T ?+WPN_8PU_7HHM5
M\?7K:+;R!)H-/MOGFEB8!@MP#_JVV]>1CZU]H>%_V;/A/X7AC%MX;M[FZ 'F
MW=R3(\SC!W%3P.>PKWJB@#GK#PGX:TU!'9Z)ID2@ #_0K=B /=HR?\:OG1M(
M8%6TK32#P0;&U((]QY5:5% ' :Q\+O 6NK(FI>&=,F60%7"VZ19!Z\HHQ^'\
MN*^<O'G[&7@#7H9IO"[2^'+S8S1)$?,BDEQD*S-RJENIP<>M?9E5;V^M--L[
MF_U"YAL[*SADN;JZN9%A@MX(4+RRRRN0B(B*69F(  YII.348IRE)I1BDVVV
M[))+5MO1):MBE)1BY2:C&*<I2DTHQBE=MMZ)):MO1+5GX8_$KX-^.OA/>E-=
ML9'T\NWDZI:[GMV3/R>9,ORAV&"%]>O6O,Q=3L!_I-P0?^FCX_'L/>O,_P#@
MH7_P<K_\$[/V:=6U[X2;Y_CWXALGN-.U>P\'-;W5EIE]$7BDC>[EPHF@E4@E
M&&&')VU_.'<_\'.'P:E\3WC6_P %/%5OX7EO':TB>ZM6O(+9F./,(SN*J>B]
M0.YKZNIP=G6'IPEC:F69=4J13IX/,,WP.&QSO9I3P<JTJ^'ET<,3"A-/1Q1\
MS'BK+\1)_4<#G69T4Y)XW Y75J8&3A+E:I8BM*@L0E\2J8>-:C.-G"I(_J$Z
MG)R2>Y))_,Y-%?G/^QQ_P5#_ &7/VTS%I/@'Q+!X>\;M&'/@S6KB.'4I,*"X
MC\QD5\9P-N>:_1?D':PPPZC^H]1[UX./R[&Y965#'4)4:DHJI!\].K2K4WHJ
ME&O1G4HUJ;::YZ52<5).+:::7MX+'X3,*<JF$J\ZIRY*L)TZE&M1FK>Y6H58
MPJTI:Z*<$I+WH.46I/TSX5_%3Q%\)_$MMK.D74S:9)+&NKZ69&^S75ON4,PC
MSL1D4%MP&21VK]K/!'C'1?'WAO3O$6D317-I?6Z2%25=HI"H\R)UYP5;CGDC
MFOP(//!Z'BOJ;]EWXSW7P\\50>&=5N6;PQK\Z0(LCDBSO9#LA,88D+'DY?D
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MP11\8>%O W[/W[4/B'QCX@TGPSH=M^UC\3?/U;6KZ#3[",M-!@-<7#I&"2I
M&<G!QT-?J=X'_:E^ _Q_T#Q;9?"7XAZ/XNO;#0M3DN;*T^T6]VD8M)<R+;W<
M4$LB#H6164'@D5_+E\!--U&V_9;^(_CG488O$OPZ\+_MR?$B3QK\-WG,1\86
M=TMQ;PVJ1[XS+Y,K"4CYL $D5,\%7P6,IX7,LOS.G4ER?[%2PM6./K.II1A2
MIU*,W!5I6C[>5*=.FKU)IPC)IO$0K4*U3"8G!2=&3C.I6Q-&%"G.GR2JTZE2
MI6H4HUE3DN2E5KT>:I.G%SCS*_\ 3E\9/C!\+?B?^S=^T%_PKOQ_X3\:&U^#
MWQ%-ROAS6['56A!\*:HN9!:S2%1N91D]"0.I KY'_P""(7_*/SX4_P#736/_
M $Y75?D_^S?X%\.6D_C?4?A5XET;PE%8? ?XX:G\1?AEIDUPKM!K&EW5SHD%
MWYDI@NY;&&1(_P!T6\LKSCI7Z1_\$COBCX#^$7_!-GX9>,/B-XCT_P *^';:
M?6$DU#4)"D9D.IW0$<<:JTLKD]$C1V-*I0^LXNGALORW.Z%:KRQAE^9X2<<P
M=65W'V,:=&DL72JT^6K2JT:25I.$DJE.HHJ-6>'P\JV/Q66N$>63Q&$Q5*="
M$)<D8JO*->O3H5O:2MR>WG%QE3E"<HSC*7ZS?&C_ )([\6/^R:>._P#U%M5K
M\KO^"$7_ "89X6_[&[QA_P"GV_K[ N/VN?V>?CU\-/C!H'PJ^)6B^*M9MOA=
MX]N)--MQ<VMTT2>&-3#-#%>PV[3[2Z[A%O*YYQ@X^/?^"$;*O[!GA<,0I'B[
MQAD,0"/^)]?]<UGB\#C<OK+#X["8C!UW!5%1Q-&I0J.$FU&:A4C&3BVFE)*S
M::O=,UI8BA64W1K4JJI3]E4<)QE[.IRQG[.=F^2?).,N25I<LHNUFCZD_P""
MGW_)CGQY_P"Q9A_].%K5K_@FA_R95\$/^Q;7_P!&&J?_  4\=6_8<^/6UE;'
MAF'."#C_ (F%KUQ5K_@FBRK^Q5\$-S*/^*;7J0/^6A]:YK/:SOVL:\RMS75N
M]U;[]CI_^"A?_)EO[0^1G_B@+K_TOL,?K7\D'A>7XP>&OA]X:U+5?B#;>&_"
M&H-H%QH<,WB&730W@^T\M_&%A!;1RJINKVP$L4) W%S\O/%?UN_\%"70_L7?
MM#X96_XH"Z&%8$Y-]8X[_C7\P_[*7B+P7\-6T2P^*_PUMOVF9OB=I^E0?#?P
M (EO)_!DUM'&+A93(PM[8W[#:@=E+[B%4YS6^'K9G0G-Y57S/#XMTY?\BM8J
M%6I2BXSJ1KXK#8K"?5,/",?:RJXBI+"SG"%*M2J\\8D2I8'$**QV PN9X=/F
M]A5JY="KS+3GP:S.E6PE2O"+?.K4Z\*'MJE&K"<=?N;PYYEY_P $J_\ @HIX
MAT&743\(/$'AK6[WX16>K7]QJ%_9^'TL5CU%9I+EWE43:@1*BL<;,8&!7ZV?
M\$PO^3"/V7O^R4>&?_2&.ORQN/"'B+PI_P $UO\ @II)K;PZ-8ZSIGB"_P!!
M^%\3JS_"S3_LF5\,S1H=D4A\V*78H Q%7W!_P3P_:.^"G@/]DC]D?X6^+OB#
MH.B>/-<^%/A1=-\/7EP5NYC/9QK"&8*8H?-8A4,KH&8@#-7AZ./S>I)X:.:Y
MI6=%XB<L11Q5?'^PIPBG/$.K+$8BK"A#DIK&5*D_K-.-/$\_+5B9XBIA,LIJ
M.(EA,NI1FZ2C+%X:5.-5WE*$Z]*%##RQ4FIU,5&C"-..(]O&"Y87.G_X*_\
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MHRW_  $&OU0 P, 8 KY5_8]T1-'^$&GXPTM[?7=S(^.2'*%5)Z_+N/YU]54
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M;R+0+V2VM+EM2@M'BO"T<>X*[NT3<# Q7ZA_#KQGH/Q"\$>&_&OA>&Y@\/\
MB+38M1TJ&[LGTZYCM)&=$66Q=4:V8%#^Z*@@8XK\'/C5\9OV@?V1-5U#X-?
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M/JVJ>$?@%X2T/4-1D8NUU=6>G1K)-N;E@YY![BOHD?\ !;K]GO\ Z)K\8/\
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M:72W%U8M,I^3[1!&\6,\D@=R3]\+_P %N?V>BVT_#;XP?Q?\RO+V!/KWQ7Y
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MB:Q</JNAR6:M'!J,#/';\-YLA$8VC*DL0/3/ZQZ9_P %LOV>K32=&MQ\-_C
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M/B1%I6JZGX U*=(8+TBXT56;:);IB&F0 G;NP6 ]21GM7Z= Y&1R* "BBB@
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M6TBE&BUC2;+4 5/! -S#(5X'52#7YX?M/_"+]F3X8^%Y+?1/@[\.HO%7B!C
MGD^'=*^U6UN_)N]OV?(&[(!XZ>F*G"<9>,63T,+EF$QO"V=X/!)4\%C\UC/"
MX["4N>\52HSRC.51JPC;W\)B\/2E/WJ='#I*,3'<*^$V=XFOF>8Y%FN7XZNE
M*O0P,<+CL+B*VCDU5JXG+ZM*DY7C&.(AF%6-.WM*]5J[_P Q7]D#_@FU^V!_
MP41^.MG\4_CTOBFQ\&76NQ:WXP\9^,S=?:=0B6Z2ZFL;.VNV\R-+GYHL!0H4
MD8_BK^\GX?\ @3PY\,? WA;X=^$+-+#PQX1TJUTK2K2,!4B2VABC<J!P!))&
M9...<=ZZ>RM+6PM8[2PLK+3K5% %MIUI#90D=MT=NJH>/;\JM5%"GFF(QF)S
M;/<P68YKB[J<Z<)PP^'IRDIRI455G.M4E.<8NK7JR4JG)!0IT:<(TUKB*V I
MX:AEV48".79;AK.G1<XU:]6:CR*I7J0IT:?NQO&E2I4:=.E%R^.<IU)%%%%=
MYPG<_"[56T+XE>#M85BIL]4C/';>R+GWZ_Y)P?WFLI_M-G:W''[^WBF&.F)4
M5QC\&K^>FQN6L]2TR[4D-!J%FPQU.ZYB4^_?M7] WAQS)X?T.0]7TC37.?5K
M.%C_ #H V:*** "HY9!%%+*QPL<;R,3V"*6)_ "I*^3_ -ICXZZ5X \,7F@:
M/J$4WBO5XGM88X) [V$<@V/+,%/R$J2HR>.<C/0 _-?XWZ_#XH^+'BO6K:02
MPS7;0!QTS;LT9''92",?EQ7E])NDDDFN)B6GN97GG8G.99#N<Y[Y8DY[TM !
M1110 Q^B_P"^O\Z_</\ 9\&/A'X.'IIJ] 0/OOV-?A\!NDMT_OW,"?7=(HQ^
M/3\:_=GX,VOV+X;>%;?!&S3(3@C'WLGI^- 'J%%%% %:\A-Q:75NIPT]M/"#
MZ&6)D!_ MFOX"/$?_!NS_P %5M \0_M/^&_A!^T+X?\ "GP=_:'^(OC'Q/K_
M (7B618]3TOQ%J=U=117<9<J9$MIU@8 J"$R2"37]_[,%4LQ"JH+,3P  ,DD
M]@!R:^.]2_X*"_L5Z/JFI:)JG[2WPCL=6T>]GT[5-/N/&&DQW5C?6KF.XM;F
M)K@-'-#("DB, 588-.&4<79G5C4X1S?B/*,3AJ=>EBZO#V7X#'U*V&QL/8NC
MB8X[+,SC3IRBIQBZ<:4I<TTY2LK*><\+Y53<.*,LX>S/#XFI1GA:7$&,QF$I
MT\1A*BK1J89X/,<NE4J1DX.2G*JHVBTHW?-_"Q\7_P#@A'_P5+^&_P"R(G[/
M_P 4_P!K_P '>&_V6O#,J&/P_JTAMM&LGGNDN623?*B@2R(Q_P!;\Q QQG/]
MXG[#W@>'X9_L@_LW_#ZWUBS\00^#O@_X(\/1ZYIY#6.JKIFB6ML+ZT96=3!<
M[/,C(9AM8<FOYZ_^#D?]M']F3XE_\$N?BOX:^%O[0?@'Q'XLO=4TC^S]*\)^
M,+.?6;@PS@2+'!87/VDKF1!T"MDXSAL?NG_P3&DEE_X)[?L;R3O)),_[/7PS
M>225WDE=V\-V19GD<L[LQY+,2QZDYK2IEW$.7PP]+BK/.+<XS6CAZ>%PL>(L
M/D^!PV%RFA%1PM+!X3 9%E>*YXR4XSK5\5B*4H<L84H34IRRI9ED.8NM5X9R
MCA7*\LJ5ZF(Q$N'JF:8FOB<SK/FQ%3&8K&9UF.&<91Y91HT<-0JQFY2G5E"4
M81^Z:***R-@K\(?'_B7PEJ'Q^^.5]\&_CC#^SAXS\/>+#H'Q&TW6K.35=)\;
M7[QMYGB"WM5!2&[\LNB2D!U)%?N]7Y6>*O!_[$'P>^)OQ>USXN:WH=]XI^(7
MB,^+=</B!XXAHRI$RM;PN64"W&=Q9R3P!UHB\0JM)X/+\3C\6Y.%'ZIG=3A^
MK14URU/]OA@\Q4J=>#=">%GE^)CB.=1O1DE465>6"CAZKS+'8;"8%)2KPQG#
M*XMPF(Y9*4%6R>6*P,)>P:^L0Q4L=AUA94_:?O?X<OI']B/X?_#/X>_!E+'X
M8^*)_&MAK'B+6=?U_P 43M(QU;Q1J,D4FLSQB0!HX?/ ,,71%8@=2*^PJ^=_
MV8O%WP&\:?#&UUG]G/4]$U;X<'5-2MK:[\/S+<::=2@DC&H1K*A8&5':,2#/
M'I7T11[&KAFZ%;#5\'6I-QJX7$XZIF6(H5$WSTZV85</A*F,J1E=2KSPU"51
M^\Z4/A5PK4\1"%:CBH8VC5A&='%T\OCE-.O2<5[.I3RR%?%1P,)0MR86.(K*
MC&T%4DE<****"@K\_P#XWR?L<>,O&_CJS^,'AG0-7\1?#F'PHOBF[U'38[AX
MD\2S1V_A])I&C<R[I9$$8Y$?&"*_0"OYVO\ @ISX4\"Z!\5?%NJ_\+<\8^%+
MKXF6W@L>-].\(Z8FI0Z7<^%YH9_"ZZNY5C:MJ=S%$EJIQYKLJCKQ,\#EV8KZ
MKFF6XO,L))J4J>#P^*Q-:E*/PS]GA$ZUJS_V-22<8SQ,7-.-TVJ^*P[53!YE
M#+:ZNHU)UJ5"-56?/3YZT90_=1OB^724OJ_+%MM)_K]^S<_P/TN^^)O@?X,:
M+;Z+_P (7XCL+'Q;;6T*P1'5;W3VN[1U"JH93:9VG' ;'2OI76;I+'1]5O9&
M*1V>FWUU(XX*I;VLLK,#V*JA(^E?DC_P266UOM#_ &@?$]SXL\8>)/%WB3XB
MZ3/XMM?&NF?V5JNBW-GHT]KI]N+4!2(;FS"SH[#YAC'6OUMUN.TFT;5X;]ME
MC+IE_'>O_<M'M95N6_X#"7/X54:.%PZC1P&'KT<)345AJ=>EBZ%:I3LG&LZ6
M-D\73^LW]M359J:A4C915DDY8B7,\77]MB'*7MZG-1J>SJ7?/1<L/&-&;PS_
M ',G!--TW>4VW)_S&^)?V>K?XJ^,-1^+S_M(:MKEE\1M \=^.-"^'7B^.[UK
MPO;:5X'N;B/4H(].E#0! 8V4;00,<U_01^RUJ=CK'[//PCU+34L(["[\&:8]
MJFEVXM-/6)5>,"TMAQ##E#M0=*_F!^)&D_"VQ^(6J:#X5^-OQWTJR&C^.O"_
MP;T[0/"8N],UNT\075Q_PDFFZ-.J_P"DV[W+R1R.F" /J*_IP_9'\+R^"_V:
M?@QX5GCU.&;0_ ND6,D>LP&VU171'<_;X"!Y5R=^Z1,?*3BBJZ4L3.O6_M&6
M98N'-7GFF98S'8ETL+.5'V--8K&8ANA@ZU26 4^2/++!\D)R@[R<(<M""HX/
M+\/AJ#C3C4R_AFGD:K2KTXUJ=7$8FEE> CBJF+HJ./IKVM>4X8IU)**C%+Z+
MHHHH$96NWUMIFB:QJ5XKO::?I6H7UTD>?,>VM+2:XG6/'.]HHV"XYW$8K^87
M6/V9M4^)=O\ %W]M7X27H^'7PU2YUK7M7\+07J1^*/'5EH%Q/_:8NK]6,FGR
M2&-Q$)RI(Y'6OZ?-:N;&RT;5KS4T#Z;::9?W.H(R[E>Q@M99;M64_>#0+("O
M<'%?RR?$;QMI6L?$[6O#GP]@^)6E?#GXU2:I<_#KX4>$["6YT#Q\EI=RVNI_
MVR58_P!E:5-<AQ=2P[5"$Y)SS%2DIJ%2<\OPRHS=>EB\;'(*TG5P].=>>#IX
M?B2<<#"%7#4J]>MCL-%YAA(X9.C4HTYU:BVH8C&T93C@*N(]O7A&C6H0I9W+
M#RPM6I"E.M.6183%XF6(A4J4Z6&H8J$<%4=:=2=2G6I4JD?Z._V9O%&G>-/@
M#\)/%.DV=UI^G:UX)T:\M;&]G^U7=K&8/+\FXN<GSY%9&S+DA^H.#3/VE=';
M6_@OXVLEUK0_#^W2Y[EM4\162:AI<*6\,KE9K5\B5Y.%C !8MP.M;_P+T.7P
MS\'?AOH$_AVV\)3:3X2TBSE\-6DAEMM$DBME#V$4AY=8&)&X\EB<\UX%^W[<
MZG!^SGKD6G:!<Z_#?:_X?L-82T,GG:3H=U<2QZEKJB+YF&EP_ORIRI_B&*?-
M0KPYZLZ-+#UH\TI4ZL)4(TZBNO9UI4\33G3LTJ=25*O"4;2<*J?++-QJ1DXT
MXU:U2+:C&K1]I6G*+WJ4'6P_/4TYITOK%%N5XJK!VDOS\_8M_: \/_$G6_"?
MAJ;]E*YBF\&^+&\-6GQ1M]&33/#U]>6TKC_A,M/LGME\HR;=HN%8L0>'[U^Z
M]?S>?!;XT_'6'XC_  8E\,^*M7B\!6/QHM?@_9^!X?#]M;P^*OAXL*RM\0[R
M1(TD ,VZ W6.=OWC7](=*G##03^KQX>@[VJPR#!9EA$I02C%XZ>/Q=6CB\3;
MW7B,MP.3X%\LHT\LP\HR3).LW>H\[E3=I4'G6,H8NIR22DXX:-/ X6MAJ.JE
M]7QF(S/$4^>,9YC7:NORX_X*7:[%\/?"GA+XIW-OX:\3VOA+4X)G^'&HZ"FM
M:YXT82D_V?I'[N62(N&"E@C*& XYKT#]B3XEZ-\46U?Q-9?LZ:E\$[_5?#FE
M:E<7VK6ZQW6H6]RZ&+1U?R(G6&Q)#QP$E4 X KYK_P""E'BG7/"WQ(\%:]!X
M=O7A\)>"M1\4>%-:@M6U"#7/&]I>R)IW@V:R=7@?[<A$N67?Z<9K?_X)]_$C
MXV:]\:OB/X7^(OBS4_%_AV_^&7A+XA6OVK2H;"S\'^)_$%S;C5/!EL\*@,=)
M1V0PG!0#) Q2]G@.?F3X<G7;YO:8S"YAB<[A7@E%T<OQ&!K9=@L"HQFTWF\,
M_P#:MUHX>.7R<;C>)M:,,[A%6YX8:O0PN43H22<:F+PU:AF,\PFY+GE6P>(R
M.I37L*=>&-Y=/U\J&XECAMYYI25BBAEDD8=5C1&9R/<*"14U5[MH4M;EK@ V
MZV\S3@C(,(C8R@CN"@85JKW5E=WT6U_F3^'F?R]>.?V9;'XS?%?XO_M7? SP
M=\16\,:+<ZZ-;\<)XR:VU+Q)_P (YYTGB*TT(-+YNFI9I#)CA<JHQS7[]?L@
M^+-!\;_LW?";Q)X:CU>+1[[PS$MM#K]ZVI:Q$UO<W$$R7]\Q)NIQ+&Y,N3D$
M#/%?SN_&#XD^)-(^*'B3P]\$?&?Q+\&_!#XRZEXET#P-\/O!FAIJ5KXH\302
M2V?BB*0-N:SL;^Z,JWDT>TQQ.<L><_T5?LE>#+_X??LY?";PCJF@Q>&M3TCP
MM;Q7^B0L76QN9)YYG1F.297$BRR^DCLO:DZT(3EA?[5AC*E253$3RWVT)RR2
MI1JRP^(P,*ZFZV<JE7<J=7,*\\9]4J06#IU\+&;P:IQ=2,,1]5S&E[*,,/\
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M,,*;TR[95P<Y(SC@?M;HGPB^%D^AZ&\OP[\&LPT;2D!/A[3.%2Q@51G[-DX
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M!"@CA@C2&*-1A4CC4(B*.P55  ]!4E%%>B<84444 %-7^+_>-.IJ_P 7^\:
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MD@$=OPQ7\T7_  ="HI^&?[-+E0774]9"L1RH;[0" >P(X^GU-?L7_P $C_\
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MPMT"^N_%7P_\)ZZ=>\-^/+KPY'X=;7[CQ',)[V$01QQB06Q V]=@R,#-<_\
M96$HXB68T\KS.EC,3&#K9IBL9C,1EV*I4[P5'"X+*:LL-@:M)RBJ57B2K&G6
MBL3'!Y<JRHXDZI9IF=3!1P$L7@*V789\E/!4,HP.#QV$E6DJTJF*S;-L+[;,
MJ52<.>-#AK$+%TW4C+')X>E71^V%%%%=)P!1110 5#<?\>\__7&7_P! :IJA
MN/\ CWG_ .N,O_H#4 ?@I_P;K?\ )EWQE_[/;_:=_P#4JL:_?&OP._X-UO\
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MCD8/;]N/@W>^-M1^%O@6^^)'V'_A/+OPYI\_BH:9+'/IXUF2$-=K9RP_NY(
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M=:5^L_PG_P"27?#C_L1?"?\ Z8K&OR8_X+>_\F]?#3_LK.A_^CK2OUG^$_\
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M'_IJDH _>FOP3_X)\?\ *6+_ (*F?]<_A=_Z+EK][*_!/_@GQ_REB_X*F?\
M7/X7?^BY: /WLK\&?^"*?_(7_;-_[.(\<?\ IW:OWFK\&?\ @BG_ ,A?]LW_
M +.(\<?^G=J /W&\6?\ (K^(?^P+J?\ Z1S5^*G_  0F_P"2+?M,_P#9V/Q.
M_P#1UO7[5^+/^17\0_\ 8%U/_P!(YJ_%3_@A-_R1;]IG_L['XG?^CK>@#]5_
MVG_^3;_CU_V1_P"(O_J)ZK7Y_P#_  1#_P"4?GPI_P"NFL?^G*ZK] /VG_\
MDV_X]?\ 9'_B+_ZB>JU^?_\ P1#_ .4?GPI_ZZ:Q_P"G*ZH _2GXT?\ )'?B
MQ_V33QW_ .HMJM?E=_P0B_Y,,\+?]C=XP_\ 3[?U^J/QH_Y([\6/^R:>._\
MU%M5K\KO^"$7_)AGA;_L;O&'_I]OZ /J+_@I]_R8Y\>?^Q9A_P#3A:U:_P""
M:'_)E7P0_P"Q;7_T8:J_\%/O^3'/CS_V+,/_ *<+6K7_  30_P"3*O@A_P!B
MVO\ Z,- '1_\%#?^3*_VB?\ LGUY_P"EMC7F?_!*3_DQWX/_ /7E=?SAKTS_
M (*&_P#)E?[1/_9/KS_TML:\S_X)2?\ )COP?_Z\KK^<- '1?\%1_P#E'I^U
MQ_V1KQ'_ #MJD_X)A?\ )A'[+W_9*/#/_I#'4?\ P5'_ .4>G[7'_9&O$?\
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MX2^,[NS$;OH&HRO<Z3<;28T@=\B)G *F1<],@]<CK0!XU10#D9'(HH ****
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M-8Z7K'@[3;FTLKAWDFM4420F&1Y"78K)$^&8DE<'-?A/XR\'>//'.N^,M5^
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MPL^>JGK3C9\T[*SN6U&2<9*G*+TE&L^6BXO1JK+2U-K2;Z1NS^8'PAX+\/\
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M9*B3"OOV\G S4G[&'Q*^)<7QS^/'[.WC3QS8?$O0_A7I?AO4_#OBZR0R2/\
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M?\BQ^SA_V6'P]_Z<[.OV^\/_ /(!T3_L$:;_ .D<-?B#_P %N/\ D6/V</\
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M<52C3P'^XTJ=*G1C$/J\,)>A"G4I24I5:L*V%XIRZI*I6?M)5_[*XKQN-Q>
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M+\6?LB0:#K&KG0[._P#A)H<?]H^9Y21S_P#",VQMXYFR/W$TNV.8'Y?+9MW
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M_KG\+O\ T7+0!^]E?@S_ ,$4_P#D+_MF_P#9Q'CC_P!.[5^\U?@S_P $4_\
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MDC"[ !BOL7_@A2<_L)>'#C&?&?C0XQC&?$&H'&/:OS7_ ."=WB_Q3-K7Q?\
M"?[1OPM\=>+?VGHOAO\ %:6\^,GC&[@U-?"/A=/#=^-+L;2=I6,=U<QLBW?D
MJTJLF#M!;/W'_P $4?BO\./ O[#OA/2O&'C7P_H.IW'BKQE/!9:IJ5M:W=S$
M/$%^IFAMY7661"QZHA'-:8?+J\ZD<-E]#%XZG4A]8P52."E1Q>/PM2$:G]I5
M\NI*I6P=7&2<\55I5I2K/VGMZOLY572A.+S3!X6A+&9EBL!EZA4=+%\V,PDL
M!@\3*?*L'0S&&*JT,52I7C2I5/W#T5*%.<(0K5?N+_@I]S^PY\>1TSX9A_\
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MJI!QDDKV/W-HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)HGQ0\-7?Q4\5_&OX5:9X@/C4_M+ZY;:9K8\-7-I!J%Q'I&FZ-\HMM/%Y9!
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MC5/[+N](\0^'O$IWMM@U"'1;B:XETJZ'W7MKY3Y<T;Y1TR&&*]E_9I\":O\
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M6-:<8TZE;%X6MDJXI]HZ7NTL+@<SJ<U"4L3B:U&C3GAJOZ_44451QA7\"/\
MP6J_:2^-7[*O_!PK\'OBO\!OACJ'QF\>Z9^SKX82Q^'VGFX>6_5R=\RQ0AO]
M68TS\O/F#G(%?WW5_-E_P4!\#_L>?LR?\%1O@I_P4.^/WQPM- \<2^#]#^%?
MA/X2@V]Q?ZR_VF"VMM02Q9'F>.65T&XC;DDY]=\,\Z>)H4\@P%?,,SK5%2H4
MH8-X["TE)-SQ.:T/K.#A_9-%1OC95,31IJ#2<TY(RKO)U0K2S[%T\)ED87KM
MXVME^*Q/O14<)EN*PU#$XB&98AOEPGL*,ZBE>4;<K:_.&7_@X#_X*YB60?\
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M ()]!E_X*Q_\%3E8%65/A>"",$$)*"#7YR?L%_\ "BE_:\^$EK^S#H>D:CX
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MA%OGG-*3BW"C*%>=.<?2/V,O@O\ !G2$^/?QBU?Q=\;KKX[>)?V?_BC/X?\
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M64HDSJ3KR^LU*E6I/%1AB'[2OC\73@JD4U#"8S,I2Q>,P5ES8;$N4J%2$O\
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M:":$,4,L4D88<%=Z%=P/J,Y'TK^"#]O'_@E!^R)^S-\5?'7C3]I?_@KIX_\
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MU/:5)ZUY8:3A]7HU*2C!0DZM2G5G*S;CK2H8>-DY2=W"4W*<GS*')3A^2_\
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MGB*V'BI2IUZE/EG1512A.,GK^0/_  3+T[]FW]IKXQ_\%._^"I/[;FB:+<?
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M;$?B=X]\<Q>,=6T&5/#]ULT_2#*\MQ;1W:HSS"$J&V$L=O#?(/PF\4Z5=?\
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MA?P/X$^"DFG:-JOANVMK>YU[6#J"S7%[J'D //+([Q!Y9"6)V@D#.'?L,?\
M!13X$?L]?LD> ?"OQ$D\1:;+X8TV:?5=570-2ET6&&1(Y0W]II;FT)VH>!+G
MIQUKW;XW?M"_%3XS_LJ_M5Z%\1?@_K/PVTW2?A?+=V6J:C#-#%?3R7<):T3S
M3@N&BCZ=B0>H-?AOX5U[]ICQ)\*OA3X$\3^)/@#X0_9<T^SCNH/#/BB\L+?Q
M3\2/W*O>6^O.ZO=VMO$N5C*E<KGKUJ<'B<KP-!5<;G^09C@Z4&O[2PF&PU#
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MI_Z0K7X9>)? GQ5\$_\ !*W]I"Y^,W[45K^U!XY\37UMJ=_<Z==P7NE?#M9
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M<^)_[4LO%?\ PK?30MGH7G%_[%^S"WPQ\O\ =^;L.,#G% '[BT5^-S_L1?\
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MA/XF>"O&T_P(O/V?_#EKK'C+0[6_M=*MM2MCC[-)K4$8ABFC$TNZ+S=W0D<
M5SXK$Y7AJ$Y9SEE+.<!4M1JY5/\ LQ5\P=1VCA<#5S>$\#0Q]:SCA:U5?NYN
M^S:>V'P&-S"K"GE^+GE^+H/ZW2S)+,)4<N=#7Z]BZ>5U:.,K83#W4J]&G/\
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M=?LI^(_B5+J(UC3]]MX_T_4A;6M@4,F1<E<J+3[[G^$UX%J/Q%35?V^_A/\
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M9Z^$OQ[U_P#9E_9J\;_ CXI?"WX9:A:>%;RUU2X\:6 FU6]CN$50EK=$@A,
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MFL:B]GA+*YTGQ5JT6IZ3 (OO)<VMO?F.YSC+KT!YK^I[P;_R*'A7_L6]#_\
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MQ_\ @1_P4/\ VCOB/^Q?\)+R\_9)^(/CC3%LE\,:++<^,3H-W<J;R[NF@?\
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M_L*_X(]?\$_OB=_P3]_9R\7^#_C%\:M9^.7Q&^*'BMOB-XF\4ZO=W-Y]FO\
M4-,Q+I]G)<R2/Y$;RL25.QG!9?E(Q_(-^WM_P1T_X+/_  ?\._#/0M+\=O\
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M2!/!7A-D-_9ZEJB7-@-8U*+(=K*V>87 VJ2-F:_1#]@;5-!\ _M*^/\ X3_
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MJ^ S/$8.C5PM>^(A/ZSA94Z*H^UHN<I2J_I5=7/B_P "?L>_M!_L]Z]\0/\
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M$^*?C"']I/XO?$Z+2O%MIX9U(VEE;ZAJM]!!<(Y@$<T<D;I<)(OF(4=<,&!
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MZT?V4;?^V_%EEXOG^T:/LU"Q*-&@_LL!T)3C+L-ZY[5^O6J_\@O4O^O"\_\
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M98^M?J/^T9\/OB-\1_@;XS\ _"CQO<?#OQ[K6A'3= \9VIQ<Z+=^6$6[B/\
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M** "BBB@ HHHH **** "BBB@ HHHH **** /\ZK_ (/1_P#DKOP#_P"P ?\
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M? +X;VE_9WD;PW5M=1>'+)98;B*0"2.:-LJZ. RL"#S7OS? +X)L,-\*_ K
M]CX<TT_^T*]2L;&STRSM]/T^VAL[*TB2"UM;>-8H+>&)0D<44:@*B(H"JJ@
M  "B.9<0YICJV)SC)>#,CH>PI0I8;A#^W53JUXRESUL4L[Q.+J.7(U&+IU[)
M+E5.,5JI8#(,NP=+#Y1FG%N:UO;5)UL1Q3/)ZM2%.48*-+#2RG#82*CSQ<FJ
ME%O6[G+3E_"W_@X;\4_#;P#^PUX.^(GQ:\3^)O"?@;P!^T]\#?%NK:EX3M;B
M\U:4:3KE[-'8BWMG226VNCN2=22A 4,.E?(WB/\ ;F\*_P#!476M-U?1_P!J
MOX;?L^?\$W4-IHWC"]UGQ-8Z!\0_C'K;^0;SP/<+=S03:)8NX?=-%*CLF$!>
M0*#_ $>?&KX$?![]HWP+>?#+XY_#OPQ\4/ -_=VM_>>%/%VGIJ>CW%Y8EVL[
MF2U<@&:V:1VB?.5+&OEN7_@EC_P3XF\*6O@AOV4_A0OA6SU9=<M=%BT62&RA
MU52"MXD45R@$H(&"<]!76<IC_L_?%K_@G!^S%X5TCX"_!/XQ?!+P?IFDV#ZO
M:^&+3QKI,^L3V<L:S2ZM>RRSF]O1)&!*UU.S C+#&37K'_#?_P"Q-_8L_B/_
M (:D^"?]@VVH?V5/JP\>:(;"'4MQ3["]Q]I\M;G>-OE$[MW&,US8_P"":W["
MB^*U\;C]F3X9#Q0NC?\ "/C5QI4_VG^Q_(%M]AS]KV^5Y(\O&,X[USH_X)5_
M\$]!X6NO!0_93^%?_",WNL?V_<Z3_9-Q]GEU?>9!>L/M>[S0YW9SC/;K0!ZT
M?VX_V/EUJR\.M^TE\'QKNHV U2QTD^-='%]=Z<4\P7L%O]H\R2W,?SB51M*\
MYQ6:/V_/V*&T?4?$"_M1?!4Z'I%Z--U/51X[T4V-C?EB@L[FX^T>7%<%@5$3
M$,2" ,BN7/\ P34_83/BC3/&9_9D^&1\2Z-I T+3=5.E3_:+725B\@64?^E;
M1$(OD VYQWK"'_!*_P#X)[KX:UOP>O[*GPK'AOQ%JHUO6=*&DW/V:^U0,7%Y
M*/MFXRAR6ZXR<XH G^,'[0?_  3T^/7A2Y^"GQ5^-OP/\7:%\1-(+Q^%K[QG
MHS76KZ;(OF"]TP+/]H7:J[X[JV(90,AL5^-&G?M.^"O^"7_C'4?&/PH_:F^%
M7QC_ .";6C7+:;XQ\ 0^,K'7O'?P!U)Y&6.S\/R13S76LV]P^W-O<2 Q;2C(
MA)-?M7_P[1_80_X2'P[XJ'[,7PP&O^$]-72/#^I#29_/TW3DC,2VL!^UX$8C
M)7D$X[UFV_\ P2Y_X)_6ND>)M!A_97^%2Z1XQO\ ^T_$E@VC2R6^JWV_S/M%
MS')=.K/O.[.,9H _.7_@@-\7/@M^T#HO[>GQU^!'B_Q9XN\"_%3]KOQ#XIM9
M?%EO<6T^FO>:8)!8Z?%<'*V CD62$Q@(5*D5[Y_P7RC\1R_\$Q_CBGA37]*\
M,ZT;_P &FWUC6C$-/MU&O0&42F?]WF1/D3/.3Q7Z1_ 7]F?X!_LN^%KWP5^S
MY\*?!WPD\*:EJ4FL:AH?@O2X]*L+[595VRZC=11LWFW<BY#S,=Q!-?E?_P '
M%.I>"M(_X)1_M :C\0K'5-1\*VM]X)EU&VT<N+Y@/$-N(FC*$$*CD&0DA0O+
M$#F@#T#_ ((L)XCC_94MQXDU_2_$5T;C2#%>Z4T30A/[+&]6\KY<L_S+WVU^
MM^N-MT76&Z;=+U!L^F+28U^*'_! [Q5\/?&O[%FF^)OAG;:G#X9U*YTDVTFI
M>86G,6EA-T1?JJ#Y7QQNQTK]J?$A(\.Z\1U&BZH1^%C/0!_,7_P3EOCJ7_!2
M+Q?>YSYFD>.TSW_=W%XN/^ X(K^HZOY1_P#@EE<&?_@H%XG:0DS?8/B,'!'S
M "^O@H8=1[9^O2OZN* "BBB@ HHHH *QO$7_ " -:_[!5_\ ^DLM;-<WXQOK
M73/"?B74+Z86]E9:'JES=3L"1#;PV<SRR$#)(1%)(')Q0!\C?L/_ /(H_$/_
M +*#JG\WK[=K\]_^">GCCPIXX\"_$74/"FL0ZQ9K\0=4S-$K)CYY4^ZP!QN5
MAG';G&:_0B@#\^O^"H'PV^'_ ([_ &(/VD[SQE\,/#OQ,O- ^$?BS4]$TO5M
M)L[R^>^L[%Y[>#3[R:%[FU>248_<R*"2<@DU^>?_  ;+R"7_ ()A>#''PS/P
MGSX_\9_\4H1*-@$]J!?XF"R 78&_#@.,88;LU^O_ .V'\*_&'QQ_9;^//P@^
M'^KQZ!XU^(WPT\3>$_#&M3.8HM,UG5K%[>RO)) &*+#*P8L 2/2OAC_@B7^Q
M-\?OV!/V)=%^ /[2'CNR^(7Q%L?&WBKQ ^LZ==S7UG;:1K,\$FG:7#=7 $\Z
MV21.GF2@.V<F@#]>:*** "BBB@ HHHH **** "BBB@ HHHH *_B/_P""H=AX
MI_;6_P""[_PB_9 ^)WQNUWX,_L^?"CX:6'Q4BT6WUR?1+/Q3KFD :FTKL+B"
MWN1=/;(I23<-A"<@U_;A7X0?\%7/^"'/PM_X*2^./"/QGT[X@>)O@[\<?">F
MQ^'H?'?A6[ELKJ[\.+A7TZXDMFCF8&/=&/F((.#6=;-J^44YUZ<,^EA<0E@L
MSEPM.C3XBAEN(:6)EE<J]?#4Y56E&%6FJ]&I/#SJQIU8/??#9?2S&O3@ZV3X
M?&8=_6\KJ\0T:N(R..945_L[S*G1HXBI&BE*;A55"LJ550E*E-;?S(_!?]EG
MP?\ \%ROV^OV\?B;\=OB1XEM_P!G/]D7PK<_#?P*MKKMS9:''=^%;2YTRSU6
M&59EM!+&MI)<S.A!?;DL=RBOU\_X-3?'WC&Z^!7[7?P0U/QIJGQ&\ ?!#X]:
MQX3^&_B[4KR?4%/A^#[9!%IT%U,\GF1K&B2#8VT",[1C%?4]U_P09\/_  O_
M .":?C?]AS]E[XLZ[\,?'OQ0\0:3K'Q&^-0N)H_$/BJ$7!FUZTU*XMBEQ-%J
M"_+M,F2&<$\Y'Z'?\$TO^"<GPE_X)F_LVP? SX7276I7%_.WB#QOXEOF\R]\
M2>*)+9X[K4IG;+G>7D*!R2 QZ#BN.AG^.QN,KU94.*Z.)SZ$9YA@\SQ,IY!E
M.1Y<HT\@P=.F\74H?VVN2]?#X&A&.#BYJOB,1%T&=5?*,-AL#0H_7N'<3A<E
MJ.&6RP.!=+/,=G&-O//,PKXAX2C464U5-PPL\17J5<3**OA\,W(^*O\ @W6_
MY,N^,O\ V>W^T[_ZE5C7[6?%V+79_A=X_@\,>=_PD,WA/7(]&\C/G_V@]A,M
ML(L<^89" N.<D8YK\4_^#=;_ ),N^,O_ &>W^T[_ .I58U^V?Q4N?%EG\-O'
M-UX%@%UXQM_"^L2^&K<C/FZPEE*;),'(),VW;Q][%>AS<GO^U5#E][V[3DJ/
M+K[5Q5VU3MSM)7:5EJ>=R\WN^R]MS>[['F4?;7T]ES2]V/M/@YI:*]WH?Y\G
MA%OC#^RK^T;\$OCKH/[,/Q:L?'WPF_:-\:>-?C_XXFN=8DL/B/X/U,/%I^BF
M)Y#!*BS;&CA^91T"CK7]YG[)_P <]0_:/^!7@OXPZGX)U?X>W/BZ"ZNAX5UR
M%X-3T^".X>. W$;A6!FB"R*<#<#D#!K^'_2_%/QX^/.L^-?A5\7_ (@_'OPM
M\/?@?\0/'7Q._:*\36L5S#=%[ZTN_P#A'O#&AS_9E>?3X-7^SI##$SA5(X -
M?U1?\$1M8^,.M_\ !/7X67WQKF\0W/B;^V_&,&BW?BI77Q!=^"8=9=?"5SJ0
M=$/FRZ7Y; E02N,\TZ>94*]#ZG_:^3YM*-:IB</B<'@:E.M4=>-.OC:='$SX
MFSB:FIUZ&89M2EA*=%8S,J5*A5H5*&(PJJOEV/IUXX[$91FN6VHQPM:.,Q^8
M5J4(4W[/!<U'%\.951<>2C6PF5^RQDZU/+L%"K.C7P^*P^).#_X+>_\ )O7P
MT_[*SH?_ *.M*^\/B'K6N^'_ -C2ZU3PX+C^UX/@MIBVKVBL]U%YWA2WB>6W
M"_-YT:L3&1R&P1TKX/\ ^"WO_)O7PT_[*SH?_HZTK[S^('B:[\(_L:WFO65N
MMS/9_!.P"JT1F6,3>$H(FG\H*QD,(;S%4*3N (Y%.,I1E&4)0A-23A.IS>SC
M).\93Y?>Y4[-\MY6^%.5B>53]V4)U(R]V5.GR\\T]'&/-[K<EHE+W?YM+G\M
M?PZU3P+>_%3X2_"[5?C'\7O"O[/'BWX<:OXN_:'L?-U2YD\7_$R/5Y?)T.XO
M&G:73H9_D79&RX09%?>GQ2\'P>)/^"EOA;P3\,[V71=-NOV:-'L/!5R99?.3
M2TT(I:VTMQ*QF!N0?+>65C(%8$MQ7R[^Q#\4_P!D7X0?'SP;I/C+XBV7C3P9
M\3/A3KWC/X@7/CG1[Z^M?#OQ(&L3"WTC3C):N+.-5;:L/ )Q@9P:^M/C@^J:
MY_P5(L[CX3SPK<ZI^SM93^#IK53'"^GRZ$WE?V>FU3$\B\6PVC$A4@5TXNEG
M4.3%YK2S3!87E='!YEC,PXAQ=:G[-^VK4I8+.\,N3%T75^NO&1Q.+QE>A7PV
M'K2C1H4E'.CA\OHIX; 5J>)JRE[6O@7DV197AZTY6IT\0\3E56=2M3FH_4%0
MQ%.EAL/'#3JX9+V\XKD=/_:2^&GP^_97\6_LD^+/@#K\'QEU"/Q=\/;;7H/!
M\=]X3F\4^([^]BTJ_D\:/"SK)(\J7#7!E\R%@NUEPM?N_P#L?^ _$GPP_9C^
M"G@'Q>RMXE\,>!-(TW5U2X:[2*Z1'D,*7+%FG6))$02,Q)QUP!7XE:9^TA^S
MS9?L->-?V?\ QIK_ (E3]HUH_&26?AO5M,OYO'9^(,FH77]ARVU\MH4,AG$1
MLI3+A(OX@!BOVG_8VM_&VF?LJ?!"#XC#4SXUM?AWI'_"0)J[&35_MBQ2.$U!
MFY>]\GRQ*2>6K@C2IT7!+"X/+Y8BC'$T(8.6'G#/,)*3]GG=3V6(JNA/GG*'
MLJ#Q& ?UJ3P^-JSC4BNAQKVG*5/'RC&JZ5:ICXYA%X7%)7E@L-]<P&#4Z35Y
M2E4<L:E2H^WA"$Z4JGT_17\YOP$_X+B^(?C)_P %9?%'_!.Z;X$>)-#\/Z7%
MK"V/CJZMID6.;1HA)+/>!HPJ6MSN7R)"=K<J#N'/]&5>AC<)#"3I1IYAEN8*
MK0I5Y5,LQM/&TZ$JL>9X:O.EI3Q-+:I3U6JE"<X24GQ8:MB*T:KQ&6YGEDJ=
M:I2A3S/"2PE3$4Z;26*H0E*3GAJCNJ<WRRO&49PA*+045_.9X+_X+B^(?%G_
M  5W'_!.$_ ?Q+8^'+F6YL(?'D]M,HM[JTB>5KV?,806$VQMDI.P$JF[)7/]
M&=&,PM/"N@J>899F'ML/3KR>6XVEC8X:51.^&Q4J6E+$T[>_3O*-FI0G*+N&
M&K8BM[;V^6YGEKIUITJ<<SPDL)+$TX6MBL-&4I.IAJC;4)OEDW&2<(Z7*_CM
M_:W\+ZWX@_X*6_M :C%X8UOQSX/\->+_ (=ZSXQ\(^'A.^IW>F64*2W%X(+<
MB2XA@C&9(6S&XX88-?<&J_\ !<7Q!8_\%>O"7_!-^/X#^)CX;\2ZC!H;>/7M
M)]EK=2),W]I$^6$.G8@DS+D*C-"K',JU\2?M<?%_Q#\(_P#@I'^TA_8'B\^
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M+E,XP.:^U/V([/XO^$/VEO"'AKQ9\0?B!XUU3Q1\&?B-XE^/NG:_<W=QX?\
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M2%7.3ND(#2'L"W(''2O9IHH[B&6"50\4\;PRH>C1R*4=3[,K$?C4E% 'R_\
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MTEC\=.IAZL\9BIU,)3A2PM2=>K*>&I4[\E.A)R;I0A=\L(<L5=V6I_-YX?\
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MM4^ FN^((SH>L2;]-OD^T6#Q03*-^]2 P+KC.#C^SG_A']!_Z FD?^"VS_\
MC-*=!T-OO:+I)QP,Z=9G ].8:ZI8/"3HRPTL-0EAYS=2=%TX^SG4<N?GE"UI
M3YTI<S3;:39C&M6C.-2-6HIQ2C&:G)2C%*R497NDEI9'\Y_Q;_X+I?L;:_\
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M"?A'XD?LU?']?BAX-\ :!X>\2W=Y^SMJ^KWL6HZ;;+'+''J,VGM(8XG&$VL
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M'I?_ "6']GO_ + ,O_HF>OS%_P"#3'_E+Y\.O^R9_$K_ --$=?IU_P 'I?\
MR6']GO\ [ ,N?7_4S]J_,7_@TQ_Y2^?#K_LF?Q*_]-$= '^LI1110 4444 %
M%%% !1110 4U?XO]XTZFK_%_O&@!1T_$_P S2T@Z?B?YFEH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR/\ )J /S@_X(;_\@CX^_P#8R:9_Z!)7[\5^ _\ P0W_ .01\??^QDTS_P!
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M[QH 4=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJGJ&HV&E6<^H:G>6VGV-K&9;F[O)H[>W@C7[
MSRS2LJ(H[EF H N4UW2-&DD98T0%G=V"HJCJ69B H'<D@"OSG_:'_P""F'[/
M?P0.H:!8Z]'XR\9_8W?2]/T%H[_3IKG:=B3ZA [Q(%; D .1Z\5^/WC3]NO]
MK;]J6UNH/!%PG@KP?'-)HOB3P]X=7[7XDO[2=R/M=BD/^DDK&5SY9P#[<T!_
M2\_3NS]Z_CK^VE\ O@##<V_C'QOI;^(UMOM%CX9L)Q=:EJ+'[D$ @\R-9'/
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M#B77M*G0X.-C1M@'_:^8?KZ5^_M !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M T?X5?ME_"+5M+\1?#KXG:-8V]AJFA1.;36;2\5;BV\0LP5<QW$.,2R*I)#
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M^#TC_DB_[/W_ &$YO_3D]?W(U_#=_P 'I!_XLO\ L_?]A.;_ -.3T ?R@_\
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M!1110 4444 %-7^+_>-.IJ_Q?[QH 4=/Q/\ ,TM(.GXG^9I: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?%^O+X6\*^)/$KQ
MF9- T/5-8:(9S*-.LYKLQ\?W_*V_C715YS\8/^24_$C_ +$?Q1_Z9KR@#\6X
M?^"VGA5O-63X?WHDBN+B!@@E*Y@GDAR,G/)3/TJS_P /KO"?_0A7OY2?XU_/
MO%I8_L#4=<W@2#Q#J-F(L<[3>W!W9_\ UGV[5[#\-_V;_B[\6="_X2;P-I.D
M7VE"22(/?:U96$AEB!WCR;B17VYZ';SP>F#0!^T__#Z[PE_T(5[^4G^-,/\
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M_P!^IZX]_P!A'XF>9+CX)6./,;&+BU(QVP0<$>A%-_X81^)O_1$K+_P(MO\
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MM#9FZN)(8_L\CHS"!%D/S952>.R^H- 'Z$_\/L_"/_0@:C_WZGH_X?9^$?\
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M'7A.W>V\,>&/&-A9Z1;3OYTD=L[Q.!(_&\]#G'4_G_8[\(QCX7?#X   >$-
MX P/^0;;]!0!Z)1110 5\9_MN_M4G]DGX6Z=\0$T1->EU+Q!;Z%#:2%@BR7"
M;EE8J5. ??%?9E?CG_P6K_Y-H\*_]E$TS_T70!\QVW_!;+Q+A_MGPVTA#G*!
M)K@Y4],XD//M4Q_X+;:R#Q\-K _C=?\ QROS-^#OB/\ 9W^''A2/Q9\:?AAX
MB^)>I:Q<30Z-#HNH_8X-/-I]XW*$_O?,VX &<9 Q7[>? CX&_L#_ !M^%OA_
MXDR>&].\%OJ]H]Q<^'M9\0V=OJ&GF/JLD;MN.5&0 -V<_+T) /G3_A]OK/\
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M^)_F:6D'3\3_ #-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;?\ 95_%?\J_K!K^3[X$_P#*6BV_[*OXK_D: /ZP:*** /Y]?^"YC 1? ')
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M2LZ?_P!E8\)_^A-7]7E?RA_M,_\ *5G3_P#LK'A/_P!":@#^KRBBB@ HHHH
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M@YC#$Y\M?X5XQZ]J /V _P"'HW[)O_0W7O\ X '_ .+H_P"'HW[)O_0W7O\
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M+\5NUX_3Z?CQ7]&%?SW?\$3K<&Z^(UTH^4VPC'3M<+^?/;\>HY_H1H ****
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M*$#'-?KA^SM_P2OL--T/P_>_%;4(K2YL4MK_ $VW\/ VVLP$JLGV35[UPPG
MSM=06[CB@#\YO%_QC_:[_;"U 0:UK>OV/P\UW5)[&\\%^"(IVU;P[.#A%N'M
M=LXB5B SNQ&WOZ?7OP"_X)3^);Z/3=6^(5W#X9ELIH[RP\20R#4?$^JVNX.E
MOJUO=Y:-V0[7WG(.>>N?W"\ _"'X=_#*W\KP;X5TG1KAXU6[O[6TC2^OI N&
MGNIP-SRR=788STZ5Z50!\O>!_P!C_P"!?@;1K_3+#P;IUU<:S''_ &U?WD*S
MO?7*%6:Z$#@PP2NRALQ*"/4U]*Z?86NEV-GIMC#';V=C;0VMM#$BQQQPP1K'
M&JH@"@!5'0=:N44 %%%% !7SU^U+\&[/X[_ _P >?#R=+9;S5=%NCI-Y<1JY
ML;^%?-CFA8@F-W5&BW+C[XSTKZ%I" 000""""",@@\$$'@@CJ* /YL/^"1?Q
MDN_A9\9_'7[-?B=;A3K5_?\ ]E37]R88=/F\/,]L(H(I2$_XF#(2JH%+LRD=
M,'^DUT65'C=0R2(R.I (9'!5@0<@@@D$'@BOY@?^"E_PXOOV:/VK_!?Q^\-2
M/8:3XLU2RUHV>BQ-;+;_ -BR^9J5M,\0"(;YE8LN1OW9Z$5_1C\%_B5I_P 7
M_A;X)^(^FQB"V\5Z#9ZI]E\Q9'M9)4*RP2[?NNKHQVG! (S0!\A_ R8_ ?\
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MP$,/1]M*MB:E/EJ\^)Q%>JG#GY3_ !VOVN?V#/VPO^"!/[1GP8^*DWC?PO\
M\+(TVY7Q%X+U[P[/%J,%G=B"5?WJ<HWR%E*D<$<^E?L3_P $(?\ @JI^VO\
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M[QH 4=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>J7.N>$/"^L7@"W>J:!I%_=!>5^T75A!-.5_V3([$>Q%=-0 5_+)_P %;?\
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M22B^633W2D](MK9O1/4_+[]BK]MW5/CI\</%7PL^(^ES:;XTT>WU2X\,KN:
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MGCPQXE\,^+]-\ 6,GB/PC;O;Z-JE\[7MS%O.3/.TP/VFY!Y2>3+H>5Q7U
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MR/\ )J /S@_X(;_\@CX^_P#8R:9_Z!)7[\5^ _\ P0W_ .01\??^QDTS_P!
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MQ[X8T7X+>,/!FH7YB\1ZIXWN;JRL0A(EMVUAAYFX9[XX.?7BO[+/@*"/@O\
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M4VK<MW'-\>Z%)IPP]9\[F_U!_P""3?\ R89\ ,<C_A$+3!]?W<5?H[7YQ?\
M!)S_ ),,^ '_ &*%IT_ZYQ5^CM2:G^>K_P ';=E\,M:_:_\ @1H'C#P?XETS
M5-9\.^$].3XRZ=)<II/@ZQO=;LK>9;M864.\D4C(#N5HSB0$%01_;?\ L'?
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M>-[_ ->ES_Z)>K=5+_\ X\;W_KTN?_1+UD:'\I7_  3K_P"4D>J?]ACXF?\
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M\0?^E,- 'Z5UR?CN6:'P;XFEM].&JRIHFI%; A3]H_T24%55@P9@"65<$L0
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MZYU#4[V\N+<VT$LT6V'4YLQ-Y:L?-<H=B]6X !S0!_'G_P $;_@/\/?VI_\
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MYEF9L(H.YR3@GFO7?VN/^";/[('[<&F_#_2_VAOA@GB>#X6RW<W@*?2=6O\
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M7\I/[,G_ "E5UG_LJWBK_P!&&OZMJ_E)_9D_Y2JZS_V5;Q5_Z,- ']6U%%%
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M&*_D'US_ )*3\'_^O+P;_P"G"WH _ML\-?\ (N>'_P#L":5_Z005MUB>&O\
MD7/#_P#V!-*_]((*VZ /)?CK$LWPC\>HUA/J!_X1O4V6&V!,\3K:RE;J,+\Q
M-L1YN%!8XP!S7X1_LN^'+GP1I7QYT?2_B!JOCK2/%OP,\3>)]7L&M+VWL-%U
MK==J+6Y6= C7\2?+D8; )Z5_1G)''-&\4J)+%*C1R1R*'1T<%61U8%65E)#
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M8+M4#*C@HV2!QT_1[3=+TW1K2&PTFPL]-LK>-(H;6RMXK:"-(U"(JQPHB\*
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MBZ98S*\%O]@4B'S8T5@5P,$9KTG]JM53]FWXT(@"*OP^UY55 %"K]E(V@#
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M2VDVVV[W;9_4?'(DJ))$ZR1NH=)$8,CJPRK*RDAE(Y!!((Z4^O _V6KR[O\
M]G7X-7E]<2W=W/X!T%I[F=VDFF86H4/+(Q+.Y51N8G)(S7OE !1110 4444
M%?S(_P#!;'_DNOPO_P"Q7LO_ $\I7]-U?S(_\%LC_P 7T^%__8KV7_IY2@#^
MB;X.?\DF^&?_ &(?A/\ ],=E7I%>;_!S_DDOPS_[$/PG_P"F.QKTB@ HHHH
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M_P $-_\ D$?'W_L9-,_] DK]^*_ ?_@AO_R"/C[_ -C)IG_H$E?OQ0 4444
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MLY_O;1116YF%%%% !1110 4U?XO]XTZFK_%_O&@!1T_$_P S2T@Z?B?YFEH
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M[.H##L:CATK3+>^N=4@TZRAU*\CCBN[^*VA2\N8HO]7'/<J@FE2/'R([E5[
M5S2Q.?NK&,<5AHX6C-*A*-;.:>(E0J)4JM/$T*69PRVJL-A?;87 TXX.G0;Q
MN*Q>-IXG%>SG'HC1R=0<WAL3]8J0O6C'^SWAI5J;<Z;C*>!GC(QK8APQF,D\
M3*K.MA,'1P\Z&&A.G+0HHHKI.<**** "BBB@ IJ_Q?[QIU-7^+_>- "CI^)_
MF:6D'3\3_,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5YS\8/^24_$C_ +$?Q1_Z9KRO1J\Y^,'_ "2GXD?]B/XH_P#3->4
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MTS3;9.%BMK=.$7IDDEFQDDFNXHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ?[QIU-7^+_>- "CI^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444
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M7GTJ:58EGC 521N8>U9E'UK1110 4444 %%%% !1110 4444 %%%% !1110
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M=)063Y)TC*K-'R<H^5/IS7]&;=#]#_*OYDOCS+\3I_\ @H%X'F\<>#[KP[H
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MVW_!0K]ERZA2=/B#:*KC($B[7'U4MD'V-3_\/ OV7O\ HH5C^7_V5?"FM?\
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MQJJ<LP['- '[0?#G]K[X$?%3Q5:^#?!GC.SU37[R*2:WLU*JTB1#+X);DXZ
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M\!_^"&__ ""/C[_V,FF?^@25^_% !1110 4444 %%%% !1110 4444 %%%%
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M\$Y?VT_"NI7WC'X0^-U^%VI:#9^%?'>C3:/XGU#5I[JS<V^B6H\PW4T;0.H
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M.OC/XB^,]2\6W$MI+901W[LRV[QB4F1?F(!..>G/X"@#WG_@AO\ \@CX^_\
M8R:9_P"@25^_%?@/_P $-CG2/C[CG_BI-,^GW)._3-?OQ0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-7^
M+_>-.IJ_Q?[QH 4=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@
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M#7]J^"8/".K_ &]SJMS:?\>>OWY13<ZM9[?D^S7<F98MGR;2-O% '[\T444
M%?,?[17['W[/_P"U)H\.F?%[X?Z/KMY8RQW&D>(DMH[?Q%HUU&XD2XT[5(U$
M\,H90=Q+'@ 8%?3E% 'XYW'_  1C^#O_  LK4OB/I?[07[4>B-J/AY_#G_")
MZ;\5-3A\*65JUM]F2XL-+&([:[B3#1S)\P< YK'T[_@A1^QK??"3Q-\&_BOJ
M/Q7^//A;Q-?7>J32_%WQQ>^*M2T[4;D/BZTNZNANM7A9@8@O "*,CJ/VDHH
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M;.FS$[AP?^6?KT]J=_PU/_P51_Z$F#_P63?_ !NOZ4S969Y-I:DGDDV\7/\
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M?[QIU-7^+_>- "CI^)_F:6D'3\3_ #-+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %><_&#_DE/Q(_[$?Q1_Z9KRO1J\Y^,'_)
M*?B1_P!B/XH_],UY0!_'G\.?^3;_ (@_]C]=_P#IW:OZ]_@+_P D6^%W_8C>
M&_\ TUVU?R$?#G_DV_X@_P#8_7?_ *=VK^O?X"'_ (LM\+O^Q&\-_P#IKMJ
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MXH'@KX:_&7P3XG\6/&TT/AZQUFT?5;B-!N=K>S$OG3!%^9MBG Y-?4= !7X
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M@ HHHH **** "BBB@ HHHH *\Y^,!Q\*/B23P/\ A!_%'_IFO*]&KS/XS_\
M)(_B7V_XH?Q-_P"FBZH _BP\+_$[0] ^$OB[P#>6MW)K.L>,+F_M9XQFTCB;
M6& 61NS=,]O7M7]FG[.K^9\"_A2V[?GP/H W#H2MA$I_+&/PK^%V;_EZP/\
MF-RG@>FL.2?H!DDU_;3^S_\ $WX<6/P2^%UK/XV\+6TL'@O08I;>36;%)8I5
MLH@Z21M,'1P^=P8#!ZT ?4%%>97OQF^%6GP&XN?'_A98PP3Y-8LY&+'HJHDI
M8DY'0=Z]"L+ZUU.SM[^RE6>TNXDGMYD.4EBD4,CH>ZLI!!H _/;]M[]C_P >
M_M37WA6WT/QY_P (UX7T>WN(]7T4I'LU:24DKYDA7S$49 .T]!UK[-^$/@@_
M#;X9^"O 9:-SX5T&ST??"28F^RH060DDX))ZFO1Z*YZ="<*]6L\5B:D:EDL-
M)T88:E912E&E0HTO:5=&O;XF5?$*,G3554N6$=YU,/*C3IPR_ TJ\'+GQ].G
M6>.KQD[^RJUJE>I%44[25&C3HT^=*;BYMR9111708!1110!_/C_P<%)X4?X3
M?LT#Q7JFKZ3;CXRWYLY](W^8US_8]I\L^S_EEMP>>,Y]Z^XO^"2/]E#]AWX7
MC1;V\U#3A=>(/(N[[=]IE']HMN,F[GKT]J^.O^"]R^)F^%7[./\ PC.B:5KD
MP^+]\;NWU41%([?^R+7$D(EX\PMD';SC%?:7_!*$:DO[$_PT&K:?;:7??:M?
M\ZRL]OV>+_B8-MV;/EY')Q0!^C]%%% 'X?\ QV_X1#_A]W^R7]MO=<@\7?\
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M4QN*]K54%F&*Q&*ITH8FE&CA\(J:4U^</_!;G_DWKX>?]E*L?Y6M?=7["_\
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M0_+T_P 8QWY6ZU(WX,VM:?-=JJ+%<8.V%<D#;GV_6W_@FE_R99\$/^Q9@_\
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M&E&!#:6NI8^87L<6U9P_S;P<G-?</_!69_&*?\$\OVH6\!Z=H6J^)Q\.;_\
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MT85^7_\ P53_ &=V^,_[/6I>(M#L+(^*O ##6SJ<R_Z3'X?M-T^I6T)^\2V
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M^4O /PX.B?M3_&7XA?V]97G_  E7@_PQIW]AQ.IO--^PS0/Y\Z EU2;9A2P
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MB?YFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O,_C/\ \DC^)?\ V(_B;_TT75>F5YG\9_\ DD?Q+_[$?Q-_Z:+J@#^);X1_
M";Q5\:/%.K^%/!T<,NK6CZIJ+).VV,Q1WER>3CJ2" .YQ^'-^)]!\:>!=>U#
MPOXHF\3:#J^F2O%+97&I7MOF-&(\^&/S0!;M@M&0-I7!&,U]P_\ !,^_T_2?
MCC\0=6U:XAM-.TWPOK5U=W=PRK';0QW]RS29; .W!/'/7/%>7?MT>._"GQ,_
M:%UWQ-X,UB'Q!H4FBVE@NHVX"QM<P1E)85P.64\9[]>: / /"UIK\?B_P(VM
M77B.'2M8UNRDM9+[4KX6VHVHE&^2+?)MDC7 RW(%?V^?"R_T>'X=^"[>WU"R
M,<7AS2HT'VN%B EI$I!)?)(((.>>*_BE\2Z[J/BW3?A'X;MM4M+N\T>Q;2M+
MALU\NYTJ:XDS''=O@%I<\@\_7-?8VE_LW_MN#3[)],^(_C"ULI+>-K2*'59A
M'' 5RD:#?PH4G'''Y4 ?UJ?VCI__ #_6?_@3#_\ %T?VCI__ #_6?_@3#_\
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M75)5V*JJI=@)"#(^T%V/)/Z ']@O]HZ?_P _UG_X$P__ !=!U'3QR;ZSP/\
MIYA_^+K^3S_AG+]NO_HJ'C7_ ,&TO_Q=03?L[_MW1CY?B3XVF)STU>8?A]_T
M[Y% 'T!_P4B_:[_9C_8O_P""KG[+GQJ^/WQ!UGP\EK^SIXYTS1=#TH^?;:U+
M<ZMJ'E*T(;RY+EI9%\M20S(." 0:Q?">N:%_P46\:WOC3]O;XY?"GP9^SAJ]
MQ;:M\$OV;='\=6^F:IXBT6VECN]+\2>-/]*CNTOIHXEDNK-25R-FU5/'Y[_'
M;_@F1\8OVD==\/\ B7XY>&]2^)GB#PE;"T\-:OKLYO+_ $>U!!\FTFD;]W&6
M'(4X]N*Y&+_@DY\1M3\2:9K%]X+U.VU+1+);#3=5ENY@MO:JAC$$:I*%4*GR
M\+C!% '];_@W]J3]B/P'X1MM"\'?&_X,Z)X2\'6MIH20:?XJT6*STR*RB2UM
M[:XD289F5$52TS-*YR6))KLF_;'_ &5UNM-LF^/OPM%WK$/VG2[8^+M*\Z_@
M()$MLGGYE3 )W+Q7\?:_\$:O$J:9J^CKH-Q_9VNW?V[5+?[5<;;BZ!W^:W[_
M ).[Z>_3(TF_X) ^-6U#1-4;2+HWWAJV%EHLYN[@M9VRJ56./]]@  X[^U '
M]=@_;0_9/:WU2[7]H/X4FVT67R-6G'C#2?*T^;=M\NZ?S\1/GC#8/XT__ALO
M]E02Z5!_PO\ ^%GG:X@DT>/_ (2[2M^HH<X:T7S\S X/*U_(*G_!'/Q8EGKV
MGKHET++Q//\ :=<M_M=QMO)@=V^3]_S\W/;GVJ<_\$>_&1G\/77]D70N/"L8
MAT*7[5<9LHUSA8P)N ,X[\^W- ']$?[7N@_\$W?VS_#PL_B5\9_A;:^+OAO=
M-J7AKQ]H_C;3M.\0^ ]>0@VMX]W;W4+.D5PJ,UK<N4;!'L?R$_:)_P""DMU^
MRS^RG^T]^S]^V9\7O!/Q0\">,_A3XL\+?LX_&+X:ZG!KFN^,-+U#3)M-M(O%
M5O;2;;6]MTEB G7+NRG<&W;A\IC_ (([^+@GB%/[%NL>*VW:Z/M5Q_IK$[BT
MA\XECG/8=:S]?_X(OZSXJT'3?"_B/PL-8T'2('MM/TZ^9KB""*3&Y%261L=!
MW(^M ']'_P#P2.^+7PC3_@GC^R5I&G_$/P_<3I\+-$MHK6[U6VCU-I6DN9%B
MEMY9!+YH5UW<=<\U^C&I_&'X6:->2:?JOQ \*:?>P@-+;76LV<4T:D9!=&E!
M4$<@FOY'_!W_  3W^/OP^T?1=!\%_:O#^F>&[>.TT2'3[B2!;&"$8C6%4=53
M:!Z?@,"NBU']B3]J'6;N6_UC5M5U.^G&V:[NKR=YI% ( 9A*,X!P.^.] ']8
MUS\5OAM::7;ZU=>./#-OI5TVRVOY=7LTMIWZA8Y3+M8GL >XHTKXK_#77&G3
M1_'/AC46M8S-<"TU>SE\F)1N+R;9?E 7G)[5_*#<?L7_ +5EYIUOHUWX@UNY
MT>T?S+73);Z8VMN_3=&GF#! ''/%)I?[%W[5>AFX;1->UG2FNT,5T;2]F3[1
M$R[&CDS(<J5XQQ0!_5=%\;?A%-.EK#\1_"$MQ)+Y"0IKEDSO-DCRU42\OD%<
M=<@BKFJ_%SX8:'="RUCQYX6TV[:)9A;W>L6<,OE/]U]C2YVGL:_DVB_88_:5
M@G2ZAO=1BN8Y?/2X2[G$B39)\U3YN ^23G&,GI5S4_V*?VIM<N?MNMZWK&JW
M@C6$7-Y>SO*(4&%C#"4?** /ZP3\5_ALND?V\WCCPRNC;Q'_ &DVK68M"[<!
M1-YNTL3QC-?-?AOXX^#/%/[76J^ _#UEX8U86?POL]:E\>Z;?VUU=/YETH_L
M22:-V3RXU_>A0V1CD YK^=9OV,/VK'TH:$VOZT=##B0:2;Z8V?F+R'V>9G(/
M.<Y]"*?H7[&?[5_A6\FU/POX@UK0-4N(1;3ZCIU[+%=RVPR1;O)O+&($\+G'
M;UR ?UW_ -HZ>?\ E^L^_P#R\P]N#_'ZT?VCI_\ S_6?_@3#_P#%U_)Y_P ,
MY?MU_P#14/&O_@VF_P#BZ/\ AG+]NO\ Z*AXU_\ !M+_ /%T ?UA_P!HZ?\
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M[;_X=[^!?[1\7Z?XOTL"(>';ZU,9O%T80)]B&I[/G%\8=OG^9\^_.>:^U_\
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M)K\C/^":&F:)I/AK]HC3_"OC2W^,?CR\T6YN[GQ7:1RVUGJ-C>I(MKI-M:7
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M4?\ D8?VE?\ L>IO_3BM?UV7'^HF_P"N;_R-?R)_%'_D8?VE?^QZF_\ 3BM
M'ZI_\$H?^1A^/O\ UU\'_P#IN-?L_7XP?\$H?^1A^/O_ %U\'_\ IN-?L_0
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M:0JFL01L%\W3-J_*65LA0!U!K](P,  # '  &  .@ H _/C]I1[GX/\ Q_\
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M^R;:?&W?)\9/"UKX/L_%5IXGO[]Q_;>K6,MX";"^U&)I$#+CR78.KDBO)_\
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M^TMCH*^JJ^2OA]\-=7T/]J_XT_$:YO;&72?%G@WPOIMC9Q.IO8)K":W:5[A
M=RHPC(4D 9QCK0!]:T444 %%%% '#_$UM*3X=^.&UU6;1U\*:\=25,[FL_[-
MN/."X[E,X]Z\:_8WE\*3?LX_#>3P.DJ>%VT^^_LI9@5D$(U6]#[@>0?-#GZ&
MO8?BEI4^N_#;QYHUM)'%<:GX2U^SADE($:23Z;<(C.3P%!(R?2O&/V+_  I?
M^"/V;/AIX7U*>"YO=*TZ_AFFM2&@<OJU],#&RD@C;(!P>H(H ^HZ*** "BBB
M@#Y0_:<N?AG;ZG\$!\0X+F6ZF^*.F1^#FMU)6/Q&4'D--CI'C9R>,BOJ^OD7
M]J;X::Q\0]4^!-SI5[8V:^#OBMI7B._6\=4:YM8%4-#;;F7=,=IP!D],5]=4
M %%%% %>[_X];C_KC)_Z :_EZ_9CT<ZI_P %/O'<J*P_L[QK=7;&,XRJLPP^
M/X0!R.AR._3^H#491#87LI5F$=K/(57[Q"1,Q ]SC ]Z_CGO/BE\3?AE^V1\
M6?&/P@T9]7\6S>++V.#371I)"F]MJLJ@MDD_3CF@#^R6BOYJ8_\ @H)_P47B
MW*WP=C=@V"6L)<@@G/\ !Z_X]ZD_X>$_\%%?^B-0_P#@!)_\;H _I2HK^:W_
M (>$_P#!17_HC4/_ ( 2?_&Z/^'A/_!17_HC4/\ X 2?_&Z /Z4J*_FG?_@H
MC_P4/CSO^#L"XZYL)1_[2Y_"JC?\%(/^"@<?W_A+:*.Y.GSY'_D+\P>>E ']
M,=%?S(O_ ,%+_P!O:/[_ ,++-?KIUQ_2$GWJG)_P4^_;JB_UGPTL%P<?\@VY
M_P#C/2@#^G2X_P!1-_US?^1K^1/XI?\ (P_M*]?^1ZF['_H(IUQ7MDG_  5-
M_;=5'63X>:<NY65LZ7<MM!&-V?)^7@GT[9(K\]+[XH?$#Q)?^.[NZTB-CXPU
MN'4?%<GELG]F3W%VCML4@%%$GRX.#@^F* /WR_X)0_\ (P_'W_KKX/\ _3<:
M_9^OQ<_X).B9=?\ C\)RC2"X\)#,8PA0:>=F.3SC[W/6OVCH **** "BBB@
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MC0 HZ?B?YFEI!T_$_P S2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>M '35E:SH>C>(K";2]>TNQU?3KA2D]EJ-K%=VTBD8.Z&970GT.,CJ"*U:*
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M75]-U&ZT34I[/QS9B2,MHGE+;JLD>R/RP2#C=Z"OU)A_;?\ VJ;5?@_I]O\
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M#KOC>\^'6G2?#VX23Q=8>9]ITN1[RU6!D\OY]LLI2-\?P,<\5_/A_P $A?\
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MV'[6/QH^(FKIH]]H7B?P=X8T_2K>2."YO;:YL9H&G>6.17:)'56"D!=Q/<T
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M  2H_P""WG[-?_!07]G1O'_B+Q=X>^&GQ-\ :*DGQ9\)^(M2MM-_LJXLX/\
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MSKC6UM#?K+_:FG^>$\[]X$1<LA (R!CFOZH_ GFCP/X-$RHDW_"*>'?-2/\
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MU:VUS4?CSJ-FZO;O=>%80R$%=\%B4< C_:SGTQ[U^VM !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'YG_\ !4?_ )([X+_[&Z+_ - 2OTT_X)=#
M;^QW\/QQ_P ?VLG@$#F6 ]#[5^97_!4C_DCG@O\ [&^#^25^G_\ P3%7;^R!
M\/QC'^E:L?\ Q^WS^N?KU[T ?H%1110 5_-+_P %A?BS\5/"_P ?M&\%>&_'
MWB'1O!>L_#B&?6/"]C=O%I6I2^<0SW,"D!V8#!)]:_I:K^6C_@M 2/VI/"9
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M_P" L_\ \17ZK_\ #*/P!_Z)OX?_ / .'_XW1_PRC\ ?^B;^'_\ P#A_^-T
M?E1_P^[\&_\ 1'O&/_@+/_\ $4?\/N_!O_1'O&/_ ("S_P#Q%?JO_P ,H_ '
M_HF_A_\ \ X?_C='_#*/P!_Z)OX?_P# .'_XW0!^5'_#[OP;_P!$>\8_^ L_
M_P 11_P^[\&_]$>\8_\ @+/_ /$5^J__  RC\ ?^B;^'_P#P#A_^-T?\,H_
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M_A[XFT;]K[XY^/[ZS@C\.>)_!/A33M(NTD4S3W-C/;-<)(@^90H0[2>O;.:
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MO:0I*KA*M*I3PD7.;C)OZG5AB?<K148^R52I/#T95*5.I&I*-=?;7_!'O/\
MP[2_9&SC/_"M'SCID>)->STK]*J_-3_@CRV[_@FA^R(V.OPR)]?^9CUW/2OT
MKK<Y2&X_U$W_ %S?^1K^.GXL_"O2/%OQ!_:5\9ZA=7*WOA;QC<R64,<A\F0W
M-Z(I!*F0&&T\<<>N*_L6N/\ 43?]<W_D:_D\\8?\?_[7?_8VM_Z<5H _0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_,[_ (*D?\D<\%_]C?!_)*_4?_@F<GE_LB?#Y0,?O]3..XRUOU]_Z8K\N/\
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MD\L28V$ @'/2@#Z]_P"&V?V6SROQC\)NO9DNW=#_ +KI&5/X$T?\-L_LN?\
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M5M9O6W37E]=2%I99)'8!G.WUKZ'HHIB"BBB@ HHHH *:O\7^\:=35_B_WC0
MHZ?B?YFEI!T_$_S-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<5\2-6DT'X?>-]:A7=-I?A37[Z)3T:6VTRYEC4^Q=5!]J[6
MO,_C/_R2/XE_]B/XF_\ 31=4 ?Q!>*?B9XL\2ZEXLNWOFM++Q/XFN-1U'3(Q
MF%[H:D8P^[.0<(/T/K7]-WP<DFE^$_P]>=55U\,:.J[3GY?LZ@?F.OX_6OY4
MY/O77_89G_\ 3M)7]5_P=X^$_P /L#_F5]'_ /29* /2**** "BBB@ HHHH
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MTJ* /AOP-^RQ\7_"FO1:OJW[5/Q%\4V<=K+ ^DZC9V0M99)%(6X8AR1(AY7
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M?^'JO[8W_1O+?^ T_P#\31_P]5_;&_Z-Y;_P&G_^)K^A+_A!O!W_ $+&A_\
M@MM?_C='_"#>#O\ H6-#_P#!;:__ !N@#^>AO^"KG[8"</\ L^E3Z-;3CU]4
M]JK-_P %9_VMD_UGP$1?K!-^/\/O7]#;?#_P0^=WA306W=<Z;;<_^0ZKM\-/
MA^XPW@[PZW.>=+M3S]?+SVH _GD?_@KI^U7'][X&VXY(),,_&!GGY:K-_P %
M?_VHD^_\%K%<=<Q3\8]>*_H:?X4?#1_O^!O#+9]=)M??OY?N:KO\'?A7)]_X
M?^%6^NCVG_QN@#^>*7_@L1^TML=9/@]IJ!U*\I/E<@\_=QD Y_\ KU^>#_&_
MQKKLWQ/D/AA9T^)&KV][XEN(U8KH#37J/NSCY07^7+5_8_<?!/X1>3*6^''A
M!\(QPVC6F#QTR(\CCTK^7SQ+I.EV%W^UI#8:;9V4-KXH\BUBMXPJVT":BFR&
M'@;47H .E 'Z<_\ !* 3#Q#\?EG"B19O""_)RI0:<0I![DCKZ&OV@K\8_P#@
ME)_R,/Q[_P![P;_Z;37[.4 %%%% !1110 5_'!_P5%_8>_X+N_%S]MGXG>/O
MV.?CJ_@[X :O::+'X/T$>(CI\=F\%MMOP;,6TA21YP7\S?@H0"N1FO['Z_E#
M_P""W/\ P<B^#?\ @GGXN\6?LR?!?PP_C#]HS3--MVU"^OAC0/",FI6[2VKW
M:$#[3<%"'6-6) &<8(([\OPG%.+K2CPKQ52X.Q5.FZN.SFO#!U*-/+E*,:M.
MI#%N\U*K*C)4\+3KXJI*"A2HSN[>=F=;(*5"'^L'"M/C"C4JQA@\HJ4*]:^-
MY92A7C*C.C"@Z=*-52KXFO1P].$Y<T^9P3_GY_:L^$?_  7P_8O^'NH_$;X_
M?MT^'O!NG6-K)=6VE77CR$:SJPC_ .6.G6;6X>>5CPJ#&2:_.+]C#]O'_@M%
M^UK\>?AUX'^$WQB^,WC^VA\>^&)/$4VDQ3SZ/;:'!K=H=4?5+R.!H8K.2Q6?
M>C.&=3@8ZCH/V?O$/@[_ (*M_&B[^-?_  52_;SM_A]X"M-<:\?P#>:A<B6>
MR\TR?8M!LO.-O8P%!Y*G9YA!SD=!_;)^Q5^WQ_P01_8O\,>%_A/^S9\6_AAH
M%WJ%SIGAV#6(+$OXD\0ZC?2Q65H-0U/[,L\LEQ/(B DJFYAZYKU/K/C57YL!
MPIC^->*\)&WUWC?/>&HY)DREHJU/(<LPL/K>:4XQ3=.O6K4</-N,JM?5T5Y5
M/ ^$6%MC.*,@X)R;'-0EA>#^&Z=?,L32NDZ=3.,\Q='$4*$I2252C@Z<ZT'>
M$80TJO\ I!\-I?1^'= CU,L=231=*34"_+&]6Q@%V6/]XSB3/OFMJJUG=P7]
MI:WUJXEMKVV@N[>4=)(+B)9H7'L\;JP]C5FOG/>6DM9+XG:UY=7;IKT/IE:R
MY5:/V5VCT7R04444 %%%% !1110!\'_\%-?^3&?VA_\ L26_].FG51_X)@_\
MF3?!7_L C^4=7O\ @IK_ ,F,_M#_ /8DM_Z=-.JC_P $P?\ DR;X*_\ 8!'\
MHZ /OZBBB@ HHHH **** "BBB@ IJ_Q?[QIU-7^+_>- "CI^)_F:6D'3\3_,
MTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YG
M\9_^21_$O_L1_$W_ *:+JO3*\S^,_P#R2/XE_P#8C^)O_31=4 ?PB2?>NO\
ML,S_ /IVDK^J_P"#W_))_A]_V*^C_P#I,E?RH2?>NO\ L,S_ /IVDK^J_P"#
MW_))_A]_V*^C_P#I,E 'I%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^9W_  5(
M_P"2.^"O^QQMOYQU^M/_  3U7;^RK\.AW\BYS[G$//XC'3ITK\E?^"I/_)'/
M!/\ V.5K_P"A15^N7_!/]/+_ &6?ARN,?Z+*>^.5@Z>@H ^T**** "OY:/\
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M:$&1KJ"?)\H#(5 <5S'@CX+QW'[/?Q+_ &A?"7A^V\1:)_;?BF/6?!UU&O\
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M&UO_ $XK7]8=Q_J)O^N;_P C7\GGC#_C_P#VN_\ L;6_].*T ?I;_P $I/\
MD8OCW_O>#?\ TVU^SE?C'_P2D_Y&+X]_[W@W_P!-M?LY0 4444 %%%% !7\W
M?_!2'_@A]_P33^.'Q>^(/[9O[6OBI/!FH>);.R7Q#JVJ^(DT?2BNE6_EQ&!+
MBXBC>X,0VA4!<C YS7](9(4$G@#K7^>3_P %?/$W[1'_  6!_P""R^C?\$MO
MAIX\N?"GP?\ A["MSJ[6M[-;V%];V4$-YXDU'48H66.YFMDD,=FDNY2S$LA\
MO!Y\9E'#^9X/$5N)\1G5'*,K@\=5I</XS,,%FN-K1C*G1P.$J9?7H5)U*[J2
M;C4E4I*,)35&K5C2IRWPN9Y]E^*H4>'%E,,SS&:P4<5GF"P6/RW 4).,ZV-Q
M-#'4JM-JBH1Y>3V=24I1BZM.E*K)</XB_9O_ .#7#P[XBF\,W?QC\6W-W!<-
M;/=Z;<W-QIOF+)L)6XCD*,FX</R".:_3[]DK_@@Q_P $1OVG)O#7Q(_9L^)I
M\;R^&-;T?Q-#I^G>*Q-JEK<Z3>0:A:+J.FI=&XCB:6)"ZO'M8#TR*]:\*?\
M!G[_ ,$\=,\'V>D>(?$_Q+U?Q%]ACCO];34+:,M?&'$TMO'L $8F)9%<9V@
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ME;_7]+^!?Q<\(?$J_P#"UO;W7B"U\,ZG%?RZ7;W4BQ6\MTL9S&DLCJB$\$G
MKZ/KY_'8#'99B9X/,<'BL!BZ:@ZF&QE"KAL1!5(*<'.C6C"I%3A*,HMQ5XM-
M:,]O"8S"8^A'%8'$T,9AIN2A7PU6%>C)PDXR4:E.4H-QDG&23TDFGJF?!_\
MP4U_Y,9_:'_[$EO_ $Z:=5'_ ()@_P#)DWP5_P"P"/Y1U>_X*:_\F,_M#_\
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M_A]O\!?^A/\ %_\ X S?_&Z /VOHK\4/^'V_P%_Z$_Q?_P" ,W_QNC_A]O\
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M(TO@^38#D OIQ8\_Y'I7[/T %%%% !1110 UU#JR'HPP?I7^<[^WSXW\<_\
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M^[.F_P!]1II5_P"*VY29\'_\%-?^3&?VA_\ L26_].FG51_X)@_\F3?!7_L
MC^4=7O\ @IK_ ,F,_M#_ /8DM_Z=-.JC_P $P?\ DR;X*_\ 8!'\HZ"#[^HH
MIDDD<2,\KI&B@EG=@BJ!U)9B  /4FA7>B5V]$EU$VDFVTDM6WHEZL?17Q_\
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MQK8V<=_>^&M O]6M;*5BD=U/:1%TA=A@JKG@D$''2@#T&O,_C/\ \DC^)?\
MV(_B;_TT75?B1X0_X*M_M ^*->?3U^$/A:&"TMK74+Y?[2?*:=<WBVPDC8OE
MY0I+[,]>#Z5^S_Q&U&36/@+XPU::,12ZI\,=5U&2)>5B>]\.RW+1J>XC:0H#
MW S0!_"Y)]ZZ_P"PS/\ ^G:2OZK_ (/?\DG^'W_8KZ/_ .DR5_*A)]ZZ_P"P
MS/\ ^G:2OZK_ (/!O^%3_#[Y6_Y%?1_3_GV3WH ](HHPV<;3D^N!T_&D!S0
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M/[1W[.8_X3'X)>,&^U?%3X6PXNCI+3MB^U.STWYQ;WEMOD62Q,>W&=RLA!(
MW#?"S_C(W]G'=XP^"7C$";XG?"^W/FG2UG1/[0O+&R*O]CGM][_;(1&"5W*0
MR-\SBH^&"_\ #2'[.!'C'X(^, ;CXI?"VW4RKH_V@N-0U"PTY@YMOL0D?[59
MF,%F!(#(P8L91\*Q_P -&?LY9\9? SQEB7XG?#"';<MHS7 1M3O+/3OG,%Q$
M6D^VVFS]RN008R"5^?X5M_PT=^SB5\8?!/QB1<_%#X808N4TIY]_V^_LM/\
MF\FYLA)();3RPIP592AY $Y^%A'[1_[.1;QA\$?&.)_B=\+X"9CI*W!5;^_M
M+##_ &.>$M)Y]OY88#<"K(>?R;_X*>>&/A;9ZC\*/B7\']2:;PY\3+#5-1F\
M.13YT_P[?Q[GNH;73RV;"5YF*W$91"9%(&5PQ_6;CX7@_M(?LXC_ (3'X(>,
M")_BE\+(<7+Z.;@Q_P!I:A9Z<-_D7D1DD%U8^7^Y&[Y3&REOR6_X*=^%OA?8
M:G\)_B3\(-4^T>&_B7I^I:D_A^*8-:>';],R7=O#;!C]CF:9RMQ"57;(K 97
M!H ^M_V+X/'?P=^!NB_&SX</)XW^',["P^*OPY#?:Y+6$X6]UFU@'F#S$60E
MHPN=N<C&:^LHF7X8,O[1?[.A;QA\$?&)$GQ3^%]M^];25N%']I7NG6+!_LDU
MHKR&]A\L;\,I!1N?E+]BJ+QW\&_@9HWQK^',I\;_  VN)%L?BM\-D/VV2SB+
M!;S7+&V.XR7<8<[X-I7R\AE*Y!^J9(A\+,?M(?LX?\5A\$?&($OQ0^&,!6X_
MLO[0H.I7-E8?.;>>VW2?;;8(!%AEP4() /F#PA\2+OX#?M$>)_%?PC@M/%/P
M.^,%K/XWU?P):1JJ:/II21-0?[&=PCO8)GD7[*R"63#?*58U1FU75OAA87O[
M0/PYU?0O%/PL\?\ B^YBU_X:WVFB\;PY827 ^UR16FUOL%P(?,$V40MDC'-=
MA\>_@W,^DZ9^U;^R3<QZYH,%VGB'Q'X"B82"VN4+?:[5K-23!%'ND$]@R",N
M,[2"I/GWP\O?"OB/P_JWQB^%$DNKZ7KU["?CM\&;I0=1\.7:2A]3U3P_I+8)
MCDVRF41)A(^16579*5&5>*?.Z*6%Y:DH6Y8SEB:55T[IR<)45&3DN2=2$)\R
MN"=[QJTZ$[J/M9*NY1C*ZDX^QDDXZ1]K&:E>%W",I+E=[]IOX_P?LL:7X=^+
M?[*OBW2)]"^,6F"]UCX8:C9/J&A)?"+9<R6UK@KI:J[NMQ;R*GF'S -R'YOD
M6Q^(NG>$OB5^S[^T!XA\4:5XGM[SQ:NN>+? .CQI9Z=HEU?A8[Q([5@8XHX8
MW<ME " ?7-?8?[0_P5S#H'QZ_9[\(Z5\5/@=J6CO)XX^'<CB2XT#6H(@OGVD
M',ME]G<YNHD55WHP.0":_/:]^"VG^'_$OPM^(_CNPCU3PMX[\:I#=_#KPI.]
M_+8Z*[H6MGBC)>*^@7=YT6 RHK''2M?E;R[?G^;(_'S5]?O/L"W^*7@CP'^W
MMJ/QB^#L>CZY\,=8T9)/$>C6]S:V=I%%JD);7KN))6\GS+0O))+" 4=AM^8=
M>9\ _&NS\ >*?VE/C;\.=3T6?X,^-/&%_H$O@</%"IL+J"7[1J5E9;@66.:5
MEW*I#8)KD]1\ ? ZR_;&%U\._ 4_CGX'V^D6)UGP+IUY=K+:*\0_MFYD2)Q.
MTM@=[7-NQP"I1CCFO.XOV=/#OQ-N_CW\3/A+IVHK\(_"7BBZLX?"]O+.DFAZ
M!'$S3WL-B#BXNH9E*8=3G:<G- '4^'+ZZT[]C'Q_XJ\'>/[*3P[X\\9ZFOCC
MX7ZC<Q-+8:*;EC8W>CVCMN@=EVF4QJ-P!//6NE_9$\;ZSX/^'OCJUTO7++7_
M (/ZG:R:/XQ\':GJ$2S:?IEY%F[US3(IY/D-D,?+& V5.*\6T?\ 9;A;]CV\
M_:<T&_O=:TN#Q)JFE^(/#UU=2VS:7I-A.L-O>16*,$EGEWQ><DB_+OXR,FNS
M^,O[/'@#P7^R[\&?VG/ =[=W>C:I?Z=8?$'PM8:A*@OKB[D56LI[>!QDNN[?
M$ZY"E"1AE- &%\/?B%X2^''QM^$/Q(T*]'B/P#X:\>:A8V/AO[7$L;:-*/)>
M\D24NBN(C(SEE.\#'4XKZ1TOXO\ @KX;?MW>)?C)\*(-*U;X6ZSIH3Q%H<,T
M%E:V]MJ,3-KUY%#(?*+VSR.\D(#)(XP 5X+OBK^R=\(9_A]\+_VK/@AH$>N?
M#>Q@TC_A:GPZM;YY?[*(DMAJ5S;K&?,CNH6D=;F$@,!\Q^5A7C>H^"?A#XO_
M &J[O6/AKX/N/%'P:FT'3)]5\*Z3=7"RZ;9FT5]9NU6%M\LMD2?-B8%69?F'
M6@#6\ _M+>&_AQXV_:"\:^!?$&FR>!_B;XKU>QB^')C$=JVA7,$O_$SLXSB.
M,B9W4''.,^M/T_0_$_A_]@OQ%\4O"/C6SD\&^-/&>J3>/?ASJ5["\EM:07I.
MGOHEF[[XFQ@SK&@9TW-R :\K\(_LQZ#XT;XH_&OP#I5WX@^%?PZ\8:C:WOA*
M8-#?CPQ;PR 2K$N)#<1S@YCQR!GUK0?]G"QD_8TD_:;\/3ZCJ.D7/BK5H/$'
MA*XU.YCA\/Z7%=E+%+?2U?R990K(LZO'N&0?H >T?%7PUX9^'G[./[-?QB\)
M^-[;5/AYJ7BS0]7\=?#F:^BNG376<1M<0VHD9K:&%5)FB9%V!HV(PXK]!X-9
MT3X0Z?IW[1GP$\2:!KGP?\4V5LWQ2^&$NLV:QVPN(T-[>Z5;3.1#<1@S?:(U
MCW.JE2K(^#^8/Q?_ &=/A=X6^ O[.?[17AN]U'6_"&MZOI.E?$'P/;ZA/>0/
M=W<BK)''8"1H[>Y"ABT80.B[2?O U]H>)_V4/@;IVG>%/VBOA/X6U+X@_!F?
M3[2'X@_"NR\0WY710L<7VV[M[&WD!DN[=G<7EM)'N0*3@HRF@#*\0^)? OPW
M_:V^%?QU_9QT]/B!X4^(7P\U_4O&?A'1[E+JT\-:-F4ZS+:Z>AD%J\6]GF@,
M8#R@[00 3[/\2?$$/P/\(ZO^TW^S9JEMK'PP\=6D\7C3X922;TM+Z\B=+FYL
MM.SFVOHG>3S+9$$B[3D%&YP;/X7_  F_9[U;0_VROV<[*SU'X9OI$NB>./"%
MU?/,OAW2M01QJ@L;.5V9+BVW,)+9E_UBCY6##/A]H+CXJ>.9_P!ICX%>%KO5
M_P!DWPM?:MJ7BOP!(TJ7>J^)C;-%?ZC9Z*&*O DK[_($9C0$$<9- 'YE_LW2
M0:G^UIX-U&V!CAUWQO%K!C8;#:OJ>H?:'MW!P4,!;:0<;3UXK^CWP9H]A\?_
M -J;XH>+M0MUOO"7@#PW)\+)K*<>9:MJLZ?:)KJ-6^1I@7D='&=N!SQBOYE?
M"?B^TLOCUK?C/1;=M-5]7US4=!T\KY4EG>RW,LUA8E!_JY(6*QF,8*D$>E?U
ME_L8>#9_#WP8T?Q/JL+0^)_B.$\7>)5<$/\ VC<*\*AR?F+B)03G/##F@#Y0
M^'^K7^C_ +/WQZ^#7B&9V\2?#[Q!K.H)%(2'C\.:I=JVE(4;YE2*&,*O 7#9
M&,5[M/\ \F#^)_\ LDOB;_TGO*^>/VQ8I?A)\8I?$5J'73OC[HR>&]:E0$00
M2>'[96C:<XV(TF%(8\L3UZU]$7( _8)\4!2"!\)O$X!'(*^1>;2/J,'\: /X
M[="427'AR%AF.XUW2;>53T>*?5(HI%/LR,17]E7A?]B7]FV_\+>&+N?X;Z,9
M[CP[HLT[^2N99I=.MY996R/O.[DFOXU_#_\ Q^^%O^QCT3_T\0U_>OX*_P"1
M-\)?]BSH/_IJM: /FO\ X8:_9I_Z)OH__?E/_B:/^&&OV:?^B;Z/_P!^4_\
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M48OFE@:6#S#"8Q>TQ$E&,)X6%/%W2A2K14Y*7]!/_$()_P $X?\ G_\ '_\
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M+M \-:E=W^J:I>ZMHMVUY;_;;^ZEF6.#SXA(R1A-Q4+T&*_T9J_BC_X-:_\
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MK6DAI+S0/$.G2Z+K(ME./M<=C=8EDMCP1*H*X.>E?75 !1110 4444 %%%%
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M1U_XG_"G2)-8\ :H+X1^'M7+2-]DUEWEO+,]>(@_EH.5&.AKV_\ X=P^&_\
MHX3P/_X.++_XY2#_ ()P^&@,#]H3P.!_V&++_P".4 >+^ _VV?$WPR\<?%WQ
M)X2T:V@\+_%Z[OVU/P?-'_Q*]-M+]'5S8VP 1;D,Y(8C&:\UTC]I'Q+X9^&W
MBKX8Z%+>R^'?'FM3:MXFTB^<OI=LIF,ULFD0'*PDY"S8 R,CM7UG_P .XO#?
M_1PG@?\ \'%E_P#'*/\ AW%X;_Z.$\#_ /@XLO\ XY0!\K7'[0RVVF^ M!T*
MTU&+PWX9UZT\4:]X>O9&DTN_UBTP!);0L2@C*9&-N,_I]+^%O^"CNL?"_P 8
MZIXA^%?A9+#PUXFMO*\4>"-45GT W++B6]T^UZ1S7)R)R  RL5P02*AUG_@G
M7:6L5LVB_'/P)J4TEPL=U')KEA&L%KD;YUS)\S+G 7N:U5_X)P^'2JEOVAO!
M(8@%Q_;-EPW<?ZSG!H \6\,?M=WEU\6KCQ+XXMKRP^$VLZLFIZ]\+O#+-%X=
MNF65GD5K$D1LDV<RK@;C],U]L6_[??P7^#7C8^*?@1I.I6?PU\3Z?-:>,OA9
M/A+2"XGMC%]NT:T7='#<><2TF00R$JVY685XE_P[A\-XQ_PT)X'/UUBR/_M2
MJ\W_  3?\/)'(]M\?_ CS@$HO]L6(WMV!/F<?7M0!^?FG:_ILGQ;M_&UQ"T&
MA3_$8^++FT8#S%TB;4S>M9.JX!80MY; #&0>.:_I.L/^"N'[-NEV%EIUCIFL
MP6EC:6UM#"D44:1)#"BF-%7(VH054_Q 9(!)K\C8O^">=\][;PS?&/P!'82%
MOM-T/$%@7A7)"D)YF3D<D=ORKJ_^';GA?_HX+P,?KJ]A_1Z /IK]LS_@H=\"
M/CG\(;S0O"NEZK_PG5C>VUUX<O9PJQV@#@WF6'.98P$ ]<<T_3_^"G'PANOV
M6-2^#MUH'B"T\477P\U#PRLS+$UFVHW5J\(<L3O"%G9SP3C'0'C\QOVD?V:M
M&_9]M_"MQI?Q"T+QW)XCGGAFCT6Z@NCIRPY(>?R&;:'V\;O7(KY9?RE(9]H+
M, ">[=@/>@"31(FAU'PQ$_WE\1Z'G\=7@/\ (U_>GX*_Y$WPE_V+.@_^FJUK
M^#73_P#D,^'?^QDT'_TZ6U?WE>"O^1-\)?\ 8LZ#_P"FJUH Z:O/OBGJ.OZ/
MX#\1ZMX9@^TZQIFGSWUM;!@C3_9HWD>)6/ 9U7"YXS7H->;?%^!+KX9^-+9K
MM[%Y_#^IQ07,<AB=+E[258 K@@@M(0HP<\TXR<6I1?*XM23<5)*VMW%RBFNZ
M<HZ7U0FDTU**DGHXOGLT^GN>^[]H>\]EJ?A[JG[4_P"U/X]^''[6UA\0/ VN
M?#7PWIG[/_BG6_!7B-YT6X>]MYGMH[NS9&#^85Y213A<CD=3Y-_P3K_X)/\
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M4*D*<54_>*,4IZH^#_\ @IK_ ,F,_M#_ /8DM_Z=-.JC_P $P?\ DR;X*_\
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MZ$4 %%%% !1110 4444 %>(?M)Y_X4-\52.H\&ZN>@/2 ^H/\J]OKQ#]I/\
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M$FP[?\N\7_QN@#^;?P_JEYKGB;P-I.M7L]SI6G:I:V5E;W*,([*SDDS)%&"
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M^">'_(V_'S_LVWQ=_P"DLE 'PCH4C2ZAX8=LDMXCT/)/7C5X /T%?WJ>"O\
MD3?"7_8LZ#_Z:K6OX*/#_P#Q^^%O^QCT3_T\0U_>OX*_Y$WPE_V+.@_^FJUH
M Z:O(?CQ'!+\*?&"7/VA(#I<_FSV@)N+5/+;-U'CG=!]_P#"O7JX3XGV^MWG
MP^\7VOAV""ZUBXT#4XK*VN4$D-Q*]K*ODLC<'S =@SW-)RY4Y<ZI\JO[22DU
M3MKSM1]YJ/Q::Z#2<FHI2;;22@XQDVW9*,IIQC)]').*>K36A_/U\/T\#0?L
MB_MVP^$_BYXK\9WS?#SQ,VH>$_$4JF&)M\F=7LD.7VQMFWRNT*#@YR17Q]^S
M?\&?VAO&_A'X":G\.?"6L7/P^N=,\&-XEFM(5?1M;AL[FWF>*[=CN4VH!D)7
MIC\_M6/X6:UH_P &OVH?^$0^'5_I"ZG^SOXNMOB 7LIS>7?CPW4LR66C)LWS
M020;G$< 93VKS;_@G/\ \%D_V'O@Y^RE\//AAX^\3?$7P[XQ\&(^@^(=(OOA
MGXJ:6RU&W$<5PJO%8LDD4;QD;U/S#! KFQ-26:T(3I9Q5Q\^91J8[$QP>*J6
MA=/#_P"RXO%89P]E*"@UB*E2%.:^":CR[TZ5+"U)0S/*)UH-<T<%FU*IAZRD
MG&5+%5:+PF!G&I&I!RP\GA::G34*J<U.[^A?A3&8/^"T7B6V>-8I+7X+7-O+
M"O2*2'1FC:,#L$92@_W?QK]\*_EP_8I_;)^"G[5__!:+QYKGP9'CK5='_P"%
M5^('DUW6?!>M:#H;&*SN 8XK[4+>*,RL1A(R=[<8&*_J/KJ7]65OP.=A114<
MTT5O%)//(D,,2-)++*P2.-%&6=W8A551R6)  ZT 25^;O[97@;P=K_QC_9ZU
MW6O#ECJ>LV'BFQMK'4;B/=+;027;%XAQ@HS$D@^N:]L^('[9GPB\&:PWAC3+
MN_\ &7B8LT<=AX:L9]2M1.IP8IM0MEDMXF!X.6.#UXR:_.G]H_XR?M&^/_C'
M\"]8\+?!76K+P9IGB.R:YCNM\T^I7+7&^-C(L0%G$%8 L^!QR<YH _<I$6-%
M1%"(BA451A551A54#@    #H*=5'3+B[N].LKF_LSI][/:PRW5B9!*;2=T#2
MVYD7Y7,3$IN'!QFKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %#5;<76FW]LV2)[2XAP#C/FPO'C\=V*_([]FW_ ()Q?\(A\?OB%\;/
MB7)8ZK9ZQK5U<>&?#S()H4MY'=HY[J.0%=V".",G/M7[ =>",BO,O&WQ?\ ?
M#S6?"_A_Q9KL&E:IXQU)=)\/VLH)>^O7^[$H'W<G@,V![T 63\)/AH2S'P1X
M<RQ+'_B66W4^VSC\*3_A4?PS_P"A(\.?^"RV_P#B*]%HH \Z_P"%1_#/_H2/
M#G_@LMO_ (BJTGP8^%4O^L\!^&F'<?V;  ?KA17IU% 'D<GP%^#DI)D^'7A9
MR?73(?\ "L^7]G'X&S?ZWX8^$W/<G3(LG\1C_/2N^\5^/_ W@2""Y\:^+_#?
MA.WN9/*MI_$6M:?H\4\G_/.&2_N(%D?_ &4)/M7$C]HGX",Z1K\9OAB7E<)&
M@\;^'2SNW"HH_M#)8GH!R>U &5)^S#^S_(&+_"CP<^58?-I<?\0Y[]?2OXY_
MVE#HUK\>/B58Z!IJ:;I6F^)-3T^UL+*!_)MUMKDH%1%!V(,84'MT)S7]P]G>
MV>I6D%]I]U;WME=Q"6VN[29)[>XB?[LD,T3-'(C=G1B#V-?!.C_L-_!6;XX?
M$[QKK/@FTU"R\66%A.D5XHE@34Y&1[ZX@5D(1Y&+%N^2/2@#^1?0O%?B'PK/
M?77AK4M3T6XU2PFTK4IK6"96N],N>)[*4A>8I0</^=>S?"^&U/PW\?\ [F+S
MHX]-9-R O'F\4D@L,@YY(X^M?UK3_L7?LW>1/GX:Z+@Q..((P1P?F7]W]X=1
MZX%?S,^,O#&C>&-4_:)TW1+8VEC8>+VL;. $!(K6+44\N)4'"@>E 'ZY?\$H
M !XA^/N H_>^#_NJ%'_(.QP% ';GU/)K]H*_&#_@E#_R,/Q]_P"NO@__ --Q
MK]GZ "BBB@ HHHH *3 ]!^5+7\BW_!3#_@Y4\=?L%?MD_$G]E[2/V4_$_P 2
M+#P);:/-#XKTZ6X6+4CJ5L+AFBC2UE7RHB?++>83O&, 5V8'!T<;5=*MF64Y
M9&,'45?.,?0R[#2:E%>SA6Q#4'6:DY1@G=QC)[)G'C<3B\-3C/!Y1FN<U7-1
M>&RBA1KXB$+-NM.%;$8>*I1:47)3<N:<$HZMK^NC ]!^5?QL_P#!U%^U#\?_
M -GKXF?\$[M-^"WQ3\5_#FQ\8_%BV@\46WAF_>PCUVW37["#[+J.S_CXMFBD
M:-X&PKJ>:^3#_P 'B_Q,_P"C%_'7XR77KS_RX_Y-?C!_P5+_ ."NGQ _X*Y?
M%W]C2&Y_9O\ &'PK3X1_%GPY+YMS9W]]_:;:QXDTM64%;15B$*@O\W& Q)Q7
MINC3R!/-<!Q?PF\3ATU364\2Y=B,>U62HS5"E1J>TG>%1J?+M3YI/0\Z$L?G
M4HY=F/ G$U/"8AWJ3S;*<'4R^/LDJT'7C'&8EZ3A#V;5&=JG(_=M>/\ JJ>#
M)YKKP?X4N;B1I;BX\-:%//*_+2S3:7:R2R,>[.[,Q/J372URW@8,O@GP>K J
MR^%O#X96!!4C2;0$$'H0>".QKJ:\"]]=[ZW[GNI6T2LEI;M;H4[W4+'38&NM
M0O+:QME(5I[J:."%2WW0TDK*@)P< GG!QTKE=7USP!KVF7VC:QK'AG4M+U.U
MFLK^PO+^PGM;NUN(VBF@GADE*21R1LRLK @@^M?!O_!5[]DSXF?MJ_L@>*?@
M5\)?C/<_ 7QEK'B/PSK%K\0K6^GTZ2UM='N+F2[TU[FVDAG6'45F6.01RHS*
MI 92 1_+;#_P;(?\%(IHDEA_X*:>,9XG4-'-#K7B&2*13T:-UU!PRGL0Q^M8
MU\[X+R^G+"\22XS^L5HRO#(N",=Q#EL\-47(H5,;0JPHNO)JHJN%<7*%/DE+
M2HB5E?$^-K1JY'F/!>&ITU&7LL]SRIEV9PJQE?VL*%.$FL/\/LJVEZBG&]XG
MUY^V=_P:^?LD?&;XG^(/C#^S?\<]2_9]\4^)K^XU34]$\-:[86/AW^T+J5YY
MY[>*WF62+S97+,@(7)/'>OG+X7_\&G/POU3Q7INI_M-?MF^*OB/X>TZYM[A_
M#\'B>":VOT@</]FG%W<L CA</MVY7(+&N6_XAC/^"E!_YR8^-_\ P<>)!_*^
MH_XAC/\ @I0/^<F/C?\ \''B0_SOJ^:AFOA[0PE3*L%Q[](S+L@J/7AW \-<
M34,E5)N+EAH87ZW*I##SM:5*%:*LTHN-HV^DY./9U(XS$X'P%QF<P2]GGV,J
MX:OG$)1MRU/K,L+[.I5ARJTZM"<I-)SYI79_99^S#\#O@7^S7\*/#GP3^ &D
M^'M!\$^#K**WM],T)[1F>38D<E_??9F)>ZNF0-)(_5CQ[_1%?SZ?\$6O^"4O
M[47_  3I\;?'#Q+^T%^U)K?[0>G_ !*\/Z%I/AW3=5OM5NT\/W>F:A'=W-^B
MZE<W CENH4^S-Y.U2BJ2-Q;/]!=?08&ID-3"4/\ 5F&:4\EITU1P<,XRFODN
M/BJ7N5%6R_$5*M:FO:J;A4J5)2KP:K-MS/#KQSF->J\_Q668W-JE257%XG*,
M9+'X&K*J^>+IXJ2BZDE!Q5562A44H+2*/@__ (*:_P#)C/[0_P#V)+?^G33J
MH?\ !,,;OV)/@NI (;0,$$9!RL8Y'<>M7_\ @IK_ ,F,_M#_ /8DM_Z=-.JC
M_P $P?\ DR;X*_\ 8!'\HZZS$_CY_P""IO["O[>?_!+O_@HCXK_X*9?\$_=!
MUGQKX1^*6HW6N_$/PYHEI<7D=I/>-&VH:1JFGVJF232)A"'W+DHP9PIWM7GT
M_P#P=K_\%!'TT^&X?V.=.3QR8OL7_("\0X%^5\L.(2A;_6<@;<^OO_H<:AIU
MAJUI-8:G96NH6-RACN+2\@CN+>9&&"DD,JLCJ1U#*17C/_#,G[/(U#^UA\%?
MAI_:/F>;]L_X0_1//\S.=^_['G=GG/7-<N6YYQOP]2J9=E^&X*XCRB-2K4RN
M/%N5XBOF.3O$5'5JTJ6+PW.L7A83:=&C5A!QBN64I.\GW8K*^",ZJQQ^<8?B
MO+,UG2HT,=6X6SR.783-*="*A"IBL-4IR5/$2CI.I1E=N\HN%^5?PX?\$E?V
M _VXO^"EO_!0G3_^"FW_  4$\/:WX/\ "O@6_&O?#W0-9@N;&0ZQ"1/I<.A6
M%T T.DVK9W2%<N[;L#8N?] *J6GZ=8:39P:?IEE:Z?8VR".WM+.".WMX8UZ)
M%#$JHBCL%  J[487^UZU7%YCGV/I9AF^8UHUL7/"8?ZGE]!4X*G1PN PBE/V
M&&HP5HIR<I-N_+%0A&<3++*=/"X#)< \NRG+Z3H8/#U*TL3B9)R<JF(Q>)DE
M*MB:\O?JR24$_A5W*4BBBBNTXPHHHH *:O\ %_O&G4U?XO\ >- "CI^)_F:6
MD'3\3_,TM !1110 4444 %%%% !113'DCC&Z1TC7.-SL$&3T&6(&30!^-_[9
M6G#X[_MI? G]G3QI=W,?PNL$L_&>JZ)'/):VOBB[9D_XEUT\;*9E&T?NSN&T
M$8J;Q#X(\(> ?^"DO[/^@>#/#ND>'-(LO ?B2*"TTFQAM4"#3I0 [1H&DP/E
MR[.<=2#7T=^VM^RKXI^-:^"OBE\&O$5OX3^-WPLU-=:\*:K+DV>L)!AO[)U#
M9_K() I50Q*_-QVS^6OB/Q#_ ,%'D_:3^'_QCUK]E2\\0^(_ .AZEX=>XTV[
MBBTK7);V![8ZC$F0R6Y),A4'(0\&@#ZU^-UC9?"S_@I;\'O%_@@BSUKXE>%V
MT3QEI%FS>7J-I+<R*^K7=LIV>8  #,5R6R01DBOV3'0?0?RK\J?V3OV6_C9K
M'QEU+]K3]K'4+*;XF:AI<NB^$/!=F,V'@O0Y6+I R']V+V(,%W*,AAG/6OU7
M'' Z#B@ HHHH **** "BBB@ KQ#]I/\ Y(-\5O\ L3-8_P#1!KV^O$/VD_\
MD@WQ6_[$S6/_ $0: /Y;?AA_Q]?$O_LDG_M:XK]+?V$/^3;/"_\ V%-3_P#1
M]?F;\-)H8;GXE&:>" 'X2X3SY4B\UO.N/EBWD;V_V5!/Z5^F/[!Y!_9L\+D'
M(_M34^1_UV% 'V+1110 4444 %%%% !2'H?H?Y4M(>A^A_E0!^;_ .UJH;]H
M#X ?*K-_;,F,@9XV]SS_ )%?H[%D0VH/7[+#WSTC0'I[_I@]Z_)__@HC>ZSI
MWC?X47WAVX6SUR&]?^SKEP=D4Y("EO;)'X9K]!_@3<^*K[X3^$;SQM>0W_B:
M:S5M0O+<%89,[3&%![[#AOZ<4 >NT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?F;_P %2?\ DCO@C_L=+/\
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MGW&*/M5M_P _$'_?V/\ ^*IC7MJA0&XAR[;% D0DL>@&&ZT 6J*** "BBB@
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MU^CV #G R>IQR:_-;_@CT /^":7[(H X'PS8=/3Q)KP/ZU^E58E$-Q_J)O\
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MV;;XN_\ 262@#X*T:00-HEVV=ECJMA?R =3'9Z@EPX'?)6,@8[^U?TK^'O\
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M&%RK!16'R7*,'D>70NZ.6X#VOU6C*3YJLH>VG4J7JU'*K/FF_?D[65D?!_\
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M/VPO&'C*\TSXY?"[PWX-\,Q0![;4='EGDGEFP,H?,D=2 2?NCTK[VH _,/\
M:%\6^ M _;5^ &D>*O!0NM4UR2&V\->+IKD6MI9Z@1_J-C82XE4?P\G'%?IM
MY$##+0Q$D9),:$G/7)*\U^6/_!2O]GS]H[]H/2?!.D_ +2O!UEK7AC58M;T_
MQUK,[6VN>'-01HR9=+E4J0-J %6;;]XXYKR;P'>_\%>O!/AS2_"FH6?P-\<Z
MCIUK';?VQJFLAM5O1$@4S7$<,^?,;:6D)7()R: /VL "@*H"@<  8 'H .!2
MU^>'P%\1_P#!0_4/'\$'Q]\&_"C2/A^;?,UYX3OY9]66YR?E\IG8!0,'IG]*
M_0X9P,]<#/UH 6BBB@ HHHH **** "O$/VD_^2#?%;_L3-8_]$&O;Z\0_:3_
M .2#?%;_ +$S6/\ T0: /Y;?AA_Q]?$O_LDG_M:XK]+?V$/^3;/"_P#V%-3_
M /1]?FE\,/\ CZ^)?_9)/_:UQ7Z6?L('_C&SPOU_Y"FI]C_SW^E 'V+129^O
MY'_"C/U_(_X4 +129^OY'_"C/U_(_P"% "T4F?K^1_PHS]?R/^% "T4F?K^1
M_P *,_7\C_A0!XQ^T-_R1WQ;_O6/_HPUT'PB_P"2:^%?^O&'_P!!2O/_ -JC
MQ-H_ACX'^+[S5[R*T#QP/:)(VV2YDA8L5A'<\$'VJU^S+XLM_&GP5\(:_:G]
MS<V@ C/#QB$JIR,<YX([T >_4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?F;_P %2?\ DCO@C_L=+/\ ]&0U
M^Q'["_\ R;)\-_\ L&_^R15^._\ P5)_Y([X(_['2S_]&0U^Q'["_P#R;)\-
M_P#L&_\ LD5 'UU1110 5_+;_P %H/\ DY_PA_V3FW_]*&K^I*OY;?\ @M!G
M_AI_PA@$_P#%N;?I_P!?#4 ?LI_P3'_Y,Y^&7_<4_P#2A:^_J_+C_@G+\8?A
M?X7_ &2?AUI7B'QUX;TG4[5]22XL+W4H(+J$O,'7S(7?>H(!P2,=J^X_^&A/
M@G_T4SPC_P"#>V_^+H ]DKE_&VHRZ1X1\1ZG "TUAI%[<QA5+DO%"S !!DL<
MC[O?I7!_\-"?!/\ Z*9X1_\ !O;?_%U'/\?/@=<PRV\_Q)\'2PS(T<L;ZO:,
MKHPPRL"Y!!'!!HNUJHQDUJHR;49-;*3CJHO9M:I;:@DGI)M)Z-I*32>[2>C:
M71Z/9Z'Q;X"\<R^,/B9\)I=2U>YNII-<N)(M/BTQ[1;60J<_:9 HR@'3>1S[
M5^G5?.%E\2?V9].O(=0L?%_@"VO;=S)!<1:C9+)$YZLC!_E)[XQ76?\ #0?P
M4_Z*9X0_\'-I_P#'*B$ZD^:53"T<([JU.ABL1BX-**][FKTZ3IZW2IQBU9*3
ME*4I,TG"C3484*KK02^)X'#8"SOM[/"SJ1J.R3=6<N=MM644D>QT5XY_PT'\
M%/\ HIGA#_P<VG_QRH+C]HWX&VJ;Y_BCX.C7KEM9M<<=>=]69GM5?R9_\%1O
M^3ZM/_Z[>#O_ $[6E?T@W'[6_P"S7:MMN/C-X$B;.,/KEJ/_ &:OYE/^"C/C
MCP?X]_;)T_Q9X*\1Z9XE\-B3PHTFLZ9.L]A&;;4[:2X'GK\K>0BLTA!P%&<T
M ?UK>$_^15\,_P#8OZ-_Z;K:MFYN;>S@EN;N:*VMX4,DT\SK'%$@ZN[N0JJ.
MY) K\W/&'_!0[X2>#=*\,^$? EW'XZ\37'A_1X(;W3I$D\.V%W_9\$934KQ7
M#1^4ZXE48VGC.:XB.36OC3)#J_QT_:5\+>"M"F(EC\#^ -;@CM+^R8Y%KJTT
MLRNK%/EE"DMDGOQ0!]6_$O\ ;#^%_@:\'A_0IKOQ]XMN<Q6&C^%8)-5@DNN0
ML-U?V:RV]K\WROO;Y3UKR-=#_:Y_:"8OK]_!\!?!,^/,T6T":GK.L:?)_"UT
MF)+*26(\_,I7)XS7I_PTO_V0?A)9&S\$:_\ #_3&DPUQ>/J=K=7US+P6FDN;
MEY90[MEFV,HR3VKUW_AH3X)C@?$SPB!_V%[7_P"+H Y#X6_LI_"'X6C[59:(
M_B/7)'6>XUWQ7-_;U]]J.&DEM7OED^RAG&X+']WC!%?22JJ*J(H55 554!55
M0, *!@  <  8 KQS_AH3X)_]%,\(_P#@WMO_ (NE_P"&@_@I_P!%,\(?^#BU
M_P#BZ /8Z*\<_P"&@_@I_P!%,\(?^#FT_P#CE'_#0?P4_P"BF>$/_!S:?_'*
M /8Z*\<_X:#^"G_13/"'_@YM/_CE'_#0?P4_Z*9X0_\ !S:?_'* /8ZAN+>"
M[@EMKJ"*YMYE*303QK+#*AZI)&X9'4]U8$'TKR+_ (:#^"G_ $4SPA_X.;3_
M ..4?\-!_!3_ **9X0_\'-I_\<H \P^)?['GPL\<W9U_0X+SP%XM@_>V&K^%
M+E])MDN0<K)=Z?9B."Y&[E@PYYX->0_VU^US^SZ?*URPM_CUX(M\--K=DL>E
MZOHFF1X&6M54S7LL<8 /#%V'7YLU]6_\-!_!3_HIGA#_ ,'-I_\ '*@G_:)^
M!L:D3_$[P<$8?,'U>U*E>^07((]>M ')_"[]J[X1?% ?9+36G\.:W&PAGT3Q
M3$=#O_M0P)(K>.]\K[0%<D*T?W@,@=J^E$=)$62-E='4,CJ0RLK#(92."".0
M1UKX*^*U]^Q!\43]L\4^-OA_9Z["F+'Q%IVLVMAJEA,!A)HG@DC1Y$Z_O%.3
MG)ZU\T2?&FX_9^WWOP^_:B\ ?%KP;"QDN]#\;ZW$VN6%FA)^RZ2;>8^;(D8V
MQ L=Q ![T ?17_!4/_DRKXN?]>NF?^ET=?S[_P#!/#_D;OCY_P!FV^+O_262
MOTI_:P_;T^"?[2'['/Q8\,^']5?2O&K)IUI'H&HJ(Y=2GANDDGETP@DS0#:2
M&8 X(ZC-?FO_ ,$\05\7_'T'J/V;O%X/U%K(#0!\&^'_ /C]\+?]C'HG_IXA
MK^]?P5_R)OA+_L6=!_\ 35:U_!1X?_X_?"W_ &,>B?\ IXAK^]?P5_R)OA+_
M +%G0?\ TU6M '34454O[ZTTRRNM1OYX[6RLH)+FZN93MB@@A4O++(W9$0%F
M/8 TTG)J,4Y2DTHQ2;;;=DDEJVWHDM6P;LFWHEJV]$DMVV<?\3_B+X<^$GP]
M\8_$SQ=/);>&?!&@W_B+6YXD,DD6GZ?$99V1!RSX&%7N37X<^%/^"\7@GXBV
M-QX@^'?[/'Q=\2^%#J5Q8:9KEOX<U/[/J2POM6YA*VI4Q2#!4@D'/&:^YOVR
M_CA\)/B=^R#^U!X<\!^/?#?BK6[7X/>);VYTG2M0ANKR.S4+"\[P(2PC21&1
MR1\I'/%>&?\ !,;XQ? KP7^QU\"?"/C7Q;X"\.^*[_2;**UT74SI=EJ%S+=+
M"EJ5@:)9)'E?Y5D;)R1DC-=-; XW#UGAJ^$Q-'$12DZ%6A5IUE&3M&3IR@II
M-Z)VLWHB*=2G5BITIPJ0DG*,X24XN*7,VI1;32CJWLEJ]#N?V)?^"K'PG_;)
M^+'C7X&V7@[QC\//BAX*MI+Z\\/^*]+NK!KJPAC:26XMVN8HBP15.< ]*_56
MOP1^&=O:1_\ !;/QPUI:V5O$_P *=8EB:SM;>W$T<NGSM'*[0QIYNY2&5F)S
MG.3QC][JY2_^'^\**** "OYT/^"N7_)U?[-7_7DW_I>:_HOK^=#_ (*Y?\G6
M?LU?]>3?^EQH _?WX=\> _"  P/^$=TG_P!(XJ[*N-^'?_(B>$/^Q=TG_P!(
MXJ[*@ HHHH *^,OAIX]\2ZO^V)\>/ U]J"S>'/#?@CPG?Z38 8:VN;V>V6XD
M8]PZN0/K7V;7RMX"\2>!+[]J/XQ>'M)T V?C?2O"'AJX\1ZYMP-2L9YH!9P!
ML<^2Q0X!XQZ] #ZIHHHH **** ///BWJ-WI'PO\ B#JEC((;RQ\'^(;FVE(R
M(YHM,N61_P #S_+FO$?V'O$>J^+/V7_A;X@UNZ^V:IJ.F:A+=W(_Y:.NL7\0
M/X(BC\*]Y^)EWIUC\._'%YJ]M]LTRV\*:]-?6NW=]HMDTVY,L6.^]>/;.:\;
M_8YU7P]K?[.7PWU3PKIG]CZ#=Z??/I^G;=OV:,:K?(Z8]Y%=OQH _);]K1?B
M9X=_:VN?BQ\-/$>CZ?IGPR31+[6Y=8N(H=79=2O8+>[M8+68B6^MMC,D2JK#
M&"HQG'D_B#4/B=XT_P""FGP\\0>$]6TC[-?7/AC4QHFJSI#H^HZ4\ EUB^N+
M&8B(:K'N<V99?.R 4YK]W?B!^S-\'?B1XKC\;>+/"-GJNNI';17,KM*B:C%9
M.DEI#>QI(L<R0R('&Y2<CG.37X]^,='\$7/[8=QXJLM(\KXH^#OB9X/T/2/!
MUE*UO:W/A@RB.?5U7<A9;&(9(3*G;@Y-9T9NHL3!X9X6G3<I5L7CIXW'4W3J
M\E&M/"0P6/YJ6#]BHSKO'K#4?K52M&>$K8:4$:UJN%I1PTFH<\N7#0I8;+LN
MIO%8B4W4P\<=4J0A*KB9592HT\10?M:.%ITZRK4:ZG-?#O@;X-?%CXZ_&C]N
M;P/\)=+TG59[CX\ZX=>75?*1K&R^4&>RFE_U4IF)"E<$KA17N'[;OPX\6_"'
MX.?L&?#WQT+-/$>@_%31X;J&QV>1&IU6#R@=G#28P6;O7GG@7]J+XP_\$[/V
MS_VN;;Q=^Q'^TQ\8O#_Q5\<W_B[PMXV^$OA0ZWH$]C=>7+%;R3/M43;N&PQQ
MR0*\U_;%_;N^,/[;OQ-_9C\,^!/^">7[7OA6U\-_$_0+_P 0>(O&G@G^S-)T
MBS?4X#-=S3(6S;V\8\V1CM(4'TJ%2J?695W7J2@Z2I1P_+35*'O*3FGR<_/)
MK5\RYE92YN6-J=6E]75&.$P\:OM/:3Q:]K]9J*W*J<FZCI^SBK62IJUEKN?T
M2_M5^/?$O@FX_9KM_#U^EE%XH^*OA_0]95EW?:M.FMH2\"^A)8_G7V]7R-^T
M9XB\#>'I?@)!XW\/MK-SJOQ%T/3O#9VY.DZZ;>(1WK<';Y60#[CKQ7US6Y@%
M%%% "'H?H?Y5\$?!P_\ &67Q<_[![_\ HY*^]ST/T/\ *OS2^!7C[PQJW[;/
MQG\+:5K-CJ&HZ?HSR7L%O*K26LPN%5K=QG[Z8.0,GUZ4 ?I=1110 4444 <;
MXP^'7@'X@VT%GXZ\%^%_&-K:R>=;6WB;0M-UN"WE_P">D,6HV]PD3_[2!6]Z
M\\D_9?\ V;YD,<OP'^$4L;##))\/?"SHP/4,K:858')R""#WKW6B@#*T/0M%
M\,Z38:#X=TG3M"T32X%M=-TC2+*WT_3;"V4DK;V=E:QQ6]M"I9BL<4:("3@<
MUJT44 0W'^HF_P"N;_R-?R)_%'_D8?VE?^QZF_\ 3BM?UV7'^HF_ZYO_ "-?
MR)_%'_D8?VE?^QZF_P#3BE 'ZI_\$H?^1A^/O_77P?\ ^FXU^S]?C!_P2A_Y
M&'X^_P#77P?_ .FXU^S] !1110 4444 %?R._P#!6W_@V,TK_@H'^T?X\_:P
M\%?&^7P+X^\7VNEFZT"^TW[5ICW>CVXAMY5G+J(A( -_; '?)/\ 7%7^<3_P
M<)?\%L_V]?@-^WY\7_V5/@G\2[KX;?#OP;;>'8+*\T)94U63^U;(375S-/M(
M 4D!-H.,9R3Q1_86 S]2PV/XGQG"<:$7B:&9X"GB:^)E7C[D</##T:&)HUW4
MC.3]GC:+PON<TW&<:;&LXS+)G[;+<CP.?U,0UAJ^#S'ZM'"0P\VIRK5:E=.M
M1C&5.$)5<!_ML8S?LG9R/(/B%^Q/_P %3_\ @E-IUWK32_LR_$SX:^'@\CIX
MD@\)S:Q>6,';[/>/]J\UD7!&TG)Z9!KL_P!DO_@Y(^ MSXV\"_#_ ./7_!/O
MX0:MKNH^,O#WA\>+_#NBZ)%/8ZM>:Q;:;'J,,0M7YMKN59D:/D*@*D=:_'+P
M+\7/V=_CWJ,&N_M_?M@?M$^++BYD6?4-/\.WEY>6SEB&DB\B1WCVGD'Y /QY
MK]G/V2/VB_\ @VI^"GBOP#IUA\%OB7\4O&MSXK\-6&AZ_P",]#-PUMKUUJEM
M!IU_+'F-?W-\\,K,2V#AMO&*T7"69<_U>AX8X/Q1PEZ4IYWXB<*^'G!V-<4D
MO;T\ZPN?4LXS&DF_:4O8T\+545"+PTFSF^O97%+%8KB7&\"8N5YQRCPPQ/B+
MG>5SDVE)U*6+PZRM8BWQQQW-2?O:\G+?_1^T&\@U'0]&U"UB$%M?:5IUY;P
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MJV<MJ?%/B>&X=HKBPW+A[-_X64D!"IW=37[>C@ >@Q0 M%%% !1110 4444
M%>(?M)Y_X4-\5L?]"9K'_H@U[?7B'[2>?^%#?%;'_0F:Q_Z(- '\BJ?$Y?A]
M=ZY'%H]WK+^+? 8T(26Z,5TM_.F_TJ; (\OGOQD#'6O:/@+^W5J7P7^'6F^
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M%:;X]^%G@^[U?P7JKS1Z;?0ZPMHLSV[!)R+<R(R@/P6V@9XKT9/^"<O[>3,
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MO[ :* /X\[#_ ()P?MUZ7&8],^&5SI\;Y+I;:U @;/)!_>$]?>B?_@GA^W9
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MVT)<;M!FG0@%7768Y(G5AD,C++AE(.0>AS7]+W[1?[.O@K]HOP1<^&/$]O\
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M)&'$4K*&Q*N<,.Q!J73_ -M+0;_P'>>.1\)_BU EI=/:_P!AS>%[A=8F9/\
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MU_Y,9_:'_P"Q);_TZ:=5#_@F%S^Q+\%AZZ !^D=7_P#@IK_R8S^T/_V)+?\
MITTZJ'_!,([?V)?@L3T&@ ^G01]SP*Y#L/YE/^"S'_!#C]J[1/VK+G_@HO\
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M3=2++>:DD(4R[0 IEE!)7&3R37[&#@#Z 4 +1110 4444 %%%% !7B'[2?\
MR0;XK?\ 8F:Q_P"B#7M]>(?M)_\ )!OBM_V)FL?^B#0!_+;\,/\ CZ^)?_9)
M/_:UQ7Z6_L(?\FV>%_\ L*:G_P"CZ_-+X8?\?7Q+_P"R2?\ M:XK]+?V$/\
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M?^SKX#_:(\#7GASQ9;16FI6T;7/A_P 31!(=2T'4(OWD%U;W?#QHLJH7&X#
MKY>_:0_;?\1?#[XX^"O@3\&O"^B_$7Q5XAM)VUQ)-32%-!NA(ZVT4[(Q 9E
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M=-N7EB1I8'^:&19(9$>-N592#7JM("&X_P!1-_US?^1K^1/XH_\ (P_M*_\
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M'[(D>B>,?VO_ -DZ[^*'PEOH+34+OQKX.T^:;3H]'N%CE?48KW3;:6W9(X)
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MY/:U"BBBN0Z HHHH *:O\7^\:=35_B_WC0 HZ?B?YFEI!T_$_P S2T %%%%
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MQCS%L;2*U#X[;A%NQ[UJ5*=]=====]>_F8[:=M--OD?SZ?\ !SKXZ\=^ ?\
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M$?5?'GQ!LO!EEH#^*+G7+C5+2.SCT-+,Z@;PR,P'EFUQ(N#EL@#DBOQ6\)_
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M_8*^*'BLZ9+HFM:?YV@^(]%GRLNGZQIES%'=A5;YS;O(S>0Y^^JDYXK\1O\
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M?VG?CG_P6$^,/P&^+OPRT#]BS[#J/CWP;XB\.6,AOK5A"=6L9K:%/G<CY2X
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M'_8Z6?\ Z,AK]B/V%_\ DV3X;_\ 8-_]DBH ^NJ*** "OGO]JO\ Y-\^)_\
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MU]X8^&_A#XL>$;/P?#XRM+Z3P/KNGR*^EZL8[Z9#9SJG[NTNVG+A(L@N"#C
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MPK_X?>?#K_HD_C+_ ,!I_P#XU1_P^\^'7_1)_&7_ (#3_P#QJ@#]U**_"O\
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M9_\ @H#_ ,$IO@[^R#\;?@?\2/V.;WX/?M-ZS\-M3\.:9XLU71;G4[B]\1O
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M^"[#!\$:<0>O[B'_ .O7MU% '@[_ +,OP-D^_P""+,'/:.,_CP#Z53D_97^
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M$OA[2=7MG(;?I]P8-1AMGR-T4BL(W*D A\=&K\O?^">A+>*OVBG8[I)/V?\
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MVH_C'XDTK7Y;SQKJ_A'PU;>(="8KY6FV-O- UG<(H^8&9@H)/7- 'U51110
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MAEV91]^K@\/C(8Z-"G5_>8>%3$4XQA*O["4/;P@N6G5YX)R4;OX/_P""FO\
MR8S^T/\ ]B2W_ITTZJ/_  3!_P"3)O@K_P!@$?RCJ]_P4U_Y,9_:'_[$EO\
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MHH *\1_:2_Y(/\5?^Q-U?_T17MU>(_M)?\D'^*O_ &)NK_\ HB@#^3_X??\
M(3\:_P#9.7_]&S5^KG["?_)M_AK_ +"VJ?\ I17Y1_#[)U/QL1C ^'+DDD
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MK\=_^"I/_)'?!'_8Z6?_ *,AK]B/V%_^39/AO_V#?_9(J /KJBBB@ K\)O\
M@J1^V=\2/A%XZ_X43X<M-/?PYXR\#V^HWUU<0;[F.5KI6*QR=E+1KZ\CL*_=
MFOY:_P#@LW_R=1X/_P"R;V__ *4&@#] O^"3O[3OQ(^.>G_$7PKX\O-+.F>
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M!.DZ=$\UR=5FTF*Z"H"S;++_ (^7?C@",G.*_FO_ &C_ /@I'_P0P^''Q4\
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M? FC_#[5O$O[+OB;6T\1:'IUWJ4OAWQ/.VH/K M8FE:TL9(P,7$RJ=@*@EN
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M'/ACX1>#]"^);0/XWL;3;J[6S*\)!*F'8R\$*F-QH ]BHHHH **** "BBB@
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M^$_"QE:<^&M :=Y/-:9M'T]I6ESGS6D-N7,F>=Y.[/.<UO@!0%4!54 *H&
M!@  <  < #@"I&+1110 5\^?M46&IZE\ OB7::193:A?R>&M0,5K I:5PMO(
MS%% )8J!NP 2<5]!TUT21&CD19(W4HZ.H='5AAE96!5E8$@@@@C@B@#\J/\
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M]\!M.)P3Z#H*_:"OQC_X)2?\C%\>_P#>\&_^FVOV<H **** "BBB@ K\=_\
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M1<HXS$\*YWE/&7#TZ<E&3CB,NE4HXJI4JJ-IT:.5XBJH)KG:N?K!_P $4/\
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M>,,;QA4Q4W6J8S'970RRKAY_:A:A2I?6'6;=6=2ISS4KKFULBBBBK*"BBB@
MIJ_Q?[QIU-7^+_>- "CI^)_F:6D'3\3_ #-+0 4444 %%%% &'XG/_%->(?^
MP'JW3_KPN*_S7?BK\1=8^$O[;WB;XK>'K)+S7/A]\5YO%&DVE]!,;.YO=/O'
MDACN=JY\IF!!(-?Z5VKR1Q:5J<LL?G11V%Y)+"?^6L26\C21<\?O$#)SZU^.
MWPX^$_\ P3B_:1^('C'39OA[X?L_B79ZO<Q:]I>IF&WN+N[$LBO+;,X'VC>R
ML<*2W/ K^@O SC2EP32XSS#'<,YMQ%E&(RO"X/-'ED82IX'#UZU2#GCN:2E#
M#UTY4O:)*,7I*<7)7_F[Q^X9H\6XW@')Z'%N2<,Y]4S7'8C(J6;UY8>KF>*P
M]&C4=++FH2C6Q5!*-7V%_:3C=PC+E=OPT;_@X^_:[9BP^%'PTC!QA%MM2*K@
M8X+,3SUY)Q0O_!Q[^UVK*Q^%/PU< Y*-;:D P]"5((^H(/N*_ID'_!,+]BX\
MCX/Z+SS]U?\ XW1_P["_8N_Z(]HO_?*__&Z^G_XB5]'O_HT-7_P='RZ_7+_T
M_(\/_B&WTB?^CLX;[JW_ ,R?U;T/X OV@_VA_&/[1_QGU/XW^+](L],\2:KJ
MEMJLNGZ9!.+".>VNH[I(T#+NV%XPIZG:3WK]@/#O_!Q'^UGX<\.^'_#=G\*_
MAPUIX>T73=#MYI+?4C+<0:7:164$TV6($K0PIOV@+D9 R23^S_[7/@'_ ()8
M?L<Z+:W/Q"\!^&+WQ7JE]::;H7@W3Y8+C5;Z[N[F.W43P1@O;1)YFYGE"CCT
MXK[!\+?\$WOV*O%'AGP]XEA^#.C00^(=#TG7(H&5<PQ:M86]_'$?W?6-)PIY
M/(-?:<0^+_ACFV1<.U.(_"G-\1D.%CB<%PU/&.G3PL:>'AAHXFG@9?6*<JM.
MG'ZO"<_?C>*BI<RD?$<.>$/BEE.>\1TN'/%3)J.>XJ>&QO$E/"3KU,1[3$3Q
M%3#U,;_LTU3J5)O$2C"\9VN^11<6_P M/^":O_!9/]H7]L7]I*U^$'Q"\#>#
M= \/3:-+J!OM$@O$O?/1B I:;*;".PYX)Y-?TSCH/H/Y5\D_"?\ 8>_9L^"7
MBQ?&WPV^'>F>'?$:VYM1J%LJ^;Y)).W.P'N>]?6XX 'IQ7\N>(6=<)9[GT<;
MP7P_+AK*%@L-1>7RE&3>*I\WMZ]XU*B_>7C]K[-[(_JGP\R?B[(\@>"XUSZ'
M$6</&UZJQ\.;E6%G&FJ-&\J=.7N.,Y-.-DY63:2"BBBOA3[L**** "BBB@ K
MQ']I+_D@_P 5?^Q-U?\ ]$5[=7B/[27_ "0?XJ_]B;J__HB@#^3_ .'Y_P")
MGXTZ_P#).7[$_P#+6;TK]6_V$S_QC?X9Z_\ (6U3L?\ GX]A7XRCQ/?>%KS6
M)[&W6X%_X,-I>9_Y9Q--(H89[@'->Z? O]O>]^"OPYTWX?IX&;65T^YN;H:A
M]HV"0W3[R N>"O'7IS0!^]&?K^1_PI:_')/^"G/B+6M0TG2]+^'_ -AN+W4(
M8'E:<2;HI'5"@&<@X8\_XFOUVT*^DU/0]%U691%-JFG6M[-$?^6<D\0=E^JG
MCZ>XH UZ*3(]11N'J/SH 6BDW#U'YT;AZC\Z %I#T/T/\J-P]1^=!(((R.>.
MM 'YO?M;.H^/_P  0<Y&M/TSDG*_=[G'?%?H]$<PVIR3FUAY))/^K3UYKSGQ
M?\)_ _CGQ'X6\5^)=/DNM:\&W#W7A^XCEV)#,_#>>G_+4<<9X&*]'7  Y'"[
M0,C"J.PQ]!GW% #Z*3</4?G1D>OY<_RH 6BC/YCJ.XHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\S?^"I/_ "1WP1_V
M.EG_ .C(:_8C]A?_ )-D^&__ &#?_9(J_'?_ (*D_P#)'?!'_8Z6?_HR&OV(
M_87_ .39/AO_ -@W_P!DBH ^NJ*** "OY9_^"T/_ "='X4_[)G%_Z.:OZF*_
MEH_X+0 M^U)X34=6^&D('U,[ ?K0!^P'_!*GC]BKX98'_+?6_P#TK6OT7K\'
M_P!@;]O7]F;X&_LP^!_AU\1_'8T7Q=HL^IG4-+_L^[G,27,XDB?S8D:-@P&,
M!B0:_1WX0?MW_LS?''Q-=>$_ 'Q!L[W6+.P.HS1W\;Z9%]G4D'9->>6CN,9V
M YQSVH ^PZ*Y+_A/?!'_ $-OAS_P<6'_ ,?H_P"$^\$?]#=X<_\ !Q8?_'Z
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M (3[P1_T-WAS_P '%A_\?H ZVBN2_P"$^\$?]#=X<_\ !Q8?_'Z/^$^\$?\
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MQY\ Y3\WA1 .?NQJ,'.01QV_PH ^:O\ AZ#\'O\ H >(/_ 4T#_@J!\'C_S
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MM?BM_P $EK*TL-<^/D%E:PVD(G\),(H$"1AI-/W2-M '+M\S>]?M30 4444
M%%%% !7\0_\ P7*_X.2_CI^QI^TU\0OV+?V>_ &C6OB7PS:Z/:W?Q"UJ283P
MWNNVRR0MIT"YC81%U.]QMR",\5_;Q7X2?\%(?^" '[&'_!1;Q7KOQ8\:Z9JW
MA/XUZM906W_"=Z%=FW>66RCV64M];HN;CR.",MQC QDTUQ%C^&/^%++L@H<0
M5E^Z=&I1P>*Q&"BVJBQ^!P>8U:.!Q6+I3IPA&CB9N#A4J2Y)M*(_["RWB&^
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M]M;X"?\ !Q[KO[7?Q_UG]G?Q!K4'P.U+QY>S_#""'4X8K>/PRRK]E6&,S*R
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M=^(?!R:?X0^(,-N?LNH:;'!'8ZC)"F(+6ZBA BC5L;2ZCC.<#%?R >-OV_\
M_@HS^V-XRNSX*\5>.[%YG=HO#WP[%[;Z9#"S9CA9XP8OD& 07!'0]:R=*_;
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MWDD8U^&'[#_[<OP)_P""J/@9OA;\<?#.CZ3\9_#T5M=RVI2&*2Z>WDCD74=
MED/F;BZ;C$.<$X *@5^\&C:9#HNDZ;H]L6:UTNPL].M2W+?9[*WBMH0Q[MY<
M2Y/<U^0>/W&6-XGQ.18#B?A2EPYQ[D+QV&XBQ.'ITOJV<8:K'"/+L9AL1']Y
M5H/V>(E3A.52%-5/W=1IN,?N_HI>$E+PP_UQQ/"G'&(XL\+>)O[+QW"&!QM:
MLL=P_C:4\>LWP.-P<E]7HXA1JX.,\10C2EB53BZM&,H*4M.BBBOYT/[$"BBB
M@ HHHH **** "O"/VG_^3>OC!_V(FN?^DQKW>O"/VG_^3>OC!_V(FN?^DQH
M_D*^"7@33/'?A;QDFIRO#_8FGI=VQ3.'DEORC*V.Q!(Y'3/X_JSH?_!/OX'W
MNA:!>S1RF:_T;3[RX(+<RW$,<DA ^K$@?_7K\X/V6?\ D6?B7_V!;;_TY&OZ
M!O"__(K>%/\ L6])_P#22*@#X&'_  3O^&R^)+'5=+U2YT:'2;F.YA,89FGE
MC8,H/'R@X'/IQ7Z#:99_V=IUAIPD,B:?:Q6L<AZR+$@4.W?)'4>M7Z* "BBB
M@ HHHH **** "BBB@ KY-_: '_%R/@T>?^/F;N?^>A[9Q7UE7R=^T!_R4CX-
M?]?,W_HQJ /K ?P_]<H?_0!2T@_A_P"N4/\ Z *6@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S-_X*D_\D=\$?\ 8Z6?
M_HR&OV(_87_Y-D^&_P#V#?\ V2*OQW_X*D_\D=\$?]CI9_\ HR&OV(_87_Y-
MD^&__8-_]DBH ^NJ*** "OY:_P#@LW_R=1X/_P"R;V__ *4&OZE*_EK_ ."S
M?_)U'@__ +)O;_\ I0: /B_X;:;XZN?V9OVA]3T/^S?^$%T_5O#B>-#<PQ/J
M0N))(Q8_V?,RF6)<D"01LN<?-Q7WM_P36U+XE?#GX1^,OC)X=TFT\;?#73O%
MT>C>._!$FGPWFH6^G?*;GQ!I^^-Y)9X4;#0!60IG(()KX.^&=E\1)_V8?VC+
M[P[>V4/PZL]7\-+X\LIA_IMW=/(G]GFS;LJ''F9K[Q_X)K:W\5OAE\(O&?Q@
M\+6__"6_"VQ\6C1/'W@)(S<7"6#J%NM?@M^CO%'(=PVG*9# J2" ?HC+;6OP
MJ_XR-_9ZL[/QM\#O&FV;XF_#B*WBN[G1FG\M]0O;*U996@N('9_MMF4!A /6
M,@GS;Q=\0-,^ ?BW0_C/\!=%@\<?!7XH6CZG\1_!4%G%=P:%<EF-S<)&4<V=
MQ;%R&M60(SJRX*CGTY6'PI'_  T1^SLK>,_@5XU'F_$[X86^)VT?[2H_M"]T
MVP)?[-<6X9VOX3&!LW#!5AGQ#XI7'A_X8:WIOQ>^#'G^(O@%\6]$OH?'GABS
MC-Y;>$[^[9EFN+"Q D;3Y8"^9D9$(E#!2=H8INHE^ZA2J5&U&%.M[7EG*32Y
M(JBG-U9*_LHK24[*7NMEPA"I+EJ2K0I[SG0C"4X16KFU4:BJ<=ZCW4.9Q]ZQ
MU_@#Q6?#^FZM^T[\"?#<.N?!+Q'KEU9_$KX7&R2ZO=*B\R-;[6].MF5R)<N3
M/;*FU$;E2N17</!;?"EA^T;^SU9V7C;X(>-"D_Q-^'<5O#=R:2TH\R]N[.U*
M2&*6Q+,;FWV *R;2&0\^,_ ./Q-\&?!]Y\;O@U)<^._@AJFLW-AX[^'TA^T7
M5KINX+<ZO:V1#;+I1(S7&Z/YD)4J5+ ^U@CX3K_PT1^SJ/\ A-/@-XU#3?$_
MX8V_[\:(;D/_ &A>Z7I[;C:FT#2?;X"@P0PVLA&ZYSC.3G"*A&5FH14DHZ+W
M;2<I*SWO*3O?5F<8N"4'-U''3VC5G.STE:RW6NRTW2V%DCM?A;)_PTA^SQ96
M7C;X)>,F6[^*/PXBMH;NYT9IROV[5;&TVNT%W S.LUAL 4 @JR-DPW%O:_"P
MC]H[]GBRL_&OP0\9A)OB?\.HK>&[GTHS!)+^ZL[4I*T$UL2QO+78/**XY4@F
M1B?A(Z_M%?L[L?&?P(\9DW7Q)^&EOF<:*+EMM[?V.G[F^S30%G$L#("H# JR
M$9DX^% /[1/[.RGQG\"/&H,WQ/\ A?;GSSHXNE_XF-[I=@=_V26V#2'4(=G8
MC!0C=(R!H[?X6O\ \-(?L\65EXU^"GC,K=?%#X;QVT-W<:0\K?Z9J5E:%7:"
MZLV+B2R*!3M.5VD9^4/VV? >FV/[/WBOXO?L]:G87OP>^)"P2^-?##+%N\-:
ME(5EN;JW7E[2\>4R136>%,+*0,K@M]9R?\6G _:,_9T9?&?P)\99N?B7\-+<
M-/'HHN&D6]OK#3B3]G>UWN+B!D!#@_*T9!;Y/_;7\$6VG_L^^+/BQ^SUK\4_
MP:^)"0R^-_!KRAK7P]?NWFS7%I:!F^Q7KS%TG0JI4@@=1D ^<O\ @F?XN^)/
MPO\  WQ3^*OA[3K;Q3\*= U:PL_B3X4D@CN+E[":,/+K5O&ZN7-G#\[1@%6"
MG<"H(KH/VO\ X@_!W7/ NL:[^S?XWM&\(^/-]]XJ^'M[$JKIVH3L3<:GIJ.&
M>VG9MP-O%A4/"\8->4_L.ZI\8?"?[/'[2OC'X>6,7B/P,NES^'_%WA8#=?\
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M]\.Z1<-)I^A^)5TBQ1@>+6VU!53.>^.,_0_7^R.X_P!1-_US?^1K^1/XH_\
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M-<_])C7N]>!_M2-(O[/'Q?,:[F_X0?6@?93;D$]Z /Y2?V6<_P#",_$O@_\
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M_P!&0U^Q'["__)LGPW_[!O\ [)%7X[_\%2?^2.^"/^QTL_\ T9#7[$?L+_\
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MA,#^T/\ L[M'XU^ _C8";XG?"ZUD2Z;1OM(!U*]TJP#2"&>W+2?VC $_=X(
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MO@U?> -;\#>-]&NKCQ'\-?"DANQHES=Q.NJW$5D^X17\:,YN(U1?+!&,!LT
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MEI3E3@YRE24YRISIQDI.E.,9K6U:A[/%<O,HRG06(CA:_*HXJA7@E%>OR_\
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MS]F3_GX\0_\ DI_A0!V7_#VO]BO_ **%>_\ @DO?_B:/^'M?[%?_ $4*]_\
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MI0HX7$XW^T*U/DIQC+GQ;P^&=3FDG)7HQ<8M1;FTY/X/_P""FO\ R8S^T/\
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MOD[]H#_DI'P:_P"OF;_T8U 'U@/X?^N4/_H I:0?P_\ 7*'_ - %+0 4444
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M\5?AG\(?&?Q>\,6Y\7_"RQ\7+HOC[X>B$7$RZ>ZXNM?L[8@^=<1QNP9&5E*
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M>)/VC? *7'B[X5>,OB9XM7QW\*IXT-SH/A]KS NM.L""@DBCD4W,:H JDC!
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MP-RC (QV-?54NG6$\20365K+#&<QQ/!$T:'&,HA4JIP/X0*^(_C%%JK?M>?
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M *:O\7^\:=35_B_WC0 HZ?B?YFEI!T_$_P S2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>$?M/_\ )O7Q@_[$37/_ $F->[UX/^U
M0/V>OC!DXSX%UP#/J;8X% '\HO[+/_(L_$O_ + MM_Z<C7] WA?_ )%;PI_V
M+>D_^DD5?SI?LT^+-,T[3/'>E3I=O=:EIMO;0>1$SQQO_:7WKAA_JT.1\QXZ
MU_1=X8!7POX5!QD>'-*''3BTB'\_TYH VZ*** "BBB@ HHHH **** "BBB@
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MD@"6XCS(UZ@3$A#<NK$'Y1M?^"-?QJT_4-'O+36M!#K=P37\GFQ P".1'+*
MN9L;2"K9W?0U^E.G?L8_&FPTVRT^#Q[X8BAM[""T:(>&K'!$<01@Q$/SYQRQ
MY;J: /%]3^._PI^!?BJV^*_P-\27/B+X9?$"X4_$#X0KI=_(FF&\8"ZU+3K5
MXQ';F,2R;XPI7*N!N4\_$>K_ +0?PB^!W[>-[\7OAY8I/\(==T73QJ^C)836
MOGW>NQJNK[(+F/'^AEY&GC"E<#;DKU_4R+]CCXV01F*'Q]X7CB(VE$\,V 4@
M]B!#R/K7R#^T+_P2\^-WQ-USP]>V/B?P_J$"><NI/%:6VE?9 >%,<42*LQ?^
M+.<9H Z?6?VLOV<_@5XXB^(7P3^)VD>(OA[\0;M4\?\ P="221Z9-?[C<ZCI
MUM)^[MXHDF8318*[PXRR')^:/VROBK\#%^'WB2/]G#XL:?J'A[XI+%-XJ^%>
M9'31KQF$TUW81-\EK<.Y*R*@P,'DC!*K_P $7?BS&2R>(=%5B,%E:-2<]02%
M!/OG.?QK,NO^",_QOM7=M.U;092VWYS-%$S>N2%R<#G)YS^% 'Y]?#3XU^/?
MAK\./&/P_P#"GB,Z'H'CF[ME\16<9*W%Y"$6-\GH80@*N#R>1WKV_P"&_P"T
M+J_P$2+4_"(^''C"WU'3UTN\T+Q!I:W=K;(_#W8B967[2?,8L^T9KZ7T[_@C
MC\>Y[FX34=:T6TMD"_9Y8KQ9'ER,MO4#(VG@?3WK4_X<R_&,/@>)]+"GDGSE
MZ^G0<8_*@#\]_B%X^\0:K\0!X_\ !.L+I/B#5[6:.32_AU:SP0Z3;W:G[;;V
MUE;JQ$4X++.53!&<]JSM$\9?'?0='O;+P/XV^(UOH5X\C:UH^C+J+V[229\[
M[=;1H^QVW'>KJI&6R,=/UM^ _P#P2W^/WP>^+FD^--+\3>'+6"TL+RUEU"\M
M[?5$1;E-K(=/G1D<OR Q4E<\$5]<>!_V'OCG\./$OB76O"7Q.\.6]OXOFGOM
M>LKWPW8WL$M_/O5Y;9)8BMLF'.V./ !QZ"@#^=CP]XN^//AW1+NR\%^,_B'8
MZ!>2W#ZQHV@I?FV=[H$7C7MM"C!'E!;SC(@)R<D5FVGB7X@:%:Z*UQKVN:AX
M-TS7[?6)O#>K_:G\-G5T?S-VI6TN8EE:0DM&X#'D8Q7]&W@C]AKXX_#C7_$>
MK>$?B=X=MK?Q<\TNN65[X=LKV&26<YF:V66)EMU;G:$QM!P.E?/GQE_X)A?&
MSQ#X6\0:5X8\=:)J,/B?78M?UC1IK.WLDDU&+E)K:Y55-O""3F!"%/IQ0!^=
M/AK]IS7OA;KNH^./#%I\+_$3>*($M]4\*:AI FTG3PX"R7%K;."J38Y8A<')
MQS6'H/[4NO?"_P ?^/?&.A7.CMI'Q:\+:GI'B?P=X7MQ:>'[2[U"!H8YQ9;1
M'YD18_-MSD#!KZDL?^"-/QLD@A>\\1Z1;3NH,T4=RC*C=2 V.0/I^%37'_!&
M?XSQ12-:^)=)DE$;LB>>JJ\@'R(Q[!CU- 'YR?#OXM^+?AC\/_%^@>%M>^RV
M_CZ2;2?$&C$G#:9<7+SO.H'RY.\AL]J]U^'_ .T=JWP0N7U[PHOPW\6C6;#3
M]/O_  UK>E?:K*R2% CSQ0NI19W&?M+!?G;-?1^B?\$<OV@+O>=;U?0].89V
M>1>)+NP3C<1TR#G'^%;G_#F/XP*XV^)]) .=S"5!U['CGUZ\]* /SV^(7C?Q
M#KGQ"NO'?@;5(M,UW7K1FU+3OAS:3P0:?;R@F:RAM(%;%OEV##8!QQ6=HOC'
MX[^'='N[3P3XU^(UIH-W+/)K&CZ*NH20/-=*RW;7UM&C!&D4D2[U& 3GKS^O
M/P"_X);?'?X0?$L>*-.\7^'M.@_LN6!K^XM;;5%:1MP\@V,R.C!@QR^!C]:^
MJO!7[#?QQ^'7B#Q'K'A/XH^'K>#Q<\\VNV5[X;L;R&6>YSYSVR31,MLK9(58
M\!>V* /YU/#OBCXY>&-'OK/P1XN^(-AH>H&4Z[I/A^._:WE:<EKC^T+:)'"N
M[$EPZALD_A@3ZYXXT_3M,BN_$>OW'AF#6%U)-&OWN1I<>K&16FFFAD.Q;A\$
M3*RA@"00*_I+\#_L-_'#X;^(O$6L>$OBEX?@M_%TK7>O65[X:L;R"2[)+![5
M)8F6W0%ON( ,?E7S!\<O^"7'QP\1Z=/#X3\9Z)J\6JZY)KFIZ9/;0:>B:C<L
M/M%S!,JC9$06(@4A1Z4 ?GUX9_:BUGX3Z[=>,O"UI\+_ !$WB&TT^RU/PGJ.
MCB?2;%((UC:>&V=2BRR?>NF"@NV3R<5R$G[0?B'P-??%G6?#.K:#/8?'/P[<
MZ%XD\':- UOH.B&]W&2XTVS7"PRH7(!V\8KT;XS?\$S/VA/@UX7U_P ;3:;:
M:]X>\.P6\UVVF2?:=0E25 UU+';QJ6:WMN?,DZ*N<U^><+1.FZ(+@E@<#&&5
MBK ^X8$'W!H +>$6\,4*DE8D" GK@"O<_@1\9;GX(ZSX]U>UL1?MXW^'^K^!
M9E;/[B'5D:-IQCNN[^?O7B5'S$A54N[$*B*,LS'LH[F@!FF6_EWN@68WL)-=
MTBW)0;I L^I0J64#/S+OSD=*_NQ^#WAN#PG\,/ VAV]Q<74=KX9T9C/<L7FD
M>:PMYGW$Y.%9RJCLH'3I7\U/_!-S]A_6/C-\0=(^+'CRR^S?#GP=>+=Q:7=H
M<>(KY"ICMY$(W*L$J^9N&.G:OZFX((K:"&V@C6*"WBC@AB086.*)!''&H[*B
M*% [ "@"6BBB@ HHK^6;]H']OC]M;P]\>_'G@/P/XL:*STS7M1M-$T"RT.&^
MO&L;64A)441-))MB&YR <+D_0 _J8(!!! ((P01D$'J"#U!KY$_;#\&>$_\
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MG@[PVFA2/-HZZ19#3I9%VN]KY">2S+V)3&1V.:ZR@!#T/T/\J_/7X,ZK9/\
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M[V:-21;QQVAF5)&;"_.1@YK^-WXI?M<?\' __!53PW\0M?\ A/X UO\ 9I^
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MXO9O'FBZ1J,^CZI:W>K[(M16WG@= VFSI@O"<CJ1@DY^Y_\ @BU_P0_^)/\
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MF#T'N*^6(_\ @H)X#=$?_A"_%)WJ'&-*O""&Y!!\OD8/!]* /T!KY._: /\
MQ<CX-?\ 7S-_Z,->9?\ #P'P'_T)7BK_ ,%%Y_\ &Z^>/BA^UU<?$3XF_"QO
M!_PT\3W-EI.LVVGWEVVFW:JB7TX5IY/D/EI%NW$G@ <D=* /V$'\/_7*'_T
M4M1QL6CMW/!DM;>1E/5&:)&*GW!8@@]",#I4E !1110 4444 %%%% !1110
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MLY?%?]I/X-^$/"OPDTJUU?7=&\8C6+NVN[I+2,68MECW"1\ MN!&T'->Q?\
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MYSV9<1\,.N01SS3M%UO2/$5C;ZCH&I6NKV5S$DT,EG-',X1^1YJ1LQC*]"K
M$=#WK6977ED=0.I88 H :!C_ #_GIT'H.*6BB@ HHHH **** "BBB@ HHHH
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M_P"T-(E<0ZII5YL0W-G>64NV='@E8Q[RFU]NX'FN4_:N_P"3<OC!_P!B;?\
M_HR"@"]^S+#!!\!/A6EO!%;QGPAI+>7"BQKN-NNYB$ !9L9+=3WZ5[M7AW[-
M7_)!OA7_ -B=I/\ Z(%>XT %%%% !1110 4444 %%%% 'YD_M&_"V#XB?$'Q
M</#VJ>($FTZUT_4?&L=HSK#:6MG")8A9,&&'>%2S*#ACDX/2ONOX.RZ;)\,O
M!O\ 8\MU/I\6C00V\E[_ ,?;+$SHQN!VDW Y]L5\H?$CQ!;6OQ4\>Z5X?UJY
M\-7=UI]C!XQDFL+B]BU6QN+8Q#["T:L(98X)"I;('4]J^J_ L_A;PA\/_"5M
M:7[1Z*;2*WL+N\W(\S2O(Q>8M]PO(6Y<C P.*5-5)5)4ES5+M2ITHJE)T6XQ
MY^:I3J3G6GB$HSCS0C*E3IPH3;]E",7.I*--2JU*T:<4US5E6A1G%/W7"-3#
M4J-.-&[IKV=>NIN<ZONN<[^GT57@N[6Z&;:Y@N!@$F&5)0 >A)0G@Y&*L534
MHNTDXOLTT_N9*DI*\6I)[-.Z?S6@4444AA1110 4444 %%%% !3)8TFC>*1=
MT<B,CJ<@,C A@<8.""0:?10!^.7@G]F;X+_$K]O7]H*/Q=X)TS5+#P7H?A'6
M=$TV:/\ T2'5[N:"2:^*#[SF0E\-D$]>.*_8>VMX+2WAM;:*."WMXDA@AB14
MCBBC4(B(B@*JJH     %?GG\#/\ D_3]J[_L4? __H<%?H9<7$%K#)<W4T5O
M;PH9)9YY%BBB11EGDD<JB*!U+$ 4 </\4O$VE^$/A[XOU_6)UM[&ST+45DE8
M@+YES;26T"DG@;YI8U_&OG?]@WPWJ/A;]FSPEI^IQ-#<W.I^(]5564@M;ZIJ
MT]W;/SUWPR(P/>O'_B_XUO/VL/'T/[/?PSN9)OAWI%[:WWQ9\86RO]BGM+:X
MAECT;3+L 1RRK.@$K1.0^<<@"OT2T32+/0-'TO1-/C6*QTFPM-.M450H$-G
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MM;?4H=:TGRHIII_*1+A[*XN%9K9IBP.T$'D5^N]?P?\ _!N1<77[+7_!6O\
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M&9.L17W]IQ?M1:W'J??4$=%O/?\ TD 3?^/U^>'PO_X*7_#C_@EO_P %_/\
M@HG\<OB7X/UGQEHGB'Q7XZ\&6]AH3A+VWO+N32KI;C+*Z^61'L<$=&)Z@5^X
M(_X/,/V3._P$^(W_ ($Q_P#R-77/P^SWB54LRRCCGBS*\%"<?98''>)N1498
M?&T+*KB,)ALTCA<5@Z,I23PT%2:I07)2KU4N9[4.-J630E@LPX/R7.<0G)_7
ML%X?9U6A4PTVO94:]?*YXG"XBO".E>KSQJ59MSJ4H2DD^,_9I_X-//%WP%_:
M)^"OQMF_:B\1Z[;?"OXA:!XVN-'N;R=EU)-%NTNOL61)\J3E=DHY#H60C#&O
M[;:_D@^ /_!VI^S+\?OCI\)O@=H'P.\?Z?JOQ7\;Z+X)L-4N[F/[+IUWK=TE
MK;W-ROD!FB61U!"\@$DG -?UOUG7X:SOAIJCG7$N9<2U<4O;4:V8\3Y9Q/4P
MT(>Y*E3KY94J1PJG*TI4ZS4ZC2E&\$K34X@PF?\ +5PG#^'R".&7LYTL/P_F
M60+$RG[ZJSI9C"$\0X+W%4I+D@O=>H4445@9A1110 4U?XO]XTZFK_%_O&@!
M1T_$_P S5 _>?_>/\A5\=/Q/\S5 _>?_ 'C_ "% !1110 4444 %%%% !111
M0!Y3\6_@M\./CIX6N/!?Q4\-VWBSPQ<,7DTJZ++$Y.#\Q7!(R.GOSZ5\!_$7
M_@G+?Z=X8/A?]FGXJ7'P5\)V=U;ZM;^ =(T:S73=4O=/;SK>TO+]%2=8IG1$
M>3YN#N;V_5+-% 'X]>&/VO/VP_@]\3/A=\&?VA?@!91:3XR\4V7@[0OB%X0N
MI]9LIK''E)JNK2*&CLIG"JTJD@*Q([5^R@S@9]!6!>Z9I^I261O[.WO397"W
M-G]IB24VUPG*SPLZLT;KCAE((.*Z < #TXH **** "BBB@ HHHH *^7_ -LN
M^U:P_9M^*DNCQ)+._AF_@G#G&VTDA<3L/<**^H*\%_:BC23]GGXP*Z*X'@76
MV ;H&%N2#[$=C0!_(A^S)8:Y?VGCZ:RU22QTNQTZVENX%4,+X'4/F@;/10V>
M1^%?T?>&"#X7\*D# /AS22!ST^R18SGTZ?A7\]O[)O\ R*WQ1_[!D'_IR:OZ
M$?"__(K>%/\ L6])_P#22*@#<HHHH **** "BBB@ HHHH *Y?QC>^$[#PYJ4
M_C>;3(?#)A=+XZMY9MI,KS'")00+AAPC*-WI70W-Q#:6]Q=7+B.VM+>:[N9"
M0NRWMD,LIR>^Q3CUYQ7Q1H.D7G[47C6]\5>)'GB^#/A6_:T\,Z*C,EMXHN+>
M5DENKI,@31PRJ <@@XP..* / GTKXA:[XBN)OV/3KGA71A=.VH+XB6:/2=0^
M;YGT^6<[#;O\VPIP>!7U;\%-$_:?TS76D^,^I:7?:&83@6,RR.LW !V@GCID
MX/8\U]1V-E9:990:=IMG;Z?I]JBQ6UG:Q)%'#&@PJKM4'IUYS5K'U_,G^9H
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MC^Z>>!GZ;_Q:U'PS:? 7PQ%XDUO4-)T?48[*VGU06YM]21G#-(4@4 Q3>9N
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M@#)4\9S^DFFZA;:KI]CJEE()K/4;.VOK64=)+>[A2>%_^!1R*?;I0!=HHHH
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MU^TS<^(]:\,WMU9>$_#MV=(T6*6&^TN6YU2&26.\23EXPT2;'48R#@FOT/\
M^">7_)G7P-_[$W3_ /T4M57IPHU94Z=:.(@E%QK0HXS#QFI).\:6/PV#Q22=
MTI3P\(SMS4W.#4F0E*4;S@Z4TVI4W4H590DNDIX:K7HM]U&K)K:5G='VE111
M6)04444 ?*7Q(^(5KH7[1OPJ\&2^%K'4Y_$/A_5+J'7IB!=Z6(+B9#% .NV3
M:23VW'VKZMKY6^(OACP5J7[17PMU[5_$L6G^*=+\/ZG#HN@L3YFI6\ES*TLR
M#./D9BI^G>OJF@ HHHH **** /@?]C#XH:5X\\1_'/2-/\$:;X4F\,?$#6+*
MZO;%@TFLR1W8C-U<XZ22<.1SR.W2OOBO@S]C3P5X!\+>(?CC?^$?&=IXHU+6
MOB!K-SKUG;$YT>Z:[#26LH/1D<!#[].]?>= !1110 5\^?M0>+X/ OP>\0>)
M;G0K3Q'#8W.E!M)O<"WN//OX(@7SQF,MO'N*^@Z^?_VG-#\,^(_A!X@TGQ?K
M4?A[0;BXTPW>JRDA+=H[^%X02,$&20*@^M 'J?@/5$UKP;X:U6.SCT^._P!'
ML;E+*+_5VRRP(PA3_93H/8"NMKD_ EI86'@[PW9Z7=K?:=;:18Q6=VOW9X$@
M01R#V=>>>>:ZR@!#T/T/\J_G#_:@@MX_V^/A:T5K:PL_Q#M3))#;QPO*Q>/F
M5D 9V/?=U[U_1X>A^A_E7Y 2_LZ^&OC9^VUJ'B;Q%J%_;2_#74?^$ATZVM'*
MQ75S%(@19AD<9 )]L]^: /U[@_U$/_7*/_T 5+2*H1551@* H'L!@?H*6@ K
M\5/^"BFK:7JWQ1^'GA_Q-J_B#0=/ANXK6"YT+3_M1,=S(3+>7,B@GRH&.6C;
MY& P01FOVKK\.?\ @H]+\7M,^+?@>\^$\6@^)FLH#XD\2Z/JD2.^FZ+IC%KN
M9RX_X\C&"\H'.,]Z4OJMG]=>4QPVGM*F>5L7ALMIOF7)*OB,%"I7HRY[*DU"
M2E5<8->\73E.-2$J>+Q.!J1;<,1@\)A,=B8NSNJ>%QT986I=74G55H1O---7
M/'/VK["VM?V^/V!-)TNX.MV4&@P6UE>W*+;?VE;_ -FX2YGCCPL)((9E4<9P
M><X\5^,OPEFL8?BUXOO?%7@G69?"_P //CV-)T#P_J5L^JZ(FHV.H&9-3MH#
MOD=N2IF!([8XKV/]HW5QXX_;S_X)UZUBUA3Q/H=C)<+I VV-M]KLA%*MB!S'
M A=@@/(P![U[K^T5_P $]/A1\#/@Q^UE\</#%_XAO?%^M?#+XG:G*MW=RW%O
M_P 373+R:6/RF=@!'YG&%P!GCTYJTWAYX:C2K8VE!S5/ERW!8'&X.K&FHPC]
M8QF,='%83"JDYPI5\'"%>K2JS52*CS4*F^'^KU*6(J5VY5'2YL/*5;%X*?M)
MVDW/!X5/#2E+W7.A7YJ5)QG2C%<T:M+Z2_X(]G/_  33_9&/K\,V)^I\2:\3
M^M?I37YJ?\$>"3_P30_9$)&#_P *R.1@C!_X2/7>Q .?PK]*ZZCE(;C_ %$W
M_7-_Y&OXR_C=I7Q&U+XG_M"S^';E(?"5CXSO3XB@.-TJ37@2)E/J'()(_E7]
MFEQ_J)O^N;_R-?R>>,/^/_\ :[Y./^$M;CM_R$5]J /OW_@C5I6KZ)_PO?3M
M=F%SJ2:CX<F:93N!MY[,R6ZY_P!E"!^'M7[F5^,?_!*3_D8?CW_O>#?_ $VF
MOV<H **** "BBB@ K^23Q7^R5\+_ (*_\' OB7_@H;\3?VI?@[X,\-V_A273
M[WX>:]XHT[3_ !79W>HZ(NF1-<VD]PDD<$BQADW( 23S@8K^MNOXV?\ @H[_
M ,$(_P!F_P#X*"_\%$_B5XPF_;#M?"?QI\;:7I-Q<_!NSU-1K-A;:3:>6;H6
M:R>>(WB&_ 3;_%@GFLZD*-EB<3E/'&<83 M8S%87@7"8#%XV.'HZU:F:1S"A
M7I4<F4?<Q5>$L/5A4G04<13C*3>M)SDWAJ6><'Y!7QJ^IX;&<9+%RPE2O7:C
M3H9;'"8G#3EFTG[^&4O;P<(5;T)NSC_25_P\;_88_P"CG?@W_P"%GHW_ ,D5
M+;?\%%?V';N\LK"V_::^#TUYJ-Y;V%C;Q>,M&>6YO+J016]O"@N,O+-*RI&B
MY9F. ,U_)"W_  9P^!([A;.3]JK64NW^Y:M?,MP_IM@,HE;\%-=5X3_X,Z_#
M7A?QCX-\50_M+>(YSX5\5Z!XD-O(TY6Y&B:G;ZB+?G.WSFMQ&6&" QPPS4?Z
MW<!:+_B'WB[!S^"53 <.1AK:TFU6E+E3M=J+V>UKJH\$\5:O_B)?AE/D^*,,
M-F[EHDW!?O;*32LKM6;\D?W#PS17$,5Q ZRPSQQS0R(<I)%*H>-U(X*NC!E(
MZ@@U)67H>G#1]%TC20YD&EZ7I^G"0]9!96D5L'/NWE;C]:U*WO?5)I/5)[KR
M=NJZ^9AJM&TVM&ULWU:\GT/YGO\ @ZK_ &>/%/QK_P""8GB?Q'X&TJ\U?Q1\
M*_&OA?Q>;2QB::?^PK.YDFUBX"*K$"TMX/,!Z%I,$BOK;_@@W^V]\*/VP/\
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MXKZ+,HB/PVTZ ^?;EFGDU!0%6>-GXE8(WR@\<U^I/P\^(7C/XX?M%?!'X8>
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MD_M6?!?PWINL75KH.L>&=6FU33(US;WDT=W.L<DI SN154 9Z<U]JT %%%%
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M445N9GP?_P %-?\ DQG]H?\ [$EO_3IIU4/^"86/^&)?@MGI_8 S],1YJ_\
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MD?M/_''XHCX^_$/P_(M[X2/VE-3T2QU('?#K/VJ7S)9+N$X\H[CMYVD G/\
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M@RYT#PMH6AW<_C"VAGNM*L(K6>:)VCS'(\2AFCRQRN<5S?[%&C#0?VP?V=K
M1^6'\,ZY>8'0_:-/+9^IZ_CQTKT+_@J/_P D?\#^WC6S8]>B/"S?H#[5Q?[(
MGB?0O$7[;O[/8T6^AO/L'@O4;:Z$+!A%.FFD.C;> 0?Q_&@#^G2OSQ_:7\!W
M7P1\4Z7^U'\+[9K&32+ZU@^*'AK3P8[7Q3HMU/%;+<FTB C^UP-(7GFV[F4
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M%?8WAWPWH/A'1=.\.>&-(T_0=!TFVCL]-TG2[6*SL+*VB4+'#;V\*K'&BJ
M /K6W16YSGY0_P#!7_\ Y-FMO^QB7_TG%=U_P2;_ .3)/AI_U^:[_P"E4=<+
M_P %?_\ DV:V_P"QB7_TG%=U_P $F_\ DR3X:?\ 7YKO_I5'0!^DE%%% 'RK
M\1O&7A?2?VBOA9X8U+PM_:6OZSH&IW&E>(-RC^RX8KB9)(-I^8F1U9N/7I7U
M57RO\1? 6D:Y^T3\+?%UUXFL=.U+0= U*VL]"FE5;O4HY;B9VF@C^\ZQLY5B
M.F",U]44 %%%% !1156\O;33K6:]O[F&TM+>-I9[BXD6*&*-!EG=W(55 &22
M: /A3]C+QYX%\6^(?CGIWA+P5)X6O]"^(.L6NN7LDBR?VS=)=['NUP3M$CD,
M >F*^]:_.W]BKPSX$\(>+/C3/HGQ+\,>+-7\8^.-6UAM'TG48;BZL()[D3*)
M(U;=D8P=H/7GM7Z)4 %%%% !7S]^T[XET+PE\(/$&N^)-!/B32+2XTL7&D A
M?M)EOX8XCD\#RI&$G_ :^@:^?_VG/"FG>-?A!K_A[5=;M?#ME>7&EM+JMY((
MK>W,-_#*H=VX'F,H0>I(% 'J?@2^L]2\'>&[_3[/^S[*[TBRGMK+(/V:*2!&
M2+(X^0?+^%=;7)^!--@T?P=X;TRVNTOX++2+*WBO(R&CN$2%0LJ,."KCYE/H
M:ZR@"&Y<QV\TBD I$[@M]W*J3STXXYK^5KX=?M1O\ ?^"@'QE\>>-/$ER/#&
MI>([O2-8-RS7,*:<'8^19QDE80&PPVXY4>E?U+:XADT?4U!=2;"\ :,9<$V\
MH!7W&<CWQ7\G7P/^!7AS]H']NOXF^ ?&%O>7^BVGB*]O;^/RBTI0229:YRI5
M0 .2><=* /VGC_X*S_L>N"6\:SQ\_*&M3DKV/7TP>,]14O\ P]D_8[_Z'B;_
M ,!3_C5)O^"3G[*I9B/#L@4L=HVQ':O8<KVI/^'3?[*W_0NR?]\0_P#Q- %[
M_A[)^QW_ -#Q-_X"G_&C_A[)^QW_ -#Q-_X"G_&J/_#IO]E;_H79/^^(?_B:
M/^'3?[*W_0NR?]\0_P#Q- %W_A[+^QU_T/$_X6C'^1H_X>R_L=?]#Q/_ . ;
M?XUDR_\ !);]EQQA-&GC[C$</!]N/\_C6;+_ ,$B?V99#E;2\CXYVQ0GG.>A
MH ZH?\%8OV/#R/&]P>W_ !YO_C2_\/8?V/?^AVN/_ -O\:X*7_@CY^S=(#M?
M4X\Y^[%![]SSZ?J.:SI?^"-_[.K[MNHZQ'N.?EAMOP]* /2I?^"K_P"QZ\<B
M?\)K<$M&P4?8W^9B#A?;/'/O7X'Z[\:/ &J7G[0IAU1E;XA^(UN_":>6?]/A
MEOED7/\ =^3DY_"OV1N/^",O[/I21AX@UZ,!#@^1;$*0.">IV@]<<XK\7[SX
M'>#O#DWQ_MP&U&3X<:Y#IWARXF4*\0M[Y4$XX^\R@ @8'!% '['?\$GY5E\0
M?'QDS@2^#T^8$'<NG$,,$= > >]?M#7XQ_\ !*7_ )&/X^' RS^#F8@8R3IQ
M)/YFOV<H **** "BBB@ INY"=I*EO3(S^76G5_&['_P40_:'T+_@YTU[]E'Q
M3\:9]%_9DL_"=TP\%:I<6UIX=AO$\-QWUK(T\Q39<RW<AQ(TFT\ KQFN[ 82
MCC9U:-2O.E5]A.6#I4\)7Q=3&XM.*HX.G"@G*$ZUVHU&G&+237O'%C<16PT*
M=6G2P\Z2K1^N5<3BHX2GA<(DW6Q//*G4C.5))/V<G2C)7;JPMK_9#@>@_*C
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M=3M*MB<IIYCA*E7$YG03G.KE\\13CB,/!/"MUXRIS_4S_B+]_8M_Z)3\3?\
MP N/_D2C_B+\_8M_Z)3\3?\ P N/_D2OV^\#?\$W?^"=/Q#\&^%O'FA_LQ?#
M+^R/&.@:3XDTX'0+562TUFQ@OX8G79\DD*3B*1/X71E[5U7_  ZK_P""?_\
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M*'_T 4M(/X?^N4/_ * *6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M':Q>^#HDEGU*[L;N63[/A&:=KBU1VEC<*&,@905&0>U?N]8?#CP/\&=9T_\
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M>?&G[R)F+LHR=@5NC5^Z->!F&">7XJ>%>+RW'.FH/ZSE.8X/-<#/G@IVI8W
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MC0 HZ?B?YFJ!^\_^\?Y"KXZ?B?YFJ!^\_P#O'^0H ***3DYV*SX_NCC\^F:
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MX<TG_P!)(L?I@?A0!MT444 %%%% !1110 4444 %%%% !7R=^T!_R4CX-?\
M7S-_Z,:OK&OD[]H#_DI'P:_Z^9O_ $8U 'U@/X?^N4/_ * *6D'\/_7*'_T
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MWBX3:EXY\"H\=^NG.^4O)K?1D#FS\II7W6JHO<L,$YYZ63]JCX?> _%WQQ^
M-CIFH?#+QKI]]<^*O"D;QZA_9+74+)?2VND+N-G/$LK":%45HPP##!H Z']F
M^[\9_![X;:W^T'\+(&\;_"O6-2U:X^)WPQ!^TW6G"YN)9+BYL[,%M@L8I&29
M-G)1\J4W"MW0_C/J?PN\1:9\</@YX/U;4O@)\3K\VWC/P"8GGAM+JX/^G7>G
M6 W?9[A 9&D5XPAC5E*D9!^./V,M:_:W^&W@OXA?%+X?:7:>*_A+>ZK>W'CG
MPO< 7<L3W;R-?26^G-N:/RA-(CPJN2N]2,9KZ;T!?VA_AYI$_P ??A+H&D^(
M_A!K(FU3Q-X)+1:FVBRW)$=]/:Z0-_V*:+S6\RW5%:($9'4U,JE:*Y:=*A*+
M<7.51_O&N9)PINS]G:+=3G5^9Q]G97YE48T7+FJNO=1<81IU)0IJ3U]I4IQL
MJST4%&348I\VK5G]0W]O)\+;/4?C_P#LXH?&?P/\<VET/B1\+[?=-_8DUVCB
M_OM,L"6-HUL6D_M&+8"GSX!4@G\7?%=MJT_PY^,OQ ^'MVC?#?6O&EW87'AC
M[L=B\S,\MXL!P4:-V*$[1RIK]"M#N?VE_A]H/B#X[?!K2M+UGX2^.+:ZG\:>
M"HIH[P:<\\1^VS6NF(6-BT22NMQ&%4D%@PQFOR9\33_%>]\(>/?%OAFW2U^$
M6M^++B+6K6W&P6VM2.QEA^R+_JE#%LY Z'IFJ)/F2V*Q)"R,7RI7;_L@#!8<
M_IU/6OK;]DCQ)XY\*:E\6]0\$Z!_PD;:C\,->TG7[-5W&PT6XC;[5J>T8.+=
M23GL/T^2(F"!3& 1C '?H?S(_P :^N?V1/$GCKPGJGQ;U#P/X>'B8ZC\+M?T
MCQ!9[]G]GZ)<Q.+K5>.6^SC)"9)Q@=J /E#0!&-=\,^4=T9\4:*RGV.JP<?G
MFO[R_!O_ "*'A7_L6]#_ /39:U_!IH C&N^&O);=$?%&C%#C'!U6#/'L<U_>
M7X-_Y%#PK_V+>A_^FRUH Z2BBB@ K^6[X)?\I;=/_P"QM\5_RK^I&OY;O@E_
MREMT_P#[&WQ7_*@#^I&BBB@ HHHH **** "BBB@#\H?^"O\ _P FS6W_ &,2
M_P#I.*[K_@DW_P F2?#3_K\UW_TJCKA?^"O_ /R;-;?]C$O_ *3BNZ_X)-_\
MF2?#3_K\UW_TJCH _22BBB@#X;^,&AZS>?M;_ _5K.PNYM-L?"^L1WMY%YGV
M>!WO+AE68I\@+*05+<\<5]R5\@_%#XD>)_#_ .TU\(O!&G3V2:!XD\.:K=:I
M%+;J]T\\-U/'&89R"T:[4&X#&3U%?7U !1110 4444 ?E]_P3YT'6](\;_M+
MW.IZ=?V5K?\ Q.UR6RENQ,(KA#?*0\'FG&TCD; %QTXK]0:_//\ 8B^+OC#X
MC>*OC]HWB:739+/PG\0]9T_1Q8VB6TBVL5X(T%RR &60*3EFR2>:_0R@ HHH
MH *^5/VT-+U'6?V?_%FGZ5:7%[?376BF*VM=_GOLU.W9MGE_/PH)..U?5=?-
M_P"U?XSUSP!\%/$GBCPY+;0ZM87.DK;R7<*SP 3ZA!%)NB<%6)1CMXX/- 'J
M7PMM[BT^'?@ZVNHI(;F'0-.CFBESYB.MN@*OGG<.,YKOJXSX>:K=ZWX'\+:O
M?-&]WJ&BV-U<-$FR,RRP(SE5'"C=G [5V= "'H?H?Y5^97@GXG^ _ G[8WCG
M1?%WB6PT35O%JG3?#UC=OL?4[UI5(@@.,%R!D GDG'IG]-3T/T/\J_G$_:GM
M8V_;Z^%,LL*^8OQ"M3'*ZCS!EX^5?J.?3O0!_1Y144'^HA[_ +J/K_N"I: "
MOQH_X* ?#_XI>//&D^B?"SQWIGAZ*#P?JOBGQ,=0NC;O%!I4;.;6W^=,M<(H
M*[>!D9QFOV7K\9O^"A=KX9\1?$[P3ITGBN/P?J\UK-X:GE.J+I8U6#5V8&UN
M/G031-G89",(!R<"MJ-1TY\_M,SI12?-/)Z6.Q.8Q35KX;"Y>UB:\[V]V,HQ
M@KU)MJ'+).FZMH1P6$Q\FURX7'1P+PM2S3?MIYC7P^%I12UYYU5*Z48IN6GQ
M7\:]!T+QE^V/_P $O(?%^G:?XF^S^']':X.HQK=VC744*B2X\N7>DG*L=S ]
M<Y%?J#^WAX9_9_U+]DO]IG2+'P]\/KO7H_A/X[D-G9V.E#48KN#2+EI)$$$?
MF1R1L"20 5/I7YY?M/\ ANV\'_MS?\$_/"=OAK;0?#45A$]G(LXF,6FMAX+B
M,D3;VRPD4\D@@GBO#/B-8ZI:V?QRNY_ WBC04U'P'\>/MWB._P!<N-1M=<2.
MRU 6QGL'9AIRH,>6& #CIFE"I2DIRJ4,34G45X-8K#T94ISC*?/7ACY0QF(:
MY9.I"-+ZS[LW5M4N@^K5JC7LL9@\)##ZU*-7!UJKQ48N*='"5,'7^J8244N2
M$N;%4.:I1C23I+G?Z]_\$<84M_\ @F5^Q_#$I2.+X7A(TR3L1?$6N@(">2%
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M"3;^T/\ L]$>-?@/XT/G_$GX;6Y^U+HIN"_VZ]TZP)81268=Q<6Y3 (8%2C
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M!_LXQ2^-/@IXVTC4)_B%\,("TCZ1/=6C">^L+$;OL5Q#+(3<P>6"%W J8V-
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M^H'3M)6/^T[X6LWV?3]_")=R[=D,G\)21@0?3I7U)^R+XC\<^%=2^+>I>!]
M;Q-_:/POU[2?$%G&V&T_1+F-OM.K-_>2!23CG@8H ^4M $8UWPUY1S&?%&BL
MGT.J0<?@<BO[RO!O_(H>%?\ L6]#_P#39:U_!IX?$8UWPUY3!HCXHT8H0".#
MJL/;V.:_O+\&_P#(H>%?^Q;T/_TV6M '24444 %?RW?!+_E+;I__ &-OBO\
ME7]2-?RW?!+_ )2VZ?\ ]C;XK_E0!_4C1110 4444 %%%% !1110!^27_!8N
MZ^S_ +->EID S^)Q$,]_]'4__7_^M7I/_!)O_DR3X:?]?FN_^E4=>'_\%K+H
MV_[.O@U!C_2?'2Q'/?-HAQ_C7N/_  2=X_8F^&P_Z?=>_'_2TY_'K0!^D=%%
M% 'RM\1=2^&T'[1?PML/$%E?R^.+G0-3D\-W4*YLX;1;B43K.^/E<R!\<\C]
M/JFOE#XD?#35?$7[1WPJ\=6U]90:?X9\/ZG9W5K-/&EU.]Q<S2*T$+'>ZJ'
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MT?58-"N_)MD42:C ]R0JQDYV)@D#!QZ<;^TS^VY_P5A^,?P'^+/PKT+_ ()
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M+&<?SSLOA;^T?_P<K?\ !1K]HC2?$?Q7\1_"_P#8[_9C\87_ (*N?#VA:C-
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MV;O^A\T_]:/^&VOV;O\ H?-/_6@#ZPHKY/\ ^&VOV;O^A\T_]:/^&VOV;O\
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MU)SQZ9_S[4 ?6U%?)_\ PVU^S=_T/FG_ *T?\-M?LW?]#YI_ZT ?6%%?)_\
MPVU^S=_T/FG_ *T?\-M?LW?]#YI_ZT ?6%%?)_\ PVU^S=_T/FG_ *T?\-M?
MLW?]#YI_ZT ?6%%?)_\ PVU^S=_T/FG_ *TO_#;'[.&,_P#"=V&/7#8_.@#Z
MOHKY/_X;:_9N_P"A\T_]:/\ AMK]F[_H?-/_ %H ^L**^3_^&VOV;O\ H?-/
M_6C_ (;:_9N_Z'S3_P!: /K"BOD__AMK]F[_ *'S3_UH_P"&VOV;O^A\T_\
M6@#ZPHKY/_X;:_9N_P"A\T_]:/\ AMK]F[_H?-/_ %H ^L**^3_^&V?V;_\
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M'0,0, '%,TWPO^TQ=^!]2.D0^,KOX>W;/>:OI]O+--8RR,6\R6[LP69'SN+
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M6GC[X?6[0N^E:A=V;PB]@B!:6*6Q\QTN$/\ JR"N2""?PD\'>!_VA]#TB_\
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MO>&A'G8?%&BLN1@@'5(#R.@.<].*_O*\&_\ (H>%?^Q;T/\ ]-EK7\'6C?\
M(P>&?^QET+_TY6]?WB^#?^10\*_]BWH?_ILM: .DHHHH *_EN^"7_*6W3_\
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M9RP@U"QF*@LPBNH)"JCJS;)#@#N3Q48UG1V(5=5TTL3@*+ZU))] !+DGVZT
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M*^"E_P""EG['S#)^*NEK[$'_ .M3O^'E?['W_15]*_(_XT ?>=%?!G_#RO\
M8^_Z*OI7Y'_&C_AY5^Q\>GQ6TK\C_C0!]YT5\&_\/*OV/_\ HJVE_D?\:/\
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M8BK4KUZM2M6K3E4JUJLY5*E2I)WE.<Y-RG*3=W*3;;W9\'_\%-?^3&?VA_\
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MRO\ M8?\B5X?_P"QBTK_ -+8J^J*^5_VL/\ D2O#_P#V,6E?^EL5 'U!:?\
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M_#QP?WJ<8ZY^;M7\\/[7G[2'QW\&?\$:_BO\9O OQ9US3OC=<:GHVFMXSO\
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MX\1_#;]GS0+J2$>--<M;WQS%$3OE\%QR*+F+"G=M>1#N)P,8K[VK\_;PF?\
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MJ4&KV^G:3;0QZC;.)(+E5C50\;KD%3MX(H ]8HHHH 0]#]#_ "K^<?\ :FF
M_;X^%,<DBY_X6%:B.-B@8G?%PJ@ D\#GFOZ.#T/T/\J_+;PQ\&OAY\3/VS/%
M_B#QIH*ZQJO@=SJ_ANXDF9$L+])%59Q&IP[ =-W'3/04 ?J+!_J(?^N4?_H
MJ6BB@ K\//\ @I%#\(?$'Q8^'NG?&"R\4/#!(NFZ?/X;^T QZ7>N3>S3_9\D
MHI)+(02W8=J_<.OQ!_X*)W'Q"TSXO^#+GX9+%K-_I5C+XS\0V-QIL.H0V6C:
M(2]T&:57\L2(I81_Q ].*F4XPC*53'U\LIJ-ZF.P]+'5*F'BVHWYLNJ4\92C
M-R5*56C+W5.TTX.2$Z>(JVIX7#8C&8B7\/"X3&X+ 5ZSC[THPKYC&>#:C%.<
MH5HOFC%J'OV/$/VG]/T+0OV\O^"?6E^#D:Z\+Z5X=@A\-I=;@]QIL6G!H!="
M4+(&==OFJX4\LN.*^7?'$\-WXN_:EURVA\!_;]7^'OQK@U;0_#NG_9+KPB+6
MQU!(Y0XX,U^ 'F9 -S$D]:^G?VB/$$/Q$_;Q_P""<WB=XO+A\7Z)974\$2BW
M6%KNT$<HCC0 0*CL^U%'   Z5]._M._L._#+X/\ P&_:M^+N@RWMWXGU/X8_
M$K42\N%VC4],NY7C8K_K/+W_ "EL],^U95JKP]2C2_L[$8V4Y>R^LQJ86*P:
MBX*57$_7E];JQEI5<:"AB?;48>T?+*K2J=F&G7=+$SAC</A%.E_M&&Q4L9.M
MBU/5T<,\OY\$ZT7S0J5*]18>49J5*4U9Q]L_X(]_\HT_V1L9/_%LVZ]>?$FO
M&OTIK\U/^"/!)_X)H?LAD]3\,CGC_J8]=K]*ZW.0AN/]1-_US?\ D:_C$^.6
MM^-[;XL?'/2M%T^.3PQ=^/[E=<NW7<\"#4$V%&_A^;N"!@=*_L[N/]1-_P!<
MW_D:_D2^*(_XJ']I7&/^1ZFSQR?^)BO?/^- 'ZG_ /!)Q94U_P"/RS,LC"X\
M(X=?NE/[/.SCL<=?_K5^TE?C!_P2A_Y&'X^_]=?!_P#Z;C7[/T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^,'_ &(FN?\ I,: /Y1/V6?^19^)?_8%MO\ TY&OZ!O"_P#R*WA3_L6])_\
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M*X&,'K76000VL$-M;0QV]M;1)!;P1($CAAC&(XT1<* B\ XJ4AAR48#U(HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "FK_%_O&G4U?XO]XT *.GXG^9J@?O/_O'^0J^.GXG^9J@?O/\
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M11^!99B-;U(C<=N7FSMSQGY^M-_X<H? S_H-:C_WW-_\50!]\_\ #=?[*O\
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M_P#@E JKXA^/VU%0-/X0;:@PH)T\DX'OWK]H* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IJ_Q?[QIU-7^
M+_>- "CI^)_F:H'[S_[Q_D*OCI^)_F:H'[S_ .\?Y"@ HHHH **** "BBB@
MHHHH ,9_S_G/TI,#T'Y5S&O>,/#GA6;3T\3:[I>A1:M=&STV74[RWL8[JZ !
M\B.6YDC0N!_M9Y'>E/C/P801_P )EX4[C/\ PD.D9Y_[?, T =*N"RA< AN?
MF"9&.W0MG(X&<_A6E7YP_M=>-K'3?'?[,^I^$?BI::??ZM\7M&\.:CH6C^(K
M&>VUW2KA09K>>RM;F1Y#G )*$?-CKBOT=7H/H/Y4 +1110 4444 %%%% !7A
M'[3_ /R;U\8/^Q$US_TF->[UX1^T_P#\F]?&#_L1-<_])C0!_*)^RU_R+/Q+
MX_Y@MM_Z<C7] OA<#_A%O"G _P"1;TGM_P!.D5?S]?LL_P#(L_$O_L"VW_IR
M-?T#>%_^16\*?]BWI/\ Z214 ;>!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>
M@_*C ]!^5+10 F!Z#\J"%') P/:EI#T/T/\ *@#F-9UWPIIVHZ5I^O:IIMGJ
M.H2NNBVEY+&L]W.,EQ;1L<N?H#@\^E=,F,#&.F>.X[$>H]/3I7YP_M;;O^&@
M/V?CO<>7K4ACPQ4)G / (!SG'/M7Z-Q<PVISG_18N>O)C0GGW/- $M%%% !7
MRO\ M8?\B5X>_P"QBTK_ -+HJ^J*^5_VL/\ D2O#_P#V,6E?^EL5 'T_: ?8
M-+X'_(+L>W_3M#5C ]!^506G_'AI?_8+L?\ TFAJQ0 F!Z#\J,#T'Y4M% 'D
MWQQ>.'X5^+I)"J(ME(68C@#R7Y/TK@_@9\2_AM9_"'P1:7OCGP]:WD%@R3VT
MUW$LL+K,Q9'5OF!&._I7T)JNE6&M6%UIFI6T5Y8WL30W-M,H:.5'7:=P/<+G
M\.*\8A_9K^#<*;$\(6:KEFP$8 %R68 9XY)[#/X4 =S_ ,+5^%G_ $4'PU_X
M&Q4?\+5^%G_10?#7_@;%7%_\,X_!W_H4K3_OEO\ &C_AG'X._P#0I6G_ 'RW
M^- ':?\ "U?A9_T4'PU_X&Q4?\+5^%G_ $4'PU_X&Q5Q?_#./P=_Z%*T_P"^
M6_QH_P"&<?@[_P!"E:?]\M_C0!VG_"U?A9_T4'PU_P"!L5'_  M7X6?]%!\-
M?^!L5<7_ ,,X_!W_ *%*T_[Y;_&C_AG'X._]"E:?]\M_C0!VG_"U?A9_T4'P
MU_X&Q4?\+5^%G_10?#7_ (&Q5Q?_  SC\'?^A2M/^^6_QH_X9Q^#O_0I6G_?
M+?XT =I_PM7X6?\ 10?#7_@;%1_PM7X6?]%!\-?^!L5<7_PSC\'?^A2M/^^6
M_P :/^&<?@[_ -"E:?\ ?+?XT =I_P +5^%G_10?#7_@;%7S'\:/&G@WQ%\4
M_A!:^'/$VDZY=)XALGDM]/G6:5$5D.\A.BY')/?%>T?\,X_!W_H4K3_OEO\
M&M?0/@7\+/#.L0:]I'A*PAU:U&+6\,?[VWQT:-CG!!P>.: /8KD#[1+P/OGM
M7->*]!'BCPMXB\,G:!K^DW>FY887]^F!GM^)_#TK?R3R22>Y/4_6CGL2#ZCK
M0!\O_LMZ]:7GA#6O =]8V4.M_#[6KK0OL4UK";A]-M'817@#KO:*3JK\AL]:
M^FOLUI_SX:?_ . 4/^%?+'Q;\"^*O!OB^+XX?"NU^TZE;P1VWC/PK ,?V[I,
M1!=K9%X-VJ*79\%CCKS7K7PX^,7@GXFZ>EQI&I06&KQ*%U70=1=;*[T^ZZ20
ME9RIDV/E/ESTH ]-%O:JRNEG91R*<I)':Q)(A]4=1N4^XJ<DDDDEB3DEB22?
M4DT@R1N78R?WU<%/4'>/E (Z9-(&#="#VRIR/S'% "T444 %?)WQU_; ^&WP
M \8Z9X*\7VVISZKJ-E#J):S@:2)+2=E2((PSF5F8#9Z]*^L:_"W_ (*<H#\?
MO"!"[F_L'1 ,#+'_ $ZV(Z]>>: /T43X_P#Q.\<00I\*?AC=YU"))+.]\5PO
MI\'V:4;DNE8@#[AW)S\P]\5T'@;X#:C/XBB^(/QBUN3Q?XLB<3:9H\K;M)\/
M/RRQVL9/ES"(G"N5S\HQ[?0/A"21O!'@A25 'A'0!A8T0C_08SC*@']:W>E
M"DDG)Q[ #"J.RJO15'0 8 I*** "BBB@ KX]_;[_ .34?B!_U\:?_P"AU]A5
M\>_M]_\ )J/Q _Z^-/\ _0Z /9O^".W_ ";=JG_8Q1?^DTM?K97Y)_\ !';_
M )-NU3_L8HO_ $FEK];* "BBB@ HHHH **** "BBB@ HHHH **** /'/VAO^
M2%_%S_LGWBG_ ---S7XK?\$0/^/'XC_[I_\ 2XU^U/[0W_)"_BY_V3[Q3_Z:
M;FOQ6_X(@?\ 'C\1_P#=/_I<: /Z#**** "BBB@#^'7XT_\ )TOQ'_[+0?\
MT]P5_;-X-_Y%#PK_ -BWH?\ Z;+6OXF?C3_R=+\1_P#LM!_]/<%?VS>#?^10
M\*_]BWH?_ILM: .DHHHH *_EN^"7_*6W3_\ L;?%?\J_J1K^6[X)?\I;=/\
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M,/[2O_8]3?\ IQ6@#]4_^"4/_(P_'W_KKX/_ /3<:_9^OQ@_X)0_\C#\??\
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M"NM0L[)[4WEY;VBW4ZVUM]H<1FXN6^[##O*EW;/W1D]\=,[P.0#Z\T %%%%
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M]>M__0TC?\%G/VE5.&^%'A4=_P#CVU#I^5 ']-]%?S&G_@M!^TD.OPJ\*?\
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MY'X&@#I**** "OY;O@E_REMT_P#[&WQ7_*OZD:_EN^"7_*6W3_\ L;?%?\J
M/ZD:*** "BBB@ KQK]H>*2?X&_%2&*-Y))?!6MQI'&I9V+VK+A%&26YX YS7
MLM>:_&/7I?#'PL\>^(8+2VOIM'\-:E?QV=XH:UN7MX2ZPSJ>#&Y&&!ZB@#\^
MOV)_V+_!GA;P;X9^)5UK_C"ZUS6=&E9M,N]7O5L+%[V%HY1':.^Q2BR90!<
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MV3?^16^*/_8,@_\ 3DU?T(^%_P#D5O"G_8MZ3_Z214 ;E%%% !1110 4444
M%!Y!'KQ110!\I?M8?"KP7XS\!R>+]?L9YM?\%W%K/X?NH93&D,DLGSF901O
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M3_P46W_QNC_A!_ G_0C>%/\ P46W_P ;KIZ* .8_X0?P)_T(WA3_ ,%%M_\
M&ZJWGPX^&FIVYL]5^&_@G4[)G25K.^T*SN+=I(SF.1HGB*EXS\R''RGD5V-%
M '+KX%\ HJI'X#\)1QJ J1IH]JJ(JC"JJB/ 50  !T%+_P (/X$_Z$;PI_X*
M+;_XW73T4 <Q_P (/X$_Z$;PI_X*+;_XW1_P@_@3_H1O"G_@HMO_ (W73T4
M<Q_P@_@3_H1O"G_@HMO_ (W1_P (/X$_Z$;PI_X*+;_XW73T4 <Q_P (/X$_
MZ$;PI_X*+;_XW2?\(-X#/7P+X3_\%%M_\;KJ** .5/@/P">O@3PD>_\ R![7
M_P"-T'P%\/CU\ >#SG_J#6O_ ,;KJJ* .3_X5_\ #P]?A_X/_P#!-;?_ !ND
M_P"%??#O_HGW@[_P2VO_ ,;KK:* .2_X5]\._P#HGW@[_P $MK_\;H_X5]\.
M_P#HGW@[_P $MK_\;KK:* .2_P"%??#O_HGW@[_P2VO_ ,;H_P"%??#O_HGW
M@[_P2VO_ ,;KK:* .2_X5]\._P#HGW@[_P $MK_\;KXV_;A^ &I_$KX7^&_#
MGP;^'^A?\)4/%,=Q.-)LH+"X-DJJ6#S(@9D.T_(<@_A7WM6WX:)'B#22N ?M
M<?./<4 ?E9^S?\6/'?[._P +K+X4>*OV+)_B'K>A:IJ$EYXGGTNVE:[,TBXB
M\R>QFD<0;2J,)-I#,<5[O_PV)K7_ $CU'_@GL?\ Y6U^XD5E9F.,FTMB2B$D
MV\1))49))3))[DT_[#9?\^=K_P" \7_Q% '\Y/QW_:RN]=T3POHNJ?L>P_#.
M"\\3Z5';ZY-I]M 1*^H0*5A,5I =PSD\L<ANW%?T0^$W\SPMX:DV[?,T#1GV
M_P!W=IULV/PSBOR)_P""E7B33_%?B[X2_"OP\MO+J/A?Q1I?BSQ='#%'FTT>
MZN+5+;>8QP=R[MI((+'CO7Z]^&E5/#N@(GW$T72E7_=6Q@"_H!0!M4444 %?
MRW?!+_E+;I__ &-OBO\ E7]2-?RW?!+_ )2VZ?\ ]C;XK_E0!_4C1110 444
M4 %><?%^#0KKX8>.K?Q-=M8>'YO#FHQZQ>*"S6U@T1$\H4<DJO.!7H]>7?&S
M1+_Q+\)?B%H&EQ";4=6\+:I8V<1QB2XG@*QH<\?,>.: ,[X!6?A2P^$W@VU\
M$W[:IX:CTJ$:9?.I5IX,?*Q4\C/7!]:]BKP[]G#PKJ_@OX->"/#FN0+;:GIN
MD00W,*8PC@<CY>/_ *^:]QH **** "O@_P#:YT;X6:K\2/V<9/B-XBET.\L_
M&5]+X6@CB:3^TM2,5L# S#A OR')(SG%?>%?GG^VA\+_ !9\1/B?^S!=^&[!
M;RV\,^.K[4-7E8+BUM6BM<29;GG8W3GB@#T7]I?]L'P3^RW#HI\5V,U];:G:
M(UE%9RA]0GVA418+-0TLP.,%D4@&OS@_X*N:WH/Q!^"WP?\ 'Z^'/&=W9:];
MVVLR:?X?MKU;N^TW4D15LK\P)NMC9+(;ES+@;5Q5;_@J!XO\&>'/B=X(NO$W
MA^]U7QGHFBK%X)LK>)KE;N-OFGG6UPT<I29G RIQTSP:^I_C_P##'XX_M ?L
MJ?"&Q^#OC72OAYXQF\.Z5JNJV6NVUI&NHZ>UI UUICQ3IFW)C66-Q&H*[^V*
MVQ.*KX;#4*M'#TL+.C%UJ.-PF*<LRQ46^2K4]A@,5G.*PV'A>="&)J9/AFY^
MV=2-&-)57SX?#J>)Q$J>85*\JLH4)X3$XS$99@,OK-*4(2S&IDF IPG7@XUI
M1PF<9C6A'DITJ<JM56_$/XR_L[^ ?C#\8O\ @D#^S7K?CWQ_J'P8\4^#/B5X
M@UFR\,>(;W0I]4U,-+/;V&K/;R*T[Z5(1;,9 7!CR!7V]^VA_P $8?V-O!/[
M*OQR\5^'3\6=+UWP_P""+G5=(U*V^).M_:+&\L9K<PRQ990Q+$;LD<#'>O#_
M -HG2[WP3^V1_P $J]-M+C1O#NM^'?A%\8A=:E82AM%M-;M(;A;S5#*,@1M=
M*T\N.%)('I7HVA_%#X[^._A%^VQI_P 4?CAX=^)WAJW^#NK7.@Z#HLT<K6JB
MZ=4OT*J&$:A%5CD E><X J(SP]2#G7QLJ6)J6E0P^,E/%8S%R:4IJ6+PN$HX
M.K7BFY5I^SPL9N\Z=&,7RK>4VYV:C[S?O0E4G33TTC*JYUG!_8G6G*<E;GDY
M7D_TO_X),W>IW7["?P6CU35]3UR?3]*DTR'4=8NI+W49K2S2WCMQ<W,I9Y9%
M0X+$\G)KK/@)I'PFMOVH/VBM2\.>()K[XA7>N@^)](>-ECL#L;(5NC=SQTKC
MO^"2W_)C/PD_ZXWW_MM6I^SS\*_%WA[]K?\ :8\?ZE81P>'?$NNH=*NAM\R8
M&-QR =WIUJ!GZ)4444 %%%% 'E?QO@\/W7PG\=V_BNZ:R\.2Z!=)K%VB[G@L
MLH99%'<C IGP/MO"]I\+?!]OX-O'O_#D>DVPTRZD4J\T'E)M9@><D8_E4'Q\
MT#4?%7P<^(?AW28UEU+6/#EY96<;X"-/*4VAL\8X/6H/V?\ PSJG@_X0^"?#
MNLQ)#J.FZ/;07,:8VK(L2 XQQU!H ]EHHHH 0]#]#_*OYF/CWX0^/.A_M^>!
M-?\ BKI5G:>"M9^*D3_#^^M)8W>ZTHR((?/5?F63.,AL8(/H:_IHK\<O^"A+
MJ/VCOV45+$?\5Q9G!)P3YZ]!T)Q[9H _8B#_ %$/_7*/_P! %2U%!_J(?^N4
M?_H J6@ K\1_^"AL/Q5_X6YX6G^#GB2VTR]T#2+GQIXCAU*_33H@FC9D3R!*
MRB[5D +PH&R?EK]N*\(^+/[.7PM^-%_I>J>-]!2_U#2H);.WNXY98)6L;@EK
MBSE,+IYL,V<,KYP.!QQ7/B>7V3<\-B,7#FCS4L+4I0Q#5U[U)5\1A:$Y)VO&
MM7A#EYG:<E&$M\.Z:JQ=6.&G%7?L\9A88O"S=M%6I3A-I+XHSIQ]I&:BTU'F
M/P^^//B"\\?_ +=O_!-_Q%K!BN=2\4Z%I]QK+0)MAGGNK58KEX8QP%<ER".F
M<BOM+]JW]C+X%_"7]G+]J?XG>!_"TMGXRU'X6_$C4YM1DNI+@I-J>E7<MV$1
MQ\J%G;:,_*.*B_;L_P""5.A?M?7?P2UWP!\<_B#^S)XN^!%S _@[Q-\,8[4W
MJV5LJK%I\RW;J/(4+UW$DDG'3'QW\0O^"'O[2?Q.\'^(_ OBS_@K-^U;?^&_
M%FFWND:[8FUT94O-.U")H;NV8+.!Y<L;LI48&#QCLZN'HXF=&M6H052C)5:4
M8N?+AYM7Y:?O:JG?DBY.7NK=W;=4L5B,-"O1P^(K0I8B/LZRBU35>FKI*K"'
MN:WNX+W4VU%6/T#_ ."/!)_X)H?LB9(+#X9$-CU_X2/7?Z8K]+*^;OV0/V<-
M%_9#_9H^#O[-?AWQ#JWBS1OA!X1MO"=CXDUT(-8UJ."ZNKM[_4!&3']IFENY
M"^TD<#FOI&MSF(;C_43?]<W_ )&OY.O&"C^T/VNSM7/_  EK<[1G_D(KWK^L
M6X_U$W_7-_Y&OY//&'_'_P#M=_\ 8VM_Z<5H _2W_@E)G_A(OCWDD_-X-Y/_
M &#:_9ROQC_X)2?\C%\>_P#>\&_^FVOV<H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FK_ !?[QIU-7^+_
M 'C0 HZ?B?YFF^6G)VCDY-.'3\3_ #-+0 SRT_NBCRT_NBGT4 ,\M/[HH\M/
M[HI]% #/+3^Z*/+3^Z*?10 SRT_NBCRT_NBGT4 ,\M/[HH\M/[HI]% %.YTZ
MQO?(^UVEO<_991/;>?$DI@F'26(N"4D'9UPWO5P<<#H.*** "BBB@ HHHH *
M*** "O"/VG_^3>OC!_V(FN?^DQKW>O"/VG_^3>OC!_V(FN?^DQH _DY_9-_Y
M%;XH_P#8,@_].35_0CX7_P"16\*?]BWI/_I)%7\YG[-'BK0?#OASXAV^LZA#
M8RZE81Q62S2!#-*FHNS*,GG:O)QGBOW4\,?'SX.+X9\-12>/M!CEM]!TR":-
M]1A5DECMHE=""_!!!!]P: />Z*\@_P"%^?!K_HH/A[_P90?_ !='_"_/@U_T
M4'P]_P"#*#_XN@#U^BO(/^%^?!K_ **#X>_\&4'_ ,71_P +\^#7_10?#W_@
MR@_^+H ]?HKR#_A?GP:_Z*#X>_\ !E!_\71_POSX-?\ 10?#W_@R@_\ BZ /
M7Z*\@_X7Y\&O^B@^'O\ P90?_%T?\+\^#7_10?#W_@R@_P#BZ ,_]H^XBMO@
MMXSGFDBB2&.UE+2NJ#]TQ8A2V 3CCVS4_P"S]K<.O_"/PGJ=NZO;RVJI&58,
M/W6%;)&?8\]J^&OV_P#XU^#-=^$5GX?\&^+K'5)]5FF2]M]+O$D<1IN*F;RF
M) /!^;KTQ7T5^PD2?V:? RLTCE+6=29"S$_.O<]: /L.BBB@ KX3_;GU?QMI
MGAOX>6_A'1?[5LKWQ/8C7+GC%@B7B^4>>[\XQTX]C7W97RQ^U>2/!7A_!8 ^
M(M*S@D9_TV+KCK_GVH ^C]!FO+C0]#EOX3;WCZ58^? ?X/\ 18OZXY]P/7&Q
M5>T_X\-+Z_\ (+L>N3_R[0]S5B@ HHHH **** "BBB@ HHHH **** "BBB@
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M',AW ?A0!\/_ /!2+P;K^I?&KX2^,/#?BW0;;6/"NGVWB*[TG5M*;49;/1;
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MP=U2_;1O#?AZT?3;WQ!J48AA7Q1'*=]MN)Q]F$8(67.,XST.0#]/AQP!@#@
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M;1 9/6YFSC_OYBJC_P#!++6#GR?&]G[EIYS[#_EIZ#M^-?LA@>@_*C ]!^5
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MF=XWM(Q!9?&'5;*W4Y6WM)9X(5/.2L:,%!.>3CFI?^':WQ!_Z+9KW_@5=?\
MQR@#]<OVT_B]\-M<\$^']#TCQAHFHZI+XDTR5;2UO899 AN[=0S!6.,D8K]!
M_#/_ "+?A_O_ ,232N1T/^@6_(K^*OX^?"/Q-\ OBWX9\"ZKXSU;Q),^H>&M
M1%_-=3?=FU.U_=89N@&0>Q]Z_M)\%DGP=X3)))/AG0<D\DG^R[7))[D]S0!T
MU%%% !7\MWP2_P"4MNG_ /8V^*_Y5_4C7\MWP2_Y2VZ?_P!C;XK_ )4 ?U(T
M444 %%%% !7G'Q?T[2]7^&'CK3-;U!-*TB^\.:C;:CJ,GW+*UDB*RW#>T:\F
MO1Z\U^,?AO4?&'PK\?>%](B6;5-=\,:IIUA"YVI+=7$#+#&S'@!WPI/;- &/
M\ ]$T'P[\)_!VD^&=8CU[1;32H8['58CF.ZB XD'UKV*O@#]E3Q#^T%X9\.:
M9\,O''P7B\.:?X3TV6T@U^+4Q)%J!MHW,)6#;P;AU5,@\$UIM^T#^T[_ &P]
M@O[-CFR&IR6B7W]N\-9K.8TN]NS #Q@28R<9H ^[**^2OB9\8?CUX3U'1K7P
MA\#V\7VM]I$5YJ-TFK?9QI^H,%,EAC:=^PDC?WQ5G3_BW\=KGX:ZQXKN_@H;
M7Q=9SQQZ=X1.J[GOXF.))?M 7]V(QD]#GTH ^K*^$/VN/!7@7Q9\2/V<KGQC
MXQM?"]QHOC*^N]$M;C[^LWABM@;6'_:&%_[Z'X];\./C3^T'XI\36VD^*_@,
M?"FCRH6N-8?6/M @(5C@1;1NRP"_CD5\5?M7:;^U+\8?B1\,=6\-_ .*2R^$
M'C+4-5M9KG6 4\06SE(XI8\JOV;?'$I"G)W$\]!0!^R5NJI!"J'<BQ1JC>JA
M%"G\0 :_(?\ X*Y:?=:K\.?AY9VT7VH_\)(\ALHH)Y;V<[4XM&@&Z.0[< DA
M?7O7V<OQ3_:!A^%2^)5^!\9\=175K:)X+_MH 26NQ%FO/M>WY=AR5CQTXK \
M#>/?C9\1?$$6G?%#]F_2M#T>RCENK;5;_4;?5?(NEC+1K#%-"X5GD 3<I!!(
M-3-U%%NBJ3JIQ=/VT(5(1FI)J5IPFHR@_>A4BE4I34:E*=.K&$XZT94XU$ZO
MMO9M2C/V%5T:O+.+B^6I:2V?O1E%PJ1O3J)PE)/(_8Z\"^&_%O[*GPWT;QQX
M,@U"V@MK@C2?%VGP7MS;LLQ4,1<QL\>X?=VD$KC<37O4W[.'P&N(F@G^$G@2
M:%P \4GA^Q=&"D, RM&0<$ C(ZBOGD_&[]J73]4ETG3OV7K6+1H-3FM+6Y@U
M^.&)K%9F2*\6%(PB"1 )"@'!.#7??$OXL_M#>%[K0(O!7P+C\80:AI$=YJ\W
M]MBV&E:BP!?3P-I\S821YGM1&5648RKN#K22=5TY590=1J\^65:4JLES7M*I
M*4WO*3=V1-4U*2HJ2I)M4U-04^2_N\RIQC34K;J$8Q3^%)61]1Z7I6FZ'I]K
MI6CV%IIFF6,*6]G8V,$=M:VT$8"I%##$JHB*H  4#BOASX"^"? .E_M/_M$^
M*='\8VNJ^+]7UU?[;\.1,?.T@E'RLJGOSG_ZU>DZ+\5?V@+SX=:[XFU3X'I8
M^,-/EA&D^$%UQ6;5HV?$I%V5Q"43D94]?:O@3X-:/^USX!_:+^*'Q;O?V>K2
M73_BOJT=U<6Z:XL<VC(058/+C][M#$\CV'>J)/VEHKY&^)WQ<_:*\*ZW9V/@
MCX#Q^,]+FTBVN[G4O[<%I]GU*0 SV CVG=Y)R-_?%6E^*_[09^&-YXI?X'QK
MXXBOX8+3P8-:5OM-FQ7SKDW>/D\L$_+CG% 'U?17R%\-/B_^T;XH\1C3O&OP
M%C\':+Y,KOK']N"ZVND19$$.T;M[@)D>OXUQ][\>/VKX-;O+"U_9FCN=-BU2
M:TM=2_X2,+]HL$EV17QCV_+YD>'V9Z\"@#Z9^-VFZ/K'PG\=Z9X@U!=)T6]T
M"Z@U+4FX6SM6*;YSTX7 _.F? _2="T/X6^#]+\-:HFLZ+:Z3;1V.I(<K<Q")
M 'S[XS^-?,O[37B;]HC7OA]<^!/!'P2A\22^.?"9M=8O)-96"+P]J-RT7G6K
M)M/VA8US\_&2O'-?2'P"\):QX'^$/@;PQX@@CM=:TS0[.'4K6)M\=M=K$BRP
M*PX81E<9[_6@#V&BBB@#+UL3G2-2^S,$G^PW?E.>BR?9Y-C'V#X)_P BOY!/
M"/[/_P#PTM^VC\2_AMK.J?86F\47MSJ-];,ZLP,K_<:,AQZ9]^M?V%3IYD,L
M9&X.C(5/ (8$$9]P37Y-_LL_ [P;X+_;)^-GBF/3,^(=1CN+L7$C;XX!+,01
M&AR%?YC\U '@C?\ !$7P'N;;X[U<J&(0_:[P$KQC.).O'>D_X<B^!/\ H>]7
M_P# R]_^.U^\M% 'X-?\.1? G_0]ZO\ ^!E[_P#':/\ AR+X$_Z'O5__  ,O
M?_CM?O+10!^"$O\ P1%\(9/D^/=3Q_M75W_\<X]_Y5G2?\$1-$_Y9?$&Z4X.
M-T]YQT])>3U_/TS7] %% '\]LG_!$.'GR_B*_MOFO._; D[?7IZUGR?\$0[X
M;O)^),0_NAI+S\/X^GKDYYK^B*B@#^<N;_@B)XB"L8OB99# + /)?8) X&2_
M )XR>@]J_-.3]G>#1)_BZNKZH;BZ^$VL06-D;5W\J\N(;U(G>4;L-&PZ;MWK
M]/[6KC_43?\ 7-OY&OY._& 'V_\ :[X'_(VMV_ZB*T ?I9_P2B1$\1?'WRT"
M*TO@^38OW0SZ<2Q'U[]L]*_9ZOQC_P""4G_(Q?'O_>\&_P#IMK]G* "BBB@
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M0X'Y5YO\%X_)^#?PNBP!Y?@[2U  Z 1UZ10 NY_^>C_G_P#6HW/_ ,]'_/\
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M+6QQ7O=>#_M0 -^SU\8,C./ NN$?46QQ0!_(;^S'J7B"&R\?6.DV$%QI\EA
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M_P!B]IO_ *(6OF[]LA/$K_"FW'ABXM+:Y&L6WVQKU"\;6IFBRL0[.>>:^AO
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M%73?_1*UWE !1110 4444 %%%% !7P/_ ,%'_P#D@-E_V,4?_H*U]\5\#_\
M!1__ )(#9?\ 8Q1_^@K0!K?\$Y?^36=#_P"QBU3_ -"K[BKX=_X)RY_X99T/
M((_XJ+5.O^]7W%0 4444 %%%% !1110 4444 %%%% !1110!^$W_  448/\
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M4 ?,>F?LI?#?2OA[JGPXM[CQ&=&U:8S7$\NM7DE^"3NVQW+2&1%!)X5A6/\
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MU_\ BJ_+C_AV!JG_ $/^I_\ @=<?_':/^'8&J?\ 0_ZG_P"!UQ_\=H _4?\
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MYIHQN>+R'$@'<A"@8_@#0!_1;Y,W_/&3_OG_ .O7YQ_\%0DD3X!>&"\;H/\
MA-8!E@ ,X3WK\[XOVX/VCII)(8]9OFGB ,D)@=9%S_L,@8_@.O%>;_$W]HCX
MN?&K0X/"?C.[OM1L-/O!J26C6\BNER@'S["@8E<8^4'/L: /V9_X)VQR-^R[
MH12-V'_"0:GRHR/O'WK[;\F?_GC)_P!\_P#UZ_F:^&O[3GQH^%_AJ/P/X*O[
MZSTFRN);M;$02*Z2S9WMY;('))]%/\JZT_MJ_M(W4DD,/B+4HYH^'A$,@D7@
M\JK*&;IV!.: /Z.OL]P>EO-_WQ1]GN?^?>;_ +XK^;!_VP?VFKR26&'QQK<<
M\0R\*VTBRHO/1"H9O^ @UE#]J_\ :AE=T3XF^(HWCR9(6A,;H/\ <;:Q ]0#
M0!_3&;>X'6WE';E/_KTGDS_\\9/^^?\ Z]?S3:5^V5^T=9-<&?XBZKJ!D4Q
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M17G7[)]IX8L?V>/A9:>#-0?5?#,/AT+I.H2(4>YM_MMV?,9#RIWEACT%=_\
M&+3[K5_A/\2=*LH_-O-1\#^)[*UB_P">D]UH]W#$G/'S.X'/K7F7['WAK5?"
M'[-7PD\.:W +75-*\,K;WD  'E2?;KQ]O''W7!XXYH ^E:*** "BBB@#Y/\
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M_"ZUG*M-J>J:G#"T=O<Z<Q(=&8$,AQQS7]B$ 8!PQR0_WO[WRJ2<=N:_A?\
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MJ%E;WL2[3E8[E%>-3CJ=K"N-_9:S_P (S\2^2/\ B2VV<=_^)D:_H'\,,_\
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M]9:VW/<PR67E1K?6VI%&^R7 1_(WA)&/!'GN@_ +P]\2([_QW^SAJNH? /\
M:F^'SRS>*/ <\[BSUW4[5@+II+><@W.F7VUEMI@CIN;!^\*\IUCXZ_&#Q'KR
M^*-;^'MUX2^/7PQE%I<:GX4MW?6O&"6Y*W,.LZ1$%W6%XRO_ *0Z,$B8D=*
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MX!6MYX3L?$S>,?BWI?ANUFO=H.@SW$:E=6MMP/[^+("@<F@#ZTHHHH ****
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M\P8DDY-?V)1J44+C & H&,!5 51QQT% $E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4U?XO]XTZFK_ !?[QH 4=/Q/\S2T@Z?B?YFEH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\(_:?_P"3>OC!_P!B
M)KG_ *3&O=Z\%_:BD6/]GGXP,W /@;6U_$VYQ0!_*/\ LM'_ (IGXE_]@6V_
M].1K^@;PO_R*WA3_ +%O2?\ TDBK^<C]FC7M9BLO'>G:=H_VRVGTRW34;POL
M6SMQJ7$R]=YZX&/UK^CCPQ@>%_"H!) \.:2 ?^W2+'UXY^M &W1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?A-_P %.?\ DX30O^Q*M?\
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M^%DLGPQ_:=^%?A314?0[E?L3^)=)L;"-8[>^@(B_M"#4TC/E2LK^49<$X"T
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MX1^T_P#\F]?&#_L1-<_])C0!_*%^RPBCPU\3&"@,=%MLG'/_ "$C7]!'A?\
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MQ'X-L)?@O^U;\.T>S\2Z'HK_ -AW^JSVCDRPH(?*^T6]T8V*7H#@!PC-SNH
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M/PSPNO:993I]D\1M8[%FM+D1$1ZC:780K"Y#A6?G/!JT@_X:&)\>> L_"O\
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M^&A_^*]\"'_A5?[7/PKRFOZ!*#:)XD^P!!/;7D+!!J5G?[&6V<JX0N-W&&(
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M-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X1^T_\
M\F]?&#_L1-<_])C7N]>$?M/_ /)O7Q@_[$37/_28T ?RB?LL_P#(L_$O_L"V
MW_IR-?T#>%_^16\*?]BWI/\ Z215_/I^RW-$GAOXDH\L*,^C6P17D57<_P!I
M=$4\L>>@YK^@OPO_ ,BMX4_[%O2?_22*@#<HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_L(=;RUGC9D%]:ZBRLD4I#%5D4<@@G^?SX2_!#X_?'&]U&Z^#^B:CXFU+38
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M[-<E7<,P0D@JU?S7V?AKQ;#XRL_!&FVU[;>-I]8&A6>EPSO#.^L/*84M@^\
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M7R=^T[XJ\!^&M9^ L/C7PW<>(+G7?BUI>D^%98" -&UZ6,&#4IL@YBC7A@*
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M0 4444 %%%% !1110 4444 %?A-_P4Y_Y.$T+_L2K7_T-:_=FOPF_P""G/\
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MX:MO"GB#PO"VBZK9VT:J;NZA!AENWF #3F616=6).,XZ=?U8_P"%A>&OBU\
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MI^)_F:6D'3\3_,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\-$A?'W@$'X6_M<?"U8H_$?AJ4_8V\026B@S64\/[L7^GW2HRI>,L@4L$8D
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M%CJ]YH?B+PAJ<C376CZC92R0R1-*RH7!>*3!V] *ZJU_:K^!?BV36/A/X?\
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MN"X') U)L#/IQT[=!T%?T)^%_P#D5?"G_8MZ3_Z214 ;E%%% !1110 4444
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MX!?LM>*YO!GA7X3>#]:OM(?5[RTU+[%-?7ZVT\+B"3!99&!!'3)(H [O3O\
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M*N5\$>&M*\&^%-!\*Z);&STK0=+LM/L[3S&F%O%! @\L3,29/FR2V>2<UU5
M!32X#!>=Q&0 ,\5%,Y0*=VWDY[9'?KZ=J_(?_@HA^UQ^U%^S#J.C:QX7\$>$
M6^ >IA+#Q+\1Y]5 \7^'YYV56FTO1F8?:6C+$J=K9QCO0!^O9E0-M8E3R>1C
M@=ZD!SR.AKXD_8D\1ZCXW^$]AX^O_B7KOQ(M/%Z?VCIFH:]8"PN]/A8!WM5@
M 4&-0V <= #Q7VTO0?0=?I0 M%%% !35_B_WC3J:O\7^\: %'3\3_,TM(.GX
MG^9I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"/VG
M_P#DWKXP?]B)KG_I,:]WKPC]I_\ Y-Z^,'_8B:Y_Z3&@#^3G]DW_ )%;XH_]
M@R#_ -.35_0CX7_Y%;PI_P!BWI/_ *215_/=^R;_ ,BM\4?^P9!_Z<FK^A'P
MO_R*WA3_ +%O2?\ TDBH W**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K\)O^"G/_)PFA?]B5:_^AK7[LU^$W_!3G_DX30O^Q*M?_0UH ^8
M/ ]MX.E^!7QFN=8U;4+7QE;ZEHJ^$](MYBEAJ<!9?M;WL(8"9X@28R5.#]*Y
M[X+_ !;\2_ [QSIOQ%\)W+6VNZ2J26R9Q;73(,_9KT<;[=LME1U]*\O^;H&8
M*?O("0KGL6'0D'IG-=SX!LO EWJ&K2_$#6+G2;"PTQ[K1X+6$S'6M44_)ILI
M _<QRJ,>9VR>: /N7QO_ ,%(_&WB[QGX;^*6C>'=+\)?$OP^L2WNH:(OV>R\
M1PH%#6VLJ#_I$"J,1A]S>I)KY[_:I_:=U']JSQ/X<\7Z[X:T/PUK>C:6UCJD
M^B1+"=:G(&;N]88:21<'#,3M'&:] U>']B?6?AO9ZAIFK:UX7^)-HD;W>@+;
M27%IJ,B9:2'[01B,2L-F>@5L^M0ZW#^Q9K7PXL=4TK6-:\*?$JUC$UYX;6V>
MYL]1EA 4VGVGD1B[ +%A]W..HH YCX9?M:>)_A38^&+CP;96VC^,/"5\+F'6
M;(^6-=LQQ_9FN!2!<6B+]U2#R:ZO]HC]M+4/VAKK0O%5SX6TOP=\2] 2(#Q1
MX<3[)<7CQ@'[1<R(P:22(Y,19CC'TK-GT_\ 8WOOAI#?Q^)=:TCXFV\BW4NA
M"TDDM+L9RVGFXP0JX  D]_K6IJ\7[$VM_#>SU'3-5UKPK\2;5%ENM 6VDN+3
M4'MP/]&-QSL6\.5+#[G7B@#QO0?VHOC5X?\ %-AXUTWQI?GQ;IX6.773<LM[
MJ5H@ %GJ#J0);<@ ,&R2,UKZY^UC\7?$'Q:TGXY-J-G8_$K14$<&MZ>%CDFB
MSAHKG: '1U&UP<[@3N!!KTO5HOV*-;^'%EJ>FZIK?A;XEVL:7%WX=6V>YL]1
MF5@KV7V@Y$:R $F3.06/H35#Q'8_L:^(/A[IFIZ'XCUKP7\1+"(MJ'AM;1[J
MTU:6-01']I((C$S#9G@C.?6@#R^']ISXO6GQ;U'XX:7XC;2?B'K$OF:OJ=A)
MY7]H+L*/;W(4@/#(&)<$<Y/'2N7M/C=X]L-3U_6-(U?^RM4\4:AJ&I>)+JQE
M,<NL2ZF&%Q!>8;$D"[B44@^O&:]NDTS]CR]^'%IJB^*M:T?XD6R?:;GPVEE)
M+:7\D3 "Q-QC$8N%!8OU7)'85M:Q#^Q-K/PVL]0TO5=:\*_$JUCBDNM 6WDN
M+3495YDM_M!&(Q(1MSG@'/;% 'S!JGQ-\1:MX8TSPI&]IIUEI!N9$N;!O+N[
MV6YE,LDUZ00'<.3M9N0/2O:]8_:CU!O _AOPWX#TZ/P%XETBSBLM<\4^'F^R
M7WB>WB #1:K+&5\Y)0"'#9R"0?2NTU2+]BC6?AO9ZC8:KK7A/XDVJ">ZT 6T
MEQ::E);@ 6@N.1&MZ026_ASWS2:M#^Q/K/PWLM2T[5-:\+_$JTCCGNO#RV\E
MQ9ZA(&(>T-P<A%<#._MN]J /#=&_:$^('AWQQH/Q'\+3V/ASQAX<0I;ZEI.V
M*2\$G_'P;W'$GVGGSPWWMQSG.*N67[3/Q:T[XK:I\:-&\1OI'C[6YFGUG4;"
M7RQJ2O&T<EO<["!)"ZL2P(ZDU[/JL/[$VM?#>SU'3]6UKPM\2K15DN=!6VDN
M;74'MP"8#<<A1=M\I/&WZ"DU>']B;6_AO9:GIVIZWX5^)5I$MS=^'5MGN;34
M94*@V)N#D1K, 7W_ ,.Y@3Q0!\YVOQG\<6-SK5YI&J#2KWQ%?:GJ'B"YL93%
M+K$NJEOM4=[M;$D2[FV ]!^&*NI?%;Q%JWA_P]X9VV-E9^&5D-K<V?[NZNVD
ME\UY+TJ1O8R?Q,,X_*OI75H?V*=9^&]EJ&G:KK7A;XDVBQ/=: ML]Q::BT>6
MDB-P>(Q.1LS_  YSS3M7C_8HUKX<66IZ=JFL^%?B7:(MQ=>'5MI+FSU*6$*/
ML7VDY$:W6&8O_#G'M0!XQKW[1_Q \2Z]X)\47)TNT\2_#Z"WM]!UFQ41WIM[
M3:(8[EUP&"[ #GG'>NTUC]M/XYZWXSLOB!!KD.A>,+2S%E<:YHLAMKO4K<+L
M_P!/V,!*54_Q@]\]:[/5XOV)]:^&]GJ.G:IK7A;XE6D<4UWH"VTES::A*"2]
MM]HY5 ^,;AC[WMBC5HOV*-<^&]IJ&GZKK7A/XE6J++<Z$MO)<6FHO;@?Z,9R
M"(Q>D$%OX-V>: .1T_\ :CU#2_%VA_%*W%]K?Q6T+54UE==UJ43Q7%PN-UK-
M'RLEKD'Y64GGUJQ\>?VL=6^.WC:T^*3VLG@KXD0V=M9W.J>&)6M(Y(X%"MR&
MR<@=2Q/KD\UTFK1?L4ZW\-K/4M-U36O"OQ+M(TN+KP\EO)<VFI2JP#V9N.D8
MD"[MW4%B#TS3M4A_8GUOX;66H6&JZSX5^)5HD;W.@I;2W%IJ#PKN,)G((07+
M#86Z+NH ^:Y_B9KW]I?\)%I?B_Q3;^+I(O*N=9_M&1;B6,_>5RCC()).6!/O
M60/B1X]76Y/$5KXWUV+Q#+$D5QJ\=\Z7<R(>$=D<;@N.X.3R:^JM5C_8IUKX
M;V6IZ?JFL^%/B7:(+BZ\/);R7-IJ4L)5?L7V@Y6-;E59]_\ "6Q1J\/[%&M_
M#2"^TW5]:\)_$VV@#2Z(MO)<VE].JDF(SD$('(P3V!]J /F_PY\9/B7X:\<:
M%\0+7QAJMYXBT/5+755>YO)-E^]H^]8+P(RF2!_NN&ZCJ:^U_'G_  4C\:^-
M?&'ACXH:3X<TSPA\3?#?DBXU/0E-O:Z_#'L#6.L*&S<V9"GY'W<G'W<"O$XM
M'_9(O/AFFHS^,]9TCXG1,;DZ EB\UG<>01LL#<=%%V <N#\I)SZUTNJ0?L4:
MS\-;+4+#5M;\,_$RSABGN]"%N]Q9ZG.I_>6OG\B-7 ^]GC=[4 >B^.?^"C_C
M3QAXN\.?$S2/#VF^$?B5X>6)+O4M"4P6WB*)5 EBUE%(^TQL,J V?EKRG]HO
M]L&__:-US0O'&HZ+%X-^(>A6D=H-9\,-]F2X*%0]S*5.YIC@_.Q)&< X %:6
MJ0_L3ZW\-K/4+#5M:\*_$NT59+G0DMY+FTU&2W7F W!X07C97/\ !GL!2:I'
M^Q1K?PWL]2T_4M;\*_$NT1;FY\/);R7-IJ,L9"M9&X/$8G"EB_\ #O\ 04 ?
M-EY\3/$?]JIXDT7Q?XI@\52Q1QZGK3W[_:9PG49C<9' V[AZ9S4]U\2M:^U1
M^(M(\5^+;7QJX$=_KC7TJ23PGB1,HXW$_-C<">>H[]C\7[SX#7_A+P)<_"6S
MO=-\8%I4\=:?<[F@C55/ERP2-]YG;!('3/K7@= ':W/Q-^(]U*9;KQIKEVCW
M-K=7,,]TQCOC93I<01W2YPZ,\:A]W.TG-?J1X3_X+*?&;1M$T[2M7\(>%YVT
MRQL].@DM(I )(;.!+>*20ESF5DC!?'&>@'-?D+ GG7VF6QZ7FJ:?9,/47=U'
M 1GMG?C/:OW5TG_@EGJ6HSZ?<P^"]-?0K_P]8:A;WK:QMD>\N[..X"21YW("
MSC.>F>] 'P[^TQ^VWI_[6,&CV_Q/\*O8+H;B2S?0I&MY'[A9'W;MI.>0>_XU
M\D>?\$!UT;Q3_P"#.X_^/5^FGPO_ .">OB/Q_:>.HK?P%:-JWA#QS=>&[F&Y
MU,V\*P6Y.6@D8XF4(.&'M7KWAK_@F[X;'QGT?X=^-_"]KIN@:MICW:ZC::JL
MUXEQ%%YDD26V=Q7=P'Y'?/6@#\;1<? [/.C^*<<]-4GSTX_Y;>M?5?\ P3AO
M$C_;=^$=IHMU>VNBSW6KLEE)<.WFQK;YC6<%SO. <YSU-?L^/^"/G[.V[F;4
MBO.!N.>AQGYO7&>:@_9L_P""7GASX*?&_2OC5%XIN]_AB^U!-$\.^3NB^S3+
MY:2RSG'S,O( !/OTH _7:BBB@ HHKYB_:=_: O\ X":'X,N-%\+-XO\ $7CO
MQ=:^#] T87!M1-J%V@="TH!V@9^E 'T[17RO#\4OC]_PK6Z\37/P8@A\:P7+
M0Q^$5UC>)8U;'F_:@.!CG_.*R?AK\8/VB?%'B(Z9XQ^!D/A/2!9R3_VI_;/G
MGST!*P>60/O' !S_ #H ^OJ*^%]5^.W[4EIKM[86'[.D5]I<&I_9;;4?[=V?
M:+/S53[7LV_+\I+[?08%=W\2?BO\??#']@#P?\%HO%9U&R6?5?\ B;^1_9=R
M4#&WX7]YACMW>U 'U;17RKX;^*OQ[U3P#KOB+6/@Q#I7BFPE:/2O#/\ :_F?
MVDH.%;S\?N\\9X[CBOF_PC^V/^T?XQ^)OBKX7:=^SC;+KO@5M(D\6>9XB 2Q
MM-6*F.:/(Q(50[@HSG% 'Z=45\E?$SXJ?M'>&=1TRV\#? ^T\7V=SIR7%_>/
MK@M!9WI4%K4+CYP&RN[_ &<U9T[XG_M$7'PTU#Q+>?!6TMO&\$YCLO"']MAE
MN8@V/--UCY<CG'Y4 ?5E%?'GPV^+?[3/B3Q+'IOC;X#V?A+0VM9)9-777A=%
M)U7*P^5WW'C(S7-:Y\;?VM+'7M0L-*_9PLM1TFWU'[/9ZF?$8C-U9>8%^UF/
M'R?)EMM 'W117Q[\9?C5\>_AQX8M_$_A_P""]IXFM+#P_=:[XK#:X+8Z.EE;
M-<7,,0ZSLBHW3)P"<<&N8_9T_:.^.GQPTC2O%^H?!*V\,^"M?T>75-%U<ZX)
MY;ID:2-(6A(ROF2)M#?7T- 'W317PG<_&_\ :WCUR:Q@_9ML9=+35?LD6H?\
M))AI+#S=GVSR\<'R_P!YL]1BNZ^)?Q3_ &C?#-YHT/@CX(6GB^VO+!9]3N6U
MP6O]GWA0,UJ!C]YALKN'IF@#ZRHKY2TKXH_M$77PVU;Q)J'P4M;+QK:S%-.\
M)C6@ZWT88#>US_RSR.>F*P_AU\7OVG/$?B6WTWQG\!+/PKH<EN\D^L)KPN3%
M*J9$8BQSN8X'^% 'V317P#X@_:I^,7@3XP> ? GCWX+PZ-X/^(WC-_"/A_Q=
M#K(G=Y @=+F2T ^4,K [3C@YZ=?OZ@ HHHH #SP>AXK\8/\ @J5X3\,:7XA_
M9L\1Z=H.F6&OZE\58;74-9M;:.&]O+4&Q?[/<RH%:5=[LP+$G)/M7[/U\??M
M5_LJQ?M,W'PLDG\42^&X_AOXO7Q45B@\_P#M/8MN!:-_<!,&=W3GG.* /JGP
M]_R -#_[ ^F?^D4%;%5-/M186%E8ABXL[2VM0Y&"XMX4A#$>K!,_C5N@#Q[X
MV?!W1?C5X,G\*:K?7^D2BZMK_3]8TJ00ZA87MG()89()3]T%U4..X _'\K/V
MW?\ @E_\1_C+^S?I/@7X"_%"TT7XT>'OC9X=^.&F^,_B(DNJZ5<^(?#JJEK:
M7EM"K-]DVQ1AE&<[F)Z8K]M**Q]E+VRJ_6,2J=DWA55:PLJJC*$*\J-M:T*<
MZE.,N:RA4E[KE:2T]K+V?L^6%M5S\D?:J#E&;IJI;F5.4X0FXWLY13[I_P \
M5Q\(O^#B*[T*YT:X_: _8P?[7I%QI,TP\%:P&"W-J]J\ZX4#S41]RG &1T[5
M]C_\$H/V,_CY^QG\'/%?A3]HGQ[X0^(/C[Q9XKN?$MYJ_@RQFT_24>\DGGFA
M2"958 2SMMX^[P37ZK45L9A1110 5_-K^V[_ ,GE^/O^Q#_]LWK^DJOYM?VW
M?^3R_'W_ &(?_MF] 'Z?_P#!,7_DU/PA_P!?>H_^E4M?H77YZ?\ !,7_ )-3
M\(?]?>H_^E4M?H70 4444 %%%% !1110 4444 5KD H24W JROQT0CYOTSQW
MZ5_'O^V'_P $Z?B1\#OVN_&G[6W_  3'_;/^%/P.\8>/KAW^+?PG\6>)M.@T
MK7=167S)9I-/^V(5G\U29/,CW9)SD]?["+IB(\ '#AE.!G (Z_A_GI7\4'_!
M6W]D;_@D;^S7XP\7?$_XI_$SXL^-_P!HOXFZKJ%WX=^#?P]\?ZI=:C?ZW>2%
MTM[C2-/NVETRU>Y<1!GC4(IS@"@#U3]CW_@G!\3?C;^U[X'_ &O_ /@IQ^V7
M\+OC=XR\!7,3?"'X7^#_ !'82Z=H^L1RE[.:VL?M3J[B1LXC0N2,CFO["[5_
M,BW[-A9LE?3Y5&/R QZ=.U?P$_\ !(/_ ((6_'GQY\?_  ?^VW\:_'WB_P"
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M\'O /P_U#X56=GXLT;PLOQH\36TEKID2ZG<FVDOM/6X18+A8 2Y*LPP.O!H
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A'[3_\ R;U\8/\
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ML!C^S'.X?<W8Z>_US5;]D+5O#HU_]HU[9+;2V?XQZJ)I9[R(#4)"LG^DP[F
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M]W_P0PMW?RK3XV65O*PRL3:0[2-CN$+;L#U Z9H _8+_ (;4_99_Z+;X%_\
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MR_\ 8_67_I%<U^Y%?AO_ ,$._P#DD_QE_P"Q^LO_ $BN:_<B@ HHHH ****
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M#KSVH 6BBB@ IJ_Q?[QIU-7^+_>- "CI^)_F:6D'3\3_ #-+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5X1^T__P F]?&#_L1-<_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_#3_@IDN_\ :"\&KZZ'HG;/_+[;'IS7[EU^'7_!2D;OVBO!*9QG0]%S_P"!
MMN!^?(]?2@#]I_"(QX,\%CT\)Z$/RL8ZWJP_"O'@_P '#T\*Z(/_ "32MR@
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MR1E1L=7_ (PPP0W\6<]ZGKYW^)OBC7V_9\OO$_P4L4U/4+KPG:WOA2W*MO\
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MW_LS<S;I''5F)W9]P,]J^HE9T 5',:@Y"1?(BG_94<+^'X4%F8Y=F<^K$L:
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MEO,ZT*N&QF:UEA*6%Q]/_=X9?BH8;%XN&:8E.5+#T\'1=2M'FA.48.Y^KO\
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M+_>-.IJ_Q?[QJB!1T_$_S-+2#I^)_F:6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KXR_;2TGXNZG\$OB(G@36M TW3!X;U*35H]1@=
M[JXTU8";F"WD'RI+(H(4GO@"OLVO$?VDN?@/\5<C_F3=7_\ 1!H _B0LO#^K
M6D&I1QSM:QPVDEY=IR/M-NT\@*,,X8;LGGLWM7-3 O:2A%.6AD"J/4J<8],G
M\1]:]SURTU:\NYK?2+0W)D\.*MV$4G9&]TR(QQZE@,UNVO[)WQYN;6UNH?"$
MK07=O'<P-A_GAF4/&W3NI!H WM5\2Z'XB\:_LR6^C:C%J$V@:)I^F:ND:@-8
M7RS*3;28'+XZG/\ A7]&>D?\@;1_^O"V_P#1(K^<7PW^S?\ &KP7XQ\)Z[J7
M@J\:UM=<M9IOLT,CM\LB_.^%X SG)].H K^C30)'DT'0VD1HYCIMJ98F!#1/
MY(#(P/(*MP>^>* ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
M,O\ @I-_R<YX*_[%[1O_ $LMZ_<VOPR_X*3?\G.>"O\ L7M&_P#2R"@#]LO"
MW_(H>#O^Q6T7_P!(TK;K'\*QR_\ "(>#OW3_ /(K:)V'_/FGO6P<J<,"I]\?
MXF@ HHHH **** "BBB@ HHI,C_\ 4"?Y4 +13G1XXFGE'E0(I9YI,+$BCJS-
MG@>]>8^*_C)\+/!FFSZGKGCG0/*M=WGVMEJ%O/>H5ZKY"N7+>@Q]10!Z9G'7
MBE57?[B.X]5&17YQ_$#_ (*6_!GP_;;O MK=^++]6=)+6]C:UCW(3@*_<'Z\
MY[5\M>*/V[OVEOB3- WPJ\#ZIX8MIG$6^RTZ;4;=R_R@M*$( (.<YXSF@#]M
M[F]L+**2:]U'3[..%6>4SWL$;HJC+'RW8,2 "< =/>OG+QI^UW\ ?!5O>_:_
M'6GZAJEF64Z1;,#-(RY!57'RYR".M?E_#^S%^V=\:[RU\1^,-;OM,TW4'WW$
MZ:M/8RQ1R8+DV*LN,<_*0/3O7T=X(_X)A^"M,OK;5?'7C2Y\6;MLEYITL15R
MYYDC^T-ECR3DD^O?F@#G?'7_  5 TV6VEMOACX&U1M5B=E6\NX'O;60 \$)"
MK$ ^_)Z'FO"-0^,7[<7[15FMYX4T+5-.L8V*>?X=CETU\'CYPZH21]/K7ZT^
M ?V9/@;\,I?/\(^![*.8\M_:<:7Z9/!(6=2%SQP,^U>XV=K::<I32[&RTJ(D
MDQ:;;QVD9)]4B51^A_2@#\4-$_X)Y?'CXFP67B#XD?$1+>>617OM-UF>:345
MCX+J'#X#8R ?7 ( KZZ\%?\ !.3X#>%KK2M7U"36]9U6QV/<VUS.TFF74H +
M!XF+9C++T]#]:^_&)<EG)=CU+<FB@#@_#OPM^&?A&[CU'PMX$\/:%J448C6_
MLK*))]@&,$X;)/4Y[UZ!)++*<R."?]E53/U* $U'10 ?F?J2?YT444 %%%%
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M_L7=*_\ 26*@#;R3U6)O]Z&-OP&1Q_/WIH &<#J<\# Z <#MTZ4M% !1110
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M & OCSI'AGPM;^ T\::]X6^-?C_5(+6UO]#T.:RMXM!SK,X4QQRW,P@A@:0
ME-JCF@#]K*K7MW#86=W?7+;+:RMI[NX?^Y!;1/-*W_ 8T8_A4D$\-S!#<V\B
M36]Q%'/!-&0T<L,J"2*1&'#(Z,K*PX*D$5@^,?-_X1'Q3Y 5IO\ A'-;\E7Q
ML,O]F77EA\\;2^ V>,9S0!_$=\3_ /@ZN^+5O^W7\4O@3\&/A'X1\<? [PGK
M]UHWAWQ0UIJ2>(;G_A';@VOB8WC%EMY'25)$MO(4@%&!SQG^RW]G?XLQ_';X
M(?#+XP0Z?)I2?$'PII_B(:=,K+)9M=[UD@96^8;9(VP#S@BO\Y7X+Z)XBLM5
MU_4/&/PK\$/X^N/B/\9CX0\4>';2P%G:0#7;WR_^$DGMU*-)*N"?M#;@?2O]
M"']A8ZL?V0_@ ==2RCU<_#[33?IINS["L_GW61;>7\GEA=OW>,YH ^L****
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MQY^Q=='Q[XO-O?:_J=Q+?^/K73;N8RR>&O!UE/O-G&C3L('2%%S@!^#C[_\
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M'UN5S<'R.+IQ*:O\7^\:=35_B_WC0,4=/Q/\S2T@Z?B?YFEH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\1_:2_Y(/\5?\ L3=7_P#1
M%>W5XC^TE_R0?XJ_]B;J_P#Z(H _D(TKQ_H?@76[M]86YE_M[P_8Z;8BT5G(
MN?[2 Q-C[JG. >QK^BWP3?+J'@SPE>I#- DOAW2<13J5EYMH@'P?X3UK^?/P
M/H6DZKKVN?VC8P7GV+PQ8W=H)D#K#<?VEGS4S]U^!\PYR*_H9\,C'A?PJ.R^
M&]*5>.BBUBP..PH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K\,_^"DIQ^T[X)_[%_1>/7%[;\'VSCT'K7[F5^-?[=OPC^)WQ<_:+TD?
M#CPU=Z\VG>$+07-S$#%%;2)(AR)2-I="-P .00/2@#N/$MU8?"/]KSX/>.SJ
M<"V?CCP9HNF:CI\4J;(K@V210-,JL0&8X R/?T%?J\W9NTBI*O\ NRH)!^C<
M>V*_&+X<_L"_''7]7\-^-?'OC^.SO_#U]87D.D:V[7=RD%FZNMM&Y)V*%&U0
M, 5^R\'FBWMDG8/-%;6\,CKPCM%$D991V!VT $T*7,%Q:2!3'>6\MG)N&5\N
MX0QON_V=K'/;%?F%X"^$?[1]O\8_B)X.T/Q=JG@CX0VU[*^FWD"<%[@O(TFF
MY^5ER03MX!K]0:4LS*JDY5?NC &,^N.OT/XYH ^2Y/V1/!6N:?<6?Q#\2:S\
M0;BXCP;W5W==DA'^L\D-L8@G(R".!6KX*_8[_9^\%V]N(O ]CJVHVTADCU2Z
M \T$L&5?+/R_(, <>U?3U% %2RT_3M.MH;33]-TZS@MT$<"P65O&\:*,*!(B
MAL@=\U<+.PP[NX'0,Q('X=*2B@ Z=!1110 4444 %%%% !1110 4444 %%%%
M !1110 4A (P0"/0C(/U!X/XTM% $7V>T/W]/TV4^LNGVTA'?@NA(/)YSWKY
MI^)R!?C/\/1#H^F20;81*_V*W39R,D($VMCMD'/Y5]-U\D?&K7_#OAWXQ?#Z
M^\0:]%HT21Q';/(L<<B[AG=N8+SD<DCUH ^O!#:&[4_V?IA!G3KIUKT+CK^[
M]*_#7XGI&G_!1KX;".**)?\ A:'AXA((DAC'[WLD8"C\!7Z]CXW_  D^U*W_
M  G6C >>I_X^[; &\'KOZ"OQP\;:[I'B/_@H9\,M3T._AU/3YOB?X>,5W;NK
MQ.!*<X9"1Q]>OZ ']=-%%% !1110 5\G?ML?LJ>%OVS?V=_&WP)\5WU]I$'B
M!;+4=*UG3)&@U#2M>T6X74-(N[>="KH%O(HUF"L-T3,"#Q7UC10!^17[ O[9
M5U]M\0_L@_M#V^L>#OC)\"9[+P59>)O&$8TS2OBCI5I']ETC4_#=Y<;([^86
M4,*3['8NPSDMG/ZG>-?*;P9XM\UV6$^&->\R2+EUB.E76]X\=6"99,=\8KY5
M_;%_87^#W[:'@^U\-^/9?$'A36]+O[?4]$\>^ [\Z!XQTJ\M3NA,.K6P2>2
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M_26*@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F)'''*
M9XHHHIV&UKF- EPR=HVD'S%!Z$XY/%/HH "2QRY+GU;DT444 %%%% !1110
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M  4B_P"CC=0/_<-B_H:/^'M?_!2+_HXW4!_W#8OZFOSWHH_UCS[_ *'&9?\
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MBOH#\3"FK_%_O&G4U?XO]XT *.GXG^9I:0=/Q/\ ,TM !1110 4444 %%%%
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M"+_@D3XZBT/Q_HP_;^_:>9_'-^+U=0;5+/[5X?42%_LVE'S2$A.=N"0=OUH
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M>*-!\(:#!)'#-K/B/5+/1],BEF)$4<E[?306Z22E6$:-(&?:=H.#74U^;O\
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M-2$DI1G"2G"46KJ491;C)-:IIM-:H****1056N_^/>?_ *X2_P#H-6:K7?\
MQ[S_ /7"7_T&LZO\.?\ A8UNO5?F?W*?\&^7_)EEO_V%7_\ 1QK]_!T'T'\J
M_ /_ (-\O^3++?\ ["K_ /HXU^_@Z#Z#^5?V1PA_R3.2?]B_#_\ IM'_ "F?
M2G_Y2*\8O^RZSO\ ]2&+1117TA^ A35_B_WC3J:O\7^\: %'3\3_ #-+2#I^
M)_F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ']I
M+_D@_P 5?^Q-U?\ ]$5[=7B/[27_ "0?XJ_]B;J__HB@#^4#X;_\A[Q-_P!B
MA8?C_P 3$U_0'X:_Y%CPO_V+NE?^DL5?S^?#;_D/>)?^Q0L/_3B:_H#\-?\
M(L>%_P#L7=*_])8J -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'B#1M)O)M>$4NGZM#;SG5HE53Y%FEPK#[1DG&S#'WKYS\8^)-?\ CY_P3?\
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M\: %'3\3_,TM(.GXG^9I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/QYG\6WE_J5YX9\:W0LE:4%UU#1+K9!.7)W>5S[9!P!D5\7_ +17_!,#X_\
MQ!_8G^$?P=^''BN#1/B[\#OCSHGQGT36M3O?MD?B6?1BK):W5Q,6,?F;=F"<
M =.,UJ:U9?\ !;O5/"FO:(;'X:M=:GX6UC1HYC?V0Q=WVFSV<-QG'WEDD#[B
M<]3UK!R>-CA\11Q./P=#G5:.'P>(S#+J5>FK>SHXS"UG2Q-6E"*4?J^/5:I%
M\WM*N(E*6(JZS52C4KT\PPN7XW&ZQGB,33P695,/B)>]4Q&"Q5'$X_#TZLW9
M^WP>)G"RC[.-!1C0H^G_ /!#C)^ GQ.+ @GXL>)R0P(.3JNH'OBOVZK\A_\
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M/V(/A\M_J$&IW7]M^*C+=VV/)9CJ"G;&%X 7I@4 ?IM1110 $X!/IS7^;_\
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M%AOVH?V7_%.I?L7>%_A]\6/AYK>LWO[3/PX-MI'AK6--N9Y@VKP",&&U?/\
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M+'@Y["O2S.?$.70EE7!G#-#"4J5H1Q]:>&I)*WQ4*:DY5):M*55IQU:2T2^
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MEUG?_J0Q:***^D/P$*:O\7^\:=35_B_WC0 HZ?B?YFEI!T_$_P S2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>(_M)?\ )!_BK_V)
MNK_^B*]NKQ']I+_D@_Q5_P"Q-U?_ -$4 ?R@?#;_ )#WB7_L4+#_ -.)K^@/
MPU_R+'A?_L7=*_\ 26*OY_/AMSKWB; )QX0L"< G _M$\G'2OZ _#7_(L>%^
MO_(NZ5U!'_+K%ZT ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-?@C_P +N\+?]%G\2?\ @PF_^+H_X7=X6_Z+/XD_\&$W_P 70!^]WDR^D?\
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MS\$>.])\0W5C"P66[ALMSM#&S<*[ 8!/'K0!_9E17X/+_P %S_AG*^V'X/\
MBV0GHHO[,OTYR%![U-_P_(^'091)\'/%T88XR][:C\LKS0!^[=%?ALO_  6[
M^%[+D?"OQ5G!X^U6YP0.F0,9[5]G?L5?MTZ)^V5>?$"/0_!NI^$[?P/)81M_
M:<JRRWAO<$,NS"@ '.* /ONBBB@ HHHH _F7_P""_P ^EKXO_9R77O"=WJ6B
M-X?\>?;_ !7IH?\ M+PVODRX^S%/G!FZG%?M-_P3_&E#]C']G0:)<WMYI/\
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MX_3_ /%4 ?U#45_+S_P\6\1_]#UX@_\  T__ !5'_#Q;Q'_T/7B#_P #3_\
M%4 ;7_!?U-$D\;_LVKX@\.ZE+IS:!X\$OC33!(;GPN!#*25,>,><,GKR<5^U
MW[ BZ:G[&G[.RZ/J-WJ^F+\.-,%EJ5\"+N\@^T7>V6<-SOSE>><**_BA_P""
MN7[3O[3/Q?/P:U[X''5_B"_AQ+[1_$GAZ[E2>U>VU8NDES/&2<K$C98]2!]:
M_2_]G']NGQGX!^ /PH\%ZSXFU71-9\/>%K6QU/2+"Y\JST^Y #M;6Z C;&C.
M^!T!+>IR ?UVT5_+S_P\6\1_]#UX@_\  T__ !5'_#Q;Q'_T/7B#_P #3_\
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MO;^ ]3N]1:'[4UQ9W-K&BL"$$\;1$DYP.&SB@#^@#_@B+Q\,OCF!T'Q/8?\
MD.]K]P:_#C_@AZYE^%GQMEZB?XCPW Z''GVUW+C(ZXW5^X] !1110 4444 %
M%%% !1110!^4O_!9+_DQCXI?]@]O_09*_DV_X(7_  Z\.^.?VT/"7B#Q';PS
M6O@/2[G5@LZJ8E6.V$KS.&! $07<#U7&0<XK^L?_ (+*,!^PQ\4B>VG.<>HV
MN#_.OY;?^"!^GR:S^T[K>@1OY'_"0^#-4T83KG= =0TYK83 ]?D,@;/!&.*_
M%>+*<9^(G#//2]M:CAG"%VDYQK56K]TI<M]-+G^L'T6,5BL%]!3Z45?"8RM@
M:CQN(HRQ-%M2A1Q&59?A\1'1:N5&I/EM).ZLKMV/V[_:2_X. /@+\&/BGKWP
MZ\)^';WQG_PBNH/IFLZDJ;;07%N[12"UD (E6,J1U/0 \UW?@KXE?LI?\%C;
M;X=>+].MD.M_ S7/^$JU_0-6C1+F".$I,A57R[P))&&0D;0Q^AK\^/&'_!MM
MXV\0^*_$WB"T^,6E%=<US4]5472RO-MO[N:Y"2N5SN02;0,G&.P%?>/_  3@
M_P""0'CO]A3QU\1_%UY\2;+7[7QYX0O/"YL+'S$$#7-M/ MPRG:H*-*)-_WA
MA1G@5Z>7U?$''YQ]6X@RK"5>'ZKJNI04::5)TGSX=M\SYK346VTM6[:*Q^8\
M8Y7]"CA7PMH9]X+^)W$^7>-F3Y5@W2S'_A:C3S3%YAAZ.%XBH2P]7#+#83GH
MXG$QI*A.,'[.UG=LXC]J;_@O;\'_ -GGQU=_"#X;>$&\<7?@N--&U"<_N["!
M[!#;+!;3)\KB)8?+(!^7'O7K7[%/_!8OX*?MR:]>_!#Q)H#>$/&?B#2M0M[3
M1[E?-TS5HI+697MD>0!99", )SAMIQC&?SI\:?\ !M]\1?%/C7Q;XL/QCT<G
MQ+X@U;65683/+$FHWDMRD3N5+9C$@7T&...*]I_9%_X((^./V:_VA/ ?QOU+
MXK:7J=EX'OIM3DTVS$RSWA%N\8BR ,ACMSN.!QZUCAL=XFK.:=2OET7E%3%J
M%3"QA@G1IX*I-4G[]_K#]G3ESM<W2R6UOH,_X7_9WT/!W'87(>-LY?BG@^&(
MYGEG$,:_$+Q^(XNH8"EB(8:KA9X=9?##5,P4J37(HTY-U(UFS^9']L;X=P_"
M#]J?XS^";2,):V?B_6;Z&%.$B6ZO92(T4<*J#  P!P>M?/:-N4-C&1TK[3_X
M*/W/V[]M_P"-MRP)+Z[=\L.?^/F3@CU[GC]:^+J_!LYA3I9OF=.E%1I4\?BH
M4U%6BHQK22Y5T71+H?[>^$N-QF9>%GAQF&85YXK'8W@CAG$XO$5-:E>O4RG"
MNI5F^LYRO*3>MWKJ%%%%>:?H(4444 %%%% !5:[_ ./>?_KA+_Z#5FJMX?\
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M9I;R:>-455Y+!=Q9@.AP.OI0!HYJ.66."![F>2."UC&9+F9UC@C4#)9Y&.%
M]\5\@?$C]L?P!X1B\OPX?[?>9V@M_$89?[ M+M<C9>'(95W8W#T!/I7YU_$'
M]JCXI?%#5-0T+PY)J6K^)=/N!.- \-!D\*:OI*Y:4O,=H8A.&VL3UQQB@#]/
MOBY^U-\-_A=I=[)'>CQ)K(@F33[?3L3Z7)=&-E"7%\A*1,A(;#$?2ORUF_;F
M^*/B_1]8TFRN+R*_M=0>2#PKI-H]W>Z[I4DF;A1/$&>$01Y0.#R03Z5SO@[X
M(>.OB7=%+YM4U;0-=O&.I^!? T4MUJVA:@_#&[:4$I&CGY]K#Y037ZB?L_\
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M7[/T4 ?C!_PYB^#'_0T:G_WX'_Q5'_#F+X,?]#1J?_?@?_%5^S]% 'XR1?\
M!&CX/P-N@\7:M$""&"0A=P(]FIC?\$8_@RQ+-XIU0L3DDP DGU)W5^SU% 'X
MP?\ #F+X,?\ 0T:G_P!^!_\ %4?\.8O@Q_T-&I_]^!_\57[/T4 ?C!_PYB^#
M'_0T:G_X#C_XJ@?\$8_@WMPWBK5&]<PCGG/]ZOV?HH _&#_AS%\&/^AHU/\
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M_P $C_V CD']GOPB0>O[IZ;_ ,.C/V ,$?\ #/?A$ G.!$?ZJ?\ .?6A\/\
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M?^?VW_[['_Q-?Z//_#HK]@'_ *-\\)?]^?\ [&E_X=%_L!?]&^^$_P#OT?\
MXFL_^(-9Y_T.LN_\)ZWE_=]?Z;/1_P"*KGA1_P!&WX]Z?\QF1_W=_P![_5GY
MG^<)_;^F_P#/[!_WW_\ 8TO]OZ:/^7VW_P"^P?Y+7^CS_P .BOV ?^C??"7_
M 'Y_^QI?^'1?[ 1Z_L^^$_\ OT?_ (FC_B#6=_\ 0ZR[_P )ZWE_=]?7YL/^
M*KGA1_T;?CV__89D?]W_ *>^M_1^9_G"?V_II_Y?8/\ OO'\UH_M_31_R^P?
M]]Y_DM?Z/7_#HO\ 8!'3]GWPE_WY_P#L:/\ AT7^P">O[/OA+_OS_P#8T?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U?XO\
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M[+7P8^"VFQ6'@_PA8(Z!&:YU!%U"7SQ@M/!]J5Q;,S9/[H+@<9H _%#]G_\
MX)R^,]:EM=:3PE%X0@GA%KKTGC^(:H=3@8 ?:]&@Y-L[J?,B.T;,BOUO^$W[
M$GP@^&MO:MJ-C-XWO[4QRVC^*=FH6VE3C#,-)@<8MH5?_5+SM4*,8&*^QU 4
M!5 "J  !T '  '8 < =AQ2T 0V]M;VD,=O:P16\$*JD4,,:QQQHHVJJH@
MX&!TJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.$D#$8)/3%>'>'/@[\5/B/K<-OK%Q=6GBNU,<$G@_P -V\QN/%6F2\,EWK4
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M 4444 %-7^+_ 'C3J:O\7^\: %'3\3_,TM(.GXG^9I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O#?VE_^2!_%C_L2]8_]$&O<J\-_
M:7_Y('\6/^Q+UC_T0: /Y@=?G2W\3:!+*XCC7X3:'DL0 ?\ B8(<<]<X(^M?
ML[;>-/"_AGP5X6O_ !'KEAHD3^'-,,,=_.D4]P1:QD+!&QRS./N#')K^>W]H
MO4]1M=:^&R6+W<)G^'^EQW$-HK23W<,5T7*I%&&=^%) "G#8/8UZI'8?%;XE
M66FS7T]UX?\ AIK6F6UKIWC#QS*]Y)HU[I\(39:641-S '=<1;HQA>HS0!^@
M'Q3_ &Y=#\.V^KP>"--CGN]+A:2^D\1,+*1X5X-QI*'/VD@99 ,[N,=:^&=<
M^)?Q@^/%]#%8OJNH^$?$422:+XN\2M+H7AW0-2B_>20&]78KHC?(JOPP&.E?
M1'P5_8Q\2>,=2T?4=+\+ZMXR\4:<5CB\?>,T=_AY?6F<;4L' D= IRFY#QC/
M?'ZQ_"S]@GPMHL,5U\1M3?74FD^TW/@33 MOX"MKAL%S9:?@.%+9XRHQ]<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4U?XO]XTZFK_ !?[QH 4
M=/Q/\S2T@Z?B?YFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "FK_%_O&G4U?XO]XT *.GXG^9
MI:0=/Q/\S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !35_B_WC3J:O\7^\: %'3\3_,TM(.GX
MG^9I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ IJ_Q?[QIU-7^+_>- "CC\S^IS2T44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !31D9XSDD\8_KBG44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>atra-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-26T00:32:35.7636505+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:atra="http://www.atarabio.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.atarabio.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.atarabio.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atra-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atra-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atra-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atra-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100090 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements" id="Role_DisclosureInLicenseAndManufacturingAgreements">
        <link:definition>100120 - Disclosure - In-license and Manufacturing Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements" id="Role_DisclosureOutLicenseAgreements">
        <link:definition>100130 - Disclosure - Out-license Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100210 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100220 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100230 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100240 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100250 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail" id="Role_DisclosureDescriptionOfBusinessDetail">
        <link:definition>100270 - Disclosure - Description of Business (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" id="Role_DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
        <link:definition>100300 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" id="Role_DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail">
        <link:definition>100310 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" id="Role_DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail">
        <link:definition>100320 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100340 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100350 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail" id="Role_DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - In-License and Manufacturing Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Out-license Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1" id="Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail1">
        <link:definition>100390 - Disclosure - Out-license Agreements - Additional Information (Detail 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1Default" id="Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail1Default">
        <link:definition>100390 - Disclosure - Out-license Agreements - Additional Information (Detail 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail">
        <link:definition>100410 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2">
        <link:definition>100420 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail" id="Role_DisclosureLeasesComponentsOfLeaseCostDetail">
        <link:definition>100430 - Disclosure - Leases - Components of Lease Cost (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail" id="Role_DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail">
        <link:definition>100440 - Disclosure - Leases - Summary of Other Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail" id="Role_DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail">
        <link:definition>100450 - Disclosure - Leases - Summary of Activity for ARO Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" id="Role_DisclosureStockholdersEquitySummaryOfRSUActivityDetail">
        <link:definition>100480 - Disclosure - Stockholders&apos; Equity - Summary of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail">
        <link:definition>100490 - Disclosure - Stockholders&apos; Equity - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail" id="Role_DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail">
        <link:definition>100500 - Disclosure - Stockholders&apos; Equity - Summary of Estimated Weighted-Average Assumptions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" id="Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail">
        <link:definition>100510 - Disclosure - Stockholders&apos; Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail" id="Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail">
        <link:definition>100520 - Disclosure - Stockholders&apos; Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Losses Before Provision for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
        <link:definition>100540 - Disclosure - Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail" id="Role_DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail">
        <link:definition>100550 - Disclosure - Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100560 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="atra_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_LicenseAndCollaborationRevenue" name="LicenseAndCollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" name="IssuanceOfCommonStockNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" name="IssuanceOfCommonStockNetOfOfferingCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" name="IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" name="IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" name="IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" name="IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" name="IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" name="IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" name="StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" name="StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_NonCashOperatingLeaseExpense" name="NonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_IncreaseDecreaseInOperatingLeaseAssets" name="IncreaseDecreaseInOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" name="IncreaseDecreaseInAccruedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" name="ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" name="NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" name="NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" name="ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_BusinessDescriptionTextBlock" name="BusinessDescriptionTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_DescriptionOfBusinessAbstract" name="DescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_FinancialInstrumentsDisclosureAbstract" name="FinancialInstrumentsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" name="InLicenseAndManufacturingAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_InLicenseAndManufacturingAgreementsAbstract" name="InLicenseAndManufacturingAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_OutLicenseAgreementsDisclosureTextBlock" name="OutLicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LeasesDisclosureTextBlock" name="LeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LiquidityRiskPolicyTextBlock" name="LiquidityRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" name="CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_ContractBalancesPolicyTextBlock" name="ContractBalancesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_ClinicalTrialAccrualsPolicyTextBlock" name="ClinicalTrialAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_DefinedContributionPlanPolicyTextBlock" name="DefinedContributionPlanPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_OtherCurrentLiabilitiesPolicyTextBlock" name="OtherCurrentLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" name="SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" name="ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" name="SummaryOfOtherInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CommonStockReservedForFutureIssuanceTableTextBlock" name="CommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" name="BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_PierreFabreCommercializationAgreementMember" name="PierreFabreCommercializationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_InvestmentMaturityPeriod" name="InvestmentMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CashAndCashEquivalentsMaturityPeriod" name="CashAndCashEquivalentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_DefinedContributionPlanContributionsByEmployer" name="DefinedContributionPlanContributionsByEmployer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_CashEquivalentsAmortizedCost" name="CashEquivalentsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" name="CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" name="CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_CashEquivalentsFairValue" name="CashEquivalentsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_WriteOffOfAccruedInterestReceivable" name="WriteOffOfAccruedInterestReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_DueToLicensorsCurrentAndNoncurrent" name="DueToLicensorsCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" name="LicenseCollaborationAndManufacturingAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_UpfrontCashPaymentReceived" name="UpfrontCashPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" name="AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" name="AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" name="AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" name="RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" name="AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" name="LicenseCollaborationAndManufacturingAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" name="ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_BayerLicenseAgreementMember" name="BayerLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_BayerTechnologyTransferAgreementMember" name="BayerTechnologyTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_BayerManufacturingAgreementMember" name="BayerManufacturingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_LongTermLiabilitiesMember" name="LongTermLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" name="DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" name="DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" name="DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_LicenseAgreementPercentage" name="LicenseAgreementPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LicenseAgreementAmount" name="LicenseAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_LicenseAgreementTotalFee" name="LicenseAgreementTotalFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_TechnologyTransferAgreementsFeeRemainder" name="TechnologyTransferAgreementsFeeRemainder" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_TransactionFeePrice" name="TransactionFeePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" name="WrittenAcceptanceOfBindingPurchaseOrderPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" name="DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" name="DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" name="AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_YearsOfManufacturingAndSupplyingCost" name="YearsOfManufacturingAndSupplyingCost" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_YearsOfPotentialToManufacturingAndSupply" name="YearsOfPotentialToManufacturingAndSupply" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_YearsOfPotentialToPerformCellSelectionServices" name="YearsOfPotentialToPerformCellSelectionServices" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" name="DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_UpfrontPaymentRecognized" name="UpfrontPaymentRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_LetterOfCreditRenewalTerm" name="LetterOfCreditRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" name="LetterOfCreditDecreaseFromPriorLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_RestrictedCashRelatedToLetterOfCredit" name="RestrictedCashRelatedToLetterOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_SouthSanFranciscoCaliforniaMember" name="SouthSanFranciscoCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_ThousandOaksCaliforniaMember" name="ThousandOaksCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_AuroraColoradoMember" name="AuroraColoradoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" name="LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" name="LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_LeaseOptionToExtendAdditionalTerm" name="LeaseOptionToExtendAdditionalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" name="LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LeaseAgreementRenewalTermOptionOne" name="LeaseAgreementRenewalTermOptionOne" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_LeaseAgreementRenewalTermOptionTwo" name="LeaseAgreementRenewalTermOptionTwo" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_IncrementalContractualObligationsUnderLeaseAmendment" name="IncrementalContractualObligationsUnderLeaseAmendment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_OperatingLeaseCostIncludingShortTermLease" name="OperatingLeaseCostIncludingShortTermLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_FinanceLeaseCost" name="FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_OperatingLeaseCostAbstract" name="OperatingLeaseCostAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_FinanceLeaseCostsAbstract" name="FinanceLeaseCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" name="NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_AccruedTerminationCharges" name="AccruedTerminationCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_LiabilitiesRelatedToIndemnificationAgreements" name="LiabilitiesRelatedToIndemnificationAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_CowenAndCompanyLimitedLiabilityCompanyMember" name="CowenAndCompanyLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_TwoThousandAndFourteenEquityIncentivePlanMember" name="TwoThousandAndFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_EmployeesAndNonEmployeesMember" name="EmployeesAndNonEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_FromDateOfGrantMember" name="FromDateOfGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_TenPercentShareHolderMember" name="TenPercentShareHolderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_InducementPlanMember" name="InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" name="TwoThousandFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" name="ClassOfWarrantOrRightNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_ClassOfWarrantOrRightPricePerShare" name="ClassOfWarrantOrRightPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_MaximumOwnershipPercentage" name="MaximumOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" name="PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" name="StockIssuedDuringPeriodAdditionalSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_AggregateOfferingPriceOfCommonStock" name="AggregateOfferingPriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" name="PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CommonStockAveragePrice" name="CommonStockAveragePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CommonStockValueAvailableToBeSold" name="CommonStockValueAvailableToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_ShareholderOwnershipPercent" name="ShareholderOwnershipPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" name="CommonStockCapitalAdditionalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="atra_RestrictedStockSharesIssued" name="RestrictedStockSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_SharesWithheldForTaxObligationsValue" name="SharesWithheldForTaxObligationsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" name="TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_EmployeeStockPurchasePlanEffectiveDate" name="EmployeeStockPurchasePlanEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_EmployeeStockPurchasePlanDescription" name="EmployeeStockPurchasePlanDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" name="EmployeeStockPurchasePlanOfferingCommencedStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_TwoThousandEighteenInducementPlanMember" name="TwoThousandEighteenInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_DeferredTaxAssetsLicenseFees" name="DeferredTaxAssetsLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_DeferredTaxAssetsLegalFees" name="DeferredTaxAssetsLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_DeferredTaxAssetsTaxCredits" name="DeferredTaxAssetsTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" name="DeferredTaxLiabilitiesOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="atra_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_OtherStatesMember" name="OtherStatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" name="AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>atra-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-26T00:32:35.7636505+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="atra-20211231.xsd#TemplateLink" roleURI="http://www.atarabio.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="atra_AccruedResearchAndDevelopmentExpensesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredIncomeCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="atra_LicenseAndCollaborationRevenue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashOperatingLeaseExpense" xlink:type="locator" xlink:label="atra_NonCashOperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atra_NonCashOperatingLeaseExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionExpense" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atra_IncreaseDecreaseInOperatingLeaseAssets" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atra_IncreaseDecreaseInOperatingLeaseLiabilities" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10310.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsFairValue" xlink:type="locator" xlink:label="atra_CashEquivalentsFairValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="atra_CashEquivalentsAmortizedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_CashEquivalentsAmortizedCost" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_CashEquivalentsAmortizedCost" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_CashEquivalentsAmortizedCost" xlink:to="atra_CashEquivalentsFairValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OperatingLeaseCostIncludingShortTermLease" xlink:type="locator" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinanceLeaseCost" xlink:type="locator" xlink:label="atra_FinanceLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_FinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_FinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_OperatingLeaseCostIncludingShortTermLease" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="atra_OperatingLeaseCostIncludingShortTermLease" xlink:to="us-gaap_ShortTermLeaseCost" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCredits" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCredits" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLegalFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLegalFees" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLicenseFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLicenseFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atra_DeferredTaxAssetsLicenseFees" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atra_DeferredTaxAssetsOperatingLeaseLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atra_DeferredTaxAssetsLegalFees" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="atra_DeferredTaxAssetsTaxCredits" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>atra-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-26T00:32:35.7636505+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="atra-20211231.xsd#TemplateLink" roleURI="http://www.atarabio.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_DefinedContributionPlanContributionsByEmployer" xlink:type="locator" xlink:label="atra_DefinedContributionPlanContributionsByEmployer" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InvestmentMaturityPeriod" xlink:type="locator" xlink:label="atra_InvestmentMaturityPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PierreFabreCommercializationAgreementMember" xlink:type="locator" xlink:label="atra_PierreFabreCommercializationAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_PierreFabreCommercializationAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_LicenseAndCollaborationRevenue" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_CashAndCashEquivalentsMaturityPeriod" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_InvestmentMaturityPeriod" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_DefinedContributionPlanContributionsByEmployer" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:href="atra-20211231.xsd#Role_DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atra_EmployeeStockPurchasePlanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsFairValue" xlink:type="locator" xlink:label="atra_CashEquivalentsFairValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="atra_CashEquivalentsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAmortizedCost" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="13150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsFairValue" order="13510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="atra_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atra_ComputerEquipmentAndSoftwareMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontPaymentRecognized" xlink:type="locator" xlink:label="atra_UpfrontPaymentRecognized" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToPerformCellSelectionServices" xlink:type="locator" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToManufacturingAndSupply" xlink:type="locator" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfManufacturingAndSupplyingCost" xlink:type="locator" xlink:label="atra_YearsOfManufacturingAndSupplyingCost" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" xlink:type="locator" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingCosts" xlink:type="locator" xlink:label="us-gaap_ManufacturingCosts" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" xlink:type="locator" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TransactionFeePrice" xlink:type="locator" xlink:label="atra_TransactionFeePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TechnologyTransferAgreementsFeeRemainder" xlink:type="locator" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementTotalFee" xlink:type="locator" xlink:label="atra_LicenseAgreementTotalFee" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementAmount" xlink:type="locator" xlink:label="atra_LicenseAgreementAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementPercentage" xlink:type="locator" xlink:label="atra_LicenseAgreementPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" xlink:type="locator" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" xlink:type="locator" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontCashPaymentReceived" xlink:type="locator" xlink:label="atra_UpfrontCashPaymentReceived" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PierreFabreCommercializationAgreementMember" xlink:type="locator" xlink:label="atra_PierreFabreCommercializationAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LongTermLiabilitiesMember" xlink:type="locator" xlink:label="atra_LongTermLiabilitiesMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="atra_CurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerManufacturingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerTechnologyTransferAgreementMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerManufacturingAgreementMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="atra_CurrentLiabilitiesMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="atra_LongTermLiabilitiesMember" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_PierreFabreCommercializationAgreementMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_UpfrontCashPaymentReceived" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementPercentage" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementAmount" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementTotalFee" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_TechnologyTransferAgreementsFeeRemainder" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_TransactionFeePrice" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ManufacturingCosts" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAndCollaborationRevenue" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfManufacturingAndSupplyingCost" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfPotentialToManufacturingAndSupply" order="12820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfPotentialToPerformCellSelectionServices" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_UpfrontPaymentRecognized" order="12910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail1" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerTechnologyTransferAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1Default" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail1Default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1Default">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerTechnologyTransferAgreementMember" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10050.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_IncrementalContractualObligationsUnderLeaseAmendment" xlink:type="locator" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionTwo" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionOne" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionOne" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseCommencementDate" xlink:type="locator" xlink:label="atra_LeaseCommencementDate" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseOptionToExtendAdditionalTerm" xlink:type="locator" xlink:label="atra_LeaseOptionToExtendAdditionalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" xlink:type="locator" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedCashRelatedToLetterOfCredit" xlink:type="locator" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" xlink:type="locator" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditRenewalTerm" xlink:type="locator" xlink:label="atra_LetterOfCreditRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OfficeSpaceMember" xlink:type="locator" xlink:label="atra_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AuroraColoradoMember" xlink:type="locator" xlink:label="atra_AuroraColoradoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ThousandOaksCaliforniaMember" xlink:type="locator" xlink:label="atra_ThousandOaksCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="atra_SouthSanFranciscoCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_SouthSanFranciscoCaliforniaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_ThousandOaksCaliforniaMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_AuroraColoradoMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atra_OfficeSpaceMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LetterOfCreditRenewalTerm" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_RestrictedCashRelatedToLetterOfCredit" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligation" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseOptionToExtendAdditionalTerm" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseCommencementDate" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementRenewalTermOptionOne" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementRenewalTermOptionTwo" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_IncrementalContractualObligationsUnderLeaseAmendment" order="11550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanDescription" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanDescription" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanEffectiveDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SharesWithheldForTaxObligationsValue" xlink:type="locator" xlink:label="atra_SharesWithheldForTaxObligationsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedStockSharesIssued" xlink:type="locator" xlink:label="atra_RestrictedStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareholderOwnershipPercent" xlink:type="locator" xlink:label="atra_ShareholderOwnershipPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockValueAvailableToBeSold" xlink:type="locator" xlink:label="atra_CommonStockValueAvailableToBeSold" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockAveragePrice" xlink:type="locator" xlink:label="atra_CommonStockAveragePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" xlink:type="locator" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="atra_AggregateOfferingPriceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_MaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_MaximumOwnershipPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightTerm" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightPricePerShare" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightPricePerShare" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InducementPlanMember" xlink:type="locator" xlink:label="atra_InducementPlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TenPercentShareHolderMember" xlink:type="locator" xlink:label="atra_TenPercentShareHolderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FromDateOfGrantMember" xlink:type="locator" xlink:label="atra_FromDateOfGrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="atra_EmployeesAndNonEmployeesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CowenAndCompanyLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CounterpartyNameAxis" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atra_CowenAndCompanyLimitedLiabilityCompanyMember" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandAndFourteenEquityIncentivePlanMember" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atra_EmployeesAndNonEmployeesMember" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="atra_FromDateOfGrantMember" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="atra_TenPercentShareHolderMember" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_InducementPlanMember" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="13320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="13440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="13520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightPricePerShare" order="13750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ProceedsFromIssuanceOfCommonStockGross" order="13790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ProceedsFromIssuanceOfCommonStockNet" order="13830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="13900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightTerm" order="13980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_MaximumOwnershipPercentage" order="14020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" order="14100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="14140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" order="14290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="14310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_AggregateOfferingPriceOfCommonStock" order="14550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" order="14610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockAveragePrice" order="14760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockValueAvailableToBeSold" order="14940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" order="15150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="15220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="15240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareholderOwnershipPercent" order="15260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="15320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="15400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" order="15420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" order="15490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="15740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="15800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_RestrictedStockSharesIssued" order="16010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="16050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="16090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_SharesWithheldForTaxObligationsValue" order="16130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="16200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="16420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" order="16480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="16570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanEffectiveDate" order="16660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanDescription" order="16780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" order="16840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="16900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="17190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="17210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfRSUActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandEighteenInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandEighteenInducementPlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandAndFourteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandEighteenInducementPlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OtherStatesMember" xlink:type="locator" xlink:label="atra_OtherStatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesTable" xlink:type="locator" xlink:label="atra_IncomeTaxesTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesLineItems" xlink:type="locator" xlink:label="atra_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atra_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="atra_OtherStatesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" xlink:type="locator" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>atra-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-26T00:32:35.7646444+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="atra_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash - short-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash - long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue - long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities - long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock&#8212;$0.0001 par value, 500,000 shares authorized as of December 31, 2021 and 2020, respectively; 91,671 and 83,372 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAndCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseAndCollaborationRevenue" xlink:to="atra_LicenseAndCollaborationRevenue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAndCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAndCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) gain:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding used to calculate basic and diluted net loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock net of offering costs shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsShares_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of offering costs, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsValue_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock, Net of Commissions and Offering Costs, Shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock, net of commissions and offering costs, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock pursuant to employee stock awards shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock pursuant to employee stock awards value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and pre-funded warrants, net of offering costs, shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" />
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and pre-funded warrants, net of offering costs, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" />
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" xlink:to="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" />
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised of pre funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" xlink:to="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="atra_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AtTheMarketOfferingMember" xlink:to="atra_AtTheMarketOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="atra_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_UnderwrittenPublicOfferingMember" xlink:to="atra_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants, net of offering costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of offering costs, values</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Offering Costs Value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net Of offering costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Offering Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of commissions and offering costs, value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Commissions And Offering Costs Value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of commissions and offering costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Net Of Commissions And Offering Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised Of Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised Of Pre Funded Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSU settlements, net of shares withheld</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Value Shares Issued Net Of Tax Withholdings</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSU settlements, net of shares withheld, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Issued Net Of Shares For Tax Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to employee stock awards</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Pursuant To Employee Stock Awards Value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to employee stock awards, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Pursuant To Employee Stock Awards Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance, discounts, commissions and offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashOperatingLeaseExpense" xlink:type="locator" xlink:label="atra_NonCashOperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="atra_NonCashOperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_NonCashOperatingLeaseExpense" xlink:to="atra_NonCashOperatingLeaseExpense_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="atra_IncreaseDecreaseInOperatingLeaseAssets_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:to="atra_IncreaseDecreaseInAccruedResearchAndDevelopment_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="atra_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of pre-funded warrants in underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" xlink:to="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" xlink:type="locator" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash investing and financing activities accrued costs related to underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" xlink:to="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" xlink:type="locator" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" />
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash investing and financing activities accrued costs related to at the market facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" xlink:to="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" />
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock through at the market offering facilities not yet received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" xlink:to="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashOperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashOperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization (accretion) of investment premiums (discounts)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposals of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset retirement obligation accretion expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets And Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Research And Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Short Term Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities and sales of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collection Of Shortterm Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock and pre-funded warrants in underwritten offerings, net</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Pre Funded Warrants In Underwritten Public Offering</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock through ATM facilities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance and capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Principal Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other financing activities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Other Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued costs related to underwritten public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued costs related to ATM facility</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock through ATM facilities not yet received</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_BusinessDescriptionTextBlock" xlink:type="locator" xlink:label="atra_BusinessDescriptionTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_BusinessDescriptionTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for the business description concept. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_BusinessDescriptionTextBlock" xlink:to="atra_BusinessDescriptionTextBlock_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="atra_DescriptionOfBusinessAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_DescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DescriptionOfBusinessAbstract" xlink:to="atra_DescriptionOfBusinessAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_DescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BusinessDescriptionTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BusinessDescriptionTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_FinancialInstrumentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">financial instruments disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="atra_FinancialInstrumentsDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_FinancialInstrumentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">In-license and Manufacturing Agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" xlink:to="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InLicenseAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_InLicenseAndManufacturingAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_InLicenseAndManufacturingAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">In-license and manufacturing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_InLicenseAndManufacturingAgreementsAbstract" xlink:to="atra_InLicenseAndManufacturingAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_InLicenseAndManufacturingAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In License And Manufacturing Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-license and Manufacturing Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In License And Manufacturing Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_OutLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="atra_OutLicenseAgreementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_OutLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Out-license Agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OutLicenseAgreementsDisclosureTextBlock" xlink:to="atra_OutLicenseAgreementsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_OutLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Out-license Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OutLicenseAgreementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Out License Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LeasesDisclosureTextBlock" xlink:type="locator" xlink:label="atra_LeasesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_LeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeasesDisclosureTextBlock" xlink:to="atra_LeasesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeasesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LiquidityRiskPolicyTextBlock" xlink:type="locator" xlink:label="atra_LiquidityRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_LiquidityRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity risk.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LiquidityRiskPolicyTextBlock" xlink:to="atra_LiquidityRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LiquidityRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LiquidityRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:type="locator" xlink:label="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents and Short-Term Investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:to="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Short Term Investments Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Retirement Obligations ("ARO")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationsPolicy" xlink:to="us-gaap_AssetRetirementObligationsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Retirement Obligations Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ContractBalancesPolicyTextBlock" xlink:type="locator" xlink:label="atra_ContractBalancesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract balances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ContractBalancesPolicyTextBlock" xlink:to="atra_ContractBalancesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Balances Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="atra_ClinicalTrialAccrualsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_ClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trial Accruals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ClinicalTrialAccrualsPolicyTextBlock" xlink:to="atra_ClinicalTrialAccrualsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Study Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClinicalTrialAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Accruals Policy [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DefinedContributionPlanPolicyTextBlock" xlink:type="locator" xlink:label="atra_DefinedContributionPlanPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DefinedContributionPlanPolicyTextBlock" xlink:to="atra_DefinedContributionPlanPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Policy [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_OtherCurrentLiabilitiesPolicyTextBlock" xlink:type="locator" xlink:label="atra_OtherCurrentLiabilitiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_OtherCurrentLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OtherCurrentLiabilitiesPolicyTextBlock" xlink:to="atra_OtherCurrentLiabilitiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_OtherCurrentLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OtherCurrentLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" xlink:type="locator" xlink:label="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of estimated fair value and related valuation input hierarchy of available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" xlink:to="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Estimated Fair Value And Related Valuation Input Hierarchy Of Available For Sale Securities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" xlink:type="locator" xlink:label="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of maturities of lease liabilities under operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" xlink:to="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Lease Liabilities Under Operating And Finance Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of other information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Other Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity for ARO Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Change In Asset Retirement Obligation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options Estimated with Weighted Average</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="atra_CommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="atra_CommonStockReservedForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Related to Stock Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Losses Before Provision for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Provision for (Benefit from) Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Statutory Tax Rates to Effective Tax Rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity incorporation state</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="atra_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer license agreement, Bayer tech transfer agreement and Bayer manufacturing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:to="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer License Agreement Bayer Tech Transfer Agreement And Bayer Manufacturing Agreement [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_PierreFabreCommercializationAgreementMember" xlink:type="locator" xlink:label="atra_PierreFabreCommercializationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="atra_PierreFabreCommercializationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pierre Fabre commercialization agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_PierreFabreCommercializationAgreementMember" xlink:to="atra_PierreFabreCommercializationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_PierreFabreCommercializationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pierre Fabre Commercialization Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_PierreFabreCommercializationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pierre Fabre Commercialization Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reportable Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_InvestmentMaturityPeriod" xlink:type="locator" xlink:label="atra_InvestmentMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="atra_InvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_InvestmentMaturityPeriod" xlink:to="atra_InvestmentMaturityPeriod_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashAndCashEquivalentsMaturityPeriod" xlink:to="atra_CashAndCashEquivalentsMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_InvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_InvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DefinedContributionPlanContributionsByEmployer" xlink:type="locator" xlink:label="atra_DefinedContributionPlanContributionsByEmployer" />
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan contributions by employer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DefinedContributionPlanContributionsByEmployer" xlink:to="atra_DefinedContributionPlanContributionsByEmployer_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, plan name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Defined Contribution Pension And Other Postretirement Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, matching contribution percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum percentage of an individual&apos;s eligible earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan contributions by employer</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DefinedContributionPlanContributionsByEmployer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Contributions By Employer</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and Unvested Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_EmployeeStockPurchasePlanMember" xlink:to="atra_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP Share Purchase Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="atra_CashEquivalentsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashEquivalentsAmortizedCost" xlink:to="atra_CashEquivalentsAmortizedCost_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, accumulated gross unrealized gain, before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, accumulated gross unrealized loss, before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsFairValue" xlink:type="locator" xlink:label="atra_CashEquivalentsFairValue" />
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents, fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashEquivalentsFairValue" xlink:to="atra_CashEquivalentsFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Agency Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Shortterm Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-Backed Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Backed Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts Classified As Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts Classified As Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Unrealized Gain</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Unrealized Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashEquivalentsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing within one year, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Amortized Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing in one to five years, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total available-for-sale securities, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Fair Value [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing within one year, Estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturing in one to five years, Estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total available-for-sale securities, Estimated fair value</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_WriteOffOfAccruedInterestReceivable" xlink:type="locator" xlink:label="atra_WriteOffOfAccruedInterestReceivable" />
    <link:label xml:lang="en-US" xlink:label="atra_WriteOffOfAccruedInterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Write off of accrued interest receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_WriteOffOfAccruedInterestReceivable" xlink:to="atra_WriteOffOfAccruedInterestReceivable_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:type="locator" xlink:label="us-gaap_InterestReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WriteOffOfAccruedInterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write off, of accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WriteOffOfAccruedInterestReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Write Off Of Accrued Interest Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="atra_ComputerEquipmentAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="atra_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ComputerEquipmentAndSoftwareMember" xlink:to="atra_ComputerEquipmentAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net By Type [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DueToLicensorsCurrentAndNoncurrent" xlink:type="locator" xlink:label="atra_DueToLicensorsCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="atra_DueToLicensorsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of obligations due all licensors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DueToLicensorsCurrentAndNoncurrent" xlink:to="atra_DueToLicensorsCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License, collaboration and manufacturing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:to="atra_LicenseCollaborationAndManufacturingAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Collaboration And Manufacturing Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DueToLicensorsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligations due to Bayer, MSK and QIMR</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DueToLicensorsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Licensors Current And Noncurrent</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontCashPaymentReceived" xlink:type="locator" xlink:label="atra_UpfrontCashPaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_UpfrontCashPaymentReceived" xlink:to="atra_UpfrontCashPaymentReceived_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" xlink:type="locator" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" />
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional upfront reimbursement payment for research and process development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" xlink:to="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" />
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional upfront cash payment entitle to receive for translational activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments entitle to receive upon Achieving certain development, regulatory and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" xlink:type="locator" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" />
    <link:label xml:lang="en-US" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty eligible to receive term after first commercial sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" xlink:to="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" />
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional upfront cash payment entitle to receive for translational activities invoiced amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License, collaboration and manufacturing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseCollaborationAndManufacturingAgreementsLineItems_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of license, collaboration and manufacturing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of License Collaboration And Manufacturing Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of License Collaboration And Manufacturing Agreements [Table]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_BayerLicenseAgreementMember" xlink:to="atra_BayerLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BayerLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer License Agreement [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer technology transfer agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_BayerTechnologyTransferAgreementMember" xlink:to="atra_BayerTechnologyTransferAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer Technology Transfer Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BayerTechnologyTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer Technology Transfer Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerManufacturingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bayer Manufacturing Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_BayerManufacturingAgreementMember" xlink:to="atra_BayerManufacturingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_BayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bayer Manufacturing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_BayerManufacturingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bayer Manufacturing Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="atra_CurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="atra_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CurrentLiabilitiesMember" xlink:to="atra_CurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LongTermLiabilitiesMember" xlink:type="locator" xlink:label="atra_LongTermLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="atra_LongTermLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LongTermLiabilitiesMember" xlink:to="atra_LongTermLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LongTermLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LongTermLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration and Manufacturing Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Collaboration And Manufacturing Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontCashPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional upfront reimbursement payment for research and process development</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Upfront Reimbursement Payment For Research And Process Development</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional upfront cash payment entitle to receive for translational activities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Upfront Cash Payment Entitle To Receive For Translational Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional upfront cash payment entitle to receive for translational activities, invoiced amount</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Upfront Cash Payment Entitle To Receive For Translational Activities Invoiced Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments Entitle To Receive Upon Achieving Certain Development Regulatory And Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty eligible to receive term after first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Eligible To Receive Term After First Commercial Sale</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined upfront payment for license in order to evaluate transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" xlink:to="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined research and process development activities in order to evaluate transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" xlink:to="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined additional specified translational activities in order to evaluate transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" xlink:to="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined upfront payment for license in order to evaluate transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Determined Upfront Payment For License In Order To Evaluate Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined research and process development activities in order to evaluate transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Determined Research And Process Development Activities In Order To Evaluate Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined additional specified translational activities in order to evaluate transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Determined Additional Specified Translational Activities In Order To Evaluate Transaction Price</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementPercentage" xlink:type="locator" xlink:label="atra_LicenseAgreementPercentage" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseAgreementPercentage" xlink:to="atra_LicenseAgreementPercentage_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementAmount" xlink:type="locator" xlink:label="atra_LicenseAgreementAmount" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseAgreementAmount" xlink:to="atra_LicenseAgreementAmount_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementTotalFee" xlink:type="locator" xlink:label="atra_LicenseAgreementTotalFee" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementTotalFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement total fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LicenseAgreementTotalFee" xlink:to="atra_LicenseAgreementTotalFee_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TechnologyTransferAgreementsFeeRemainder" xlink:type="locator" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder" />
    <link:label xml:lang="en-US" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology transfer agreements fee remainder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TechnologyTransferAgreementsFeeRemainder" xlink:to="atra_TechnologyTransferAgreementsFeeRemainder_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement amount</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementTotalFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement total fee</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LicenseAgreementTotalFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Total Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology transfer agreements fee remainder</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Technology Transfer Agreements Fee Remainder</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TransactionFeePrice" xlink:type="locator" xlink:label="atra_TransactionFeePrice" />
    <link:label xml:lang="en-US" xlink:label="atra_TransactionFeePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction fee price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TransactionFeePrice" xlink:to="atra_TransactionFeePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TransactionFeePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction fee price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TransactionFeePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Fee Price</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" xlink:type="locator" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" />
    <link:label xml:lang="en-US" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Written acceptance of binding purchase order percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" xlink:to="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written acceptance of binding purchase order percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Acceptance Of Binding Purchase Order Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingCosts" xlink:type="locator" xlink:label="us-gaap_ManufacturingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingCosts" xlink:to="us-gaap_ManufacturingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Costs</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined fee constituted entire consideration included in transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:to="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined fee constituted entire consideration included in transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Determined Fee Constituted Entire Consideration Included In Transaction Price</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" xlink:type="locator" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" />
    <link:label xml:lang="en-US" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development or sales-based milestone payments earned or received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" xlink:to="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development or sales-based milestone payments earned or received</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Or Sales Based Milestone Payments Earned Or Received</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue expected to be recognized over period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments Entitle To Receive Upon Achieving Certain Regulatory And Commercial Milestones</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfManufacturingAndSupplyingCost" xlink:type="locator" xlink:label="atra_YearsOfManufacturingAndSupplyingCost" />
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfManufacturingAndSupplyingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Years of manufacturing and supplying cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_YearsOfManufacturingAndSupplyingCost" xlink:to="atra_YearsOfManufacturingAndSupplyingCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfManufacturingAndSupplyingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Years of manufacturing and supplying cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfManufacturingAndSupplyingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Years Of Manufacturing And Supplying Cost</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToManufacturingAndSupply" xlink:type="locator" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply" />
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Years of potential to manufacturing and supply.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_YearsOfPotentialToManufacturingAndSupply" xlink:to="atra_YearsOfPotentialToManufacturingAndSupply_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToPerformCellSelectionServices" xlink:type="locator" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices" />
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Years of potential to perform cell-selection services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_YearsOfPotentialToPerformCellSelectionServices" xlink:to="atra_YearsOfPotentialToPerformCellSelectionServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Years of potential to manufacturing and supply</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Years Of Potential To Manufacturing And Supply</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Years of potential to perform cell-selection services</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Years Of Potential To Perform Cell Selection Services</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined upfront payment constituted entire consideration included in transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:to="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontPaymentRecognized" xlink:type="locator" xlink:label="atra_UpfrontPaymentRecognized" />
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontPaymentRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_UpfrontPaymentRecognized" xlink:to="atra_UpfrontPaymentRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined upfront payment constituted entire consideration included in transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Determined Upfront Payment Constituted Entire Consideration Included In Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontPaymentRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UpfrontPaymentRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Recognized</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditRenewalTerm" xlink:type="locator" xlink:label="atra_LetterOfCreditRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LetterOfCreditRenewalTerm" xlink:to="atra_LetterOfCreditRenewalTerm_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" xlink:type="locator" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" />
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit decrease from prior lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" xlink:to="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedCashRelatedToLetterOfCredit" xlink:type="locator" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit" />
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash related to letter of credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_RestrictedCashRelatedToLetterOfCredit" xlink:to="atra_RestrictedCashRelatedToLetterOfCredit_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="atra_SouthSanFranciscoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="atra_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SouthSanFranciscoCaliforniaMember" xlink:to="atra_SouthSanFranciscoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco California</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SouthSanFranciscoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco California [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ThousandOaksCaliforniaMember" xlink:type="locator" xlink:label="atra_ThousandOaksCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="atra_ThousandOaksCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Thousand Oaks California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ThousandOaksCaliforniaMember" xlink:to="atra_ThousandOaksCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ThousandOaksCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thousand Oaks California</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ThousandOaksCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Thousand Oaks California [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AuroraColoradoMember" xlink:type="locator" xlink:label="atra_AuroraColoradoMember" />
    <link:label xml:lang="en-US" xlink:label="atra_AuroraColoradoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aurora Colorado.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AuroraColoradoMember" xlink:to="atra_AuroraColoradoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_AuroraColoradoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aurora Colorado</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AuroraColoradoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aurora Colorado [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_OfficeSpaceMember" xlink:type="locator" xlink:label="atra_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="atra_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OfficeSpaceMember" xlink:to="atra_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit maintained</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit, decrease from prior lease agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit Decrease From Prior Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash related to letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Related To Letter Of Credit</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement area of office lab and warehouse space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" xlink:type="locator" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" />
    <link:label xml:lang="en-US" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease percentage of annual increase in base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" xlink:to="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseOptionToExtendAdditionalTerm" xlink:type="locator" xlink:label="atra_LeaseOptionToExtendAdditionalTerm" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseOptionToExtendAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease option to extend additional term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseOptionToExtendAdditionalTerm" xlink:to="atra_LeaseOptionToExtendAdditionalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement area of square feet of office, lab and warehouse space</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Area Of Office Lab And Warehouse Space</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease initial term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Term Of Contract1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Percentage Of Annual Increase In Base Rent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseOptionToExtendAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend additional term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseOptionToExtendAdditionalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Option To Extend Additional Term</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement area of office lab and manufacturing space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseCommencementDate" xlink:type="locator" xlink:label="atra_LeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseCommencementDate" xlink:to="atra_LeaseCommencementDate_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionOne" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionOne" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement renewal term option one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseAgreementRenewalTermOptionOne" xlink:to="atra_LeaseAgreementRenewalTermOptionOne_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionTwo" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement renewal term option two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LeaseAgreementRenewalTermOptionTwo" xlink:to="atra_LeaseAgreementRenewalTermOptionTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement area of office, lab and cellular therapy manufacturing space</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Area Of Office Lab And Manufacturing Space</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension term, option one</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Renewal Term Option One</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension term, option two</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Renewal Term Option Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit issued, classified as long-term restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_IncrementalContractualObligationsUnderLeaseAmendment" xlink:type="locator" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment" />
    <link:label xml:lang="en-US" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental contractual obligations under lease amendment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncrementalContractualObligationsUnderLeaseAmendment" xlink:to="atra_IncrementalContractualObligationsUnderLeaseAmendment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental contractual obligations under lease amendment</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Contractual Obligations Under Lease Amendment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating leases, Total minimum payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities - long-term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases, Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance leases, Total minimum payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_OperatingLeaseCostIncludingShortTermLease" xlink:type="locator" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease" />
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease cost including short term lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OperatingLeaseCostIncludingShortTermLease" xlink:to="atra_OperatingLeaseCostIncludingShortTermLease_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinanceLeaseCost" xlink:type="locator" xlink:label="atra_FinanceLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_FinanceLeaseCost" xlink:to="atra_FinanceLeaseCost_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OperatingLeaseCostAbstract" xlink:type="locator" xlink:label="atra_OperatingLeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OperatingLeaseCostAbstract" xlink:to="atra_OperatingLeaseCostAbstract_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinanceLeaseCostsAbstract" xlink:type="locator" xlink:label="atra_FinanceLeaseCostsAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_FinanceLeaseCostsAbstract" xlink:to="atra_FinanceLeaseCostsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost:</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost Including Short Term Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease cost:</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Costs [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease cost</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_FinanceLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Cost</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash increase to operating lease assets due to remeasurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" xlink:to="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="atra_WeightedAverageRemainingLeaseTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atra_WeightedAverageRemainingLeaseTermAbstract_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="atra_WeightedAverageDiscountRateAbstract" />
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_WeightedAverageDiscountRateAbstract" xlink:to="atra_WeightedAverageDiscountRateAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Payment On Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows for finance leases</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease assets obtained in exchange for lease obligations:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease assets obtained in exchange for lease obligations:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Finance Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash increase to operating lease assets due to remeasurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligation" xlink:to="us-gaap_AssetRetirementObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Retirement Obligation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationAccretionExpense" xlink:to="us-gaap_AssetRetirementObligationAccretionExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Retirement Obligation Accretion Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetRetirementObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance as of December 31, 2021</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AccruedTerminationCharges" xlink:type="locator" xlink:label="atra_AccruedTerminationCharges" />
    <link:label xml:lang="en-US" xlink:label="atra_AccruedTerminationCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued termination charges.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AccruedTerminationCharges" xlink:to="atra_AccruedTerminationCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_AccruedTerminationCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued termination charges</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AccruedTerminationCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Termination Charges</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_LiabilitiesRelatedToIndemnificationAgreements" xlink:type="locator" xlink:label="atra_LiabilitiesRelatedToIndemnificationAgreements" />
    <link:label xml:lang="en-US" xlink:label="atra_LiabilitiesRelatedToIndemnificationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities related to indemnification agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_LiabilitiesRelatedToIndemnificationAgreements" xlink:to="atra_LiabilitiesRelatedToIndemnificationAgreements_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_LiabilitiesRelatedToIndemnificationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities related to indemnification agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_LiabilitiesRelatedToIndemnificationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Related To Indemnification Agreements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CowenAndCompanyLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and Company Limited Liability Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CowenAndCompanyLimitedLiabilityCompanyMember" xlink:to="atra_CowenAndCompanyLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cowen And Company Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="atra_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="atra_EmployeesAndNonEmployeesMember" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and non-employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_EmployeesAndNonEmployeesMember" xlink:to="atra_EmployeesAndNonEmployeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees And Non Employees</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Non Employees [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_FromDateOfGrantMember" xlink:type="locator" xlink:label="atra_FromDateOfGrantMember" />
    <link:label xml:lang="en-US" xlink:label="atra_FromDateOfGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expire from date of grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_FromDateOfGrantMember" xlink:to="atra_FromDateOfGrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_FromDateOfGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">From Date Of Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_FromDateOfGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">From Date Of Grant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TenPercentShareHolderMember" xlink:type="locator" xlink:label="atra_TenPercentShareHolderMember" />
    <link:label xml:lang="en-US" xlink:label="atra_TenPercentShareHolderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ten percent share holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TenPercentShareHolderMember" xlink:to="atra_TenPercentShareHolderMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TenPercentShareHolderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">10% Shareholder</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TenPercentShareHolderMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ten Percent Share Holder [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_InducementPlanMember" xlink:type="locator" xlink:label="atra_InducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_InducementPlanMember" xlink:to="atra_InducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Member]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized capital stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightPricePerShare" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ClassOfWarrantOrRightPricePerShare" xlink:to="atra_ClassOfWarrantOrRightPricePerShare_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ProceedsFromIssuanceOfCommonStockGross" xlink:to="atra_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet" />
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ProceedsFromIssuanceOfCommonStockNet" xlink:to="atra_ProceedsFromIssuanceOfCommonStockNet_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from sale of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Net</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightTerm" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightTerm" />
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ClassOfWarrantOrRightTerm" xlink:to="atra_ClassOfWarrantOrRightTerm_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_MaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_MaximumOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="atra_MaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_MaximumOwnershipPercentage" xlink:to="atra_MaximumOwnershipPercentage_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior notice period to increase or decrease maximum ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" xlink:to="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities called by each warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ClassOfWarrantOrRightTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Term</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_MaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_MaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior Notice Period To Increase Or Decrease Maximum Ownership Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, additional shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:to="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares of our common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option price to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="atra_AggregateOfferingPriceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="atra_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Offering Price of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AggregateOfferingPriceOfCommonStock" xlink:to="atra_AggregateOfferingPriceOfCommonStock_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" xlink:type="locator" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" />
    <link:label xml:lang="en-US" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission to be paid on gross sales proceeds of common stock sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" xlink:to="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Offering Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission to be paid on gross sales proceeds of common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission To Be Paid On Gross Sales Proceeds Of Common Stock Sold</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockAveragePrice" xlink:type="locator" xlink:label="atra_CommonStockAveragePrice" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockAveragePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock average price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CommonStockAveragePrice" xlink:to="atra_CommonStockAveragePrice_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockValueAvailableToBeSold" xlink:type="locator" xlink:label="atra_CommonStockValueAvailableToBeSold" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockValueAvailableToBeSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock value available to be sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CommonStockValueAvailableToBeSold" xlink:to="atra_CommonStockValueAvailableToBeSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockAveragePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock average price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockAveragePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Average Price</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockValueAvailableToBeSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock value available to be sold</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockValueAvailableToBeSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value Available To Be Sold</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" />
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award percentage of annual increases in number of shares available for issuance as percent of common stock outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in EIP/ESPP, subject to other limitations</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increases In Number Of Shares Available For Issuance As Percent Of Common Stock Outstanding</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" />
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments options and restricted stock units outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareholderOwnershipPercent" xlink:type="locator" xlink:label="atra_ShareholderOwnershipPercent" />
    <link:label xml:lang="en-US" xlink:label="atra_ShareholderOwnershipPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shareholders ownership percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ShareholderOwnershipPercent" xlink:to="atra_ShareholderOwnershipPercent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employees purchase price of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option granted description terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareholderOwnershipPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percent</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareholderOwnershipPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholder Ownership Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation award expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock, reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock, reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options and RSUs</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options And Restricted Stock Units Outstanding</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital additional shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:to="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares of common stock, reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Additional Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value, vested in period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation weighted average recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Unvested as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Outstanding as of December 31, 2021</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2021</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedStockSharesIssued" xlink:type="locator" xlink:label="atra_RestrictedStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of restricted shares issued as compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_RestrictedStockSharesIssued" xlink:to="atra_RestrictedStockSharesIssued_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SharesWithheldForTaxObligationsValue" xlink:type="locator" xlink:label="atra_SharesWithheldForTaxObligationsValue" />
    <link:label xml:lang="en-US" xlink:label="atra_SharesWithheldForTaxObligationsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares withheld for tax obligations, value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_SharesWithheldForTaxObligationsValue" xlink:to="atra_SharesWithheldForTaxObligationsValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units, settled</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_RestrictedStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units withheld for tax obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SharesWithheldForTaxObligationsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units withheld for tax obligations, value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_SharesWithheldForTaxObligationsValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Withheld For Tax Obligations Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation Gross</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2014 EIP and Inducement Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" xlink:to="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 EIP and Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan And Inducement Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Shares, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited or expired, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Shares, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Weighted Average Exercise Price, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited or expired, Weighted Average Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Weighted Average Exercise Price, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vested and expected to vest, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option intrinsic value, exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxExpenseFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tax benefits related to exercised options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:to="us-gaap_DeferredTaxExpenseFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxExpenseFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Expense From Stock Options Exercised</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options estimated grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated grant date fair value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of stock option, vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanEffectiveDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan effective date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_EmployeeStockPurchasePlanEffectiveDate" xlink:to="atra_EmployeeStockPurchasePlanEffectiveDate_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanDescription" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanDescription" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_EmployeeStockPurchasePlanDescription" xlink:to="atra_EmployeeStockPurchasePlanDescription_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan offering commenced start date.,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" xlink:to="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan effective date</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan description</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Description</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan offering commenced start date</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Offering Commenced Start Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock may be issued or transferred, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum increase in number of shares available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Including Additional Paid In Capital Net Of Discount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandEighteenInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandEighteenInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandEighteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_TwoThousandEighteenInducementPlanMember" xlink:to="atra_TwoThousandEighteenInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandEighteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_TwoThousandEighteenInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Inducement Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total reserved shares of common stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current provision for (benefit from) income taxes:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provision for (benefit from) income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible executive compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLicenseFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsLicenseFees" xlink:to="atra_DeferredTaxAssetsLicenseFees_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="atra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLegalFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLegalFees" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLegalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets legal fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsLegalFees" xlink:to="atra_DeferredTaxAssetsLegalFees_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCredits" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsTaxCredits" xlink:to="atra_DeferredTaxAssetsTaxCredits_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="atra_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLegalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsLegalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Legal Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesLineItems" xlink:type="locator" xlink:label="atra_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesTable" xlink:type="locator" xlink:label="atra_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_IncomeTaxesTable" xlink:to="atra_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_OtherStatesMember" xlink:type="locator" xlink:label="atra_OtherStatesMember" />
    <link:label xml:lang="en-US" xlink:label="atra_OtherStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other states.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_OtherStatesMember" xlink:to="atra_OtherStatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="atra_OtherStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other States</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_OtherStatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other States [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research and development expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear_lbl" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net tax operating losses, expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards not subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research And Development Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases for tax positions related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross increases for tax positions related to prior year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross decreases for tax positions related to prior year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits if recognized would impact effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="atra-20211231.xsd#atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" xlink:type="locator" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" />
    <link:label xml:lang="en-US" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of closing adjustment related to asset purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" xlink:to="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of closing adjustment related to asset purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Closing Adjustment Related To Asset Purchase Agreement</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>atra-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-26T00:32:35.7646444+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 682e36b8f31f46f59b5cdd8a2bfad1af -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.atarabio.com/20211231/role/TemplateLink" xlink:href="atra-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atra-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="atra_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="atra_AccruedResearchAndDevelopmentExpensesCurrent" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeNoncurrent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="atra_LicenseAndCollaborationRevenue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" xlink:type="locator" xlink:label="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsValue" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfOfferingCostsShares" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="atra-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" xlink:type="locator" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" xlink:type="locator" xlink:label="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_IncreaseDecreaseInOperatingLeaseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashOperatingLeaseExpense" xlink:type="locator" xlink:label="atra_NonCashOperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="atra_NonCashOperatingLeaseExpense" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="atra_IncreaseDecreaseInOperatingLeaseAssets" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="atra_IncreaseDecreaseInAccruedResearchAndDevelopment" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="atra_IncreaseDecreaseInOperatingLeaseLiabilities" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="13440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="atra-20211231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="atra-20211231.xsd#atra_BusinessDescriptionTextBlock" xlink:type="locator" xlink:label="atra_BusinessDescriptionTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="atra_DescriptionOfBusinessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_DescriptionOfBusinessAbstract" xlink:to="atra_BusinessDescriptionTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare" xlink:href="atra-20211231.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements" xlink:href="atra-20211231.xsd#Role_DisclosureInLicenseAndManufacturingAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements">
    <link:loc xlink:href="atra-20211231.xsd#atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InLicenseAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_InLicenseAndManufacturingAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_InLicenseAndManufacturingAgreementsAbstract" xlink:to="atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements">
    <link:loc xlink:href="atra-20211231.xsd#atra_OutLicenseAgreementsDisclosureTextBlock" xlink:type="locator" xlink:label="atra_OutLicenseAgreementsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="atra_OutLicenseAgreementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases" xlink:href="atra-20211231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="atra-20211231.xsd#atra_LeasesDisclosureTextBlock" xlink:type="locator" xlink:label="atra_LeasesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_LeasesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="atra-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="atra-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OtherCurrentLiabilitiesPolicyTextBlock" xlink:type="locator" xlink:label="atra_OtherCurrentLiabilitiesPolicyTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DefinedContributionPlanPolicyTextBlock" xlink:type="locator" xlink:label="atra_DefinedContributionPlanPolicyTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClinicalTrialAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="atra_ClinicalTrialAccrualsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ContractBalancesPolicyTextBlock" xlink:type="locator" xlink:label="atra_ContractBalancesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" xlink:type="locator" xlink:label="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LiquidityRiskPolicyTextBlock" xlink:type="locator" xlink:label="atra_LiquidityRiskPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_LiquidityRiskPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetRetirementObligationsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_ContractBalancesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_ClinicalTrialAccrualsPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_DefinedContributionPlanPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_OtherCurrentLiabilitiesPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="atra-20211231.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" xlink:type="locator" xlink:label="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" xlink:type="locator" xlink:label="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="atra_CommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="atra_CommonStockReservedForFutureIssuanceTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail" xlink:href="atra-20211231.xsd#Role_DisclosureDescriptionOfBusinessDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="atra_DescriptionOfBusinessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_DescriptionOfBusinessAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_DescriptionOfBusinessAbstract" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_DefinedContributionPlanContributionsByEmployer" xlink:type="locator" xlink:label="atra_DefinedContributionPlanContributionsByEmployer" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InvestmentMaturityPeriod" xlink:type="locator" xlink:label="atra_InvestmentMaturityPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashAndCashEquivalentsMaturityPeriod" xlink:type="locator" xlink:label="atra_CashAndCashEquivalentsMaturityPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PierreFabreCommercializationAgreementMember" xlink:type="locator" xlink:label="atra_PierreFabreCommercializationAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="atra_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atra_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_PierreFabreCommercializationAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesTable" xlink:to="atra_SignificantAccountingPoliciesLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_LicenseAndCollaborationRevenue" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_CashAndCashEquivalentsMaturityPeriod" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_InvestmentMaturityPeriod" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_SignificantAccountingPoliciesLineItems" xlink:to="atra_DefinedContributionPlanContributionsByEmployer" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails" xlink:href="atra-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:href="atra-20211231.xsd#Role_DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atra_EmployeeStockPurchasePlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsFairValue" xlink:type="locator" xlink:label="atra_CashEquivalentsFairValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="atra_CashEquivalentsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10090.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10090.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAmortizedCost" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="atra_CashEquivalentsFairValue" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WriteOffOfAccruedInterestReceivable" xlink:type="locator" xlink:label="atra_WriteOffOfAccruedInterestReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable" xlink:type="locator" xlink:label="us-gaap_InterestReceivable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_InterestReceivable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="atra_WriteOffOfAccruedInterestReceivable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_RestrictedCash" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="atra-20211231.xsd#Role_DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinancialInstrumentsDisclosureAbstract" xlink:type="locator" xlink:label="atra_FinancialInstrumentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinancialInstrumentsDisclosureAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="atra_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atra_ComputerEquipmentAndSoftwareMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_DueToLicensorsCurrentAndNoncurrent" xlink:type="locator" xlink:label="atra_DueToLicensorsCurrentAndNoncurrent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:to="atra_DueToLicensorsCurrentAndNoncurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontPaymentRecognized" xlink:type="locator" xlink:label="atra_UpfrontPaymentRecognized" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToPerformCellSelectionServices" xlink:type="locator" xlink:label="atra_YearsOfPotentialToPerformCellSelectionServices" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfPotentialToManufacturingAndSupply" xlink:type="locator" xlink:label="atra_YearsOfPotentialToManufacturingAndSupply" />
    <link:loc xlink:href="atra-20211231.xsd#atra_YearsOfManufacturingAndSupplyingCost" xlink:type="locator" xlink:label="atra_YearsOfManufacturingAndSupplyingCost" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" xlink:type="locator" xlink:label="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAndCollaborationRevenue" xlink:type="locator" xlink:label="atra_LicenseAndCollaborationRevenue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingCosts" xlink:type="locator" xlink:label="us-gaap_ManufacturingCosts" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" xlink:type="locator" xlink:label="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TransactionFeePrice" xlink:type="locator" xlink:label="atra_TransactionFeePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TechnologyTransferAgreementsFeeRemainder" xlink:type="locator" xlink:label="atra_TechnologyTransferAgreementsFeeRemainder" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementTotalFee" xlink:type="locator" xlink:label="atra_LicenseAgreementTotalFee" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementAmount" xlink:type="locator" xlink:label="atra_LicenseAgreementAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseAgreementPercentage" xlink:type="locator" xlink:label="atra_LicenseAgreementPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" xlink:type="locator" xlink:label="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" xlink:type="locator" xlink:label="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" xlink:type="locator" xlink:label="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" xlink:type="locator" xlink:label="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UpfrontCashPaymentReceived" xlink:type="locator" xlink:label="atra_UpfrontCashPaymentReceived" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PierreFabreCommercializationAgreementMember" xlink:type="locator" xlink:label="atra_PierreFabreCommercializationAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LongTermLiabilitiesMember" xlink:type="locator" xlink:label="atra_LongTermLiabilitiesMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="atra_CurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerManufacturingAgreementMember" xlink:type="locator" xlink:label="atra_BayerManufacturingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerLicenseAgreementMember" xlink:type="locator" xlink:label="atra_BayerLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerTechnologyTransferAgreementMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerManufacturingAgreementMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="atra_CurrentLiabilitiesMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="atra_LongTermLiabilitiesMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_PierreFabreCommercializationAgreementMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_UpfrontCashPaymentReceived" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementPercentage" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementAmount" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAgreementTotalFee" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_TechnologyTransferAgreementsFeeRemainder" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_TransactionFeePrice" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ManufacturingCosts" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_LicenseAndCollaborationRevenue" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfManufacturingAndSupplyingCost" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfPotentialToManufacturingAndSupply" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_YearsOfPotentialToPerformCellSelectionServices" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="atra_UpfrontPaymentRecognized" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1" xlink:href="atra-20211231.xsd#Role_DisclosureOutLicenseAgreementsAdditionalInformationDetail1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_BayerTechnologyTransferAgreementMember" xlink:type="locator" xlink:label="atra_BayerTechnologyTransferAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:type="locator" xlink:label="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:type="locator" xlink:label="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsAbstract" xlink:to="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atra_BayerTechnologyTransferAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable" xlink:to="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_LicenseCollaborationAndManufacturingAgreementsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_IncrementalContractualObligationsUnderLeaseAmendment" xlink:type="locator" xlink:label="atra_IncrementalContractualObligationsUnderLeaseAmendment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionTwo" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionTwo" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementRenewalTermOptionOne" xlink:type="locator" xlink:label="atra_LeaseAgreementRenewalTermOptionOne" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseCommencementDate" xlink:type="locator" xlink:label="atra_LeaseCommencementDate" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseOptionToExtendAdditionalTerm" xlink:type="locator" xlink:label="atra_LeaseOptionToExtendAdditionalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" xlink:type="locator" xlink:label="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" xlink:type="locator" xlink:label="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedCashRelatedToLetterOfCredit" xlink:type="locator" xlink:label="atra_RestrictedCashRelatedToLetterOfCredit" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" xlink:type="locator" xlink:label="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" />
    <link:loc xlink:href="atra-20211231.xsd#atra_LetterOfCreditRenewalTerm" xlink:type="locator" xlink:label="atra_LetterOfCreditRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OfficeSpaceMember" xlink:type="locator" xlink:label="atra_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AuroraColoradoMember" xlink:type="locator" xlink:label="atra_AuroraColoradoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ThousandOaksCaliforniaMember" xlink:type="locator" xlink:label="atra_ThousandOaksCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SouthSanFranciscoCaliforniaMember" xlink:type="locator" xlink:label="atra_SouthSanFranciscoCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_SouthSanFranciscoCaliforniaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_ThousandOaksCaliforniaMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="atra_AuroraColoradoMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="atra_OfficeSpaceMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LetterOfCreditRenewalTerm" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LetterOfCreditDecreaseFromPriorLeaseAgreement" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_RestrictedCashRelatedToLetterOfCredit" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ContractualObligation" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseOptionToExtendAdditionalTerm" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseCommencementDate" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementRenewalTermOptionOne" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_LeaseAgreementRenewalTermOptionTwo" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atra_IncrementalContractualObligationsUnderLeaseAmendment" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiability_li0l2" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesComponentsOfLeaseCostDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_FinanceLeaseCost" xlink:type="locator" xlink:label="atra_FinanceLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FinanceLeaseCostsAbstract" xlink:type="locator" xlink:label="atra_FinanceLeaseCostsAbstract" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OperatingLeaseCostIncludingShortTermLease" xlink:type="locator" xlink:label="atra_OperatingLeaseCostIncludingShortTermLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OperatingLeaseCostAbstract" xlink:type="locator" xlink:label="atra_OperatingLeaseCostAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_OperatingLeaseCostAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_OperatingLeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_OperatingLeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_OperatingLeaseCostAbstract" xlink:to="atra_OperatingLeaseCostIncludingShortTermLease" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_FinanceLeaseCostsAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinanceLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinanceLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_FinanceLeaseCostsAbstract" xlink:to="atra_FinanceLeaseCost" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="atra_WeightedAverageDiscountRateAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="atra_WeightedAverageRemainingLeaseTermAbstract" />
    <link:loc xlink:href="atra-20211231.xsd#atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_WeightedAverageRemainingLeaseTermAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="atra_WeightedAverageDiscountRateAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligation_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationAccretionExpense" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligationAccretionExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:type="locator" xlink:label="us-gaap_AssetRetirementObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetRetirementObligation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetRetirementObligationAccretionExpense" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetRetirementObligation_li0l2" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_LiabilitiesRelatedToIndemnificationAgreements" xlink:type="locator" xlink:label="atra_LiabilitiesRelatedToIndemnificationAgreements" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AccruedTerminationCharges" xlink:type="locator" xlink:label="atra_AccruedTerminationCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atra_AccruedTerminationCharges" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atra_LiabilitiesRelatedToIndemnificationAgreements" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanDescription" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanDescription" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeeStockPurchasePlanEffectiveDate" xlink:type="locator" xlink:label="atra_EmployeeStockPurchasePlanEffectiveDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:loc xlink:href="atra-20211231.xsd#atra_SharesWithheldForTaxObligationsValue" xlink:type="locator" xlink:label="atra_SharesWithheldForTaxObligationsValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="atra-20211231.xsd#atra_RestrictedStockSharesIssued" xlink:type="locator" xlink:label="atra_RestrictedStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareholderOwnershipPercent" xlink:type="locator" xlink:label="atra_ShareholderOwnershipPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockValueAvailableToBeSold" xlink:type="locator" xlink:label="atra_CommonStockValueAvailableToBeSold" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CommonStockAveragePrice" xlink:type="locator" xlink:label="atra_CommonStockAveragePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" xlink:type="locator" xlink:label="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="atra_AggregateOfferingPriceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="atra-20211231.xsd#atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:type="locator" xlink:label="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="atra-20211231.xsd#atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_MaximumOwnershipPercentage" xlink:type="locator" xlink:label="atra_MaximumOwnershipPercentage" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightTerm" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockNet" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="atra_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightPricePerShare" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightPricePerShare" />
    <link:loc xlink:href="atra-20211231.xsd#atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:type="locator" xlink:label="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember_li0l2" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_InducementPlanMember" xlink:type="locator" xlink:label="atra_InducementPlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TenPercentShareHolderMember" xlink:type="locator" xlink:label="atra_TenPercentShareHolderMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_FromDateOfGrantMember" xlink:type="locator" xlink:label="atra_FromDateOfGrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_EmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="atra_EmployeesAndNonEmployeesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_CowenAndCompanyLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="atra_CowenAndCompanyLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="atra_AtTheMarketOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="atra_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_UnderwrittenPublicOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atra_AtTheMarketOfferingMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CounterpartyNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atra_CowenAndCompanyLimitedLiabilityCompanyMember" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandAndFourteenEquityIncentivePlanMember" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="atra_EmployeesAndNonEmployeesMember" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="atra_FromDateOfGrantMember" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="atra_TenPercentShareHolderMember" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_InducementPlanMember" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember_li0l2" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="13310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightNumberOfWarrantsIssued" order="13700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightPricePerShare" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ProceedsFromIssuanceOfCommonStockGross" order="13780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ProceedsFromIssuanceOfCommonStockNet" order="13820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="13890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ClassOfWarrantOrRightTerm" order="13970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_MaximumOwnershipPercentage" order="14010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage" order="14090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="14130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_StockIssuedDuringPeriodAdditionalSharesNewIssues" order="14280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="14300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_AggregateOfferingPriceOfCommonStock" order="14540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold" order="14600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockAveragePrice" order="14750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockValueAvailableToBeSold" order="14930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding" order="15140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="15210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="15230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareholderOwnershipPercent" order="15250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="15310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="15390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding" order="15410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance" order="15480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="15730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="15790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_RestrictedStockSharesIssued" order="16000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="16040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="16080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_SharesWithheldForTaxObligationsValue" order="16120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="16190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="16410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredTaxExpenseFromStockOptionsExercised" order="16470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="16560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanEffectiveDate" order="16650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanDescription" order="16770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atra_EmployeeStockPurchasePlanOfferingCommencedStartDate" order="16830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="16890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="17180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="17200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfRSUActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" xlink:type="locator" xlink:label="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandEighteenInducementPlanMember" xlink:type="locator" xlink:label="atra_TwoThousandEighteenInducementPlanMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="atra_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandAndFourteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandEighteenInducementPlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="atra_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail" xlink:href="atra-20211231.xsd#Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCredits" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCredits" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLegalFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLegalFees" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsLicenseFees" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsLicenseFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="atra_DeferredTaxAssetsLicenseFees" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="atra_DeferredTaxAssetsOperatingLeaseLiabilities" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="atra_DeferredTaxAssetsLegalFees" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="atra_DeferredTaxAssetsTaxCredits" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="atra_DeferredTaxLiabilitiesOperatingLeaseAssets" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="atra-20211231.xsd#atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" xlink:type="locator" xlink:label="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesLineItems" xlink:type="locator" xlink:label="atra_IncomeTaxesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="atra-20211231.xsd#atra_OtherStatesMember" xlink:type="locator" xlink:label="atra_OtherStatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="atra-20211231.xsd#atra_IncomeTaxesTable" xlink:type="locator" xlink:label="atra_IncomeTaxesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="atra_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="atra_OtherStatesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesTable" xlink:to="atra_IncomeTaxesLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atra_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="atra-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="atra-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="atra-20211231.xsd#atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" xlink:type="locator" xlink:label="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989767208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ATARA BIOTHERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001604464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,097,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,149,785,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0920988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">278-8930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DELOITTE & TOUCHE LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989498712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,084<span></span>
</td>
<td class="nump">$ 200,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">264,984<span></span>
</td>
<td class="nump">300,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,373<span></span>
</td>
<td class="nump">21,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">384,621<span></span>
</td>
<td class="nump">523,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">53,780<span></span>
</td>
<td class="nump">50,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">26,159<span></span>
</td>
<td class="nump">12,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">468,127<span></span>
</td>
<td class="nump">588,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,368<span></span>
</td>
<td class="nump">7,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">25,150<span></span>
</td>
<td class="nump">20,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">13,451<span></span>
</td>
<td class="nump">15,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred revenue</a></td>
<td class="nump">40,760<span></span>
</td>
<td class="nump">33,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">9,057<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,786<span></span>
</td>
<td class="nump">82,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred revenue - long-term</a></td>
<td class="nump">55,708<span></span>
</td>
<td class="nump">27,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">25,518<span></span>
</td>
<td class="nump">13,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">188,513<span></span>
</td>
<td class="nump">125,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;$0.0001 par value, 500,000 shares authorized as of December 31, 2021 and 2020, respectively; 91,671 and 83,372 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,744,695<span></span>
</td>
<td class="nump">1,586,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(368)<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,464,722)<span></span>
</td>
<td class="num">(1,124,581)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">279,614<span></span>
</td>
<td class="nump">462,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 468,127<span></span>
</td>
<td class="nump">$ 588,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989723352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">91,671,000<span></span>
</td>
<td class="nump">83,372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">91,671,000<span></span>
</td>
<td class="nump">83,372,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989669432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="nump">$ 20,340<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">282,001<span></span>
</td>
<td class="nump">244,650<span></span>
</td>
<td class="nump">216,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">78,801<span></span>
</td>
<td class="nump">64,402<span></span>
</td>
<td class="nump">79,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">360,802<span></span>
</td>
<td class="nump">309,052<span></span>
</td>
<td class="nump">295,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(340,462)<span></span>
</td>
<td class="num">(309,052)<span></span>
</td>
<td class="num">(295,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">2,447<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(340,095)<span></span>
</td>
<td class="num">(306,605)<span></span>
</td>
<td class="num">(290,964)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(340,141)<span></span>
</td>
<td class="num">(306,620)<span></span>
</td>
<td class="num">(290,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(664)<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (340,805)<span></span>
</td>
<td class="num">$ (306,544)<span></span>
</td>
<td class="num">$ (290,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (3.63)<span></span>
</td>
<td class="num">$ (4.15)<span></span>
</td>
<td class="num">$ (5.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used to calculate basic and diluted net loss per common share</a></td>
<td class="nump">93,670<span></span>
</td>
<td class="nump">73,973<span></span>
</td>
<td class="nump">51,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAndCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAndCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984549256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th"><div>Underwritten Public Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At The Market Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 339,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (340)<span></span>
</td>
<td class="num">$ (526,985)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfOfferingCostsValue', window );">Issuance of common stock, net of offering costs, values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfOfferingCostsShares', window );">Issuance of common stock, net Of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue', window );">Issuance of common stock, net of commissions and offering costs, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares', window );">Issuance of common stock, net of commissions and offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">RSU settlements, net of shares withheld</a></td>
<td class="num">(6,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue', window );">Issuance of common stock pursuant to employee stock awards</a></td>
<td class="nump">7,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares', window );">Issuance of common stock pursuant to employee stock awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">51,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(290,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">290,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="num">(817,961)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue', window );">Issuance of common stock and pre-funded warrants, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares', window );">Issuance of common stock and pre-funded warrants, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue', window );">Issuance of common stock, net of commissions and offering costs, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares', window );">Issuance of common stock, net of commissions and offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">RSU settlements, net of shares withheld</a></td>
<td class="num">(1,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue', window );">Issuance of common stock pursuant to employee stock awards</a></td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares', window );">Issuance of common stock pursuant to employee stock awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">51,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(306,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">462,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="num">(1,124,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue', window );">Issuance of common stock, net of commissions and offering costs, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares', window );">Issuance of common stock, net of commissions and offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">RSU settlements, net of shares withheld</a></td>
<td class="num">(1,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue', window );">Issuance of common stock pursuant to employee stock awards</a></td>
<td class="nump">6,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares', window );">Issuance of common stock pursuant to employee stock awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">53,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(340,141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 279,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,744,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (368)<span></span>
</td>
<td class="num">$ (1,464,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants, net of offering costs, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants, net of offering costs, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock, Net of Commissions and Offering Costs, Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of commissions and offering costs, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock net of offering costs shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockNetOfOfferingCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, net of offering costs, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockNetOfOfferingCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to employee stock awards shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to employee stock awards value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989427864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - Common Stock - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance, discounts, commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance, discounts, commissions and offering costs</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">$ 1,887<span></span>
</td>
<td class="nump">$ 1,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989092552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (340,141)<span></span>
</td>
<td class="num">$ (306,620)<span></span>
</td>
<td class="num">$ (290,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">53,865<span></span>
</td>
<td class="nump">51,351<span></span>
</td>
<td class="nump">51,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">9,345<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
<td class="nump">7,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_NonCashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,948<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization (accretion) of investment premiums (discounts)</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="num">(1,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposals of property and equipment</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Asset retirement obligation accretion expense</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">264<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,182<span></span>
</td>
<td class="num">(8,666)<span></span>
</td>
<td class="num">(998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncreaseDecreaseInOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,727)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="num">(815)<span></span>
</td>
<td class="nump">4,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">4,692<span></span>
</td>
<td class="nump">5,752<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncreaseDecreaseInAccruedResearchAndDevelopment', window );">Accrued research and development expenses</a></td>
<td class="num">(2,362)<span></span>
</td>
<td class="nump">7,472<span></span>
</td>
<td class="num">(10,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">35,218<span></span>
</td>
<td class="nump">61,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(1,316)<span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(509)<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(220,522)<span></span>
</td>
<td class="num">(180,759)<span></span>
</td>
<td class="num">(235,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(301,129)<span></span>
</td>
<td class="num">(425,868)<span></span>
</td>
<td class="num">(270,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities and sales of short-term investments</a></td>
<td class="nump">333,967<span></span>
</td>
<td class="nump">309,653<span></span>
</td>
<td class="nump">336,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10,580)<span></span>
</td>
<td class="num">(4,513)<span></span>
</td>
<td class="num">(5,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">22,258<span></span>
</td>
<td class="num">(120,728)<span></span>
</td>
<td class="nump">60,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering', window );">Proceeds from sale of common stock and pre-funded warrants in underwritten offerings, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">353,780<span></span>
</td>
<td class="nump">140,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock through ATM facilities, net</a></td>
<td class="nump">98,697<span></span>
</td>
<td class="nump">69,189<span></span>
</td>
<td class="nump">47,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock awards</a></td>
<td class="nump">6,762<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="nump">7,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(1,244)<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="num">(6,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance and capital lease obligations</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">103,944<span></span>
</td>
<td class="nump">427,574<span></span>
</td>
<td class="nump">188,786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(94,320)<span></span>
</td>
<td class="nump">126,087<span></span>
</td>
<td class="nump">13,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">201,798<span></span>
</td>
<td class="nump">75,711<span></span>
</td>
<td class="nump">62,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">107,478<span></span>
</td>
<td class="nump">201,798<span></span>
</td>
<td class="nump">75,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and other accrued liabilities</a></td>
<td class="nump">2,139<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering', window );">Accrued costs related to underwritten public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility', window );">Accrued costs related to ATM facility</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived', window );">Proceeds from issuance of common stock through ATM facilities not yet received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IncreaseDecreaseInAccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IncreaseDecreaseInAccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash investing and financing activities accrued costs related to at the market facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash investing and financing activities accrued costs related to underwritten public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock through at the market offering facilities not yet received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of pre-funded warrants in underwritten public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993840408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DescriptionOfBusinessAbstract', window );"><strong>Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_BusinessDescriptionTextBlock', window );">Description of Business</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atara Biotherapeutics, Inc. (&#8220;Atara&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;the Company&#8221;) was incorporated in August 2012 in Delaware. <span style="Background-color:#FFFFFF;color:#000000;">Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (&#8220;CAR T&#8221;) programs. Our most advanced T-cell immunotherapy program, tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (tabelecleucel), is currently in Phase 3 development, and in October 2021, we entered into a commercialization agreement (&#8220;Pierre Fabre Commercialization Agreement&#8221;) with Pierre Fabre Medicament (&#8220;Pierre Fabre&#8221;), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia, following regulatory approval. Atara will retain full rights to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in other major markets, including North America, Asia Pacific and Latin America. See Note 7 for further information. In December 2020, we entered into a research, development and license agreement (&#8220;Bayer License Agreement&#8221;) with Bayer AG (&#8220;Bayer&#8221;) pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271. In March 2021, as contemplated under the Bayer License Agreement and to further advance our collaboration, we entered into (i) a Manufacturing and Supply Agreement; (ii) a Pharmacovigilance Agreement; (iii) a Quality Agreement; and (iv) a Technology Transfer Agreement (collectively, the Bayer License Agreement, the Manufacturing and Supply Agreement and the Technology Transfer Agreement are referred to as the &#8220;Bayer Agreements&#8221;). See Note 7 for further information. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (&#8220;MSK&#8221;), rights related to our next-generation CAR T programs from MSK and from H. Lee Moffitt Cancer Center (&#8220;Moffitt&#8221;), and rights to know-how and technology from the Council of the Queensland Institute of Medical Research (&#8220;QIMR Berghofer&#8221;). See Note 6 for further information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_BusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description concept. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_BusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991152136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and follow the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Atara and our wholly owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment <span style="color:#000000;">and Geographic Information</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate and manage our business as one operating and reportable segment, which is the business of developing and commercializing therapeutics. Our Chief Executive Officer, who is our chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Substantially all of our assets are located in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $20.3 million license and collaboration revenue recognized in 2021, $19.8 million related to our agreements with Bayer, a German company, and $0.5 million related to our agreements with Pierre Fabre, a French company. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and have relied primarily on public and private equity financings and receipts from license and collaboration agreements to fund our operations. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: our ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates, if approved by applicable regulatory authorities; our ability to collect amounts due from our collaboration partners, future customers or distribution partners; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions and monetary assets and liabilities that are denominated in a foreign currency are translated into U.S. dollars at the current exchange rate on the transaction date and as of&#160;each balance sheet date, respectively, with gains or losses on foreign exchange changes recognized in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. Foreign currency-denominated monetary assets and liabilities as of December 31, 2021 were not material.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents and Short-Term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase, and generally consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, and commercial paper. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than 90 days are classified as short-term investments on the balance sheet, and consist primarily of U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As <span style="color:#000000;">our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale and as current assets, even though the stated maturity may be more than one year from the current balance sheet date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheet.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both recorded to interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the fair value of available-for-sale securities impact the consolidated statements of operations and comprehensive loss only when such securities are sold, if an allowance for credit losses is recognized or if an impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security&#8217;s cost basis. We regularly review our investment portfolio to determine if any security is impaired, which would require us to record an allowance for credit losses or impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, our intent to sell or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. Realized gains and losses, allowances for credit losses and impairments on available-for-sale securities, if any, are recorded to interest and other income, net in the statements of operations and comprehensive loss</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain of our financial instruments including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Short-term investments are comprised of available-for-sale securities, which are carried at fair value. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial assets are measured at fair value <span style="color:#000000;">on a recurring basis using the following hierarchy to prioritize valuation inputs,</span> in accordance with applicable GAAP: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities that we have the ability to access</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs that are unobservable data points that are not corroborated by market data</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Costs incurred to acquire, construct or install property and equipment during the construction stage of a capital project or costs incurred to purchase and develop internal use software during the application development stage are recorded as construction in progress. Leasehold improvements are amortized over the lesser of the life of the leasehold improvements or the lease term. Maintenance and repairs are charged to operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate the carrying amount of our long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. To date, there have been no such impairment losses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Retirement Obligations (&#8220;ARO&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO are legal obligations associated with the retirement of long-lived assets pertaining to leasehold improvements. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Subsequent to initial recognition, the Company records period-to-period changes in the ARO liability resulting from the passage of time and revisions to either the timing or the amount of the original estimate of undiscounted cash flows. The Company derecognizes ARO liabilities when the related obligations are settled.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement is a lease at inception in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span>. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize short-term lease expense for these leases on a straight-line basis over the lease term. Finance leases are included in other assets, other current liabilities, and other long-term liabilities on our consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The lease term includes renewal options that we are reasonably certain of exercising as of the commencement date. None of the lease terms used to calculate the future minimum lease payments at commencement date include renewal options. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. Lease assets also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized over the shorter of the lease term or the asset&#8217;s estimated useful life.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facilities and equipment operating leases have lease and non-lease components and we have made a policy election to account for the lease and non-lease components as a single lease component. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception, we determine whether contracts are within the scope of Accounting Standards Codification Topic 606 (ASU No. 2014-09), <span style="font-style:italic;">Revenue from Contracts with Customers</span>, and all subsequent amendments (collectively, &#8220;ASC 606&#8221;) or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for our out-license agreements in Note 7. Our out-license agreements do not contain a significant financing component. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> typically determine standalone selling prices using an adjusted market assessment approach model.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced or (iii) our performance does not create an asset with an alternative use to the entity and we have an enforceable right to payment for performance completed to date. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring control of a promised good or service to a customer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, our deferred revenue is related to the Bayer Agreements and the Pierre Fabre Commercialization Agreement, which are both within the scope of ASC 606. As discussed in further detail in Note 7, the terms of these arrangements include potential payments to us for some or all of the following: nonrefundable, upfront fees; development, regulatory, and commercial milestone payments; research and development funding payments; and royalties on the net sales of licensed products. These payments relate to promised goods or services for which revenue will be recognized upon our satisfaction of the underlying performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property<span style="font-style:normal;">: If the license of our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Upfront payments</span>: Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the we have satisfied our obligations under these arrangements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Milestone payments</span>: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a significant reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenues and the consolidated statements of operations and comprehensive loss in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Royalties</span>: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue resulting from our out-licensing agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive payments from our customers based on billing schedules established in each contract. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Our contract liabilities consist of deferred revenue.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation expense, including the expense of restricted common stock awards (&#8220;RSAs&#8221;), grants of restricted stock units (&#8220;RSUs&#8221;), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the closing market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. Stock-based compensation expense for awards with time-based vesting criteria is recognized as expense on a straight-line basis over the requisite service period. Stock-based compensation expense for awards with performance and other vesting criteria is recognized as expense under an accelerated graded vesting model. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key assumptions used in the Black-Scholes valuation model used for employee stock awards include:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;"> &#8211; We derived the expected term using the &#8220;simplified&#8221; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;"> &#8211; Prior to 2021, expected volatility was estimated using comparable public companies&#8217; volatility for similar terms. </span><span style="color:#000000;font-style:normal;">Beginning in 2021, volatility is estimated using an average of Atara&#8217;s historical volatility and comparable public companies&#8217; volatility for similar terms. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend<span style="font-style:normal;"> &#8211; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends; therefore, we assumed an expected dividend yield of 0%. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;"> &#8211; The risk-free interest rate is based on the yield on U.S. Treasury securities with the expected term of the associated award. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of our common stock is measured at the closing market price on the measurement date. <span style="color:#000000;">We account for forfeitures of stock-based awards as they occur.</span> </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of costs incurred in performing research and development activities, including compensation and benefits for research and development employees, including stock-based compensation; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies; the costs of acquiring and manufacturing clinical study materials and other supplies; payments under licensing and research and development agreements; other outside services and consulting costs, and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Study Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Defined Contribution Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have one qualified 401(k) plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to 50% of each dollar contributed up to the first 6% of an individual&#8217;s eligible earnings, up to the annual IRS maximum. For the years ended December 31, 2021, 2020, and 2019 we recorded matching contributions of approximately $2.6 million, $2.1 million, and $1.6 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Current Liabilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued operating expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,960</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,016</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,730</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the asset and liability method to account for income taxes. We record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2021 and 2020. We intend to maintain valuation allowances until sufficient evidence exists to support their reversal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. Our other comprehensive income (loss) is comprised solely of unrealized gains (losses) on available-for-sale securities and is presented net of taxes. We have not recorded any reclassifications from other comprehensive income (loss) to net loss during any period presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider the applicability and impact of any recent ASU issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Based on our assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on our condensed consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993773480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Common Share </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential dilutive securities, which include unvested restricted stock units (&#8220;RSUs&#8221;), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (&#8220;ESPP&#8221;), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,253,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,868,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,200,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,832,386</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,934,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP share purchase rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,438</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,480,922</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,727,142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,865,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991159656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinancialInstrumentsDisclosureAbstract', window );"><strong>Financial Instruments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(138</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,695</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,346</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,174</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,150</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000509">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000511">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(199,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(199,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,959</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,457</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one to five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,383</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,221</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. <span style="color:#000000;">During the years ended </span>December 31, 2021<span style="color:#000000;">, 2020 and 2019, we did not recognize any impairment losses on our investments. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our consolidated balance sheet. As of December 31, 2021 and 2020, accrued interest receivable was $0.8 million and $0.7 million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have not written off any accrued interest receivables for the years ended December 31, 2021, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of December 31, 2021 and 2020, restricted cash totaled $1.4 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,084</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,404</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short-term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinancialInstrumentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>financial instruments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinancialInstrumentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991129512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,066</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">879</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,738</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,676</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $9.3 million, $8.3 million and $7.1 million for the years ended December 31, 2021<span style="color:#000000;">, 2020 and 2019</span>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993732808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-license and Manufacturing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_InLicenseAndManufacturingAgreementsAbstract', window );"><strong>In License And Manufacturing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock', window );">In-license and Manufacturing Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In-license and Manufacturing Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MSK Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies. <span style="color:#000000;">We are required to make </span>payments<span style="font-size:12pt;">&#160;</span>to MSK based on achievement of specified regulatory and sales-related milestones, <span style="color:#000000;">as well as </span>mid-single-digit percentage tiered royalty payments based on<span style="font-size:12pt;"> </span><span style="color:#000000;">future sales of products resulting from the development of the licensed product candidates, if any. </span><span style="Background-color:#FFFFFF;color:#000000;">In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. </span><span style="color:#000000;">The license agreement expires on a product-by-product and country-by-country basis on the latest of: (i)&#160;expiration of the last licensed patent rights related to each licensed product, (ii)&#160;expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii)&#160;a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May and December 2018, we licensed additional technology from MSK.&#160;We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we amended and restated our license agreement with MSK to: (i) terminate our license to certain rights related to WT1 and cytomegalovirus (&#8220;CMV&#8221;); and (ii) license additional know-how rights not otherwise covered by our existing agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QIMR Berghofer Agreements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology that we exercised in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to terminate our license to certain rights related to CMV and again in August 2020 to terminate our license to certain rights related to BK polyomavirus and JC polyomavirus. Our current license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other In-license and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next-generation CAR T programs from the National Institutes of Health in December 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of December 31, 2021 and 2020, there were no outstanding obligations for milestones and royalties under our license and collaboration agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cognate Manufacturing Agreement<span style="font-weight:normal;"> </span>&#8211;<span style="font-weight:normal;"> In December 2019, we entered into a Commercial Manufacturing Services Agreement (the &#8220;Manufacturing Agreement&#8221;) with Cognate Bioservices, Inc. (&#8220;Cognate&#8221;). Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement, as amended, runs until May 31, 2022. We may terminate the Manufacturing Agreement for convenience on six months&#8217; written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_InLicenseAndManufacturingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-license and manufacturing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_InLicenseAndManufacturingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-license and Manufacturing Agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993623032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-license Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_OutLicenseAgreementsDisclosureTextBlock', window );">Out-license Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Out-license Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bayer Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research, Development and License Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we entered into the Bayer License Agreement to develop mesothelin-directed CAR T-cell therapies for the treatment of solid tumors, pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271 (the &#8220;Licensed Products&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Bayer License Agreement, we will be responsible at our cost for all mutually agreed preclinical and clinical activities for ATA2271 through the first in human Phase 1 clinical study in collaboration with MSK, following which Bayer will be responsible for the further development of ATA2271 at its cost. Bayer will be responsible for the development of ATA3271, except for certain mutually agreed preclinical, translational, manufacturing and supply chain activities to be performed by us relating to ATA3271, in each case at Bayer&#8217;s cost. Bayer will also be solely responsible for commercializing the Licensed Products at its cost.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we received an upfront cash payment of $45.0 million from Bayer for the exclusive license grant, net of applicable withholding taxes, which were fully recovered in August 2021, and an additional $15.0 million upfront reimbursement payment for certain research and process development activities to be performed by us. We are also entitled to receive (i) up to $5.0 million for additional, specified translational activities under the Bayer License Agreement, of which we have invoiced $1.3 million, and (ii) an aggregate of up to $610.0 million in milestone payments upon achieving certain development, regulatory and commercial milestones relating to the Licensed Products. In addition, we are eligible to receive from Bayer tiered royalties at percentages up to low double digits on worldwide net product sales of the Licensed Products on a country-by-country and product-by-product basis until the later of 12 years after the first commercial sale in such country or the expiration of specified patent rights in such country, subject to certain reductions and aggregate minimum floors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bayer and we have formed a joint steering committee (&#8220;JSC&#8221;) that will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer License Agreement represent transactions with a customer. We concluded that the Bayer License Agreement contains the following promises: (i) a development and commercialization license; (ii) performance of early-stage research and development (&#8220;R&amp;D&#8221;) services, including technology transfer services; (iii) JSC participation; and (iv) chemistry, manufacturing and control (&#8220;CMC&#8221;) services. In accordance with ASC 606, we determined that the license, early-stage R&amp;D and CMC services were not distinct from each other, as the license, early-stage R&amp;D and CMC services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;D and CMC services. Accordingly, we determined that these promises should be combined into a single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price at inception consisted of a $45.0 million upfront payment for the license, $15.0 million for certain research and process development activities and the $5.0 million for additional specified translational activities, and this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Technology Transfer Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a Technology Transfer Agreement with Bayer (the &#8220;Bayer Tech Transfer Agreement&#8221;), which was contemplated as part of the Bayer License Agreement, to transfer to Bayer the ATA3271 manufacturing process being developed as part of the CMC services in the Bayer License Agreement. Upon entering into the agreement, we invoiced Bayer 20 percent<span style="font-size:12pt;">&#160;</span>of the total fee of $15.3 million under the Bayer Tech Transfer Agreement, or $3.1 million, which we received in the second quarter of 2021 and invoiced 40 percent of the total fee, or $6.1 million, in January 2022. The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer Tech Transfer Agreement represent transactions with a customer. We concluded that the Bayer Tech Transfer Agreement should be combined with the Bayer License Agreement and accounted for as a modification of that agreement and that the Bayer Tech Transfer Agreement contains the following promises: (i) technology transfer services and (ii) supply of materials required for the technology transfer services. In accordance with ASC 606, we determined that the technology transfer services and supply of materials required for the technology transfer services were not distinct from each other, as they are highly interdependent upon one another. In addition, we concluded that the technology transfer services and supply of materials required for the technology transfer services were highly interdependent with the license, early-stage R&amp;D and CMC services identified in the Bayer License Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bayer Tech Transfer Agreement, in order to evaluate the appropriate transaction price, we determined that the $15.3 million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Manufacturing and Supply Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a Manufacturing and Supply Agreement with Bayer (the &#8220;Bayer Manufacturing Agreement&#8221;), which was contemplated as part of the Bayer License Agreement, to manufacture Phase 1 and 2 allogeneic mesothelin-directed CAR T-cell therapies for Bayer to use in clinical trials at a price based on our costs plus a reasonable margin, which is consistent with our standalone selling price. Under the Bayer Manufacturing Agreement, we will also provide storage and distribution services to Bayer at a price that is consistent with our standalone selling price for these services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entering into the Bayer Manufacturing Agreement, Bayer submitted, and we approved, a binding purchase order for manufacturing services and storage services. Any fees for the manufacturing services will be invoiced as follows: (i) 50 percent upon written acceptance by us of the binding purchase order, and (ii) the remainder upon delivery of the certification of analysis of such lots to Bayer. Storage and distribution services are billed monthly as those services are provided to Bayer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we invoiced Bayer 50 percent of the total estimated supply price of $13.1 million for manufacturing services under the initial purchase order for the supply of six lots, or $6.6 million, which we received in the second quarter of 2021. The remainder of the supply price will be billed upon the release of the lots ordered by Bayer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the manufacturing and supply agreement represent transactions with a customer. We concluded that the Bayer Manufacturing Agreement contains the following promises: (i) manufacturing services; (ii) storage services provided on a month-to-month basis; and (iii) distribution services. In accordance with ASC 606, we determined that the manufacturing services for the initial purchase order of six lots, that are expected to be provided prior to completion of the technology transfer, are not distinct as they are highly interdependent on the manufacturing process being developed and transferred under the Bayer License Agreement and the Bayer Tech Transfer Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. We also determined that each of the other services were distinct and separate performance obligations. We determined that the initial binding order for the manufacture and supply of six lots should be combined with the Bayer License Agreement and accounted for as a modification of that agreement along with the Bayer Tech Transfer Agreement. We also concluded that a binding purchase order from Bayer, together with the Bayer Manufacturing Agreement, form the contract for manufacturing services and storage services and a shipping order from Bayer forms the contract for distribution services. We also determined that the storage services provided on a month-to-month basis and distribution services are distinct and separate performance obligations. All the performance obligations identified above are priced at their standalone selling price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bayer Manufacturing Agreement, in order to evaluate the appropriate transaction price, we determined that the $13.1 million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. Revenue for the manufacturing services for the initial six lots will be recognized based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. Revenue for the storage services will be recognized over time as those services are provided. Revenue for the distribution services will be recognized at a point in time when the product is delivered to a clinical site designated by Bayer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Bayer Revenue Recognition</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. For the year ended December 31, 2021, we recognized license and collaboration revenue of $19.8 million under the Bayer License Agreement, Bayer Tech Transfer Agreement and Bayer Manufacturing Agreement, collectively, the Bayer Agreements. We did not recognize any license and collaboration revenue in 2020 under Bayer License Agreement. Deferred revenue related to the Bayer Agreements aggregated to $51.5 million and $61.3 million as of December 31, 2021 and 2020, respectively. Of the $51.5 million of deferred revenue as of December 31, 2021, $40.8 million is included in current liabilities and $10.7 million is included in long-term liabilities. This revenue is expected to be recognized over approximately the next three years. No development or sales-based milestone payments have been earned or received through December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre Commercialization Agreement<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the Pierre Fabre Commercialization Agreement, pursuant to which, we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia (the &#8220;Territory&#8221;) following regulatory approval. Atara will retain full rights to tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in other major markets, including North America, Asia Pacific and Latin America. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible at our cost for the conclusion of the ongoing Phase 3 ALLELE clinical study and the Phase 2 multi-cohort clinical study. We will also be responsible at our cost for certain other activities directed to obtaining regulatory approval for tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for EBV-positive lymphoproliferative disease pursuant to the terms of the Pierre Fabre Commercialization Agreement in Europe and the UK. Pierre Fabre will be responsible at its cost for obtaining and maintaining all other regulatory approvals and for commercialization and distribution of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> in the Territory. We will own any intellectual property rights developed solely by us under the Agreement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre paid us an upfront cash payment of $45.0 million for the exclusive license grant in October 2021. We are also entitled to receive an aggregate of up to $318.0 million in milestone payments upon achieving certain regulatory and commercial milestones. In addition, we are eligible to receive double-digit tiered royalties as a percentage of net sales of tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> until the later of 12 years after the first commercial sale in such country, the expiration of specified patent rights, or the expiration of all regulatory exclusivity for such product on a country-by-country basis. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will negotiate a separate manufacturing and supply agreement with Pierre Fabre for us to manufacture tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for Pierre Fabre to use in the Territory based on a fixed price until January 1, 2024 and cost plus a margin post January 1, 2024. We are responsible for manufacturing and supplying Pierre Fabre with tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for commercialization in the Territory at Pierre Fabre&#8217;s cost for a minimum of seven years. Following this period, we have the option to transfer the related manufacturing technology to Pierre Fabre. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also responsible for cell selection services at our cost until January 1, 2024 unless the parties agree to transfer the related cell selection technology to Pierre Fabre prior to this date. From January 1, 2024 onwards, if we agree to continue to provide cell selection services, it shall be at the sole expense of Pierre Fabre. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pierre Fabre and we have formed a joint steering committee (&#8220;JSC&#8221;) that will provide oversight, decision making and implementation guidance regarding the commercialization activities covered under the agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Pierre Fabre Commercialization Agreement represent transactions with a customer. We concluded that the Pierre Fabre Commercialization Agreement includes transfer of intellectual property rights in the form of a license, the potential to manufacture and supply tab-cel<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> for a minimum of seven years and until tech transfer, the potential to perform cell-selection services for a minimum of three years and until tech transfer, and obligation to participate in the JSC. We concluded that the promises are not distinct because Pierre Fabre cannot benefit from the license without the other services and vis versa. Consequently, the license, manufacture and supply, cell selection and participation in the JSC is a single performance obligation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pierre Fabre Commercialization Agreement, in order to evaluate the appropriate transaction price, we determined that the $45 million upfront payment, constituted the entire consideration to be included in the transaction price at the outset of the arrangement. Revenue associated with the upfront fee for the single performance obligation will be deferred until the initial delivery of services related to the manufacture and supply and cell selection and then recognized over the contract performance period&#8203;. We did not recognize any of the $45.0 million upfront payment as revenue in 2021. All of the $45.0 million of deferred revenue as of December 31, 2021 is included in long-term liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. No development or commercial milestone payments have been earned or received through December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_OutLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Out-license Agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_OutLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993774872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease our corporate headquarters in South San Francisco, California under a non-cancellable lease agreement. In December 2021, we entered into a second amendment with the landlord to extend the lease term through <span style="-sec-ix-hidden:F_000606">May 2025</span>. The amended lease agreement does not include an option to extend the lease term. In connection with the amended lease, we are required to maintain a letter of credit in the amount of $0.1 million to the landlord, a decrease of $0.1 million from the prior lease agreement, and which expires and is renewed every 12 months, and is classified as restricted cash in our consolidated balance sheet. As of December 31, 2021, we were still working to update our letter of credit and continued to report an amount of $0.2 million as restricted cash related to this letter of credit on our consolidated balance sheet. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="letter-spacing:-0.2pt;">n March 2021, we entered into a new lease agreement for approximately 33,659 square feet of office, lab and warehouse space in Thousand Oaks, California. </span>During the third quarter of 2021, the initial 10.5-year lease term commenced, upon substantial completion of the landlord&#8217;s work as defined under the agreement. The contractual obligations during the initial lease term are $21.0 million in aggregate. Base rent is subject to annual increase of 3% with each annual anniversary of the rent commencement date.<span style="letter-spacing:-0.2pt;"> We have the option to extend this lease for two additional <span style="-sec-ix-hidden:F_000616">five-year</span> periods after the initial term.</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a lease agreement for approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California. The initial 15-year term of the lease commenced on February 15, 2018, upon the substantial completion of landlord&#8217;s work as defined under the agreement. The contractual obligations during the initial term are $16.4 million in aggregate. We have the option to extend the lease for two additional periods of ten and nine years, respectively, after the initial term. In connection with the lease, we were required to issue a letter of credit in the amount of $1.2 million to the landlord, which is recorded as long-term restricted cash in our consolidated balance sheet. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into a lease agreement for additional office space in Thousand Oaks, California that expires in <span style="-sec-ix-hidden:F_000624">February 2026</span> and for which we have the option to extend the lease for an additional period of five years after the initial term. Additionally, in 2021, we entered into an amended lease agreement for our office and lab space in Aurora, Colorado, to add additional lab space. Incremental contractual obligations under the lease amendment are $0.2 million, and the lease term continues to expire in <span style="-sec-ix-hidden:F_000628">April 2024</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of lease liabilities under our operating and finance leases as of December 31, 2021 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,806</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,257</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,586</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,827</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,578</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands,&#160;except lease&#160;term&#160;and discount rate)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Cash Flows Information</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; lease liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,346</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows for finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">486</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets obtained in exchange for lease obligations:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,427</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease assets obtained in exchange for lease obligations:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash increase to operating lease assets due to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remeasurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">&#160;</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Lease Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Discount Rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Retirement Obligation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ARO consists of a contractual requirement to remove the tenant improvements at our manufacturing facility in Thousand Oaks, California and restore the facility to a condition specified in the lease agreement. The Company records an estimate of the fair value of its ARO in long-term liabilities in the period incurred. The fair value of the ARO is also capitalized in property and equipment, net and depreciated over the lease term. The fair value of our ARO was estimated by discounting projected cash flows over the estimated life of the related assets using our credit adjusted risk-free rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for our ARO liabilities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">866</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993840408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Research and Development Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into contracts in the normal course of business with clinical research organizations <span style="color:#000000;">for clinical trials, with contract manufacturing </span>organizations for <span style="color:#000000;">clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on </span>notice. As of December 31, 2021 and 2020, there were no amounts accrued related to termination charges for minimum purchase volumes not being met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we consider the fair value of these indemnification agreements to be minimal. Accordingly, we did not record liabilities for these agreements as of December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991161912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 520,000,000 shares, all with a par value of $0.0001 per share, of which 500,000,000 shares are designated as common stock and 20,000,000 shares are designated as preferred stock. <span style="color:#000000;">There were no shares of preferred stock outstanding as of </span>December 31, 2021 and 2020<span style="color:#000000;">. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Offerings</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we issued and sold 6,871,727 shares of common stock at a public offering price of $15.28 per share and pre-funded warrants to purchase 2,945,026 shares of common stock at an offering price of $15.2799 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this offering were $150.0 million, resulting in aggregate net proceeds of $140.7 million, after deducting underwriting discounts and commissions and offering expenses payable by us.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each pre-funded warrant entitles the holder to purchase one share of common stock at an exercise price of $0.0001 per share and expires seven years from the date of issuance. These warrants were recorded as a component of stockholders&#8217; equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder&#8217;s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% after giving effect to the exercise (&#8220;Maximum Ownership Percentage&#8221;). Upon at least 61 days&#8217; prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed 19.99%. As of December 31, 2021, 2,888,526 of the pre-funded warrants from the July 2019 offering were outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, we issued and sold 12,633,039 shares of common stock at a public offering price of $11.32 per share and pre-funded warrants to purchase 2,866,961 shares of common stock at a public offering price of $11.3199 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. We granted the underwriters an option to purchase up to 2,325,000 additional shares of our common stock at a public offering price of $11.32, less underwriting discounts and commissions. The full option was exercised by the underwriters in June 2020. The gross proceeds from this public offering were $201.8 million, resulting in net proceeds of $189.3 million, after deducting underwriting discounts and commissions and offering expenses payable by us. The terms of the pre-funded warrants issued and sold as part of this public offering were similar to those above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we issued and sold 5,102,041 shares of common stock at a public offering price of $24.50 per share and pre-funded warrants to purchase 2,040,816 shares of common stock at a public offering price of $24.4999 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this public offering were $175.0 million, resulting in net proceeds of $164.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, all of the pre-funded warrants issued and sold as part of the 2020 underwritten public offerings were outstanding.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ATM Facilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we entered into a sales agreement (the &#8220;2019 ATM Facility&#8221;) with Cowen, which provided for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent.<span style="color:#000000;"> </span>We paid a commission of up to 3.0% of gross sales proceeds of the common stock sold under the 2019 ATM Facility.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, we entered into a sales agreement (the &#8220;2020 ATM Facility&#8221;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and did not replace the 2019 ATM Facility in any way. We paid a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we entered into a sales agreement (the &#8220;2021 ATM Facility&#8221;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2021 ATM Facility is separate from and does not replace the 2020 ATM Facility in any way. We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2021 ATM Facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended <span style="letter-spacing:-0.2pt;">December 31, 2020</span>, we sold an aggregate of 4,785,514 shares of common stock under the ATM facilities, at an average price of $14.60 per share, for gross proceeds of $69.9 million and net proceeds of $68.0 million, after deducting commissions and other offering expenses payable by us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, we sold an aggregate of 6,240,601 shares of common stock under the ATM facilities, at an average price of $16.23 per share, for gross proceeds of $101.3 million and net proceeds of $98.9 million, after deducting commissions and other offering expenses payable by us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#FF0000;"> </span><span style="color:#000000;">issuance and sale of these shares by us pursuant to the ATM facilities are deemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and are registered under the Securities Act. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, we had<span style="color:#000000;"> fully utilized the 2019 ATM Facility, and the 2020 ATM Facility and we had</span> $78.3 million of common stock <span style="color:#000000;">remaining and available to be sold under the 2021 ATM Facility. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2022 through February 15, 2022, we sold an additional 1,319,878 shares of common stock under the 2021 ATM Facility, at an average price of $15.88 per share, for gross proceeds of $21.0 million and net proceeds of $20.5 million, after deducting commissions and other offering expenses payable by us. As of February 15, 2022, we had $57.4 million of common stock remaining and available to be sold under the 2021 ATM Facility, subject to certain conditions as specified in the agreement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, we adopted the 2014 Equity Incentive Plan (&#8220;2014 EIP&#8221;), which was amended and restated on October 15, 2014 upon the pricing of our initial public offering (&#8220;IPO&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 EIP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to five percent of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by our board of directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the 2014 EIP, we may grant stock options, RSAs and RSUs to employees, directors, consultants and other service providers.&#160;RSUs generally vest over four years. In 2020, we granted performance-based awards to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based awards that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee&#8217;s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of RSUs, including those with performance conditions, is determined as the closing stock price on the date of grant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options are granted with exercise prices at no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. The estimated fair value is generally equal to the closing market price of the Company&#8217;s common stock on the measurement date. Options granted generally vest over four years and expire in seven to ten years. As of December 31, 2021, a total of 16,086,987 shares of common stock were reserved for issuance under the 2014 EIP, of which 4,018,597 shares were available for future grant and 12,068,390 shares were subject to outstanding options and RSUs, including performance-based awards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we adopted the 2018 Inducement Plan (&#8220;Inducement Plan&#8221;), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees.&#160;In September 2020, we amended the Inducement Plan to reserve an additional 1,500,000 shares of the Company&#8217;s common stock for issuance under the Inducement Plan, and in September 2021 we made a further amendment to reserve an additional 1,500,000 shares of the Company&#8217;s common stock for issuance under the Inducement Plan. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 4,022,184 shares of common stock were reserved for issuance under the Inducement Plan, of which 1,278,379 shares were available for future grant and 2,743,805 shares were subject to outstanding options and RSUs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of RSUs granted during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $16.42, $12.19 and $27.04, respectively. The estimated fair value of RSUs that vested in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $27.1 million, $23.6 million and $13.8 million, respectively. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, there was $75.7 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 2.8 years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S. GAAP. The aggregate intrinsic value of the RSUs outstanding as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span> was $88.1&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,829,620</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,624,257</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,307,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,553,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,592,358</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our RSU settlement procedures, for some of the RSUs granted to our employees, we withhold shares at settlement to cover the estimated payroll withholding tax obligations.&#160;During 2021, we settled 1,553,893 shares underlying RSUs, of which 154,341 shares underlying RSUs were net settled by withholding 61,385 shares.&#160;The value of the shares underlying RSUs withheld was $1.2 million, based on the closing price of our common stock on the settlement date. During 2020, we settled 1,218,945 shares underlying RSUs, of which 276,822 shares underlying RSUs were net settled by withholding 106,459 shares.&#160;The value of the shares underlying RSUs withheld was $1.5 million, based on the closing price of our common stock on the settlement date.&#160;The value of RSUs withheld in each period was remitted to the appropriate taxing authorities and has been reflected as a financing activity in our consolidated statements of cash flows. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<span style="font-family:Calibri;">&#160;</span>Average Exercise&#160;Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,851,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,643,378</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.97</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,028,560</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,219,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000827">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,810</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,219,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000828">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,073,289</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000829">4.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on <span style="letter-spacing:-0.2pt;">December 31, 2021</span> and the exercise price of outstanding, in-the-money options. As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, there was $41.9 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 2.5 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options for 246,867, 268,938 and 347,716 shares of our common stock were exercised during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019, with an intrinsic value of $0.8 million, $1.0 million and $3.8 million, respectively. As we believe it is more likely than not that no stock option related tax benefits will be realized, we do not record any net tax benefits related to exercised options.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option issued was estimated at the date of grant using the Black-Scholes valuation model. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model and resulting weighted-average grant date fair values of stock options granted during the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assumptions:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000843">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000844">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average estimated grant date fair value per share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.06</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,643,378</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641,125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,535,425</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total estimated grant date fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,808,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,023,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,790,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of stock options that vested in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019 was $26.6 million, $29.4 million and $31.6 million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, we adopted the 2014 Employee Stock Purchase Plan (&#8220;2014 ESPP&#8221;), which became effective on October 15, 2014 upon the pricing of our IPO. The 2014 ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Eligible employees can purchase shares of the Company&#8217;s common stock at 85% of the lower of the fair market value of the common stock at (i) the beginning of a 12-month offering period, or (ii) at the end of one of the two related 6-month purchase periods. No participant in the 2014 ESPP may purchase shares of common stock valued at more than $25,000 per calendar year. The first offering under the 2014 ESPP commenced on June 1, 2016, and subsequent offerings commence on each anniversary of this date. The Company recorded $1.7 million, $1.8 million and $1.3 million of expense related to the 2014 ESPP in the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021,</span> 2020 and 2019, respectively. A total of 319,190, 282,514 and 139,466 shares were purchased under the ESPP during the years ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there was $0.6 million of unrecognized stock-based compensation expense related to the ESPP that is expected to be recognized by the end of second quarter of 2022.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 ESPP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to the lower of (i) one percent of the number of shares of our common stock outstanding as of such date, (ii) 230,769 shares of our common stock, or (iii) a lesser number of shares as determined by our board of directors. As of December 31, 2021, there were 1,817,511 shares authorized under the 2014 ESPP.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reserved Shares</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares of common stock were reserved for future issuance under our equity incentive plans as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares Reserved</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,086,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Inducement Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,022,184</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total reserved shares of common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,971,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense related to all stock awards was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,063</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,527</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,802</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,351</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679077388040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Losses before provision for income taxes were as follows in each period presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(340,301</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,758</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(340,095</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(290,964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of provision for (benefit from) income taxes were as follows in each period presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current provision for (benefit from) income taxes:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision for (benefit from) income</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible executive compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities were as follows for each of the dates presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237,010</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,672</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,972</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,366</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,136</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,133</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,048</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,758</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376,071</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,349</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,409</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,409</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes, as well as for tax attribute carryforwards. We regularly evaluate the positive and negative evidence in determining the realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance and reported cumulative net losses since inception, we maintained a full valuation allowance on the net deferred tax assets as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span> and 2020. We intend to maintain a full valuation allowance on our&#160;deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $88.7 million for the year ended <span style="letter-spacing:-0.2pt;">December 31, 2021</span> primarily due to federal and state NOLs and other U.S. deferred tax assets, which includes accelerated Bayer revenue recognition for tax purposes during 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law on March 27, 2020, providing companies with various tax relief provisions and other stimulus measures. Such measures include, but are not limited to, temporary changes regarding the prior and future utilization of net operating losses, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property, acceleration of AMT credit refunds, and changes to business interest limitations. The Consolidated Appropriations Act was also signed into law on December 27, 2020 to provide further relief measures and renew various expiring tax provisions. Additionally, the IRS issued final regulations and proposed regulations on calculating the limitation on business interest expense, the allowance for the first-year depreciation deduction under IRC Section 168(k), as amended by the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), for qualified property acquired and placed in service after September 27, 2017, and meals and entertainment deductions. Based on our evaluation, these regulations did not have a material impact on the income tax provision for the years ended December 31, 2021, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Tax Act, federal net operating losses generated in tax years beginning on or after January 1, 2018 and in future years may be carried forward indefinitely, but the utilization of such federal net operating losses is limited to 80% of current year taxable income. The CARES Act temporarily suspends this 80% taxable income limitation, allowing a net operating loss carryforward to fully offset taxable income in tax years beginning before January 1, 2021.<span style="color:#000000;"> It is uncertain if, and to what extent, various states will conform to the Tax Act or the CARES Act. </span>The Tax Act nor the CARES Act had a material impact to our financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>, for federal income tax purposes, we had net operating loss carryforwards of approximately $1,064.4 million, of which $65.2 million begin to expire in 2032 and $999.2 do not expire, research &amp; development tax credits of approximately $18.0 million which begin to expire in 2032, and orphan drug tax credits of approximately $94.5 million which begin to expire in 2035. For California income tax purposes, we had net operating loss carryforwards of approximately $1,045.5 million which begin to expire in 2032, and research &amp; development tax credits of approximately $30.4 million which do not expire, and Competes tax credit of $2.0 million which begins to expire in 2024. For other states income tax purposes, we had net operating loss carryforwards of approximately $226.6 million which begins to expire in 2030. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, our ability to utilize net operating loss carryforwards or other tax attributes in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section&#160;382 &#8220;ownership change&#8221; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Similar rules may apply under state tax laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have performed a Section 382 analysis of transactions in our stock through December 31, 2021. <span style="color:#000000;">We have experienced ownership changes since inception and our utilization of net operating loss carryforwards will be subject to annual limitations. However, it is not expected that the annual limitations will result in the expiration of tax attribute carryforwards prior to utilization</span><span style="color:#000000;">. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the years ended December 31, 2019, 2020 and 2021 are as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,126</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,601</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any uncertain tax position be favorably settled in the future. For 2021, 2020, and 2019 total unrecognize benefits in the amount of $144.1 million, $110.6 million, and $86.0 million, respectively, no amount, if recognized, would affect the Company&#8217;s effective tax rate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to account for interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company has not accrued interest and penalties as of December 31, 2021 due to available tax losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our significant jurisdictions are the U.S. federal jurisdiction and the California state jurisdiction. All of our tax years remain open to examination by the U.S. federal and California tax authorities. We also file in other state, local and foreign jurisdictions in which we operate, and such tax years remain open to examination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2017 Tax Act imposed a mandatory transition tax on accumulated foreign earnings and generally eliminated U.S. taxes on foreign subsidiary distribution. As of December 31, 2021, the Company is not permanently reinvested with respect to its foreign earnings and has not recorded deferred income taxes and withholding taxes as these taxes are immaterial to the financial statements.<span style="font-size:9pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993788232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 26, 2022, the Company announced it has entered into an asset purchase agreement with FUJIFILM Diosynth Biotechnologies California, Inc. and, for certain limited purposes, FUJIFILM Holdings America Corporation, to sell all of the Company&#8217;s right, title and interest in and to certain assets related to the Atara T-Cell Operations and Manufacturing facility located at 2430 Conejo Spectrum Street, Thousand Oaks, California for $100 million in cash, plus or minus certain closing adjustments pursuant to the asset purchase agreement. The closing of the proposed transaction is expected to occur in the quarter ending June 30, 2022, subject to certain closing conditions, including clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989780840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and follow the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Atara and our wholly owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment <span style="color:#000000;">and Geographic Information</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate and manage our business as one operating and reportable segment, which is the business of developing and commercializing therapeutics. Our Chief Executive Officer, who is our chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Substantially all of our assets are located in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $20.3 million license and collaboration revenue recognized in 2021, $19.8 million related to our agreements with Bayer, a German company, and $0.5 million related to our agreements with Pierre Fabre, a French company. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LiquidityRiskPolicyTextBlock', window );">Liquidity Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and have relied primarily on public and private equity financings and receipts from license and collaboration agreements to fund our operations. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Uncertainties</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: our ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates, if approved by applicable regulatory authorities; our ability to collect amounts due from our collaboration partners, future customers or distribution partners; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions and monetary assets and liabilities that are denominated in a foreign currency are translated into U.S. dollars at the current exchange rate on the transaction date and as of&#160;each balance sheet date, respectively, with gains or losses on foreign exchange changes recognized in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. Foreign currency-denominated monetary assets and liabilities as of December 31, 2021 were not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents and Short-Term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase, and generally consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, and commercial paper. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments with original maturities of greater than 90 days are classified as short-term investments on the balance sheet, and consist primarily of U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As <span style="color:#000000;">our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale and as current assets, even though the stated maturity may be more than one year from the current balance sheet date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheet.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both recorded to interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the fair value of available-for-sale securities impact the consolidated statements of operations and comprehensive loss only when such securities are sold, if an allowance for credit losses is recognized or if an impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security&#8217;s cost basis. We regularly review our investment portfolio to determine if any security is impaired, which would require us to record an allowance for credit losses or impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, our intent to sell or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. Realized gains and losses, allowances for credit losses and impairments on available-for-sale securities, if any, are recorded to interest and other income, net in the statements of operations and comprehensive loss</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of certain of our financial instruments including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Short-term investments are comprised of available-for-sale securities, which are carried at fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial assets are measured at fair value <span style="color:#000000;">on a recurring basis using the following hierarchy to prioritize valuation inputs,</span> in accordance with applicable GAAP: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities that we have the ability to access</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:9.06%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3:</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inputs that are unobservable data points that are not corroborated by market data</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Costs incurred to acquire, construct or install property and equipment during the construction stage of a capital project or costs incurred to purchase and develop internal use software during the application development stage are recorded as construction in progress. Leasehold improvements are amortized over the lesser of the life of the leasehold improvements or the lease term. Maintenance and repairs are charged to operations as incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Long-lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate the carrying amount of our long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. To date, there have been no such impairment losses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Asset Retirement Obligations ("ARO")</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset Retirement Obligations (&#8220;ARO&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO are legal obligations associated with the retirement of long-lived assets pertaining to leasehold improvements. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Subsequent to initial recognition, the Company records period-to-period changes in the ARO liability resulting from the passage of time and revisions to either the timing or the amount of the original estimate of undiscounted cash flows. The Company derecognizes ARO liabilities when the related obligations are settled.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement is a lease at inception in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span>. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize short-term lease expense for these leases on a straight-line basis over the lease term. Finance leases are included in other assets, other current liabilities, and other long-term liabilities on our consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The lease term includes renewal options that we are reasonably certain of exercising as of the commencement date. None of the lease terms used to calculate the future minimum lease payments at commencement date include renewal options. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. Lease assets also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized over the shorter of the lease term or the asset&#8217;s estimated useful life.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facilities and equipment operating leases have lease and non-lease components and we have made a policy election to account for the lease and non-lease components as a single lease component. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At inception, we determine whether contracts are within the scope of Accounting Standards Codification Topic 606 (ASU No. 2014-09), <span style="font-style:italic;">Revenue from Contracts with Customers</span>, and all subsequent amendments (collectively, &#8220;ASC 606&#8221;) or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for our out-license agreements in Note 7. Our out-license agreements do not contain a significant financing component. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> typically determine standalone selling prices using an adjusted market assessment approach model.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced or (iii) our performance does not create an asset with an alternative use to the entity and we have an enforceable right to payment for performance completed to date. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring control of a promised good or service to a customer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, our deferred revenue is related to the Bayer Agreements and the Pierre Fabre Commercialization Agreement, which are both within the scope of ASC 606. As discussed in further detail in Note 7, the terms of these arrangements include potential payments to us for some or all of the following: nonrefundable, upfront fees; development, regulatory, and commercial milestone payments; research and development funding payments; and royalties on the net sales of licensed products. These payments relate to promised goods or services for which revenue will be recognized upon our satisfaction of the underlying performance obligations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property<span style="font-style:normal;">: If the license of our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Upfront payments</span>: Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the we have satisfied our obligations under these arrangements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Milestone payments</span>: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a significant reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenues and the consolidated statements of operations and comprehensive loss in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;">Royalties</span>: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue resulting from our out-licensing agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ContractBalancesPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We receive payments from our customers based on billing schedules established in each contract. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Our contract liabilities consist of deferred revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation expense, including the expense of restricted common stock awards (&#8220;RSAs&#8221;), grants of restricted stock units (&#8220;RSUs&#8221;), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the closing market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. Stock-based compensation expense for awards with time-based vesting criteria is recognized as expense on a straight-line basis over the requisite service period. Stock-based compensation expense for awards with performance and other vesting criteria is recognized as expense under an accelerated graded vesting model. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key assumptions used in the Black-Scholes valuation model used for employee stock awards include:</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;"> &#8211; We derived the expected term using the &#8220;simplified&#8221; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;"> &#8211; Prior to 2021, expected volatility was estimated using comparable public companies&#8217; volatility for similar terms. </span><span style="color:#000000;font-style:normal;">Beginning in 2021, volatility is estimated using an average of Atara&#8217;s historical volatility and comparable public companies&#8217; volatility for similar terms. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend<span style="font-style:normal;"> &#8211; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends; therefore, we assumed an expected dividend yield of 0%. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;"> &#8211; The risk-free interest rate is based on the yield on U.S. Treasury securities with the expected term of the associated award. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of our common stock is measured at the closing market price on the measurement date. <span style="color:#000000;">We account for forfeitures of stock-based awards as they occur.</span> </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of costs incurred in performing research and development activities, including compensation and benefits for research and development employees, including stock-based compensation; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies; the costs of acquiring and manufacturing clinical study materials and other supplies; payments under licensing and research and development agreements; other outside services and consulting costs, and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ClinicalTrialAccrualsPolicyTextBlock', window );">Clinical Study Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Study Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DefinedContributionPlanPolicyTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Defined Contribution Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have one qualified 401(k) plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to 50% of each dollar contributed up to the first 6% of an individual&#8217;s eligible earnings, up to the annual IRS maximum. For the years ended December 31, 2021, 2020, and 2019 we recorded matching contributions of approximately $2.6 million, $2.1 million, and $1.6 million, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_OtherCurrentLiabilitiesPolicyTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Current Liabilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued operating expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,960</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,016</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,730</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the asset and liability method to account for income taxes. We record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2021 and 2020. We intend to maintain valuation allowances until sufficient evidence exists to support their reversal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. Our other comprehensive income (loss) is comprised solely of unrealized gains (losses) on available-for-sale securities and is presented net of taxes. We have not recorded any reclassifications from other comprehensive income (loss) to net loss during any period presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider the applicability and impact of any recent ASU issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Based on our assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on our condensed consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents and Short-Term Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ClinicalTrialAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ClinicalTrialAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ContractBalancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ContractBalancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LiquidityRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LiquidityRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_OtherCurrentLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_OtherCurrentLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993733656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued operating expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,960</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,016</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,730</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991164136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested RSUs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,253,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,868,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,200,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,832,386</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,934,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP share purchase rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,438</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,480,922</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,727,142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,865,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679073920424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinancialInstrumentsDisclosureAbstract', window );"><strong>Financial Instruments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock', window );">Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(138</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,695</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,346</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(190</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,993</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,174</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,150</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000509">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000511">&#160;</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Input Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,343</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government agency obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,080</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,865</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amounts classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(199,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(199,090</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts classified as short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,959</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing within one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,457</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278,354</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturing in one to five years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,383</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,118</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,221</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,084</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,404</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - short-term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinancialInstrumentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>financial instruments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinancialInstrumentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of estimated fair value and related valuation input hierarchy of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993794504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following as of each period end:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,033</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,066</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">879</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,738</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,676</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678990709960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock', window );">Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of lease liabilities under our operating and finance leases as of December 31, 2021 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,806</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,257</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,004</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: amount representing interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,586</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,518</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,827</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,578</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">836</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,348</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock', window );">Summary of Other Information Related to Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information related to leases was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands,&#160;except lease&#160;term&#160;and discount rate)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Cash Flows Information</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; lease liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,346</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows for finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows for finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">486</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets obtained in exchange for lease obligations:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,427</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease assets obtained in exchange for lease obligations:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash increase to operating lease assets due to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remeasurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">639</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">&#160;</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Remaining Lease Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Discount Rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock', window );">Summary of Activity for ARO Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the activity for our ARO liabilities:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO Liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">866</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of lease liabilities under operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of other information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13201-110859<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679073207192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,829,620</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,624,257</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,307,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,553,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.41</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,592,358</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted<span style="font-family:Calibri;">&#160;</span>Average Exercise&#160;Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,851,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,643,378</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.97</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,028,560</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,219,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000827">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,810</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,219,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000828">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,073,289</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000829">4.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Options Estimated with Weighted Average</a></td>
<td class="text">The fair value of each option issued was estimated at the date of grant using the Black-Scholes valuation model. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model and resulting weighted-average grant date fair values of stock options granted during the periods indicated:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assumptions:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000843">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000844">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average estimated grant date fair value per share</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.06</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,643,378</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641,125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,535,425</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total estimated grant date fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,808,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,023,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,790,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares of common stock were reserved for future issuance under our equity incentive plans as of <span style="letter-spacing:-0.2pt;">December 31, 2021</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares Reserved</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Equity Incentive Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,086,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 Inducement Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,022,184</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2014 Employee Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total reserved shares of common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,971,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Related to Stock Awards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense related to all stock awards was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,063</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,527</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,802</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,351</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679073207192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Losses Before Provision for Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Losses before provision for income taxes were as follows in each period presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(340,301</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,758</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291,049</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loss before provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(340,095</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(290,964</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for (Benefit from) Income Taxes</a></td>
<td class="text">The components of provision for (benefit from) income taxes were as follows in each period presented:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current provision for (benefit from) income taxes:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current provision for (benefit from) income</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory Tax Rates to Effective Tax Rates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible executive compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities were as follows for each of the dates presented:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237,010</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,672</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,499</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,159</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,972</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,366</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,136</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,133</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,048</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,758</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(376,071</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,349</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,409</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,409</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the years ended December 31, 2019, 2020 and 2021 are as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,126</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,601</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross increases for tax positions related to prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross decreases for tax positions related to prior year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678993685800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DescriptionOfBusinessAbstract', window );"><strong>Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity incorporation state</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation date</a></td>
<td class="text">Aug.  01,  2012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678987870504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="nump">$ 20,340,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashAndCashEquivalentsMaturityPeriod', window );">Cash and cash equivalents maturity period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_InvestmentMaturityPeriod', window );">Investment maturity period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan, plan name</a></td>
<td class="text">401(k)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, maximum percentage of an individual's eligible earnings</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DefinedContributionPlanContributionsByEmployer', window );">Defined contribution plan contributions by employer</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember', window );">Bayer Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember', window );">Pierre Fabre Commercialization Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashAndCashEquivalentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashAndCashEquivalentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DefinedContributionPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan contributions by employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DefinedContributionPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_InvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_InvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAndCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAndCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989100344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued operating expenses</a></td>
<td class="nump">$ 5,960<span></span>
</td>
<td class="nump">$ 3,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 9,057<span></span>
</td>
<td class="nump">$ 6,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989641048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">14,480,922<span></span>
</td>
<td class="nump">10,727,142<span></span>
</td>
<td class="nump">8,865,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,253,347<span></span>
</td>
<td class="nump">2,868,407<span></span>
</td>
<td class="nump">1,910,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Vested and Unvested Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">9,200,337<span></span>
</td>
<td class="nump">7,832,386<span></span>
</td>
<td class="nump">6,934,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atra_EmployeeStockPurchasePlanMember', window );">ESPP Share Purchase Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">27,238<span></span>
</td>
<td class="nump">26,349<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atra_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atra_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678985080488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 369,472<span></span>
</td>
<td class="nump">$ 499,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">369,840<span></span>
</td>
<td class="nump">499,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">369,472<span></span>
</td>
<td class="nump">499,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">89,738<span></span>
</td>
<td class="nump">168,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">89,738<span></span>
</td>
<td class="nump">168,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasury Obligations | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">111,832<span></span>
</td>
<td class="nump">230,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">111,695<span></span>
</td>
<td class="nump">230,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government Agency Obligations | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">21,346<span></span>
</td>
<td class="nump">22,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">21,323<span></span>
</td>
<td class="nump">22,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate Debt Obligations | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">99,757<span></span>
</td>
<td class="nump">50,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">99,573<span></span>
</td>
<td class="nump">50,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">36,993<span></span>
</td>
<td class="nump">17,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">36,993<span></span>
</td>
<td class="nump">17,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-Backed Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">10,174<span></span>
</td>
<td class="nump">9,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">10,150<span></span>
</td>
<td class="nump">9,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Amounts Classified As Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashEquivalentsAmortizedCost', window );">Total Amortized Cost</a></td>
<td class="num">(104,488)<span></span>
</td>
<td class="num">(199,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashEquivalentsFairValue', window );">Total Fair Value</a></td>
<td class="num">(104,488)<span></span>
</td>
<td class="num">(199,090)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Amounts Classified As Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">265,352<span></span>
</td>
<td class="nump">299,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total Unrealized Gain</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total Unrealized Loss</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 264,984<span></span>
</td>
<td class="nump">$ 300,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, accumulated gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, accumulated gross unrealized loss, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashEquivalentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents, fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashEquivalentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678982218088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing within one year, Amortized cost</a></td>
<td class="nump">$ 278,457<span></span>
</td>
<td class="nump">$ 434,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing in one to five years, Amortized cost</a></td>
<td class="nump">91,383<span></span>
</td>
<td class="nump">64,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total available-for-sale securities, Amortized cost</a></td>
<td class="nump">369,840<span></span>
</td>
<td class="nump">499,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing within one year, Estimated fair value</a></td>
<td class="nump">278,354<span></span>
</td>
<td class="nump">435,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing in one to five years, Estimated fair value</a></td>
<td class="nump">91,118<span></span>
</td>
<td class="nump">64,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available-for-sale securities, Estimated fair value</a></td>
<td class="nump">$ 369,472<span></span>
</td>
<td class="nump">$ 499,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678987763832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinancialInstrumentsDisclosureAbstract', window );"><strong>Financial Instruments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_WriteOffOfAccruedInterestReceivable', window );">Write off, of accrued interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinancialInstrumentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>financial instruments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinancialInstrumentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_WriteOffOfAccruedInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_WriteOffOfAccruedInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678982219464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinancialInstrumentsDisclosureAbstract', window );"><strong>Financial Instruments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,084<span></span>
</td>
<td class="nump">$ 200,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - short-term</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - long-term</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 107,478<span></span>
</td>
<td class="nump">$ 201,798<span></span>
</td>
<td class="nump">$ 75,711<span></span>
</td>
<td class="nump">$ 62,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinancialInstrumentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>financial instruments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinancialInstrumentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984498936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 82,518<span></span>
</td>
<td class="nump">$ 70,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(28,738)<span></span>
</td>
<td class="num">(19,676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">53,780<span></span>
</td>
<td class="nump">50,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">50,142<span></span>
</td>
<td class="nump">50,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,060<span></span>
</td>
<td class="nump">8,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,228<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atra_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,325<span></span>
</td>
<td class="nump">$ 879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atra_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atra_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989722504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property Plant And Equipment Net By Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 9,345<span></span>
</td>
<td class="nump">$ 8,332<span></span>
</td>
<td class="nump">$ 7,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989407896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>In-License and Manufacturing Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsAbstract', window );"><strong>License Collaboration And Manufacturing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DueToLicensorsCurrentAndNoncurrent', window );">Contractual obligations due to Bayer, MSK and QIMR</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DueToLicensorsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all licensors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DueToLicensorsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseCollaborationAndManufacturingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License, collaboration and manufacturing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseCollaborationAndManufacturingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984458632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Out-license Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,340,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_YearsOfManufacturingAndSupplyingCost', window );">Years of manufacturing and supplying cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember', window );">Bayer License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment', window );">Additional upfront reimbursement payment for research and process development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount', window );">Additional upfront cash payment entitle to receive for translational activities, invoiced amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale', window );">Royalty eligible to receive term after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice', window );">Determined upfront payment for license in order to evaluate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice', window );">Determined research and process development activities in order to evaluate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice', window );">Determined additional specified translational activities in order to evaluate transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice', window );">Determined fee constituted entire consideration included in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived', window );">Development or sales-based milestone payments earned or received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember', window );">Bayer License Agreement | Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember', window );">Bayer License Agreement | Long-Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember', window );">Bayer License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities', window );">Additional upfront cash payment entitle to receive for translational activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones', window );">Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember', window );">Bayer Technology Transfer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementPercentage', window );">License agreement percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementAmount', window );">License agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementTotalFee', window );">License agreement total fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_TechnologyTransferAgreementsFeeRemainder', window );">Technology transfer agreements fee remainder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_TransactionFeePrice', window );">Transaction fee price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember', window );">Bayer Technology Transfer Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementPercentage', window );">License agreement percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementAmount', window );">License agreement amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerManufacturingAgreementMember', window );">Bayer Manufacturing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAgreementPercentage', window );">License agreement percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage', window );">Written acceptance of binding purchase order percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerManufacturingAgreementMember', window );">Bayer Manufacturing Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerManufacturingAgreementMember', window );">Bayer Manufacturing Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Manufacturing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember', window );">Bayer Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,300,000<span></span>
</td>
<td class="nump">51,500,000<span></span>
</td>
<td class="nump">$ 61,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember', window );">Pierre Fabre Commercialization Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale', window );">Royalty eligible to receive term after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived', window );">Development or sales-based milestone payments earned or received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice', window );">Determined upfront payment constituted entire consideration included in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_UpfrontPaymentRecognized', window );">Upfront payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember', window );">Pierre Fabre Commercialization Agreement | Long-Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember', window );">Pierre Fabre Commercialization Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones', window );">Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember', window );">Pierre Fabre Commercialization Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_YearsOfPotentialToManufacturingAndSupply', window );">Years of potential to manufacturing and supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_YearsOfPotentialToPerformCellSelectionServices', window );">Years of potential to perform cell-selection services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional upfront cash payment entitle to receive for translational activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional upfront cash payment entitle to receive for translational activities invoiced amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional upfront reimbursement payment for research and process development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments entitle to receive upon Achieving certain development, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined additional specified translational activities in order to evaluate transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined fee constituted entire consideration included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined research and process development activities in order to evaluate transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined upfront payment constituted entire consideration included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined upfront payment for license in order to evaluate transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development or sales-based milestone payments earned or received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAgreementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAgreementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAgreementTotalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement total fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAgreementTotalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseAndCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseAndCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License, collaboration and manufacturing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseCollaborationAndManufacturingAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty eligible to receive term after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_TechnologyTransferAgreementsFeeRemainder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technology transfer agreements fee remainder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_TechnologyTransferAgreementsFeeRemainder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_TransactionFeePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction fee price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_TransactionFeePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_UpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_UpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_UpfrontPaymentRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_UpfrontPaymentRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written acceptance of binding purchase order percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_YearsOfManufacturingAndSupplyingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Years of manufacturing and supplying cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_YearsOfManufacturingAndSupplyingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_YearsOfPotentialToManufacturingAndSupply">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Years of potential to manufacturing and supply.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_YearsOfPotentialToManufacturingAndSupply</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_YearsOfPotentialToPerformCellSelectionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Years of potential to perform cell-selection services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_YearsOfPotentialToPerformCellSelectionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=atra_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=atra_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=atra_LongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=atra_LongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_PierreFabreCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679080207640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Out-license Agreements - Additional Information (Detail 1)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember', window );">Bayer Technology Transfer Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems', window );"><strong>License, Collaboration and Manufacturing Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue expected to be recognized over period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LicenseCollaborationAndManufacturingAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License, collaboration and manufacturing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LicenseCollaborationAndManufacturingAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atra_BayerTechnologyTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984289016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_SouthSanFranciscoCaliforniaMember', window );">South San Francisco California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_SouthSanFranciscoCaliforniaMember', window );">South San Francisco California | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Letter of credit maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LetterOfCreditRenewalTerm', window );">Letter of credit renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LetterOfCreditDecreaseFromPriorLeaseAgreement', window );">Letter of credit, decrease from prior lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_RestrictedCashRelatedToLetterOfCredit', window );">Restricted cash related to letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_ThousandOaksCaliforniaMember', window );">Thousand Oaks California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace', window );">Lease agreement area of square feet of office, lab and warehouse space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lease initial term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligations</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent', window );">Percentage of annual increase in base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseOptionToExtendAdditionalTerm', window );">Lease option to extend additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace', window );">Lease agreement area of office, lab and cellular therapy manufacturing space | ft&#178;</a></td>
<td class="nump">90,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Feb. 15,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseAgreementRenewalTermOptionOne', window );">Lease extension term, option one</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseAgreementRenewalTermOptionTwo', window );">Lease extension term, option two</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_ThousandOaksCaliforniaMember', window );">Thousand Oaks California | Additional Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">we have the option to extend the lease for an additional period of five years after the initial term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LeaseOptionToExtendAdditionalTerm', window );">Lease option to extend additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_ThousandOaksCaliforniaMember', window );">Thousand Oaks California | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Letter of credit issued, classified as long-term restricted cash</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=atra_AuroraColoradoMember', window );">Aurora Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncrementalContractualObligationsUnderLeaseAmendment', window );">Incremental contractual obligations under lease amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IncrementalContractualObligationsUnderLeaseAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental contractual obligations under lease amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IncrementalContractualObligationsUnderLeaseAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement area of office lab and manufacturing space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement area of office lab and warehouse space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseAgreementRenewalTermOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement renewal term option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseAgreementRenewalTermOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseAgreementRenewalTermOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement renewal term option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseAgreementRenewalTermOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LeaseOptionToExtendAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease option to extend additional term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LeaseOptionToExtendAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease percentage of annual increase in base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LetterOfCreditDecreaseFromPriorLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit decrease from prior lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LetterOfCreditDecreaseFromPriorLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LetterOfCreditRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LetterOfCreditRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_RestrictedCashRelatedToLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash related to letter of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_RestrictedCashRelatedToLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=atra_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=atra_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=atra_ThousandOaksCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=atra_ThousandOaksCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=atra_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=atra_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=atra_AuroraColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=atra_AuroraColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989506968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating leases, 2022</a></td>
<td class="nump">$ 5,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating leases, 2023</a></td>
<td class="nump">5,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating leases, 2024</a></td>
<td class="nump">5,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating leases, 2025</a></td>
<td class="nump">4,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating leases, 2026</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Operating leases, Thereafter</a></td>
<td class="nump">19,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating leases, Total minimum payments</a></td>
<td class="nump">42,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(14,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">28,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 2,582<span></span>
</td>
<td class="nump">$ 1,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">$ 25,518<span></span>
</td>
<td class="nump">13,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 28,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance leases, 2022</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance leases, 2023</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance leases, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance leases, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance leases, 2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance leases, Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance leases, Total minimum payments</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984504456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_OperatingLeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,827<span></span>
</td>
<td class="nump">$ 3,020<span></span>
</td>
<td class="nump">$ 2,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_OperatingLeaseCostIncludingShortTermLease', window );">Total operating lease cost</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="nump">4,007<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinanceLeaseCostsAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization expense</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_OperatingLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_OperatingLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_OperatingLeaseCostIncludingShortTermLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease cost including short term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_OperatingLeaseCostIncludingShortTermLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989689544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Other Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="nump">$ 2,878<span></span>
</td>
<td class="nump">$ 2,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows for finance leases</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows for finance leases</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations:</a></td>
<td class="nump">13,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease assets obtained in exchange for lease obligations:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities', window );">Non-cash increase to operating lease assets due to remeasurement of lease liabilities:</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash increase to operating lease assets due to remeasurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679073952392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Activity for ARO Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Balance as of December 31, 2020</a></td>
<td class="nump">$ 866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAccretionExpense', window );">Accretion expense</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Balance as of December 31, 2021</a></td>
<td class="nump">$ 953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679073955576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AccruedTerminationCharges', window );">Accrued termination charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_LiabilitiesRelatedToIndemnificationAgreements', window );">Liabilities related to indemnification agreements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AccruedTerminationCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued termination charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AccruedTerminationCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_LiabilitiesRelatedToIndemnificationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities related to indemnification agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_LiabilitiesRelatedToIndemnificationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678977366888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jul. 18, 2019</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Stock option granted description terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. The estimated fair value is generally equal to the closing market price of the Company&#8217;s common stock on the measurement date. Options granted generally vest over four years and expire in seven to ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareholderOwnershipPercent', window );">Ownership percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,971,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance', window );">Additional shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock, shares exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,867<span></span>
</td>
<td class="nump">268,938<span></span>
</td>
<td class="nump">347,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Option intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Net tax benefits related to exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Estimated fair value of stock option, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,600,000<span></span>
</td>
<td class="nump">29,400,000<span></span>
</td>
<td class="nump">31,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,865,000<span></span>
</td>
<td class="nump">$ 51,351,000<span></span>
</td>
<td class="nump">$ 51,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="nump">$ 12.19<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Estimated fair value, vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100,000<span></span>
</td>
<td class="nump">$ 23,600,000<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_RestrictedStockSharesIssued', window );">Restricted stock units, settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,553,893<span></span>
</td>
<td class="nump">1,218,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,341<span></span>
</td>
<td class="nump">276,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Restricted stock units withheld for tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,385<span></span>
</td>
<td class="nump">106,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_SharesWithheldForTaxObligationsValue', window );">Restricted stock units withheld for tax obligations, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | From Date Of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=atra_EmployeesAndNonEmployeesMember', window );">Employees And Non Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vested and Unvested Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation weighted average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock options, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding', window );">Annual increase in EIP/ESPP, subject to other limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,086,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,018,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding', window );">Outstanding options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,068,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,022,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding', window );">Outstanding options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,743,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance', window );">Additional shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of employees purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock, reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">862,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_EmployeeStockPurchasePlanEffectiveDate', window );">Employee stock purchase plan effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_EmployeeStockPurchasePlanDescription', window );">Employee stock purchase plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the beginning of a 12-month offering period, or (ii) at the end of one of the two related 6-month purchase periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_EmployeeStockPurchasePlanOfferingCommencedStartDate', window );">Employee stock purchase plan offering commenced start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,190<span></span>
</td>
<td class="nump">282,514<span></span>
</td>
<td class="nump">139,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,817,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of employees purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 10% Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of employees purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employees And Non Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employees And Non Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding', window );">Annual increase in EIP/ESPP, subject to other limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock may be issued or transferred, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Maximum increase in number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued</a></td>
<td class="nump">6,871,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,633,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 15.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of common stock, gross</a></td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from sale of common stock, net</a></td>
<td class="nump">$ 140,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,888,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_StockIssuedDuringPeriodAdditionalSharesNewIssues', window );">Additional shares of our common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">2,945,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ClassOfWarrantOrRightPricePerShare', window );">Warrant, price per share</a></td>
<td class="nump">$ 15.2799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.3199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ClassOfWarrantOrRightTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_MaximumOwnershipPercentage', window );">Maximum ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Warrant | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage', window );">Prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Warrant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_MaximumOwnershipPercentage', window );">Maximum ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember', window );">At The Market Offering | Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,319,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,240,601<span></span>
</td>
<td class="nump">4,785,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,300,000<span></span>
</td>
<td class="nump">$ 69,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,900,000<span></span>
</td>
<td class="nump">$ 68,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CommonStockAveragePrice', window );">Common stock average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.23<span></span>
</td>
<td class="nump">$ 14.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_CommonStockValueAvailableToBeSold', window );">Common stock value available to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember', window );">At The Market Offering | Maximum | Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold', window );">Percentage of commission to be paid on gross sales proceeds of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Offering Price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ClassOfWarrantOrRightPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ClassOfWarrantOrRightPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CommonStockAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CommonStockAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital additional shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_CommonStockValueAvailableToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock value available to be sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_CommonStockValueAvailableToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_EmployeeStockPurchasePlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_EmployeeStockPurchasePlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_EmployeeStockPurchasePlanEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_EmployeeStockPurchasePlanEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_EmployeeStockPurchasePlanOfferingCommencedStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan offering commenced start date.,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_EmployeeStockPurchasePlanOfferingCommencedStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_MaximumOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_MaximumOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission to be paid on gross sales proceeds of common stock sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior notice period to increase or decrease maximum ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_RestrictedStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of restricted shares issued as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_RestrictedStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments options and restricted stock units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award percentage of annual increases in number of shares available for issuance as percent of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ShareholderOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders ownership percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ShareholderOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_SharesWithheldForTaxObligationsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares withheld for tax obligations, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_SharesWithheldForTaxObligationsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_StockIssuedDuringPeriodAdditionalSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, additional shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_StockIssuedDuringPeriodAdditionalSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=atra_FromDateOfGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=atra_FromDateOfGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=atra_EmployeesAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=atra_EmployeesAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=atra_TenPercentShareHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=atra_TenPercentShareHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atra_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atra_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=atra_CowenAndCompanyLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=atra_CowenAndCompanyLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989026840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity (Detail) - Unvested RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested as of December 31, 2020</a></td>
<td class="nump">3,829,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">4,624,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(1,307,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(1,553,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Outstanding as of December 31, 2021</a></td>
<td class="nump">5,592,358<span></span>
</td>
<td class="nump">3,829,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested as of December 31, 2020</a></td>
<td class="nump">$ 15.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">16.42<span></span>
</td>
<td class="nump">$ 12.19<span></span>
</td>
<td class="nump">$ 27.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="nump">14.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">17.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2021</a></td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="nump">$ 15.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989219624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Shares</a></td>
<td class="nump">2,643,378<span></span>
</td>
<td class="nump">2,641,125<span></span>
</td>
<td class="nump">2,535,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Shares</a></td>
<td class="num">(246,867)<span></span>
</td>
<td class="num">(268,938)<span></span>
</td>
<td class="num">(347,716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember', window );">2014 EIP and Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Shares, beginning balance</a></td>
<td class="nump">7,851,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Shares</a></td>
<td class="nump">2,643,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Shares</a></td>
<td class="num">(246,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired, Shares</a></td>
<td class="num">(1,028,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Shares, ending balance</a></td>
<td class="nump">9,219,837<span></span>
</td>
<td class="nump">7,851,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, Shares</a></td>
<td class="nump">9,219,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Shares</a></td>
<td class="nump">5,073,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, beginning balance</a></td>
<td class="nump">$ 22.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price</a></td>
<td class="nump">15.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">13.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired, Weighted Average Exercise price</a></td>
<td class="nump">25.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, ending balance</a></td>
<td class="nump">20.81<span></span>
</td>
<td class="nump">$ 22.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Stock options vested and expected to vest, Weighted Average Exercise Price</a></td>
<td class="nump">20.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 24.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 12,810<span></span>
</td>
<td class="nump">$ 26,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">12,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678988828264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Estimated Weighted-Average Assumptions (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.90%<span></span>
</td>
<td class="nump">76.80%<span></span>
</td>
<td class="nump">76.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated grant date fair value per share</a></td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="nump">$ 18.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">2,643,378<span></span>
</td>
<td class="nump">2,641,125<span></span>
</td>
<td class="nump">2,535,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue', window );">Total estimated grant date fair value</a></td>
<td class="nump">$ 27,808,000<span></span>
</td>
<td class="nump">$ 21,023,000<span></span>
</td>
<td class="nump">$ 45,790,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options estimated grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679080216232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
<td class="nump">20,971,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
<td class="nump">16,086,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandEighteenInducementPlanMember', window );">2018 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
<td class="nump">4,022,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserved shares of common stock</a></td>
<td class="nump">862,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandEighteenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandEighteenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atra_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678988799800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 53,865<span></span>
</td>
<td class="nump">$ 51,351<span></span>
</td>
<td class="nump">$ 51,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">32,063<span></span>
</td>
<td class="nump">31,527<span></span>
</td>
<td class="nump">26,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 21,802<span></span>
</td>
<td class="nump">$ 19,824<span></span>
</td>
<td class="nump">$ 24,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678990997320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Losses Before Provision for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (340,301)<span></span>
</td>
<td class="num">$ (306,758)<span></span>
</td>
<td class="num">$ (291,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (340,095)<span></span>
</td>
<td class="num">$ (306,605)<span></span>
</td>
<td class="num">$ (290,964)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984510056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision for (benefit from) income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision for (benefit from) income taxes</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139679080213800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Impact of stock compensation</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible executive compensation</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.70%)<span></span>
</td>
<td class="num">(18.80%)<span></span>
</td>
<td class="num">(20.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678989212072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 308,997<span></span>
</td>
<td class="nump">$ 237,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">24,181<span></span>
</td>
<td class="nump">20,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Capitalized expenses</a></td>
<td class="nump">10,499<span></span>
</td>
<td class="nump">12,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsLicenseFees', window );">License fees</a></td>
<td class="nump">8,716<span></span>
</td>
<td class="nump">8,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">7,972<span></span>
</td>
<td class="nump">4,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsLegalFees', window );">Legal fees</a></td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsTaxCredits', window );">Tax credits</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">12,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="nump">5,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">383,492<span></span>
</td>
<td class="nump">291,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(376,071)<span></span>
</td>
<td class="num">(287,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">7,421<span></span>
</td>
<td class="nump">4,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(7,421)<span></span>
</td>
<td class="num">(3,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(7,421)<span></span>
</td>
<td class="num">(4,409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets legal fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678984304024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance tax</a></td>
<td class="nump">$ 88,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards, federal</a></td>
<td class="nump">1,064,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 94,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear', window );">Research and development tax credit carryforwards, expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, state</a></td>
<td class="nump">$ 1,045,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 144,067<span></span>
</td>
<td class="nump">$ 110,601<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 41,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits if recognized would impact effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=atra_OtherStatesMember', window );">Other States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net tax operating losses, expiration</a></td>
<td class="text">begins to expire in 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, state</a></td>
<td class="nump">$ 226,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">$ 65,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net tax operating losses, expiration</a></td>
<td class="text">begin to expire in 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not subject to expiration</a></td>
<td class="nump">$ 999,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear', window );">Research and development tax credit carryforwards, expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net tax operating losses, expiration</a></td>
<td class="text">begin to expire in 2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research and development expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=atra_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=atra_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678994522536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 110,601<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 41,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases for tax positions related to current year</a></td>
<td class="nump">28,171<span></span>
</td>
<td class="nump">24,648<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases for tax positions related to prior year</a></td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases for tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 144,067<span></span>
</td>
<td class="nump">$ 110,601<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139678991164696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement', window );">Amount of closing adjustment related to asset purchase agreement</a></td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of closing adjustment related to asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>atra-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atra="http://www.atarabio.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atra-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001604464_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="C_0001604464_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001604464_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atra:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:LongTermLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:BayerTechnologyTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">atra:LongTermLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atra:PierreFabreCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-14</startDate>
            <endDate>2018-02-15</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20180215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-15</instant>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:ThousandOaksCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">atra:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">atra:AuroraColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-18</startDate>
            <endDate>2019-07-18</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-18</startDate>
            <endDate>2019-07-18</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-18</startDate>
            <endDate>2019-07-18</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190201_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211101_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">atra:CowenAndCompanyLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atra:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_atraFromDateOfGrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">atra:FromDateOfGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_atraTenPercentShareHolderMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">atra:TenPercentShareHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">atra:EmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0001604464_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atra:TwoThousandEighteenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">atra:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">atra:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604464</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_atraSegment">
        <measure>atra:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001604464_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001604464_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001604464_20210101_20211231" id="F_000007">0001604464</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001604464_20210101_20211231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityIncorporationDateOfIncorporation contextRef="C_0001604464_20210101_20211231" id="F_000403">2012-08-01</dei:EntityIncorporationDateOfIncorporation>
    <atra:LeaseAgreementRenewalTermOptionOne
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215"
      id="F_000621">P10Y</atra:LeaseAgreementRenewalTermOptionOne>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231"
      id="F_000625">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000835">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_20210101_20211231"
      id="F_000606">2025-05-31</us-gaap:LeaseExpirationDate1>
    <atra:LeaseOptionToExtendAdditionalTerm
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331"
      id="F_000616">P5Y</atra:LeaseOptionToExtendAdditionalTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231"
      id="F_000624">2026-02-28</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231"
      id="F_000628">2024-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210301_20210331"
      id="F_000615">0</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">0</atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">0</atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001604464_20211231" id="F_000640">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001604464_20211231" id="F_000642">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001604464_20211231" id="F_000654">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001604464_20211231" id="F_000656">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">0</atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20200101_20201231"
      id="F_000826">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      id="F_000827">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      id="F_000828">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      id="F_000829">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001604464_20210101_20211231" id="F_000843">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001604464_20200101_20201231" id="F_000844">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001604464_20190101_20191231" id="F_000845">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001604464_20211231"
      id="F_000079"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001604464_20201231"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001604464_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001604464_20210101_20211231" id="F_000031">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001604464_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001604464_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001604464_20210101_20211231" id="F_000032">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001604464_20210101_20211231" id="F_000018">001-36548</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001604464_20210101_20211231" id="F_000006">ATARA BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001604464_20210101_20211231" id="F_000027">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001604464_20210101_20211231" id="F_000019">46-0920988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001604464_20210101_20211231" id="F_000020">611 Gateway Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001604464_20210101_20211231" id="F_000021">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001604464_20210101_20211231" id="F_000022">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001604464_20210101_20211231" id="F_000023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001604464_20210101_20211231" id="F_000024">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001604464_20210101_20211231" id="F_000025">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001604464_20210101_20211231" id="F_000026">278-8930</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001604464_20210101_20211231" id="F_000028">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001604464_20210101_20211231" id="F_000005">ATRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001604464_20210101_20211231" id="F_000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001604464_20210101_20211231" id="F_000009">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001604464_20210101_20211231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001604464_20210101_20211231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001604464_20210101_20211231" id="F_000030">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001604464_20210101_20211231" id="F_000012">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001604464_20210101_20211231" id="F_000016">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001604464_20210101_20211231" id="F_000017">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001604464_20210101_20211231" id="F_000033">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001604464_20210101_20211231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001604464_20210630"
      decimals="0"
      id="F_000014"
      unitRef="U_iso4217USD">1149785847</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001604464_20220218"
      decimals="INF"
      id="F_000013"
      unitRef="U_xbrlishares">93097679</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000344">Portions of the Registrant&#x2019;s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001604464_20210101_20211231" id="F_000035">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001604464_20210101_20211231" id="F_000034">DELOITTE &amp; TOUCHE LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001604464_20210101_20211231" id="F_000036">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">106084000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">200404000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">264984000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">300255000</us-gaap:ShortTermInvestments>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">194000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">194000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">986000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">1250000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">12373000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">21170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">384621000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">523273000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">53780000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">50517000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">26159000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">12303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">2367000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">827000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">468127000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">588120000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">17368000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">7118000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">25150000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">20458000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <atra:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">13451000</atra:AccruedResearchAndDevelopmentExpensesCurrent>
    <atra:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">15813000</atra:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">40760000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">33455000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">9057000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">6057000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">105786000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">82901000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">55708000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">27795000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">25518000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">13041000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">1501000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">2044000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">188513000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">125781000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">91671000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">91671000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">83372000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">83372000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">1744695000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">1586616000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">-368000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">296000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">-1464722000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">-1124581000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">279614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">462339000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">468127000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">588120000</us-gaap:LiabilitiesAndStockholdersEquity>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">20340000</atra:LicenseAndCollaborationRevenue>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">0</atra:LicenseAndCollaborationRevenue>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">0</atra:LicenseAndCollaborationRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">282001000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">244650000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">216097000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">78801000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">64402000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">79584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">360802000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">309052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">295681000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">-340462000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">-309052000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-295681000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">367000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">2447000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">4717000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-340095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-306605000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-290964000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-340141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-306620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-290976000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-664000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">76000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">560000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-340805000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-306544000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-290416000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001604464_20210101_20211231"
      decimals="2"
      id="F_000134"
      unitRef="U_iso4217USD_xbrlishares">-3.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001604464_20200101_20201231"
      decimals="2"
      id="F_000135"
      unitRef="U_iso4217USD_xbrlishares">-4.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001604464_20190101_20191231"
      decimals="2"
      id="F_000136"
      unitRef="U_iso4217USD_xbrlishares">-5.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000137"
      unitRef="U_xbrlishares">93670000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_xbrlishares">73973000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_xbrlishares">51308000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000140"
      unitRef="U_xbrlishares">45951000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">866541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">-526985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20181231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">339221000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">284000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <atra:IssuanceOfCommonStockNetOfOfferingCostsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_xbrlishares">6872000</atra:IssuanceOfCommonStockNetOfOfferingCostsShares>
    <atra:IssuanceOfCommonStockNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">1000</atra:IssuanceOfCommonStockNetOfOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">140715000</atra:IssuanceOfCommonStockNetOfOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">140716000</atra:IssuanceOfCommonStockNetOfOfferingCostsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">1553000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000150"
      unitRef="U_xbrlishares">3135000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">48909000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">48909000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000153"
      unitRef="U_xbrlishares">361000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">6695000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">6695000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000156"
      unitRef="U_xbrlishares">487000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">7350000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">7350000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">51696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">51696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-290976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-290976000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">560000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">560000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_xbrlishares">56806000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">1108516000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-817961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">290781000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">583000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_xbrlishares">20060000</atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares>
    <atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">2000</atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue>
    <atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">353586000</atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue>
    <atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">353588000</atra:IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">1887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_xbrlishares">4786000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">68004000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">68004000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <atra:StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_xbrlishares">57000</atra:StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_xbrlishares">1112000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">1521000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">1521000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_xbrlishares">551000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">6680000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">6680000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">51351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">51351000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-306620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-306620000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">76000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">76000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_xbrlishares">83372000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">1586616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-1124581000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">462339000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">2501000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000197"
      unitRef="U_xbrlishares">6241000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">1000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">98696000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">98697000</atra:IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000201"
      unitRef="U_xbrlishares">1492000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">1244000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">1244000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000204"
      unitRef="U_xbrlishares">566000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">6762000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">6762000</atra:IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">53865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">53865000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-340141000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-340141000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">-664000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">-664000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000213"
      unitRef="U_xbrlishares">91671000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">1744695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">-368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">-1464722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">279614000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">-340141000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">-306620000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">-290976000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">53865000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">51351000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">51696000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">9345000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">8332000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">7070000</us-gaap:DepreciationAndAmortization>
    <atra:NonCashOperatingLeaseExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">1948000</atra:NonCashOperatingLeaseExpense>
    <atra:NonCashOperatingLeaseExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">1457000</atra:NonCashOperatingLeaseExpense>
    <atra:NonCashOperatingLeaseExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">964000</atra:NonCashOperatingLeaseExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">-1769000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">-828000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">1330000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-21000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-130000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">-1027000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccretionExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">87000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">78000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">71000</us-gaap:AccretionExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-264000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">1250000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">-8182000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">8666000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">998000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <atra:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">0</atra:IncreaseDecreaseInOperatingLeaseAssets>
    <atra:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">-886000</atra:IncreaseDecreaseInOperatingLeaseAssets>
    <atra:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-239000</atra:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">1727000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">219000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">-322000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">9067000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">-815000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">4213000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">4692000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">5752000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">4070000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <atra:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">-2362000</atra:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <atra:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">7472000</atra:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <atra:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">-10869000</atra:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">1618000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">-187000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">-394000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">35218000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">61250000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <atra:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">-1859000</atra:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atra:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">-1316000</atra:IncreaseDecreaseInOperatingLeaseLiabilities>
    <atra:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">-731000</atra:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-509000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">778000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">-220522000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">-180759000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">-235626000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">301129000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">425868000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">270230000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">333967000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">309653000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">336261000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">10580000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">4513000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">5733000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">161000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">22258000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-120728000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">60459000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">0</atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering>
    <atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">353780000</atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering>
    <atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">140888000</atra:ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">98697000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">69189000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">47729000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">6762000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">6680000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">7350000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">1244000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">1521000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">6695000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">254000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">389000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">486000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">-17000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">-165000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">103944000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">427574000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">188786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">-94320000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">126087000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">13619000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">201798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20191231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">75711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20181231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">62092000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">107478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">201798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20191231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">75711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">2139000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">326000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">276000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">0</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">192000</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">172000</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">87000</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">0</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility>
    <atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">0</atra:NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility>
    <atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">0</atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived>
    <atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">0</atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived>
    <atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">1185000</atra:ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived>
    <us-gaap:InterestPaidNet
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">32000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">62000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">50000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">15000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">10000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxesPaidNet>
    <atra:BusinessDescriptionTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000345">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Description of Business&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Atara Biotherapeutics, Inc. (&#x201c;Atara&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d; or &#x201c;the Company&#x201d;) was incorporated in August 2012 in Delaware. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Atara is a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have several T-cell immunotherapies in clinical development and are progressing multiple next-generation allogeneic chimeric antigen receptor T-cell (&#x201c;CAR T&#x201d;) programs. Our most advanced T-cell immunotherapy program, tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; (tabelecleucel), is currently in Phase 3 development, and in October 2021, we entered into a commercialization agreement (&#x201c;Pierre Fabre Commercialization Agreement&#x201d;) with Pierre Fabre Medicament (&#x201c;Pierre Fabre&#x201d;), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia, following regulatory approval. Atara will retain full rights to tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; in other major markets, including North America, Asia Pacific and Latin America. See Note 7 for further information. In December 2020, we entered into a research, development and license agreement (&#x201c;Bayer License Agreement&#x201d;) with Bayer AG (&#x201c;Bayer&#x201d;) pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271. In March 2021, as contemplated under the Bayer License Agreement and to further advance our collaboration, we entered into (i) a Manufacturing and Supply Agreement; (ii) a Pharmacovigilance Agreement; (iii) a Quality Agreement; and (iv) a Technology Transfer Agreement (collectively, the Bayer License Agreement, the Manufacturing and Supply Agreement and the Technology Transfer Agreement are referred to as the &#x201c;Bayer Agreements&#x201d;). See Note 7 for further information. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have licensed rights to T-cell product candidates from Memorial Sloan Kettering Cancer Center (&#x201c;MSK&#x201d;), rights related to our next-generation CAR T programs from MSK and from H. Lee Moffitt Cancer Center (&#x201c;Moffitt&#x201d;), and rights to know-how and technology from the Council of the Queensland Institute of Medical Research (&#x201c;QIMR Berghofer&#x201d;). See Note 6 for further information.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</atra:BusinessDescriptionTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001604464_20210101_20211231" id="F_000402">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000346">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and follow the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Atara and our wholly owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment &lt;span style="color:#000000;"&gt;and Geographic Information&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We operate and manage our business as one operating and reportable segment, which is the business of developing and commercializing therapeutics. Our Chief Executive Officer, who is our chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Substantially all of our assets are located in the U.S. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Of the $20.3 million license and collaboration revenue recognized in 2021, $19.8 million related to our agreements with Bayer, a German company, and $0.5 million related to our agreements with Pierre Fabre, a French company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidity Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have incurred significant operating losses since inception and have relied primarily on public and private equity financings and receipts from license and collaboration agreements to fund our operations. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: our ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates, if approved by applicable regulatory authorities; our ability to collect amounts due from our collaboration partners, future customers or distribution partners; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions and monetary assets and liabilities that are denominated in a foreign currency are translated into U.S. dollars at the current exchange rate on the transaction date and as of&#160;each balance sheet date, respectively, with gains or losses on foreign exchange changes recognized in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. Foreign currency-denominated monetary assets and liabilities as of December 31, 2021 were not material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents and Short-Term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase, and generally consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, and commercial paper. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments with original maturities of greater than 90 days are classified as short-term investments on the balance sheet, and consist primarily of U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As &lt;span style="color:#000000;"&gt;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale and as current assets, even though the stated maturity may be more than one year from the current balance sheet date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both recorded to interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the fair value of available-for-sale securities impact the consolidated statements of operations and comprehensive loss only when such securities are sold, if an allowance for credit losses is recognized or if an impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security&#x2019;s cost basis. We regularly review our investment portfolio to determine if any security is impaired, which would require us to record an allowance for credit losses or impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, our intent to sell or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. Realized gains and losses, allowances for credit losses and impairments on available-for-sale securities, if any, are recorded to interest and other income, net in the statements of operations and comprehensive loss&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of certain of our financial instruments including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Short-term investments are comprised of available-for-sale securities, which are carried at fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our financial assets are measured at fair value &lt;span style="color:#000000;"&gt;on a recurring basis using the following hierarchy to prioritize valuation inputs,&lt;/span&gt; in accordance with applicable GAAP: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities that we have the ability to access&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs that are unobservable data points that are not corroborated by market data&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Costs incurred to acquire, construct or install property and equipment during the construction stage of a capital project or costs incurred to purchase and develop internal use software during the application development stage are recorded as construction in progress. Leasehold improvements are amortized over the lesser of the life of the leasehold improvements or the lease term. Maintenance and repairs are charged to operations as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We evaluate the carrying amount of our long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. To date, there have been no such impairment losses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset Retirement Obligations (&#x201c;ARO&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARO are legal obligations associated with the retirement of long-lived assets pertaining to leasehold improvements. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Subsequent to initial recognition, the Company records period-to-period changes in the ARO liability resulting from the passage of time and revisions to either the timing or the amount of the original estimate of undiscounted cash flows. The Company derecognizes ARO liabilities when the related obligations are settled.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determine if an arrangement is a lease at inception in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize short-term lease expense for these leases on a straight-line basis over the lease term. Finance leases are included in other assets, other current liabilities, and other long-term liabilities on our consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The lease term includes renewal options that we are reasonably certain of exercising as of the commencement date. None of the lease terms used to calculate the future minimum lease payments at commencement date include renewal options. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. Lease assets also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized over the shorter of the lease term or the asset&#x2019;s estimated useful life.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our facilities and equipment operating leases have lease and non-lease components and we have made a policy election to account for the lease and non-lease components as a single lease component. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At inception, we determine whether contracts are within the scope of Accounting Standards Codification Topic 606 (ASU No. 2014-09), &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, and all subsequent amendments (collectively, &#x201c;ASC 606&#x201d;) or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for our out-license agreements in Note 7. Our out-license agreements do not contain a significant financing component. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; typically determine standalone selling prices using an adjusted market assessment approach model.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced or (iii) our performance does not create an asset with an alternative use to the entity and we have an enforceable right to payment for performance completed to date. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring control of a promised good or service to a customer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, our deferred revenue is related to the Bayer Agreements and the Pierre Fabre Commercialization Agreement, which are both within the scope of ASC 606. As discussed in further detail in Note 7, the terms of these arrangements include potential payments to us for some or all of the following: nonrefundable, upfront fees; development, regulatory, and commercial milestone payments; research and development funding payments; and royalties on the net sales of licensed products. These payments relate to promised goods or services for which revenue will be recognized upon our satisfaction of the underlying performance obligations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Licenses of intellectual property&lt;span style="font-style:normal;"&gt;: If the license of our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Upfront payments&lt;/span&gt;: Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the we have satisfied our obligations under these arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Milestone payments&lt;/span&gt;: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a significant reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenues and the consolidated statements of operations and comprehensive loss in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Royalties&lt;/span&gt;: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue resulting from our out-licensing agreements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Balances &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We receive payments from our customers based on billing schedules established in each contract. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Our contract liabilities consist of deferred revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation expense, including the expense of restricted common stock awards (&#x201c;RSAs&#x201d;), grants of restricted stock units (&#x201c;RSUs&#x201d;), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the closing market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. Stock-based compensation expense for awards with time-based vesting criteria is recognized as expense on a straight-line basis over the requisite service period. Stock-based compensation expense for awards with performance and other vesting criteria is recognized as expense under an accelerated graded vesting model. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key assumptions used in the Black-Scholes valuation model used for employee stock awards include:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;span style="font-style:normal;"&gt; &#x2013; We derived the expected term using the &#x201c;simplified&#x201d; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;span style="font-style:normal;"&gt; &#x2013; Prior to 2021, expected volatility was estimated using comparable public companies&#x2019; volatility for similar terms. &lt;/span&gt;&lt;span style="color:#000000;font-style:normal;"&gt;Beginning in 2021, volatility is estimated using an average of Atara&#x2019;s historical volatility and comparable public companies&#x2019; volatility for similar terms. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;span style="font-style:normal;"&gt; &#x2013; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends; therefore, we assumed an expected dividend yield of 0%. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;span style="font-style:normal;"&gt; &#x2013; The risk-free interest rate is based on the yield on U.S. Treasury securities with the expected term of the associated award. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of our common stock is measured at the closing market price on the measurement date. &lt;span style="color:#000000;"&gt;We account for forfeitures of stock-based awards as they occur.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense consists of costs incurred in performing research and development activities, including compensation and benefits for research and development employees, including stock-based compensation; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies; the costs of acquiring and manufacturing clinical study materials and other supplies; payments under licensing and research and development agreements; other outside services and consulting costs, and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical Study Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Defined Contribution Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have one qualified 401(k) plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to 50% of each dollar contributed up to the first 6% of an individual&#x2019;s eligible earnings, up to the annual IRS maximum. For the years ended December 31, 2021, 2020, and 2019 we recorded matching contributions of approximately $2.6 million, $2.1 million, and $1.6 million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Current Liabilities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities consisted of the following as of each period end:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use the asset and liability method to account for income taxes. We record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2021 and 2020. We intend to maintain valuation allowances until sufficient evidence exists to support their reversal. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. Our other comprehensive income (loss) is comprised solely of unrealized gains (losses) on available-for-sale securities and is presented net of taxes. We have not recorded any reclassifications from other comprehensive income (loss) to net loss during any period presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We consider the applicability and impact of any recent ASU issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Based on our assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on our condensed consolidated financial statements. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000357">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and follow the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000358">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Atara and our wholly owned subsidiaries. All intercompany balances and transactions are eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000359">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment &lt;span style="color:#000000;"&gt;and Geographic Information&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We operate and manage our business as one operating and reportable segment, which is the business of developing and commercializing therapeutics. Our Chief Executive Officer, who is our chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Substantially all of our assets are located in the U.S. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Of the $20.3 million license and collaboration revenue recognized in 2021, $19.8 million related to our agreements with Bayer, a German company, and $0.5 million related to our agreements with Pierre Fabre, a French company. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000404"
      unitRef="U_atraSegment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000405"
      unitRef="U_atraSegment">1</us-gaap:NumberOfOperatingSegments>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000406"
      unitRef="U_iso4217USD">20300000</atra:LicenseAndCollaborationRevenue>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000407"
      unitRef="U_iso4217USD">19800000</atra:LicenseAndCollaborationRevenue>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000408"
      unitRef="U_iso4217USD">500000</atra:LicenseAndCollaborationRevenue>
    <atra:LiquidityRiskPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000360">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidity Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have incurred significant operating losses since inception and have relied primarily on public and private equity financings and receipts from license and collaboration agreements to fund our operations. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support our cost structure. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. We expect that existing cash, cash equivalents and short-term investments as of December 31, 2021 will be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. &lt;/p&gt;</atra:LiquidityRiskPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001604464_20210101_20211231" id="F_000361">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: our ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates, if approved by applicable regulatory authorities; our ability to collect amounts due from our collaboration partners, future customers or distribution partners; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="C_0001604464_20210101_20211231" id="F_000362">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000363">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transactions and monetary assets and liabilities that are denominated in a foreign currency are translated into U.S. dollars at the current exchange rate on the transaction date and as of&#160;each balance sheet date, respectively, with gains or losses on foreign exchange changes recognized in interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. Foreign currency-denominated monetary assets and liabilities as of December 31, 2021 were not material.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <atra:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000364">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents and Short-Term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase, and generally consist of money market funds, U.S. Treasury, government agency and corporate debt obligations, and commercial paper. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments with original maturities of greater than 90 days are classified as short-term investments on the balance sheet, and consist primarily of U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As &lt;span style="color:#000000;"&gt;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale and as current assets, even though the stated maturity may be more than one year from the current balance sheet date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity, which are both recorded to interest and other income (expense), net in the consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the fair value of available-for-sale securities impact the consolidated statements of operations and comprehensive loss only when such securities are sold, if an allowance for credit losses is recognized or if an impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security&#x2019;s cost basis. We regularly review our investment portfolio to determine if any security is impaired, which would require us to record an allowance for credit losses or impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, our intent to sell or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis, the financial condition of the issuer and any changes thereto, and, as necessary, the portion of a decline in fair value that is credit-related. This assessment could change in the future due to new developments or changes in assumptions related to any particular security. Realized gains and losses, allowances for credit losses and impairments on available-for-sale securities, if any, are recorded to interest and other income, net in the statements of operations and comprehensive loss&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</atra:CashEquivalentsAndShortTermInvestmentsPolicyTextBlock>
    <atra:CashAndCashEquivalentsMaturityPeriod contextRef="C_0001604464_20210101_20211231" id="F_000409">P90D</atra:CashAndCashEquivalentsMaturityPeriod>
    <atra:InvestmentMaturityPeriod contextRef="C_0001604464_20210101_20211231" id="F_000410">P90D</atra:InvestmentMaturityPeriod>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000365">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of certain of our financial instruments including cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Short-term investments are comprised of available-for-sale securities, which are carried at fair value. &lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001604464_20210101_20211231" id="F_000366">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our financial assets are measured at fair value &lt;span style="color:#000000;"&gt;on a recurring basis using the following hierarchy to prioritize valuation inputs,&lt;/span&gt; in accordance with applicable GAAP: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities that we have the ability to access&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Observable market-based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:9.06%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Inputs that are unobservable data points that are not corroborated by market data&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. We have no Level 3 financial assets or liabilities. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000367">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Costs incurred to acquire, construct or install property and equipment during the construction stage of a capital project or costs incurred to purchase and develop internal use software during the application development stage are recorded as construction in progress. Leasehold improvements are amortized over the lesser of the life of the leasehold improvements or the lease term. Maintenance and repairs are charged to operations as incurred. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000411">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000412">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000368">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We evaluate the carrying amount of our long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. To date, there have been no such impairment losses. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001604464_20210101_20211231"
      decimals="0"
      id="F_000413"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:AssetRetirementObligationsPolicy contextRef="C_0001604464_20210101_20211231" id="F_000369">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset Retirement Obligations (&#x201c;ARO&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARO are legal obligations associated with the retirement of long-lived assets pertaining to leasehold improvements. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Subsequent to initial recognition, the Company records period-to-period changes in the ARO liability resulting from the passage of time and revisions to either the timing or the amount of the original estimate of undiscounted cash flows. The Company derecognizes ARO liabilities when the related obligations are settled.&lt;/p&gt;</us-gaap:AssetRetirementObligationsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000370">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determine if an arrangement is a lease at inception in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize short-term lease expense for these leases on a straight-line basis over the lease term. Finance leases are included in other assets, other current liabilities, and other long-term liabilities on our consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The lease term includes renewal options that we are reasonably certain of exercising as of the commencement date. None of the lease terms used to calculate the future minimum lease payments at commencement date include renewal options. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. Lease assets also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease assets are amortized over the shorter of the lease term or the asset&#x2019;s estimated useful life.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our facilities and equipment operating leases have lease and non-lease components and we have made a policy election to account for the lease and non-lease components as a single lease component. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000371">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At inception, we determine whether contracts are within the scope of Accounting Standards Codification Topic 606 (ASU No. 2014-09), &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, and all subsequent amendments (collectively, &#x201c;ASC 606&#x201d;) or other topics. For contracts that are determined to be within the scope of ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods and services. To achieve this core principle, we apply the following five steps (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation. We only apply the five-step model to contracts when we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, we apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment, which is discussed in further detail for our out-license agreements in Note 7. Our out-license agreements do not contain a significant financing component. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; typically determine standalone selling prices using an adjusted market assessment approach model.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by our performance, (ii) our performance creates or enhances an asset that the customer controls as the asset is created or enhanced or (iii) our performance does not create an asset with an alternative use to the entity and we have an enforceable right to payment for performance completed to date. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. If we do not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring control of a promised good or service to a customer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, our deferred revenue is related to the Bayer Agreements and the Pierre Fabre Commercialization Agreement, which are both within the scope of ASC 606. As discussed in further detail in Note 7, the terms of these arrangements include potential payments to us for some or all of the following: nonrefundable, upfront fees; development, regulatory, and commercial milestone payments; research and development funding payments; and royalties on the net sales of licensed products. These payments relate to promised goods or services for which revenue will be recognized upon our satisfaction of the underlying performance obligations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Licenses of intellectual property&lt;span style="font-style:normal;"&gt;: If the license of our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Upfront payments&lt;/span&gt;: Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the we have satisfied our obligations under these arrangements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Milestone payments&lt;/span&gt;: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a significant reversal of revenue would not be probable. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and collaboration revenues and the consolidated statements of operations and comprehensive loss in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-style:italic;"&gt;Royalties&lt;/span&gt;: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue resulting from our out-licensing agreements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of our revenue recognition policy. For example, we record short-term and long-term deferred revenue based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months, and long-term deferred revenue consists of amounts that we do not expect will be recognized in the next 12 months. This estimate is based on our current operating plan and, if our operating plan should change in the future, we may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <atra:ContractBalancesPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000372">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Balances &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We receive payments from our customers based on billing schedules established in each contract. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Our contract liabilities consist of deferred revenue.&lt;/p&gt;</atra:ContractBalancesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001604464_20210101_20211231" id="F_000373">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation expense, including the expense of restricted common stock awards (&#x201c;RSAs&#x201d;), grants of restricted stock units (&#x201c;RSUs&#x201d;), and stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair value is determined on the measurement date, which is generally the date of grant. The fair value of our RSUs is measured at the closing market price of our common stock on the measurement date. The fair value for our stock option awards is determined at the grant date using the Black-Scholes valuation model. For awards with performance-based vesting criteria, we assess the probability of the achievement of the performance conditions at the end of each reporting period and begin to recognize the share-based compensation costs when it becomes probable that the performance conditions will be met. For awards that are subject to both service and performance conditions, no expense is recognized until it is probable that performance conditions will be met. Stock-based compensation expense for awards with time-based vesting criteria is recognized as expense on a straight-line basis over the requisite service period. Stock-based compensation expense for awards with performance and other vesting criteria is recognized as expense under an accelerated graded vesting model. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Key assumptions used in the Black-Scholes valuation model used for employee stock awards include:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;span style="font-style:normal;"&gt; &#x2013; We derived the expected term using the &#x201c;simplified&#x201d; method (the expected term is determined as the average of the time-to-vesting and the contractual life of the options), as we have limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;span style="font-style:normal;"&gt; &#x2013; Prior to 2021, expected volatility was estimated using comparable public companies&#x2019; volatility for similar terms. &lt;/span&gt;&lt;span style="color:#000000;font-style:normal;"&gt;Beginning in 2021, volatility is estimated using an average of Atara&#x2019;s historical volatility and comparable public companies&#x2019; volatility for similar terms. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;span style="font-style:normal;"&gt; &#x2013; We have not historically declared or paid dividends to our stockholders and have no plans to pay dividends; therefore, we assumed an expected dividend yield of 0%. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;span style="font-style:normal;"&gt; &#x2013; The risk-free interest rate is based on the yield on U.S. Treasury securities with the expected term of the associated award. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of our common stock is measured at the closing market price on the measurement date. &lt;span style="color:#000000;"&gt;We account for forfeitures of stock-based awards as they occur.&lt;/span&gt; &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001604464_20210101_20211231"
      decimals="2"
      id="F_000414"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001604464_20210101_20211231" id="F_000375">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expense consists of costs incurred in performing research and development activities, including compensation and benefits for research and development employees, including stock-based compensation; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies; the costs of acquiring and manufacturing clinical study materials and other supplies; payments under licensing and research and development agreements; other outside services and consulting costs, and facilities, information technology and overhead expenses. Research and development costs are expensed as incurred. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <atra:ClinicalTrialAccrualsPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000376">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical Study Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#x2019; progress towards completion of specific tasks, using data such as patient enrollment, clinical site activations or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided. &lt;/p&gt;</atra:ClinicalTrialAccrualsPolicyTextBlock>
    <atra:DefinedContributionPlanPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000377">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Defined Contribution Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have one qualified 401(k) plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to 50% of each dollar contributed up to the first 6% of an individual&#x2019;s eligible earnings, up to the annual IRS maximum. For the years ended December 31, 2021, 2020, and 2019 we recorded matching contributions of approximately $2.6 million, $2.1 million, and $1.6 million, respectively. &lt;/p&gt;</atra:DefinedContributionPlanPolicyTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="C_0001604464_20210101_20211231" id="F_000415">401(k)</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000417"
      unitRef="U_xbrlipure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <atra:DefinedContributionPlanContributionsByEmployer
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000418"
      unitRef="U_iso4217USD">2600000</atra:DefinedContributionPlanContributionsByEmployer>
    <atra:DefinedContributionPlanContributionsByEmployer
      contextRef="C_0001604464_20200101_20201231"
      decimals="-5"
      id="F_000419"
      unitRef="U_iso4217USD">2100000</atra:DefinedContributionPlanContributionsByEmployer>
    <atra:DefinedContributionPlanContributionsByEmployer
      contextRef="C_0001604464_20190101_20191231"
      decimals="-5"
      id="F_000420"
      unitRef="U_iso4217USD">1600000</atra:DefinedContributionPlanContributionsByEmployer>
    <atra:OtherCurrentLiabilitiesPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000378">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Current Liabilities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities consisted of the following as of each period end:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</atra:OtherCurrentLiabilitiesPolicyTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000382">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities consisted of the following as of each period end:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">5960000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">3016000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">2582000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">1730000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">171000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">255000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">344000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">1056000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">9057000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">6057000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000379">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We use the asset and liability method to account for income taxes. We record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2021 and 2020. We intend to maintain valuation allowances until sufficient evidence exists to support their reversal. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000380">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period resulting from transactions from non-owner sources. Our other comprehensive income (loss) is comprised solely of unrealized gains (losses) on available-for-sale securities and is presented net of taxes. We have not recorded any reclassifications from other comprehensive income (loss) to net loss during any period presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000381">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We consider the applicability and impact of any recent ASU issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Based on our assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on our condensed consolidated financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000347">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss per Common Share &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock and pre-funded warrants outstanding during the period, without consideration of common share equivalents. Diluted net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock, pre-funded warrants and common share equivalents outstanding for the period. The pre-funded warrants are included in the computation of basic and diluted net loss per common share as the exercise price is negligible and the pre-funded warrants are fully vested and exercisable. Common share equivalents are only included in the calculation of diluted net loss per common share when their effect is dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential dilutive securities, which include unvested restricted stock units (&#x201c;RSUs&#x201d;), unvested performance-based RSUs for which established performance criteria have been achieved as of the end of the respective periods, vested and unvested options to purchase common stock and shares to be issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;), have been excluded from the computation of diluted net loss per share as the effect is antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in all periods presented&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,253,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,868,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,910,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and unvested options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,200,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,832,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,934,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP share purchase rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,480,922&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,727,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,865,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000383">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table represents the potential common shares issuable pursuant to outstanding securities as of the related period end dates that were excluded from the computation of diluted net loss per common share, as their inclusion would have an antidilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,253,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,868,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,910,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and unvested options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,200,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,832,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,934,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP share purchase rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,480,922&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,727,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,865,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">5253347</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000432"
      unitRef="U_xbrlishares">2868407</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="INF"
      id="F_000433"
      unitRef="U_xbrlishares">1910764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">9200337</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">7832386</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">6934262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000437"
      unitRef="U_xbrlishares">27238</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">26349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_atraEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlishares">20438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">14480922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">10727142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">8865464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000348">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Financial Instruments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government agency obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amounts classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000509"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000511"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts classified as short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government agency obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amounts classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(199,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(199,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts classified as short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;299,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;434,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing in one to five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the available-for-sale securities we hold, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that our investments were not significantly impacted. For all securities with a fair value less than its amortized cost basis, we determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. &lt;span style="color:#000000;"&gt;During the years ended &lt;/span&gt;December 31, 2021&lt;span style="color:#000000;"&gt;, 2020 and 2019, we did not recognize any impairment losses on our investments. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have elected the practical expedient to exclude the applicable accrued interest from both the fair value and the amortized cost basis of our available-for-sale securities for purposes of identifying and measuring an impairment. We present accrued interest receivable related to our available-for-sale securities in prepaid expenses and other current assets, separate from short-term investments on our consolidated balance sheet. As of December 31, 2021 and 2020, accrued interest receivable was $0.8 million and $0.7 million, respectively. Our accounting policy is to not measure an allowance for credit losses for accrued interest receivables and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. We have not written off any accrued interest receivables for the years ended December 31, 2021, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy. As of December 31, 2021 and 2020, restricted cash totaled $1.4 million. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106,084&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash - short-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000384">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the estimated fair value and related valuation input hierarchy of our available-for-sale securities as of each period end: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government agency obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(190&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amounts classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000509"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000511"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(104,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts classified as short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;264,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Input Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.6%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168,343&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Government agency obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,080&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amounts classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(199,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(199,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts classified as short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;299,959&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">89738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">89738000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">111832000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">111695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">21346000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">21323000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">99757000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">190000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">99573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">36993000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">36993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">10174000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20211231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">10150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">369840000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">376000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">369472000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <atra:CashEquivalentsAmortizedCost
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">104488000</atra:CashEquivalentsAmortizedCost>
    <atra:CashEquivalentsFairValue
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">104488000</atra:CashEquivalentsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">265352000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">376000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">264984000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">168343000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">168343000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">230239000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">113000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20201231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">230346000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">22537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesShorttermDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">22556000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">50080000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">166000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">50245000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">17990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">17990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">9860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">9865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">499049000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">311000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">499345000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <atra:CashEquivalentsAmortizedCost
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">199090000</atra:CashEquivalentsAmortizedCost>
    <atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">0</atra:CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">0</atra:CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <atra:CashEquivalentsFairValue
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">199090000</atra:CashEquivalentsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">299959000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">311000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">300255000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000385">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amortized cost and fair value of our available-for-sale securities by contractual maturity were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing within one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;434,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;435,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturing in one to five years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,221&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;369,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;499,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">278457000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">278354000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">434828000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">435023000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000517"
      unitRef="U_iso4217USD">91383000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">91118000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">64221000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">64322000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">369840000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">369472000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">499049000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">499345000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000527"
      unitRef="U_iso4217USD">800000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_0001604464_20201231"
      decimals="-5"
      id="F_000528"
      unitRef="U_iso4217USD">700000</us-gaap:InterestReceivable>
    <atra:WriteOffOfAccruedInterestReceivable
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000529"
      unitRef="U_iso4217USD">0</atra:WriteOffOfAccruedInterestReceivable>
    <atra:WriteOffOfAccruedInterestReceivable
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000530"
      unitRef="U_iso4217USD">0</atra:WriteOffOfAccruedInterestReceivable>
    <atra:WriteOffOfAccruedInterestReceivable
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000531"
      unitRef="U_iso4217USD">0</atra:WriteOffOfAccruedInterestReceivable>
    <us-gaap:RestrictedCash
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000532"
      unitRef="U_iso4217USD">1400000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001604464_20201231"
      decimals="-5"
      id="F_000533"
      unitRef="U_iso4217USD">1400000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000386">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets that sum to the total of the same such amounts in the consolidated statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106,084&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash - short-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">106084000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">200404000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">194000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">194000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">107478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">201798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000349">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Property and Equipment &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following as of each period end:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;879&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,676&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense was $9.3 million, $8.3 million and $7.1 million for the years ended December 31, 2021&lt;span style="color:#000000;"&gt;, 2020 and 2019&lt;/span&gt;, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000387">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following as of each period end:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,245&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;879&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,676&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">50142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">50132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">14060000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">8033000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20211231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">5228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">5023000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20211231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">4245000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraComputerEquipmentAndSoftwareMember_20201231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">4060000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">2518000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">2066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">6325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">879000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">82518000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">70193000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">28738000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">19676000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">53780000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">50517000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000560"
      unitRef="U_iso4217USD">9300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20200101_20201231"
      decimals="-5"
      id="F_000561"
      unitRef="U_iso4217USD">8300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001604464_20190101_20191231"
      decimals="-5"
      id="F_000562"
      unitRef="U_iso4217USD">7100000</us-gaap:DepreciationAndAmortization>
    <atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000350">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In-license and Manufacturing Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;MSK Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2015, we entered into an exclusive license agreement with MSK for three clinical stage T-cell therapies. &lt;span style="color:#000000;"&gt;We are required to make &lt;/span&gt;payments&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;to MSK based on achievement of specified regulatory and sales-related milestones, &lt;span style="color:#000000;"&gt;as well as &lt;/span&gt;mid-single-digit percentage tiered royalty payments based on&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;future sales of products resulting from the development of the licensed product candidates, if any. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;In addition, under certain circumstances, we are required to make certain minimum annual royalty payments to MSK, which are creditable against earned royalties owed for the same annual period. We are also required to pay a low double-digit percentage of any consideration we receive for sublicensing the licensed rights. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The license agreement expires on a product-by-product and country-by-country basis on the latest of: (i)&#160;expiration of the last licensed patent rights related to each licensed product, (ii)&#160;expiration of any market exclusivity period granted by law with respect to each licensed product, and (iii)&#160;a specified number of years after the first commercial sale of the licensed product in each country. Upon expiration of the license agreement, Atara will retain non-exclusive rights to the licensed products. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May and December 2018, we licensed additional technology from MSK.&#160;We are obligated to make additional milestone payments based on achievement of specified development, regulatory and sales-related milestones as well as mid-single-digit percentage tiered royalty payments based on future sales of products resulting from the development of the licensed product candidates, if any. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, we amended and restated our license agreement with MSK to: (i) terminate our license to certain rights related to WT1 and cytomegalovirus (&#x201c;CMV&#x201d;); and (ii) license additional know-how rights not otherwise covered by our existing agreements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;QIMR Berghofer Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer. Under the terms of the license agreement, we obtained an exclusive, worldwide license to develop and commercialize allogeneic T-cell therapy programs utilizing technology and know-how developed by QIMR Berghofer. In September 2016, the exclusive license agreement and research and development collaboration agreement were amended and restated. Under the amended and restated agreements, we obtained an exclusive, worldwide license to develop and commercialize additional T-cell programs, as well as the option to license additional technology that we exercised in June 2018. We further amended and restated our license agreement and research and development collaboration agreements with QIMR Berghofer in August 2019 to terminate our license to certain rights related to CMV and again in August 2020 to terminate our license to certain rights related to BK polyomavirus and JC polyomavirus. Our current license agreement also provides for various milestone and royalty payments to QIMR Berghofer based on future product sales, if any. Under the terms of our current research and development collaboration agreement, we are also required to reimburse the cost of agreed-upon development activities related to programs developed under the collaboration. These payments are expensed on a straight-line basis over the related development periods. The agreement also provides for various milestone payments to QIMR Berghofer based on achievement of certain developmental and regulatory milestones. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other In-license and Collaboration Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, we have entered into other license and collaboration agreements with other parties. For example, we licensed additional rights related to our MSK-partnered next-generation CAR T programs from MSK in May 2018 and we licensed rights related to our next-generation CAR T programs from Moffitt Cancer Center in August 2018, and we agreed to collaborate through sponsored research in connection with each of these licenses. We also licensed rights related to our MSK-partnered next-generation CAR T programs from the National Institutes of Health in December 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestones and royalties under each of the above agreements are contingent upon future events and will be recorded as expense when it is probable that the milestones will be achieved or royalties are due. As of December 31, 2021 and 2020, there were no outstanding obligations for milestones and royalties under our license and collaboration agreements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cognate Manufacturing Agreement&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&#x2013;&lt;span style="font-weight:normal;"&gt; In December 2019, we entered into a Commercial Manufacturing Services Agreement (the &#x201c;Manufacturing Agreement&#x201d;) with Cognate Bioservices, Inc. (&#x201c;Cognate&#x201d;). Pursuant to the Manufacturing Agreement, Cognate provides manufacturing services for certain of our product candidates. The initial term of the Manufacturing Agreement, as amended, runs until May 31, 2022. We may terminate the Manufacturing Agreement for convenience on six months&#x2019; written notice to Cognate, or immediately if Cognate is unable to perform the services under the Manufacturing Agreement or fails to obtain or maintain certain necessary approvals. &lt;/span&gt;&lt;/p&gt;</atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock>
    <atra:DueToLicensorsCurrentAndNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="0"
      id="F_000563"
      unitRef="U_iso4217USD">0</atra:DueToLicensorsCurrentAndNoncurrent>
    <atra:DueToLicensorsCurrentAndNoncurrent
      contextRef="C_0001604464_20201231"
      decimals="0"
      id="F_000564"
      unitRef="U_iso4217USD">0</atra:DueToLicensorsCurrentAndNoncurrent>
    <atra:OutLicenseAgreementsDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000351">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Out-license Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bayer Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Research, Development and License Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, we entered into the Bayer License Agreement to develop mesothelin-directed CAR T-cell therapies for the treatment of solid tumors, pursuant to which we granted to Bayer an exclusive, field-limited license under the applicable patents and know-how owned or controlled by us and our affiliates covering or related to ATA2271 and ATA3271 (the &#x201c;Licensed Products&#x201d;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Bayer License Agreement, we will be responsible at our cost for all mutually agreed preclinical and clinical activities for ATA2271 through the first in human Phase 1 clinical study in collaboration with MSK, following which Bayer will be responsible for the further development of ATA2271 at its cost. Bayer will be responsible for the development of ATA3271, except for certain mutually agreed preclinical, translational, manufacturing and supply chain activities to be performed by us relating to ATA3271, in each case at Bayer&#x2019;s cost. Bayer will also be solely responsible for commercializing the Licensed Products at its cost.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, we received an upfront cash payment of $45.0 million from Bayer for the exclusive license grant, net of applicable withholding taxes, which were fully recovered in August 2021, and an additional $15.0 million upfront reimbursement payment for certain research and process development activities to be performed by us. We are also entitled to receive (i) up to $5.0 million for additional, specified translational activities under the Bayer License Agreement, of which we have invoiced $1.3 million, and (ii) an aggregate of up to $610.0 million in milestone payments upon achieving certain development, regulatory and commercial milestones relating to the Licensed Products. In addition, we are eligible to receive from Bayer tiered royalties at percentages up to low double digits on worldwide net product sales of the Licensed Products on a country-by-country and product-by-product basis until the later of 12 years after the first commercial sale in such country or the expiration of specified patent rights in such country, subject to certain reductions and aggregate minimum floors. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bayer and we have formed a joint steering committee (&#x201c;JSC&#x201d;) that will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer License Agreement represent transactions with a customer. We concluded that the Bayer License Agreement contains the following promises: (i) a development and commercialization license; (ii) performance of early-stage research and development (&#x201c;R&amp;amp;D&#x201d;) services, including technology transfer services; (iii) JSC participation; and (iv) chemistry, manufacturing and control (&#x201c;CMC&#x201d;) services. In accordance with ASC 606, we determined that the license, early-stage R&amp;amp;D and CMC services were not distinct from each other, as the license, early-stage R&amp;amp;D and CMC services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;amp;D and CMC services. Accordingly, we determined that these promises should be combined into a single performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price at inception consisted of a $45.0 million upfront payment for the license, $15.0 million for certain research and process development activities and the $5.0 million for additional specified translational activities, and this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Technology Transfer Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, we entered into a Technology Transfer Agreement with Bayer (the &#x201c;Bayer Tech Transfer Agreement&#x201d;), which was contemplated as part of the Bayer License Agreement, to transfer to Bayer the ATA3271 manufacturing process being developed as part of the CMC services in the Bayer License Agreement. Upon entering into the agreement, we invoiced Bayer 20 percent&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;of the total fee of $15.3 million under the Bayer Tech Transfer Agreement, or $3.1 million, which we received in the second quarter of 2021 and invoiced 40 percent of the total fee, or $6.1 million, in January 2022. The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Bayer Tech Transfer Agreement represent transactions with a customer. We concluded that the Bayer Tech Transfer Agreement should be combined with the Bayer License Agreement and accounted for as a modification of that agreement and that the Bayer Tech Transfer Agreement contains the following promises: (i) technology transfer services and (ii) supply of materials required for the technology transfer services. In accordance with ASC 606, we determined that the technology transfer services and supply of materials required for the technology transfer services were not distinct from each other, as they are highly interdependent upon one another. In addition, we concluded that the technology transfer services and supply of materials required for the technology transfer services were highly interdependent with the license, early-stage R&amp;amp;D and CMC services identified in the Bayer License Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Bayer Tech Transfer Agreement, in order to evaluate the appropriate transaction price, we determined that the $15.3 million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Manufacturing and Supply Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, we entered into a Manufacturing and Supply Agreement with Bayer (the &#x201c;Bayer Manufacturing Agreement&#x201d;), which was contemplated as part of the Bayer License Agreement, to manufacture Phase 1 and 2 allogeneic mesothelin-directed CAR T-cell therapies for Bayer to use in clinical trials at a price based on our costs plus a reasonable margin, which is consistent with our standalone selling price. Under the Bayer Manufacturing Agreement, we will also provide storage and distribution services to Bayer at a price that is consistent with our standalone selling price for these services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entering into the Bayer Manufacturing Agreement, Bayer submitted, and we approved, a binding purchase order for manufacturing services and storage services. Any fees for the manufacturing services will be invoiced as follows: (i) 50 percent upon written acceptance by us of the binding purchase order, and (ii) the remainder upon delivery of the certification of analysis of such lots to Bayer. Storage and distribution services are billed monthly as those services are provided to Bayer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, we invoiced Bayer 50 percent of the total estimated supply price of $13.1 million for manufacturing services under the initial purchase order for the supply of six lots, or $6.6 million, which we received in the second quarter of 2021. The remainder of the supply price will be billed upon the release of the lots ordered by Bayer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the manufacturing and supply agreement represent transactions with a customer. We concluded that the Bayer Manufacturing Agreement contains the following promises: (i) manufacturing services; (ii) storage services provided on a month-to-month basis; and (iii) distribution services. In accordance with ASC 606, we determined that the manufacturing services for the initial purchase order of six lots, that are expected to be provided prior to completion of the technology transfer, are not distinct as they are highly interdependent on the manufacturing process being developed and transferred under the Bayer License Agreement and the Bayer Tech Transfer Agreement. Accordingly, we determined that these promises should be combined into a single performance obligation. We also determined that each of the other services were distinct and separate performance obligations. We determined that the initial binding order for the manufacture and supply of six lots should be combined with the Bayer License Agreement and accounted for as a modification of that agreement along with the Bayer Tech Transfer Agreement. We also concluded that a binding purchase order from Bayer, together with the Bayer Manufacturing Agreement, form the contract for manufacturing services and storage services and a shipping order from Bayer forms the contract for distribution services. We also determined that the storage services provided on a month-to-month basis and distribution services are distinct and separate performance obligations. All the performance obligations identified above are priced at their standalone selling price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Bayer Manufacturing Agreement, in order to evaluate the appropriate transaction price, we determined that the $13.1 million fee constituted the entire consideration to be included in the transaction price, and this amount was allocated to the single performance obligation as identified under the Bayer License Agreement. Revenue for the manufacturing services for the initial six lots will be recognized based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. Revenue for the storage services will be recognized over time as those services are provided. Revenue for the distribution services will be recognized at a point in time when the product is delivered to a clinical site designated by Bayer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Bayer Revenue Recognition&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a cost-based input method to recognize revenue based on the amount of actual costs incurred relative to the total budgeted costs expected to be incurred for the combined performance obligation. For the year ended December 31, 2021, we recognized license and collaboration revenue of $19.8 million under the Bayer License Agreement, Bayer Tech Transfer Agreement and Bayer Manufacturing Agreement, collectively, the Bayer Agreements. We did not recognize any license and collaboration revenue in 2020 under Bayer License Agreement. Deferred revenue related to the Bayer Agreements aggregated to $51.5 million and $61.3 million as of December 31, 2021 and 2020, respectively. Of the $51.5 million of deferred revenue as of December 31, 2021, $40.8 million is included in current liabilities and $10.7 million is included in long-term liabilities. This revenue is expected to be recognized over approximately the next three years. No development or sales-based milestone payments have been earned or received through December 31, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pierre Fabre Commercialization Agreement&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2021, we entered into the Pierre Fabre Commercialization Agreement, pursuant to which, we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia (the &#x201c;Territory&#x201d;) following regulatory approval. Atara will retain full rights to tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; in other major markets, including North America, Asia Pacific and Latin America. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are responsible at our cost for the conclusion of the ongoing Phase 3 ALLELE clinical study and the Phase 2 multi-cohort clinical study. We will also be responsible at our cost for certain other activities directed to obtaining regulatory approval for tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; for EBV-positive lymphoproliferative disease pursuant to the terms of the Pierre Fabre Commercialization Agreement in Europe and the UK. Pierre Fabre will be responsible at its cost for obtaining and maintaining all other regulatory approvals and for commercialization and distribution of tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; in the Territory. We will own any intellectual property rights developed solely by us under the Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pierre Fabre paid us an upfront cash payment of $45.0 million for the exclusive license grant in October 2021. We are also entitled to receive an aggregate of up to $318.0 million in milestone payments upon achieving certain regulatory and commercial milestones. In addition, we are eligible to receive double-digit tiered royalties as a percentage of net sales of tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; until the later of 12 years after the first commercial sale in such country, the expiration of specified patent rights, or the expiration of all regulatory exclusivity for such product on a country-by-country basis. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We will negotiate a separate manufacturing and supply agreement with Pierre Fabre for us to manufacture tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; for Pierre Fabre to use in the Territory based on a fixed price until January 1, 2024 and cost plus a margin post January 1, 2024. We are responsible for manufacturing and supplying Pierre Fabre with tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; for commercialization in the Territory at Pierre Fabre&#x2019;s cost for a minimum of seven years. Following this period, we have the option to transfer the related manufacturing technology to Pierre Fabre. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are also responsible for cell selection services at our cost until January 1, 2024 unless the parties agree to transfer the related cell selection technology to Pierre Fabre prior to this date. From January 1, 2024 onwards, if we agree to continue to provide cell selection services, it shall be at the sole expense of Pierre Fabre. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pierre Fabre and we have formed a joint steering committee (&#x201c;JSC&#x201d;) that will provide oversight, decision making and implementation guidance regarding the commercialization activities covered under the agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We assessed this arrangement in accordance with ASC 606 and concluded that the promises in the Pierre Fabre Commercialization Agreement represent transactions with a customer. We concluded that the Pierre Fabre Commercialization Agreement includes transfer of intellectual property rights in the form of a license, the potential to manufacture and supply tab-cel&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt; for a minimum of seven years and until tech transfer, the potential to perform cell-selection services for a minimum of three years and until tech transfer, and obligation to participate in the JSC. We concluded that the promises are not distinct because Pierre Fabre cannot benefit from the license without the other services and vis versa. Consequently, the license, manufacture and supply, cell selection and participation in the JSC is a single performance obligation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Pierre Fabre Commercialization Agreement, in order to evaluate the appropriate transaction price, we determined that the $45 million upfront payment, constituted the entire consideration to be included in the transaction price at the outset of the arrangement. Revenue associated with the upfront fee for the single performance obligation will be deferred until the initial delivery of services related to the manufacture and supply and cell selection and then recognized over the contract performance period&#x200b;. We did not recognize any of the $45.0 million upfront payment as revenue in 2021. All of the $45.0 million of deferred revenue as of December 31, 2021 is included in long-term liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The potential development and commercial milestone payments that we are eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement. None of the future royalty and sales-based milestone payments were included in the transaction price, as the potential payments represent sales-based consideration. We will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust our estimate of the transaction price. No development or commercial milestone payments have been earned or received through December 31, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</atra:OutLicenseAgreementsDisclosureTextBlock>
    <atra:UpfrontCashPaymentReceived
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000565"
      unitRef="U_iso4217USD">45000000.0</atra:UpfrontCashPaymentReceived>
    <atra:AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000566"
      unitRef="U_iso4217USD">15000000.0</atra:AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment>
    <atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231"
      decimals="INF"
      id="F_000567"
      unitRef="U_iso4217USD">5000000.0</atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities>
    <atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000568"
      unitRef="U_iso4217USD">1300000</atra:AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount>
    <atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201231"
      decimals="INF"
      id="F_000569"
      unitRef="U_iso4217USD">610000000.0</atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones>
    <atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      id="F_000570">P12Y</atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale>
    <atra:DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000571"
      unitRef="U_iso4217USD">45000000.0</atra:DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice>
    <atra:DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000572"
      unitRef="U_iso4217USD">15000000.0</atra:DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice>
    <atra:DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20201201_20201231"
      decimals="INF"
      id="F_000573"
      unitRef="U_iso4217USD">5000000.0</atra:DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice>
    <atra:LicenseAgreementPercentage
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331"
      decimals="2"
      id="F_000574"
      unitRef="U_xbrlipure">0.20</atra:LicenseAgreementPercentage>
    <atra:LicenseAgreementTotalFee
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">15300000</atra:LicenseAgreementTotalFee>
    <atra:LicenseAgreementAmount
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210301_20210331"
      decimals="-5"
      id="F_000576"
      unitRef="U_iso4217USD">3100000</atra:LicenseAgreementAmount>
    <atra:LicenseAgreementPercentage
      contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131"
      decimals="2"
      id="F_000575"
      unitRef="U_xbrlipure">0.40</atra:LicenseAgreementPercentage>
    <atra:LicenseAgreementAmount
      contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20220101_20220131"
      decimals="-5"
      id="F_000577"
      unitRef="U_iso4217USD">6100000</atra:LicenseAgreementAmount>
    <atra:TechnologyTransferAgreementsFeeRemainder
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231"
      id="F_000579">The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion</atra:TechnologyTransferAgreementsFeeRemainder>
    <atra:TransactionFeePrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000580"
      unitRef="U_iso4217USD">15300000</atra:TransactionFeePrice>
    <atra:WrittenAcceptanceOfBindingPurchaseOrderPercentage
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20211231"
      decimals="2"
      id="F_000581"
      unitRef="U_xbrlipure">0.50</atra:WrittenAcceptanceOfBindingPurchaseOrderPercentage>
    <atra:LicenseAgreementPercentage
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331"
      decimals="2"
      id="F_000582"
      unitRef="U_xbrlipure">0.50</atra:LicenseAgreementPercentage>
    <us-gaap:ManufacturingCosts
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331"
      decimals="-5"
      id="F_000583"
      unitRef="U_iso4217USD">13100000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraBayerManufacturingAgreementMember_20210301_20210331"
      decimals="-5"
      id="F_000584"
      unitRef="U_iso4217USD">6600000</us-gaap:ManufacturingCosts>
    <atra:DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000585"
      unitRef="U_iso4217USD">13100000</atra:DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000586"
      unitRef="U_iso4217USD">19800000</atra:LicenseAndCollaborationRevenue>
    <atra:LicenseAndCollaborationRevenue
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000587"
      unitRef="U_iso4217USD">0</atra:LicenseAndCollaborationRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20211231"
      decimals="-5"
      id="F_000588"
      unitRef="U_iso4217USD">51500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember_20201231"
      decimals="-5"
      id="F_000589"
      unitRef="U_iso4217USD">61300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000590"
      unitRef="U_iso4217USD">51500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000591"
      unitRef="U_iso4217USD">40800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000592"
      unitRef="U_iso4217USD">10700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231"
      id="F_000594">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraBayerLicenseAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000593"
      unitRef="U_iso4217USD">0</atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived>
    <atra:UpfrontCashPaymentReceived
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031"
      decimals="-5"
      id="F_000595"
      unitRef="U_iso4217USD">45000000.0</atra:UpfrontCashPaymentReceived>
    <atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211031"
      decimals="INF"
      id="F_000596"
      unitRef="U_iso4217USD">318000000.0</atra:AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones>
    <atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031"
      id="F_000597">P12Y</atra:RoyaltyEligibleToReceiveTermAfterFirstCommercialSale>
    <atra:YearsOfManufacturingAndSupplyingCost contextRef="C_0001604464_20210101_20211231" id="F_000598">P7Y</atra:YearsOfManufacturingAndSupplyingCost>
    <atra:YearsOfPotentialToManufacturingAndSupply
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231"
      id="F_000599">P7Y</atra:YearsOfPotentialToManufacturingAndSupply>
    <atra:YearsOfPotentialToPerformCellSelectionServices
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231"
      id="F_000600">P3Y</atra:YearsOfPotentialToPerformCellSelectionServices>
    <atra:DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031"
      decimals="-6"
      id="F_000601"
      unitRef="U_iso4217USD">45000000</atra:DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice>
    <atra:UpfrontPaymentRecognized
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000602"
      unitRef="U_iso4217USD">0</atra:UpfrontPaymentRecognized>
    <atra:UpfrontCashPaymentReceived
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211001_20211031"
      decimals="-5"
      id="F_000603"
      unitRef="U_iso4217USD">45000000.0</atra:UpfrontCashPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001604464_us-gaapBalanceSheetLocationAxis_atraLongTermLiabilitiesMember_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20211231"
      decimals="-5"
      id="F_000604"
      unitRef="U_iso4217USD">45000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived
      contextRef="C_0001604464_us-gaapTypeOfArrangementAxis_atraPierreFabreCommercializationAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000605"
      unitRef="U_iso4217USD">0</atra:DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived>
    <atra:LeasesDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000352">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We lease our corporate headquarters in South San Francisco, California under a non-cancellable lease agreement. In December 2021, we entered into a second amendment with the landlord to extend the lease term through &lt;span style="-sec-ix-hidden:F_000606"&gt;May 2025&lt;/span&gt;. The amended lease agreement does not include an option to extend the lease term. In connection with the amended lease, we are required to maintain a letter of credit in the amount of $0.1 million to the landlord, a decrease of $0.1 million from the prior lease agreement, and which expires and is renewed every 12 months, and is classified as restricted cash in our consolidated balance sheet. As of December 31, 2021, we were still working to update our letter of credit and continued to report an amount of $0.2 million as restricted cash related to this letter of credit on our consolidated balance sheet. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;I&lt;span style="letter-spacing:-0.2pt;"&gt;n March 2021, we entered into a new lease agreement for approximately 33,659 square feet of office, lab and warehouse space in Thousand Oaks, California. &lt;/span&gt;During the third quarter of 2021, the initial 10.5-year lease term commenced, upon substantial completion of the landlord&#x2019;s work as defined under the agreement. The contractual obligations during the initial lease term are $21.0 million in aggregate. Base rent is subject to annual increase of 3% with each annual anniversary of the rent commencement date.&lt;span style="letter-spacing:-0.2pt;"&gt; We have the option to extend this lease for two additional &lt;span style="-sec-ix-hidden:F_000616"&gt;five-year&lt;/span&gt; periods after the initial term.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2017, we entered into a lease agreement for approximately 90,580 square feet of office, lab and cellular therapy manufacturing space in Thousand Oaks, California. The initial 15-year term of the lease commenced on February 15, 2018, upon the substantial completion of landlord&#x2019;s work as defined under the agreement. The contractual obligations during the initial term are $16.4 million in aggregate. We have the option to extend the lease for two additional periods of ten and nine years, respectively, after the initial term. In connection with the lease, we were required to issue a letter of credit in the amount of $1.2 million to the landlord, which is recorded as long-term restricted cash in our consolidated balance sheet. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, we entered into a lease agreement for additional office space in Thousand Oaks, California that expires in &lt;span style="-sec-ix-hidden:F_000624"&gt;February 2026&lt;/span&gt; and for which we have the option to extend the lease for an additional period of five years after the initial term. Additionally, in 2021, we entered into an amended lease agreement for our office and lab space in Aurora, Colorado, to add additional lab space. Incremental contractual obligations under the lease amendment are $0.2 million, and the lease term continues to expire in &lt;span style="-sec-ix-hidden:F_000628"&gt;April 2024&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturities of lease liabilities under our operating and finance leases as of December 31, 2021 were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,806&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to leases was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands,&#160;except lease&#160;term&#160;and discount rate)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental Cash Flows Information&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;486&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;281&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash increase to operating lease assets due to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;remeasurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;639&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000693"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Remaining Lease Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.4 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Discount Rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset Retirement Obligation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s ARO consists of a contractual requirement to remove the tenant improvements at our manufacturing facility in Thousand Oaks, California and restore the facility to a condition specified in the lease agreement. The Company records an estimate of the fair value of its ARO in long-term liabilities in the period incurred. The fair value of the ARO is also capitalized in property and equipment, net and depreciated over the lease term. The fair value of our ARO was estimated by discounting projected cash flows over the estimated life of the related assets using our credit adjusted risk-free rate. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the activity for our ARO liabilities:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARO Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</atra:LeasesDisclosureTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">100000</us-gaap:RestrictedCashAndCashEquivalents>
    <atra:LetterOfCreditDecreaseFromPriorLeaseAgreement
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231"
      decimals="-5"
      id="F_000609"
      unitRef="U_iso4217USD">100000</atra:LetterOfCreditDecreaseFromPriorLeaseAgreement>
    <atra:LetterOfCreditRenewalTerm
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20210101_20211231"
      id="F_000608">P12M</atra:LetterOfCreditRenewalTerm>
    <atra:RestrictedCashRelatedToLetterOfCredit
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231"
      decimals="-5"
      id="F_000610"
      unitRef="U_iso4217USD">200000</atra:RestrictedCashRelatedToLetterOfCredit>
    <atra:LeaseAgreementAreaOfOfficeLabAndWarehouseSpace
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331"
      decimals="0"
      id="F_000611"
      unitRef="U_utrsqft">33659</atra:LeaseAgreementAreaOfOfficeLabAndWarehouseSpace>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331"
      id="F_000612">P10Y6M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:ContractualObligation
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331"
      decimals="-5"
      id="F_000613"
      unitRef="U_iso4217USD">21000000.0</us-gaap:ContractualObligation>
    <atra:LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20210331"
      decimals="2"
      id="F_000614"
      unitRef="U_xbrlipure">0.03</atra:LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent>
    <atra:LeaseAgreementAreaOfOfficeLabAndManufacturingSpace
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215"
      decimals="0"
      id="F_000617"
      unitRef="U_utrsqft">90580</atra:LeaseAgreementAreaOfOfficeLabAndManufacturingSpace>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215"
      id="F_000619">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <atra:LeaseCommencementDate
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215"
      id="F_000618">2018-02-15</atra:LeaseCommencementDate>
    <us-gaap:ContractualObligation
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180215"
      decimals="-5"
      id="F_000620"
      unitRef="U_iso4217USD">16400000</us-gaap:ContractualObligation>
    <atra:LeaseAgreementRenewalTermOptionTwo
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_20180214_20180215"
      id="F_000622">P9Y</atra:LeaseAgreementRenewalTermOptionTwo>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20180215"
      decimals="-5"
      id="F_000623"
      unitRef="U_iso4217USD">1200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231"
      id="F_000626">we have the option to extend the lease for an additional period of five years after the initial term.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <atra:LeaseOptionToExtendAdditionalTerm
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraThousandOaksCaliforniaMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_atraOfficeSpaceMember_20210101_20211231"
      id="F_000627">P5Y</atra:LeaseOptionToExtendAdditionalTerm>
    <atra:IncrementalContractualObligationsUnderLeaseAmendment
      contextRef="C_0001604464_srtStatementGeographicalAxis_atraAuroraColoradoMember_20210101_20211231"
      decimals="-5"
      id="F_000629"
      unitRef="U_iso4217USD">200000</atra:IncrementalContractualObligationsUnderLeaseAmendment>
    <atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000388">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturities of lease liabilities under our operating and finance leases as of December 31, 2021 were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,806&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,004&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: amount representing interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">5171000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000644"
      unitRef="U_iso4217USD">181000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">5265000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000645"
      unitRef="U_iso4217USD">29000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">5183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000646"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000633"
      unitRef="U_iso4217USD">4806000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000647"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000634"
      unitRef="U_iso4217USD">3257000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000648"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000635"
      unitRef="U_iso4217USD">19004000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000649"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000636"
      unitRef="U_iso4217USD">42686000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000650"
      unitRef="U_iso4217USD">210000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000637"
      unitRef="U_iso4217USD">14586000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000651"
      unitRef="U_iso4217USD">10000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000638"
      unitRef="U_iso4217USD">28100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000652"
      unitRef="U_iso4217USD">200000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000639"
      unitRef="U_iso4217USD">2582000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">171000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000641"
      unitRef="U_iso4217USD">25518000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000655"
      unitRef="U_iso4217USD">29000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000643"
      unitRef="U_iso4217USD">28100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">200000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000389">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease cost were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;836&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">3827000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">3020000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">2578000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">836000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">987000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">770000</us-gaap:ShortTermLeaseCost>
    <atra:OperatingLeaseCostIncludingShortTermLease
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">4663000</atra:OperatingLeaseCostIncludingShortTermLease>
    <atra:OperatingLeaseCostIncludingShortTermLease
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">4007000</atra:OperatingLeaseCostIncludingShortTermLease>
    <atra:OperatingLeaseCostIncludingShortTermLease
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">3348000</atra:OperatingLeaseCostIncludingShortTermLease>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">244000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">389000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">324000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">29000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">60000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">56000</us-gaap:FinanceLeaseInterestExpense>
    <atra:FinanceLeaseCost
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">273000</atra:FinanceLeaseCost>
    <atra:FinanceLeaseCost
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">449000</atra:FinanceLeaseCost>
    <atra:FinanceLeaseCost
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">380000</atra:FinanceLeaseCost>
    <atra:SummaryOfOtherInformationRelatedToLeasesTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000390">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information related to leases was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands,&#160;except lease&#160;term&#160;and discount rate)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental Cash Flows Information&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows for finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;486&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;281&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-cash increase to operating lease assets due to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;remeasurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;639&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000693"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Remaining Lease Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.4 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Discount Rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</atra:SummaryOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">3738000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">2878000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">2346000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">32000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">62000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">50000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">254000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">389000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">486000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">13427000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">838000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">281000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">323000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">1760000</atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities>
    <atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">639000</atra:NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20211231" id="F_000694">P9Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20201231" id="F_000695">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20191231" id="F_000696">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20211231" id="F_000697">P1Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20201231" id="F_000698">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001604464_20191231" id="F_000699">P2Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20211231"
      decimals="3"
      id="F_000700"
      unitRef="U_xbrlipure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20201231"
      decimals="3"
      id="F_000701"
      unitRef="U_xbrlipure">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20191231"
      decimals="3"
      id="F_000702"
      unitRef="U_xbrlipure">0.104</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20211231"
      decimals="3"
      id="F_000703"
      unitRef="U_xbrlipure">0.097</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20201231"
      decimals="3"
      id="F_000704"
      unitRef="U_xbrlipure">0.097</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001604464_20191231"
      decimals="3"
      id="F_000705"
      unitRef="U_xbrlipure">0.100</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000391">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the activity for our ARO liabilities:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ARO Liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock>
    <us-gaap:AssetRetirementObligation
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">866000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligationAccretionExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">87000</us-gaap:AssetRetirementObligationAccretionExpense>
    <us-gaap:AssetRetirementObligation
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">953000</us-gaap:AssetRetirementObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000353">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potential payments related to our license and collaboration agreements, including milestone and royalty payments, are detailed in Note 6.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Research and Development Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We may enter into contracts in the normal course of business with clinical research organizations &lt;span style="color:#000000;"&gt;for clinical trials, with contract manufacturing &lt;/span&gt;organizations for &lt;span style="color:#000000;"&gt;clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination on &lt;/span&gt;notice. As of December 31, 2021 and 2020, there were no amounts accrued related to termination charges for minimum purchase volumes not being met. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indemnification Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for indemnification for certain liabilities. The exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations. We also have indemnification obligations to our directors and executive officers for specified events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date and we consider the fair value of these indemnification agreements to be minimal. Accordingly, we did not record liabilities for these agreements as of December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business or otherwise. The ultimate outcome of any litigation is uncertain and unfavorable outcomes could have a negative impact on our results of operations and financial condition. Regardless of outcome, litigation can have an adverse impact on us because of the defense costs, diversion of management resources and other factors. We are not currently involved in any material legal proceedings.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atra:AccruedTerminationCharges
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000709"
      unitRef="U_iso4217USD">0</atra:AccruedTerminationCharges>
    <atra:AccruedTerminationCharges
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000710"
      unitRef="U_iso4217USD">0</atra:AccruedTerminationCharges>
    <atra:LiabilitiesRelatedToIndemnificationAgreements
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000711"
      unitRef="U_iso4217USD">0</atra:LiabilitiesRelatedToIndemnificationAgreements>
    <atra:LiabilitiesRelatedToIndemnificationAgreements
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000712"
      unitRef="U_iso4217USD">0</atra:LiabilitiesRelatedToIndemnificationAgreements>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000354">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our authorized capital stock consists of 520,000,000 shares, all with a par value of $0.0001 per share, of which 500,000,000 shares are designated as common stock and 20,000,000 shares are designated as preferred stock. &lt;span style="color:#000000;"&gt;There were no shares of preferred stock outstanding as of &lt;/span&gt;December 31, 2021 and 2020&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity Offerings&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, we issued and sold 6,871,727 shares of common stock at a public offering price of $15.28 per share and pre-funded warrants to purchase 2,945,026 shares of common stock at an offering price of $15.2799 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this offering were $150.0 million, resulting in aggregate net proceeds of $140.7 million, after deducting underwriting discounts and commissions and offering expenses payable by us.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each pre-funded warrant entitles the holder to purchase one share of common stock at an exercise price of $0.0001 per share and expires seven years from the date of issuance. These warrants were recorded as a component of stockholders&#x2019; equity within additional paid-in capital. Per the terms of the warrant agreement, a holder of the outstanding warrants is not entitled to exercise any portion of any pre-funded warrant if, upon exercise of the warrant, the holder&#x2019;s ownership (together with its affiliates) of our common stock or combined voting power of our securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% after giving effect to the exercise (&#x201c;Maximum Ownership Percentage&#x201d;). Upon at least 61 days&#x2019; prior notice to us by the holder, any holder may increase or decrease the Maximum Ownership Percentage to any other percentage not to exceed 19.99%. As of December 31, 2021, 2,888,526 of the pre-funded warrants from the July 2019 offering were outstanding.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the second quarter of 2020, we issued and sold 12,633,039 shares of common stock at a public offering price of $11.32 per share and pre-funded warrants to purchase 2,866,961 shares of common stock at a public offering price of $11.3199 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. We granted the underwriters an option to purchase up to 2,325,000 additional shares of our common stock at a public offering price of $11.32, less underwriting discounts and commissions. The full option was exercised by the underwriters in June 2020. The gross proceeds from this public offering were $201.8 million, resulting in net proceeds of $189.3 million, after deducting underwriting discounts and commissions and offering expenses payable by us. The terms of the pre-funded warrants issued and sold as part of this public offering were similar to those above.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, we issued and sold 5,102,041 shares of common stock at a public offering price of $24.50 per share and pre-funded warrants to purchase 2,040,816 shares of common stock at a public offering price of $24.4999 per warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. The gross proceeds from this public offering were $175.0 million, resulting in net proceeds of $164.3 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, all of the pre-funded warrants issued and sold as part of the 2020 underwritten public offerings were outstanding.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;ATM Facilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, we entered into a sales agreement (the &#x201c;2019 ATM Facility&#x201d;) with Cowen, which provided for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent.&lt;span style="color:#000000;"&gt; &lt;/span&gt;We paid a commission of up to 3.0% of gross sales proceeds of the common stock sold under the 2019 ATM Facility.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, we entered into a sales agreement (the &#x201c;2020 ATM Facility&#x201d;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2020 ATM Facility is separate from and did not replace the 2019 ATM Facility in any way. We paid a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2020 ATM Facility. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, we entered into a sales agreement (the &#x201c;2021 ATM Facility&#x201d;) with Cowen, which provides for the sale, in our sole discretion, of shares of our common stock having an aggregate offering price of up to $100.0 million through Cowen, as our sales agent. The 2021 ATM Facility is separate from and does not replace the 2020 ATM Facility in any way. We pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the 2021 ATM Facility. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fiscal year ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2020&lt;/span&gt;, we sold an aggregate of 4,785,514 shares of common stock under the ATM facilities, at an average price of $14.60 per share, for gross proceeds of $69.9 million and net proceeds of $68.0 million, after deducting commissions and other offering expenses payable by us. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fiscal year ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, we sold an aggregate of 6,240,601 shares of common stock under the ATM facilities, at an average price of $16.23 per share, for gross proceeds of $101.3 million and net proceeds of $98.9 million, after deducting commissions and other offering expenses payable by us. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="color:#FF0000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;issuance and sale of these shares by us pursuant to the ATM facilities are deemed &#x201c;at the market&#x201d; offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and are registered under the Securities Act. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, we had&lt;span style="color:#000000;"&gt; fully utilized the 2019 ATM Facility, and the 2020 ATM Facility and we had&lt;/span&gt; $78.3 million of common stock &lt;span style="color:#000000;"&gt;remaining and available to be sold under the 2021 ATM Facility. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From January 1, 2022 through February 15, 2022, we sold an additional 1,319,878 shares of common stock under the 2021 ATM Facility, at an average price of $15.88 per share, for gross proceeds of $21.0 million and net proceeds of $20.5 million, after deducting commissions and other offering expenses payable by us. As of February 15, 2022, we had $57.4 million of common stock remaining and available to be sold under the 2021 ATM Facility, subject to certain conditions as specified in the agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, we adopted the 2014 Equity Incentive Plan (&#x201c;2014 EIP&#x201d;), which was amended and restated on October 15, 2014 upon the pricing of our initial public offering (&#x201c;IPO&#x201d;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2014 EIP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to five percent of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a lesser number of shares as determined by our board of directors. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the 2014 EIP, we may grant stock options, RSAs and RSUs to employees, directors, consultants and other service providers.&#160;RSUs generally vest over four years. In 2020, we granted performance-based awards to certain of our employees that provide for the issuance of common stock if specified Company performance criteria related to our clinical programs are achieved. The number of performance-based awards that ultimately vests depends upon if, when and which performance criteria are achieved, as well as the employee&#x2019;s continuous service, as defined in the 2014 EIP, through the date of vesting. The fair value of RSUs, including those with performance conditions, is determined as the closing stock price on the date of grant. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options are granted with exercise prices at no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. The estimated fair value is generally equal to the closing market price of the Company&#x2019;s common stock on the measurement date. Options granted generally vest over four years and expire in seven to ten years. As of December 31, 2021, a total of 16,086,987 shares of common stock were reserved for issuance under the 2014 EIP, of which 4,018,597 shares were available for future grant and 12,068,390 shares were subject to outstanding options and RSUs, including performance-based awards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, we adopted the 2018 Inducement Plan (&#x201c;Inducement Plan&#x201d;), under which we may grant options, stock appreciation rights, RSAs and RSUs to new employees.&#160;In September 2020, we amended the Inducement Plan to reserve an additional 1,500,000 shares of the Company&#x2019;s common stock for issuance under the Inducement Plan, and in September 2021 we made a further amendment to reserve an additional 1,500,000 shares of the Company&#x2019;s common stock for issuance under the Inducement Plan. As of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 4,022,184 shares of common stock were reserved for issuance under the Inducement Plan, of which 1,278,379 shares were available for future grant and 2,743,805 shares were subject to outstanding options and RSUs.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value of RSUs granted during the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 2020 and 2019 was $16.42, $12.19 and $27.04, respectively. The estimated fair value of RSUs that vested in the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 2020 and 2019 was $27.1 million, $23.6 million and $13.8 million, respectively. As of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, there was $75.7 million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 2.8 years. This excludes unrecognized stock-based compensation expense for performance-based RSUs that were deemed not probable of vesting in accordance with U.S. GAAP. The aggregate intrinsic value of the RSUs outstanding as of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt; was $88.1&#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,829,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,624,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,307,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,553,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,592,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under our RSU settlement procedures, for some of the RSUs granted to our employees, we withhold shares at settlement to cover the estimated payroll withholding tax obligations.&#160;During 2021, we settled 1,553,893 shares underlying RSUs, of which 154,341 shares underlying RSUs were net settled by withholding 61,385 shares.&#160;The value of the shares underlying RSUs withheld was $1.2 million, based on the closing price of our common stock on the settlement date. During 2020, we settled 1,218,945 shares underlying RSUs, of which 276,822 shares underlying RSUs were net settled by withholding 106,459 shares.&#160;The value of the shares underlying RSUs withheld was $1.5 million, based on the closing price of our common stock on the settlement date.&#160;The value of RSUs withheld in each period was remitted to the appropriate taxing authorities and has been reflected as a financing activity in our consolidated statements of cash flows. &lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Average Exercise&#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,851,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000826"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,643,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,028,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,219,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000827"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,219,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000828"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,073,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000829"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt; and the exercise price of outstanding, in-the-money options. As of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, there was $41.9 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 2.5 years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options for 246,867, 268,938 and 347,716 shares of our common stock were exercised during the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 2020 and 2019, with an intrinsic value of $0.8 million, $1.0 million and $3.8 million, respectively. As we believe it is more likely than not that no stock option related tax benefits will be realized, we do not record any net tax benefits related to exercised options.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each option issued was estimated at the date of grant using the Black-Scholes valuation model. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model and resulting weighted-average grant date fair values of stock options granted during the periods indicated: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assumptions:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000843"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000844"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000845"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average estimated grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,643,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,641,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,535,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total estimated grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,808,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,023,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,790,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated fair value of stock options that vested in the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 2020 and 2019 was $26.6 million, $29.4 million and $31.6 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, we adopted the 2014 Employee Stock Purchase Plan (&#x201c;2014 ESPP&#x201d;), which became effective on October 15, 2014 upon the pricing of our IPO. The 2014 ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Eligible employees can purchase shares of the Company&#x2019;s common stock at 85% of the lower of the fair market value of the common stock at (i) the beginning of a 12-month offering period, or (ii) at the end of one of the two related 6-month purchase periods. No participant in the 2014 ESPP may purchase shares of common stock valued at more than $25,000 per calendar year. The first offering under the 2014 ESPP commenced on June 1, 2016, and subsequent offerings commence on each anniversary of this date. The Company recorded $1.7 million, $1.8 million and $1.3 million of expense related to the 2014 ESPP in the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021,&lt;/span&gt; 2020 and 2019, respectively. A total of 319,190, 282,514 and 139,466 shares were purchased under the ESPP during the years ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, there was $0.6 million of unrecognized stock-based compensation expense related to the ESPP that is expected to be recognized by the end of second quarter of 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2014 ESPP provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with 2015 and ending in 2024, equal to the lower of (i) one percent of the number of shares of our common stock outstanding as of such date, (ii) 230,769 shares of our common stock, or (iii) a lesser number of shares as determined by our board of directors. As of December 31, 2021, there were 1,817,511 shares authorized under the 2014 ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserved Shares&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following shares of common stock were reserved for future issuance under our equity incentive plans as of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Shares Reserved&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,086,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 Inducement Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,022,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;862,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total reserved shares of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,971,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense related to all stock awards was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,063&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,802&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000713"
      unitRef="U_xbrlishares">520000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000714"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000716"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000715"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000717"
      unitRef="U_xbrlishares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000718"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001604464_20201231"
      decimals="INF"
      id="F_000719"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731"
      decimals="INF"
      id="F_000720"
      unitRef="U_xbrlishares">6871727</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731"
      decimals="INF"
      id="F_000721"
      unitRef="U_iso4217USD_xbrlishares">15.28</us-gaap:SharesIssuedPricePerShare>
    <atra:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731"
      decimals="INF"
      id="F_000722"
      unitRef="U_xbrlishares">2945026</atra:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <atra:ClassOfWarrantOrRightPricePerShare
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731"
      decimals="INF"
      id="F_000723"
      unitRef="U_iso4217USD_xbrlishares">15.2799</atra:ClassOfWarrantOrRightPricePerShare>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731"
      decimals="-5"
      id="F_000724"
      unitRef="U_iso4217USD">150000000.0</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190731_20190731"
      decimals="-5"
      id="F_000725"
      unitRef="U_iso4217USD">140700000</atra:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718"
      decimals="INF"
      id="F_000726"
      unitRef="U_xbrlishares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718"
      decimals="INF"
      id="F_000727"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <atra:ClassOfWarrantOrRightTerm
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718"
      id="F_000728">P7Y</atra:ClassOfWarrantOrRightTerm>
    <atra:MaximumOwnershipPercentage
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718"
      decimals="4"
      id="F_000729"
      unitRef="U_xbrlipure">0.0999</atra:MaximumOwnershipPercentage>
    <atra:PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718"
      id="F_000731">P61D</atra:PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage>
    <atra:MaximumOwnershipPercentage
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20190718_20190718"
      decimals="4"
      id="F_000730"
      unitRef="U_xbrlipure">0.1999</atra:MaximumOwnershipPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20211231"
      decimals="INF"
      id="F_000732"
      unitRef="U_xbrlishares">2888526</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630"
      decimals="INF"
      id="F_000733"
      unitRef="U_xbrlishares">12633039</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630"
      decimals="2"
      id="F_000734"
      unitRef="U_iso4217USD_xbrlishares">11.32</us-gaap:SharesIssuedPricePerShare>
    <atra:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630"
      decimals="INF"
      id="F_000735"
      unitRef="U_xbrlishares">2866961</atra:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <atra:ClassOfWarrantOrRightPricePerShare
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630"
      decimals="4"
      id="F_000736"
      unitRef="U_iso4217USD_xbrlishares">11.3199</atra:ClassOfWarrantOrRightPricePerShare>
    <atra:StockIssuedDuringPeriodAdditionalSharesNewIssues
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630"
      decimals="INF"
      id="F_000737"
      unitRef="U_xbrlishares">2325000</atra:StockIssuedDuringPeriodAdditionalSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200630"
      decimals="2"
      id="F_000738"
      unitRef="U_iso4217USD_xbrlishares">11.32</us-gaap:SharePrice>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630"
      decimals="-5"
      id="F_000739"
      unitRef="U_iso4217USD">201800000</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200401_20200630"
      decimals="-5"
      id="F_000740"
      unitRef="U_iso4217USD">189300000</atra:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231"
      decimals="INF"
      id="F_000741"
      unitRef="U_xbrlishares">5102041</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231"
      decimals="2"
      id="F_000742"
      unitRef="U_iso4217USD_xbrlishares">24.50</us-gaap:SharesIssuedPricePerShare>
    <atra:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231"
      decimals="INF"
      id="F_000743"
      unitRef="U_xbrlishares">2040816</atra:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <atra:ClassOfWarrantOrRightPricePerShare
      contextRef="C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201231"
      decimals="4"
      id="F_000744"
      unitRef="U_iso4217USD_xbrlishares">24.4999</atra:ClassOfWarrantOrRightPricePerShare>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231"
      decimals="-5"
      id="F_000745"
      unitRef="U_iso4217USD">175000000.0</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20201201_20201231"
      decimals="-5"
      id="F_000746"
      unitRef="U_iso4217USD">164300000</atra:ProceedsFromIssuanceOfCommonStockNet>
    <atra:AggregateOfferingPriceOfCommonStock
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200229"
      decimals="INF"
      id="F_000748"
      unitRef="U_iso4217USD">100000000.0</atra:AggregateOfferingPriceOfCommonStock>
    <atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200201_20200229"
      decimals="INF"
      id="F_000751"
      unitRef="U_xbrlipure">0.030</atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold>
    <atra:AggregateOfferingPriceOfCommonStock
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211130"
      decimals="INF"
      id="F_000749"
      unitRef="U_iso4217USD">100000000.0</atra:AggregateOfferingPriceOfCommonStock>
    <atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211101_20211130"
      decimals="INF"
      id="F_000752"
      unitRef="U_xbrlipure">0.030</atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold>
    <atra:AggregateOfferingPriceOfCommonStock
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190228"
      decimals="INF"
      id="F_000747"
      unitRef="U_iso4217USD">100000000.0</atra:AggregateOfferingPriceOfCommonStock>
    <atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20190201_20190228"
      decimals="INF"
      id="F_000750"
      unitRef="U_xbrlipure">0.030</atra:PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000754"
      unitRef="U_xbrlishares">4785514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <atra:CommonStockAveragePrice
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="2"
      id="F_000757"
      unitRef="U_iso4217USD_xbrlishares">14.60</atra:CommonStockAveragePrice>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000760"
      unitRef="U_iso4217USD">69900000</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000763"
      unitRef="U_iso4217USD">68000000.0</atra:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="INF"
      id="F_000753"
      unitRef="U_xbrlishares">6240601</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <atra:CommonStockAveragePrice
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="2"
      id="F_000756"
      unitRef="U_iso4217USD_xbrlishares">16.23</atra:CommonStockAveragePrice>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-5"
      id="F_000759"
      unitRef="U_iso4217USD">101300000</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20210101_20211231"
      decimals="-5"
      id="F_000762"
      unitRef="U_iso4217USD">98900000</atra:ProceedsFromIssuanceOfCommonStockNet>
    <atra:CommonStockValueAvailableToBeSold
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20211231"
      decimals="-5"
      id="F_000765"
      unitRef="U_iso4217USD">78300000</atra:CommonStockValueAvailableToBeSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215"
      decimals="INF"
      id="F_000755"
      unitRef="U_xbrlishares">1319878</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <atra:CommonStockAveragePrice
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215"
      decimals="2"
      id="F_000758"
      unitRef="U_iso4217USD_xbrlishares">15.88</atra:CommonStockAveragePrice>
    <atra:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215"
      decimals="-5"
      id="F_000761"
      unitRef="U_iso4217USD">21000000.0</atra:ProceedsFromIssuanceOfCommonStockGross>
    <atra:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220101_20220215"
      decimals="-5"
      id="F_000764"
      unitRef="U_iso4217USD">20500000</atra:ProceedsFromIssuanceOfCommonStockNet>
    <atra:CommonStockValueAvailableToBeSold
      contextRef="C_0001604464_srtCounterpartyNameAxis_atraCowenAndCompanyLimitedLiabilityCompanyMember_us-gaapSubsidiarySaleOfStockAxis_atraAtTheMarketOfferingMember_20220215"
      decimals="-5"
      id="F_000766"
      unitRef="U_iso4217USD">57400000</atra:CommonStockValueAvailableToBeSold>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000767"
      unitRef="U_xbrlipure">0.05</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_atraFromDateOfGrantMember_20210101_20211231"
      id="F_000768">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_20210101_20211231"
      decimals="INF"
      id="F_000769"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="C_0001604464_20210101_20211231" id="F_000770">the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. The estimated fair value is generally equal to the closing market price of the Company&#x2019;s common stock on the measurement date. Options granted generally vest over four years and expire in seven to ten years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <atra:ShareholderOwnershipPercent
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000771"
      unitRef="U_xbrlipure">0.10</atra:ShareholderOwnershipPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_atraTenPercentShareHolderMember_20210101_20211231"
      decimals="INF"
      id="F_000772"
      unitRef="U_xbrlipure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001604464_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231"
      id="F_000773">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001604464_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231"
      id="F_000774">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_atraEmployeesAndNonEmployeesMember_20210101_20211231"
      id="F_000775">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000776"
      unitRef="U_xbrlishares">16086987</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlishares">4018597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlishares">12068390</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding>
    <atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20200930"
      decimals="INF"
      id="F_000779"
      unitRef="U_xbrlishares">1500000</atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance
      contextRef="C_0001604464_20210930"
      decimals="INF"
      id="F_000780"
      unitRef="U_xbrlishares">1500000</atra:CommonStockCapitalAdditionalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231"
      decimals="INF"
      id="F_000781"
      unitRef="U_xbrlishares">4022184</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231"
      decimals="INF"
      id="F_000782"
      unitRef="U_xbrlishares">1278379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraInducementPlanMember_20211231"
      decimals="INF"
      id="F_000783"
      unitRef="U_xbrlishares">2743805</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_000784"
      unitRef="U_iso4217USD_xbrlishares">16.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_000785"
      unitRef="U_iso4217USD_xbrlishares">12.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="2"
      id="F_000786"
      unitRef="U_iso4217USD_xbrlishares">27.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="-5"
      id="F_000787"
      unitRef="U_iso4217USD">27100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-5"
      id="F_000788"
      unitRef="U_iso4217USD">23600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="-5"
      id="F_000789"
      unitRef="U_iso4217USD">13800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="-5"
      id="F_000790"
      unitRef="U_iso4217USD">75700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      id="F_000791">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="-5"
      id="F_000792"
      unitRef="U_iso4217USD">88100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000392">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of RSU activity under our 2014 EIP and Inducement Plan:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,829,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,624,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,307,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,553,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,592,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="INF"
      id="F_000793"
      unitRef="U_xbrlishares">3829620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="2"
      id="F_000798"
      unitRef="U_iso4217USD_xbrlishares">15.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000794"
      unitRef="U_xbrlishares">4624257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_000799"
      unitRef="U_iso4217USD_xbrlishares">16.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000795"
      unitRef="U_xbrlishares">1307626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_000800"
      unitRef="U_iso4217USD_xbrlishares">14.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000796"
      unitRef="U_xbrlishares">1553893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_000801"
      unitRef="U_iso4217USD_xbrlishares">17.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="INF"
      id="F_000797"
      unitRef="U_xbrlishares">5592358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="2"
      id="F_000802"
      unitRef="U_iso4217USD_xbrlishares">16.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atra:RestrictedStockSharesIssued
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000803"
      unitRef="U_xbrlishares">1553893</atra:RestrictedStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000805"
      unitRef="U_xbrlishares">154341</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_000807"
      unitRef="U_xbrlishares">61385</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <atra:SharesWithheldForTaxObligationsValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="-5"
      id="F_000809"
      unitRef="U_iso4217USD">1200000</atra:SharesWithheldForTaxObligationsValue>
    <atra:RestrictedStockSharesIssued
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000804"
      unitRef="U_xbrlishares">1218945</atra:RestrictedStockSharesIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000806"
      unitRef="U_xbrlishares">276822</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlishares">106459</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <atra:SharesWithheldForTaxObligationsValue
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-5"
      id="F_000810"
      unitRef="U_iso4217USD">1500000</atra:SharesWithheldForTaxObligationsValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000393">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of stock option activity under our 2014 EIP and Inducement Plan. The table below also includes the activity relating to options for 275,000 shares of our common stock which were issued in 2017 outside of these plans:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Average Exercise&#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,851,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000826"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,643,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,028,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,219,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000827"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest as of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,219,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000828"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,073,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000829"&gt;4.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231"
      decimals="INF"
      id="F_000811"
      unitRef="U_xbrlishares">275000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231"
      decimals="INF"
      id="F_000812"
      unitRef="U_xbrlishares">7851886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231"
      decimals="2"
      id="F_000819"
      unitRef="U_iso4217USD_xbrlishares">22.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20201231"
      decimals="-3"
      id="F_000830"
      unitRef="U_iso4217USD">26834000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000813"
      unitRef="U_xbrlishares">2643378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="2"
      id="F_000820"
      unitRef="U_iso4217USD_xbrlishares">15.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000814"
      unitRef="U_xbrlishares">246867</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="2"
      id="F_000821"
      unitRef="U_iso4217USD_xbrlishares">13.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000815"
      unitRef="U_xbrlishares">1028560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231"
      decimals="2"
      id="F_000822"
      unitRef="U_iso4217USD_xbrlishares">25.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="INF"
      id="F_000816"
      unitRef="U_xbrlishares">9219837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="2"
      id="F_000823"
      unitRef="U_iso4217USD_xbrlishares">20.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="-3"
      id="F_000831"
      unitRef="U_iso4217USD">12810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="INF"
      id="F_000817"
      unitRef="U_xbrlishares">9219837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="2"
      id="F_000824"
      unitRef="U_iso4217USD_xbrlishares">20.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="-3"
      id="F_000832"
      unitRef="U_iso4217USD">12810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="INF"
      id="F_000818"
      unitRef="U_xbrlishares">5073289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="2"
      id="F_000825"
      unitRef="U_iso4217USD_xbrlishares">24.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20211231"
      decimals="-3"
      id="F_000833"
      unitRef="U_iso4217USD">5496000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001604464_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231"
      decimals="-5"
      id="F_000834"
      unitRef="U_iso4217USD">41900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000836"
      unitRef="U_xbrlishares">246867</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000837"
      unitRef="U_xbrlishares">268938</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000838"
      unitRef="U_xbrlishares">347716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000839"
      unitRef="U_iso4217USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001604464_20200101_20201231"
      decimals="-5"
      id="F_000840"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001604464_20190101_20191231"
      decimals="-5"
      id="F_000841"
      unitRef="U_iso4217USD">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000842"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000394">The fair value of each option issued was estimated at the date of grant using the Black-Scholes valuation model. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model and resulting weighted-average grant date fair values of stock options granted during the periods indicated:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assumptions:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000843"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000844"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000845"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average estimated grant date fair value per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,643,378&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,641,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,535,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total estimated grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,808,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,023,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,790,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001604464_20210101_20211231"
      decimals="3"
      id="F_000846"
      unitRef="U_xbrlipure">0.759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001604464_20200101_20201231"
      decimals="3"
      id="F_000847"
      unitRef="U_xbrlipure">0.768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001604464_20190101_20191231"
      decimals="3"
      id="F_000848"
      unitRef="U_xbrlipure">0.761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001604464_20210101_20211231"
      decimals="3"
      id="F_000849"
      unitRef="U_xbrlipure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001604464_20200101_20201231"
      decimals="3"
      id="F_000850"
      unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001604464_20190101_20191231"
      decimals="3"
      id="F_000851"
      unitRef="U_xbrlipure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000852"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000853"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000854"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_20210101_20211231"
      decimals="2"
      id="F_000855"
      unitRef="U_iso4217USD_xbrlishares">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_20200101_20201231"
      decimals="2"
      id="F_000856"
      unitRef="U_iso4217USD_xbrlishares">7.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001604464_20190101_20191231"
      decimals="2"
      id="F_000857"
      unitRef="U_iso4217USD_xbrlishares">18.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000858"
      unitRef="U_xbrlishares">2643378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000859"
      unitRef="U_xbrlishares">2641125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000860"
      unitRef="U_xbrlishares">2535425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
      contextRef="C_0001604464_20210101_20211231"
      decimals="0"
      id="F_000861"
      unitRef="U_iso4217USD">27808000</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
      contextRef="C_0001604464_20200101_20201231"
      decimals="0"
      id="F_000862"
      unitRef="U_iso4217USD">21023000</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
      contextRef="C_0001604464_20190101_20191231"
      decimals="0"
      id="F_000863"
      unitRef="U_iso4217USD">45790000</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000864"
      unitRef="U_iso4217USD">26600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001604464_20200101_20201231"
      decimals="-5"
      id="F_000865"
      unitRef="U_iso4217USD">29400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001604464_20190101_20191231"
      decimals="-5"
      id="F_000866"
      unitRef="U_iso4217USD">31600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <atra:EmployeeStockPurchasePlanEffectiveDate
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      id="F_000867">2014-10-15</atra:EmployeeStockPurchasePlanEffectiveDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="2"
      id="F_000868"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <atra:EmployeeStockPurchasePlanDescription
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      id="F_000869">(i) the beginning of a 12-month offering period, or (ii) at the end of one of the two related 6-month purchase periods</atra:EmployeeStockPurchasePlanDescription>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000871"
      unitRef="U_iso4217USD">25000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <atra:EmployeeStockPurchasePlanOfferingCommencedStartDate
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      id="F_000870">2016-06-01</atra:EmployeeStockPurchasePlanOfferingCommencedStartDate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="-5"
      id="F_000872"
      unitRef="U_iso4217USD">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000873"
      unitRef="U_iso4217USD">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000874"
      unitRef="U_iso4217USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000875"
      unitRef="U_xbrlishares">319190</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000876"
      unitRef="U_xbrlishares">282514</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000877"
      unitRef="U_xbrlishares">139466</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231"
      decimals="-5"
      id="F_000878"
      unitRef="U_iso4217USD">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000879"
      unitRef="U_xbrlipure">0.01</atra:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001604464_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000880"
      unitRef="U_xbrlishares">230769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000881"
      unitRef="U_xbrlishares">1817511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <atra:CommonStockReservedForFutureIssuanceTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000395">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following shares of common stock were reserved for future issuance under our equity incentive plans as of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Shares Reserved&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,086,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018 Inducement Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,022,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2014 Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;862,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total reserved shares of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,971,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</atra:CommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandAndFourteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000882"
      unitRef="U_xbrlishares">16086987</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20211231"
      decimals="INF"
      id="F_000883"
      unitRef="U_xbrlishares">4022184</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000884"
      unitRef="U_xbrlishares">862382</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001604464_20211231"
      decimals="INF"
      id="F_000885"
      unitRef="U_xbrlishares">20971553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000396">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense related to all stock awards was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,063&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,802&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000886"
      unitRef="U_iso4217USD">32063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000887"
      unitRef="U_iso4217USD">31527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000888"
      unitRef="U_iso4217USD">26773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000889"
      unitRef="U_iso4217USD">21802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000890"
      unitRef="U_iso4217USD">19824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000891"
      unitRef="U_iso4217USD">24923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000892"
      unitRef="U_iso4217USD">53865000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000893"
      unitRef="U_iso4217USD">51351000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000894"
      unitRef="U_iso4217USD">51696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000355">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses before provision for income taxes were as follows in each period presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(340,301&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306,758&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(291,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loss before provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(340,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(290,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of provision for (benefit from) income taxes were as follows in each period presented:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current provision for (benefit from) income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current provision for (benefit from) income&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible executive compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities were as follows for each of the dates presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,672&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,366&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,758&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes, as well as for tax attribute carryforwards. We regularly evaluate the positive and negative evidence in determining the realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance and reported cumulative net losses since inception, we maintained a full valuation allowance on the net deferred tax assets as of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt; and 2020. We intend to maintain a full valuation allowance on our&#160;deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance. The valuation allowance increased by $88.7 million for the year ended &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt; primarily due to federal and state NOLs and other U.S. deferred tax assets, which includes accelerated Bayer revenue recognition for tax purposes during 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law on March 27, 2020, providing companies with various tax relief provisions and other stimulus measures. Such measures include, but are not limited to, temporary changes regarding the prior and future utilization of net operating losses, technical corrections to prior tax legislation for tax depreciation of certain qualified improvement property, acceleration of AMT credit refunds, and changes to business interest limitations. The Consolidated Appropriations Act was also signed into law on December 27, 2020 to provide further relief measures and renew various expiring tax provisions. Additionally, the IRS issued final regulations and proposed regulations on calculating the limitation on business interest expense, the allowance for the first-year depreciation deduction under IRC Section 168(k), as amended by the Tax Cuts and Jobs Act (the &#x201c;Tax Act&#x201d;), for qualified property acquired and placed in service after September 27, 2017, and meals and entertainment deductions. Based on our evaluation, these regulations did not have a material impact on the income tax provision for the years ended December 31, 2021, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Tax Act, federal net operating losses generated in tax years beginning on or after January 1, 2018 and in future years may be carried forward indefinitely, but the utilization of such federal net operating losses is limited to 80% of current year taxable income. The CARES Act temporarily suspends this 80% taxable income limitation, allowing a net operating loss carryforward to fully offset taxable income in tax years beginning before January 1, 2021.&lt;span style="color:#000000;"&gt; It is uncertain if, and to what extent, various states will conform to the Tax Act or the CARES Act. &lt;/span&gt;The Tax Act nor the CARES Act had a material impact to our financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;span style="letter-spacing:-0.2pt;"&gt;December 31, 2021&lt;/span&gt;, for federal income tax purposes, we had net operating loss carryforwards of approximately $1,064.4 million, of which $65.2 million begin to expire in 2032 and $999.2 do not expire, research &amp;amp; development tax credits of approximately $18.0 million which begin to expire in 2032, and orphan drug tax credits of approximately $94.5 million which begin to expire in 2035. For California income tax purposes, we had net operating loss carryforwards of approximately $1,045.5 million which begin to expire in 2032, and research &amp;amp; development tax credits of approximately $30.4 million which do not expire, and Competes tax credit of $2.0 million which begins to expire in 2024. For other states income tax purposes, we had net operating loss carryforwards of approximately $226.6 million which begins to expire in 2030. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, our ability to utilize net operating loss carryforwards or other tax attributes in any taxable year may be limited if we have experienced an &#x201c;ownership change.&#x201d; Generally, a Section&#160;382 &#x201c;ownership change&#x201d; occurs if one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#x2019;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Similar rules may apply under state tax laws. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have performed a Section 382 analysis of transactions in our stock through December 31, 2021. &lt;span style="color:#000000;"&gt;We have experienced ownership changes since inception and our utilization of net operating loss carryforwards will be subject to annual limitations. However, it is not expected that the annual limitations will result in the expiration of tax attribute carryforwards prior to utilization&lt;/span&gt;&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the years ended December 31, 2019, 2020 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,601&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any uncertain tax position be favorably settled in the future. For 2021, 2020, and 2019 total unrecognize benefits in the amount of $144.1 million, $110.6 million, and $86.0 million, respectively, no amount, if recognized, would affect the Company&#x2019;s effective tax rate. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to account for interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company has not accrued interest and penalties as of December 31, 2021 due to available tax losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our significant jurisdictions are the U.S. federal jurisdiction and the California state jurisdiction. All of our tax years remain open to examination by the U.S. federal and California tax authorities. We also file in other state, local and foreign jurisdictions in which we operate, and such tax years remain open to examination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2017 Tax Act imposed a mandatory transition tax on accumulated foreign earnings and generally eliminated U.S. taxes on foreign subsidiary distribution. As of December 31, 2021, the Company is not permanently reinvested with respect to its foreign earnings and has not recorded deferred income taxes and withholding taxes as these taxes are immaterial to the financial statements.&lt;span style="font-size:9pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000397">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses before provision for income taxes were as follows in each period presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(340,301&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306,758&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(291,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loss before provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(340,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(306,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(290,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000895"
      unitRef="U_iso4217USD">-340301000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000896"
      unitRef="U_iso4217USD">-306758000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000897"
      unitRef="U_iso4217USD">-291049000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000898"
      unitRef="U_iso4217USD">206000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000899"
      unitRef="U_iso4217USD">153000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000900"
      unitRef="U_iso4217USD">85000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000901"
      unitRef="U_iso4217USD">-340095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000902"
      unitRef="U_iso4217USD">-306605000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000903"
      unitRef="U_iso4217USD">-290964000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000398">The components of provision for (benefit from) income taxes were as follows in each period presented:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current provision for (benefit from) income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current provision for (benefit from) income&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000906"
      unitRef="U_iso4217USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000907"
      unitRef="U_iso4217USD">42000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000908"
      unitRef="U_iso4217USD">13000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000909"
      unitRef="U_iso4217USD">12000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000910"
      unitRef="U_iso4217USD">46000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000911"
      unitRef="U_iso4217USD">15000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000912"
      unitRef="U_iso4217USD">12000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000399">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of statutory tax rates to effective tax rates were as follows in each of the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible executive compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000913"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000914"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000915"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000916"
      unitRef="U_xbrlipure">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000917"
      unitRef="U_xbrlipure">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000918"
      unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001604464_20210101_20211231"
      decimals="3"
      id="F_000919"
      unitRef="U_xbrlipure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001604464_20200101_20201231"
      decimals="3"
      id="F_000920"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001604464_20190101_20191231"
      decimals="3"
      id="F_000921"
      unitRef="U_xbrlipure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001604464_20210101_20211231"
      decimals="3"
      id="F_000922"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001604464_20200101_20201231"
      decimals="3"
      id="F_000923"
      unitRef="U_xbrlipure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001604464_20190101_20191231"
      decimals="3"
      id="F_000924"
      unitRef="U_xbrlipure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001604464_20210101_20211231"
      decimals="INF"
      id="F_000925"
      unitRef="U_xbrlipure">-0.187</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001604464_20200101_20201231"
      decimals="INF"
      id="F_000926"
      unitRef="U_xbrlipure">-0.188</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001604464_20190101_20191231"
      decimals="INF"
      id="F_000927"
      unitRef="U_xbrlipure">-0.202</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001604464_20210101_20211231"
      decimals="3"
      id="F_000928"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001604464_20200101_20201231"
      decimals="3"
      id="F_000929"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001604464_20190101_20191231"
      decimals="3"
      id="F_000930"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000400">Significant components of our deferred tax assets and liabilities were as follows for each of the dates presented:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,672&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,499&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,366&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,136&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,758&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(376,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,409&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000931"
      unitRef="U_iso4217USD">308997000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000932"
      unitRef="U_iso4217USD">237010000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000933"
      unitRef="U_iso4217USD">24181000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000934"
      unitRef="U_iso4217USD">20672000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000935"
      unitRef="U_iso4217USD">10499000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000936"
      unitRef="U_iso4217USD">12590000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <atra:DeferredTaxAssetsLicenseFees
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000937"
      unitRef="U_iso4217USD">8716000</atra:DeferredTaxAssetsLicenseFees>
    <atra:DeferredTaxAssetsLicenseFees
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000938"
      unitRef="U_iso4217USD">8159000</atra:DeferredTaxAssetsLicenseFees>
    <atra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000939"
      unitRef="U_iso4217USD">7972000</atra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <atra:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000940"
      unitRef="U_iso4217USD">4251000</atra:DeferredTaxAssetsOperatingLeaseLiabilities>
    <atra:DeferredTaxAssetsLegalFees
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000941"
      unitRef="U_iso4217USD">2366000</atra:DeferredTaxAssetsLegalFees>
    <atra:DeferredTaxAssetsLegalFees
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000942"
      unitRef="U_iso4217USD">2136000</atra:DeferredTaxAssetsLegalFees>
    <atra:DeferredTaxAssetsTaxCredits
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000943"
      unitRef="U_iso4217USD">1580000</atra:DeferredTaxAssetsTaxCredits>
    <atra:DeferredTaxAssetsTaxCredits
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000944"
      unitRef="U_iso4217USD">1580000</atra:DeferredTaxAssetsTaxCredits>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000945"
      unitRef="U_iso4217USD">12133000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000946"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000947"
      unitRef="U_iso4217USD">7048000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000948"
      unitRef="U_iso4217USD">5360000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000949"
      unitRef="U_iso4217USD">383492000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">291758000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">376071000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">287349000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">7421000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">4409000</us-gaap:DeferredTaxAssetsNet>
    <atra:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">7421000</atra:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <atra:DeferredTaxLiabilitiesOperatingLeaseAssets
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">3541000</atra:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000957"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000958"
      unitRef="U_iso4217USD">868000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000959"
      unitRef="U_iso4217USD">7421000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000960"
      unitRef="U_iso4217USD">4409000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001604464_20210101_20211231"
      decimals="-5"
      id="F_000963"
      unitRef="U_iso4217USD">88700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000964"
      unitRef="U_iso4217USD">1064400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000965"
      unitRef="U_iso4217USD">65200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000966">begin to expire in 2032</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000967"
      unitRef="U_iso4217USD">999200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000968"
      unitRef="U_iso4217USD">18000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000969">2032</atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000970"
      unitRef="U_iso4217USD">94500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear contextRef="C_0001604464_20210101_20211231" id="F_000971">2035</atra:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000972"
      unitRef="U_iso4217USD">1045500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000973">begin to expire in 2032</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000974"
      unitRef="U_iso4217USD">30400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000975"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <atra:DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear contextRef="C_0001604464_20210101_20211231" id="F_000976">2024</atra:DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20211231"
      decimals="-5"
      id="F_000977"
      unitRef="U_iso4217USD">226600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_0001604464_us-gaapIncomeTaxAuthorityAxis_atraOtherStatesMember_20210101_20211231"
      id="F_000978">begins to expire in 2030</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000401">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The changes in the balance of gross unrecognized tax benefits, which excludes interest and penalties, for the years ended December 31, 2019, 2020 and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,601&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross increases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross decreases for tax positions related to prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20181231"
      decimals="-3"
      id="F_000979"
      unitRef="U_iso4217USD">41074000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000980"
      unitRef="U_iso4217USD">22800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000981"
      unitRef="U_iso4217USD">22126000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20190101_20191231"
      decimals="-3"
      id="F_000982"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20191231"
      decimals="-3"
      id="F_000983"
      unitRef="U_iso4217USD">86000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000984"
      unitRef="U_iso4217USD">24648000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000985"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20200101_20201231"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">47000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20201231"
      decimals="-3"
      id="F_000987"
      unitRef="U_iso4217USD">110601000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000988"
      unitRef="U_iso4217USD">28171000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000989"
      unitRef="U_iso4217USD">5295000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001604464_20210101_20211231"
      decimals="-3"
      id="F_000990"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20211231"
      decimals="-3"
      id="F_000991"
      unitRef="U_iso4217USD">144067000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20211231"
      decimals="-5"
      id="F_000992"
      unitRef="U_iso4217USD">144100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20201231"
      decimals="-5"
      id="F_000993"
      unitRef="U_iso4217USD">110600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001604464_20191231"
      decimals="-5"
      id="F_000994"
      unitRef="U_iso4217USD">86000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0001604464_20211231"
      decimals="-6"
      id="F_000995"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001604464_20210101_20211231" id="F_000356">
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Subsequent Events&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 26, 2022, the Company announced it has entered into an asset purchase agreement with FUJIFILM Diosynth Biotechnologies California, Inc. and, for certain limited purposes, FUJIFILM Holdings America Corporation, to sell all of the Company&#x2019;s right, title and interest in and to certain assets related to the Atara T-Cell Operations and Manufacturing facility located at 2430 Conejo Spectrum Street, Thousand Oaks, California for $100 million in cash, plus or minus certain closing adjustments pursuant to the asset purchase agreement. The closing of the proposed transaction is expected to occur in the quarter ending June 30, 2022, subject to certain closing conditions, including clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <atra:AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement
      contextRef="C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126"
      decimals="-6"
      id="F_000996"
      unitRef="U_iso4217USD">100000000</atra:AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .*"7%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #B@EQ4[_(_C>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OI\V*:.CFHGA2$%Q0O(5D=C=L\X=DI-VWMXV[740?P&-F?OGF
M&YA.1Z%#PI<4(B:RF*]&U_LL=%RS/5$4 %GOT:E<3PD_-;<A.473,^T@*GU0
M.P3>-#?@D)11I& &5G$A,MD9+71"12&=\$8O^/B9^@(S&K!'AYXRM'4+3,X3
MXW'L.[@ 9AAA<OF[@&8AENJ?V-(!=DJ.V2ZI81CJ855RTPXMO#\_O99U*^LS
M*:]Q^I6MH&/$-3M/?EO=/VP>F>0-YU7#*WZ[X:W@7%S??<RN/_PNPBX8N[7_
MV/@L*#OX=1?R"U!+ P04    " #B@EQ4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .*"7%24#]K-*@<  *L<   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9EK<^(X%H8_S_X*%3LU-5/5@&_A,IVDRN$RS4XZ80.9J=ZM_2!L@55M6ZPD
MA_#O]T@83/>:8[;V2X+!Y_5C7=YS)-WNA/RJ$L8T><_27-VU$JVWOW:[*DI8
M1E5';%D.OZR%S*B&2[GIJJUD-+9!6=KU'*?7S2C/6_>W]KNYO+\5A4YYSN:2
MJ"++J-P_L%3L[EINZ_C%"]\DVGS1O;_=T@U;,/VZG4NXZIY48IZQ7'&1$\G6
M=ZW0_74<V ![QQ^<[=399V)>927$5W,QB^]:CB%B*8NTD:#P[XV-6)H:)>#X
M=RG:.CW3!)Y_/JI/[<O#RZRH8B.1_LECG=RU!BT2LS4M4OTB=I]8^4(W1B\2
MJ;)_R>YP;Q"T2%0H+;(R& @RGA_^T_>R(<X"!LZ% *\,\+X+<"\]P2\#_.\#
M;BX$!&5 8%OF\"JV'<94T_M;*79$FKM!S7RPC6FCX?5Y;OI]H27\RB%.WX]%
M5$ W:D+SF$QRS?6>S/+#>#+]TB:OBS'Y^<=?;KL:'F>"NE$I_7"0]BY(NQ[Y
M+'*=*-"-6?RM0!<X3[#>$?;!0Q7'+.H0W_U /,=S:X!&>/B4K3K$'=APKR9\
MC(?_K<CAZ4[=T[]Y&__4]+[5\R_HC<0;D^2?X4II"</_7XAD<)(,K&30U)O+
M_9;5]1@>[CKMWQ&*FQ/%#2H3 D)L,:8IW=1AX/%KFBJ&</1.'+WK6F/.)!=F
M>,<$)DEMPS0HE0/O+S_\T-#Y_1-;_SJV*5<13<D71B69PI>JC@[7:D :G) &
M_Q-2V6H7H7"UZ1<$:7A"&J(B2TECGF_(8I^M1%H'@<>'RY<0P7"=RB4=5*AT
MQA>VX6:V0B,]T:QV(#4(A<OP)20/L^?EI\E+.)^\+F>CQ0<R>QIU,- S.W>O
M 1U!/TKHPQDX[SOYG>UK47$IQW'<GA,$O0 C\RHR#Y4;%5)^/^"Q&=D@UVZ[
M7MO'QKU;&;'K7]-H?T+UT?Z:BUU.%HPJD;.8S)0JF*SEPS6_,(6Q58[NXIY\
M[-"R]5[85DAMYX2FNGYB-B@VD%4N[^(V79+](=(BUU S0L^F3-83X4I/ @.J
M[-[%7;H$LAAD!,-J(V3]P,=U'JG<,!)&$52G$F3B@R3&6-F^BWOUL3M%ED%U
MM= B^OJ!+!(JF2+/A58:ZC#HW;KBIE2^L<JFGG^['_K.L-_K#V^[;W54E?.[
MN%F75/-BE?((LK:@NJX^*E5Z9P2N&PS[@YM!T+_ 4%F]BWMUR;!(8!::]MG2
MO+[S<)FFXL&K/-^[RO,7&06@AT+!SZIV=#?H-!)5YNY=9>Z3C,F-L8#?0$$G
M6&,U"#:B5>[NX79\-O?(4Y&MZCVS00023MOOW00##*ER=>\J5U_2=S*+P3OY
MFD>'10T"B$L&O;8S])SA "6LO-V[RMO#.(;IKSX</Y!'N(\\Y[5IL4&RY[KD
M-_"L'=V3A_0MQJH*K[)Z[RJKKP==[D0M*"ZY*+AF9.@X&&!E_=Y5UG\"')DK
M(<D2DGDM'"ZW$ 7,JP7-R12*O0@J%BQ#>97[>U>Y_PG3Y'!F..=2O/$\JN]Q
M7'.$5;A>E0*\JU+ "6TN(!>EY!]\"_X2UX/ABL/ &:"]6Z4&#_=TVYNA9/0R
M"B[0N\% _"HE^+B5/PJ[,$J@-$1,I$'$ZP_: \C<&%&5$ORK4L(LCX2$RM#Z
MV]FX&@FHS>3^8KLUJ(\G&&25''S<UY=<0UH0:^)Z/Z]^@>(Z*B10UP(U+"*^
MJ9NVL(1XHVG!R(].QRQ7R!8J/V6J*8S[;(,&M_LC*)F\1PG-H2B\M.IK$'H*
M%^/P[QA3E3/\JW+&+-=,'C9-S0J*'A<(M7#_SWK KY*$CSOZ:?\@S/,"ILEA
MJ5(+A MI6:#]5V4%_\H-H"6XN.(V]R-4N%A3K>176<#''7LVFKZ0L(BYAAD:
M:LW :2W;I>VR!KVF]JIR@(\[]I%IRF5&9N-:%%S!Q_8*_,KP_89]FQ+DXG3#
MP\>3Q^?9<CDA/]%L^Y$LGU]'GR;D\7&.;;%622!HV,(IX4PR,-U6N\^*2WQ3
M64"U0E.^%C+G% .L<D+0X-KEL%=G:0$6L2NS?[5FX!+U=4:#ZMSL.XA<&1_7
M"3O;"_OIKP//[7]4YKR%Y]QZTE:*]STQ YO9&2A92NVVA1:$ YG9@C\:Q6?&
M[$\@;(T]$6G,I")@XX1_]P;R^ ;P"TC-J83'NSWGXVPV.Y!Q5<YQLDN858A-
MW<_B#ED44?)?9#L.R[L5(VM8NL1P!86?>;W7SJ)SS%0<%N?V?.28!DP:XLJ>
M?9D GD-F<TA,]W#?&HS9*C"(*-MJ?=CSVIL]+Z#>)3Q*#JCR@&J;AZG::KU[
M=KIC5G[VE$R1R*3VPT'/Z=O325QHSY^ZU>V'8[S/U"P<%4G9&D*=3A^,6!Y.
MQ@X76FSM6=%*:"TR^S%A%'K#W "_KX70QPOS@-/YY/U_ %!+ P04    " #B
M@EQ4N;'QP1(&  !!&   &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U9
M;6_;-A#^*X17#"V0Q"3UGB8&V@3#]F%KT+3;9T:F8Z*2Z(J4T^S7[R@YDBQ2
M= KL2ZR7X_&YT]T]=\S5DZR_J2WG&OTHBTI=+[9:[RZ72Y5O><G4A=SQ"MYL
M9%TR#;?UXU+M:L[6[:*R6%*,XV7)1+587;7/[NK5E6QT(2I^5R/5E"6KGS_R
M0CY=+\CBY<%G\;C5YL%R=;5CC_R>ZZ^[NQKNEKV6M2AYI82L4,TWUXL/Y/(F
MH&9!*_&WX$]J=(V,*0]2?C,W?ZRO%]@@X@7/M5'!X&?/;WA1&$V X_M!Z:+?
MTRP<7[]H_ZTU'HQY8(K?R.(?L=;;ZT6Z0&N^84VA/\NGW_G!H,CHRV6AVK_H
MZ2"+%RAOE);E83$@*$75_;(?!T>,%I!P9@$]+*"O71 <%@2MH1VRUJQ;IMGJ
MJI9/J#;2H,U<M+YI5X,UHC*?\5[7\%; .KVZD962A5@SS=?H(RM8E7-T;]0I
M=(Z^WM^BMV_>H3=(5.C+5C:*56MUM=2PLUF_S ^[?.QVH3.[W/+\ @7D#%%,
MB6/YS>N7X^/E2["W-YKV1M-67S!G=%/7O-*(*05V7GHT!KW&H-48SFED:HO
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M*',L<69X<L?;4ZGB^3W*R%F<=*_3X"Q(Z(M.H91AU782:[32<&'2_^?T.X/
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MQ@70_EIK?)ZXUM1_B;(_4$L#!!0    ( .*"7%2AN(+IU00  #L1   8
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M! ]'CYLK1A7SNA+GJD1 B.=*ABY5L2%VG:[0E4;(0R0,VC$[&<+K#.$79NA
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M5C<\G]=?E=SEG.>S^G+*:,R*2D"\G^0Y?[ZI/E19?U=V_#]02P,$%     @
MXH)<5->,+"2K @  $ <  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R]
M5=]OVC 0_E>L:-):J6M^ "FK(%()G;:':JBLV[-)+L3"L:GME/:_W]D)&:6
M>-I+XK/O^^Z^N^0\VDBUTB6 (:\5%WKLE<:L;WU?9R545%_+-0@\*:2JJ$%3
M+7V]5D!S!ZJX'P5![%>4"2\9N;V92D:R-IP)F"FBZZJBZFT"7&[&7NAM-Q[9
MLC1VPT]&:[J$.9BG]4RAY7<L.:M :"8%45",O;OP=AI;?^?PF\%&[ZR)5;*0
M<F6-'_G8"VQ"P"$SEH'BZP52X-P281K/+:?7A;3 W?66_9O3CEH65$,J^1^6
MFW+L#3V20T%K;A[EYCNT>@:6+Y-<NR?9M+Z!1[):&UFU8,R@8J)YT]>V#CN
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MCZ[FO?]A7_:*(I>RF??2=GH-)?NZTJB)^[&K8:6C[@:!*@S,WA4"8;&]IUA
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M^9ES0)$F;VG$;-4-T:T/9HM"7 THK$L@7A:_6#(8FZZX1C@-S_4ARQG%A)-
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MMKDUL4VL81II](:-@-1S>L-1UQHA ^H\W#QW$BK*= G' )S!+)C-/,P@A"/
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MET&0E_<G7I,5TKEP+@0LB]>P5YU>AB-[)R\TQSM"6"./^ Z_T!9/")PLX@]
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ME@Z"[H"PX>"ONRRVT=A2=4/\2P>$0K8L$=_RLBE\B\VWVQ(K@'7<+G/=0)(
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ME>A &J$DU5!O@IMD=9LY?:_PIX"C.:.IRV2OU _'_%YM@M@%!"V4UB%P_#S
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M!,LQ"&E+<>=LU'9#5FD*5XL($WQPH7IUMUG=ZAOJSE?B/3340?QH2RJ?*U@
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M]8G+-+799L6MHO,+MX;'1QVH9F1;A!@_!=\W%#&LDHD9)H/\C8!"@?8&UB:
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MSZ,ST_IOO]3%EE^S7!9U76SXXUI)6#0-P/-54=3M%UK O7?[XG\!4$L#!!0
M   ( .*"7%1R EQ"#PT  .0B   9    >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;+U:67/;1A)^QZ^8TCI;4A5, >#MJTJ6G42I.$Y9=E);6_LP!(;D;$"
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M>&D!WB_KVK4WM$'WPY87_P%02P,$%     @ XH)<5%PM[$.9 P  @ <  !D
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M*+$\$T%,Q\ZNR,770(N+%&JR!CEE8E+N@\.M@EV8WK=SST\MFT!?GO'KQWD
M;+S,Y1KBI(,HWH$8%G1M3:@\?3$EES\"Y."S)55L2)T4'R*>L>S3:-BC8E ,
M/\ ;;8,<);S1?PV2_IK-?7 HB;\_@-_?PN\G^/W_H^&'$+'UCGTC)$\R])9G
M]\P9A.W3S]1O#%T)TZ*#J#A($A4]"A73J:T;85Y)&&-;([DD%:@2GF#&+FY-
ML+@EX3VZO6F=Q"V36#KF.GI8J5#1^?>KR_/+K]=TIJQ_15[I1-G LC)6VZ5B
M3Z="*XP#HT2/+@U2)4S9(YR09!<P"$BK6@5XA(_&>O:]-]0+JTMEEIYF-3LE
M!6CCC1.Q1Q&')72L)H$_N]@-Z[=?CHKAX>^>7.PSO%1!<_0<PT)X/F"1]L#8
M\$B1PH2UB'1P$Q%G03A!W_;B+*";ACOG/AE?0]H%ZJ)U($E8*:W"*VDK$X((
M5.R/!B!E^,'2?8/AXMJ:D$MT8(^^5;;U$>=&/"+J-Z62/+\.!P,TL=9Q'H&>
M%+[J4:-;3[A%=V.QH2ZU]9&"*!\P!>J4>LCI6X%$K0-Y+Y%]\. MPEK'QMF8
M"ZC@A/&B&XH*U?$2@^C4L5*V+C*+!D^H,2B+\HD)HZO6,(T&FXKS[?P!=KMJ
M;QQ*"XLD:0]84K?)7FJ&[*C+#:%='BTFATNG%W"Z=R]M"'MW%H:69@:Y=A"!
M+FL$\<R=&#,X!]+P\^%!G_ZMB_.=J8A:6Z;9#X'1'*$;D-O3[>=EUDW5M^?=
MM^E:N*5"A6A>P'30/_R4=76XV03;I!D[!V];IV6%3R2[^ #W"XL66F^B@^U'
M=_H/4$L#!!0    ( .*"7%1T^,I)@B0  $]X   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;+T]VW+;1I;O^@J4-[ME5U&T1-^M)%6R$L^X-HF]DCWS
ML+4/3:!)]AA$,VA ,O/U>VY] T'(<:JF:B:61*#[].ESO_'[.]M^=ANMN^++
MMF[<#P\V7;=[_?BQ*S=ZJ]S<[G0#GZQLNU4=_-JN'[M=JU5%+VWKQXNSL^>/
MM\HT#W[\GO[VH?WQ>]MWM6GTA[9P_7:KVOT;7=N['QZ</_!_N#;K38=_>/SC
M]SNUUC>Z^[3[T,)OC\,JE=GJQAG;%*U>_?#@\OSUF\4+?(&>^(?1=R[YN<"C
M+*W]C+^\JWYX<(80Z5J7'2ZAX)];?:7K&E<".'Z711^$/?'%]&>_^ELZ/!QF
MJ9R^LO4_3=5M?GCP\D%1Z97JZ^[:WOU=RX&>X7JEK1W]M[CC9Y\]?5"4O>OL
M5EX&"+:FX7_5%T%$\L++LR,O+.2%!<'-&Q&4/ZE._?A]:^^*%I^&U? '.BJ]
M#<"9!F_EIFOA4P/O=3_>\&T4=E7<F'5C5J9435=<EJ7MF\XTZ^*#K4UIM"L>
M^I\>??^X@ZUQ@<>E;/.&MUD<V>9\4?QJFV[CBI^;2E?Y H\!Y@#XP@/^9C&Y
MXD^ZG!=/SF?%XFQQ/K'>DX"()[3>DR/KC9WX?R^7KFN!</YO8H.G88.GM,'3
M(QN\4<XXQ/.'5CO== JI<@R3W[!,\4]= %/N5*L+V[=%:1L'AZA4IZMB91K5
ME$;5A8.G-;!4YPJ##%':MH*/--!<MZ'?!0.[UL ;NQIPL-:-;E5=[_%SO<,%
MX=UNHXM/C<'?;G!1@NARJUL@G^+A?_W'R\7B[.+3_&9>_.WR\@/]?G[QJ% -
M@&-K$ 6T0MOC#OC'5J_[FHY"*]'R^/:-+OO6=$8>^_E+N5'-6A=7=KLUCD2#
MW^WFYRN_SWSBNIZ%ZWHVB></$04 T%5 Z)%+FUP,1>MKMU.E_N'!#J^MO=4/
MIG8H/@("ON82R[JO-*%+;H\OHE.M(H0A,=QM+%Z?O6M@'=<OG:F,:@&E\^*R
MKF&13K>EW>Y4LP<!5R-!,+:!]!NG2KX5)"U=&Q!!2FB@3"&>%Q,X?QYP_GP2
MYS=ZC0>CS?^F[;I5NXTIBW<-:Y\CJ)]<<QSU]V^$' 6JKX7#TE-;U8"2(GPN
M>P=[.$ )(+OQCR';,"7O;-NI9:T+Q[O,X 9,N2F ;?&BPNMP496^!;VX\^_"
M+0 +X2V;/_!O\#A IOO.E'!9[V'OJXW1*V #8 O49L7[%0ALW>(6%C<@YJ=G
M(E25+@UQRE9]QD=;?8NZ+2$IDYP;-27\;[T&EL3#+TG>P.?%KF]WUC&U@D"P
M)2\/2(5=/<WH6U7W_$%<'T"A#8"R@*6! CO0,8:%"E @K(=P*^=TQX1&BR>2
M!D7!>Q8+WRW.YD] $]8U0@N"&BP$+=BK:[6T+9\#3JF;'F2,+BWHM3]X-506
ML^*[\U?SEV&-5M>T66<9##BY\!>)Q3=JCUA30"AXA$)8949[?G<V?_:U"WTP
MNH6SO57+5N-Z;UO= %G(>I,,]"(PT(M)!OK%_-X#=W?[XMJXSV/,,OG^.+/D
MBR)C;!20'@B?'LX#(B6Q&R+5U=8AK0"ME_0LJ ZRP@!I]#H@R\#+H&G _C H
MGQJ@L"5<*#T#?[]%\M.P-^PLM-2LO;HHM=D!8E>MW4X007(%<"FK7B2B0 GR
M"T0@W [)6H :R 4>HX,)_#-ZG@2AH17A\UUK5P8XW-0(V1U</K 86,D5'@%)
MU/6@*9U;];5G<!8#:@>O G\<\+IPW@J7KOJR*P"7%0E^/JZLJY"S;^D\^+#K
MD?D-_B;$3J=T_0XED-@!K@.%T<*:?0N\!W>W5?NB@<=;OUQ^'B;KOJE)P-&/
MG:D1196=X3]TWD8SF:=H:Y7!.Z@J0A2<LE0[6+:F7?67'9CA< K5P<_&$8F4
MRFUF]%^Z9L ,W13NZC9PA%-03%NXCEOM.KY$1<('3#^]7<()O/G'0"UUBI+T
MOG>@U%#YQ7LG@0:PU%JYCI#;Z"_PPYVN 2-;-E6)N/ SO G<&"R.GNPE-E'@
MN&-J>9*37P9.?CG)R6 . %%W;2"-*V UTS$+(H;>HW( &PRD?P?.%YI(8_P^
MN<LXOW_+UF2 UK 07R<1^/!>19B34U.1QY%J("")KN>[(2IAA4NTOD11<:M9
M-<!K&_"TBI*!^KU73+;$(%LT@? 1UKBP3 <N)' Q4OT2Y1!07RG*-WD#MN]1
ME"WW]->WND*;%P@-%!YL\@X_IHN_LJ #6[%XX,RJ=I;TZC&*A1V!FO0>'FH_
M@Y.--.DN6*-]!#<:%@;@UQ88LF&3! SN<B\B@C<# M1+.!8(QS63[T4B/HH=
MF @M_ 5N@\2P6.,5 W]!2Y%N/5VJ\C,*[&!4>],$Y VSS_)?Q*:VD+OU:&[A
M[N?%W^T=2@Z2 UM8@ P$,N3A8X?8XZ,C<\.[>$^G8%M5FNZW[0DELP*M2'H&
M>1,D@T7DXZ9H@:)%A7R& @KM+@M>AFW%&H)/UY9$!X$%#G^W"<84?GZ$HG E
M7M3QM;6CA^5CL-1+B1O_(D3(Q,E>"'M1S3YL3IX-&7-XLW!'?2W:3L'] VT@
M8*H"%(+HT*L5;@\LMNI1.J?VDA5M T(*V+*OV:R/XNLU&QBB@M#>6-(!\I6:
M]85WK"RX^)GZ$7)DGTYDVDQTJ]DN>X"0R!'D).O 0]4T*\Q*%F76@9]!%9/I
MFV[;=\ :1&X70[!16R,2F U=48$J(:G+RBM5Y>#;=N")PJYR2 Z.P%\02Q6H
ME-8L^^S1B]3PY$LR;76*'^^+$F0A %LC@K5J@0ELNU:-*&/GC?Y^I4AWPC;]
M#M9F?KDC^V5_D>IW4LD*O3FDCD;7N']K.PD_B9&+WA:=N<=[;O%*.UBG9FZ2
M.R]K9;8 PEHA%1>]H\ 3V0&C[\_@R!V9&')+L_0"8$%+$AN/8A$MWC-,;D)U
M%.@0"B!BTMM=;?<:#M1HE)D8)AK8%VO0:MUF4N&]"@KOU:3"^^3HBGX&KD56
M&55FDRN,*[/ALN19<Z@DZ+=C 1*P;I!ZV,H# S[$,P!#H-=@CU1+=:((M-]J
MAE*WW^XB/?VKK]9BC:(442P!HAYRXCU&SV<4-!+HI?@-*&X:H#(0;&D +T#A
M#6VB7EB5SR[R](@%$P(+V2K>MQEX5GB\660GU_45JR\F.@"T!5H%; "[EI]/
MF9(1>+#9^0K0./3V.^P,3%UTZ@O%)YC.O0QD@5H9P%L;!"JX#F*H69= /$F4
MYV<Q/'HV299O+<C#=5-<H:\#BGDT]/GGE@"]G\956,D!RZ&L%!<8_E8;YD[4
M/TPM+=H!C4TB, K%,ZU=^K7Q*7)7:GD(+HSHMD)I"E),=6*%X0MHC$M$C>P,
M<322P _;OFQ"(*]H\!I\E*C@O $^@0+'H8EO0!Z"/")^(?&%XD=\051U F_8
MUFO2W$VGF!1<94)'0A@/A5@>S4 J=<&F3$-E"1UG2M.[7< !&TPKW&H";%Z\
M'2#Q-$7S?7=SU"6! R!C!CJ="DJ>)^'Z\VF_ *WJGP?>T@W9GA_1]GP7;<]1
M4IU<_8@_\/5;%E<'SAQ1+0@93104K>09F8? O#6%%S*CF:@';(:U03\2$.AC
MP(#I5V= <'LF*_)1N\Q%V_6@RD'$L"T3@]=((6 CX".']OCLK]KCLX%+SS;Y
M/$/-U*'6L#,@!1F]"2=$U($EX!S(]"'V,G0)UV9<Z2'B4R=1EM5?/^OPG%,>
M!@58R,X'4[K5"=P%:CHPF0T%+@E2\+KPH+?*U&1%HI/>.W+;O+R*[$Q>B."'
MXXB#2$%8YQ36.473S,LQOQBS]*Q A8;ZHP>_D@(X';,^W]'>>X];VVJ^(G12
M]F UQA"!7_)0- (&#@%Q25X#KUFU+=TQ$*0R;8%!5"U2M&_@JFJ2C"Q020*Q
M1$W-!5"T_;9GL<\B\U#6):%H!3"0$:3I.3B1F+"HI3>VAKMPF$\Y?W'A@W!C
MPC8[[YRL*[!EP!/]@[0\<UQR6MRY^A>8[IC3P!@,/YQ$P/36]-M@Y( M*I^
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MVMSJ6/HAYB](GC4)*P[EM9JLV16:-ACB0Z4*0+A8[T:V"CFO,R)'*J_B"P;
MZYB6'9P,?'$/=W@-20->6HOW+253N +5)E@NX<HW]R%NP0LYC<R%&%A&$>3L
MJKLC^H];2G*><SI)UIIWS]PWY7( *6MHUW"K@(Q?@-XUQ@?14<34?Y2DT3L/
M5X A!-2KC/+:K'3X>7P=V\9/"V3>>?&KHH #A5BDPA;87,0!A52XY#+Q'B/"
MIGDE%H.?3U>#_V*;]6E-^O&2Z&:40[ZA"/Q@8:J6D[@.TTKN,WH_L8XOBI!
M.4B%?63_#$,(N04$*HTJA5AM17;@\D#;<82&@B\LI2ZS " YXQP66V8EMB2+
M(]_Y4@TO6IT4 OI$,EF=(8;>.YTQ)X<C "@Z$%IV(*Y#;0S5"8<(U1%,A;5
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M"D8YZ)FKM[RF=<ZI(!]J;50#^VTT&=_3N6#ZU<7$P!HX<Y)W]JY;>\$+]OR
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MP7@'W*^T=L\3GV#\HRS_ E!+ P04    " #B@EQ4J&V-,7T%   3#P  &0
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MAYVK+LC. JLUV3>"_,Z9-%F (ET\<I:55*]%K8!>G1. ]T@X=&.7O"%NXN*
M#P->%!)O@KT IQ.?_/A#XKG>3S@4DF"8.%%W*"+^T OC=@B< G5IJ;DD[F3H
M.,%N1FB6-RZJV L4%:V ._"&41)!PW,=\H$K=4%9(>I20[F!$J= #&W)2H#D
M2I,S-QB&L. <6@[\/U@9^LSRFI\, F(G0]=QL '_URPW+GO%Z>1>@PVP[Z5$
MW ,@X/;08^"W72R.X_Z.YJ)<O0.="^*%P]!-6C]8^'9ZCZ!U[,2ZZT#UGDT3
MMILF[$W:&U%4HD3?[S;*C5#Z5/KW(V'ZIWMHU@TIH!TG+B:FK4ZO-(_C<#CB
M'(ZXD\.L/N@>1@A5NS@Y"O[UAXD7FR]2F5#'"7E:"ZF;0.VD$S\BDR0F<>PT
M>2U.@P;#*/+-UW$LN!\D[:;M:C4K@"C[FYESDG^# U]QU"((<%DRP7_8DW?-
M/J @=9SID#>10\*H46IYQ(.(L5$H,(A)7TY%;4Y%_8787B8P!6QRWY7VIH*F
M//*<:;Z@6O04VEY\O!-=J(JE_&I@*H)\YH.I9<HZ3'+'U)35#5/_>Q(.(7@I
MKW3C=),Y6/$7F4IM60,ES\E3754YQR((<;IA:DUO4<>NZX@9KE@&QX603554
M8'*:UZ L-:QP! %/+0W4R?+73?@4$9>&""$/DE:9!(W]Q&1_$MNO'T2O(^R?
M8Y"A)()CQ6DR_/L+O# PR1TDT=&^9$IQ+"QS#?=::R^X=LW*%3=05DK,\VQE
M_ 660F'VAX'9QMM2^@8VZ^&.^P_(;66&H]*'D_)74;XSID$XI(VT."H"#<^B
M-K,8H^^%RAW&L($C?T*^F+LL*#=[!E!0[)'C_;X]^NDG/%ON#R,X&7GT!2\!
MT J:ENN,_*9YN^]^=^1L949QT_)&8=,Z4N']-H<?(8=/<4?DK6&SGP ^!X23
M40R#]A\D'/*6]A2@N"U \;\M0#-\863ZQ<1Q]GC?O06>JCS]P'C&V>J!9FJ\
MG]/F4J+,YF-=.KSF(>5>1+LZO)"SN[T#JO\J@J=0$D5DED**[9T+</1\[Q;S
MADQ"_Y1OQYV'2L'ERCS'%#6!M6^6=K1]\<WL0V<G;I^+'YE<9:6"X"YAJ3.*
MX<8@[1/,=K2HS+-G+C0\HDQS#:]6+E$ YI="Z&T'"=IW\/0?4$L#!!0    (
M .*"7%2Y%GSHCP8  ),0   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;)U8WT_C.!!^SU]A57<Z5@IIXOPL J3"PAX/*Q"PNSJ=[L$D;FN1Q%W;H7!_
M_<W8:0IL*>@>ECKV>&8\\WTS]AZNI+K7"\X->6SJ5A^-%L8L#\9C72YXPW0@
ME[R%E9E4#3/PJ>9CO52<57934X]I&&;CAHEV='QHYZ[4\:'L3"U:?J6([IJ&
MJ:<37LO5T2@:K2>NQ7QA<&)\?+AD<W[#S;?EE8*O\:"E$@UOM9 M47QV-)I&
M!R<%REN![X*O]+,QP9/<27F/'Q?5T2A$AWC-2X,:&/P\\%->UZ@(W/C9ZQP-
M)G'C\_%:^[D].YSECFE^*NL?HC*+HU$Q(A6?L:XVUW+U)^_/DZ*^4M;:_B6K
M7C8<D;+31C;]9O"@$:W[98]]'#ZR@?8;J/7;&;)>?F:&'1\JN2(*I4$;#NQ1
M[6YP3K28E!NC8%7 /G-\8V1YOY!UQ97^@YS][(1Y(GNW[*[F^M/AV( )%!R7
MO;H3IXZ^H2ZBY*MLS4*3L[;BU4L%8_!M<)"N'3RA.S5^YF5 XL@G-*31#GWQ
M<.#8ZHO?TB=T64O=*4XN9^14-@!OS2Q"KGG-#*]@4AM-;A9,<4QX1:[8$^ 0
MYOZ>WFFC $G_[/ D&3Q)K"?)6Z%W/"!R1JYOOI$IXA.BORWHNQ7=+CB9R1KX
M)=HY$9JP-<?6NEFOFW20%45DIR"<44+.+JX(:RMRT59=R?&,Y*IF[8$'F[1G
M(Z"]'Q;9$(;I U= 5/)%,1 $N'%RSH0BWUG=<>^$P<Z2$Z;1*J2--W=@JT]=
MZ,5^02=^!J/?O"@-)I%G]?#*2V V\6F:XTH6)-0#PLVXP+6]R(_#' 0R[Q,N
M)T&6>-^Y[M?2%-1.8K>6!TGTCAN1E_KIA/IQ6CACE.[(9#ID,OUH)BV?R.72
M FI72G=KW)U2;8W(Y::N?3RW 4'=!@E.[K F$U9K241;UEW%-3&P.JA4R CT
MP,C>G :WP$">^F$8$FT1@BZAV5(V#3CDO%LM1+D@*PX\$UIW !_1HF,YB!HM
M*HZ[P)CF9 ENZ8/7</L5=]<<NPRZ<PHU!FG8L9K<<M60O;\X4_J3-YW/%9\C
M,B] 0D#O*!T\R1Z8-PO9:8@)"+Z'UMPOTL@OB@Q@0FE03#P )HXSOXB3 ;K4
MSY+8C_/"0CKWSAZY*H5&<-($1+,<H!G%N#1@FD  ^>-2* ?AD!9^FH4@1T$%
M?1? $Y]&$W "V4+#H(AZSR+J%U'8<\-F'HQ [X,/R-X#3/]?E?VA+&3>IE68
MQSZ%.(&*)(@S+PF08JF?3+(=%,L&BF4?I=AE#\0S;41C"_9*F 5Y#9=MI-MM
MPY(."]J#10R8X@PPW/.L1_$*(L 'R\Q8PE2(.)"?V\K8:4L9F#^I67F_?U-"
M@P6:H%K7:1I9\=HQ<<-RQTE'<_%O3\55?ZI]UI. @1M-'X$.FQ/X(]HE< K3
M_*M1:\K" <@%5Q6T](M2Y[<]Q28 ^G6IT4X.;%:=6A]QR960%?I0B1)C<N A
M%PG'_O\"*)X%BF47U(&)-]V<Y  PML:JI?.3HW,6A/8?$&,C\2"Q*-50G[P<
M%W[W\@RP9G\B^+D6^GY_IC@4'G!6(? 5..:%5C:THM1*#BHK*'<5>$R>!*\K
MD FMY.;OIL\=#'5IB-X&#EOCB"%RE1(I%08IA=\\F&!IB8H@S+S+E^%]5E5P
M%/D136&4QD F&-U* V7O':-(0ZAA88%U&C^PT,3]1Y+Z^23$CQW,S =FYKN9
M">^$JJLM_D]=!W!-\!IJNWH ![%CG'<&KUP7D'-;W;[99M7?-R]@IL7;N>U0
M>AMS=_OPDDB;KO2R(V$O4L^=FCFGQ-JI30?ESC$Q.&9[U)O5SZ7$-;#AW)YK
MP]N."#<//RPR?U+D*%6\;M)P)0HI]:,BZ94TRUH^ :)=9*\Z52[@9NIDBPSN
M,P7MG1@.N#T*H,^?Y/;BM"/WQ9#[XL.YMZ[MNPOSUFLUE"?G_G3%5+4UR[NM
MN0/J9W;*YW:PW;6:NTN+L\?J7IXP:]-6;Z9[K.B^5)V]6ZI>71XPPPQ28,MJ
MQ1_@&K7$W &U8NJ'68P#B#'-W8TASV/O"V^A6KA*S"IXR0E\22 BD)M%2#UL
MP102GO@3&GL?.RQV6+@!9RD.X*J<1FZ0;6^ZXV</Q8:KN7T.:]#<M<:]&8?9
MX<4]=0_-C;A[KG]E:@[W*U+S&6P-@QPNM,H]@=V'D4O[[+R3!AZQ=KC@# B&
M K ^D]*L/]# \/\0Q_\!4$L#!!0    ( .*"7%3X6*&F'08  -T1   9
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M(E<K?M#Q6V]_R=>(8C"$&I?K;_#Y&YB 0H=L198P&[*1 ,SW#EWVPZ/'9;G
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M= #?3Z4TJP4QZ/[HG/X#4$L#!!0    ( .*"7%0MP*_D$@(  /P$   9
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M";1+L/N%4G@,G,#XX*4O4$L#!!0    ( .*"7%0V^<K"C@0  ),2   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+U8;6_B.!#^*Q:ZTW6E;A.;EY:*
M(I6RJZVT/:%%>_?A=!],,H!5Q\[:#I33_?BS'9I &PS7TY4/D#B>Q\_,>)X)
M'JRE>M1+ (.>,B[T36MI3'X=13I90D;UA<Q!V"=SJ3)J[*U:1#I70%-OE/&(
MQ'$ORB@3K>' CTW4<" +PYF B4*ZR#*J-B/@<GW3PJWG@6]LL31N(!H.<KJ
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M=@<JW13?KSRE2J5Q\7/-V8*+'*"O+]-4_3K(/XG9?P(U^1]02P,$%     @
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M\$;!5C#<3M,T3^(/+!>4*\3(''C>U0""*>MGIIYHL;1]="8T=&4[+.!E)M(
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MI,K49W[XD[8%^29?S#-9_X)#BX4.B"NI>-X&:P8Y*YI_\M@*,0A LQ,!N W
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M^KV)Y@+5=!0OZSO(/5?Z1E,W4WWII,( ]/,=Y^JI8ZXUW35V]2]02P,$%
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MR@;@?B&E.4YL^XZO5?(&4$L#!!0    ( .*"7%3ESL<Z;P@  -<N   9
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MQ-?/<_+FI[>78P5R:&[CL)KSMIS3.3"G39Y$HC89N4N6;-E!?]]#[R ,QF"
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M]STS]0MM<H&'@S4:-8.*<:]QPN"=+'X,C'HXC.[/E#&Y!:FZBLBY=VQ'Q#.
MZ@UI^R-6YTF?U0UN>B<["/ ,1'HX1!YA]0Z ##"C&X#TA@"DT1)1S#>8Z)\,
M$WV#B?Y 3#SF[,YO5[KV^;1KBU2-'-#L\@U8^GU-\M[NPYW?+H&#SH.(^VHD
MVCVL=!G <U\E Z4^#J4?N=:(W-,%_)W56U7^5^F*(;G8-UCJGPQ+_<8)*XZE
MQQ[PS?PVI.(G%[Z!5!^'U!]\8C3KF6[ B9%O(-H?6-H>M7[;C0NL7^X;K/9Q
MK/XG^N75E$,@Q."YC^,Y<L[VPX]'9I4LPR,W,"DDP#L=7U\)#W84ZX3_U6W)
MH-T*/R2!R1\!GC^&(M??:(H')B,$)VN*!P;#@^]OB@?MIGA/*!A4#_ ^PQ&.
MZ"_, X/CP<FZY$'C)DQ/E_S'](__9LMX5DFWW_B;HFXU^![@^'Z,6WLK_\
M>3 ]F5L-2@<X2M?7L%*AM!?!$>#$0W>R.M<;/D'_9:R)@>()#L7=PL)>75\E
MA1"+HC-S@1G9Q=SWS.,>EGG<N!4+<;(N;DAG$,=YHLH+A?7;^A;V37'W^-7[
M6_OBSNYX?V]?/)1WK W[\LKW$Y5KGF0D8BN8RGH_ =20Y2WJ\D&)M+B3NQ!*
MB;CXNF$4DJH> +^O!)BM>M 3U'?9K_\/4$L#!!0    ( .*"7%3.9$[P70(
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M#=(U"L.2'CJP/H#V-\;@?N+O4O]T9F]02P,$%     @ XH)<5"^3*]^J#@
MEU,  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULS5Q9<]LX$GZ>_14H
M[Y54>62"!PC..JZR8R>Q<]@5KV<>MO:!EB")&XK4D)05;\V/WP8O4"38I.UL
ME>9A8MG=C08:^+YN'#K>QLFW="E$1KZOPBA]<[#,LO4O1T?I="E6?CJ)UR*"
MO\SC9.5G\#%9'*7K1/BS7&D5'IF&P8Y6?A =G!SGO[M)3H[C318&D;A)2+I9
MK?SD\4R$\?;- 3VH?O$U6"PS^8NCD^.UOQ"W(KM;WR3PZ:BV,@M6(DJ#."*)
MF+\Y.*6_7%/J2(U<Y-= ;-/&ST3VY3Z.O\D/E[,W!X9T281BFDD;/OSS(-Z*
M,)2FP)'?2ZL'=:-2L?ES9?U=WGOHS;V?BK=Q^%LPRY9O#O@!F8FYOPFSK_'V
M@RA[E#LXC<,T_S_9EK+& 9ENTBQ>E<K@P2J(BG_][^5(-!0HZU$P2P6SK6#W
M*%BE@C6V!;M4L,<J.*6",U:!E0ILK();*KAM!:='@9<*?.PH>:6"UU+H#YQ1
M1<X8ZQ2M@]V)=I];M HW'1UO6@6<=B+>JU*%G'9BWJM2!;V8\$?%C,^7R[F?
M^2?'2;PEB90'>_*'?,WE^K!*@DCBPVV6P%\#T,M.;K-X^FT9AS.1I'\G%[]O
M@NR1_$Q.9[- +E\_))=1@4)R,;\Z%YD?A*]!XN[VG+SZR^OCHPR\D+:.IF6+
M9T6+9D^+5YMP0BQZ2$R#>AKUMR/4*>]5/\?5O\0/T+HAU4VJ4;_ U<_%M'+>
M-#3J[W#U=^)^0DRO5_W]&/7^OG\8H4Z=O'53HWXY-/)1/70ZYZ_&#YUNY#^^
M;.0_C5;7#MWG\>JN1OT+KGXKUNBLNQZOWNK[$:SW>M&;]:(W<WM6G[VEGPAR
M!JPZ(V_C%>0::;&^3Y/$CQ8"^#\C9X^D*7?C/^:_/MWZR8S\ZQ.8))>96*7_
M1ARR:H>LW"&[QZ'33;:,D^"_T,[47P<9P$XJ@4DWRPI+3FY)9C\/)PXD0_E_
MQT</&B?LV@D;=0)&8@5CD#=\2-9^0A[\<"-T(%$8<AL^&!-HG]8.%*Z.$_LX
M*+;3':?NCO.$[J0RE"GQZX'6=<OI#JW1'MJB9Z,E/XZ1W.D?J_O'T/[=0!XI
MD@2FS(B(7;$GC;%;^^ ^S8<QPWSE=H8$G\"\]H8_RQLH"]+,CV9!M-!%G7?<
M:4=[4.(C)K'3%Z_NBX?V)<]+2+S.86D!J)1!MV8BG29!\;M,)*M4-[JXW6PI
MB/@NDFF0"K).@JD@\9SX4;NI+"8^H<9?BS$L$B3 IBB*,W(O2"C2E&1+T*-2
M"$SDAM,L@$P)U.=^4$[&ZF]5+*+\TPRDY%_RYB;DGWW*04H6(A*)'X:/1/R^
M 6 $SZ2%:1BG$%!(!I-O4$;679%_DYCN1X]_^S,WJ?N/E$P;4%!YL!)^NDD*
MJ)?>3,AU/@)I/02JX0?PC<0/, +S>).01^$G,,>C&8SD.@"&","V>!!1[AO\
MDPM,$%Z@ADI/#31>UUMP(ET&:[*&H(&SVL0#MT'E4O\KYDXC6Z;XM"RC.-\9
MTT.HE%.1/,C8Q0D$+=WXT52+0Z7]W<7ON=1Q+/V"H8K4J8F3J,K9TQ>Z^:5L
MJNDF=1"(HHKI*4[U6EJJ5J06+FF7\4V;<>:V,$@GQ[AG\5VY3QHYRW9=RGJZ
MIO('BB<0Q0*"U9 E090&TV(-'P[TKK#)&MYP'8]JY*B.<#]I!"V.A4XE%!3/
M*+X SF3^=\"_2,R#+(7I%/HE6-9]+(%4"\VTFPST.:6R (JG 1<]F)LV".0P
M1[">\6>:6<.T$=!(>K8V!%U)BS(L!BKAH'C&D?/BS_=Y2CYMINX Q?"S'G/<
MSHQP+,X<31<UDM1RJ*:+.DGFL?XNJBR&XFG,5X@5L)D,:9$%W$5RLKWZ>GN7
MOL907.46U-N/^L=4/&?B'/5;OH\)[?A L_Y"%"Q<Y F-B0TD6&"F+LYE$[P)
M$6QBFZT@Z\3,B:R*=R*L$3/=B6'KPVLJ"C5Q"M4MV&J!RDP"NAC$VJ5:&F8[
M'E'=4M5)6KI%_4DC25&X-!M%-L['=U$BIO$BRLO:]!GKMK3?],UU7,PWQ<(F
MSL+C?-NV)V6IE/\1B1/>MEDFD!Z!1"!;IH1RF.>/*;:.% >;. >?+A:)6,A5
MTZ)AK:,:[N44&V#%E2;.E0T0*YAH(T$,$AZ19:&>B<PN.\JT$#*8]NS6")J4
M>[;3X[4B4Q,G4X#8TD.)=>!N!)0OR;1(T[9!MER*<%;E;=I>=+F/.K9EMS<]
M-'*FR[AI]O1!,:2),Z1^Y&O?\]179C'Q?1@L_-Y<Q>Q6Z0R0P6EWHRM&#68[
M7D\W% N:HUEP;#<.D9G.NS!G:I%3(X@E_J8B71.OO%%:)W^0=TF\(N=RY5[/
MR7O)?MC&HB)6R]@/KK<4 UHCBDC2Q=N"!651WX^M Z;M ELQ-Q5_63A_7:S6
M8?PH8-V?0JG_!8:L_@UFO['G:^U)9!1[6#A[O"@RN.D1D5'D8N'D\FN1+,D=
MF+NHS)RN=677KGU% Q;;D\@H5+=P5/^_)BP#;5<)"RL3%JQ#"M\M'-^;&YR
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M!5H CT[0L U.6X*7.D'.F,?:=QU'6-P= <4\'LX\98!'$:[7?6<J"=?UO/8
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MVR)X<ULT5H9F7>+-CR=R:4.7R<WE#SH,U"XO^_.<Q)(\H R0UU7,WD "3Y%
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MKXW/:"_DLUHC:G@I>*G&WEKKS4??5XLU%E3UQ 9+\V4I9$&U&<J5KS82:>Y
M!?=#0E*_H*ST)B,W]R G(['5G)7X($%MBX+*PQURL1][@?<Z\<A6:VTG_,EH
M0U<X1_UU\R#-R&]8<E9@J9@H0>)R[$V#CUE +,!%_,UPKX[>P4IY$N+9#O[,
MQQZQ&2''A;84U#QV.$/.+9/)XWM-ZC5K6N#Q^RO['TZ\$?-$%<X$_\9RO1Y[
M P]R7-(MUX]B_PEK08GE6PBNW"_LZUCBP6*KM"AJL,F@8&7UI"]U(8X 07H!
M$-: \!P07P!$-2 Z X275HAK0.PJ4TEQ=<BHII.1%'N0-MJPV1=73(<V\EEI
M^S[7TGQE!J<G<RT6SVO!<Y3J-[C_OF7Z +<PK[8!B"7<*\U,?3&';ZZ(F-].
M=RC-IH"I,MME8_NGX"9#31G_8,!?YQG<_/)AY&N3H%W&7]3)W%7)A!>2"4+X
M+$J]5G!?YIB?$OA&62,O?)5W%W8R9KCH013\#B$)@Y:$9N^'DQ9X]FYX,.Q0
M$S7-BAQ?=(F/J047:BL1OBQA)@IS^A5UY^<1N>O13"BM8+ZF$NUQR.&!'LPQ
M-7/_3)^4EN:<_=N12=QD$KM,X@N9W+]LS,$U]!IE 3<'I%*U-KR;)@6';&O,
MSP*S;F!2 2$@4%1;+8PAIP?5492D*4KROJ+LA&D&X^8HM96DFZ2?](;DU[:*
M7,&EO4$K+KN*"\YQ)^K31GW:2?3(U//M4B("*\VN0*5!FBW95H%N(G*I -=@
M%_1WP\(K\ON-_/[[FI^S'<NQS.' D.=M\KN)2(^TR_\Y6/:_82?R!XW\02=/
M<S?0^F[ YMI825IJ<\8TPI(R"3O*MP@;-.[#_DVU5:A::^#6LLYE-PE(+PE'
M_NZX(#]&]7O#]#0H:Z$:],A;U(G:8:-VV*GV2WWI.6GG%U4EH2)(CM8-TSB*
M^H,S$:UQ01 F9SI:XI(HB8_B3I0$Y,T D$XM?PE-^;5VM=[E%6]ZG%)_0 :$
MD#.-;9$!":,?(K.6R#CI#\EQ9*73/_(\!<J5\XX*%F);ZLH?-+.-/YTZ5W8V
M?V=]J_-2;S25Z?U,Y8J9+G-<&DK2ZYOJR\I'5@,M-LY9/0EM?)I[71OOC=(&
MF.]+(?3KP"[0N/G)?U!+ P04    " #B@EQ43KPB<*,"   ."   &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,2YX;6RUEEUOFS 4AO^*Q<TV:2O820BI$J0U
M7;5(FQ8UZW8Q[<*%0T UF-HF:?_]C@VAV9JTN\E-\-=Y_)[7<)SI5JH[G0,8
M\E"*2L^\W)CZW/=UDD/)]9FLH<*93*J2&^RJM:]K!3QU0:7P61"$?LF+RHNG
M;FRIXJELC"@J6"JBF[+DZO$"A-S./.KM!JZ+=6[L@!]/:[Z&%9B;>JFPY_>4
MM"BATH6LB()LYGVDYQ>4V0"WXD<!6[W7)C:56RGO;&>1SKS *@(!B;$(CH\-
MS$$(2T(=]QW4Z_>T@?OM'?W*)8_)W'(-<RE^%JG)9U[DD10RW@AS+;>?H4MH
M9'F)%-K]DFVW-O!(TF@CRRX8%91%U3[Y0V?$7@ [%L"Z &>$WV[D5%YRP^.I
MDENB[&JDV89+U46CN**RI[(R"F<+C#/QRLCD+I<B!:7?D$_W36$>R0>RPM-/
M&P%$9F0NRQ+]<RO)-6A0&T@)OA#DJC&- K+0NN%5 N2F0LP.LL"1REI.EH)7
MFKR]!,,+\6[J&]1M=_>33N-%JY$=T7@)R1D9T/>$!8SJG"O0?T-\3+K/G/69
M,T<='*'.!=>:?,NZQ'Y]P7FR,%#JWR_0!SU]X.C#(_3OTG"!KVWG5JO:NIFT
M;FJ[Z2$K6NS(8>TGM8E9,!G3T6@P]3<'! U[0<,7!;& #@\?S0O9CGKXZ 1>
MACT]/(V7X3,O:1A$X20:'_9RW L:O^9EA":F30)8H,QK+D8]-CJ!BY.>/CF-
MBY-G+@X#QF@T/&PB#9Y*3_ ?KV19"_D(T"6];%228Y5]S5.Z5^#H"5RE3V6$
MLM/XVG'WC8U"-HC8/[[Z>]7=WI1?N5H76% %9!@8G(V1H-K+I^T86;N"?RL-
M7A^NF>.%#<HNP/E,2K/KV#ND_PL0_P%02P,$%     @ XH)<5 LR!E F P
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M,D_1^=D%.D.4H>>"KR5AN1R[2H=GG+A9&\JT"<4_$HKGHT?.5"'19Y9#?FC
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M#BE6.(D%WR%AHC6;&=C#M&AMGS!3]I42>I=HG$H>6,8IH&?\!A)]1@M.:\Z
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M;IAARPO*'L#]A91F,[$7U$WT^#]02P,$%     @ XH)<5#)F&0[? P  > X
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MN4R2U"209^2V*,O0I//C%#1/LT\XXNEA2CY^^$0^D+0@CTNQ5KQ(U-C32,9
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M=FZ;L#CR/&\7E311H>_UPAJU8Z-;V^@>M5%^O8RG>&(J+  \1HG&M"V%8J8
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M%^J*F$8C+0)(<)+$\8((RF24I6%NJ[-4M98SB5L-IA6"ZC]KY*I;1M/H./'
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MJ#'N>C:MSFO7@$ KC2C^L]CO?5]Q$2KZ&WG(IG&<DL.I3'+2+_[JW5-=,6F
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M&*:M'T3ZJ$\?]?%>(63L/EB<L$]FK_!.LRQ)TA3+Z'@<5##&\I:F\ VS8=K
M XL#D?XLUWBU\0[9WP=83?=U"+93O!.QG>*Y!B2<-_#(LG"UL3C@@54!ZQV(
M'XX#/17V21*H*J8->X)Q),LP!'HQW*-IBF0GA4^X/MA3DB19%D8 "RM($@R!
MIQ%', 6@ 4.2Q)V#.^=1O#ZGXLUO1*/?4$L#!!0    ( .*"7%27BKL<P
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M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
M;T>]G4!O1[V=0&]'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3
MZ!VH=Q#H':AW$.@=J'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?J'01Z!^H=
M!'H'ZAU_J?=8/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#
M!!0    ( .*"7%07R,P;VP$  -$B   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W:74^#,!0&X+^R<&M&UZ_Y$>>->JM>^ <JG TRH$W;S?GO+4Q--$I<9N)[
M X&VYSVTR7/%Y>.+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1K
MLR(F9K,Y*VP7J8O3V-?(KBYO:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI
M"Q/3.-MVY9>4Z5M"GE8.<T)5NW"2)F3LVX1^Y.> MW7W6_*^+FGR8'R\,VV:
MQ78-"_&EH9"/E_BF1[M<U@65MMBT:4D>G"=3AHHHMDV^+WHRGAS3#M/^RH_.
M'\J,!::9#]ZZD$[,T^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV
M?CV<1V##[?@]_GS&'_4/[$. ]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((
MBJ@<A52.8BI'096CJ,I16.4HKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19
M!8JL D56@2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4
M616*K I%5H4BJT*15:'(JE!D52BR:A19-8JL&D56C2*K1I%5H\BJ4635*+)J
M%%GU?\KZ9.WZKW^RZ.]Y:^KN/9\-?[)<O0)02P$"% ,4    " #B@EQ4!T%-
M8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+
M 0(4 Q0    ( .*"7%3O\C^-[@   "L"   1              "  :\   !D
M;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .*"7%297)PC$ 8  )PG   3
M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ XH)<5)0/VLTJ!P  JQP  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .*"7%2YL?'!$@8  $$8   8
M              " @6T/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #B@EQ4J=)RY&8"  "5!@  &               @(&U%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ XH)<5*&X@NG5!
M.Q$  !@              ("!41@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( .*"7%1?VWR]3@<  &,F   8              " @5P=
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #B@EQ4UXPL
M)*L"   0!P  &               @('@)   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ XH)<5*4J]$%L"0  ;2H  !@
M ("!P2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .*"
M7%1 !S=;"00  +((   8              " @6,Q  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #B@EQ4:MC#TKTB  !-:@  &
M        @(&B-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ XH)<5*IL3K:[!   L@L  !D              ("!E5@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #B@EQ4E;/KK6T(  !E%@
M&0              @(&'70  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( .*"7%2U&]]&/@,   0'   9              " @2MF  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ XH)<5/0M0W.%
M"   B!@  !D              ("!H&D  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #B@EQ4F##O8P,0  #:/@  &0
M@(%<<@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .*"
M7%0N@5^W)@@  +@4   9              " @9:"  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ XH)<5"T9.[%M!0  O P  !D
M         ("!\XH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #B@EQ4#_)494P2  "#.P  &0              @(&7D   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .*"7%1R EQ"#PT  .0B
M   9              " @1JC  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ XH)<5%PM[$.9 P  @ <  !D              ("!8+
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #B@EQ4=/C*
M28(D  !/>   &0              @($PM   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( .*"7%2[9KN\J (  .0%   9
M  " @>G8  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MXH)<5 U7TN$Q P  @@8  !D              ("!R-L  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #B@EQ4\[RHJ-4%   !$   &0
M            @($PWP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( .*"7%3V5*_J_P(  %T&   9              " @3SE  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ XH)<5*AMC3%]!0
M$P\  !D              ("!<N@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #B@EQ4N19\Z(\&  "3$   &0              @($F
M[@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .*"7%3X
M6*&F'08  -T1   9              " @>ST  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ XH)<5"W K^02 @  _ 0  !D
M     ("!0/L  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*"7%2(SSJ0^0(  .D(   9              "
M@5X/ 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ XH)<
M5 TU8WB/ @  $0<  !D              ("!CA(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #B@EQ47LYW:K0"  #W!P  &0
M        @(%4%0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( .*"7%1EEC;XDP,  -(.   9              " @3\8 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ XH)<5/QF@PMO @  X 4
M !D              ("!"1P! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #B@EQ4M$560B4"  "Y!   &0              @(&O'@$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .*"7%3ESL<Z
M;P@  -<N   9              " @0LA 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ XH)<5,YD3O!= @  [@0  !D
M ("!L2D! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #B
M@EQ4)R7P_)H%  !>%P  &0              @(%%+ $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .*"7%2.LEE?? 0  &L4   9
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M970T-BYX;6Q02P$"% ,4    " #B@EQ4+Y,KWZH.  "74P  &0
M    @(%:0P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M .*"7%3E<Y[Z< ,  )P+   9              " @3M2 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ XH)<5!U4Y/+[!   X10  !D
M             ("!XE4! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #B@EQ4>FT_,)X#  #9"P  &0              @($46P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .*"7%1.O")PHP(
M  X(   9              " @>E> 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ XH)<5 LR!E F P  XPD  !D              ("!
MPV$! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #B@EQ4
MY*XD>;,"  !<!P  &0              @($@90$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( .*"7%1I_YRSF@(  &,'   9
M      " @0IH 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ XH)<5-FVK!HI P  4 L  !D              ("!VVH! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #B@EQ4,F89#M\#  !X#@
M&0              @($[;@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( .*"7%2.U+S/7@0   83   9              " @5%R 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ XH)<5*]E&*$B
M P  :@D  !D              ("!YG8! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #B@EQ4R[GV A<"  !?!   &0
M@($_>@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .*"
M7%2X$@,(&P,  # 2   -              "  8U\ 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ XH)<5)>*NQS     $P(   L              ( !TW\!
M %]R96QS+RYR96QS4$L! A0#%     @ XH)<5%=-L?2X!   <"<   \
M         ( !O( ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .*"7%19
M=@'X]0$  #@C   :              "  :&% 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( .*"7%07R,P;VP$  -$B   3
M      "  <Z' 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(
' -J) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>525</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - In-license and Manufacturing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements</Role>
      <ShortName>In-license and Manufacturing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Out-license Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements</Role>
      <ShortName>Out-license Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Description of Business (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail</Role>
      <ShortName>Description of Business (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail</Role>
      <ShortName>Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail</Role>
      <ShortName>Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - In-License and Manufacturing Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail</Role>
      <ShortName>In-License and Manufacturing Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Out-license Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Out-license Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Out-license Agreements - Additional Information (Detail 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1</Role>
      <ShortName>Out-license Agreements - Additional Information (Detail 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Components of Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail</Role>
      <ShortName>Leases - Components of Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Summary of Other Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Summary of Other Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Summary of Activity for ARO Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of Activity for ARO Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stockholders' Equity - Summary of Estimated Weighted-Average Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Estimated Weighted-Average Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Losses Before Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Losses Before Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="atra-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="atra-10k_20211231.htm">atra-10k_20211231.htm</File>
    <File>atra-20211231.xsd</File>
    <File>atra-20211231_cal.xml</File>
    <File>atra-20211231_def.xml</File>
    <File>atra-20211231_lab.xml</File>
    <File>atra-20211231_pre.xml</File>
    <File>atra-ex1035_105.htm</File>
    <File>atra-ex1036_104.htm</File>
    <File>atra-ex1037_103.htm</File>
    <File>atra-ex1038_102.htm</File>
    <File>atra-ex1039_101.htm</File>
    <File>atra-ex211_9.htm</File>
    <File>atra-ex231_6.htm</File>
    <File>atra-ex312_8.htm</File>
    <File>atra-ex321_7.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gbn5n5jlnzog000001.jpg</File>
    <File>gbn5n5jlnzog000002.jpg</File>
    <File>gbn5n5jlnzog000003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="742">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "atra-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "atra-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atra-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "atra-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atra-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atra-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atra-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 610,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 19,
    "http://www.atarabio.com/20211231": 5,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 29
   },
   "keyCustom": 111,
   "keyStandard": 414,
   "memberCustom": 25,
   "memberStandard": 32,
   "nsprefix": "atra",
   "nsuri": "http://www.atarabio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Net Loss per Common Share",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Financial Instruments",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Property and Equipment",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - In-license and Manufacturing Agreements",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements",
     "shortName": "In-license and Manufacturing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:OutLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Out-license Agreements",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements",
     "shortName": "Out-license Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:OutLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:LeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:LeasesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments and Contingencies",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Income Taxes",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Events",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "atra:OtherCurrentLiabilitiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "atra:OtherCurrentLiabilitiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Leases (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Description of Business (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail",
     "shortName": "Description of Business (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_atraSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_atraSegment",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "atra:OtherCurrentLiabilitiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "atra:OtherCurrentLiabilitiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
     "shortName": "Net Loss per Common Share - Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail",
     "shortName": "Financial Instruments - Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail",
     "shortName": "Financial Instruments - Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Financial Instruments - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atra:DueToLicensorsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - In-License and Manufacturing Agreements - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail",
     "shortName": "In-License and Manufacturing Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "atra:InLicenseAndManufacturingAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "atra:DueToLicensorsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atra:LicenseAndCollaborationRevenue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Out-license Agreements - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Out-license Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "atra:YearsOfManufacturingAndSupplyingCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atra:LicenseAndCollaborationRevenue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Out-license Agreements - Additional Information (Detail 1)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1",
     "shortName": "Out-license Agreements - Additional Information (Detail 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_us-gaapTypeOfArrangementAxis_atraBayerTechnologyTransferAgreementMember_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_srtStatementGeographicalAxis_atraSouthSanFranciscoCaliforniaMember_us-gaapShortTermDebtTypeAxis_us-gaapLetterOfCreditMember_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock",
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock",
       "atra:LeasesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Components of Lease Cost (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail",
     "shortName": "Leases - Components of Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Summary of Other Information Related to Leases (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail",
     "shortName": "Leases - Summary of Other Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetRetirementObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Leases - Summary of Activity for ARO Liabilities (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail",
     "shortName": "Leases - Summary of Activity for ARO Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetRetirementObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atra:AccruedTerminationCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "atra:AccruedTerminationCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail",
     "shortName": "Stockholders' Equity - Summary of RSU Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapPlanNameAxis_atraTwoThousandFourteenEquityIncentivePlanAndInducementPlanMember_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stockholders' Equity - Summary of Estimated Weighted-Average Assumptions (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail",
     "shortName": "Stockholders' Equity - Summary of Estimated Weighted-Average Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:CommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail",
     "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "atra:CommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapPlanNameAxis_atraTwoThousandEighteenInducementPlanMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stockholders' Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail",
     "shortName": "Stockholders' Equity - Schedule of Stock-based Compensation Related to Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Losses Before Provision for Income Taxes (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail",
     "shortName": "Income Taxes - Losses Before Provision for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail",
     "shortName": "Income Taxes - Components of Provision for (Benefit from) Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail",
     "shortName": "Income Taxes - Reconciliation of Statutory Tax Rates to Effective Tax Rates (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atra:AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220126_20220126",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atra:AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_atraUnderwrittenPublicOfferingMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:BusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of Business",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atra:BusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "atra-10k_20211231.htm",
      "contextRef": "C_0001604464_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "atra_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AccruedTerminationCharges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued termination charges.",
        "label": "Accrued Termination Charges",
        "terseLabel": "Accrued termination charges"
       }
      }
     },
     "localname": "AccruedTerminationCharges",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional upfront cash payment entitle to receive for translational activities.",
        "label": "Additional Upfront Cash Payment Entitle To Receive For Translational Activities",
        "terseLabel": "Additional upfront cash payment entitle to receive for translational activities"
       }
      }
     },
     "localname": "AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivities",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional upfront cash payment entitle to receive for translational activities invoiced amount.",
        "label": "Additional Upfront Cash Payment Entitle To Receive For Translational Activities Invoiced Amount",
        "terseLabel": "Additional upfront cash payment entitle to receive for translational activities, invoiced amount"
       }
      }
     },
     "localname": "AdditionalUpfrontCashPaymentEntitleToReceiveForTranslationalActivitiesInvoicedAmount",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional upfront reimbursement payment for research and process development.",
        "label": "Additional Upfront Reimbursement Payment For Research And Process Development",
        "terseLabel": "Additional upfront reimbursement payment for research and process development"
       }
      }
     },
     "localname": "AdditionalUpfrontReimbursementPaymentForResearchAndProcessDevelopment",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments entitle to receive upon Achieving certain development, regulatory and commercial milestones.",
        "label": "Aggregate Milestone Payments Entitle To Receive Upon Achieving Certain Development Regulatory And Commercial Milestones",
        "terseLabel": "Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones.",
        "label": "Aggregate Milestone Payments Entitle To Receive Upon Achieving Certain Regulatory And Commercial Milestones",
        "terseLabel": "Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones"
       }
      }
     },
     "localname": "AggregateMilestonePaymentsEntitleToReceiveUponAchievingCertainRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AggregateOfferingPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Offering Price of common stock.",
        "label": "Aggregate Offering Price Of Common Stock",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfCommonStock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of closing adjustment related to asset purchase agreement.",
        "label": "Amount Of Closing Adjustment Related To Asset Purchase Agreement",
        "terseLabel": "Amount of closing adjustment related to asset purchase agreement"
       }
      }
     },
     "localname": "AmountOfClosingAdjustmentRelatedToAssetPurchaseAgreement",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_AuroraColoradoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurora Colorado.",
        "label": "Aurora Colorado [Member]",
        "terseLabel": "Aurora Colorado"
       }
      }
     },
     "localname": "AuroraColoradoMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer license agreement, Bayer tech transfer agreement and Bayer manufacturing agreement.",
        "label": "Bayer License Agreement Bayer Tech Transfer Agreement And Bayer Manufacturing Agreement [Member]",
        "terseLabel": "Bayer Agreements"
       }
      }
     },
     "localname": "BayerLicenseAgreementBayerTechTransferAgreementAndBayerManufacturingAgreementMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_BayerLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer License Agreement.",
        "label": "Bayer License Agreement [Member]",
        "terseLabel": "Bayer License Agreement"
       }
      }
     },
     "localname": "BayerLicenseAgreementMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_BayerManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Manufacturing Agreement.",
        "label": "Bayer Manufacturing Agreement [Member]",
        "terseLabel": "Bayer Manufacturing Agreement"
       }
      }
     },
     "localname": "BayerManufacturingAgreementMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_BayerTechnologyTransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer technology transfer agreement.",
        "label": "Bayer Technology Transfer Agreement [Member]",
        "terseLabel": "Bayer Technology Transfer Agreement"
       }
      }
     },
     "localname": "BayerTechnologyTransferAgreementMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_BusinessDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description concept. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.",
        "label": "Business Description [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_CashAndCashEquivalentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents maturity period.",
        "label": "Cash And Cash Equivalents Maturity Period",
        "terseLabel": "Cash and cash equivalents maturity period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMaturityPeriod",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "atra_CashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, accumulated gross unrealized gain, before tax.",
        "label": "Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Total Unrealized Gain"
       }
      }
     },
     "localname": "CashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "atra_CashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, accumulated gross unrealized loss, before tax.",
        "label": "Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total Unrealized Loss"
       }
      }
     },
     "localname": "CashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_CashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, amortized cost.",
        "label": "Cash Equivalents Amortized Cost",
        "negatedTotalLabel": "Total Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAmortizedCost",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents and Short-Term Investments.",
        "label": "Cash Equivalents And Short Term Investments Policy [Text Block]",
        "terseLabel": "Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_CashEquivalentsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "atra_CashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents, fair value.",
        "label": "Cash Equivalents Fair Value",
        "negatedLabel": "Total Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsFairValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of warrants issued.",
        "label": "Class Of Warrant Or Right Number Of Warrants Issued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_ClassOfWarrantOrRightPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, price per share.",
        "label": "Class Of Warrant Or Right Price Per Share",
        "terseLabel": "Warrant, price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPricePerShare",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "atra_ClassOfWarrantOrRightTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, term.",
        "label": "Class Of Warrant Or Right Term",
        "terseLabel": "Warrants, term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTerm",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_ClinicalTrialAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Accruals.",
        "label": "Clinical Trial Accruals Policy [Text Block]",
        "terseLabel": "Clinical Study Accruals"
       }
      }
     },
     "localname": "ClinicalTrialAccrualsPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_CommonStockAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock average price.",
        "label": "Common Stock Average Price",
        "terseLabel": "Common stock average price"
       }
      }
     },
     "localname": "CommonStockAveragePrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "atra_CommonStockCapitalAdditionalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital additional shares reserved for future issuance.",
        "label": "Common Stock Capital Additional Shares Reserved For Future Issuance",
        "terseLabel": "Additional shares of common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalAdditionalSharesReservedForFutureIssuance",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_CommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock reserved for future issuance.",
        "label": "Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance Under Equity Incentive Plans"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_CommonStockValueAvailableToBeSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value available to be sold.",
        "label": "Common Stock Value Available To Be Sold",
        "terseLabel": "Common stock value available to be sold"
       }
      }
     },
     "localname": "CommonStockValueAvailableToBeSold",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_ContractBalancesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract balances.",
        "label": "Contract Balances Policy [Text Block]",
        "terseLabel": "Contract Balances"
       }
      }
     },
     "localname": "ContractBalancesPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_CowenAndCompanyLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company Limited Liability Company.",
        "label": "Cowen And Company Limited Liability Company [Member]",
        "terseLabel": "Cowen"
       }
      }
     },
     "localname": "CowenAndCompanyLimitedLiabilityCompanyMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities.",
        "label": "Current Liabilities [Member]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_DeferredTaxAssetsLegalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets legal fees.",
        "label": "Deferred Tax Assets Legal Fees",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "DeferredTaxAssetsLegalFees",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeferredTaxAssetsLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license fees.",
        "label": "Deferred Tax Assets License Fees",
        "terseLabel": "License fees"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicenseFees",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards expiration year.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Expiration Year",
        "terseLabel": "Tax credit carryforwards, expiration year"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsExpirationYear",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "atra_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research and development expiration year.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research And Development Expiration Year",
        "terseLabel": "Research and development tax credit carryforwards, expiration year"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpirationYear",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "atra_DeferredTaxAssetsTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, tax credits.",
        "label": "Deferred Tax Assets Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCredits",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeferredTaxLiabilitiesOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease assets.",
        "label": "Deferred Tax Liabilities Operating Lease Assets",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseAssets",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DefinedContributionPlanContributionsByEmployer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan contributions by employer.",
        "label": "Defined Contribution Plan Contributions By Employer",
        "terseLabel": "Defined contribution plan contributions by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanContributionsByEmployer",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan.",
        "label": "Defined Contribution Plan Policy [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_DescriptionOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business.",
        "label": "Description Of Business [Abstract]"
       }
      }
     },
     "localname": "DescriptionOfBusinessAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "atra_DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined additional specified translational activities in order to evaluate transaction price.",
        "label": "Determined Additional Specified Translational Activities In Order To Evaluate Transaction Price",
        "terseLabel": "Determined additional specified translational activities in order to evaluate transaction price"
       }
      }
     },
     "localname": "DeterminedAdditionalSpecifiedTranslationalActivitiesInOrderToEvaluateTransactionPrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined fee constituted entire consideration included in transaction price.",
        "label": "Determined Fee Constituted Entire Consideration Included In Transaction Price",
        "terseLabel": "Determined fee constituted entire consideration included in transaction price"
       }
      }
     },
     "localname": "DeterminedFeeConstitutedEntireConsiderationIncludedInTransactionPrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined research and process development activities in order to evaluate transaction price.",
        "label": "Determined Research And Process Development Activities In Order To Evaluate Transaction Price",
        "terseLabel": "Determined research and process development activities in order to evaluate transaction price"
       }
      }
     },
     "localname": "DeterminedResearchAndProcessDevelopmentActivitiesInOrderToEvaluateTransactionPrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined upfront payment constituted entire consideration included in transaction price.",
        "label": "Determined Upfront Payment Constituted Entire Consideration Included In Transaction Price",
        "terseLabel": "Determined upfront payment constituted entire consideration included in transaction price"
       }
      }
     },
     "localname": "DeterminedUpfrontPaymentConstitutedEntireConsiderationIncludedInTransactionPrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined upfront payment for license in order to evaluate transaction price.",
        "label": "Determined Upfront Payment For License In Order To Evaluate Transaction Price",
        "terseLabel": "Determined upfront payment for license in order to evaluate transaction price"
       }
      }
     },
     "localname": "DeterminedUpfrontPaymentForLicenseInOrderToEvaluateTransactionPrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development or sales-based milestone payments earned or received.",
        "label": "Development Or Sales Based Milestone Payments Earned Or Received",
        "terseLabel": "Development or sales-based milestone payments earned or received"
       }
      }
     },
     "localname": "DevelopmentOrSalesBasedMilestonePaymentsEarnedOrReceived",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_DueToLicensorsCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all licensors.",
        "label": "Due To Licensors Current And Noncurrent",
        "terseLabel": "Contractual obligations due to Bayer, MSK and QIMR"
       }
      }
     },
     "localname": "DueToLicensorsCurrentAndNoncurrent",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_EmployeeStockPurchasePlanDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan description.",
        "label": "Employee Stock Purchase Plan Description",
        "terseLabel": "Employee stock purchase plan description"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDescription",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_EmployeeStockPurchasePlanEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan effective date.",
        "label": "Employee Stock Purchase Plan Effective Date",
        "terseLabel": "Employee stock purchase plan effective date"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanEffectiveDate",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "atra_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP Share Purchase Rights"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_EmployeeStockPurchasePlanOfferingCommencedStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan offering commenced start date.,",
        "label": "Employee Stock Purchase Plan Offering Commenced Start Date",
        "terseLabel": "Employee stock purchase plan offering commenced start date"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingCommencedStartDate",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "atra_EmployeesAndNonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and non-employees.",
        "label": "Employees And Non Employees [Member]",
        "terseLabel": "Employees And Non Employees"
       }
      }
     },
     "localname": "EmployeesAndNonEmployeesMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease cost.",
        "label": "Finance Lease Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease costs.",
        "label": "Finance Lease Costs [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_FinancialInstrumentsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financial instruments disclosure.",
        "label": "Financial Instruments Disclosure [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "atra_FromDateOfGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expire from date of grant.",
        "label": "From Date Of Grant [Member]",
        "terseLabel": "From Date Of Grant"
       }
      }
     },
     "localname": "FromDateOfGrantMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_InLicenseAndManufacturingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-license and manufacturing agreements.",
        "label": "In License And Manufacturing Agreements [Abstract]"
       }
      }
     },
     "localname": "InLicenseAndManufacturingAgreementsAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "atra_InLicenseAndManufacturingAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-license and Manufacturing Agreements.",
        "label": "In License And Manufacturing Agreements Disclosure [Text Block]",
        "terseLabel": "In-license and Manufacturing Agreements"
       }
      }
     },
     "localname": "InLicenseAndManufacturingAgreementsDisclosureTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureInLicenseAndManufacturingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_IncreaseDecreaseInAccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued research and development.",
        "label": "Increase Decrease In Accrued Research And Development",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopment",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease assets.",
        "label": "Increase Decrease In Operating Lease Assets",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IncrementalContractualObligationsUnderLeaseAmendment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental contractual obligations under lease amendment.",
        "label": "Incremental Contractual Obligations Under Lease Amendment",
        "terseLabel": "Incremental contractual obligations under lease amendment"
       }
      }
     },
     "localname": "IncrementalContractualObligationsUnderLeaseAmendment",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement plan.",
        "label": "Inducement Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_InvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment maturity period.",
        "label": "Investment Maturity Period",
        "terseLabel": "Investment maturity period"
       }
      }
     },
     "localname": "InvestmentMaturityPeriod",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants, net of offering costs, shares.",
        "label": "Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Shares",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of offering costs, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsShares",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants, net of offering costs, value.",
        "label": "Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Value",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of offering costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Common Stock, Net of Commissions and Offering Costs, Shares.",
        "label": "Issuance Of Common Stock Net Of Commissions And Offering Costs Shares",
        "terseLabel": "Issuance of common stock, net of commissions and offering costs, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsShares",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock, net of commissions and offering costs, value.",
        "label": "Issuance Of Common Stock Net Of Commissions And Offering Costs Value",
        "terseLabel": "Issuance of common stock, net of commissions and offering costs, value"
       }
      }
     },
     "localname": "IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IssuanceOfCommonStockNetOfOfferingCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock net of offering costs shares.",
        "label": "Issuance Of Common Stock Net Of Offering Costs Shares",
        "terseLabel": "Issuance of common stock, net Of offering costs, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockNetOfOfferingCostsShares",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_IssuanceOfCommonStockNetOfOfferingCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock, net of offering costs, value.",
        "label": "Issuance Of Common Stock Net Of Offering Costs Value",
        "terseLabel": "Issuance of common stock, net of offering costs, values"
       }
      }
     },
     "localname": "IssuanceOfCommonStockNetOfOfferingCostsValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock pursuant to employee stock awards shares.",
        "label": "Issuance Of Common Stock Pursuant To Employee Stock Awards Shares",
        "terseLabel": "Issuance of common stock pursuant to employee stock awards, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockPursuantToEmployeeStockAwardsShares",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock pursuant to employee stock awards value.",
        "label": "Issuance Of Common Stock Pursuant To Employee Stock Awards Value",
        "terseLabel": "Issuance of common stock pursuant to employee stock awards"
       }
      }
     },
     "localname": "IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LeaseAgreementAreaOfOfficeLabAndManufacturingSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement area of office lab and manufacturing space.",
        "label": "Lease Agreement Area Of Office Lab And Manufacturing Space",
        "terseLabel": "Lease agreement area of office, lab and cellular therapy manufacturing space"
       }
      }
     },
     "localname": "LeaseAgreementAreaOfOfficeLabAndManufacturingSpace",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "atra_LeaseAgreementAreaOfOfficeLabAndWarehouseSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement area of office lab and warehouse space.",
        "label": "Lease Agreement Area Of Office Lab And Warehouse Space",
        "terseLabel": "Lease agreement area of square feet of office, lab and warehouse space"
       }
      }
     },
     "localname": "LeaseAgreementAreaOfOfficeLabAndWarehouseSpace",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "atra_LeaseAgreementRenewalTermOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement renewal term option one.",
        "label": "Lease Agreement Renewal Term Option One",
        "terseLabel": "Lease extension term, option one"
       }
      }
     },
     "localname": "LeaseAgreementRenewalTermOptionOne",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_LeaseAgreementRenewalTermOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement renewal term option two.",
        "label": "Lease Agreement Renewal Term Option Two",
        "terseLabel": "Lease extension term, option two"
       }
      }
     },
     "localname": "LeaseAgreementRenewalTermOptionTwo",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "atra_LeaseOptionToExtendAdditionalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease option to extend additional term.",
        "label": "Lease Option To Extend Additional Term",
        "terseLabel": "Lease option to extend additional term"
       }
      }
     },
     "localname": "LeaseOptionToExtendAdditionalTerm",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_LeasesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases disclosure.",
        "label": "Leases Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesDisclosureTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease percentage of annual increase in base rent.",
        "label": "Lessee Operating Lease Percentage Of Annual Increase In Base Rent",
        "terseLabel": "Percentage of annual increase in base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeasePercentageOfAnnualIncreaseInBaseRent",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_LetterOfCreditDecreaseFromPriorLeaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit decrease from prior lease agreement.",
        "label": "Letter Of Credit Decrease From Prior Lease Agreement",
        "terseLabel": "Letter of credit, decrease from prior lease agreement"
       }
      }
     },
     "localname": "LetterOfCreditDecreaseFromPriorLeaseAgreement",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LetterOfCreditRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit renewal term.",
        "label": "Letter Of Credit Renewal Term",
        "terseLabel": "Letter of credit renewal term"
       }
      }
     },
     "localname": "LetterOfCreditRenewalTerm",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_LiabilitiesRelatedToIndemnificationAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities related to indemnification agreements.",
        "label": "Liabilities Related To Indemnification Agreements",
        "terseLabel": "Liabilities related to indemnification agreements"
       }
      }
     },
     "localname": "LiabilitiesRelatedToIndemnificationAgreements",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LicenseAgreementAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement amount.",
        "label": "License Agreement Amount",
        "terseLabel": "License agreement amount"
       }
      }
     },
     "localname": "LicenseAgreementAmount",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LicenseAgreementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement percentage.",
        "label": "License Agreement Percentage",
        "terseLabel": "License agreement percentage"
       }
      }
     },
     "localname": "LicenseAgreementPercentage",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_LicenseAgreementTotalFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement total fee.",
        "label": "License Agreement Total Fee",
        "terseLabel": "License agreement total fee"
       }
      }
     },
     "localname": "LicenseAgreementTotalFee",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LicenseAndCollaborationRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration revenue.",
        "label": "License And Collaboration Revenue",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "LicenseAndCollaborationRevenue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_LicenseCollaborationAndManufacturingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, collaboration and manufacturing agreements.",
        "label": "License Collaboration And Manufacturing Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseCollaborationAndManufacturingAgreementsAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "atra_LicenseCollaborationAndManufacturingAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, collaboration and manufacturing agreements.",
        "label": "License Collaboration And Manufacturing Agreements [Line Items]",
        "terseLabel": "License, Collaboration and Manufacturing Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseCollaborationAndManufacturingAgreementsLineItems",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_LiquidityRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity risk.",
        "label": "Liquidity Risk Policy [Text Block]",
        "terseLabel": "Liquidity Risk"
       }
      }
     },
     "localname": "LiquidityRiskPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_LongTermLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term liabilities.",
        "label": "Long Term Liabilities [Member]",
        "terseLabel": "Long-Term Liabilities"
       }
      }
     },
     "localname": "LongTermLiabilitiesMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_MaximumOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum ownership percentage.",
        "label": "Maximum Ownership Percentage",
        "terseLabel": "Maximum ownership Percentage"
       }
      }
     },
     "localname": "MaximumOwnershipPercentage",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash increase to operating lease assets due to remeasurement of lease liabilities.",
        "label": "Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities",
        "terseLabel": "Non-cash increase to operating lease assets due to remeasurement of lease liabilities:"
       }
      }
     },
     "localname": "NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash investing and financing activities accrued costs related to at the market facility.",
        "label": "Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility",
        "terseLabel": "Accrued costs related to ATM facility"
       }
      }
     },
     "localname": "NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash investing and financing activities accrued costs related to underwritten public offering.",
        "label": "Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering",
        "terseLabel": "Accrued costs related to underwritten public offering"
       }
      }
     },
     "localname": "NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_NonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash operating lease expense.",
        "label": "Non Cash Operating Lease Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpense",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Additional Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_OperatingLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease cost.",
        "label": "Operating Lease Cost [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCostAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_OperatingLeaseCostIncludingShortTermLease": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease cost including short term lease.",
        "label": "Operating Lease Cost Including Short Term Lease",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCostIncludingShortTermLease",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_OtherCurrentLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current liabilities.",
        "label": "Other Current Liabilities Policy [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_OtherStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other states.",
        "label": "Other States [Member]",
        "terseLabel": "Other States"
       }
      }
     },
     "localname": "OtherStatesMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_OutLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-license Agreements.",
        "label": "Out License Agreements Disclosure [Text Block]",
        "terseLabel": "Out-license Agreements"
       }
      }
     },
     "localname": "OutLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission to be paid on gross sales proceeds of common stock sold.",
        "label": "Percentage Of Commission To Be Paid On Gross Sales Proceeds Of Common Stock Sold",
        "terseLabel": "Percentage of commission to be paid on gross sales proceeds of common stock sold"
       }
      }
     },
     "localname": "PercentageOfCommissionToBePaidOnGrossSalesProceedsOfCommonStockSold",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_PierreFabreCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pierre Fabre commercialization agreement.",
        "label": "Pierre Fabre Commercialization Agreement [Member]",
        "terseLabel": "Pierre Fabre Commercialization Agreement"
       }
      }
     },
     "localname": "PierreFabreCommercializationAgreementMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior notice period to increase or decrease maximum ownership percentage.",
        "label": "Prior Notice Period To Increase Or Decrease Maximum Ownership Percentage",
        "terseLabel": "Prior notice period"
       }
      }
     },
     "localname": "PriorNoticePeriodToIncreaseOrDecreaseMaximumOwnershipPercentage",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Proceeds from sale of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_ProceedsFromIssuanceOfCommonStockNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock net.",
        "label": "Proceeds From Issuance Of Common Stock Net",
        "verboseLabel": "Proceeds from sale of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock through at the market offering facilities not yet received.",
        "label": "Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received",
        "terseLabel": "Proceeds from issuance of common stock through ATM facilities not yet received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of pre-funded warrants in underwritten public offering.",
        "label": "Proceeds From Issuance Of Pre Funded Warrants In Underwritten Public Offering",
        "terseLabel": "Proceeds from sale of common stock and pre-funded warrants in underwritten offerings, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreFundedWarrantsInUnderwrittenPublicOffering",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_RestrictedCashRelatedToLetterOfCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash related to letter of credit.",
        "label": "Restricted Cash Related To Letter Of Credit",
        "terseLabel": "Restricted cash related to letter of credit"
       }
      }
     },
     "localname": "RestrictedCashRelatedToLetterOfCredit",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_RestrictedStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of restricted shares issued as compensation.",
        "label": "Restricted Stock Shares Issued",
        "terseLabel": "Restricted stock units, settled"
       }
      }
     },
     "localname": "RestrictedStockSharesIssued",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_RoyaltyEligibleToReceiveTermAfterFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty eligible to receive term after first commercial sale.",
        "label": "Royalty Eligible To Receive Term After First Commercial Sale",
        "terseLabel": "Royalty eligible to receive term after first commercial sale"
       }
      }
     },
     "localname": "RoyaltyEligibleToReceiveTermAfterFirstCommercialSale",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of license, collaboration and manufacturing agreements.",
        "label": "Schedule Of License Collaboration And Manufacturing Agreements [Table]",
        "terseLabel": "Schedule Of License Collaboration And Manufacturing Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfLicenseCollaborationAndManufacturingAgreementsTable",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of maturities of lease liabilities under operating and finance leases.",
        "label": "Schedule Of Maturities Of Lease Liabilities Under Operating And Finance Leases Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities Under Operating and Finance Leases"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesTableTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments options and restricted stock units outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options And Restricted Stock Units Outstanding",
        "terseLabel": "Outstanding options and RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAndRestrictedStockUnitsOutstanding",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options estimated grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value",
        "terseLabel": "Total estimated grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award percentage of annual increases in number of shares available for issuance as percent of common stock outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increases In Number Of Shares Available For Issuance As Percent Of Common Stock Outstanding",
        "terseLabel": "Annual increase in EIP/ESPP, subject to other limitations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreasesInNumberOfSharesAvailableForIssuanceAsPercentOfCommonStockOutstanding",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_ShareholderOwnershipPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders ownership percent.",
        "label": "Shareholder Ownership Percent",
        "terseLabel": "Ownership percent"
       }
      }
     },
     "localname": "ShareholderOwnershipPercent",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_SharesWithheldForTaxObligationsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares withheld for tax obligations, value.",
        "label": "Shares Withheld For Tax Obligations Value",
        "terseLabel": "Restricted stock units withheld for tax obligations, value"
       }
      }
     },
     "localname": "SharesWithheldForTaxObligationsValue",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_SouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco California.",
        "label": "South San Francisco California [Member]",
        "terseLabel": "South San Francisco California"
       }
      }
     },
     "localname": "SouthSanFranciscoCaliforniaMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_StockIssuedDuringPeriodAdditionalSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, additional shares, new issues.",
        "label": "Stock Issued During Period Additional Shares New Issues",
        "terseLabel": "Additional shares of our common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalSharesNewIssues",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised of pre-funded warrants.",
        "label": "Stock Issued During Period Shares Stock Options Exercised Of Pre Funded Warrants",
        "terseLabel": "Exercise of pre-funded warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedOfPreFundedWarrants",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "atra_StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options exercised of pre funded warrants.",
        "label": "Stock Issued During Period Value Stock Options Exercised Of Pre Funded Warrants",
        "terseLabel": "Exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedOfPreFundedWarrants",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of estimated fair value and related valuation input hierarchy of available-for-sale securities.",
        "label": "Summary Of Estimated Fair Value And Related Valuation Input Hierarchy Of Available For Sale Securities Table [Text Block]",
        "terseLabel": "Summary of Estimated Fair Value and Related Valuation Input Hierarchy of Available-for-Sale Securities"
       }
      }
     },
     "localname": "SummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesTableTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_SummaryOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of other information related to leases.",
        "label": "Summary Of Other Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Other Information Related to Leases"
       }
      }
     },
     "localname": "SummaryOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atra_TechnologyTransferAgreementsFeeRemainder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology transfer agreements fee remainder.",
        "label": "Technology Transfer Agreements Fee Remainder",
        "terseLabel": "Technology transfer agreements fee remainder"
       }
      }
     },
     "localname": "TechnologyTransferAgreementsFeeRemainder",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_TenPercentShareHolderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ten percent share holder.",
        "label": "Ten Percent Share Holder [Member]",
        "terseLabel": "10% Shareholder"
       }
      }
     },
     "localname": "TenPercentShareHolderMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_ThousandOaksCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thousand Oaks California.",
        "label": "Thousand Oaks California [Member]",
        "terseLabel": "Thousand Oaks California"
       }
      }
     },
     "localname": "ThousandOaksCaliforniaMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_TransactionFeePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction fee price.",
        "label": "Transaction Fee Price",
        "terseLabel": "Transaction fee price"
       }
      }
     },
     "localname": "TransactionFeePrice",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen equity incentive plan.",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_TwoThousandEighteenInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen inducement plan.",
        "label": "Two Thousand Eighteen Inducement Plan [Member]",
        "terseLabel": "2018 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenInducementPlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen employee stock purchase plan.",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 EIP and Inducement Plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan And Inducement Plan [Member]",
        "terseLabel": "2014 EIP and Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering",
        "verboseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "atra_UpfrontCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment received.",
        "label": "Upfront Cash Payment Received",
        "terseLabel": "Upfront cash payment received"
       }
      }
     },
     "localname": "UpfrontCashPaymentReceived",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_UpfrontPaymentRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Recognized",
        "label": "Upfront Payment Recognized",
        "terseLabel": "Upfront payment recognized"
       }
      }
     },
     "localname": "UpfrontPaymentRecognized",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "atra_WriteOffOfAccruedInterestReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of accrued interest receivable.",
        "label": "Write Off Of Accrued Interest Receivable",
        "terseLabel": "Write off, of accrued interest receivable"
       }
      }
     },
     "localname": "WriteOffOfAccruedInterestReceivable",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atra_WrittenAcceptanceOfBindingPurchaseOrderPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written acceptance of binding purchase order percentage.",
        "label": "Written Acceptance Of Binding Purchase Order Percentage",
        "terseLabel": "Written acceptance of binding purchase order percentage"
       }
      }
     },
     "localname": "WrittenAcceptanceOfBindingPurchaseOrderPercentage",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "atra_YearsOfManufacturingAndSupplyingCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Years of manufacturing and supplying cost.",
        "label": "Years Of Manufacturing And Supplying Cost",
        "terseLabel": "Years of manufacturing and supplying cost"
       }
      }
     },
     "localname": "YearsOfManufacturingAndSupplyingCost",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_YearsOfPotentialToManufacturingAndSupply": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Years of potential to manufacturing and supply.",
        "label": "Years Of Potential To Manufacturing And Supply",
        "terseLabel": "Years of potential to manufacturing and supply"
       }
      }
     },
     "localname": "YearsOfPotentialToManufacturingAndSupply",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "atra_YearsOfPotentialToPerformCellSelectionServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Years of potential to perform cell-selection services.",
        "label": "Years Of Potential To Perform Cell Selection Services",
        "terseLabel": "Years of potential to perform cell-selection services"
       }
      }
     },
     "localname": "YearsOfPotentialToPerformCellSelectionServices",
     "nsuri": "http://www.atarabio.com/20211231",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation Date Of Incorporation",
        "terseLabel": "Entity incorporation date"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "verboseLabel": "Entity incorporation state"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r46",
      "r102",
      "r103",
      "r211",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r210",
      "r220",
      "r267",
      "r268",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r457",
      "r459",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r210",
      "r220",
      "r267",
      "r268",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r457",
      "r459",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r210",
      "r220",
      "r258",
      "r267",
      "r268",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r457",
      "r459",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r210",
      "r220",
      "r258",
      "r267",
      "r268",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r457",
      "r459",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r102",
      "r103",
      "r211",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r254",
      "r256",
      "r458",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r254",
      "r256",
      "r458",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r152",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r184",
      "r189",
      "r190"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Asset retirement obligation accretion expense"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued operating expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r178"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r49",
      "r50",
      "r51",
      "r448",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r58",
      "r59",
      "r60",
      "r105",
      "r106",
      "r107",
      "r360",
      "r460",
      "r461",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r305",
      "r306",
      "r307",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r269",
      "r271",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r234",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Stock issuance, discounts, commissions and offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r271",
      "r302",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r166",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-Backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligation": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.",
        "label": "Asset Retirement Obligation",
        "periodEndLabel": "Balance as of December 31, 2021",
        "periodStartLabel": "Balance as of December 31, 2020"
       }
      }
     },
     "localname": "AssetRetirementObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationAccretionExpense": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion expense recognized during the period that is associated with an asset retirement obligation. Accretion expense measures and incorporates changes due to the passage of time into the carrying amount of the liability.",
        "label": "Asset Retirement Obligation Accretion Expense",
        "terseLabel": "Accretion expense"
       }
      }
     },
     "localname": "AssetRetirementObligationAccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfActivityForAROLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationsPolicy": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.",
        "label": "Asset Retirement Obligations Policy",
        "terseLabel": "Asset Retirement Obligations (\"ARO\")"
       }
      }
     },
     "localname": "AssetRetirementObligationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r136",
      "r144",
      "r148",
      "r171",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r355",
      "r361",
      "r377",
      "r408",
      "r410",
      "r428",
      "r446"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r43",
      "r96",
      "r171",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r355",
      "r361",
      "r377",
      "r408",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Total Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r157",
      "r173"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Total Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost",
        "terseLabel": "Maturing in one to five years, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r161",
      "r164",
      "r442"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Fair Value",
        "terseLabel": "Maturing in one to five years, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Debt Maturities Fair Value [Abstract]",
        "terseLabel": "Estimated Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r165",
      "r440"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis",
        "totalLabel": "Total available-for-sale securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis [Abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Amortized Cost",
        "terseLabel": "Maturing within one year, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r161",
      "r163",
      "r441"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "Maturing within one year, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r156",
      "r158",
      "r173",
      "r432"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Total Fair Value",
        "totalLabel": "Total available-for-sale securities, Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r272",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units Authorized",
        "terseLabel": "Authorized capital stock"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r85"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r85",
      "r90"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r378"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Amounts Classified As Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrants, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right",
        "terseLabel": "Number of securities called by each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r195",
      "r433",
      "r452"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r196",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Total reserved shares of common stock",
        "verboseLabel": "Shares of common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Including Additional Paid In Capital Net Of Discount [Abstract]"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock\u2014$0.0001 par value, 500,000 shares authorized as of December 31, 2021 and 2020, respectively; 91,671 and 83,372 shares issued and outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r63",
      "r436",
      "r454"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r243",
      "r244",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r243",
      "r244",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r243",
      "r244",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligations"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r259",
      "r266",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Obligations"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r337"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense Benefit",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r337",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Current provision for (benefit from) income taxes:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income Noncurrent",
        "terseLabel": "Deferred revenue - long-term"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic",
        "terseLabel": "Net operating loss carryforwards, federal"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local",
        "terseLabel": "Net operating loss carryforwards, state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r334",
      "r335",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r334",
      "r335",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets Tax Deferred Expense",
        "terseLabel": "Capitalized expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.",
        "label": "Deferred Tax Expense From Stock Options Exercised",
        "terseLabel": "Net tax benefits related to exercised options"
       }
      }
     },
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r317",
      "r331"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Defined contribution plan, maximum percentage of an individual's eligible earnings"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Defined contribution plan, matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r83",
      "r176"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Description Of Defined Contribution Pension And Other Postretirement Plans",
        "terseLabel": "Defined contribution plan, plan name"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Basic and diluted net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r99",
      "r319",
      "r347"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal income taxes at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r319",
      "r347"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r319",
      "r347"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Other",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r319",
      "r347"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Impact of stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r319",
      "r347"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryTaxRatesToEffectiveTaxRatesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized stock-based compensation weighted average recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Vested and Unvested Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r58",
      "r59",
      "r60",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r123",
      "r172",
      "r234",
      "r241",
      "r305",
      "r306",
      "r307",
      "r340",
      "r341",
      "r367",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r460",
      "r461",
      "r462",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r370",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r212",
      "r259",
      "r260",
      "r265",
      "r266",
      "r370",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r259",
      "r260",
      "r265",
      "r266",
      "r370",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r390",
      "r397",
      "r406"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": 10020.0,
       "parentTag": "atra_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r392",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease Interest Payment On Liability",
        "terseLabel": "Operating cash flows for finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r388",
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease Liability Current",
        "terseLabel": "Current portion of finance lease liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease Liability Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Payments Due",
        "totalLabel": "Finance leases, Total minimum payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due After Year Five",
        "terseLabel": "Finance leases, Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "Finance leases, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Five",
        "terseLabel": "Finance leases, 2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Four",
        "terseLabel": "Finance leases, 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Three",
        "terseLabel": "Finance leases, 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Two",
        "terseLabel": "Finance leases, 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r391",
      "r400"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease Principal Payments",
        "negatedLabel": "Principal payments on finance and capital lease obligations",
        "terseLabel": "Financing cash flows for finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r390",
      "r397",
      "r406"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": 10010.0,
       "parentTag": "atra_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r402",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain Loss On Sale Of Property Plant Equipment",
        "negatedLabel": "Loss on disposals of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r83",
      "r175",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r98",
      "r346"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r136",
      "r143",
      "r146",
      "r147",
      "r149",
      "r426",
      "r434",
      "r437",
      "r455"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r98",
      "r346"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossesBeforeProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r320",
      "r327",
      "r333",
      "r342",
      "r348",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r115",
      "r116",
      "r135",
      "r318",
      "r343",
      "r349",
      "r456"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r315",
      "r316",
      "r327",
      "r328",
      "r332",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Other Operating Assets And Liabilities Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r80",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "negatedLabel": "Amortization (accretion) of investment premiums (discounts)"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Amortized Cost and Fair Value of Available for Sale Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Finance Lease Term Of Contract1",
        "terseLabel": "Lease initial term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Operating leases, Total minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10170.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Operating leases, Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "Operating leases, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10160.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "Operating leases, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "Operating leases, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "Operating leases, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "Operating leases, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r96",
      "r145",
      "r171",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r356",
      "r361",
      "r362",
      "r377",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r96",
      "r171",
      "r377",
      "r410",
      "r429",
      "r450"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r96",
      "r171",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r356",
      "r361",
      "r362",
      "r377",
      "r408",
      "r409",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManufacturingCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred in the production of goods for sale.",
        "label": "Manufacturing Costs",
        "terseLabel": "Manufacturing services"
       }
      }
     },
     "localname": "ManufacturingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r52",
      "r54",
      "r60",
      "r62",
      "r84",
      "r96",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r115",
      "r116",
      "r117",
      "r136",
      "r143",
      "r146",
      "r147",
      "r149",
      "r171",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r368",
      "r377",
      "r435",
      "r453"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number Of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r143",
      "r146",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r398",
      "r406"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": 10030.0,
       "parentTag": "atra_OperatingLeaseCostIncludingShortTermLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail2": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "positiveTerseLabel": "Present value of lease liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities - long-term",
        "verboseLabel": "Operating lease liabilities - long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesUnderOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r393",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r402",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards Limitations On Use",
        "terseLabel": "Net tax operating losses, expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r35"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities Table [Text Block]",
        "terseLabel": "Summary of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOtherCurrentLiabilitiesDetails",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments To Acquire Short Term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r272",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock through ATM facilities, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds From Payments For Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds From Sale Maturity And Collection Of Shortterm Investments",
        "terseLabel": "Proceeds from maturities and sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds From Sale Of Property Plant And Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from employee stock awards"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r52",
      "r54",
      "r60",
      "r78",
      "r96",
      "r108",
      "r115",
      "r116",
      "r136",
      "r143",
      "r146",
      "r147",
      "r149",
      "r171",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r354",
      "r358",
      "r359",
      "r363",
      "r364",
      "r368",
      "r377",
      "r437"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r177"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r179",
      "r410",
      "r443",
      "r451"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Net By Type [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r179",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r313",
      "r424",
      "r500"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r90",
      "r427",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r85",
      "r90",
      "r427",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "terseLabel": "Letter of credit maintained"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r85",
      "r90",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Letter of credit issued, classified as long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r11",
      "r90"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Current",
        "terseLabel": "Restricted cash - short-term"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r90",
      "r484"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash - long-term"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings",
        "verboseLabel": "RSU settlements, net of shares withheld, shares"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Value Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "RSU settlements, net of shares withheld"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r241",
      "r308",
      "r410",
      "r449",
      "r463",
      "r465"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r172",
      "r305",
      "r306",
      "r307",
      "r340",
      "r341",
      "r367",
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Revenue expected to be recognized over period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r401",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability",
        "terseLabel": "Finance lease assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r401",
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "verboseLabel": "Operating lease assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerCommonShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Antidilutive Securities Excluded From Computation of Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r162",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.",
        "label": "Schedule Of Change In Asset Retirement Obligation Table [Text Block]",
        "terseLabel": "Summary of Activity for ARO Liabilities"
       }
      }
     },
     "localname": "ScheduleOfChangeInAssetRetirementObligationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Components of Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Statutory Tax Rates to Effective Tax Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r271",
      "r301",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationRelatedToStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r271",
      "r301",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Related to Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Losses Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r90",
      "r427",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r272",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r280",
      "r290",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Options Estimated with Weighted Average"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r94",
      "r124",
      "r125",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r227",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceUnderEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r326",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Share based compensation, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Shares, Outstanding as of December 31, 2021",
        "periodStartLabel": "Shares, Unvested as of December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2021",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested as of December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Estimated fair value, vested in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Maximum increase in number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares of common stock, reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Option intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Forfeited or expired, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Granted, Shares",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r282",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Outstanding, Shares, ending balance",
        "periodStartLabel": "Outstanding, Shares, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Weighted Average Exercise Price, ending balance",
        "periodStartLabel": "Outstanding, Weighted Average Exercise Price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Vested and expected to vest, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Stock options vested and expected to vest, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award",
        "terseLabel": "Stock option granted description terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRSUActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired, Weighted Average Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r272",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Option price to purchase shares"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Share based compensation award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r296",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfEstimatedWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Stock options vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Estimated fair value of stock option, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of employees purchase price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "verboseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid For Tax Withholding For Share Based Compensation",
        "terseLabel": "Restricted stock units withheld for tax obligations"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r15",
      "r430",
      "r431",
      "r445"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short Term Investments [Member]",
        "terseLabel": "Amounts Classified As Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r399",
      "r406"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail": {
       "order": 10040.0,
       "parentTag": "atra_OperatingLeaseCostIncludingShortTermLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r91",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r58",
      "r59",
      "r60",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r123",
      "r172",
      "r234",
      "r241",
      "r305",
      "r306",
      "r307",
      "r340",
      "r341",
      "r367",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r460",
      "r461",
      "r462",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r123",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r234",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "verboseLabel": "Shares purchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r234",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation Gross",
        "terseLabel": "Stock options, issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r234",
      "r241",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Exercised, Shares",
        "verboseLabel": "Common stock, shares exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r234",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "verboseLabel": "Stock may be issued or transferred, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r96",
      "r155",
      "r171",
      "r377",
      "r410"
     ],
     "calculation": {
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r385",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r385",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r385",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r385",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToLeasesDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureOutLicenseAgreementsAdditionalInformationDetail1",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).",
        "label": "U S Government Agencies Shortterm Debt Securities [Member]",
        "terseLabel": "Government Agency Obligations"
       }
      }
     },
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r101",
      "r259",
      "r266",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Obligations"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfEstimatedFairValueAndRelatedValuationInputHierarchyOfAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r314",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "negatedLabel": "Gross decreases for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Gross increases for tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Gross increases for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits if recognized would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance tax"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding used to calculate basic and diluted net loss per common share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.atarabio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13201-110859"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r505": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r506": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r507": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r509": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r510": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001564590-22-007633-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-007633-xbrl.zip
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MHK40<8**SU$P&L>&1P*&.W'=!_F5SE'&D.TNIS5O/_<;A/QXH[S7!)#\NSW
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MPZ55P;J"!X'>"T0P1@,#N 9P2P&XII+XJP/N,J7$[P+AV6($>FTFB>:2<Y7
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M9&<>PN"H/T;2&T/IU-TX%)X.5$ES<RK8]NH1<!+_Q2?HZ_CDE3)/7P2@NK.
MBB6B"9Q:DCUB+R]W;%!]<WG3H+I!=8/J)43U"<T\1*CV@YR&GF3T*#4=D#O*
M:-SN&-"9A;[,UH0EB8U/<:,YSF"UP6J#U27$:MD:.!(A(C-&B*C25K;OR=(G
M(06$<T<ET*O?0FQ<G[V>@?H=D:$DZ:*DKFY%+&!6IWJ&8N VU<U15;_.!1O"
M7R0T)ELKX?O%*)KHW90T39*" 1YG9,-&<KB1#48V&-E01MD@&]11\H\?1F$6
MV?^*@80]W6).E=;*QX[+-F\3IG2E[\--M05U^63A,LO2:(Z*%H[F*CR450HF
MEB#GXOMJD:7=^=B9;.6.@9>^AXFPJMV]:FJ>2$.\((R[Z&-&$G\#7/-4WWOY
M=R#";V$%/JJV]9'(]2&L4(@_MA>D!N0J[8MN4H_)W(<2VX<EP?6DS  IV<,(
M!JCZ)?*JE/2TF ,&\[)Y3.T $^_*1+J7K:UU^+#T=>-\VUR9%"S%=F%/W(HR
MT@W9V IAHQ*C>3@R92S<%7LY"V$E26?()!>K1NM%&]^F;(D/RW%4_>_SX+&0
MNUZ0G?;5= :!GL^(]7FU"^?D;U76@^F<,O>1C<,=ZUW1MBG&MZ?GF)7/R^W&
M->Z]::&RGG'DM@? X;0I.]5TD9\SIFOA66W8R@.K#3.Y###H+[1E;@]]SP//
M.D,,]@-/,(D?4=Z]&07DO)2=KF?8S-$PDS>8XR/(:%Y%H_DX:[8)*DDZT8S\
M(7H<Y??D[>Z$,(\#?XB&=SQ;('BDNW=7J V=,1LQ0@E=V4O6$X#KX$(</]F$
M]'!1OOBXWK[]+865I/*7/4XN9.$@4R-L5JU'_<Z9*LIZN"F3/84+@J%&5 D-
M8=)F<2@=W\K)G08?'3<;[S_ 9&4DOTKXK5@N\B:M.)[\'NC<E8DIQ><P>R#@
M*BF^8$FZW,)2FH&TT#FBU^,DR'H!+"Q('FQ3"\+%%B,2*]TQK0,\\9$!.[F^
M_PT9/16)->L/ZOEJQ[#0\-:Q.DW"<Z34@DT ?!2J/NSXL0]XAXEN#@?)XJJB
M^?B6 6>TC4@IK']HM&K6/3S#NI24HJ\;'V0_7C?DCT!%/O'\FO6G'ULA2% 7
M^,*/R$-DQ2/?FS,'W%!909XF4@/E:([('SB=9-&F93&N(#PNZ'-%2ZIRY]._
MDO,%S#ZD08W\,!1X3NU)FRI(@:$ZG*MQ6+ \L\1^3NMZ$>U*<C/N%V'_(.8O
ML1>NU,JU/ ^Y^EXR"*S4)5QA->K5WU!/<A%!E,D"'ZY+O89R&SV*$,BK.(;L
M%!7-)]DOK4^"+F<C4G_"R8O.?-!*O/'DUX]\\AO8EY4L(ZJOXX0[AQQE1/%+
MK2O/KN%MJ!UQ;4,?!:C"@1P!3@3=,12. %K!.O_8^FH]0*U/UW>=I=?VN3#7
M1MM2,,YMWQ?CUO4@]VW6FRW"K);OQ;#O_3B<J:<G$#]@#[#H"0)C!1X> %1R
M@&&;>#^O$J>I HDQ3S8Y3RH^I(*_9G4RL(L'D:$/_Y&%>QP>VH'H(J*#-O.8
MOU8J,(A2((+[<E^%IVJ]C*VM9!8#8VLSMC9C:RNAK0V.183O *=H'7)(F$=,
M]B%Q?0IN F"WN5+N;3XB0*=S7Z)S2V$!SZ+JQZCT""\F39*>FWLH:96>C7YV
MU&C5.W3V+_P+&,\)I*4^:T*E-I=Y#>P;V#>P7T[85]X 5RGXGE\4'$4F=3@D
MZ$L"-"[$B-=H+K"G^A2B5<<;YQ^ 9P@/[@NL/O=0\><3CY&Q *ZN&2'O3,U
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MHU;(R92!@^G310B(:*@)+([5DE'=/JS_G>2XGB,.,K,W4Z(EK*]7;/,Q,5,
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ME6(N*PWA>:JD0:EI<W-WMH4'D!M&)=V#L:>JNL/AVH,76[LPWST*,;8BM,J
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M-I-' Q**A9@5U$>$V,+E3U@Y^A: +325"N!Y3(6B#^GS;PK0?<MP>B3^>PY
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M/5.1)>[''V[B+M?_NM@Q8R*CGHN5^TNZDA;X XJKIHL^V^Z.Q>Z.*;.TB-,
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M-CM";3?]';\[^?YPQ$&,W 8:KL(F#'U[)'8/+(V2204FO%7AI;EX?;YCF%:
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M2,J^T,Q;</O*(!W/@I JUA%WUJ'%.GAQ?O8&;&1+:R;/72+IT@5GOVZT_Z.
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M%:81Z^:^C7Z,7IEFOA42P>.KB(Z:^I,4B\(R/CLFFE!7,,@ I!5C)70M+ T
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M&=K,7VLV"^.-P7WL7V5JD[FID#$4U)J)2/J(V"B4S,O&U"M(3(#+H)C:[NL
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MSN7'3Y:_DUZ&X_RK>^0D@@M3Q^4]OKE?5?(.-85[:->;XE@7\3Y[C'Z23Z<
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MR5/=:H^T*VL3BK?E)J:-+X&*6RT*BV /9/OAH.9S4P+;BIF;U44&]C9_-R_
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M+58Z3&V*'S\X<%PZRM9B'? ]"6+DK+/Z'IR<G0C%OWCOP0HSH0;5&V/!C]"
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M'\N)C<E<E*9NA^S\N;OZ ^'B1L@M.83+D$KB$WB*XB=**G[@,UI4K:&7^PE
M_"PKS;MTP(@+CEJ?8/<Q/4CGGOYPI17B3X4LJ,1++[Z[XF47_AWTBTM?N:/_
M4$@\9V90.<WV^TZ+>B[DJOXKC)-2"@B>1Y\,]&6(+OGCP%\,U)E%.@MYZL*
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M_9;9^9Y WP:=>6C"8'D'T"N]_,P!Z :"[>1U0D!)).\F@U;L)N1,%G!%BP_
M8Z"5YD"S"W#B%/A:W\@(9Q8#>;XB"3!,@,%VCU]V4S<T<@%6;-V@4Q6>0.#D
M3P(N:-:;LMX:P_0"4J9-75W6(L2YQ?%"L2,^?[]\=ZD#%-'T9.Z"H- R?T@(
MZ7S+"NF</EP V.%B!7[)=4T*'%)7 "AH+:M&8OTJ:V@QGSQZ\HAK$.M:8+,'
M$Z07PZSS,=B4Y#TS3%_(_N"8ZW$*9 ](:FG*;3V^+H8).G#(K;/Z<E6YR07S
MEB2(J^@?# @K6H-!ICNP=:-+94VAI9#+Y"4ZG\C"!<0P8@O7)FL%JMFC")/D
M_&09+9BX$Q0*M#I@G@&TMB#EUWWG6.$\3JE;_$RY92P$KUR#;ND1+:/\FL9T
M@WO6T(>YL>C$'K97Q[4&JN\.QX:@ M:-H#U?T"_D?G<-GAL5.;V/QS!/>&VR
MP3NZ;J>.5&8WHF4#U:X@C1[GB?=2[0J=+U!R_,+TJ/ V&B$ *&O&EEJ9$IXI
M-AY"XO[LRUT7)'PUEA;T.CBK%>/!TP1&TKJI2_#VM*-QT!KV#93CA4PX40X/
M.39*ZU&0(LS\1@A7#2A5.8NK)D,=$;Z7GEI@]%T3P$Z/0)K:BXWVHHMXF_"F
M9!;2;QU@GJN>]_"'SD*F%I(1BD@55 O.'@719!QI"UYNA4EFQ_#6UKA48UAS
M1;8<SD-M%^T&"5J#/#8JE9\=!/27)PP!?0;AQ&Y(_=N,XX6R9PTTQ(1J<>=\
MST%Q4.BD1RLH/M#WD&RGR<+D0,M-59VQ/6(%YO648/2S.TKQB]D("0JT,W,T
M6\76KOHNKV]"-H7!:/24NU.YF'('U&VJY_.^D:L=ZD71<"L>8IZ&%N>@Z?<#
M*2JN7-4]>!=:$"VP=X)G!U[ST((.Z'*DXVSJ8GAPZ;LP3K_\G30?C?!=YRX*
MRD#F(%9M+/$'4\8)N8-H+9YQJQ1DXJ"[F% P\4/EW/9DOIC"K*C8RON @_>S
MRK,F%U(X@)LHX?8*P6X9AEJR!":WA&9^N(-IDE8WK3"!.^* HA7<1/@&]AK.
M:''"1$>;/'CVZG7[4+Q02Q:FC_6.4&&!MKTO8JH5?"!R(Y#:SA!>M-[U\7SB
MUJ7A];#4"JFX'&%TR0[3=N!0S(QPI3A6D,)"!?,RTYZ4IO^0;?"HMFBYF]Q8
MM@S9(_UHD]WX_4OZ5IS+,#MSN3=W]]LHFN1VY/AST-NO^UWL-6PS_9?W]]8(
M;#K_$&H908C6E,".RKE,GCET4=( M.TD@)F# M+0B*2Y(>%A^>4W^BQ3;E-+
MV6Z,,YEEL!YT0$]C?7^?7%S5K1"T>,SPKKZ!=ABX[!EY! )_-UY$)+J& V+B
M1(DT8%WF2%8@%VL]=]6K&(]5N4*ZHHAX>=XP]\8[]G!M9V](':<0^0SFNI6P
M93@L!EJJZ1BVZ \+;"1>3G;-+?>:;)DE-W%'7 5@SHK&--<<,@@;DQN.4VEN
MF; 0#=/?S<4"^==>)B\\71!KA-)("#D:-B3#WS)WX.I^+_'K-TSL],7XNQ"%
M;(8KZ?]!RF8WZ__U'W__+7SPBY6<JL=/R$EC]BEZACJTG- G/^VK+Y'Y[S?_
M*:ZXSID7^OG3?_Q[\N;]#]^E&NXF'%VQ(G:BBQGX8+_%1LK46*;9.1>NOZ2=
M-W2FW/'QCZ#I( WF7JY2[)T/3)D=C*DXDXWH@N)A/,?:>!9X_XEP+.FDWE>2
M'#L&YC/]ZMO$&W^$X +L/@\/-PFO?<V%&UR3 3-@X/@X!>1%#Y'\:&,]F'XJ
M?E763LE-DF==1E)%>J5V&02#^"^;4^PF",46DJQJR\S2->%KWF*E%N[ /B*C
M#VU;S.E*#BU%^*TYI'I <#'#P>&$4V<HF&T04;5E?7,!1Q!2U=+ON>8K81T%
MLKDX!.J6E$BFDS;MUS[Y[4B<<B.D6")#%%HNF4+-GNI-O>EE?NZ*[R<X&O8<
MXIANV:NX(OU:<I*(%T%5_&@5-LP9:#V( ^+O1%\]A.>OGK[^X3MY'?Y^]?[J
M\==?[Y[0-Z_>@;&D6S%7%#B3X.$X:BG2TVOSZU[N/ZX[L"B:MG/+;^?&GZ4?
M_JNOC*[*8:]<>%=#*D2X]D77<_RAS"L?8_G(N$A85&[3<7*@(=GJBTXS4YRM
MHVVM0-Y<*MT&7$IF;('DXNB12[U )J/FI&5@/M!%44@4Y(17A,Q4S(I+3C)2
M1@/5I?DVGQZV;OCY4P2/R7&/=I_&.;[#98DPBQQ0"*K*LH%=-<Q8C=.F(3IC
MP"F$)X VCI-7 =F8M=HAX^"8U4,3A"'9NB<A6]$R,Y6T(]Q#6IUB,O%Z-@WN
M-$&;B,-35PM0NY![E75"'(@LFS<1&"=Y9 7"#;*>S8"D-\B![]JE=)15J#G'
M#D@<I9D;9.S!.8Y)Z<%=VS/G4O;X-,[@.,RUB^F:1RME2!GF))9E/>-JE$J
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M=X#!B@JN:9&-8I1R+><.8HIT4/^U&&CTVXV9<R58(%,I*@&6ISS'!2Q!\FF
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M]_#LVSF&:0,+ >!A*RLGY,C3/XMV-9(-A8 ,-[&%1[_(% M:2\4W16MN*5
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MAA-B'<KRP*H >L)E7SNHAF6!BIC/>VKF<+S2G \DGW]'*>KW;"(JW_DFHKV
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M(?@EG5K; #@QAD/[_Z?3-PM_W[=3OFGF@#*'"(A@;)W$U&.Q"(]PW\H&3'K
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M0<9>X+-^]/K+%V\^5@(<Z8)A+U#&G!I'MD'/BM@ZL-W:(&HE%;7>P#R#?UO
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M9L%4TRM\YSSV8U1"PNVW#\^LZA3$>76RR,(#1E0^TVP=1Y?$K"+J:^<%37A
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MBG;X]Y))D  [:L\[0CA/B=FUA?'V"_4FFEK[FGNPBA38^,S48"1E1,7\XKI
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MQ"Z[<N8=^OV][T%A922<T<5,]1:<=\F)AT$O<=2;$2U$ZA#&%?R3L'WBQCN
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M9'R-!?H[M"K(0S8N!*&8U5W%JQ*?J1!W> ][V'D< 7?](JB_9%)'\8HICU=
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M%43%\']A Q%S3C1O$>I^=.M"3.]'_0/8"KB\>KKCU.>\KBA%#D.*7ZLH<%[
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M=[PK%^70RB>?:_WV7HV#.F/#UCH46<7R6HM_&<X09</=)V)#8,6.6+\G4!J
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MK$!8!K#Z>'TU6 IG:R/=YXU:<(G-RS4:&2QC_KTJ8 ;?!+34\(<=Q*)M".B
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ME&Y!):\(W 985['2VR0!\*2^@IT+KC+5!%0=;+1--R6IA?M[50 KFP*OE*(
M\P&/)>#=,(.F!GX'!P;GA>I?BX?ZJS0S]%Z.4)5-#6KLKIU]O/\JTNUVEX6
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MGE6CQ#JN6,<5Z[CVL(YKA18X,^%I#=I[D)1*,59.#5GASZ?'*3R%__>22MA
M;+1$)Q4#& SF&YB06>O2-'.#OA*07Q$YX7#)-3+ZR.@CH]]'1H\9,I2EB#FA
M8 I<9C.,^1H;I-KD_[Y';N!<J\Q5N4Y0]T=[PSZQ*%8M.393=!H;S!=IV<#$
MTD4-\U*.#YD?4\I3*EW6#^;UP7:2.XARTRCME&H7T%<42J<%E61AX4&!^8-J
M:)08%X9UHK?Y7WW=],LH40[W7D2)$B5*E"A[*%%L$B3+E"TF! 5$4/+D'$[L
M%EAW3?6V5&N*QH+)L-Z42G I28>",?"UH[7)T#F475Q0PCLY>EQ^W7L,P6TX
MK3S78B@X<(+>O*B\<%$WG93E4OP&MC3*BL.E^"@KHJR(LF(/987F=[+U4:T5
M:H';Y6$ JQJ-$RW[ML-O<&0+PQSP>)+W:'MD9#=P40,EL:P,HVX80\D.6# V
M#%!AQJ3_PJL& ^N4O]$2-D+D_8=*P9'W1]X?>?\>\O[ \Q1P9(5*P,153.#E
M0BY!E)AB00[I\%OX.:>>88H7!@VP"B8O<JP(I;BUPFR@ \I+<>IV#$C"1F<K
M^! H,1@<C&0%/"8)@9AZ1Q)GO@XK.[)6"[)LW14F<2J@E?]*"\7#+XG2YW#O
M4)0^4?I$Z;.'T@<U?N7IE+K>+ZF&D.,+5'TJ86IJ CO%K.JROM*$X #]PO<F
M49W*.+("9K-V)2?H4@P#?4U@\UB1-(RQTP=:]X,#NT]M:KHOTR*J]6&3?!06
M45A$8;&'PB(T54)_DD.M&P'Y$V=4795K]6.-A=,I27:1%0W7=-L"S<VPB4*^
M+0HSQW*E64\BBT/=S1U'SD8 5)&$4G63E @V!&;7%-.""3FIZ0E<B1+(;<XY
M>A8_4]XY/K_,R#X=SXS>-O#2(#I6N_UP,8)54^T2PJQ@#WNMJ\M6J[I@_!BJ
M90E'\C.@#QS7(2A$GKJB=MP4EP+/M76:L)[J%Q@7A7-&WHI*=7K\4$G&)KC_
M79J%G'L9]3]BUHD#Z'#E$2D#W/K4A* /M58G^CGM5.MH<(,O.(#9(_HOUQC"
M1ZAR LD4A(JOZ2X(UKRS@&*2_$R546%^?I;X]0""BYD&X/&FNL#R#@IH>K 0
MRRGZ15Q%(EP-@4^!?3IY]&=;L(E5!PAQ%H #])5DT:@*3)@P"U/F'I0]EU]C
M/!<#M;@MVR")S!B/(Y09@C$UN5;\.4A29 (8\%7JWU4*@6OA6@?\*2B5L3CW
M5'HHI6)S/FQR C5<A]HP?): +7%))^&U<H4$(9$))C[B)/45V@&C1>G$"F:&
M*O L!JA#_]P!8N<*I,F]Y.&!2H$TB24L&'(EF[A.K)A3/UJVOAE>Z.'4:;V8
M^_7)5'-B6_YDY1HQ0@0+@U!@6D*O GJ$*XZ76?X&EP$1$45@]-4\NP3B80!Z
M^38(E[X;(*,,:]0)3D@*4P6D3@JM#$)B[\0=.( RI7=>W:V"Q8]0DZ*](-"_
M-J#0 DRWG521Q*!B3+G7G*(>%9]#WUKPN@# @NXQ\^=KQD,I2\"-.%9>7U47
MA/;OCM0CCQT$T5MM;#M97 F3>(^ ATH*"5"N7QG/\JDU;H8SPU@-,$</-%PQ
M]Q"G*BM*BV]$E,W["7O=MX*'U)1K%%Y+:5G@S<U2)I5H6;E'8,/C$ PCY$TP
M@=?2]J?PD%N0^L?2M:H"?C>:3[JI7QJ37H 1VGZ& -5R%6TJ;S:5AA(65(9A
M  9FA.!DUZ@S-]2=1"%HL):SAJ\BN_Q7#VN9%\9#HCIP+B<XC L8D*XK[ATR
M%,(CW;%3K-6\-VM73&_QY0C.2OV"@C2EP#IRKT=&M>@"P: !G/BL0'_B''OD
M4*L/0KBK Y0P>RY:SUDL5X81:4%O!1/RTOAX0 YAL"8@2IC1""C6@=?%/]SC
MNO@#,- VG51?KF[Z)DQNUO2%Y5^I7(Z0CP4@&&!?E-T">ZJ@54GTS?FI_ T&
MWW,86-K>(&$'EJ"D#F U6+B[LGT_[" 0F!EL#JA.BG_I7F:%LT$(#)LFI9S#
MLANQ1DQVZ2^(I^NPOB6OMF;(&U1B.,(\ 5L86$/'E?WDQ'C/Y1<.9%"$1=!7
M\\(@Y.\*9DBXS]0-65"_6V,K_]E&&AS-HA#D4Q$M(]($#Q24<[/B:(2 (3!X
M>5D2;@S.!M03 HO![[@-H=-?DM#J?.TI]5&K",TS U5)(&\S,@@$=J1UL+]R
M8OD T(2. PTN[LUB 8JDLX.E&L,L/WQ8/(0>#I1ML\2> ?1!,<'(U@>86$0)
M#:(OK&M1A]4RU7WW#A[?5%1MC_*E,(PU0Y#$!N4[JZ%E/VLR%4.$HN9@)5T_
MM>M1%_;<;$3.06A02*Y8E\1W8@94#1:T[1%2-/D18QN Z5PWK47D\E":/:Q1
M MQX7\S>3S.L=9TW6<_8"QD8!R:EVM9LMO;4!=M&+0#)]7LLF0\$2\S8E[.F
MP(26$NBUFLF79U@O"_<%_LR(5D0!&?;P BLL6P*K:Y'WK?I.F\5@%S !J87A
MP'3 "]?4\T+@1 ;(@@>NT/W@FL_)%0Z+UU:+=8N.MZI-=Q[["CV Z+0IEL@K
MFII T,2LI?96"&FL8$28LP3'M=*8+EY" 1P=9B,Y+-\I<4&_"9]M*/3*\T-[
M9T1 9!?"(@3";&/ZC.2MI(U<(:"J:5-G>;GV*7E NA[%>JW\QHB7>9*T.D0?
MO.R0#\GJ &6#V?-(_IWL%@T+8=T@!*#%#0S<"%>"4H(.B921[02 N6N*:2_"
M7<%>!8MR6M2C71S74BGHQ+^%4A6D:T)3%B;+U>W4XF@>-#FT.CYVX4-O"/DU
M&;#ZI<F+&;FL^:<B=YK^YN$!&P%MO1$X8H)PN?8,5HQ@)EZ_L;-<P3=QTR7)
M3$$B,Q''MA]9@*,\\+;,/9)]_OW91M.I$&77)WI\Q114A2KH"L>!#21+"\PK
MQ/-S1<VEWN+BQ;_B,-:(E/$J,'88]\;#70D0UD(1FUKOD;9+H%Z8^!*6 P[K
MF7YW@](.H?]5W#D,^"\@;HP\0]^CQAG2U7/,Z^V'E3SH:'J;:WK&GEP$#]=K
M;"E?3S" [^$$20'\F7M0H:G<#X6B1@SE3+MT4<.&U%T88F%6O4TE#E)Q?B/A
MS;6M0,]9'#K7DD4F!GM&OG#6(WC1CHNXG@$^!Y"H!6)D;X#16NIB/_BPF>"U
M-(=(CH68O0$]"7Z]=Z8JW*7UBS3Z1,4-WN^W7QC>PR5#=1ML>#KLP*##X!<G
MR1N_WR@3KL]];WWC+=>5L( >QO@^*_%[FKC"R ML4@I/LFJ)[(YT=TI9DB:F
MM61!14BE/4V%B$E$,8DH)A'M81(1L4]A[QY3/T/+\9]B.9)@ KV5 OQJ\=EP
M-2<XH%[HMQCE%! 5\;8C3.HD/8SA9+TV.'<MJS>U;])%%B/&DU-7*9F5'I^2
M=;,HIEH&,:+SL$]'7 KO*Y(@TF<(9?"\+[DA&/82I4%4=4@E9BXA>9X(]X99
M]I7 7:=.R>: G_R6DE]&_CR3G\D!1)X>;F?^'KZ?LC)'OB3*_T$732I?: PH
M4^05@RTM9%G&&@"L?]!;86H]-Y)Q??0$>!W_D',:R,!BK.<IZ2\7=9U[[2A2
MSSX$<V#)24CD,EIBM%(TAS&*DK.V#7?4ZJ#M5L,C%I4<+J.*(CZ*^"CB]U3$
M/__^_(PX[>L?WIZI0U<%)*=O%NVTD?(-\LWD?=F9QEJSTP*&O2#/E'6'6'^_
MF'X,:Y\WO1K7V@&0/_4@SZ6B<610+A>),N @*3G*@"@#H@S80QF@"CD'Y\AE
MJ8;</"M;PK@JEBTY\X:M3?B9Y_2U<_Z:U]Y5VB>;"C9H1JG1'"/AI^ [;5>:
M:5E?L9WQK[Y(NFPID"HB)OB[8*&9#B-9'#M<LV=1VJ#:Z;KOVQ!CDF$3F+;S
MS!VR"=4:)*/%V7=2O<\674.YA1*9F!K]T+#UY5O';.=R^D.X0:.FC&?<RM[.
MJ>T:&TU</L$.9"M%^20P((41DKZ4+TI=1R:?V^;<%.R]K(L\]5H9-MPDAC;*
M:_2IV=:XQ^OM*XOVU^%RD"A[H^R-LG</9:_7[ALD%B52L9_,Y\&<%)*\J-J^
MH3COZ[KI-!Z&<N6,N[7KGZ03]LG3IX^3^S^\>'UV]F"'J"P+?2X4A:&K4U)^
MV:DIE8DB&?DC\@"WLX7A+KD9USA)UKV&]=>^UT_[IJCWSZ+1#.<:S'#<7;MM
MVB@6B_E:HL$D_&0-Y%VE*KB5WV 8RS1]P5JM[6<RG"=EV[&.>01[8$ILB\PQ
M7B?9<8,W-P"5*A@O:.T;A>WALHPH;*.PC<)V#X4MB4+*0=)>8]-U\L.+=\_.
M?_ %3^O91H'!BX5IG.KHIZTJEC/R?BR#EU3;-IN;BSYKK"4H";6I5ONMM4:M
M:C5)B=JFJ9F*';5SKI@A-LZ" [Z A\"&&U4Q3]<LRS#96XU:J>4I_.0E31OS
M/VW[J2Z%^Q!DF$ED.(VJK-EH=%T/0%)3_<)M)ADEV>'>QRC)HB2+DFP/)9EO
M';[6DH#D-9L9;?*VQ[28RK OML"LFR4Y+J5-6?)J9;ROOV8#++4A.0(!;6UB
M)JRP1[NH;P3#1:)XN;GDO!T-U4GO5/)REI146Q9:V43YM8QQS:G(YR_?!L),
M&YZS-])+_F1#CPY-WF^KE5PY1'(?K,RBXN>UGV9>"TP-B:BVXY;/]=)T#?^V
MJG,0B?0+6\2+HJE7(@ZY+6F'/1U0AB_JEG!%-#?XJC+4)D@:PF/R,QEY6$R&
M_4M;*YZ]63K16RQQGS#RR31E,7+(#';YM4@X*\W*8=OU(JLDE;B=)-]A;CJE
MSQ<('G-ZFOI/AT=G$\)M^R)W-.%17(CB<ON30$6C:#ON.%_U#:D-Z-&G;..&
M7-X%U_[RIX).Q0>2@:Z"U8=,4&T7C"8=9@VE$R.,$JZ !Y'G.G>2]KO\A661
M7V&)W&U"R'>E@OBK_:@@CNK=G@FIJ-Y%]2ZJ=Y^LWMWFR'>?Z\V4OYM\ARMQ
M!$C'UO*,E^)P=#H#@5M3%5%JZ[&GANLM"5(@:6?UBNJXI<I)%=#1D7.J*)TR
M\%VW*-JD0<0:1D%,;::OSM.K1>99;R8>4,40:#9KJ8'GBD4O94P3O3?*AV08
MT-'JDO*R/1_\AN<=5E$LIZ@SD.X&AWGD8N 4D=^L>O3J<QN&:,#2=52Y(L#Q
M85_T*"*CB(PB<@\]("PX2/20$-.^7*.%\N*$H$KIM8O2#KZK0#&VF0GBQE64
M=>;56%_T!49W*P\QJS&EN82]&WZ-?E@U];(O+[+.M0;>DEO%@)C>PG1-Z&X9
M6/+7VNU2,\627$7D9W2WC((LN*HKK\Z;R^2#0^)-0Q/>Y9 /#H,%/*R1<^X(
MYL5)4]XJ?O_(AG&XI>Y<EP(O ,//:PS&8B'XFQ,"ZQ)<$M6!47M/?BOJ0ZY*
M/T'KF?=DCEW8M!AYA87IJTXC3:_/SNXXX/6S^9QA,NO$D KDM50=+>]V,""$
MO5D0,I2[IIXKZ[JR<H%00!V/,&_(:U00#V@12N,% 1FOZI91JKWZ1-'L@"4M
MZD:Q#<J2$D;(C[BY!ENTJ) ;_J05*Z%VZ(9<)$G8-F[&E&#*( R><GKS)3,N
M)TR+"^)I3,H5148K.:M IY=%70Z!!SJ'_H#).OA'(NM@0T*<'V,!H!R>D'\%
M*)LH#3.,LIPP>SJ!:?* ?RS8#SIM6W)2@X%02PZM^0 ;3R%1NG=N5D?SG@*W
MF\6#;;J[?#!-=LJ3O&@OZH:I,K5P#K0)R&:Y@--KCH76!DRJ)0C2@N!%IE@F
M&<(M>0B%Z!:^X+"OPE60V0&[56:-^V.JSDF5+D!-75:4^@"ZEIL>Y8#4R80$
M,(*>M 5EZ>:82JE2C8_UE.6X?&,AP+:!-(177\ <8!%]R=@4;NI$S@0]Y,2,
M->JVU?;:D#?=O*L%4 O"X'W0,#Q<3X_Q>'=#&F@RKDL H.)=0+8\80+KZXA?
MJ%XAKO!2A;3OH6 Y<]'2>7L+0M^-F;__6&8.8H[0G2SH^Q*A6Q@SR1X[L@6D
M$ ]WQM\_>-7P]#Q *FHY1-!US#C=]0UARQA!V#_.,"=2 )P)B8RI5V_8@:.-
M"7PL VSEFOI/CAI$_Y-S$E F>R;NG/RC( Q%X3H(]MPWFTHW(B\-!*#RO^#/
M<];;&<1:'5@^TIB3U*GK<ZBHZ+Z6*TO"%]?-;4;UI^U4;\*QM52E8(NV?SQ6
MAO@/[L3&&4)=C2HU]*1LT>@7O'<S6)+6VDS7MUFN&!,.[<S?1.PLD'69W6&&
M)[ I0GTE0_T;Y^#PH6#O>V!6SY2,O/OM]090C0V/R=YV0O2>AY,@\"[U)Q)8
M?</?LO'$M@-2-(/+S:(F":'J+#,68Z IT/5)%URPP[P[+IHC :M1F,Q3(FM-
M?V*S@AHPN(OCWQ05YV 2 +\1E94;.'..=$>MTQB-CU#AR6LJ^[G6CAFNAS0*
M%=?=@=*:^PKSH"ON"\#(L3E=9[IJ".RL"//6/.(V( /A$Z!YZ4T5Y^K,_@'I
ML4>5H>W,<DFMW:B_B%Y_IX%NARBKFPV%%C4 UN1F3J7%$JX"5>C<%G3U6D=L
MK+DE^+KSGL!?<S,W7+-,I )$QLHN[ (K='3.MF<>DK*^DDF'+G<6" :&25/@
MWD"O&=5IAN5@E&%8J#+NCTQZL-MG2Z$'W._BM2";.6EJ2<8=8B"#&<4,MHS
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M\O  D<2K=5*!R+)A*Y_5(0<1*];DVD-U=9>29Q_O9_+LCLW[@AK'IDS^,O/
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M<3A*<[ '\%T..#AR'=0[^  (7I/:^5 BBYL-02.HE;4)VC2VO?%1/S>PUPE
M@]H/M!:4=!?^!P%G[ 36*0+ AQ%'@53ES8NR:[0(<&'FW< %)]9\9K5)+=CU
ME*D0?\&67J&HKKGTR%H1/M+O.Q'(S0K;4\'B/)^:3R7BC_"6@_H80^V''46G
M7%DGD1"O@-J%ME&!((X@U1]^!0J8#[VHBM+$C0P0JKXA9*)!;YIT$P)1<I2H
MU,IBNPMX>+JE M@#4['\.+/<JZ8>Y;.>RH&44&6FFF@;]'CA,<<KS"TPAV"
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M:\N^L!D&\KE]A%Y:SI>!I7DKR?N2<-&I^X)\;6#A^D</D9<D(H"E[X,5@6Q
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MGO?^VYAU2H6>O4:DA)V30N9^LTIH6W':_X\8$'0.1)3 L["_G)1(C)@6C\7
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MQZ"\:8!:/J! C%PS.'E<4'28Y4>C;XK"]&Y8_(/>_> LP#) *CC&Y+&XRX[
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M&*DWHN!KY+@"L3AW>R4&]XE7( )B6*NB7:<8N<X>/%A$7_CJ7J63%(T">Y?
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M]?7BV]G-);8]"RC>H6M@U.IK!!.@GB-7L/H.XJ!,8I9N;UIX<?. 5NW]Z\O
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M 3"D,J3N6DSF0>I)J6Z3(75#D-I^,4C])A+G_[/WYLUM(TD>Z%=!])M]T8X
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M\(9QO:94X()-=K)T(8.6 L+8P*S?4"IPP29C@RYDT%) &!N8]1M*!2[8W"4
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M2#A8@;D0?F21Z(L?^&^A7X$R&RA<%=Y,*G %"5\=U(4,6@H(8P.S?D.IP-C
MV* +&;04$,8&9OV&4H&K"W<(;/:7;Y5?.'\F44SC0FZ#-?5^=">+@BF7A5C*
M5_%7XD9P^C<BO'=M<2U"-W"^"CNX\^DIQU:)V.^8O1KO?+'Z.6GUP\C+K-]0
M*G I(GMENI!!2P%A;&#6;R@5N!21L4$7,F@I((P-S/H-I0*7(NX0L1MH%+'C
M.%NCE 9WCGQM&GP1L>$%$?>!/#3KZW'H35= 6E"!:U#X<ITN9-!20!@;F/4;
M2@7&!L8&7<B@I8 P-C#K-Y0*7)_(V* +&;04$,8&9OV&4H$KZ!@;="&#E@+"
MV,"LWU J< 7=+N,RA\ME$E]$_,FW@[GX+8CJFB?U5<26ZPOG@Q7Z0+MHXZ%2
MQ%*M#>LC>NV!.>AR8R?=N/*-?@1@E&2N;R85N)9P%Y0<[8J2#'&-$/9Z!D>_
MM"*S5.MG3(+0$6%ZO%'@N8XA/VC0IA96".=XNC3YYH<"3OYOX1AW8'T:(.C6
MO>5ZUL03+?AV*P*I,B)A)Z$;NV+GVL%ZJ$8F2>-IIFD!?N=ITJ3GUB2-IRFE
M9&%)+<0Z91/HP%?M-I*JHL)CR6(T:AHE&(V.GE*,1HQ&1T\;1B.F!*/1"5!*
M%E8R&C$:'3%M&(V8$HQ&)T I6<K):%1[XY/Q<J[R*IZ)$ MS0C$3?N3>"YFZ
MS!,D_PX\)-*_+-?'?.:5?Y-E12Y"-X*WWL.?_IUL?/)%Q%?36^M'72V*;3N9
M)QY\TEFWTHWKA;)$Z7"@39\4!G1ME1,#NBZ48$ _>DK)^EL&='8OCY@VC$9,
M"4:C$Z"4K'-E-*K;O1RW-7 OV1%L@!KA+IJO38-WEF?YMC"LR BFQGMA4]C%
MZ'5, P5-OR)SOL9SD,K^5'_AF;+]HR>9RJ5'NU.JH<;/CTGHN1%V X]*UD]G
MV?JACN'151)'L>4C*6J*BL.K\\"_B0/[>R'ZO7/O\%'/[ V[?&](,P[45'DP
ML#*P,ID86%\OJM"MX"HBWRSPX) CB9.O#JP%]&3@U(S#-%4.#)P,G$RF3<J/
M&3CK <[>JP'GA?/<*/F=O=..V1\-S$&GOE@]X^Q)ZQ+&6<99)M,FA=6,L_7@
M[/GKX>Q6]=!/.Z[=,4.J;KRGJ=I@2&5(93)M4MK,D%I/5\5Q_]4P]8D&Q"]O
MRM@Q.]US\&#K&\W,4,N=AX_QO#55WXRR1T&F<LDVHVP]CNO@12#[HK#N^:!K
M]GICAD7-F*C&6NN]W=\X]5KK3U&44+%U, 7IPY($V"0(IA'/X(#O9L;%[6=C
M:MFN1_<D3,,7,7P6B7:B)R*Y4OZ7CL2-(M 6D6'Y#NQ\*O"*"+P1Q52>_H]M
M56&W6\F573A_)E&,SD-T&ZS);Y&Z1&H))Z79):YA;^4HZ;>32>0ZKA4^WH ^
MO9K21^B;%ISG17P[$Y^M\#M>EI%'D_LTG?1N3&=GU=TU^^WZ_)G]W<=C<_H@
MER";C99:4(%'J.]2OY^-NT(E^C95Z%?3@AJF^X>7.?Y<^$ZJ8DGQWZBGGK+Z
M'YC=\V-0_ZR)=* "@S"S?C.IP""\0T1J]'(,_H_E)>)H(;B0.F*,U8R=-54T
MC+',^@VE@KPWP!B[%<:.]<+8I^\.:.'RCD?FH,9J259*)ZV4&(^9]1M*!7F_
MH-%X?. >KBP@6@L(8P.S?D.I( OE&1L8&PY/!BT%A+&!6;^A5)#EW8W&AJU+
M%MOMUXOC'3[Z-N3HFV8,RUVY#T^#KS??C$C$L4=1]JP2W)#5;<:#&\]FPG/T
MNU3!I@[?9&DF%;@L:/O:W&Z[TEO[JXCBT+5CX9 Q(@MOY54,,GKD"Q^#\-;Z
M\3NJ03EG9'^UN?78.AWS?,RMN'5C6$U5":,HLWY#J< H^M)@,@O(20L(8P.S
M?D.IP$6AVS?< J?E&0^+0L45-VL_WM73):%U>5K=\W/VM#1C7.[*Q2J\>5RO
M*16XFI.=+%W(H*6 ,#8PZS>4"ES-R=B@"QFT%!#&!F;]AE*!JSEW"<!5.E#6
M'(#CL-GI*H(WM91A<L/>'8]_;</>11+B.[$1!X:8+[S@40CUEO5@A4ZD7Q$S
MFRU<.=Y,*G!-R2Z5F>?/WT*Y5EKP-OB@=*"\0$(:<,\M4[=HN-8?<(L7W1A2
M4U7!*,FLWU J,$KR-7Y=R*"E@# V,.LWE I<>;G#-?[^"QVHU^O%6=?\B.&@
MOBMNK%%.6J,PF#+K-Y0*7'W)CI8N9-!20!@;F/4;2@6NOF1LT(4,6@H(8P.S
M?D.IP-67.P3A!GL.PG'HK$EZ@!MAOC8-2!1;$RL2#E9@+H0?623ZX@?^6^A7
MH,P&"E>%-Y,*7$'"5P=U(8.6 L+8P*S?4"HP-C VZ$(&+06$L8%9OZ%4X.K"
M'0*;P^5;Y1?.GTD4T[B0VV!-O1_=R:)@RF4AEO)5_)6X$9S^C0CO75M<B] -
MG*_"#NY\>LJQ52+V>^9HT.?+[)HQN:;JAY&76;^A5.!21/;*="&#E@+"V,"L
MWU J<"DB8X,N9-!20!@;F/4;2@4N1=PA8C?2*&+'<;9&*0WN'/G:-/@B8L,+
M(NX#>6C6U^/0FZZ M* "UZ#PY3I=R*"E@# V,.LWE J,#8P-NI!!2P%A;&#6
M;R@5N#Z1L4$7,F@I((P-S/H-I0)7T#$VZ$(&+06$L8%9OZ%4X JZ7<9ECI?+
M)+Z(^)-O!W/Q6Q#5-4_JJX@MUQ?.!ROT@7;1QD.EB*5:&]9'],[;9N>\PXV=
M-./*-_H1@%&2N;Z95.!:PAU0LM/>%249XAHA[/4,CGYI16:IUL^8!*$CPO1X
MH\!S'4-^T*!-+:P0SO%T:?+-#P6<_-_"H=)  P3=NK=<SYIXH@7?;D4@548D
M["1T8U?L7#M8#]7()&D\S30MP.\\39KTW)JD\32EE"PLJ858IVP"'?BJW492
M551X+%F,1DVC!*/1T5.*T8C1Z.AIPVC$E& T.@%*R<)*1B-&HR.F#:,14X+1
MZ 0H)4LY&8WJ3U9VEI.55_%,A%B9$XJ9\"/W7LC<99XA^7?@(97^9;D^)C2O
M_)LL+7(1NA&\]1[^].]DYY,O(KZ:WEH_ZNI1;-O)//'@D\ZZE6Y=,%08]C8X
MUZ9E"F/[/LJ$&-9/'BP8UH^%4K(*EV&=G<PCI@T[F4P)1J,3H)2L=F4TJM_)
M[&K@9+([>,(:I9Z2VI<6.#]54NL$R<031O>L,7C\SO(LWQ:&%1G!U'@O; K+
M&+V.:: ('JH*?;W)U#P2:7KMI*#D\$Q70O!3M&.;2AM2EHN:]DO-4S:ZGK"Y
M?DQ"SXVP%WE4,KIZRT87]2N/KI(XBBT?R5532!Y>G0?^31S8WPNA]YT[EX\[
MYF"HSZVE=7;76K1@K<-0WC1*,)372,I_:$=%1O$##2;IG%= '&%V%GAPSI$$
MY5='\0)4,TH? ]LQ2C,E&*5/'J7+)=N,TJ^'TOU70^D+9^4HLCK\[HXY/#\W
M!^/ZAH8QJ)\LE#"HZT()!O63!O5RY3N#^BM6+0Q>#]6W*FK?L'BA-Q@QDA\#
M:QZLY26#.(/X"9)2/Q OU[DSB+\BB ]?#<2?Z%O]\EZ>'1.68PZ[78;T8V!4
MAG0-B,"0?C*DU _2RY<%&-)?+]@^>A&BORA$WAV.S4&GOCL!C<+@SL'5O[H8
M\,\8NSK#JXY[O]WF2WO]K^+>NHNX])/U/'9<]U.?.GJYD?83/UG00S8\583%
MGZ0CJ"YJ_9&U7YD?QAVUGUF8;FAAW8G6)!36]Y8UA?V\M;P'ZS'ZR?AG77SQ
MU''J1,'M%J&H,@&=N_S+2P1)%@L1VE8D-EA]D:YK:'@16Z%EO',#C)):"Y'$
MKAV9QB??/GO]K6ZWH\TYE<#N\NK+S=5OG]Y?W'YX_\?-+?S/YP]?;F_^N+RX
M^?<?'W^[^OWFIU\O Y^,#HP;&YF/2M=M+JUH9GST@H?H=,[EUY\_^48\"Y+(
M\IWHS7\#C/GIKI94\0K=D8L$?N_7/1T++:%?E4 %-80\"JS_YZ<VV"G"\Q".
M =BSOQ70T]\E5?'62N+@%P7U +.>M8C$V_0?OQC*'&BWU;RB0PV5Z _/QL_<
MI%WO@.Y B.=MDIPVHX-;(8?H#] [8'^ BKI89R!N1)I:Z0 K067P/S_AS)[#
M7T#OC<^&&[: ?BV9.3C=_C]AA<8'6)93ND)Z\%O8K^%)Z4&!M7X4PXONA&*H
MT88.&=1T=4":3O>LO4-94;.AZ"5="QAWCE^=[20EK.]8WQTI74'?M5G?-4S?
MC3>0DL9(P#%HMO99;X>[V<VF:[?=&1]<L^G4QTT/LM08:=A;W8<*/AR. N-]
M4N!J(4(KAHT;6-EP_Z)1Q_LKH$*C_$0)<,0U:UKIJ482J;.9D\.$.C2A-'-K
M&DD#!A$&$282@\C1$HI!Y/ TP' 9'SF#"!-IJ6G%1C%)IM/AA:G)-#A8'=.K
M1Q=?=. U5L-^$;'A!='.,<7]I5'VX@[J<NR:#EQZ)?6C"Q5VOL2Z/P)(9T^K
M"ZBO397M>TIT*TV9K\-@ZL8XIZJ6 50;W47MG;?-SGE]<Q)8RH]\,C%CFU:'
MWBRN9VS3D2H[8%NEE?&FV-9.L:U= [:U!^8 BP\9V[3B)QVQK1*!/66!9K#3
M@0KZ@9T,N#+6;8=UE0:_&V)=9ZRPKC-^.=9UQVUS/!PPUFG&3WJ,%&YLI/C"
M^3.)8MG/) Z,4( \VJXG#%^%D/%5_+>-G4Z22#B&ZQO!BOK5M_JE7=@A/]E<
M%U.!O?(C)0T+B Y48&Q@UF\H%1@;M"4-"X@.5.!@IPY48%G0@ H<\=25,HV7
MCU,L*QV<C?I:DX&& +0F%@8"[6"^$'YD41I _,!_"_W"Z>SH<0ZCH51@1V_[
MN2?=ZB2SF16*=ZCQ+@L*[R45J!LE+/L]<S2H;T@XR_IIRSK#'+-^0ZG ,+<#
MS%7'>^T <T\7HVX&<QVSU^?K%;HQE*ZROI=. 'SHS/K:4X$CL3N@W+@&E'NF
M#'53E!N,N?A4-X9J1B=4[8/*[\4B!)F1@63+=PQK'H2Q^W<MD64N(>*L%U.!
M7>Z#&R.]]K(Q4M1[%[YS4=!Z>P\OC\W>>7W199;WTY9WACIF_892@:%N!ZCK
MU 9U-8281V:OUV6HTXRI=)5WCC SZS>3"AQAW@'ING4A71UAYJ'9'M;7SH?%
M7;LH,Y<NOZ I;N"WJ(M!WKW $U8DN'19$ZG0X]";KIOTH )[W3O8(KW4%K'@
M%]Z"OKL$=9?-&OP-E=T'J>OV'E[NF./S$>>[-6,I7:6=@8Y9OZ%48*#; >C.
M:P*Z&H++'?.\/V2@TXRE=)5V#BXSZS>3"AQ<W@'G^O7@W'.-=/.BH,$Y0YEF
M7,,UREJ0H9C',7ZV;#L4^,\W1C U7/]>R":ZQB(4<S>91\;/CAO9</AQM',W
M?R[G.J7L:N/5EAY48'][!SNDTL'_4Z;Q/OEV,!=?1%Q4D%?3]TK[7?C.M52)
MKS>RK6,.!V/.@FO&=;HJ!,9"9OV&4H&Q< <LK/2'JAT+ZQSQ-NK6EX5E=7#:
MZH"#T\SZS:0"!Z=WF.O6J[20JAL)ZRB)[IB]'I=$Z\9M]4Q]XVKHW2F TQ<-
M$'/'C19!!#*%@>Q%B+71\2,UX1!_)>X"A5F_#!#[[)QV:R@5V&??P6>OM '[
ME^7ZJ &O_!LP%*ZFUTKQ77OP4Q]2Q?=Z(>LN=\#4C<MT50",?<SZ#:4"8]_V
MV'=>Z3I5!_;5&:+NU.B?LP8X;0W (6IF_692@4/4.V!?I0U5#=CW7#'UEJ5*
M[2[?'M*-T;CD6@LR7$21B VLLPX%%5<'$SAUU24Z+<#F]M":B(@>A]YT1:4'
M%=A1W\%8J702NTAU7 U-.PH58?79&RS&IRW&C&#,^@VE B/8#@C6>QF"/1-4
MSKM<<DFS;KRBJQASO)A9OYE4X'CQ#@!V_B( V[C-QK"^:A^68NU"OER5O#L9
M+F>6?P>_X/J%+LT6QH$CJDGV7&OB>F[LBNBM?ED2]I<Y-=50*K"_K"UI6$!T
MH )C [-^0ZG V* M:5A =* "1RF9]9M)!8Y2ZDJ9QLO'*99\=GIG0ZW)<&'+
MGKE&*&SAWEL3CPL[#RT(>AQZT]61'E1@5VZ'K&*_VB?)#K%W_WLA__>3G^J]
MKYG:>\7> S4V_6?Y/VWY9^ACUF\H%1CZ=N@1>+ZB<_Q+L:^6H6W=/C<%U(V]
M=!R4PI%9YOI&4H$CLSMX>BMZP[\0[;9H@?NW" /'BF;(4J-NI_L+ YQF#-6,
M(E/M@\S7H5A8KI-V#I"5I4$\$Z%A)V&(G09DR:E^21GVOSD3UE JL/^]@T&R
MHD7_LD&BM.%[,16@^QQUT>7"=ZY0(U(/ENCU@M$CLS/J<D,DS1A/5YW <,BL
MWU J,!SN$HZN-(+?!Q[6$* >F8/!@&%0,X;;.4#-I<,GI7N;Q?6:4H$#U#L
M8+_2#7X/ +AQ'X3QN+Y./BSM.DUFXQKHW2EPE34^\% @7QB+YEJP4\K*-DP9
MZ4H%=KZWCT7WLV;\%OS""KLCTWN_X=\O#SQS;OR8^$E746>48]9O*!48Y79
MN6[M*%?GK+71J+ZH,HO_:8L_AY:9]9M)!0XM[P!\O;J!K]9!:]W>F(%/,Q[C
M<F@MR$!I':YXUD,"]#CTINLA/:C _O<N&>Y*#_\5I@AJO,P>J3?2_,2=XR&/
M>M6.P70LZ6+$8ZYO)A48\79!O WZ2VV/>)L.8^MVZG.L6;Q/%]0XF,Q<WT@J
M<#!YAV#R!FVCMH:T6N/)O2[?4M6-S;B'LQ9DR'HX+ZQ';N"L@13H<>A-UT5Z
M4($][!VLD2W:>EU+G;?W:/+8; _JBR:SU)^VU#/@,>LWE H,>+N$E#?H&[45
MXFU8PUPH5.[T&=TTXR/NS\PJM7E<KRD5.*R\@R.W0?NG;6!MB^;,:QVY<[/;
MZ3'4:<9:7)JL!1E &,-$.""#<VQ"8Z%LZ)=E8>^:4UL-I0)[U]M;(8,->G!]
MF"^\X%&(K\*S8N'\YEH3UW-C5^R_3OG<'(PYMZT;E^FJ !C[F/4;2@7&OAVP
MK[,_[*NA[7+?'/89^W3C,ET5  >?F?6;204./N\ ?=V]05\]<>CVL+Z1N"S_
MVL6AN:3YY7'H4$3""NT930QTQ+WP@L4<YP6FHP3UR]NP@\[)LH92@1WT'4J_
M!L_U\5*Z\*M2A1>^\SY7A*\W*+!K]@;UN>JL"DZW1(P!D+F^F51@ -S!33_?
M'_[5$*$>FN=#ACW=N$Q7!< 1:F;]9E*!(]2[^'[]O6%?K<TW.FUS-.!^SKHQ
M7#VC [E>^J6MG.TD##$H[>7I(_WR..R6<_*LH51@MWP'MWS3CF"74OF]9L5T
MQQQT>)"Q;BRFJ_0S\#'K-Y0*#'R[..4;=)_:"?FV[LG1&?'\ MWXB5L]LVIM
M'M=K2@4..N^";QOTFMH%WS:-.!=Z.H_/&=\TXZ=Z8LI<^[P[!=Z+J0#!P^+G
M>^$GW,[YF*".4UNG307VJ'<()6_0!2Q5>E^ESMM["+G7-[LUQI!9[$];[!GQ
MF/4;2@5&O.T1;[A!QZFM$*^&0N9!Q^SVZ[MPS&)_VF+/065F_692@8/*.P#>
M!FVFM@&\+1IL_"W"P+&B&?+3J-OI_L(0IQDW<6]G+<B0C>XT/!1(KE;62"#T
M./2FJR4]J, .]PY)[6'WF9M4F?;[#?^NJ5IYRUM4YJA?WR4J5@.G6]#%X,=<
MWTPJ,/CM G[/M9#:$?PV+%C>$/QZG0&#GV:\IB/X<>"9N;Z15.# \R[8]US[
MJ-VP;_MBYF&OP_"F&3OI4<Q<BC ;DR!T1)@>;Q1XKF/(#QJTJ86%1?>G'8FF
MKAE> ,<4BW!>1R2Z'AJ1Y_T*%-);:C3-RW:>)DUZ;DW2;[I22GKQM5"+K9V2
MM=/?\.[6E\"W:VW,L<+BZ;?U:0FVD8HH:N\FJ8F#-8EF5-5?5S.J'@NE&%7W
M5+RV::NK'4#UF1!Z'CT8ZG,9B;%46^50B)$SH&JJIAE0CX12,M[.>%H[GF[:
M0&M[/#V)NG#&U\87B^M-@R\B-FP0'2.)A&.XOA%DI>,H.O=<,ZZ#7.AQZ+D6
MPS-E4T=3,I5C![N3ZI0-G1W"\956:J Z+T%S7H?!O>L(Y]WC-U"AA2*$BTQ_
MON+DQF[;['?K&V+%U0FG6WS'$,H0RF1B"'T]"*TT!ZL+0FNM7A^US2%?WM*.
MWW2$4*Y?9PAE,CT?<&<$K0=!1Y5F8S4A:*TC)+N]OCGH\@TPW?A-CQ+Y5P^U
M%X]Q$GC.R^BQZ^%_\N]%5%-<G9N?GE)NNF%:2%<J\'5T;4G# J(#%1@;F/4;
M2@7&!FU)PP*B Q4X$LJLWTPJ<"</72G3>/G@:MK7IL%U$MHS*X+?"*9&- O"
M6':]<"GX-X?U<BWMH:5"CT-ONF[2@PKLU^V2A*P,@+BV'DFWW087]E^)&XH;
M5'VWH/D^Y8IO_W/^VAVST^7"'=TX3,?"'88\YOIF4H$A;Q?(Z^X!\FH8]'?>
M[9NC07WM)%CX3Q?R.$++7-](*G"$=A?$Z]6/>%MT=%A?6SILF]U>?;-M6?:Y
MMO0$CO\Z#&PAG,B8AL'< #%*0JHP-2S?,2(0GCU$I+G2B+-E3 5VS^LFS?:V
MRGG%5E'J\"-HPQO0?I^E0GR\\)W+P/,$/?AJ2A9,_-IAZE[/' ^&VK2H8HV@
MMT9@,&36;R@5& QW ,/*V("]@6$- >Q>>VP.^CT&0\W83E>-P%%L9OUF4H&C
MV#M@8:7;_[ZPL([0=J\W,+N#^B8+LD+@PNI3H4&IL'H18I/B^)&"V^*OQ%V@
M@.J7 6+/G=-N#:4">^Z[Y-PKPQ0J.?=KI?JN/?@Q,%H^I-IO[V'K3MOLCSCO
MKAN7Z5AIQK#'7-],*C#L[0)[E<[Z=<%>'1769K]37WB:Y?]T48\CT\SUC:0"
M1Z9W ;U*+_R:0*^.2'3?'/88]'1C,CU*K$OQYL8/IBW776.A=?T!ZKH&"?>8
M7KHF=WF0\-%0JCP:Z$74.F6+:&N#:%P9;;"<J[^:[CWZS8.$CY+9#JLK&%]U
MH03CZ_%3BO%U3_A:[=I5%[YN'F9G?#U*9M,#7\>,K]IJ;<;7(Z%4>2X?PVMM
M\%KM$%83O#XWFB^OT-*H=ISAE O*M:;!%Q$;-EBB&*NGR9G&Y-'X.8G@'Z[_
M1K5'<6N9UL>5=J>4[>;YP\=!IG(<87=2L953M'(J7>'6S!_.IIUN.'^XC@KU
M;M?L]KD7JFY,IJN"8/!D\&0R,7B^7LW?N-*GK"[T?#H"'Q$[M3:]Z-5MF\,N
MXZAN_,8U[ZR;&4*/A4SE.#LC:#WN9Z6W64T 6D?1_*!MGO=Y^I1N3%9CL/WH
MNI,7SW(2>,[+B+(K!3ZZON7;]<32N<WJ*26C&Z^*]* "WUK7EC0L(#I0@;&!
M6;^A5&!LT)8T+" Z4(%CH,SZS:0"]_W0E3*-EP^NI]6C$88=S.>!#]L-[._4
M#&,1BM84SELXQH,5PI/CR'!])-V)GHOD3?E?W'?X$+IQ+'PXG:D(@54BT_ %
M-Z\^M,;0X]";KK?UH +[O#ND9K-1&Q;\0NGRTZ<H2BS?I@M0XB,I_]^5[O_D
M?ROHQ.MDXKGVE5*,^O?T8#UPVGJ (9!9OZ%48 C< 0*'KPN!=8Q?[/?,(4]U
MT([W=%4+'.QFUF\F%3C8O0,@CEX5$.LHXNV<M\W1B"^_Z,9[3:[BU84&Y1"_
MJR2X$N:/9W#<=S/CXO:S,;5LUZ."WQ=%N;FRB[.33 5V\0]OT52G=JPT:BY)
M(=Z@/MQ[VXOQR!R,A]IT_F*QUUOL&?&8]1M*!4:\K1&OUWYR+,,.B%=#U'HP
M-CNC^F[:LMB?MMAST)I9OYE4X*#U#H#WY)R$[0&OCJCT^= <=AGP=.,MKCL_
M/ W*06DQ7WC!HQ!IQ?F#%3K<M_G04J''H3==-^E!!?;!=S!)GIXM@:H.1TKL
MO\/RP!P.NIP;UXR?=!5U1CEF_892@5%N!Y2KS!;8!>7J""^; RZ)UHZ?=!5U
MCBXSZS>3"AQ=W@'D*B, =@"Y.D+*0[/79Y#3C9^XS/GP-+BU?L#S%Y;K&*'P
MK%@X1AQ@];(1S:Q0&)&(8T_@V$XL?0Y%%(>NC9^2,6=4 =S>^-!BH\>A-UUY
MZ4$%=L:WGU74:U=&+5Q;CZCTHJ]2*=X&H"A_=^/9+/#PX#\&X0WJQW=6))S+
M8+X0?F3A;^T]*MTQN^?GG!S7C.5V'E?$&'A2VK=97*\K%1@#=\' P>M@8 TQ
MZX[9[W88 S5C.1TQD,/5S/6-I *'JW>!P.&K0& M\_?,P;C/$*@9R[WA\NC#
MED>[ONTN+,]8*+DU0.RG-)%/4$=NVUJX,;SO"9!8(Y@ 14A>N6SZF%"3$W"G
M307VWW<Q7D;+QHL<12I^0UV7J<;4HGE)H#HW0[K]^F+1+-4']L,9RTY*BS:+
MZW6E F/9+EA6Z3SU BQ[.N!<: ]=8Y<-ENK3Q3*.*3/7-Y(*'%/> <HZE992
MNT/9,X'C0@N-T8"A3#/6J2<V_-)(?2D0;$R"T!%A>KQ1X+F.(3]HT*865@CG
M>+HTN8IG(E0!8C@H T7E_O =G M><^-)I&E^M?,T:=)S:Y*"TY52T@.OA5IL
MVI1,FR>;AZ46S<<@)#7[,=6R%YF2?5$,FMBJ52H+TZ<O]$9*HJB_FZ0H#E8H
MQKBJO[9F7#T62C&N[@M7G^R ]6)<?28>O@)7!_I4FC&PZ@RL8P96;=4U ^N1
M4$J&V1E7Z^Y&TGFRY=9+876+HNZ_11@X5C1##AQU.]U?&%V/@>&X ?;A:?!%
MQ(8-HF,LPN#>=81C3!Y7QN_URW9Q#=Q!4HRI)L,S98M'4S*50PF[DXKMG:*]
M4^F^!MKS$I3GM=*=[QZ_1<+YY-<<F=_L"G>[9XYK;&3"50JGK2$8/1D]F4R,
MGJ^'GI668'6A9PT-4,Z[0[,_9/34C<MTU1#5FO53EG5=J<!P>@QD*H??&4WK
M0=-*<[&:T+2.7BJ=T<@<<L6\=ERF47]P+ILO$N:3;X?40.5GD";ZUQO#]2DP
M;\KPO/@K<8$XU((%^ZX4&H?C^X>N4^ "0&VSWURG<#24X@+ ?14 5OK0H:F$
M__\AUZM?,Y6*;USX3OF%PB>O1>@&3JJTWRN5_>&'[25(6?C'S/+OQ%<K%A^F
M4V''M=3E;V1ZC<_-7K>^R2Q<_W#*U86,VOIB :/VL5"*47M/(8Y*_S6=0+N.
MKNO=@=D>\1V[HV#?PVJ?%]\'.&7-HBLP,(0?":7X@L">$+S2=4XC!*\ET=$S
M!YWZFMPQ@!]'\N.E^2A.?A0)<[EQEL.P8F,B8%L^WDT(IL:"-,*ATHH<1M&^
M]F"3$A$VTHZ#E!M69;(95[<9UZUT7'R1&?=,7&5G8PR^:@['(VVJ3M@:TU;)
M,'+K0@E&[@:0DI'[4,A=:2BX/^1^01AEV#>'G?KFSS)PGZR.X3R(MJ1A)#]]
M4FYXE8.!O'8@KW0PW".0CW8?HMLUV^,N _DQ\."17 9Q@F3B":-[UAB'?+M\
MB("77YP)V5]!:?/(IVF-PPY66(EV3;3"_J$?%7<+I>Q&2;; BA98I=GE'I,@
M+VD#-33/A_4E0?95DK(6%YJD7_2H*670/C0E&+09M!FT]P':E8Z-C:A<8- ^
M6:A8GP#9$+1/63\PBI\,*?5#\=UR'PSB+P?Q2N/()A0Q,(8?1^[CZ"9/%,]R
M$GC.RXBR*P6^!'Z+4ABN?P^2BO<Y,,'!DR<TE T]#KV,O8TWD'0E4S76P2;0
ML="NZ=TP]: "HPNC"Y.)T>74:,?HH@,5>'*!#E1@N#D&,E5#OHPV1T*ZQJ,-
M%W-K09CK,%B(,'ZDZ":6<R]P*+:Q2$)[9D7PTZZ/[:N$@_W^+=L&2L21L; >
M+3PH_%* P[.1LB=Z0I)UY7_A ,($SL)SK8GKO2CZR]5QNNCX5VRPV'A#2K^T
M^>KVR&Q'O3PM7ID =6DMW-CR/OQ8"-]QXR04T2??3L)0..^2^$L0_W\BOK9<
M9^^SB+MFIZ=_5T3.A!]<M3/(ZD()!ED&60;9*LBN&!Q4!\@^/3T@1U) ><;1
M8^ L/7!TYZIPI@3C*./HZD$ #*,OA]$5HWQJ@-%G6O@7'-(AP^A1<)9&A=F<
MQR@2YD)%YNT@BB,C%)Z%36CB &0?SN4A=.-8^,8"CL6UC6 Z%2$<YZ&[!')8
M0>?\[+-Y=;:7:K*7#EZ/QQ95[195-EK)@E]X^R7P\9K;I_0RS87O?$ROTEQD
M-VF4$K]$'?Y5JO#;X%M!@5^3_KY2ZKNN/,'?(@P<6!TJHU&WT_U%^P:!;(L=
M'#D8PW6A!&,X8SAC^!XPO-<^-(9OFH;H'$%37\;L@R,%IR%TH01C]DEC]H87
M$QBR:X?LSH$A>^.41V?(D'T4/,A7-S0ES-J4Q\7M9V-JV7A!X?'0%1\<'CF&
MB@\VM8ZV)(3#(P>SM;IUV5H7\>U,?+;"[R+^J/3V2W(;N9$U&G)9R3'PGA[5
MF8S5AZ8$8S5C-6/U/K"Z=S"L?CJ'\3IU" S>)PL9G-/0A1(,WB<-WIS3.!1V
MGQ\*NY])9C!V'STS\GT.30ES'0:V$$YD3,-@;KA1E("$"YPD; ?S.:B-* [L
M[T8\ QK<S8HI#Q!^>$QL/(K8"(4MW'NQ\]QA+A+5Q3CC@A.-2*E?P0E'5@YF
MG?5+UEFJMS^"VOZDM/;5]))T]@VJ[%NIL0NF6%I7\C'3W_)Z[5>EO/F:!YMH
M!R\9900_-"48P1G!&<'W@>"#PR*X#@D21O"3Q0U.D.A""4;PDT9P3I <"L"'
M!P7P+;(D:SLR=\S.J,]H?@SLJ=%]D+6JZ+1G$]\DBX4G<$Z'Y1DTI'CJ!0^&
MXT:V%T1)*+3+G?/,2$W+3IJMN/0@4UTS(YE4KR!13(7#4X'!A,&$R<1@<N2D
M8C#1@0K5><-\Z PF3*8:QPLSI1A+= U!<M5VG83!BQG&PG(=C/H;KA^+4$3Q
MH3._7+MU#)E?3NSJFMCEZ7W[2MQ6Q@Y]4BH31PM]$7$]76!ZW&GO*/A'CSHI
M1LM#4X+1DM&2T;**EN,7H>6FO>0'C)9'P3]ZH"57%1^:$HR6QXR6/-%V/V!Y
MWGX)6&[<Q;W?9K \!O[1J&B7(^9/1<SM8"Z,V/HAHD,WE.,X@,[I/KXO]5JF
MS\%KM=@XJMTXZE2-(U2\MZAW:PV]=^J[U,1]X$Y6T3/DZD()AER&7(;<?4!N
M]Z60N_$LV/I"$@RY)ZOH.7ZO"R48<D\:<KDKR*$0M_="Q.7NYZ^M+3H'5_PJ
M*_#/V(+3@5<=]WZ[S9?V^E_/[T;N&[]97,X:H;8%YK"*/]GI+E9)^:I5Y+_T
MFD<\[JK]S,)T0POK3K0FH;"^MZPI[.>MY3U8C]%/QC]??M3/'Z=.%-QN$<6^
M*TN_O$209+$0H6U%8H/5%^FZAH87L15:QCLWB&<"](%(8M>.3 /4Z9GQ^GO=
M;DN;LRI!QY>KVP\W?]Q>_7%Y]>7FZK=/[R]N/[S_X^.G+Q=?+C]=_/;'S2V\
M\/G#EY]^_1+$\--Q8%P&?A1XKD/3A]4D#LLS;F)X 7O41+5P(.U_4#=?KWRJ
M0MHOR5R$KEU$U'*KZW=)Y/HBBMZ+R [=!<+<+?S&.R^POV\7/88' %L!\X2)
M(+ !M9ON2_(2@HG$(=+,"LS^YZ<V_)#P/(0K +[L;P6$]'<*K1+^ 'H\:Q&)
MM^D_?C$41+;;ZB)L)24,)Y@]1G[X_*Q_ONK*V99(>2A6__6_8=%^NLR#K:)S
M]M__Q(6L,X[PW&LYT)W6MY7B+\@ SNA(12/;&!D6SYH5N(W!LX NF6^+Y=6-
MZ4_AP<]H '?;O]!GZ-^=7TQ#O?@@EE\)DE"]9 1A^B(\%K3J'#CC4;WYQGBP
M(JH."!=!2)K6]8V+Y"Z)8@,#8OCG.KUUWLYB;XYPWW[P8S=^_)0]R\6N@/#(
M2S"[X_#Q,G#$=MJKX BT(F&_C?!IBS"XQ]\4/C*'9SU8V):LM,)? 3V+<OAN
M74E0V5Q.S]^-#,M8P.J%P,()X[:%FL]PY_/$5Y1Y- U/W,._@)ON##?&P3#W
MPC,LSPONA"_@E#Z\^T_ZS85GQ;@7!#4'ON8%"R-C"#BG>V'(Q^*$&:S66,"+
M"'"@0>.9$<&>@B3"-FP"3 ]@"*"7EZ >-@@@C3B9!R&\/A/P.-C3'?R^C=T9
M0]B*[QA6$@>T?)$^I*@@ULC+!A;PP07F=V',+#B^B(CAK2(5GBD0T?9<W[7A
M(XH :$#(LPF% 3QU%X)6P1.=)U[L+@ )?5P&$E.R<I&V]LR5H@"K<>$U&@>T
MB(%R:@&IL%Y>?#5N,U&CG['FT9EQE83&/  1LYQ[I).SDLG2+Y@&J#=\_[^C
M9%$"%SK94?^_?H'=B=9,'FRG"X +YQ'C?I7)2!H?+)'A.5@B\)1?C9_AF<(3
MMB<2>/(;$]G>3D)T5;U'/+'K&?")T2L>F$DG!N]=V7$P >E 636-!V&014K*
M WC<HE%*8"B#N>;^K4X/#IBLMNQLKET!OV9\M,!C0:VT](6+] NYID)A*'WK
MLW!@CVN?FG[3-!9)B.U*8Y1 ,"[L&:X9CM9'A0>OE9X*BD/\  &+0#!-8^H*
MSVEY[MS%SWHN&-]P+/"=XAX%'0S(5ARZDR06^R 8'/N') P6\K<BI%ULP F%
MI(/FU&Z56!VU_&?7<8"'/U@1$.UB"KQJF?27"$N/N82S0\&YB%SXP!1,M^ !
M'Q>*NP2T5A ^&M8"5:[EG1E2/3ZXP*>AB"WXJ6F"_\9-D,6^GUV3., &_PS"
M=)M%%?@E"($O+D@@80^X$^,:K-8IR:=C_ ;\Y*?OGQDW0ACH8AA#4K73)*3'
MN[Y2QH%_!H!KO >)GBL6;Z]B<= 7P@KMF5G1*"F/5%G^G?4(3_Q-O;^&P^6'
M+OY5_E:N1)YA9?GU37@8\! ^B=P")(87R?X'Z"'DP8U\!]N[-0L>C.#!A^_!
M:2%ZA\ D\-?DT4CDQ\#4,*SIU/5<"STW&Y 06_[BYT,Y(!'7=7%[T>T.._0-
M^'</_DT'_1D/42D2*Y+VP7PAOY:O<,W)T=/@X2D5E3JE)9$?,E&&2)6"/[MO
M@(J?+3^96G:<T(KQ:=0#];%(G/[X%_@T?1QT(C )[-"]<SWZI>KGZ(/_EU@X
M!'+Y;?R!G]U[_,2ML&<^8O6C<4M8AT3/.097+W#HI/# V'CB".2;S^]#'A5\
M].D?1C@,Q135(9TLD 2_5&+@[--1RI6;B=6)&!M*?IR"XDL-O3!P$M#*8'LY
M%+=04P8_"[#/*';A!2"9_ROB6(K()1EII(7A?U*!_WSSOSETJ1\I2!(R][)Q
M0H9&9F"H7[WY7R(Z_?'O,^,W(-'G  0UCM?]L'PW_W'\>K[+3!\0*^5L1#\@
M?8O$MUT/'37\\_\2L-(C#S_]R8_ .4!DA/<D;'O&5Z5"L]__OT^?OQKO -%F
MP317>07F&JQEKOJB-N/EJ,V2<[%SR%XR</%W6P6>+CK73ZUF;0QIL)R5N0%$
M110$+KZP;73"@.6NP6&PP2:N(Z!$WW3]1#@7<;Z,/QS;C_^8],?C;KO?;5GG
M=K]U/K:'K?&P8[6<X7!B3::#B=WK<T2J,1&I[NE$I&Z2.2SE$1590<*,7,2,
M5,:>"E*ME>/^<%F.WUF1&UU-EV3X4?ZWKL#P9@??&>F35OB5S@7)<(VVN!\3
M$&R% X/U)L9ADGJ_8RQ"8,)8F;"%#,@TRX!$608$W2,+^")TR!@E_\'*&7$!
M1H:-P8S(D+:"!Q8AO"\6*M"'*/W-)Z^ 0G5TG,I5RE#YV]G-F?&OBXOKS <A
MJX)\17I"F. OD*T@W4:@0Y0: ?3M&V&#94H3E/%C'W[8,\N_DVZ_&T5HP:2_
M=O/A,@/^5?"[7G J/6_R!!+\P'[%)1..S5+&STQZV,*^W973KG/6 $*53NH)
M,WW3&/K+]E2C0-T"!VXB11A,$-(7EN(C)8$"'JF/^S +4'ZD,QPED\AU7/A!
M$9T9%QBZ0U/:EM%U8V*1>RC9G98JRU4B<K $NN)^&FVWBX<OO:3-F;[2NN)&
MW.&FOHI%$+X66!P=]ZM#*J<)EK,!2+I_"?2H%C,X]$^YM_%T\/QXL"98H/\H
M(X'P$]:=A)V)2K*A\_]$=1CFJM5!_E1,"ITOLR2P[42$5U/)DV@$J:]%N]Z%
M^O3E8S4]Y"?S!T#""#-#.RR[OV[95W1*($I[7S50:T5]V](+BFIIG"?,#M6(
MY/I,%1=T9>@FHR8H-!6J3+];#&'C:\6THTQ27,Y<,06\!ORF/-75%,Q=$>)/
M!/@#9*709_)5X88)TN?6=_QH*.Y=\1 55&_!<3<P-X#I@3NP'9 7)V35418L
M"1=!) $*DR^V?#P8>_"KJ6X5X$$D\HW\^; 4^@'0P&![@*:.,5$CK1^/PA,4
MLXPBC)BC0J:'%TPBM%F.6[JOI/7UCVVK.\_;Y:&M*MYXX3N7Q7CJ5V D/]DR
MGULH\^QG%RL&X!RVSWI5-H=C\G#%63B=&+:P!F0L7 1FWP)PQ/Z6!)2AY!TV
M/JQGXTI]W#XN!#AM88B&+HKEQ0\W(N5#0=3T\6DHE5[$T&P:D\W>@170FZ40
M;_;N9\I2;'/:G?'9:/UI+\49LQQ&5$A.F(8%P(CR92A[1T8*=SCST2N=N4SP
M47ZODFI\P5FVSZK7<#<]RF+.$4_T8RA\T-KJ1-?8@4_$(H^\G+6G03DK\J^*
M:4H-4PRO;A'7?"HPVNV.)N=B:+?Z/6?<.I_VG=:XTW%:':LW' O[O#^>#'Y:
M;_ /VDL2\U<";DC\^-6-OC<^(I2=AH''<=P GF:;P#=-*!D7%8*-N;'E!1&:
M2&#BV?19(4OE4!W3UT$)N?#E10CZ*W31??7!L)IX*CD.K]^CU27@X.#8E GE
MWZ7A'%NXBUCED]8#<4&U43)6.<QJE>#>@H<<808VE0O\&&U,K=^DS]/!N/1$
M>'\1!E,7#%N7$JE4=>"(A<!G2RLM2FRP J-IXBW5J*B"A8J):Z55A"OR=%;^
M7 L-VGN9#H4/1PG:O%B/E1H<M,LH6:#AK>)T40Q<%B:(SF!R NWFUJ/A8U52
M^KCR?B1@)KY';A;],W8]/"(GH%PU[=<7$CZ*QQ9:+M+ <>B@:$[G A[KT:^*
M'PNL"HEG5@S_=B-B$1SD:<IQGDAF.)DLPQ_-8 LMT*US(,>]B&))1(ML[JP$
MH@?V%"H*N:B)*!Y)D=X+S_*I4""C.]GQL!9/6%%,AXN)2R-^$!Z<R!RV-8OR
M]"%2 G_85;.%50@1MKLJ:K-EI&10:<UQ&?@VE;^0C0$*XQ+$# P6^%?S5&?I
M,"@D2(=!BI18Y8I2KM\P;8RE/Q3+/7H-"QP+;$:B0<IB64:4/V@G41PXE/(I
M.K$RI4U\3A(G0RBD-R:H=N^%]"[A:S-8M6'+(_U+UH;(P@UKCM%&_(ATVN$Q
M,>[;) TR09V.E3S*?R]\ WX^"64=#K[Z43A4 ?E>@,\,/_()WR8ANLS+<4E'
M@!D;D&N^3OKA%T$RQ:,JMB+YCF3]"CG&MV"2P<-A W=8ZN/+NI$[L%X?E<I5
MM<2@EB>P-0";.ZD.Y$-RE6PL0&Y"]2I6@B&\J2R$(S>2U\V0N]["BWP(AEE"
M(8UV@"Z7JFGR)ZG P%"<FAY[")Q\9OP[>$"M3#IV#@^@F ,E,>#M"$]3'@75
M]?I$M]9=:#F"Z!TF=$2F0;545.0$>@^T+DU'IGH9'R%6D ZC.BP'#].-@U %
M6.#=NX#4,BWK :O7LO@,OK^&PZCRDAX:;5?L0*:_;H*'8K&"5)(($@^+B@9?
M42(E14WFCV3^RW_,CBZK7[201X'3$D_9019P,Q;=H%G@  , J(CI%'\^P#)&
MQ.UB "E0=@C5L$6))_,!.;"]E2Z=,D[0PYNH@LCBD_P[R;XKJBE5S)4$3&;D
M%.*IHAOASB<)K)*$"TY46DA5P\4TW*EZJ%0&A5J^XL\F,0@["8Q<TM+R5;F9
M4BZ1X8"Q0;A<J:0#F0UC7V"YN=HL:<<YUIK#:64UL,6/RI\L1.4DP=S0:>%'
M'O/J[+2J$AYU9_G*9(O2 +6*?^!/)0MX?E;_"%;NH_R18C$F&F\69KB06WSA
MI>L(@UC8*<[A!C%U0_M/+"KB@I7&ZGF>U!&*%VS/<N>PG#L+91,+("<65H*A
MJ[CJ&::JIS13RIE%HL #96TK;BM(CRDKJ<RI8\4Q1A<49Q"C88UD\"A@<[Y
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MF'Q.A,T- KP!)232$6^0%>:YWX7W*+^.41Z*TZ7U2Q.1'J>3/888)?WUB<!
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M9%C1:4<6C4QO#4+)NM)$"S)PQ*: ,P,=<*;7/^LU23!^IDON01)9OA.]T4]
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MN<X3H+5 ?*"1;EJF2#* 7J# MX38LX2H7#G6U2*\]XJ'[%O=5D^$V%ZP1.<
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MA_=[W6YKT"6TDTZP9+E9O;D!]_>UYO9VZJ!F62_DK,G::V*&K#GRQELE.=A
MKD@95R1WIBI[DNI6G%HO$6BGHNEI=;X%:;$4D31AV)493Y)^*=A &%8&PW+3
M2$I@V,;PF3!,:DF1I2!=P0&":V)+/FBV'"#8,3%S59."RW?77A.#Y$WGTXVY
M%\*JWL'=SN3,%'-F<F/*LL[,5\?62\?DAQ6_6[VN_/?AT?VW]=?#"54OP503
MJEX,JPA53X6JN;MIRZ%J^2([H>KEB)<L=?==>8537"NO]CMCN3DC;I8_?!I=
M7?6-'9[1*1AW<?HD2[J4+B(Z6P_BJ8LF=!'1^=VJ0>Z*05YOR78QYD:S9G^1
M^N3IVOG'K<$X/U%>MK/ILMU.)"%:$'++PPM"[HOB)2$W(7>"W.H9D?N8HPEJ
M:SPEY+X,*3P\;U)?@^$9CRQ(<KFC%&0_7U\G47VKGT0^D*Q\RCM"Y.1<#/,:
MWW4I!QL(80AAB$WG YCJ1LT1\R0%&$FX(.GU]'P)F/<P[4 3:8EM5]<-<OTG
MWUQGQ5S_Y9L%N[^Q#4RFK/ RL_>FIUL.7G3XP(Z_LTX)U\>,&S]9S#\-W?;_
M.1M-NVS8'[<'@_Z\/8!_MZ?SD=%6]=Y4U^:#T7@RY5(&](Y(*U0?I2B\?:SD
M56?[KC=3NUOO-TOW7(@/B]OU\CI20$7BP8GI*8N;'*E3#%;,7']>VRJ&G=3-
MZ!L,(-*]$H*66E\A'8V4B[>$Q)JEQ!OC%F7-GFR]=3)WNFRKZE:AL)LHC/0<
MK38%<VE#5ONUKQFJLYCJ_!IH#SMRPML=DYLG-7[I*M/T170M-+,-NK^QKGH,
MW=](H[93U*<K'>AR-'G4H]F3MN7@ 9DH,E%DHLA$R76)#-W?*"^6T+5F5P$P
M=*T9W=\H.UO(T%T6:\C0R<XVNK]12K9(Y'I+D$J6E2=2L($R-G1_8ZT<H?L;
MY>&%+.,R93B;44_I\3/3/+8  5#,Y<IUGMB2+F^\N HP76]3]X%4NLY*KK.D
MO8,[I/[A.MZNPZ+A [9^_]W+P\N*W?PTO>BCL4G]E+*H7WB1Z+BA$<-N2QWT
MI)G815:CDB9MPDS"S$MF V&FE&PICIE]>3&S_+@&Q,P^8:9TXBG+0,L&1_[:
M+&F)E^^$&3DO5YQ])#:0!W,"#V90HP<3_ZF*2%\=M+JCZF9SD[F0(M(GL+PR
M*TW2+P4;""S+@.50+K L'^)/6MU^G[!2-HFDVG[='/BBZ0O39N[:\7<J5-2N
M"91R)#:0^W*4^S*JT7V)#6OZ8Y54^%N]7G6CI<ER2!'V$VY>F<$FZ9>"#82;
M97#S\-EA9\?-(ZK\K6ZONA0 60[)4@!4Y"_+@5MGN0I\YJ:&WV$NP'/F_K/F
M,JIDU*X1E)LD-I!+<Y1+,ZG#I=%@-Y%UC?\.G[T/36L5Z8!!JS<84F5#-@FE
M+@#YR$[2WW0V$':6P<[#;P&H!3O+IP2H@TY*":6N@+HY\#%PP2H$+N.9@#DH
M$?R;3OS7KPB4HB0VD#=SC#<S[-98W(CM*GSL8VA5JT@"]%I#E7H"I!-.Z@F0
MC^PD_4UG \%F&=A4I87-\O%_#^+_$<&F;,(I2TM !3<T7!-;;AW;\]U & S3
M5E:N\PB*6#HM4/_L\FOBCJPI]\.&DS?<OLG!JM[!L^3)>2KF/-4Y:C!MMC_9
MWT*C74768=3J]^1I/9!R]+XT,EMO/P)!]278?X+JBV$50?6IH+K."8?[H'IC
MIB,UY& \)32^"+&D#H>Z.1!I97;L04MY1*6FBDWM^B!+XC4R7TA4<H=DY5/6
M'2K/*_*%,KY0=;,2C\HS3*B]04J!HO8&^<A.8$E\(K"L RRKFY5X5$_#N-M2
MIS3G0#J!HJ8&*=GRF7G>:T73]6 96)K/#-"YE0MJI7&UQ^R MG1<W_P/_P45
M4&1@FJQ9>2J@7 RKJ(!RX$W(Q1VAW-3%F\2ZOD\95_BWQ? ?X!O=I&SL5K_I
M5/F%WJ0U[E>77Z#2R2D%<MMMW 3!9-<)@B^)503!)X/@W #'\T!P^:R%.FV-
MQM4=Q2 (/AL$U].XL"N+83C!S&)*K],<--[6S6"SVFYRV.$N-9!!LM8"#J@#
M[&)>(_TI:2^S/@\KK]K7*NYJ'3Y8\BL[609CV&^-)]5-LJK(]A]N^!ME/^IM
MFR!<)ER^3EX2+A,N)[A\^-#*O;A\Q)T3W=90'1,N%Y0Q(4>1&.V2N',T:/SN
M:T =^*UA/KV->/DU6#+7U',_;]%(';;+W#1QU-YJDXIFR//+1K4Z$SW4KHK$
M@ TMW&A'*^V1M6<NTWZTM3ELZ+5F/6LOWBOE]V)2L7N7&5X >5$W33L0'1FQ
MBO<'TW\:NNW_<S::=MFP/VX/!OUY>P#_;D_G(Z.MZKVIKLT'H_%D6E!J-ZWO
M,,.77GM%).E5]=A!9S@HM)FJ1>K]KM8:A?U<,=MCRK/F*7\M;/!'N;E^Z;>M
MY;?WQ&%=^)_- =DPMNZC5V^GG7R?G0)TM> ?K3);R,U8*KV%;K2%/'9EMC#9
ML07.H1*[R T[*+L+=1KN0IWNWL6XHV[?!4BEXB^8\L(TUU,8J(*AO&<Z/U2I
M]-66@HS^&V"<'2E5%I%>O>4?Z7)RX%K^]CM^&'[K,F_%X&U/S'KI*(55,PV-
M0C73RMI.:2O7R.FZ9?Q]S32>]^T9V$M9Y62^)D[P?OW)_FSJJ-; ^"^:'<R!
M/8$+?LG-H\L8NE_>>]/3+<<+7/8 *WAG.?J/8OK)0!)6B+=NP,0W@23,N/&3
M-0FDZ(Y'VGPRUMH]0^^V!Y.!UIX,9O,VTT?J4)\S-NG-.5( TD>$%/B-9!*N
M#W<&0O_I[Z]@LSJS+/208$_QSZ'OQ7^.O#GA<8%L6=K*8Z^C?[Q10J^LVPT/
M+>PLI8@/"^[DO;.",)>V[S/',@J[&Z7=^;2ZU;:*42=4Y2W^.-*]$H*66E\A
MI^,3:++0,VZF,IJF)*H6;Y3[MEG/]N"-CK9X*W6P\,O]_UO;7NEMK%N\LSO<
MGVSE?P*;(<8,6\HS4WC, &AEVKX#; 4'2;<"#^!&B7D=;1V,B+]0D!H"[N#7
MBFZ9M@D8"=0 MUUY:*-E0B@$0V$R#Q!K%^C]"4]W&6 <A,FX"%C"4OO!E%!E
M5MJ+('E.DS<YK?PK\ 1<X$SSX''H7N@+DSV)Y3MS!;'4G)OP-Y<]8JN"$UY*
M[P',>VV7B?9L8 7S?""CU]J] ? BGW'#\-]P 4O3@-79CQ9K&^:CZ2LKYF)@
MAM3Q34YJUWG1+/]%B;87KW;W/J,W[%S0/. 3]?EV<,,KUS$"'=X!?D1@^:BI
M<]=9<F?% ,)8SBJB#?XJY+D1?4_1@3BF 40!2IAS(!5W0O+K>+>M/6)]@2"
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M^.K8(5P7; [O9GK0VA[3L0\-'%##8W:)CKG1H-+UYAH/]JS7=C:TR:W7])W
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M'FT';MYFA=T!PI4561C,#/ .ZB/LF)HMJ&:-V'>1@G]PLO26F/_[M*NW<^S
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MLRQ493 *\<^AD> _9Q;S6@M\YTUH)D!%+6WEL=?1/]XHPI1,NN&1QUR=K#Y
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MVI4!= :@& UBR:^F+;CB+YS TVS#:XF?V4^=@07G#5GA)YB[%/^"CRF&Z>G
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M-36V4LV-V$ .BQ0.2VY:_R$.2_I43>6)Z],%ZV0"I C6J2_KRBPO2;\4;"
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MN.LG',0/$YK4S;,&=&Y?' =DJ<4WENI4EVLZ&PC.Y>4-J8@D^$#Q'DE_4]E
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MN? K_("G:+[B!*X"2P_F^  7NZ7A7Z9E^B^*:2L/"R?P--M0[K0?7DNY!;L
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M\9-0,SSWQ#P/@-!?*+IEVJ;.C\:%M'+<1\TV_\/%"30I;:RS$<&KMWB:)GZ
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M?*NZL-Z2S%,G"*/5#DK;Y*N:&<YC3I64=##]0"^."KRM#1ZO+PX^B;&D\!P
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M@50NSJB=,Y6WC^'HM(P"H$*Y/I#0N7S7N1/:&$M"&^.B'0S#5COOFO%YYPL
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M_9$YY_KR0OS$?W?N;J#U&PHZDL]Q,!Z)2AT*BO(IWZ% W0=5=!\,JW8S!>"
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M=N;90>PBUR?C^I2:>R8,[K7W@4U9$# ;/G09ABP*_QG;W\O8_%8^9,08*52
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M1Z_?[@&LZJZV(6N@7IQ*%5NJV#96Z]1@%55L=SQ<NC]0YX;9'KUD^P10I\X
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MA'J) G_CZH\V]QI##P]TYRIF_#T(V4JEQ">!DO5&X2\9&R.D*%R K'%9P*0
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M>1_ER)0=.,J1J2^V*$<NC<5H5$WSQ!,7.MIP=NM[V.F90DJ%C30H:P[0F?C
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M9?(P\X@@\S0 #!:)*PN37_*!9^ CJQ &BFX0#):5A#C8-L2!A/D"@UV)P7;
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M S!'FEUA*QXP1P(-!W-DXA<-<SP\..4B6C#'5V6.AS+PLB#?>O34#[]W9:)
M((EZ2> "/BX4!!*:9&!N$3[.MA@$DD8R1"&+(^EY2S_J#%PC8@ "2;,K;,4#
M DF@X2"03/RB(9!'QR=<1 L"^:H$\DCU_= '@.1@)4$+^)A0 $AHDH&W1?@X
MNV( 2!JY$(4DCJ3E+?VH,W"-B $ ),VNL!4/ "2!A@- ,O&+!D">'KSG(EH
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M C0>0]_^MO!=A_+@YH\(QLDF<"C)K8/ 3PT@H++_$UGYP9\M64IO^KV8OM&
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M6^+6[5O"^-^)&^'&FS'%@_<._BF4O_/ 3G]CE!-N+R#3\ FL@"[LK<\?B:M
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M:#EI!U6,SU1.1*Q=\+M:$#Y7UN^J";H2A3/;P92VL#2J> =>UU+>H8)"9GM
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MRXK+2+#0?:LEH3C-,<-LH;-6B[DD+34#;:%/5@NZ.I\XPVZA5U:+72@[/*-
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M\U87U]0PCYM;)U87SM3Q.S;<;]5BF*6[O.D/_#^/8'U^^#]02P,$%     @
MXH)<5( $;"'S+@  ?QL# !4   !A=')A+3(P,C$Q,C,Q7V1E9BYX;6SM?5MS
MXSJ2YOM&['_P5K_,Q&Z5;U6N2W3-A*^G/>&R'+*K:_KI!$Q"$KLH0@V2MC6_
M?@&0(BB)%P $ 5)4/YPN2V(B\R.02&0F,O_ZGV]S_^ %XM!#P?=WQQ^.WAW
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MEJ!.^\^89F$6]L)+3M#4.I%4)D7/*\V/9%&S52P9E"AXT@AX#QB1[2Y:/OB
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M(F&T!87WP@HA$.5X&[BQPSBC'XBG_.L8Q<AT4,_DMY*#OQI4-@5__;E]!K[
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M3::'NPQ>[],U7/\<91EAGOO9Y]#CY-+:=3A/:_<T4]EE\'3#9 .?A7"]J]'
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M>PZ+ HD>@1MZ4:S(DIC^%7?-?9H$<\1G:RT=!P%F""W.,GH."<I+CX\8$#F
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MQK!VS!8>BB@K;FL;4PM_("K $WQ.TI2:#"U]9,3>0%1T'N1FC5GAA2"K*H2
M=,(-_BI=&_D.I'W/Q[W&7W2]1O@S[:- ?JRK]-)UQ^* /MV&<+[/H$F-FCTO
M.\^QX>WQ74^IY)180KAK76>F@EW#LG2SD&,JE08(<>2Z56(:G35PM4PSWL>^
MX&<:K'7_.BF(,/D-[\NR/M\7'W'QW["XBY*U7K10I6D#OQH/+V47'==#P*ZZ
M[I6D- GG75&B5C=IZ:F,2#33#*ZQD;9)8%-8E@)_Y>7\_$_F"DJV@/ EWE\
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MTXF4VT=/F(PG3Y[39$/DHS?0/J<D5!%^5 =4-1DD=L[VD:C^B\.W\\8F=<?
MRK;ZG8ES2N16FY*'SMZ "A5#]QRDZL4_)8[4<$HK#,%8U(#"ZJH+%Y1RGI+
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MQV51?8S^H9U2"^*QXK9A#2\*SF-/;92[=2(\>[WI3;K;%SD+'>\LRDR[R#@
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MY/D>KD] C*(\3S8)7(,H!PBGS[P/6M:L,PUCB]8 ?8V;!6W]+P=IX;,JMPU
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M[/<A/+"A#S(V4[71,YBRNU .RI9V_$5#@VH3\F(WC4,E9C4AF$:O\O&@;HR
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MOAGDV%SIRX%7CAO:V-I'DQE&C(X'*UC3\HX6<W"F,%A//?OB%[C>([C:/)#
M!\^C'*XO\)8F8%PO648KG9ALYX?Z;T05]]GG*%L_1D](:V7BD*E%JSI70GAH
M+"A$HX4_C#%@G($L'I#E ^>'QA^6%?U,2/ +$S.0-R+<&QSVANF;,2XTGUVI
MQ.=/)!QFG[.D*&!ZMR=+M'BUV9"55?K\@:V?W'N8S!%PEJ#D.74(_CFB&B_X
M4'7":.N+YM;:(.3A+)N3#R/^=&L;#RHC*,VBAE+!+YRV[;EYGA62Q9)_M:V5
M?/2W"_8T;;:+LN+P,=K"LR^)TMJE_[OZFNVCY>$.O,0%4#;S&O H 'A,.:$I
M&_7H&?Q">4QBT?=P1Z1^H;7A90K>'N\EIE5%JF:N0= ,#F4&_Q .H8\?-E+C
M(K 2_E1SK=>5H,/).&MU-^MK388_P_0L9>EME!YNDVU"7ZZO7D3E'ZMG-P9$
M3?NN:##QTUN,"@"BE&?@A!<0,LAOM_+?A+#!980T-E;V8E!MQDC"W4';F\D'
M@23YP9F*2;I*/;473'=$>3KI9_?WS)-ZF8Y["Z+4 YA=!Y6-AY01DF)12Z=N
M4DMCBU7/)?N^::]<7]EAH'9[G/X-*20L]1Y;KZ.<[?$S?GS!^YRD'B347Q/!
M"@C3J]_V)+S?I+10,'F%E*UFVJ9-UW".U^3C)7DC,H!"",%RN(T0 T F![T;
MS04!.R))" F<*>S81NU+@EB.9^^_?_<[P/F!BB&@'.W3NUD&)Z()M=N2.4OT
M2O;=@YTMR^-G(&2TNFE>ZXL6-7(R(0\%-.P0A=(/8\;L5C@>U$=0RD5MO<Z4
M[9D?^=5*2=?F.:,?_C:/PKF7Y^V[HU<KPE.@\Q8MICQ)MS\]E\(4G85UDGP-
M3=[#O,B2N(#KAP+'OWY*DR*_?_CD*VFJV0'&#S"&X&O",O_&=M5RM=TA?( P
M)_KZB-/JGYJ+E#$RA@GK,%DO2Y"*!UM_I#@]A>4G(2PW%/'"&@H,&!O9#6I@
MJ&O3_D_5)_:+ARD&@T;',=NZX!)N8);US@P_)\7+3;I.7I/U/D)'DP29.&C(
M76TZR6BN-+R+8CZ#>A;-@\NPQ><IGRGE6?0$U(*2N39E;2+(IVSF9)=LN(B-
M>3B,%&XJ4\43X_[&S5($OT[#DDT34'%EZ^Q(]E@2R$QUU6.J,RU2N;\Q665O
MJT=3N5J_RO67IBZYFENA.RG^&0=5XJ '6\/^T'P[=H5DDP+')M5I46/1RM$1
MU#6QD,NH(%KX2:_Z>>C;ALN#3FI^5FQ?=@F9(JA[@#7MRT$<]YGR#&&]-@P)
M'E=6>.IOM+NA2J=\J''_-%Z1/K/HJ$_J24N^'Y."WF*I X5.S7?/E\V**3N)
MN;<2QH:Z9<UH_C+7813PJ(*"TSB2E;V2E3UA\??1^&@^SVYITK;^+\GN$5^E
M!9DZ]4K M<DZ0F>8S3^JIRABVN=#*DI=$'X#?L<6LS)_>E&92^"N[@BFHA$9
M6RK_!:,US'1KC(9HF!:;]-/T4SL$4[#C#$'.-@U>&,L0LD 5C+"JWD+%0XYC
M[[[_O_C.#<? 076/;^E++Z9W5X45\:TGSDH_0>QQ5Q(=]C%;*AK4 G9_V= @
MNHAY\<R:43!5>X,HX%$%!:=QV?<D=;NIK/,G-NJ4V)FO226!53V@.&MC)^EW
MXDZ7756N,FG[JDU%5OYK<^NZ7"$)R%EI0G5++A1'MS"!C@I=+?TO#.[C.MT2
M6EYU4O)U7ZX[Z3#+>5ZNV*VK=0>&K!"5%%<I'Z(OR7:_=3FJYH.=@D%P-9I]
M!6:W20IO"KC5*A1PP<UC-=TH=P\MCA0*Z$:ZSU#I !,OE-9&[FQ*ISY3$;WE
MVP^:UG3\!)Z+:)<4$6)UD6=[DJ1DR=_A6B>8]%$P![B;HH<2ZXHVB#E+GHJ%
MX;XCR& U?86)@G =P4)4Y=9,)K\/FXFS99X^1=DJ>RAH<\2_1FA/'TM@OJOC
M%*H4+2YX*G'P<*^VY,M]Y03LH@R\4IYAN(TFEMA,H\O #;4A$[DY06R5 <X6
M,+YTXX[/4//Z'A/!<"(:H^0*LS;E"7R,;<KG(%*(D//Y6B]VO3[6K<FP<>KQ
M*<XLF#F,B[/:%WE!5NE)^FSK2 U2;A&22/M8T?<Y$Z[9ANM-70B.N-.1.@-'
M:]BA5BHH*78&0U&>KS:B4^4JNZ<O5'W<TYVDZM/\)L_W:M../DW3#E+J//RT
M!:/\:6'%9]'C$V<@HS* E DA_2H'"9,CA.UK$[BQJ<J_<V:0=UD2:RTYE$FY
M-+\&Z6FMCJPX*'-:L,!#>;#&U@WEH(UUZ-7(M.XR'$.XSFFY)K53^@K0:G.!
MMUN<LOCZ4X9S]8<^5,D9FI@:>2]F5K+F-=")8$[M+F;LQ>'<,Q4@!$/3!!8;
M:-B/P7V$2L^>:A#S96R$^)RFEL(@JN^U %4VLTJWPT;FZE2-LN33].6>]M*_
MX\]@LM3R(_S,?J5W<J9(T>)T0XF#CX72A62%U2J)YW-A+) TX<1F2ET&=.7A
M$PL9G"?@3 'G6BZ@"%_^^^G?\F$"<-FTLUH%(I8GB%U$?;C5@^Q(1\EK()XU
M"E7[!+A?>\'"@AIX")]A?%1VOX-=K<L;QQ_[%N0+'%=Y1LC6@:L-*%\8666
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M1O&0Q5NMFP#!50)QUM6G8I##U,:]I%(%Q'4XAU-6+>3Z.7L=-O^9H-3K.>T
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M8BP7?ZN<Q1FRB.A[V:U?H<O+V\%'K;ENHHWT!) #YW?X9]R'O8) R\R27=^
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MBY%0I9Y,_1J2FCS.G,[<<DG)EY<5 $$:XUQ9BH2?3)>%2#BXY _A75C^*UW
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M"UN8MFZ_=.DIEGKK$R2L)RXSN9RI:N$_@"UPS\7?FBK)=#:1,S43.>MF(M^
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M\6OLY(>%YH_A^A6@Z8+^JS\)@Q7>N'\QI/A2QY4/KBEAOB'?;-4[A:^*#3U
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MPCU^A!)7]PX^U&B_$0$-/2S=9$VQ' %-CU;8ZB5"^8 )7_1>K2$D)3"_>W.
M?B G"(#W%+ZZCBTI-^L)Z0';(NZ.Z(4=7R73Q0QO5A_;V%(6/ \U31TE7WUG
M[EAHEV%)>/^4$]$S"7L%YB$=6=I<FI&04J%)JQM4CP\FK0Q(@S!2/N/:D23?
MU,\%N$M5$&\Z4N=U.15!!5O9+*R.Y[G1Q5'5'VK();&&4O:\7O)#L?N* 7=I
M-G#\F@#DUF$8>%_,!J_54UVMQ^Z?['-S,>:R"V"M$<,Z^)I]TU0;@;#40F7X
M7!B-3RMG]L UL7\V+XS#LMAU PL\1ZP_IIF[JLR[!@L=? P-,Y6*.C3V?;$,
M#<.U!'$5J\*]GG8!_&CFB6I=3A>_H^R+[$OC8*U]?8+"KV3I3KPP4Z.2>X6$
M4L^H#,OQ5$M;3/LOZOLG^HNQD!;&'Q2@<GAL\3!&;[62,!(H&_O"<#-3W&DY
MH@?14'MG],Q<3(NCQ[+.GE8BX](M>V:XAMUF7&-FE6IB.%.XS\V6K&W#S17]
MR\ >Q;&T.&X]?GQ?P)OKI=:5$Y#S<ZO)FT@/TT>S)5<+&2Z)O"I)W&'(CF)*
MREU3DIJU+UC,=+%7I[25X5.7@<=VI+E.:-ELQ]0XK,K19 ":K577*&C%:;4I
M.)\,=V1I,CDJ,JE3J+^8>9#%'3G<F?0)=!\-]8&)/$LF%1)23,Z48[(%Z!5V
MCXJ>L!T%]332I3!<'5=8Z22S F7%6QBJ9R.JXJCRE/=A$'\:(6X"<;XD%(/V
MZPBM,+2\%<12E"\,CY?6@'+%'K[X/**K!-V]8H4IO)^47W!]T^!: 9BWRF6*
M\Z5RG]XP<"ZOC\J@56[3&@VM>#G=%.G/HXVA N>RC?QYX'XP<7AY2VTSB,WV
MPW8!,:V[G@+\9;SGI.RYYB7ZV1*,5I^B!:AO%I&"_G4T E5<C5'_$8;J:/P)
MHEK5:":!]>)T]&H*WX(-&P\Q[$?IK$@Z%SHT+LY&02RXM\7;GJ5@GX_JM*1/
M(VZ ER(Y/M^);ENN/H@IOD./,9&X\E1TRTSQOQSWMZA^7-9G-<7T\_AR*H]I
M64_=%-W1HA-6)&1)MM_+.5G53V?C/2"IL2CK=,[68C2%)-?BM9[J:^Z0)<&-
M.34I/CV9E3D?'00:3PEQ>F'EB?XYNPCC!21S :UH!/ZA$R:+ZZ@V:10[MV\;
M!]%?CBZ S$*,P97-(O_BZ-5(,7K&\T-;,,=ZT5T8A @DVE$6<.7N]$$\SDE3
M+5==:>)?=F5&54B7L9'4[? #%-*X_2A5AB2/%R7M%YL1%Z/HDC>]8[EUZ&#F
MD6 7H\-9H_S*'Y5@!=!L97GQF?DEBA.+K_;? 'F6 ?/8747_D>0YWUD.HNZ6
MS$)>CB^[?5I(8J.#>;*0,XB/9]&J?1Y-$O%52U,,L73#IG?Q((_0V](UH/1\
MN@+9?R>U]Q]A\$\0/ ,;+CT2)<\H11\=+FIVX4;]HD<+%YTR?,_%/R*_EW6,
M?1DM5(W",3XM&47OWL-JH.<[]J'\^SJJ?8)JWX%*G8WG9[A>&II;W>Z&KX#V
MD10#CGZ I<S,>B-%+8AC#&]N/XN[\M>0X3@$?/(,GD,7_Z!XS"SJHQ$C8^S[
M%&;@QJ!/7UUG&55I.1#3EV>&%U#2G])6/.1!=L7E^*#7)RTS4P<FNTBF-^WH
MX'!D@$Y2!K+:C?H*!\.Y91LH],E2^'MNC3+=_G)TZ4JL45+U$-_'MV^$*B!Y
M8G4'8LSIU_D"6^CB2[U[&;_#Y2>SJX.UH)B6E@^[72R 3>K"$P=X!N++T;6C
M"N(;X-O(V1P85Y]'V:(*X"2PGCS= <\F&J6%@H,-_65\$E"F3E*!7+H<6="5
M&UJ#T"@G+FW@G'TYR9*/-9@,SE]'::W85BK=W1D3];/Z_-1!;._&<4J'$1E%
M!;D^#[U!2*<A9$4+<J[A\>3O'W+K@>?[1_1O])_(A\]@<4+^^_WY?F\("^L-
MUJL#W]MPC8<Y/SL[_WCV(;#>H ?7NVA,UGN>BH8HBM>/ A=>PO7:0KOIXOGE
M^X1HU:0<-P@LQTVP7N'Y1>K,NX3^^S=__B_/F/3OS4A'N\UWL. "*1R%:.Q]
M -X"X,U!NLMR&[1%4/;.$+[R]D B+/B8![KN"\M_I8L?;U3*R ?@!G[R$XKG
MN].S=S&B[<>BI+Y.CGBB+.+T;H=I!6,WVNE]XC>IG_SAN!=HWY-P)*LDS/21
M+](=1 O@D#!*_TA62(SC(U\>X<C)/JR0,--'ODCFWD3F+$VD(/<,_X@I(Z_[
M?B!]R-.10QQ??7U#N8"M(P=Z_P;K!\J'/!TYQ,<@F?L.<MZ7U"9ZF=&TP%+3
M&Y=_QC6$^K'&3;I[J5AUJ?&U0%?<ZIICS@<?ZEEGY9V@>!97W:!:0&+^2EI@
M).63]E,DK/N!GPM2\2>O/NVD*H),TY$Z?V=0!!5L9;.PEJF&1U*WV=[M0$KM
MM:$U&--BJ2[R%B9U8S%X!Q[$IJB;:(UNQ>!6_AS<M[?Z8VD!>7HV\)W?LYSZ
MG,W)%DIYC.(F"K$A\7GC<JEQPZ2K-=9AZ]4Z%3@EV5*IBXO\&BV51TM,S\?%
M4N.G3U=*84[4N%(MOEVE"Z8^/2JZLVZ]<<DT//>FZ_A)>;3@J'MT5T?K5'W*
M5M_,KR-;2K$HIG0=U?>''95,G=&";"''\/@^+:1X<&ZZDNK;L19K/#V)K<\D
M;;<58U\[1.]C[<MGH.VM^;7^F+P>'I/]7'SBC-PO@W F_.+<$A?]>+*O*2P1
M70X3C]0V!\1#/H/D1YD"<FEOJL-J$QJB.9HS>12+4%&N3Q_(%4SH U'-43RX
M'Y\!>1BBR=\>?7$.+9?TJ>A*4O"S=Q3 UY_./JZ'2JZ/8IG$9W:N<SVDV#L*
MZ5Y^\O=Z<NN4]=PL'07 PD>Y,]R;<GH4R]%#W#E9ZE>22VD$1MX[5^+<:0]O
MY;P=!^2Y,GR] 5R0L^. N_(IH3NL1=CJ!]#&2NPC 3BC;VG,)"H?_"A JU>6
M]&/)S]-10-PIEKG!^Z5^B6LX.L$K'%X/<!+EHP5PD:!^%/ME7VF(J\WKVR^%
MPQ\%</V247T'+?\TW8MLV_Q+*RW7.OL!9RL8^ACA.QBB   O>04GC8Z=+2VG
MB*_;>V\>VI05\@/^[%H5HVA9</FDV4[279-!1;-=][\;DUTY!AV37<=DUS'9
M56<BV[Z0&DJN:Z%(+T!E:$FJY>FE*I2+%G-/>X7B\62>GAN^$/T*>BVWL]I(
MA!NS/!1X#5C>V]@B3V))&G1?.[T8<T*[. :%SE:6MC0N2B^NC%S2PV5+%\>8
MYJGLE8PEJ(QWB?YU*G@93A=$?5NF<4'413TDRW2FWL\S*L=MQ &E"S;V\^YB
MJ03#X]+5.A]7JX/5$HX>3=?KX[A>O;VU#O7SLXN6[JY1/V\Y#2%=P4_C<>M4
M:^=<IK$@A^PRO=93?166BA4);>F2?1Z[M>I?,I4YH>E*CGUW.UA)J6SK9,G.
M3\<EZU2+/*P_D"[,V*^WE]IB:?6-=.$^C@O7J1#,%:=)5^9"P\KTI"K4K1\X
M:RM?/VOB^^$Z@DQUE2CA(7M?-8I_1C(!X8UMHX0[N;:6[?/0[^R!,5=%)>?]
MZ+0JRUJ_ 4\9S<B=1#^Y<;;.'(O#9SPA+1#S,W-\H#X[_A]W"! - N ;*.@4
MU&)FC@_49'/\"EU,QL7W:R_VZB$[_:YK5343?>7$.+@8,WB,S^!I<?>P# 'E
M70MZ94.WM"IMRTBV/,H;(8W+TU0S8%VJS,[=ZOGB%.O";'',#C7LT>(T;M%Q
M;O;+2-^7*I>!HUPEZ%G'%'4+TKYKCZV*!DV@8Y=ZFLV)<5Q#C_[&,V8%;<'\
M#J*[D 3OD2PGR[/!=P]_69 4J\S;W@8WO77$*YVL#LLTP^>UM7$"RXV2W4J9
M%C%&)8AK,<>O7<OWXQX;^4<^GHD5$U!69@?O:[@#T09["I&]PB)/46V=.M)-
MYW!+]17@J2H*5$VO*;>3RL( \ESST1V+%YE2O(B<IJL=%0M-RA'ER>B1ATQ.
MXWWJAC1L9#YW(GWHR7+F]UXLP!]!,%V0*Q"&6/N2<% V'ZMSO5<97,5EAO*;
M8("%@TH/U%@*:"P%5(E+?2D@OLMY*,5_^'&K5L68QU!YX]\CQ8M;YV;0C?(=
MUEI9#"WE?3-[A5:UE0H;F=D,0PT^X[ZXPZ)-=^A@C+V5,TC_F3H4U?N^9(?N
MOZ-+>&8Z#)J)2XT0,"_V*9,G+\\7,M)X*6JQU](+!1]OQP8ECO.(8_RGZ>(9
MV'#I.7^!>?1405WS4IXOY4-K >P7X %DN5CQF\S7CN<0.XSH>_&R\?MY! EJ
MF1P1\_A666%F;L 6N'!#5#/IJ7&1TS(QK);#-18^^-@1%A[B/27NR*HAU.5D
M1-U<E60T>[W4R((&_C*E#(R!@,8' K:S<8;GG6OCX$-.&3<4-Q_/?5&/V="<
M@'PJ Q34=H;B"A1&CU,-'HIK4)N$5&Z%#<4#V9;E#,4]!2V&/Q?%">ITPD5R
M9&:] ?\!^C[PK\ "(O"$X-;Q\<!W$&5^1<K9UF2(?CC5I&:@SU(E/-WALT,J
ML3A>Z'C+Z08@BDS,:8:[VS>\7GA#.YZ%=O1D/$+\KUZ Y^Q&-4-HX+^XI=L2
M&QI-?J$9X$4'SE+"N2$W2E]AP!H'7B;';AD'-HQ&(/#(3 C(6/:59#J_87DF
MF;-;)%=M6+9@FYBF$H%!:G;>3_N0\E]&;3[&PL!R^Z '$A48>L1#-UUD59PK
M;$$NG("@JE E;#):[[1#J<EH"1L-$3EFZ>"Q:1/S)1046D-)3Q1LQ$0L"E7,
MIYR4S@E1?\[$FQ-WCJMB6G4$=4ZN9,L426BI:.4&HXPZ94>7=9-%&XI*J>#X
MY!&O$PQ:H\Y, [?\,F$)X&87(6D%UE*=@Z&J/F.X+UHY\6Y[MN,ZL;>;'. 0
MWQ([_*^D#H0_@[>+!;#)FT[RHZ:Z>?,Q>Z>A-YB2EG#!9.R49<)!T7D1B@04
MH*HG*K*0H?VUN5Z18@+WWDU\7/$O37P?!#XI$Y ^_OP03716/G1O )L&*X F
M\_\._8#&UZA&)4^_-U-_A$1:A/C77MWD19NRJQJ#BH%Z#4;Q R=Y(=6!4-7H
MO8%M$MR!.0F12*^$O5]6C5/M<!T"4W0S%$]"PGY5-F3G2JYJ\*#B'3242+*.
MUT%4X@TF@*=_RQ)?U6P%S X2['@%\@HC,]3-S@?M&'@A^X656S,[XE/[FA3;
MUPQN]9=R7WQ5V6?0W!XD3F<'DW6=P%'[?"PT5.\\4^(ST9(%=<A)AHU'();F
M5$=*3UH7XR(SON0\]BATR+ZPKZ.2C%2EMA**D>3SE@\ *\/1LO/P*4Q25_&M
MHB.:84ZRS!8W5=U[+(*WZ4'OY'2K<!;WQP&<XT2XFU09A6[8;R*Q]BATPW[R
M@^C^;C2/0U)-I6]$%?_A&O_=D1.W>1IJN'H 2\N] WSW;2T)-3SMWR>".H$P
M244X.C9Q9S1$,DNDFV-$XH3BGTD4>N$BUY>)[66M>?,X=L%7\S#3SO@=W0SI
MX<'7T[6%T&X!$:U*U.RZJ"#;F58E52VBDLX8R=A1)&/ULC"/L]E/,5R;O JU
MJF,Z%.]Q8Q"52'^&MMF/)"V@G?7RFOW&QPL>AP;:IF/<',@J3(L4P NS'W(:
M[CEF/S+ QOND'+"L%X A-MX)E7?"H5,G!>[3>!]4ZW\'$1J?QLN@$J_#3G:7
MZF5_[E7YF/&JC("X5'</?(W \_!M$\2_:P)\]"6'X:7^%NC39A/-911XQTLA
M_&SV?2#Q8EJ@B-2^_J9P?E$G_OIY@N4 Y7KV9R":+@;; #&+GSJQN(_?K$_2
M41F(Q<% *9I?U4O(OL3)L4YD]]X"HG54PK-A1!P'T=[%OE7QK.-!X[N'TN*1
MF*'$/3I;6<%O,'3G]^L-WL>'B:$B;QVR(VAYSREA3L'\E(<S[#T)W+YMG"BP
M]I_ XF_^*4F]LY?D MZ:/@X7DNS;>^]>C8J6'G\/QFASMY;6KVYQ#_.-V:>=
MG7#<P@YGI/NVTQ]A\!*^_C>6_3/(%J>E+5\VF!90RMEZ<-9.I'CX4^^[6"20
M"-6^K;V^A>]NU068E*DG*T5>R\3S[L9#7I-<K<F:]!T6F;4X;:G;+5O\6J0-
M6<7'>IH?96_V_QLBQY\[-H%+O,]6+2D]ARC>NM=D,=%.?!HE!*1V!?4945Q\
M?D;*OM0;M#8)@Q7U),AV)RNBT=$4Y'J2Y2DTE0S<G<%*/AS#%C4_6I2L@^D-
MLJKW;:Z*=/Z@#*7H9(VHJ41JF)VL*FX66'[U#:M?535&-7K*4%I3B4!5JYFR
M*%XS0:L5Z!5F",/&3/E4;[[!)M9DFU57CPX^*1>$Z5'B;2%8Z,@R/7Y<"$P1
MAZCI<>-M[<(R/[KI8>7-\*Q[FC$]Q)P+/?5/?*8'H+=VU>R_#[<1*FP.C&6!
M!2S:=<!7<Y/0DS;B6X\.P-I0(Q8R:&;/$A4HU0:<)2 2-TOK(/:DE\856#J>
MA\4_%O2WWIS\@=JXTP5-KRF!,HI/3,%OWEY#"1N]B^U4.\OC#H?\W75.W?-N
MHSIO@(U([@11'$.7*#VD+>$3.>51WW3\NT_0=^)ZI8WG+#A>E]#@7:L5&L'Q
M^@=-W)A)(S@5(QH>*CT^@K>6N5>O4:I7AC9T!V/S$@5=ZY5J41,^MPQD,]5V
M'?"6WAECDW 1< 5U%?8BK2X8I)\9DVK@3=1?AIORE\-(K&*[HC,[\R5\]<&?
M(?'!;DEVI+HD/PG*_; &11B7"41,#,AK/!RQ)].6(\_ C?)FJ;/M*43VBF2-
M+Q$ Y)^Y Q;E!] 3ZKR/;]XOQ!/C7$JCBRE(Q&@7$^B"^1EF5SRVN()(5Y,0
MC2XN)=')!'A#DJN_[X)UJ38"Y30ZUQYJIP?K5L'TN&2N/5R!4GK2AA*?7">M
MJK$:6H1R_055CM?0(I4EC^!#05RIX8'*M6HG;*P^,R@[?8V,_X7\SRMF\-__
M/U!+ P04    " #B@EQ492.WS9@- 0!DS@@ $P   &%T<F$M97@Q,#,U7S$P
M-2YH=&WL?7MSVT:6[_];=;\#;N;NEC27DD6]%6=2I<BRXXEE:RQGIO9N;6TU
M@2;9,0@@>$A6/OT]C^Y& P0EBI(-A<#45"R20*/1?<[I\_R='_[WJP]GG_[S
M\MS[^=/%.^_RUY_>O3WSOMMZ\>)?>V<O7KSZ](I_V-_>&7J?4A%E*E=Q),(7
M+\[??^=]-\WSY/L7+VYN;K9O]K;C=/+BT\<7TWP6[K\(XSB3VT$>?/?C__JW
M'_ [^E>* /_-51Y*^$/DJ=B27X8[>P?_,]PYV(;KX-<7YN<?7I@;_O?6EO?^
MC7<61]<RS67J71]L[VSO;A\-O:TMO& 4![?P[[_]D'A9?AO*OWV7RR_YE@C5
M)/H^59-I_G(FTHF*MD9QGL>S[W<2^TT>)_21[E!1(*/\^YU_?SF.HWPK4W_(
M[X?X*WT<BYD*;[__I&8R\][+&^]C/!,1_W8C\3'?1W$Z$Z&^&Z=BOJ'A<US%
M,7P!WT:2K[H6J1+P3$]?^-V//P@O$C-XB?_Y.?Q\O'=RO'^XMP=?OQ _GG^1
M?H&[ (N1W/[P(OEQ3=[Y_,M4C53N#7>V]PZ^XGOMWO->W_WX']$H2UXNGL)O
M19:K\6UM$C3PD\WBJU+4R<'^T<'.P0Y3U'_]]:]__6_O;]X9<)90D:<B'$T0
MC?DP&GPG _C6RZ<J\X+8+V;P/@,/WO4S_#"Z]4:I\#_+/!MX4Y%Y(RDC+YZI
M/,=?I2^*3'JPL7 S+-44YI3#O<#$2H2>B +O)BY"O!*>-DLD,+^ZEN$MC)7.
MQD7HJ;&7%*-0^?!=H#(_!,D2;"_>'A]F)]/52.2NW>"-&\*=]Y/(8^;0$H'@
M]Y4W":0?IT0&WQ<PPS0$.H +?Y+Y#>SP#R_PAA^_7]]]T(L[BL/@P1NSZBZ<
MYB(5WD\*^$2F(I$@Z7U@J[>1O\8$_QSF\,R9[C0*>H;[&@QWJ62:2N^U&,%_
M+V2@?(&GV_HN<C^')YC#_!-'<0K<:KZYBD,5>,/M _@E$4&@HHE5$Q\BC_:_
M*<^U]V0_#N/T^[_LT/^^&>^??;BX./]X]O;TW=O_=_KI[8?W7D4>5R<%,OC-
MQ_/SB_/WG[0D7F%9GII*GL?N+?GDY\"FSU\X/8X5GE W>270?OO@Y_%(IM[N
MP-O=V1T^0UG\'.;@C$_[M)RS8*'</WZ BP*]:JF91R(F<@LT&?%Y2XQA*;X7
MX8VXS5[>J""??C_<@:=\MS[^HCL<8=_>/_3\"']9AU0;:O?2AL^GTY_>G7L?
M7GMG']Y_@K/WZM[#]Q&$W(H! BS[55YF%=H*U#7\-Q>C4'JLJ_SMNYWO/%^&
M898('Q04^UDK+/29Y@H*$U'A=^8UM+(#!UHHDDQ^;_YXZ=7$49[B?P)SG_YU
M=_MX%W__X44>-/Q^O+>]MW?'[WO;QP?.SR_X(?I),!5X'YCR[G?>M9X]K.5W
MWMT<O5BLFXW0'T,YSNES=6?PBV9"NW^SK'A=V;64YLJ'?1UZK^18113)R7#;
MRP5<N!0KG+'/>"6&SEL_"5VL]NK+O:G+H*WNU,K3[5G/L-ZN]T[!KF0R>^G]
M$L4WH0PFD@.K8YFVOL.M\.)ASXSM,6-'B&QW>[CDCJV9X'D#5^5>'GN7(LVC
M7L1TEOYWNTG_5Y0W0"?N=C=I_ZBG_;UNTO[[V/N 603>1WQVYL6I]W:6A$H&
M5@OM)DL<]RRQWTV6^"BS/%4^YI=Y9_&UC.#GKAX,/1=L'W23"\Z_*)AR-/%.
M)ZF4)MNE>QQP\G .:-U\_]-.[MF[0KKLE]QC'='[*"<BQ:B.]R'1D=4B@A.S
MHYKB[D[OF^P9L@V&W/?^'JLH]ZYR*5/DQ[-X1@45LO7=[1FQ:XS8$2+;[VJ0
M &1+$G-E9^LD^\RD2T=68+^K\8&/,DOB*%,C%0+]]VIN9^F_HS&"JV+D&\TR
M\\XSS/Q3V;2S/J'=W9X5.AH;N) 2G:(=/0)ZNN]J-.!"147>5<VG)_OMPVZ2
M_6D8PC>^]"Y$)"8R[1F@JPQPU$T&N/+C1'KQV'L37\LT0E[H6:"C+'#<319X
M)7V589CS0GP&U;^;B4"[>P^G_]8#%'_:R3W[8$^7HZX'#L:E=QF*CH9#%@N$
M/MCZU?FO(T1VT-5@:TW"]#I'KW-T7N9U6><X]%[):QG&"<;<P!#)\\[ZHO9[
MO:/7.[XRD1UV5>^H9[IX__&7X]WA\*5WF2J8]JWW-D+L4U),$)/[+%01? Z]
MJ[P(5%?+9^^021U9@<,^-4PSS)9W&@2Z_X7#+5G/+B6['/3LTM%,LC<RDJD(
M>[+O*-EW-&OLHTSB-.^HP=:3?5>3QCXB6&O0DWU7R;ZC26,?;D#)R:8JP;P9
MUV_W2N2"[ "-LP;VP35\WUF$U=W.0ZX==C6OC)$$\M@[!4,XKW#)*2+O=+C.
MJF>*KF::,5/ H?%1CF4J.YMKN0('M!XG^=-.[MG'G+H<]SU"L)TB%'F<WG8[
M[+L8H;0/^WYU%NP(D1UU->S[883MFQ%!R!$WITF2QK "'0U2=1X2^:BK,5W3
M:0,U\0OL7LXPF$4^C5/U!R<_P"#>>9%B<10Z='[]Q=MJR)'H)N?4,6/A/]@J
M"O[EQE&KOK?;J>R^%R];<CU=/\ '/_K>%7_"/G?JAQ?BQQ8Z_3UH47:^\:(\
MKOG?D^YW-SNH=43D5?H4MGA@[SEM#[MW;E].!?SEQ]=JHL+N5BIW'K+]J*MI
M)F_">(3)A6(L\UN*-HY$)CMJOZV V[Y>*W#4U;23<Y&&M]ZI[\LL Z,LGJ1B
MUE&O:<\$74U"<1UY&&+O&: /)78^CM'E4.(Q=0>0J:_@3?XH2[C@@)S%.>/;
M=#>^N-?W#NCCBU^;R(Z[&E_L =3O%C$=68'CKD847P'=3SJ;S]<3_G%7ZSWG
M5<[. J;U7'#<5;_\9:HPI-N3?4?)OJ-^>.M9$"'Z%B3\'O:J?U>9H*-^^+(8
ME/($,P)3!\X("C]'(-E PN0_9\855W[MO4IEUE&$F+UASR]=+0SM,%3&7N>;
M#!QWM?03NZMRJYF>\CM*^2?=I'R=M/837(QYSMX5W);+R6W/!YWD@__XR_!P
MY^7Q]G"GF^QP)L/0NY*A]#M;0-0S@66"CL:+W\<PX2[7T.VMT/I@O5; LD!'
M0\8?L*;+^QF4HA";CGG\.8^],Y%->Y[H-D]T-)K\3LU4SF%D^+_&#$.;@;"U
MG5 S?I=/I76H?BCR3 62OGNM9!CT#-1M!NIH(+K*0"70GO<VJO('<=0GF:8*
M*PAZ;NDVMW0U?JU16M_'T1;Z9V7>4>=LSPF&$SH:Q*Z>&Y=%FA6*@"JIGX/R
MC:+5LT=?8_:5)_?U:*>O,7MTC=F)=R&B8BS\O$B-7795)$G8;?#*.R1$7USV
MU1FR(T1VTM7BLH4BYW222HF0\JU3\C,3.AU9@9.^W*R3A-_Y;IPG72TW^T<!
M,\\[+_E[!NAJI=E'"6I0Y)08] S040;HJ,_^-!>I, ; AQ&\!;DM.UI&LP(?
MM&Z\_VDG]^P=(5WV3 YWO+>P)R'FU8*2B,=C(M.\XW[)Q3U*>[]D[Y=\&B(;
M[G35,5GI \N*2:,,:IV@GYGLZ<@* &-TU#\)A)_IQAP][7>5]COJHCR/X!*?
MG).>BBCCLN-YECTS['357?DV&F/0EKD!E*1/4Y4&'N9=WL)_<_R6>B)WU#SK
M?"=PX(R.^C$U]5^(]'-GD>-6Z,#9NHG_IYW<LW>7=-I[.83C\!9/R8Z>A'WW
M[]Y1^=65C6%7'96_)N,4?C$RIG6Z?68BIB,K /3?47^DKB0G*_1"A3++X>+^
MI.TL&W34-5DB*/1<4.."'_H6]@M6_"E;V"M\P;Y_?=^_ON]?W\7^]7#R[G>Z
M@?W'^%:$A,<"'/]>YMZ5@&.XH[FKO2(Z[&KPPPT#OE.PE5FOAW:7"3J*N6*@
M51AY"/-#NLD"QST+=+47R*F/[7& !WZ.LT3EU$;*U/K+GATZRPX=[1%BG7*>
M;I+#3:-T8+BC9D+/#\.N=@YA<_FVYX:2&TZZS@V,U,C_Q8!^1[N(G!:!ZFJN
M4,\#-1[H:%;+)_&EJ\[3_<[WFZWS0$<S6TX#. >X _-5#F="SQ!]+GF?T=KM
M7/)=-)A2F<&4"!N'#:=_B12&P>#C2^^5ROQ0P%RZZ6/;7]Q]NL\V_^J\V1$B
MTZK);E=SSM_'-3&$]9]7A>_+K)MVZQU2IR,K8%FBH\KZW<>R!9'IN:/;W-'1
M[/3[N4/W:^HF?W0>[=WR1T>Q-.K\ 0SQ4YQ/B2M41_/G]CL/!&RYHJ.II&<R
MS86*-(P,'1HE*G"I4W74*]JSAV&/CB:9WL\>6JGJ*(-T'IO,,DA'4U#?Q]Z'
M?"I3Q]3H.:$/H'7=2=_I -J>]Q;F,XO46/ET4+[$_ND%#.++/GBV&+2P#YY]
M=;[L")%IK62OJ\&SFOSQ1K==#@UT'B;5LD-' V<-[-#I6$#/$(8A.AHK>Q^#
MJBK1?7.&JFC/!=WF@HY&Q*Q1UDWZ[SQVA*7_CL:^WJF9*G/KWBDQ4M@=N>>&
MWG_9=3])I_V7^]Y9'(T53DD)E @OO<MB%&KK"?/_12ZP.UTN_<[VZ+I#8/1^
MS-Z/^:0:RGY7_9BN'/+>8F>TF>@E3L\.'?5CGDY2R;W0:@=T-_FA\] ^EA\Z
MZL8\_^++A'32G@&ZS0 =]6!2+DF<%2D\X:/\O5"I#"C8FR1HKB'Z^CMQTS-'
MMYFCH^[-M]%O1>3GZAKQ$$,EQST?=)L/.IK#_^$FDFDV50G%>WN+NN>-!M[H
M:/K^1YD7:>3%J?=*9GE:^"8:UO.)RR<]9*+ADXY"2_<1GYX+'"[H**"T&P7M
M:,%CSP,.<&@9GNLHC#0S1%<#$ <]:&B?D]#G#%'.T(%W58Q\N"@5H"%&D]8W
MM16!T .#]CE!WQ2Y_*"KF4'=+6>\0\AT9 5J'-#19* N5S#V/%#C@8XF 'V4
M61)'F>+"%>]UG+IJ:)QV,R]HCCO@/Y@+ O\&ZOH1[SW<7?[%^5UV:XK;-UGS
M\M'WKKC>'KUTCUIUI12^X?_ZMQ^FJ7G'1$SDUBB5XO.6&,,K?B_"&W&;O;Q1
M03Z%G=[Y=[BQ>4U2G-@3+\G.-UZ2\R_2+RBB=A8GM[7]_[:[725"9@-B"F\4
MIX%,__;=SG>>+T.TTGRP7^WG1 2!^:S%!Y/K=^9%>( ML/!"D63R>_/'2Z^V
MS>:(TO?I7W>WCW?Q]U),57X_WMO>V[OC][WMXP/GY]X-U74SN--NJ$/ODTQG
MA%.)?ZBHNT'[WAG5.Z.^K1ERV%5G%(J:U@GWF<F8CJQ C0$ZZHMRSEH/+O8N
M!.PK9L[]!+://QUXGV@8F6*FW6F6P5MB&=L <3'C\%I&_OW6P9]Z@<[A'?-N
MIHST,J(F(SKJJZO+B$N0$5C).A5A**-)-T&8#G9[YJ@P1T<+^>K,<19'<&(H
M.!AEU]$J>Q:IL4A'R_E<%@&6N"CR A1,"XG0\T;/&X==+?&K'Q]78BSS6^^C
M%%E7P1%ZUJBQ1D<K_$Y#V$=DC6OIY;%WCZ>BFZS2]P:MLDI'B_S Z,CD[P4:
M'=3:S>&5CKJN>L:H,D9'Z_[<0^-]G'M7<8B8(C,9=+3PJ6_VUL>Z^XP3RC@Y
M\M[(2*:@05ZF\;7*.HM&=X=0Z/--OCH/=H3(M"9RU-5,D_,H5ZGLNM>S[[IL
MV*"C^297\AJ.W ZW*^E9P+) 1],IRBRJG@&ZS0 =39DXBPO<PT2D>4<-KKZ!
MH6&!KJ9$3%4:4'+0K?>3C.18^0HNDCT_=)P?.IH&\3I.?>E=B-]DD78TG[3G
M <,#7<UWZ%L_]$Q@F:"CF0S_$NJZJ^G2/?$;XN]HML+[.%=^5VV OD>BF[%S
MU%EDXE<J2XH<LW2R."PZG,+6,T2-(3H:.?Y9"L0QZNBQT#?ZJ7%!1P/';RED
MD,J\P[A /2_4>*&C$>3719I/)>%Q%'!#9TV&GA]J_-#1@/+[V-39<[/$U/M[
MK*+<^R=,K;/QA)XY:LS1T5#S59%>*WC9G@N8"Y9 5,8WN?^U*V_Y[\N^TC!Y
M2ESEMN= Z+U-D_@:(-)W/^?>=W]*Q.CK'UZ('UL C5Z\!#O?> GN1(A^RA=[
M&#[T\D4IWYQU7 SVNR8Q)R<?0.,KI^1]N+@X_WCV]O3=V_]W^NGMA_?>Z9N/
MY^<7Y^\_+7[+VEFXY&L>;1^>M,J\GZ8J Z*=S63J*WB3/[@\U%9F>!LY7O$?
M?SG>W=UY^0..8EY^;G_HL8'TXY0&^;Z =TQ#!0__[D>GU /O^Y$&'+[<]&#P
MF0BD)ZA6^X.?QR,PYG8'WN[.[A"?+A__\//Q&!N^7DOOE<AE;08#A.%!I.61
MS&^DA'?'GCS>3RI&LU(D$AC;SQ#CT=\>>"J")R3X$!EX] P/IQB*&YK_*PE_
MB532@%-QK:*)I_+,2^5$9< %<%,\'BL?+LB]P^'0>P,#@5CT?@JO QC^JE"Y
M]$YV=N#/N,BGWI6(O-=HUJK,CP?>V:EWLK]SO.-M/'Y'N/50;2UPWI=*IO *
MKP5(;^]"!LH7#'-YWPOM'PR\)!3PX70D0W@WL,8'WLDN"'OOI[@(XTDD86'#
M$'Z(P6P?\*O))W@;"RU6>9]MEDW\7]Y7>D&^V,.-2N48WS9 5 T5>43M)?4#
MFZIK%10B#&^11,7CB9'R'*OSI$DAWCY3*3_J22@?'T:)E/2X;?T\=U762&Y_
ME+[*19BMG9#^07@1L.#?OON?3[%_,#PYV3O8/]S#9@FBX;?]PY,C_NU?/Y]_
M/#^]&FB1!I0MHPFH90%3NO0""=06)T3J2(,P^6(L?/03$'+&%K:.\-1L5D1:
M&@(QO?36;H'G%\J/HZ"@%I!>HJYC("O/!YX"41C":Q<!K(-WHT! XS)>IC%>
M[&T VP9R#*R'ITD8WVRN\UH9*3J%MY9?$@F2)I-(6;ZC3N "CE0,HI^6#HDL
MF0H8RJ=S%;Y*>/$RPC'"U<S!9LB))($$8S@IZ&8O@-%%!J^F:?<3B&V5Q^EM
M9=F!2*6*-EFDKN_:,YT&,E,I/!".+I+5L#3PIX S+>3NWN@ )"HU>W7#ZU-^
MAL.XHO[)"D'KI7ZM9!AX&XR!/;_8\SN2%&E6P-1Q9K2E,IUE^I2#$Y7FAKM;
M.VWI J C 0.>@LH#B@(,9G_/FG:Z>J#CI;0>0>QE\?;Z4<#[#_\:>)^0#%Y_
M^'@^8':+,@5'/FONM*H2F4E.8A)?J9PIY!M<*/QIQI"3?GPM(X&KJFD"^XT)
M7-H!799*7ZJ$-R4K4,=#'-=;?,#-5/E3TI[P5E2?_<]1?!/*8()WSRM:YC+<
M'B2@,>@Z\4WV_;+*!WE7CI.ZZ;S0X;+$9I2:B5WD#)8XW/)%DC7N\+U;YAS4
MOV>?9DG# 0W:U\'>WN[)3M-O!X<[.SO#X6[#;\=[N\=[P^.F,Y]O@_\UW;8/
MWQ\,M3I@P3Y^&*7>BQ_U?[_I%%XA\S+_KQUK?K*";MZ.("%,;PZ<%\H<K@,=
M ]2IG(0N<!CBAZ.!Q0)X)D6$:2Y>)G/D9;B;%(J!IP])?0%+8RRA)8-4"V*T
M6GSZ@JPQM"72N)A,P:*L36Q.0C8M\+V[LF ;VK !AMO#BK7DNN/W#LE?I8VA
MA4:5$S-AZZOA^CL-:]_'FD[<G:L<I*!(@^QASP2+D.D!=WG Q /G? +F(9YM
M)%\'WIO3TTLVV.L7:+$[\-Z^_GBU;9Z];AN]V_I&!ZS* $N_98ZC9)P'[C3N
M,1[.AFOQ$*_H761YP6<1:=U,S5 M*A])7JFPP+RX@3<"'@=CS0O53.7DU@ :
M\2Z*,%=;9_$41(ESY]K2QE[[M'$-(EYZU#%EZ8<-#%&L^-0KF:JX /F^TM-=
M;]033>!56DP0O]E?B346'8H)0I0%[+/+"E!%G6-7>F_/?O8F!?R.<R*K$J@2
MZ!9X!@,TQHK7X-*O1 [L(2(QT?[N\]W3@>?H*;0<5I#3>.=@[0;$71]E AP%
MD]I<6U;:;YV5P/8(5>FX?Z!HG3\_!=>:X]EYZR$4%9 !B-><+* T#N$6]@#A
MAQ!].;>D=\&7[/%'!T<<F2N,'P@&H'$K3N?76E\#BSB),VF-WL 2V,#PFAZN
M>B[<2U4EP3R(K"IAQ>,'1!7[&._SCO$^3-*T)E?N9^) I<BO++[UWS<VJVWL
MC=48^#:1J4]B^V#GWS?QXEF<2N,$@?,C90SH+(_]S^@D4WG(Y\9UG$OK<I04
M>6'O"3\K3K.!.5!\P8PK/!/[([:%>Y>8@_R]0/FBT)TALWQN3!!!6L&[3>B;
M4$[@=**I@MC)<I'#>4JAIXE&Z$RT5P6&PMN3,MN/)E4.*5+8"WVNW6@?##Y<
MRSPC[O"FJ8XX$?7B^ACAAE^.8CCZ*FN#M^";78L0!Y_$<-R3/3J*@]NYM<*K
M>4;FM?2Z:^PS>IXH,C[F^2&.+VM6GLYP7Q*'Z(K*[GW*=C7,M9ZG\T'KIW,(
M9W-$>!6X2^F##VE#><:C,5&@M")M7VDJV-\^7%OEZK#U[6MPLZ^J9[D1;/8A
M7]AX(OFJ4)$NDB1T'L;777)("+3ZB0J)FIP+C-_Z'X4@85$ZK]:5*H[:IPKR
M%J1ID1 +OA,W*U(%[=RO$1E+8$3EL$R@$L,=J$;1^-YEBN8ANBE/?4T/^H9?
M@&J">.;]E*J11!+U-3F41]P[G7@CO$S!5HC4BP2%K\W1GJ02C6!]G(Q3401(
MJ>;5!AX\_;/,I4S)?0)ZO;SU0D&K88@6CNXT3E4V(Y4 PV!\?K/DNH4#ZM8;
MP4<@2K1*QRG,.0>2H/ 7_+NVA'K<.J$FZ M VBI&H!;(*),/-Q/O/8%VMW<W
MQ/I:^">M[R(%#'=W#D!$%,'M(R3-#/V<'#L<Z _D\P2-,Y'P4F(D0U"J89=#
MN05GS@"/'N#D7<<OA%,PJ6XXIOGE$S98RK9!U_44;IP:*Q! [\\^[>P?'.R?
M#/<'930&*%)D1G^MIA^N+1D-=YX''>WM[#XM';FDP^2R]RARV=L[V=\[/.@Z
MN;0?J"-R.0%R.3^]]#Z,,IE>"QW0>2P!Q1%G7S2,BGON@T9C" ;LIO V4[3_
M 7JCM1[-1('6O:$,GO#YKSC?%U>7OV*>SB05L^4H:6T)J?U (.W+V<6'IU<]
M3K8/UEGU&+8?J%O 4ROR/@V'7PV/7F96"IR+%(U>'XR<S#R (P8ZE)79E#NT
M6S![)MA*8++H\RHXJ[*:8=?AHZ-,+_HHQ\=[Q_O'^\.#>N;1S^'GX[W=_?V3
MPT/^:8@%X2W3VAW38S*L^DM>"U^WAEB)%&$)K3-ZS$-IMRE(%.^__OK7O_XW
M.6(WIIN.0:VO9">N*8:Q(3B\WH5KSHH1.8H%>H7=3"0*!S70)!;;Z/R5BBF]
MH39QL-]TB"Y)%?(!0< Y&2UE(F(>WI+_.[@F=Y%B^B]*ISK%A>]:5<Y]3=&+
MC?4ZGC]%7SG%!R/L.3PI0D&L]AHN1]> \Q6;G2*D];L0Z6=)Z3ZG10[&AJFA
M,AZ(6C*MY6%V96RHZIOK-[4BA%?B!F[))>=Z<ET*!Q?0M<&"I"IX]$+0(M3V
ME3,](WV^V!SV1*;(>;2:<"?6^,1@4D\XD=B6.E6SVN(B#' /,-:/&S)+!+\H
M+N',]*0UH5?Q!*M:)9M!PZ)R<JI9*$XAP(28$9!'E%(K:3$*;^G-IY1?@X0;
MBEM,78TYJN(#^P:T%+0^SF&\?7]$]D\I5(<("? LCN*W\,TL0FL)A P0U@IY
M(_=J5<.][=T%IV-?\[T,N>SV)=]].L!3ZG1K)TW;C^QI:9I+\B84W-H3R[16
M52A1;>11+^%HAUL_XM69UF-&F]XO47RS]3-FJ1N=YU,J0)K#4:ZO$B6L^XT<
M>0$L-8AE5(IU17&J]8V-6FPED#EU+Y;!YH 5'BP_0:WQ+';RM$SMR0*+B,YZ
M5@.UUC!SM##0B< ^PU@H7.9H"J!,C8L0E;-77"\Y\#(I/S>I+OHUJQ55HKF>
M:EYUT3J8]SM&.ND 3.@ Q((N2>H.%>-(+*+":5X*_[.8F"C5._10X@?]ZJY%
MB?I@?6*55&,[BY>X>#=8]@G_GN&_5S8[!D>H*M-JS GH4TG#X%-PM=G2P!UB
M?K$5UD:/KQ:(52H2&*.([1/SP631B>M8!49%#>)BE)MJHT8ZU]H?9T?#W?#W
M*Z?B%5,_U]1&!@'4?A"9-N8#H0.DCPD?QWH(+T3( 6*<A\VE\3GG7Z9JI'+O
M[=(S6V/=O_U [ORY\HA3BL2?.Y8A'1!B9M]?H>1Z@?Z/$?L_JC<\XEC!D\JZ
M[*VQC(<6EV<8QX .6&?>!+;)Q1-QY>% 6]DC= *.\1D\(QS %6;QF$\EG$3#
MP80/M0<,7O.[SJ:Q>7XRR\D@7W3XZ"?,GSUQZAX]9$.?U2K :R?2/<=@NP<0
MUS]L^)MT7@A=XP,'.R*!9/PG+IJ*"J%_R8H1+%Y>Z(^IW%)95DC^4WX!EHV$
M_<W1<F!#F.:(8H [@!S,B* HT72X0C[7"X#5T; Y6-RG58U41O)&A)E-)JW7
M_U;)&JM^4Y:A.&L>EIE&:W'K>R(^CSP'ZZ.S)=./.!KM&-40H3ETM1M61Z<U
MIH4,2N56<F(RQB95A)Y0\A!'Z+NC$E76M%UE.$D+W$XC'-!;AO40"3P6ATOB
MC/B%, G036>\D+6)6:'&<$EPE9XD@4%5YJ>GM;ZG[V[KB1,_%1G\D65PFJUJ
M'*+L"80NI %YBBY7X5UA,AY\C36(5_!$<5MF:=.'2/MK1R+ZG&E )O+(DU]6
M:-<O'WFAN$&R J+QPS@KRYTIKQ!)"'?D/^/T\Z"6<0@C@=Q7F<&;6F-2:CVI
MX@PK D!#P'3=-%\A'YS)B61'/D6\B(V]34S+S*<H<U0<,+Y,Y*.T^#LH ZB-
M#,$.3%(5XA]_+T!,#7'3#9K<T!R.MU*D+VWYX,";QC?8@EU[%(SF.%9IEGOU
M%S$2%IT&VK"D$]OD>\YKA1K\!"\QIS*-/"X0=*4^//*$)'E=.E086F[)R< ]
M11+KP-"71)55$>PZ<?!!*@;WVO)"ZWDA=M?^$^CN$:>\IOL1Z(X1!33T+@\S
M2@TR3(!4 \]S+MC35[R2OIR-2K+)T.&V$C/@FS00GV9):1Y<XP0],_S53F5O
M.#>;.^A^B>=:66"NJ]ZLS%%3"V(:YN!S@AA'@^7H&5--DCYA*IR45MBL.WS5
M>LY.U2I\#&.E,:7DP.;I? BP.4E=-;^@^QF]S$YZ/^54!&PB6]? 7,[_P*E2
M)R7:Y"30,*:8C0?2J _X+!VI5C-M_LEY=(]Y'VZS>5TF"^$(B/W21SQ7I_N]
M/N+91SR_:0&T8P0O2H=2VKC6N4MM9S19,"(4-DLF,F&J4>D-<!P-""GI,X*-
M324*^1%S&4?"NSBEB9^>FM+B>Z7DZ+;$2;(AP)%V&)(/@_S%OEU N-_>@.E1
M-BDNX[)KM]R8*TR\IO*DBNO1)*0L?88=4RO,)2\>6+S'\J7X;9IGIDG'G(U-
M^P6+H-/W'IIG-2BQ'Z6;=+7M_8I6"^.X:&?MH.[X=8[&L>[WY#IV1_ILM?M3
M25AL?%=#IJ3CZB&7>N5!0_*=AEG6T(JA03JDWTC#97)(*&<2-N!F"MH"*PX5
M<L-3'M$<=5D\\EO= UYZM\G)XH4Q\#A0'XH)A,,!6L_&E(ZIPEL;46;-P]X[
M>%A>W/JJLJVG!-/V?B)H913169XJ$GI:2CU]ZAL(D/TU]G^UGL1XQH<N" T=
M07Q$&%/ WRER=YR2-(I#%=BS3*,8L7D@*EG9)'= EA1A;E&QKF,ZT#/0X5*;
M"&[& $&8(<(51=3@W Q0=)*S7\7:,X4X<AI<Q!F# (?Y)" 1,_\40N\:29:G
M<&SG+/SE%]9.\%@ V4.ATQCFG,"T"0HX]S#JF#=#K/!)#L;_B*" ]5.3^,9Q
M<5"G)_R:T4",7@ R6 OUQJO<M^?@";W7@GT8</"8A;CPC5L@DZE>8$)B1AVF
MO" K/1&571O  DPDG4.,%EI3,49 ;S-]-C=@XXQD)#$U7H0,D[,D1,Z=:^B2
M12/A</V OZG=.*$LO?OF>&; +9<Z\780>KA.&#<%%M::'7YIA[9Z(^IFU;70
M/X&MGLD\6]_#J?44PK-0J%4+H:I[CDF $?(ZCCCPF!,&[&61#%P9IP%J;F.E
M/9BI!](B4 BK#UHLT92?*O2^$>WXP+:AP;^F A1DH#2W%'BC,KEI4R)0=-V(
ME(8.8R <#.B+&9CO\ =#+OEQALF,&D((K _*S="1 T:5&!C<(VJ;!MR-PF+^
M(@O'B4+8) 8P(4>_%1$[1D$T*#E>7^IM/?^L6J+]B+ FA<@UB @,-RU@>:K=
M(&[KQB7E:8+]2LZ]D*Q9RD'D 1N*@M>7#EI/+3N[.%MQ\_TI0N?GF),TFT,R
M,NAIZ[MSK>?+G)%RPAKOJ@:1.8UTFQ'*54E59G+U#,,F85&MF/Q QP#,  QR
MV(Z-;'T3H_9:SS^IY,M_2[SB.2_APQ^>4MEIP*<$&S7D1T&W)= >"7QR6F(V
M8>F]8;6=W9NZ='5 *O0 \YVQ8!,59%2I26^8)7&) Z&)=J!5"CA9,M0HT$&9
MRJUW E2,Z8! K/!?H/Q9S/K6S#AV\5OETQ^I5+-1D68ZVY2G@ ,'*/K4J&AP
MGCHJSO=DJ5)*H\0V/<XC<"@"3/:I?D-HKS-Y;W-BP8'N.H6W<,,0S8Z8_P@O
M_)+M*PST B^!^9.:7\H2$W>:.*_KF%Z,CV":@>OW0F/%/(_+\9T]V;"+<LE_
M.&YQSK5TEDHG3 8P'K7(J^QN/69WI]><<C$3=X-IWLT[Y^EJCGMB?HT@Q$WE
M$YIQ*AS8P%ASC%+%Z+8E%DCL#41.!378E(CM_"8\!)W/.J\;T<[40/#OA6ZQ
MJ($6WZ$/?JY^1NSWP<\^^/E-@Y\U-!;=F51;4<N*&:<^8BZB1&%.1Z=?7Y_X
M7OLYH?;P"#'(8</:YV-L;;0RWFS]D,7PFO(+! %UH2OP\!/99ZJJ\*=>B$2!
M!Z#DI^N3/8N+%#%(J4*5U3)?I"GYQC6.1L.8G/^> 250YS0T$R/)3F(L.(KR
M$F"C^7'<2H"+3&U"\TC%M2:)MH,%=E'C?'N.2#NI]TA,B] ] I<3*ET^TTJ[
M1AM=,%T9!Z85+:&T<#'N@'RZ/CXZ5-ET\>H,/!/_Q P_6",.C+A=1YN>3\\L
M*X4'NH<'URF$M^9^Z@$HPGSJHPYNVTCRCF@P6/A%\"J8;[3RE\2X.XHTN]RY
MP4X2IJU2:S6&:BSAG<B5R$T6N<G30->IKJWL:#^'=HXZ+T/QF)P_$]Y/8)B*
M%;9L7EUSV1H"#6-L*4"+ZEK)&_P+;!,P7#+\LT@"!D9"4W 14/!=X#/'VWOK
M2V;MIY3:S?>NP/A:V5NL#5#)$AG-=S?/J!+'&BS,3:F'S 9:\6&S]E:;M5PM
M"H]LLJ;66)UI/V<CCL8,Z4J=WP@VZS&MWT(J\4Q2)7/,7R]1-(HH0:K(IEB,
MRV6<^E@L.U.Q8:S*6;#O!G%$*9@Z5A'($CKHRH,6ZY"YXHO0;5-C.E.MB#_E
MP(8&4L=D@N]M.< KD&AAG'%A:<IA=:V*5(.TE(E"9:R*%7,;E.,2/W$MX,#5
M64L4;*87N6?01O6F5BZM@X4Z=R%NP/PP)<-T76TVL.$AMB\ MHU+MP(%&O'D
MT!X8!"%#2R*-8:U0/YF]]'0I.3[D(_;.O2X7"=<BE"*-I%,M%-27TK2&B='%
M-%]04$/,*X.,[N8[[NV:,>1C+F.29WPJ81DP.<1 7G%DBP*BN1AH%#_2XG!<
MT*?I7#)-I9L@.SK0:&6O_<RB>+5\(MC'QSTQE,&*HFVN\YH#"SBP@JY,&G$I
M6>O\%M0E,: NY&+A/A$)1?*Q9KY,$L!"43Y(!V[KS"P.,:<'?KU6:5YPJZ4Z
M ,-<XUXZHVW;J4TVOZR,J@DGK2XZ38UHW"8!Q[YGK(HMYYJ2)3G:TM^4JZ)[
M,F$6%I_Y)G<5?6_^U&1+J-@P^]0T(M9Y"0[JDK!U3W;X2I>HN62R-58DVL^O
MB;-\ZS(L'@..(WS=S9UZB_F%R8?694EU-U<9P:&(IZYZHC1Q=ZC,>/0'EMBH
MH:PP/5-N+!_3&8+DQGES=+Y01AJ<IW%J0DGT#8>KS(<PC'UK9SD M:56@X<4
MF/B!GA(VCM>9VAQ.>G(LH.43!6Q\X?X61VO,0>WG^'PZ?3#OE*VUT95FTGAR
M@JIUU&MOH]2P2(B:NKW,),1N$CZ_J?)C)Y5W7N Y)2)R)Q01'@2ON*'=M?1V
M=W:&+W9W7IR?&? A>_FO$3Y35^3@GP=[AW#I<-]26FI_HZ>"8C;AW%)[,,P[
MSHA'M%!WJWVXK*?4.6O3&$G$CS$)HE1AJT&&JHTO%,=W2X0[FR/L^"7'%/?5
MLZ@6(E7F46)0_P;,E&'JGU'R%3?W*_(,EKKF=ZEMTUO09X%[)L:D06*G+L2G
MSM8NO2Y5' FW<F=WZ)UMO][^N.TA1MW1R[WA[J(,D3[&N(PX.>ACC.L88WQ&
M!];"(^);'YO'36=6*_KG]<H +4VFG0LUQHYNCM'>:DP)7:/G7-2,;>=6JUE1
M+$:9U*DKC>!Y=T&*.OZ)-57&JJTE=@]W=O8/=TSGB[WV,SG1+H%+M=*P]./N
M>*UY4ZC61F[@?&E[@KE?WI$^-)C/'ZIE)*RO5K_?>CHH O/B.AO4PT>T'Z6L
MR]+]@2.Y]1FXPS]3$!D4QZP@=##O,DYSX\1!,CCE6*_YRG8I/4.@S#B-E,!:
MOZS ],3+5%T+GRY"204*_'%)2V]T ^_Z^SE:/]QP^.+PZ*3L<QI9YSSIQB$"
M2.J+7?=NHA]LO?\E:J2UR"M)A#@ASEF5B7&X^6RSE&:YX^2>(3;VA%W&U1ZH
M.IPY<&KC. RZ)2-1YN4DH? [U1UUO_7$&R*T*VXNLW+F/,6!T '+B(\WTQA+
MSS'4:=H:T@:;3\1GU7LJ!_!I=->E.#2FX>-3?!&1:F ?8P@YO'5+'S%: R3I
M9/^ "I'*,5C%%KW!;<'(V@6_V8QRG>VOFO"C A&J!IYU4'%@!"Z,(UQ9=S0=
M8ZKV6@)C,K/U/\;_FTQO,[2<!_Q7',83_C@!L0!3'WB,]SKP$&0WGN$W\#Z\
M.I@,'E-XFI^=ZY(CT*KN6.NUY:S6TU)T:N$W#,8XR8R/J&5KJ$2P-<I8?YU)
MD6+1 *S_EO&-82*ZM)^XCT#="W1'PKMSWC9[DW7R^[P'!Q;K"O$P8O1IVT=^
MTEYGA-(N\R*J?MB&%@C$@D6:Q!Q;U6"X1@DH\9++E>F"W0"\U'KN3;TGPXH>
M74(:N!/[XG#[L+*G]0>;H(<F+HUB2Z1*_%%!3%KK[A'[K2?9O%)94N0/3\1:
MEA:&1]O#G75NK;K?>L+"*U.9%3_<R;3L-NYN[ZXS9OU^ZS'J5Q>O5[8< HR[
MS$2&,"H8<K':!T(H7",ZJ\[7IH 1F-C<>JD2_JEASI5VL6]*<S.+,6^OR8K1
M#+-\ R=AHP[:9B)PE'1A4B\IM;TA(+36^//[K8=Q7\5AN )"\NK*]/]Y1,8%
MHX4@\G>)E%.)$ZZO-&H=RZ&2ZFR;KCT.6GNF,MUU17Z1LT3G0@JGHYL+@FGE
MQHU0B$)9]BL8-8:V38C<% GGJ10YIQ&X$8L%:=PF-4=7B-<EG5%1T8]'%07H
MBAAA+5(U(WADD XS,9:<NR8-0G>D 9 =(;O&HJ[U2$C3+G]#P7=^>OFX9+,F
M_ )" '",>.WJ@M6W*%[()6#5;V2;<RBRC1WO!YQ!0IR),)[TE?R2"")S4[H/
MJL TSA*%79(L\\Z7YN33-"XFTSDFL\VQ3-XV@YRQ_Z!9U-!LK9YA7L5ES9+!
M![:3%./9<X\L;/JD6V<-JA@+!K& FE^2_$E25%4V&\:N" _ZK7F^?4K*(^3%
M89^2TJ>D="(EY: 15+J-X_&G?WX[&-QUU7(.6@\\GJ\*N59)1L446E;.2^S9
M@@XX5& Y"J9S<=W6EJ:6>TQ0BZ"RK^]&MQX'.[]X> )VPTY?H'6$!8G>Z41&
M_NTC]WMM[9>#UH,UY[0-J\/P<2DT5E,-;&2E\<M0F82;RL\PJ43/J^E:#8U1
M%KB"S@Q[._!^BQ5--?8_EQ?IWU1D1D7;(J- .S^ [\(*20V686BM!)6.TPF<
M,>P<6%]!TWH\Z#S)<NQD\9-(4^^?*EVA:.H15O-/_UR1XADL%F16(K-KG+6W
MQNC[!ZV'G&"C_N_EIW>O5MPMN'V+.]A>4W&I?G6$"LF]\':63,$DCQ$,!I]]
M337<V!M[C;>T]0 4ZP@K;JB!+<AO8#5OMS+LV>)M[!YMZGB3*LMV:R50(J-T
M1D+OED%S7\.R4>=;7X8$</Y.27^*?;Q16/'O[^/T1JPOP/-!Z]$CNW/6X[<J
M^]- -EU7!W5^ 1TSB&?>QJ^_K&^@^:#]T Z[FH"U3)/PI[?Z][>/@5L''ML0
M:RRUVP]S?%$9=Y S53@K\B357]@P N7[$=BQ04DH 0TH!?'BZA<4W:<:80M9
M&=U)0LOP"\QN]'9W!][NSNZ0ZF55KF'M;''Y8G@N\M!S.K5)<F2@!0T(S^W-
MLH9FL)U()3QLO7+D_(L.A'Z,;T4(!AK"_3R]'!D.M_<[(4@.6_<D$MK>(XI_
MV #+J<,:H6EBL$Y7K4>W58U?:_,$MR83D M%F*L$@=S\4*9PE0M.(8H\5E@N
M(QW.7V-*:-W5^)H[D3\%4-\\=JR;@M80/[9]T*M/KT)"CM@?A$4K4Q&.%S<,
MM=A!RX#_N0 '])N35KG)V/'4AY/FOHU@!#LOP>;(\0UM]ZY*BON WG;ARC&-
M8$Q=^4T!Q>]^',41 LL%RZ^^@44TD/S4JJ ,_PL'F\YCTF(<UX5;LA!5\<ZU
M'<=A&-]P8R9?JH1J]!J[X&+^=XD@1RDUC)Y3[0O@;<CMR?9@_JT(5';^I1B_
MB5\%6SJ(,E/(Z;'[:R9-:@B^^6LJ2]PT33M'".>+G:?@"9J5&EG#NKWF4$RK
M%-.!>J'#UMWFKPO8N4<I)5IPQ0Y;;(UNM^R? H\G#992X96!2713,9;:PYL3
M*6N/1D \,]9BK$G&.51=HQW&9-?]VB*=Y9*1/(U]OZ#L2/3 $,J4;J>X^#FF
MSK^LUM6/>6GS<^271*46'DZ,X/EQ9)!I[./_"<2)]4)"S2SQ.Z #E57B\NZW
M+M#<I0&:H^HZPDC0M5-\6N@A'PP7[*[<2[=QHOM6W!O1$4GGVN(Q_8"KZ7]W
M/*+/_'F$R#CJ,W_ZS)].9/X<[C^3S)\WIX]*39TPMD+(V)I)SEFB* JIK6T*
M2C2:<K8?<A79"PQ^9P!VYN@.#N&M[0EA8!77U@M\V'H CR RP$C'QGLR5ZN4
MCBVR\!R,NF8=RKM+AW(K_&O-.723",QMIDQHV#,#SHX.1PVY457S#6H1UB=%
MKL[3B$8W;Q-J% 9,_H?['>O'VIR<0=-L!Y')Y=J1 ZUBB9SZ6H*UDY6-.^#J
MD84K ':PS34X$@8OEV(;7-@>[3<SZHG%Y,4,[]BJ*S2HAI:VNER9Q>/\4!UO
MLTRH5CI!^IHA0+&7KNEK)K3=MFCE:UJ:LQ$U[;-I)USL&)/\W=15C9%!FR=@
M.F-7@%IAA\V^&1NQXC]>8\=2ZQ%F(W-XP[PKX.ZG\RNYNKH5.DP@>8QU"X@1
MZEW'83$C IH7@"A7ZG4_)&-J"C^C?YIV[V4;F[+'>^U1E1$YM %?-$Y@8*VS
M"9 DXH[./]WP@Z^QOLZPP#, COY' 90-)+VAMN6VA4ZJ_H8WWTP5C)>2D4Q
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M?2*!VY(ETHTJN6CH&RE\B]"]0-AS T9LD6<]3PH5(41>P':U#+XP<+Q-TMN
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M__KK7__ZWV6;;VH&I1CH07L**X.($7P5:Y#BL8K(DQ&H#!L%W>A*+BQRI;%
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M*Y.S+)'@44"-!\:5]31?W[.<S!H%R'6^VU*,[6S61V96B<P<]9&9=8S,M.F
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M]BR1/FI:S.@&PPW1GVJG%C^.X)Q''+@!_JV[T]*"S21UAJ^V>BT5+[V>6K7
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MZ<4Y9M5?B&AVDEM"XDC2QW&Z.]%V"@V887,L7 VP+\\",^K743],U,5J%?]
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MVX$?D0JR1!B;0PDFY^L#!)]1,!]O^0FJH8DC&(<S"SO_Z9.30W, QZQP1M
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MJ7-3\=737'QH\1O+;[CZNN\]L)NENW;L+"[?2>@),TT)10Y57UU:K1:FNS
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M8AHZEM<EUL%*D^1A1]%,O0XHK,6O#+G@T=V"XA:.760\265-<."PQ"UC9Z5
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M<I)>-5J=%%<#O@ XXLR[9=0H!D# Q8'_^/+Z^G4R*$<JGG*ZZGH0.@^([;F
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MI"A#E"%ZUZL%5>,%*JI:6.?_@/&P%!-971NQOE6]:&VS^!#I64%D@+N:???
M &_1S4"K+8/90N.Q,US%0KBZ1!8JG%[1Y6268S\Z=*]](M\.Z:BIV*9?P9??
MM*UVNZF_3LK[43ZX$:X!!O.H%2:<(2XSC<4*$+C%"-KU!X 46KDC_8UTI,-6
M4"MT#L:#Y4MTWRO<2W?$PLUD1ZP[3>[#(? 8&0?Z>33B KCUK (6 &NKV-W;
M5O(@I"2UA2OZ9N5(3;=)48M:?Z3BECL.5TB\4/XDE$7)CN4,2=&O^[JC'$19
MV54)%!<YT3:1CK)XSK3Z-80:0^H^-4]K!*1\V1(!4N_W_?5O5DQX(;&CT^?:
M_"$R]@!KC7D0).O9E06K7<,EEZ8O.\H+S 8GF7U0RT;8Q'Y$7C/.A7VN@#,^
MJ[X^ZM*_\*53Y5OF3"FDMMQ\W*O@C."7=<MX5(J.3#QD)T9R[:["9SH0LCD6
M'*'6EBEO;,R7LN]29=_.2]GWB9=]M^"$:29A?]!)=[O["#;)'SCPSU&_+V5"
MFT&ACL8YQ!WWMR4W3!=38?JAGKH[(D01?"^[1_KO=4*%0?V+M;PR# *PN3#7
M?E=6 ^V0%GW! U1G-OD(R N*="QLD,BM&"4[BET)'RQ/XL!N?WH>Z,1BZ1AD
MP<*Q0<]4S[A1C@'/[I!EI^04%D7<=9;%)EP9$U]BHX#T8YHPW/ X8:1![9!]
M)(PROP7"G$& QDD=>1/D9I(*HD4!0--"*H8!O=GEYF +#?O.'ZOD2]9:;-_$
M=7U22ZGQA%L99'[=A,DRE1?D)BIJJ^5C@(<:?/G5K8H&_9!^8+"HJ;OR@$)$
M:X<QD8>U]+;R;8Q62&)!;TR%K?,DX)TFT'&.>6>U9_*;?""T@]'W-KM%!4=(
M3U*5!HLCF$FLR.NHZ5K2>^Z\6LMGV?SK#=3X,73-ON8.:0W0.&1S\I.(: T0
MZ[E4<74'/U3_^ YT-9V?6/*4V,;E-EZ]M H;7-("T5R>)7Q<"\6!)M&&-V\+
MQYHT4)NCHGX4Q!7%LNPF_4TE%:JPNZ4=IP@L#V5E0O0UMM%%F&S4U*QL:=C0
MI&QF4N)I&.85]696R8U=?H%@2$VLU#: #G)TA]DY?4[OF)2=G]7S#%'0]&1V
M]S:LU\!J@X_>GYV1D:,&%F!WW4T7K5[4,(?KVD7J5.[$Q1N'93YMG4TJ%UBT
M\^U%B!2YO(I*N4Y0F^S#IH14+;2CW\"FK0HB@M'4-,%W!.-U7L0V;HMR/9/8
MJ\HYPDUHKLRIB21P0UAEN1"RN+K9;M3?LHC<!N7VEVW?0&Z/[\_US>HE;[V-
M+WJZ"<<7[J 3-D0XOU88#M95;2W$O"",P(*V;./D_WOU769(EJP3VFH]ZY=3
MPIG^G83B+68HD=]5MX/^QTKH=J$#_F%23IG-G?A+Z:M 13BE7CHP\N4PI8**
MTTK)5=U?WGU"-U0^JN4C-U168T6H8%FK^]4:$D5BZ_8HJ6>?(URMLHCGHO37
M6?*-[LDA9>.+]V>IXXSKT:D!+QZLJ P2?9;+RFU-$7*JSST69<!>V8_#!W&]
MA<NX6G89*Y/LZ&94UBSJ\BGY".KC7GZ;C8:FF.DL>*/#(72^65*5Y3@E<!T%
M2+/R)B?,$B",[F_+44Z@)6PVGH#3C2^.3H11GC$1WDNI;O527?>E5+>-I;J7
MNMP_:A!UT%P[U@&%*-Q%,0I0($,C^@PS NZO4XW!!UXLH1B''/)7Z%I7/WMB
ME3YB$S</D0U  "I_:L,LQE.<W2<V+*9>#"5PTN2]'8H_L8&#9_,W=4@:RBH-
M W<7L-?>]M0>PP<^/;'Q;7%)N%ZE$H?.7 231C82^6.(U'0R,"#C*KFWN4PA
ME>/L-FF 234WC/-]G36U:>/A&]2!P&@%7SS0+?'74<=_&P/8V8I<+?UR7M4Z
M5> D(X<&=>CFE% \!IQU$&@L'W)\SX#CG8^0.Q@0):8A)^]E%5/Z^>E+W?[$
MZV1&*C1_<#T7?XIC03TO),6N*5$57D-+9!N)X)K'7;L#MTNU\]H,V<F*-:.@
M"&[>F\MH"6ED8EWN[FL+N4(I9"M!+/\T#V*N&>@]\G=*[T&W#C08\H"-CX\8
M@R(7R8FJP#1 =*=M8Y%JO@JP/XPD9G' !'-J-)E8L/+>E7K/NDLL\5-.3=;U
M#R5_58I@S7OK-\1+R,/5AFI-UII2VSGK6U"QX U\NGB^X%8NA;MEE\('-P4.
M5A*951'TC,*-V!B4FK^0SM@DOREGA4[2U(5ZKDPK"[4!UCF&Z6.945[[Z,&4
MM6BG^R3SFE:4BT"UJ FC\*U[6Z?1=QM?[_WJ6>%Q5DRX])M!LUR,HPS\)$O5
M&7M-Y;=H$% 6+FHG'&NK<8^U772,]3&T=*)2BX6D>ZUKN34$_L*N*Z?,[5_Q
MOJ^0 F,@88R5AZ P=.!IJ(/@3C>?Y5Z"W1Z(UPAG?M%[T*R\*$;6MJU<@\M@
M5'H8Z(L,/,P.CA\\'58<)=*!*7M?T&G+L=I-<<?%7U$^ ARK6CI(T:B?"9)X
MF 8G$\(^0=N@M]'A_7.=NJCEP7"9DR=31 8#G"'WAC,$:M,37BZ$G28X26#&
MX:=;..L/*Q0IJ8D4#4>D;TX"#".LAZ9,O//<Z)&H8PB0 H025Q,\$(IQY<AJ
MR#>A$,;EP!!<\/T"EH-HE^FL\R3[<&W87]2#T;;,3;?(;?AI\> EV$)HJ*DS
MQ-0Z<LV=[OUC&RM:E..#_Z)3P#^\6\YG?1*Y]*9H._FF+G.F%AH=YVT\IUM)
M@13B.6(*I!;^YI/@SX@"R? <[7]_GB-^Y>LQ<,EZ69[0B#,W+W1&[2]85U"_
M%:'1LF1&[(4M)*K!2BBIOH<8 $J6>[3C2OB@ 6C,:NG?U,PVCRS /M=*[_Y+
MI7<;*[U/RZ(]E9H,\&[]-9LR76/Y5"BK-$5[@+3*@K-M/VW5MGHB*U&J_04H
MJAR':7,D53H_#8^[A<M@:::R;T55E6V"JLJR2#^:K,J7K-O*$#@4YW((W- B
MLD+@X,\H!&[0I_>G_P.C_)_._QPVZ*KEL^[_",VU"IT/OG7HK!;"SR)NO(K6
M4=LSA8+IM%'.5>LO'PU#^7",HZU%6,DASTU'IAKWQFYMM KE;UERS0BKQ$!$
M 82X2T]DHOXT$O*GT9@_-5K1T>O87,AM5VI;*)RX<C*]W(N/;U5<":O",,CA
M.(&)^WN %V(;#X6ELQ03+G&H__/ =8I"G:S*2O?!+TM)$C&'?VETA6XD(QMO
M^[B8)4#I8Z0Q)I #KFX^I E@<J9.A%?G905^)*Q+.+4;%&M;^%J6IA9V7LO$
MFV[RG9TY3C'L4.\*PH24"AFI]6)2:L,HQP5C?*!+"$M1I/BZ@SS$0SF-+0\J
M\*KJW51H6FBA8#X+R6?HOU))Z].(;78S_N 3"9-_%+U-]?,+\!(>TA!7 H+0
MQL1YC27NH1JS<O59:%*K=A),6#U('Q4L?R+D60% &?BNXQ-4R.OFN0G8Q$.&
MD=:KM)Q#TFTX'ZF8#CJS"=.F+HV2D=)UQP-4;V2B9I)(:C1E^  ((3( *SF%
MA1UX-+18G9_HFKM2^%.#TK3QO'D(2;7@Y3R+C;1T[(,;" T0A#$HZWK'1DAH
MA:08"]YI7L]PJ_0+%KC ^!.^'61G;1+ZX0HR+<KU'#]1_^&LI^7>VY;6&)<.
M6/#=41^XU+^==F#<83GN[*JL.6&",$+SLK[/J]JXRO53#!F"&J6=D_V]D\,V
MX9!0.,$APZEV_0\W[?J?,ROHE2E4?+3B/\%=OOY66D,_?I\U0KON7E1MJ'L8
M?(48$.X=QM6OC@YC%]R+ZLRH>T6#S[W#V 75O1HR,^9>L<&K>P67']TK=D%U
M+Z[GKBI>8H . _(+P$I -C60J8"3G[A0B;T$'+8I YHM&E5,I,YNT'4 *X4>
MQXQQ?LH6VNJI%@V*9%(A_?+O>:&\/*SE<G/Q;K+3+[$K7)V&RJ,"#Z2[]],B
MO?IW:I 2->-/.C_M!I#+SF,:S@G#&:>);==E>):F O4Q='T1%B-Y5W ^,9O-
MP,-J&PPID>,H/)>LX _A:E$6ER5PM2\"I.L5/0]>BIY/O.BY#8?C$ZD=_F6+
MGE] D1M.MF+BI!9#0'6)Z'5@;(J32/IPBT96 ]=*4I5VP8-$'0N&%IC<,3^@
MCD7KQL;(8\1,E$EU"T"0;@W7GM>YE2L=02^3IGN[& Z!NP,!T$!)FTL]5?I_
MGMA[$4K]SO'KP_@[B51%MV%C![S#F+NIO,.H:[MW&)**9>^02QTK5&"70<LV
MW)P7^&P,/MOH>OF1\-F4Z],R.& Y0XHNZ#30S)&4?[C-1P,LE0\*>#K*/ S4
M>GA0_]PA^ =<*SB_EMVDX4&7@[34LBO]__[G?_[G__<]-T&"[EB22?J,5@&8
M?'&D5UF0Y&\CJ>OF7NYNFRN^388N%NNJ=QR-J_<.@[K7](Y75D/S#99X"'G,
MSMA-,].J,,"0P*K?U$9[+LLAMJ_5<HBF/O::M7J]'(XYI;.".IKMP5%7VPPG
M HNS#R:>7M#7&F@MHXM"26L*]2=(X@\-C,34<N947;+X0-V6H-#9-W1$\PAO
M5R?9?5:YO1*_\^(=%6,^%=0%00#VID2LTR*;_*U>$-MDMU\>:Q_3F4R-7_T0
M>XQ-C/C(F%&Z1\XU<V+S]W'O]?!A9[?T79?^S4ZN\X1KT@>RT7B]4+C@V1#[
MM6IN/,@VJ0]DSE&42<<9[GT19U#GZL'GVL7BAW">&0 %DW#CM;SG:97_,1\4
M?<U=:FR3GF;+4;(;>!W/BK^C_AOI 9QVZD+-0, )T4DG]#RRK\KUF.53)-H#
M<=]L(FM]\>JNM.YOMFP$)VKL^BG[93VK@WTDL#!PMH=#[E\TU-G9 W6Q8A-Y
M@ IA 0C,*];B H)9J#6N%5?=&!3P:K@;X56MY5,Z*]#U$AJGPE86<>*Y_..V
M(D[P9U#$41_K(L[1]R_BK-SZ%*GW;$-===7.)-G,!-SR[9B!J+G('PT'$KPO
MHH2(.M00KE@RXA8N+;BOG00]63Q&OX-]0.-GT/"F$YZPI"2[+JI"=AX>2%-B
MCX1'@H%1D 0.6M=4^2<SUC/4%1;NV*>0KZALI21$HQ8U-,]5](1W%"HZ1XM\
M@_YN.(ZL(I'AZ\%HI\: "J936SHSC\B\B4<(HEC4N815%7J4 LUNRLXTG ^0
MV2*PC'>=K>1T6!IBI1L?YU6EQCY"U@YNP7#8&JRW]#E8RDL=&)3R-(&:V\-Y
MILQ I][ZM5!N:";U-Z!24?3FL)>P+EC/$=($2_K?ZE!7\3&W@JA)0(P6 :LF
M^8B;-6NU?+3D(I;&#-)[J [X">&CX IY_Y:8>/O9-.M+[Y\ ,*'E8CX:P@3X
MF&G-0N]FK3+D-YJ!C3 R8\[!^ASPU/&Z]7%;2W'P9W2N=O2Y>KSI<_5#F7Q$
M^V'ZB-=K'K[X[_.+3Y^3L^ODXK\_75U<7[_[5W+]^>SSQ9OD\D/R^=?+Z^0,
M%.B41>UTTV3G;#?Y\#&YNH#O7GQ07[S\^"%-SC]^>',)_TP^7B6_GUU=G7WX
M_*_D]U_//E]_O/CGQ56B+O/^[,T%?/S+Y3\O/B0__PO^K7[P\\6O9^_>)A_?
M)I_.KCY_4-]5?S_[?'9U]E.R\_-N<O;N7?+Q\Z_J[_HFUXLA'R_EV7AY]O"E
M-+MMI=D?9TD76INS#V_$(EQ>7"N;<(&;^>SJ\OKRPR]H!SY=7)V1\7B;O#O[
M'0T#?.GWR^L+]<6+1/W[0GW16"AEM=Y]>7/Q)E5&"OX%5SK[\"_;1'CW59=^
M?W%U_JOZS[.?+]]=?OY7FKR]5/;F^CIY"Q8'S<_E^9=W9U?)IR]7GSY>H[7Z
M\/'#J\L/;Z_4'2[>*X/W$UYXYYP,TV\?/O[^ZM>/O\,XU%7>TV/ -]0_+ZXN
MS]Y=)Y^N/O[S4HT5'O7B$A\>;O6OY/-'95\OV+C1G[Y\>*/^35;WEZL+O"/.
M@+X(XWS.KE]=7K]F!,]BI<RHP4([>#+U%WK4-"ZQ2<WZT\NE5DMA]$IY*W5P
M82Y<?)$3NY%A(SACYWCO))X1/VYKC@KF[.@P9Q] 'X;[_T^O2O[V#_Z_3V5X
ME^IUC2>Z&O-3<JDB.D2A_00^*LG"5AO/GC]%?RY>^#H.Y4)DCH,_HSF.P&<[
MQYV#QD>_CKX>G^R?'!_OL8/8V7_=V;07Z+UMG9]=HRVN,5['2[PV?>0:GK#_
M>M_-]!8\F@=H4![F$XIW;M5"4'%9-7:*L\TVNI1#\WK>L_(2U)$6BKOT);A?
MM,!D:Y7#_3"[L:@#"J0]^><VJ=B=7!HV3@[1'(1* J]<\07)X^H7!6H_U%:[
M]#O2,$UN9!B87*F:]'/2V=+B7%E%Z8I04X^7E"#5&RQX5-D<>HZJ4KVB27ZC
M+(%HJD$@#6TS6-8K)S?P[ZQ/L%3H1:H=,#;WZV2-@H&1K"HP\^-U=58VAUN8
MO)+:=7"T63&"C+DM=F)7HSSJ7&[VN=OU$N!.,Z9AE,^3'4.*K:LFO+:Q!X'+
M]J.L;SH[WU^?,>T#IIPP]00J;^>Y^O8UHJ%@TX#09-'G%;:HN;..<@W[5/+Y
MGT3KXX T<-SG)"T&BZ)>;E786-]Q-IO!%H"R3*/#GV:)=&5<,V0K?UOFHOOZ
M&V&6GN+ITW+"AS(&<OH$?T:G3^/0XM/GZ$30^##'W^&(<3/V+O7<0FL6/4G<
MBMDR9\DB1:OP8?+4CPQ!T6_]@:%9/1I'A@<!V/2A8=42ESHV_"*$<W!X90CK
M'.%$/M,!D2G)J\KM-;!-I9^27ON,T&";'W5*,/O^&F=$YSF=$2TPD%"D)V=$
M\&=T1C2.%AURRA7!V&X^&4U8C"$MI/4.ADL4U&7Y49 JJ4F#$%:FOWA"F_U1
M1I?-[2S/5[:R*? 7A:%,," "BM!S;6*$Y?*5<GT.6*!778ID@,T(#+@P[MC\
M]_@F7?U8]0TSBBBR!<_;<H1_Q*.[S@7T0W:V7\[5WT9BUONW)2P>95Y&)9:"
M:8#RK:).+%P@\5<*T,:\-1==IDR3^2@ZT"K'VB#6R.XG^H:@*L9_ OD,&/Z0
MF\YH(*$:. ZY,7VIQO:FRG6Y5\=&);IE9#G#H[2>5]T'.@/A KT,>!_FT+21
M:>A7.2TFNL>]G,]J=;-$O5FH#=+S\ WQ#0B1*;?"P0N0 KFHA,[<ERPKPQJH
MB$CRJ[5KVX#UGH56R32CS3"4N)UG%OT T,,=9?<@IS"F (F6@;P0P82Y8R"D
M&@'@P[,?7;PY',WJ%1NM&?*1B.R&1NR\ ^AA! "LAC%Y,P07HTGWO4*>+*_G
M?=C0KF&G3" &R%_N%&#]9RE=$ U]6Z<F[7Z#Z934\>"6+V6S1Y3-CE[*9B]E
ML^]6-JOSV6RDP<SVYEWX4\NP+/T;L4#2\6'=OA"Z3VY1$:R_A>[O691L O$W
M)B@&[G?P_!<99Y<XPZ9^F"[76N!Y62F/G9[C.TR:U\R%L95R@1[DO?TQ']R,
M[0_]'BK[55?ZZRK87GH@Q=+?W#6$H.H$S3-RSAPOE;(&ZA6,BJQ7C$*\*S%W
M1YKZ69.505BF"\CO ,+KV/>&J<R@F;/Q">"J)_UYQ<1*#?$8^*D>\.ODLQ7R
M@V@,T4UZD'EY(]9QSGC_S 8](V<MX?%IW2,:S]F;K@ODO&=!G+.D%Z:?>%IQ
M8)C<<GXO'LBHR-EGM08HH;=Y<.\A\MP.CR2T7GJ!8'RX%I+H$DT%<\4"\3VN
M\'(R>G"J/I0;Z&<3-[:;/42BNM*XZ)+A\-(=\+%Y>J V,QRFUM]ULY%.:?@#
M,,0/RYN YY.NZ,;H8/:[QZ&B*:<K3H,_HW2%R4ELG#A4U[W7RT:8XRBU(T)H
MFK #&-JK*?4'I6I55TROJ[7!4!;,6-)"AD6^OH;T5D7]%04$H5G'UG9D)0F?
MX[L&#F5#3C>%#'?! F3$TN(P:=KA0JQSXMFLX[AVS'&H_"+K.*H=<[1WK-?Q
MQEFPWD%CFHX;W\E"6F]5?W#P1X"J^OPQ^?WRW;ODYXODW>79S^\N$ QU^>'-
MY=7%^6>$5UV^ 9SG.P1Y7E_\UQ?U7Y?PG]>?+L[Q'Q?_??'^T[NSJW^E )CZ
M].7#Y>?+?UXD;\[>G_UR<6U#M-Y]O/X,4*:WEY_5WP4"]O;JXWOXY=7%N[//
M\ <$1MD0J%1]]LO9U9MW@-;Z^!:A7A\^?KX\OX#_NOYR_JNY&P-:+S^HW\ 0
M/\L/?KZZ.%-?5/^UT]EEO)<@KG3H?  #V>GNPA1<O/]P^?;RG*%I/[^[_.6,
MH&4V2LO$W#!QZF]7;_C*Y^_.+M]?.V^(OG*1G/WSX^6;LP\T_#<?O_RLGE ]
MSZ_P\(*Z53__<GV17/\*.+-WE^\O/\/0&/B&#P0O#)%L,&%GSKWA1F^OSKX@
MZ R^BW]>8I=O#SJLVP!M:[1."W7V<2BY+A8@2IU]M'?BH<,.%J'#?LCPSLO)
ML( W!O4DH$$E$E<Z&'X"YN8,"DLS<AJ?PUD0Y9;KGH3\%IGJ*"/B49.@C]_K
MZ8FTYW4.-H\$L]^L<GJQR9+>X3KGQ&?C02C/P_!T2RHYL6^G.;@7EWC,N)A/
M.$?R8HJR*F@IK?-^E7.)G>J'R@_*9QF[5117J5_6P),R%78YT4@G\6620X6_
M-[$!SD1\\95?H>L5^Z&I82PYF_15" LWMSN%O&8B%&2%3#"T]!0J[E&C07^0
MDNX8.%)>G+AKS? XYP^@!G]2[7=(G!N%ED%M/J?10E#CAD:D/NE]P-78*30\
M253QC=ZK'&$'D4OAC$EFJR,PK!C[H9R!<ZH%S[Q>>O<-:_Z3&;;U8\=<=%0X
MOZ9"A+2R7+]A'(?RD>;H0#MW:>3-_5< ,2&&J"+<'1\#QMFEQDJTH$24-:PF
M^4.CPY(K#--RQI?/^M !65I]G.:SVNDQ \F>7-HT+:C+#M;WLW6KBE=.O6+U
MRN+];4DU*V7M6#,9K 7#'DJ,9GH4JCSX-8N^>QCA;X#0&]9H,.$4?S,H9 B!
MTRR!G!9VM$%9"S8"$BK5_.K,!B=].[<5RNJZU]8/]CU4HO^>[&2[D,$J*&6F
MUMR55^SAG]HV:Y+-&'32NL'%M+&,/'7B$NV)5=[1.1'3.*L-LC^94I8KK+OT
M<DO[FL1T=GJ[:!.L;%>=#?.;>591_5UX!N832R( ?M'CI)<W"<T)M4U=+\>7
MJIZJ@%M)7=4F/' >5-V$D#^X$.!-^K=[J6@]HJ)U_%+1>JEH;<J[?@;!0IQY
M(R@L+,%"G'E#&+951+!QX*ZQHE[4MV;JB.5"C,,)QS):=>TZ>3101;U\:&!Q
M?Y866R'KI8@"F?Q9'7L3HQCTH)&9WNE *C>4^+>9D8R*F2N4 K!/MZ1!\ VA
MVJ%GMRJ9/:K1U"QLUW)9K/7(/,'S.?-DAQ>:]0'55Y0O40+NAW_+SH0%OHQ>
MQTR/L'>-1NR9V8"JNBZ(\<^IMH%?G7T50G(J3,&82$-E]*#] JRZ 8&WKH*9
MD3XC*&<W3AX0%%P3TQ G#^B89,'&\9H7" 0N5L&4NVG,0'#H+[\U Y(%>8RE
M0Q,+?L"9AA=!\UET=D6>LR8]%B++FY+ D\G^[ @ORJ1,AAGCP.U@28N/^9&1
M(\;$^@7/F[IF\9O0IA:IUAR".3F)X)B98/UZFN,4P"ZL!J2\2ERT:))9^8JO
M085(*,#W)(4&^8]\7(+H*Z1B=I^UWM3B5Y.-U DZP%.27\7_K;9+62M36&,X
M3P<JXD809%O@M82^D021?6RX?EOD %B7XU=EOR%X]="[DB/$)+^C1-\N]JQL
MX;M;FKQV\;NS=@NN>FSE$=$I#4*"K(-OQ/0+LC?<P/0"+?^>-L]>^Q1=HK@V
M3U!02ERB.,=!LRXF\E6G^UWM+6T<2?)&.[2P)HR'?^9X^&NR+]E!%80IB]/0
M>B5[4LSRRV#T 9"I:F!:ZH+J:MYU?@IT+\2E$G#E%#.UB/NA_6\AI1;.D$YJ
M<O12V@4/!MR /&;#AD*H9RRHA_7+G$82!LS(B<HJ1 4EF_/\*U1SN!!ZE\O<
M">UKK2*>4293VE1/:L_TIDY=R NAL1:!377JU!C/Q_$K15]_,>&!Z?[&!MN@
M/W'PQ+1(4$"[-M&<,PFAQU^E &0GH\UXF=M7U]T<W")L:!=*;'[H9 IL-.K2
ML&&_D/:L8%!Q?I0@5ZS8YS@_BI#7JW>V<1C4Y>2/^41* *,B'ZYI;TU%PJIK
M2P,0E7IN&>_GT# OG\EJ*VO9%3"_%(7FG\#/156!W#4:)^AV%ZO2J/O266 4
M%X#.&V,&]#DFM; G,VTS/(OR37)US&3C#)][I/XSY?I3ILFU.;<CK5UZ*D(D
M[,&!Z7(/INU&M%G1KH+5H@8^!#B#,K H"QN\_TB#WL!HZ#=/O]AU^P*()9-K
M7GAB$6,M,&G+8Y(_C0V0ZF'*R< CMU&/T1B7?@3P\@=4C".3,^"T BC^S74Z
MC@G!\;=.M.9-$ 5G4*G,[JG%FN[]\)S297%VC""?IMB>.#N&L&(KV[-Q#NN/
M]Y.\JF^+*78X/S9!Y;:J B%#NZ?GY-V-^F$H0J$E2V=X0DGD^#4"U5NSYE%]
M'+MM 5QLM>J7$6IW+_<LUZ%L\YAQ&@@N68C:274Y/(*7(2EH2QY3NEAK5-($
MC@/E4^1_PJ/5Z.LQG0\9VEWS'*VP@I71DB_%9;NX?/(B KF-!>:G?K+$.36"
M[(ERLL0Y-30O=,RR?]=G5N?;\2/D)MNQ8+-YA>?&&X!.S?O2=+#9(^]R#)HI
MRH=4EAG9# C3.2TJW<>79VI,$,#ZTB;N*1,](E+)P%HQKE%WF9)?6='C1ESK
ME$16\.  S@1U8!']2"Z4!7P&\R971])'Q@(BVHROZDYDUG;:&S\8O]<OIT5N
MJ3W/@$2(CU$K-\QGJ#\-K7Y"+"*" (1!E?" T"615?U;4)Z&X1A06>P9I/4W
M#BX5OZ V+&!!]%HP3M*T]!ID_XQ<YOUX]UV0LI1^UMF+=]\)/ZV:QI.-YTS]
M3H)'!NNT<#S)L:*RD8'-%C<K">J-IXGT^!WY46#9TPTERU0S! 6#R5DF"]:^
MK]UZ'@R&B]I!/8)6 Q+%)>,\GYG]K@&?&LZ*G"*C!R?51R@.W <6)@20E/%J
MO&U;P/CV64A"F>&;"<3%?1A@#IN=_FX5->2JNZX1'_I@#[0> NH7LC-&C5OS
MIVM?%W,( [))<J&>O!RK(9PIKS#9N;@XVZ4:)R1-LH%Z=#"Z0 8#/?7*M@[R
M(0IH,!C^%]1B&35>\55^,^>*<W>O<_2WH^/39.>7-Y^N=B6KH4>)?>H\R5;2
MD,AWQ,QFK%BF1FJD/6W:'(__ #'J)@@AYJ(TF 7OEZ.R^OO_M8?_+YP]-T1J
M@LPOQJS#Z=#"C;%!U>H?U0\YSONWV:2HQX$$L270!??1%'TXOVK*;.$0]4C*
M&C??K+ /J1?X>OE<?W+&J158Z&EC75N+*DWRUS>O4]H[&OML;41< $PO65.4
MR&$L9VS@(0=5=B\] YP,9IB86FX/X^)_D20+>"E>T8%D%.INY\JP>P^MP5H+
M44_;*$6V'^^D#1*9RID4[Z05TFYU)IUN^DRR>]U>U,96@0W9)-]-'C7$"=6W
MZ' 6MC,(.P3W%K%&UIR9XNHI440ZU?CFP16JK5E:VUS6@9N01B@=QC &W3@_
MP6:FN47&)BE^P]J'7C[M9<,,(J05_AC@BA/U5BP:4+(]<EF+OI#G9O/"A#]^
M^3C4\:>'!R=[)])9OSP,2OD13F[284AL#;@7[O3Z5GM@?#/3M:0^S.N%:]=>
MNI5RQ2I=T_3DWM\6P&;D:[^;Y4Z,.D9$SVZE"2J96Z&@&EACH=&@T!D0=^J<
M)-"2Z]E\P#I]F.1%!3)T6OXH5;B;C3!A:OT90B_E^DY(>DP=N)-YW:]895;:
MF;#<.C7VDW?.L*B0.C"QN8^BA)=KO\XK-[CUWZ9N^O)$>AO+DBHY=X[XJ/U0
M0WS?=T5^WV@;]%>4#D@FX/-@+OD&*&^&F3A2WJ MV=4QJ1_J-E+UZJE=E-M'
MP7"QE'W@0KQ,Z;/&L"RFS^CU-;PB^&;'<WJEHFAO.XL,!@!LA)8K-%**2-ZD
M7,P;#E3NRL+'K;=-3#1I ,[9 ,RBNNZ.1UZLUS''2=+%MFM&8/-%&0XJ<)\S
MX,"D36MO,76_1:S+:7CV=7ICJ':R;5Z(XH5,2;S!@.(^FOG6W6>!?UI'@D1K
MT%U,-&/S'M-O<[CHKGR(?3/MC/-B29,Y*A0SOTU9V<1<LEYK!P0,+OMX#N57
MF&VP:=MX^BT/)PWS&G-";I6#QSI ;)GNI<^C#1PKF%BM'\9J21:9\;<XCX$A
MXVV>C6:W?4A?J+4[I#2E.G927:BCA"ZE(/ZF_OCE&C[2^0!E4V\@9LZI?5H.
M)_B.N4]UHT+9_Q78YDN!;IT"W>E+@>Z)%^C6LI,_,B1HN'@_9ARVX4GJ4CD)
M5!)ALY$9IFJ=[B*'L-<?(0 +VN*Y:0[IDY>#O?['/]2YIRX.*%1$0,;3##]F
M7N"XB).*_I@QQ:E+?\QX=C$;G_5JY.W@9+QH/J$+-0-'U/>@2,,$D+R5,IM)
M/:*,@JU7 C]!=-^$TA7.IUKVF2\#<#6H)3JWYU\ 9I:Y4Z]-(/>>#D<_S0&K
M_(E-,<5I3VM,'/B)3UOE1JH%<4)-RX!MQ,KKHB\]L<=YBE/\G,#5^W$*MZ!\
MBV3&XQ1N34$QS2LF[&[ *[;W;;+FQ0JLV,WD"4>&?*)"2)B@BL4?94$$R76M
MV:@]:0<*]L5-"X! AB441"4QQSVKZNBM<QLZ0B4Y4*_*_8Z;<?85#7NM(FHJ
M>,HEO,0%<#EAYD9R1\ YI1-VE#N;( ;8EN^ ]GJ=R69E$[J."V,>SBL<&-;N
M '$18C;G,V*75)U:H-9HO_A12/Z!JM8TL8)EM<-V]8L1<;QKF(7.PMM/1TGN
MNO%H<*W@^ZSKN2G63NEN#0PL)Q1DK:7N16J+T%F-HIPS^[8?"#N#YC(I[F$B
M,*AIZL=3JF5"Q;_7B(KMZ]/#&B@ +49\ZGX>J%8PZF9A,LF*Y!<4.$PTS^4,
M+Z*WCB(XONCM28ZS]\ ]BP[6QEY@(=Y^_?EB O^?M*28FJ>7_OK9/]1DW9+8
M6:.+J;.GRTTNG0CF6K1RU)A9-TQ/&/8=(L=@,<+D!RZ90 ,?5A8P_X;V"(!?
MH"4@0 6#(L&$J@I[.'T;0'/;-I< (4B?'ZK0E4**/ZGGX[$VN +A9LY 7(^,
M95MU6X;;0NS9L7E7T,[-1[FH- H(1.,9KB_.4[8EH2Y( @,8Y% ]*_M?89UC
M9MOWKGG]WR-Z2'UT6_2*6:@%$V&-?X)*XBSI%U5_/H8FN3[+'C?P>S-U*%G]
MBD!:4ZN[#0$(Q_E#*EH& 4=N123<#EDV$3P[&G=O)++0*29"NC&][XF;ES:_
M9]Y]8RZYEU&-!A C5A:]G<@O-!]%'01#Z;9)MHQ5I+;@*&*):-8VDAPL77@-
M:)%X&QN/W FV?8Y+XP4%*%%962'7O:C*4ME%?FU4<.M98 *+[&ALV(9P69*Q
M\WXJB]X7$9<72S*>9FVJ59*A2P,EGZ#_2&O>]&\%"5\=B<]=:<!VZOSPQ,Y@
MR0"6U*<\F.>Z5*@]6[BI+@9JJV*KGU;.PV%9T*5JM.P!-_W80%HB5L6G'$KA
M1F\>LVVW<1LL79QQHP=>=++2?;\NL#B":QO[^'.HHO=R*N4,N7Y*9K!>Z0Y&
M537R<@N2\W'1!K(,FZW0;--+-]00,=XM7 Q+DX?HMY?2T96M[EDL<!X<IKP/
M^2RYSN!Z'NWT@YJ)AVRDCKVK'+&6_-<\JR;H 7)8E";_GJO7AO0]%7T3U]%D
M3DJ$Z@^I5&=! 1@79B]W98%;5XC5+J_5FM7#O]3;UEB'AWLO];9MK+<]+6OW
M5)*]._GN(]K4?N# G?R@ ^AQ\W5M H2L@EQ,Y@8%U+<YY@6/5&,VH"CGV"&
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MD35-\$0GJI1%*08%V88<FMKZN8CM<DZ-QT57*FPX3W ?IN3 Q[%7NL\3=74
M7:JL!W';E/$C#4\CPR<MK\#+ZZRRY*(=AK;3JY[1U='2;=^62>=$6^TJ:-$,
M#!DX8NNR%;5%X>-43)K$>M):)J\PE\X9]5<PCNK,X1EW3:HZ,\:].7 &6N/
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M ;T<B84>WB>E0M,W&/Q-5R,Q@SX%1"K9JXZC9_DNLP($]<Z&"97:E$@:R[&
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M3($VN+/"TQ3'!_6K/\R#$_SXALDH>1!?*PQ"AL+SC8N_O]E_XT$L44Z"4$R
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M$$: !V;X%$[3N%!Y&P>^X2I(^OTX'V05(Q\P+,^E:7IWC7M!6FHCS@^L9V2
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MC+W&BNQ@W:+9UC3EZ=*4%S\P37F3Q)]4<D_+?E.."@7&@!2;J)1#;N"G.YG
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M(@',.*3_SJ<SV"!N5]N>?@E""+>I*IR%VULCH'(4]MV6,[?/0I_J'1#759,
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M0Y.+X/"DY=\,TO=)RYR>__CN; U:.F>P9SX93/S Q<GZQB&:1Q.&(J-?]%$
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MI%>[ OF[P@,E.4 +('*G&?#_7-%]'3F8->7@LTE96-G$:RY%$7@AFDY9[/E
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M%HB 'QHT(UW.Y5@3XE/ZD<^P9! DXS8(A]#^*.V./MNIF>@P9<52_\(%\+?
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M@?EDJ-EZU<PE.N?L\L8P(HKF@LL]#<"_#BB("N>1?PM.?.-G4&RA\:][&+C
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MN&.7_@4^_2SQ&%T4,J[PGHA#/,8-JO)BTZ!RA =C""5] Q?,]:C4-48()1S
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M$,9:.W/Q"2?H=/V5]I6?5G,7O>I239ZM%4N]])4\71/E\S!*!B!#.S".[$#
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MS)_:U\\8/3/;9:4L;9)SD3-V9DD8)9CP6K[U5A9!V(AP09\9N2X?>:1ZJVB
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MJS(["B=P^@QI*"QH)\ !/9+:F>IF%;R ?MGX+,<9XRP]=\81HXF/T\\,CXH
MA3GV4I*2TG7J:-^R@E!#9;Y7UXIU;Z^&6WUO;["\VEBA"_*;+!\EBZ#8YZU0
MG2XU!LFBZHN14PIF7\-\%TUNHEFM$FHGO]B,JA0W]7@J8PEUH=:Z4EU4OX:2
MA!9\CN?4)1GR\ZZP=A%C\0D+:S_IKEE?9+%29S/^D"D?A)S@XZ@O+2/O&%"5
M+>"B@#RC58N(*$5<4B0M-/0TM['.J^F*#FP;"-[I@1)?QHHKR.A<8:("):.$
M\&#O"9H<PA<=PXD&ZE"XHT)=G*J?,PRDPD\V,BUO<J@S]<A<XPNJG8-GNT*B
MGT!B,%@7<+N1=#;;G<1Y)J^GJ?OD.+/@.@+FI80T^+>!A"OOO9IKCXK@SW&.
MRQ2K\"5Q-DZ+?+39WY;08*E8H-R6V!&9FXX3;C*4F^6";!4Z<<N>VWH,U43C
M)$C%&[J1;JQ-QW+@PWN7"9X1C668G2^M)OYA*G[&#S6W8S[6FX[C)G1O;V$)
MSXANN]]+0</EPR** HJ5EH]-XA$K7S9KM_1,"P1+UIP[0D4JVR6LCGM*W&?6
MLLG_ZO&CJ$N,MI,8[7>)T98%XLE$L T@ZZ(X5O@!W!:>/'B516RF2T</81-H
M?WL/1J\^HO1#[K,;.5OJ[_?I=/$(!H?;A__Y3KX:36X4>. )[6P?@GA9ZI13
M/Y#37?L;&EKM+R@?5_Z3.KFK-(_IB?AW5@;P@P6E(,5/ZA79?:(5.3C<'NRM
M[9(LH)8;+I)IC\VKNA?5TR7&LE[[U[PGNXVY#E+0?QHIR%A_-?CYE2UZ?_N@
MV_M/L^H%M_3:)"L_)7(6#M05?<><:LI:CKEF,<\@18/MHZ-.BIY'BI82%HE,
M*H:4GD>*#@<O4(J>QV.44E!A?3S)@N]O'QZL[7HOXH*N]8+WGV-+_R V)=[T
M)]O/QA)/7<?Q1&=$_IR*^RD7^H7:>2]QH3M3K#/%UF2]?SI3;-"98D]IBC7R
MQUM<7BYE&2&7F&.'U@.XUMS=!A.[]T'H.?<NM3SQL9_=I8C3Y@I-G/HFX9[.
MY/N9#XC.Y.L6NC/Y?J:%[DR^G]SDV^U,OI\Y^E9K\M49>C4:OTO\_K3JODO,
M=JO<F6X_QRIWIMM/;KKM=:9;9[IUIENG[CO3K5OESG3[B5:93;<JQN-G+4'K
M*K2?DD?CJT^=+>WRDLF(<=K"H8Y^LBH3:S&G02A;_>$5%[ZCVEUE:IGM87 G
M*NM/53<+==],!2\6?6+Y9R]'EL<%H#$L#8SYUKT3NL^;41?-1;$1MV[0KZ!'
MT&M4Y5I3W&H62&=+?CL"@O7BGB-V*2DMJ02"9*NZ\1X*B6_4\Q:))PHES& G
M>Z[Y4\E61>U"L)SX06#C$[@M,9TH.<<*86J_*>4]!LFC1^I62,4]HNJ>TV]4
MTRY[%"=4/J'>I!.]!41OA?T%+])F:;V""%7K+A 0]66J5D&'>G E-5O5S92I
M^0UW4]8L&68O9=VW"+D0RO48:&N0Y$3]J%P9CE5K9W,\M&LVW$UNLY75T3#/
MU-PS,]I&(Z7'5!$*Y)@4@GNA6BY%XJ\$[UNR=W'3Z1>HNC..9\-5+T,WI,YF
M%J@F^1D]$IDT'J@9$/RGL*2@0DH&H+O[&#0<\&O8?%7C8:K3\L6(>I*E3FH:
MVPN%[3P8VD9IC/+K7R[O45F?Y8/=I3G.]IZRQ5DJ7I_'XT@TXIO)]K<R&CA*
M_E4^3Y@@0XQ@I]HA4>AP/TG01:JA%;98MXT.5YO<&0_%_F;BAHXD<>2RJ@U;
M;AS\>D8\OM3LB_^I]H+LU'6//,/8"0Q/PWLWXDY8(>@4YG6Q,P^@ 8\\VYU:
MU#S^3F@NV930&#=GD$A"8UNR.SXH8W!$5$1Q2)L-;B(E*-(J2-[O'L8C\/X!
M-UI ]I<F3\%;+/O2S/,B*7Y2_K("E5Q*B2-_"]Y"XZD'/8+O88.:=@,DB^%F
M;_17EC?M\47RU9A!:LC9QAM(K=^SIO:?< R2WIK:#OPSB>!_KH7G]6#6QT8K
MT8XO9<5\*8..*^6Y(Q=K?$[6G25H6V R /6 .YT%(5,\%EG'2 .JQHTR   &
MYC(\8<<ICYQ\WGR$8>1Y&?1G;! 6;HKGH.QYS#TK;59M6>ZZC2;/SF"5ZWZX
M638>/NQPQIM;SL6%:'?&Y^)B3*>>? 5M=TQM)/%$\Z64!77A6=2TS>4SJ7B]
MVGZF\N4-?K#2GA=!>;/LQ1_=Y$>E(X'SF:A1I8=6+CFM#[?14TGMD]4A=$>K
M3/O9HDSVVAUGOHMN1FS1XY*BBSJA9H.0WZEF7[0\E=1XV/,*TT<--NQ;6.A;
MG+/'6,H7'D"M+Z6V_=R^29,+,K2&!8YGW:!7KE'=^O#:5*SB&&97V?=N0VT_
M;*3IS6C"$(/'PS]D^*!U,<E,[F40X\M$L<WTDA1*#T!0 NG28&,6042,/#C\
M@9Q&V'MU,XD\CTC$W^XNS/"6\NG=ZA,*I(ZEJK*:>#8SN\>/*(.VS07L"OX=
M?76M%]M5,*CKAFUK+3.]T_IRYM6VKY6 ?)<8_$\_.X;5& 2FZ]SX$"M5A"\N
M1+=,%&[_Z:)PNB/6W%KX.E7W9=?F7XXY[EUXP_Q=KSD^S:=)10BRN$4*';TH
M,V6/1F&"&5?++E@46\.'K8*1-K0C-Y*>2.+'X0/^2OZ3O^SI*+23A-I%(45*
MSWZP;D0XI5ODD\ 9G7P_*4F11!1-=_V[ +YP>N2+CF4? ?4979@VB<F$K<3W
MF1=0E[/A XTIS=*X</,JUFBRK4";^+X(.7R(8^3H&?K$+S>ROLRV/7BZ;9N1
M_H>Y]^YQ9(V3D/*U11Y[H_/A+<QC7-7XD+)[W,D"]Y^-7]3\= G.^S0C)_B]
M\^S7N98=H=R8V"O)A'P6=]]2,87Y%T'Y$V_+]]>+H"H.@_L"(RJ_8B4^#Z%M
M!8!>YD.%T.-G[LX)NOP1H';/05)XK-WOXQR ^G&NX]:6M([PN/\209?/(0G*
MU/DBPE$=W?'3K?Y@9[O#53\MXK;V<,Q)(GB/)M*CPB4LPK2?0' &V_LO47+6
M@>4V6H[F-HU!-V6Z?0)QVEWG*KZ?6YQ2_.B2],FRD=Y2Y: MR-*\=NO/5"_X
MU.Q>7X*0/%Z/T:>VOS19UXJ%HS-XGMS@>99E?J'FR8M;YQ=J-ZS'.G?'^PLY
MWL$]L!F&@^5]H27^PCC6(\U9NM/^96N'[K3OUKD[[7^>=:XG"*C.:N?+,BHR
M<8?;>_UG+8-X!! WECU^:\(GIZY]ZP?P\J.TD!#ODDUQ6AKKIQLW4[)8?AO"
M21M5M0*G\OGM#E P#Z#@\*EQ0 _/48O'4=U'BKM.@NHBNHWEFK:;MUJ@&F/1
M$K&&]2<5Q1XE@RZK]D@;?Y==N!3ZP;R13@^V5%+AB)2:B^JY0>NDKY*IC3"'
MH5"0)9HKN.=)T< 26)$9%Z]3P2,^):/4C KGW*VZVKXGJNW;[7JA=_5]"]?W
MN5R_S.P3&5[  MR]3I6M')_.ZH=LM++!MEQ'T0$[%[##CI[>#D-,\7,NZ$]-
ME&.OCBCG.EL$%8JI[9)]2V8%6&BM8N5+!;.(E2^QAW)0]=Z\D'DV2^FB&N \
M<FH0<EY6C#!)ZXFN^94&<%7%+ZA>^D+=%O[7Y6HNSXZX.&XT2D)ELFF8\-N4
MS$=\G[D*M0\:=@BC#GRN81VG=_IF8XCDA'DXQM;&L<$Z(7_WA9V2*P9&B^]N
MQ'CY2/W@,]-J>-:9+I0YM6/)<<7,'ESP!\]@2[/12_>LC?<%#HQR+TF2><"]
MI.>='7.6UZAVN+ !(X1T8V@@%%'BQ>DTA&B#RS)%$_\]"GP<O\@Z*U6H;^3V
M.#'>BV;DG4%<1!YC2OKT@*.SK;/O\(81/O(!)RR6U$9PM\_A#$/\IV%RF_E5
MEJFHT92_H]&Y>B@4Q(!13ZR-_DX\V40Z82S&((]6SLN2DOU8>6OKYX;ROKKS
M8X'S8X44EH_5MHZY="=5#DI(?>%2/8>41RI_S07CVCUZX!2%AS<R<269SPJ>
MWW  %(>ALR)D[?AH]7[/4$7(4:5H0F&'S^R0U(GI-6A\HZ9G*VQY&@-1FT6P
M@0L:@!V F0C=P-'!B)ZIANCGCSW?"63UV#@$@1&D.7.GF^9!,FIOP#"1'S%]
MW%V!"R^EDI*#[!FU-4Z"3Y-?GRCWY5\)C W49.%=L>:-?ZOJC2JNK#5=0@P2
M48VL #><R1:"7!!GBD^LC$FWO2=*"\"*NP$CX=9&.K5L96#<U:P3EW'15@=8
M&E NE&1G_.-SKA-#X2]1/S8'+8F4M(1H:^F#LJ=,I4Z/+:K'NAWT##NHLZKF
MMZI6R)Q\GG%]3)^P6,G=HVR#XOO2);"P,?1IB=N%94LE1$<!*D 1S@02&?<P
M8D@>"+-#C!/D-L:TQ58RZT)PBX3@WCQ]"$[15E^/)J GO49)P<S1>6/4XU=4
M-Z/T%)@,2ND#_F*3B)CDT1H="G0+K',Q#.&;!]9/@R/4BFQ2Y8TI2[!'<2I&
M8CH4(5^QV]_L69_L!_77X]=_0E?>N/@XN05Y;7[]/Q-?R%_O;-+VN 1M;HQH
MY_%[7(M9G+ED$W<R,?-51_J)/GV6X^O')Q46@%DD'$699/(J:'ZF:0!F3"@P
MK^8AH]YT!D(/U^2'W&WW1;9[?^?I]OL)6E/^: $6!1"A+'T"$C$9C!\Y.A"3
M(@1! 6@]??6)O>,Z)NR,@\7SX# -T4;#IA0T^6R6V3[*)5ICEB,B$!Q;TG[H
M!V8&]ULUW<@U^I_<^,)'<>=> 820+1U.B0U)NP0#P"4<$O2*W-H"&P7 K@BG
MKI]&)5%OP?"MD9QW=0@K[U!W[<H:M%W:_8G2[GM=VKU+NR^<=M>:YEXH52/9
M7WS4$W<BC$D58.N1OQ+W#H_+N%SO%(PIL*I!2=T*0AIJ54IN*MP7)"/WB[^2
M@!]6Z@,:L^G&L#JC$HB3L'Y#$^TZ#@4XP/\,DM"WO<:\ECBR60+FDAU1B*-<
MV<O@69K6FK@$SD*KQ@'9UC!+@2 Q_"D'X#K+8B'+HO_TGL05K=S\%&OO!0S*
M5^2=]>$SNWC:]Y0!JV*M&2?8=[3-G+=9"^U)$,UH>" :\,OOE754,NX)W3[O
MHV0<CH(#4>H1J)&6&_79\;!BX(SK4J9[:K!%D^#>2"JG@3%-TZ;AG&P7/4([
MI?NHD'XT%$#5T+17(Q?!S)2FX=9*@#<]QDS6H]V82=:_RR<\\^8>\:I^W;[>
M3JU"9=?FF\=4O_@[([7 0RY&)^$WZB>V?"^X)TS */%0J>NI?<>YBCMW4T9U
M#-4?(=ZVTY"+:<C!TVG(&_O[ M23!5?D<:*W*F=%N?JNWY/4^+PI@B3&7Y%D
M98]MR<&J8N>R6TB,+]*SQD)$FJ'1 H$,;^$#A'='*4?C+:HF#4+)@CW2?BSQ
M!*[)W)=8*N4M;=3E!MV>8,[8B/NQC&7KJK'KNRK.*=$%>IXD F#Y$/XQ&"4C
M4 .E!VL'0&QE2^X^W9;\B$IV'B!_OA"D>'*@]/9@Q[C381)&@G&U>&!*@!+L
MTDB,$I+4$S@!C2VD0A1Y^#Z=GICIQL/2O<M%0B1G:B)Z&0N@(@CKHH\NX.#%
M0YD]!P4.$U%$F(JW:1,HF2>7-56P>Q&IQ,9^*.* <J+]P=L=L&2VI]NHFM)6
MGPZUBR@WNG)QCYG"'^.+HL+ V)+9$8G,!?N[.TVF/.89QEEB&13Z:-_GV'I'
MD_1%E>ND3U4GA]7385);L?\C\DZW:2R=]&YK+[2UG[#EVO'H3S^X]X1S*RFS
M%DAH2  @R(*^%YN9= 8IH37KD%2TT^0K;\!63[S(N=-:E0)EV6G-U!R=\T.0
M-EDW1O?6?.GUSRQN&/4$^4")KT3;$H=R9WL)&<"_PDQL_1+<2Z1E3_/=ZB8.
M,YRUD8N8314&_>?UB?Z=Q$XJM7-J-,GYXMF(&$(L)M:7N9&&DLI:LRKW0O7X
M& I25OCG2& @@I:DQPX2;V&MVS* T5ZJ:_+82\9OJGZ2%=#+HI_&6"7Q?89-
M-*G;JY:AR*P7A#EP0])6/H,;\*OPT< SA=I=BO=@I#QT;'\D4M<9X]"1QF$;
M6%2\G^&#<72E 'G(7N,7<'IT>!0\,&4MLF^S-03_E0 +=-)($Y*UMP&:;1E@
M4@Y7+$2LI%S:PTC@O,%$D8A@6 UEQ"V7$3P'TT8WF<PZG6/%GZ>>:[E8I7YH
ME6!U!\TB!TU[704:EQ\]>B)9YZ*A_V?-RUDNNU.K\ZC,2BP[!'JFC8D?1JJ6
MUCQFTIC+N6"@?*HM@J4Q41)P8%4M6NTAW27*GBI1MM\ERMH1B#;HZ-5[S,U'
MGV& D3?AGS*O!_ADL2!%C%)R']JS*NZ4%>;VECDW&B[+(+<L%1PYZSI#SW,(
M-U<J^2.YXOA^EE?:-RVJ\G7_B44^[0!X$XSV=OJ#O</#DE;J\ZQB,[-I(8OI
M].+CQ8>SRY.S=];5V8>O'X]O/E_]VSH^N;GX=G%S<7:=7TDB/UJ ^^BGL9GU
MZEZ)\7Z_OZ.;.RYA3>]O/V$6^8/PP=3UK%,7U@E=L[E-PK0IE-%)Y[N*N)9X
MQ!0?Q"A'FFCV,(UM1X'/E"CCL<K\SL* >B9J/]MH\8L\.'XRQKAAR+$9E:XN
M;?>96M4W(@S=. BS083?S!;U:76<?*4>V//$YIRVQY(]B63>186NJ(3E/E2W
M %\<4Y?NV!W)X.98(#"-8A("0SUI/"F?&7_[N+7]LR+]B_NJ3&NN3V4^5QB_
MV.5:8E%66.ZZV*(TY.5[7O\PT\.32N<*0)2Q[7JH&$&+3A%?EN.=<I3"-S20
MJFEJ%EG(!0/AV$H74P9:C?I^'>+3$9"RD<Y$B.]._07-2'M)U%7S*)2S .CP
M=R'>O9&FP55Y(;Z/&66A=)OK;W+,T*1(^*2/'+P^?1I%&!3V,'LDY.*2=MK3
M--.O/B4[R V0D2=T'$XS3Z?#,:)\9GKU9IH>D<,X/SW.T,A)CKQ0W&)V+@B)
MQ@#D"0;$=<*E97X^<15Q$40D9)5>>(N"!1,X#D%=9T0ME2\YGFE)S?CR@E;H
M?YQED>P1O$<BG:1$RME)IVS;RN2><$UE_\%<%BJMT8*'3D5,8EJZD>PEW]3"
ME]3GU0MDMBQIG+ZW?R1M@+(O#W;JOMRO^_*PYLO#?MV7N]5?#@[>U%U9-Z!2
M#W%>'^()<5:UBW4MK=_4PR ML]K(?ZV$I UYYO1TSDW_!OR62$,YRO@&Y%/R
M/4B?V/$AO<4#ROA \H]J5T@C>VLW5.:5:W=7R7RPJI:F3*:T"=X9,YAR8I"R
M$XXLI&<U3\P9'N9J "I[8_X@2T<13V#WW$YP<J_2H^]8'7U+D^3HUUIQ4BMO
MS\Q%R%,NS@7;43:$UM536?K=HDF5Y3XUW6%>8T06)!$GUZ>)Q/GP09O,)(B)
MH$'T%P.5LMMF*#*P#TDC0&0%9"=1EKAT6]:J=>MQ 59*7@EP1E*664=XWX77
M[D9O9+P-$JR!7LW.;"$R0:@.72_7'B1 0C0E +^TMK*)?M8')AI/CHA&H3O$
MEP!)NS?,.@XM\=N)%/<AK?U0D 3IKN."*AL-B[O,6".PH%S<&CG85\,+W0AE
M3H/::J[)*3^S*DERF92.:%6,)!FK\O$2([/)9O&UM<]U@EFP8:! S[[#I9E@
M\2N(EDT8I6(P,(_N-,45,5J)KVK565D$YA%V:LNS0A]5K 7:UV:280BTV Q%
MBF51%Z&"J-H,<Y1+>L;1SSO!.%3P@0,OD1QZ!3>VQ=4=[)1'CHN<C;A&[EA"
M7&%T=]EZ=&;<8;:H@E/<,[<=346OO :H0(1AWE;I73U7YC2U3JW2?&8,T<IZ
MDATN:!$OY FAY1^H\,%>)(5AN/\EW)/E"%(972H)/&FYP0%%@L&A$I1)X0IE
MJ[:HY3-G<.FD%Q2\8J<IO$!6*?LIXU\*Q2UY:PSXD6U!FA";8>'^%[*^'_&H
M9,<Q9RV^,)CO(_9>X+2.73\A/1_,!"$6\P&4BJ=*C0OS9-"5RB.C@RH]$53I
MH(,J=37]"]?T/Z)IS:JU?"UH:HBDN027 ^LCJE;#VF)R#Y-X$H3$V+LZVM+=
M[=V-<3/CNIGN/9<VDGT7N&PQPG5.D PE\9[I[I*!FKZF60[!YQ&\JQ]8]]3_
M!"8)#-O_V]Z;\+:-I6FC?X7H#SVP!XPK7K)5!@,HCE*E:<=V>ZFZC8N+!B4>
MV:Q(I(:4[/C[]??=SL9%EF19L6,",]6Q1)&'9WG7YWW>B+B9R2U,0&XGQ76C
M0^+6/3H,9:U-M(I-M,&:''([,46T*DG ":(9V"86VO7^C BF,3'%1@'LJI'M
M@FD)N'8+MI)\2C#\U":2'#8MLHQ&&;.>FZVF38/"Z7\D-H,.H<)R5^.>Y:AK
M,>MC(PQ&9H"MH*OYO5(AJDC0[DO%B]RBE!!SMF/>IS,<PDG!JEUM,V*1_JPO
MY'[FXVW7EB1*3>TI-HDY?,AL$E-!,";DX/N8LV=B[E0\5LY6F:?T%=YF&<[T
M8 M7!-;@02'0TG9[4'3+I5O0I5%)BH>5?4HG.ES,8"D&B=B#BF,&=EDQ>E ,
ML% +K4X]1+]@[#;*8\I=\O*[*V/#"(MD--<:JUFA=AT)*YR9TW&T$(M6<QSY
M2-V0>#-E6<R4!??7A0'$]Z$+RF)-]HU57LE(%5,08TBUT#?$T>.Q,/#>9ODW
MAU:"@@QVQKT=[O32*F_F4)=+<:4JA0L^VGJP\O/<-:6J#/V'+*HK*$PTHHX[
M(M8/ +U%<*T4.RODDXS\$5(5T4"C$6ZRT8T3.7<%CW^.K4 PQ2.UZ#FCI?5.
M%^/&/U$V4#ZOWT5M.T8C= V[LILW;S7Y*II\?45/]XI6-V5E!'W;P^?Y]? I
M'?B^0L9^1<C08H*E9X1B<< F1O^H[Q/JQ(BA4S0]$)3*6!X6-J# X-_F;[AY
M39[3J9[6(5@/A90N*C%1RK!.*:>21=74TT,ZF>N8^E;"?Y% 2!I7.EQ'MG5E
MD\@D#:<[?I*1!_*M]ITQXH0Z[#:E)$VP1:\>448BLG: ,>F8.I97"']DZL+!
M\4JFPK9I" \2-L T2WK="#CDSFQ7\*N$/HJQ0I7O9.T:TV9'PNUT 3.QLV6*
M/!#>?-S3U8/>Q&\<Q<7*$GKCW%C1[).Z18MFTSJ[E5;,W8AW"VP\ K;!'D98
M-"A7G!#'8/4**>5JLS@.+4W=8#UH9&7H&FW@;*(I*L5)PN0^9A_!P_"(Z6G*
M^85CL?_\Y>!)+IULHM./I$H?[FR0WV20HFT&RQ_:_5#9">C[1)K;5.A KEW8
M'@L!_F'=C+>B_VGAD<M[T27@M1P3*'*&VM"KR@>_5[%33HSRQ4W1^H1RU2!;
M<^LL"U6M:\ %3X6+[%V*&=CH3 YE^]QZ[3IBA_2F%J(1EK&E4:FS,SZP4,/9
MJ$YIA258;*,.ZW[ZXY6!HW5@$XRRJVQ6& 7U<HW@.NS"^W54,M6VW'@D_AG;
M?F\58BES #%V''/ 23KZT:F(,R[NP7WF?%'7V-")+=C/<%=^C?Z".WV-\F^*
MNA^Z?W-\K6*085>_Q>PQ#S6NSY78EGYFODV,;2@Q]JY-BK5)L9628F4U^2!,
MZ4+H:"WNC89=ZR,U &Y;\%0E6YGBIV2)IQDNK,>?9ZHI4826;2BRLCTV+(-"
MJ$3811B6LXCX:U<2;Q7;);H\M[,KEGXPY1<!&$*!K$I: 8?/%K[M?K= (RU\
M9%E!P&=^0PCX:8$1 ,U5QCM1VW :86C(#9NR#HOIEQJM9GP_']KGS$WBJE'4
MEP@P$S_H*LMB.$C)]-KEWLHL^&.A,$3M['G3=(G+09?IC9!D0K]:^^.B\EYG
M"G$[^$"K6PF2.M3.V!JC_!]VWBY(H;7-7N9:G[U0PS&9( P6^V4",#WCR=0S
M+VB*Y1"@Z'*7H H+YV*QS,##86IQFP2\3<BC\3'BNN*-9!0*7HI=D%WC)O(<
MPB8N_W)2A8TM<TOUD>Y1U*1[>*\LC[5T03PJ!5F6V+N34H]>!S/E/M'GZB5A
M1[X-YAZM,Q@V10/(<ZP$C3R[KZ7%>3(<(2TMS@NDQ7G;TN+XM#CO'QQN>#1:
MG*^=X\LOG<.+R[-NT#G^')Q?GIX>_:LEP[D_BK1GZF=77]:W:^3#6:@028_9
MJPK/%?/L2F1(\C]L%5!H@DO_W7;>D78]I R3\E7,S^]SQI;+.8L9VEKXC5^!
M0[T_;JL?>L5+KNF@J6=T"VSWAVA#F0R,/''(@5:T3NJY"=R;E],W[ ]X@6*G
M4J2,0:K%,,V+3:\'HM3 W[ R5*EC$F==PWG$)7E>+9/!TPB7K_9&G-*T)F8)
M PPQ6)2!6SZ<V_)AWD^F_0NQ.DQR2IDQL4.1P+&/L,D.&,XS,CI+H7.?M]C'
MI,!M1RH2U(XU^>$)*;S;"#>'AZZERKVUN4L%^RQO%Z]@TP6_#WO\5KS0TT*'
M.%JG]&1!>*$+G*@!9V2+.E^H6A;[J[O1W/^V>;TG!>E8(#T^O5;KE?)NN%^D
M/)QFPSQ O]JNE?%.';S<B2-=2"8N1SUT 0.\,:UHT/+.L-O07;9#1%BHT3"@
MM^5'@%2W67O4BK+'7TF!,OGU%]=)'HN2P&!0'A&SN2N6LOPJ2K4GO?40\7_X
M]>1!J-0!-1#QZXSH?)?DJ(V]Z>KU2C5310'.4WYM*O^)IO(-.LNIWO:(FKRS
M_HC5)TLH1B.E#/I'40,W#S'@;VB,U^IR7XGH+H0O<^>A-FM9(Z%8E?HMZ.X=
MC6/K2(B-(#01;B;L=^F'TZ(^"*4IL:YC\3:J6UP;/?1M([.=D[Z*D'8)L2S/
M&&T(30K)X"L#6G)AZ3B(2J32FS#'2+]?0K19W?5D==^WY8Y/(;/[?-78,K%)
M4&.#QU-C%Q4WI#X50Z(PSY&'T/97FV_3WB/J&Z@/K5LI=222.SFE+L>]X%#_
M_L)B)H>+8V3*4.5*FD6-A'^/F]ZZ:J5.!85!Q7:F]++A$98TC4K(,60C%W'-
M7OT8][FIT/>XAC'8K8V )=1:JM!!)K><S9;5:U[-*E).6R;N&E353F&+/B6#
M7W)Z/)<A55?9-+%T,([O4(I\<>Z]-O!193F3H3:D<9V<>VAITS37@GEBR5KW
M[LP1K(JEWC# UB9?P2:OCZ:L79BYU)TVCTP'Q.F=CHU3:5/ ZJ)!:-*E2\DU
M<@$GICQK;40BKG!B'B&,]'EH#B?]Z]4DDD0LIJ\4E7@G-RK5Y7&P(FDV%K [
MV[[P#VLR.X6S*-1('H8LLG2[,0O+U5-Y:@/C!M/<*&DP>@YJAJH]X/U+4HZ>
M5;I$5J>QYYONI,0Q=A_<0PR_>DQ>J)V66@VN4X0!HR:0 +VN$' "JU%1)%A>
MP<@>2OQ;>4[%.B15G ^-6^C<1=?OE HR.#SH*M>(TPUVGID/<HH_@.4;)B@F
M,+[HXL*E]A&4E9KB;W#_O[I&ZC1,4'"I/R,.]&P04SUY);"247&M[Z(5&&Q7
MA.4D13Z;:+]V_MDH>4PU**<6@_!$$[(M!N$%8A#>M1@$'X/PX>EB$ Z[9Q>=
MWG%P>/)'][AS?-'VXEF?5?KN1W3<.9N-EF>J.[=VPQICQ^_JV<*K.<Y*(UNP
M!V&*"($IKMU)GEP1!U-7VY[,IDC&)Q>HRI4N060>@/$[2L11$\AH7?.@U'.E
M.6:Q%8/A.T @*MJIJ?Z+X\AR/=F%66Z,FPALC#0*T)8*!H:_-,NW;;ODV13[
M@')<8)!-5-UPLN9*.K0\)QP-=I+R#!IAZYWMN"%VI@4#:PQG)#0<-Z68!B*H
M#[/QA E*-.[YQ=:K/>2H;Y 8O_M]H":&8OA0*&A<CT<[D4L+@G+1]UJEP8)<
MJ8XTN(!36W(=HP$YI'PF7PD)"I>F1MX<&"8:TPC=\<O<S(W]?D)]GXM0_J&=
M#NT(_0+/U/[/=N"W[C")&79<G?[1)"Y*W=:#D?9AO&);M[[#!,:D!%<M6K>Z
M#-F"$WV3]S,$/!;HWLR/%;F)*AQ5*7<5E!FP Z=OP-;#$%<UVWV9%+Q75.*,
MC7Q9829S<F;P(G:92HUTZ"<UP[$(!H]IT _B@J8;1(B-:[R+V<=ZE$KG]+UB
M9;-P\R_3RSQ8X&IW!NJI,O! ZJBL\D.P''_PWD@?5EM+9,-5W/0&2ZDH5Y!3
MB'X9/@IW/45&%,[1KAF.:4-4JAHS4[)$_47C\H?FB*(LJ]/U/K%$,N>&\#LI
M@R^!'LTTE,BE3?!DC.Q,;M>.-JV[J;3NAS:M^]32NL_+$%TNK?MND]SH#MF%
M:'UR2Y:V.A?YP4( .S330%''8K0A&8+]2U.-EL3]O-)@:5ZPWIKEX;P&.:Z?
MZEN8Q@Z@= *6P)(:6+#N-@TZ\-0K!8[NP#/1'&Q^%%QA3L>9P/K<TESO-+:6
MB*G5O242X$P/>&'5BJ.N;+'RJ$E=VB&72TD=W5JZDKA@LJFPS7  A!^JOB<%
MK7^N7Y&J'UUDI5BU\UEO[J\J;[:MZU^\F//FQKKDKB+W3C#3N48!RG],,XEI
MLL:. 0O5 8<F5ZGM0R&T]-RA]?45\CMX+!:BJN3_FE9'BQ2B'$8+U^0FD6KL
M07NYH9&T,8"KV'\!W82VQ")*4\:"&+2V[A]Q>ZW()'?X!3"BA X@YVD+#?R0
MLNAU"Q\<B7US)[15.IZ-1]+)B-]/3#R'^4\G:FDM?&K@JR@GUX/Z<R[L&]2_
M.^5C$P?72GEW0S[,#W8D2!V^0+</PE7&26O3H$\T)]2F05]@&O1]FP;UTJ#O
M7S_=-.BGDY-_G%,1]EGW\.3L<YL&75]NY/TFTZ"= 3&1P\"7]D)+?N$@&@T0
M!<<U*1)"8V-5PUXU(Y)^)!/)Q#,*/8I>#YOQ>7Z]5S*MZ^/W6Z=S.F^4WY2:
MN%6U\E@ND7;:1N 3Y%KL;HJOU<^R;X7P .-#T6QDOQ1O5$T6U'$L2S@9J98=
M7\C!X3:V9?Q4>?IXQHT/)VCBY3>:T5?;KD/,^6Z]V::V'H7M%^G2@':C'(N.
MSK*[:(3%X=&=;N?%@&JXY@Y7#Q-F57HG!U3'7$,A3!E=#Q^G:A363)FNPQM'
M+K;O+HANHF3$*#_"ODGKMHDBO)OZ'ADOOX\@2WKG%%,"-]*=XXH1ET/'!)3$
M&*,S$78X1#XD< IRR=-(%U9\S227A1YP$].H*!"K68DXP'<4.W=[W9?WCKXX
M9/1\8G?GG,4N![9M<%[ZG;@]36PH1NJNL!^*5_FFK7)X*7P/(D*@SC#4HE:8
MC#E\,;U5(]PJNWO;<%TZU=T>VKSV*K)[@WGMSBQ.5LA9]VPK7NWP&79L+[?*
MIXX]RNI)-MSK-PG,NW?PN<Q>=O-ZZRL;E&,E !'ULQOE1)1"G3)#'GD$9=M.
MY!&RO<=JHFA[!A'.JL%YLW :((! *Q[W9%9D0>0I$6I6='N=$5VA:9E<JFAQ
ML<2)QE&3'%['$$B8B)9CP@/]@J+A2!*X?CNH#](*(&B3$M)9$9("ES=5*M9.
M.&'N<6[ISOB+P6A6<%3"X8/;#J5 AZ-")-?H![0#I2..V5YNIS.JRW%?2E22
MA%;P]]KZ,"&4N^"KZ9-#S_)T'48]8J[)L5N^SO"HMR7NGW:?YE[:PM&\%ZP*
M1##K RAO;526T:Q]F$DJ&R"]54*A#<Q]<#U('X#6%+&>V6P[UM)0+$@LAXSJ
M@)$IT^H$TF)H*QCB'/JN9$9P;V?7CL"'V#9>?=E?I681B_'_:_K.-MFZF63K
M_NLVV?H4DJW/Q!2J9 \-P2@*?U.SB;Y9@XQG\5/BP2TY(2B6+9@+1=J(!"4*
M(Y#-!%7;?[T-\N>N\!L<H$K-T 73HBE79)LXJF2N'1_5&?%FU"[RS-Y&9+HO
MET%4CV)/UPX3L>+IK;2?!0-SE!1<5M%1#J*HDH@U"<Z))H"%^Y;H5]D--[%O
M]^EN\SAQA9-Q'W2,JHFBH\5DT#'X3J%!WGAO!'8&U@-3W^D!J*3Z]-C*N>"/
MG# =V!=O5*^I;#PV;87(FS2J)*F+Y'NP]59<'JW8[)O#LBMR+LTKBY8K%P"7
ME[F@AN-Z0KP%K./<KLMQ4JZ'ZMN<.S%D$[;0<$8U7WFS(>,C\6BI4JEPJ_R8
M&?7N^ 34E11CQYR99!S=\;AFZ*/D_5=;$0]K%RML(RAD;8C:QG@!UBXKXBR^
M\7M9NE3CLJ!X$^V$BS3!SJM\I=1BHHC"I-(H*_QU^&B<H!"LMUODLPZ=S+H>
M'#[:^O/8RBI/9/UE&$;<)"F\_U2[^90_-+9VF\QZHI']-IGU I-9']IDEI_,
M>C@![:,ELRZZ9U\_!OC?WG'GHG=RW":SUA80_;#)9!9"QI<.AUZFY%]0;NH6
M>[TXO0"PR=I$Y2:L-(INP_6V?EBPX@]4?9_880Q=BV9!KLF!S<TRE/)JE&G)
M%;8LI>YOS%!@DD5-9828OQM5R@>Y;Z/Q;DQ"PBF<";;P1P\J9%EPD0UY9)O&
M6.'4;C"-\2E*OR&WQ>!NZ;-[4;.9\;W0H!\P<,^T(=)H3_)C:G-EX!%B<.&M
M!!<T=8R$.1Z1-/)#/0B]XA&!%'C84S_L'"ST(-/IA;N9<"<B]I^DBC)7HT0-
MG1SV98I!W^!\BE1:@5W3X#"+E72K=/O-VUAZ@2PSJH_N%EXS&JDKC.'0)^WA
M7>7P;K"DX<+!WP^I;XZ0;G\BE/0J+2 C*>,:1@G3V1OX2![<)-F(-A@&0CR"
M[WI=I](R3Q"Y[)@A*3<+@]\+LEO"B?P7%7KC#^OB/J5+[)!S-8D276HZC&:C
MJ8Z1I' N4<I\T"',:D:% AT3&[4K#S"L?:>FAFMX]F(XK3>**:! BF%M?>GU
MRV\G:2.Z4IZ?H "T(.'2N]=;%DW"6,1+;*CXW1<EE"_%>L@"JUN+5BRL(!9J
M9?]FQ,)AEMZH-,&^VRLH>4=;7 MK/T=+I8<#LF?-ZSD8Z*X?_3M1]E2L5#G_
M7C%1YH$'$,46W55:G'$UR+=@"$.CV#=^/4R&4T)##*A?QIO7?]_V*TOU7RFL
ME,T P-:6R"HQJ%$.H6^"L_YSJ9LAYUCJLALD^,88LX_B&W0,3%OT^FY]%_/8
M/@P:R]#8E2VE$KBLW/:OX5R;MVG(%)=:%V*:^;[FDD)":O9:*R=6D1-O?HR<
M2(8E(HA##(JK%*S!%3!.>A?Y F/>WEE..-BL3E)"JJ1W.B5JN66YW"5%B"07
M H4!_)7-\NB*?J29*_''40S/28II3NC&,/AK%B=8)V-Y %I\Q(;P$;LM/J+%
M1ZR,CY ^3XQR5[$8#P,MU4@L84(@)@IKA9G(@=(]$5 H:+HKH_LT>2U^X,G*
M^TA3''H?<>G1YQ[ Z)BV%F3,E:D*S%+;>-E R$H</;DRGCJCOI*47H6X=E+S
M+B/EP P&B8#^$;,!9KQ7=[C_)KC<.=\YW GPXG<?]U_OAH$9JY!K2^CAE8L'
ME_G1SI(_SOE/V--X?/E@=Y<BK:@%LF_<\0;Y9K(Q#V)"OA;AZACY2L2X.NK*
MJ$[#?S045;#DH';WWWP,7,(9'8')M0K1-#K^-"!YV23C1KQA,$";;S22;]+9
MR&RIRI8L3%2F8;2"%:>:C;SUO%:RJ-YND.R,C'0*_7M6?1YT3:1^)1=LZM_-
MC_O7>0R,9A@E2@ NUDABZZ@4A$6N,D2W*&3BM_@48_1(6@$1W"QT'"^,0XK6
M/]&1E(HGX@_<E)K@4),QA6S( AL,\AD\I J++W<J,%:E.#95!%=-?F:-C $+
MA7/]3HFFU2$<D98Z?^G#_)@=[*BJRMF?6X@U(LH-NX6W&P*=F@VBJ*6#8+-A
MK400B]5A;)69(&J(^S5S@1" (:D9DT!P?G%J8B+X-Q-UH5?75RK5P#X56RBH
MG<!M79J820L.//,8F)DH[/$!ASG/U4VFR[B^$Y0*7:[A;$1PRB1^-9MH:73W
M:HC="X@5Y^4VG:CIU'OP_LV#P1V/V26.CI6K!<RY<K=*S;$B]*,EI9Q[PAZ<
M$?3D^F(L*[R[34##:_ZRUO3DHL0T=K[<\AV;)+R?Z%-#3F\4UY.48K!>560I
MQ")G76&+(OP7$J68)IGEY^*GI6=[:O*+(9U:S+((&XJ C7#K?OKCU;GN ^WQ
MFE1Y0(L*$2AUJW6QZK+TB*O@!%(?,TVP;^,'@2O.<.(13KH4):Y +9RRZK[Z
ML7MQ*29,X<&^$4A^9!.+DA#T2&>KUNX$M\%TZC*4S0TT/A(WTX(H MI*PX0,
M0%L#'7NC0H<;U/!,QP(>T8+=>[TH]*'<F$M2@YK#R6&9A6]N(PX)@ X;T:QO
M^[S(80.%JI2U@JQ7L_IS3G4NIGBRM+1(BCR*!DHHCG3GKS4P#C?V'8,I3V+N
M^C-W1,Y+5>26]JU<]P8_K^2FZDLIPU+*JE*0X,BI>UD/2IRL<PT.4Y_""+:8
MFPMI]MA:SL079[ ]P"9[Q):'#[/);+\M#H]YIQ^OZ!U_YJWZZ:A3;-._:KOD
M4H$:7,\AAC@;S'B7>TV?=/.Z9O)!)DTKJT[=8OZ."1+Q+]F=S5;$EAE135J7
M;"LX;,E4>#)*)RQ)M6T#PBS;MB<).V==I:6P2<FB\@MSO>.+ F!K%WLR3$R#
M*<NA;&>-VD#*@DC=.1'"P,WJ9L>Q$*J5=:8:35?*54OX!M01G7N!P_+/\ISI
M!G1K+<*[,"W=5(V+FI>?($ZG?%F"! %I*M6,I.^\CETE.Q&[:<(],(1_/W\E
MVJ3^[+6YO WE\O;:7%Z;RULYEV=< J=@,#2. HL^D.J15A*E'N(2TZH1+57)
MMU7I3(O6K^'^D>NV_3X%Y6Z M>9E50B_W#C6 \RB1VR>NK)9Y#FQ/H$4QDJQ
M<#0EVT?2I96&]M(W.=9WJNX5O]B^&A+Q[)BZ*F<.W5J\Z]Q;:"H4(2++T$?#
MZGYC-ME7VG(,"2Z-,17*GMM.65.O:MJ6I9#-A'/[X/J4GAG79QHQR(Q3XM-Z
M"D4K/_6Y5$_P7"YB7I,S'*57";6G'?>S.!EK-COB+#0]9$G#<(3"EJT?PKCS
M;#0JJ9R:"&DB5.T$6K#>R )Y4S\94VT]O%!THT&L8&$-/J_FJ[+?M$@<5H1!
M^$"W A$TV)(Y&WQ34TMVAK5PW-E.' ]J;B<MA1=P0LI^!_XUCKX]Q 4I;3%*
M3O!C4*;!EJ!/RN[/7.>KKH1O[2G$Q=,*1+YPW[KQ<N!&J<R\,=-"/_UWF^6C
M&$QL9+Z0'TET7?/ $/):L.8V R1S0?>^YW"*X8?G9"O1K<*$7IVBSW)RZ-](
M]84!Z3%B0>F?A1J-]#;)L!&W[D)>8,OPFA,CVOL"7Q^54"@*5(_<A 1,MI-N
MY[*DDPB#&4"X$PY:NE0D>OBR76F#13?X3R+SK#O9Z=TM[L'*J#21O7Y7?70C
MB6O0J]KW7/BE0!.\6NS%^%7PI5I5NX*J'3Y!5?N#DY]U8O@>*<R]4PSJ0,,,
M^HIUP]:CEIPN]%IP^/%,N=)1G[K0%IN;\!:_M)&>F!FP@%7I%DD(RTJ_R*+)
MC(&K'0MFGBG@[AEQ-=*XA"YI#_L*A_WJ"1[V1>QJZNF"2OF*>CTC8L/IE5I?
M-%KJA5+A(*]OCR+[K58%Q@;7-,_B:G?GJKOS^O%VYW%-E^N^TJ#6V$#/'2 K
M21N!C]X3+_$;;T?N,6@WP@H;(7F\C= A 'S)W7.23J["JO'=J/*34G V3Z95
M:L'6LWL'AX=XK1J_%H7> "KK$U-<JOQ"S399M:%DU7Z;K'H*R:KG*SN7(<@#
MV?G7(RK1;$K$#>3$_V"1)@A)4,E4'"=U5/#1G>UYXNE\)-; 8$E*F L2]$X7
MFJ/HMM74*VCJ;X^WVRX<1"#A!-DD._S:@+X-#;X6=#)<)9:\Y6/M4X.& IP+
M5/0U%KX%M)6Z%1%F$B9L=(<($41^;/6W ]UU KPJ 2VA\V]]'-G@ >QMNHW]
M^YT_*K<;$@-^-H%W^[GK]&IC(H]3IV=W$B;F"8"^"EF2D^#L8TN,0@/PI6RS
MLF%K'%P7COO!13%1;9P/8BK<V'?UYH\7KEI(TI>;*"7N!!%PM[!AJLC$CXF
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MA!J<6L#DTB+F,AU1*8PY>J0[8Z>5AA^[I=#<0![M@D$UPM.$Q#,XNU=R;'1
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M;0YL)1&[P=*5,R7N!B6<,G!+P!G!8^ N..8BS!%?0?AZJ;!B!GXG^&4:+CE
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M7_I9?(>"^I?KZ7@$__C_ 5!+ P04    " #B@EQ4]N-N2SA"  !DO $ $P
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M<+)W?/#I['#_- P./^[WOK6M'OS?@WW8WN\'P<&'X_='?WXX^'@6[/UV<G"
MOWUKNX4'OK4M_?5Q[\/!W[-W]>^J*./A](;;>ME[\>JK4K2S45P$!U_TH"KC
M"QT<C"=)-AW#TH*]\UQK^FVMQ(?^ZX>?=G:V=NW']/?V[GH8P)=C%>E I5%
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M8LJC,*_/0@&;/K8<MKP'Q-"10B2[+C:BE6' 9A5)B.O'4;->@Z67-A^ :AS
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M#_V8E6A3L_TQQ&JHSS-*8P)NN*;6J3 U^[.C6=GQ9=V1Z7EZ7-X+)UHI%SW
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MA?/V=CBG$ O/8+NZ#&A1P9Y<*&.+HG!&Z^F:RPOE1TX^!,\343#+\T030!K
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M'(Q,!'Z23R5# 0@'&3WA A+2P-,J8=+9P"JJ<S0<QDE,Q32YQV!JHDC)*0H
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M[BZEN B9:ZRLXD<"72'&-JJ0 F(,01JDG ]43J4>1:->BBTL*BG3_OA4ADN
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MMHFE2(&DK3A?OZ0N:2YH4J?.VEC$#Y)G>)LY<XYD3^=U[ZP[_OO\%+Z,_QC
M^=>30;\+GH_07WM=A'KC7C6P'X01C!46FADF!>8(G0X]\.;&Y#%"15$$Q5X@
MU0R-+]#<9'P?<2DU#8@AWM$OKSK.5]XI)NYNF.'4?L%&89]>MJ)H\BFPD^P0
M:L8ZJ)G]VO=A^!FZ4BRI,E3!\GT0!JW@( +?=Q,225;V_JJ3@S8K3@^]#*L9
M$WXBC9%9'.:F77N,S$O3T$OC,T&H,''X:WLJA?&G.&-\%8]91C4,:0$7,L.B
M&M/LBL:16^D=O16)SML=E!_=.+'<$',V$[%BL_GU@>N%4%"W-DXD)W?/?3Q$
M%T@LI,HPKS8WKF13Z[!>0:M92ZP8MB="/=$[.KV<LX09:$5!]/VD4ALF50]G
M%;5V**T.!H$SF\0_]"#\$$:35 IM@YK(Z<2%E],RQLG$C;?VHGV[!.%ORXQ,
M)\W25C4VZ(_&</8;C+Z>C/J]_O%%_W1T![&GX;,&'#64=9H_A=!X3F$J.9<%
M$S-@&C!PI@W(*>A%HAEA=HF-P-K&3NW*+,=B!;CT]&A*L\2*<2]Z!ZVP%<7K
M(+&F!&]KCK"EO1J<< J)5(2J0R_T(*6<ZQRG-IEK.\>$-';)XT.O(K+7A%EM
MX*<6!YQK&C=?VE P8N:V*C8VSYVGW(7 LMZG2LR#9J-J.EX8V:ZC:G+7DC,"
M87#P/C?P)BP_[6+.#/5=O*YTA<)Y><J/PU>;G$Y-:=_&TSD>D-['YU3>J"'/
M"@9TACD,K:!<Z>S#G6P$Q#*.'"N;ZO.@]N,@;5"/;]]$'\)V==TH7 WG_C<$
M,]A0D JD?2XI^'VAF"8L=;]-W*.I+U*I<JEPY5!PIF98L*O2O@$LJB1]1]<V
M_0<!=O!L&-WRO7 +7K]R;?'E<&RPPG#"2HAQ3A>&I1J.%]HNYPS#N5D%,# D
M6)NISR?8_QRDC2CV&0BU<T!=\^;)\MN"NMYM1V-]13D6! 8LLS\1R&[H:_W_
M1MN/>9NEK8OX0O='Z3ZDSG1@:3@)_MR1]\D+W]>K[8TJOG#^4<Z/"F:N*KC@
M<Y9\V0W^O'!^S;\AWZIXC_.H;$]87]6L^+FN2)5DZ_O-Q[L]IONG/*W?&=VK
M=]UJ[:"ZI?LO4$L#!!0    ( .*"7%1_X\MU50,  %H)   0    871R82UE
M>#(S,5\V+FAT;=56;8_B-A#^?M+]ASFJKEJ)Q'EA@4"ZTE[(WJ%RL&*S.O43
M,HD#5A,[<LRR]-=W'&";;>]%JU:ZZQ?"S#PSGN>Q/4GX9K*(DM]N8WB??)C!
M[?W;V32"CD7(1S\B9)),CH&>[;B0*"IJKKD4M" DGG>@L]6Z&A&RW^_MO6]+
MM2')DFQU6?1((67-[$QGG:O7KT+C:YZ,9N:IN2X8_J%:48L]>KZ[ZML(PA Y
MQT)R1K^Q+)B_@TB*!Z8T4_!P:3NV9P]<L"P#6,OL@,]7806U/A3LEXYFC]JB
M!=^(D>*;K1Z75&VXL-92:UF.G.K)HV75F$T&%QD3>N3\.,ZET-:>F=S16A;9
MT5'S/]C(-?#&S&G)B\,HX26K8<[VL)0E%2>H:60DI"II<2RNC8 Y.M KV!'U
M0!6GN"*<@)VK^''+UUR#Y]MN2*JK3Y-*L4VFOLS*]3Y#ZP4L3@J<NOM7Q$(*
M@I9(XW<V</J.NTJEJ+&ME<Q7IL&*-5VN5B:.)Z*'*83^E:9ENCJG>L=8M)C?
MQ?,$%C<PG4_BVQA_T%S&[Z9W2;R,)^<C?1U%B_MY,L53=#-=?OB;KE]4L?]=
MB?B1P4DVT!+TE@$7J5255-3<3%@?0+&<*292$T)CPVM]"M:::E9B+G8H;?!]
MWW*#X-(9=I]LS^DY@W[;#H*^V[+=7L]_9@>#OM^R/=^[[+7M8/@LW^\/G':\
M%P3/UKOT!WX/J,A:KF X] #[OT$5X,X:@LQ![A220]Y()D-:&=RPM=I1=0 /
M^7B.YW414"!SL3EK9:23!3_B<RZH2#DMVKI@Y6M-%86W7&*&HA7;:9[679B*
MU&[ZJG?KFF<<MP9W^B=3]N*'H><YXTB6%16'QG+'/S=@$V9YSE+-'YA@=;."
M<;; [F!<XU[A?<;):GK42A8@<=:U>CQR12Y=H%7%<'6DA1NLM[R&:R%VB%DV
MF">E7,?Z]6N$\, U[1RP(I@+F,&$I:Q<X^)FGU%'UW[)=?G.A@ZI26A"Y]Y;
MQ;C&49HB!B;Q;#%-DA@N:%F-(5G<1^]CF,UN0V+P5_]C_G<4#X,R9ZA.91<B
MI(PY@E-X)LN)0,%R/?(&9N29 ?MB\I][CWX;[O\8"/\9E: 1Z$*LZVILBH;D
M] 42DM.7SI]02P,$%     @ XH)<5$N2WT=$"   V#X  !    !A=')A+65X
M,S$R7S@N:'1M[5MM<QHY$OZ^5?<?>DEMRJX"!K"=I,!Q%<%X0VT.IQQ<=_?I
M2LQH0&7-:%;2@-E??]W2\&*#$[SQ;>X /C!(TY):C?K1TZV9\Y\OKSN#?WWN
MPL?!WS_!Y]L/GWH=*%6"X!\GG2"X'%SZ&Z?56AT&FJ5&6*%2)H.@VR]!:6QM
MU@R"Z71:G9Y4E1X%@YM@;!-Y&DBE#*]&-BI=_.VG<ZIS5\XBNEIA)<<?S&I6
MX?<G]<:_WU51"&\%\WOGP5SZYTH%^K]"1Z43KBW7,#FKUJJ-ZMLZ5"HD,%31
M#*\_G6=@[$SR]Z6$Z9%(*T-EK4J:M<RVBAJK,E>T_-Y61!KQU#9KO[1BE=J*
M$7_P9AUOEBY>IT.3M<Z#[&*E4]>&23%*FUJ,QHL^GS?*E%/;YE#):'58$G?%
MF"5"SIH#D7 #?3Z%&Y6PM! E19JIT@F3OG-+_TJ,%5B;<B\U85HP'!$*P=)%
M]WXLAL+"2;W:@*=G%:*>7']]6O7&_]"\SJG^P40B'BK-:)4V<]1/2X&M2Q>=
M[LV@=]7KM >]ZSY<7\'@8Q<Z'WO=*[CJ]=O]3J_]":M1HGMS'E"O%]]GIC?_
MCU;Z?'OSY;;='\#@>G^-\*7;N;WI#7K=+]#]9^=CN_]K%]J= =S<?L*J^DF[
M4C\]:A]#NW\)];-+7]ILKC_G2,\P1F'(8I+?99]>&6YMQB3\IK),W#%=AA#1
M5L0SL&.&DGYND9B 6P#O2Y+'MH15E@TEAZ'2:,/WI5H)VTEI,A:*=+0H9RR*
MYN6Y>7R32JBD9)GAS?F/%DQ%9,=H S2)&T'35P238F0T7VG>B1<]K9Z=_M*:
MCH7E%1J:+##5+"MM_7>\F=O[QYC_P?+\@7K4JRM+&3?C:-WRSS?IB^GW;718
M& U7-(S9A(/F$\&G/,)E+ RTTS3'17[#,Z4MJ!2NL&>HURJ_@8JA;9EF\$$H
M.^:X>GAN16C*T$O#:FMA$/S2]$7+'J_H$0>_V'F_:.R.7WQ@!KT!EWXR@SM<
M#I)'(U[V[J&]7T0*NTB5A1 ;,Y$"2V>0IU;G'&?(+$]PPR*'89!@"961$+,0
MJS2H!(FF55YN32#E(3>&Z1F)).R.X[@K?1JLBU 9'%*2;6@,$@B%#O,$Q5)L
M#FZ[!ES5X1A,3E_+]E.N>=$)32 11F(8@2Z&SF/'.$&3\= I2/UFJ)J*<)H8
M6:!1AK-5,[3@X//[[/,G>^#S'&*1HE>1@RZ]J(P.C^*T"Z[<%RFIY!@S_@YE
M'F&?Z*DK+E-&+Q=:SB!#1R.,(.R0<@D"A?^91T,CSD0NMU FB5RB 'J^0O=T
MPQFG3\C,&&*IIF8."YJ/A"%C66!4Z?5&+<LKWFWFRJQI>W#P_7;PT]UQ\,$#
M;WC]ZEVC_K9E"A<N CG:!%4<"RPZ/^D!T]QY)'J8H'6-&@$WM,:%&9,XB25(
M (@$4#D2)I3*Y-B.J(%6TKMFIE7((ZPV<(2>&'%T;>]NW?MPS-(1AS;NNC>Y
M1(GZ":O4SX[XL6M:/XM\R1<%I152#PG4/]#6O((4WG-)EZT'BA\,%.- -,_'
M^($2%"\T]QX3?LP"7F9<-SOB 0+_*WH<L>.=P<!+;E!G1 ,7$WP;JLH4KH0L
M-]LWH;AAR!%VBI%\)*)RC1T@VY@(XS@,2O'4]4.YLR7[6650FDOF<*P(1998
M5"[8%=T4R(10%Z.DB)AUB@Z-B 3:B28@?,#D.%U*/>6&@A@'^\9%/([Q*,-1
M(8L,BQIE# $TS"4CHH;3<DHL@R%LX4.KU8@0?PTY"2*7PO8\.G"G T[N$TX.
MCV%'@7)KQK6&E]MSM:UA$Z%V(B)"0V94Z@"#&4122OP01#(=S>$* 52PH9#"
MSB@>W#0L@;=#-@=:'G<?B*XDCASWO2\FE.4Z0] T+GX-0\0?IX!+(8UXBF&I
M1.S$.SPC4":1/+4>'Q&\18;T<^\SQ@> W"> #'>'2'91Z=RQ+0(/'L<\M&*"
M;F\V9)X6L?86[-$7-R>C'!QB0V1^QJ>\ABJW3VNP#;]E"VE.^;SXVSEO&,XS
MA0[AN;<$ZM-RG1\@[0!I^P-IT>Y VJ5'BW74H9.](G'F[FR$MF<0/8IW51CF
MFK!E);C<T&NBC,5Z>I((^S(A=O1[SMP3?D=/-(D1))&"/9(N% \1NMRA))U7
MNF-^K]>QUVK,S"(2)_+F0)5'CM4Z>Q2,<P92W'%9G% ^DB]_MXD.0'I EK-]
M/WAP3^9$<TPJ+UD'D:!57%@2$/+L9X2J:UFUA6HLCX15VBRB0U>!72:)L);S
MKU"\H<+XD^Y' O5SG1PA>B"C,L38\$JFG4,>_ST7J+Z#MSP-W4'F\>%\X<"A
M]@CI=NE\H2TE4 )+()+1D2$=/H:"(_04H=TBSS_E[(YB-9] <M&:2WVYYZ/F
M#S4\"]"*E+P_L-U 5%B$#0U?\)0GP:](F&$33<\_(_:Z@-%@M&CR!(V-$W:3
M*?CAQL<_#ASF &3[!F3#'0(RC/EBC;2GC+#"'5-#8'*/2Q8(5O8ADT@G2DXX
MQ4TI&Q5/?>J"W/$DDVK&\>YTK#RC8P_P$?'L18+*ZC>0YB7>^FH\_=K7=_3Z
M5R_22_S[FG#%ASJG1VP;[\K0J#4:+S>AQE\\H=>OZF]JK;573]SK=W]J1]ER
M0SE[8C_Q-EMN3$OI0HFY5=V!/=2J;\\R"Z]J[K,!AEO;8\9*D?935W[X3RTJ
M_!M:)/4C%V-@@D>O%*T@9^ M^VSSDB4VVG:'#;ENQ)V=:F<L> Q7BSW@VF<-
M=GK.1Y_]D3%.=SEQXM?MY:ER88?C-0]Z:BM\F7>5MP/]K^^;BW<=US5XF2'/
M@^+][_.@>,_\/U!+ P04    " #B@EQ4-?5\P;8&  !U)   $    &%T<F$M
M97@S,C%?-RYH=&WM&EUSVCCPO3/W'[9TVDEFP,:0] -H9B@AUTQ[22:A<]>G
MC+!ET%1(/EF&<+_^=F6; "EITN2N;5H>,-:NM-^[THK.X_WCWN#C21_>#OYX
M#R<?WKP_[$&EYOM_-GN^OS_8SP$[7CV @6$J%59HQ:3O]X\J4!E;F[1\?S:;
M>;.FI\W('YSZ8SN1.[[4.N5>9*/*WF^/.C3FGIQ%]+3"2HX_F#6LQB^:C>#\
MA8=("/)+6,<OL1_7:G#T._2TFG)CN8'IKE?W&MZ+ &HU0ACJ:([/1YT$4CN7
M_'5EPLQ(J-I06ZLGK7IBV\6(U8E[M?S"UH2*N+*M^M-VK)6MQ6PBY+PU$!.>
MPA&?P:F>,)7#4O$/;P4TL[+W3 W3I-WQD[TEBFY!)L5(M8P8C1<$;\?"C-/<
MUE#+:)WNEUDD1EI*FPF3^>*63!;C (XJGF--F1$,*4*!6-GK7XS%4%AH-KP
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M%B$6\D+3A1RYDC[8!*>^TTDB/C%3SCT0BJE0(&337,/3A#0[Y1+?(@V<A6-
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MP2+FKG)P/R0[?O'GG(Y?_ GH7U!+ P04    " #B@EQ4PG*]P'?[  "Z3P$
M%@   &=B;C5N-6IL;GIO9S P,# P,2YJ<&?LO =4%-NV+EQD!,F2HQ(E2<Y!
M1;)DR4G)04!RI@4$E2@@H$B0#$*#"$U. I*A@29G:'+.F>Z_/??<<[?[G;/W
M?O=_=_SW?^\58S%&5:U:ZYMS?G.N.6L5(,>1\P"QBH*R H"&A@8\1?T R"E
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MD)&'\^%1A>2(4>&L  2K":/5CAFT/I7;;#&!S[MNE55HT!K+0^)J0T3F]^?
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M8$;^,YNY!<:WEYD.7D[%A*Y<%HU)<P[+".[+-Y9Z%LD72\R9?,GYAFLYN:!
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MN\(U.>5/,9C^_?6AW]+A[)<9AY3$Y;#T#&E4HB)[3'SN(()@LD*PO5FP]?0
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M;V\F//33:<=N,B-819O\$3ZB9[KW?E5P2ZZ2N1N<VOA/K)X]*5=C4EJ6*.^
M!'ZK>Q1'1VM0'(V<NSQ <;3B]8OEP/]U)OU?1,00Z,_O__R*=7MD"39#R)
MZ:<Y5 <IVBO.CM]ZE8=",4^MH&OBR9]9E;.A6#+SOVU0^$N@W/XP$O2@##"&
MTD,!V/Q7X_WB8APG[W;H_EN20O?O=<(7)/!;(56=%L#NV_@_"8 R[,&/!IE$
MK4)\\",XUW/%/]::*4JY@QE_T4QZ.)]S_T)82/K_("S\Y7@%B[Q6 =7>_35+
MN3MKW")5J!7_Z-S0X&DA_8-21K%4:]R)8ZG4"6'<N9H-64K9I2<0)%"ZA-(C
M2RE5J>T9B@=W<DNO0>R(8%:?'][62."[=+W&SXUZ;ZJ?GU_^46-\>.:.D ]D
M1]1GHL;#LA^U?2V[I#\$VNQFO ;TT@(@&M'I%5X/Y&\]N<F1%0'\9QJ7P"Y"
MQGP/H9MOF S:/T "KP\^X]K]J\XV944V_W+7B\L<5&!^VI19?#'0B 0TFW9!
M<H9'@);\K7_6T#(M$9E-LXB0XA%'QF,"Q.D1^;\>F;_@7P#B=-0X.]?X6UV<
M?Q60#[\JP%#_HT\MZT51_A87J8.R4 WH2-!LV8RV%-3Y Q54QJ:;+JB+N;9B
M,601=-(:#WYG-W_9']!S<A[0YKGLT0VN=JYU-R0PGW:6$85"L?.G^X$R87NK
M5Q$7&M>^<B@^XBTX23V#@\T6C^QI1#ZY8T%:'QK&#.%*V7J$0KS-Z%  S5'1
MNI0#=(1FII9UYF\RXG1\V4=I7%N>A-\%5$0H/!"TE?7A^]Z!$:LN_W<.*!J[
MP/L>FN,ZZI>/MV*7YBHQI[!AMBL_]^@/5!"<$E\I$(UL9#)>5RV"?E[OT#@8
MM8DS3J#^WB_5HH@#BU6!0B2TSM1*KE^9\.PL7[J9-*YC?AHK;(:7B!WOIF06
MG('T8 '">0Z4D_V%!7:"K=2UD' ;.3R!D,_8W#D8,:V?Z6SO8/MCQQ4J%JU3
MI$0I=2:3W$"OTH4ZS".!!9[]RLSBC=%:WKA\D^^67GL4[I"O5,&IG0(O)/%V
MA6*_(@'+B6C^N.)'G$R</I,XC$N'9IRC0;=J]Q7?Q+XYEJP3I]1*[B*^>SO\
MI/]%]/;Z??K9S$40N5TC0<V(L)-(^^PUKY[8(K65E=C2MGN_^VQYR=4S>-^=
M+D]IC?NP9 WM/ 5E&8N<E_QOJ4+<QW 8$C^!04_E][[MC+6.P6:FY'W"9JUO
MAY**+>O#AKX*TS)B&-OUN><ZZL,<WA0,MG(;/IR@QN$/CD&%-YE7&##8CV1'
MN+\TI\]M-5&M"K))I2=O,<C[J7:8RV^B30<)]BU*3L@PR2UL<GQVM-N^VNPR
M5;8ZPL!$&_&+72SQ;W>=[5D@P&G;9>C3T."#<DS%-E1Y*;I\HO/J*JPGR >Y
M&#A>C*QYT$S'/_IPV4/)]5W\F!F!<9]>;)\BP&:6X?*>JD;%.<*V462[8S-E
M(C'BX8[$EWA!,R49RHD,ZLH4A<+K]SQ2@YX=%[UPY^M/?E[MCL/P2E4>5B=F
M;LL0-)JDC8<EV(%GGXE$8%?V\&U]U4"5CD<PM@JU"==W069-=Y/9#\ +B[$D
MCF;4,(@&@;T>K$]08OJ'9)3"$WB(H7LZI/U,\/MD>L-"J'33VUUNGG3%:+"E
M'D>@&T8P=*C!4FX0[$' 0" "=0TG#K(5MV%92CA+ >8][E'[P$W>]6#'YC6D
M"KXIL3(I?&SIA9:0BC%.LQ% L$C;1.;C?_GP1(PYN=]N'^]=-=4Q^^A7&2HD
MT(F!6N%*UT%')(8@PBOKSW9FE)<,N: E$]^=2ZF/M*%1;E\4'8"U>OU%$+']
M+-NWP0I:+LG"$J?>3%M,T@?/YW>UHG@4L\XZC&/;--<:[PYE?4M9=W?BQN%4
MV@JRP=D@HG/M=V0WVF=+H&S3('*,]8X6&N]\-&M\>G@KH!IJ[A"466)XUM-A
M1A?ZZ)X[_:MH=ZDI:EU]KNMYHKV80 --',M%*(G\0C2V\2G>4,)R<Q0AP\,;
M +P23;K6LSCVID_O[)DSW&CLGM"X$_R= D&M4AVM':N!Z*RSX@P4KM_(!.I\
M6P0:NXT$,O'@PH%E/J!F2N^G:;P443-6UM@/G7BV7\Z! >])[PB/:.>A%5.V
M"\G7P?@"Y-;/@L<< ===DXPK]HO2J]LT09 3_WL5TQOH(V.6SV^$+Q%,0#$:
M%#W=';\$:*J"&0Q*[KQ^_,Y,S5GN=G?E@,$+C;OGEE5TS4@@7B,+"8S;@=@_
M$QF-!FAEG07"U;2OF7RQ=47*RQBJ-948CJ(7TTB<MGAE*YCYYCKO5'GJ/>UW
M_<X4D)^QV"YY5*(RN3.F? 8I5@-KD#>E/0_O]P_'_?2B!D\#(Y,QN,2-0!A"
MA.&3<O*=1I+*D]D__V7=_2?L+(3-*(D[7"=?2AMZ;O-#1@<IUNCER?SERJJI
M<$KX!V($#:H8^"LSM(86ATJW4JAW)B==9*BK!'FGBZUX!0\]I=RD-WN7AN\]
M2T"0#>LI5C>D8VF-4WW-2)9-=&+[=)U,U%K]T96[BD?J=0WO8)7,&5/0+;19
MT[/=5A$R$SGW+RQN4SU+W>DZ2030^Y1QWY>L/([)@UR(U_GL"HM5 TG7=S*3
MG)6>GV"4!):E$[Q ,(:PC\HP=>X7R:P^CLMX?_Z142[X7%_865>*?('K$V0F
M[_L7\9KNY?MSZ2""8;0-/^^H>MDB,^-)@PTNX1_-EC2XTV15XOV*/0-[KA<1
M,Z7"J"Q/;3A(T%[0OKQ5S%C?T/I5N)Y3C&O<=R:2"\*1]2=_6QGUK.>N IH6
MKHK4RWF1 'P9"1 MWR<>_-N::;-A=/(QNXO.^U1&54F4XV#BFRS@D$VM/,FY
MZ,3J9:]E2"'#/GC,!8%4U!^RO5 I?0\7HY:*BR@)<%Q8MB#,[!23K4E  F^+
M3H1=G/5/\=,EI^>ROF6TI3SR(C$77KQ.T1__AFDAZD='2#1&[G:!F%*K\"^J
M>:29)]!&-@S_O)(+2_'Z>I[LUG>KTT;U#7/*G<=N')XL).\4%+$S-/FR(CC0
MOBG%*0PI;;QY62Y(!^!HJQF@,K#8GRO>:!H2"%9&"">4H/RZX>=JF]-T@59*
M7++%1BJ\..55%N;0_TF9><W\3.E(]H+ ?N[L5@9<\8K%C_$:NV+W"D]COS2]
MH*1IJQ/$'SN:8?G'_;(O!1A[&8T"8S-!"\P#J-Q-.!\TKPV*9MR+6P,=T<":
M]N[*MC?Z9<6BAN,+M#^1"?L=3"%0B^+/?,M1'0DTYR !FO.-"-GRVU??C_/'
M+R@1I-)$B% C;P06^]D@$KC!\!H)/ !+(@'TA"O'U2\<B-[7ASA_'61@_3[A
MFX&7M>WIZCMC=Q'"BI?>BB@HX%@$)OO9V!LMQ1,KV0\R%9<,<]=UV2A0>AVH
MF<BN[! SJ,G7N"Q1B&\@A!=O:5U_)%HA LMTH%)VYS4D<$1>AD+_"H5>MLH#
M=($WCLI7'H*B?<)N@6SDSD,W-<JVD<!4K>PUUG/0WFW9]MCM&49$2*7L&7$&
MW$PY^\Q?=VS2&L83<(B+K3'+"1?OF&4>&&$MKW;<MV"6M1<XES%D"CAOEY9
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M3V:2)R7YNHV/1#FR(@[4OV9%< #_K)42C#4M6?P,CCOFUS?':O3#-^<.^!U
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M2./UPWV"^BXA";W"6P7>S+GUP>\O0G#(C\AO@?X?]MXZ+.IM[1O_$H)!J("
ME H"@H"4T@,B+0S=H0)2TIT#**!(IX0,W2'=W=T@W5U#US#SCGMO/=M]]C[G
M/,_U>YYSWO?Z71?SSV*M>]VQXK[7NC_K:]1[*OM-65@[$KO\\&G;96C69 ?6
MU+XP8PD_FXC0G_2A%A;A2R^060GE_P.GH)_'I.LU$:IQ:X3L6>:VR^$?Z-#_
M06BB Z9?6!%>SRK?K_V]19-^;T25TGZQHU@D$(;J/N[N[RU*_WLK$FT=R%VD
M@9;P,W-7WO]LT9^LZ.SZH]/YGRP:^/L!ICWS0PX'G_\&:PR(X#D*L'R-:EIQ
MW,"-KI!N4DW\-X><FX3R$?IR6?=?9C\TSV)45=4PBK <'V^Y24..MW@&55#9
M BTL@7YY! .ZNP<-W,OC+ID:&PCWYZ%/#/K+I H'LVHD0'TK#;5OHG:6U=?5
M'7]("5!5&:/$@L"YG.+>_KR?'D$^0O<8U%%1S!YD]::*G\K $A*HY]T%D<AI
M$?OD5-WGC,V;9Y+9&["DI5:E?GAU(:/AB<NH5-Z)1ET-1=DY!2(_H]FA[[2_
MM=1-B 9/^1Y/QHYZ+\%EJ? TR%-JB6(;QV8BA]7H"K6+3"W:,R[T;3;.2B^,
M4:X6QE>=C1''$/Q#7%NWP?MP8B-,V18AE<G^@$_M(.Y55T8)I7=*$_>%2G6C
M$K.UOFJO;6<X&UB^Z6++XM"_0CE&I%TDS2]W5T3KMD#Z&\0(QT2C::E][!W3
M3X=3?J\2B@LJ:B,["DNBYY\;Z+%&<IU=U>PLVVRCSR&39E;('5L;A?6:#8+)
MS7*]R+%>L'N"4FSW'-@E"W9M1MCX]M2S@S0:"DJD.AD*79HM[-S]+!Z!,>X5
M9&A?GTP?#"OA0_BN<_JSM7:4!US3-7(V-2S-H6P-/-;W_+3H/]4ASD;R\CV#
M$QYC9%::/"=17PHQ<3K**4NX*T(HBX;Z8??5_,'+\)H[JOF6]R0U1G[)K?76
M@.H*V27#[2'02GCMQ8')4J;+F\.D F8YQ6-CJOV.&<09A]EO_S/&TDS,^%[1
M<"H=TLL(.5_MN]3!$+<EC'#40 (SHO[C/O"]4B10XP_\_Y5_JIS=67MR"FD\
M53POQC]=,D<"KK>3+,RJCJ:#L1:X=-<$KXD(QP1NMYY&LUM>?$4"[(($<K++
M"^?YB-=^DQ [4%<?YI B=QEB$Q*5](1J*G"? XV3",\,5$FU;-C=>JP+[P:D
M_RF%X4)5TE](Y/#_QRE(X/SB*1*HOL U&!HU=5["W6W VNXRCOM50G1C!O)?
M9.C_54(@VM?G5RV\_D5 =]K$A%^U\*M\\5?2TZU_U8+HOTB!,QLR].1\ID\I
MNJO(9(9^,^#F$WM=A1_\HR\1@>T2D !?#A+821+](8'[G\V4_]G:X?]EN__7
M1X[B;WM!IN,O#3-,NT?C*F_>FUQXZ$J/8>R;5HD*;N*4D<!Q?]+?.!<DIL]T
M_C&ZGWSG',WJWU:?L=%VYY2D&'1V'HD$A#DW)WZTWO4WMS]")%4!,\:17&N?
M6[[D%?#A(($3BT/^:_,K<-^(VD,X] PS?(%H$Q62_R$9,:43"7C:S[L]RGN^
M6QR+&K_$11J&M-<[1H*)@M)-RR*$8RGQ9;RK>HI8#KM5%(?GA\W-M:7:E.0?
M/&4@O-KL_=AC,L[$>"B%NT4J!0G<O,L1"FX[<L7;I6H^2XV0R;-GJKJCJ:4M
MR><I,\D@6B87!.85$Q[E;#KA69#WF6TI?!RALY5EU4PJL.<G4A9H4?G^3!EM
M=^<C3@;=T62YX%,/'%6XZ"152_K7DU"-@<WDHB]#<>.D!N?"V9;QG8OD*^88
M2^1XK"VLFG+U0Q(Y/&Y8VU5F=K<G][7@Y%\JAO5#-.JM$J\8@'@]FVS7K<I7
M:M@5NP/=E;?;.:;4C[:7\NX(X^P^$A6^Y]/.ZG$LL:-9DI>[?G;>-)Z;<+_/
MAY:#(3/3U2(>YWQ87(LZ2EW\7;K 'H%?8)XNPC'W_<L5DFK3+#N=8/+=L!!X
MK_1(,818 RY;5C"@:Y1P:YTIAV8>6]J]\$80UQN_11N,\4"\CZ[L<XA*2[9I
MC4FF_5;[B\#2'A\<K"&:("(KQ_:Z=JSRVA-5];J"\]O=CWP,PD#.^YMKGT^F
M:B^R%RZB$Y(<XLSQ(W@4F<PT3=](JK*=!0EA@8_R X], L<4%Y<6M_8/>4ZI
MN]ULCS][USI3#$WCZNIFB+%,W-O+M<5^U\ZA1MHFQA2[M9Z4EY'IQC*:R\'R
M_KB7T.2A.2%.V^3U#K;L-&P<-@MQZM @,:+NJ9,XDPMU"OGM6W%[Z)CR?%4,
M;X.>>A0).'N47D3G9)N8YDQ).-H#SJUR5+$:5/2KDNY8.Y8>B%ZG"L64;B+Z
M2I.38/D'(L6<QQ\AN=4]49104S-8TSU52J-EM=>&BDNO<-+=[_ =T,Q:NU_2
MZQ=QLD@C87PV%Q9;B@HJLX-^._/ 6-7!@[3E):-<JS#0&9!=C=&JKO*^V/&@
M4SPW*8[00, J'0<-6,!Q7"[F^\,IA:Y@&:*A''SS^G/EL^2(?=/M )^\)1TF
MA06#'(K@]0@$ST!NE;H+-Z&*Z*;X;M1CELAP^=;/8YMB,L6#*A\=E$?$JUSG
MG,O+HQ$CSAF7*=2J]N'YRC:4 K@G/GR0Y#;N,S%9]@%SN(A1VL:X6^!#Z^)F
MF"[!/<^WE&G<<(^TYOEK9%&VXCE\$QD<_><'7FQ2\)E[9Z6=@T,><67[GX+U
M1FJHJ/VR5%\$RLHGP! ^:74NM@P:IB%UFD)O[$NW^[+?4CC.XLD88@P7;<QL
M7;N<B^BV-EU&=XGY="1>M;!,D<78%,<ZP/<P^.,IC6,RJ?A=V1ZQY[-!P%EP
M++D!48>A&_60#0OZZK67<^<YBM*$*5V7:NU]N'IN5*Q,I-!^M"2::8[Y^%E^
M9O-8P0C6;H1:)9P>LR;HDV(L4W&MXD_'XR4UNCWIKY+=$]';:[:(_40GFZL2
M^.E%D)A >6[ %PHX/]5'6L.1X:JG3 6*5--L[A;\3W01ETHI\K6=4]=D'=[6
M\Y1^9-E.XQDR?=@WF=V5BD$RF9G$11E7Y_?*G9\!"30I1[M5IZWNM?)JZF"Q
MLM'3LZY;0]MNC^9151BY2&2=D*SCWW&.L2-@8Q6UN((=[/D$K8=?6FTP#7+5
M1("C8,#^?G5*>IDG[:OUP"+KWO.9 "PG6>RL?NTGULE"J2X"A;NV.5,=&RD#
M!I7L^4;7'E\-DKE<OS)*OEP$*C"M N]*.AS2?ZH;U[/NO%IY1_?=[.Q;=U6J
M.EGL1-I"7>9RVD#RRIU[/CWAP#QK"YNKS.;"X*#?JDK$J@#9P(N3TLP)L=<W
MR4ATX\8P2FZT^:WD\>7/[FI->\U-@/&9YL<E>"\RK7E/L_%(SE[@T:/[?*BR
M3'607[_FO,J\Z!A4\>F&.$!N'4&D(7CBG^P0J!PH75A2(_%9[>WS]\0>H?T?
M+ABOM5H:*\ %87 GD2:[XRV<N.<%?IG0&.[9HUY=+7R?AWQ&IAE%<7>&-W,W
MX068%O&XM=38%^J[?L?Q.!$GC7-+KU)[%687+A0A<"UCB5T"$>FK,ZJ*%2$C
M:E4^8[>WO79CN9A:*:-RR>H?4W*4]^N'-IY5AZ= QS5)E@4UW+# 9R4+:4ZU
M<]5L_ 9UE'?[JJ GG^JMMF@\WF87XBEF4& IF%.4[_@"!TS.3;<$*/HG%*J8
M8=Y*2N_0>\#/]3P&Z?*$P)6C;VRV'D\C+J9''G0P^#Q59<?QNFO]]DPE8FT\
MZ63 _(HA.%+JT>L:W+Y3QVO03#](W?I.TT<0(3T[.$.]).@X_Z,ANO_J5UX)
M7H'J;L"IFLAG+D;G^OA85\V]VM*J,K;7CST$KY:M6F3-<);_?13W6@L)M'8B
MJ#J*-GY+7U=$P_VKD._-*-,?T\ZZ'A-,I.Z8D SG;$YEN[**N/2*V$+TD0 $
MAMH@=0_SJ-=\&9>=Z!&="%1XBP0P!8H7?ZU%-0:9@8-F?4:J E/I\Z)6D\Y9
M4#&L#_SZV6CP03/1/C_A#S)4ZGL"GQ)K#!(#-VMW$%0PX0UML?[CF77BBYU5
M$X$J=%]0 1*H/8'4X^<X4B(!$8=+/[7E1_C"KO[$@?,%T2RAW$7D!1)H1%QV
M-6D[/F.LH_\]!SL'*NYR8D<ZQT@ _^0N2HR9U3S@I_Z/0.MDJ/X9NO\5600>
MZ'GJ1= 9+HKBY*9=$E\5^E[CQH5)VYFR[T(5\8+XX:IRQV$X)XU._">\A9DA
M-^J)_+S'*=P*D0]1 :J$%LH":F'?#]5U_RJKX[O;EF[\6SZ_+-;G?P2-^!^(
MXDDK$U=+CIV8"[-FVA_:5;B02K]CB6*T^!B"[X)Q2)22<W)K0Q26$I>I+$%K
MA3NP+?C%NTX6RZHIOT4,-1L*&UTH1H:=<N BB)BDU@WU,^^X\3Q/^%VK D=E
M904/1ZN"3+*79;2;H?78>^D9ZL;V-9&ELXHOB2DJR'-F/*O$=%-K$JQ3VB+:
M8J9*,_1UY..W279:*3;4=^J((V^__FB=,*&IQ3^5![72"R:BYM($9'@6=T,<
M<N>*5@I"FXYVC4I@8I:OMLPMCD6=LQH+<:38;WTM%WK;!W5J&.;CS39!4,!T
MCO3<R4ST[!4>"9.92A?,'DZ\'0R.XQF1(N7FS-2)F+)]T.\+SJ@?/[%6K1Y.
M&9@=7#9I^W!35)",=1T,.-UT7* PD9*"^??"[Q^ITY9B'M6XS4NR+;HG+VD$
M.5(>KK)DK#G5E,]7/QZ99MSX<,>7&BC;<QM1TK"Z@FT92]7ZA5.2.YJ*^$1,
M(E2Z*#]D2+(34V7+FN9R/U7P7A+I CFT<DUQ-YQB."=MK?;@7;J([;J%I8."
MPM"AO\R@6$'$/"-OU,OIKLQ'N8KZ 5B6XYET/L5&G!$#MQITW7QP\7B<5U)G
M7!;BBE<CC$RS#'D0D;>"HG.ZU*>:0E5C&M_H80G[3/)XU-4C=KYD>*='UC ,
MV]0>,/*K'83J8\*T.>II.E]>*\C NX)- K+/%7V0K2]B:UJ;Y9,?:.W]L7X\
M/*XZ575#.61"V)&MM9I"P].Q$<?O_#8+'[4SR/>0B?I92=S:PZ^X/1V/KK[=
M9ZWKI=O+J:2XIMSW&N9:DI6>_9(%"=BGF&.V2!E .H,:=ZS 9%]XHE?WS2&6
M"TQW5%.3[(X_/,A_(CK9%4.]NM#WMG76:2""P6B*X^#4_,+VDB23ZKXM+*[L
MK-,(O=YKKW69)&I(WU68P%/ .T-]C7BT0FLDQ?RR,Z^FX\".7"D_%QT=+$\I
M?YCZ;6N%0(PM[F>_B!%\P)MQI(Q>XZ7X5!0QKA<7*7=O60\1U"</_@36VE02
M'=)*47_U*8WOBN$=K%D8/E<OW^UBO_!BJ;1EEA<5Y,VEGG 1QU3F!/.4CJ,N
MKR%OV2[46"U;*<'FS\2E:C@;J;[6G:K*MWNWWJKC(U10U0]!P768]W3HH%I,
M?9<B\ .'J3(C$P,_5T+5=%E)G6E]$-02^MS:[^I'4=\9-9AVC+YI6FONY-?I
M\EB($7_YA\YR@HCS+GP:<H/0 ._0%G#$&20"M>8TQA^Q5@>(B<*Z[-4A'VB&
M1+J(U:6SGN>C$Z]<;<6YS.>2E,J0FY]8;Q"_6E$=&])N[GI#S:7+;5O_O,Z"
MBV_A8K ]=RZO)8FEZ4I5I6*P31ZS@@EW%.G( S1>WUQQ$@J0=WFUA"><K#]\
M3ZV8[=4122AH=#^1<WG%?LIHW6/05_D0WB/@2Y\GOOP')$_+MT/29,A+K34L
MD\9+P[WC:IVYAVX":Q-^EI.4Q85SO:=$!]"S/1\D($C$V9*?,JZ5D]*38H#;
MJ?N&329SA?_1E5[.WZ[/2#?F^/DY_1D5Q#[K#S(ANM&QR*Z:,N[C&'#I]OFV
M0^=2_5DKA>PSFDUMEL6* U9N8"-@FE9B;Y8K8J9D&J453<XW3)2LO=@[TLG6
M0KNIURML[!A=CH^R7L_8S78ELD]X]S!@Z:6]+3K9/C )YARYN,?" *A9-)*<
MUFB#!XE(8:)QG/R21XS=3V^D)^4T5UFC$1#+IY0$CX:(2M0+Q"IW\93$6-N-
M!!G?"IE,[Q0F[^AA78]?#ME1'7S(?&MZ7ZZH-*I./\!HF-2#"Q/=>N@V8.:?
M7)^P=NO,M+ -5G=9.<RSE2;. MA94T/0P.R"Y\/]9EKO@:^/AS;4:S);!PAA
MN@JUR+"&:A#;CT2[4+IN#=WJ-S"/XO @%HCB:,SXR@P].JHIN:7:.XZ3M738
M.MW#LRM(4D,&$_"?,Z*);K\?,;?'=^Z-4^]P*@H EFM0IQQKV(9H6<7G$><3
M)C.:FV#=2RV=CJKD>V6].D]9)XBJHI=#[W6U9ZJQU3UY+M)P@^30S(%*797S
M\^/M:<<MEJU<70][R1?A>N./P%P"+>X/-!TTP%#E@4- _\-!T][6_'L/RDE=
M3%T^_*</3.&L+\WSC'EJUO2B$:SD_>**K:7 "QQG>]H"3BT=[1*8.BH.$8\V
M]&]LOTNUNMY$)*+ITHKK!WWJ.*N\61HZX1 P/2XV8^IXS5$7X]B*]@J<%.QR
M,>,$-/G,U7P@W"7@A)=82NH'@B-FBRN>I&L:[/,==[]IG-L0=P%;YF6'QI3/
MWMKT\JXK5PABC84G59O("9*PG\CTZ!#DUE),'19/$^F+TUXCKW?")FDG 72Y
M9NTS#ECPQAT<S6\-2,QL*43-=+^P:!T$+-4/9+'9Y\TQUN(8*SSGSYS+I@GI
M$[%E+]/Q+4DK]M60&2(H1^X.;3&;QQD*7U+3>YK&H+AR%5]X0\N?$&VE&^;<
MV-7LOYS6WGOV%0F<^*[#07-3H$8>^Z]%!Z8II7PAY)50>4A#<7H\'D089A<Y
M=Z%\+E>P7[518,_XA9&$J<RK#A-G(8/_TILIM?$9T?RI"6'+VU\L"EK(L2CP
M\)WB_HO@1<;>*LB1SE;UDZT:^S%XR3Y?K'F+LX'OP>U%N'3:QLV-:+>$%'6:
MK3=I.Q4>H>M7L"HL0N2R[,Y/2955O/P"+[?.K8PNF/*>*VQ=]FO<HM3NTL7>
MWI\NSP)O4J"<-B/4GR/"1'=S6GNJNN:8>T/[0\JT0ZZ6),U04:?XFQZ7=NH7
MJA:6<(,:7F7:4/,%W)O3&B;2M&,+CNK/.^^%AGJ,M:;8B^95TX[70(T<#Q]9
M]!O-)$B.MV@)UQ&S7?&#ZL=VOJGT<!BRQ:;@:D?MG6FYZWDY#LYBA1ZUD(P*
MG_JUHKE:W)F.8A>FQ*FO$SI2&30FG =><9@MP^2[K>2+,-Y7A7R<<QI3H*:;
M8"?HZDC]R- .MAU8TX#:T^ELQ"SGR8/'"&+;8TB4Y,T"K9Z>:<R2$M_+WM0?
MT.D/@!>*87+:NO8\WSY<@7-ACQ#9 B.J[R.!/EP'+V>W2E3T?83RNK1#4%X7
M5M73ZMC"V>!FWRF44Z8=U?&/\BG^V>_O?,T\/9B*/X'..S7M<&E)SK,K[MO\
M%V+S_%5N'1T+LE4! P.T$8YX1,2U2$"]NK1!^V8I;"IN>8()_O:X4#?MG'$+
MOM'31<$L)>7F(T,J%2,=$():OJ]O_U\ *!T9L&T9V.34H"TAOG7F51NVL?R&
MH9%7DYPRBN]5IK_RN;'W)W*T(#GQASRL"Y$4,7G5"HD5]Y_&?E[TDJF6-.[7
M[]W2&(SMPG,T;4NSMK-N9095.1['KY>F\:9.Q6E8/9B<BMWM#-RA=%W_3 12
M2H*G0K7RX#.>B-JTR<J+/(@GSBEV1,>#R9D9/A1#6Y2NJ[>+8;T[^Y4_%:Z'
M$[HJ!^[YC)H@@2>SM7EKQ\R?U4_\.,X]%KU%>&/.5P)T+I)ZJS%4:DDO$-:=
M^H3;YCMQW)"C0(%#25^!++%3X8UB)! #TQD].(\4S7&Y(N#V4ZT#B(G.B[<"
M0DL%OO9/CGO):\_%H$XI(E0H?A,.QY% ]PG+QIEK9]+?TS^ CI=6+;^PLAI#
M\5$8QVUYL="+TE!@9C]"]FP+L@PG/KP06!H9SHO9 5>63Z+(&_!9+9RW0IW(
ME&M>>D,MUNWOQ99^+_O[+M.4:ZAQ!68=>8-EEA&G"Y%(P'!_1\'D]F1T3FJX
MWI?+3#:KDEXW;[%UM++<G;4]6"'EBQW1)USP22.V\5MYGR&G+C,G0JB\3/>'
MZRUMRWBCLUL9<[TWM1W",B=S]EU39W/UWZ%7VL7>9+-ZQ'.0)_:3WY$"F0W$
M,W;Z4%LUL!"R]/YA_93PC<GT.U1-UM\/O]K6-TRR'1HF) :9#DING5F S&OM
MRI1\_$B&2EI>X%F-]5JW\G6!]L2*16Z:*PW#LKE(&FPHO)QZ,N9P,=2BKY@?
M?$UV(*31EZ(EM*%Z0(KQA:/W1)@/=/'9,LV?CRFE*]'HKIKF \O)ES4Z\77I
MI,WKT5H!_O,[F!"#\68SS3?!2;*I,H3Z[]<=^>+*TP\T<*F4P22]\]*>\[RI
M^Z]?X 2)LGM&80:\P[&M(Q]-U#+DT5]:\I]J+CG=Q#.-Z7I9F/;"P@FO/-,I
MS1/.FSUS48$$G@=HA  &>&N5%&R$[N#R(XITC+>C+TUZ24Z<&J5X7(<]O[YN
MMB4VNA,$KULAO?\%&[M/\0G*.0Z?!=UJYM^.9.!OPF$J6I.Z7W@:SQ-.O82X
M$7CDFC5P",8U'.\.NV5_YB(O9-Y$7PY^J$LB7W;G!1XV.;ZD/]^#A-8$B<34
MN ]I'<(2-PO1%Z_71?3,6V&[?5T3) _(GW,5 /N<F:9\[HE)F90Z<GP>>4E7
M(^*JFPJ_*KPI %\R9VZR<7ZLR%6G,<+I=9+SZUFIM#9E]EOX6(^:'<<=9P\6
M8D?CIU8K;!%A')U9SZ*[%>^UG/(*DI#P"V'46"O9Z%Q=C:.,4+.IQ/244#$1
M.+)KC7\H@?'5MNX@_FI[JG36">,YY6)Q3MT[#?%E-E$%# MR/7*]%\=9*M<E
M[.<_<O.5J#Y\:<]&=(>]AA!PGL6BHTPL^1<^1_3CLT0_ (CJME'V2("*Y03"
M 'C_1?6K/$/FS%[I8K?9*R?$,S/9)!@L@+R[?\QBV HOU')PT4RG#:GN,I93
MHICX5[([5K\E;41=_"^E@OQOIQ0M5?'GI'<:GKE3'O4B"&=^2JQ  JZ(!,@T
MPKMP]?^=#*!_D34)%_Z<+QVK9QZ4(RB]U/ZD[.J]U@MA2/7%);7_3ZQS4L6:
M)\4@6L%_\E#PTM:8X%G(HTNNEWY):E&D4@JTCH%%OLN!/S$H+^F$W+G8_+J&
MZ#B'\*S1)U:=]BA$<I3RZ!(1?<LF%6SX;3+@&/]5TEWT($) 81>AA/LW,!8P
M^%>YH/_&?%!G&)Q8K%%=3F,@\\U\PZG@PB)1TI%S[RD2 !VO&>/_=%^C@W.R
M/=/$,WP4=E2K7U;*M+2L-2^;ADV.0^E#C@C_+;REP!_; :W D<!,2M+F,70?
M =D9&-'Q@<M6+%845'\IEN:92S PLL?" #T1"H@[3-//-G+R\Z<(2#&PO>??
M]44F5_#P#F4X!O'WMOT_N#$*S%ECG;[X<"AUO_(A09O)._RR S+KV-@ AN:I
MI9QW6,Z=GTSG,#%H!C!EP>7QEVMZ'5'-5A 73%0&54@ NH\$W")B*\(_?G6M
M9C$=[T)WZ[NO0(E6SUL84*4H9Q(MW=QD!UN/D ??Z7@6>5G-FST(K7TA&H#\
MB3A<NZY%;@Q#-LY%OB-D]/+*E1$6F1,ELR_<L:</<^HAKT= 9AIEN*E3TPY!
MC@Z'4X.$:%1_3V5@S#C:+679U1,QLM'9@O(9]5W+>]C?MEA &+)=I.,9LBBL
MI:_.V,24P2#J0/X/+1B>\W\C!#T_*#H])"/3$*DLJRKU'ONB;'1?23CNTRO+
M;I''Q2D:51D":?H$#6CAVG.*\5SUW'P&U*2'A,!.X33D&Z%:*;$?'&7H5A5'
M]VX%:S8<54J==MYY4&3+6_$JJSG7B.#3,YX<OSCK3_-C%CY=+_TR9_=$Q3"&
M9#$0?Z;;#[:FCZ\-%<3(%@6LM5W!Z$J8X'^4O+C\V3E#=2T]S]79W#C (H<O
MTQTJ%"J(^S<I7.-0ZNB].%/O'H6#S9-.7DE;#;\:NBN?X)+A/=II.N=._1:>
M]6H 4JPF9%EJ'G.[9G*%E+09$/X3C11;^0)I__9R8_\FA0]?.7L66GF!+0VE
MOVVI:4O=2( ?">S6BT4^@1\C@=9+TB* \+^I5!WR-].E2]P3(9.@SKR'WM5E
M 5!(<.K^'F\[3-^^^6Y<(_3BNZ4$?IA?Z)\@?CDN8L^QV;;!?Z8T[-]#Y9-^
M OANKGSECK2"_,E@30?]-4@YT$"@OJORO\6F,_<1GOXD].\7'6/\OT3W)XWU
M?K%F7D0"?]-CX ^.9?^(9OZ9;\H>U[=1]M?*F"/NJ,.^3 UVHF><6D-Z(7 +
MQ<BXN_VWKQ.K#K9/C2^!6M+_"//G_T6CZGO+2" ."9S,)G7&()Q1'IQGYC]\
M$.#7'ID<?^U%[L<P4(+\%23Y5W5&5)77KM0BN.A_=)A9^Q?/"8@50E\L:W5J
M:\[LSR !<L+?^E+2^2NL]:\:7,IC-C_=00(!5_E^[8HA[Z=*/X&P?QT9H]]'
M-.7WOC2T)K1%]8K+?&VP+R5:- I$$7%*21NV2!M=&GPF.4U$5N'X8NCWEH)^
M?Y5J !WZ]VOS< ?]OZ$8 ^.[*0._:R3:%_#Y7R],*?6UYO$J'W=<><&?\>.F
M#O//![H**B2 _*?_HTI7 ]/D[/WKR89US1)6Z*?1\M%_$]P& A[8KNG..OGX
MO/?(.S2CRAWM\RX2N [GN7BB\L7A]X_ \4KW%4W=-5-N^?JL5)Z4]M)8:?ZZ
MVRL(PZDQE(S?<#/P_L!AC!+,_*/Y<N&3&UK3N5]OB\I%TO@WBW-1U/$M4*PO
M0W4?Q^Q2-\;I&N5+\>%TFZ>)%'"-ZJ*%'L<&L4<@E%8CIJ_WO3G8Z!; Y;XU
ML!\US]Q%-DC*IUO"&C!,%.D!YT[3U-!4-_I(.-*CYRL2?HQN&?MYYM%"0MO&
MNC&68_A(*'.@KK/=$0_+^P-V*_WH(^ZZ*#;!B65&+,Q%<MQ&J-.J^5+)*!]D
M[OWAY6,CZ[6&^>EK;\O517$LQLY;O39&,48J8@+1'+0W9$W6BMX_WYR;P.MX
M%ZB(;3X:X-BKWC]<A,NH62QE*MG!/>^WA,V@L"IZ>>UK'_:GJ>3']@B^_$%
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M@9P>U:+<#*-O@6E$OQ94-I%ZJ'9.;Q4)[&]!D(#;X"]!WBT95#PC,(I:C[9
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MM5$,,'?S\OJ2&0J)8#9AU=>O&_FO?$".-Q0-A@":QEXDL%P\4@N9U7V[M>3
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MCPIK%<CXS7.T/KM@C<LR-T,+%*7U1%1;F]7,Y9TK:4.K9T)/ONKR<MU4:>F
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M1 .\BG^Y<.BG1PUUHHDM)C S L*R^0%R=HJ"6Z,!7Z4P0'V;X#F6[[?T_/%
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M6PK!V85R(^@>^+%/K&?N8JG^RXTC>*%"3DDQ)H ;#M'KNNI_7&.9#=<"KWY
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M&0Z[50YW"UMUK1W]&:Y6P?W1/*L$_=["5\85ZIU%*Z[\ZE0K-:\M\C9T(FI
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MY"@<4V/33SN41#&GC%/7%9402]Y3]O0[ \S16>:]F^#=E6J785<Z1<AHM8$
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MQ2RVA'$+:B(0XDC 3E'+]CEH_9KZ@HKO5)3O0HP08?I8RAD)^!/95Z!V7"1
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MW"XOU\+KN8[_;J,8A9V26%7+%#=ZAUV+2ZKWYG9PJ?SN'*0%Q'%$!WU#1\Y
M26S2=&OR3T/@-P'7])>Q4>I/?1D2L3[$V]RTPK4=?3RN0F'-2DU6-9'0F(PY
M\RD<D"MVIK;](.=%KPT&"24BA\/9BT/] 'UN;3[!Z73T16 X!6M%Y:>CIP_
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MDQY-U_H5%]C\:BY%X8Q.GA57B$YY9A;LD[Y-Z_V1@0[+16FQM9W@P+Z?*R@
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M@BA]J%4_R04N4D<;*N]B2V[?Z_1;*%(^5,<"]:SE@2:6S2_N5Y0M"5^!R5#
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M)+GZJ\J9_-[_B&)]TGL3C![.,KI_UU./[*L]"'_;44*P&&;E2E64I=M+^RT
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MY 9BI7L)E)9X]T0!%S>#)0KT%C<S-A20:)QS;?';MRWZSCK"7:IX1!F&:RB
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M>9-SK3GIE#O;;^:FT&G0P7D0P U[W[^C>+//O40$*]E6&^O@J3W$%%T]NN/
MYB,R,*OW>=JC1[>CP%A>R_++&,\D04O)MR$SD@I)$S!>K='U?.1&\>65$A9
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M[E".7Y!T[BAY6+>7/B1[=!78:$U:B> AX8ETJ,"K[1X_&=;&_W6WSM%9(Y"
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M;+SQXEID4]>LY3*02YMI'(P[A/=\?"WSTPD2GZPBHED[B5-7%M.\;J>SX>K
M>,?"6KVXC]3TJX</7_^&./YP7"O)9&$Z2;#%Z%0G^1O6 )/&B(3D0@^5^YIA
MA>!)&7_KHM2?<&OJV?=RM1VVXA)FM"6FOFAB!VY\Q;"S^ATJ&V^>UY6#;(IY
MN5!KW?EVTI]]PRJ2@J1KV7S@:_SXN3.)Y!>'UM?#<N>G5 D]#84\B,F\31_\
MVCB=9#6$]9%">176FE2^'MF=DE S4NQ07\$-B4<S8'"1Q07;Z/BH]G&.\3<I
MVD@!)M%\W)301]X;U7Q)F:#6,,/5BSGYR+<''=_Q0XMS-0]0)1X$XJ<;NOAN
MFD@V%N4*/)/G@:H*7;5!=_'G::KSTA.P 66&*IB"-?\J0F_4F6IOJT:V-D7N
M7)X)PY6*VU/E?L:!J.:!'*6TUBO6X@"@&#U+&5W\>.W$4&Q8J<H8[/H\D%4K
MFM50*K2??F!G7:=^H<.+)M/91[&]80'O^<;H[.)%/QAN)?&B9QB]3VC=O? ]
MQ\.SV)>9':)02OY)[U_J#[:?.G'[S\<*SB^)HH5" ?^&E>RK,/ 5BZ$BN'4R
M<7MCX,/17+'.KX''M:YS(D6S$Q5^_62\APM?$#6GY:A-4]7+CBLC2J?+V1FQ
MC2B+^N<(#EOI3^Y95R$'[Q,R%\7/J.I/>FNIW5=][^];;U\G9SV/,,4?X4#]
MZG!HE;%=29#5#I?%\ NO0C&QBLH5Z%D))Q8%61<LZE$\<7H'GVZ6C.[LZA-L
M?] GI3)\U(GB,4]S)Q\I*\Q'^T9_VOU*X-FU)7KDJ8.=C%@>#5Z'_2(51)\\
M["H1J9B="2^Q/#\PF=9;U@2Y+25<#MR9.CNY>BTP%NWF-2[?$Z_G.3-FS_*(
M6]JNU14=.EHW6JL@WI!K"67+@O:\CQ2$;B3@_9";\D<JFS:2KL',IMSHWFB%
M#($AV%BRW9]<H%;Q<:K(@H=W/,RAR"VG*IB79+Y1C;1QK?8KJXP="J)/26+K
MZ,E5^[\:QH5?[4F9VT)R=M&W2]WM7I8&L$Z;)[QU7DW,=BL$]RAJ]IW#O^3G
M>_)7:OV,[ZN(L7/((/PJV4A[W"O#\=$F_@6"#B>[)T>;-U,-R<$_J^'" +[#
M+>)P7QI'&R'*XHU3GG:JLAX[]I@?9DNDZYP2]ICV0#]L3=0>$?X-@-@@3_$M
M/5P^F67#IF/Q9WZ-4<0^4 F]IV'H+M210CRXP6/4GRU]D9BF.WM'4W;)#FGG
M1GN!WX='Q]<OM[!MU6HY!N7K#6KXV,9:2%>-;1RI]572Z/LCQ^->)_+7Y)])
M'E9G3NK/E)*XA',&55T34]F)*3_WY?C;07:(?RSBO+!FD*AM\%/-_"C637\W
M5XC*3@JP'-2'?!0U<%V4J0ZY('T:]4PKHEL-G8F>L$NLL:#3"Y*C[];&FS,/
MOR2<.6=Y(CVK)=CG:GJ4@O?R+XBM2]%G5)E /)"\1E_F<3R=Z</T4#S'7@"L
MJC\2%V2SX^4,2:VUP])S\VJURW8',:@G0/"W#=AN[90.-<,(PZ"7B'..'KTM
M[Q.78#1FAT;'CV(6Z(8A:\]&^*:2L2Q/+Q03R]J.F].[*!)HU3*BN%OJ1<9>
MQ8<PV0=TT'K\@=3RN\$\VHHXZ^AVK=C^^WZU&CE#T@)?LZ [T[M4G5175K63
M:6>7';IL?6%9TR^)O_GML&=*X XT_93M7+J+"PFIKJG#4HM;S(R%QTX@%LNX
M:J?& EKV0]<JMPT2 ??1L!O@6:G^#5#$A4K+FR-Y$MYN0*%5+A5^SLY)=9_,
MMXGLN(D&)J(V5&N<[24Q[-R+)_=Q521H])GEBF*&]>O].B4'^-'>7(B75J'V
M[%DN6\'65KS'9&-31<*G\0I]["@/)R*T:7WPI-2W>L75?%-;3N#[:N4KXV03
M1_VU4"\^,YC.#-CUL=KT2]OL&CV)B$O8E/9Y@O,V E%G996$N7=2YG,Z&9"\
MIE^)EMP7Z0 TSG,2.ZHC2A? O?SM[.6V=_%W;H"W>:'11\M0H.4/R0">$D=<
M'D#6WR?N\UR_HGJY27,=4 9N]-#8"5N@T*-Z0?-\E=^AJY*?NS5<DBY3I$/8
M;+5X@:*'XH'7YH^''Q2;' /O'LA2W0,4%Z;<;%"$F9+V! I8XZT%X55W/U#E
M]WG1[^+YU]IFLQ!:VT215LV;Z=,,2EE--+3V6#/CL..0-S]8]'\K]RO$ "#%
MN?X9>DWC#[84QTY^M<>>G\WR)5'I@@S;7PG-(>/>W:4(1Z0%>L">U^&9)-S;
M0<8T YF:4BV6;K>%!O+%N+XHC%[HPC#<][O[R(;[P0W@(3\VB'K&UM$BBP+E
MOZ"M9&%0H^GQWNJ>P*#J>+G]1IS\S$A[;V]D3!W^Z'R1"Y\@WZ8==<1 ):,+
M+*,HEECFL-8?FXC=63P9VWXN4ZW%&"2K"D_\;.XW5^<T>[^D=A2EY;K$!)N'
MEU6&9JA*T9KT-M(O;?39.7AH%K7,X<YN4)/7(8[C^4+[[;9,S+6P_8D<X9'C
M(QS8;K9Z>Q%?;&#;QN (O!G*W<,WI!&F\(1E)T'*4!HKX(CYW_L\]I<K"KK$
MR=[7=9"9ZRQ?EO_,=5"GCS0)2ZQF[!4O=7;G>OB*YS AN05U'=,? MMB[,XV
M,6?7+I<"8S94@7]42;A1EQ4-I54$2=I$^@TX'N=:<;I!3)6-@I%S/W@7NFN[
M)_USZV]=7/3//,W[]^D$IQ_T;QK:6R_$#&?;XE0$%2Q?/E(69G0ZEGN12T5_
MO!$=/08]$C,\ .,\7UV=G%3X,8@70V2A7>I$B3NQN6UH#TYSBW\E[ .[BB.*
MGI(?TH<3/$Y:>0?B9 F7[5\('4O%FG*PTMU\.8*!3M3UASN,0F^X.9ON)Q20
MO00DZ$1#R75[^1,'\^7R>>[/R@R5$8)Y" FQTZF74%*VFLI!M-R6UQX0F-^G
MW&O(VB1L(X[&$I$:-V*ODI-G"Z7!+LI^7W$N,L-^*FB'<-I4P&&'%LE<*Q^Q
M#4H1R[C]-[ED?5--L6IMV896^%D;"43^;FN4I\>"J+S3P*.:HR%;IRNE.\%,
MS[2KRUUQ/0B/"[Q?ZL/+]E8*DS-F0= ,6R?LSZZB\\Y\"B_V<7H+\PGG#*?E
M/DAJ'=*;HX=77HS%"&OD23LJN!XB3-<W3.R&&>2C74M*+0N-/#UO@);OCJ\&
ME.G9.=?;M#U#ME"_B31Q>W %K954C])7_?PF1YG"8RR_4$V=X@TA1XPY>U+T
MXXQ/ZO77NY7;&H1R^=,>2 N/22E9=G^#;2[;JYXXI0=E_RHO&?/V(' C;^WR
M%#O$+F IALR"KFS7]*AI2D?>#I=A#+.%M#@I+%<G4!XU,A1?L9#@O.]1W LN
M*ZVRK>CJL=94RTAR[WC+-5IRM.US/:=:$>NY^>.)%L7(ROM[GOO0]DSF,OWE
MV'AP?6)XGF"".#GOVREKJZV1PJ.Q0>)=>-?\R YK:H@<N8"(!E%T1?'2%''=
M@K4:"X7_T$HQEW[W"OE2V'R2[T=0?Z;(F[$MX_U[A;G9W<_/L1VSVO4C6G$A
MC1HWP'8_UI>B;<Z,65/!@RD7R!'E)2)?J \:.C\SMK3**L;,FU^%R"<V'QVU
M/_"^H"P*<CI%. >;N.M:WP"UN'-NGS9W1\OABLQ4Y,2C9:X'Y8?8H%;E0C'O
M!D(-:V<PRPU 6)Z>QQE"1!;\,):,QLE./'M3+^XB[O.QD*9"UZ^"=*S61K0C
M2O5\X=KBK,63D<PS+!P9W#7AO01;B+/<U.K%!>5[6$Y7'E)MIG*J<D'K,D_X
MX<;^E=_\UXV8ZKIVO<K.ZR\7T+7CY*WT7(83G;;"IDK4C(/C:=41#$1B=:(;
MJFFOW;LJ\\BZ\8F^$WH.]7'&4O_6 FD9S<'DFAA3GN%L05;"B>ZN:[Z,B*T]
M6\:F**[:F\L"$2W+!3GZ^!<C[V(F9GY\X:&,/M#",5 .Y/.DP"&_F%V%L.O(
MC=>0KJUT&&N%?HH!.1MLG$?&C*@4[79W][MF=;!)$6FIKO[URYJ_F]OQDP']
M><[+0LO'CT'O ]\41\TGN,O9^3?0.FK//;(NPRJZ;]B6%4QN"J^62?SUX]RW
MH\)FB6_E)'^>348NI/=Z+-TJCXAON6G%8*D(K3BBR5Z?X:=G&W&?$?BDGGBO
M+K'M:@J)J_HT1/:;3=4'.QF&G#4A%/*;H4!EV3 ;6]G5?6\F#@KKVG:S&+DM
M"L :R8B>':U2$G(BPL3!-H14K18D5Z'J$/7O4WYYKE+M'STG%C*K5S;)ONHK
MCQTBN%SH@$%W6(AG> -$]2_< !?'H$LU^(<BWM&SW!S=YS&E*GIO^[U/ D3&
MK+SJC22'';<EJ#(UX<,?BGY][#N8G6]UZ5KN+OIY04F-X]"UE+M[#*ZQII"L
M'+;^$&_=UOPZ]U.?2[[W3B Z+;3]3.YI[U4#\QIX.A\[W,Y5!2-ST-!ZGU!W
MM."XE[IO=%:JS'TDSJPYI^:MUC)=GJ_;VJ=DJ]EAE)%CQO0Z?P54)LX^3VZE
MBV92\@!WA>K%USG/25_A:I;$?8:0A@7J8:<ORL7>Z9?2MBRN\:4]*]+VGY+K
MMH=RY\XFP4;$_0N7!B1Z/3&?1:6%/N[2HW^*]"?M%Q(3=I2@<B9NG$3)5-?#
M:RX9 @K-ZDI8;5(N7WP.UJH_$!*EOG/"5P9>,N"'8-P S3*<413.G6Z5YK.X
M_!%JRLI%@BFX42&+>*U8\;+6N\=&N 83E@+8=UU]'#HEQ+!HR52OI:WF@FL_
MU-]J-Z5]M%;_N%N>5\W7\2L16KB#[ XC>D%:%<4-0&:P0>Z<C_2@D\R9?6U<
M7J*0Z3TC9-Y.]"Y"-_KU?NC0YD8:6%<4JK'550^8ZZA);E0"/$VH''2]-]6#
MOQYS6GV<U7XK%?L.RH9,B7K\\0%]9"/2\V%XA_J@=<%SDB VMFUM3)-+ED;3
MF8%OS \P+L<[,))PS,>5+7'C\V>1]ICVN?(ZNF);O\)):/-G?N9&>&G,@)23
MW#G*<-3HP_4Z6XW>=QH3L22P4/N'KS)4"%)Q2_"O%T1@*=)?DR#>Q7RI\O,Q
M'?&=IVE].UKW[WXN^.,K;TV\,-"RTO -L!EQ3%SWA@\F<&DD4XU S;'T*]:_
MGYER/^I,P6-!%$$6R#])C[SAGXK'"E*^;/I>A-0,$V^= !OBO:<113XSW?Q!
M&C$0LG6,AY9Y P3 MVGGMCR?TRLOK]D)=4[5A*<W6%6Y+]!7C<#!XSN_P%G,
M*1$]?7MU0IT=RY9^[?VNN%6+,+U+(Z419Q9/+<ZIIG?^L:P$ I3XGSJ6^C,M
MUTU;U=VT=!!+(==DZ:!U#I< H8>$IY)B>V)N#!MZ<?6$\9<FWLHR(QD(\RI]
MI;M/I2!>!)S>2#W0_5LGFKIRZ!FW4@6#UR%72^D-X.9A2@G1E7!O[K+.XBN:
M+.!CPU,/;@+OUZMR[<AS45+7$IZ-&2R"NYQM\2T\R V$M0VR$WF:I[P6^LF.
M&C=V-9.;M,;X[3<JDIXF6;,]:*NLD/J ^PEB*!Z36^"FBWCS\9<4:ZPKB> E
M[][Q:]-05TJ\0RBPNLMFNN?Z!6YQ%! K(G)ZD%7&S<.TC#,=W=^;W)RKZP91
MB%X,V_ZBNSK+^'D]R=3N[&7"FIA<85Y'<\GS8FI8/C(*J?6U<%SA57&:YS;5
M!@>*1;2>_GH*<:Q9DC@@PWR.16O'A72;Q],%5L=>?]$\R\^;FA9-PZ/E#:;T
M%VTJ$U>3$>S"V,NGI@EV,@J")D6^&WJ>5'[]UK?J+<4#!YYCOL%)-]NM>O;:
ML?JQFFTN=Q^9N+ &U\2)M9T+US0\G'-QSJJQZ[&:_B"I97>(JS_93/*)M\@
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M;(6(\#<L/*^Y 9+U."X/;X"Q]&L"<,/Y<<D-T'#[$VUI$;==JER<T)U/E-T
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M@1QEDEE35C^[G)1&5"C -!+CD\H#B#(0J06Y6&OY14#:UUZ2F?UO)G.<G8W
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M)+H.JV#\F&R?Q(D+.#;0[7N'@/5VO>.*Y?<Q?<_=,^;746ZES<&&DBER"S?
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MVPWE$U,P'.:E&#\:JZOPSPA9[).VT ZU<XP>J;K #VG>XZVGC>L0WG M=JA
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M,!\-MD&C,U:T=T8_[9=M7#^S"E.$RP Z1SW&F:_%!+AXUHBONK$[M3R089B
M6ZR1KT@C#;%MG-P?_JC$\5.T7U(EU7WOO-Y_(.%SW=!U3ZJ;A*(WI;]-1%_N
M:9 -@!3!/LX5%<FU4'0;A5IGMN)Q+Y\'/BF^ >Z('[<;;CZ^",5O<18_6Q*2
M>I"'0;IU3[.\"MJWPLXV]R[' >9K?SZ&WE0EK=^OM98=N<TZRON_V'L+L+BZ
M)EUT PDDA$"P$)P$MQ#<+00/[AX"!&D:=VLD0&@< @0GN!/<);@$]\;=W1KM
MRS<SOWS_G7]F_IDYY\XY]^-YUO/T:FJMKKU7[5I5>[U5M:VBNK+?09VO<7+=
MYS87-%H9G&AI*&:E<*'PJLX:%]+]/1LR(WP+3-)ZYNI9J 05KYU0/:G@&FKP
M0IG/K!L_*&%:KJA)]< V^KBK%(*!*3(H,Z%JRO)I_FAV/8#F*[Y9![^"=7-Q
MCLJ26K#TT.M*4 RXV*5E-7<E/(\F.7U[GE1.Z7GGP#;A!C]WO3')U=H@Q&*-
M>H)E?33VYT9_OO<#0SR'K6["?-ON(YDR2K##RZ]A[:H"E(F)B>/G$-NZ7^/4
M\AP9F>Y9[F?51H5C'/SF A_!^\9FW^M5J$S>L,UU"2W>?2S4=-%' /)'3'8M
M[5J4IOVOV?IN1P0A&!HLGH4&VW*X>H/K'%I3;QDB+Y&VU+&"*J/1HL\ON58(
M6^;N77PCX2):2>SN],RJ<@3 VD7@>UYLA;6\+J=]%ZY7,C4V:1E0NH(",JVV
M5<-I_B"I[.6'7%6\RTG*HJ#S%'7P *//3@\%%Y[2=%NO\=0H3V]KM.(\VM6N
M;(])E4M2?W$B\(:Z;N,& 4!6J1  NMJ;L\:ICNPX]QA)TH"+#4YJ7NY"</IN
M"3Q^\IQ VW$PVI6L1VK.]V>-X/%3QY1G""#27>6J^LY'-^;\NV.>KNN%W674
MPYEZ,Q(OY*SR\8-"YK7JJM0^J$%3/=Y&B#-^I85*@6P,[,J-Y)NN.(D0]9C&
MVL2,@1*,.7*,4ZIH8F-WP$[YO7WD($D8J*JB[ A]!SMK;BNV%;?>!3U;GN<!
MIMO5E48R(QM?':NZ2H3H3]1*JJ/7I<RU/@>94Q*8 -H)"B</%)]!V&GB1,<U
MXSWF:_]'U]L:C:=NPC3UN"YE>Z]O1%E# J1:0I[9)SG>2A?*T!5#;11]H9LV
M&OD[JC&2X[-TZ=#ROWZ;A9)Q:' 30(, 2NP1P'=F9[76WY^9'K*3KZ2:1R*
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MEW90NCFJZ62=.M]G$Z1#&5X>=]A:2C&SWC.&+@C99_:J"SC.BJX<Y:;J#Z]
MZ8W'"Y_S-H_SZZ9A#?#P;J3*G&"A,=#ZW!A'5JTJ4:C3\A(3)XVG8KDXR]3
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M'QM,%@<Y-U\.8Z'#0]O0__;!,[\I*,."Z''LP)-O.:-L_<BRD51:&U9NV E
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M9<CEBQOV>_M? 0&D017(^<72IV<7+[DN#ONXA.L>WV6J)3M+C%4R:\C75Z;
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MAK:F,.+!:I)AD1#[W9JY32ZW9UVFC"U&)<I+%^EV99*S4ASX"+=NX](G*$^
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MVXX^(+]!%UXW5M*^5U+#PIO,+'<H"4)=Z9 A;8,;- YWLW.(/0*@N,J\[D(
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M5QP,'7V+VF85;*9U0HQ'^+G/7%]Z2^A=-RE*T_*0%A1,XC#K2(PQ?R",Z@\
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M*IIG#+8[H7R796P];]=&DH)&.U((@N8=1;?E0O'51Y%$6E NOB+-SUMP:3N
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MC)$Z/CJ4R!JX]=)UJ,@<7DVH5C4'=O<#T\-.D2ML/6/;3"4FV_1,,^3\W!;
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MEA+I&]30OFCK^#ACZ"NG&:Y%^OYS]$(H?QN7]J?Z7(O#/GY= TB1Q@=%^Q2
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M4M(^V&"5R"Q;K36/>3$VSPCPXL\68/XTXFRW_,[:MAK:>!+N-O]7 6W9'0B
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MQ2]M#CO:\,KR\[)I_F5<7U373-GPG(&DS"3^?5HZ8'N]P$"6;(:$I0.E41-
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M)> K^I$7UR^">(\]=[PN<S;'G311]U0D&S0U0?NF//Q%1TX&PYV;;CCMVL5
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MQ)KRDI>.EWVKCD1,CT*TFO]WL^L<YY]1K$G(,KPB>3/V()[5 ZTS;[;(PK3
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M RM$.4&K\+L.F_HI->5 E]/_ E!+ P04    " #B@EQ4^*;>0UF>  !#!P$
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MKVF E)  +SQ""@ $(%O(/&T?CJ)!=EY>-N:U[^L\A&H'F4+,X ;S^T$H*#8
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M4U5N!"V^-1^M6I+U3?T^%;7W:/Y,P!0F,2&)+5TN_"B\=^GAD8&DH$JQ8ZG
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MPN;F)B,27T9#7,V)YK@XRV5(CIGSEW(O+PQ89[$Z/15U]F1I$)Z]VT9_):+
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M/Z8/\'&\WD)XKW HO8"N.T#>5;==RF2E_NA)=8KJ_>5*4<&/RJ<4W=M:M[I
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M1^U/>]?V.31;,X:G,]YKL?55\G.O6D/?%LO=SQ3! &.CXAU#UZQ?B/<%KV\
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M[EGP:P^AHP)>)Z0;RI.Z!HM_14QL'^P4KBO989!H9Q(3:>[<4*VK4T0:_-<
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MO/K9 !5<].L&T-)[$*I)L71NU#!R\'/+B0.K/J<*);/*:4:\,V;<'^W"_7W
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MA?9^"=,Z:<@)9/);C4S)3-:_?;HG38:T,9ODK2MW?CZE-5LI6/A1A*)D@&Z
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M,NF+:U("6SJ9/")^X()HTY.,QS7OX'F_U%18R8ZAXVBGRH% 9_(QR,VP/UE
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M\,&[1B8;+O%@;;'>>R>><K)D:;4Z(ZF1R^ 5IVW&TZUB\%+1#0#9M"TAM+H
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M.+UR%L#YT!ZMY+M''*_C92ACPV9_QST)(I'>TG=H8=VDGL9U:(WOELQ_,VN
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MTF^;3>P%DM($(I$[\[Q_1(6O;$'\(=EV-B>7UY 9K.6 ;B7U.NI/"?RQL80
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M+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( .*"7%0X?X).)1,  /4Y 0 5
M          "  9!0! !A=')A+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" #B@EQ4@ 1L(?,N  !_&P, %0              @ 'H8P0 871R82TR,#(Q
M,3(S,5]D968N>&UL4$L! A0#%     @ XH)<5$H9_;_WE0  OT4) !4
M         ( !#I,$ &%T<F$M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M .*"7%2XQP\>,%4  $UH!@ 5              "  3@I!0!A=')A+3(P,C$Q
M,C,Q7W!R92YX;6Q02P$"% ,4    " #B@EQ492.WS9@- 0!DS@@ $P
M        @ &;?@4 871R82UE>#$P,S5?,3 U+FAT;5!+ 0(4 Q0    ( .*"
M7%0,:^NJ$C8  )F" 0 3              "  62,!@!A=')A+65X,3 S-E\Q
M,#0N:'1M4$L! A0#%     @ XH)<5)S8]0-^A@  5;@$ !,
M ( !I\(& &%T<F$M97@Q,#,W7S$P,RYH=&U02P$"% ,4    " #B@EQ4J@:0
M9KC9  ">O < $P              @ %620< 871R82UE>#$P,SA?,3 R+FAT
M;5!+ 0(4 Q0    ( .*"7%3VXVY+.$(  &2\ 0 3              "  3\C
M" !A=')A+65X,3 S.5\Q,#$N:'1M4$L! A0#%     @ XH)<5"<];#.% P
M0Q8  !               ( !J&4( &%T<F$M97@R,3%?.2YH=&U02P$"% ,4
M    " #B@EQ4?^/+=54#  !:"0  $               @ %;:0@ 871R82UE
M>#(S,5\V+FAT;5!+ 0(4 Q0    ( .*"7%1+DM]'1 @  -@^   0
M      "  =YL" !A=')A+65X,S$R7S@N:'1M4$L! A0#%     @ XH)<5#7U
M?,&V!@  =20  !               ( !4'4( &%T<F$M97@S,C%?-RYH=&U0
M2P$"% ,4    " #B@EQ4PG*]P'?[  "Z3P$ %@              @ $T? @
M9V)N-6XU:FQN>F]G,# P,# Q+FIP9U!+ 0(4 Q0    ( .*"7%1PVH=@..L
M !9  0 6              "  =]W"0!G8FXU;C5J;&YZ;V<P,# P,#(N:G!G
M4$L! A0#%     @ XH)<5/BFWD-9G@  0P<! !8              ( !2V,*
M &=B;C5N-6IL;GIO9S P,# P,RYJ<&=02P4&     !( $@"7!   V $+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
